Small|O cell|O carcinoma|O of|O the|O gallbladder|O :|O a|O clinicopathologic|O ,|O immunohistochemical|O ,|O and|O molecular|O pathology|O study|O of|O 12|O cases|O .|O 
Small|O cell|O carcinomas|O of|O the|O gallbladder|O are|O unusual|O neoplasms|O that|O have|O been|O characterized|O only|O recently|O .|O 
The|O authors|O describe|O the|O clinical|O ,|O histopathologic|O ,|O immunohistochemical|O ,|O and|O molecular|O features|O of|O 12|O small|O cell|O carcinomas|O of|O the|O gallbladder|O .|O 
The|O mean|O age|O at|O diagnosis|O was|O 69|O years|O ,|O and|O the|O male|O -|O to|O -|O female|O ratio|O was|O 5|O :|O 7|O .|O 
The|O neoplasms|O had|O an|O average|O size|O of|O 3|O cm|O ,|O and|O 90|O %|O showed|O invasion|O of|O the|O muscularis|O propria|O and|O perimuscular|O connective|O tissue|O .|O 
Seventy-five|O percent|O of|O the|O carcinomas|O had|O metastasized|O or|O extended|O locally|O beyond|O the|O gallbladder|O at|O surgery|O .|O 
Survival|O was|O uniformly|O poor|O ,|O with|O a|O mean|O survival|O of|O 10.7|O months|O (|O range|O ,|O 3|O -|O 25|O months|O )|O .|O 
Half|O the|O small|O cell|O carcinomas|O were|O combined|O with|O other|O neoplasms|O .|O 
Four|O had|O foci|O of|O adenocarcinoma|O ,|O one|O contained|O areas|O of|O squamous|O differentiation|O ,|O and|O another|O had|O a|O component|O of|O carcinosarcoma|O .|O 
Immunohistochemical|O analysis|O showed|O focal|O reactivity|O for|O chromogranin|gene-protein (|O six|O of|O six|O cases|O )|O ,|O neuron|O -|O specific|O enolase|gene-protein (|O six|O of|O six|O cases|O )|O ,|O and|O Leu-7|gene-protein (|O three|O of|O three|O cases|O )|O .|O 
The|O molecular|O changes|O in|O small|O cell|O carcinomas|O were|O similar|O to|O those|O of|O adenocarcinomas|O occurring|O at|O this|O site|O ,|O with|O a|O high|O frequency|O of|O p53|gene-protein (|O 75|O %|O )|O and|O p16INK4a|gene-protein (|O 33|O %|O )|O abnormalities|O ,|O and|O a|O low|O frequency|O of|O deleted|O in|O pancreatic|O carcinoma-4|O inactivation|O (|O 0|O %|O )|O and|O K-ras|gene-rna codon|O 12|O mutations|O (|O 17|O %|O )|O .|O 
In|O contrast|O to|O pulmonary|O small|O cell|O carcinomas|O ,|O p16INK4a|gene-protein function|O appears|O to|O be|O abrogated|O more|O frequently|O in|O these|O carcinomas|O .|O 
Concurrent|O mutations|O of|O K-ras|gene-rna oncogene|O at|O codons|O 12|O and|O 22|O in|O colon|O cancer|O .|O 
K-ras|gene-rna mutation|O is|O the|O most|O common|O oncogenic|O alteration|O in|O various|O human|O cancers|O including|O colorectal|O carcinomas|O .|O 
Point|O mutations|O have|O the|O potential|O to|O activate|O the|O K-ras|gene-rna gene|O if|O they|O occur|O in|O the|O critical|O coding|O sequences|O .|O 
Almost|O all|O of|O these|O mutations|O have|O been|O localized|O in|O codons|O 12|O ,|O 13|O and|O 61|O .|O 
We|O report|O a|O case|O of|O colon|O cancer|O presenting|O point|O mutations|O at|O both|O codons|O 12|O and|O 22|O of|O the|O K-ras|gene-rna gene|O .|O 
PCR|O -|O SSCP|O and|O subsequent|O sequencing|O revealed|O that|O GGT|O (|O glycine|O ,|O wild|O -|O type|O )|O to|O AGT|O (|O serine|O )|O substitution|O at|O codon|O 12|O and|O CAG|O (|O glutamine|O ,|O wild|O -|O type|O )|O to|O CGG|O (|O arginine|O )|O substitution|O at|O codon|O 22|O occurred|O in|O the|O same|O allele|O .|O 
Novel|O colon|O cancer|O cell|O lines|O leading|O to|O better|O understanding|O of|O the|O diversity|O of|O respective|O primary|O cancers|O .|O 
A|O major|O obstacle|O to|O obtaining|O more|O detailed|O insights|O into|O the|O diversity|O of|O phenotypic|O and|O molecular|O changes|O occurring|O in|O colon|O cancer|O cells|O is|O the|O lack|O of|O low|O -|O passage|O colon|O cancer|O cell|O lines|O ,|O which|O would|O still|O closely|O reflect|O the|O phenotype|O of|O the|O colon|O cancer|O cells|O in|O vivo|O .|O 
Here|O ,|O we|O characterize|O eight|O novel|O ,|O low|O passage|O number|O human|O colon|O carcinoma|O cell|O lines|O ,|O originating|O from|O colorectal|O cancers|O extensively|O characterized|O in|O the|O clinics|O .|O 
All|O cell|O lines|O closely|O resemble|O the|O original|O tumors|O with|O respect|O to|O phenotype|O ,|O markers|O and|O detectable|O genetic|O changes|O .|O 
Cell|O morphology|O and|O marker|O expression|O is|O highly|O variable|O ,|O ranging|O from|O fully|O polarized|O cells|O correctly|O expressing|O all|O basolateral|O epithelial|O markers|O ,|O to|O cells|O with|O mesenchymal|O characteristics|O and|O a|O complete|O loss|O of|O polarity|O due|O to|O delocalization|O or|O loss|O of|O junction|O complex|O proteins|O .|O 
The|O alterations|O in|O phenotype|O and|O epithelial|O marker|O expression|O correspond|O to|O changes|O already|O detectable|O in|O the|O primary|O tumor|O in|O vivo|O .|O 
Seven|O of|O the|O cell|O lines|O show|O chromosomal|O instability|O ,|O while|O one|O cell|O line|O is|O characterized|O by|O microsatellite|O instability|O .|O 
p53|gene-generic associated|O with|O K-ras|gene-rna mutations|O were|O detected|O in|O three|O cell|O lines|O .|O 
Hitherto|O non|O -|O described|O E-cadherin|gene-rna mutations|O were|O found|O at|O both|O alleles|O in|O one|O cell|O line|O whereas|O in|O another|O cell|O line|O the|O E-cadherin|gene-protein protein|O was|O down|O -|O regulated|O .|O 
A|O stabilizing|O beta-catenin|gene-rna mutation|O (|O S|O 45|O F|O )|O appears|O in|O the|O same|O cell|O line|O that|O carried|O the|O mutated|O E-cadherin|gene-rna gene|O .|O 
Six|O cell|O lines|O carried|O APC|gene-rna mutations|O ,|O which|O in|O five|O of|O the|O lines|O led|O to|O an|O activated|O beta-catenin|gene-generic /|O Tcf|gene-generic /|O LEF|gene-generic signaling|O pathway|O .|O 
In|O accordance|O with|O beta-catenin|gene-generic /|O Tcf|gene-generic /|O LEF|gene-generic activation|O ,|O the|O cell|O lines|O show|O increased|O migration|O and|O invasiveness|O .|O 
Our|O results|O show|O that|O the|O characterized|O ,|O low|O -|O passage|O cell|O lines|O mirror|O the|O diversity|O of|O the|O individual|O tumors|O from|O which|O they|O were|O derived|O .|O 
Through|O molecular|O analyses|O of|O these|O cell|O lines|O we|O demonstrate|O that|O tumorgenicity|O events|O are|O much|O more|O diverse|O in|O human|O colon|O cancer|O than|O expected|O ,|O despite|O the|O common|O origin|O of|O the|O tumors|O from|O a|O small|O patient|O group|O with|O similar|O tumor|O grading|O and|O clinical|O prognosis|O .|O 
Common|O occurrence|O of|O multiple|O K-RAS|gene-rna mutations|O in|O pancreatic|O cancers|O with|O associated|O precursor|O lesions|O and|O in|O biliary|O cancers|O .|O 
Recent|O studies|O on|O small|O series|O of|O pancreatic|O cancer|O (|O PC|O )|O with|O foci|O of|O pancreatic|O intraepithelial|O neoplasia|O (|O PanIN|O )|O ,|O a|O putative|O precursor|O lesion|O ,|O have|O shown|O that|O multiple|O K-RAS|gene-rna mutations|O may|O coexist|O in|O the|O same|O neoplastic|O pancreas|O .|O 
To|O see|O whether|O mutant|O -|O K-RAS|gene-rna polyclonality|O is|O a|O common|O and|O specific|O feature|O of|O pancreatic|O carcinogenesis|O ,|O we|O investigated|O a|O unselected|O series|O of|O periampullary|O cancers|O (|O 41|O pancreatic|O ,|O 13|O biliary|O and|O two|O ampullary|O adenocarcinomas|O )|O .|O 
After|O hemi|O -|O nested|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O ,|O mutations|O identified|O with|O single|O strand|O conformation|O polymorphism|O (|O SSCP|O )|O were|O confirmed|O by|O allele|O -|O specific|O PCR|O and|O sequencing|O .|O 
K-RAS|gene-rna codon|O 12|O was|O mutated|O in|O 34|O (|O 83|O %|O )|O pancreatic|O cancers|O and|O in|O 11|O (|O 85|O %|O )|O biliary|O cancers|O .|O 
Multiple|O distinct|O K-RAS|gene-rna mutations|O were|O found|O in|O 16|O PC|O (|O 39|O %|O of|O all|O cases|O ,|O 47|O %|O of|O those|O with|O mutated|O K-RAS|gene-rna )|O and|O in|O eight|O biliary|O cancers|O (|O 62|O and|O 72|O %|O ,|O respectively|O )|O .|O 
In|O PC|O ,|O multiple|O K-RAS|gene-rna mutations|O were|O more|O frequent|O (|O P|O <|O 0.001|O )|O in|O cancers|O with|O (|O nine|O of|O 12|O ,|O 75|O %|O )|O than|O in|O those|O without|O detectable|O PanIN|O (|O seven|O of|O 29|O ,|O 24|O %|O )|O .|O 
Individual|O precursor|O lesions|O of|O the|O same|O neoplastic|O pancreas|O were|O found|O to|O harbor|O distinct|O mutations|O .|O 
Results|O show|O that|O multiple|O K-RAS|gene-rna mutations|O are|O frequent|O both|O in|O PC|O with|O associated|O PanIN|O and|O in|O biliary|O cancers|O ,|O and|O indicate|O that|O clonally|O distinct|O precursor|O lesions|O of|O PC|O might|O variably|O contribute|O to|O tumor|O development|O .|O 
Phase|O I|O clinical|O and|O pharmacologic|O study|O of|O chronic|O oral|O administration|O of|O the|O farnesyl|gene-protein protein|gene-protein transferase|gene-protein inhibitor|O R115777|O in|O advanced|O cancer|O .|O 
PURPOSE|O :|O 
To|O determine|O the|O maximum|O -|O tolerated|O dose|O ,|O toxicities|O ,|O and|O pharmacokinetics|O of|O R115777|O ,|O a|O farnesyl|gene-protein transferase|gene-protein inhibitor|O ,|O when|O administered|O continuously|O via|O the|O oral|O route|O .|O 
PATIENTS|O AND|O METHODS|O :|O 
Patients|O with|O advanced|O solid|O malignancies|O were|O treated|O with|O R115777|O using|O an|O interpatient|O dose|O escalation|O scheme|O starting|O at|O 50|O mg|O bid|O .|O 
Pharmacokinetics|O were|O assessed|O on|O days|O 1|O ,|O 28|O ,|O and|O 56|O .|O 
RESULTS|O :|O 
Twenty-eight|O patients|O were|O entered|O onto|O the|O study|O and|O the|O median|O duration|O of|O treatment|O was|O 55|O days|O .|O 
The|O dose|O -|O limiting|O toxicities|O were|O myelosuppression|O and|O neurotoxicity|O .|O 
At|O a|O dose|O of|O 400|O mg|O bid|O ,|O grade|O 4|O leukocytopenia|O and|O neutropenia|O were|O seen|O in|O two|O of|O four|O patients|O .|O 
Neurotoxicity|O grade|O 3|O developed|O in|O one|O of|O five|O patients|O at|O 500|O mg|O bid|O and|O in|O one|O of|O 13|O at|O 300|O mg|O bid|O after|O 8|O weeks|O of|O treatment|O .|O 
Common|O nonhematologic|O toxicities|O were|O nausea|O ,|O vomiting|O ,|O and|O fatigue|O .|O 
The|O recommended|O dose|O for|O phase|O II|O /|O III|O testing|O in|O this|O scheme|O is|O 300|O mg|O bid|O .|O 
The|O pharmacokinetic|O studies|O indicated|O dose|O proportionality|O .|O 
Little|O accumulation|O occurred|O and|O steady|O -|O state|O levels|O were|O reached|O within|O 2|O to|O 3|O days|O .|O 
Analyses|O of|O historic|O tumor|O material|O showed|O that|O five|O of|O 15|O of|O patients|O had|O a|O K-ras|gene-rna mutation|O in|O codon|O 12|O .|O 
Three|O patients|O with|O pancreatic|O ,|O colon|O ,|O and|O cervix|O carcinomas|O had|O stable|O disease|O and|O one|O patient|O with|O a|O colon|O carcinoma|O had|O a|O minor|O response|O accompanied|O by|O a|O more|O than|O 50|O %|O decrease|O in|O carcinoembryonic|O antigen|O tumor|O marker|O .|O 
A|O fifth|O patient|O ,|O with|O platinum|O -|O refractory|O non|O -|O small|O -|O cell|O lung|O cancer|O ,|O showed|O a|O partial|O response|O that|O lasted|O for|O 5|O months|O .|O 
CONCLUSION|O :|O 
Continuous|O dosing|O of|O R115777|O is|O feasible|O with|O an|O acceptable|O toxicity|O profile|O at|O a|O dose|O of|O 300|O mg|O bid|O .|O 
APC|gene-rna /|O CTNNB1|gene-rna (|O beta-catenin|gene-rna )|O pathway|O alterations|O in|O human|O prostate|O cancers|O .|O 
Genetic|O alterations|O serve|O as|O beacons|O for|O the|O involvement|O of|O specific|O pathways|O in|O tumorigenesis|O .|O 
It|O was|O previously|O shown|O that|O 5|O %|O of|O prostate|O tumors|O harbor|O CTNNB1|gene-rna mutations|O ,|O suggesting|O that|O this|O tumor|O type|O may|O involve|O a|O deregulated|O APC|gene-rna /|O CTNNB1|gene-rna pathway|O .|O 
To|O explore|O this|O possibility|O further|O ,|O we|O searched|O for|O mutations|O in|O genes|O implicated|O in|O this|O pathway|O in|O 22|O samples|O that|O included|O cell|O lines|O ,|O xenografts|O ,|O and|O primary|O tumors|O .|O 
We|O identified|O seven|O alterations|O :|O two|O in|O CTNNB1|gene-rna ,|O three|O in|O APC|gene-rna ,|O and|O two|O in|O hTRCP1|gene-rna (|O also|O known|O as|O BTRC|gene-rna )|O which|O controls|O the|O degradation|O of|O CTNNB1|gene-rna .|O 
Alterations|O in|O the|O CTNNB1|gene-rna regulatory|O domain|O ,|O APC|gene-rna ,|O and|O hTRCP1|gene-rna were|O mutually|O exclusive|O ,|O consistent|O with|O their|O equivalent|O effects|O on|O CTNNB1|gene-rna stability|O .|O 
These|O results|O suggest|O that|O CTNNB1|gene-rna signaling|O plays|O a|O critical|O role|O in|O the|O development|O of|O a|O significant|O fraction|O of|O prostate|O cancers|O .|O 
Moreover|O ,|O they|O provide|O the|O first|O evidence|O that|O hTRCP1|gene-rna plays|O a|O role|O in|O human|O neoplasia|O .|O 
Secondary|O malignant|O giant|O -|O cell|O tumour|O of|O bone|O :|O molecular|O abnormalities|O of|O p53|gene-rna and|O H-ras|gene-rna gene|O correlated|O with|O malignant|O transformation|O .|O 
AIMS|O :|O 
We|O report|O two|O cases|O of|O secondary|O malignant|O giant|O -|O cell|O tumour|O occurring|O without|O irradiation|O therapy|O .|O 
To|O elucidate|O the|O mechanism|O of|O malignant|O transformation|O in|O this|O tumour|O ,|O we|O searched|O for|O the|O molecular|O abnormalities|O of|O p53|gene-rna ,|O MDM2|gene-rna and|O the|O H-ras|gene-rna genes|O .|O 
METHODS|O AND|O RESULTS|O :|O 
These|O cases|O were|O retrieved|O after|O a|O review|O of|O 103|O cases|O of|O primary|O giant|O -|O cell|O tumour|O of|O bone|O ,|O registered|O in|O our|O institute|O .|O 
One|O case|O occurred|O in|O the|O distal|O femur|O of|O a|O 42|O -|O year|O -|O old|O female|O after|O surgical|O curettage|O ,|O while|O the|O other|O arose|O in|O the|O acetabulum|O of|O a|O 25|O -|O year|O -|O old|O male|O after|O en|O bloc|O resection|O .|O 
Microscopically|O ,|O the|O malignant|O tumour|O in|O the|O distal|O femur|O was|O composed|O of|O a|O proliferation|O of|O ovoid|O or|O fusiform|O cells|O arranged|O in|O fascicles|O with|O high|O mitotic|O activities|O .|O 
The|O malignant|O transformed|O tumour|O in|O the|O acetabulum|O was|O made|O up|O of|O pleomorphic|O tumour|O cells|O with|O atypical|O mitoses|O .|O 
In|O the|O tumour|O of|O the|O distal|O femur|O ,|O both|O p53|gene-rna and|O H-ras|gene-rna mutations|O were|O detected|O .|O 
Abnormal|O nuclear|O accumulation|O of|O p53|gene-protein protein|O and|O c-myc|gene-protein expression|O were|O also|O revealed|O by|O immunohistochemistry|O .|O 
In|O both|O cases|O ,|O the|O recurrent|O malignant|O tumour|O over|O -|O expressed|O MMP-9|gene-protein and|O revealed|O a|O higher|O MIB-1|gene-protein -|O labelling|O index|O compared|O with|O the|O primary|O conventional|O giant|O -|O cell|O tumour|O .|O 
CONCLUSIONS|O :|O 
Our|O results|O suggest|O that|O multiple|O oncogene|O or|O tumour|O suppressor|O gene|O mutations|O may|O play|O an|O important|O role|O during|O malignant|O transformation|O in|O conventional|O giant|O -|O cell|O tumours|O .|O 
Cigarette|O smoking|O is|O strongly|O associated|O with|O mutation|O of|O the|O K-ras|gene-rna gene|O in|O patients|O with|O primary|O adenocarcinoma|O of|O the|O lung|O .|O 
BACKGROUND|O :|O 
The|O majority|O of|O lung|O carcinoma|O cases|O occur|O in|O current|O or|O former|O smokers|O .|O 
K-ras|gene-rna gene|O mutations|O are|O common|O in|O lung|O adenocarcinoma|O and|O have|O been|O associated|O with|O cigarette|O smoking|O ,|O asbestos|O exposure|O ,|O and|O female|O gender|O .|O 
METHODS|O :|O 
In|O the|O current|O study|O ,|O the|O authors|O examined|O the|O contribution|O of|O cigarette|O smoking|O to|O K-ras|gene-rna gene|O mutations|O in|O patients|O with|O primary|O lung|O adenocarcinoma|O .|O 
Smoking|O histories|O were|O obtained|O from|O 106|O prospectively|O enrolled|O patients|O with|O primary|O adenocarcinoma|O of|O the|O lung|O .|O 
RESULTS|O :|O 
K-ras|gene-rna mutations|O were|O detected|O in|O the|O primary|O tumor|O using|O an|O allele|O -|O specific|O ligation|O assay|O .|O 
Ninety-two|O of|O the|O 106|O patients|O (|O 87|O %|O )|O with|O lung|O adenocarcinoma|O were|O smokers|O .|O 
Nonsmokers|O with|O this|O tumor|O were|O more|O likely|O to|O be|O women|O (|O 11|O of|O 14|O ;|O 79|O %|O )|O ,|O whereas|O the|O majority|O of|O smokers|O (|O 57|O %|O )|O were|O men|O .|O 
K-ras|gene-rna mutations|O were|O detected|O in|O 40|O of|O 106|O tumors|O (|O 38|O %|O )|O and|O were|O significantly|O more|O common|O in|O smokers|O compared|O with|O nonsmokers|O (|O 43|O %|O vs.|O 0|O %|O ;|O P|O =|O 0.001|O )|O .|O 
CONCLUSIONS|O :|O 
The|O results|O of|O the|O current|O study|O confirm|O and|O extend|O previous|O observations|O that|O smokers|O with|O adenocarcinoma|O of|O the|O lung|O are|O more|O likely|O to|O have|O K-ras|gene-rna mutant|O tumors|O compared|O with|O nonsmokers|O .|O 
The|O strong|O link|O between|O cigarette|O smoking|O and|O K-ras|gene-rna mutations|O in|O adenocarcinoma|O of|O the|O lung|O supports|O the|O role|O of|O specific|O tobacco|O carcinogens|O in|O the|O etiology|O of|O this|O malignancy|O .|O 
beta-catenin|gene-protein expression|O in|O pilomatrixomas|O .|O 
Relationship|O with|O beta-catenin|gene-rna gene|O mutations|O and|O comparison|O with|O beta-catenin|gene-protein expression|O in|O normal|O hair|O follicles|O .|O 
BACKGROUND|O :|O 
beta-catenin|gene-protein functions|O in|O signal|O transduction|O in|O the|O Wnt|gene-rna signalling|O pathway|O ,|O which|O has|O recently|O been|O implicated|O in|O hair|O follicle|O (|O HF|O )|O morphogenesis|O .|O 
beta-catenin|gene-rna gene|O mutations|O affecting|O exon|O 3|O have|O been|O reported|O in|O a|O high|O percentage|O of|O human|O pilomatrixomas|O .|O 
However|O ,|O the|O expression|O pattern|O of|O beta-catenin|gene-protein in|O human|O HFs|O and|O pilomatrixomas|O has|O not|O been|O reported|O .|O 
OBJECTIVES|O :|O 
To|O analyse|O immunohistochemically|O the|O expression|O pattern|O of|O beta-catenin|gene-protein in|O normal|O anagen|O HFs|O and|O in|O 40|O human|O pilomatrixomas|O .|O 
METHODS|O :|O 
In|O 11|O of|O these|O tumours|O we|O also|O studied|O exon|O 3|O beta-catenin|gene-rna gene|O mutations|O by|O polymerase|gene-protein chain|O reaction|O and|O direct|O sequencing|O .|O 
As|O these|O mutations|O have|O been|O related|O to|O a|O replication|O error|O (|O RER|O )|O phenotype|O in|O other|O tumour|O types|O ,|O we|O explored|O whether|O or|O not|O this|O association|O also|O occurs|O in|O pilomatrixomas|O .|O 
RESULTS|O :|O 
beta-catenin|gene-protein was|O expressed|O in|O the|O cell|O membranes|O of|O the|O outer|O and|O inner|O root|O sheaths|O and|O in|O matrix|O cells|O located|O at|O the|O base|O and|O periphery|O of|O the|O HF|O bulb|O .|O 
However|O ,|O central|O matrix|O cells|O that|O differentiate|O into|O cortical|O cells|O ,|O cortical|O and|O cuticular|O cells|O expressed|O beta-catenin|gene-protein in|O the|O nucleus|O ,|O suggesting|O a|O role|O in|O signal|O transduction|O .|O 
In|O addition|O ,|O some|O fibroblasts|O of|O the|O dermal|O papilla|O also|O showed|O nuclear|O expression|O of|O beta-catenin|gene-protein .|O 
All|O 40|O analysed|O pilomatrixomas|O showed|O intense|O nuclear|O and|O cytoplasmic|O beta-catenin|gene-protein expression|O in|O proliferating|O matrix|O (|O basaloid|O )|O cells|O .|O 
In|O areas|O of|O maturation|O ,|O transitional|O cells|O mainly|O showed|O cytoplasmic|O and|O membranous|O expression|O of|O beta-catenin|gene-protein ,|O while|O only|O a|O few|O cells|O retained|O nuclear|O expression|O .|O 
Shadow|O or|O ghost|O cells|O did|O not|O show|O beta-catenin|gene-protein expression|O .|O 
Three|O of|O 11|O tumours|O (|O 26|O %|O )|O had|O beta-catenin|gene-rna mutations|O .|O 
All|O three|O had|O the|O same|O heterozygote|O mis|O -|O sense|O mutation|O :|O a|O G|O to|O T|O change|O affecting|O the|O first|O nucleotide|O at|O codon|O 32|O (|O D|O 32|O Y|O )|O .|O 
None|O of|O the|O 11|O tumours|O studied|O had|O a|O positive|O RER|O phenotype|O .|O 
CONCLUSIONS|O :|O 
Present|O and|O previous|O studies|O suggest|O that|O the|O Wnt|gene-rna /|O beta-catenin|gene-rna /|O Tcf-Lef|gene-rna pathway|O is|O activated|O in|O normal|O matrix|O cells|O of|O the|O HF|O to|O induce|O differentiation|O to|O the|O hair|O shaft|O .|O 
Additionally|O ,|O the|O beta-catenin|gene-rna mutation|O in|O matrix|O cells|O of|O the|O HF|O stabilizes|O beta-catenin|gene-protein protein|O ,|O which|O translocates|O into|O the|O nucleus|O ,|O where|O it|O activates|O of|O gene|O transcription|O together|O with|O lymphoid|gene-generic enhancer|gene-generic factor-1|gene-generic producing|O pilomatrixoma|O .|O 
These|O mutations|O occur|O without|O an|O underlying|O defect|O in|O DNA|O mismatch|O repair|O .|O 
Fibroblast|gene-rna growth|gene-rna factor|gene-rna receptor|gene-rna 3|gene-rna S|O 249|O C|O mutation|O in|O virus|O associated|O squamous|O cell|O carcinomas|O .|O 
An|O S|O 249|O C|O mutation|O in|O fibroblast|gene-rna growth|gene-rna factor|gene-rna receptor|gene-rna 3|gene-rna (|O FGFR3|gene-rna )|O gene|O was|O recently|O identified|O in|O patients|O with|O cervical|O carcinomas|O (|O CC|O )|O .|O 
However|O ,|O its|O importance|O in|O cervical|O tumorigenesis|O is|O still|O inconclusive|O .|O 
Apart|O from|O CC|O ,|O nasopharyngeal|O carcinoma|O (|O NPC|O )|O is|O the|O other|O major|O virus|O associated|O squamous|O cell|O carcinoma|O .|O 
We|O sought|O to|O clarify|O the|O frequency|O of|O the|O FGFR3|gene-rna S|O 249|O C|O mutation|O in|O 75|O primary|O CC|O in|O the|O Thai|O population|O and|O to|O determine|O its|O prevalence|O in|O 69|O primary|O NPC|O by|O PCR|O and|O restriction|O enzyme|O digestion|O .|O 
None|O of|O the|O patients|O but|O one|O NPC|O showed|O the|O enzyme|O digestion|O pattern|O consistent|O with|O the|O mutation|O .|O 
This|O is|O the|O first|O report|O demonstrating|O the|O role|O of|O FGFR3|gene-rna in|O the|O development|O of|O human|O NPC|O .|O 
This|O study|O confirms|O the|O low|O frequency|O of|O the|O FGFR3|gene-rna S|O 249|O C|O mutation|O in|O CC|O .|O 
Nevertheless|O ,|O the|O discovery|O of|O the|O mutation|O ,|O not|O only|O in|O CC|O as|O reported|O by|O previous|O studies|O ,|O but|O in|O NPC|O based|O on|O this|O report|O ,|O suggests|O that|O FGFR3|gene-rna may|O play|O a|O significant|O role|O in|O human|O CC|O and|O NPC|O development|O .|O 
Microsatellite|O instability|O and|O alternative|O genetic|O pathway|O in|O intrahepatic|O cholangiocarcinoma|O .|O 
BACKGROUND|O /|O AIMS|O :|O 
Intrahepatic|O cholangiocarcinoma|O (|O ICC|O )|O arises|O from|O intrahepatic|O bile|O duct|O epithelium|O and|O is|O the|O second|O most|O prevalent|O among|O primary|O liver|O cancers|O .|O 
The|O aim|O of|O this|O study|O was|O to|O clarify|O the|O mechanism|O of|O cholangiocarcinogenesis|O .|O 
METHODS|O :|O 
We|O studied|O the|O incidence|O of|O microsatellite|O instability|O (|O MSI|O )|O involving|O eight|O highly|O polymorphic|O microsatellite|O markers|O and|O alternations|O of|O the|O K-ras|gene-rna ,|O p53|gene-rna and|O mdm-2|gene-rna genes|O in|O human|O ICC|O tissues|O .|O 
Overexpression|O of|O mdm-2|gene-protein oncoprotein|O was|O also|O immunohistochemically|O studied|O .|O 
RESULTS|O :|O 
Of|O all|O 65|O cases|O examined|O ,|O K-ras|gene-rna gene|O mutation|O was|O found|O in|O three|O cases|O (|O 4.6|O %|O )|O at|O codon|O 12|O .|O 
Analysis|O of|O p53|gene-rna alterations|O was|O performed|O in|O 28|O cases|O including|O 22|O frozen|O samples|O and|O mutations|O were|O found|O in|O three|O cases|O (|O 10.7|O %|O )|O .|O 
Overexpression|O of|O mdm-2|gene-protein protein|O was|O observed|O in|O 25|O (|O 41.7|O %|O )|O out|O of|O 60|O cases|O analyzed|O .|O 
In|O 22|O frozen|O samples|O ,|O seven|O (|O 31.8|O %|O )|O cases|O showed|O mdm-2|gene-protein amplification|O and|O four|O (|O 18.2|O %|O )|O cases|O revealed|O MSI|O -|O positive|O phenotype|O .|O 
Among|O the|O cases|O analyzed|O ,|O all|O the|O tumors|O with|O mdm-2|gene-protein amplification|O /|O overexpression|O harbored|O the|O wild|O -|O type|O p53|gene-rna gene|O and|O all|O the|O microsatellite|O instability|O -|O positive|O cases|O were|O from|O mass|O -|O forming|O (|O MF|O )|O +|O periductal|O -|O infiltrating|O (|O PI|O )|O subtype|O .|O 
CONCLUSIONS|O :|O 
These|O results|O suggest|O that|O mdm-2|gene-protein plays|O a|O role|O ,|O which|O might|O be|O partially|O through|O inhibiting|O p53|gene-rna activity|O ,|O in|O cholangiocarcinogenesis|O and|O that|O M|O 
Molecular|O analysis|O of|O p53|gene-rna and|O K-ras|gene-rna in|O lung|O carcinomas|O of|O coal|O miners|O .|O 
Thirty-three|O cases|O of|O non|O -|O small|O cell|O lung|O cancers|O (|O NSCLC|O )|O from|O the|O archives|O of|O National|O Coal|O Workers|O '|O Autopsy|O Study|O were|O studied|O for|O mutational|O alterations|O in|O p53|gene-rna and|O K-ras|gene-rna using|O PCR|O -|O SSCP|O ,|O DNA|O sequencing|O and|O PCR|O -|O oligonucleotide|O probe|O hybridization|O techniques|O .|O 
Mutations|O of|O the|O p53|gene-rna were|O observed|O in|O 4|O smokers|O (|O 19|O %|O )|O and|O one|O in|O a|O never|O smoker|O (|O 8|O %|O )|O .|O 
Two|O polymorphisms|O in|O smokers|O were|O detected|O at|O codon|O 213|O ,|O a|O common|O site|O for|O sequence|O variation|O .|O 
Among|O the|O smokers|O the|O p53|gene-rna mutations|O were|O in|O the|O heavy|O smokers|O .|O 
In|O never|O smokers|O there|O was|O only|O a|O single|O p53|gene-rna mutation|O and|O two|O K-ras|gene-rna mutations|O .|O 
In|O never|O smokers|O the|O frequency|O of|O K-ras|gene-rna mutations|O was|O similar|O (|O 17|O %|O )|O in|O smokers|O ,|O but|O one|O never|O smoker|O had|O two|O K-ras|gene-rna mutations|O .|O 
Mutations|O of|O p53|gene-rna were|O more|O frequent|O in|O adenocarcinomas|O (|O 27|O %|O )|O and|O they|O were|O AT|O -->|O GC|O transitions|O .|O 
Four|O of|O 11|O (|O 36|O %|O )|O adenocarcinomas|O were|O found|O to|O have|O K-ras|gene-rna codon|O 12|O mutations|O ,|O and|O one|O adenocarcinoma|O had|O two|O K-ras|gene-rna mutations|O .|O 
There|O were|O two|O large|O cell|O undifferentiated|O carcinomas|O with|O p53|gene-rna mutation|O and|O one|O with|O a|O K-ras|gene-rna mutation|O .|O 
Two|O of|O the|O 16|O squamous|O cell|O carcinomas|O were|O positive|O for|O p53|gene-rna mutation|O ,|O while|O no|O K-ras|gene-rna mutations|O were|O found|O in|O this|O group|O .|O 
The|O results|O of|O these|O preliminary|O studies|O indicate|O a|O moderately|O different|O mutational|O spectrum|O of|O p53|gene-rna and|O K-ras|gene-rna in|O coal|O miners|O independent|O of|O cigarette|O smoking|O .|O 
The|O mutational|O spectrum|O observed|O in|O this|O study|O of|O coal|O miners|O with|O heavy|O cigarette|O smoking|O history|O suggest|O a|O protective|O effect|O of|O coal|O mine|O dust|O in|O preventing|O abnormal|O mutations|O induced|O by|O chemical|O carcinogens|O in|O cigarette|O smoke|O or|O reactive|O oxygen|O species|O .|O 
These|O limited|O preliminary|O studies|O provide|O insight|O into|O the|O possibility|O of|O accurately|O measuring|O changes|O in|O etiologic|O markers|O to|O unravel|O the|O uncertainties|O of|O cancer|O in|O coal|O miners|O .|O 
Lung|O tumor|O KRAS|gene-rna and|O TP53|gene-rna mutations|O in|O nonsmokers|O reflect|O exposure|O to|O PAH|O -|O rich|O coal|O combustion|O emissions|O .|O 
We|O determined|O the|O TP53|gene-rna and|O codon|O 12|O KRAS|gene-rna mutations|O in|O lung|O tumors|O from|O 24|O nonsmokers|O whose|O tumors|O were|O associated|O with|O exposure|O to|O smoky|O coal|O .|O 
Among|O any|O tumors|O studied|O previously|O ,|O these|O showed|O the|O highest|O percentage|O of|O mutations|O that|O (a)|O were|O G|O -->|O T|O transversions|O at|O either|O KRAS|gene-rna (|O 86|O %|O )|O or|O TP53|gene-rna (|O 76|O %|O )|O ,|O (b)|O clustered|O at|O the|O G|O -|O rich|O codons|O 153|O -|O 158|O of|O TP53|gene-rna (|O 33|O %|O )|O ,|O and|O (c)|O had|O 100|O %|O of|O the|O guanines|O of|O the|O G|O -->|O T|O transversions|O on|O the|O nontranscribed|O strand|O .|O 
This|O mutation|O spectrum|O is|O consistent|O with|O an|O exposure|O to|O polycyclic|O aromatic|O hydrocarbons|O ,|O which|O are|O the|O primary|O component|O of|O the|O smoky|O coal|O emissions|O .|O 
These|O results|O show|O that|O mutations|O in|O the|O TP53|gene-rna and|O KRAS|gene-rna genes|O can|O reflect|O a|O specific|O environmental|O exposure|O .|O 
Frequency|O of|O fibroblast|gene-rna growth|gene-rna factor|gene-rna receptor|gene-rna 3|gene-rna mutations|O in|O sporadic|O tumours|O .|O 
Mutations|O in|O FGFR3|gene-rna have|O been|O identified|O in|O several|O tumour|O types|O including|O bladder|O carcinoma|O ,|O cervical|O carcinoma|O ,|O and|O multiple|O myeloma|O .|O 
In|O bladder|O carcinoma|O ,|O we|O recently|O identified|O FGFR3|gene-rna mutations|O in|O 41|O %|O of|O tumours|O ,|O making|O this|O the|O most|O frequently|O mutated|O putative|O oncogene|O identified|O in|O bladder|O cancer|O to|O date|O .|O 
We|O have|O now|O investigated|O the|O frequency|O of|O FGFR3|gene-rna mutation|O in|O a|O panel|O of|O 125|O tumours|O and|O 13|O cell|O lines|O from|O various|O other|O organs|O .|O 
We|O analysed|O the|O mutation|O hotspots|O in|O exons|O 7|O ,|O 10|O and|O 15|O by|O direct|O DNA|O sequencing|O ,|O and|O found|O one|O mutation|O in|O exon|O 7|O (|O S|O 249|O C|O )|O in|O 1|O /|O 28|O (|O 3.5|O %|O )|O cervical|O tumours|O .|O 
Mutations|O were|O not|O detected|O in|O stomach|O ,|O rectum|O ,|O colon|O ,|O prostate|O ,|O ovarian|O ,|O breast|O ,|O brain|O ,|O or|O renal|O tumours|O ,|O nor|O were|O they|O found|O in|O any|O of|O the|O cell|O lines|O included|O in|O this|O study|O .|O 
We|O conclude|O that|O FGFR3|gene-rna is|O commonly|O mutated|O in|O bladder|O carcinoma|O and|O only|O rarely|O in|O cervical|O carcinoma|O .|O 
Several|O tumour|O types|O appear|O not|O to|O possess|O any|O mutations|O in|O FGFR3|gene-rna ,|O suggesting|O that|O these|O mutations|O are|O important|O only|O in|O the|O development|O of|O certain|O types|O of|O tumour|O .|O 
Genetic|O alterations|O in|O gallbladder|O adenoma|O ,|O dysplasia|O and|O carcinoma|O .|O 
Adenoma|O and|O dysplasia|O in|O the|O gallbladder|O (|O GB|O )|O have|O been|O reported|O as|O precancerous|O lesions|O ,|O but|O the|O genetic|O evidence|O of|O this|O is|O not|O clearly|O defined|O .|O 
The|O purpose|O of|O this|O study|O was|O to|O analyze|O the|O frequencies|O of|O K-ras|gene-rna ,|O p53|gene-rna ,|O and|O p16|gene-rna gene|O mutations|O ,|O of|O microsatellite|O instability|O (|O MI|O )|O and|O of|O loss|O of|O heterozygosity|O (|O LOH|O )|O in|O GB|O cancer|O ,|O dysplasia|O ,|O and|O adenoma|O .|O 
Tissues|O from|O 15|O GB|O cancers|O ,|O five|O dysplasias|O around|O cancerous|O tumors|O ,|O and|O three|O adenomas|O were|O collected|O prospectively|O .|O 
The|O mutation|O rates|O of|O K-ras|gene-rna ,|O p53|gene-rna ,|O and|O p16|gene-rna were|O 20.0|O ,|O 35.7|O ,|O and|O 30.7|O %|O ,|O respectively|O ,|O in|O GB|O cancers|O .|O 
However|O ,|O no|O mutations|O were|O found|O in|O dysplasia|O or|O adenoma|O .|O 
Reduced|O staining|O for|O p16|gene-protein was|O seen|O in|O 23|O %|O of|O carcinomas|O .|O 
All|O of|O the|O GB|O carcinomas|O and|O four|O out|O of|O five|O (|O 80|O %|O )|O of|O the|O dysplasias|O showed|O LOH|O in|O a|O minimum|O of|O one|O locus|O ,|O but|O one|O out|O of|O three|O (|O 33|O %|O )|O cases|O of|O adenoma|O displayed|O LOH|O in|O only|O one|O locus|O .|O 
All|O of|O the|O loci|O of|O LOH|O in|O the|O dysplasias|O ,|O except|O one|O ,|O showed|O the|O same|O patterns|O of|O allelic|O loss|O as|O the|O adjacent|O carcinomas|O .|O 
Only|O one|O dysplasia|O showed|O multiple|O MI|O .|O 
In|O conclusion|O ,|O multiple|O LOH|O may|O be|O associated|O with|O the|O development|O of|O dysplasia|O and|O the|O malignant|O transformation|O of|O GB|O carcinoma|O .|O 
Gene|O alterations|O of|O K-ras|gene-rna ,|O p53|gene-rna ,|O and|O p16|gene-rna are|O important|O steps|O in|O the|O malignant|O changes|O of|O dysplasia|O .|O 
However|O ,|O MI|O seems|O to|O have|O only|O a|O limited|O role|O in|O GB|O cancer|O development|O .|O 
beta-Catenin|gene-protein expression|O pattern|O ,|O beta-catenin|gene-rna gene|O mutations|O ,|O and|O microsatellite|O instability|O in|O endometrioid|O ovarian|O carcinomas|O and|O synchronous|O endometrial|O carcinomas|O .|O 
beta-Catenin|gene-rna gene|O mutations|O and|O microsatellite|O instability|O (|O MI|O )|O have|O been|O reported|O in|O endometrioid|O ovarian|O carcinomas|O .|O 
In|O colon|O but|O not|O endometrial|O cancer|O ,|O beta-catenin|gene-rna gene|O mutations|O are|O associated|O with|O a|O replication|O error|O phenotype|O and|O MI|O .|O 
In|O this|O study|O the|O authors|O investigate|O whether|O beta-catenin|gene-rna mutations|O and|O MI|O are|O two|O independent|O oncogenic|O pathways|O in|O endometrioid|O ovarian|O carcinomas|O .|O 
They|O also|O evaluate|O the|O usefulness|O of|O these|O molecular|O markers|O in|O determining|O the|O primary|O origin|O of|O simultaneous|O tumors|O in|O the|O ovary|O and|O endometrium|O .|O 
This|O study|O was|O performed|O on|O 26|O patients|O diagnosed|O with|O primary|O endometrioid|O ovarian|O carcinoma|O ,|O five|O of|O whom|O also|O had|O pathologically|O diagnosed|O primary|O synchronous|O endometrioid|O endometrial|O carcinoma|O .|O 
Immunohistochemical|O and|O molecular|O analyses|O indicated|O that|O there|O were|O 25|O primary|O ovarian|O tumors|O with|O four|O primary|O synchronous|O endometrial|O cancers|O and|O one|O ovarian|O metastasis|O of|O a|O primary|O endometrial|O carcinoma|O .|O 
All|O studies|O were|O performed|O on|O formalin|O -|O fixed|O ,|O paraffin|O -|O embedded|O tissue|O samples|O .|O 
The|O beta-catenin|gene-protein expression|O pattern|O (|O nuclear|O vs.|O membranous|O )|O was|O analyzed|O immunohistochemically|O .|O 
Mutations|O in|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O were|O studied|O by|O polymerase|gene-protein chain|O reaction|O ,|O single|O -|O strand|O conformational|O polymorphism|O ,|O and|O direct|O sequencing|O .|O 
MI|O status|O was|O established|O by|O studying|O BAT-26|O and|O BAT-25|O mononucleotide|O repeats|O .|O 
In|O the|O group|O with|O 21|O single|O ovarian|O tumors|O ,|O 18|O (|O 85|O %|O )|O had|O beta-catenin|gene-protein nuclear|O expression|O ,|O eight|O (|O 38|O %|O )|O had|O beta-catenin|gene-rna gene|O mutations|O (|O always|O associated|O with|O beta-catenin|gene-protein nuclear|O expression|O )|O ,|O and|O four|O (|O 19|O %|O )|O had|O MI|O .|O 
Only|O one|O case|O (|O 5|O %|O )|O had|O both|O beta-catenin|gene-rna gene|O mutations|O and|O MI|O .|O 
The|O mutations|O affected|O one|O of|O the|O serine|O /|O threonine|O residues|O targeted|O for|O phosphorylation|O by|O glycogen|gene-protein synthase|gene-protein kinase-3beta|gene-protein or|O adjacent|O residues|O .|O 
At|O codon|O 32|O ,|O a|O GAC|O -|O to|O -|O TAC|O (|O D|O 32|O Y|O )|O change|O was|O found|O ;|O at|O codon|O 33|O ,|O two|O TCT|O -|O to|O -|O TGT|O (|O S|O 33|O C|O )|O changes|O were|O found|O ;|O at|O codon|O 37|O ,|O three|O TCT|O -|O to|O -|O TTT|O (|O S|O 37|O F|O )|O changes|O and|O one|O TCT|O -|O to|O -|O TGT|O (|O S|O 37|O C|O )|O change|O were|O found|O ;|O and|O ,|O lastly|O ,|O one|O ACC|O -|O to|O -|O GCC|O change|O at|O codon|O 41|O (|O T|O 41|O A|O )|O was|O detected|O .|O 
Four|O of|O the|O 25|O endometrioid|O ovarian|O carcinomas|O (|O 16|O %|O )|O had|O an|O associated|O synchronous|O endometrial|O carcinoma|O .|O 
There|O was|O a|O higher|O percentage|O of|O beta-catenin|gene-rna mutations|O (|O n|O =|O 3|O ,|O 75|O %|O )|O in|O synchronous|O ovarian|O carcinomas|O than|O in|O single|O ones|O ,|O although|O with|O a|O similar|O percentage|O of|O MI|O (|O n|O =|O 1|O ,|O 25|O %|O )|O .|O 
beta-catenin|gene-rna mutations|O were|O S|O 37|O C|O in|O two|O cases|O and|O D|O 32|O G|O in|O one|O .|O 
One|O of|O the|O four|O endometrial|O carcinomas|O showed|O an|O S|O 33|O C|O beta-catenin|gene-rna mutation|O ,|O and|O two|O carcinomas|O had|O MI|O .|O 
None|O of|O the|O four|O tumors|O had|O both|O beta-catenin|gene-rna gene|O mutation|O and|O MI|O .|O 
beta-catenin|gene-rna gene|O mutations|O were|O always|O associated|O with|O a|O nuclear|O beta-catenin|gene-protein expression|O pattern|O ,|O whereas|O MI|O was|O associated|O with|O a|O membranous|O pattern|O .|O 
In|O one|O patient|O both|O the|O ovarian|O and|O the|O endometrial|O carcinomas|O had|O beta-catenin|gene-rna gene|O mutations|O ,|O in|O another|O patient|O both|O tumors|O showed|O MI|O ,|O whereas|O in|O the|O remaining|O two|O patients|O the|O ovarian|O carcinomas|O showed|O beta-catenin|gene-rna gene|O mutations|O and|O the|O endometrial|O carcinomas|O showed|O MI|O .|O 
To|O summarize|O ,|O the|O results|O of|O this|O study|O suggest|O that|O beta-catenin|gene-rna mutations|O and|O MI|O could|O represent|O two|O independent|O pathways|O in|O endometrioid|O ovarian|O carcinomas|O because|O they|O occur|O simultaneously|O very|O infrequently|O (|O in|O 5|O %|O of|O these|O cases|O )|O .|O 
beta-catenin|gene-rna mutations|O are|O always|O associated|O with|O a|O nuclear|O beta-catenin|gene-protein expression|O pattern|O ,|O whereas|O cases|O with|O a|O replication|O error|O -|O plus|O phenotype|O showed|O no|O abnormal|O beta-catenin|gene-protein subcellular|O localization|O .|O 
The|O study|O of|O the|O beta-catenin|gene-protein expression|O pattern|O ,|O beta-catenin|gene-rna mutations|O ,|O and|O MI|O ,|O together|O with|O conventional|O clinicopathologic|O findings|O ,|O could|O aid|O in|O distinguishing|O between|O the|O metastatic|O or|O independent|O origin|O of|O simultaneous|O endometrioid|O ovarian|O and|O endometrial|O carcinomas|O .|O 
Tumors|O with|O identical|O immunohistochemical|O and|O molecular|O features|O should|O therefore|O be|O considered|O to|O have|O a|O common|O origin|O .|O 
Unique|O K-ras|gene-rna mutational|O pattern|O in|O pancreatic|O adenocarcinoma|O from|O Taiwanese|O patients|O .|O 
To|O assess|O the|O prevalence|O and|O spectrum|O of|O K-ras|gene-rna mutations|O in|O Taiwanese|O patients|O with|O pancreatic|O adenocarcinoma|O ,|O we|O analyzed|O 20|O patients|O of|O ductal|O adenocarcinoma|O of|O the|O head|O of|O the|O pancreas|O undergoing|O pancreaticoduodenectomy|O .|O 
The|O study|O included|O K-ras|gene-rna mutations|O that|O were|O detected|O using|O DNA|O direct|O sequencing|O analysis|O of|O the|O polymerase|gene-protein chain|O reaction|O products|O and|O confirmed|O by|O reverse|O sequencing|O primers|O .|O 
The|O results|O showed|O that|O K-ras|gene-rna codon|O 12|O mutation|O was|O detected|O in|O 90|O %|O of|O the|O cancer|O tissues|O (|O 18|O /|O 20|O )|O .|O 
Moreover|O ,|O the|O results|O from|O direct|O sequencing|O indicated|O that|O missense|O mutations|O were|O found|O to|O be|O a|O GGT|O to|O GTT|O in|O 94.5|O %|O of|O the|O cases|O (|O 17|O /|O 18|O )|O and|O a|O GGT|O to|O TTT|O in|O 5.5|O %|O of|O the|O cases|O (|O 1|O /|O 18|O )|O .|O 
All|O cases|O with|O K-ras|gene-rna codon|O 12|O mutations|O were|O found|O to|O be|O G|O to|O T|O transversion|O .|O 
However|O ,|O no|O alterations|O were|O found|O at|O codons|O 13|O and|O 61|O .|O 
From|O these|O findings|O ,|O the|O high|O prevalence|O of|O K-ras|gene-rna codon|O 12|O mutation|O in|O pancreatic|O adenocarcinoma|O and|O the|O predominant|O G|O to|O T|O transversion|O with|O the|O preferential|O substitution|O of|O glycine|O with|O valine|O might|O indicate|O an|O unusual|O sensitivity|O and|O specificity|O of|O this|O codon|O in|O genetic|O alterations|O for|O pancreatic|O carcinogenesis|O .|O 
The|O strikingly|O high|O mutational|O rate|O and|O the|O unique|O mutational|O spectrum|O of|O K-ras|gene-rna codon|O 12|O in|O Taiwanese|O pancreatic|O adenocarcinoma|O can|O provide|O us|O with|O more|O information|O about|O the|O alternative|O diagnostic|O and|O therapeutic|O strategies|O in|O Taiwan|O .|O 
Prognostic|O value|O of|O K-ras|gene-rna mutations|O and|O allelic|O imbalance|O on|O chromosome|O 18q|O in|O patients|O with|O resected|O colorectal|O cancer|O .|O 
PURPOSE|O :|O 
We|O designed|O this|O study|O to|O assess|O the|O frequency|O of|O K-ras|gene-rna mutations|O in|O patients|O with|O resected|O colorectal|O tumors|O and|O their|O association|O with|O survival|O .|O 
A|O second|O objective|O was|O to|O analyze|O the|O prognostic|O value|O of|O different|O K-ras|gene-rna genotypes|O .|O 
In|O a|O subgroup|O of|O patients|O we|O also|O investigated|O the|O presence|O of|O allelic|O imbalance|O on|O chromosome|O 18q|O and|O its|O relationship|O to|O clinical|O outcome|O .|O 
METHODS|O :|O 
One|O hundred|O fourteen|O colorectal|O tumors|O resected|O between|O 1983|O and|O 1986|O were|O analyzed|O to|O detect|O K-ras|gene-rna point|O mutations|O at|O codons|O 12|O ,|O 13|O ,|O and|O 61|O by|O polymerase|gene-protein chain|O reaction|O followed|O by|O allele|O specific|O oligonucleotide|O hybridization|O .|O 
A|O subgroup|O of|O 77|O tumors|O was|O further|O screened|O to|O detect|O loss|O of|O heterozygosity|O on|O chromosome|O 18q|O using|O three|O polymorphic|O microsatellite|O markers|O (|O D18S67|O ,|O D18S474|O and|O D18S58|O )|O .|O 
RESULTS|O :|O 
K-ras|gene-rna mutations|O were|O detected|O in|O 29|O percent|O (|O 33|O /|O 114|O )|O of|O patients|O .|O 
K-ras|gene-rna mutations|O correlated|O with|O age|O and|O preoperative|O carcinoembryonic|O antigen|O levels|O ,|O and|O there|O was|O some|O indication|O that|O they|O may|O be|O linked|O to|O poor|O survival|O ,|O especially|O in|O Stage|O II|O tumors|O ,|O where|O a|O subgroup|O of|O patients|O with|O aspartic|O and|O serine|O mutations|O showed|O significantly|O reduced|O survival|O (|O P|O =|O 0.03|O )|O compared|O with|O K-ras|gene-rna -|O negative|O patients|O .|O 
18q|O loss|O of|O heterozygosity|O was|O present|O in|O 39|O percent|O (|O 25|O /|O 63|O )|O of|O tumors|O .|O 
A|O multivariate|O analysis|O of|O Stage|O II|O tumors|O showed|O that|O 18q|O loss|O of|O heterozygosity|O was|O significantly|O associated|O with|O a|O worse|O prognosis|O (|O P|O =|O 0.006|O )|O .|O 
A|O significant|O decrease|O in|O survival|O was|O identified|O in|O ten|O patients|O harboring|O both|O genetic|O alterations|O (|O K-i|gene-rna mutations|O and|O 18q|O loss|O of|O heterozygosity|O ;|O P|O =|O 0.02|O )|O .|O 
CONCLUSIONS|O :|O 
In|O colorectal|O tumors|O ,|O K-ras|gene-rna mutations|O and|O 18q|O loss|O of|O heterozygosity|O are|O two|O genetic|O markers|O which|O may|O identify|O patients|O with|O more|O aggressive|O behavior|O ,|O mainly|O in|O Stage|O II|O tumors|O .|O 
These|O findings|O warrant|O further|O research|O ,|O because|O they|O can|O be|O useful|O in|O customizing|O adjuvant|O chemotherapy|O .|O 
Inverse|O relationship|O between|O microsatellite|O instability|O and|O K-ras|gene-rna and|O p53|gene-rna gene|O alterations|O in|O colon|O cancer|O .|O 
Some|O studies|O have|O shown|O an|O inverse|O relationship|O between|O microsatellite|O instability|O in|O colon|O cancer|O and|O mutations|O in|O p53|gene-rna and|O K-ras|gene-rna ,|O whereas|O others|O have|O not|O .|O 
We|O therefore|O evaluated|O these|O features|O in|O a|O population|O -|O based|O sample|O of|O 496|O individuals|O with|O colon|O cancer|O .|O 
Microsatellite|O instability|O was|O determined|O by|O a|O panel|O of|O 10|O tetranucleotide|O repeats|O ,|O the|O Bethesda|O consensus|O panel|O of|O mono|O -|O and|O di|O nucleotide|O repeats|O ,|O and|O coding|O mononucleotide|O repeats|O in|O transforming|gene-protein growth|gene-protein factor|gene-protein -|gene-protein beta|gene-protein receptor|gene-protein type|gene-protein II|gene-protein ,|O hMSH3|gene-protein ,|O BAX|gene-protein ,|O hMSH6|gene-protein ,|O and|O insulin|gene-protein -|gene-protein like|gene-protein growth|gene-protein factor|gene-protein receptor|gene-protein type|gene-protein II|gene-protein .|O 
Mutations|O in|O codons|O 12|O and|O 13|O in|O K-ras|gene-rna were|O evaluated|O by|O sequencing|O .|O 
p53|gene-protein overexpression|O (|O as|O detected|O by|O immunohistochemistry|O )|O was|O used|O as|O an|O indicator|O of|O p53|gene-rna mutation|O ;|O this|O was|O evaluated|O in|O 275|O of|O the|O tumors|O .|O 
K-ras|gene-rna mutations|O were|O present|O in|O 33.2|O %|O of|O tumors|O ,|O p53|gene-protein overexpression|O in|O 51.5|O %|O ,|O and|O microsatellite|O instability|O (|O as|O determined|O by|O the|O Bethesda|O consensus|O panel|O )|O in|O 12.5|O %|O .|O 
K-ras|gene-rna mutations|O were|O significantly|O less|O common|O in|O unstable|O tumors|O than|O stable|O tumors|O (|O 11.8|O %|O versus|O 36.9|O %|O ,|O P|O :|O <|O 0.001|O )|O .|O 
p53|gene-protein overexpression|O was|O significantly|O less|O common|O in|O unstable|O tumors|O than|O stable|O tumors|O (|O 20.0|O %|O versus|O 55.7|O %|O ,|O P|O :|O <|O 0.001|O )|O .|O 
These|O inverse|O relationships|O between|O microsatellite|O instability|O and|O ras|gene-rna gene|O mutations|O and|O p53|gene-protein overexpression|O were|O shown|O to|O be|O independent|O of|O tumor|O site|O in|O logistic|O regression|O analyses|O .|O 
All|O other|O measures|O of|O instability|O also|O showed|O statistically|O significant|O inverse|O relationships|O independent|O of|O tumor|O site|O with|O alterations|O in|O ras|gene-rna and|O p53|gene-rna ,|O and|O instability|O results|O determined|O by|O the|O panel|O of|O 10|O tetranucleotide|O repeats|O were|O highly|O significantly|O related|O to|O those|O determined|O by|O the|O Bethesda|O consensus|O panel|O .|O 
Coding|O mononucleotide|O repeat|O mutations|O were|O significantly|O more|O common|O in|O unstable|O tumors|O than|O stable|O tumors|O (|O 85.7|O %|O versus|O 1.0|O %|O ,|O P|O :|O <|O 0.001|O )|O .|O 
We|O conclude|O that|O there|O is|O an|O inverse|O relationship|O between|O microsatellite|O instability|O and|O mutations|O in|O p53|gene-rna and|O K-ras|gene-rna ,|O and|O that|O the|O molecular|O profile|O of|O colon|O cancers|O with|O microsatellite|O instability|O is|O characterized|O by|O relatively|O infrequent|O mutations|O in|O K-ras|gene-rna and|O p53|gene-rna and|O relatively|O frequent|O mutations|O in|O coding|O mononucleotide|O repeats|O .|O 
Colloid|O (|O mucinous|O noncystic|O )|O carcinoma|O of|O the|O pancreas|O .|O 
In|O the|O past|O ,|O colloid|O (|O mucinous|O noncystic|O )|O carcinoma|O (|O CC|O )|O of|O the|O pancreas|O had|O been|O included|O under|O the|O category|O of|O ordinary|O ductal|O adenocarcinoma|O ,|O a|O tumor|O with|O a|O dismal|O prognosis|O ,|O or|O was|O frequently|O misdiagnosed|O as|O mucinous|O cystadenocarcinoma|O .|O 
The|O clinicopathologic|O features|O of|O CC|O have|O not|O yet|O been|O well|O characterized|O ,|O because|O most|O cases|O on|O record|O have|O been|O parts|O of|O studies|O on|O either|O mucinous|O cystic|O neoplasms|O (|O MCN|O )|O or|O intraductal|O papillary|O mucinous|O neoplasms|O (|O IPMN|O )|O ,|O with|O which|O colloid|O carcinomas|O are|O frequently|O associated|O .|O 
To|O determine|O the|O clinicopathologic|O characteristics|O of|O CC|O ,|O 17|O pancreatic|O tumors|O composed|O predominantly|O (|O >|O 80|O %|O )|O of|O CC|O (|O defined|O as|O nodular|O extracellular|O mucin|O lakes|O with|O scanty|O malignant|O epithelial|O cells|O )|O and|O in|O which|O the|O invasive|O carcinoma|O measured|O larger|O than|O 1|O cm|O were|O studied|O .|O 
Ten|O of|O these|O were|O originally|O classified|O as|O mucinous|O ductal|O adenocarcinoma|O and|O four|O as|O mucinous|O cystadenocarcinoma|O .|O 
The|O mean|O age|O of|O the|O patients|O was|O 61|O years|O ;|O 9|O were|O men|O and|O 8|O were|O women|O .|O 
The|O mean|O size|O of|O the|O CC|O was|O 5.3|O cm|O (|O range|O ,|O 1.2|O -|O 16|O cm|O )|O .|O 
In|O more|O than|O half|O of|O the|O patients|O ,|O CC|O represented|O the|O invasive|O component|O of|O an|O IPMN|O (|O in|O nine|O cases|O )|O or|O MCN|O (|O in|O one|O case|O )|O .|O 
The|O tumors|O were|O composed|O of|O well|O -|O defined|O pools|O of|O mucin|O with|O sparse|O malignant|O cells|O in|O various|O patterns|O of|O distribution|O .|O 
Signet|O -|O ring|O cells|O floating|O in|O the|O mucin|O (|O but|O not|O as|O individual|O cells|O infiltrating|O stroma|O ,|O a|O characteristic|O finding|O of|O signet|O -|O ring|O cell|O adenocarcinomas|O )|O were|O commonly|O identified|O and|O were|O prominent|O in|O five|O cases|O .|O 
Perineurial|O invasion|O was|O noted|O in|O six|O cases|O and|O regional|O lymph|O node|O metastases|O in|O eight|O .|O 
Mutation|O in|O codon|O 12|O of|O the|O k-ras|gene-rna gene|O was|O detected|O in|O only|O 4|O of|O 12|O cases|O studied|O and|O p53|gene-rna mutation|O in|O 2|O of|O 9|O .|O 
Immunohistochemical|O and|O histochemical|O mucin|O stains|O suggested|O luminalization|O of|O the|O basal|O aspects|O of|O the|O cells|O .|O 
Five|O -|O year|O survival|O was|O 57|O %|O .|O 
At|O an|O overall|O mean|O follow|O up|O of|O 57|O months|O ,|O 10|O patients|O were|O alive|O with|O no|O evidence|O of|O disease|O (|O median|O ,|O 79|O mos|O )|O ,|O including|O four|O with|O lymph|O node|O metastasis|O ,|O three|O others|O with|O perineurial|O invasion|O ,|O and|O another|O with|O vascular|O invasion|O .|O 
Four|O patients|O died|O of|O disease|O (|O 18|O ,|O 18|O ,|O 25|O ,|O and|O 26|O mos|O )|O ,|O and|O three|O died|O of|O thromboembolism|O (|O with|O persistent|O disease|O )|O at|O 2|O ,|O 5|O ,|O 10|O months|O .|O 
All|O seven|O patients|O who|O died|O with|O or|O of|O tumor|O had|O undergone|O incisional|O biopsy|O of|O the|O tumor|O either|O before|O the|O operation|O or|O intraoperatively|O ,|O whereas|O none|O of|O the|O patients|O who|O were|O alive|O had|O incisional|O biopsy|O .|O 
When|O compared|O with|O 82|O cases|O of|O resectable|O ordinary|O ductal|O adenocarcinoma|O on|O whom|O follow-up|O and|O staging|O information|O was|O complete|O ,|O it|O was|O found|O that|O the|O patients|O with|O CC|O present|O with|O larger|O tumors|O (|O p|O =|O 0.03|O )|O but|O lower|O stage|O (|O p|O =|O 0.01|O )|O .|O 
The|O prognosis|O of|O CC|O is|O significantly|O better|O :|O 2|O -|O year|O and|O 5|O -|O year|O survival|O are|O 70|O %|O versus|O 28|O %|O and|O 57|O %|O versus|O 12|O %|O ,|O respectively|O (|O p|O =|O 0.001|O )|O .|O 
In|O conclusion|O ,|O pancreatic|O CC|O may|O occur|O with|O or|O without|O an|O identifiable|O IPMN|O and|O MCN|O component|O ,|O and|O should|O be|O distinguished|O from|O mucinous|O cystadenocarcinoma|O ,|O ordinary|O ductal|O adenocarcinoma|O ,|O and|O signet|O -|O ring|O cell|O adenocarcinoma|O .|O 
CC|O of|O the|O pancreas|O is|O associated|O with|O a|O significantly|O better|O prognosis|O than|O ordinary|O ductal|O adenocarcinoma|O .|O 
In|O addition|O to|O its|O distinctive|O morphologic|O and|O clinical|O characteristics|O ,|O CC|O of|O the|O pancreas|O also|O appears|O to|O have|O a|O low|O incidence|O of|O mutation|O in|O codon|O 12|O of|O the|O k-ras|gene-rna gene|O .|O 
In|O cases|O with|O a|O clinical|O suspicion|O of|O colloid|O carcinoma|O ,|O the|O possibility|O that|O an|O incisional|O biopsy|O may|O contribute|O to|O thromboembolic|O complications|O or|O even|O dissemination|O of|O the|O tumor|O may|O need|O to|O be|O considered|O .|O 
The|O luminalization|O of|O the|O basal|O aspects|O of|O the|O tumor|O cells|O may|O be|O the|O cause|O of|O stromal|O mucin|O accumulation|O that|O characterizes|O colloid|O carcinoma|O and|O may|O act|O as|O a|O containing|O factor|O .|O 
Characterization|O of|O the|O mutations|O of|O the|O K-ras|gene-rna ,|O p53|gene-rna ,|O p16|gene-rna ,|O and|O SMAD4|gene-rna genes|O in|O 15|O human|O pancreatic|O cancer|O cell|O lines|O .|O 
Human|O pancreatic|O cancer|O is|O one|O of|O the|O most|O malignant|O diseases|O in|O the|O world|O .|O 
In|O order|O to|O save|O patients|O with|O pancreatic|O cancer|O ,|O it|O is|O necessary|O to|O develop|O novel|O methods|O for|O treatment|O .|O 
For|O such|O a|O purpose|O ,|O a|O series|O of|O well|O -|O characterized|O cancer|O cell|O lines|O are|O of|O great|O help|O for|O in|O vitro|O studies|O that|O are|O generally|O the|O first|O step|O in|O approaching|O the|O invention|O of|O novel|O methods|O for|O treatment|O .|O 
In|O the|O present|O study|O ,|O we|O analyzed|O 15|O human|O pancreatic|O cancer|O cell|O lines|O for|O genetic|O alterations|O of|O the|O K-ras|gene-rna ,|O p53|gene-rna ,|O p16|gene-rna ,|O and|O SMAD4|gene-rna genes|O ,|O which|O are|O very|O frequent|O targets|O for|O mutation|O in|O pancreatic|O cancer|O ;|O these|O cell|O lines|O are|O useful|O resources|O in|O cancer|O research|O .|O 
Mast|O cell|O disease|O associated|O with|O acute|O myeloid|O leukemia|O :|O detection|O of|O a|O new|O c-kit|gene-rna mutation|O Asp|O 816|O His|O .|O 
Mast|O cell|O disease|O (|O MCD|O )|O ,|O a|O proliferation|O of|O mast|O cells|O (|O MC|O )|O ,|O is|O occasionally|O associated|O with|O hematologic|O malignancies|O .|O 
Neoplastic|O MC|O have|O activating|O c-kit|gene-rna mutations|O .|O 
c-kit|gene-protein is|O a|O receptor|gene-protein tyrosine|gene-protein kinase|gene-protein required|O for|O the|O development|O ,|O proliferation|O ,|O and|O survival|O of|O MC|O .|O 
Interaction|O of|O c-kit|gene-protein with|O its|O ligand|O stem|gene-protein cell|gene-protein factor|gene-protein induces|O dimerization|O ,|O receptor|O phosphorylation|O ,|O and|O signal|O transduction|O .|O 
The|O most|O common|O c-kit|gene-rna mutation|O detected|O in|O neoplastic|O MCD|O is|O Asp|O 816|O Val|O ,|O which|O results|O in|O ligand|O -|O independent|O autophosphorylation|O of|O the|O receptor|gene-protein leading|O to|O MC|O proliferation|O .|O 
We|O describe|O the|O rare|O occurrence|O of|O MCD|O associated|O with|O acute|O myeloid|O leukemia|O ,|O report|O a|O novel|O c-kit|gene-rna mutation|O Asp|O 816|O His|O ,|O and|O discuss|O the|O pathogenesis|O of|O MCD|O associated|O with|O hematologic|O malignancies|O .|O 
Molecular|O changes|O in|O second|O primary|O lung|O and|O breast|O cancers|O after|O therapy|O for|O Hodgkin|O 's|O disease|O .|O 
The|O risk|O of|O lung|O and|O breast|O cancer|O is|O significantly|O increased|O after|O therapy|O for|O Hodgkin|O 's|O disease|O (|O HD|O )|O ,|O but|O there|O are|O few|O data|O that|O describe|O the|O molecular|O profiles|O of|O these|O tumors|O .|O 
We|O investigated|O the|O genetic|O abnormalities|O in|O second|O primary|O lung|O (|O n|O =|O 19|O )|O and|O breast|O cancers|O (|O n|O =|O 19|O )|O that|O follow|O therapy|O for|O HD|O (|O "|O post|O -|O HD|O cancers|O "|O )|O and|O compared|O these|O with|O changes|O observed|O in|O corresponding|O tumor|O types|O (|O 57|O lung|O and|O 20|O breast|O cancers|O )|O arising|O in|O the|O general|O population|O (|O "|O sporadic|O cancers|O "|O )|O .|O 
DNA|O obtained|O from|O archival|O tissues|O was|O examined|O using|O PCR|O -|O based|O analyses|O for|O loss|O of|O heterozygosity|O and|O microsatellite|O alterations|O (|O MAs|O )|O at|O several|O chromosomal|O regions|O ,|O TP53|gene-rna and|O K-ras|gene-rna gene|O mutations|O ,|O and|O frameshift|O mutations|O at|O minisatellite|O sequences|O at|O the|O coding|O regions|O of|O several|O genes|O (|O TGF-betaRII|gene-rna ,|O IGFIIR|gene-rna ,|O BAX|gene-rna ,|O hMSH6|gene-rna ,|O and|O hMSH3|gene-rna )|O .|O 
The|O occurrence|O of|O loss|O of|O heterozygosity|O at|O all|O chromosomal|O regions|O taken|O together|O and|O frequencies|O at|O most|O individual|O areas|O were|O similar|O for|O the|O post|O -|O HD|O and|O sporadic|O cancers|O for|O both|O lung|O and|O breast|O sites|O .|O 
The|O overall|O frequency|O of|O MAs|O in|O the|O post|O -|O HD|O tumors|O was|O substantially|O greater|O (|O lung|O ,|O 2.4|O -|O fold|O ,|O P|O =|O 0.004|O ;|O breast|O ,|O 4.2|O -|O fold|O ,|O P|O =|O 0.16|O )|O than|O that|O in|O the|O respective|O sporadic|O cancers|O .|O 
No|O differences|O in|O the|O pattern|O of|O TP53|gene-rna and|O K-ras|gene-rna mutations|O were|O detected|O between|O post|O -|O HD|O and|O sporadic|O cancers|O .|O 
No|O mutations|O were|O detected|O at|O the|O minisatellite|O sequences|O examined|O .|O 
MAs|O ,|O which|O reflect|O widespread|O genomic|O instability|O ,|O occur|O at|O greatly|O increased|O frequency|O in|O post|O -|O HD|O lung|O and|O breast|O cancers|O .|O 
Although|O the|O mechanisms|O underlying|O the|O development|O of|O increased|O MAs|O are|O unknown|O ,|O they|O have|O been|O associated|O with|O immunosuppression|O and|O radiation|O exposure|O .|O 
Future|O research|O should|O address|O the|O role|O that|O MAs|O ,|O as|O well|O as|O other|O influences|O ,|O may|O play|O in|O the|O development|O of|O neoplasias|O that|O occur|O after|O therapy|O for|O HD|O .|O 
Detection|O of|O c-kit|gene-rna mutation|O Asp|O 816|O to|O Val|O in|O microdissected|O bone|O marrow|O infiltrates|O in|O a|O case|O of|O systemic|O mastocytosis|O associated|O with|O chronic|O myelomonocytic|O leukaemia|O .|O 
BACKGROUND|O /|O AIMS|O :|O 
The|O occurrence|O of|O myeloid|O leukaemia|O in|O patients|O with|O systemic|O mastocytosis|O is|O a|O well|O recognised|O phenomenon|O .|O 
However|O ,|O the|O pathophysiological|O basis|O of|O such|O a|O coevolution|O has|O not|O been|O clarified|O .|O 
Recent|O data|O have|O shown|O that|O the|O c-kit|gene-rna mutation|O Asp|O 816|O to|O Val|O is|O detectable|O in|O neoplastic|O mast|O cells|O in|O most|O patients|O with|O systemic|O mastocytosis|O ,|O including|O those|O who|O have|O associated|O haematological|O disorders|O .|O 
The|O aim|O of|O this|O study|O was|O to|O study|O clonal|O disease|O evolution|O by|O analysing|O bone|O marrow|O cells|O from|O a|O patient|O with|O systemic|O mastocytosis|O and|O associated|O chronic|O myelomonocytic|O leukaemia|O (|O CMML|O )|O for|O the|O presence|O of|O this|O mutation|O .|O 
METHODS|O :|O 
The|O DNA|O of|O microdissected|O bone|O marrow|O cells|O from|O a|O patient|O with|O systemic|O mastocytosis|O and|O associated|O CMML|O was|O analysed|O for|O the|O presence|O of|O the|O c-kit|gene-rna mutation|O Asp|O 816|O to|O Val|O by|O means|O of|O HinfI|gene-protein digestion|O and|O direct|O sequencing|O of|O semi|O -|O nested|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O products|O .|O 
RESULTS|O :|O 
The|O two|O neoplasms|O could|O easily|O be|O identified|O and|O discriminated|O in|O paraffin|O wax|O embedded|O bone|O marrow|O sections|O by|O tryptase|gene-protein and|O chloroacetate|gene-protein esterase|gene-protein staining|O .|O 
A|O total|O number|O of|O 10|O tryptase|gene-protein positive|O systemic|O mastocytosis|O infiltrates|O and|O 10|O tryptase|gene-protein negative|O CMML|O infiltrates|O were|O removed|O by|O microdissection|O .|O 
As|O assessed|O by|O HinfI|gene-protein digestion|O and|O direct|O sequencing|O of|O semi|O -|O nested|O PCR|O products|O ,|O the|O c-kit|gene-rna mutation|O Asp|O 816|O to|O Val|O was|O detected|O in|O five|O of|O seven|O systemic|O mastocytosis|O infiltrates|O and|O four|O of|O six|O CMML|O infiltrates|O .|O 
By|O contrast|O ,|O no|O c-kit|gene-rna mutation|O Asp|O 816|O to|O Val|O was|O found|O in|O bone|O marrow|O infiltrates|O in|O patients|O with|O CMML|O without|O associated|O systemic|O mastocytosis|O (|O n|O =|O 20|O )|O .|O 
CONCLUSION|O :|O 
These|O data|O support|O a|O monoclonal|O evolution|O of|O systemic|O mastocytosis|O and|O concurrent|O CMML|O in|O the|O patient|O studied|O .|O 
Activation|O of|O the|O beta-catenin|gene-rna gene|O by|O interstitial|O deletions|O involving|O exon|O 3|O as|O an|O early|O event|O in|O colorectal|O tumorigenesis|O .|O 
beta-Catenin|gene-rna has|O been|O identified|O as|O an|O oncogene|O in|O several|O tumors|O including|O colorectal|O cancers|O .|O 
beta-Catenin|gene-rna gene|O is|O activated|O by|O interstitial|O deletions|O involving|O exon|O 3|O in|O colorectal|O carcinomas|O of|O Japanese|O population|O ,|O in|O contrast|O to|O amino|O acid|O substitutions|O detected|O among|O Caucasian|O population|O .|O 
The|O aim|O of|O this|O study|O was|O to|O examine|O the|O type|O and|O frequency|O of|O beta-catenin|gene-rna gene|O mutation|O during|O early|O stages|O of|O colorectal|O tumorigenesis|O .|O 
We|O screened|O 100|O colorectal|O adenomas|O for|O somatic|O mutations|O in|O the|O beta-catenin|gene-rna gene|O by|O single|O -|O strand|O conformation|O polymorphism|O method|O ,|O as|O well|O as|O polymerase|gene-protein chain|O reaction|O amplification|O .|O 
In|O cases|O with|O mutations|O ,|O sequencing|O analyses|O and|O immunohistochemical|O staining|O were|O also|O performed|O .|O 
Somatic|O interstitial|O deletions|O of|O 272|O -|O 413|O bp|O ,|O each|O of|O which|O included|O all|O parts|O of|O exon|O 3|O ,|O were|O detected|O in|O three|O tumors|O .|O 
However|O ,|O no|O adenoma|O carried|O missense|O mutations|O .|O 
We|O confirmed|O accumulation|O of|O aberrant|O beta-catenin|gene-protein protein|O in|O cytoplasm|O and|O nuclei|O of|O adenoma|O cells|O by|O immunohistochemical|O analysis|O .|O 
Our|O results|O suggested|O that|O activation|O of|O the|O beta-catenin|gene-rna gene|O by|O interstitial|O deletions|O involving|O exon|O 3|O might|O be|O less|O frequent|O compared|O with|O frequent|O alterations|O of|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|O APC|gene-rna )|O gene|O ,|O but|O could|O be|O an|O early|O event|O in|O colorectal|O tumorigenesis|O equivalent|O to|O APC|gene-rna gene|O alterations|O in|O the|O Japanese|O population|O .|O 
High|O frequency|O of|O K-ras|gene-rna mutations|O in|O biliary|O duct|O carcinomas|O of|O cases|O with|O a|O long|O common|O channel|O in|O the|O papilla|O of|O Vater|O .|O 
The|O frequency|O of|O K-ras|gene-rna mutation|O in|O biliary|O duct|O carcinomas|O in|O different|O locations|O and|O the|O relationship|O to|O the|O form|O of|O the|O junction|O of|O the|O pancreaticobiliary|O duct|O (|O JPBD|O )|O are|O not|O understood|O clearly|O .|O 
These|O points|O were|O investigated|O in|O the|O present|O study|O .|O 
Thirty-seven|O biliary|O duct|O carcinomas|O in|O patients|O without|O anomalous|O JPBD|O were|O investigated|O for|O K-ras|gene-rna mutations|O .|O 
Regarding|O location|O ,|O 12|O were|O hilar|O ,|O 4|O in|O the|O upper|O ,|O 11|O in|O the|O middle|O ,|O and|O 10|O in|O the|O lower|O portion|O of|O the|O duct|O .|O 
Furthermore|O ,|O with|O 14|O cases|O for|O which|O the|O form|O of|O the|O JPBD|O could|O be|O confirmed|O by|O endoscopic|O retrograde|O cholangiopancreatography|O or|O postoperative|O cholangiopancreatography|O ,|O division|O was|O made|O into|O two|O types|O :|O those|O with|O a|O long|O common|O channel|O (|O >|O 5|O mm|O )|O in|O the|O papilla|O of|O Vater|O (|O type|O 1|O ,|O n|O =|O 4|O )|O ,|O and|O the|O other|O with|O a|O shorter|O or|O nonapparent|O common|O channel|O (|O type|O 2|O ,|O n|O =|O 10|O )|O .|O 
The|O overall|O frequency|O of|O K-ras|gene-rna mutation|O was|O 30|O %|O ,|O the|O incidence|O gradually|O increasing|O from|O upper|O to|O lower|O regions|O .|O 
K-ras|gene-rna mutations|O were|O significantly|O more|O frequent|O in|O biliary|O duct|O carcinomas|O associated|O with|O long|O common|O channels|O (|O P|O <|O 0.05|O )|O .|O 
These|O results|O suggest|O that|O a|O long|O common|O channel|O may|O bear|O a|O relation|O to|O K-ras|gene-rna mutations|O in|O biliary|O duct|O carcinogenesis|O ,|O presumably|O through|O its|O influence|O on|O pancreatic|O juice|O regurgitation|O .|O 
Rapid|O and|O reliable|O detection|O of|O N-ras|gene-rna mutations|O in|O acute|O lymphoblastic|O leukemia|O by|O melting|O curve|O analysis|O using|O LightCycler|O technology|O .|O 
We|O applied|O a|O new|O strategy|O for|O the|O detection|O of|O N-ras|gene-rna gene|O mutations|O based|O on|O LightCycler|O technology|O .|O 
We|O designed|O two|O sets|O of|O amplimers|O and|O internal|O hybridization|O probes|O representing|O N-ras|gene-rna codons|O 12|O /|O 13|O and|O codon|O 61|O ,|O respectively|O .|O 
Genomic|O DNAs|O from|O 134|O childhood|O acute|O lymphoblastic|O leukemia|O (|O ALL|O )|O patients|O (|O 83|O common|O ALL|O ,|O nine|O pre|O -|O pre|O -|O B|O ALL|O ,|O 19|O pre|O -|O B|O ALL|O ,|O 23|O T|O -|O ALL|O )|O were|O amplified|O ,|O followed|O by|O the|O analysis|O of|O the|O melting|O temperatures|O of|O the|O PCR|O products|O on|O the|O LightCycler|O .|O 
PCR|O products|O exhibiting|O an|O abnormal|O melting|O characteristic|O were|O directly|O sequenced|O .|O 
Sequence|O analyses|O unravelled|O nucleotide|O substitutions|O at|O codon|O 12|O in|O 10|O patients|O ,|O at|O codon|O 13|O in|O three|O ,|O and|O at|O codon|O 61|O in|O one|O case|O .|O 
The|O incidence|O of|O N-ras|gene-rna mutations|O (|O 10|O %|O )|O is|O compatible|O with|O previous|O reports|O .|O 
The|O LightCycler|O technology|O facilitates|O the|O rapid|O analysis|O of|O other|O genes|O exhibiting|O hot|O spot|O mutations|O in|O human|O malignancies|O .|O 
Ras|gene-rna mutations|O are|O uncommon|O in|O sporadic|O thyroid|O cancer|O in|O children|O and|O young|O adults|O .|O 
Mutations|O in|O the|O ras|gene-rna genes|O (|O H-ras|gene-rna ,|O K-ras|gene-rna ,|O and|O N-ras|gene-rna )|O occur|O in|O 10|O -|O 15|O %|O of|O all|O human|O cancers|O ,|O and|O commonly|O arise|O from|O single|O base|O substitutions|O at|O codons|O 12|O ,|O 13|O ,|O or|O 61|O .|O 
Although|O ras|gene-rna mutations|O have|O been|O found|O in|O adult|O thyroid|O cancers|O ,|O they|O were|O absent|O from|O the|O two|O studies|O which|O examined|O childhood|O thyroid|O cancers|O .|O 
Both|O studies|O included|O only|O children|O with|O radiation|O induced|O thyroid|O cancer|O ,|O and|O it|O remains|O unclear|O if|O ras|gene-rna mutations|O occur|O in|O children|O without|O radiation|O exposure|O .|O 
To|O answer|O this|O question|O ,|O we|O examined|O archival|O tissue|O blocks|O from|O 31|O children|O with|O papillary|O thyroid|O cancer|O (|O PTC|O )|O 4|O with|O follicular|O thyroid|O cancer|O (|O FTC|O )|O ,|O 2|O with|O medullary|O thyroid|O cancer|O (|O MTC|O )|O ,|O and|O 1|O with|O lymphoma|O (|O LYM|O )|O .|O 
Only|O 1|O patient|O with|O PTC|O had|O previous|O radiation|O exposure|O .|O 
Genomic|O DNA|O was|O extracted|O and|O used|O for|O PCR|O amplification|O of|O the|O ras|gene-rna genes|O .|O 
The|O PCR|O products|O were|O analyzed|O by|O oligospecific|O hybridization|O for|O mutations|O at|O codons|O 12|O ,|O 13|O ,|O and|O 61|O .|O 
Two|O of|O the|O PTCs|O (|O 6.5|O %|O )|O contained|O ras|gene-rna mutations|O .|O 
Both|O patients|O had|O class|O II|O disease|O and|O no|O history|O of|O previous|O radiation|O exposure|O .|O 
One|O patient|O subsequently|O developed|O bone|O and|O lung|O metastases|O .|O 
The|O patient|O with|O lymphoma|O also|O had|O a|O ras|gene-rna mutation|O (|O N|gene-rna -|O 61|O )|O ,|O but|O ras|gene-rna mutations|O were|O absent|O from|O all|O FTC|O and|O MTC|O .|O 
These|O results|O suggest|O that|O ras|gene-rna mutations|O are|O uncommon|O in|O spontaneous|O childhood|O thyroid|O cancer|O ,|O but|O occur|O with|O a|O frequency|O similar|O to|O that|O found|O in|O previous|O reports|O of|O adult|O differentiated|O thyroid|O cancers|O .|O 
The|O number|O of|O subjects|O was|O too|O small|O to|O determine|O if|O ras|gene-rna mutations|O are|O more|O common|O in|O patients|O with|O aggressive|O papillary|O thyroid|O cancer|O .|O 
Effect|O of|O c-kit|gene-rna mutation|O on|O prognosis|O of|O gastrointestinal|O stromal|O tumors|O .|O 
Gastrointestinal|O stromal|O tumor|O (|O GIST|O )|O is|O the|O most|O common|O mesenchymal|O tumor|O of|O the|O gastrointestinal|O tract|O .|O 
Gain|O -|O of|O -|O function|O mutations|O in|O the|O juxtamembrane|O domain|O of|O the|O c-kit|gene-rna gene|O have|O been|O found|O in|O several|O GISTs|O .|O 
In|O this|O study|O ,|O we|O examined|O the|O correlation|O between|O the|O presence|O of|O c-kit|gene-rna mutation|O and|O prognosis|O in|O 124|O cases|O of|O GIST|O .|O DNA|O samples|O were|O extracted|O from|O paraffin|O sections|O .|O 
Exon|O 11|O of|O the|O c-kit|gene-rna gene|O encoding|O the|O juxtamembrane|O domain|O and|O exon|O 17|O encoding|O the|O kinase|gene-protein domain|O were|O amplified|O by|O PCR|O and|O sequenced|O .|O 
Most|O GISTs|O (|O 89|O %|O )|O express|O the|O KIT|gene-protein protein|O ,|O and|O missense|O mutations|O of|O exon|O 11|O were|O found|O in|O 71|O of|O 124|O GISTs|O (|O 57|O %|O )|O .|O 
No|O mutations|O were|O detectable|O in|O exon|O 17|O .|O 
These|O 71|O mutation|O -|O positive|O GISTs|O were|O larger|O in|O size|O and|O had|O more|O frequently|O invaded|O adjacent|O tissues|O than|O did|O the|O 53|O mutation|O -|O negative|O GISTs|O .|O 
Histologically|O ,|O the|O mutation|O -|O positive|O GISTs|O showed|O higher|O mitotic|O figures|O and|O more|O necrosis|O and|O hemorrhage|O .|O 
The|O patients|O with|O mutation|O -|O positive|O GISTs|O showed|O more|O frequent|O recurrences|O (|O P|O =|O 0.0005|O )|O and|O higher|O mortality|O (|O P|O =|O 0.0001|O )|O than|O did|O those|O with|O mutation|O -|O negative|O GISTs|O .|O 
The|O c-kit|gene-rna mutation|O was|O an|O independent|O prognostic|O factor|O for|O overall|O and|O cause|O -|O specific|O survival|O of|O the|O patients|O with|O GISTs|O .|O 
These|O results|O suggest|O that|O GISTs|O may|O be|O divided|O into|O mutation|O -|O positive|O and|O -|O negative|O subtypes|O .|O 
The|O prognosis|O was|O worse|O in|O patients|O with|O mutation|O -|O positive|O GISTs|O than|O in|O those|O with|O mutation|O -|O negative|O GISTs|O .|O 
Thus|O ,|O mutation|O of|O the|O c-kit|gene-rna gene|O may|O be|O a|O good|O prognostic|O marker|O of|O GISTs|O .|O 
Activating|O c-kit|gene-rna gene|O mutations|O in|O human|O germ|O cell|O tumors|O .|O 
The|O c-kit|gene-rna gene|O encodes|O a|O tyrosine|gene-protein kinase|gene-protein receptor|gene-protein (|O KIT|gene-protein )|O that|O is|O required|O in|O normal|O spermatogenesis|O and|O is|O expressed|O in|O seminomas|O and|O dysgerminomas|O ,|O a|O subset|O of|O human|O germ|O cell|O tumors|O (|O GCTs|O )|O .|O 
To|O determine|O whether|O activating|O mutations|O of|O the|O c-kit|gene-rna gene|O occur|O in|O GCTs|O ,|O primary|O tissue|O samples|O of|O 33|O testicular|O and|O ovarian|O tumors|O were|O examined|O for|O mutations|O in|O the|O juxtamembrane|O and|O phosphotransferase|gene-protein domains|O by|O polymerase|gene-protein chain|O reaction|O amplification|O and|O DNA|O sequencing|O .|O 
A|O novel|O missense|O mutation|O (|O D|O 816|O H|O )|O was|O found|O in|O the|O phosphotransferase|gene-protein domain|O in|O tumors|O of|O seminoma|O /|O dysgerminoma|O differentiation|O .|O 
The|O c-kit|gene-rna alleles|O in|O nonneoplastic|O tissues|O from|O these|O patients|O were|O wild|O type|O ,|O suggesting|O that|O the|O mutant|O alleles|O were|O acquired|O and|O selected|O for|O during|O malignant|O transformation|O .|O 
In|O cell|O transfection|O experiments|O ,|O the|O D|O 816|O H|O mutant|O protein|gene-protein was|O a|O constitutively|O activated|O kinase|gene-protein and|O was|O constitutively|O phosphorylated|O on|O tyrosine|O residues|O .|O 
This|O is|O the|O first|O description|O of|O an|O activating|O c-kit|gene-rna mutation|O in|O GCTs|O and|O is|O evidence|O that|O the|O KIT|gene-protein signal|O transduction|O pathway|O is|O important|O in|O the|O pathogenesis|O of|O neoplasms|O with|O seminoma|O differentiation|O .|O 
A|O clinicopathologic|O and|O immunohistochemical|O study|O of|O 22|O intraductal|O papillary|O mucinous|O neoplasms|O of|O the|O pancreas|O ,|O with|O a|O review|O of|O the|O literature|O .|O 
Intraductal|O papillary|O -|O mucinous|O neoplasms|O (|O IPMNs|O )|O of|O the|O pancreas|O are|O rare|O lesions|O .|O 
We|O undertook|O this|O study|O to|O analyze|O these|O tumors|O by|O focusing|O on|O the|O diagnostic|O criteria|O and|O correlating|O the|O histologic|O features|O with|O clinical|O prognosis|O .|O 
Twenty-two|O cases|O of|O IPMN|O were|O retrieved|O from|O the|O Endocrine|O Tumor|O Registry|O of|O the|O Armed|O Forces|O Institute|O of|O Pathology|O .|O 
Blocks|O or|O unstained|O slides|O were|O available|O for|O histochemical|O and|O immunohistochemical|O studies|O (|O including|O proliferative|O markers|O and|O cell|O cycle|O regulators|O )|O and|O K-ras|gene-rna oncogene|O mutations|O in|O 15|O cases|O .|O 
Patient|O follow|O -|O up|O was|O obtained|O in|O all|O of|O the|O cases|O .|O 
IPMN|O occurs|O in|O both|O genders|O with|O a|O slight|O male|O predominance|O ,|O with|O a|O mean|O age|O at|O presentation|O of|O 64.4|O years|O (|O range|O ,|O 48|O -|O 85|O yr|O )|O .|O 
The|O patients|O presented|O with|O abdominal|O pain|O .|O 
The|O neoplasms|O were|O radiologically|O and|O grossly|O cystic|O ,|O usually|O (|O 18|O cases|O of|O 22|O )|O located|O in|O the|O head|O of|O the|O pancreas|O .|O 
Histologically|O ,|O the|O tumors|O consisted|O of|O intraductal|O papillary|O proliferations|O protruding|O into|O and|O expanding|O the|O pancreatic|O ducts|O .|O 
Invasion|O into|O the|O surrounding|O pancreatic|O parenchyma|O was|O detected|O in|O 15|O cases|O .|O 
Chronic|O pancreatitis|O was|O present|O in|O all|O of|O the|O cases|O .|O 
p27|gene-protein immunoreactivity|O always|O exceeded|O the|O immunoreactivity|O of|O cyclin|gene-protein E|gene-protein .|O 
K-ras|gene-rna oncogene|O mutations|O were|O detected|O in|O two|O cases|O .|O 
Patients|O were|O treated|O with|O a|O complete|O surgical|O resection|O (|O n|O =|O 7|O )|O or|O a|O Whipple|O procedure|O (|O n|O =|O 13|O )|O .|O 
Only|O 2|O of|O 22|O patients|O died|O of|O disease|O (|O 3|O died|O immediately|O postoperatively|O and|O 3|O died|O of|O unrelated|O causes|O )|O ,|O whereas|O the|O remaining|O 14|O patients|O were|O alive|O at|O last|O follow|O -|O up|O ,|O without|O evidence|O of|O disease|O ,|O an|O average|O of|O 58.2|O months|O after|O initial|O presentation|O .|O 
IPMNs|O are|O rare|O ,|O distinctive|O neoplasms|O ,|O with|O complex|O intraductal|O papillae|O ,|O that|O can|O be|O easily|O separated|O from|O in|O situ|O ductal|O adenocarcinoma|O and|O mucinous|O cystic|O neoplasms|O .|O 
The|O high|O ratio|O of|O p27|gene-protein protein|O to|O cyclin|gene-protein E|gene-protein supports|O the|O excellent|O prognosis|O of|O these|O neoplasms|O ,|O despite|O the|O presence|O of|O invasion|O and|O K-ras|gene-rna oncogene|O mutation|O .|O 
Prognostic|O significance|O of|O K-ras|gene-rna codon|O 12|O mutations|O in|O patients|O with|O resected|O stage|O I|O and|O II|O non|O -|O small|O -|O cell|O lung|O cancer|O .|O 
PURPOSE|O :|O 
The|O aim|O of|O this|O study|O was|O to|O investigate|O the|O prognostic|O importance|O of|O codon|O 12|O K-ras|gene-rna mutations|O in|O patients|O with|O early|O -|O stage|O non|O -|O small|O -|O cell|O lung|O cancer|O (|O NSCLC|O )|O .|O 
PATIENTS|O AND|O METHODS|O :|O 
We|O identified|O 260|O patients|O with|O surgically|O resected|O stage|O I|O (|O n|O =|O 193|O )|O and|O stage|O II|O (|O n|O =|O 67|O )|O NSCLC|O with|O at|O least|O a|O 5|O -|O year|O follow|O -|O up|O .|O 
We|O performed|O polymerase|gene-protein chain|O reaction|O analysis|O of|O DNA|O obtained|O from|O paraffin|O -|O embedded|O NSCLC|O tissue|O ,|O using|O mutation|O -|O specific|O probes|O for|O codon|O 12|O K-ras|gene-rna .|O 
RESULTS|O :|O 
K-ras|gene-rna mutations|O were|O detected|O in|O 35|O of|O 213|O assessable|O specimens|O (|O 16.4|O %|O )|O .|O 
K-ras|gene-rna mutations|O were|O detected|O in|O 27|O of|O 93|O adenocarcinomas|O (|O 29.0|O %|O )|O ,|O one|O of|O 61|O squamous|O cell|O carcinomas|O (|O 1.6|O %|O )|O ,|O five|O of|O 39|O large|O -|O cell|O carcinomas|O (|O 12.8|O %|O )|O ,|O and|O two|O of|O 20|O adenosquamous|O carcinomas|O (|O 10|O %|O )|O (|O P|O =|O .001|O )|O .|O 
G|O to|O T|O transversions|O accounted|O for|O 71|O %|O of|O the|O mutations|O .|O 
There|O was|O no|O statistically|O significant|O difference|O in|O overall|O survival|O for|O all|O patients|O with|O K-ras|gene-rna mutations|O (|O median|O survival|O ,|O 39|O months|O )|O compared|O with|O patients|O without|O K-ras|gene-rna mutations|O (|O median|O survival|O ,|O 53|O months|O ;|O P|O =|O .33|O )|O .|O 
There|O was|O no|O statistically|O significant|O difference|O in|O overall|O or|O disease|O -|O free|O survival|O for|O subgroups|O with|O stage|O I|O disease|O ,|O adenocarcinoma|O ,|O or|O non|O -|O squamous|O cell|O carcinoma|O or|O for|O specific|O amino|O acid|O substitutions|O .|O 
The|O median|O survival|O time|O for|O stage|O II|O patients|O with|O K-ras|gene-rna mutations|O was|O 13|O months|O ,|O compared|O with|O 38|O months|O for|O patients|O without|O K-ras|gene-rna mutations|O (|O P|O =|O .03|O )|O .|O 
CONCLUSION|O :|O 
Codon|O 12|O K-ras|gene-rna mutations|O were|O more|O common|O in|O adenocarcinomas|O than|O in|O squamous|O cell|O carcinomas|O .|O 
For|O the|O subgroup|O with|O stage|O II|O NSCLC|O ,|O there|O was|O a|O statistically|O significant|O adverse|O effect|O on|O survival|O for|O the|O presence|O of|O K-ras|gene-rna mutations|O .|O 
However|O ,|O when|O the|O entire|O group|O was|O considered|O ,|O the|O presence|O of|O K-ras|gene-rna mutations|O was|O not|O of|O prognostic|O significance|O in|O this|O cohort|O of|O patients|O with|O resected|O early|O -|O stage|O NSCLC|O .|O 
Frequent|O nuclear|O /|O cytoplasmic|O localization|O of|O beta-catenin|gene-protein without|O exon|O 3|O mutations|O in|O malignant|O melanoma|O .|O 
Beta-Catenin|gene-protein has|O a|O critical|O role|O in|O E-cadherin|gene-protein -|O mediated|O cell|O -|O cell|O adhesion|O ,|O and|O it|O also|O functions|O as|O a|O downstream|O signaling|O molecule|O in|O the|O wnt|gene-generic pathway|O .|O 
Mutations|O in|O the|O putative|O glycogen|gene-protein synthase|gene-protein kinase|gene-protein 3beta|gene-protein phosphorylation|O sites|O near|O the|O beta-catenin|gene-protein amino|O terminus|O have|O been|O found|O in|O some|O cancers|O and|O cancer|O cell|O lines|O .|O 
The|O mutations|O render|O beta-catenin|gene-protein resistant|O to|O regulation|O by|O a|O complex|O containing|O the|O glycogen|gene-protein synthase|gene-protein kinase|gene-protein 3beta|gene-protein ,|O adenomatous|gene-protein polyposis|gene-protein coli|gene-protein ,|O and|O axin|gene-protein proteins|O .|O 
As|O a|O result|O ,|O beta-catenin|gene-protein accumulates|O in|O the|O cytosol|O and|O nucleus|O and|O activates|O T-cell|gene-protein factor|gene-protein /|O lymphoid|gene-protein enhancing|gene-protein factor|gene-protein transcription|O factors|O .|O 
Previously|O ,|O 6|O of|O 27|O melanoma|O cell|O lines|O were|O found|O to|O have|O beta-catenin|gene-rna exon|O 3|O mutations|O affecting|O the|O N|O -|O terminal|O phosphorylation|O sites|O (|O Rubinfeld|O B|O ,|O Robbins|O P|O ,|O Elgamil|O M|O ,|O Albert|O I|O ,|O Porfiri|O E|O ,|O Polakis|O P|O :|O Stabilization|O of|O beta-catenin|gene-generic by|O genetic|O defects|O in|O melanoma|O cell|O lines|O .|O Science|O 1997|O ,|O 275|O :|O 1790|O -|O 1792|O )|O .|O 
To|O assess|O the|O role|O of|O beta-catenin|gene-generic defects|O in|O primary|O melanomas|O ,|O we|O undertook|O immunohistochemical|O and|O DNA|O sequencing|O studies|O in|O 65|O melanoma|O specimens|O .|O 
Nuclear|O and/or|O cytoplasmic|O localization|O of|O beta-catenin|gene-protein ,|O a|O potential|O indicator|O of|O wnt|gene-generic pathway|O activation|O ,|O was|O seen|O focally|O within|O roughly|O one|O third|O of|O the|O tumors|O ,|O though|O a|O clonal|O somatic|O mutation|O in|O beta-catenin|gene-rna was|O found|O in|O only|O one|O case|O (|O codon|O 45|O Ser|O -->|O Pro|O )|O .|O 
Our|O findings|O demonstrate|O that|O beta-catenin|gene-rna mutations|O are|O rare|O in|O primary|O melanoma|O ,|O in|O contrast|O to|O the|O situation|O in|O melanoma|O cell|O lines|O .|O 
Nonetheless|O ,|O activation|O of|O beta-catenin|gene-generic ,|O as|O indicated|O by|O its|O nuclear|O and/or|O cytoplasmic|O localization|O ,|O appears|O to|O be|O frequent|O in|O melanoma|O ,|O and|O in|O some|O cases|O ,|O it|O may|O reflect|O focal|O and|O transient|O activation|O of|O the|O wnt|gene-generic pathway|O within|O the|O tumor|O .|O 
Beta-catenin|gene-rna mutations|O in|O human|O prostate|O cancer|O .|O 
Beta-catenin|gene-protein plays|O essential|O roles|O in|O both|O intercellular|O adhesion|O and|O signal|O transduction|O .|O 
As|O a|O signaling|O molecule|O ,|O beta-catenin|gene-protein supplies|O an|O activating|O domain|O to|O the|O T-cell|gene-protein factor|gene-protein /|O lymphoid|gene-protein enhancer|gene-protein -|gene-protein binding|gene-protein factor|gene-protein family|O of|O DNA|O -|O binding|O proteins|O and|O activates|O gene|O transcription|O .|O 
Posttranslational|O stabilization|O of|O beta-catenin|gene-protein ,|O leading|O to|O elevated|O protein|O levels|O and|O constitutive|O gene|O activation|O ,|O has|O been|O proposed|O as|O an|O important|O step|O in|O oncogenesis|O .|O 
Stabilization|O of|O beta-catenin|gene-protein can|O occur|O through|O mutation|O to|O highly|O conserved|O amino|O acids|O encoded|O in|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O (|O CTNNB1|gene-rna )|O .|O 
To|O determine|O whether|O this|O pathway|O of|O malignant|O transformation|O is|O important|O in|O prostate|O cancer|O ,|O we|O analyzed|O 104|O prostate|O cancer|O tissue|O specimens|O ,|O 4|O prostate|O cancer|O cell|O lines|O ,|O and|O 3|O prostate|O tumor|O xenografts|O for|O activating|O mutations|O in|O exon|O 3|O of|O CTNNB1|gene-rna .|O 
Mutations|O were|O detected|O in|O 5|O of|O the|O 104|O prostate|O cancer|O tissue|O samples|O .|O 
Four|O of|O the|O five|O mutations|O involved|O serine|O or|O threonine|O residues|O implicated|O in|O the|O degradation|O of|O beta-catenin|gene-protein .|O 
A|O fifth|O tumor|O had|O a|O mutation|O at|O codon|O 32|O ,|O changing|O a|O highly|O conserved|O aspartic|O acid|O to|O a|O tyrosine|O .|O 
Mutational|O analysis|O of|O multiple|O regions|O from|O several|O tumor|O samples|O showed|O that|O the|O beta-catenin|gene-rna mutations|O were|O present|O focally|O and|O therefore|O may|O occur|O during|O tumor|O progression|O .|O 
K-ras|gene-rna mutations|O in|O sinonasal|O adenocarcinomas|O in|O patients|O occupationally|O exposed|O to|O wood|O or|O leather|O dust|O .|O 
Of|O 39|O males|O diagnosed|O with|O sinonasal|O adenocarcinomas|O over|O 30|O years|O in|O the|O Lund|O University|O Hospital|O catchment|O area|O (|O 1.5|O million|O inhabitants|O )|O ,|O archival|O tumor|O tissue|O was|O available|O from|O 29|O .|O 
Of|O these|O ,|O 16|O had|O been|O exposed|O to|O wood|O dust|O and|O three|O had|O been|O exposed|O to|O leather|O dust|O .|O 
The|O intestinal|O -|O type|O and|O papillary|O adenocarcinomas|O were|O more|O common|O in|O the|O exposed|O patients|O (|O P|O =|O 0.0002|O ,|O Fisher|O 's|O exact|O test|O )|O .|O 
The|O tumors|O from|O all|O but|O one|O of|O the|O 29|O sinonasal|O adenocarcinomas|O could|O be|O analyzed|O for|O point|O mutations|O at|O codons|O 12|O ,|O 13|O and|O 61|O of|O the|O K-ras|gene-rna gene|O .|O 
Four|O mutations|O were|O detected|O in|O the|O 28|O tumors|O .|O 
The|O three|O mutations|O in|O the|O patients|O exposed|O to|O wood|O and|O leather|O dust|O were|O all|O G|O :|O C|O -->|O A|O :|O T|O transitions|O ,|O with|O two|O at|O position|O 2|O of|O codon|O 12|O and|O one|O at|O position|O 2|O of|O codon|O 13|O .|O 
The|O high|O proportion|O of|O G|O :|O C|O -->|O A|O :|O T|O mutations|O in|O this|O rare|O tumor|O may|O reflect|O a|O genotoxic|O agent|O in|O wood|O and|O leather|O dust|O .|O 
Mutational|O analysis|O of|O the|O APC|gene-generic /|O beta-catenin|gene-generic /|O Tcf|gene-generic pathway|O in|O colorectal|O cancer|O .|O 
Mutation|O of|O the|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|gene-rna APC|gene-rna )|gene-rna tumor|gene-rna suppressor|gene-rna gene|gene-rna initiates|O the|O majority|O of|O colorectal|O (|O CR|O )|O cancers|O .|O 
One|O consequence|O of|O this|O inactivation|O is|O constitutive|O activation|O of|O beta-catenin|gene-generic /|O Tcf|gene-generic -|O mediated|O transcription|O .|O 
To|O further|O explore|O the|O role|O of|O the|O APC|gene-generic /|O beta-catenin|gene-generic /|O Tcf|gene-generic pathway|O in|O CR|O tumorigenesis|O ,|O we|O searched|O for|O mutations|O in|O genes|O implicated|O in|O this|O pathway|O in|O CR|O tumors|O lacking|O APC|gene-rna mutations|O .|O 
No|O mutations|O of|O the|O gamma-catenin|gene-rna (|O CTNNG1|gene-rna )|O ,|O GSK-3alpha|gene-rna (|O GSK3A|gene-rna )|O ,|O or|O GSK-3beta|gene-rna (|O GSK3B|gene-rna )|O genes|O were|O detected|O .|O 
In|O contrast|O ,|O mutations|O in|O the|O NH2|O -|O terminal|O regulatory|O domain|O of|O beta-catenin|gene-rna (|O CTNNB1|gene-rna )|O were|O found|O in|O 13|O of|O 27|O (|O 48|O %|O )|O CR|O tumors|O lacking|O APC|gene-rna mutations|O .|O 
Mutations|O in|O the|O beta-catenin|gene-rna regulatory|O domain|O and|O APC|gene-rna were|O observed|O to|O be|O mutually|O exclusive|O ,|O consistent|O with|O their|O equivalent|O effects|O on|O beta-catenin|gene-generic stability|O and|O Tcf|gene-generic transactivation|O .|O 
In|O addition|O ,|O we|O found|O that|O CTNNB1|gene-rna mutations|O can|O occur|O in|O the|O early|O ,|O adenomatous|O stage|O of|O CR|O neoplasia|O ,|O as|O has|O been|O observed|O previously|O with|O APC|gene-rna mutations|O .|O 
These|O results|O suggest|O that|O CTNNB1|gene-rna mutations|O can|O uniquely|O substitute|O for|O APC|gene-rna mutations|O in|O CR|O tumors|O and|O that|O beta-catenin|gene-generic signaling|O plays|O a|O critical|O role|O in|O CR|O tumorigenesis|O .|O 
K-ras|gene-rna point|O mutation|O occurs|O in|O the|O early|O stage|O of|O carcinogenesis|O in|O lung|O cancer|O .|O 
In|O order|O to|O determine|O the|O topographical|O distribution|O of|O the|O K-ras|gene-rna codon|O 12|O mutations|O in|O carcinoma|O and|O preneoplastic|O lesions|O of|O the|O lung|O ,|O selective|O ultraviolet|O radiation|O fractionation|O ,|O as|O well|O as|O microdissection|O followed|O by|O polymerase|gene-protein chain|O reaction|O -|O restriction|O fragment|O length|O polymorphism|O (|O PCR|O -|O RELP|O )|O ,|O was|O performed|O .|O 
Fourteen|O of|O 61|O samples|O amplified|O (|O 23.0|O %|O )|O had|O a|O mutation|O in|O the|O K-ras|gene-rna codon|O 12|O .|O 
Of|O 41|O adenocarcinoma|O ,|O 12|O samples|O (|O 29.3|O %|O )|O had|O a|O mutation|O ,|O whereas|O none|O of|O the|O squamous|O cell|O carcinomas|O had|O a|O mutation|O .|O 
One|O of|O six|O large|O -|O cell|O carcinomas|O ,|O one|O of|O three|O carcinoid|O tumours|O and|O none|O of|O three|O other|O carcinomas|O had|O a|O mutation|O .|O 
Direct|O sequencing|O revealed|O that|O K-ras|gene-rna codon|O 12|O of|O six|O samples|O were|O TGT|O (|O Cys|O )|O ,|O five|O samples|O were|O GTT|O (|O Val|O )|O ,|O two|O samples|O were|O GCT|O (|O Ala|O )|O and|O one|O sample|O was|O TTT|O (|O Phe|O )|O .|O 
A|O total|O of|O 113|O lesions|O of|O 13|O cases|O covered|O by|O dot|O were|O amplified|O after|O UV|O radiation|O .|O 
All|O of|O 74|O carcinoma|O lesions|O had|O the|O mutation|O ,|O and|O intratumour|O heterogeneity|O was|O not|O observed|O .|O 
Of|O 39|O non|O -|O malignant|O lesions|O ,|O one|O type|O II|O cell|O hyperplasia|O had|O the|O mutation|O ,|O which|O suggests|O that|O the|O K-ras|gene-rna mutation|O occurs|O in|O the|O early|O stage|O of|O carcinogenesis|O .|O 
The|O lack|O of|O intratumour|O heterogeneity|O supports|O the|O hypothesis|O .|O 
Molecular|O analysis|O of|O occupational|O cancer|O :|O infrequent|O p53|gene-rna and|O ras|gene-rna mutations|O in|O renal|O -|O cell|O cancer|O in|O workers|O exposed|O to|O gasoline|O .|O 
Occupational|O exposure|O to|O gasoline|O has|O been|O identified|O in|O several|O studies|O as|O a|O risk|O factor|O for|O renal|O -|O cell|O cancer|O .|O 
Cases|O of|O renal|O -|O cell|O cancer|O with|O and|O without|O work|O -|O related|O exposure|O to|O gasoline|O or|O gasoline|O and|O diesel|O fuel|O were|O studied|O for|O the|O presence|O of|O mutations|O in|O the|O tumour|gene-rna -|gene-rna suppressor|gene-rna gene|gene-rna p53|gene-rna (|O n|O =|O 23|O exposed|O and|O 30|O non|O -|O exposed|O cases|O studied|O )|O and|O ras|gene-rna oncogene|O (|O n|O =|O 30|O exposed|O and|O 36|O non|O -|O exposed|O cases|O studied|O )|O .|O 
An|O average|O cumulative|O exposure|O was|O estimated|O at|O 10|O ppm|O -|O years|O benzene|O among|O the|O exposed|O .|O 
Three|O p53|gene-rna mutations|O were|O detected|O by|O denaturing|O -|O gradient|O gel|O electrophoresis|O (|O DGGE|O )|O among|O the|O 23|O exposed|O cases|O (|O 3|O /|O 23|O ,|O 13|O %|O )|O .|O 
Of|O the|O non|O -|O exposed|O referent|O cases|O ,|O 4|O had|O a|O mutation|O (|O 4|O /|O 30|O ,|O 13|O %|O )|O .|O 
All|O but|O one|O of|O the|O cases|O with|O a|O p53|gene-rna mutation|O had|O smoked|O .|O 
A|O ras|gene-rna gene|O (|O K-ras|gene-rna or|O N-ras|gene-rna )|O mutation|O was|O found|O in|O 3|O (|O 3|O /|O 66|O ,|O 4.5|O %|O )|O cases|O ,|O all|O of|O whom|O were|O smoker|O referents|O .|O 
We|O conclude|O that|O p53|gene-rna and|O ras|gene-rna mutations|O are|O infrequent|O in|O renal|O -|O cell|O cancer|O associated|O with|O occupational|O exposure|O to|O gasoline|O .|O 
However|O ,|O the|O majority|O of|O the|O mutations|O (|O 6|O /|O 7|O for|O p53|gene-rna ,|O and|O 3|O /|O 3|O for|O ras|gene-rna genes|O )|O were|O seen|O in|O smokers|O .|O 
Mutations|O of|O the|O RAS|gene-rna genes|O in|O childhood|O acute|O myeloid|O leukemia|O ,|O myelodysplastic|O syndrome|O and|O juvenile|O chronic|O myelocytic|O leukemia|O .|O 
Using|O the|O polymerase|gene-protein chain|O reaction|O -|O single|O strand|O conformation|O polymorphism|O method|O and|O direct|O sequencing|O ,|O 12|O acute|O myeloid|O leukemia|O (|O AML|O )|O cell|O lines|O and|O 108|O fresh|O childhood|O myeloid|O tumor|O specimens|O ,|O including|O 67|O AML|O ,|O 29|O myelodysplastic|O syndrome|O (|O MDS|O )|O ,|O and|O 12|O juvenile|O chronic|O myelocytic|O leukemia|O (|O JCML|O )|O were|O examined|O for|O mutation|O in|O H|gene-rna -|gene-rna ,|O K|gene-rna -|gene-rna ,|O and|O N|gene-rna -|gene-rna RAS|gene-rna genes|O .|O 
The|O mutation|O was|O found|O in|O eight|O of|O the|O 120|O samples|O (|O 6.7|O %|O )|O ,|O which|O consisted|O of|O four|O cell|O lines|O (|O 33.3|O %|O )|O and|O four|O fresh|O myeloid|O tumors|O (|O 3.7|O %|O )|O .|O 
The|O frequency|O of|O the|O mutation|O in|O the|O cell|O lines|O was|O apparently|O higher|O than|O that|O in|O fresh|O myeloid|O tumors|O .|O 
K-RAS|gene-rna gene|O mutations|O were|O found|O in|O two|O of|O the|O 67|O fresh|O AML|O specimens|O (|O 3|O %|O )|O .|O 
Interestingly|O ,|O these|O two|O patients|O had|O 11q23|O translocations|O .|O 
The|O N-RAS|gene-rna gene|O mutation|O was|O found|O in|O one|O of|O the|O 29|O specimens|O (|O 3.4|O %|O )|O of|O MDS|O and|O in|O one|O of|O the|O 12|O specimens|O (|O 8.3|O %|O )|O of|O JCML|O .|O 
All|O mutations|O were|O found|O in|O codon|O 12|O ,|O 13|O or|O 61|O of|O the|O N-RAS|gene-rna and|O K-RAS|gene-rna genes|O .|O 
Frequency|O of|O mutation|O of|O RAS|gene-rna genes|O in|O fresh|O myeloid|O malignancies|O was|O very|O low|O .|O 
These|O findings|O suggest|O that|O mutation|O of|O RAS|gene-rna genes|O does|O not|O play|O an|O important|O role|O in|O the|O development|O of|O childhood|O myeloid|O malignancies|O .|O 
Frequent|O somatic|O mutations|O of|O the|O APC|gene-rna and|O p53|gene-rna genes|O in|O sporadic|O ampullary|O carcinomas|O .|O 
Although|O a|O close|O relation|O of|O somatic|O mutations|O of|O the|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna gene|O with|O ampullary|O carcinomas|O in|O familial|O adenomatous|O polyposis|O patients|O has|O been|O reported|O ,|O the|O possible|O association|O with|O sporadic|O ampullary|O neoplasms|O has|O not|O been|O fully|O examined|O .|O 
We|O have|O therefore|O investigated|O loss|O of|O heterozygosity|O at|O the|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna locus|O and|O the|O mutational|O status|O of|O a|O portion|O of|O the|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna gene|O ,|O including|O the|O mutation|O cluster|O region|O ,|O in|O 17|O ampullary|O carcinomas|O of|O non|O -|O familial|O adenomatous|O polyposis|O patients|O .|O 
Alteration|O of|O the|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna gene|O was|O found|O in|O 8|O of|O 17|O (|O 47.1|O %|O )|O cases|O ,|O as|O missense|O or|O insertion|O mutations|O ,|O with|O or|O without|O loss|O of|O heterozygosity|O .|O 
Additional|O investigation|O of|O p53|gene-rna (|O exons|O 5|O -|O 8|O )|O and|O K-ras|gene-rna (|O codons|O 12|O and|O 13|O )|O gene|O mutations|O revealed|O a|O striking|O mutational|O pattern|O of|O the|O p53|gene-rna gene|O .|O 
Nine|O of|O the|O 17|O cases|O demonstrated|O a|O total|O of|O 12|O mutations|O ,|O 6|O clustered|O at|O codon|O 189|O and|O 3|O at|O codon|O 166|O .|O 
Furthermore|O ,|O 5|O of|O the|O 12|O mutations|O were|O nonsense|O mutations|O .|O 
Regarding|O the|O K-ras|gene-rna gene|O ,|O 4|O of|O the|O 17|O (|O 23.5|O %|O )|O cases|O had|O mutations|O in|O codon|O 12|O ,|O 3|O of|O the|O 4|O cases|O being|O derived|O from|O the|O intraduodenal|O bile|O duct|O .|O 
The|O findings|O indicate|O that|O alterations|O of|O the|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna and|O the|O p53|gene-rna genes|O are|O relatively|O frequent|O in|O sporadic|O ampullary|O carcinomas|O .|O 
In|O particular|O ,|O the|O clustering|O at|O specific|O p53|gene-rna codons|O might|O offer|O an|O etiological|O clue|O to|O clarify|O ampullary|O carcinogenesis|O .|O 
Mutations|O of|O the|O K-ras|gene-rna gene|O ,|O on|O the|O other|O hand|O ,|O might|O be|O characteristic|O of|O intraduodenal|O bile|O duct|O origin|O .|O 
Frequent|O translocation|O t|O (|O 4|O ;|O 14|O )|O (|O p16.3|O ;|O q32.3|O )|O in|O multiple|O myeloma|O is|O associated|O with|O increased|O expression|O and|O activating|O mutations|O of|O fibroblast|gene-rna growth|gene-rna factor|gene-rna receptor|gene-rna 3|gene-rna .|O 
Dysregulation|O of|O oncogenes|O by|O translocation|O to|O the|O IgH|gene-rna locus|O (|O 14q32|O )|O is|O a|O seminal|O event|O in|O the|O pathogenesis|O of|O B-cell|O tumours|O .|O 
In|O multiple|O myeloma|O (|O MM|O )|O ,|O translocations|O to|O the|O IgH|gene-rna locus|O have|O been|O reported|O at|O an|O incidence|O of|O 20|O -|O 60|O %|O .|O 
For|O most|O translocations|O ,|O the|O partner|O chromosome|O is|O unknown|O (|O 14q|O +|O )|O ;|O for|O the|O others|O ,|O a|O diverse|O array|O of|O chromosomal|O partners|O have|O been|O identified|O ,|O with|O 11q13|O (|O cyclin|gene-rna D1|gene-rna )|O the|O only|O chromosome|O that|O is|O frequently|O involved|O .|O 
Recently|O ,|O we|O developed|O a|O Southern|O -|O blot|O assay|O that|O detects|O translocation|O breakpoint|O fragments|O in|O most|O MM|O tumours|O ,|O including|O those|O with|O no|O translocation|O detected|O by|O conventional|O karyotyping|O .|O 
In|O a|O continuing|O analysis|O of|O translocation|O in|O 21|O myeloma|O cell|O lines|O and|O primary|O tumours|O ,|O we|O show|O that|O the|O novel|O ,|O karyotypically|O silent|O translocation|O t|O (|O 4|O ;|O 14|O )|O (|O p16.3|O ;|O q32.3|O )|O is|O present|O in|O five|O lines|O and|O at|O least|O three|O of|O ten|O primary|O tumours|O .|O 
The|O chromosome|O -|O 4|O breakpoints|O are|O clustered|O in|O a|O 70|O -|O kb|O region|O centromeric|O to|O the|O fibroblast|gene-rna growth|gene-rna factor|gene-rna receptor|gene-rna 3|gene-rna gene|O (|O FGFR3|gene-rna )|O ,|O the|O apparent|O dysregulated|O oncogene|O .|O 
Two|O lines|O and|O one|O primary|O tumour|O with|O this|O translocation|O selectively|O express|O an|O FGFR3|gene-rna allele|O containing|O activating|O mutations|O identified|O previously|O in|O thanatophoric|O dwarfism|O .|O 
We|O propose|O that|O after|O the|O t|O (|O 4|O ;|O 14|O )|O translocation|O ,|O somatic|O mutation|O during|O tumour|O progression|O frequently|O generates|O in|O FGFR3|gene-protein protein|O that|O is|O active|O in|O the|O absence|O of|O ligand|O .|O 
No|O concomitant|O occurrence|O of|O the|O N-ras|gene-rna and|O p53|gene-rna gene|O mutations|O in|O myelodysplastic|O syndromes|O .|O 
Mutations|O of|O the|O N-ras|gene-rna oncogene|O and|O p53|gene-rna tumor|O suppressor|O gene|O were|O simultaneously|O investigated|O in|O bone|O marrow|O cells|O from|O 44|O patients|O with|O myelodysplastic|O syndrome|O (|O MDS|O )|O or|O MDS|O -|O derived|O leukemia|O by|O single|O -|O strand|O conformation|O polymorphism|O (|O SSCP|O )|O analysis|O followed|O by|O direct|O sequencing|O .|O 
The|O mutations|O of|O the|O N-ras|gene-rna gene|O were|O detected|O only|O in|O two|O cases|O with|O MDS|O -|O derived|O leukemia|O .|O 
Three|O patients|O with|O MDS|O -|O derived|O leukemia|O and|O one|O with|O refractory|O anemia|O with|O excess|O of|O blasts|O exhibited|O five|O mutations|O of|O the|O p53|gene-rna gene|O .|O 
No|O concomitant|O mutations|O of|O both|gene-rna genes|gene-rna were|O observed|O in|O our|O study|O ,|O suggesting|O that|O alterations|O of|O both|gene-rna genes|gene-rna could|O play|O an|O important|O role|O in|O the|O progression|O of|O MDS|O in|O a|O non|O -|O cooperative|O manner|O .|O 
c-kit|gene-rna Point|O mutation|O in|O patients|O with|O myeloproliferative|O disorders|O .|O 
Myeloproliferative|O disorders|O (|O MPD|O )|O constitute|O a|O group|O of|O hematopoietic|O neoplasms|O at|O the|O myeloid|O stem|O cell|O level|O .|O 
Myeloid|O stem|O cells|O and/or|O progenitor|O cells|O from|O MPD|O have|O been|O considered|O sensitive|O to|O hematopoietic|gene-protein growth|gene-protein factors|gene-protein ,|O including|O erythropoietin|gene-protein ,|O thrombopoietin|gene-protein and|O stem|gene-protein cell|gene-protein factor|gene-protein (|O SCF|gene-protein )|O .|O 
SCF|gene-protein is|O a|O ligand|O for|O c-kit|gene-protein receptor|gene-protein with|O tyrosine|gene-protein kinase|gene-protein .|O 
We|O analysed|O the|O gene|O alteration|O of|O the|O c-kit|gene-rna extracellular|O domain|O in|O MPD|O patients|O by|O PCR|O -|O SSCP|O and|O subsequent|O nucleotide|O sequencing|O .|O 
The|O point|O mutation|O in|O the|O N|O -|O terminal|O part|O of|O the|O domain|O ,|O codon|O 52|O (|O Asp|O -->|O Asn|O )|O ,|O was|O found|O in|O two|O patients|O with|O primary|O myelofibrosis|O and|O one|O with|O chronic|O myelogenous|O leukemia|O .|O 
We|O review|O the|O literature|O regarding|O the|O role|O of|O SCF|gene-protein /|O c-kit|gene-generic system|O in|O the|O oncogenesis|O of|O leukemia|O and|O MPD|O ,|O and|O then|O discuss|O the|O significance|O of|O our|O finding|O in|O the|O context|O of|O growth|O advantage|O of|O the|O mutated|O clones|O over|O the|O normal|O clones|O .|O 
N-ras|gene-rna gene|O point|O mutations|O in|O Brazilian|O acute|O myelogenous|O leukemia|O patients|O correlate|O with|O a|O poor|O prognosis|O .|O 
The|O frequency|O of|O ras|gene-rna gene|O mutations|O varies|O from|O 11|O to|O 27|O %|O in|O AML|O populations|O from|O the|O United|O States|O and|O Europe|O but|O it|O seems|O that|O there|O is|O no|O study|O regarding|O the|O frequency|O of|O mutated|O N-ras|gene-rna gene|O in|O patients|O with|O AML|O in|O South|O America|O .|O 
In|O order|O to|O study|O the|O frequency|O of|O N-ras|gene-rna gene|O mutations|O (|O exons|O 1|O and|O 2|O )|O in|O Brazilian|O patients|O with|O AML|O and|O to|O evaluate|O the|O possible|O correlation|O between|O the|O presence|O of|O the|O mutation|O and|O clinical|O features|O ,|O 40|O patients|O were|O analyzed|O .|O 
N-ras|gene-rna mutations|O were|O identified|O in|O DNA|O samples|O from|O eight|O of|O 40|O AML|O patients|O (|O 20|O %|O )|O .|O 
No|O significant|O correlation|O was|O found|O between|O N-ras|gene-rna mutation|O and|O age|O ,|O sex|O ,|O race|O ,|O response|O to|O therapy|O ,|O FAB|O subtype|O or|O occupational|O exposure|O .|O 
However|O ,|O the|O overall|O survival|O and|O AML|O -|O free|O survival|O were|O significantly|O shorter|O in|O patients|O with|O N-ras|gene-rna mutations|O than|O in|O those|O without|O these|O abnormalities|O .|O 
Germline|O and|O somatic|O mutations|O in|O the|O tyrosine|gene-protein kinase|gene-protein domain|O of|O the|O MET|gene-rna proto|O -|O oncogene|O in|O papillary|O renal|O carcinomas|O .|O 
Hereditary|O papillary|O renal|O carcinoma|O (|O HPRC|O )|O is|O a|O recently|O recognized|O form|O of|O inherited|O kidney|O cancer|O characterized|O by|O a|O predisposition|O to|O develop|O multiple|O ,|O bilateral|O papillary|O renal|O tumours|O .|O 
The|O pattern|O of|O inheritance|O of|O HPRC|O is|O consistent|O with|O autosomal|O dominant|O transmission|O with|O reduced|O penetrance|O .|O 
HPRC|O is|O histologically|O and|O genetically|O distinct|O from|O two|O other|O causes|O of|O inherited|O renal|O carcinoma|O ,|O von|O Hippel|O -|O Lindau|O disease|O (|O VHL|O )|O and|O the|O chromosome|O translocation|O (|O 3|O ;|O 8|O )|O .|O 
Malignant|O papillary|O renal|O carcinomas|O are|O characterized|O by|O trisomy|O of|O chromosomes|O 7|O ,|O 16|O and|O 17|O ,|O and|O in|O men|O ,|O by|O loss|O of|O the|O Y|O chromosome|O .|O 
Inherited|O and|O sporadic|O clear|O cell|O renal|O carcinomas|O are|O characterized|O by|O inactivation|O of|O both|O copies|O of|O the|O VHL|gene-rna gene|O by|O mutation|O ,|O and/or|O by|O hypermethylation|O .|O 
We|O found|O that|O the|O HPRC|O gene|O was|O located|O at|O chromosome|O 7q|O 31|O .|O 1|O -|O 34|O in|O a|O 27|O -|O centimorgan|O (|O cM|O )|O interval|O between|O D7S496|O and|O D7S1837|O .|O 
We|O identified|O missense|O mutations|O located|O in|O the|O tyrosine|gene-protein kinase|gene-protein domain|O of|O the|O MET|gene-rna gene|O in|O the|O germline|O of|O affected|O members|O of|O HPRC|O families|O and|O in|O a|O subset|O of|O sporadic|O papillary|O renal|O carcinomas|O .|O 
Three|O mutations|O in|O the|O MET|gene-rna gene|O are|O located|O in|O codons|O that|O are|O homologous|O to|O those|O in|O c-kit|gene-rna and|O RET|gene-rna ,|O proto|O -|O oncogenes|O that|O are|O targets|O of|O naturally|O -|O occurring|O mutations|O .|O 
The|O results|O suggest|O that|O missense|O mutations|O located|O in|O the|O MET|gene-rna proto|O -|O oncogene|O lead|O to|O constitutive|O activation|O of|O the|O MET|gene-protein protein|O and|O papillary|O renal|O carcinomas|O .|O 
Stabilization|O of|O beta-catenin|gene-protein by|O genetic|O defects|O in|O melanoma|O cell|O lines|O .|O 
Signal|O transduction|O by|O beta-catenin|gene-protein involves|O its|O posttranslational|O stabilization|O and|O downstream|O coupling|O to|O the|O Lef|gene-protein and|O Tcf|gene-protein transcription|O factors|O .|O 
Abnormally|O high|O amounts|O of|O beta-catenin|gene-protein were|O detected|O in|O 7|O of|O 26|O human|O melanoma|O cell|O lines|O .|O 
Unusual|O messenger|O RNA|O splicing|O and|O missense|O mutations|O in|O the|O beta-catenin|gene-rna gene|O (|O CTNNB1|gene-rna )|O that|O result|O in|O stabilization|O of|O the|gene-protein protein|gene-protein were|O identified|O in|O six|O of|O the|O lines|O ,|O and|O the|O adenomatous|gene-protein polyposis|gene-protein coli|gene-protein tumor|gene-protein suppressor|gene-protein protein|gene-protein (|O APC|gene-protein )|O was|O altered|O or|O missing|O in|O two|O others|O .|O 
In|O the|O APC|gene-protein -|O deficient|O cells|O ,|O ectopic|O expression|O of|O wild|O -|O type|O APC|gene-generic eliminated|O the|O excess|O beta-catenin|gene-protein .|O 
Cells|O with|O stabilized|O beta-catenin|gene-protein contained|O a|O constitutive|O beta-catenin|gene-protein -|O Lef-1|gene-protein complex|O .|O 
Thus|O ,|O genetic|O defects|O that|O result|O in|O up|O -|O regulation|O of|O beta-catenin|gene-generic may|O play|O a|O role|O in|O melanoma|O progression|O .|O 
Prevalence|O of|O activating|O ras|gene-rna mutations|O in|O morphologically|O characterized|O thyroid|O nodules|O .|O 
Ras|gene-protein proteins|O are|O signal|O -|O transducing|O proteins|O that|O share|O common|O properties|O with|O membrane|gene-protein -|gene-protein anchored|gene-protein G|gene-protein proteins|gene-protein .|O 
Mutations|O at|O codon|O 12|O /|O 13|O or|O codon|O 61|O alter|O GTP|O -|O binding|O or|O GTPase|gene-protein activity|O ,|O respectively|O .|O 
Such|O activating|O mutations|O are|O present|O in|O nearly|O 30|O -|O 50|O %|O of|O various|O malignancies|O including|O colon|O ,|O breast|O ,|O and|O lung|O carcinomas|O .|O 
There|O are|O conflicting|O data|O regarding|O the|O prevalence|O of|O ras|gene-rna mutations|O in|O the|O thyroid|O and|O their|O possible|O pathogenetic|O role|O in|O the|O different|O tumor|O types|O .|O 
To|O address|O this|O question|O ,|O we|O examined|O 45|O morphologically|O characterized|O thyroid|O carcinomas|O ,|O adenomas|O ,|O and|O hyperplastic|O nodules|O using|O a|O highly|O sensitive|O single|O -|O stranded|O conformation|O polymorphism|O (|O SSCP|O )|O approach|O combined|O with|O DNA|O -|O sequencing|O .|O 
DNA|O from|O cell|O lines|O with|O known|O mutations|O served|O as|O controls|O .|O 
A|O G|O to|O A|O H|gene-rna 13|O codon|O substitution|O replacing|O an|O Asp|O for|O a|O Gly|O residue|O was|O detected|O in|O 1|O papillary|O carcinoma|O .|O 
Although|O no|O H|gene-rna 12|O or|O H|gene-rna 61|O codon|O substitutions|O were|O identified|O ,|O 2|O discrete|O alterations|O were|O identified|O in|O codons|O H|gene-rna 17|O and|O 22|O .|O 
No|O N|gene-rna 12|O /|O 13|O codon|O substitutions|O were|O identified|O .|O 
N|gene-rna 61|O codon|O substitutions|O of|O A|O to|O G|O resulting|O in|O a|O Gly|O to|O Arg|O substitution|O were|O detected|O in|O 2|O papillary|O carcinomas|O ;|O the|O same|O mutation|O was|O also|O found|O in|O one|O follicular|O adenoma|O .|O 
Interestingly|O ,|O K|gene-rna 12|O /|O 13|O and|O K|gene-rna 61|O ras|gene-rna mutations|O were|O not|O present|O in|O any|O of|O the|O tumors|O examined|O .|O 
These|O data|O establish|O a|O low|O prevalence|O of|O mutations|O in|O all|O ras|gene-rna gene|O family|O members|O in|O human|O thyroid|O neoplasms|O .|O 
This|O difference|O from|O neoplasms|O of|O other|O organs|O may|O explain|O the|O relatively|O indolent|O biologic|O behavior|O of|O many|O thyroid|O tumors|O and|O supports|O an|O alternate|O early|O genetic|O mutation|O that|O is|O more|O characteristic|O of|O these|O neoplasms|O .|O 
Relevance|O of|O ultraviolet|O -|O induced|O N-ras|gene-rna oncogene|O point|O mutations|O in|O development|O of|O primary|O human|O cutaneous|O melanoma|O .|O 
Intermittent|O or|O recreational|O exposure|O to|O sunlight|O is|O thought|O to|O contribute|O to|O development|O of|O human|O cutaneous|O melanoma|O .|O 
We|O investigated|O the|O incidence|O of|O ras|gene-rna oncogene|O mutation|O in|O human|O cutaneous|O melanoma|O in|O connection|O to|O sun|O -|O exposed|O body|O sites|O in|O the|O patient|O ,|O using|O a|O large|O series|O of|O DNA|O samples|O derived|O from|O paraffin|O -|O embedded|O material|O as|O well|O as|O from|O fresh|O tumor|O samples|O and|O cell|O lines|O .|O 
We|O first|O show|O that|O ,|O of|O the|O ras|gene-rna family|O ,|O predominantly|O N-ras|gene-rna is|O activated|O (|O 15|O %|O )|O ,|O whereas|O rarely|O H-ras|gene-rna or|O K-ras|gene-rna are|O mutated|O .|O 
The|O occurrence|O of|O N-ras|gene-rna mutations|O correlates|O with|O continuous|O exposure|O to|O sunlight|O of|O the|O primary|O tumor|O site|O .|O 
Of|O all|O tumors|O initiated|O on|O chronically|O sun|O -|O exposed|O body|O sites|O ,|O 26|O %|O contained|O mutated|O N-ras|gene-rna ,|O in|O contrast|O to|O 0|O %|O of|O sun|O -|O protected|O melanomas|O .|O 
Melanoma|O lesions|O obtained|O from|O patients|O from|O North|O or|O Central|O Europe|O contained|O fewer|O N-ras|gene-rna mutations|O (|O 12|O %|O )|O as|O compared|O with|O patients|O from|O Australia|O (|O 24|O %|O )|O .|O 
Mutations|O were|O specifically|O associated|O with|O nodular|O melanoma|O and|O to|O a|O lesser|O extent|O with|O lentigo|O malignant|O melanoma|O .|O 
N-ras|gene-rna mutations|O did|O not|O correlate|O with|O metastasis|O or|O survival|O parameters|O .|O 
This|O study|O identifies|O a|O subset|O of|O cutaneous|O melanomas|O that|O contain|O in|O the|O primary|O lesion|O ultraviolet|O -|O induced|O N-ras|gene-rna mutations|O ,|O which|O are|O maintained|O through|O further|O progression|O .|O 
N-ras|gene-rna and|O p53|gene-rna gene|O mutations|O are|O very|O rare|O events|O in|O multiple|O myeloma|O .|O 
The|O frequencies|O of|O p53|gene-rna and|O N-ras|gene-rna gene|O mutations|O were|O examined|O in|O multiple|O myeloma|O .|O 
DNA|O samples|O of|O 45|O cases|O of|O multiple|O myeloma|O were|O obtained|O from|O stored|O bone|O marrow|O smears|O .|O 
All|O samples|O were|O analyzed|O for|O the|O N-ras|gene-rna gene|O at|O codon|O 12|O by|O the|O allele|O specific|O restriction|O analysis|O method|O and|O at|O codon|O 61|O by|O direct|O sequencing|O .|O 
DNA|O was|O screened|O for|O mutations|O by|O single|O -|O strand|O conformation|O polymorphism|O analysis|O for|O the|O p53|gene-rna gene|O in|O exons|O 5|O to|O 8|O .|O 
DNA|O fragments|O showing|O an|O altered|O electrophoretic|O pattern|O were|O further|O studied|O by|O direct|O sequencing|O to|O confirm|O the|O mutations|O .|O 
Ras|gene-rna mutations|O were|O found|O in|O two|O cases|O at|O codon|O 61|O (|O 4.4|O %|O )|O .|O 
A|O point|O mutation|O of|O the|O p53|gene-rna gene|O was|O detected|O in|O one|O of|O 45|O cases|O (|O 2.2|O %|O )|O .|O 
These|O 3|O cases|O with|O mutations|O were|O in|O an|O advanced|O stage|O .|O 
In|O conclusion|O ,|O N-ras|gene-rna and|O p53|gene-rna gene|O mutations|O may|O occur|O at|O a|O late|O stage|O of|O multiple|O myeloma|O ,|O but|O the|O frequencies|O of|O the|O mutations|O are|O very|O low|O .|O 
Detection|O of|O c-ras|gene-rna gene|O mutation|O and|O expression|O of|O p21|gene-protein protein|O in|O dysplasias|O and|O carcinomas|O complicating|O ulcerative|O colitis|O .|O 
Point|O mutations|O of|O c-ras|gene-rna genes|O and|O the|O expression|O of|O p21|gene-protein protein|O were|O analyzed|O in|O 13|O patients|O with|O colorectal|O carcinoma|O complicating|O ulcerative|O colitis|O ;|O in|O 12|O of|O the|O 13|O ,|O there|O were|O dysplastic|O lesions|O close|O to|O the|O carcinomas|O .|O 
Point|O mutations|O of|O c-ras|gene-rna genes|O were|O studied|O by|O polymerase|gene-protein chain|O reaction|O and|O dot|O blot|O hybridization|O with|O 32p|O -|O labeled|O oligonucleotide|O probes|O .|O 
Findings|O indicated|O mutations|O of|O c-Ki-ras|gene-rna at|O condons|O 12|O ,|O 13|O ,|O and|O 61|O and|O c-Ha-ras|gene-rna and|O c-N-ras|gene-rna at|O condons|O 12|O and|O 61|O .|O 
The|O expression|O of|O p21|gene-protein protein|O was|O analyzed|O by|O immunohistochemical|O staining|O using|O a|O monoclonal|O antibody|O .|O 
Only|O 1|O of|O the|O 13|O patients|O with|O carcinoma|O showed|O a|O point|O mutation|O ,|O this|O being|O from|O G|O to|O A|O transition|O at|O the|O second|O position|O of|O codon|O 12|O of|O c-Ki-ras|gene-rna .|O 
No|O point|O mutations|O of|O c-Ki-ras|gene-rna ,|O c-Ha-ras|gene-rna ,|O or|O c-N-ras|gene-rna were|O found|O in|O other|O carcinomatous|O lesions|O and|O dysplasias|O .|O 
In|O the|O dysplastic|O or|O carcinomatous|O lesions|O of|O 11|O patients|O ,|O the|O increased|O expression|O of|O p21|gene-protein protein|O was|O observed|O .|O 
These|O results|O suggest|O that|O point|O mutations|O of|O c-ras|gene-rna genes|O are|O rare|O in|O dysplasias|O and|O carcinomas|O complicating|O ulcerative|O colitis|O and|O that|O the|O increased|O expression|O of|O p21|gene-protein protein|O is|O not|O always|O correlated|O with|O point|O mutations|O of|O c-ras|gene-rna genes|O .|O 
Clonal|O analysis|O of|O multiple|O point|O mutations|O in|O the|O N-ras|gene-rna gene|O in|O patients|O with|O acute|O myeloid|O leukemia|O .|O 
We|O have|O screened|O mutations|O of|O the|O N-ras|gene-rna gene|O at|O codons|O 12|O ,|O 13|O ,|O and|O 61|O in|O leukemia|O cells|O obtained|O from|O 100|O patients|O with|O acute|O myeloid|O leukemia|O (|O AML|O )|O ,|O and|O found|O mutated|O N-ras|gene-rna alleles|O in|O 9|O patients|O .|O 
We|O further|O analyzed|O the|O polyclonality|O of|O multiple|O N-ras|gene-rna gene|O mutations|O in|O 4|O AML|O patients|O .|O 
One|O patient|O ,|O who|O had|O the|O monoclonal|O karyotype|O ,|O t|O (|O 11|O ;|O 17|O )|O ,|O had|O two|O types|O of|O double|O missense|O mutations|O at|O codons|O 13|O and|O 61|O in|O the|O same|O allele|O .|O 
Each|O of|O the|O remaining|O three|O patients|O ,|O one|O of|O whom|O had|O t|O (|O 15|O ;|O 17|O )|O with|O a|O monoclonal|O rearrangement|O of|O the|O retinoic|gene-rna acid|gene-rna receptor|gene-rna alpha|gene-rna and|O PML|gene-rna genes|O ,|O carried|O two|O missense|O mutations|O in|O a|O relatively|O small|O population|O of|O leukemia|O cells|O .|O 
We|O have|O demonstrated|O that|O multiple|O clonality|O of|O the|O N-ras|gene-rna gene|O is|O occasionally|O observed|O in|O leukemia|O with|O a|O monoclonal|O karyotype|O .|O 
These|O findings|O indicate|O that|O the|O N-ras|gene-rna mutations|O may|O not|O always|O be|O characterized|O simply|O by|O an|O accumulative|O process|O and|O that|O the|O activated|O N-ras|gene-rna gene|O alone|O is|O not|O sufficient|O to|O cause|O leukemia|O .|O 
High|O mutation|O frequency|O in|O ras|gene-rna genes|O of|O skin|O tumors|O isolated|O from|O DNA|O repair|O deficient|O xeroderma|O pigmentosum|O patients|O .|O 
Xeroderma|O pigmentosum|O (|O XP|O )|O patients|O are|O clinically|O characterized|O by|O a|O very|O high|O incidence|O of|O skin|O cancers|O on|O exposed|O skin|O ,|O at|O an|O early|O age|O .|O 
XP|O cells|O in|O vitro|O are|O strongly|O deficient|O in|O excision|O -|O repair|O and|O highly|O mutagenized|O by|O UV|O light|O .|O 
We|O were|O ,|O therefore|O ,|O interested|O in|O measuring|O mutation|O frequency|O and|O in|O determining|O mutation|O spectra|O in|O patients|O '|O tumors|O exposed|O to|O UV|O lesions|O .|O 
We|O chose|O to|O look|O at|O oncogene|O activation|O in|O skin|O tumors|O with|O the|O idea|O that|O more|O mutations|O ,|O particularly|O of|O the|O ras|gene-rna gene|O family|O ,|O would|O be|O found|O in|O XP|O tumors|O where|O lesions|O remain|O unrepaired|O compared|O to|O normal|O individuals|O .|O 
Our|O results|O clearly|O show|O that|O more|O than|O a|O 2|O -|O fold|O significantly|O higher|O mutation|O frequency|O (|O 50|O %|O )|O of|O the|O ras|gene-rna genes|O was|O found|O in|O XP|O in|O contrast|O to|O control|O tumors|O (|O 22|O %|O )|O .|O 
The|O majority|O of|O the|O mutations|O were|O found|O at|O codon|O 12|O of|O all|O three|O ras|gene-rna genes|O with|O a|O preponderance|O for|O N-ras|gene-rna in|O XP|O samples|O .|O 
The|O mutation|O spectra|O indicate|O that|O all|O mutations|O found|O were|O located|O opposite|O pyrimidine|O -|O pyrimidine|O sequences|O which|O represent|O a|O hot|O spot|O for|O UV|O -|O induced|O DNA|O lesions|O .|O 
Most|O of|O the|O mutations|O were|O of|O the|O type|O expected|O from|O studies|O performed|O in|O vitro|O with|O model|O systems|O .|O 
This|O high|O mutation|O frequency|O in|O XP|O was|O accompanied|O by|O a|O very|O high|O level|O of|O Ha-ras|gene-rna and|O c-myc|gene-rna gene|O amplification|O and|O rearrangement|O .|O 
All|O these|O data|O are|O consistent|O with|O a|O fundamental|O role|O of|O unrepaired|O UV|O -|O induced|O DNA|O lesions|O as|O an|O initiating|O event|O in|O human|O skin|O tumors|O on|O exposed|O parts|O of|O the|O body|O .|O 
N-ras|gene-rna mutation|O and|O karyotypic|O evolution|O are|O closely|O associated|O with|O leukemic|O transformation|O in|O myelodysplastic|O syndrome|O .|O 
We|O performed|O a|O longitudinal|O analysis|O of|O the|O karyotypes|O and|O N-ras|gene-rna gene|O configuration|O of|O bone|O marrow|O cells|O in|O 35|O patients|O with|O myelodysplastic|O syndrome|O (|O MDS|O )|O .|O 
Karyotypic|O evolution|O was|O found|O in|O eight|O patients|O ,|O and|O was|O associated|O with|O disease|O progression|O ,|O including|O leukemic|O transformation|O ,|O in|O all|O the|O patients|O .|O 
We|O identified|O N-ras|gene-rna mutations|O in|O six|O patients|O ,|O using|O a|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O technique|O ,|O in|O which|O oligonucleotide|O primers|O were|O constructed|O with|O induced|O mismatches|O ,|O followed|O by|O endonuclease|gene-protein digestion|O .|O 
Direct|O sequencing|O confirmed|O single|O base|O substitutions|O at|O codon|O 12|O in|O two|O patients|O and|O at|O codon|O 13|O in|O four|O .|O 
The|O incidence|O of|O N-ras|gene-rna gene|O mutations|O was|O significantly|O higher|O in|O the|O karyotypically|O evolved|O group|O (|O five|O of|O eight|O patients|O )|O than|O in|O the|O stable|O group|O (|O one|O of|O 27|O patients|O )|O .|O 
All|O of|O five|O patients|O harboring|O both|O karyotypic|O evolution|O and|O an|O N-ras|gene-rna mutation|O showed|O concomitant|O disease|O progression|O to|O overt|O leukemia|O or|O refractory|O anemia|O with|O excess|O of|O blasts|O in|O transformation|O (|O RAEB-T|O )|O .|O 
Two|O of|O four|O patients|O with|O either|O karyotypic|O evolution|O or|O N-ras|gene-rna mutation|O and|O six|O of|O 26|O patients|O without|O any|O of|O these|O alterations|O also|O progressed|O to|O overt|O leukemia|O .|O 
Our|O results|O indicate|O that|O the|O accumulation|O of|O these|O genetic|O alterations|O is|O closely|O associated|O with|O leukemic|O transformation|O of|O MDS|O ,|O although|O other|O genetic|O alterations|O may|O also|O play|O a|O key|O role|O in|O the|O remaining|O patients|O .|O 
Point|O mutations|O in|O the|O N-ras|gene-rna oncogene|O in|O malignant|O melanoma|O and|O congenital|O naevi|O .|O 
DNA|O from|O formalin|O -|O fixed|O and|O paraffin|O -|O processed|O samples|O from|O 100|O melanocytic|O lesions|O (|O 39|O malignant|O melanomas|O ,|O 18|O cases|O of|O dysplastic|O naevi|O ,|O and|O 43|O congenital|O naevi|O )|O was|O extracted|O ,|O and|O the|O sequences|O around|O codons|O 12|O /|O 13|O and|O 61|O of|O the|O N-ras|gene-rna oncogene|O were|O amplified|O using|O the|O polymerase|gene-protein chain|O reaction|O .|O 
The|O amplified|O product|O was|O then|O analysed|O both|O by|O dot|O -|O blotting|O and|O by|O direct|O sequencing|O for|O point|O mutations|O .|O 
By|O the|O dot|O -|O blotting|O technique|O ,|O mutations|O were|O seen|O in|O 18|O of|O 100|O lesions|O .|O 
These|O were|O in|O one|O of|O five|O distant|O metastases|O (|O 20|O %|O )|O ,|O in|O one|O of|O three|O nodal|O metastases|O (|O 33|O %|O )|O ,|O in|O four|O of|O 31|O (|O 13|O %|O )|O primary|O melanomas|O ,|O in|O none|O of|O 18|O dysplastic|O naevi|O ,|O and|O in|O 12|O of|O 43|O (|O 28|O %|O )|O congenital|O naevi|O ,|O all|O at|O codon|O 61|O .|O 
On|O direct|O sequencing|O ,|O nine|O of|O 18|O mutations|O were|O confirmed|O ,|O in|O two|O of|O 31|O (|O 6|O %|O )|O primary|O tumours|O ,|O one|O distant|O metastasis|O ,|O and|O six|O of|O 43|O (|O 14|O %|O )|O congenital|O naevi|O .|O 
Of|O the|O 23|O superficial|O spreading|O melanomas|O examined|O ,|O eight|O were|O on|O sun|O -|O exposed|O skin|O .|O 
A|O superficial|O spreading|O melanoma|O ,|O in|O which|O the|O N-ras|gene-rna mutation|O at|O codon|O 61|O was|O confirmed|O ,|O was|O on|O non|O -|O exposed|O skin|O ,|O and|O an|O unconfirmed|O mutation|O was|O from|O an|O exposed|O site|O .|O 
One|O of|O three|O nodular|O melanomas|O with|O a|O confirmed|O mutation|O was|O on|O a|O light|O -|O exposed|O site|O ,|O and|O the|O other|O two|O nodular|O melanomas|O were|O from|O non|O -|O exposed|O areas|O .|O 
All|O four|O lentigo|O maligna|O melanomas|O were|O from|O exposed|O sites|O ,|O and|O one|O of|O these|O had|O an|O unconfirmed|O mutation|O .|O 
The|O only|O acral|O lentiginous|O melanoma|O ,|O which|O had|O no|O mutation|O ,|O was|O from|O a|O sun|O -|O exposed|O area|O .|O 
The|O incidence|O and|O prognostic|O significance|O of|O mutations|O in|O codon|O 13|O of|O the|O N-ras|gene-rna gene|O in|O acute|O myeloid|O leukemia|O .|O 
To|O determine|O the|O incidence|O and|O prognostic|O significance|O of|O mutation|O in|O the|O N-ras|gene-rna gene|O in|O de|O novo|O acute|O myeloid|O leukemia|O (|O AML|O )|O we|O performed|O an|O analysis|O of|O bone|O marrow|O smears|O from|O 219|O patients|O with|O de|O novo|O AML|O treated|O between|O 1984|O and|O 1986|O and|O followed|O for|O at|O least|O six|O years|O .|O 
DNA|O extracted|O from|O bone|O marrow|O smears|O taken|O at|O diagnosis|O was|O screened|O for|O the|O presence|O of|O mutations|O in|O codons|O 12|O and|O 13|O of|O exon|O 1|O by|O using|O the|O polymerase|gene-protein chain|O reaction|O to|O insert|O an|O Hph1|gene-protein restriction|gene-protein enzyme|gene-protein site|O into|O DNA|O .|O 
Presumptive|O mutations|O were|O confirmed|O by|O direct|O sequencing|O .|O 
Mutations|O were|O detected|O in|O a|O total|O of|O 26|O patients|O (|O 12|O %|O )|O ;|O in|O nine|O patients|O (|O 4|O %|O )|O in|O codon|O 12|O only|O ,|O in|O ten|O patients|O (|O 5|O %|O )|O in|O codon|O 13|O only|O ,|O and|O in|O seven|O patients|O (|O 3|O %|O )|O in|O both|O codons|O .|O 
Mutations|O in|O codon|O 12|O or|O codon|O 13|O were|O not|O associated|O with|O any|O clinical|O features|O .|O 
Mutations|O in|O codon|O 12|O had|O no|O prognostic|O significance|O but|O mutations|O in|O codon|O 13|O were|O associated|O with|O an|O increased|O remission|O rate|O ,|O a|O more|O durable|O remission|O ,|O and|O a|O significantly|O prolonged|O survival|O which|O appeared|O to|O be|O independent|O of|O other|O prognostic|O factors|O .|O 
Glutathione|gene-protein transferase|gene-protein P1-1|gene-protein expression|O in|O human|O melanoma|O metastases|O :|O correlation|O to|O N-RAS|gene-rna mutations|O and|O expression|O .|O 
Expression|O of|O the|O detoxication|O enzyme|O glutathione|gene-protein transferase|gene-protein P1-1|gene-protein (|O GST|gene-protein P1-1|gene-protein )|O at|O elevated|O levels|O has|O been|O noted|O in|O many|O types|O of|O human|O tumors|O ,|O including|O melanomas|O .|O 
The|O products|O of|O the|O human|O H-RAS|gene-rna ,|O K-RAS|gene-rna and|O N-RAS|gene-rna genes|O play|O a|O key|O role|O in|O intracellular|O signal|O transduction|O leading|O to|O transcriptional|O activation|O of|O AP-1|gene-rna (|O Fos|gene-rna /|O Jun|gene-rna )|O responsive|O genes|O .|O 
The|O oncogenic|O mutated|O forms|O of|O the|O ras|gene-protein proteins|O are|O constitutively|O active|O and|O interfere|O with|O normal|O signal|O transduction|O .|O 
Mutated|O RAS|gene-rna genes|O as|O well|O as|O increased|O expression|O of|O wild|O -|O type|O ras|gene-protein proteins|O are|O common|O features|O in|O human|O tumors|O including|O melanoma|O .|O 
We|O have|O characterized|O 30|O melanoma|O metastases|O from|O 23|O melanoma|O patients|O with|O reference|O to|O N-RAS|gene-generic expression|O and|O mutation|O as|O well|O as|O to|O GST|gene-protein P1|gene-protein expression|O (|O immunohistochemistry|O and|O genetic|O analysis|O )|O .|O 
Twenty-three|O of|O 30|O samples|O (|O 70|O %|O )|O had|O high|O N-Ras|gene-protein p21|gene-protein and/or|O N-RAS|gene-rna codon|O 61|O mutations|O and|O 18|O of|O these|O 23|O samples|O also|O had|O high|O GST|gene-protein P1-1|gene-protein immunoreactivity|O .|O 
Seven|O of|O 30|O (|O 23|O %|O )|O samples|O had|O low|O N-Ras|gene-protein p21|gene-protein immunoreactivity|O and|O no|O detectable|O N-RAS|gene-rna codon|O 61|O mutations|O .|O 
Six|O of|O these|O 7|O samples|O (|O 86|O %|O )|O also|O had|O low|O GST|gene-protein P1-1|gene-protein immunoreactivity|O .|O 
The|O results|O indicate|O a|O statistically|O significant|O correlation|O (|O Spearman|O correlation|O coefficient|O ,|O r|O =|O 0.56|O ,|O p|O =|O 0.001|O ,|O 2|O -|O tailed|O test|O )|O and|O provide|O ,|O for|O the|O first|O time|O ,|O indirect|O evidence|O for|O a|O possible|O coregulation|O of|O N-RAS|gene-rna and|O GST|gene-protein P1|gene-protein in|O human|O malignant|O melanoma|O which|O should|O be|O further|O evaluated|O .|O 
[|O Detection|O of|O ras|gene-rna gene|O mutations|O of|O pancreatic|O tumors|O by|O polymerase|gene-protein chain|O reaction|O and|O direct|O sequencing|O method|O ]|O 
Ras|gene-rna genes|O (|O H|gene-rna -|gene-rna ,|O K|gene-rna -|gene-rna ,|O N|gene-rna -|gene-rna ras|gene-rna )|O are|O converted|O to|O active|O oncogenes|O by|O point|O mutations|O occurring|O in|O either|O codon|O 12|O ,|O 13|O or|O 61|O .|O 
We|O analyzed|O 19|O pancreatic|O tumors|O (|O formalin|O fixed|O paraffin|O embedded|O tissue|O )|O of|O these|O codons|O by|O a|O method|O to|O directly|O sequence|O nucleotides|O around|O codons|O 12|O /|O 13|O and|O 61|O of|O the|O three|O ras|gene-rna genes|O ,|O using|O polymerase|gene-protein chain|O reaction|O and|O direct|O sequencing|O method|O .|O 
Of|O 19|O pancreatic|O tumors|O ,|O all|O 17|O duct|O cell|O carcinomas|O involving|O 2|O mucous|O producing|O pancreatic|O cancers|O had|O point|O mutations|O of|O the|O K-ras|gene-rna codon|O 12|O ,|O but|O 2|O islet|O cell|O tumors|O had|O ano|O point|O mutation|O around|O codons|O 12|O ,|O 13|O ,|O 61|O of|O the|O three|O ras|gene-rna genes|O .|O 
Extremely|O high|O incidence|O of|O ras|gene-rna gene|O mutation|O may|O be|O relevant|O to|O certain|O pathogenesis|O of|O pancreatic|O cancers|O .|O 
c-myc|gene-rna amplification|O coexistent|O with|O activating|O N-ras|gene-rna point|O mutation|O in|O the|O biphenotypic|O leukemic|O cell|O line|O RED-3|O .|O 
While|O activation|O of|O the|O protooncogene|O c-N-ras|gene-rna is|O observed|O regularly|O in|O acute|O myelogenous|O leukemia|O ,|O amplification|O of|O c-myc|gene-rna in|O AML|O cells|O or|O derived|O lines|O is|O uncommon|O .|O 
In|O particular|O ,|O concurrent|O ras|gene-rna /|O myc|gene-rna activation|O ,|O which|O has|O been|O shown|O to|O be|O critical|O in|O several|O elegant|O models|O of|O malignancy|O ,|O has|O been|O demonstrated|O in|O a|O very|O small|O number|O of|O human|O tumors|O or|O derivative|O cell|O lines|O .|O 
A|O cell|O line|O ,|O RED-3|O ,|O is|O described|O which|O was|O derived|O from|O cells|O of|O a|O patient|O with|O aggressive|O acute|O leukemia|O which|O exhibits|O many|O markers|O of|O lineage|O infidelity|O .|O 
DNA|O from|O this|O cell|O line|O contains|O an|O activating|O point|O mutation|O of|O c-N-ras|gene-rna as|O well|O as|O 20|O -|O 30|O -|O fold|O amplification|O of|O c-myc|gene-rna .|O 
After|O HL-60|O ,|O this|O is|O the|O second|O example|O of|O ras|gene-rna /|O myc|gene-rna activation|O in|O AML|O derived|O cells|O and|O demonstrates|O that|O this|O lesion|O is|O not|O unique|O to|O HL-60|O .|O 
Rather|O ,|O it|O may|O be|O important|O in|O leukemogenesis|O in|O a|O small|O proportion|O of|O AML|O patients|O .|O 
High|O frequency|O of|O ras|gene-rna oncogene|O activation|O in|O all|O stages|O of|O human|O thyroid|O tumorigenesis|O .|O 
Using|O polymerase|gene-protein chain|O reaction|O amplification|O and|O oligonucleotide|O probing|O ,|O the|O activation|O of|O ras|gene-rna oncogenes|O in|O 24|O benign|O and|O 20|O malignant|O human|O thyroid|O neoplasms|O was|O examined|O .|O 
The|O frequency|O of|O ras|gene-rna oncogene|O activation|O was|O similar|O at|O all|O stages|O of|O tumorigenesis|O in|O this|O system|O ,|O being|O found|O in|O 33|O %|O of|O adenomas|O overall|O (|O 50|O %|O of|O microfollicular|O tumours|O )|O ,|O 53|O %|O of|O differentiated|O follicular|O carcinomas|O and|O 60|O %|O of|O undifferentiated|O carcinomas|O .|O 
This|O supports|O the|O contention|O that|O mutation|O of|O these|O oncogenes|O occurs|O at|O an|O early|O step|O in|O tumorigenesis|O .|O 
The|O predominant|O amino|O acid|O substitution|O in|O the|O differentiated|O tumours|O was|O glutamine|O to|O arginine|O at|O position|O 61|O of|O Ha-ras|gene-rna or|O N-ras|gene-rna ,|O but|O this|O mutation|O was|O not|O found|O in|O any|O of|O the|O undifferentiated|O tumours|O .|O 
It|O was|O noted|O that|O while|O transition|O mutations|O predominated|O in|O differentiated|O tumours|O (|O both|O benign|O and|O malignant|O )|O ,|O transversions|O were|O more|O common|O in|O the|O undifferentiated|O tumours|O .|O 
Incidence|O of|O activating|O ras|gene-rna oncogene|O mutations|O associated|O with|O primary|O and|O metastatic|O human|O breast|O cancer|O .|O 
To|O test|O the|O hypothesis|O that|O ras|gene-rna activation|O is|O involved|O in|O the|O final|O stages|O of|O breast|O cancer|O progression|O ,|O we|O analyzed|O tumor|O DNA|O derived|O from|O 60|O different|O patients|O and|O extracted|O from|O 40|O invasive|O primary|O breast|O tumors|O ,|O seven|O lymph|O node|O and|O skin|O metastases|O ,|O nine|O metastatic|O effusions|O ,|O and|O five|O established|O breast|O cancer|O cell|O lines|O .|O 
The|O polymerase|gene-protein chain|O reaction|O technique|O was|O used|O to|O amplify|O DNA|O fragments|O containing|O Kirsten|gene-rna -|gene-rna (|O Ki|gene-rna -|gene-rna )|O ,|O Harvey|gene-rna -|gene-rna (|O Ha|gene-rna -|gene-rna )|O ,|O and|O N|gene-rna -|gene-rna ras|gene-rna codons|O 12|O ,|O 13|O ,|O and|O 61|O which|O were|O then|O probed|O on|O slot|O -|O blots|O with|O labeled|O synthetic|O oligomers|O to|O detect|O nonconservative|O single|O base|O mutations|O .|O 
Activating|O mutations|O were|O found|O in|O one|O of|O 40|O primary|O tumors|O (|O Ki-ras|gene-rna codon|O 13|O )|O ,|O zero|O of|O seven|O lymph|O node|O and|O skin|O metastases|O ,|O one|O of|O nine|O metastatic|O effusions|O (|O Ki-ras|gene-rna codon|O 12|O )|O ,|O and|O two|O of|O five|O cell|O lines|O (|O Ki-ras|gene-rna codons|O 12|O and|O 13|O )|O .|O 
These|O results|O indicate|O that|O activating|O ras|gene-rna mutations|O are|O rarely|O involved|O in|O either|O the|O initiation|O or|O metastatic|O progression|O of|O human|O breast|O cancer|O .|O 
Low|O incidence|O of|O ras|gene-rna oncogene|O activation|O in|O human|O squamous|O cell|O carcinomas|O .|O 
Activation|O of|O the|O ras|gene-rna gene|O family|O by|O point|O mutation|O at|O codons|O 12|O ,|O 13|O and|O 61|O has|O been|O demonstrated|O in|O up|O to|O 20|O %|O of|O unselected|O series|O of|O human|O tumours|O .|O 
The|O present|O study|O was|O carried|O out|O to|O assess|O the|O incidence|O of|O ras|gene-rna activation|O in|O 37|O squamous|O cell|O carcinomas|O of|O the|O head|O and|O neck|O ,|O seven|O squamous|O cell|O carcinomas|O of|O the|O skin|O and|O eight|O squamous|O carcinoma|O cell|O lines|O .|O 
Oligonucleotide|O probes|O and|O the|O polymerase|gene-protein chain|O reaction|O were|O used|O on|O DNA|O extracted|O from|O achival|O paraffin|O embedded|O material|O .|O 
Mutations|O in|O codon|O 12|O of|O the|O Harvey|gene-rna ras|gene-rna gene|O was|O found|O in|O a|O carcinoma|O of|O the|O larynx|O and|O a|O carcinoma|O of|O the|O lip|O ,|O both|O of|O which|O had|O received|O prior|O irradiation|O .|O 
A|O cell|O line|O (|O LICR-LON-HN8|O )|O established|O from|O the|O same|O laryngeal|O cancer|O showed|O the|O same|O mutation|O .|O 
This|O study|O indicates|O that|O there|O is|O a|O low|O incidence|O of|O ras|gene-rna mutation|O in|O human|O squamous|O cell|O carcinomas|O and|O that|O activation|O of|O this|O family|O of|O genes|gene-rna is|O probably|O not|O a|O common|O factor|O in|O the|O development|O of|O this|O group|O of|O tumours|O .|O 
RAS|gene-rna mutations|O in|O patients|O following|O cytotoxic|O therapy|O for|O lymphoma|O .|O 
The|O occurrence|O of|O Myelodysplastic|O Syndrome|O (|O MDS|O )|O and|O Acute|O Myeloblastic|O Leukaemia|O (|O AML|O )|O following|O cytotoxic|O therapy|O for|O neoplastic|O disease|O is|O well|O recognised|O .|O 
RAS|gene-rna mutations|O are|O common|O in|O patients|O with|O MDS|O and|O AML|O .|O 
To|O determine|O whether|O these|O lesions|O are|O found|O as|O early|O markers|O of|O secondary|O disease|O ,|O we|O have|O studied|O the|O incidence|O of|O RAS|gene-rna mutations|O in|O the|O peripheral|O blood|O of|O 70|O patients|O in|O complete|O remission|O from|O lymphoma|O .|O 
Patients|O were|O treated|O by|O standard|O chemotherapy|O regimes|O and/or|O localised|O radiotherapy|O .|O 
Treatment|O had|O been|O given|O 6|O months|O to|O 14|O 1|O /|O 2|O years|O previously|O and|O no|O patient|O showed|O any|O sign|O of|O residual|O disease|O .|O 
Genomic|O DNA|O from|O peripheral|O blood|O leukocytes|O was|O amplified|O in|O vitro|O at|O target|O codons|O of|O N|gene-rna ,|O K|gene-rna and|O H|gene-rna RAS|gene-rna genes|O ,|O and|O mutations|O detected|O by|O hybridisation|O with|O oligonucleotide|O probes|O .|O 
RAS|gene-rna mutations|O were|O detected|O in|O 9|O subjects|O .|O 
One|O patient|O with|O an|O N|gene-rna 12|O valine|O (|O Val|O )|O substitution|O had|O been|O in|O complete|O remission|O from|O Hodgkin|O 's|O disease|O (|O HD|O )|O for|O 9|O years|O .|O 
DNA|O from|O this|O patient|O registered|O in|O a|O nude|O mouse|O tumorigenicity|O assay|O (|O NMT|O )|O .|O 
The|O N|gene-rna 12|O Val|O mutation|O was|O not|O detected|O in|O the|O original|O tumour|O tissue|O from|O the|O same|O patient|O .|O 
A|O second|O patient|O in|O remission|O from|O HD|O showed|O evidence|O of|O co|O -|O existent|O N|gene-rna 12|O cysteine|O (|O Cys|O )|O and|O N|gene-rna 13|O valine|O (|O Val|O )|O substitutions|O which|O were|O not|O detected|O in|O presentation|O material|O or|O unaffected|O tissues|O .|O 
All|O patients|O are|O currently|O haematologically|O normal|O ,|O indicating|O that|O clones|O of|O mutant|O RAS|gene-rna bearing|O cells|O may|O be|O detected|O prior|O to|O any|O overt|O sign|O of|O disease|O .|O 
Ras|gene-rna oncogene|O mutations|O in|O basal|O cell|O carcinomas|O and|O squamous|O cell|O carcinomas|O of|O human|O skin|O .|O 
Activated|O ras|gene-rna oncogenes|O have|O been|O detected|O in|O a|O variety|O of|O human|O malignancies|O .|O 
Activation|O of|O ras|gene-rna oncogenes|O usually|O occurs|O by|O point|O mutations|O within|O specific|O codons|O of|O the|O H-ras|gene-rna ,|O N-ras|gene-rna ,|O and|O K-ras|gene-rna genes|O .|O 
For|O the|O present|O study|O ,|O DNA|O was|O isolated|O from|O 30|O basal|O cell|O carcinomas|O (|O BCC|O )|O and|O 12|O squamous|O cell|O carcinomas|O (|O SCC|O )|O .|O 
After|O amplification|O of|O genomic|O DNA|O by|O using|O the|O polymerase|gene-protein chain|O reaction|O ,|O the|O occurrence|O of|O point|O mutations|O was|O investigated|O with|O 32P|O -|O labeled|O synthetic|O oligonucleotides|O .|O 
These|O probes|O are|O complementary|O to|O the|O known|O point|O -|O mutated|O nucleotide|O sequences|O of|O the|O ras|gene-rna genes|O .|O 
In|O four|O out|O of|O the|O 30|O BCC|O studied|O ,|O point|O mutations|O were|O detected|O at|O codon|O 12|O of|O the|O K-ras|gene-rna gene|O and|O at|O codon|O 61|O of|O the|O H-ras|gene-rna gene|O .|O 
The|O K-ras|gene-rna mutations|O involve|O glycine|O to|O cysteine|O and|O glycine|O to|O asparagine|O amino|O acid|O changes|O .|O 
The|O mutation|O at|O codon|O 61|O of|O the|O H-ras|gene-rna gene|O is|O consistent|O with|O a|O replacement|O of|O glutamine|O by|O histidine|O .|O 
In|O one|O SCC|O ,|O a|O point|O mutation|O was|O detected|O at|O codon|O 12|O of|O the|O K-ras|gene-rna gene|O ,|O involving|O a|O glycine|O to|O cysteine|O substitution|O in|O the|O gene|gene-protein product|gene-protein .|O 
These|O findings|O demonstrate|O that|O mutational|O activation|O of|O ras|gene-rna genes|O takes|O place|O in|O skin|O carcinomas|O ,|O but|O the|O rate|O at|O which|O these|O mutations|O occur|O seems|O to|O be|O relatively|O low|O .|O 
High|O frequency|O mutation|O in|O codons|O 12|O and|O 61|O of|O H-ras|gene-rna oncogene|O in|O chewing|O tobacco|O -|O related|O human|O oral|O carcinoma|O in|O India|O .|O 
57|O primary|O tumour|O samples|O from|O Indian|O oral|O cancer|O patients|O with|O a|O 5|O -|O 15|O year|O tobacco|O chewing|O habit|O ,|O were|O examined|O for|O mutational|O activation|O in|O codons|O 12|O ,|O 13|O and|O 61|O of|O the|O H-ras|gene-rna ,|O K-ras|gene-rna and|O N-ras|gene-rna oncogenes|O .|O 
The|O highly|O sensitive|O assay|O based|O on|O specific|O oligonucleotide|O hybridisation|O following|O in|O vitro|O amplification|O of|O unique|O sequences|O by|O polymerase|gene-protein chain|O reaction|O was|O employed|O .|O 
Mutations|O were|O detected|O in|O twenty|O (|O 35|O %|O )|O of|O the|O samples|O and|O were|O restricted|O to|O H-ras|gene-rna ,|O codons|O 12|O ,|O 13|O and|O 61|O .|O 
Two|O cases|O had|O concurrent|O mutations|O in|O codons|O 12|O and|O 61|O .|O 
The|O majority|O of|O the|O mutations|O were|O at|O H-ras|gene-rna 61.2|O (|O Glutamine|O to|O Arginine|O )|O and|O H-ras|gene-rna 12.2|O (|O Glycine|O to|O Valine|O )|O .|O 
Three|O of|O the|O less|O frequent|O mutations|O are|O apparently|O novel|O .|O 
Interestingly|O ,|O eight|O of|O the|O samples|O with|O H-ras|gene-rna mutations|O also|O showed|O loss|O of|O wild|O -|O type|O H-ras|gene-rna ,|O as|O judged|O by|O absence|O of|O signals|O for|O wild|O -|O type|O codons|O 12|O or|O 61|O on|O dot|O blots|O .|O 
The|O specific|O H-ras|gene-rna mutations|O in|O these|O oral|O malignancies|O associated|O with|O tobacco|O chewing|O ,|O may|O represent|O an|O important|O example|O of|O an|O environmental|O carcinogen|O -|O induced|O step|O ,|O in|O a|O pathway|O leading|O to|O malignant|O transformation|O .|O 
Alteration|O of|O N-ras|gene-rna gene|O mutation|O after|O relapse|O in|O acute|O lymphoblastic|O leukemia|O .|O 
We|O investigated|O N-ras|gene-rna activation|O in|O childhood|O acute|O lymphoblastic|O leukemia|O (|O dALL|O )|O by|O the|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O and|O the|O oligonucleotide|O hybridization|O method|O .|O 
The|O frequency|O of|O point|O -|O mutation|O of|O the|O N-ras|gene-rna gene|O was|O not|O high|O (|O 2|O of|O 15|O )|O ,|O and|O one|O positive|O case|O who|O relapsed|O was|O analyzed|O in|O detail|O .|O 
Although|O N-ras|gene-rna gene|O activation|O was|O detected|O at|O both|O onset|O and|O relapse|O ,|O the|O mutation|O sites|O were|O different|O .|O 
At|O onset|O ,|O Gly|O (|O GGT|O )|O was|O changed|O to|O Ser|O (|O AGT|O )|O at|O codon|O 12|O ,|O and|O at|O relapse|O ,|O Gly|O (|O GGT|O )|O to|O Asp|O (|O GAT|O )|O was|O observed|O at|O the|O same|O codon|O .|O 
In|O addition|O ,|O the|O DNA|O at|O relapse|O showed|O a|O remarkably|O higher|O transforming|O activity|O than|O the|O DNA|O at|O onset|O on|O two|O independent|O recipient|O cell|O lines|O .|O 
The|O identical|O cell|O surface|O phenotype|O and|O the|O same|O rearrangement|O patterns|O of|O both|O the|O immunoglobulin|gene-rna (|O Ig|gene-protein )|gene-protein heavy|gene-rna chain|gene-rna and|O T-cell|gene-rna receptor|gene-rna (|O TCR|gene-protein )|O gamma|gene-rna chain|gene-rna genes|O indicated|O that|O the|O leukemic|O cells|O at|O onset|O and|O those|O at|O relapse|O were|O derived|O from|O the|O same|O precursor|O cell|O .|O 
Therefore|O ,|O this|O case|O supports|O the|O concept|O that|O ras|gene-rna activation|O is|O not|O the|O event|O initiating|O leukemogenesis|O ,|O but|O may|O be|O involved|O in|O leukemic|O progression|O .|O 
Low|O incidence|O of|O Ha-ras|gene-rna oncogene|O mutations|O in|O human|O epidermal|O tumors|O .|O 
Activation|O of|O the|O Ha-ras|gene-rna oncogene|O by|O point|O mutations|O has|O been|O suggested|O to|O play|O a|O role|O in|O animal|O skin|O carcinogenesis|O models|O .|O 
In|O this|O study|O ,|O we|O investigated|O the|O significance|O of|O the|O Ha-ras|gene-rna mutations|O in|O human|O epidermal|O tumors|O .|O 
DNAs|O from|O paraffin|O -|O embedded|O tissues|O of|O benign|O and|O malignant|O human|O epidermal|O tumors|O (|O 27|O samples|O from|O 25|O patients|O )|O were|O prepared|O and|O examined|O for|O point|O mutations|O of|O codons|O 12|O ,|O 13|O and|O 61|O of|O Ha-ras|gene-rna gene|O by|O polymerase|gene-protein chain|O reaction|O and|O oligonucleotide|O hybridization|O .|O 
Only|O one|O sample|O of|O basal|O cell|O carcinoma|O and|O one|O sample|O of|O keratoacanthoma|O were|O found|O to|O carry|O an|O A|O to|O T|O transversion|O at|O the|O second|O position|O of|O codon|O 61|O .|O 
This|O low|O incidence|O of|O Ha-ras|gene-rna mutations|O suggests|O that|O the|O mutational|O activation|O of|O the|O gene|gene-rna may|O not|O be|O primarily|O involved|O in|O human|O epidermal|O tumorigenesis|O .|O 
Infrequent|O mutation|O of|O the|O ras|gene-rna genes|O in|O skin|O tumors|O of|O xeroderma|O pigmentosum|O patients|O in|O Japan|O .|O 
By|O using|O PCR|O amplification|O and|O oligonucleotide|O mismatch|O hybridization|O ,|O base|O -|O substitution|O mutations|O of|O the|O ras|gene-rna genes|O in|O 26|O skin|O tumors|O of|O Japanese|O xeroderma|O pigmentosum|O (|O XP|O )|O patients|O were|O studied|O .|O 
Thin|O sections|O of|O tumor|O tissues|O which|O were|O fixed|O and|O embedded|O in|O paraffin|O blocks|O were|O used|O in|O this|O study|O .|O 
After|O analyzing|O codons|O 12|O ,|O 13|O and|O 61|O of|O the|O H|gene-rna -|gene-rna ,|O K|gene-rna -|gene-rna and|O N|gene-rna -|gene-rna ras|gene-rna genes|O by|O using|O 66|O oligomer|O probes|O ,|O we|O detected|O only|O one|O mutation|O of|O the|O K-ras|gene-rna gene|O at|O codon|O 61|O in|O one|O tumor|O sample|O .|O 
All|O the|O other|O tumors|O were|O therefore|O considered|O not|O to|O have|O a|O mutation|O in|O the|O ras|gene-rna genes|O .|O 
These|O results|O suggest|O that|O mutations|O of|O the|O ras|gene-rna genes|O are|O not|O particularly|O associated|O with|O skin|O tumors|O of|O Japanese|O XP|O patients|O .|O 
Detection|O of|O H-ras|gene-rna gene|O point|O mutations|O in|O transitional|O cell|O carcinoma|O of|O human|O urinary|O bladder|O using|O polymerase|gene-protein chain|O reaction|O .|O 
It|O has|O been|O reported|O that|O the|O H-ras|gene-rna gene|O is|O activated|O as|O oncogene|O in|O human|O bladder|O cancer|O cases|O ,|O and|O that|O codon|O 12|O and|O codon|O 61|O are|O the|O major|O "|O hot|O spots|O "|O of|O its|O activation|O .|O 
A|O simple|O method|O to|O detect|O point|O mutations|O in|O these|O codons|O of|O H-ras|gene-rna gene|O was|O established|O for|O the|O use|O of|O clinical|O diagnosis|O .|O 
In|O this|O method|O ,|O the|O DNA|O segments|O including|O codon|O 12|O or|O codon|O 61|O were|O amplified|O by|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O ,|O and|O the|O reaction|O products|O were|O examined|O for|O their|O susceptibility|O to|O the|O restriction|O enzyme|O NaeI|gene-protein or|O BstNI|gene-protein ,|O and|O by|O dot|O blot|O hybridization|O assay|O with|O oligonucleotide|O probes|O .|O 
Point|O mutations|O were|O detectable|O in|O small|O amounts|O of|O DNAs|O isolated|O from|O fresh|O or|O frozen|O tumor|O tissues|O ,|O urine|O cells|O and|O paraffin|O sections|O .|O 
The|O method|O was|O applied|O for|O a|O clinical|O sample|O and|O a|O case|O that|O had|O a|O point|O mutation|O at|O codon|O 12|O of|O H-ras|gene-rna gene|O was|O detected|O .|O 
The|O point|O mutation|O was|O existed|O in|O DNAs|O of|O primary|O tumor|O tissue|O ,|O all|O recurrent|O tumor|O tissues|O and|O cells|O isolated|O from|O urine|O of|O this|O case|O .|O 
Clinical|O implications|O of|O K-ras|gene-rna mutations|O in|O malignant|O epithelial|O tumors|O of|O the|O endometrium|O .|O 
Tumorigenesis|O in|O humans|O and|O experimental|O animals|O appears|O to|O involve|O the|O activation|O of|O ras|gene-rna protooncogenes|O for|O a|O number|O of|O organ|O systems|O and|O seems|O to|O be|O important|O to|O the|O development|O of|O the|O metastatic|O phenotype|O in|O several|O model|O systems|O .|O 
Clinically|O ,|O the|O presence|O of|O activated|O ras|gene-rna protooncogenes|O has|O been|O reported|O to|O be|O a|O negative|O prognostic|O factor|O in|O the|O myelodysplastic|O syndrome|O and|O in|O adenocarcinoma|O of|O the|O lung|O .|O 
In|O the|O present|O study|O we|O examined|O 49|O cases|O of|O endometrial|O carcinoma|O for|O mutations|O in|O the|O first|O exon|O of|O K-ras|gene-rna using|O the|O polymerase|gene-protein chain|O reaction|O and|O direct|O sequencing|O .|O 
Mutations|O in|O codon|O 12|O or|O 13|O of|O K-ras|gene-rna were|O detected|O in|O 6|O of|O 49|O cases|O (|O 12.2|O %|O )|O .|O 
These|O six|O cases|O consisted|O of|O five|O endometrioid|O endometrial|O carcinomas|O ,|O each|O of|O which|O had|O a|O mutation|O in|O codon|O 12|O ,|O and|O one|O case|O of|O clear|O cell|O carcinoma|O ,|O which|O had|O a|O mutation|O in|O codon|O 13|O .|O 
In|O our|O study|O the|O presence|O of|O mutations|O in|O K-ras|gene-rna appeared|O to|O be|O an|O unfavorable|O prognostic|O factor|O .|O 
Three|O of|O six|O patients|O with|O the|O mutation|O died|O during|O follow|O -|O up|O ,|O while|O only|O 7|O %|O of|O the|O 43|O patients|O without|O K-ras|gene-rna mutations|O expired|O during|O this|O same|O period|O .|O 
In|O multivariate|O analysis|O using|O the|O Cox|O proportional|O hazard|O model|O ,|O K-ras|gene-rna activation|O appeared|O to|O be|O an|O independent|O risk|O factor|O when|O compared|O with|O clinical|O stage|O ,|O depth|O of|O myometrial|O invasion|O ,|O and|O patient|O age|O .|O 
Thus|O ,|O our|O findings|O support|O the|O hypothesis|O that|O K-ras|gene-rna protooncogene|O activation|O plays|O an|O important|O role|O in|O determining|O the|O aggressiveness|O of|O endometrial|O carcinoma|O .|O 
Concurrent|O mutations|O of|O coding|O and|O regulatory|O sequences|O of|O the|O Ha-ras|gene-rna gene|O in|O urinary|O bladder|O carcinomas|O .|O 
This|O report|O concerns|O the|O study|O of|O Ha-ras|gene-rna gene|O mutations|O and|O ras|gene-protein p21|gene-protein expression|O in|O primary|O tumors|O of|O the|O urinary|O bladder|O .|O 
Polymerase|gene-protein chain|O reaction|O -|O based|O techniques|O and|O computerized|O image|O analysis|O were|O used|O .|O 
The|O data|O obtained|O were|O related|O to|O tumor|O grade|O ,|O DNA|O ploidy|O ,|O and|O tumor|O invasion|O .|O 
A|O point|O mutation|O (|O G|O -->|O T|O )|O at|O Ha-ras|gene-rna codon|O 12|O was|O found|O in|O 30|O of|O 67|O tumors|O .|O 
The|O mutation|O frequency|O was|O greater|O in|O grade|O III|O (|O 65|O %|O )|O than|O in|O grade|O II|O (|O 44|O %|O )|O tumors|O ;|O no|O mutations|O were|O observed|O in|O grade|O I|O tumors|O .|O 
The|O mutation|O was|O observed|O more|O often|O in|O aneuploid|O (|O 58|O %|O )|O than|O in|O diploid|O (|O 28|O %|O )|O tumors|O .|O 
No|O other|O substitution|O at|O codon|O 12|O was|O seen|O and|O no|O codon|O 61|O mutation|O was|O detected|O .|O 
The|O tumors|O were|O also|O tested|O for|O the|O A|O -->|O G|O mutation|O at|O position|O 2719|O of|O Ha-ras|gene-rna intron|O D|O .|O 
Concurrent|O codon|O 12|O and|O intron|O D|O mutations|O were|O identified|O in|O seven|O high|O -|O grade|O aneuploid|O tumors|O ;|O six|O were|O invasive|O .|O 
The|O levels|O of|O the|O ras|gene-rna gene|O product|O p21|gene-protein were|O approximately|O 10|O times|O higher|O in|O tumors|O with|O intron|O D|O mutation|O than|O in|O those|O without|O .|O 
These|O findings|O confirm|O on|O human|O bladder|O tumors|O the|O observations|O of|O the|O effect|O of|O synchronous|O exon|O -|O intron|O mutations|O reported|O on|O the|O bladder|O cancer|O cell|O line|O T24|O .|O 
Our|O results|O are|O the|O first|O demonstration|O of|O Ha-ras|gene-rna intron|O D|O alterations|O in|O human|O tumor|O tissues|O and|O suggest|O that|O concurrent|O mutations|O at|O codon|O 12|O and|O intron|O D|O of|O this|O gene|gene-rna within|O the|O same|O tumor|O may|O contribute|O to|O the|O aggressive|O behavior|O of|O human|O bladder|O carcinomas|O .|O 
Detection|O of|O RAS|gene-rna mutations|O in|O archival|O testicular|O germ|O cell|O tumors|O by|O polymerase|gene-protein chain|O reaction|O and|O oligonucleotide|O hybridization|O .|O 
Preliminary|O studies|O of|O RAS|gene-rna mutational|O activation|O in|O human|O testicular|O germ|O cell|O neoplasms|O have|O yielded|O conflicting|O results|O .|O 
Whereas|O two|O studies|O of|O clinical|O material|O revealed|O a|O significant|O incidence|O of|O N|gene-rna -|gene-rna and|O K|gene-rna RAS|gene-rna mutations|O ,|O two|O studies|O of|O a|O variety|O of|O germ|O cell|O lines|O failed|O to|O document|O RAS|gene-rna mutations|O .|O 
To|O clarify|O the|O incidence|O of|O RAS|gene-rna mutations|O in|O these|O tumors|O ,|O we|O studied|O archival|O paraffin|O -|O embedded|O ,|O formalin|O -|O fixed|O orchiectomy|O specimens|O from|O 25|O nonseminomas|O (|O NSGCT|O )|O ,|O 18|O seminomas|O (|O SEM|O )|O ,|O and|O one|O Leydig|O cell|O tumor|O .|O 
For|O 14|O of|O the|O 44|O neoplasms|O ,|O DNA|O was|O also|O available|O from|O nonmalignant|O testis|O adjacent|O to|O the|O tumor|O .|O 
Six|O age|O -|O matched|O patients|O had|O testes|O removed|O because|O of|O nonmalignant|O disease|O and|O were|O studied|O as|O controls|O .|O 
Polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O amplified|O the|O K|gene-rna -|gene-rna ,|O N|gene-rna -|gene-rna ,|O and|O H|gene-rna RAS|gene-rna 12|O ,|O 13|O ,|O and|O 61|O codons|O of|O these|O specimens|O ,|O and|O mutations|O were|O detected|O with|O mutation|O -|O specific|O oligonucleotide|O probe|O hybridization|O of|O Southern|O and|O slot|O blots|O .|O 
Four|O mutations|O were|O found|O in|O KRAS|gene-rna 12|O (|O 4|O /|O 44|O ;|O [|O 9.1|O %|O ]|O )|O .|O 
One|O seminoma|O [|O 1|O /|O 18|O (|O 5.6|O %|O )|O ]|O contained|O the|O mutation|O GGT|O (|O GLY|O )|O ----|O CGT|O (|O ARG|O )|O ,|O and|O three|O NSGCT|O [|O 3|O /|O 25|O (|O 12|O %|O )|O ]|O were|O found|O to|O have|O GGT|O (|O GLY|O )|O ----|O GAT|O (|O ASP|O )|O mutations|O .|O 
One|O of|O the|O NSGCT|O mutations|O was|O detected|O in|O adjacent|O nonmalignant|O tissue|O ,|O but|O the|O corresponding|O tumor|O did|O not|O contain|O any|O detectable|O mutation|O .|O 
No|O mutations|O were|O detected|O at|O KRAS|gene-rna 13|O or|O 61|O ,|O in|O NRAS|gene-rna or|O HRAS|gene-rna 12|O ,|O 13|O ,|O or|O 61|O ,|O or|O in|O the|O control|O normal|O testes|O .|O 
PCR|O ,|O slot|O blots|O ,|O and|O hybridizations|O were|O performed|O twice|O by|O two|O separate|O investigators|O for|O confirmation|O of|O results|O .|O 
PCR|O -|O generated|O mutation|O -|O specific|O positive|O controls|O were|O created|O for|O all|O possible|O RAS|gene-rna mutations|O ,|O and|O these|O along|O with|O wild|O -|O type|O DNA|O controls|O were|O integral|O to|O interpretation|O of|O the|O oligonucleotide|O mismatch|O hybridization|O assay|O .|O 
By|O using|O positive|O and|O negative|O controls|O ,|O we|O have|O detected|O a|O relatively|O low|O incidence|O of|O RAS|gene-rna mutations|O in|O archival|O human|O testicular|O germ|O cell|O tumors|O .|O 
Frequent|O deletions|O of|O tumor|gene-rna suppressor|gene-rna genes|gene-rna in|O pure|O pancreatic|O juice|O from|O patients|O with|O tumoral|O or|O nontumoral|O pancreatic|O diseases|O .|O 
BACKGROUND|O /|O AIMS|O :|O 
K-ras|gene-rna codon|O 12|O mutation|O is|O the|O most|O frequent|O genetic|O alteration|O in|O pancreatic|O cancer|O .|O 
Sensitivity|O and|O specificity|O of|O K-ras|gene-rna are|O not|O high|O enough|O to|O detect|O all|O pancreatic|O cancers|O ,|O especially|O at|O early|O stage|O .|O 
This|O study|O investigated|O whether|O detection|O of|O p16|gene-rna and/or|O DPC4|gene-rna deletions|O along|O with|O K-ras|gene-rna mutation|O in|O DNA|O samples|O could|O improve|O the|O definition|O of|O patients|O at|O risk|O of|O pancreatic|O cancer|O .|O 
METHODS|O :|O 
K-ras|gene-rna mutations|O were|O investigated|O by|O sequencing|O .|O 
p16|gene-rna and|O DPC4|gene-rna homozygous|O deletions|O were|O studied|O using|O comparative|O multiplex|O polymerase|gene-protein chain|O reaction|O of|O DNA|O in|O pancreatic|O juice|O sampled|O during|O endoscopic|O retrograde|O pancreatography|O in|O 57|O patients|O with|O either|O pancreatic|O cancer|O (|O group|O I|O ,|O 18|O patients|O )|O ,|O chronic|O pancreatitis|O (|O group|O II|O ,|O 20|O patients|O )|O ,|O or|O nontumoral|O pancreatobiliary|O disease|O (|O group|O III|O ,|O 19|O patients|O )|O .|O 
RESULTS|O :|O 
The|O frequencies|O of|O Ki-ras|gene-rna mutations|O were|O 61|O %|O in|O group|O I|O ,|O 10|O %|O in|O group|O II|O ,|O and|O 10.5|O %|O in|O group|O III|O .|O 
The|O frequencies|O of|O p16|gene-rna exon|O 2|O and|O DPC4|gene-rna deletions|O were|O ,|O respectively|O ,|O 28|O and|O 36|O %|O in|O group|O I|O ,|O 50|O and|O 58|O %|O in|O group|O II|O ,|O and|O 24|O and|O 36|O %|O in|O group|O III|O .|O 
CONCLUSIONS|O :|O 
The|O combination|O of|O p16|gene-rna and|O DPC4|gene-rna deletions|O with|O K-ras|gene-rna mutation|O does|O not|O improve|O the|O diagnosis|O of|O pancreatic|O cancer|O based|O on|O K-ras|gene-rna mutation|O alone|O .|O 
These|O data|O suggest|O that|O tumor|gene-rna suppressor|gene-rna gene|gene-rna inactivation|O can|O occur|O with|O a|O high|O frequency|O during|O nonmalignant|O pancreatic|O diseases|O .|O 
C-Ki-ras|gene-rna mutations|O in|O peripheral|O blood|O of|O pancreatic|O cancer|O patients|O :|O a|O marker|O for|O early|O tumor|O metastasis|O .|O 
PURPOSE|O :|O 
To|O determine|O the|O incidence|O of|O circulating|O minimal|O malignant|O clone|O (|O CMMC|O )|O (|O harboring|O c-Ki-ras-2|gene-rna mutation|O )|O in|O peripheral|O blood|O (|O PB|O )|O samples|O of|O untreated|O pancreatic|O cancer|O using|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O analysis|O of|O c-Ki-ras-2|gene-rna oncogene|O .|O 
METHODS|O AND|O MATERIALS|O :|O 
Experiments|O were|O carried|O out|O in|O fresh|O tumor|O ,|O peritoneal|O washings|O (|O PW|O )|O ,|O and|O PB|O samples|O of|O untreated|O pancreatic|O adenocarcinoma|O patients|O (|O both|O resectable|O and|O unresectable|O )|O .|O 
Samples|O were|O taken|O from|O 16|O patients|O diagnosed|O with|O pancreatic|O adenocarcinoma|O for|O the|O PCR|O analysis|O of|O mutated|O c-Ki-ras|gene-rna oncogene|O .|O 
Five|O tumor|O samples|O ,|O 15|O PB|O samples|O ,|O and|O 3|O PW|O samples|O were|O analyzed|O for|O point|O mutation|O of|O the|O c-Ki-ras|gene-rna gene|O at|O codon|O 12|O .|O 
RESULTS|O :|O 
Out|O of|O five|O tumor|O samples|O analyzed|O for|O c-Ki-ras|gene-rna mutation|O ,|O four|O were|O positive|O at|O the|O 12th|O codon|O .|O 
Out|O of|O total|O 15|O PB|O samples|O ,|O nine|O were|O positive|O for|O the|O c-Ki-ras|gene-rna point|O mutation|O at|O the|O 12th|O codon|O .|O 
All|O the|O positive|O PB|O samples|O showed|O a|O base|O substitution|O from|O GGT|O to|O GAT|O in|O the|O second|O position|O of|O the|O 12th|O codon|O .|O 
Out|O of|O three|O PW|O samples|O ,|O two|O showed|O mutation|O at|O the|O second|O position|O from|O GGT|O to|O GAT|O similar|O to|O their|O PB|O and|O tumor|O samples|O .|O 
CONCLUSION|O :|O 
Our|O study|O indicated|O the|O presence|O of|O the|O tumor|O cells|O (|O CMMC|O )|O in|O PB|O of|O pancreatic|O adenocarcinoma|O that|O can|O be|O identified|O by|O PCR|O analysis|O of|O c-Ki-ras|gene-rna oncogene|O .|O 
Patients|O with|O presence|O of|O CMMC|O in|O PB|O and|O mutation|O in|O PW|O had|O aggressive|O tumors|O that|O responded|O poorly|O to|O treatment|O .|O 
Mutations|O of|O p53|gene-rna ,|O c-kit|gene-rna ,|O K-ras|gene-rna ,|O and|O beta-catenin|gene-rna gene|O in|O non|O -|O Hodgkin|O 's|O lymphoma|O of|O adrenal|O gland|O .|O 
Malignant|O lymphoma|O of|O the|O adrenal|O gland|O is|O a|O rare|O disease|O ,|O usually|O with|O diffuse|O large|O cell|O morphology|O and|O B-cell|O immunophenotype|O ,|O and|O often|O associated|O with|O Epstein|O -|O Barr|O virus|O infection|O .|O 
In|O this|O study|O ,|O mutations|O of|O p53|gene-rna ,|O c-kit|gene-rna ,|O K-ras|gene-rna ,|O and|O beta-catenin|gene-rna gene|O were|O analyzed|O in|O 17|O cases|O (|O 13|O males|O and|O four|O females|O with|O ages|O ranging|O from|O 25|O to|O 84|O years|O )|O of|O such|O lymphomas|O by|O polymerase|gene-protein chain|O reaction|O -|O single|O strand|O conformation|O polymorphism|O followed|O by|O direct|O sequencing|O .|O 
Selected|O exons|O in|O each|O gene|O ,|O representing|O hot|O spots|O ,|O were|O analyzed|O .|O 
All|O 44|O mutations|O detected|O were|O single|O -|O nucleotide|O substitutions|O and|O 33|O were|O missense|O mutations|O .|O 
Nineteen|O mutations|O were|O detected|O in|O exon|O 5|O and|O /|O or|O 7|O of|O the|O p53|gene-rna gene|O in|O nine|O of|O 17|O cases|O (|O 52.9|O %|O )|O and|O 21|O in|O exon|O 11|O and|O /|O or|O 17|O of|O the|O c-kit|gene-rna gene|O in|O 10|O of|O 14|O cases|O (|O 71.4|O %|O )|O .|O 
Bilateral|O adrenal|O lesions|O in|O one|O case|O who|O had|O not|O received|O any|O adjuvant|O therapy|O showed|O different|O mutational|O patterns|O of|O the|O p53|gene-rna and|O c-kit|gene-rna genes|O ,|O suggesting|O different|O clonal|O evolution|O of|O lymphoma|O between|O the|O left|O and|O right|O sides|O .|O 
Mutation|O at|O codon|O 13|O of|O the|O K-ras|gene-rna gene|O was|O detected|O in|O one|O of|O 14|O cases|O (|O 7.1|O %|O )|O ,|O and|O in|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O in|O three|O of|O 12|O cases|O (|O 25|O %|O )|O .|O 
All|O but|O one|O mutation|O were|O transition|O mutations|O ,|O indicating|O that|O some|O endogenous|O mutagens|O act|O in|O lymphomagenesis|O in|O the|O adrenal|O gland|O .|O 
Our|O results|O suggest|O that|O p53|gene-rna and|O c-kit|gene-rna gene|O mutations|O might|O play|O a|O role|O in|O adrenal|O lymphomagenesis|O .|O 
Gene|O mutations|O in|O lymphoproliferative|O disorders|O of|O T|O and|O NK|O /|O T|O cell|O phenotypes|O developing|O in|O renal|O transplant|O patients|O .|O 
Post|O -|O transplantation|O lymphoproliferative|O disorder|O (|O PT-LPD|O )|O is|O characterized|O by|O lymphoid|O proliferation|O after|O organ|O or|O bone|O marrow|O transplantation|O .|O 
In|O Western|O countries|O ,|O most|O cases|O of|O PT-LPD|O are|O B-cell|O -|O derived|O and|O Epstein|O -|O Barr|O virus|O -|O associated|O ,|O in|O which|O alterations|O of|O c-myc|gene-rna ,|O p53|gene-rna ,|O and|O N-ras|gene-rna genes|O might|O play|O a|O role|O in|O disease|O progression|O .|O 
In|O Japan|O ,|O PT-LPD|O of|O T|O -|O and|O NK|O /|O T|O -|O cell|O types|O are|O not|O uncommon|O in|O renal|O transplant|O patients|O .|O 
Mutations|O of|O p53|gene-rna (|O exons|O 4|O through|O 8|O )|O ,|O K-ras|gene-rna (|O exons|O 1|O and|O 2|O )|O ,|O c-kit|gene-rna (|O exons|O 11|O and|O 17|O )|O ,|O and|O beta-catenin|gene-rna genes|O (|O exon|O 3|O )|O in|O 12|O cases|O of|O these|O diseases|O were|O analyzed|O by|O PCR|O single|O strand|O conformation|O polymorphism|O and|O then|O by|O direct|O sequencing|O .|O 
p53|gene-rna gene|O mutations|O were|O detected|O in|O 5|O of|O 5|O cases|O of|O peripheral|O T-cell|O lymphoma|O ,|O 3|O (|O 60|O %|O )|O of|O 5|O cases|O of|O adult|O T-cell|O leukemia|O /|O lymphoma|O ,|O and|O 1|O of|O 2|O cases|O of|O NK|O /|O T|O cell|O lymphoma|O .|O 
Twenty-five|O percent|O of|O T|O and|O NK|O /|O T|O cell|O lymphomas|O showed|O K-ras|gene-rna mutations|O .|O 
Mutations|O of|O c-kit|gene-rna and|O beta-catenin|gene-rna genes|O were|O found|O in|O 33|O %|O of|O cases|O .|O 
Among|O a|O total|O of|O 42|O substitution|O mutations|O ,|O 40|O were|O transitions|O with|O involvement|O of|O CpG|O sites|O in|O 20|O to|O 30|O %|O of|O cases|O .|O 
Most|O cases|O had|O at|O least|O one|O mutation|O that|O changed|O an|O amino|O acid|O ,|O which|O might|O have|O provided|O the|O selection|O pressure|O for|O expansion|O .|O 
These|O findings|O suggested|O that|O p53|gene-rna gene|O mutations|O might|O play|O a|O central|O role|O in|O development|O of|O peripheral|O T-cell|O lymphoma|O including|O adult|O T-cell|O leukemia|O /|O lymphoma|O in|O renal|O transplant|O patients|O .|O 
Detection|O of|O genetic|O alterations|O in|O the|O p53|gene-rna suppressor|O gene|O and|O the|O K-ras|gene-rna oncogene|O among|O different|O grades|O of|O dysplasia|O in|O patients|O with|O colorectal|O adenomas|O .|O 
BACKGROUND|O :|O 
Although|O it|O is|O believed|O that|O p53|gene-rna suppressor|O gene|O mutations|O ,|O compared|O with|O mutations|O in|O the|O K-ras|gene-rna oncogene|O ,|O occur|O at|O a|O later|O stage|O of|O colorectal|O tumorigenesis|O ,|O the|O distribution|O of|O these|O genetic|O alterations|O at|O an|O early|O stage|O remains|O poorly|O characterized|O .|O 
METHODS|O :|O 
The|O authors|O analyzed|O the|O immunoreactivity|O for|O p53|gene-protein protein|O (|O p53|gene-protein protein|O expression|O )|O ,|O which|O reflects|O the|O functionally|O altered|O p53|gene-rna gene|O ,|O and|O K-ras|gene-rna mutations|O at|O codons|O 12|O in|O 68|O colorectal|O adenomas|O with|O both|O low|O -|O grade|O and|O high|O -|O grade|O dysplasia|O obtained|O from|O 62|O patients|O .|O 
RESULTS|O :|O 
The|O prevalence|O of|O p53|gene-protein positive|O immunostaining|O was|O significantly|O greater|O compared|O with|O the|O prevalence|O of|O K-ras|gene-rna mutations|O both|O in|O low|O -|O grade|O dysplasia|O and|O in|O high|O -|O grade|O dysplasia|O .|O 
Twenty-two|O adenomas|O (|O 32.3|O %|O )|O showed|O positive|O immunostaining|O for|O p53|gene-protein protein|O in|O high|O -|O grade|O dysplasia|O and|O also|O were|O positive|O for|O p53|gene-protein in|O surrounding|O low|O -|O grade|O dysplastic|O tissues|O ;|O 20|O adenomas|O (|O 29.4|O %|O )|O showed|O positive|O immunostaining|O for|O p53|gene-protein protein|O in|O high|O -|O grade|O dysplasia|O and|O were|O negative|O for|O p53|gene-protein in|O surrounding|O low|O -|O grade|O dysplastic|O tissues|O ;|O 8|O adenomas|O (|O 11.7|O %|O )|O showed|O negative|O immunostaining|O for|O p53|gene-protein protein|O in|O high|O -|O grade|O dysplasia|O and|O were|O positive|O for|O p53|gene-protein in|O surrounding|O low|O -|O grade|O dysplastic|O tissues|O ;|O and|O 18|O adenomas|O (|O 26.4|O %|O )|O showed|O negative|O immunostaining|O for|O p53|gene-protein protein|O in|O both|O high|O -|O grade|O dysplasia|O and|O in|O surrounding|O low|O -|O grade|O dysplastic|O tissues|O .|O 
On|O the|O whole|O ,|O a|O significant|O difference|O (|O P|O <|O 0.05|O )|O was|O seen|O in|O the|O frequency|O of|O p53|gene-protein positive|O immunostaining|O between|O low|O -|O grade|O dysplasia|O and|O high|O -|O grade|O dysplasia|O (|O 44.1|O %|O and|O 61.8|O %|O ,|O respectively|O )|O but|O not|O in|O that|O of|O K-ras|gene-rna mutations|O (|O 20.3|O %|O and|O 23.4|O %|O ,|O respectively|O )|O .|O 
CONCLUSIONS|O :|O 
The|O results|O of|O this|O study|O suggest|O that|O mutation|O of|O the|O p53|gene-rna suppressor|O gene|O occurs|O earlier|O in|O the|O adenoma|O -|O carcinoma|O sequence|O than|O K-ras|gene-rna mutation|O ,|O providing|O a|O clue|O for|O further|O understanding|O of|O the|O role|O of|O the|O p53|gene-rna gene|O in|O the|O early|O stage|O of|O colorectal|O tumorigenesis|O .|O 
Genetic|O profile|O of|O 22|O pancreatic|O carcinoma|O cell|O lines|O .|O 
Analysis|O of|O K-ras|gene-rna ,|O p53|gene-rna ,|O p16|gene-rna and|O DPC4|gene-rna /|O Smad4|gene-rna .|O 
The|O K-ras|gene-rna ,|O p53|gene-rna ,|O p16|gene-rna and|O DPC4|gene-rna genes|O are|O among|O those|O most|O frequently|O altered|O in|O pancreatic|O ductal|O carcinoma|O .|O 
We|O analyzed|O 22|O cell|O lines|O for|O alterations|O in|O these|O genes|O by|O direct|O sequence|O analysis|O and|O methylation|O -|O specific|O polymerase|gene-protein chain|O reaction|O .|O 
These|O cell|O lines|O showed|O mutations|O in|O K-ras|gene-rna and|O p53|gene-rna at|O frequencies|O of|O 91|O %|O and|O 95|O %|O ,|O respectively|O .|O 
Alterations|O in|O p16INK4a|gene-rna were|O found|O in|O all|O cases|O and|O included|O nine|O homozygous|O deletions|O ,|O seven|O mutations|O and|O promoter|O methylation|O in|O six|O cases|O .|O 
Eight|O cell|O lines|O (|O 36|O %|O )|O had|O an|O alteration|O of|O DPC4|gene-rna ,|O including|O one|O mutation|O and|O seven|O homozygous|O deletions|O .|O 
The|O most|O typical|O mutational|O profile|O involved|O K-ras|gene-rna ,|O p53|gene-rna ,|O and|O p16INK4a|gene-rna ,|O concurrently|O aberrated|O in|O 20|O cases|O (|O 91|O %|O )|O .|O 
Eight|O cell|O lines|O had|O alterations|O in|O all|gene-rna four|gene-rna genes|gene-rna .|O 
Inactivation|O of|O DPC4|gene-rna was|O always|O accompanied|O by|O alteration|O of|O all|O of|O the|O other|O three|gene-rna genes|gene-rna .|O 
This|O comprehensive|O data|O regarding|O the|O cumulative|O genetic|O alterations|O in|O pancreatic|O carcinoma|O cell|O lines|O will|O be|O of|O great|O value|O for|O studies|O involving|O drug|O sensitivity|O or|O resistance|O that|O may|O be|O associated|O with|O inactivation|O of|O a|O particular|O gene|O or|O molecular|O pathway|O .|O 
Lack|O of|O association|O between|O N-ras|gene-rna gene|O mutations|O and|O clinical|O prognosis|O in|O Brazilian|O children|O with|O acute|O lymphoblastic|O leukemia|O .|O 
Point|O mutations|O in|O codons|O 12|O ,|O 13|O and|O 61|O of|O the|O N-ras|gene-rna proto|O -|O oncogene|O have|O been|O detected|O in|O several|O human|O malignancies|O .|O 
We|O studied|O 170|O patients|O with|O acute|O lymphoblastic|O leukemia|O (|O ALL|O )|O ,|O treated|O from|O 1988|O to|O 1994|O according|O to|O a|O protocol|O derived|O from|O BFM-83|O studies|O ,|O in|O order|O to|O evaluate|O the|O incidence|O and|O prognostic|O significance|O of|O mutations|O in|O this|gene-rna gene|gene-rna in|O childhood|O ALL|O .|O 
DNA|O was|O extracted|O from|O bone|O marrow|O smears|O at|O diagnosis|O and|O amplified|O by|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O .|O 
After|O screening|O with|O SSCP|O ,|O PCR|O products|O were|O hybridized|O with|O allele|O specific|O probes|O and|O ,|O in|O some|O cases|O ,|O cloned|O in|O a|O pMOS|O Blue|O T|O vector|O and|O sequenced|O .|O 
Exon|O 2|O was|O also|O studied|O in|O 101|O children|O .|O 
Our|O results|O showed|O 4|O %|O of|O mutations|O in|O codons|O 12|O and|O 13|O and|O 2|O %|O in|O exon|O 2|O .|O 
Similar|O to|O a|O previous|O report|O ,|O we|O identified|O 7|O %|O of|O mutations|O among|O children|O who|O were|O studied|O for|O both|O exons|O .|O 
A|O new|O mutation|O in|O codon|O 64|O of|O the|O N-ras|gene-rna gene|O was|O detected|O in|O one|O patient|O .|O 
No|O significant|O clinical|O differences|O between|O patients|O with|O and|O without|O mutations|O were|O detected|O (|O sex|O ,|O age|O ,|O leukocyte|O counts|O at|O diagnosis|O ,|O nutritional|O status|O ,|O and|O risk|O factor|O according|O to|O the|O BFM|O protocol|O )|O .|O 
Children|O with|O mutations|O in|O codons|O 12|O and|O 13|O showed|O significantly|O higher|O reactivity|O to|O PAS|O staining|O on|O blast|O cells|O than|O children|O with|O a|O wild|O type|O N-ras|gene-rna gene|O configuration|O .|O 
Comparison|O of|O overall|O -|O and|O recurrence|O -|O free|O survival|O did|O not|O show|O significant|O difference|O between|O groups|O with|O and|O without|O mutations|O .|O 
Our|O results|O suggest|O that|O mutations|O in|O the|O ras|gene-rna gene|O are|O infrequent|O in|O children|O with|O ALL|O at|O diagnosis|O and|O seem|O to|O be|O of|O low|O prognostic|O value|O .|O 
beta-Catenin|gene-rna mutation|O and|O overexpression|O in|O hepatocellular|O carcinoma|O :|O clinicopathologic|O and|O prognostic|O significance|O .|O 
BACKGROUND|O :|O 
beta-Catenin|gene-rna has|O been|O recognized|O as|O a|O critical|O member|O of|O the|O Wnt|gene-rna signaling|O pathway|O ,|O and|O inappropriate|O activation|O of|O this|O pathway|O has|O been|O implicated|O in|O carcinogenesis|O .|O 
METHODS|O :|O 
To|O determine|O the|O clinical|O significance|O of|O beta-catenin|gene-rna in|O hepatocellular|O carcinoma|O (|O HCC|O )|O ,|O we|O performed|O mutational|O analysis|O at|O exon|O 3|O of|O the|gene-rna gene|gene-rna ,|O investigated|O the|O subcellular|O protein|O expression|O ,|O and|O analyzed|O their|O clinicopathologic|O and|O prognostic|O significance|O in|O 60|O patients|O with|O resected|O primary|O HCC|O .|O 
RESULTS|O :|O 
By|O direct|O DNA|O sequencing|O ,|O somatic|O mutations|O of|O the|O beta-catenin|gene-rna gene|O were|O detected|O in|O 7|O (|O 12|O %|O )|O HCCs|O .|O 
All|O the|O mutations|O were|O found|O at|O the|O region|O (|O exon|O 3|O )|O responsible|O for|O phosphorylation|O and|O ubiquitination|O ,|O therefore|O likely|O to|O result|O in|O stabilization|O of|O free|O cytoplasmic|O beta-catenin|gene-protein .|O 
Nuclear|O accumulation|O of|O the|O beta-catenin|gene-protein protein|O ,|O similar|O to|O the|O response|O to|O the|O Wnt|gene-rna signal|O ,|O was|O found|O in|O 10|O (|O 17|O %|O )|O HCCs|O and|O was|O closely|O associated|O with|O gene|O mutation|O (|O P|O <|O 0.001|O )|O .|O 
In|O the|O remaining|O cases|O ,|O nonnuclear|O type|O overexpression|O ,|O that|O is|O ,|O overexpression|O in|O the|O cytoplasm|O and/or|O cytoplasmic|O membrane|O ,|O was|O observed|O in|O 31|O (|O 62|O %|O )|O HCCs|O ,|O thus|O suggesting|O that|O the|O mechanisms|O leading|O to|O beta-catenin|gene-protein overexpression|O may|O be|O heterogeneous|O .|O 
HCCs|O with|O a|O nonnuclear|O type|O of|O beta-catenin|gene-protein overexpression|O were|O more|O frequently|O larger|O than|O 5|O cm|O in|O diameter|O (|O P|O =|O 0.022|O )|O and|O had|O poorer|O cellular|O differentiation|O (|O P|O =|O 0.037|O )|O ,|O and|O the|O patients|O had|O significantly|O shorter|O disease|O -|O free|O survival|O lengths|O (|O P|O =|O 0.041|O )|O .|O 
Review|O of|O the|O data|O from|O previous|O studies|O in|O HCC|O showed|O that|O beta-catenin|gene-rna mutations|O were|O more|O frequent|O in|O HCV|O -|O associated|O HCC|O than|O in|O HBV|O -|O associated|O ones|O .|O 
CONCLUSIONS|O :|O 
beta-catenin|gene-rna mutation|O and|O deregulation|O may|O play|O an|O important|O role|O in|O hepatocarcinogenesis|O .|O 
Nonnuclear|O type|O beta-catenin|gene-protein overexpression|O appeared|O to|O have|O pathologic|O and|O prognostic|O significance|O .|O 
Rapid|O ,|O efficient|O genotyping|O of|O clinical|O tumor|O samples|O by|O laser|O -|O capture|O microdissection|O /|O PCR|O /|O SSCP|O .|O 
Background|O :|O 
Mutation|O analysis|O is|O becoming|O increasingly|O important|O in|O clinical|O practice|O ,|O since|O sporadic|O mutations|O in|O tumors|O often|O correlate|O with|O prognosis|O and/or|O therapeutic|O response|O .|O 
However|O ,|O the|O labor|O -|O intensive|O nature|O of|O the|O molecular|O analyses|O has|O limited|O the|O routine|O clinical|O use|O of|O tumor|O genotyping|O .|O 
Laser|O -|O capture|O microdissection|O (|O LCM|O )|O allows|O procurement|O of|O relatively|O pure|O tumor|O cell|O populations|O .|O 
We|O have|O investigated|O the|O possibility|O that|O the|O use|O of|O laser|O -|O capture|O microdissection|O would|O allow|O elimination|O of|O time|O -|O consuming|O intermediate|O steps|O in|O tumor|O genotyping|O .|O 
Design|O .|O 
Archival|O formalin|O -|O fixed|O ,|O paraffin|O -|O embedded|O tissues|O from|O seven|O cases|O of|O colorectal|O adenocarcinoma|O were|O laser|O -|O and|O hand|O -|O microdissected|O and|O subsequently|O evaluated|O by|O PCR|O /|O SSCP|O /|O sequencing|O for|O Ki-ras|gene-rna exon|O 1|O and|O p53|gene-rna exons|O 5|O ,|O 7|O ,|O and|O 8|O .|O 
Results|O .|O 
Mutations|O in|O Ki-ras|gene-rna exon|O 1|O and/or|O p53|gene-rna exons|O 5|O and|O 7|O were|O detected|O in|O five|O of|O the|O seven|O samples|O .|O 
In|O the|O hand|O -|O microdissected|O samples|O ,|O confident|O identification|O of|O mutations|O was|O possible|O in|O several|O cases|O only|O after|O band|O excision|O ,|O DNA|O elution|O ,|O reamplification|O ,|O and|O verification|O of|O mutant|O enrichment|O by|O a|O second|O SSCP|O analysis|O prior|O to|O sequencing|O .|O 
In|O the|O laser|O -|O microdissected|O samples|O ,|O confident|O mutation|O identification|O was|O possible|O in|O all|O cases|O with|O direct|O sequencing|O of|O the|O original|O PCR|O product|O ,|O reducing|O the|O time|O required|O for|O molecular|O analysis|O to|O 3|O days|O .|O 
Conclusion|O .|O 
Using|O laser|O -|O capture|O microdissection|O ,|O mutant|O signals|O are|O strong|O enough|O to|O sequence|O directly|O from|O original|O PCR|O products|O .|O 
With|O rapid|O ,|O efficient|O genotyping|O by|O LCM|O /|O PCR|O /|O SSCP|O ,|O results|O can|O be|O incorporated|O directly|O into|O the|O surgical|O pathology|O report|O .|O 
No|O major|O difference|O in|O K-ras|gene-rna and|O p53|gene-rna abnormalities|O in|O sporadic|O and|O hereditary|O nonpolyposis|O colorectal|O adenomas|O .|O 
K-ras|gene-rna and|O p53|gene-rna gene|O mutations|O are|O known|O to|O occur|O in|O high|O frequencies|O in|O sporadic|O colorectal|O cancers|O ,|O but|O findings|O are|O inconsistent|O in|O hereditary|O nonpolyposis|O colorectal|O cancer|O (|O HNPCC|O )|O .|O 
We|O compared|O K-ras|gene-rna codon|O 12|O and|O 13|O gene|O mutations|O and|O p53|gene-protein protein|O overexpression|O in|O 48|O HNPCC|O (|O positive|O for|O Amsterdam|O criteria|O )|O and|O 59|O sporadic|O colorectal|O adenomas|O ,|O to|O examine|O whether|O they|O may|O represent|O similar|O or|O different|O molecular|O pathways|O to|O cancer|O .|O 
In|O sporadic|O adenomas|O K-ras|gene-rna mutations|O were|O detected|O in|O 32|O %|O and|O p53|gene-protein overexpression|O in|O 31|O %|O of|O the|O cases|O .|O 
Similarly|O ,|O K-ras|gene-rna mutations|O and|O p53|gene-protein overexpression|O were|O both|O found|O in|O 25|O %|O of|O HNPCC|O adenomas|O .|O 
The|O frequencies|O of|O these|O abnormalities|O were|O not|O significantly|O different|O between|O HNPCC|O and|O sporadic|O adenomas|O .|O 
When|O taking|O differences|O in|O adenoma|O size|O into|O account|O ,|O the|O frequencies|O were|O even|O more|O similar|O .|O 
In|O conclusion|O ,|O these|O results|O suggest|O a|O similar|O molecular|O pathway|O to|O adenomas|O in|O HNPCC|O and|O sporadic|O carcinogenesis|O ,|O with|O respect|O to|O involvement|O of|O K-ras|gene-rna and|O p53|gene-rna .|O 
Combination|O analysis|O of|O genetic|O alterations|O and|O cell|O proliferation|O in|O small|O intestinal|O carcinomas|O .|O 
We|O analyzed|O K-ras|gene-rna and|O p53|gene-rna mutations|O ,|O microsatellite|O instability|O (|O MSI|O )|O ,|O and|O loss|O of|O heterozygosity|O (|O LOH|O )|O using|O the|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O methods|O ,|O as|O well|O as|O p53|gene-generic expression|O and|O the|O Ki-67|gene-protein labeling|O index|O (|O LI|O )|O using|O immunohistochemistry|O in|O 10|O duodenal|O and|O 10|O jejunal|O /|O ileal|O carcinomas|O .|O 
K-ras|gene-rna mutations|O were|O detected|O in|O two|O duodenal|O (|O 20|O %|O )|O and|O three|O jejunal|O /|O ileal|O (|O 30|O %|O )|O carcinomas|O and|O p53|gene-rna mutations|O in|O one|O (|O 10|O %|O )|O and|O three|O (|O 30|O %|O )|O ,|O respectively|O .|O 
LOH|O of|O 17p|O was|O detected|O in|O two|O duodenal|O (|O 20|O %|O )|O and|O two|O jejunal|O /|O ileal|O (|O 20|O %|O )|O carcinomas|O and|O p53|gene-generic expression|O in|O four|O duodenal|O (|O 40|O %|O )|O and|O four|O jejunal|O /|O ileal|O (|O 40|O %|O )|O .|O 
One|O duodenal|O (|O 10|O %|O )|O and|O two|O jejunal|O /|O ileal|O (|O 20|O %|O )|O carcinomas|O demonstrated|O MSI|O .|O 
LOH|O of|O APC|gene-rna was|O detected|O in|O three|O jejunal|O /|O ileal|O (|O 30|O %|O )|O ,|O but|O none|O of|O the|O duodenal|O carcinomas|O .|O 
The|O Ki-67|gene-protein LI|O was|O 44|O %|O in|O duodenal|O and|O 52.6|O %|O in|O jejunal|O /|O ileal|O carcinomas|O .|O 
A|O subset|O of|O small|O intestinal|O carcinomas|O showed|O involvement|O of|O K-ras|gene-rna and|O p53|gene-rna mutations|O ,|O LOH|O of|O APC|gene-rna ,|O and|O MSI|O .|O 
A|O difference|O was|O also|O apparent|O for|O LOH|O of|O APC|gene-rna between|O duodenal|O and|O jejunal|O /|O ileal|O carcinomas|O .|O 
Analysis|O of|O K-ras|gene-rna codon|O 12|O mutations|O and|O p53|gene-generic overexpression|O in|O colorectal|O nodule|O -|O aggregating|O tumors|O .|O 
BACKGROUND|O AND|O AIMS|O :|O 
Morphologically|O ,|O colorectal|O nodule|O -|O aggregating|O tumors|O are|O quite|O different|O from|O polypoid|O -|O type|O colorectal|O tumors|O that|O develop|O via|O the|O adenoma|O -|O carcinoma|O sequence|O .|O 
Although|O polypoid|O -|O type|O colorectal|O tumors|O are|O well|O known|O to|O have|O a|O high|O incidence|O of|O K-ras|gene-rna gene|O mutation|O and|O p53|gene-generic overexpression|O ,|O colorectal|O nodule|O -|O aggregating|O tumors|O have|O not|O been|O examined|O in|O terms|O of|O genetic|O changes|O and|O clinicopathological|O features|O .|O 
In|O the|O present|O study|O ,|O therefore|O ,|O we|O analysed|O the|O clinicopathological|O features|O ,|O genetic|O changes|O in|O K-ras|gene-rna codon|O 12|O ,|O and|O p53|gene-generic overexpression|O in|O colorectal|O nodule|O -|O aggregating|O tumors|O .|O 
METHODS|O :|O 
A|O total|O of|O 18|O colorectal|O nodule|O -|O aggregating|O tumors|O were|O surgically|O resected|O and|O then|O analysed|O clinicopathologically|O .|O 
Immunohistochemistry|O and|O polymerase|gene-protein chain|O reaction|O -|O single|O stranded|O conformational|O polymorphism|O were|O performed|O to|O analyse|O p53|gene-generic abnormalities|O in|O the|O tumors|O .|O 
K-ras|gene-rna codon|O 12|O mutations|O were|O screened|O out|O by|O the|O polymerase|gene-protein chain|O reaction|O -|O restriction|O fragment|O length|O polymorphism|O method|O and|O analysed|O by|O fluorescence|O direct|O sequencing|O .|O 
RESULTS|O :|O 
p53|gene-generic overexpression|O was|O observed|O in|O six|O lesions|O (|O 33|O %|O )|O .|O 
p53|gene-generic -|O overexpressing|O cells|O were|O observed|O in|O parts|O of|O carcinoma|O or|O adenoma|O showing|O high|O -|O grade|O atypia|O .|O 
Four|O of|O the|O 10|O (|O 40|O %|O )|O samples|O had|O a|O p53|gene-rna gene|O mutation|O .|O 
Nine|O of|O the|O 18|O (|O 50|O %|O )|O samples|O had|O a|O K-ras|gene-rna codon|O 12|O point|O mutation|O .|O 
In|O eight|O cases|O (|O 89|O %|O )|O ,|O the|O mutations|O of|O the|O K-ras|gene-rna codon|O 12|O were|O of|O the|O same|O type|O :|O GGT|O (|O glycine|O )|O to|O GTT|O (|O valine|O )|O .|O 
CONCLUSIONS|O :|O 
The|O colorectal|O nodule|O -|O aggregating|O tumor|O has|O distinctive|O characteristics|O showing|O a|O morphological|O phenotype|O of|O the|O superficial|O -|O type|O tumors|O and|O genotype|O of|O the|O polypoid|O tumors|O in|O terms|O of|O K-ras|gene-rna gene|O mutation|O and|O p53|gene-generic overexpression|O .|O 
Impact|O of|O KRAS|gene-rna and|O TP53|gene-rna mutations|O on|O survival|O in|O patients|O with|O left|O -|O and|O right|O -|O sided|O Dukes|O '|O C|O colon|O cancer|O .|O 
OBJECTIVE|O :|O 
It|O has|O been|O suggested|O that|O KRAS|gene-rna and|O TP53|gene-rna mutated|O tumors|O might|O influence|O the|O phenotypic|O behavior|O of|O left|O -|O and|O right|O -|O sided|O colon|O tumors|O .|O 
We|O investigated|O the|O incidence|O of|O these|O mutations|O in|O left|O -|O and|O right|O -|O sided|O colon|O tumors|O and|O their|O possible|O influence|O on|O survival|O in|O a|O homogeneous|O group|O of|O patients|O with|O Dukes|O '|O C|O colon|O cancers|O .|O 
METHODS|O :|O 
The|O primary|O tumors|O of|O 55|O patients|O with|O a|O sporadic|O Dukes|O '|O C|O colon|O cancer|O ,|O all|O treated|O with|O adjuvant|O chemotherapy|O were|O analyzed|O for|O the|O presence|O of|O KRAS|gene-rna and|O TP53|gene-rna mutations|O .|O 
Mutation|O detection|O of|O the|O KRAS|gene-rna and|O TP53|gene-rna genes|O was|O performed|O on|O paraffin|O -|O embedded|O tumor|O material|O ,|O using|O denaturating|O gradient|O gel|O electrophoresis|O .|O 
The|O 5|O -|O yr|O survival|O rates|O of|O KRAS|gene-rna and|O TP53|gene-rna mutated|O tumors|O were|O analyzed|O regarding|O right|O -|O sided|O tumors|O (|O defined|O as|O tumors|O up|O to|O the|O splenic|O flexure|O )|O and|O left|O -|O sided|O tumors|O (|O defined|O as|O tumors|O from|O the|O splenic|O flexure|O to|O the|O rectosigmoid|O peritoneal|O reflection|O )|O .|O 
RESULTS|O :|O 
KRAS|gene-rna mutations|O occurred|O more|O frequently|O in|O the|O right|O colon|O compared|O to|O the|O left|O colon|O (|O R|O =|O 38|O %|O (|O 10|O /|O 26|O )|O ;|O L|O =|O 10|O %|O (|O 3|O /|O 29|O )|O ;|O chi2|O test|O :|O p|O =|O 0.014|O )|O .|O 
KRAS|gene-rna mutations|O did|O not|O influence|O survival|O in|O patients|O with|O right|O -|O sided|O colon|O tumors|O .|O 
Patients|O with|O KRAS|gene-rna mutation|O -|O negative|O tumors|O in|O the|O right|O colon|O ,|O however|O ,|O had|O a|O significantly|O worse|O survival|O than|O patients|O with|O left|O -|O sided|O KRAS|gene-rna mutation|O -|O negative|O tumors|O (|O 5|O -|O yr|O survival|O ;|O R|O :|O 34|O %|O vs|O L|O :|O 65|O %|O ,|O log|O -|O rank|O test|O :|O p|O =|O 0.007|O )|O .|O 
TP53|gene-rna mutations|O of|O a|O possible|O causative|O nature|O were|O found|O in|O 24|O tumors|O (|O 44|O %|O )|O .|O 
Neither|O the|O incidence|O (|O R|O =|O 42|O %|O (|O 11|O /|O 26|O )|O ;|O L|O =|O 45|O %|O (|O 13|O /|O 29|O )|O )|O nor|O the|O survival|O of|O TP53|gene-rna mutated|O tumors|O differed|O significantly|O between|O left|O -|O and|O right|O -|O sided|O tumors|O .|O 
Furthermore|O ,|O survival|O of|O patients|O with|O TP53|gene-rna mutation|O -|O negative|O tumors|O did|O not|O differ|O significantly|O between|O left|O -|O and|O right|O -|O sided|O tumors|O .|O 
CONCLUSIONS|O :|O 
There|O seems|O to|O be|O no|O difference|O in|O survival|O rate|O between|O patients|O with|O KRAS|gene-rna mutated|O and|O KRAS|gene-rna negative|O Dukes|O '|O C|O colon|O tumors|O ;|O however|O ,|O KRAS|gene-rna mutations|O are|O more|O frequently|O found|O in|O the|O right|O colon|O compared|O to|O the|O left|O colon|O .|O 
TP53|gene-rna mutations|O do|O not|O have|O predominance|O for|O either|O side|O of|O the|O colon|O ,|O and|O there|O are|O no|O differences|O in|O survival|O in|O patients|O with|O left|O -|O sided|O versus|O right|O -|O sided|O tumors|O .|O 
Patients|O with|O KRAS|gene-rna -|O nonmutated|O tumors|O in|O the|O right|O colon|O did|O have|O a|O worse|O survival|O compared|O to|O those|O with|O such|O tumors|O in|O the|O left|O colon|O .|O 
This|O suggests|O that|O other|O genetic|O factors|O may|O play|O a|O role|O in|O tumor|O genesis|O in|O this|O subgroup|O of|O patients|O .|O 
Mutational|O analysis|O of|O the|O CTNNB1|gene-rna and|O APC|gene-rna genes|O in|O uterine|O endometrioid|O carcinoma|O .|O 
Despite|O recent|O studies|O ,|O the|O molecular|O genetic|O events|O responsible|O for|O the|O development|O of|O uterine|O endometrioid|O carcinoma|O (|O UEC|O )|O remain|O incompletely|O characterized|O .|O 
Mutations|O in|O the|O beta-catenin|gene-rna (|O CTNNB1|gene-rna )|O gene|O have|O been|O recently|O reported|O in|O a|O small|O percentage|O of|O UECs|O and|O in|O the|O endometrioid|O variant|O of|O ovarian|O carcinoma|O suggesting|O that|O the|O Wnt|gene-generic signal|O transduction|O pathway|O is|O involved|O in|O the|O development|O of|O female|O genital|O tract|O tumors|O with|O endometrioid|O morphology|O .|O 
The|O Wnt|gene-generic pathway|O is|O a|O critical|O pathway|O in|O the|O development|O of|O colorectal|O cancer|O (|O CRC|O )|O with|O mutations|O occurring|O in|O the|O beta-catenin|gene-rna (|O CTNNB1|gene-rna )|O or|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|O APC|gene-rna )|O genes|O in|O 10|O to|O 15|O %|O and|O 85|O %|O of|O cases|O ,|O respectively|O .|O 
Because|O UEC|O and|O CRC|O share|O other|O molecular|O genetic|O alterations|O and|O histologic|O features|O and|O previous|O studies|O of|O UEC|O have|O not|O reported|O an|O analysis|O of|O the|O APC|gene-rna gene|O ,|O we|O chose|O to|O further|O elucidate|O the|O role|O of|O the|O Wnt|gene-generic pathway|O in|O UEC|O .|O 
To|O this|O end|O ,|O we|O analyzed|O 32|O cases|O of|O UEC|O for|O mutations|O of|O the|O CTNNB1|gene-rna and|O APC|gene-rna genes|O .|O 
Mutations|O of|O CTNNB1|gene-rna were|O present|O in|O six|O of|O 32|O (|O 18|O %|O )|O cases|O :|O four|O grade|O 1|O carcinomas|O ,|O one|O grade|O 2|O ,|O and|O one|O grade|O 3|O carcinoma|O .|O 
Five|O missense|O mutations|O were|O identified|O ,|O three|O involving|O Ser|O /|O Thr|O phosphorylation|O sites|O and|O two|O adjacent|O to|O a|O Ser|O phosphorylation|O site|O .|O 
One|O case|O contained|O a|O deletion|O encompassing|O codons|O 34|O to|O 37|O ,|O which|O includes|O a|O Ser|O phosphorylation|O site|O .|O 
No|O mutations|O resulting|O in|O truncation|O of|O the|O APC|gene-protein protein|O were|O found|O .|O 
Our|O results|O support|O a|O role|O for|O the|O Wnt|gene-generic signaling|O pathway|O via|O mutation|O of|O CTNNB1|gene-rna ,|O but|O not|O APC|gene-rna ,|O in|O the|O development|O of|O a|O subset|O of|O UECs|O .|O 
Ras|gene-rna oncogenes|O and|O p53|gene-rna tumor|O suppressor|O gene|O analysis|O in|O cardiac|O myxomas|O .|O 
Although|O ras|gene-rna oncogenes|O and|O p53|gene-rna tumor|O suppressor|O gene|O mutations|O are|O implicated|O in|O the|O development|O of|O several|O human|O tumors|O ,|O little|O is|O known|O about|O their|O role|O in|O the|O pathogenesis|O of|O primary|O cardiac|O tumors|O .|O 
Paraffin|O -|O embedded|O tissue|O from|O 19|O cardiac|O myxomas|O were|O investigated|O for|O the|O presence|O of|O ras|gene-rna oncogenes|O and|O p53|gene-rna tumor|O suppressor|O gene|O abnormalities|O .|O 
Immunohistochemical|O analysis|O was|O used|O to|O identify|O the|O accumulation|O of|O p21|gene-protein -|gene-protein ras|gene-protein and|O p53|gene-protein proteins|O .|O 
A|O polymerase|gene-protein chain|O reaction|O was|O used|O to|O amplify|O exons|O 1|O and|O 2|O of|O the|O ras|gene-rna genes|O and|O exons|O 5|O to|O 8|O of|O the|O p53|gene-rna gene|O .|O 
The|O PCR|O products|O were|O analyzed|O by|O single|O strand|O conformation|O polymorphism|O analysis|O and|O by|O direct|O DNA|O sequencing|O .|O 
Three|O of|O 19|O myxomas|O showed|O strong|O positive|O staining|O for|O the|O ras|gene-protein p21|gene-protein protein|O .|O 
In|O contrast|O ,|O nuclear|O p53|gene-protein was|O not|O detectable|O in|O any|O of|O the|O myxomas|O .|O 
Among|O the|O ras|gene-protein p21|gene-protein immunopositive|O myxomas|O ,|O 2|O were|O heterozygous|O for|O a|O missense|O point|O mutation|O of|O the|O K-ras|gene-rna ,|O Gly|O 12|O Asp|O .|O 
Further|O screening|O of|O the|O remaining|O myxomas|O showed|O no|O mutation|O or|O even|O silent|O polymorphism|O in|O any|O exon|O of|O the|O ras|gene-rna and|O p53|gene-rna .|O 
The|O results|O suggest|O that|O although|O genetic|O alterations|O of|O ras|gene-rna oncogenes|O and|O p53|gene-rna are|O uncommon|O events|O in|O cardiac|O myxomas|O ,|O ras|gene-rna mutations|O may|O be|O involved|O in|O the|O pathogenesis|O of|O a|O subgroup|O of|O this|O type|O of|O tumor|O .|O 
ras|gene-rna gene|O mutations|O in|O salivary|O gland|O tumors|O .|O 
OBJECTIVE|O :|O 
To|O assess|O the|O prevalence|O of|O activating|O mutations|O in|O K-ras|gene-rna and|O H-ras|gene-rna genes|O in|O salivary|O gland|O tumors|O with|O ductal|O or|O acinar|O differentiation|O and|O to|O evaluate|O their|O potential|O correlation|O with|O clinical|O parameters|O .|O 
DESIGN|O :|O 
Paraffin|O -|O embedded|O tissue|O samples|O of|O salivary|O gland|O carcinomas|O were|O investigated|O by|O the|O application|O of|O a|O direct|O sequence|O analysis|O procedure|O with|O automated|O DNA|O sequencing|O of|O polymerase|gene-protein chain|O reaction|O -|O amplified|O ras|gene-rna sequences|O .|O 
SETTING|O :|O 
Tertiary|O care|O teaching|O hospital|O .|O 
PATIENTS|O :|O 
Twenty-four|O patients|O with|O salivary|O gland|O carcinoma|O were|O surgically|O treated|O .|O 
Nine|O had|O adenocarcinoma|O ,|O 1|O had|O adenosquamous|O carcinoma|O ,|O 11|O had|O mucoepidermoid|O carcinoma|O ,|O and|O 3|O had|O acinic|O cell|O carcinoma|O .|O 
RESULTS|O :|O 
Point|O mutations|O were|O detected|O in|O 7|O (|O 29|O %|O )|O of|O the|O 24|O carcinomas|O examined|O .|O 
The|O K-ras|gene-rna gene|O was|O mutated|O in|O only|O 2|O samples|O (|O 8|O %|O )|O :|O a|O GGC|O -|O to|O -|O ATC|O mutation|O at|O codon|O 13|O in|O an|O adenocarcinoma|O and|O a|O GGC|O -|O to|O -|O GTC|O transversion|O mutation|O at|O codon|O 13|O in|O a|O mucoepidermoid|O carcinoma|O .|O 
Five|O (|O 21|O %|O )|O harbored|O H-ras|gene-rna mutations|O :|O 4|O contained|O a|O GGC|O -|O to|O -|O GTC|O transversion|O mutation|O at|O codon|O 12|O and|O 1|O had|O 2|O distinct|O mutations|O ,|O the|O same|O G|O -|O to|O -|O T|O at|O codon|O 12|O as|O was|O shown|O in|O the|O other|O cases|O and|O a|O GGT|O -|O to|O -|O GGA|O heterozygous|O mutation|O at|O codon|O 13|O .|O 
All|O the|O H-ras|gene-rna mutations|O were|O in|O the|O group|O of|O mucoepidermoid|O carcinoma|O lesions|O (|O 45|O %|O ;|O 5|O /|O 11|O )|O .|O 
CONCLUSION|O :|O 
Our|O data|O suggest|O that|O K-ras|gene-rna gene|O alteration|O is|O probably|O not|O an|O important|O factor|O in|O the|O oncogenesis|O of|O human|O salivary|O gland|O tumors|O .|O 
However|O ,|O mutational|O activation|O of|O the|O H-ras|gene-rna gene|O appears|O to|O play|O a|O role|O in|O the|O development|O and/or|O progression|O of|O salivary|O gland|O mucoepidermoid|O carcinomas|O .|O 
Relative|O reciprocity|O of|O NRAS|gene-rna and|O PTEN|gene-rna /|O MMAC1|gene-rna alterations|O in|O cutaneous|O melanoma|O cell|O lines|O .|O 
Both|O inactivation|O of|O the|O tumor|O suppressor|O gene|O ,|O PTEN|gene-rna /|O MMAC1|gene-rna ,|O and|O oncogenic|O activation|O of|O RAS|gene-rna have|O been|O described|O in|O human|O cutaneous|O melanoma|O .|O 
In|O mice|O ,|O activation|O of|O a|O RAS|gene-rna -|O containing|O pathway|O is|O a|O necessary|O step|O in|O the|O pathogenesis|O of|O murine|O melanomas|O .|O 
Because|O PTEN|gene-rna negatively|O regulates|O on|O the|O downstream|O effects|O of|O phosphatidylinositol-3-kinase|gene-protein (|O PI3-K|gene-protein )|O ,|O we|O hypothesized|O that|O the|O loss|O of|O PTEN|gene-rna /|O MMAC1|gene-rna and|O the|O activation|O of|O RAS|gene-rna may|O be|O largely|O equivalent|O because|O RAS|gene-rna is|O a|O known|O positive|O upstream|O regulator|O of|O PI3-K|gene-protein .|O 
We|O expanded|O our|O previous|O survey|O of|O PTEN|gene-rna /|O MMAC1|gene-rna mutations|O and|O analyzed|O the|O RAS|gene-rna status|O of|O 53|O cutaneous|O melanoma|O cell|O lines|O ,|O 18|O glioma|O cell|O lines|O ,|O and|O 17|O uncultured|O cutaneous|O melanoma|O metastasis|O .|O 
Overall|O ,|O 51|O %|O of|O the|O cell|O lines|O had|O alterations|O in|O either|O PTEN|gene-rna /|O MMAC1|gene-rna or|O RAS|gene-rna .|O 
We|O found|O 16|O cell|O lines|O (|O 30|O %|O )|O with|O alterations|O in|O PTEN|gene-rna /|O MMAC1|gene-rna and|O 11|O cell|O lines|O (|O 21|O %|O )|O with|O activating|O NRAS|gene-rna mutations|O ;|O only|O 1|O cell|O line|O had|O concurrent|O alterations|O in|O both|O genes|gene-rna .|O 
Moreover|O ,|O glioma|O cell|O lines|O with|O a|O high|O frequency|O of|O PTEN|gene-rna /|O MMAC1|gene-rna inactivation|O had|O no|O identifiable|O RAS|gene-rna alterations|O .|O 
Ectopic|O expression|O of|O PTEN|gene-rna in|O several|O cutaneous|O melanoma|O cell|O lines|O suppressed|O colony|O formation|O irrespective|O of|O PTEN|gene-rna /|O MMAC1|gene-rna status|O ;|O furthermore|O ,|O PTEN|gene-rna expression|O in|O cell|O lines|O carrying|O activated|O RAS|gene-rna also|O suppressed|O colony|O formation|O .|O 
The|O relative|O reciprocity|O of|O PTEN|gene-rna /|O MMAC1|gene-rna abrogation|O and|O NRAS|gene-rna activation|O suggests|O that|O the|O two|O genetic|O changes|O ,|O in|O a|O subset|O of|O cutaneous|O melanomas|O ,|O are|O functionally|O overlapping|O .|O 
A|O relationship|O between|O K-ras|gene-rna gene|O mutations|O and|O some|O clinical|O and|O histologic|O variables|O in|O patients|O with|O primary|O colorectal|O carcinoma|O .|O 
Mutations|O in|O the|O Kirsten|gene-rna ras|gene-rna 2|gene-rna (|O K-ras|gene-rna )|O gene|O were|O described|O as|O early|O events|O in|O the|O process|O of|O colorectal|O carcinogenesis|O .|O 
The|O aim|O of|O this|O study|O was|O to|O find|O a|O possible|O relationship|O between|O the|O presence|O of|O K-ras|gene-rna mutation|O in|O samples|O of|O primary|O colorectal|O carcinomas|O and|O the|O clinico|O -|O pathological|O data|O of|O the|O investigated|O patients|O .|O 
Mutation|O in|O codon|O 12|O of|O the|O K-ras|gene-rna gene|O was|O determined|O in|O 18|O of|O 53|O colorectal|O carcinomas|O (|O 34|O %|O )|O in|O our|O group|O of|O patients|O .|O 
The|O presence|O of|O K-ras|gene-rna gene|O mutations|O was|O not|O related|O to|O gender|O ,|O age|O of|O subject|O at|O diagnosis|O ,|O staging|O or|O cancer|O location|O (|O p|O >|O 0.05|O )|O .|O 
Sixteen|O of|O the|O 42|O (|O 38|O %|O )|O moderately|O differentiated|O carcinomas|O ,|O and|O two|O of|O the|O eight|O (|O 25|O %|O )|O well|O differentiated|O carcinomas|O contained|O K-ras|gene-rna mutation|O in|O codon|O 12|O ,|O but|O none|O of|O the|O three|O poorly|O differentiated|O carcinomas|O contained|O the|O mutation|O .|O 
Moderately|O differentiated|O tumours|O contained|O an|O aspartate|O code|O GAT|O (|O in|O eight|O cases|O )|O ,|O a|O valine|O code|O GTT|O (|O in|O six|O cases|O )|O ,|O an|O alanine|O code|O GCT|O (|O in|O one|O case|O )|O and|O a|O serine|O code|O AGT|O (|O in|O one|O case|O )|O in|O codon|O 12|O .|O 
Well|O differentiated|O tumours|O contained|O only|O the|O valine|O code|O GTT|O (|O two|O cases|O )|O .|O 
Our|O results|O show|O that|O the|O frequency|O of|O mutations|O in|O the|O K-ras|gene-rna gene|O in|O carcinomas|O in|O Central|O Europe|O is|O not|O different|O from|O the|O frequencies|O found|O in|O other|O parts|O of|O the|O world|O .|O 
The|O homogeneous|O incidence|O of|O K-ras|gene-rna mutation|O does|O not|O seem|O to|O be|O related|O to|O ethnic|O factors|O ,|O dietary|O habits|O ,|O or|O the|O composition|O of|O the|O diet|O .|O 
Frequent|O somatic|O mutations|O of|O the|O beta-catenin|gene-rna gene|O in|O intestinal|O -|O type|O gastric|O cancer|O .|O 
The|O increased|O level|O of|O cytoplasmic|O beta-catenin|gene-generic through|O the|O mutations|O to|O either|O beta-catenin|gene-rna or|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|O APC|gene-rna )|O has|O been|O proposed|O as|O an|O important|O oncogenic|O step|O in|O various|O tumors|O .|O 
Gastric|O cancer|O showed|O frequent|O genetic|O alterations|O of|O the|O APC|gene-rna gene|O ,|O and|O the|O risk|O for|O gastric|O cancer|O in|O familial|O adenomatosus|O polyposis|O patients|O is|O 10|O times|O higher|O than|O that|O in|O the|O general|O population|O .|O 
These|O findings|O raise|O the|O possibility|O that|O mutations|O of|O beta-catenin|gene-rna may|O also|O be|O associated|O with|O the|O development|O of|O gastric|O cancer|O .|O 
We|O detected|O seven|O somatic|O mutations|O in|O a|O portion|O of|O exon|O 3|O encoding|O for|O the|O glycogen|gene-protein synthase|gene-protein kinase|gene-protein 3beta|gene-protein phosphorylation|O consensus|O region|O of|O the|O beta-catenin|gene-rna gene|O in|O 43|O gastric|O cancers|O .|O 
All|O of|O these|O mutations|O were|O missense|O mutations|O ,|O of|O which|O five|O are|O in|O the|O highly|O conserved|O aspartic|O acid|O 32|O and|O two|O are|O in|O serine|O 29|O ;|O all|O of|O these|O seven|O mutations|O were|O detected|O exclusively|O in|O intestinal|O -|O type|O gastric|O cancers|O (|O 7|O of|O 26|O ;|O 26.9|O %|O )|O ,|O but|O not|O in|O the|O diffuse|O -|O type|O (|O 0|O of|O 17|O )|O .|O 
We|O concluded|O that|O disruption|O of|O the|O APC|gene-generic /|O beta-catenin|gene-generic /|O T|gene-protein cell|gene-protein factor|gene-protein -|O lymphoid|gene-protein enhancer|gene-protein binding|gene-protein factor|gene-protein pathway|O might|O play|O an|O important|O role|O especially|O in|O the|O development|O of|O intestinal|O -|O type|O gastric|O cancer|O .|O 
Sampling|O technique|O influences|O the|O detection|O of|O K-ras|gene-rna mutations|O in|O normal|O appearing|O mucosa|O of|O colorectal|O cancer|O patients|O .|O 
Based|O on|O three|O colorectal|O cancer|O cell|O lines|O with|O specified|O K-ras|gene-rna status|O ,|O a|O sensitive|O PCR|O -|O RFLP|O assay|O was|O established|O detecting|O one|O K-ras|gene-rna mutant|O among|O 106|O wild|O -|O type|O cells|O .|O 
Using|O this|O assay|O for|O tissues|O of|O 124|O colorectal|O cancer|O patients|O ,|O 59|O tumor|O (|O 46|O %|O )|O and|O 11|O mucosa|O samples|O (|O 9|O %|O )|O were|O found|O to|O harbor|O a|O K-ras|gene-rna mutation|O .|O 
When|O using|O the|O same|O scalpel|O for|O collecting|O tumor|O and|O mucosa|O tissues|O (|O group|O A|O )|O ,|O 18|O %|O of|O the|O patients|O had|O a|O matching|O K-ras|gene-rna mutation|O in|O both|O tissues|O ,|O but|O this|O coincidence|O was|O seen|O in|O 3|O %|O of|O patients|O only|O ,|O when|O separate|O scalpels|O were|O used|O (|O group|O B|O )|O .|O 
Thus|O we|O conclude|O that|O the|O sampling|O technique|O used|O for|O collecting|O specimens|O is|O a|O major|O contributor|O to|O the|O detection|O of|O K-ras|gene-rna mutations|O in|O normal|O appearing|O mucosa|O when|O a|O highly|O sensitive|O detection|O technique|O is|O used|O .|O 
Beta-catenin|gene-rna mutations|O are|O more|O frequent|O in|O small|O colorectal|O adenomas|O than|O in|O larger|O adenomas|O and|O invasive|O carcinomas|O .|O 
Loss|O of|O serine|O or|O threonine|O phosphorylation|O sites|O from|O exon|O 3|O of|O beta-catenin|gene-rna has|O been|O identified|O in|O approximately|O half|O of|O colorectal|O tumors|O which|O lack|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|O APC|gene-rna )|O mutations|O ,|O but|O the|O overall|O contribution|O of|O beta-catenin|gene-rna mutations|O to|O sporadic|O colorectal|O tumorigenesis|O is|O unclear|O .|O 
We|O therefore|O used|O PCR|O to|O amplify|O and|O sequence|O exon|O 3|O of|O beta-catenin|gene-rna from|O 202|O sporadic|O colorectal|O tumors|O .|O 
Exon|O 3|O beta-catenin|gene-rna mutations|O were|O identified|O in|O 6|O of|O 48|O small|O (|O <|O 1|O cm|O )|O adenomas|O ,|O 2|O of|O 82|O large|O (|O >|O or|O =|O 1|O cm|O )|O adenomas|O ,|O and|O 1|O of|O 72|O invasive|O carcinomas|O .|O 
Eight|O of|O the|O nine|O mutations|O ,|O including|O all|O of|O those|O in|O the|O small|O adenomas|O and|O the|O invasive|O cancer|O ,|O involved|O loss|O of|O serine|O or|O threonine|O phosphorylation|O sites|O .|O 
The|O percentage|O of|O beta-catenin|gene-rna mutations|O in|O small|O adenomas|O (|O 12.5|O %|O )|O was|O significantly|O greater|O than|O that|O in|O large|O adenomas|O (|O 2.4|O %|O )|O and|O invasive|O cancers|O (|O 1.4|O %|O ;|O P|O =|O 0.05|O and|O P|O =|O 0.02|O ,|O respectively|O )|O .|O 
We|O conclude|O that|O mutation|O of|O beta-catenin|gene-rna can|O be|O an|O early|O ,|O perhaps|O initiating|O ,|O event|O in|O colorectal|O tumorigenesis|O .|O 
Small|O adenomas|O with|O beta-catenin|gene-rna mutations|O do|O not|O appear|O to|O be|O as|O likely|O to|O progress|O to|O larger|O adenomas|O and|O invasive|O carcinomas|O as|O other|O adenomas|O ,|O however|O ,|O with|O the|O result|O that|O beta-catenin|gene-rna mutations|O are|O only|O rarely|O seen|O in|O invasive|O cancers|O .|O 
This|O suggests|O that|O APC|gene-rna and|O beta-catenin|gene-rna mutations|O are|O not|O functionally|O equivalent|O ,|O and|O that|O the|O APC|gene-rna gene|O may|O have|O other|O tumor|O suppressor|O functions|O besides|O the|O degradation|O of|O beta-catenin|gene-protein .|O 
A|O common|O human|O skin|O tumour|O is|O caused|O by|O activating|O mutations|O in|O beta-catenin|gene-rna .|O 
WNT|gene-generic signalling|O orchestrates|O a|O number|O of|O developmental|O programs|O .|O 
In|O response|O to|O this|O stimulus|O ,|O cytoplasmic|O beta-catenin|gene-protein (|O encoded|O by|O CTNNB1|gene-rna )|O is|O stabilized|O ,|O enabling|O downstream|O transcriptional|O activation|O by|O members|O of|O the|O LEF|gene-generic /|O TCF|gene-generic family|O .|O 
One|O of|O the|O target|O genes|O for|O beta-catenin|gene-protein /|O TCF|gene-protein encodes|O c-MYC|gene-protein ,|O explaining|O why|O constitutive|O activation|O of|O the|O WNT|gene-generic pathway|O can|O lead|O to|O cancer|O ,|O particularly|O in|O the|O colon|O .|O 
Most|O colon|O cancers|O arise|O from|O mutations|O in|O the|O gene|O encoding|O adenomatous|gene-protein polyposis|gene-protein coli|gene-protein (|O APC|gene-protein )|O ,|O a|O protein|O required|O for|O ubiquitin|gene-protein -|O mediated|O degradation|O of|O beta-catenin|gene-protein ,|O but|O a|O small|O percentage|O of|O colon|O and|O some|O other|O cancers|O harbour|O beta-catenin|gene-generic -|O stabilizing|O mutations|O .|O 
Recently|O ,|O we|O discovered|O that|O transgenic|O mice|O expressing|O an|O activated|O beta-catenin|gene-protein are|O predisposed|O to|O developing|O skin|O tumours|O resembling|O pilomatricomas|O .|O 
Given|O that|O the|O skin|O of|O these|O adult|O mice|O also|O exhibits|O signs|O of|O de|O novo|O hair|O -|O follicle|O morphogenesis|O ,|O we|O wondered|O whether|O human|O pilomatricomas|O might|O originate|O from|O hair|O matrix|O cells|O and|O whether|O they|O might|O possess|O beta-catenin|gene-generic -|O stabilizing|O mutations|O .|O 
Here|O ,|O we|O explore|O the|O cell|O origin|O and|O aetiology|O of|O this|O common|O human|O skin|O tumour|O .|O 
We|O found|O nuclear|O LEF-1|gene-protein in|O the|O dividing|O tumour|O cells|O ,|O providing|O biochemical|O evidence|O that|O pilomatricomas|O are|O derived|O from|O hair|O matrix|O cells|O .|O 
At|O least|O 75|O %|O of|O these|O tumours|O possess|O mutations|O affecting|O the|O amino|O -|O terminal|O segment|O ,|O normally|O involved|O in|O phosphorylation|O -|O dependent|O ,|O ubiquitin|gene-protein -|O mediated|O degradation|O of|O the|O protein|O .|O 
This|O percentage|O of|O CTNNB1|gene-rna mutations|O is|O greater|O than|O in|O all|O other|O human|O tumours|O examined|O thus|O far|O ,|O and|O directly|O implicates|O beta-catenin|gene-generic /|O LEF|gene-generic misregulation|O as|O the|O major|O cause|O of|O hair|O matrix|O cell|O tumorigenesis|O in|O humans|O .|O 
Detection|O of|O Ki-ras|gene-rna and|O p53|gene-rna gene|O mutations|O in|O tissue|O and|O pancreatic|O juice|O from|O pancreatic|O adenocarcinomas|O .|O 
Pancreatic|O carcinomas|O have|O a|O high|O incidence|O of|O Ki-ras|gene-rna mutations|O ,|O and|O the|O genetic|O change|O is|O thought|O to|O occur|O at|O an|O early|O stage|O in|O the|O carcinogenesis|O .|O 
The|O aim|O of|O this|O study|O was|O to|O evaluate|O the|O usefulness|O of|O detecting|O genetic|O mutations|O in|O pure|O pancreatic|O juice|O (|O PPJ|O )|O .|O 
DNA|O was|O extracted|O from|O tissue|O specimens|O of|O pancreatic|O carcinomas|O and|O from|O cells|O in|O PPJ|O ,|O and|O subjected|O to|O polymerase|gene-protein chain|O reaction|O -|O single|O -|O strand|O conformation|O polymorphism|O analysis|O .|O 
Two|O types|O of|O mobility|O shifts|O that|O indicate|O Ki-ras|gene-rna mutations|O were|O observed|O in|O 13|O of|O the|O 20|O (|O 65|O %|O )|O tissue|O specimens|O obtained|O by|O operation|O or|O autopsy|O .|O 
Ten|O of|O 15|O specimens|O (|O 67|O %|O )|O of|O PPJ|O collected|O from|O patients|O with|O pancreatic|O carcinomas|O showed|O two|O types|O of|O mobility|O shifts|O .|O 
Conventional|O imaging|O techniques|O did|O not|O show|O two|O in|O 10|O of|O these|O patients|O .|O 
PPJ|O from|O patients|O with|O non|O -|O cancerous|O pancreatic|O diseases|O showed|O no|O Ki-ras|gene-rna mutations|O .|O 
The|O p53|gene-rna tumor|O suppressor|O gene|O ,|O examined|O by|O PCR|O -|O SSCP|O analysis|O ,|O was|O mutated|O in|O 8|O of|O the|O 20|O tissue|O specimens|O obtained|O by|O operation|O or|O autopsy|O (|O 40|O %|O )|O .|O 
The|O detection|O of|O Ki-ras|gene-rna and|O p53|gene-rna mutations|O in|O PPJ|O could|O be|O useful|O for|O the|O early|O diagnosis|O of|O pancreatic|O carcinomas|O ,|O especially|O for|O neoplastic|O lesions|O of|O the|O intraductal|O type|O .|O 
A|O c-rasHa|gene-rna mutation|O in|O the|O metastasis|O of|O a|O human|O papillomavirus|O (|O HPV|O )|O -|O 18|O positive|O penile|O squamous|O cell|O carcinoma|O suggests|O a|O cooperative|O effect|O between|O HPV-18|O and|O c-rasHa|gene-rna activation|O in|O malignant|O progression|O .|O 
BACKGROUND|O :|O 
Human|O papillomaviruses|O (|O HPV|O )|O have|O been|O implicated|O in|O the|O etiology|O of|O anogenital|O squamous|O epithelial|O tumors|O .|O 
Of|O the|O 65|O HPV|O strains|O ,|O subtypes|O HPV-16|O and|O HPV-18|O frequently|O are|O associated|O with|O malignant|O conditions|O and|O are|O capable|O of|O transforming|O keratinocytes|O in|O vitro|O .|O 
However|O ,|O additional|O cellular|O changes|O are|O necessary|O to|O confer|O tumorigenicity|O to|O HPV|O -|O infected|O cells|O .|O 
Secondary|O events|O implicated|O in|O the|O progression|O to|O malignancy|O include|O loss|O of|O tumor|O suppressor|O genes|O such|O as|O p53|gene-rna and/or|O activation|O of|O cellular|O oncogenes|O such|O as|O c-rasHa|gene-rna .|O 
METHODS|O :|O 
Polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O was|O used|O to|O identify|O HPV-16|O or|O HPV-18|O genetic|O sequence|O in|O primary|O penile|O squamous|O cell|O carcinoma|O and|O two|O inguinal|O lymph|O node|O metastases|O .|O 
p53|gene-rna and|O c-rasHa|gene-rna loci|O were|O analyzed|O by|O sequencing|O of|O PCR|O -|O amplified|O genomic|O DNA|O .|O 
RESULTS|O :|O 
HPV-18|O but|O not|O HPV-16|O infection|O was|O found|O in|O the|O primary|O carcinoma|O and|O in|O inguinal|O metastases|O occurring|O 5|O and|O 7|O years|O after|O the|O initial|O lesion|O .|O 
Sequence|O analysis|O did|O not|O identify|O any|O p53|gene-rna mutations|O in|O the|O primary|O carcinoma|O or|O its|O metastases|O .|O 
However|O ,|O although|O the|O primary|O lesion|O and|O the|O 5|O -|O year|O metastasis|O encoded|O wild|O -|O type|O c-rasHa|gene-rna ,|O the|O 7|O -|O year|O metastasis|O had|O a|O missense|O mutation|O within|O c-rasHa|gene-rna codon|O 61|O .|O 
CONCLUSIONS|O :|O 
To|O the|O authors|O '|O knowledge|O ,|O this|O is|O the|O first|O report|O of|O an|O activating|O c-rasHa|gene-rna mutation|O associated|O with|O squamous|O cell|O carcinoma|O of|O the|O penis|O .|O 
The|O presence|O of|O activated|O c-rasHa|gene-rna in|O the|O second|O metastasis|O but|O not|O in|O the|O first|O metastasis|O or|O the|O primary|O lesion|O suggests|O that|O activation|O of|O c-rasHa|gene-rna may|O be|O a|O late|O event|O in|O the|O malignant|O progression|O of|O HPV-18|O -|O associated|O penile|O squamous|O cell|O carcinoma|O .|O 
Analysis|O of|O additional|O samples|O from|O primary|O lesions|O and|O their|O resultant|O metastases|O is|O necessary|O to|O elucidate|O the|O incidence|O and|O significance|O of|O c-rasHa|gene-rna activation|O in|O penile|O squamous|O cell|O carcinoma|O .|O 
Role|O of|O K-ras|gene-rna mutations|O in|O colorectal|O carcinoma|O .|O 
In|O order|O to|O investigate|O whether|O two|O common|O types|O of|O colorectal|O cancer|O with|O different|O gross|O appearances|O share|O the|O same|O incidence|O of|O K-ras|gene-rna mutation|O ,|O the|O occurrence|O of|O a|O point|O mutation|O in|O codon|O 12|O or|O codon|O 13|O of|O the|O K-ras|gene-rna oncogene|O was|O determined|O in|O 50|O cases|O of|O colorectal|O carcinoma|O .|O 
The|O PCR|O technique|O was|O employed|O ,|O followed|O by|O RFLP|O analysis|O and|O sequencing|O to|O identify|O specific|O point|O mutations|O .|O 
No|O correlation|O was|O found|O between|O the|O presence|O of|O a|O K-ras|gene-rna gene|O mutation|O and|O histological|O parameters|O .|O 
A|O strong|O association|O was|O found|O between|O K-ras|gene-rna mutations|O and|O the|O gross|O polypoid|O appearance|O of|O colorectal|O carcinoma|O (|O polypoid|O 73|O %|O versus|O ulcerative|O 8|O %|O )|O .|O 
The|O results|O indicate|O a|O preferential|O association|O with|O the|O K-ras|gene-rna oncogene|O involved|O in|O polypoid|O type|O colorectal|O carcinoma|O .|O 
Activation|O of|O the|O beta-catenin|gene-rna gene|O by|O interstitial|O deletions|O involving|O exon|O 3|O in|O primary|O colorectal|O carcinomas|O without|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna mutations|O .|O 
Among|O 222|O primary|O colorectal|O cancers|O we|O examined|O ,|O 58|O showed|O no|O detectable|O APC|gene-rna mutations|O by|O the|O protein|O truncation|O test|O .|O 
We|O screened|O those|O 58|O tumors|O for|O somatic|O mutations|O in|O the|O beta-catenin|gene-rna gene|O .|O 
Although|O amino|O acid|O substitutions|O in|O serine|O or|O threonine|O residues|O in|O exon|O 3|O had|O been|O reported|O ,|O we|O found|O no|O such|O mutations|O ;|O however|O ,|O in|O seven|O tumors|O ,|O we|O detected|O somatic|O interstitial|O deletions|O of|O 234|O -|O 760|O bp|O ,|O each|O of|O which|O included|O all|O or|O part|O of|O exon|O 3|O .|O 
Short|O nucleotide|O sequences|O at|O both|O ends|O of|O each|O deletion|O were|O either|O identical|O or|O complementary|O ,|O indicating|O that|O repeated|O or|O inversely|O repeated|O sequences|O were|O involved|O in|O the|O somatic|O rearrangements|O .|O 
Reverse|O transcription|O -|O PCR|O experiments|O using|O RNAs|O isolated|O from|O three|O of|O these|O seven|O tumors|O detected|O transcripts|O that|O lacked|O exon|O 3|O ,|O in|O addition|O to|O the|O normal|O transcript|O .|O 
In|O one|O of|O these|O cases|O ,|O we|O confirmed|O accumulation|O of|O aberrant|O beta-catenin|gene-protein protein|O in|O cytoplasm|O and|O nuclei|O of|O cancer|O cells|O by|O Western|O and|O immunohistochemical|O analyses|O .|O 
This|O result|O suggested|O that|O ,|O in|O the|O absence|O of|O a|O peptide|O encoded|O by|O exon|O 3|O ,|O beta-catenin|gene-protein is|O stabilized|O and|O has|O a|O dominant|O oncogenic|O effect|O on|O colorectal|O tumorigenesis|O .|O 
Tandem|O duplications|O of|O the|O FLT3|gene-rna receptor|gene-rna gene|O are|O associated|O with|O leukemic|O transformation|O of|O myelodysplasia|O .|O 
We|O recently|O reported|O an|O internal|O tandem|O duplication|O of|O the|O human|O flt3|gene-rna receptor|gene-rna gene|O (|O FLT3|gene-rna )|O as|O a|O somatic|O mutation|O in|O 17|O %|O of|O acute|O myelogenous|O leukemia|O (|O AML|O )|O .|O 
The|O present|O study|O revealed|O the|O duplication|O at|O the|O juxtamembrane|O and|O the|O first|O tyrosine|O kinase|O domains|O of|O FLT3|gene-rna in|O seven|O of|O 92|O (|O 8|O %|O )|O patients|O with|O myelodysplastic|O syndrome|O (|O MDS|O )|O and|O AML|O with|O trilineage|O myelodysplasia|O (|O AML|O /|O TMDS|O )|O ,|O the|O diseases|O which|O may|O represent|O neoplastic|O changes|O of|O pluripotent|O stem|O cells|O .|O 
A|O tandem|O duplication|O of|O exon|O 11|O of|O FLT3|gene-rna was|O harbored|O by|O two|O of|O 58|O (|O 3|O %|O )|O patients|O with|O MDS|O and|O five|O of|O 34|O (|O 15|O %|O )|O with|O overt|O leukemia|O ,|O including|O MDS|O -|O derived|O leukemia|O ,|O AML|O /|O TMDS|O and|O therapy|O -|O related|O leukemia|O .|O 
Although|O the|O duplicated|O regions|O varied|O within|O exon|O 11|O in|O each|O case|O ,|O they|O occurred|O in|O -|O frame|O ,|O and|O altered|O mRNA|O expressions|O were|O demonstrated|O by|O reverse|O -|O transcription|O polymerase|gene-protein chain|O reaction|O .|O 
Two|O cases|O of|O MDS|O with|O a|O FLT3|gene-rna duplication|O transformed|O to|O overt|O leukemia|O within|O a|O few|O months|O .|O 
Longitudinal|O analyses|O in|O two|O other|O patients|O with|O leukemia|O revealed|O that|O the|O duplication|O was|O a|O late|O genetic|O event|O during|O the|O disease|O course|O ;|O one|O of|O whom|O showed|O two|O independent|O duplications|O of|O FLT3|gene-rna at|O the|O terminal|O therapy|O -|O resistant|O phase|O .|O 
Of|O seven|O patients|O with|O the|O FLT3|gene-rna duplication|O ,|O six|O had|O abnormal|O karyotypes|O ,|O and|O four|O harbored|O a|O point|O mutation|O of|O the|O N-RAS|gene-rna and/or|O TP53|gene-rna genes|O .|O 
Patients|O with|O FLT3|gene-rna mutations|O have|O poor|O prognoses|O .|O 
This|O study|O uncovered|O the|O fact|O that|O the|O accumulation|O of|O genetic|O events|O ,|O including|O FLT3|gene-rna duplication|O ,|O correlates|O with|O leukemic|O transformation|O from|O antecedent|O myelodysplasia|O and|O with|O subsequent|O disease|O progression|O .|O 
c-kit|gene-rna mutation|O in|O a|O population|O of|O patients|O with|O mastocytosis|O .|O 
The|O c-kit|gene-rna Asp|O 816|O Val|O activating|O mutation|O is|O found|O in|O all|O patients|O with|O mastocytosis|O with|O an|O associated|O hematologic|O disorder|O ,|O and|O at|O least|O in|O a|O subset|O of|O patients|O with|O indolent|O mastocytosis|O .|O 
The|O case|O of|O an|O 11|O -|O month|O -|O old|O child|O is|O presented|O who|O was|O categorized|O as|O having|O indolent|O mastocytosis|O ,|O and|O where|O the|O Asp|O 816|O Val|O mutation|O was|O identified|O in|O lesional|O skin|O ,|O but|O not|O in|O bone|O marrow|O or|O in|O peripheral|O blood|O mononuclear|O cell|O populations|O .|O 
The|O significance|O of|O these|O findings|O is|O discussed|O .|O 
Ki-ras|gene-rna point|O mutation|O in|O different|O types|O of|O colorectal|O carcinomas|O in|O early|O stages|O .|O 
PURPOSE|O :|O 
The|O aim|O of|O this|O study|O was|O to|O elucidate|O pathways|O of|O carcinogenesis|O in|O the|O colon|O and|O rectum|O by|O investigating|O Ki-ras|gene-rna point|O mutation|O in|O different|O types|O of|O colorectal|O carcinomas|O in|O the|O early|O stage|O .|O 
METHODS|O :|O 
We|O analyzed|O rates|O of|O Ki-ras|gene-rna codon|O 12|O mutations|O in|O 34|O small|O ,|O polypoid|O -|O type|O carcinomas|O (|O Tis|O or|O T1|O )|O ,|O 21|O superficial|O -|O type|O carcinomas|O (|O Tis|O or|O T1|O )|O ,|O and|O 42|O advanced|O carcinomas|O (|O T2|O ,|O T3|O ,|O and|O T4|O )|O .|O 
RESULTS|O :|O 
Frequency|O of|O Ki-ras|gene-rna mutations|O in|O superficial|O -|O type|O carcinomas|O was|O 14.3|O percent|O (|O 3|O /|O 21|O )|O ,|O which|O was|O significantly|O lower|O than|O 50|O percent|O (|O 17|O /|O 34|O )|O in|O small|O polypoid|O carcinomas|O and|O 40.5|O percent|O (|O 17|O /|O 42|O )|O in|O advanced|O carcinomas|O .|O 
These|O data|O suggest|O that|O another|O pathway|O of|O colorectal|O carcinogenesis|O that|O does|O not|O involve|O Ki-ras|gene-rna point|O mutation|O might|O exist|O .|O 
Among|O the|O 17|O small|O polypoid|O carcinomas|O with|O Ki-ras|gene-rna point|O mutation|O in|O which|O both|O adenomatous|O and|O carcinomatous|O tissue|O were|O examined|O ,|O 12|O showed|O a|O mutation|O of|O the|O same|O type|O in|O both|O carcinomatous|O and|O adenomatous|O tissues|O .|O 
In|O two|O cases|O ,|O mutation|O was|O present|O only|O in|O carcinomatous|O tissue|O and|O not|O in|O adenomatous|O tissue|O ;|O in|O the|O other|O three|O cases|O ,|O Ki-ras|gene-rna point|O mutation|O was|O present|O only|O in|O adenomatous|O tissue|O but|O not|O in|O carcinomatous|O tissue|O .|O 
CONCLUSIONS|O :|O 
These|O data|O suggest|O that|O carcinoma|O in|O a|O small|O polypoid|O lesion|O does|O not|O always|O develop|O from|O pre|O -|O existing|O adenoma|O with|O Ki-ras|gene-rna point|O mutation|O ;|O in|O a|O small|O number|O of|O the|O polypoid|O -|O type|O early|O carcinomas|O ,|O polyclonal|O composition|O concerning|O the|O Ki-ras|gene-rna gene|O may|O exist|O .|O 
A|O PCR|O -|O RFLP|O method|O for|O the|O detection|O of|O activated|O H-ras|gene-rna oncogene|O with|O a|O point|O mutation|O at|O codon|O 12|O and|O 61|O .|O 
To|O investigate|O the|O incidence|O of|O the|O H-ras|gene-rna gene|O activation|O in|O bladder|O tumor|O and|O the|O feasibility|O of|O using|O urinary|O washout|O samples|O for|O screening|O ,|O a|O series|O of|O 33|O human|O bladder|O tumors|O and|O their|O preoperatively|O collected|O urinary|O washout|O samples|O were|O screened|O using|O a|O mutant|O specific|O PCR|O -|O RFLP|O (|O polymerase|gene-protein chain|O -|O restriction|O fragment|O length|O polymorphism|O )|O to|O detect|O a|O point|O mutation|O of|O the|O H-ras|gene-rna gene|O .|O 
Five|O tumors|O were|O found|O to|O harbor|O H-ras|gene-rna mutations|O where|O two|O tumors|O had|O a|O glycine|O to|O valine|O (|O G|O -->|O T|O )|O change|O in|O codon|O 12|O and|O three|O tumors|O had|O a|O glutamine|O to|O lysine|O (|O C|O -->|O A|O )|O change|O in|O codon|O 61|O ,|O respectively|O .|O 
Moreover|O ,|O we|O could|O also|O detect|O the|O same|O point|O mutations|O of|O the|O H-ras|gene-rna gene|O in|O corresponding|O urine|O washout|O samples|O .|O 
The|O incidence|O of|O H-ras|gene-rna mutation|O in|O Korean|O bladder|O cancer|O was|O estimated|O at|O approximately|O 15.2|O %|O .|O 
In|O conclusion|O ,|O a|O mutant|O specific|O PCR|O -|O RFLP|O method|O for|O the|O detection|O of|O H-ras|gene-rna gene|O mutation|O is|O useful|O for|O screening|O or|O postoperative|O follow|O -|O up|O of|O bladder|O tumor|O due|O to|O its|O simplicity|O and|O high|O specificity|O even|O in|O urinary|O samples|O .|O 
Sporadic|O and|O Thorotrast|O -|O induced|O angiosarcomas|O of|O the|O liver|O manifest|O frequent|O and|O multiple|O point|O mutations|O in|O K-ras-2|gene-rna .|O 
Hepatic|O angiosarcoma|O (|O HA|O )|O is|O an|O uncommon|O neoplasm|O associated|O with|O known|O etiologic|O factors|O in|O 25|O %|O to|O 42|O %|O of|O cases|O .|O 
It|O is|O ,|O however|O ,|O one|O of|O the|O most|O common|O sarcomas|O found|O in|O the|O liver|O .|O 
The|O aim|O of|O this|O study|O was|O to|O find|O was|O to|O find|O mutations|O in|O the|O K-ras-2|gene-rna oncogene|O in|O sporadic|O and|O Thorotrast|O (|O TT|O )|O -|O induced|O HA|O .|O 
Point|O mutations|O in|O K-ras-2|gene-rna were|O sought|O in|O archival|O ,|O formalin|O -|O fixed|O tissue|O blocks|O from|O 24|O patients|O with|O angiosarcoma|O .|O 
Of|O these|O ,|O 19|O cases|O were|O sporadic|O and|O 5|O were|O TT|O -|O induced|O .|O 
Mutational|O analysis|O was|O performed|O by|O topographic|O microdissection|O with|O PCR|O amplification|O followed|O by|O genotyping|O .|O 
Specific|O mutations|O were|O determined|O by|O two|O independent|O methods|O :|O (a)|O direct|O sequencing|O of|O the|O PCR|O product|O confirmed|O by|O rePCR|O and|O by|O using|O a|O different|O sequencing|O primer|O ,|O and|O (b)|O PCR|O -|O based|O selective|O enrichment|O of|O mutant|O DNA|O by|O endonuclease|gene-protein digestion|O followed|O by|O heteroduplex|O DNA|O analysis|O using|O denaturing|O gradient|O gel|O electrophoresis|O .|O 
Eleven|O K-ras-2|gene-rna point|O mutations|O were|O detected|O in|O 7|O of|O 24|O (|O 29|O %|O )|O tumors|O ,|O including|O 5|O of|O 19|O (|O 26|O %|O )|O sporadic|O HA|O and|O 2|O of|O 5|O (|O 40|O %|O )|O TT|O -|O induced|O HA|O .|O 
There|O were|O seven|O G:C|O >|O A:T|O and|O four|O G:C|O >|O T:A|O mutations|O .|O 
All|O seven|O mutated|O tumors|O contained|O a|O codon|O 12|O -|O aspartate|O amino|O acid|O substitution|O .|O 
In|O addition|O ,|O a|O second|O codon|O 12|O -|O cysteine|O mutant|O cell|O population|O was|O present|O in|O one|O of|O two|O codon|O 12|O -|O aspartate|O mutated|O TT|O -|O induced|O HA|O and|O in|O three|O of|O five|O codon|O 12|O -|O aspartate|O sporadic|O tumors|O .|O 
Of|O these|O four|O tumors|O ,|O three|O contained|O both|O aspartate|O and|O cysteine|O mutations|O and|O were|O composed|O of|O multiple|O nodules|O ;|O the|O fourth|O was|O a|O single|O mass|O .|O 
Seventeen|O tumors|O had|O multiple|O nodules|O ;|O whereas|O 5|O had|O a|O K-ras-2|gene-rna mutation|O ,|O 12|O were|O wild|O -|O type|O .|O 
The|O molecular|O pathology|O of|O both|O sporadic|O and|O TT|O -|O induced|O HA|O is|O characterized|O by|O a|O high|O rate|O of|O K-ras-2|gene-rna mutations|O characteristic|O of|O oxidative|O damage|O (|O ie|O ,|O G:C|O >|O A:T|O and|O G:C|O >|O T:A|O mutations|O )|O resulting|O in|O two|O mutated|O population|O sets|O :|O codon|O 12|O GGT|O >|O GAT|O and|O GGT|O >|O TGT|O (|O glycine|O to|O aspartic|O acid|O and|O cysteine|O )|O .|O 
This|O is|O ,|O to|O date|O ,|O the|O first|O study|O to|O characterize|O the|O K-ras-2|gene-rna gene|O mutations|O within|O human|O sporadic|O and|O TT|O -|O induced|O HA|O by|O direct|O sequence|O analysis|O and|O denaturing|O gradient|O gel|O electrophoresis|O .|O 
These|O data|O further|O support|O the|O hypothesis|O linking|O adduct|O -|O forming|O vinyl|O chloride|O exposure|O to|O HA|O containing|O a|O much|O higher|O frequency|O of|O K-ras-2|gene-rna mutations|O and|O a|O mutational|O spectrum|O characteristic|O of|O chloroethylene|O oxide|O ,|O a|O carcinogenic|O metabolite|O of|O vinyl|O chloride|O .|O 
RAS|gene-rna gene|O mutations|O in|O Chinese|O leukaemia|O patients|O and|O members|O of|O a|O family|O with|O high|O incidence|O of|O leukaemia|O .|O 
We|O investigated|O mutations|O of|O N-RAS|gene-rna and|O K-RAS|gene-rna by|O using|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O -|O oligonucleotide|O hybridization|O techniques|O in|O 40|O cases|O of|O Chinese|O leukaemia|O patients|O and|O 17|O presently|O healthy|O members|O of|O a|O family|O with|O high|O incidence|O of|O acute|O myeloid|O leukaemia|O .|O 
The|O results|O showed|O only|O two|O patients|O carried|O the|O mutation|O in|O codon|O 12|O of|O N-RAS|gene-rna .|O 
Strikingly|O ,|O however|O ,|O in|O both|O cases|O the|O malignancies|O involved|O lymphoid|O lineage|O .|O 
There|O was|O no|O hereditary|O RAS|gene-rna mutation|O in|O the|O members|O of|O the|O remarkable|O family|O .|O 
Somatic|O c-KIT|gene-rna activating|O mutation|O in|O urticaria|O pigmentosa|O and|O aggressive|O mastocytosis|O :|O establishment|O of|O clonality|O in|O a|O human|O mast|O cell|O neoplasm|O .|O 
Mastocytosis|O is|O characterized|O by|O accumulations|O of|O mast|O cells|O in|O various|O organs|O (|O 1|O )|O .|O 
Most|O cases|O are|O indolent|O and|O confined|O to|O the|O skin|O ,|O where|O discrete|O mast|O cell|O infiltrates|O are|O associated|O increased|O epidermal|O melanin|gene-protein ,|O a|O clinical|O picture|O known|O as|O urticaria|O pigmentosa|O (|O UP|O )|O .|O 
Other|O forms|O of|O mastocytosis|O combine|O UP|O with|O aggressive|O involvement|O of|O other|O organs|O or|O with|O haemotologic|O abnormalities|O (|O 1|O -|O 4|O )|O .|O 
It|O is|O not|O known|O whether|O all|O forms|O of|O mastocytosis|O are|O true|O neoplasms|O or|O whether|O some|O might|O represent|O reactive|O hyperplasias|O (|O 5|O -|O 7|O )|O .|O 
The|O c-KIT|gene-rna proto|O -|O oncogene|O encodes|O a|O type|gene-protein III|gene-protein receptor|gene-protein tyrosine|gene-protein kinase|gene-protein (|O KIT|gene-protein )|O that|O is|O critical|O to|O the|O development|O and|O survival|O of|O mast|O cells|O and|O melanocytes|O (|O 8|O -|O 11|O )|O .|O 
The|O ligand|O for|O KIT|gene-protein (|O KL|O )|O can|O stimulate|O mast|O cell|O development|O ,|O proliferation|O ,|O and|O mediator|O release|O (|O 9|O ,|O 12|O -|O 17|O )|O ,|O as|O well|O as|O melanocyte|O proliferation|O and|O pigment|O production|O (|O 18|O -|O 20|O )|O .|O 
To|O determine|O the|O role|O of|O c-KIT|gene-rna in|O the|O pathogenesis|O of|O mastocytosis|O ,|O we|O examined|O tissue|O and|O cells|O isolated|O from|O a|O patient|O with|O UP|O and|O aggressive|O systemic|O mastocytosis|O with|O massive|O splenic|O involvement|O .|O 
We|O found|O a|O mutation|O that|O results|O in|O constitutive|O activation|O and|O expression|O of|O c-KIT|gene-rna in|O mast|O cells|O of|O both|O skin|O and|O spleen|O .|O 
This|O is|O the|O first|O in|O situ|O demonstration|O of|O an|O activation|O c-KIT|gene-rna mutation|O in|O neoplastic|O cells|O .|O 
It|O also|O demonstrates|O the|O clonal|O and|O neoplastic|O nature|O of|O this|O form|O of|O mastocytes|O .|O 
H-ras-1|gene-rna point|O mutations|O in|O soft|O tissue|O sarcomas|O .|O 
The|O H-ras-1|gene-rna protooncogene|O is|O activated|O by|O single|O base|O substitutions|O occurring|O in|O either|O codon|O 12|O ,|O 13|O ,|O or|O 61|O .|O 
These|O mutations|O have|O been|O described|O with|O varying|O frequencies|O in|O several|O human|O tumor|O types|O .|O 
Since|O ras|gene-rna oncogenes|O were|O first|O discovered|O as|O the|O transforming|O sequences|O of|O Harvey|O and|O Kirsten|O murine|O sarcoma|O viruses|O (|O which|O also|O contain|O activating|O point|O mutations|O compared|O to|O the|O homologous|O cellular|O sequences|O )|O ,|O we|O wished|O to|O investigate|O the|O possibility|O that|O ras|gene-rna mutations|O might|O also|O occur|O in|O human|O sarcomas|O .|O 
We|O extracted|O DNA|O from|O six|O malignant|O fibrous|O histiocytomas|O (|O MFH|O )|O ,|O three|O embryonal|O rhabdomyosarcomas|O (|O ER|O )|O ,|O one|O alveolar|O rhabdomyosarcoma|O ,|O one|O pleomorphic|O rhabdomyosarcoma|O ,|O and|O one|O leiomyosarcoma|O .|O 
The|O DNA|O from|O regions|O flanking|O codons|O 12|O /|O 13|O and|O codon|O 61|O was|O amplified|O by|O the|O polymerase|gene-protein chain|O reaction|O and|O sequenced|O with|O an|O automated|O DNA|O sequencer|O .|O 
As|O controls|O ,|O we|O amplified|O and|O sequenced|O normal|O DNA|O (|O placenta|O )|O and|O DNA|O with|O known|O point|O mutations|O (|O T24|O bladder|O carcinoma|O cells|O )|O .|O 
We|O found|O three|O cases|O with|O mutations|O ,|O all|O occurring|O in|O codon|O 12|O .|O 
One|O ER|O showed|O a|O G|O -|O to|O -|O T|O mutation|O in|O the|O second|O position|O of|O codon|O 12|O (|O coding|O for|O valine|O instead|O of|O glycine|O )|O .|O 
Two|O MFHs|O showed|O G|O -|O to|O -|O A|O mutations|O in|O the|O second|O position|O of|O codon|O 12|O (|O coding|O for|O aspartic|O acid|O instead|O of|O glycine|O )|O .|O 
Although|O a|O limited|O number|O of|O cases|O were|O sampled|O ,|O we|O conclude|O that|O study|O of|O H-ras-1|gene-rna mutations|O may|O be|O relevant|O to|O MFH|O and|O ER|O .|O 
Additional|O studies|O of|O N|gene-rna and|O K|gene-rna -|gene-rna ras|gene-rna mutations|O as|O well|O as|O more|O cases|O investigating|O H-ras|gene-rna will|O be|O required|O before|O we|O can|O ascertain|O the|O significance|O of|O ras|gene-rna mutations|O in|O the|O oncogenesis|O of|O human|O soft|O tissue|O sarcomas|O .|O 
Amplification|O of|O c-MYC|gene-rna oncogene|O and|O point|O mutation|O of|O N-RAS|gene-rna oncogene|O point|O mutation|O in|O acute|O myelocytic|O leukemias|O with|O double|O minute|O chromosomes|O .|O 
Two|O patients|O with|O acute|O myelocytic|O leukemia|O (|O AML|O )|O showing|O double|O minute|O (|O dmin|O )|O chromosomes|O were|O analysed|O to|O identify|O oncogene|O activation|O .|O 
Cytogenetic|O analysis|O showed|O 1|O -|O 53|O dmin|O chromosomes|O with|O the|O normal|O karyotype|O in|O the|O first|O patient|O and|O 1|O -|O 84|O dmin|O chromosomes|O with|O complex|O chromosome|O aberrations|O .|O 
Analysis|O of|O DNA|O from|O two|O patients|O revealed|O five|O -|O to|O ten|O fold|O amplification|O of|O c-MYC|gene-rna oncogene|O in|O the|O leukemic|O cells|O .|O 
The|O other|O sixteen|O oncogenes|O studied|O showed|O no|O increase|O in|O the|O gene|O content|O .|O 
Furthermore|O ,|O a|O transforming|O gene|O ,|O N-RAS|gene-rna was|O detected|O in|O the|O first|O patient|O by|O nude|O mouse|O tumorigenicity|O assay|O (|O in|O vivo|O selection|O assay|O )|O .|O 
These|O results|O suggest|O that|O the|O amplification|O of|O c-MYC|gene-rna gene|O is|O common|O in|O dmin|O -|O positive|O AML|O patients|O and|O co|O -|O ordination|O of|O c-MYC|gene-rna and|O N-RAS|gene-rna oncogene|O might|O also|O play|O a|O significant|O role|O in|O the|O pathogenesis|O of|O some|O AML|O patients|O .|O 
Cytogenetic|O studies|O ,|O ras|gene-rna mutation|O ,|O and|O clinical|O characteristics|O in|O primary|O myelodysplastic|O syndrome|O .|O 
A|O study|O on|O 68|O Chinese|O patients|O in|O Taiwan|O .|O 
Cytogenetics|O and|O clinical|O features|O were|O studied|O for|O 68|O Chinese|O patients|O with|O primary|O myelodysplastic|O syndrome|O (|O MDS|O )|O .|O 
Ras|gene-rna mutation|O was|O analyzed|O in|O 25|O of|O them|O .|O 
Thirty-four|O patients|O (|O 50|O %|O )|O had|O clonal|O chromosomal|O abnormalities|O at|O initial|O analysis|O .|O 
The|O most|O common|O cytogenetic|O aberrations|O were|O -|O 7|O ,|O +|O 8|O ,|O 5q|O -|O ,|O and|O 20q|O -|O ,|O which|O occurred|O in|O 11|O (|O 16.2|O %|O )|O ,|O seven|O (|O 10.3|O %|O )|O ,|O five|O (|O 7.4|O %|O )|O and|O three|O patients|O ,|O respectively|O .|O 
The|O incidence|O of|O -|O 7|O was|O higher|O and|O that|O of|O 5q|O -|O lower|O in|O our|O patients|O than|O in|O patients|O from|O most|O other|O geographic|O areas|O .|O 
The|O 17|O patients|O with|O multiple|O chromosomal|O abnormalities|O had|O a|O significantly|O shorter|O median|O survival|O (|O 9|O months|O )|O than|O the|O 34|O patients|O with|O normal|O karyotype|O (|O 33|O months|O )|O and|O the|O 17|O patients|O with|O patients|O with|O single|O anomalies|O (|O 26|O months|O )|O .|O 
Evolution|O to|O acute|O leukemia|O occurred|O in|O 20|O patients|O (|O 29|O %|O )|O after|O a|O median|O interval|O of|O 8|O months|O following|O the|O diagnosis|O .|O 
Patients|O with|O multiple|O cytogenetic|O changes|O at|O initial|O analysis|O or|O in|O subsequent|O studies|O had|O a|O significantly|O higher|O frequency|O of|O acute|O transformation|O than|O others|O (|O 55|O %|O vs.|O 18.6|O %|O ,|O p|O =|O 0.007|O )|O ;|O the|O same|O was|O not|O true|O if|O only|O the|O data|O of|O initial|O study|O were|O considered|O .|O 
Serial|O cytogenetic|O studies|O are|O important|O in|O patient|O follow|O -|O up|O .|O 
N-ras|gene-rna mutation|O was|O detected|O in|O 5|O (|O 20|O %|O )|O of|O 25|O patients|O within|O the|O study|O .|O 
There|O was|O no|O correlation|O between|O the|O gene|gene-rna mutation|O and|O acute|O transformation|O .|O 
But|O combing|O the|O data|O of|O N-ras|gene-rna mutation|O and|O cytogenetics|O ,|O patients|O with|O either|O the|O N-ras|gene-rna mutation|O or|O clonal|O chromosomal|O abnormalities|O were|O at|O significantly|O higher|O risk|O for|O developing|O acute|O leukemia|O than|O those|O with|O neither|O of|O the|O changes|O (|O 77|O %|O vs.|O 25|O %|O )|O .|O 
Mutations|O of|O the|O N-ras|gene-rna gene|O in|O juvenile|O chronic|O myelogenous|O leukemia|O .|O 
Juvenile|O chronic|O myelogenous|O leukemia|O (|O JCML|O )|O ,|O a|O myeloproliferative|O disorder|O of|O childhood|O ,|O is|O distinct|O from|O adult|O -|O type|O chronic|O myelogenous|O leukemia|O (|O CML|O )|O and|O bears|O resemblance|O to|O chronic|O myelomonocytic|O leukemia|O (|O CMMoL|O )|O .|O 
Since|O mutations|O in|O the|O N-ras|gene-rna gene|O have|O been|O found|O at|O high|O frequencies|O in|O CMMoL|O ,|O but|O only|O rarely|O in|O CML|O ,|O we|O analyzed|O mutations|O activating|O the|O N-ras|gene-rna gene|O in|O 20|O patients|O with|O JCML|O .|O 
We|O used|O the|O strategy|O for|O analysis|O of|O gene|O mutations|O based|O on|O in|O vitro|O DNA|O amplification|O by|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O followed|O by|O single|O -|O strand|O conformation|O polymorphism|O (|O SSCP|O )|O analysis|O and/or|O direct|O sequence|O analysis|O .|O 
Nucleotide|O sequence|O analysis|O showed|O single|O nucleotide|O substitutions|O involving|O codons|O 12|O ,|O 13|O ,|O or|O 61|O in|O six|O of|O 20|O patients|O (|O 30|O %|O )|O .|O 
Four|O of|O six|O patients|O with|O mutations|O were|O in|O chronic|O phase|O and|O the|O other|O two|O in|O blast|O crisis|O ,|O indicating|O no|O apparent|O correlation|O with|O disease|O stage|O .|O 
Most|O of|O the|O patients|O with|O mutations|O were|O in|O the|O older|O age|O group|O with|O poor|O prognosis|O ,|O although|O one|O patient|O in|O the|O younger|O age|O group|O also|O harbored|O the|O mutation|O .|O 
These|O data|O suggest|O that|O N-ras|gene-rna gene|O mutations|O may|O be|O involved|O in|O the|O pathogenesis|O and/or|O prognosis|O of|O JCML|O and|O provide|O further|O evidence|O that|O JCML|O is|O an|O entity|O distinct|O from|O CML|O .|O 
Establishment|O and|O characterization|O of|O a|O novel|O myeloid|O cell|O line|O from|O the|O bone|O marrow|O of|O a|O patient|O with|O the|O myelodysplastic|O syndrome|O .|O 
A|O novel|O long|O -|O term|O cultured|O myeloid|O cell|O line|O was|O established|O from|O the|O bone|O marrow|O of|O a|O patient|O with|O myelodysplastic|O syndrome|O (|O MDS|O )|O .|O 
This|O cell|O line|O ,|O designated|O MDS92|O ,|O proliferated|O in|O the|O presence|O of|O interleukin-3|gene-protein or|O granulocyte|gene-protein -|gene-protein macrophage|gene-protein colony|gene-protein -|gene-protein stimulating|gene-protein factor|gene-protein and|O transiently|O in|O the|O presence|O of|O Steel|gene-protein factor|gene-protein ,|O with|O a|O tendency|O for|O gradual|O maturation|O ,|O and|O formed|O myeloid|O colonies|O in|O the|O semi|O -|O solid|O culture|O condition|O .|O 
In|O addition|O ,|O the|O MDS92|O cell|O line|O represented|O rather|O complicated|O karyotypic|O abnormalities|O including|O the|O deletion|O of|O fifth|O and|O seventh|O chromosomes|O and|O a|O point|O mutation|O at|O codon|O 12|O of|O the|O N-ras|gene-rna oncogene|O .|O 
These|O characteristics|O of|O the|O MDS92|O cell|O line|O are|O exclusively|O compatible|O with|O the|O property|O of|O preleukaemia|O .|O 
State|O of|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna gene|O and|O ras|gene-rna oncogenes|O in|O Japanese|O prostate|O cancer|O .|O 
Genetic|O alterations|O of|O ras|gene-rna oncogenes|O (|O K|gene-rna -|gene-rna ,|O H|gene-rna -|gene-rna and|O N|gene-rna -|gene-rna ras|gene-rna )|O and|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|O APC|gene-rna )|O gene|O in|O tissues|O of|O prostate|O cancer|O from|O Japanese|O patients|O were|O examined|O using|O PCR|O -|O SSCP|O (|O polymerase|gene-protein chain|O reaction|O -|O single|O strand|O conformation|O polymorphism|O )|O analysis|O and|O direct|O sequencing|O .|O 
Tissues|O from|O 8|O cases|O of|O untreated|O stage|O B|O prostate|O cancer|O surgically|O removed|O and|O from|O 10|O cases|O of|O endocrine|O therapy|O -|O resistant|O metastatic|O disease|O obtained|O at|O autopsy|O were|O used|O in|O the|O present|O study|O .|O 
In|O four|O out|O of|O 18|O cases|O (|O 22|O %|O )|O ,|O ras|gene-rna point|O mutations|O were|O found|O ,|O two|O in|O either|O codon|O 12|O or|O 61|O of|O K-ras|gene-rna and|O two|O in|O either|O 13|O or|O 61|O of|O H-ras|gene-rna .|O 
These|O point|O mutations|O were|O detected|O in|O one|O of|O the|O stage|O B|O cases|O (|O 13|O %|O )|O and|O in|O three|O of|O the|O autopsy|O cases|O (|O 30|O %|O )|O .|O 
All|O these|O cases|O were|O poorly|O differentiated|O adenocarcinoma|O .|O 
In|O autopsy|O cases|O showing|O ras|gene-rna mutation|O in|O cancerous|O prostate|O ,|O the|O same|O alteration|O was|O observed|O in|O metastatic|O tissues|O .|O 
No|O APC|gene-rna gene|O mutation|O was|O detected|O in|O any|O sample|O ,|O although|O polymorphism|O was|O found|O in|O some|O cases|O .|O 
These|O results|O indicate|O that|O ras|gene-rna oncogene|O mutations|O are|O related|O to|O the|O progression|O of|O prostate|O cancer|O ,|O whereas|O APC|gene-rna gene|O alteration|O is|O not|O involved|O in|O tumorigenesis|O and|O development|O of|O this|O cancer|O .|O 
Analysis|O of|O ras|gene-rna mutations|O in|O human|O melanocytic|O lesions|O :|O activation|O of|O the|O ras|gene-rna gene|O seems|O to|O be|O associated|O with|O the|O nodular|O type|O of|O human|O malignant|O melanoma|O .|O 
We|O have|O analyzed|O the|O Ha-ras|gene-rna ,|O Ki-ras|gene-rna and|O N-ras|gene-rna gene|O for|O point|O mutations|O at|O codons|O 12|O ,|O 13|O and|O 61|O via|O restriction|O fragment|O length|O polymorphism|O /|O polymerase|gene-protein chain|O reaction|O analysis|O and|O subsequent|O direct|O sequencing|O in|O non|O -|O cultured|O fresh|O -|O frozen|O tissues|O of|O 16|O superficial|O spreading|O melanomas|O (|O SSM|O )|O ,|O 13|O nodular|O malignant|O melanomas|O (|O NMM|O )|O ,|O 2|O lentigo|O malignant|O melanomas|O (|O LMM|O )|O ,|O 1|O dysplastic|O nevus|O ,|O 1|O congenital|O nevus|O and|O 5|O normal|O nevi|O from|O 38|O patients|O .|O 
Mutations|O were|O found|O in|O 4|O melanoma|O samples|O ,|O all|O belonging|O to|O the|O nodular|O malignant|O type|O .|O 
Three|O of|O them|O were|O mutated|O in|O N-ras|gene-rna and|O one|O in|O the|O Ha-ras|gene-rna gene|O .|O 
Mutation|O in|O N-ras|gene-rna was|O also|O detected|O in|O the|O congenital|O nevus|O .|O 
All|O mutations|O were|O exclusively|O located|O at|O the|O first|O two|O base|O pairs|O of|O codon|O 61|O .|O 
No|O Ki-ras|gene-rna mutation|O was|O detected|O in|O any|O lesion|O .|O 
No|O mutation|O could|O be|O found|O in|O SSM|O and|O LMM|O in|O addition|O to|O dysplastic|O and|O normal|O nevi|O .|O 
The|O frequency|O of|O ras|gene-rna mutation|O in|O NMM|O was|O 31|O %|O ,|O whereas|O in|O SSM|O it|O was|O 0|O %|O .|O 
Our|O study|O suggests|O (a)|O an|O association|O between|O ras|gene-rna mutations|O (|O mainly|O N-ras|gene-rna )|O and|O the|O NMM|O as|O a|O subgroup|O of|O human|O melanoma|O ;|O (b)|O that|O activation|O of|O Ki-ras|gene-rna is|O not|O involved|O in|O the|O pathogenesis|O of|O melanoma|O .|O 
The|O role|O of|O UV|O radiation|O in|O point|O mutations|O of|O ras|gene-rna genes|O in|O human|O melanoma|O is|O discussed|O .|O 
Ras|gene-rna gene|O mutations|O :|O a|O rare|O event|O in|O nonmetastatic|O primary|O malignant|O melanoma|O .|O 
Ras|gene-rna gene|O mutations|O have|O been|O implicated|O in|O the|O pathogenesis|O of|O a|O variety|O of|O human|O tumors|O .|O 
Mutated|O ras|gene-rna genes|O have|O been|O isolated|O from|O human|O melanoma|O cell|O lines|O ,|O but|O subsequent|O studies|O indicated|O that|O ras|gene-rna gene|O mutations|O may|O be|O a|O rare|O event|O in|O melanocytic|O lesions|O .|O 
Recently|O ,|O a|O study|O reported|O a|O high|O frequency|O of|O ras|gene-rna mutations|O correlated|O with|O increasing|O invasion|O level|O .|O 
To|O address|O this|O inconsistency|O in|O the|O published|O data|O ,|O we|O analyzed|O 50|O primary|O melanomas|O to|O correlate|O invasion|O level|O ,|O tumor|O thickness|O ,|O histologic|O typing|O ,|O and|O body|O localization|O with|O point|O mutations|O around|O codons|O 12|O /|O 13|O /|O 61|O of|O the|O three|O ras|gene-rna genes|O .|O 
After|O micro|O -|O dissection|O of|O paraffin|O -|O embedded|O tumor|O tissue|O ,|O ras|gene-rna gene|O mutations|O were|O analyzed|O by|O direct|O sequencing|O of|O tumor|O DNA|O amplified|O by|O polymerase|gene-protein chain|O reaction|O .|O 
Only|O two|O melanomas|O exhibited|O ras|gene-rna gene|O mutations|O ,|O one|O sample|O containing|O a|O transition|O from|O A|O to|O G|O at|O position|O 2|O of|O N-ras|gene-rna codon|O 61|O and|O the|O other|O exhibiting|O a|O transversion|O from|O C|O to|O A|O at|O position|O 1|O and|O a|O transition|O from|O A|O to|O G|O at|O position|O 2|O of|O N-ras|gene-rna codon|O 61|O .|O 
Both|O tumors|O were|O classified|O as|O Clark|O level|O IV|O ,|O with|O a|O tumor|O thickness|O of|O 2.5|O and|O 1.2|O mm|O ,|O respectively|O .|O 
Both|O were|O typed|O as|O superficial|O spreading|O melanoma|O and|O localized|O to|O intermittently|O sun|O -|O exposed|O body|O sites|O .|O 
The|O low|O frequency|O of|O ras|gene-rna mutations|O in|O malignant|O melanoma|O and|O the|O lack|O of|O ras|gene-rna mutations|O in|O melanoma|O samples|O from|O constantly|O sun|O -|O exposed|O body|O sites|O argue|O against|O the|O hypothesis|O of|O ras|gene-rna mutations|O as|O a|O marker|O of|O progression|O in|O malignant|O melanoma|O and|O the|O suggestion|O that|O ras|gene-rna mutations|O occur|O predominantly|O in|O melanomas|O from|O constantly|O sun|O -|O exposed|O body|O sites|O .|O 
Mechanism|O of|O activation|O of|O an|O N-ras|gene-rna oncogene|O of|O SW-1271|O human|O lung|O carcinoma|O cells|O .|O 
An|O N-ras|gene-rna -|O related|O transforming|O gene|O was|O detected|O in|O the|O human|O lung|O carcinoma|O cell|O line|O SW-1271|O and|O molecularly|O cloned|O .|O 
The|O lesion|O responsible|O for|O its|O acquisition|O of|O transforming|O activity|O was|O localized|O to|O a|O single|O nucleotide|O transition|O from|O A|O to|O G|O in|O codon|O 61|O of|O the|O predicted|O protein|O .|O 
This|O lesion|O in|O the|O second|O exon|O results|O in|O the|O substitution|O of|O arginine|O for|O glutamine|O at|O this|O position|O .|O 
These|O findings|O ,|O together|O with|O previous|O studies|O ,|O indicate|O that|O the|O activation|O of|O ras|gene-rna oncogenes|O in|O human|O tumors|O is|O most|O commonly|O due|O to|O point|O mutations|O at|O one|O of|O two|O major|O "|O hot|O spots|O "|O in|O the|O ras|gene-rna coding|O sequence|O .|O 
A|O point|O mutation|O at|O codon|O 13|O of|O the|O N-ras|gene-rna oncogene|O in|O a|O human|O stomach|O cancer|O .|O 
A|O surgically|O removed|O human|O stomach|O cancer|O with|O the|O histological|O diagnosis|O of|O poorly|O differentiated|O adenocarcinoma|O contained|O an|O activated|O N-ras|gene-rna oncogene|O detected|O by|O an|O in|O vivo|O selection|O assay|O in|O nude|O mice|O using|O transfected|O NIH3T3|O cells|O .|O 
Analysis|O using|O synthetic|O 20|O -|O mer|O oligonucleotide|O probes|O revealed|O a|O point|O mutation|O from|O G|O to|O C|O at|O the|O first|O letter|O of|O codon|O 13|O of|O the|O N-ras|gene-rna gene|O resulting|O in|O the|O substitution|O of|O arginine|O for|O glycine|O .|O 
This|O is|O the|O first|O observation|O of|O an|O activated|O N-ras|gene-rna oncogene|O in|O human|O stomach|O cancers|O .|O 
Mutations|O of|O the|O ras|gene-rna protooncogenes|O in|O chronic|O myelogenous|O leukemia|O :|O a|O high|O frequency|O of|O ras|gene-rna mutations|O in|O bcr|gene-rna /|O abl|gene-rna rearrangement|O -|O negative|O chronic|O myelogenous|O leukemia|O .|O 
Seventy|O cases|O of|O chronic|O myelogenous|O leukemia|O (|O CML|O )|O were|O analyzed|O for|O the|O presence|O of|O ras|gene-rna mutations|O using|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O ,|O oligonucleotide|O hybridization|O ,|O and|O direct|O PCR|O sequencing|O .|O 
All|O cases|O had|O preceding|O cytogenetic|O and|O bcr|gene-rna rearrangement|O studies|O .|O 
Aberrant|O ras|gene-rna genes|O were|O detected|O in|O none|O of|O 39|O patients|O with|O Philadelphia|O (|O Ph|O )|O chromosome|O or|O bcr|gene-rna /|O abl|gene-rna rearrangement|O positive|O chronic|O -|O phase|O CML|O and|O in|O only|O 1|O of|O 18|O patients|O in|O blast|O crisis|O ,|O suggesting|O that|O ras|gene-rna mutations|O have|O little|O or|O no|O role|O in|O initiation|O or|O progression|O of|O common|O CML|O .|O 
Seven|O of|O 13|O ,|O or|O 54|O %|O of|O patients|O with|O bcr|gene-rna /|O abl|gene-rna rearrangement|O negative|O chronic|O phase|O CML|O (|O atypical|O CML|O )|O harbored|O mutations|O in|O ras|gene-rna ,|O however|O .|O 
This|O high|O incidence|O of|O ras|gene-rna mutations|O ,|O together|O with|O the|O absence|O of|O bcr|gene-rna /|O abl|gene-rna rearrangement|O ,|O provides|O evidence|O that|O atypical|O CML|O is|O an|O entity|O that|O is|O molecularly|O distinct|O from|O common|O CML|O .|O 
Moreover|O ,|O the|O clinical|O characteristics|O and|O the|O high|O frequency|O of|O ras|gene-rna mutations|O suggest|O that|O atypical|O CML|O may|O constitute|O a|O subset|O of|O the|O myelodysplastic|O syndrome|O and|O may|O be|O best|O classified|O as|O a|O variant|O of|O chronic|O myelomonocytic|O leukemia|O (|O CMML|O )|O .|O 
Oncogene|O activation|O in|O human|O benign|O tumors|O of|O the|O skin|O (|O keratoacanthomas|O )|O :|O is|O HRAS|gene-rna involved|O in|O differentiation|O as|O well|O as|O proliferation|O ?|O 
In|O vitro|O DNA|O amplification|O followed|O by|O oligonucleotide|O mismatch|O hybridization|O was|O used|O to|O study|O the|O frequency|O of|O HRAS|gene-rna mutations|O in|O the|O benign|O self|O -|O regressing|O skin|O tumors|O keratoacanthomas|O and|O in|O squamous|O cell|O carcinomas|O .|O 
We|O used|O freshly|O obtained|O keratoacanthomas|O as|O well|O as|O Formalin|O -|O fixed|O paraffin|O -|O embedded|O tissues|O from|O both|O types|O of|O tumors|O .|O 
DNA|O from|O 50|O samples|O of|O each|O tumor|O type|O was|O analyzed|O for|O activating|O mutations|O involving|O codons|O 12|O and|O 61|O .|O 
A|O relatively|O high|O percentage|O (|O 30|O %|O )|O of|O HRAS|gene-rna mutations|O was|O found|O in|O the|O keratoacanthomas|O compared|O with|O 13|O %|O in|O the|O squamous|O cell|O carcinomas|O .|O 
The|O most|O frequent|O mutation|O identified|O is|O the|O A-T|O -|O to|O -|O T.A|O transversion|O in|O the|O second|O position|O of|O codon|O 61|O .|O 
The|O present|O findings|O demonstrate|O the|O involvement|O of|O the|O HRAS|gene-rna oncogene|O in|O human|O benign|O tumors|O .|O 
Moreover|O ,|O they|O indicate|O that|O an|O activated|O HRAS|gene-rna oncogene|O is|O not|O sufficient|O to|O maintain|O a|O neoplastic|O phenotype|O and|O argue|O against|O a|O role|O of|O HRAS|gene-rna in|O the|O progression|O of|O skin|O tumorigenesis|O .|O 
Mechanisms|O of|O ras|gene-rna mutation|O in|O myelodysplastic|O syndrome|O .|O 
Using|O synthetic|O oligonucleotide|O hybridization|O ,|O we|O have|O found|O a|O ras|gene-rna mutation|O in|O 11|O of|O 27|O patients|O (|O 41|O %|O )|O with|O primary|O or|O non|O -|O therapy|O related|O myelodysplastic|O syndrome|O (|O MDS|O )|O .|O 
This|O high|O incidence|O of|O mutation|O ,|O mainly|O of|O the|O N-ras|gene-rna oncogene|O ,|O was|O generally|O found|O in|O patients|O with|O disease|O progression|O to|O acute|O leukemia|O (|O 8|O of|O 11|O patients|O =|O 73|O %|O )|O .|O 
Two|O general|O mechanisms|O of|O ras|gene-rna mutation|O were|O found|O .|O 
In|O five|O patients|O the|O ras|gene-rna mutation|O was|O present|O in|O only|O a|O fraction|O of|O the|O cells|O ;|O sometimes|O appearing|O in|O late|O stages|O of|O the|O disease|O ,|O suggesting|O that|O it|O can|O occur|O in|O a|O differentiated|O cell|O clone|O .|O 
In|O six|O other|O patients|O ,|O the|O ras|gene-rna mutation|O was|O present|O in|O the|O great|O majority|O of|O bone|O marrow|O or|O blood|O cells|O .|O 
The|O mutation|O was|O detected|O in|O mature|O normal|O lymphocytes|O and|O persisted|O following|O a|O complete|O clinical|O remission|O in|O two|O of|O these|O patients|O ,|O implying|O that|O the|O ras|gene-rna mutation|O can|O occur|O in|O an|O early|O stage|O of|O cell|O differentiation|O or|O stem|O cell|O .|O 
Patients|O with|O a|O ras|gene-rna mutation|O had|O a|O median|O survival|O of|O nine|O months|O (|O all|O patients|O dead|O )|O compared|O to|O 16|O patients|O without|O a|O ras|gene-rna mutation|O that|O had|O a|O median|O follow|O -|O up|O of|O 16|O months|O (|O 10|O patients|O alive|O ;|O P|O less|O than|O 0.005|O )|O .|O 
Since|O 9|O of|O the|O 11|O patients|O (|O 82|O %|O )|O with|O a|O ras|gene-rna mutation|O were|O found|O to|O have|O an|O abnormal|O monocytic|O component|O at|O diagnosis|O or|O during|O disease|O evolution|O ,|O it|O is|O possible|O that|O in|O myeloid|O disorders|O a|O ras|gene-rna mutation|O is|O preferentially|O associated|O with|O myelomonocytic|O cell|O differentiation|O .|O 
The|O pattern|O of|O mutational|O involvement|O of|O RAS|gene-rna genes|O in|O human|O hematologic|O malignancies|O determined|O by|O DNA|O amplification|O and|O direct|O sequencing|O .|O 
DNA|O from|O 161|O patients|O with|O various|O forms|O of|O hematologic|O malignancies|O were|O investigated|O for|O mutations|O in|O exons|O 1|O and|O 2|O of|O the|O N-RAS|gene-rna ,|O K-RAS|gene-rna and|O Ha-RAS|gene-rna gene|O by|O direct|O sequencing|O of|O DNA|O amplified|O in|O vitro|O by|O the|O polymerase|gene-protein chain|O reaction|O .|O 
Mutations|O involving|O either|O codons|O 11|O ,|O 12|O ,|O or|O 13|O of|O the|O N-RAS|gene-rna gene|O were|O identified|O in|O 18|O of|O the|O 161|O patients|O .|O 
The|O relative|O frequencies|O of|O N-RAS|gene-rna gene|O mutations|O in|O these|O hematologic|O disorders|O was|O as|O follows|O :|O acute|O myelogenous|O leukemia|O (|O AML|O )|O ,|O 15|O %|O ;|O acute|O lymphoblastic|O leukemia|O (|O ALL|O )|O ,|O 14|O %|O ;|O myelodysplastic|O syndromes|O ,|O 24|O %|O ;|O and|O myeloid|O and|O lymphoid|O blast|O crisis|O of|O chronic|O myelogenous|O leukemia|O (|O CML|O )|O ,|O 3|O %|O .|O 
No|O correlation|O was|O observed|O between|O the|O presence|O of|O mutations|O and|O cytologic|O features|O or|O immunophenotype|O of|O these|O malignancies|O .|O 
Mutations|O involving|O codons|O 12|O or|O 13|O were|O equally|O prevalent|O ,|O with|O a|O glycine|O to|O aspartic|O acid|O substitution|O being|O the|O most|O frequently|O encountered|O change|O .|O 
A|O single|O T-ALL|O case|O had|O a|O codon|O 11|O mutation|O resulting|O in|O substitution|O of|O alanine|O with|O threonine|O .|O 
We|O failed|O to|O find|O mutations|O in|O exons|O 1|O and|O 2|O of|O the|O K-RAS|gene-rna or|O Ha-RAS|gene-rna genes|O in|O any|O case|O except|O a|O single|O AML|O with|O a|O mutation|O in|O codon|O 61|O of|O the|O K-RAS|gene-rna gene|O .|O 
Also|O ,|O no|O mutations|O were|O identified|O in|O chronic|O phase|O of|O CML|O ,|O chronic|O lymphocytic|O leukemia|O .|O 
Ph1|O positive|O ALL|O ,|O non|O -|O Hodgkin|O 's|O lymphoma|O ,|O Hodgkin|O 's|O disease|O ,|O or|O multiple|O myeloma|O .|O 
These|O results|O indicate|O that|O RAS|gene-rna mutations|O ,|O especially|O those|O involving|O exon|O 1|O of|O the|O N-RAS|gene-rna gene|O ,|O are|O frequent|O only|O in|O a|O subset|O of|O hematologic|O malignancies|O .|O 
High|O rates|O of|O ras|gene-rna codon|O 61|O mutation|O in|O thyroid|O tumors|O in|O an|O iodide|O -|O deficient|O area|O .|O 
Using|O polymerase|gene-protein chain|O reaction|O and|O sequence|O -|O specific|O oligonucleotide|O hybridization|O ,|O the|O frequency|O of|O three|O ras|gene-rna oncogene|O mutations|O (|O N-ras|gene-rna ,|O Ha-ras|gene-rna ,|O and|O K-ras|gene-rna )|O in|O thyroid|O tumors|O (|O 25|O adenomas|O ,|O 16|O follicular|O carcinomas|O ,|O and|O 22|O papillary|O carcinomas|O )|O was|O investigated|O in|O both|O iodide|O -|O deficient|O and|O iodide|O -|O sufficient|O areas|O .|O 
The|O ras|gene-rna oncogene|O mutation|O rate|O was|O significantly|O higher|O in|O the|O iodide|O -|O deficient|O area|O ,|O being|O 85|O versus|O 17|O %|O in|O the|O adenomas|O ,|O and|O 50|O versus|O 10|O %|O in|O the|O follicular|O carcinomas|O .|O 
No|O mutations|O were|O found|O in|O papillary|O carcinomas|O .|O 
The|O most|O common|O mutation|O site|O was|O Ha-ras|gene-rna codon|O 61|O with|O Gln|O ----|O Arg|O substitution|O .|O 
Two|O ras|gene-rna mutations|O at|O codon|O 61|O (|O Gln|O ----|O Lys|O in|O N-ras|gene-rna and|O Gln|O ----|O Arg|O in|O Ha-ras|gene-rna )|O were|O found|O in|O a|O microfollicular|O adenoma|O specimen|O from|O Eastern|O Hungary|O .|O 
We|O conclude|O that|O dietary|O iodine|O may|O modulate|O ras|gene-rna oncogene|O mutations|O ,|O and|O that|O in|O the|O iodide|O -|O deficient|O area|O ,|O ras|gene-rna oncogene|O activation|O may|O play|O a|O more|O important|O role|O in|O the|O initiation|O and/or|O maintenance|O of|O follicular|O tumors|O .|O 
Additional|O factors|O are|O ,|O however|O ,|O necessary|O to|O initiate|O carcinogenesis|O .|O 
Ras|gene-rna mutations|O in|O human|O pituitary|O tumors|O .|O 
The|O cellular|O basis|O for|O pituitary|O neoplasia|O is|O poorly|O understood|O .|O 
Mutations|O that|O activate|O the|O ras|gene-rna protooncogenes|O have|O been|O identified|O in|O a|O number|O of|O different|O types|O of|O human|O cancers|O and|O potentially|O represent|O one|O of|O the|O genetic|O alterations|O that|O occur|O in|O pituitary|O tumors|O .|O 
In|O this|O study|O we|O examined|O 19|O pituitary|O tumors|O for|O the|O occurrence|O of|O ras|gene-rna mutations|O .|O 
The|O tumor|O types|O included|O 11|O nonfunctioning|O adenomas|O ,|O 6|O somatotroph|O adenomas|O ,|O and|O 2|O prolactinomas|O .|O 
Each|O of|O the|O three|O ras|gene-rna genes|O (|O K-ras|gene-rna ,|O N-ras|gene-rna ,|O and|O H-ras|gene-rna )|O was|O amplified|O from|O pituitary|O tumor|O DNA|O using|O the|O polymerase|gene-protein chain|O reaction|O .|O 
Oligonucleotide|O -|O specific|O hybridization|O was|O used|O to|O screen|O for|O mutations|O that|O inhibit|O GTPase|gene-protein activity|O and|O cause|O activation|O of|O the|O ras|gene-rna oncogene|O .|O 
No|O ras|gene-rna mutations|O were|O observed|O in|O 18|O of|O the|O pituitary|O adenomas|O .|O 
However|O ,|O a|O mutation|O was|O identified|O in|O codon|O 12|O of|O the|O H-ras|gene-rna gene|O (|O Gly|O to|O Val|O )|O in|O a|O recurrent|O prolactinoma|O that|O was|O highly|O invasive|O and|O ultimately|O proved|O to|O be|O fatal|O .|O 
We|O conclude|O that|O ras|gene-rna mutations|O are|O uncommon|O in|O pituitary|O adenomas|O ,|O but|O may|O provide|O a|O marker|O for|O highly|O invasive|O tumors|O .|O 
Heterogeneous|O genetic|O alterations|O in|O ovarian|O mucinous|O tumors|O :|O application|O and|O usefulness|O of|O laser|O capture|O microdissection|O .|O 
Histologic|O observation|O of|O ovarian|O mucinous|O tumors|O suggests|O that|O there|O is|O a|O multistep|O transition|O through|O the|O accumulation|O of|O genetic|O alterations|O .|O 
We|O analyzed|O loss|O of|O heterozygosity|O (|O LOH|O )|O and|O replication|O error|O (|O RER|O )|O on|O TP53|gene-rna and|O D17S855|gene-rna as|O well|O as|O K-ras|gene-rna point|O mutations|O of|O the|O heterogeneous|O histologic|O areas|O of|O the|O same|O tumor|O in|O 26|O cases|O of|O ovarian|O mucinous|O tumor|O .|O 
The|O laser|O capture|O microdissection|O (|O LCM|O )|O technique|O has|O been|O applied|O to|O the|O study|O of|O K-ras|gene-rna point|O mutation|O in|O 10|O cases|O .|O 
As|O for|O genetic|O alterations|O for|O LOH|O or|O RER|O on|O TP53|gene-rna and|O D17S855|gene-rna ,|O 2|O (|O 1|O borderline|O tumor|O and|O 1|O carcinoma|O )|O of|O 14|O cases|O and|O 4|O (|O 1|O borderline|O tumor|O and|O 3|O carcinomas|O )|O of|O 12|O cases|O ,|O respectively|O ,|O showed|O genetic|O heterogeneities|O in|O different|O histologic|O areas|O .|O 
Six|O (|O 2|O borderline|O tumors|O and|O 4|O carcinomas|O )|O of|O 18|O cases|O showed|O heterogeneity|O of|O K-ras|gene-rna point|O mutation|O in|O the|O different|O histologic|O areas|O of|O the|O same|O tumor|O ,|O and|O 5|O (|O 1|O cystadenoma|O with|O Brenner|O tumor|O component|O ,|O 2|O borderline|O tumors|O ,|O and|O 2|O carcinomas|O )|O of|O 10|O cases|O showed|O heterogeneous|O K-ras|gene-rna mutation|O pattern|O in|O the|O same|O tumor|O when|O the|O LCM|O technique|O was|O used|O .|O 
Atypical|O areas|O tended|O to|O show|O K-ras|gene-rna point|O mutations|O frequently|O .|O 
Out|O of|O 3|O cases|O of|O mixed|O mucinous|O cystadenoma|O and|O Brenner|O tumor|O ,|O 1|O case|O showed|O K-ras|gene-rna point|O mutation|O in|O the|O Brenner|O tumor|O area|O but|O not|O in|O the|O area|O of|O mucinous|O cystadenoma|O .|O 
These|O preliminary|O results|O suggest|O that|O a|O subset|O of|O ovarian|O mucinous|O tumors|O occur|O through|O multistep|O carcinogenesis|O and|O show|O that|O LCM|O is|O useful|O for|O molecular|O pathologic|O studies|O .|O 
Mutation|O of|O beta-catenin|gene-rna gene|O in|O endometrial|O cancer|O but|O not|O in|O associated|O hyperplasia|O .|O 
Endometrial|O hyperplasia|O is|O a|O recognized|O effect|O of|O excessive|O or|O unopposed|O estrogen|O stimulation|O and|O is|O considered|O to|O be|O a|O precancerous|O condition|O of|O endometrial|O adenocarcinoma|O .|O 
We|O have|O previously|O shown|O that|O the|O subcellular|O localization|O of|O beta-catenin|gene-protein in|O the|O human|O endometrium|O is|O changed|O according|O to|O cell|O proliferation|O ,|O suggesting|O a|O role|O of|O intercellular|O transduction|O in|O cell|O -|O growth|O control|O in|O human|O endometrium|O ,|O not|O only|O in|O the|O physiological|O condition|O but|O also|O in|O the|O carcinogenic|O endometrium|O .|O 
In|O the|O present|O study|O ,|O to|O clarify|O at|O which|O stage|O of|O endometrial|O carcinogenesis|O molecular|O alteration|O of|O the|O beta-catenin|gene-rna gene|O occurs|O ,|O we|O analyzed|O the|O subcellular|O localization|O of|O beta-catenin|gene-protein by|O immunohistochemistry|O ,|O and|O we|O analyzed|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O ,|O in|O 25|O patients|O -|O with|O endometrial|O hyperplasia|O and|O 20|O patients|O with|O endometrial|O cancers|O associated|O with|O endometrial|O hyperplasia|O ,|O digesting|O DNA|O from|O the|O cancer|O and|O hyperplasia|O parts|O ,|O separately|O .|O 
Fourteen|O of|O the|O 25|O (|O 56.0|O %|O )|O endometrial|O hyperplasia|O samples|O ,|O 12|O (|O 60.0|O %|O )|O endometrial|O cancers|O ,|O and|O 11|O (|O 55.0|O %|O )|O associated|O hyperplasias|O of|O the|O 20|O endometrial|O cancers|O associated|O with|O hyperplasia|O showed|O nuclear|O localization|O of|O beta-catenin|gene-protein .|O 
Mutation|O in|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O was|O found|O in|O 2|O of|O the|O 20|O endometrial|O cancer|O samples|O ;|O however|O ,|O it|O was|O not|O found|O in|O the|O 25|O endometrial|O hyperplasias|O or|O the|O 20|O associated|O hyperplasias|O .|O 
The|O results|O suggest|O that|O molecular|O alteration|O of|O the|O beta-catenin|gene-rna gene|O occurs|O in|O atypical|O hyperplasia|O or|O cancer|O ,|O rather|O than|O in|O simple|O or|O complex|O hyperplasia|O without|O atypia|O ,|O during|O endometrial|O carcinogenesis|O .|O 
Frequent|O detection|O of|O K-ras|gene-rna mutation|O in|O stool|O samples|O of|O colorectal|O carcinoma|O patients|O after|O improved|O DNA|O extraction|O :|O comparison|O with|O tissue|O samples|O .|O 
Fecal|O occult|O blood|O testing|O is|O widely|O used|O in|O the|O clinical|O screening|O of|O colorectal|O tumors|O .|O 
However|O ,|O this|O method|O has|O so|O frequent|O false|O -|O positive|O results|O that|O more|O accurate|O screening|O -|O strategy|O should|O be|O established|O .|O 
Although|O the|O molecular|O screening|O using|O K-ras|gene-rna gene|O mutation|O in|O stools|O has|O been|O attempted|O to|O improve|O the|O results|O ,|O the|O low|O rate|O of|O DNA|O extraction|O from|O stools|O leaves|O this|O measurement|O under|O utility|O value|O .|O 
In|O this|O study|O ,|O we|O investigated|O whether|O or|O not|O our|O applied|O DNA|O extraction|O method|O from|O stools|O could|O produce|O enough|O DNA|O for|O the|O molecular|O screening|O of|O colorectal|O tumors|O by|O K-ras|gene-rna gene|O mutations|O in|O stools|O .|O 
We|O applied|O cetyltrimethylammonium|O bromide|O (|O CTAB|O )|O solution|O to|O improve|O human|O DNA|O extraction|O from|O stools|O and|O a|O mutant|O -|O allele|O -|O sensitive|O amplification|O (|O MASA|O )|O method|O to|O detect|O K-ras|gene-rna mutation|O within|O codon|O 12|O .|O 
We|O were|O able|O to|O confirm|O the|O stool|O DNA|O by|O identifying|O K-ras|gene-rna fragments|O in|O all|O the|O 20|O patients|O .|O 
Tissue|O K-ras|gene-rna mutation|O was|O identified|O in|O 4|O (|O 2|O cancers|O and|O 2|O adenomas|O )|O of|O 20|O patients|O .|O 
Stool|O K-ras|gene-rna mutations|O were|O found|O in|O 6|O patients|O ,|O 3|O tissue|O K-ras|gene-rna mutation|O positive|O patients|O (|O 2|O cancers|O and|O an|O adenoma|O )|O and|O 3|O tissue|O K-ras|gene-rna mutation|O negative|O patients|O .|O 
These|O results|O indicate|O that|O it|O is|O possible|O to|O extract|O enough|O DNA|O from|O human|O stool|O samples|O of|O all|O patients|O with|O colorectal|O tumors|O for|O K-ras|gene-rna mutation|O studies|O .|O 
K-ras|gene-rna mutations|O are|O more|O frequently|O detected|O in|O stools|O than|O in|O resected|O colorectal|O tumors|O .|O 
This|O study|O indicates|O that|O K-ras|gene-rna mutation|O screening|O in|O stools|O for|O colorectal|O cancer|O may|O include|O not|O only|O a|O primary|O colorectal|O cancer|O but|O also|O precancerous|O lesions|O in|O all|O parts|O of|O a|O gastrointestinal|O tract|O .|O 
KIT|gene-rna mutations|O are|O common|O in|O incidental|O gastrointestinal|O stromal|O tumors|O one|O centimeter|O or|O less|O in|O size|O .|O 
Gastrointestinal|O stromal|O tumors|O (|O GISTs|O )|O are|O mesenchymal|O neoplasms|O of|O the|O gut|O wall|O that|O express|O the|O receptor|gene-protein tyrosine|gene-protein kinase|gene-protein KIT|gene-protein .|O 
Somatic|O mutations|O that|O result|O in|O constitutive|O activation|O of|O KIT|gene-protein kinase|gene-protein have|O been|O identified|O in|O a|O number|O of|O studies|O of|O GISTs|O ,|O although|O the|O reported|O frequency|O of|O these|O mutations|O has|O varied|O over|O a|O wide|O range|O (|O 20|O to|O 92|O %|O )|O .|O 
Several|O reports|O have|O suggested|O that|O KIT|gene-rna gene|O mutations|O are|O more|O common|O in|O malignant|O GISTs|O than|O in|O benign|O lesions|O ,|O and|O it|O has|O been|O proposed|O that|O mutations|O in|O exon|O 11|O of|O KIT|gene-rna are|O a|O negative|O prognostic|O factor|O .|O 
To|O maximize|O sensitivity|O for|O KIT|gene-rna mutations|O we|O have|O adapted|O denaturing|O high|O -|O pressure|O liquid|O chromatography|O as|O a|O method|O for|O screening|O polymerase|gene-protein chain|O reaction|O amplimers|O of|O exons|O 9|O ,|O 11|O ,|O 13|O ,|O and|O 17|O from|O GIST|O genomic|O DNA|O .|O 
This|O approach|O was|O used|O to|O assess|O the|O frequency|O of|O KIT|gene-rna mutations|O in|O 13|O morphologically|O benign|O ,|O incidentally|O discovered|O ,|O GISTs|O identified|O at|O autopsy|O ,|O endoscopy|O ,|O or|O laparotomy|O for|O unrelated|O disease|O .|O 
Representing|O the|O smallest|O pathologically|O recognizable|O GISTs|O ,|O these|O lesions|O ranged|O in|O size|O from|O 4|O to|O 10|O mm|O in|O diameter|O and|O were|O all|O immunohistochemically|O positive|O for|O KIT|gene-protein .|O 
Eleven|O of|O the|O 13|O tumors|O had|O sequence|O -|O confirmed|O mutations|O in|O KIT|gene-rna ,|O including|O 10|O mutations|O in|O exon|O 11|O (|O 77|O %|O )|O and|O one|O mutation|O in|O exon|O 9|O (|O 7.7|O %|O )|O .|O 
The|O remaining|O two|O tumors|O were|O wild|O type|O for|O exons|O 9|O ,|O 11|O ,|O and|O 17|O ;|O one|O of|O these|O was|O also|O analyzed|O for|O exon|O 13|O and|O was|O wild|O type|O in|O this|O exon|O as|O well|O .|O 
The|O mutations|O found|O in|O the|O incidental|O GISTs|O were|O identical|O to|O those|O that|O have|O been|O documented|O in|O larger|O GISTs|O .|O 
In|O addition|O ,|O the|O overall|O frequency|O of|O mutations|O in|O the|O incidental|O tumors|O (|O 85|O %|O )|O did|O not|O differ|O significantly|O from|O that|O we|O previously|O reported|O in|O a|O series|O of|O 72|O advanced|O /|O metastatic|O GISTs|O (|O 86|O %|O )|O ,|O strongly|O supporting|O the|O view|O that|O activating|O mutations|O in|O KIT|gene-rna are|O acquired|O very|O early|O in|O the|O development|O of|O most|O GISTs|O .|O 
The|O findings|O suggest|O that|O KIT|gene-rna mutations|O per|O se|O are|O of|O little|O prognostic|O importance|O in|O GISTs|O .|O 
Gastrointestinal|O stromal|O tumour|O of|O the|O oesophagus|O :|O significance|O of|O immunohistochemical|O and|O genetic|O analyses|O of|O the|O c-kit|gene-rna gene|O .|O 
Oesophageal|O gastrointestinal|O stromal|O tumours|O (|O GISTs|O )|O are|O rare|O in|O comparison|O to|O those|O of|O the|O stomach|O and|O intestines|O .|O 
Recently|O ,|O it|O has|O been|O clarified|O that|O mutations|O of|O the|O c-kit|gene-rna gene|O resulting|O in|O gain|O of|O function|O might|O be|O associated|O with|O histogenesis|O of|O this|O type|O of|O tumour|O arising|O in|O the|O stomach|O and|O intestines|O .|O 
We|O describe|O an|O oesophageal|O GIST|O on|O immunohistochemical|O and|O genetic|O analyses|O of|O the|O gene|gene-rna .|O 
A|O 71|O -|O year|O -|O old|O man|O had|O an|O intramural|O tumour|O of|O the|O middle|O third|O of|O the|O oesophagus|O .|O 
Tumour|O cells|O were|O composed|O predominantly|O of|O spindle|O -|O shaped|O and|O partially|O epithelioid|O cells|O .|O 
They|O were|O diffusely|O positive|O for|O CD117|gene-protein .|O 
Six|O base|O deletion|O resulting|O in|O in|O -|O frame|O mutation|O of|O the|O c-kit|gene-rna gene|O was|O confirmed|O at|O codon|O 556|O -|O 558|O (|O cag|O tgg|O aag|O to|O cag|O )|O of|O exon|O 11|O .|O 
Patients|O with|O mutations|O of|O the|O c-kit|gene-rna gene|O revealed|O worse|O prognoses|O in|O GISTs|O arising|O from|O other|O locations|O .|O 
A|O long|O -|O term|O follow|O -|O up|O observation|O is|O needed|O for|O the|O case|O .|O 
Genetic|O and|O immunohistochemical|O analysis|O of|O pancreatic|O acinar|O cell|O carcinoma|O :|O frequent|O allelic|O loss|O on|O chromosome|O 11p|O and|O alterations|O in|O the|O APC|gene-generic /|O beta-catenin|gene-generic pathway|O .|O 
Acinar|O cell|O carcinomas|O (|O ACCs|O )|O are|O rare|O malignant|O tumors|O of|O the|O exocrine|O pancreas|O .|O 
The|O specific|O molecular|O alterations|O that|O characterize|O ACCs|O have|O not|O yet|O been|O elucidated|O .|O 
ACCs|O are|O morphologically|O and|O genetically|O distinct|O from|O the|O more|O common|O pancreatic|O ductal|O adenocarcinomas|O .|O 
Instead|O ,|O the|O morphological|O ,|O immunohistochemical|O ,|O and|O clinical|O features|O of|O ACCs|O overlap|O with|O those|O of|O another|O rare|O pancreatic|O neoplasm|O ,|O pancreatoblastoma|O .|O 
We|O have|O recently|O demonstrated|O a|O high|O frequency|O of|O allelic|O loss|O on|O chromosome|O arm|O 11p|O and|O mutations|O in|O the|O APC|gene-generic /|O beta-catenin|gene-generic pathway|O in|O pancreatoblastomas|O ,|O suggesting|O that|O similar|O alterations|O might|O also|O play|O a|O role|O in|O the|O pathogenesis|O of|O some|O ACCs|O .|O 
We|O analyzed|O a|O series|O of|O 21|O ACCs|O for|O somatic|O alterations|O in|O the|O APC|gene-generic /|O beta-catenin|gene-generic pathway|O and|O for|O allelic|O loss|O on|O chromosome|O 11p|O .|O 
In|O addition|O ,|O we|O evaluated|O the|O ACCs|O for|O alterations|O in|O p53|gene-protein and|O Dpc4|gene-protein expression|O using|O immunohistochemistry|O ,|O and|O for|O microsatellite|O instability|O (|O MSI|O )|O using|O polymerase|gene-protein chain|O amplification|O of|O a|O panel|O of|O microsatellite|O markers|O .|O 
Allelic|O loss|O on|O chromosome|O 11p|O was|O the|O most|O common|O genetic|O alteration|O in|O ACCs|O ,|O present|O in|O 50|O %|O (|O 6|O of|O 12|O informative|O cases|O )|O .|O 
Molecular|O alterations|O in|O the|O APC|gene-generic /|O beta-catenin|gene-generic pathway|O were|O detected|O in|O 23.5|O %|O (|O 4|O of|O 17|O )|O of|O the|O carcinomas|O ,|O including|O one|O ACC|O with|O an|O activating|O mutation|O of|O the|O beta-catenin|gene-rna oncogene|O and|O three|O ACCs|O with|O truncating|O APC|gene-rna mutations|O .|O 
One|O ACC|O (|O 1|O of|O 13|O ,|O 7.6|O %|O )|O showed|O allelic|O shifts|O in|O four|O of|O the|O five|O markers|O tested|O (|O MSI|O -|O high|O )|O ,|O two|O (|O 15.4|O %|O )|O showed|O an|O allelic|O shift|O in|O only|O one|O of|O the|O five|O markers|O tested|O (|O MSI|O -|O low|O )|O ,|O and|O no|O shifts|O were|O detected|O in|O the|O remaining|O 10|O cases|O .|O 
The|O MSI|O -|O high|O ACC|O showed|O medullary|O histological|O features|O .|O 
In|O contrast|O ,|O no|O loss|O of|O Dpc4|gene-protein protein|O expression|O or|O p53|gene-protein accumulation|O was|O detected|O .|O 
These|O results|O indicate|O that|O ACCs|O are|O genetically|O distinct|O from|O pancreatic|O ductal|O adenocarcinomas|O ,|O but|O some|O cases|O contain|O genetic|O alterations|O common|O to|O histologically|O similar|O pancreatoblastomas|O .|O 
Increased|O beta-catenin|gene-rna mRNA|O levels|O and|O mutational|O alterations|O of|O the|O APC|gene-rna and|O beta-catenin|gene-rna gene|O are|O present|O in|O intestinal|O -|O type|O gastric|O cancer|O .|O 
Beta-catenin|gene-protein is|O critical|O for|O intercellular|O adhesion|O and|O also|O plays|O a|O role|O as|O a|O transcription|gene-protein activating|gene-protein protein|gene-protein in|O the|O Wnt|gene-generic signalling|O pathway|O .|O 
Increased|O protein|O levels|O and|O mutation|O of|O the|O beta-catenin|gene-rna gene|O have|O been|O demonstrated|O in|O various|O cancers|O ;|O however|O ,|O the|O role|O of|O beta-catenin|gene-rna in|O gastric|O cancer|O remains|O largely|O unknown|O .|O 
Using|O gastric|O cancer|O tissues|O and|O normal|O adjacent|O gastric|O mucosa|O obtained|O from|O 20|O patients|O with|O gastric|O cancer|O (|O eight|O diffuse|O -|O type|O ,|O 12|O intestinal|O -|O type|O )|O undergoing|O gastric|O resection|O or|O endoscopy|O ,|O we|O assessed|O the|O expression|O of|O beta-catenin|gene-generic by|O immunohistochemistry|O and|O quantitative|O PCR|O analysis|O .|O 
Furthermore|O ,|O the|O tumour|gene-rna suppressor|gene-rna gene|gene-rna APC|gene-rna ,|O which|O down|O -|O regulates|O the|O beta-catenin|gene-generic levels|O was|O analysed|O for|O mutations|O .|O 
Overall|O mRNA|O levels|O of|O beta-catenin|gene-generic were|O significantly|O increased|O in|O the|O tumour|O samples|O compared|O with|O the|O matched|O normal|O gastric|O mucosa|O (|O P|O <|O 0.05|O )|O .|O 
Increased|O beta-catenin|gene-rna mRNA|O levels|O were|O significantly|O more|O frequent|O in|O intestinal|O -|O type|O gastric|O cancers|O as|O compared|O to|O diffuse|O -|O type|O gastric|O cancers|O (|O P|O <|O 0.01|O )|O .|O 
Six|O out|O of|O 20|O tumours|O exhibited|O >|O 6|O -|O fold|O increased|O beta-catenin|gene-rna mRNA|O levels|O as|O compared|O with|O normal|O mucosa|O .|O 
APC|gene-rna gene|O mutations|O were|O found|O in|O four|O cases|O .|O 
A|O beta-catenin|gene-rna gene|O mutation|O was|O identified|O only|O in|O one|O intestinal|O -|O type|O gastric|O cancer|O exhibiting|O a|O massive|O overexpression|O of|O beta-catenin|gene-rna mRNA|O in|O the|O tumour|O .|O 
In|O intestinal|O -|O type|O gastric|O cancers|O beta-catenin|gene-rna mRNA|O levels|O are|O greatly|O enhanced|O .|O 
APC|gene-rna and|O beta-catenin|gene-rna gene|O mutations|O are|O also|O present|O primarily|O in|O intestinal|O -|O type|O gastric|O cancers|O .|O 
These|O findings|O support|O the|O hypothesis|O that|O in|O intestinal|O -|O type|O gastric|O cancers|O the|O accumulation|O of|O beta-catenin|gene-protein protein|O may|O result|O from|O impaired|O degradation|O of|O the|O beta-catenin|gene-protein protein|O due|O to|O alterations|O of|O the|O beta-catenin|gene-rna and|O APC|gene-rna genes|O ,|O as|O well|O as|O from|O enhanced|O beta-catenin|gene-rna transcription|O which|O is|O present|O in|O the|O great|O majority|O of|O intestinal|O -|O type|O gastric|O cancers|O .|O 
Frequent|O beta-catenin|gene-generic mutation|O and|O cytoplasmic|O /|O nuclear|O accumulation|O in|O pancreatic|O solid|O -|O pseudopapillary|O neoplasm|O .|O 
Significance|O of|O Wnt|gene-generic signaling|O with|O beta-catenin|gene-rna mutations|O on|O solid|O -|O pseudopapillary|O neoplasm|O (|O SPN|O )|O of|O the|O pancreas|O was|O studied|O by|O immunohistochemistry|O and|O molecular|O analysis|O .|O 
On|O immunohistochemistry|O ,|O all|O 18|O SPNs|O tested|O showed|O diffuse|O cytoplasmic|O /|O nuclear|O positivity|O for|O beta-catenin|gene-protein .|O 
Upon|O direct|O DNA|O sequencing|O of|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O ,|O 15|O (|O 83|O %|O )|O of|O the|O 18|O SPNs|O showed|O 1|O -|O bp|O missense|O mutation|O in|O codons|O 32|O (|O 5|O cases|O )|O ,|O 33|O (|O 3|O cases|O )|O ,|O 34|O (|O 3|O cases|O )|O ,|O 37|O (|O 3|O cases|O )|O ,|O and|O 41|O (|O 1|O case|O )|O .|O 
Immunoreactivity|O for|O cyclin|gene-protein D1|gene-protein ,|O one|O of|O the|O intranuclear|O targets|O of|O beta-catenin|gene-protein complexes|O ,|O was|O found|O in|O tumor|O cells|O of|O more|O than|O half|O the|O tumor|O cells|O of|O all|O of|O the|O 18|O SPNs|O .|O 
The|O present|O study|O strongly|O suggested|O a|O significant|O role|O of|O Wnt|gene-generic signaling|O ,|O mostly|O associated|O with|O beta-catenin|gene-rna mutations|O in|O the|O tumorigenesis|O of|O SPN|O .|O 
Differential|O diagnosis|O between|O chronic|O pancreatitis|O and|O pancreatic|O cancer|O :|O value|O of|O the|O detection|O of|O KRAS2|gene-rna mutations|O in|O circulating|O DNA|O .|O 
KRAS2|gene-rna mutations|O in|O codon|O 12|O have|O been|O detected|O in|O about|O 80|O %|O of|O pancreatic|O cancers|O .|O 
The|O aim|O of|O this|O study|O was|O to|O evaluate|O the|O value|O of|O KRAS2|gene-rna mutations|O detection|O in|O circulating|O deoxyribo|O nucleic|O acid|O to|O differentiate|O pancreatic|O cancer|O from|O chronic|O pancreatitis|O .|O 
Circulating|O deoxyribonucleic|O acid|O was|O isolated|O from|O serum|O in|O 47|O patients|O with|O histologically|O proven|O pancreatic|O adenocarcinomas|O (|O 26|O males|O ,|O median|O age|O 65|O years|O )|O and|O 31|O controls|O with|O chronic|O pancreatitis|O (|O 26|O males|O ,|O median|O age|O 48|O years|O )|O .|O 
Mutations|O at|O codon|O 12|O of|O KRAS2|gene-rna gene|O were|O searched|O for|O using|O polymerase|gene-protein chain|O reaction|O and|O allele|O specific|O amplification|O .|O 
Serum|O carbohydrate|O antigen|O 19.9|O levels|O were|O also|O determined|O .|O 
KRAS2|gene-rna mutations|O were|O found|O in|O 22|O patients|O (|O 47|O %|O )|O with|O pancreatic|O cancer|O and|O in|O four|O controls|O with|O chronic|O pancreatitis|O (|O 13|O %|O )|O (|O P|O <|O 0.002|O )|O .|O 
None|O of|O the|O latter|O developed|O a|O pancreatic|O cancer|O within|O the|O 36|O months|O of|O median|O follow|O -|O up|O .|O 
The|O sensitivity|O ,|O specificity|O ,|O positive|O and|O negative|O predictive|O values|O of|O serum|O serum|O KRAS2|gene-rna mutations|O for|O the|O diagnosis|O of|O pancreatic|O cancer|O were|O 47|O ,|O 87|O ,|O 85|O and|O 52|O %|O ,|O respectively|O .|O 
KRAS2|gene-rna mutations|O were|O not|O related|O to|O age|O ,|O gender|O ,|O smoking|O habit|O ,|O tumour|O stage|O ,|O or|O survival|O .|O 
Among|O the|O 26|O patients|O with|O normal|O or|O non|O -|O contributive|O (|O due|O to|O cholestasis|O )|O serum|O carbohydrate|O antigen|O 19.9|O levels|O ,|O 14|O (|O 54|O %|O )|O had|O KRAS2|gene-rna mutations|O .|O 
The|O combination|O of|O KRAS2|gene-rna and|O carbohydrate|O antigen|O 19.9|O gave|O a|O sensitivity|O ,|O specificity|O ,|O positive|O and|O negative|O predictive|O values|O for|O the|O diagnosis|O of|O pancreatic|O cancer|O of|O 98|O ,|O 77|O ,|O 87|O and|O 96|O %|O ,|O respectively|O .|O 
Detection|O of|O KRAS2|gene-rna mutations|O in|O circulating|O deoxyribo|O nucleic|O acid|O has|O a|O low|O sensitivity|O but|O a|O specificity|O about|O 90|O %|O for|O the|O diagnosis|O of|O pancreatic|O cancer|O .|O 
It|O seems|O particularly|O useful|O when|O serum|O carbohydrate|O antigen|O 19.9|O levels|O are|O normal|O or|O inconclusive|O .|O 
A|O combined|O normal|O serum|O carbohydrate|O antigen|O 19.9|O and|O absence|O of|O circulating|O KRAS2|gene-rna mutations|O makes|O the|O diagnosis|O of|O pancreatic|O cancer|O extremely|O unlikely|O .|O 
Usefulness|O of|O supernatant|O of|O pancreatic|O juice|O for|O genetic|O analysis|O of|O K-ras|gene-rna in|O diagnosis|O of|O pancreatic|O carcinoma|O .|O 
AIMS|O :|O 
To|O ascertain|O whether|O analysis|O of|O K-ras|gene-rna mutations|O at|O codon|O 12|O (|O KRM|O )|O in|O the|O supernatant|O of|O pure|O pancreatic|O juice|O (|O PPJ|O )|O is|O more|O useful|O for|O the|O diagnosis|O of|O pancreatic|O carcinoma|O (|O PCa|O )|O than|O that|O in|O sediment|O ,|O the|O authors|O analyzed|O KRM|O in|O DNA|O extract|O from|O not|O only|O the|O sediment|O but|O also|O the|O supernatant|O of|O PPJ|O and|O compared|O the|O results|O .|O 
METHODOLOGY|O :|O 
PPJ|O was|O collected|O endoscopically|O from|O 19|O patients|O with|O PCa|O and|O 25|O patients|O with|O chronic|O pancreatitis|O (|O CP|O )|O .|O 
DNA|O was|O extracted|O from|O the|O supernatant|O and|O the|O sediment|O of|O PPJ|O .|O 
Mutant|O allele|O -|O specific|O amplification|O (|O MASA|O )|O was|O performed|O for|O KRM|O analysis|O with|O the|O DNA|O extracts|O from|O these|O samples|O .|O 
RESULTS|O :|O 
The|O incidence|O of|O KRM|O in|O the|O supernatant|O of|O PPJ|O was|O 89|O %|O (|O 17|O of|O 19|O )|O in|O patients|O with|O PCa|O and|O 28|O %|O (|O 7|O of|O 25|O )|O in|O patients|O with|O CP|O ,|O whereas|O that|O in|O the|O sediment|O was|O 79|O %|O (|O 15|O of|O 19|O )|O in|O patients|O with|O PCa|O and|O 20|O %|O (|O 5|O of|O 25|O )|O in|O patients|O with|O CP|O .|O 
Although|O there|O was|O no|O significant|O difference|O in|O KRM|O incidence|O between|O supernatant|O and|O sediment|O ,|O the|O positive|O rate|O of|O KRM|O was|O higher|O in|O the|O former|O .|O 
Additionally|O ,|O with|O regard|O to|O the|O PCa|O cases|O ,|O KRM|O were|O found|O in|O the|O supernatant|O alone|O in|O four|O cases|O and|O in|O the|O sediment|O alone|O in|O two|O cases|O .|O 
Consequently|O ,|O by|O a|O combination|O assay|O ,|O all|O of|O the|O patients|O with|O PCa|O showed|O KRM|O in|O either|O the|O supernatant|O or|O sediment|O of|O PPJ|O .|O 
Although|O there|O was|O no|O relation|O between|O the|O incidence|O of|O KRM|O in|O PPJ|O and|O the|O location|O and|O size|O of|O tumor|O ,|O and|O clinical|O stage|O of|O carcinoma|O in|O the|O patients|O with|O PCa|O ,|O two|O patients|O with|O clinical|O stage|O I|O disease|O showed|O KRM|O in|O the|O supernatant|O .|O 
CONCLUSION|O :|O 
These|O results|O suggest|O that|O the|O positive|O rate|O of|O KRM|O in|O the|O supernatant|O is|O not|O lower|O than|O that|O in|O the|O sediment|O ,|O and|O simultaneous|O analysis|O of|O KRM|O in|O the|O supernatant|O and|O sediment|O of|O PPJ|O enhances|O the|O genetic|O diagnosis|O of|O PCa|O .|O 
Mutation|O and|O overexpression|O of|O the|O beta-catenin|gene-rna gene|O may|O play|O an|O important|O role|O in|O primary|O hepatocellular|O carcinoma|O among|O Chinese|O people|O .|O 
AIM|O :|O 
To|O study|O the|O role|O of|O beta-catenin|gene-rna gene|O mutation|O and|O expression|O in|O hepatocellular|O carcinogenesis|O .|O 
METHOD|O :|O 
Thirty-four|O hepatocellular|O carcinoma|O (|O HCC|O )|O specimens|O and|O adjacent|O para|O -|O cancerous|O tissues|O ,|O and|O four|O normal|O liver|O tissues|O were|O analyzed|O .|O 
Subcellular|O distribution|O of|O beta-catenin|gene-protein was|O examined|O by|O immunohistochemistry|O staining|O .|O 
Mutation|O and|O semiquantitative|O expression|O of|O beta-catenin|gene-rna gene|O exon|O 3|O mRNA|O were|O detected|O by|O RT|O -|O PCR|O -|O SSCP|O and|O in|O situ|O hybridization|O .|O 
RESULT|O :|O 
Immunohistochemistry|O showed|O that|O all|O normal|O liver|O tissues|O and|O para|O -|O cancerous|O tissues|O examined|O showed|O membranous|O -|O type|O staining|O for|O beta-catenin|gene-protein protein|O ,|O frequently|O with|O weak|O expression|O in|O the|O cytoplasm|O ,|O but|O no|O beta-catenin|gene-protein accumulation|O in|O nuclei|O was|O found|O ;|O while|O in|O liver|O cancer|O ,|O 21|O cases|O (|O 61.8|O %|O )|O of|O HCC|O examined|O showed|O accumulated|O type|O in|O cytoplasms|O or|O nuclei|O .|O 
On|O SSCP|O ,|O 15|O cases|O (|O 44.1|O %|O )|O of|O HCC|O altogether|O displayed|O three|O kinds|O of|O characteristic|O mutational|O mobility|O shifts|O .|O 
No|O abnormal|O shifting|O bands|O were|O found|O in|O tissues|O from|O normal|O liver|O or|O para|O -|O cancerous|O area|O .|O 
The|O beta-catenin|gene-rna gene|O exon|O 3|O mRNA|O expression|O index|O of|O 34|O HCCs|O was|O higher|O than|O that|O of|O para|O -|O cancerous|O tissue|O and|O normal|O liver|O tissue|O .|O 
Using|O in|O situ|O hybridization|O ,|O the|O signal|O corresponding|O to|O beta-catenin|gene-rna gene|O exon|O 3|O mRNA|O was|O particularly|O strong|O in|O cytoplasm|O of|O HCC|O when|O compared|O with|O those|O of|O paracancerous|O tissues|O and|O normal|O liver|O tissues|O .|O 
CONCLUSION|O :|O 
beta-catenin|gene-rna gene|O mutation|O and|O overexpression|O may|O have|O a|O critical|O role|O in|O malignant|O progression|O of|O hepatic|O carcinogenesis|O among|O Chinese|O people|O .|O 
Analysis|O of|O FGFR3|gene-rna gene|O mutations|O in|O multiple|O myeloma|O patients|O with|O t|O (|O 4|O ;|O 14|O )|O .|O 
The|O t|O (|O 4|O ;|O 14|O )|O (|O p16.3|O ;|O q32|O )|O in|O multiple|O myeloma|O (|O MM|O )|O leads|O to|O an|O apparent|O deregulation|O of|O the|O FGFR3|gene-rna and|O WHSC1|gene-rna /|O MMSET|gene-rna genes|O .|O 
FGFR3|gene-rna mutations|O ,|O known|O to|O be|O associated|O with|O genetic|O skeletal|O disorders|O ,|O have|O also|O been|O identified|O in|O a|O few|O cases|O of|O MM|O (|O mainly|O cell|O lines|O )|O with|O t|O (|O 4|O ;|O 14|O )|O .|O 
We|O investigated|O FGFR3|gene-rna mutations|O in|O a|O series|O of|O 53|O MM|O cases|O ;|O 11|O cases|O with|O t|O (|O 4|O ;|O 14|O )|O and|O FGFR3|gene-rna overexpression|O were|O analysed|O using|O reverse|O transcription|O polymerase|gene-protein chain|O reaction|O ,|O while|O the|O remaining|O cases|O were|O studied|O at|O DNA|O level|O .|O 
The|O Arg|O 248|O Cys|O mutation|O ,|O which|O is|O associated|O with|O some|O lethal|O forms|O of|O skeletal|O disorders|O ,|O was|O found|O in|O one|O case|O with|O t|O (|O 4|O ;|O 14|O )|O .|O 
Our|O results|O indicate|O that|O FGFR3|gene-rna mutations|O occur|O in|O only|O a|O small|O fraction|O of|O MM|O cases|O with|O t|O (|O 4|O ;|O 14|O )|O .|O 
Detection|O of|O N-Ras|gene-rna codon|O 61|O mutations|O in|O subpopulations|O of|O tumor|O cells|O in|O multiple|O myeloma|O at|O presentation|O .|O 
Activating|O point|O mutations|O in|O codons|O 12|O ,|O 13|O ,|O or|O 61|O of|O the|O K-ras|gene-rna and|O N-ras|gene-rna genes|O have|O been|O reported|O to|O occur|O in|O up|O to|O 40|O %|O of|O patients|O with|O multiple|O myeloma|O at|O presentation|O .|O 
In|O a|O study|O of|O 34|O presentation|O myeloma|O cases|O using|O a|O sensitive|O polymerase|gene-protein chain|O reaction|O -|O restriction|O fragment|O length|O polymorphism|O strategy|O on|O enriched|O tumor|O cell|O populations|O ,|O the|O present|O study|O detected|O N-ras|gene-rna codon|O 61|O mutation|O -|O positive|O cells|O in|O all|O patients|O .|O 
Quantitative|O plaque|O hybridization|O using|O allele|O -|O specific|O oligonucleotide|O probes|O showed|O that|O in|O the|O majority|O of|O patients|O ,|O ras|gene-rna mutation|O -|O positive|O cells|O comprise|O only|O a|O subpopulation|O of|O the|O total|O malignant|O plasma|O cell|O compartment|O (|O range|O ,|O 12|O %|O -|O 100|O %|O )|O .|O 
Using|O clonospecific|O point|gene-rna mutations|gene-rna in|O the|O 5|O '|O untranslated|O region|O of|O the|O BCL6|gene-rna gene|O to|O quantitate|O clonal|O B|O cells|O in|O FACS|O -|O sorted|O bone|O marrow|O populations|O from|O 2|O patients|O ,|O the|O representation|O of|O ras|gene-rna mutation|O -|O positive|O cells|O was|O independent|O of|O immunophenotype|O .|O 
These|O observations|O imply|O that|O mutational|O activation|O of|O N-ras|gene-rna codon|O 61|O is|O a|O mandatory|O event|O in|O the|O pathogenesis|O of|O multiple|O myeloma|O ;|O such|O mutations|O provide|O a|O marker|O of|O intraclonal|O heterogeneity|O that|O may|O originate|O at|O an|O earlier|O ontologic|O stage|O than|O immunophenotypic|O diversification|O of|O the|O malignant|O B|O cell|O clone|O .|O 
Carcinosarcoma|O of|O the|O uterus|O :|O immunohistochemical|O and|O genetic|O analysis|O of|O clonality|O of|O one|O case|O .|O 
BACKGROUND|O :|O 
Carcinosarcomas|O of|O the|O uterus|O are|O characterized|O by|O admixtures|O of|O malignant|O epithelial|O and|O stromal|O cells|O ,|O and|O their|O histogenesis|O remains|O controversial|O .|O 
CASE|O :|O 
An|O operated|O case|O of|O carcinosarcoma|O of|O the|O uterus|O in|O a|O 49|O -|O year|O -|O old|O woman|O is|O reported|O with|O clonal|O analysis|O .|O 
The|O tumor|O was|O composed|O of|O carcinomatous|O ,|O sarcomatous|O ,|O and|O transitional|O elements|O in|O the|O frontal|O wall|O of|O the|O uterine|O body|O and|O therefore|O was|O diagnosed|O as|O a|O carcinosarcoma|O .|O 
On|O immunohistochemical|O analysis|O ,|O the|O sarcomatous|O component|O proved|O negative|O for|O epithelial|gene-protein membrane|gene-protein antigen|gene-protein and|O keratin|gene-protein while|O both|O components|O were|O positive|O for|O vimentin|gene-protein .|O 
Analysis|O of|O X|O -|O chromosome|O inactivation|O showed|O the|O same|O pattern|O throughout|O and|O additionally|O ,|O the|O same|O K-ras|gene-rna and|O p53|gene-rna mutations|O were|O homogeneously|O detected|O .|O 
Microsatellite|O instability|O analysis|O showed|O loss|O of|O heterozygosity|O at|O D5S346|O in|O the|O sarcomatous|O but|O not|O the|O carcinomatous|O component|O .|O 
CONCLUSIONS|O :|O 
This|O tumor|O appears|O monoclonal|O in|O line|O with|O the|O combination|O tumor|O theory|O ,|O with|O late|O divergence|O in|O genetic|O alteration|O in|O the|O sarcomatous|O elements|O .|O 
Fine|O -|O needle|O aspiration|O biopsy|O diagnosis|O of|O gastrointestinal|O stromal|O tumors|O using|O morphology|O ,|O immunocytochemistry|O ,|O and|O mutational|O analysis|O of|O c-kit|gene-rna .|O 
BACKGROUND|O :|O 
Differentiating|O gastrointestinal|O stromal|O tumors|O (|O GISTs|O )|O from|O other|O intramural|O mesenchymal|O tumors|O of|O the|O GI|O tract|O on|O fine|O -|O needle|O aspiration|O biopsies|O (|O FNABs|O )|O is|O difficult|O .|O 
Recent|O studies|O have|O shown|O that|O GISTs|O are|O immunophenotypically|O and|O genetically|O distinct|O .|O 
GISTs|O exhibit|O consistent|O immunohistochemical|O expression|O of|O CD-117|gene-protein (|O KIT|gene-protein )|O and|O often|O express|O activating|O mutations|O of|O this|gene-rna protooncogene|gene-rna .|O 
The|O aim|O of|O the|O current|O study|O was|O to|O employ|O immunocytochemistry|O and|O mutational|O analysis|O of|O the|O c-kit|gene-rna gene|O to|O aid|O in|O the|O diagnosis|O of|O GISTs|O on|O FNAB|O .|O 
METHODS|O :|O 
Five|O endoscopic|O ultrasound|O -|O guided|O FNABs|O of|O gastrointestinal|O spindle|O cell|O neoplasms|O performed|O at|O the|O Veterans|O Affairs|O Medical|O Center|O (|O VAMC|O )|O in|O Portland|O ,|O Oregon|O ,|O from|O 1998|O -|O 1999|O were|O reviewed|O .|O 
A|O panel|O of|O immunocytochemical|O stains|O was|O performed|O on|O each|O cellblock|O including|O CD-117|gene-protein (|O KIT|gene-protein )|O ,|O smooth|gene-protein muscle|gene-protein actin|gene-protein (|O SMA|gene-protein )|O ,|O desmin|gene-protein ,|O S-100|gene-protein ,|O and|O CD34|gene-protein .|O 
Genomic|O DNA|O (|O gDNA|O )|O was|O extracted|O ,|O and|O amplification|O of|O exons|O 9|O ,|O 11|O ,|O 13|O and|O 17|O of|O c-kit|gene-rna was|O performed|O by|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O on|O CD-117|gene-protein (|O KIT|gene-protein )|O and|O CD34|gene-protein positive|O cases|O .|O 
Direct|O sequencing|O of|O amplicons|O identified|O the|O mutations|O .|O 
RESULTS|O :|O 
Five|O patients|O were|O diagnosed|O with|O GISTs|O based|O on|O morphology|O and|O immunocytochemical|O positivity|O for|O CD-117|gene-protein and|O CD34|gene-protein .|O 
PCR|O analysis|O of|O c-kit|gene-rna exon|O 11|O revealed|O three|O cases|O with|O novel|O -|O sized|O PCR|O bands|O in|O addition|O to|O the|O expected|O wild|O -|O type|O -|O sized|O PCR|O product|O .|O 
Amplicons|O from|O these|O cases|O contained|O an|O in|O -|O frame|O deletion|O mutation|O .|O 
One|O of|O the|O two|O cases|O with|O wild|O -|O type|O -|O ;|O sized|O exon|O 11|O amplicons|O was|O found|O to|O be|O heterozygous|O for|O a|O point|O mutation|O producing|O an|O amino|O acid|O substitution|O (|O W|O 557|O R|O )|O .|O 
No|O mutations|O in|O exon|O 9|O ,|O 11|O ,|O 13|O ,|O or|O 17|O of|O c-kit|gene-rna were|O found|O in|O the|O remaining|O case|O .|O 
CONCLUSIONS|O :|O 
Ancillary|O techniques|O such|O as|O immunocytochemistry|O and|O c-kit|gene-rna gene|O mutational|O analysis|O may|O aid|O in|O the|O diagnosis|O of|O GISTs|O on|O FNABs|O .|O 
Glutathione|gene-rna S-transferase|gene-rna mu1|gene-rna null|O genotype|O is|O associated|O with|O K-ras|gene-rna gene|O mutation|O in|O lung|O adenocarcinoma|O among|O smokers|O .|O 
Glutathione|gene-protein S-transferase|gene-protein mu1|gene-protein (|O GSTM1|gene-protein )|O plays|O a|O role|O in|O the|O detoxification|O of|O benzo[a]pyrene|O (|O BP|O )|O diol|O epoxide|O in|O tobacco|O smoke|O .|O 
Individuals|O who|O genetically|O lack|O the|O GSTM1|gene-rna gene|O are|O likely|O to|O have|O an|O increased|O risk|O of|O smoking|O -|O related|O lung|O cancers|O ,|O however|O ,|O the|O target|O oncogenes|O for|O mutation|O are|O unknown|O .|O 
To|O investigate|O the|O relation|O between|O GSTM1|gene-rna genotype|O and|O K-ras|gene-rna gene|O mutation|O we|O examined|O 193|O adenocarcinomas|O and|O 119|O squamous|O cell|O carcinomas|O of|O lung|O .|O 
The|O GSTM1|gene-rna genotype|O was|O determined|O by|O PCR|O and|O K-ras|gene-rna gene|O mutations|O at|O codons|O 12|O and|O 13|O were|O detected|O by|O dot|O -|O blot|O hybridization|O analysis|O using|O sequence|O -|O specific|O oligonucleotide|O probes|O .|O 
K-ras|gene-rna gene|O mutations|O were|O found|O in|O 29|O of|O 312|O (|O 9.3|O %|O )|O tumors|O .|O 
All|O of|O them|O arose|O in|O patients|O who|O were|O habitual|O smokers|O .|O 
Mutations|O of|O the|O K-ras|gene-rna gene|O were|O detected|O in|O 6|O of|O 100|O (|O 6|O %|O )|O and|O 15|O of|O 93|O (|O 16.1|O %|O )|O adenocarcinoma|O cases|O with|O the|O GSTM1|gene-rna (|O +|O )|O and|O GSTM1|gene-rna (|O -|O )|O genotypes|O ,|O respectively|O ,|O and|O the|O difference|O was|O statistically|O significant|O .|O 
These|O findings|O suggest|O that|O the|O cause|O of|O K-ras|gene-rna gene|O mutation|O in|O smokers|O with|O lung|O adenocarcinoma|O may|O be|O in|O part|O an|O accumulation|O of|O BP|O diol|O epoxide|O which|O is|O not|O well|O detoxified|O in|O individuals|O with|O the|O GSTM1|gene-rna null|O genotype|O .|O 
Mutations|O of|O the|O beta|gene-rna -|gene-rna and|O gamma|gene-rna -|gene-rna catenin|gene-rna genes|O are|O uncommon|O in|O human|O lung|O ,|O breast|O ,|O kidney|O ,|O cervical|O and|O ovarian|O carcinomas|O .|O 
Beta-catenin|gene-generic forms|O complexes|O with|O Tcf|gene-generic and|O Lef-1|gene-generic and|O functions|O as|O a|O transcriptional|O activator|O in|O the|O Wnt|gene-rna signalling|O pathway|O .|O 
Although|O recent|O investigations|O have|O been|O focused|O on|O the|O role|O of|O the|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|O APC|gene-rna )|O /|O beta-catenin|gene-rna /|O Tcf|gene-rna pathway|O in|O human|O tumorigenesis|O ,|O there|O have|O been|O very|O few|O reports|O on|O mutations|O of|O the|O beta-catenin|gene-rna gene|O in|O a|O variety|O of|O tumour|O types|O .|O 
Using|O PCR|O and|O single|O -|O strand|O conformational|O polymorphism|O analysis|O ,|O we|O examined|O 93|O lung|O ,|O 9|O breast|O ,|O 6|O kidney|O ,|O 19|O cervical|O and|O 7|O ovarian|O carcinoma|O cell|O lines|O for|O mutations|O in|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O .|O 
In|O addition|O ,|O we|O tested|O these|O same|O samples|O for|O mutations|O in|O the|O NH2|O -|O terminal|O regulatory|O region|O of|O the|O gamma-catenin|gene-rna gene|O .|O 
Mutational|O analysis|O for|O the|O entire|O coding|O region|O of|O beta-catenin|gene-rna cDNA|O was|O also|O undertaken|O in|O 20|O lung|O ,|O 9|O breast|O ,|O 5|O kidney|O and|O 6|O cervical|O carcinoma|O cell|O lines|O .|O 
Deletion|O of|O most|O beta-catenin|gene-rna coding|O exons|O was|O confirmed|O in|O line|O NCI-H28|O (|O lung|O mesothelioma|O )|O and|O a|O silent|O mutation|O at|O codon|O 214|O in|O exon|O 5|O was|O found|O in|O HeLa|O (|O cervical|O adenocarcinoma|O )|O .|O 
A|O missense|O mutation|O at|O codon|O 19|O and|O a|O silent|O mutation|O at|O codon|O 28|O in|O the|O NH2|O -|O terminal|O regulatory|O region|O of|O the|O gamma-catenin|gene-rna gene|O were|O found|O in|O H1726|O (|O squamous|O cell|O lung|O carcinoma|O )|O and|O H1048|O (|O small|O cell|O lung|O carcinoma|O )|O ,|O respectively|O .|O 
Neither|O deletions|O nor|O mutations|O of|O these|O genes|gene-rna were|O detected|O in|O the|O other|O cell|O lines|O examined|O .|O 
These|O results|O suggest|O that|O beta|gene-rna -|gene-rna and|O gamma|gene-rna -|gene-rna catenins|gene-rna are|O infrequent|O mutational|O targets|O during|O development|O of|O human|O lung|O ,|O breast|O ,|O kidney|O ,|O cervical|O and|O ovarian|O carcinomas|O .|O 
Deregulated|O FGFR3|gene-rna mutants|O in|O multiple|O myeloma|O cell|O lines|O with|O t|O (|O 4|O ;|O 14|O )|O :|O comparative|O analysis|O of|O Y|O 373|O C|O ,|O K|O 650|O E|O and|O the|O novel|O G|O 384|O D|O mutations|O .|O 
The|O t|O (|O 4|O ;|O 14|O )|O (|O p16.3|O ;|O q32|O )|O chromosomal|O translocation|O occurs|O in|O approximately|O 20|O %|O of|O multiple|O myelomas|O (|O MM|O )|O and|O leads|O to|O the|O apparent|O deregulation|O of|O two|O genes|O located|O on|O 4p16.3|O :|O the|O fibroblast|gene-rna growth|gene-rna factor|gene-rna receptor|gene-rna 3|gene-rna (|O FGFR3|gene-rna )|O and|O the|O putative|O transcription|O factor|O WHSC1|gene-rna /|O MMSET|gene-rna .|O 
Interestingly|O ,|O FGFR3|gene-rna mutations|O known|O to|O be|O associated|O with|O autosomal|O dominant|O human|O skeletal|O disorders|O have|O also|O been|O found|O in|O some|O MM|O cell|O lines|O with|O t|O (|O 4|O ;|O 14|O )|O but|O their|O pathogenetic|O role|O in|O MM|O is|O still|O controversial|O .|O 
Since|O cell|O lines|O may|O represent|O useful|O models|O for|O investigating|O the|O effects|O of|O deregulated|O FGFR3|gene-rna mutants|O in|O MM|O ,|O we|O analysed|O the|O expression|O ,|O activation|O ,|O signaling|O pathways|O and|O oncogenic|O potential|O of|O three|O mutants|O identified|O so|O far|O :|O the|O Y|O 373|O C|O and|O K|O 650|O E|O in|O the|O KMS-11|O and|O OPM-2|O cell|O lines|O respectively|O ,|O and|O the|O novel|O G|O 384|O D|O mutation|O here|O identified|O in|O the|O KMS-18|O cell|O line|O .|O 
All|O of|O the|O cell|O lines|O present|O a|O heterozygous|O FGFR3|gene-rna gene|O mutation|O and|O transcribe|O the|O mutated|O allele|O ;|O unlike|O KMS-11|O and|O OPM-2|O (|O which|O express|O the|O IIIc|O isoform|O )|O ,|O the|O KMS-18|O cell|O line|O expresses|O prevalently|O the|O isoform|O IIIb|O .|O 
We|O demonstrated|O that|O ,|O under|O serum|O -|O starved|O conditions|O ,|O KMS-11|O and|O OPM-2|O cells|O express|O appreciable|O levels|O of|O phosphorylated|O FGFR3|gene-rna mutants|O indicating|O a|O constitutive|O activation|O of|O the|O Y|O 373|O C|O and|O K|O 650|O E|O receptors|gene-protein ;|O the|O addition|O of|O the|O aFGF|gene-protein ligand|gene-protein further|O increased|O the|O level|O of|O receptor|gene-protein phosphorylation|O .|O 
Conversely|O ,|O the|O FGFR3|gene-rna mutant|O in|O KMS-18|O does|O not|O seem|O to|O be|O constitutively|O activated|O since|O it|O was|O phosphorylated|O only|O in|O the|O presence|O of|O the|O ligand|gene-protein .|O 
In|O all|O three|O MM|O cell|O lines|O ,|O ligand|gene-protein -|O stimulated|O FGFR3|gene-rna mutants|O activated|O the|O MAP|gene-protein kinase|gene-protein signaling|O pathway|O but|O did|O not|O apparently|O involve|O either|O the|O STAT1|gene-generic or|O STAT3|gene-generic cascades|O .|O 
However|O ,|O when|O transfected|O in|O 293T|O cells|O ,|O G|O 384|O D|O ,|O like|O Y|O 373|O C|O and|O K|O 650|O E|O ,|O was|O capable|O of|O activating|O MAPK|gene-generic ,|O STAT1|gene-generic and|O STAT3|gene-generic under|O serum|O -|O starved|O condition|O .|O 
Finally|O ,|O a|O focus|O formation|O assay|O of|O NIH3T3|O cells|O transfected|O with|O FGFR3|gene-rna -|O expressing|O plasmid|O vectors|O showed|O that|O Y|O 373|O C|O and|O K|O 650|O E|O (|O albeit|O at|O different|O levels|O )|O but|O not|O G|O 384|O D|O or|O the|O wild|O -|O type|O receptor|gene-protein ,|O can|O induce|O transformed|O foci|O .|O 
Overall|O ,|O our|O results|O support|O the|O idea|O that|O FGFR3|gene-rna mutations|O are|O graded|O in|O terms|O of|O their|O activation|O capability|O ,|O thus|O suggesting|O that|O they|O may|O play|O a|O critical|O role|O in|O the|O tumor|O progression|O of|O MM|O patients|O with|O t|O (|O 4|O ;|O 14|O )|O .|O 
Mutation|O analysis|O of|O C-KIT|gene-rna in|O patients|O with|O myelodysplastic|O syndromes|O without|O mastocytosis|O and|O cases|O of|O systemic|O mastocytosis|O .|O 
The|O proto|O -|O oncogene|O C-KIT|gene-rna encodes|O a|O tyrosine|gene-protein kinase|gene-protein receptor|gene-protein that|O is|O expressed|O on|O mast|O cells|O and|O haematopoietic|O stem|O cells|O and|O can|O show|O somatic|O mutations|O in|O patients|O with|O mastocytosis|O .|O 
Only|O scattered|O information|O is|O available|O about|O mutations|O in|O C-KIT|gene-rna in|O patients|O with|O other|O myeloid|O neoplasms|O .|O 
Moreover|O ,|O the|O prevalence|O of|O mutations|O in|O C-KIT|gene-rna in|O bone|O marrow|O specimens|O of|O individuals|O with|O systemic|O mastocytosis|O is|O largely|O unknown|O .|O 
Using|O sequence|O analysis|O ,|O we|O have|O screened|O cDNAs|O of|O the|O C-KIT|gene-rna domain|O encompassing|O codon|O 510|O -|O 626|O and|O codon|O 763|O -|O 858|O in|O bone|O marrow|O (|O BM|O )|O mononuclear|O cells|O (|O MNCs|O )|O of|O patients|O with|O myelodysplastic|O syndromes|O (|O n|O =|O 28|O )|O and|O patients|O with|O systemic|O mastocytosis|O (|O n|O =|O 12|O )|O for|O the|O presence|O of|O mutations|O .|O 
Furthermore|O ,|O restriction|O fragment|O length|O polymorphism|O analysis|O was|O applied|O for|O identification|O of|O the|O C-KIT|gene-rna 2468|O A|O -->|O T|O and|O the|O C-KIT|gene-rna 1700|O T|O -->|O G|O mutation|O ,|O as|O well|O as|O the|O C-KIT|gene-rna 1642|O A|O -->|O C|O polymorphism|O .|O 
All|O 11|O patients|O with|O systemic|O indolent|O mastocytosis|O tested|O positive|O for|O C-KIT|gene-rna 2468|O A|O -->|O T|O .|O 
In|O contrast|O ,|O no|O mutation|O was|O identified|O in|O the|O case|O of|O aggressive|O mastocytosis|O .|O 
Among|O patients|O with|O myelodysplastic|O syndromes|O ,|O no|O patient|O showed|O a|O somatic|O mutation|O in|O C-KIT|gene-rna .|O 
The|O allele|O frequency|O for|O C-KIT|gene-rna 1642|O A|O -->|O C|O among|O the|O entire|O patient|O population|O was|O 0.038|O and|O was|O 0.125|O among|O age|O -|O and|O sex|O -|O matched|O healthy|O controls|O .|O 
Our|O data|O demonstrate|O that|O myelodysplastic|O syndromes|O without|O histological|O or|O cytological|O evidence|O of|O mastocytosis|O do|O not|O exhibit|O somatic|O mutations|O in|O exons|O 10|O ,|O 11|O ,|O 12|O ,|O 16|O ,|O 17|O and|O 18|O of|O C-KIT|gene-rna .|O 
In|O contrast|O ,|O BM|O MNCs|O of|O patients|O with|O systemic|O indolent|O mastocytosis|O were|O all|O positive|O for|O C-KIT|gene-rna 2468|O A|O -->|O T|O and|O negative|O for|O additional|O mutations|O in|O these|O exons|O .|O 
The|O C-KIT|gene-rna 1642|O A|O -->|O C|O polymorphism|O is|O not|O associated|O with|O myelodysplastic|O syndrome|O or|O systemic|O mastocytosis|O .|O 
Cytoplasmic|O and|O nuclear|O accumulation|O of|O beta-catenin|gene-protein is|O rarely|O caused|O by|O CTNNB1|gene-rna exon|O 3|O mutations|O in|O cutaneous|O malignant|O melanoma|O .|O 
Beta-catenin|gene-generic plays|O an|O important|O role|O in|O the|O Wnt|gene-generic signaling|O pathway|O by|O activating|O T-cell|gene-generic factor|gene-generic (|O Tcf|gene-generic )|O /|O lymphoid|gene-generic enhancer|gene-generic factor|gene-generic (|O Lef|gene-generic )|O -|O regulated|O gene|O transcription|O .|O 
The|O level|O of|O beta-catenin|gene-generic is|O regulated|O through|O GSK-3beta|gene-protein phosphorylation|O of|O specific|O serine|O and|O threonine|O residues|O ,|O all|O of|O which|O are|O encoded|O for|O in|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O (|O CTNNB1|gene-rna )|O .|O 
Mutations|O altering|O the|O GSK-3beta|gene-protein phosphorylation|O sites|O lead|O to|O cellular|O accumulation|O of|O beta-catenin|gene-protein and|O constitutive|O transcription|O of|O Tcf|gene-generic /|O Lef|gene-generic target|O genes|O .|O 
Such|O mutations|O have|O previously|O been|O found|O in|O melanoma|O cell|O lines|O .|O 
In|O our|O study|O ,|O primary|O melanomas|O and|O their|O corresponding|O metastases|O were|O screened|O for|O CTNNB1|gene-rna exon|O 3|O mutations|O using|O single|O -|O strand|O conformation|O polymorphism|O and|O nucleotide|O sequence|O analysis|O .|O 
One|O of|O 31|O primary|O tumors|O and|O 1|O of|O 37|O metastases|O ,|O both|O originating|O from|O the|O same|O patient|O ,|O had|O a|O TCT|O to|O TTT|O mutation|O at|O codon|O 45|O ,|O changing|O serine|O to|O phenylalanine|O .|O 
Immunohistochemical|O analysis|O revealed|O membranous|O localization|O of|O beta-catenin|gene-protein in|O a|O majority|O of|O the|O samples|O .|O 
The|O mutated|O primary|O tumor|O and|O metastasis|O ,|O however|O ,|O displayed|O widespread|O cytoplasmic|O and|O nuclear|O expression|O of|O beta-catenin|gene-protein .|O 
An|O additional|O 30|O %|O of|O the|O primary|O tumors|O showed|O focal|O cytoplasmic|O and|O nuclear|O staining|O .|O 
Thus|O ,|O beta-catenin|gene-rna exon|O 3|O mutations|O are|O rare|O in|O primary|O as|O well|O as|O metastatic|O melanomas|O and|O do|O not|O explain|O the|O abnormal|O cytoplasmic|O and|O nuclear|O localization|O of|O beta-catenin|gene-protein found|O in|O a|O relatively|O large|O fraction|O of|O primary|O melanomas|O .|O 
Frequent|O deletions|O and|O mutations|O of|O the|O beta-catenin|gene-rna gene|O are|O associated|O with|O overexpression|O of|O cyclin|gene-protein D1|gene-protein and|O fibronectin|gene-protein and|O poorly|O differentiated|O histology|O in|O childhood|O hepatoblastoma|O .|O 
Hepatoblastoma|O (|O HBL|O )|O is|O the|O most|O common|O malignant|O liver|O tumor|O in|O young|O children|O .|O 
Recent|O reports|O have|O shown|O that|O the|O beta-catenin|gene-rna gene|O was|O frequently|O mutated|O or|O deleted|O in|O HBLS|O :|O To|O elucidate|O the|O role|O of|O beta-catenin|gene-rna abnormalities|O in|O HBLs|O ,|O we|O searched|O for|O mutations|O of|O beta-catenin|gene-rna and|O APC|gene-rna as|O well|O as|O expression|O of|O the|O target|O genes|O ,|O cyclin|gene-protein D1|gene-protein ,|O c-myc|gene-protein ,|O and|O fibronectin|gene-protein ,|O in|O 68|O primary|O HBLS|O :|O The|O mutation|O analysis|O revealed|O that|O 44|O (|O 65|O %|O )|O tumors|O carried|O missense|O mutations|O or|O deletions|O of|O beta-catenin|gene-rna ,|O all|O of|O which|O were|O somatic|O and|O targeted|O to|O the|O exon|O 3|O encoding|O the|O amino|O acid|O residues|O involved|O in|O its|O degradation|O .|O 
However|O ,|O no|O loss|O of|O function|O mutation|O of|O the|O APC|gene-rna gene|O was|O detected|O by|O the|O yeast|O functional|O assay|O .|O 
Of|O interest|O ,|O beta-catenin|gene-rna mutation|O was|O significantly|O correlated|O with|O overexpression|O of|O the|O target|O genes|O ,|O cyclin|gene-protein D1|gene-protein and|O fibronectin|gene-protein ,|O but|O not|O with|O that|O of|O c-myc|gene-protein in|O HBLs|O as|O measured|O by|O quantitative|O real|O -|O time|O reverse|O transcription|O -|O PCR|O .|O 
The|O immunohistochemical|O studies|O in|O 15|O HBLs|O demonstrated|O that|O the|O nuclear|O /|O cytoplasmic|O accumulation|O of|O beta-catenin|gene-protein was|O positive|O in|O 13|O tumors|O ,|O 9|O of|O which|O had|O the|O deletion|O or|O mutation|O of|O the|O gene|gene-rna .|O 
The|O significant|O correlation|O between|O the|O beta-catenin|gene-rna gene|O abnormality|O and|O the|O positive|O staining|O of|O cyclin|gene-protein D1|gene-protein was|O also|O confirmed|O .|O 
Furthermore|O ,|O the|O nuclear|O accumulation|O of|O beta-catenin|gene-protein was|O strongly|O associated|O with|O the|O poorly|O differentiated|O tumor|O cell|O components|O as|O well|O as|O with|O the|O positive|O staining|O of|O cyclin|gene-protein D1|gene-protein within|O the|O tumor|O .|O 
Thus|O ,|O our|O present|O results|O suggested|O that|O the|O gain|O of|O function|O mutation|O of|O beta-catenin|gene-rna played|O a|O crucial|O role|O in|O the|O malignant|O progression|O of|O HBL|O in|O vivo|O .|O 
Determination|O of|O microsatellite|O instability|O ,|O p53|gene-rna and|O K-RAS|gene-rna mutations|O in|O hepatic|O metastases|O from|O patients|O with|O colorectal|O cancer|O :|O relationship|O with|O response|O to|O 5-fluorouracil|O and|O survival|O .|O 
In|O vitro|O and|O clinical|O studies|O have|O suggested|O that|O high|O -|O frequency|O microsatellite|O instability|O (|O MSI-H|O )|O phenotype|O ,|O p53|gene-rna and|O K-ras|gene-rna mutations|O might|O influence|O the|O response|O to|O chemotherapy|O in|O a|O variety|O of|O tumors|O ,|O including|O primary|O colorectal|O cancers|O (|O CRC|O )|O .|O 
Unresectable|O hepatic|O metastases|O from|O CRC|O are|O commonly|O treated|O with|O 5-fluorouracil|O (|O 5FU|O )|O and|O folinic|O acid|O .|O 
Since|O several|O new|O active|O drugs|O are|O now|O used|O for|O treating|O CRC|O ,|O molecular|O determinants|O predictive|O to|O response|O to|O 5FU|O would|O thus|O be|O crucial|O for|O optimizing|O indications|O of|O chemotherapy|O to|O those|O patients|O .|O 
MSI-H|O phenotype|O ,|O p53|gene-rna and|O K-ras|gene-rna status|O were|O characterized|O in|O a|O prospective|O study|O of|O 56|O patients|O with|O CRC|O metastatic|O to|O the|O liver|O and|O treated|O with|O 5FU|O -|O based|O chemotherapy|O .|O 
The|O objective|O response|O rate|O after|O a|O 3|O -|O month|O treatment|O was|O 32.1|O %|O .|O 
The|O prevalence|O of|O p53|gene-rna mutations|O ,|O K-ras|gene-rna mutations|O and|O MSI-H|O phenotype|O was|O 62.5|O %|O ,|O 30.3|O %|O and|O 1.8|O %|O ,|O respectively|O .|O 
No|O significant|O association|O was|O found|O between|O response|O to|O chemotherapy|O and|O p53|gene-rna mutations|O (|O 78|O %|O mutated|O tumors|O in|O responders|O vs.|O 55|O %|O in|O nonresponders|O ;|O p|O =|O 0.10|O )|O and|O K-ras|gene-rna mutations|O (|O 39|O %|O mutated|O tumors|O in|O responders|O vs.|O 26|O %|O in|O nonresponders|O ;|O p|O =|O 0.34|O )|O .|O 
Survival|O was|O longer|O for|O patients|O with|O p53|gene-rna -|O mutated|O metastases|O than|O for|O patients|O with|O unresected|O wild|O -|O type|O p53|gene-rna metastases|O (|O median|O survival|O 15|O months|O vs.|O 17|O months|O ;|O p|O =|O 0.06|O )|O .|O 
The|O determination|O of|O the|O MSI-H|O phenotype|O ,|O p53|gene-rna and|O K-ras|gene-rna status|O in|O hepatic|O metastases|O from|O CRC|O does|O not|O discriminate|O a|O group|O of|O patients|O that|O should|O preferentially|O benefit|O from|O 5FU|O -|O based|O chemotherapy|O .|O 
The|O prognosis|O of|O patients|O with|O treated|O liver|O metastases|O is|O better|O when|O p53|gene-rna is|O mutated|O .|O 
Genetic|O pathways|O in|O the|O evolution|O of|O morphologically|O distinct|O colorectal|O neoplasms|O .|O 
Colorectal|O adenomas|O can|O be|O morphologically|O classified|O as|O exophytic|O or|O 
flat|O .|O Polypoid|O cancers|O and|O cancers|O arising|O de|O novo|O (|O ie.|O ,|O without|O any|O adenomatous|O component|O )|O might|O be|O the|O results|O of|O genetic|O progression|O from|O exophytic|O and|O flat|O adenomas|O ,|O respectively|O .|O 
In|O this|O study|O ,|O we|O examined|O 94|O morphologically|O distinct|O neoplastic|O specimens|O for|O mutations|O in|O K-RAS|gene-rna and|O analyzed|O 10|O microsatellite|O loci|O tightly|O linked|O to|O the|O tumor|O suppressor|O genes|O APC|gene-rna ,|O p53|gene-rna ,|O DCC|gene-rna /|O SMAD4|gene-rna ,|O hMSH2|gene-rna ,|O and|O hMLH1|gene-rna .|O 
K-RAS|gene-rna mutations|O were|O significantly|O associated|O with|O exophytic|O adenomas|O [|O 11|O of|O 21|O (|O 52|O %|O )|O ]|O compared|O to|O flat|O adenomas|O [|O 2|O of|O 13|O (|O 15|O %|O )|O ,|O P|O <|O 0.03|O ]|O and|O polypoid|O cancers|O [|O 17|O of|O 25|O (|O 68|O %|O )|O ]|O compared|O to|O cancers|O arising|O de|O novo|O [|O 7|O of|O 25|O (|O 28|O %|O )|O ,|O P|O <|O 0.01|O ]|O .|O 
Two|O polypoid|O cancer|O cases|O demonstrated|O three|O and|O four|O different|O K-RAS|gene-rna mutations|O ,|O respectively|O ,|O suggesting|O multiple|O areas|O of|O clonal|O expansion|O .|O 
Cancers|O arising|O de|O novo|O were|O significantly|O associated|O with|O loss|O of|O heterozygosity|O (|O LOH|O )|O at|O chromosome|O 3p|O compared|O to|O pol|O ypoid|O cancers|O [|O 6|O of|O 18|O (|O 33|O %|O )|O versus|O 1|O of|O 20|O (|O 5|O %|O )|O ,|O P|O <|O 0.03|O ]|O ,|O whereas|O the|O prevalence|O of|O LOH|O at|O chromosomes|O 2p|O ,|O 5q|O ,|O 17p|O ,|O and|O 18q|O and|O microsatellite|O instability|O were|O not|O different|O between|O the|O groups|O .|O 
For|O all|O cancers|O ,|O LOH|O at|O chromosomes|O 17p|O and|O 18q|O occurred|O in|O 47|O and|O 51|O %|O ,|O respectively|O .|O 
However|O ,|O LOH|O at|O 17p|O and|O 18q|O occurred|O in|O 0|O and|O 16|O %|O of|O benign|O lesions|O ,|O respectively|O ,|O suggesting|O their|O role|O in|O malignant|O transformation|O .|O 
There|O was|O no|O difference|O in|O LOH|O at|O chromosomes|O 17p|O and|O 18q|O between|O exophytic|O and|O flat|O lesions|O .|O 
These|O findings|O suggest|O that|O (a)|O mutant|O K-RAS|gene-rna is|O associated|O with|O the|O exophytic|O growth|O of|O colonic|O neoplasms|O ,|O and|O that|O (b)|O some|O colorectal|O cancers|O arising|O de|O novo|O lose|O chromosome|O 3p|O during|O their|O evolution|O ,|O which|O is|O not|O seen|O in|O polypoid|O cancers|O .|O 
Half|O of|O all|O cancers|O lose|O chromosomes|O 17p|O and|O 18q|O at|O or|O near|O the|O malignant|O transition|O of|O benign|O lesions|O as|O reported|O previously|O ,|O irrespective|O of|O morphology|O .|O 
There|O may|O be|O more|O than|O one|O genetic|O avenue|O for|O colorectal|O cancer|O formation|O ,|O and|O this|O correlates|O with|O the|O morphological|O characteristics|O .|O 
Frequent|O beta-catenin|gene-rna aberration|O in|O human|O hepatocellular|O carcinoma|O .|O 
Recently|O ,|O mutations|O in|O the|O beta-catenin|gene-rna gene|O in|O hepatocellular|O carcinoma|O (|O HCC|O )|O have|O been|O reported|O :|O approximately|O 20|O %|O of|O HCCs|O had|O activating|O mutations|O at|O the|O glycogen|gene-protein synthase|gene-protein kinase|gene-protein 3beta|gene-protein phosphorylation|O sites|O within|O the|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O .|O 
However|O ,|O changes|O in|O the|O level|O of|O the|O beta-catenin|gene-protein protein|O in|O HCC|O have|O not|O been|O well|O studied|O .|O 
We|O examined|O ,|O by|O Western|O blotting|O ,|O the|O expression|O level|O of|O the|O beta-catenin|gene-protein protein|O in|O cancerous|O tissues|O in|O comparison|O with|O that|O in|O adjacent|O non|O -|O cancerous|O tissues|O obtained|O from|O 32|O cases|O of|O HCC|O with|O hepatitis|O C|O .|O 
An|O increase|O in|O the|O beta-catenin|gene-protein protein|O level|O in|O cancerous|O tissue|O compared|O to|O that|O in|O adjacent|O non|O -|O cancerous|O tissue|O was|O found|O in|O 15|O (|O 46.9|O %|O )|O of|O 32|O cases|O of|O HCC|O .|O 
Mutation|O in|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O was|O found|O in|O six|O (|O 18.8|O %|O )|O of|O the|O 32|O cases|O ,|O in|O five|O of|O which|O the|O beta-catenin|gene-protein protein|O level|O was|O increased|O .|O 
In|O total|O ,|O beta-catenin|gene-generic aberration|O was|O found|O in|O 16|O (|O 50.0|O %|O )|O of|O 32|O cases|O of|O HCC|O .|O 
It|O should|O be|O noted|O that|O beta-catenin|gene-generic aberration|O was|O also|O found|O in|O early|O HCC|O although|O it|O was|O observed|O chiefly|O in|O advanced|O HCCs|O .|O 
These|O results|O indicate|O that|O beta-catenin|gene-generic aberration|O is|O a|O frequent|O event|O in|O the|O development|O of|O HCC|O and|O may|O facilitate|O the|O development|O of|O HCC|O in|O the|O course|O of|O chronic|O hepatitis|O .|O 
Nuclear|O localization|O of|O beta-catenin|gene-protein is|O an|O important|O prognostic|O factor|O in|O hepatoblastoma|O .|O 
In|O this|O study|O ,|O mutational|O and|O immunohistochemical|O analyses|O of|O beta-catenin|gene-protein were|O performed|O in|O 30|O hepatoblastomas|O ,|O to|O assess|O the|O prevalence|O of|O alterations|O of|O the|O Wnt|gene-rna pathway|O with|O respect|O to|O clinicopathological|O parameters|O and|O survival|O .|O 
Four|O missense|O mutations|O of|O beta-catenin|gene-rna (|O 13.3|O %|O )|O were|O detected|O and|O there|O was|O strong|O immunoreactivity|O for|O beta-catenin|gene-protein in|O the|O cytoplasm|O and/or|O the|O nucleus|O in|O 97|O %|O of|O hepatoblastomas|O .|O 
Nuclear|O and|O cytoplasmic|O staining|O was|O demonstrated|O in|O 19|O of|O 30|O tumours|O (|O 63|O %|O )|O ,|O while|O ten|O revealed|O only|O cytoplasmic|O staining|O .|O 
Statistically|O ,|O this|O nuclear|O beta-catenin|gene-protein staining|O was|O significantly|O higher|O in|O the|O embryonal|O (|O Fisher|O exact|O test|O ;|O p|O =|O 0.00393|O )|O or|O undifferentiated|O type|O (|O p|O =|O 0.00156|O )|O of|O hepatoblastoma|O than|O in|O the|O fetal|O type|O ,|O but|O there|O was|O no|O difference|O between|O clinical|O stages|O I|O and|O II|O and|O clinical|O stages|O III|O and|O IV|O (|O p|O =|O 0.175|O )|O .|O 
Cumulative|O survival|O curves|O showed|O that|O nuclear|O beta-catenin|gene-protein staining|O (|O generalized|O Wilcoxon|O test|O ;|O p|O =|O 0.0088|O )|O ,|O undifferentiated|O histological|O type|O (|O p|O =|O 0.0305|O )|O ,|O and|O clinical|O stages|O III|O and|O IV|O (|O p|O =|O 0.0107|O )|O were|O significantly|O correlated|O with|O shorter|O survival|O time|O in|O these|O patients|O .|O 
Moreover|O ,|O Cox|O multivariate|O analysis|O provides|O evidence|O that|O nuclear|O beta-catenin|gene-protein staining|O is|O the|O most|O important|O prognostic|O factor|O for|O survival|O (|O p|O =|O 0.0090|O )|O .|O 
It|O is|O therefore|O concluded|O that|O immunohistochemical|O analysis|O of|O beta-catenin|gene-protein might|O be|O a|O useful|O clinical|O tool|O for|O estimating|O the|O prognosis|O for|O patients|O with|O hepatoblastoma|O .|O 
Novel|O method|O for|O simultaneous|O analysis|O of|O p53|gene-rna and|O K-ras|gene-rna mutations|O and|O p53|gene-protein protein|O expression|O in|O single|O histologic|O sections|O .|O 
BACKGROUND|O AND|O OBJECTIVE|O :|O 
Abnormal|O protein|O expression|O and|O gene|O mutation|O should|O be|O examined|O on|O exactly|O identified|O lesions|O .|O 
To|O perform|O simultaneous|O analyses|O of|O oncogene|O or|O tumor|O suppressor|O gene|O mutations|O and|O related|O protein|O expression|O in|O single|O histologic|O sections|O ,|O we|O have|O developed|O a|O novel|O method|O using|O an|O antigen|gene-protein -|O retrieval|O solution|O for|O a|O polymerase|gene-protein chain|O reaction|O template|O before|O immunohistochemical|O staining|O .|O 
METHODS|O :|O 
Using|O 20|O cases|O of|O sporadic|O colorectal|O carcinoma|O ,|O several|O kinds|O of|O antigen|gene-protein -|O retrieval|O solutions|O were|O tested|O after|O heating|O rehydrated|O ,|O 4|O -|O microm|O -|O thick|O ,|O formalin|O -|O fixed|O ,|O paraffin|O -|O embedded|O histologic|O sections|O at|O 96|O degrees|O C|O for|O 20|O minutes|O .|O 
Polymerase|gene-protein chain|O reaction|O -|O single|O -|O strand|O conformation|O polymorphism|O analysis|O was|O conducted|O for|O p53|gene-rna (|O exons|O 5|O through|O 9|O )|O and|O K-ras|gene-rna (|O exons|O 1|O and|O 2|O )|O ,|O and|O the|O histologic|O sections|O were|O then|O immunostained|O with|O monoclonal|gene-protein antibody|gene-protein against|O p53|gene-protein .|O 
RESULTS|O :|O 
DNA|O analysis|O of|O antigen|gene-protein -|O retrieval|O solutions|O was|O possible|O in|O all|O 20|O cases|O and|O revealed|O completely|O consistent|O results|O (|O 100|O %|O )|O with|O fresh|O cancer|O tissue|O and|O microdissected|O cancer|O tissue|O of|O paraffin|O -|O embedded|O histologic|O sections|O .|O 
With|O this|O method|O ,|O K-ras|gene-rna mutations|O were|O positive|O in|O 10|O of|O 20|O cases|O (|O exon|O 1|O in|O 9|O cases|O and|O exon|O 2|O in|O 1|O case|O )|O and|O p53|gene-rna mutations|O were|O positive|O in|O 9|O of|O 20|O cases|O (|O exon|O 5|O in|O 4|O cases|O ,|O exon|O 6|O in|O 1|O ,|O exon|O 7|O in|O 3|O ,|O and|O exon|O 8|O in|O 1|O case|O )|O ,|O with|O 8|O of|O the|O 9|O p53|gene-rna mutation|O cases|O showing|O diffuse|O p53|gene-protein protein|O expression|O on|O immunostaining|O .|O 
Base|O alterations|O of|O all|O abnormal|O conformers|O were|O confirmed|O with|O direct|O sequencing|O .|O 
For|O polymerase|gene-protein chain|O reaction|O -|O single|O -|O strand|O conformation|O polymorphism|O analysis|O ,|O sodium|O citrate|O buffer|O (|O pH|O 6.0|O )|O was|O found|O to|O be|O the|O optimal|O antigen|gene-protein -|O retrieval|O solution|O .|O 
CONCLUSIONS|O :|O 
This|O newly|O developed|O method|O can|O be|O used|O for|O routine|O immunostaining|O and|O genetic|O analysis|O with|O single|O histologic|O sections|O .|O 
More|O frequent|O beta-catenin|gene-rna exon|O 3|O mutations|O in|O gallbladder|O adenomas|O than|O in|O carcinomas|O indicate|O different|O lineages|O .|O 
To|O clarify|O the|O contribution|O of|O beta-catenin|gene-rna ,|O which|O is|O related|O to|O cell|O adhesion|O and|O intranuclear|O transcription|O ,|O to|O gallbladder|O carcinogenesis|O ,|O we|O investigated|O its|O expression|O using|O immunohistochemistry|O ,|O and|O beta-catenin|gene-rna exon|O 3|O mutations|O by|O DNA|O direct|O sequencing|O ,|O in|O 18|O gallbladder|O adenomas|O and|O 82|O adenocarcinomas|O .|O 
Membranous|O expression|O was|O significantly|O lower|O in|O moderately|O and|O poorly|O differentiated|O than|O in|O well|O -|O differentiated|O adenocarcinoma|O cases|O (|O P|O <|O 0.001|O )|O .|O 
The|O gallbladder|O adenomas|O showed|O significantly|O stronger|O expression|O in|O the|O cytoplasm|O and|O the|O nucleus|O than|O carcinomas|O (|O P|O <|O 0.05|O and|O P|O <|O 0.001|O ,|O respectively|O )|O ,|O and|O exon|O 3|O mutations|O were|O observed|O in|O 62.5|O %|O (|O 10|O of|O 16|O )|O of|O adenomas|O ,|O but|O only|O 4.8|O %|O (|O 1|O of|O 21|O )|O of|O carcinomas|O .|O 
With|O beta-catenin|gene-protein as|O a|O molecular|O marker|O ,|O the|O adenoma|O -|O carcinoma|O sequence|O can|O be|O considered|O to|O be|O a|O minor|O pathway|O in|O gallbladder|O carcinogenesis|O .|O 
p53|gene-protein overexpression|O and|O K-ras|gene-rna gene|O mutations|O in|O primary|O sclerosing|O cholangitis|O -|O associated|O biliary|O tract|O cancer|O .|O 
Cholangiocarcinoma|O occurs|O frequently|O in|O patients|O with|O primary|O sclerosing|O cholangitis|O (|O PSC|O )|O .|O 
We|O evaluated|O the|O incidence|O and|O prognostic|O significance|O of|O p53|gene-protein protein|O overexpression|O and|O K-ras|gene-rna gene|O mutations|O in|O patients|O with|O biliary|O tract|O cancer|O and|O PSC|O .|O 
p53|gene-protein protein|O expression|O was|O determined|O in|O specimens|O from|O 12|O patients|O with|O biliary|O tract|O cancer|O ,|O using|O the|O antibody|O ,|O D07|gene-protein .|O 
K-ras|gene-rna mutations|O were|O detected|O using|O DNA|O sequencing|O and|O a|O mutation|O ligation|O assay|O .|O 
Accumulation|O of|O p53|gene-protein protein|O was|O detected|O in|O 6|O of|O 12|O tumors|O (|O 50|O %|O )|O .|O 
K-ras|gene-rna mutations|O were|O detected|O in|O 4|O of|O 12|O tumors|O (|O 33|O %|O )|O .|O 
Overall|O survival|O in|O patients|O with|O p53|gene-protein -|O negative|O tumors|O was|O significantly|O longer|O (|O P|O <|O 0.05|O )|O than|O that|O in|O patients|O with|O p53|gene-protein -|O positive|O (|O mutant|O )|O tumors|O .|O 
Similarly|O ,|O overall|O survival|O was|O significantly|O longer|O (|O P|O <|O 0.05|O )|O in|O the|O absence|O of|O a|O K-ras|gene-rna mutation|O than|O in|O patients|O with|O a|O tumor|O containing|O a|O K-ras|gene-rna mutation|O .|O 
Mean|O interval|O from|O the|O time|O of|O diagnosis|O of|O PSC|O until|O the|O diagnosis|O of|O biliary|O tract|O cancer|O was|O significantly|O shorter|O (|O P|O <|O 0.05|O )|O in|O patients|O with|O p53|gene-protein overexpression|O than|O in|O those|O patients|O without|O p53|gene-protein overexpression|O (|O 2|O versus|O 47|O months|O )|O .|O 
p53|gene-protein overexpression|O and|O K-ras|gene-rna mutations|O occur|O commonly|O in|O patients|O with|O PSC|O and|O biliary|O tract|O cancer|O and|O are|O associated|O with|O a|O shortened|O survival|O .|O 
Patients|O with|O longstanding|O PSC|O are|O less|O likely|O to|O have|O these|O genetic|O alterations|O and|O may|O have|O a|O better|O prognosis|O .|O 
Constitutive|O activation|O of|O the|O Wnt|gene-rna signaling|O pathway|O by|O CTNNB1|gene-rna (|O beta-catenin|gene-rna )|O mutations|O in|O a|O subset|O of|O human|O lung|O adenocarcinoma|O .|O 
Constitutive|O activation|O of|O the|O Wnt|gene-rna signaling|O pathway|O as|O a|O result|O of|O genetic|O alterations|O of|O APC|gene-rna ,|O AXIN1|gene-rna ,|O and|O CTNNB1|gene-rna has|O been|O found|O in|O various|O human|O cancers|O ,|O including|O those|O of|O the|O colon|O ,|O liver|O ,|O endometrium|O ,|O ovary|O ,|O prostate|O ,|O and|O stomach|O .|O 
To|O investigate|O the|O pathogenetic|O significance|O of|O constitutive|O activation|O of|O the|O Wnt|gene-rna signaling|O pathway|O in|O human|O lung|O carcinogenesis|O ,|O CTNNB1|gene-rna alterations|O in|O exon|O 3|O ,|O a|O region|O known|O to|O represent|O a|O mutation|O hot|O spot|O ,|O were|O screened|O in|O 46|O lung|O cancer|O cell|O lines|O and|O 47|O primary|O lung|O cancers|O .|O 
Missense|O mutations|O causing|O substitutions|O of|O Ser|O /|O Thr|O residues|O critical|O for|O regulation|O by|O GSK|gene-protein -|O 3beta|O were|O detected|O in|O one|O (|O 2|O %|O )|O of|O the|O cell|O lines|O ,|O A427|O ,|O and|O two|O (|O 4|O %|O )|O of|O the|O surgical|O specimens|O .|O 
The|O three|O lung|O cancers|O with|O CTNNB1|gene-rna mutations|O were|O adenocarcinomas|O .|O 
To|O explore|O the|O prevalence|O of|O constitutive|O activation|O of|O the|O Wnt|gene-rna signaling|O pathway|O in|O human|O lung|O cancer|O ,|O we|O assessed|O 15|O lung|O cancer|O cell|O lines|O representing|O major|O histological|O subtypes|O of|O lung|O cancers|O for|O constitutive|O Tcf|gene-rna transcriptional|O activity|O (|O CTTA|O )|O .|O 
CTTA|O was|O observed|O only|O in|O the|O A427|O adenocarcinoma|O cell|O line|O ,|O but|O not|O in|O the|O remaining|O 14|O cell|O lines|O .|O 
The|O data|O indicate|O that|O constitutive|O activation|O of|O the|O Wnt|gene-rna signaling|O pathway|O caused|O by|O CTNNB1|gene-rna mutation|O is|O involved|O in|O the|O development|O and/or|O progression|O of|O a|O subset|O of|O lung|O carcinoma|O ,|O preferentially|O in|O adenocarcinoma|O .|O 
K-ras|gene-rna mutations|O in|O Mullerian|O inclusion|O cysts|O associated|O with|O serous|O borderline|O tumors|O of|O the|O ovary|O .|O 
OBJECTIVE|O :|O 
Mullerian|O inclusion|O cysts|O (|O MIC|O )|O are|O small|O benign|O appearing|O glands|O that|O are|O occasionally|O noted|O in|O lymph|O nodes|O and|O peritoneal|O biopsies|O .|O 
They|O occur|O most|O frequently|O in|O women|O with|O serous|O ovarian|O tumors|O ,|O with|O borderline|O tumors|O (|O SBOT|O )|O having|O a|O higher|O incidence|O than|O invasive|O cancers|O .|O 
The|O aim|O of|O this|O study|O was|O to|O examine|O whether|O MIC|O and|O SBOT|O have|O identical|O K-ras|gene-rna mutations|O ,|O which|O would|O suggest|O that|O they|O are|O related|O .|O 
Methods|O .|O 
Six|O patients|O in|O whom|O adequate|O tissue|O was|O available|O from|O SBOT|O ,|O MIC|O ,|O and|O normal|O tissue|O were|O identified|O from|O a|O consecutive|O series|O of|O patients|O with|O SBOT|O who|O underwent|O lymph|O node|O sampling|O from|O 1992|O to|O 1997|O at|O Duke|O University|O Medical|O Center|O .|O 
DNA|O extraction|O was|O performed|O using|O laser|O capture|O microdissection|O .|O 
Exon|O 1|O of|O the|O K-ras|gene-rna gene|O was|O amplified|O using|O PCR|O and|O subjected|O to|O single|O -|O strand|O conformation|O analysis|O to|O screen|O for|O mutations|O .|O 
Shifted|O bands|O were|O sequenced|O to|O confirm|O the|O presence|O of|O mutations|O .|O 
RESULTS|O :|O 
Mutations|O in|O codon|O 12|O of|O K-ras|gene-rna were|O found|O in|O three|O of|O six|O (|O 50|O %|O )|O SBOT|O .|O 
In|O two|O of|O these|O three|O cases|O ,|O the|O identical|O mutation|O was|O found|O in|O the|O SBOT|O and|O the|O MIC|O (|O gly|O to|O val|O in|O both|O cases|O )|O ,|O but|O not|O in|O the|O corresponding|O normal|O DNA|O .|O 
In|O one|O case|O ,|O a|O mutation|O was|O seen|O in|O the|O ovarian|O tumor|O (|O gly|O to|O asp|O )|O ,|O but|O not|O in|O the|O corresponding|O MIC|O .|O 
CONCLUSIONS|O :|O 
Mutations|O in|O codon|O 12|O of|O the|O K-ras|gene-rna gene|O are|O a|O hallmark|O of|O serous|O borderline|O tumors|O .|O 
The|O presence|O of|O identical|O K-ras|gene-rna mutations|O in|O some|O SBOT|O and|O their|O associated|O MIC|O suggests|O that|O they|O are|O related|O processes|O .|O 
Both|O may|O arise|O due|O to|O a|O field|O effect|O ,|O or|O alternatively|O some|O MIC|O may|O represent|O metastases|O from|O the|O primary|O ovarian|O tumor|O .|O 
K-ras|gene-rna point|O mutation|O in|O the|O nerve|O plexuses|O around|O the|O superior|O mesenteric|O artery|O in|O resectable|O adenocarcinoma|O of|O the|O pancreatic|O head|O :|O distribution|O pattern|O and|O related|O factors|O .|O 
BACKGROUND|O :|O 
Adenocarcinoma|O of|O the|O pancreas|O is|O likely|O to|O spread|O into|O the|O nerve|O plexuses|O around|O the|O superior|O mesenteric|O artery|O (|O SMA|O )|O at|O a|O microscopic|O level|O .|O 
Since|O there|O has|O been|O no|O detailed|O report|O on|O how|O minute|O cancer|O invasion|O is|O distributed|O among|O the|O peri|O -|O SMA|O plexuses|O or|O which|O cases|O are|O more|O vulnerable|O to|O such|O an|O event|O ,|O it|O has|O long|O been|O controversial|O how|O to|O treat|O this|O area|O when|O resecting|O the|O pancreatic|O head|O cancer|O .|O 
HYPOTHESIS|O :|O 
The|O K-ras|gene-rna mutation|O assay|O is|O more|O sensitive|O than|O the|O conventional|O histologic|O diagnosis|O in|O detecting|O minute|O cancer|O invasion|O around|O the|O SMA|O .|O 
DESIGN|O :|O 
Prospective|O consecutive|O series|O .|O 
SETTING|O :|O 
Cancer|O center|O hospital|O .|O 
PATIENTS|O AND|O METHODS|O :|O 
The|O entire|O circle|O of|O the|O peri|O -|O SMA|O tissues|O was|O obtained|O from|O 24|O patients|O who|O had|O received|O an|O extended|O pancreatectomy|O for|O adenocarcinoma|O of|O the|O pancreatic|O head|O .|O 
They|O were|O divided|O into|O right|O and|O left|O hemicircular|O samples|O (|O 48|O samples|O )|O ,|O and|O each|O sample|O was|O used|O for|O both|O histologic|O and|O genetic|O diagnoses|O .|O 
Since|O all|O patients|O '|O primary|O tumors|O were|O positive|O for|O point|O mutation|O at|O codon|O 12|O of|O the|O K-ras|gene-rna gene|O ,|O the|O presence|O or|O absence|O of|O the|O mutation|O was|O determined|O for|O the|O peri|O -|O SMA|O plexuses|O using|O the|O mutant|O allele|O specific|O amplification|O method|O .|O 
RESULTS|O :|O 
Compared|O with|O results|O of|O the|O histologic|O examination|O ,|O the|O K-ras|gene-rna mutation|O assay|O was|O more|O sensitive|O in|O detecting|O positive|O findings|O in|O the|O peri|O -|O SMA|O plexuses|O (|O 12|O samples|O from|O 9|O patients|O )|O .|O 
According|O to|O the|O distribution|O of|O the|O K-ras|gene-rna mutation|O into|O the|O right|O -|O and|O left|O -|O half|O samples|O ,|O 24|O patients|O were|O classified|O into|O the|O following|O 4|O patterns|O (|O right|O /|O left|O )|O :|O negative|O /|O negative|O in|O 15|O patients|O ;|O positive|O /|O negative|O in|O 6|O patients|O ;|O positive|O /|O positive|O in|O 3|O patients|O ;|O and|O negative|O /|O positive|O in|O 0|O patients|O .|O 
In|O 3|O patients|O who|O showed|O a|O positive|O /|O positive|O pattern|O in|O the|O genetic|O diagnosis|O ,|O their|O right|O -|O half|O samples|O included|O more|O cancer|O cells|O that|O were|O detectable|O by|O routine|O microscopy|O .|O 
There|O was|O no|O relation|O between|O K-ras|gene-rna mutation|O and|O lymphatic|O invasion|O ,|O while|O K-ras|gene-rna mutation|O was|O particularly|O related|O with|O the|O invasion|O of|O portal|O vein|O (|O P|O =|O .04|O )|O and|O posterior|O peripancreatic|O tissues|O (|O P|O =|O .002|O )|O .|O 
All|O 3|O patients|O with|O K-ras|gene-rna mutation|O in|O bilateral|O plexuses|O were|O classified|O by|O the|O TNM|O staging|O system|O as|O T4|O using|O Union|O Internationale|O Contre|O le|O Cancer|O classification|O .|O 
CONCLUSIONS|O :|O 
The|O K-ras|gene-rna mutation|O (|O at|O codon|O 12|O )|O assay|O indicated|O a|O simple|O and|O regular|O pattern|O of|O cancer|O extension|O into|O the|O nerve|O plexuses|O around|O the|O SMA|O from|O adenocarcinoma|O of|O the|O pancreatic|O head|O :|O (1)|O The|O left|O half|O of|O the|O plexus|O was|O unlikely|O to|O be|O involved|O by|O cancer|O in|O cases|O in|O which|O the|O right|O half|O was|O intact|O .|O 
(2)|O Cancer|O extension|O into|O the|O peri|O -|O SMA|O plexuses|O occurred|O after|O the|O posterior|O confine|O of|O the|O pancreas|O had|O been|O involved|O by|O direct|O invasion|O from|O the|O primary|O pancreatic|O tumor|O .|O 
(3)|O The|O left|O half|O was|O not|O involved|O in|O cancerous|O tumors|O classified|O as|O T1|O to|O T3|O but|O was|O occasionally|O involved|O in|O those|O classified|O as|O T4|O tumors|O .|O 
These|O data|O seem|O to|O provide|O a|O useful|O indicator|O of|O some|O additional|O treatments|O (|O resection|O ,|O irradiation|O ,|O etc|O )|O for|O the|O peri|O -|O SMA|O region|O when|O a|O locally|O advanced|O pancreatic|O head|O cancer|O is|O treated|O with|O a|O curative|O intent|O .|O 
Somatic|O mutations|O of|O fibroblast|gene-rna growth|gene-rna factor|gene-rna receptor|gene-rna 3|gene-rna (|O FGFR3|gene-rna )|O are|O uncommon|O in|O carcinomas|O of|O the|O uterine|O cervix|O .|O 
Germline|O mutations|O of|O the|O gene|O encoding|O human|O fibroblast|gene-rna growth|gene-rna factor|gene-rna receptor|gene-rna 3|gene-rna (|O FGFR3|gene-rna )|O have|O been|O shown|O to|O be|O responsible|O for|O several|O related|O autosomal|O dominant|O forms|O of|O syndromic|O craniosynostosis|O and|O short|O limb|O dwarfism|O .|O 
Somatic|O activating|O mutations|O of|O FGFR3|gene-rna were|O recently|O reported|O to|O occur|O in|O three|O of|O 12|O (|O 25|O %|O )|O uterine|O cervical|O carcinomas|O and|O nine|O of|O 26|O (|O 35|O %|O )|O bladder|O carcinomas|O ,|O suggesting|O that|O constitutive|O activation|O of|O FGFR3|gene-rna may|O be|O an|O important|O mechanism|O underlying|O the|O development|O and/or|O progression|O of|O these|O common|O epithelial|O malignancies|O .|O 
In|O order|O to|O investigate|O further|O a|O possible|O role|O for|O FGFR3|gene-rna mutations|O in|O cervical|O carcinogenesis|O ,|O we|O performed|O sequence|O -|O based|O mutational|O analysis|O of|O FGFR3|gene-rna in|O 51|O primary|O cervical|O carcinomas|O and|O seven|O cervical|O carcinoma|O -|O derived|O cell|O lines|O .|O 
The|O regions|O analysed|O (|O exons|O 7|O ,|O 10|O ,|O 13|O ,|O 15|O ,|O and|O 19|O )|O encompassed|O all|O previously|O described|O FGFR3|gene-rna mutations|O .|O 
A|O single|O nucleotide|O substitution|O at|O codon|O 249|O ,|O predicting|O a|O serine|O to|O cysteine|O amino|O acid|O substitution|O (|O S|O 249|O C|O )|O in|O the|O FGFR3|gene-rna extracellular|O domain|O ,|O was|O identified|O in|O one|O primary|O tumor|O .|O 
Only|O wild|O type|O FGFR3|gene-rna alleles|O were|O identified|O in|O the|O remaining|O tumors|O and|O cell|O lines|O .|O 
The|O S|O 249|O C|O mutation|O is|O the|O only|O FGFR3|gene-rna mutation|O described|O to|O date|O in|O cervical|O carcinomas|O .|O 
These|O findings|O suggest|O that|O while|O activating|O mutations|O of|O FGFR3|gene-rna occur|O in|O cervical|O cancer|O ,|O they|O may|O not|O be|O as|O common|O as|O initially|O reported|O .|O 
Frequent|O activation|O of|O the|O beta-catenin|gene-rna -|O Tcf|gene-rna signaling|O pathway|O in|O nonfamilial|O colorectal|O carcinomas|O with|O microsatellite|O instability|O .|O 
It|O has|O been|O reported|O that|O wild|O -|O type|O APC|gene-protein protein|O forms|O a|O complex|O with|O beta-Catenin|gene-protein and|O GSK3beta|gene-protein ,|O inducing|O degradation|O of|O beta-Catenin|gene-protein in|O normal|O cells|O .|O 
Both|O beta-Catenin|gene-rna and|O APC|gene-rna gene|O mutations|O have|O recently|O been|O shown|O to|O activate|O the|O same|O signaling|O pathway|O .|O 
Frequent|O mutations|O of|O beta-Catenin|gene-rna in|O hereditary|O nonpolyposis|O colorectal|O carcinomas|O have|O also|O been|O reported|O .|O 
It|O was|O ,|O however|O ,|O controversial|O whether|O the|O mutation|O of|O the|O beta-Catenin|gene-rna gene|O was|O frequent|O in|O nonfamilial|O colorectal|O carcinomas|O with|O high|O -|O frequency|O microsatellite|O instability|O (|O MSI-H|O )|O .|O 
We|O analyzed|O the|O mutations|O of|O the|O APC|gene-rna and|O beta-Catenin|gene-rna genes|O in|O 56|O nonfamilial|O colorectal|O carcinomas|O stratified|O according|O to|O the|O presence|O or|O absence|O of|O microsatellite|O instability|O (|O MSI|O )|O .|O 
APC|gene-rna mutations|O were|O identified|O in|O 11|O of|O 22|O (|O 50|O %|O )|O cases|O of|O MSI-H|O and|O 14|O of|O 34|O (|O 41|O %|O )|O cases|O of|O microsatellite|O -|O stable|O (|O MSS|O )|O /|O low|O -|O frequency|O microsatellite|O instability|O (|O MSI-L|O )|O .|O 
In|O contrast|O ,|O the|O frequency|O of|O beta-Catenin|gene-rna mutations|O was|O significantly|O higher|O in|O MSI-H|O (|O 6|O /|O 22|O ;|O 27|O %|O )|O than|O in|O MSS|O /|O MSI-L|O (|O 1|O /|O 34|O ;|O 3|O %|O )|O (|O P|O =|O 0.01|O )|O .|O 
beta-Catenin|gene-rna mutations|O were|O not|O detected|O in|O carcinomas|O with|O APC|gene-rna mutation|O .|O 
APC|gene-rna mutation|O occurred|O irrespective|O of|O MSI|O status|O .|O 
beta-Catenin|gene-rna mutation|O ,|O however|O ,|O occurred|O frequently|O in|O MSI-H|O carcinomas|O .|O 
Our|O data|O suggest|O that|O activation|O of|O the|O beta-Catenin|gene-rna -|O Tcf|gene-rna signaling|O pathway|O ,|O through|O either|O beta-Catenin|gene-rna or|O APC|gene-rna mutation|O ,|O frequently|O contributes|O to|O MSI-H|O nonfamilial|O colorectal|O carcinomas|O (|O 17|O /|O 22|O ;|O 77|O %|O )|O .|O 
Somatic|O mutations|O of|O LKB1|gene-rna and|O beta-catenin|gene-rna genes|O in|O gastrointestinal|O polyps|O from|O patients|O with|O Peutz|O -|O Jeghers|O syndrome|O .|O 
Peutz|O -|O Jeghers|O syndrome|O (|O PJS|O )|O is|O characterized|O by|O multiple|O gastrointestinal|O hamartomatous|O polyps|O ,|O mucocutaneous|O melanin|gene-protein deposition|O ,|O and|O increased|O risk|O of|O cancer|O ,|O mainly|O in|O the|O gastrointestinal|O tract|O .|O 
We|O examined|O mutations|O of|O the|O LKB1|gene-rna ,|O beta-catenin|gene-rna ,|O APC|gene-rna ,|O K-ras|gene-rna ,|O and|O p53|gene-rna genes|O in|O 27|O gastrointestinal|O hamartomatous|O polyps|O from|O 10|O patients|O in|O nine|O PJS|O families|O .|O 
Of|O these|O hamartomatous|O polyps|O ,|O one|O intestinal|O polyp|O had|O an|O adenomatous|O lesion|O ,|O and|O one|O gastric|O polyp|O contained|O adenomatous|O and|O carcinomatous|O lesions|O .|O 
Germ|O -|O line|O mutations|O of|O the|O LKB1|gene-rna gene|O were|O detected|O in|O six|O PJS|O families|O .|O 
Somatic|O mutations|O of|O the|O LKB1|gene-rna gene|O were|O found|O in|O 5|O polyps|O ,|O whereas|O loss|O of|O heterozygosity|O (|O LOH|O )|O at|O the|O LKB1|gene-rna locus|O at|O 19p|O was|O seen|O in|O 14|O other|O polyps|O .|O 
In|O adenomatous|O lesions|O microdissected|O from|O hamartomatous|O polyps|O ,|O both|O beta-catenin|gene-rna mutation|O and|O 19p|O LOH|O were|O detected|O .|O 
Furthermore|O ,|O a|O carcinomatous|O lesion|O in|O a|O gastric|O hamartomatous|O polyp|O was|O found|O to|O contain|O a|O mutation|O of|O the|O p53|gene-rna gene|O and|O LOH|O at|O the|O p53|gene-rna locus|O in|O addition|O to|O LOH|O at|O the|O LKB1|gene-rna locus|O and|O a|O beta-catenin|gene-rna mutation|O .|O 
K-ras|gene-rna mutations|O were|O detected|O in|O a|O few|O polyps|O ,|O whereas|O no|O APC|gene-rna mutation|O or|O 5q|O LOH|O was|O detected|O in|O hamartomatous|O polyps|O .|O 
These|O results|O suggest|O that|O gastrointestinal|O hamartomatous|O polyps|O in|O PJS|O patients|O develop|O through|O inactivation|O of|O the|O LKB1|gene-rna gene|O by|O germ|O -|O line|O mutation|O plus|O somatic|O mutation|O or|O LOH|O of|O the|O unaffected|O LKB1|gene-rna allele|O ,|O and|O that|O additional|O mutations|O of|O the|O beta-catenin|gene-rna gene|O and|O p53|gene-rna gene|O convert|O hamartomatous|O polyps|O into|O adenomatous|O and|O carcinomatous|O lesions|O .|O 
Frequent|O association|O of|O beta-catenin|gene-rna and|O WT1|gene-rna mutations|O in|O Wilms|O tumors|O .|O 
The|O etiology|O of|O Wilms|O tumor|O ,|O an|O embryonic|O kidney|O tumor|O ,|O is|O genetically|O heterogeneous|O .|O 
One|O Wilms|O tumor|O gene|O ,|O WT1|gene-rna ,|O which|O encodes|O a|O zinc|O finger|O transcription|gene-protein factor|gene-protein ,|O is|O mutated|O in|O 10|O -|O 20|O %|O of|O Wilms|O tumors|O ,|O but|O it|O is|O still|O not|O clear|O what|O critical|O cellular|O pathway(s)|O is|O affected|O by|O these|O mutations|O .|O 
Recently|O beta-catenin|gene-rna mutations|O have|O been|O reported|O in|O 6|O of|O 40|O (|O 15|O %|O )|O of|O Wilms|O tumors|O .|O 
Beta-catenin|gene-rna is|O the|O central|O effector|O in|O the|O Wnt|gene-generic signal|O transduction|O pathway|O ,|O and|O deregulation|O of|O beta-catenin|gene-rna signaling|O is|O critical|O in|O the|O development|O of|O a|O number|O of|O malignancies|O .|O 
The|O observation|O of|O beta-catenin|gene-rna mutations|O in|O Wilms|O tumors|O suggests|O that|O abrogation|O of|O the|O Wnt|gene-generic signaling|O pathway|O also|O plays|O a|O role|O in|O some|O Wilms|O tumors|O .|O 
To|O assess|O the|O relationship|O of|O WT1|gene-rna mutations|O vis-a-vis|O beta-catenin|gene-rna mutations|O in|O Wilms|O tumor|O ,|O we|O analyzed|O 153|O primary|O tumors|O ,|O and|O 21|O of|O 153|O (|O 14|O %|O )|O carried|O beta-catenin|gene-rna mutations|O .|O 
Surprisingly|O ,|O we|O observed|O a|O highly|O significant|O (|O P|O =|O 3.6|O x|O 10(-13)|O )|O association|O between|O WT1|gene-rna and|O beta-catenin|gene-rna mutations|O ;|O 19|O of|O 20|O beta-catenin|gene-rna -|O mutant|O tumors|O had|O also|O sustained|O WT1|gene-rna mutations|O .|O 
By|O analogy|O to|O the|O patterns|O of|O concordant|O and|O discordant|O gene|O mutations|O observed|O in|O other|O tumors|O ,|O our|O data|O suggest|O that|O mutation|O of|O WT1|gene-rna and|O beta-catenin|gene-rna affects|O two|O different|O cellular|O pathways|O ,|O both|O of|O which|O are|O critically|O altered|O in|O at|O least|O a|O subset|O of|O Wilms|O tumors|O .|O 
K-ras|gene-rna oncogene|O subtype|O mutations|O are|O associated|O with|O survival|O but|O not|O expression|O of|O p53|gene-rna ,|O p16|gene-rna (|O INK4A|gene-rna )|O ,|O p21|gene-rna (|O WAF-1|gene-rna )|O ,|O cyclin|gene-rna D1|gene-rna ,|O erbB-2|gene-rna and|O erbB-3|gene-rna in|O resected|O pancreatic|O ductal|O adenocarcinoma|O .|O 
Previous|O studies|O of|O molecular|O prognostic|O markers|O following|O resection|O for|O exocrine|O pancreatic|O cancer|O have|O produced|O conflicting|O results|O .|O 
Our|O aim|O was|O to|O undertake|O a|O comprehensive|O analysis|O of|O potentially|O useful|O molecular|O markers|O in|O a|O large|O ,|O multicentre|O patient|O population|O and|O to|O compare|O these|O markers|O with|O standard|O pathological|O prognostic|O variables|O .|O 
Formalin|O -|O fixed|O ,|O paraffin|O -|O embedded|O specimens|O of|O pancreatic|O ductal|O adenocarcinoma|O were|O analysed|O from|O 157|O patients|O [|O 100|O men|O and|O 57|O women|O with|O a|O median|O (|O range|O )|O age|O of|O 60|O (|O 33|O -|O 77|O )|O years|O ]|O who|O had|O undergone|O pancreatectomy|O .|O 
Immunohistochemistry|O was|O used|O to|O detect|O expression|O of|O p16|gene-rna (|O INK4|gene-rna )|O ,|O p53|gene-rna ,|O p21|gene-rna (|O WAF1|gene-rna )|O ,|O cyclin|gene-rna D1|gene-rna ,|O erbB-2|gene-rna and|O erbB-3|gene-rna .|O 
Mutations|O in|O codons|O 12|O and|O 13|O of|O the|O K-ras|gene-rna oncogene|O were|O detected|O by|O SSCP|O and|O sequencing|O following|O DNA|O extraction|O and|O amplification|O by|O PCR|O .|O 
The|O median|O (|O range|O )|O survival|O post|O -|O resection|O was|O 12.5|O (|O 3|O -|O 83|O )|O months|O .|O 
Abnormalities|O of|O p16|gene-rna (|O INK4|gene-rna )|O ,|O p53|gene-rna ,|O p21|gene-rna (|O WAF1|gene-rna )|O ,|O cyclin|gene-rna D1|gene-rna ,|O erbB-2|gene-rna and|O erbB-3|gene-rna expression|O were|O found|O in|O 87|O %|O ,|O 41|O %|O ,|O 75|O %|O ,|O 72|O %|O ,|O 33|O %|O and|O 57|O %|O of|O cases|O ,|O respectively|O .|O 
There|O was|O no|O significant|O correlation|O between|O expression|O of|O any|O of|O these|O markers|O and|O patient|O survival|O .|O 
K-ras|gene-rna mutations|O were|O found|O in|O 73|O (|O 75|O %|O )|O of|O 97|O cases|O with|O amplifiable|O DNA|O .|O 
The|O presence|O of|O K-ras|gene-rna mutation|O alone|O did|O not|O correlate|O with|O survival|O ,|O but|O there|O were|O significant|O differences|O in|O survival|O according|O to|O the|O type|O of|O K-ras|gene-rna mutation|O (|O p|O =|O 0.0007|O )|O .|O 
Reduced|O survival|O was|O found|O in|O patients|O with|O GaT|O ,|O cGT|O and|O GcT|O K-ras|gene-rna mutations|O compared|O to|O GtT|O ,|O aGT|O and|O GaC|O mutations|O .|O 
In|O conclusion|O ,|O survival|O was|O associated|O with|O type|O of|O K-ras|gene-rna mutation|O but|O not|O expression|O of|O p16|gene-rna (|O INK4|gene-rna )|O ,|O p53|gene-rna ,|O p21|gene-rna (|O WAF1|gene-rna )|O ,|O cyclin|gene-rna D1|gene-rna ,|O erbB-2|gene-rna and|O erbB-3|gene-rna .|O 
Specific|O mutation|O in|O exon|O 11|O of|O c-kit|gene-rna proto|O -|O oncogene|O in|O a|O malignant|O gastrointestinal|O stromal|O tumor|O of|O the|O rectum|O .|O 
Gastrointestinal|O stromal|O tumor|O (|O GIST|O )|O in|O the|O distal|O third|O of|O the|O rectum|O was|O detected|O in|O a|O 57|O -|O year|O -|O old|O man|O who|O underwent|O an|O abdominoperineal|O resection|O of|O the|O rectum|O .|O 
Because|O the|O tumor|O expressed|O CD34|gene-protein and|O c-kit|gene-protein gene|O product|O ,|O but|O did|O not|O express|O smooth|gene-protein muscle|gene-protein actin|gene-protein or|O S-100|gene-protein protein|O ,|O it|O was|O diagnosed|O as|O an|O uncommitted|O type|O of|O GIST|O .|O 
Moreover|O ,|O a|O specific|O mutation|O in|O the|O sequence|O coding|O the|O juxtamembrane|O domain|O in|O exon|O 11|O of|O the|O c-kit|gene-rna proto|O -|O oncogene|O was|O revealed|O by|O a|O polymerase|gene-protein chain|O reaction|O -|O single|O -|O strand|O conformation|O polymorphism|O method|O .|O 
One|O year|O after|O resection|O ,|O the|O patient|O developed|O multiple|O liver|O metastases|O .|O 
It|O is|O suggested|O that|O a|O specific|O mutation|O in|O exon|O 11|O of|O the|O c-kit|gene-rna proto|O -|O oncogene|O may|O have|O played|O an|O essential|O role|O in|O the|O development|O of|O the|O liver|O metastases|O .|O 
Mutations|O in|O beta-catenin|gene-rna and|O APC|gene-rna genes|O are|O uncommon|O in|O esophageal|O and|O esophagogastric|O junction|O adenocarcinomas|O .|O 
Beta-catenin|gene-generic plays|O important|O roles|O in|O both|O intercellular|O adhesion|O and|O signal|O transduction|O .|O 
Mutations|O in|O the|O beta-catenin|gene-rna or|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|O APC|gene-rna )|O gene|O can|O alter|O the|O degradation|O of|O beta-catenin|gene-protein and|O cause|O aberrant|O accumulation|O of|O beta-catenin|gene-protein result|O in|O increased|O transcription|O of|O target|O genes|O .|O 
The|O dysregulated|O APC|gene-rna /|O beta-catenin|gene-rna pathway|O has|O been|O recently|O discovered|O as|O an|O important|O mechanism|O of|O tumorigenesis|O in|O various|O cancers|O ,|O but|O its|O role|O in|O esophageal|O adenocarcinomas|O is|O not|O clear|O .|O 
Therefore|O ,|O we|O studied|O the|O beta-catenin|gene-rna gene|O mutation|O ,|O allelic|O loss|O of|O chromosome|O 5q|O ,|O and|O APC|gene-rna gene|O mutation|O in|O esophageal|O and|O esophagogastric|O junction|O adenocarcinomas|O .|O 
Two|O (|O 2|O %|O )|O somatic|O mutations|O in|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O ,|O encompassing|O the|O region|O for|O glycogen|gene-protein synthase|gene-protein kinase|gene-protein -|gene-protein 3beta|gene-protein phosphorylation|O ,|O were|O detected|O from|O 109|O adenocarcinomas|O .|O 
Chromosomal|O allelic|O loss|O on|O 5q|O was|O frequent|O in|O 45.3|O %|O (|O 44|O /|O 97|O )|O of|O tumors|O .|O 
Only|O one|O missense|O mutation|O in|O the|O mutation|O cluster|O region|O of|O the|O APC|gene-rna gene|O was|O detected|O from|O 38|O esophageal|O and|O esophagogastric|O junction|O adenocarcinomas|O with|O the|O 5q|O allelic|O loss|O .|O 
Our|O results|O based|O on|O partial|O screening|O mutational|O analyses|O indicate|O that|O mutations|O of|O APC|gene-rna /|O beta-catenin|gene-rna pathway|O ,|O unlike|O in|O colorectal|O carcinoma|O ,|O involve|O only|O a|O small|O subset|O of|O esophageal|O and|O esophagogastric|O junction|O adenocarcinoma|O .|O 
Frequency|O of|O p16|gene-rna (|O INK4A|gene-rna )|O alterations|O and|O K-ras|gene-rna mutations|O in|O intrahepatic|O cholangiocarcinoma|O of|O the|O liver|O .|O 
BACKGROUND|O :|O 
Inactivation|O of|O the|O tumour|gene-rna suppressor|gene-rna gene|gene-rna p16|gene-rna (|O CDKN2|gene-rna /|O MTS-1|gene-rna /|O INK4A|gene-rna )|O and|O K-ras|gene-rna mutations|O are|O among|O the|O most|O frequent|O genetic|O alterations|O in|O human|O malignancies|O .|O 
AIMS|O :|O 
To|O investigate|O the|O tumour|gene-rna suppressor|gene-rna gene|gene-rna p16|gene-rna and|O its|O possible|O association|O with|O K-ras|gene-rna mutations|O in|O intrahepatic|O cholangiocarcinomas|O of|O the|O liver|O .|O 
METHODS|O :|O 
The|O status|O of|O p16|gene-rna was|O evaluated|O in|O 41|O cholangiocarcinomas|O by|O methylation|O specific|O polymerase|gene-protein chain|O reaction|O ,|O microsatellite|O analysis|O ,|O DNA|O sequencing|O ,|O and|O immunohistochemical|O staining|O .|O 
K-ras|gene-rna mutations|O were|O determined|O by|O direct|O DNA|O sequencing|O analyses|O after|O microdissection|O .|O 
The|O results|O obtained|O were|O correlated|O with|O histopathological|O variables|O and|O patient|O survival|O .|O 
RESULTS|O :|O 
Hypermethylation|O of|O the|O 5|O '|O CpG|O island|O of|O the|O p16|gene-rna gene|O was|O found|O in|O 34|O of|O 41|O (|O 83|O %|O )|O carcinomas|O .|O 
Homozygous|O deletion|O at|O the|O p16|gene-rna region|O was|O present|O in|O two|O (|O 5|O %|O )|O ,|O and|O loss|O of|O heterozygosity|O (|O LOH|O )|O in|O eight|O cases|O (|O 20|O %|O )|O .|O 
We|O failed|O to|O detect|O p16|gene-rna gene|O missense|O mutations|O .|O 
K-ras|gene-rna mutations|O were|O found|O in|O 22|O of|O 41|O (|O 54|O %|O )|O cholangiocarcinomas|O and|O in|O two|O cases|O of|O tumour|O surrounding|O non|O -|O neoplastic|O liver|O tissue|O .|O 
All|O 22|O cancers|O with|O K-ras|gene-rna mutations|O also|O exhibited|O methylated|O p16|gene-rna .|O 
We|O failed|O to|O observe|O a|O correlation|O between|O K-ras|gene-rna or|O p16|gene-rna status|O and|O histopathological|O factors|O or|O prognosis|O of|O patients|O .|O 
CONCLUSION|O :|O 
These|O data|O suggest|O that|O inactivation|O of|O the|O p16|gene-rna gene|O is|O a|O frequent|O event|O in|O cholangiocarcinoma|O .|O 
The|O most|O common|O somatic|O alteration|O is|O promotor|O methylation|O of|O the|O p16|gene-rna gene|O which|O is|O closely|O associated|O with|O K-ras|gene-rna mutations|O .|O 
We|O failed|O to|O establish|O p16|gene-rna or|O K-ras|gene-rna status|O as|O independent|O prognostic|O factors|O in|O these|O tumours|O .|O 
Gastrointestinal|O stromal|O tumors|O and|O leiomyosarcomas|O in|O the|O colon|O :|O a|O clinicopathologic|O ,|O immunohistochemical|O ,|O and|O molecular|O genetic|O study|O of|O 44|O cases|O .|O 
Gastrointestinal|O stromal|O tumors|O (|O GISTs|O )|O ,|O mesenchymal|O tumors|O largely|O specific|O for|O the|O gastrointestinal|O tract|O ,|O have|O been|O well|O defined|O in|O the|O stomach|O and|O small|O intestine|O ,|O but|O have|O not|O been|O extensively|O documented|O or|O contrasted|O with|O true|O smooth|O muscle|O tumors|O in|O the|O colon|O .|O 
This|O study|O was|O undertaken|O to|O determine|O the|O clinicopathologic|O features|O of|O GISTs|O of|O the|O colon|O ,|O excluding|O the|O rectum|O ,|O and|O to|O compare|O them|O with|O leiomyosarcomas|O (|O LMSs|O )|O of|O the|O same|O location|O .|O 
A|O total|O of|O 37|O colonic|O GISTs|O and|O seven|O LMSs|O from|O the|O files|O of|O the|O Armed|O Forces|O Institute|O of|O Pathology|O and|O the|O Haartman|O Institute|O of|O the|O University|O of|O Helsinki|O were|O analyzed|O .|O 
The|O GISTs|O occurred|O predominantly|O in|O adults|O older|O than|O 50|O years|O of|O age|O (|O median|O ,|O 67|O yrs|O )|O ,|O and|O most|O were|O histologically|O malignant|O ;|O four|O small|O benign|O tumors|O (|O <|O or|O =|O 1|O cm|O )|O were|O incidentally|O detected|O ,|O and|O 10|O others|O had|O minimal|O mitotic|O activity|O (|O five|O or|O fewer|O mitoses|O per|O 50|O high|O -|O power|O fields|O )|O .|O 
The|O colonic|O GISTs|O were|O typically|O transmural|O tumors|O with|O frequent|O intraluminal|O and|O outward|O bulging|O components|O .|O 
Histologically|O ,|O they|O usually|O showed|O a|O spindle|O cell|O pattern|O (|O 92|O %|O )|O ,|O whereas|O 8|O %|O were|O epithelioid|O .|O 
Most|O tumors|O (|O 19|O of|O 25|O )|O were|O positive|O for|O CD117|gene-protein (|O KIT|gene-protein )|O and|O for|O CD34|gene-protein (|O 16|O of|O 27|O )|O ;|O six|O tumors|O coexpressed|O alpha|gene-protein -|gene-protein smooth|gene-protein muscle|gene-protein actin|gene-protein and|O CD117|gene-protein ;|O none|O showed|O desmin|gene-protein or|O S-100|gene-protein protein|O .|O 
C-kit|gene-rna mutations|O in|O exon|O 11|O were|O seen|O in|O 5|O (|O 36|O %|O )|O of|O 14|O colonic|O GISTs|O .|O 
None|O of|O the|O patients|O with|O incidental|O small|O tumors|O had|O a|O recurrence|O ,|O whereas|O 2|O of|O 10|O patients|O with|O tumors|O larger|O than|O 1|O cm|O but|O minimal|O mitotic|O activity|O died|O of|O the|O disease|O with|O liver|O metastasis|O .|O 
Nearly|O all|O patients|O whose|O tumor|O was|O larger|O than|O 1|O cm|O and|O showed|O more|O than|O five|O mitoses|O per|O 50|O high|O -|O power|O fields|O died|O of|O disease|O ;|O half|O had|O evidence|O of|O metastasis|O .|O 
LMSs|O were|O typically|O intraluminally|O bulging|O ,|O polypoid|O masses|O that|O showed|O a|O histologic|O likeness|O to|O differentiated|O smooth|O muscle|O cells|O .|O 
They|O occurred|O in|O five|O men|O and|O two|O women|O with|O a|O median|O age|O of|O 61|O years|O .|O 
Most|O LMSs|O were|O high|O -|O grade|O histologically|O and|O showed|O smooth|gene-protein muscle|gene-protein actin|gene-protein ,|O desmin|gene-protein ,|O or|O both|gene-protein .|O 
All|O were|O negative|O for|O CD34|gene-protein and|O CD117|gene-protein and|O lacked|O c-kit|gene-rna mutations|O .|O 
Five|O of|O the|O seven|O patients|O died|O of|O disease|O ,|O and|O two|O had|O a|O long|O -|O term|O survival|O ,|O despite|O high|O mitotic|O activity|O .|O 
These|O results|O show|O that|O KIT|gene-protein -|O positive|O GISTs|O are|O more|O common|O than|O LMSs|O of|O the|O colon|O ,|O and|O these|O tumor|O groups|O have|O clinicopathologic|O differences|O that|O warrant|O their|O separation|O .|O 
Detection|O of|O tumor|O cells|O in|O blood|O using|O CD45|gene-protein magnetic|O cell|O separation|O followed|O by|O nested|O mutant|O allele|O -|O specific|O amplification|O of|O p53|gene-rna and|O K-ras|gene-rna genes|O in|O patients|O with|O colorectal|O cancer|O .|O 
A|O new|O method|O for|O detecting|O circulating|O tumor|O cells|O that|O is|O based|O on|O magnetic|O -|O activated|O cell|O separation|O (|O MACS|O )|O and|O nested|O mutant|O allele|O -|O specific|O amplification|O (|O nested|O MASA|O )|O was|O evaluated|O in|O patients|O with|O colorectal|O cancer|O using|O the|O p53|gene-rna and|O K-ras|gene-rna genes|O as|O genetic|O markers|O .|O 
By|O negative|O selection|O with|O anti|gene-protein -|gene-protein CD45|gene-protein monoclonal|gene-protein antibody|gene-protein -|O conjugated|O supermagnetic|O microbeads|O ,|O the|O proportion|O of|O tumor|O cells|O was|O enriched|O 9|O -|O fold|O .|O 
By|O the|O combination|O of|O MACS|O and|O nested|O MASA|O ,|O 10|O tumor|O cells|O in|O 10(7)|O normal|O peripheral|O blood|O mononuclear|O cells|O could|O be|O detected|O without|O false|O -|O positives|O .|O 
Using|O this|O method|O ,|O we|O examined|O blood|O taken|O from|O the|O tumor|O drainage|O veins|O of|O 23|O patients|O with|O colorectal|O cancer|O .|O 
Eighty-seven|O percent|O (|O 20|O /|O 23|O )|O of|O primary|O tumor|O tissues|O showed|O p53|gene-rna and/or|O K-ras|gene-rna gene|O mutations|O .|O 
Forty-five|O percent|O (|O 9|O /|O 20|O )|O of|O patients|O with|O p53|gene-rna and/or|O K-ras|gene-rna mutations|O in|O the|O primary|O tumor|O showed|O the|O same|O mutated|O genes|O in|O the|O blood|O samples|O .|O 
There|O was|O a|O significant|O association|O between|O the|O presence|O of|O p53|gene-rna and|O K-ras|gene-rna gene|O mutation|O in|O the|O blood|O and|O tumor|O size|O ,|O depth|O of|O invasion|O ,|O and|O venous|O invasion|O .|O 
Blood|gene-generic gene|gene-generic mutation|O was|O detected|O in|O 80|O %|O (|O 4|O /|O 5|O )|O of|O samples|O from|O patients|O with|O synchronous|O liver|O metastases|O .|O 
Sixty|O percent|O (|O 3|O /|O 5|O )|O of|O patients|O with|O mutant|O genes|O in|O the|O blood|O developed|O asynchronous|O liver|O metastases|O after|O surgery|O .|O 
The|O overall|O survival|O of|O patients|O with|O p53|gene-rna and/or|O K-ras|gene-rna gene|O mutation|O -|O positive|O findings|O in|O blood|O was|O significantly|O shorter|O than|O that|O of|O patients|O testing|O negative|O on|O Kaplan|O -|O Meier|O analysis|O .|O 
Our|O results|O suggest|O that|O the|O method|O may|O be|O useful|O for|O reliable|O detection|O of|O tumor|O cells|O circulating|O in|O the|O blood|O and|O may|O help|O to|O identify|O patients|O at|O high|O risk|O for|O relapse|O .|O 
K-ras|gene-rna gene|O mutations|O and|O loss|O of|O heterozygosity|O at|O the|O p53|gene-rna gene|O locus|O relative|O to|O histological|O characteristics|O of|O mucin|gene-protein -|O producing|O tumors|O of|O the|O pancreas|O .|O 
Mucin|gene-protein -|O producing|O tumors|O (|O MPTs|O )|O of|O the|O pancreas|O accompanied|O by|O carcinomas|O usually|O include|O various|O grades|O of|O dysplasia|O in|O the|O ductal|O epithelium|O ,|O and|O invasive|O areas|O are|O histologically|O similar|O to|O those|O of|O common|O invasive|O ductal|O carcinomas|O ,|O suggesting|O that|O MPTs|O provide|O a|O good|O tool|O to|O investigate|O early|O stages|O of|O pancreatic|O carcinogenesis|O .|O 
Thus|O ,|O to|O clarify|O genetic|O alterations|O in|O the|O early|O stage|O of|O pancreatic|O carcinogenesis|O ,|O we|O analyzed|O K-ras|gene-rna gene|O mutations|O and|O loss|O of|O heterozygosity|O (|O LOH|O )|O at|O the|O p53|gene-rna gene|O locus|O using|O 37|O cases|O of|O MPTs|O harboring|O dysplastic|O epithelium|O .|O 
Further|O ,|O we|O conducted|O an|O extended|O ,|O multifocal|O microdissection|O analysis|O focusing|O on|O the|O histological|O features|O of|O ductal|O epithelium|O and|O the|O distribution|O of|O genetic|O alterations|O for|O 3|O cases|O of|O MPT|O positive|O for|O LOH|O of|O the|O p53|gene-rna gene|O to|O determine|O the|O relation|O to|O tumor|O progression|O .|O 
K-ras|gene-rna gene|O mutations|O were|O detected|O with|O high|O frequency|O in|O 50|O %|O or|O more|O cases|O of|O the|O adenomas|O (|O 14|O of|O 19|O )|O ,|O borderline|O tumors|O (|O 4|O of|O 7|O )|O ,|O and|O carcinomas|O (|O 8|O of|O 11|O )|O ,|O whereas|O LOH|O of|O the|O p53|gene-rna gene|O was|O limited|O to|O carcinomas|O (|O 3|O of|O 5|O informative|O cases|O ,|O 60|O %|O )|O and|O always|O accompanied|O by|O K-ras|gene-rna gene|O mutation|O .|O 
Investigation|O of|O a|O total|O of|O 126|O microdissection|O sites|O from|O 3|O cases|O showed|O the|O presence|O of|O K-ras|gene-rna gene|O mutations|O in|O mild|O dysplasia|O and|O all|O (|O 100|O %|O )|O regions|O of|O moderate|O or|O more|O marked|O dysplasia|O ,|O whereas|O LOH|O of|O the|O p53|gene-rna gene|O showed|O more|O gradual|O tendency|O to|O increase|O with|O grade|O from|O moderate|O dysplasia|O .|O 
In|O addition|O ,|O the|O multifocal|O genetic|O analysis|O showed|O K-ras|gene-rna gene|O mutations|O to|O be|O widely|O distributed|O throughout|O tumors|O ,|O whereas|O LOH|O of|O the|O p53|gene-rna gene|O was|O localized|O to|O 1|O or|O a|O few|O areas|O .|O 
Further|O ,|O topographically|O delimited|O areas|O with|O the|O same|O histology|O in|O the|O same|O tumor|O did|O not|O always|O show|O the|O same|O genetic|O alteration|O .|O 
In|O conclusion|O ,|O we|O could|O confirm|O that|O both|O the|O K-ras|gene-rna and|O p53|gene-rna gene|O alterations|O occur|O in|O the|O intraductal|O stage|O of|O MPT|O ,|O and|O the|O latter|O is|O superimposed|O on|O the|O former|O during|O the|O course|O of|O tumor|O progression|O .|O 
However|O ,|O the|O pattern|O of|O association|O of|O histological|O features|O with|O genetic|O alteration|O differs|O from|O tumor|O to|O tumor|O .|O 
Specific|O c-kit|gene-rna mutations|O in|O sinonasal|O natural|O killer|O /|O T-cell|O lymphoma|O in|O China|O and|O Japan|O .|O 
Sinonasal|O lymphoma|O is|O one|O of|O the|O constituents|O of|O lethal|O midline|O granuloma|O ,|O which|O is|O a|O clinical|O term|O for|O progressive|O ,|O destructive|O lesions|O affecting|O the|O midline|O of|O the|O face|O .|O 
The|O majority|O of|O sinonasal|O lymphomas|O ,|O especially|O those|O showing|O polymorphous|O patterns|O of|O proliferation|O and|O thus|O termed|O polymorphic|O reticulosis|O ,|O recently|O were|O categorized|O as|O sinonasal|O natural|O killer|O /|O T-cell|O lymphomas|O .|O 
They|O are|O more|O prevalent|O in|O Asia|O than|O Europe|O or|O North|O America|O and|O are|O associated|O with|O EBV|O infection|O .|O 
Twenty-three|O cases|O with|O sinonasal|O natural|O killer|O /|O T-cell|O lymphomas|O were|O collected|O from|O two|O high|O -|O incidence|O regions|O :|O Beijing|O ,|O China|O (|O 14|O cases|O )|O and|O Osaka|O ,|O Japan|O (|O 9|O cases|O )|O .|O 
c-kit|gene-rna mutations|O were|O analyzed|O on|O paraffin|O -|O embedded|O specimens|O by|O PCR|O -|O single|O -|O strand|O conformation|O polymorphism|O followed|O by|O direct|O sequencing|O ;|O the|O c-kit|gene-rna proto|O -|O oncogene|O encodes|O a|O receptor|gene-protein of|gene-protein tyrosine|gene-protein kinase|gene-protein ,|O which|O plays|O an|O important|O role|O in|O the|O regulation|O of|O normal|O and|O neoplastic|O hematopoiesis|O by|O the|O interaction|O with|O its|O specific|O ligand|O ,|O termed|O stem|gene-protein cell|gene-protein factor|gene-protein .|O 
Twelve|O single|O nucleotide|O substitution|O mutations|O were|O seen|O in|O 23|O cases|O .|O 
Ten|O of|O 14|O Chinese|O cases|O (|O 71.4|O %|O )|O had|O mutations|O at|O exon|O 11|O or|O exon|O 17|O ,|O whereas|O only|O two|O of|O nine|O Japanese|O cases|O (|O 22.2|O %|O )|O had|O mutations|O ,|O showing|O a|O significant|O difference|O in|O frequency|O between|O Chinese|O and|O Japanese|O cases|O .|O 
Furthermore|O ,|O seven|O of|O eight|O mutations|O (|O 92|O %|O )|O in|O exon|O 17|O occurred|O at|O codon|O 825|O and|O three|O of|O four|O mutations|O (|O 75|O %|O )|O in|O exon|O 11|O occurred|O at|O codon|O 561|O .|O 
Such|O a|O specificity|O has|O not|O been|O reported|O before|O ,|O and|O these|O results|O ,|O taken|O together|O ,|O suggest|O that|O location|O -|O specific|O differences|O in|O etiological|O factors|O cause|O specific|O mutations|O in|O c-kit|gene-rna gene|O .|O 
Anticorresponding|O mutations|O of|O the|O KRAS|gene-rna and|O PTEN|gene-rna genes|O in|O human|O endometrial|O cancer|O .|O 
PTEN|gene-rna is|O a|O newly|O isolated|O candidate|O tumor|O suppressor|O gene|O and|O its|O mutation|O is|O the|O most|O frequently|O found|O in|O endometrial|O cancer|O (|O EC|O )|O ,|O a|O very|O common|O female|O pelvic|O malignant|O disease|O .|O 
Mutations|O of|O the|O KRAS|gene-rna gene|O are|O also|O reported|O in|O this|O disease|O .|O 
Recent|O analysis|O of|O the|O PTEN|gene-protein protein|gene-protein suggested|O the|O possibility|O that|O this|O protein|gene-protein acts|O in|O the|O same|O pathway|O as|O does|O the|O RAS|gene-protein protein|gene-protein .|O 
To|O elucidate|O this|O possibility|O further|O ,|O we|O performed|O a|O mutation|O analysis|O of|O these|O two|O genes|gene-rna in|O 44|O endometrial|O cancer|O specimens|O (|O 38|O primary|O tumors|O and|O 6|O cell|O lines|O )|O .|O 
Altogether|O 23|O (|O 52|O %|O )|O of|O 44|O tumors|O had|O mutations|O in|O either|O PTEN|gene-rna or|O KRAS|gene-rna ,|O but|O none|O of|O them|O had|O mutations|O in|O both|O of|O these|O genes|gene-rna .|O 
These|O results|O support|O the|O idea|O that|O the|O protein|gene-protein products|gene-protein of|O these|O two|O genes|gene-rna act|O in|O the|O same|O growth|O regulatory|O pathway|O in|O the|O endometrium|O .|O 
Ki-ras|gene-rna point|O mutation|O and|O p53|gene-rna expression|O in|O human|O pancreatic|O cancer|O :|O a|O comparative|O study|O among|O Chinese|O ,|O Japanese|O ,|O and|O Western|O patients|O .|O 
The|O aim|O of|O this|O study|O was|O to|O clarify|O features|O of|O Ki-ras|gene-rna point|O mutation|O (|O PM|O )|O and|O p53|gene-rna expression|O in|O Chinese|O pancreatic|O cancer|O and|O to|O compare|O those|O with|O that|O in|O other|O countries|O .|O 
Dot|O blot|O hybridization|O and|O immunohistochemical|O methods|O were|O performed|O in|O 59|O Chinese|O patients|O .|O 
The|O results|O showed|O that|O Ki-ras|gene-rna PMs|O at|O codon|O 12|O and|O p53|gene-rna expression|O were|O frequent|O in|O this|O group|O .|O 
No|O relationships|O were|O found|O between|O Ki-ras|gene-rna PM|O alone|O and|O p53|gene-rna expression|O alone|O ,|O and|O clinicopathological|O parameters|O ,|O including|O age|O ,|O gender|O ,|O clinical|O stage|O ,|O and|O histological|O grade|O and|O classification|O in|O Chinese|O patients|O .|O 
However|O ,|O their|O cooperation|O was|O significantly|O associated|O with|O a|O poor|O prognosis|O in|O this|O group|O .|O 
Comparison|O showed|O that|O there|O were|O significant|O differences|O in|O the|O overall|O frequency|O and|O substitution|O of|O Ki-ras|gene-rna PM|O and|O in|O the|O ratio|O of|O transition|O :|O transversion|O in|O pancreatic|O cancer|O among|O various|O countries|O .|O 
In|O addition|O ,|O the|O effect|O of|O Ki-ras|gene-rna PM|O and|O p53|gene-rna expression|O on|O a|O poor|O prognosis|O of|O pancreatic|O cancer|O may|O be|O different|O among|O various|O countries|O .|O 
These|O findings|O suggested|O that|O not|O only|O Ki-ras|gene-rna PM|O and|O p53|gene-rna expression|O are|O frequent|O in|O Chinese|O pancreatic|O cancer|O ,|O but|O also|O a|O gene|O component|O to|O pancreatic|O cancer|O may|O be|O different|O between|O Asian|O and|O Western|O pancreatic|O cancer|O .|O 
In|O addition|O ,|O it|O seems|O that|O cooperation|O of|O Ki-ras|gene-rna PM|O and|O p53|gene-rna expression|O may|O predict|O a|O poor|O prognosis|O in|O Chinese|O patients|O with|O pancreatic|O cancer|O .|O 
Mutational|O status|O of|O K-ras|gene-rna and|O TP53|gene-rna genes|O in|O primary|O sarcomas|O of|O the|O heart|O .|O 
We|O investigated|O three|O patients|O with|O cardiac|O angiosarcomas|O and|O two|O with|O cardiac|O rhabdomyosarcomas|O ,|O all|O for|O mutations|O at|O exons|O 5|O ,|O 6|O ,|O 7|O and|O 8|O of|O the|O p53|gene-rna gene|O and|O at|O exon|O 1|O of|O K-ras|gene-rna .|O 
No|O point|O mutations|O were|O observed|O in|O the|O p53|gene-rna gene|O in|O any|O of|O the|O five|O cases|O ;|O however|O ,|O at|O exon|O 1|O of|O K-ras|gene-rna ,|O three|O patients|O (|O 60|O %|O )|O presented|O the|O same|O mutation|O at|O the|O first|O base|O of|O codon|O 13|O (|O G|O to|O A|O transition|O )|O .|O 
Interestingly|O ,|O this|O mutation|O was|O detected|O in|O both|O rhabdomyosarcoma|O and|O angiosarcoma|O histologic|O sarcoma|O types|O .|O 
Analysis|O of|O the|O surface|O expression|O of|O c-kit|gene-generic and|O occurrence|O of|O the|O c-kit|gene-rna Asp|O 816|O Val|O activating|O mutation|O in|O T|O cells|O ,|O B|O cells|O ,|O and|O myelomonocytic|O cells|O in|O patients|O with|O mastocytosis|O .|O 
OBJECTIVE|O :|O The|O Asp|O 816|O Val|O c-kit|gene-rna activating|O mutation|O is|O detectable|O in|O the|O peripheral|O blood|O cells|O of|O some|O patients|O with|O mastocytosis|O and|O in|O lesional|O skin|O biopsies|O obtained|O from|O adult|O patients|O with|O urticaria|O pigmentosa|O .|O 
These|O observations|O led|O to|O the|O conclusion|O that|O this|O mutation|O is|O present|O in|O mast|O cells|O and|O mast|O cell|O precursors|O that|O express|O c-kit|gene-generic .|O 
However|O ,|O the|O distribution|O of|O the|O Asp|O 816|O Val|O mutation|O among|O hematopoietic|O lineages|O is|O unknown|O .|O 
To|O determine|O the|O distribution|O of|O the|O Asp|O 816|O Val|O mutation|O among|O hematopoietic|O lineages|O and|O to|O explore|O its|O relationship|O to|O clinical|O disease|O ,|O we|O examined|O cells|O bearing|O differentiation|O markers|O for|O myelomonocytic|O cells|O as|O well|O as|O T|O and|O B|O lymphocytes|O ,|O in|O both|O peripheral|O blood|O and|O bone|O marrow|O obtained|O from|O patients|O with|O mastocytosis|O .|O 
MATERIALS|O AND|O METHODS|O :|O The|O presence|O of|O Asp|O 816|O Val|O c-kit|gene-rna mutation|O in|O cells|O magnetically|O sorted|O from|O peripheral|O blood|O or|O bone|O marrow|O according|O to|O surface|O differentiation|O markers|O was|O studied|O by|O reverse|gene-protein transcriptase|gene-protein polymerase|gene-protein chain|O reaction|O (|O RT|O -|O PCR|O )|O restriction|O fragment|O length|O polymorphism|O (|O RFLP|O )|O analysis|O .|O 
The|O surface|O expression|O of|O c-kit|gene-generic was|O determined|O by|O flow|O cytometry|O .|O 
RESULTS|O :|O The|O mutation|O was|O detectable|O by|O RT|O -|O PCR|O in|O at|O least|O one|O cell|O lineage|O in|O the|O bone|O marrow|O in|O 7|O of|O 7|O patients|O examined|O and|O in|O the|O peripheral|O blood|O of|O 11|O of|O 11|O adult|O patients|O with|O urticaria|O pigmentosa|O and|O indolent|O disease|O .|O 
The|O mutation|O was|O identified|O most|O frequently|O in|O B|O cells|O and|O myeloid|O cells|O .|O 
Flow|O cytometric|O analysis|O demonstrated|O that|O the|O differentiated|O cells|O expressing|O mutated|O c-kit|gene-generic were|O negative|O for|O surface|O KIT|gene-generic .|O 
CONCLUSION|O :|O These|O results|O are|O consistent|O with|O the|O conclusion|O that|O the|O c-kit|gene-rna Asp|O 816|O Val|O mutation|O occurs|O in|O an|O early|O progenitor|O cell|O and|O is|O carried|O by|O myelomonocytic|O cells|O ,|O T|O cells|O ,|O and|O B|O cells|O in|O addition|O to|O mast|O cells|O .|O 
However|O ,|O unlike|O mast|O cells|O ,|O these|O myelomonocytic|O cells|O ,|O T|O cells|O ,|O and|O B|O cells|O do|O not|O concomitantly|O express|O surface|O c-kit|gene-rna and|O thus|O may|O be|O less|O susceptible|O to|O the|O effects|O of|O this|O mutation|O .|O 
The|O K-ras|gene-rna gene|O regulates|O vascular|gene-rna endothelial|gene-rna growth|gene-rna factor|gene-rna gene|O expression|O in|O non|O -|O small|O cell|O lung|O cancers|O .|O 
Tumor|O angiogenesis|O is|O an|O essential|O step|O for|O tumor|O cell|O growth|O ,|O progression|O and|O metastasis|O .|O 
Vascular|gene-protein endothelial|gene-protein growth|gene-protein factor|gene-protein (|O VEGF|gene-protein )|O is|O mitogen|O specific|O for|O endothelial|O cells|O ,|O and|O therefore|O is|O believed|O to|O play|O a|O key|O role|O in|O tumor|O angiogenesis|O .|O 
However|O ,|O the|O mechanisms|O underlying|O the|O regulation|O of|O VEGF|gene-rna expression|O remain|O virtually|O unknown|O and|O the|O only|O major|O regulator|O of|O VEGF|gene-rna expression|O has|O been|O reported|O to|O be|O hypoxia|O .|O 
Recently|O ,|O it|O was|O reported|O that|O a|O mutant|O p53|gene-rna in#duced|O the|O expression|O of|O VEGF|gene-rna mRNA|O ,|O and|O that|O wild|O -|O type|O p53|gene-rna down|O -|O regulated|O endogenous|O VEGF|gene-rna mRNA|O levels|O .|O 
In|O contrast|O ,|O it|O has|O also|O been|O reported|O that|O mutant|O ras|gene-rna oncogenes|O were|O associated|O with|O the|O marked|O up|O -|O regulation|O of|O VEGF|gene-rna in|O transformed|O epithelial|O cells|O .|O 
Based|O on|O these|O results|O ,|O we|O performed|O a|O retrospective|O study|O of|O the|O p53|gene-rna and|O K-ras|gene-rna genes|O status|O and|O VEGF|gene-rna gene|O expression|O in|O the|O tumor|O tissues|O from|O 181|O patients|O with|O non|O -|O small|O cell|O lung|O cancer|O using|O SSCP|O ,|O sequencing|O ,|O RT|O -|O PCR|O and|O immunohistochemical|O techniques|O .|O 
Forty-six|O carcinomas|O (|O 25.4|O %|O )|O were|O evaluated|O as|O having|O high|O VEGF|gene-rna expression|O ,|O and|O 135|O tumors|O (|O 74.6|O %|O )|O had|O low|O VEGF|gene-rna expression|O .|O 
Of|O the|O 181|O primary|O NSCLC|O studied|O ,|O 63|O carcinomas|O (|O 34.8|O %|O )|O contained|O mutations|O of|O p53|gene-rna ,|O whereas|O only|O 14|O carcinomas|O (|O 7.7|O %|O )|O had|O mutations|O of|O K-ras|gene-rna .|O 
There|O were|O no|O significant|O relationships|O between|O VEGF|gene-rna expression|O and|O p53|gene-rna status|O or|O each|O mutant|O exon|O of|O p53|gene-rna .|O 
In|O contrast|O ,|O a|O significant|O difference|O was|O found|O between|O VEGF|gene-rna expression|O and|O K-ras|gene-rna status|O .|O 
Of|O the|O 14|O tumors|O with|O mutant|O K-ras|gene-rna genes|O ,|O 7|O cases|O (|O 50.0|O %|O )|O had|O high|O VEGF|gene-rna expression|O whereas|O only|O 39|O of|O the|O 167|O tumors|O with|O wild|O -|O type|O K-ras|gene-rna (|O 23.4|O %|O )|O had|O high|O VEGF|gene-rna expression|O (|O p|O =|O 0.0278|O )|O .|O 
The|O mean|O VEGF|gene-rna conservation|O rate|O for|O the|O 14|O tumors|O with|O mutant|O K-ras|gene-rna genes|O was|O 0.77|O +/-|O 0.58|O and|O the|O rate|O of|O the|O 167|O tumors|O with|O wild|O -|O type|O K-ras|gene-rna genes|O was|O 0.49|O +/-|O 0.46|O (|O p|O =|O 0.|O 0350|O )|O .|O 
Moreover|O ,|O the|O overall|O survival|O rate|O of|O patients|O with|O high|O VEGF|gene-rna expression|O was|O lower|O than|O patients|O with|O low|O VEGF|gene-rna expression|O (|O 45.7|O %|O vs|O 60.7|O %|O ,|O p|O =|O 0.0419|O )|O .|O 
On|O the|O other|O hand|O ,|O there|O was|O no|O significant|O difference|O in|O the|O overall|O survival|O rate|O between|O patients|O with|O a|O mutant|O p53|gene-rna and|O those|O with|O a|O wild|O -|O type|O p53|gene-rna ;|O there|O was|O also|O no|O difference|O in|O the|O overall|O survival|O between|O patients|O with|O a|O mutant|O K-ras|gene-rna and|O those|O with|O a|O wild|O -|O type|O K-ras|gene-rna .|O 
The|O Cox|O regression|O model|O analysis|O indicated|O that|O three|O variables|O ,|O VEGF|gene-rna status|O ,|O K-ras|gene-rna status|O and|O nodal|O status|O ,|O were|O found|O to|O be|O significant|O indicators|O for|O prognosis|O (|O p|O =|O 0.0236|O ,|O p|O =|O 0.0172|O and|O p|O <|O 0.0001|O ,|O respectively|O )|O .|O 
Our|O data|O suggest|O that|O a|O high|O expression|O of|O VEGF|gene-rna in|O lung|O cancer|O may|O be|O associated|O with|O a|O poor|O prognosis|O .|O 
This|O may|O be|O a|O clue|O to|O improving|O lung|O cancer|O diagnoses|O and|O therapies|O aimed|O at|O inhibiting|O tumor|O angiogenesis|O due|O to|O VEGF|gene-generic .|O 
APC|gene-rna mutations|O in|O sporadic|O medulloblastomas|O .|O 
The|O cerebellar|O medulloblastoma|O (|O WHO|O Grade|O IV|O )|O is|O a|O highly|O malignant|O ,|O invasive|O embryonal|O tumor|O with|O preferential|O manifestation|O in|O children|O .|O 
Several|O molecular|O alterations|O appear|O to|O be|O involved|O ,|O including|O isochromosome|O 17q|O and|O the|O p53|gene-rna ,|O PTCH|gene-rna ,|O and|O beta-catenin|gene-rna gene|O mutations|O .|O 
In|O this|O study|O ,|O 46|O sporadic|O medulloblastomas|O were|O screened|O for|O the|O presence|O of|O mutations|O in|O genes|O of|O the|O Wnt|gene-rna signaling|O pathway|O (|O APC|gene-rna and|O beta-catenin|gene-rna )|O .|O 
Single|O -|O strand|O conformational|O polymorphism|O (|O SSCP|O )|O analysis|O followed|O by|O direct|O DNA|O sequencing|O revealed|O 3|O miscoding|O APC|gene-rna mutations|O in|O 2|O (|O 4.3|O %|O )|O medulloblastomas|O .|O 
One|O case|O contained|O a|O GCA|O -->|O GTA|O mutation|O at|O codon|O 1296|O (|O Ala|O -->|O Val|O )|O ,|O and|O another|O case|O had|O double|O point|O mutations|O at|O codons|O 1472|O (|O GTA|O -->|O ATA|O ,|O Val|O -->|O Ile|O )|O and|O 1495|O (|O AGT|O -->|O GGT|O ,|O Ser|O -->|O Gly|O )|O .|O 
Miscoding|O beta-catenin|gene-rna mutations|O were|O detected|O in|O 4|O tumors|O (|O 8.7|O %|O )|O .|O 
Three|O of|O these|O were|O located|O at|O codon|O 33|O (|O TCT|O -->|O TTT|O ,|O Ser|O -->|O Phe|O )|O and|O another|O at|O codon|O 37|O (|O TCT|O -->|O GCT|O ,|O Ser|O -->|O Ala|O )|O .|O 
Adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|O APC|gene-rna )|O gene|O and|O beta-catenin|gene-rna mutations|O were|O mutually|O exclusive|O and|O occurred|O in|O a|O total|O of|O 6|O of|O 46|O cases|O (|O 13|O %|O )|O .|O 
Although|O germline|O APC|gene-rna mutations|O are|O a|O well|O established|O cause|O of|O familial|O colon|O and|O brain|O tumors|O (|O Turcot|O syndrome|O )|O ,|O this|O study|O provides|O the|O first|O evidence|O that|O APC|gene-rna mutations|O are|O also|O operative|O in|O a|O subset|O of|O sporadic|O medulloblastomas|O .|O 
Implications|O and|O prognostic|O value|O of|O K-ras|gene-rna mutation|O for|O early|O -|O stage|O lung|O cancer|O in|O women|O .|O 
BACKGROUND|O :|O 
Because|O there|O is|O no|O clear|O consensus|O as|O to|O the|O predictive|O value|O of|O K-ras|gene-rna gene|O mutation|O for|O survival|O in|O patients|O with|O lung|O cancer|O ,|O we|O examined|O the|O occurrence|O of|O K-ras|gene-rna mutations|O in|O a|O large|O ,|O prospective|O case|O series|O of|O non|O -|O small|O -|O cell|O lung|O cancer|O (|O NSCLC|O )|O .|O 
Our|O goals|O were|O to|O define|O the|O patient|O characteristics|O associated|O with|O K-ras|gene-rna mutation|O and|O to|O determine|O whether|O mutation|O of|O this|O gene|O might|O be|O a|O biomarker|O of|O patient|O prognosis|O .|O 
METHODS|O :|O 
Consecutive|O ,|O newly|O diagnosed|O patients|O with|O lung|O cancer|O treated|O with|O potentially|O curative|O resection|O over|O a|O 4|O -|O year|O period|O were|O recruited|O for|O study|O .|O 
The|O mutation|O status|O of|O K-ras|gene-rna codon|O 12|O in|O each|O patient|O 's|O tumor|O DNA|O was|O determined|O by|O means|O of|O polymerase|gene-protein chain|O reaction|O -|O restriction|O fragment|O length|O polymorphism|O analysis|O of|O archived|O pathology|O specimens|O .|O 
Analyses|O were|O restricted|O to|O adenocarcinoma|O .|O 
RESULTS|O :|O 
There|O was|O a|O statistically|O significant|O association|O between|O female|O sex|O and|O K-ras|gene-rna mutation|O after|O adjustment|O for|O carcinogen|O exposures|O (|O odds|O ratio|O =|O 3.3|O ;|O 95|O %|O confidence|O interval|O [|O CI|O ]|O =|O 1.3|O -|O 7.9|O )|O ;|O mutations|O were|O found|O only|O in|O smokers|O .|O 
Comparison|O of|O Kaplan|O -|O Meier|O curves|O indicated|O a|O strong|O association|O between|O K-ras|gene-rna mutation|O and|O decreased|O patient|O survival|O (|O two|O -|O sided|O P|O =|O .009|O )|O ;|O analysis|O stratified|O by|O pathologic|O staging|O groups|O revealed|O that|O this|O association|O was|O statistically|O significant|O only|O for|O stage|O I|O tumors|O (|O two|O -|O sided|O P|O =|O .002|O )|O .|O 
Cox|O proportional|O hazards|O modeling|O indicated|O that|O K-ras|gene-rna codon|O 12|O mutation|O was|O a|O statistically|O significant|O predictor|O of|O patient|O survival|O ,|O after|O adjustment|O for|O the|O effects|O of|O age|O ,|O sex|O ,|O and|O stage|O (|O risk|O ratio|O =|O 1.8|O ;|O 95|O %|O CI|O =|O 1.1|O -|O 3.1|O )|O .|O 
CONCLUSIONS|O :|O 
After|O adjustment|O for|O environmental|O exposures|O ,|O non|O -|O small|O -|O cell|O lung|O tumors|O in|O women|O appear|O to|O be|O more|O likely|O than|O those|O in|O men|O to|O harbor|O K-ras|gene-rna mutations|O ,|O suggesting|O a|O possible|O role|O of|O estrogen|O exposure|O in|O either|O the|O initiation|O or|O the|O selection|O of|O K-ras|gene-rna mutant|O clones|O in|O adenocarcinoma|O .|O 
In|O addition|O ,|O our|O data|O suggest|O that|O K-ras|gene-rna codon|O 12|O mutation|O is|O a|O marker|O of|O aggressive|O NSCLC|O ,|O as|O evidenced|O by|O its|O association|O with|O decreased|O patient|O survival|O ,|O particularly|O for|O early|O -|O stage|O disease|O .|O 
Analysis|O of|O genetic|O changes|O in|O intrahepatic|O cholangiocarcinoma|O induced|O by|O thorotrast|O .|O 
Thorotrast|O ,|O a|O colloidal|O suspension|O of|O radioactive|O (232)ThO(2)|O that|O emits|O alpha|O particles|O ,|O was|O used|O as|O a|O radiographic|O contrast|O agent|O in|O the|O 1930s|O -|O 1950s|O .|O 
Several|O decades|O after|O injection|O ,|O Thorotrast|O causes|O liver|O cancers|O ,|O among|O which|O intrahepatic|O cholangiocarcinoma|O (|O ICC|O )|O is|O prominent|O .|O 
We|O investigated|O mutations|O of|O the|O RAS|gene-rna and|O the|O TP53|gene-rna genes|O in|O archival|O sections|O of|O ICC|O induced|O by|O Thorotrast|O .|O 
Compared|O to|O ICC|O that|O was|O not|O associated|O with|O Thorotrast|O ,|O the|O frequency|O of|O mutation|O of|O the|O KRAS|gene-rna gene|O was|O lower|O ,|O while|O that|O of|O the|O TP53|gene-rna gene|O was|O more|O than|O two|O times|O higher|O .|O 
The|O most|O common|O mutation|O of|O the|O TP53|gene-rna gene|O was|O A|O -|O G|O transitions|O .|O 
Interestingly|O ,|O TP53|gene-rna mutations|O were|O also|O found|O in|O noncancerous|O areas|O of|O livers|O in|O which|O Thorotrast|O had|O been|O deposited|O .|O 
Furthermore|O ,|O mutations|O tended|O to|O accumulate|O in|O tissues|O from|O more|O advanced|O tumors|O .|O 
These|O results|O suggest|O that|O deposited|O Thorotrast|O continuously|O damages|O DNA|O in|O liver|O cells|O in|O some|O way|O ,|O resulting|O in|O A|O -|O G|O transitions|O of|O the|O TP53|gene-rna gene|O .|O 
However|O ,|O we|O have|O not|O been|O able|O to|O rule|O out|O the|O possibility|O that|O genetic|O insults|O occur|O indirectly|O in|O the|O proliferating|O cells|O adjacent|O to|O the|O necrosis|O rather|O than|O being|O a|O direct|O effect|O of|O alpha|O particles|O .|O 
Mutational|O analysis|O of|O the|O N-ras|gene-rna ,|O p53|gene-rna ,|O p16INK4a|gene-rna ,|O CDK4|gene-rna ,|O and|O MC1R|gene-rna genes|O in|O human|O congenital|O melanocytic|O naevi|O .|O 
Eighteen|O human|O congenital|O melanocytic|O naevi|O (|O CMN|O )|O from|O 17|O patients|O were|O screened|O for|O activating|O point|O mutations|O in|O the|O oncogenes|O N-ras|gene-rna and|O CDK4|gene-rna and|O for|O sequence|O variants|O in|O the|O MC1R|gene-rna gene|O by|O combined|O RFLP|O -|O PCR|O /|O SSCP|O analysis|O .|O 
In|O addition|O ,|O all|O lesions|O were|O screened|O for|O deletions|O and|O point|O mutations|O in|O the|O tumour|O suppressor|O genes|O p53|gene-rna and|O p16INK4a|gene-rna (|O CDKN2A|gene-rna )|O by|O combined|O multiplex|O PCR|O /|O SSCP|O analysis|O .|O 
Positive|O screening|O data|O were|O specified|O by|O sequencing|O of|O the|O corresponding|O PCR|O product|O .|O 
Activating|O point|O mutations|O in|O the|O N-ras|gene-rna gene|O (|O nine|O CAA|O (|O Gln|O )|O to|O AAA|O (|O Lys|O )|O transversions|O and|O one|O CAA|O (|O Gln|O )|O to|O CGA|O (|O Arg|O )|O transition|O at|O codon|O 61|O )|O were|O detected|O at|O high|O frequency|O (|O 56|O %|O )|O .|O 
Furthermore|O ,|O three|O missense|O mutations|O (|O V|O 92|O M|O )|O and|O two|O silent|O mutations|O (|O CGA|O (|O Arg|O )|O to|O CGG|O (|O Arg|O )|O ,|O codon|O 213|O ,|O exon|O 6|O )|O were|O found|O in|O the|O MC1R|gene-rna and|O p53|gene-rna genes|O ,|O respectively|O .|O 
No|O mutations|O were|O found|O in|O p16|gene-rna or|O CDK4|gene-rna .|O 
The|O activated|O N-ras|gene-rna oncogene|O ,|O which|O is|O also|O found|O in|O human|O cutaneous|O melanomas|O ,|O may|O constitute|O a|O potential|O risk|O factor|O for|O melanoma|O formation|O within|O CMN|O .|O 
H-ras|gene-rna and|O K-ras|gene-rna gene|O mutations|O in|O primary|O human|O soft|O tissue|O sarcoma|O :|O concomitant|O mutations|O of|O the|O ras|gene-rna genes|O .|O 
ras|gene-rna gene|O mutations|O have|O been|O described|O with|O varying|O frequency|O in|O several|O types|O of|O human|O malignancies|O .|O 
To|O determine|O the|O incidence|O and|O type|O of|O ras|gene-rna mutations|O in|O human|O soft|O tissue|O tumors|O ,|O we|O studied|O 45|O sarcomas|O ,|O including|O 27|O malignant|O fibrous|O histiocytomas|O (|O MFHs|O )|O ,|O 10|O liposarcomas|O ,|O 2|O rhabdomyosarcomas|O ,|O and|O 6|O leiomyosarcomas|O .|O 
Al|O of|O the|O tumors|O were|O investigated|O by|O direct|O sequence|O analysis|O with|O the|O automated|O DNA|O sequencing|O of|O polymerase|gene-protein chain|O reaction|O -|O amplified|O ras|gene-rna sequences|O .|O 
Twenty|O (|O 44|O %|O )|O of|O the|O sarcomas|O examined|O harbored|O K-ras|gene-rna mutations|O ,|O 18|O (|O 90|O %|O )|O of|O which|O were|O MFHs|O .|O 
All|O of|O the|O K-ras|gene-rna mutations|O were|O G|O -|O to|O -|O A|O transition|O mutations|O in|O the|O second|O position|O of|O codon|O 13|O (|O glycine|O -->|O aspartic|O acid|O )|O .|O 
Of|O the|O samples|O with|O K-ras|gene-rna activation|O ,|O 7|O (|O 16|O %|O of|O the|O total|O of|O 45|O tumors|O )|O ,|O including|O 6|O MFHs|O and|O 1|O leiomyosarcoma|O ,|O also|O contained|O H-ras|gene-rna mutation|O .|O 
All|O of|O the|O tumors|O that|O showed|O H-ras|gene-rna alteration|O had|O G|O -|O to|O -|O T|O transversion|O mutations|O in|O the|O second|O base|O of|O codon|O 12|O (|O glycine|O -->|O valine|O )|O .|O 
These|O data|O possibly|O implicate|O that|O ras|gene-rna gene|O activation|O may|O be|O a|O relatively|O uncommon|O event|O in|O soft|O tissue|O tumors|O ,|O with|O the|O exception|O of|O MFH|O .|O 
It|O is|O suggested|O that|O the|O oncogenic|O process|O underlying|O the|O development|O of|O tumors|O between|O these|O groups|O may|O be|O different|O and|O that|O ras|gene-rna gene|O mutations|O may|O play|O a|O role|O in|O the|O etiology|O and/or|O progression|O of|O MFH|O .|O 
It|O is|O noteworthy|O that|O when|O ras|gene-rna gene|O activation|O occurs|O in|O sarcoma|O ,|O it|O predominantly|O affects|O the|O K-ras|gene-rna gene|O ,|O particularly|O codon|O 13|O .|O 
Moreover|O ,|O H-ras|gene-rna mutations|O in|O our|O samples|O were|O detected|O only|O in|O association|O with|O tumors|O that|O also|O displayed|O K-ras|gene-rna -|O mutated|O genes|O .|O 
This|O study|O demonstrates|O for|O the|O first|O time|O concomitant|O mutations|O in|O two|O different|O members|O of|O the|O ras|gene-rna gene|O family|O in|O sarcoma|O 
Mutational|O analysis|O of|O beta-catenin|gene-rna gene|O in|O Japanese|O ovarian|O carcinomas|O :|O frequent|O mutations|O in|O endometrioid|O carcinomas|O .|O 
To|O investigate|O the|O contribution|O of|O the|O beta-catenin|gene-rna gene|O to|O the|O development|O of|O ovarian|O carcinomas|O ,|O mutational|O analysis|O of|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O was|O conducted|O .|O 
We|O analyzed|O 61|O primary|O ovarian|O carcinomas|O ,|O consisting|O of|O 49|O non|O -|O endometrioid|O -|O type|O and|O 12|O endometrioid|O -|O type|O tumors|O ,|O for|O genetic|O alteration|O of|O the|O beta-catenin|gene-rna gene|O .|O 
Five|O carcinomas|O showed|O beta-catenin|gene-rna mutations|O (|O S|O 37|O C|O ,|O T|O 41|O I|O ,|O T|O 41|O A|O )|O ,|O including|O 4|O (|O 33|O %|O )|O of|O 12|O endometrioid|O -|O type|O tumors|O and|O 1|O (|O 14|O %|O )|O of|O 7|O mucinous|O -|O type|O tumors|O .|O 
All|O of|O these|O mutations|O altered|O at|O the|O serine|O /|O threonine|O residues|O that|O are|O potential|O sites|O of|O GSK|gene-protein 3-beta|gene-protein phosphorylation|O .|O 
We|O detected|O no|O carcinomas|O with|O interstitial|O deletion|O involving|O exon|O 3|O of|O beta-catenin|gene-rna .|O 
Furthermore|O ,|O we|O immunohistochemically|O studied|O 27|O of|O the|O 61|O ovarian|O carcinomas|O .|O 
Both|O nuclear|O and|O cytoplasmic|O beta-catenin|gene-protein expressions|O were|O demonstrated|O in|O 4|O of|O the|O 27|O ovarian|O carcinomas|O for|O which|O tissue|O samples|O were|O available|O for|O examination|O .|O 
All|O 4|O cases|O exhibited|O mutations|O in|O exon|O 3|O of|O beta-catenin|gene-rna ,|O including|O a|O mucinous|O carcinoma|O .|O 
Our|O results|O suggested|O that|O beta-catenin|gene-rna gene|O mutation|O at|O potential|O GSK|gene-protein 3-beta|gene-protein phosphorylation|O sites|O results|O in|O accumulation|O of|O beta-catenin|gene-protein protein|O within|O the|O cells|O and|O its|O translocation|O to|O nuclei|O .|O 
Accumulated|O beta-catenin|gene-protein protein|O may|O be|O involved|O in|O the|O development|O of|O endometrioid|O -|O type|O ovarian|O carcinomas|O ,|O and|O some|O mucinous|O -|O type|O ovarian|O carcinomas|O .|O 
N-ras|gene-rna mutations|O in|O 43|O Chinese|O cases|O of|O acute|O myeloid|O leukemia|O .|O 
OBJECTIVE|O :|O 
To|O detect|O 3|O kinds|O of|O N-ras|gene-rna mutations|O in|O Chinese|O patients|O with|O acute|O myeloid|O leukemia|O (|O AML|O )|O .|O 
METHODS|O :|O 
In|O vitro|O DNA|O amplification|O followed|O by|O oligonucleotide|O dot|O analysis|O were|O used|O to|O study|O N-ras|gene-rna gene|O mutations|O in|O 43|O cases|O of|O acute|O myeloid|O leukemia|O (|O AML|O )|O .|O 
25|O healthy|O people|O were|O used|O as|O controls|O .|O 
Patients|O were|O selected|O in|O the|O Beijing|O district|O and|O consisted|O of|O 19|O males|O and|O 24|O females|O .|O 
The|O average|O age|O was|O 37|O .|O 
The|O controls|O were|O healthy|O individuals|O with|O the|O average|O age|O of|O 36.5|O from|O the|O same|O region|O .|O 
3|O oligonucleotide|O probes|O were|O artificially|O synthesized|O to|O detect|O mutations|O in|O codon|O 12|O and|O 13|O of|O N-ras|gene-rna .|O 
RESULTS|O :|O 
Five|O out|O of|O 43|O AML|O samples|O have|O been|O found|O contain|O G|O -->|O A|O mutation|O in|O codon|O 12.2|O have|O G|O -->|O T|O mutation|O in|O codon|O 12|O .|O 
One|O has|O G|O -->|O A|O mutation|O in|O codon|O 13|O .|O 
The|O mutation|O rate|O was|O 18.6|O %|O .|O 
None|O of|O the|O controls|O presented|O these|O mutations|O .|O 
The|O frequency|O of|O mutation|O of|O N-ras|gene-rna in|O the|O AML|O samples|O showed|O statistical|O differences|O with|O that|O of|O the|O controls|O .|O 
CONCLUSION|O :|O 
Analysis|O of|O the|O results|O suggests|O the|O N-ras|gene-rna mutations|O may|O have|O some|O relationship|O with|O the|O etiology|O of|O acute|O myeloid|O leukemia|O .|O 
Gene|O mutations|O of|O K-ras|gene-rna in|O gallbladder|O mucosae|O and|O gallbladder|O carcinoma|O with|O an|O anomalous|O junction|O of|O the|O pancreaticobiliary|O duct|O .|O 
OBJECTIVE|O :|O 
In|O this|O study|O ,|O we|O examined|O the|O mutational|O spectrum|O of|O K-ras|gene-rna in|O cases|O of|O gallbladder|O and|O gallbladder|O carcinoma|O with|O an|O anomalous|O junction|O of|O the|O pancreaticobiliary|O duct|O (|O AJPBD|O )|O .|O 
METHODS|O :|O 
We|O examined|O 35|O gallbladders|O with|O AJPBD|O (|O 20|O with|O hyperplasia|O ,|O 15|O with|O carcinoma|O )|O and|O 38|O gallbladders|O without|O AJPBD|O (|O four|O normal|O gallbladders|O ,|O four|O with|O hyperplasia|O ,|O six|O with|O adenoma|O ,|O 24|O with|O carcinoma|O )|O .|O 
Polymerase|gene-protein chain|O reaction|O single|O -|O strand|O conformation|O polymorphism|O (|O PCR|O -|O SSCP|O )|O and|O direct|O sequencing|O were|O performed|O to|O detect|O mutations|O in|O codon|O 12|O or|O 13|O of|O K-ras|gene-rna .|O 
RESULTS|O :|O 
In|O the|O cases|O with|O AJPBD|O ,|O the|O prevalences|O of|O K-ras|gene-rna mutation|O were|O 15|O %|O (|O 3|O /|O 20|O )|O in|O hyperplasia|O ,|O 60|O %|O (|O 6|O /|O 10|O )|O in|O stage|O I|O carcinoma|O ,|O and|O 100|O %|O (|O 5|O /|O 5|O )|O in|O stage|O II|O -|O IV|O carcinoma|O .|O 
In|O the|O cases|O without|O AJPBD|O ,|O the|O prevalences|O of|O K-ras|gene-rna mutation|O were|O 0|O %|O (|O 0|O /|O 4|O )|O in|O normal|O gallbladder|O ,|O 0|O %|O (|O 0|O /|O 4|O )|O in|O hyperplasia|O ,|O 17|O %|O (|O 1|O /|O 6|O )|O in|O adenoma|O ,|O 7|O %|O (|O 1|O /|O 16|O )|O in|O stage|O I|O carcinoma|O ,|O and|O 38|O %|O (|O 3|O /|O 8|O )|O in|O stage|O II|O -|O IV|O carcinoma|O .|O 
Prevalences|O of|O K-ras|gene-rna mutation|O in|O hyperplasia|O and|O carcinoma|O with|O AJPBD|O were|O greater|O than|O those|O without|O AJPBD|O (|O p|O <|O 0.05|O )|O .|O 
The|O point|O mutation|O of|O GGT|O to|O GAT|O in|O codon|O 12|O was|O frequently|O observed|O in|O the|O cases|O with|O AJPBD|O .|O 
CONCLUSION|O :|O 
These|O results|O suggest|O that|O the|O specific|O K-ras|gene-rna mutation|O in|O codon|O 12|O (|O GGT|O to|O GAT|O )|O may|O contribute|O to|O the|O early|O stage|O of|O carcinogenesis|O in|O the|O gallbladder|O with|O AJPBD|O .|O 
Detection|O of|O mutations|O of|O p53|gene-rna tumor|O suppressor|O gene|O in|O pancreatic|O juice|O and|O its|O application|O to|O diagnosis|O of|O patients|O with|O pancreatic|O cancer|O :|O comparison|O with|O K-ras|gene-rna mutation|O .|O 
Because|O of|O the|O difficulty|O in|O obtaining|O biopsy|O specimens|O from|O pancreatic|O cancer|O patients|O ,|O K-ras|gene-rna mutation|O analysis|O in|O pancreatic|O juice|O has|O been|O used|O for|O specific|O diagnosis|O .|O 
But|O recently|O ,|O false|O positives|O have|O been|O obtained|O with|O this|O method|O .|O 
To|O improve|O the|O genetic|O diagnosis|O of|O pancreatic|O cancer|O ,|O detection|O of|O p53|gene-rna gene|O mutation|O in|O pancreatic|O juice|O was|O studied|O .|O 
Pancreatic|O juice|O was|O sampled|O endoscopically|O .|O 
Single|O -|O strand|O conformation|O polymorphism|O analysis|O was|O used|O for|O p53|gene-rna mutation|O analysis|O .|O 
Furthermore|O ,|O K-ras|gene-rna mutations|O at|O codon|O 12|O were|O also|O studied|O in|O the|O same|O pancreatic|O cancer|O patients|O .|O 
Of|O 26|O cases|O of|O pancreatic|O cancer|O ,|O p53|gene-rna mutations|O were|O detected|O in|O 11|O (|O 42.3|O %|O )|O .|O 
No|O mutations|O were|O seen|O in|O the|O cases|O with|O mucin|gene-protein -|O producing|O adenoma|O nor|O with|O chronic|O pancreatitis|O .|O 
K-ras|gene-rna mutations|O were|O detected|O in|O 84.0|O %|O of|O cases|O by|O RFLP|O analysis|O ,|O which|O has|O high|O sensitivity|O ,|O and|O in|O 65.3|O %|O by|O hybridization|O protection|O assay|O ,|O which|O has|O high|O specificity|O .|O 
Using|O a|O combination|O assay|O with|O both|O genes|O ,|O genetic|O abnormalities|O were|O detected|O in|O 92.0|O %|O by|O RFLP|O and|O 73.1|O %|O by|O hybridization|O protection|O assay|O including|O two|O cases|O in|O which|O p53|gene-rna alone|O was|O positive|O by|O both|O methods|O .|O 
The|O specificity|O of|O p53|gene-rna mutation|O for|O pancreatic|O cancer|O is|O very|O high|O .|O 
Therefore|O ,|O simultaneous|O analysis|O of|O p53|gene-rna and|O K-ras|gene-rna mutation|O is|O suggested|O to|O enhance|O the|O genetic|O diagnosis|O of|O pancreatic|O cancer|O .|O 
Association|O of|O K-ras|gene-rna mutations|O with|O p16|gene-rna methylation|O in|O human|O colon|O cancer|O .|O 
BACKGROUND|O &|O AIMS|O :|O 
K-ras|gene-rna mutations|O are|O early|O genetic|O changes|O in|O colon|O cancer|O .|O 
p16|gene-rna ,|O a|O tumor|O -|O suppressor|O gene|O ,|O is|O inactivated|O in|O neoplasms|O by|O mutation|O ,|O deletion|O ,|O or|O methylation|O .|O 
The|O aims|O of|O this|O study|O were|O to|O determine|O p16|gene-rna methylation|O status|O and|O its|O possible|O association|O with|O K-ras|gene-rna mutations|O in|O human|O colon|O cancer|O .|O 
METHODS|O :|O 
DNA|O isolated|O from|O 8|O colon|O cancer|O cell|O lines|O and|O 41|O microdissected|O human|O colon|O tissue|O samples|O was|O analyzed|O .|O 
p16|gene-rna methylation|O status|O was|O determined|O using|O two|O analytical|O methods|O .|O 
The|O level|O of|O p16|gene-rna expression|O was|O determined|O by|O reverse|O -|O transcription|O polymerase|gene-protein chain|O reaction|O and|O Northern|O blot|O .|O 
K-ras|gene-rna mutations|O were|O determined|O by|O DNA|O sequence|O analysis|O .|O 
The|O DNA|O methyltransferase|gene-protein activity|O was|O determined|O by|O microassay|O .|O 
Parental|O and|O K-ras|gene-rna -|O transformed|O IEC-18|O cells|O were|O used|O to|O determine|O the|O potential|O association|O between|O K-ras|gene-rna mutations|O and|O p16|gene-rna methylation|O .|O 
RESULTS|O :|O 
Methylated|O p16|gene-rna was|O found|O in|O 100|O %|O of|O colon|O cancer|O cell|O lines|O ,|O 55|O %|O of|O colon|O cancers|O ,|O 54|O %|O of|O adenomas|O ,|O and|O 25|O %|O of|O transitional|O mucosa|O but|O not|O in|O normal|O colonic|O epithelium|O .|O 
Forty-five|O percent|O of|O cancers|O and|O 38|O %|O of|O adenomas|O showed|O both|O K-ras|gene-rna mutations|O and|O p16|gene-rna methylation|O .|O 
Of|O 11|O cancers|O and|O adenomas|O with|O K-ras|gene-rna mutation|O ,|O 10|O specimens|O showed|O methylated|O p16|gene-rna .|O 
In|O contrast|O ,|O of|O 13|O adenomas|O and|O cancers|O with|O wild|O -|O type|O K-ras|gene-rna ,|O only|O 3|O specimens|O showed|O methylated|O p16|O (|O P|O =|O 0.001|O )|O .|O 
Stable|O transformation|O of|O IEC-18|O cells|O with|O K-ras|gene-rna increased|O the|O DNA|O methyltransferase|gene-protein activity|O ,|O methylated|O the|O p16|gene-rna gene|O ,|O and|O suppressed|O the|O expression|O of|O p16|gene-rna .|O 
Treatment|O with|O a|O DNA|O methylation|O inhibitor|O (|O azadeoxycytidine|O )|O resulted|O in|O reexpression|O of|O p16|gene-rna in|O K-ras|gene-rna -|O transformed|O IEC-18|O cells|O ,|O suggesting|O that|O the|O expression|O of|O p16|gene-rna was|O suppressed|O by|O DNA|O methylation|O .|O 
CONCLUSIONS|O :|O 
p16|gene-rna methylation|O occurs|O frequently|O in|O human|O colonic|O adenomas|O and|O cancers|O and|O is|O closely|O associated|O with|O K-ras|gene-rna mutations|O .|O 
Frequent|O mutation|O and|O nuclear|O localization|O of|O beta-catenin|gene-protein in|O anaplastic|O thyroid|O carcinoma|O .|O 
Beta-catenin|gene-protein is|O an|O ubiquitously|O expressed|O cytoplasmic|O protein|O that|O has|O a|O crucial|O role|O in|O both|O E-cadherin|gene-protein -|O mediated|O cell|O -|O cell|O adhesion|O and|O as|O a|O downstream|O signaling|O molecule|O in|O the|O wingless|gene-generic pathway|O .|O 
Stabilization|O of|O beta-catenin|gene-protein followed|O by|O nuclear|O translocation|O and|O subsequent|O T-cell|gene-protein factor|gene-protein /|O lymphoid|gene-protein -|gene-protein enhancing|gene-protein factor|gene-protein -|O mediated|O transcriptional|O activation|O has|O been|O proposed|O as|O an|O important|O step|O in|O oncogenesis|O .|O 
Stabilization|O may|O occur|O through|O activating|O mutations|O in|O exon-3|O at|O the|O phosphorylation|O sites|O for|O ubiquitination|O and|O degradation|O of|O beta-catenin|gene-protein .|O 
Immunohistochemical|O subcellular|O localization|O of|O beta-catenin|gene-protein and|O mutational|O analysis|O of|O exon-3|O of|O the|O beta-catenin|gene-rna gene|O by|O single|O -|O strand|O conformational|O polymorphism|O followed|O by|O DNA|O sequencing|O was|O performed|O on|O 37|O samples|O from|O 31|O patients|O with|O anaplastic|O thyroid|O carcinoma|O .|O 
Immunofluorescent|O staining|O showed|O nuclear|O localization|O in|O 15|O (|O 42|O %|O )|O of|O the|O 36|O samples|O examined|O .|O 
Nucleotide|O sequencing|O of|O mobility|O shifts|O detected|O by|O single|O -|O strand|O conformational|O polymorphism|O revealed|O somatic|O alterations|O in|O 19|O (|O 61|O %|O )|O of|O the|O 31|O patients|O analyzed|O .|O 
We|O conclude|O that|O mutations|O in|O beta-catenin|gene-rna are|O common|O in|O anaplastic|O thyroid|O cancer|O and|O that|O they|O may|O activate|O transcription|O ,|O as|O illustrated|O by|O frequent|O nuclear|O localization|O of|O the|O protein|O .|O 
These|O findings|O support|O the|O idea|O that|O beta-catenin|gene-rna acts|O as|O an|O oncogene|O and|O contributes|O to|O the|O highly|O aggressive|O behavior|O of|O this|O tumor|O .|O 
Immunohistochemical|O and|O molecular|O analysis|O of|O giant|O cell|O carcinoma|O of|O the|O pancreas|O :|O a|O report|O of|O three|O cases|O .|O 
We|O performed|O molecular|O biological|O studies|O as|O well|O as|O immunohistochemical|O analysis|O of|O three|O cases|O of|O giant|O cell|O carcinoma|O of|O the|O pancreas|O .|O 
Histologically|O ,|O one|O case|O was|O a|O pleomorphic|O giant|O cell|O carcinoma|O consisting|O of|O pleomorphic|O giant|O /|O small|O cells|O and|O spindle|O cells|O ,|O one|O an|O osteoclast|O -|O like|O giant|O cell|O tumor|O composed|O of|O osteoclastoid|O giant|O cells|O and|O pleomorphic|O small|O cells|O ,|O and|O one|O a|O pleomorphic|O giant|O cell|O carcinoma|O with|O osteoclastoid|O giant|O cells|O .|O 
Immunohistochemically|O ,|O pleomorphic|O giant|O cells|O and|O small|O pleomorphic|O cells|O were|O positive|O for|O epithelial|O and|O mesenchymal|O markers|O throughout|O the|O cases|O .|O 
Osteoclastoid|O cells|O were|O strongly|O positive|O for|O PG-M1|gene-protein (|O CD68|gene-protein )|O ,|O but|O negative|O for|O lysozyme|gene-protein and|O epithelial|O markers|O .|O 
Pleomorphic|O spindle|O cells|O showed|O the|O same|O immunoreactivity|O as|O pleomorphic|O giant|O /|O small|O cells|O .|O 
Genetically|O ,|O all|O cases|O contained|O a|O mutation|O in|O the|O K-ras|gene-rna (|O codons|O 12|O ,|O 13|O )|O oncogene|O ,|O but|O neither|O p53|gene-rna (|O exons|O 5|O -|O 8|O )|O nor|O p16INK4|gene-rna (|O exons|O 1|O ,|O 2|O )|O gene|O mutations|O were|O found|O in|O any|O case|O .|O 
Furthermore|O ,|O Loss|O of|O heterozygosity|O (|O LOH|O )|O of|O the|O p53|gene-rna ,|O p161NK4|gene-rna .|O APC|gene-rna ,|O and|O DPC4|gene-rna gene|O loci|O was|O not|O found|O in|O any|O of|O the|O cases|O .|O 
Immunohistochemical|O study|O demonstrated|O this|O tumor|O to|O be|O of|O epithelial|O origin|O with|O mesenchymal|O differentiation|O .|O 
Genetically|O ,|O initiation|O of|O the|O tumor|O is|O similar|O to|O that|O of|O usual|O ductal|O adenocarcinoma|O ,|O but|O progression|O might|O be|O rather|O different|O .|O 
The|O peculiar|O histologic|O and|O biologic|O features|O of|O this|O tumor|O would|O be|O the|O result|O of|O changes|O in|O other|O functional|O genes|O .|O 
K-ras|gene-rna oncogene|O mutations|O indicate|O malignancy|O in|O cystic|O tumors|O of|O the|O pancreas|O .|O 
OBJECTIVE|O :|O 
To|O evaluate|O clinical|O parameters|O ,|O presurgical|O diagnostic|O tests|O ,|O histologic|O findings|O ,|O and|O the|O presence|O of|O K-ras|gene-rna oncogene|O mutations|O in|O cystic|O tumors|O of|O the|O pancreas|O to|O determine|O which|O best|O predict|O malignancy|O .|O 
SUMMARY|O BACKGROUND|O DATA|O :|O 
Because|O presurgical|O ,|O intraoperative|O ,|O and|O final|O pathologic|O differentiation|O is|O difficult|O in|O cystic|O tumors|O of|O the|O pancreas|O ,|O it|O would|O be|O a|O major|O benefit|O to|O identify|O markers|O that|O accurately|O predict|O malignancy|O in|O these|O rare|O tumors|O .|O 
The|O role|O of|O K-ras|gene-rna oncogene|O mutations|O as|O an|O indicator|O of|O malignancy|O has|O not|O been|O determined|O in|O these|O tumors|O .|O 
METHODS|O :|O 
Nineteen|O patients|O with|O cystic|O tumors|O of|O the|O pancreas|O were|O evaluated|O ,|O including|O K-ras|gene-rna mutation|O analysis|O based|O on|O polymerase|gene-protein chain|O reaction|O and|O restriction|O digestion|O assays|O and|O direct|O DNA|O sequencing|O ,|O to|O screen|O for|O parameters|O that|O accurately|O predict|O malignancy|O .|O 
RESULTS|O :|O 
All|O malignant|O cystic|O pancreatic|O tumors|O (|O five|O cystadenocarcinomas|O and|O three|O mucin|gene-protein -|O producing|O adenocarcinomas|O )|O harbored|O K-ras|gene-rna mutations|O at|O codon|O 12|O or|O 13|O .|O 
K-ras|gene-rna mutations|O were|O also|O detected|O in|O the|O percutaneous|O fine|O -|O needle|O aspirates|O of|O two|O of|O these|O patients|O .|O 
In|O contrast|O ,|O none|O of|O nine|O benign|O cystadenomas|O or|O the|O solid|O -|O papillary|O neoplasm|O had|O K-ras|gene-rna mutations|O .|O 
None|O of|O the|O patients|O with|O a|O benign|O tumor|O carrying|O K-ras|gene-rna wild|O -|O type|O sequences|O developed|O recurrent|O disease|O after|O a|O mean|O follow-up|O of|O 50|O months|O .|O 
Seven|O of|O the|O 8|O malignant|O cystic|O pancreatic|O tumors|O ,|O but|O none|O of|O the|O 11|O benign|O tumors|O ,|O showed|O dilatation|O of|O the|O main|O pancreatic|O duct|O on|O computed|O tomography|O or|O endoscopic|O retrograde|O cholangiopancreatography|O .|O 
CONCLUSIONS|O :|O 
K-ras|gene-rna mutation|O analysis|O seems|O to|O be|O a|O powerful|O tool|O to|O determine|O the|O malignant|O potential|O of|O cystic|O pancreatic|O tumors|O before|O and|O after|O surgery|O .|O 
Dilatation|O of|O the|O main|O pancreatic|O duct|O on|O computed|O tomography|O or|O endoscopic|O retrograde|O cholangiopancreatography|O is|O highly|O suggestive|O for|O malignancy|O in|O these|O rare|O tumors|O .|O 
Prognostic|O value|O of|O K-ras|gene-rna mutations|O ,|O ras|gene-protein oncoprotein|O ,|O and|O c-erb|gene-protein B-2|gene-protein oncoprotein|O expression|O in|O adenocarcinoma|O of|O the|O lung|O .|O 
This|O trial|O was|O undertaken|O to|O determine|O the|O prognostic|O role|O of|O K-ras|gene-protein (|O p21|gene-protein )|O ,|O c-erb|gene-protein B-2|gene-protein (|O p185|gene-protein )|O protein|O expression|O ,|O and|O the|O presence|O or|O nonpresence|O of|O a|O K-ras|gene-rna gene|O mutation|O in|O patients|O with|O adenocarcinoma|O of|O the|O lung|O .|O 
This|O was|O a|O retrospective|O study|O of|O 103|O patients|O with|O adeno|O -|O or|O large|O -|O cell|O carcinoma|O of|O the|O lung|O who|O had|O available|O paraffin|O -|O stored|O tumor|O material|O .|O 
The|O relation|O of|O several|O clinical|O variables|O to|O survival|O was|O analyzed|O .|O 
Immunohistochemical|O techniques|O were|O used|O to|O determine|O expression|O of|O p21|gene-protein and|O p185|gene-protein .|O 
Polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O and|O sequencing|O were|O used|O to|O determine|O K-ras|gene-rna mutation|O status|O .|O 
Tumor|O stage|O was|O the|O only|O nonmolecular|O clinical|O variable|O predictive|O of|O survival|O (|O p|O =|O 0.0001|O )|O .|O 
A|O combination|O of|O K-ras|gene-rna mutation|O and|O p|gene-protein 185|gene-protein expression|O (|O p|O =|O 0.0144|O )|O ,|O ras|gene-rna mutation|O and|O strong|O p21|gene-protein expression|O (|O p|O =|O 0.0137|O )|O ,|O and|O K-ras|gene-rna mutation|O and|O the|O combined|O expression|O of|O p21|gene-protein and|O p185|gene-protein were|O predictive|O of|O poor|O survival|O (|O p|O =|O 0.0415|O )|O in|O univariate|O analysis|O of|O all|O patients|O .|O 
The|O sole|O presence|O of|O K-ras|gene-rna mutation|O was|O predictive|O of|O survival|O .|O 
Additionally|O ,|O when|O combined|O with|O elevated|O p21|gene-protein or|O p185|gene-protein expression|O in|O a|O subset|O of|O patients|O with|O 4|O or|O more|O years|O of|O follow|O -|O up|O ,|O negative|O correlation|O with|O survival|O was|O observed|O .|O 
Can|O K-ras|gene-rna codon|O 12|O mutations|O be|O used|O to|O distinguish|O benign|O bile|O duct|O proliferations|O from|O metastases|O in|O the|O liver|O ?|O 
A|O molecular|O analysis|O of|O 101|O liver|O lesions|O from|O 93|O patients|O .|O 
It|O can|O be|O difficult|O to|O distinguish|O benign|O bile|O duct|O proliferations|O (|O BDPs|O )|O from|O well|O -|O differentiated|O metastatic|O peripancreatic|O adenocarcinomas|O on|O histological|O grounds|O alone|O .|O 
Most|O peripancreatic|O carcinomas|O harbor|O activating|O point|O mutations|O in|O codon|O 12|O of|O the|O K-ras|gene-rna oncogene|O ,|O suggesting|O that|O K-ras|gene-rna mutational|O status|O may|O provide|O a|O molecular|O basis|O for|O distinguishing|O BDPs|O from|O liver|O metastases|O .|O 
The|O ability|O of|O tests|O for|O mutations|O in|O codon|O 12|O of|O K-ras|gene-rna to|O make|O this|O distinction|O was|O examined|O in|O a|O two|O -|O part|O study|O .|O 
In|O the|O first|O part|O we|O determined|O the|O K-ras|gene-rna mutational|O status|O of|O 56|O liver|O lesions|O and|O 48|O primary|O peripancreatic|O adenocarcinomas|O obtained|O from|O 48|O patients|O .|O 
In|O the|O second|O part|O of|O this|O study|O an|O additional|O 45|O liver|O lesions|O were|O studied|O .|O 
In|O the|O first|O 48|O patients|O ,|O activating|O point|O mutations|O in|O codon|O 12|O of|O K-ras|gene-rna were|O detected|O in|O 28|O (|O 61|O %|O )|O of|O the|O 46|O primary|O carcinomas|O ,|O in|O 8|O (|O 100|O %|O )|O of|O 8|O liver|O metastases|O ,|O in|O 2|O (|O 6.5|O %|O )|O of|O 31|O BDPs|O ,|O and|O in|O none|O (|O 0|O %|O )|O of|O 14|O liver|O granulomas|O .|O 
Three|O BDPs|O and|O two|O primary|O carcinomas|O did|O not|O amplify|O .|O 
To|O further|O estimate|O the|O prevalence|O of|O K-ras|gene-rna mutations|O in|O BDPs|O we|O analyzed|O an|O additional|O series|O of|O 45|O mostly|O incidental|O BDPs|O for|O K-ras|gene-rna mutations|O .|O 
Three|O (|O 6.7|O %|O )|O of|O these|O 45|O harbored|O K-ras|gene-rna mutations|O .|O 
These|O results|O suggest|O that|O K-ras|gene-rna mutations|O may|O be|O useful|O in|O distinguishing|O BDPs|O from|O metastases|O in|O the|O liver|O ;|O however|O ,|O there|O is|O some|O overlap|O in|O the|O mutational|O spectra|O of|O BDPs|O and|O pancreatic|O carcinomas|O .|O 
Ras|gene-rna oncogene|O mutations|O in|O childhood|O brain|O tumors|O .|O 
Although|O N-nitroso|O compounds|O (|O NNC|O )|O are|O ubiquitous|O in|O the|O human|O environment|O and|O are|O known|O neurocarcinogens|O in|O animal|O models|O ,|O results|O of|O epidemiological|O studies|O have|O not|O yet|O convincingly|O associated|O NNCs|O with|O brain|O tumor|O occurrence|O in|O humans|O .|O 
Animal|O studies|O have|O suggested|O that|O specific|O codons|O (|O 12|O ,|O 13|O ,|O and|O 61|O )|O in|O the|O ras|gene-rna family|O are|O mutable|O by|O exposure|O to|O NNCs|O .|O 
The|O purpose|O of|O this|O study|O was|O to|O measure|O the|O presence|O of|O mutations|O in|O the|O ras|gene-rna family|O of|O oncogenes|O in|O tissue|O from|O childhood|O brain|O (|O CB|O )|O tumors|O as|O a|O preliminary|O step|O toward|O investigating|O their|O potential|O use|O as|O biomarkers|O of|O chemical|O exposure|O .|O 
DNA|O was|O extracted|O from|O paraffin|O -|O embedded|O formalin|O -|O fixed|O CB|O tumors|O from|O tissues|O resected|O during|O neurosurgical|O operations|O .|O 
Using|O the|O PCR|O ,|O designed|O RFLP|O -|O screening|O methods|O ,|O and|O sequencing|O ,|O we|O attempted|O to|O screen|O brain|O tumors|O from|O 46|O children|O for|O the|O presence|O of|O H|gene-rna ,|O K|gene-rna ,|O and|O N|gene-rna -|gene-rna ras|gene-rna mutations|O at|O codons|O 12|O ,|O 13|O ,|O and|O 61|O .|O 
Screening|O for|O oncogene|O mutations|O using|O PCR|O ,|O RFLP|O methods|O ,|O and|O DNA|O sequencing|O was|O successfully|O completed|O for|O a|O high|O proportion|O of|O the|O available|O specimens|O .|O 
Astrocytoma|O specimens|O from|O three|O children|O for|O whom|O screening|O with|O PCR|O was|O successfully|O completed|O were|O found|O to|O contain|O CAA|O -->|O GAA|O point|O mutations|O in|O K-ras|gene-rna at|O codon|O 61|O .|O 
None|O of|O the|O specimens|O contained|O mutations|O at|O any|O of|O the|O other|O locations|O .|O 
These|O results|O ,|O although|O preliminary|O ,|O provide|O a|O potential|O clue|O for|O future|O mechanistic|O studies|O of|O CB|O tumors|O .|O 
The|O possible|O roles|O of|O NNCs|O in|O inducing|O this|O mutation|O ,|O or|O of|O this|O mutation|O as|O an|O early|O or|O late|O event|O in|O tumor|O progression|O ,|O however|O ,|O remain|O unclear|O .|O 
Identification|O of|O mutations|O in|O the|O Ki-ras|gene-rna gene|O in|O human|O retinoblastoma|O .|O 
PURPOSE|O :|O 
To|O investigate|O the|O mutational|O status|O of|O the|O Ki-ras|gene-rna gene|O in|O retinoblastoma|O and|O to|O evaluate|O a|O correlation|O of|O the|O genotype|O with|O clinical|O and|O histopathologic|O variables|O .|O 
METHODS|O :|O 
Tumor|O samples|O were|O microdissected|O from|O sectioned|O archival|O paraffin|O -|O embedded|O tissue|O .|O 
Ki-ras|gene-rna genomic|O sequences|O (|O exons|O 1|O and|O 2|O )|O were|O amplified|O by|O polymerase|gene-protein chain|O reaction|O then|O analyzed|O by|O single|O -|O strand|O conformation|O polymorphism|O and|O direct|O sequencing|O .|O 
Tissue|O sections|O ,|O flanking|O the|O analyzed|O samples|O ,|O were|O stained|O with|O hematoxylin|O and|O eosin|O for|O examination|O by|O light|O microscopy|O .|O 
RESULTS|O :|O 
Four|O of|O 12|O tumors|O had|O mutation|O in|O exon|O 1|O ,|O codon|O 12|O of|O the|O Ki-ras|gene-rna gene|O ;|O none|O had|O mutation|O in|O exon|O 2|O .|O 
Signal|O intensity|O of|O the|O mutated|O alleles|O indicates|O clonal|O mutation|O in|O the|O tumor|O cell|O populations|O .|O 
One|O of|O four|O bilateral|O tumors|O was|O mutated|O ,|O and|O all|O three|O samples|O with|O undifferentiated|O histologic|O appearance|O harbored|O a|O clonal|O Ki-ras|gene-rna mutation|O .|O 
However|O ,|O only|O one|O of|O nine|O moderately|O to|O poorly|O differentiated|O tumors|O harbored|O a|O mutation|O .|O 
CONCLUSIONS|O :|O 
Ki-ras|gene-rna ,|O an|O oncogene|O seldom|O altered|O in|O neuroectodermal|O neoplasms|O ,|O is|O mutated|O in|O one|O third|O of|O the|O retinoblastomas|O studied|O .|O 
The|O Ki-ras|gene-rna mutations|O are|O clonal|O ,|O suggesting|O that|O affected|O cells|O have|O a|O selective|O growth|O advantage|O .|O 
The|O mutations|O are|O present|O and|O are|O likely|O to|O play|O a|O pathogenetic|O role|O in|O heritable|O and|O sporadic|O retinoblastomas|O .|O 
These|O results|O suggest|O that|O mutations|O in|O Ki-ras|gene-rna are|O preferentially|O associated|O with|O undifferentiated|O tumors|O .|O 
c-kit|gene-rna point|O mutation|O of|O extracellular|O domain|O in|O patients|O with|O myeloproliferative|O disorders|O .|O 
c-kit|gene-protein is|O a|O tyrosine|gene-protein kinase|gene-protein receptor|gene-protein whose|O ligand|O is|O stem|gene-protein cell|gene-protein factor|gene-protein (|O SCF|gene-protein )|O .|O 
Gene|O alteration|O of|O the|O c-kit|gene-protein extracellular|O domain|O was|O analysed|O by|O polymerase|gene-protein chain|O reaction|O -|O single|O strand|O conformation|O polymorphism|O (|O PCR-SSCP|O )|O in|O 25|O patients|O with|O myeloproliferative|O disorders|O (|O MPD|O )|O .|O 
In|O the|O N|O -|O terminal|O part|O of|O the|O domain|O ,|O mobility|O shifts|O indicating|O sequence|O alteration|O were|O detected|O in|O three|O of|O the|O patients|O ,|O two|O primary|O myelofibrosis|O (|O PMF|O )|O and|O one|O chronic|O myelogenous|O leukaemia|O (|O CML|O )|O .|O 
The|O subsequent|O sequencing|O revealed|O the|O same|O point|O mutations|O at|O codon|O 52|O causing|O amino|O acid|O substitution|O (|O Asp|O -->|O Asn|O )|O .|O 
To|O our|O knowledge|O this|O is|O the|O first|O report|O with|O a|O c-kit|gene-rna point|O mutation|O found|O in|O human|O fresh|O tumour|O cells|O .|O 
Molecular|O defects|O associated|O with|O the|O acute|O phase|O CML|O .|O 
Parts|O of|O the|O Bcr|O /|O Abl|O hybrid|O transcript|O supposed|O to|O be|O important|O for|O its|O transforming|O ability|O were|O sequenced|O in|O a|O series|O of|O CML|O blast|O crises|O ,|O in|O order|O to|O evaluate|O the|O possible|O presence|O of|O alterations|O responsible|O for|O the|O disease|O transition|O from|O the|O chronic|O to|O the|O acute|O phase|O .|O 
In|O addition|O ,|O the|O N|gene-rna -|gene-rna and|O Ki|gene-rna -|gene-rna ras|gene-rna as|O well|O as|O the|O p53|gene-rna involvement|O was|O investigated|O by|O exploring|O their|O structure|O and|O expression|O in|O the|O same|O patients|O .|O 
We|O used|O traditional|O types|O of|O molecular|O analysis|O including|O Southern|O and|O Northern|O blot|O ,|O together|O with|O methods|O that|O allow|O a|O rapid|O detection|O of|O point|O mutations|O and|O microdeletions|O ,|O such|O as|O SSCP|O ,|O single|O strand|O conformation|O polymorphism|O and|O direct|O sequencing|O .|O 
The|O results|O obtained|O may|O be|O summarized|O as|O follows|O :|O no|O alterations|O were|O found|O in|O the|O parts|O of|O the|O Bcr|O /|O Abl|O transcripts|O investigated|O in|O the|O present|O study|O (|O SH2|O ,|O SH3|O and|O the|O region|O surrounding|O codon|O 832|O )|O ;|O p53|gene-rna alterations|O were|O observed|O in|O 5|O %|O and|O N|gene-rna -|gene-rna and|O Ki|gene-rna -|gene-rna RAS|gene-rna mutations|O in|O 5|O %|O of|O the|O cases|O examined|O .|O 
These|O molecular|O defects|O are|O therefore|O responsible|O for|O the|O clinical|O progression|O of|O the|O Ph1|O -|O positive|O CML|O only|O in|O a|O minority|O of|O cases|O .|O 
Occurrence|O of|O point|O mutations|O in|O p53|gene-rna gene|O is|O not|O increased|O in|O patients|O with|O acute|O myeloid|O leukaemia|O carrying|O an|O activating|O N-ras|gene-rna mutation|O .|O 
The|O frequency|O of|O simultaneously|O detecting|O N-ras|gene-rna and|O p53|gene-rna gene|O mutations|O was|O studied|O in|O leukaemia|O cells|O of|O patients|O with|O acute|O myeloid|O leukaemia|O (|O AML|O )|O or|O with|O myelodysplastic|O syndrome|O (|O MDS|O )|O .|O 
Using|O in|O vitro|O DNA|O amplification|O followed|O by|O oligonucleotide|O hybridization|O analysis|O ,|O 45|O AML|O and|O six|O MDS|O patients|O were|O screened|O for|O activating|O mutations|O in|O codons|O 12|O ,|O 13|O and|O 61|O of|O N-ras|gene-rna .|O 
Ten|O of|O them|O (|O eight|O AML|O and|O two|O MDS|O )|O were|O found|O positive|O .|O 
These|O 10|O patients|O and|O 10|O others|O without|O activating|O N-ras|gene-rna mutation|O were|O further|O analysed|O by|O direct|O sequencing|O of|O the|O amplified|O exons|O for|O p53|gene-rna mutations|O and|O for|O atypical|O N-ras|gene-rna mutations|O .|O 
Beside|O the|O activating|O mutations|O in|O the|O N-ras|gene-rna gene|O ,|O no|O additional|O transforming|O or|O nontransforming|O mutations|O could|O be|O detected|O in|O the|O N-ras|gene-rna .|O 
However|O ,|O exon|O 7|O of|O p53|gene-rna was|O mutated|O in|O two|O AML|O patients|O without|O activating|O N-ras|gene-rna mutation|O .|O 
These|O data|O show|O that|O p53|gene-rna mutations|O occurred|O with|O half|O the|O frequency|O of|O N-ras|gene-rna mutations|O in|O AML|O and|O that|O no|O positive|O correlation|O could|O be|O found|O between|O the|O onset|O of|O mutations|O in|O N-ras|gene-rna and|O p53|gene-rna genes|O .|O 
Comparison|O of|O mutations|O of|O ras|gene-rna oncogene|O in|O human|O pancreatic|O exocrine|O and|O endocrine|O tumors|O .|O 
BACKGROUND|O .|O 
Ras|gene-rna oncogene|O mutations|O have|O been|O found|O in|O many|O human|O cancers|O ;|O however|O ,|O pancreatic|O endocrine|O tumors|O have|O rarely|O been|O studied|O .|O 
The|O purpose|O of|O this|O study|O was|O to|O analyze|O ras|gene-rna mutations|O in|O pancreatic|O endocrine|O tumors|O and|O to|O compare|O these|O results|O with|O the|O incidence|O of|O ras|gene-rna mutations|O in|O pancreatic|O exocrine|O cancers|O studied|O in|O our|O laboratory|O .|O 
METHODS|O .|O 
Ras|gene-rna oncogene|O mutations|O were|O studied|O in|O 33|O foregut|O endocrine|O tumors|O (|O pancreatic|O 31|O ,|O duodenal|O submucosa|O 2|O )|O .|O 
Eleven|O were|O insulinomas|O ,|O 12|O gastrinomas|O ,|O 2|O glucagonomas|O ,|O and|O 11|O others|O were|O nonfunctioning|O islet|O cell|O carcinomas|O .|O 
Thirteen|O were|O benign|O and|O 20|O were|O malignant|O .|O 
These|O were|O compared|O with|O 65|O pancreatic|O exocrine|O cancers|O .|O 
Tumors|O were|O microdissected|O from|O paraffin|O -|O embedded|O sections|O .|O 
DNA|O was|O extracted|O and|O amplified|O by|O polymerase|gene-protein chain|O reaction|O .|O 
Mutations|O were|O detected|O by|O a|O oligonucleotide|O hybridization|O method|O with|O sequence|O -|O specific|O phosphorus|O 32|O -|O radiolabeled|O probes|O .|O 
RESULTS|O .|O 
No|O ras|gene-rna mutations|O were|O identified|O among|O the|O 33|O pancreatic|O endocrine|O tumors|O .|O 
In|O contrast|O ,|O 51|O of|O 65|O (|O 78.5|O %|O )|O pancreatic|O exocrine|O cancers|O exhibited|O a|O ras|gene-rna mutation|O .|O 
Fifty|O were|O K-ras|gene-rna mutations|O and|O one|O unusual|O tumor|O exhibited|O a|O N-|gene-rna 61|O ras|gene-rna mutation|O .|O 
CONCLUSIONS|O .|O 
Ras|gene-rna oncogene|O mutations|O do|O not|O play|O a|O role|O in|O the|O tumorigenesis|O of|O pancreatic|O endocrine|O tumors|O .|O 
Association|O of|O H-ras|gene-rna mutations|O with|O adenocarcinomas|O of|O the|O parotid|O gland|O .|O 
We|O have|O examined|O 17|O adenocarcinomas|O and|O 2|O mixed|O tumors|O of|O the|O salivary|O glands|O for|O mutational|O activation|O of|O the|O oncogenes|O H-ras|gene-rna ,|O K-ras|gene-rna and|O N-ras|gene-rna .|O 
The|O presence|O of|O mutations|O was|O determined|O by|O in|O vitro|O amplification|O of|O gene|O fragments|O spanning|O codons|O 12|O ,|O 13|O and|O 61|O and|O the|O use|O of|O mutation|O -|O specific|O oligonucleotide|O hybridization|O .|O 
ras|gene-rna mutations|O were|O present|O in|O 3|O of|O 13|O adenocarcinomas|O (|O 23|O %|O )|O of|O the|O parotid|O gland|O .|O 
The|O mutations|O were|O confirmed|O and|O characterized|O by|O means|O of|O cycle|O sequencing|O of|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O fragments|O .|O 
In|O all|O 3|O cases|O ,|O the|O mutation|O was|O an|O A|O :|O T|O to|O G|O :|O C|O transition|O at|O the|O second|O position|O of|O codon|O 61|O of|O the|O H-ras|gene-rna gene|O .|O 
This|O rather|O unusual|O ras|gene-rna mutation|O could|O provide|O a|O clue|O to|O identify|O one|O or|O more|O carcinogens|O involved|O in|O the|O pathogenesis|O of|O parotid|O cancer|O .|O 
International|O comparison|O on|O ras|gene-rna gene|O mutations|O in|O latent|O prostate|O carcinoma|O .|O 
Latent|O carcinomas|O of|O the|O prostate|O ,|O discovered|O at|O autopsy|O in|O men|O with|O no|O prior|O treatment|O for|O prostatic|O disease|O ,|O were|O studied|O for|O ras|gene-rna proto|O -|O oncogene|O mutations|O .|O 
Subjects|O included|O 21|O Japanese|O ,|O 15|O U.S.|O whites|O ,|O 15|O U.S.|O blacks|O ,|O 20|O Hawaiian|O Japanese|O and|O 10|O Colombians|O .|O 
PCR|O and|O sequence|O -|O specific|O oligonucleotide|O hybridization|O identified|O mutations|O in|O 5|O Japanese|O ,|O in|O 1|O Hawaiian|O Japanese|O ,|O in|O 1|O U.S.|O black|O ,|O in|O 1|O U.S.|O white|O and|O in|O 3|O Colombians|O .|O 
The|O 5|O Japanese|O tumor|O samples|O contained|O 3|O point|O mutations|O in|O codon|O 12|O of|O K-ras|gene-rna and|O 2|O mutations|O in|O codon|O 12|O of|O N-ras|gene-rna respectively|O .|O 
One|O tumor|O in|O a|O Hawaiian|O Japanese|O man|O also|O showed|O a|O K-ras|gene-rna point|O mutation|O at|O codon|O 12|O .|O 
Two|O Colombians|O and|O one|O U.S.|O black|O man|O had|O tumors|O with|O mutations|O at|O codon|O 61|O of|O H-ras|gene-rna ,|O while|O 1|O Colombian|O showed|O an|O N-ras|gene-rna mutation|O at|O this|O codon|O .|O 
The|O overall|O frequency|O of|O ras|gene-rna gene|O mutations|O was|O low|O ,|O but|O point|O mutations|O in|O codon|O 12|O were|O most|O common|O in|O latent|O tumors|O of|O Japanese|O ,|O who|O experienced|O the|O lowest|O incidence|O and|O mortality|O from|O this|O tumor|O .|O 
Latent|O tumors|O in|O men|O from|O ethnic|O groups|O with|O high|O mortality|O and|O incidence|O rates|O showed|O fewer|O ras|gene-rna mutations|O than|O the|O Japanese|O ,|O and|O these|O were|O more|O likely|O to|O involve|O codon|O 61|O .|O 
This|O finding|O is|O consistent|O with|O prior|O studies|O of|O more|O aggressive|O clinical|O cancers|O in|O Japanese|O men|O that|O indicated|O a|O higher|O frequency|O of|O mutations|O at|O codon|O 61|O .|O 
High|O incidence|O of|O H-ras|gene-rna oncogene|O mutations|O in|O squamous|O cell|O carcinoma|O of|O lip|O vermilion|O .|O 
Nine|O specimens|O of|O well|O -|O differentiated|O squamous|O cell|O carcinoma|O of|O the|O lip|O vermilion|O have|O been|O analyzed|O for|O the|O presence|O of|O H-ras|gene-rna oncogene|O mutations|O ,|O using|O the|O technique|O of|O hybridization|O with|O synthetic|O oligonucleotide|O probes|O on|O in|O vitro|O amplified|O tumour|O DNA|O .|O 
Five|O specimens|O harbored|O mutations|O :|O four|O in|O codon|O 12|O and|O one|O in|O codon|O 13|O .|O 
This|O high|O incidence|O (|O 55|O %|O )|O of|O mutated|O H-ras|gene-rna genes|O suggests|O that|O their|O activation|O may|O play|O an|O important|O role|O in|O lip|O tumour|O development|O and|O may|O be|O connected|O to|O the|O exposure|O to|O chemical|O and/or|O physical|O carcinogens|O .|O 
Selective|O activation|O of|O ras|gene-rna oncogenes|O in|O follicular|O and|O undifferentiated|O thyroid|O carcinomas|O .|O 
A|O total|O of|O 96|O tumour|O samples|O (|O 88|O primary|O tumours|O and|O 8|O nodal|O metastases|O )|O from|O 88|O patients|O with|O thyroid|O adenomas|O and|O carcinomas|O were|O investigated|O for|O ras|gene-rna gene|O mutations|O using|O polymerase|gene-protein chain|O reaction|O ,|O oligonucleotide|O probing|O and|O sequencing|O .|O 
Neither|O the|O 19|O adenomas|O nor|O the|O 31|O papillary|O carcinomas|O analysed|O harboured|O point|O mutations|O .|O 
In|O our|O cases|O ,|O mutations|O in|O all|O three|O ras|gene-rna oncogenes|O were|O found|O in|O follicular|O carcinomas|O (|O five|O out|O of|O 21|O )|O and|O in|O the|O less|O differentiated|O thyroid|O tumour|O :|O poorly|O differentiated|O carcinomas|O (|O three|O out|O of|O 11|O )|O and|O undifferentiated|O carcinomas|O (|O one|O out|O of|O five|O )|O .|O 
Finally|O ,|O mutated|O ras|gene-rna oncogenes|O had|O a|O significant|O association|O with|O the|O appearance|O of|O haematogenous|O (|O particularly|O bone|O )|O metastases|O ,|O suggesting|O a|O role|O of|O ras|gene-rna genes|O activation|O in|O the|O metastatic|O capability|O of|O these|O tumours|O .|O 
Allele|O -|O specific|O mutations|O involved|O in|O the|O pathogenesis|O of|O endemic|O gallbladder|O carcinoma|O in|O Chile|O .|O 
Although|O gallbladder|O carcinoma|O is|O one|O of|O the|O most|O frequent|O neoplasms|O in|O Chile|O ,|O there|O is|O limited|O information|O about|O the|O molecular|O changes|O involved|O in|O its|O pathogenesis|O .|O 
We|O investigated|O the|O incidence|O of|O ras|gene-rna gene|O mutations|O and|O loss|O of|O heterozygosity|O (|O LOH|O )|O at|O the|O following|O genes|O /|O loci|O :|O p53|gene-rna ,|O DCC|gene-rna ,|O rb|gene-rna ,|O 5q|O 3p|O ,|O 8p|O ,|O and|O 9p|O .|O 
We|O precisely|O microdissected|O 194|O relevant|O areas|O from|O paraffin|O -|O embedded|O microslides|O from|O 25|O gallbladder|O carcinomas|O and|O their|O accompanying|O nonneoplastic|O lesions|O (|O which|O were|O present|O in|O 15|O cases|O )|O from|O patients|O in|O Chile|O .|O 
The|O specimens|O were|O analyzed|O by|O PCR|O -|O based|O assays|O for|O LOH|O ,|O and|O we|O designed|O a|O RFLP|O method|O for|O ras|gene-rna mutations|O and|O immunohistochemistry|O for|O p53|gene-protein protein|O overexpression|O .|O 
We|O determined|O that|O LOH|O at|O p53|gene-rna (|O 91|O %|O )|O ,|O 9p|O (|O 50|O %|O )|O ,|O 8p|O (|O 44|O %|O )|O and|O DCC|gene-rna (|O 31|O %|O )|O are|O frequent|O events|O and|O that|O LOH|O at|O p53|gene-rna ,|O 9p|O ,|O and|O DCC|gene-rna are|O early|O events|O ,|O while|O ras|gene-rna mutations|O and|O LOH|O at|O 3p|O ,|O rb|gene-rna ,|O and|O 5q|O occurred|O occasionally|O .|O 
LOH|O at|O p53|gene-rna occurred|O more|O frequently|O and|O earlier|O than|O protein|gene-protein overexpression|O .|O 
The|O mean|O number|O of|O mutations|O present|O in|O invasive|O carcinomas|O was|O 2.1|O ,|O and|O in|O six|O cases|O ,|O LOH|O at|O the|O p53|gene-rna gene|O was|O the|O sole|O mutation|O detected|O .|O 
The|O same|O allele|O was|O lost|O in|O 61|O (|O 93|O %|O )|O of|O 71|O nonneoplastic|O foci|O as|O in|O the|O corresponding|O invasive|O carcinomas|O for|O all|O four|O mutations|O studied|O .|O 
The|O odds|O of|O this|O occurring|O by|O chance|O are|O approximately|O 4|O x|O 10(-15)|O .|O 
Although|O clonality|O cannot|O be|O excluded|O ,|O allelic|O loss|O appears|O to|O be|O highly|O directed|O ,|O but|O the|O mechanism|O for|O allele|O -|O specific|O mutations|O remains|O to|O be|O determined|O .|O 
Mutations|O of|O the|O p53|gene-rna and|O ras|gene-rna genes|O in|O childhood|O t|O (|O 1|O ;|O 19|O )|O -|O acute|O lymphoblastic|O leukemia|O .|O 
We|O have|O investigated|O the|O alterations|O of|O p53|gene-rna and|O ras|gene-rna genes|O including|O H|gene-rna -|gene-rna ,|O K|gene-rna -|gene-rna ,|O and|O N|gene-rna -|gene-rna ras|gene-rna genes|O in|O 22|O acute|O lymphoblastic|O leukemia|O (|O ALL|O )|O cases|O and|O five|O cell|O lines|O carrying|O t|O (|O 1|O ;|O 19|O )|O by|O use|O of|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O -|O single|O -|O strand|O conformation|O polymorphism|O (|O SSCP|O )|O analysis|O and|O direct|O sequencing|O .|O 
The|O mutations|O of|O the|O p53|gene-rna gene|O were|O found|O in|O 2|O of|O 20|O t|O (|O 1|O ;|O 19|O )|O -|O ALL|O cases|O at|O diagnosis|O (|O 10|O %|O )|O ,|O all|O of|O 4|O cases|O at|O relapse|O (|O 100|O %|O )|O ,|O and|O 4|O of|O the|O 5|O cell|O lines|O (|O 80|O %|O )|O .|O 
Four|O of|O the|O five|O patients|O who|O died|O had|O missense|O mutations|O at|O codons|O 49|O ,|O 177|O ,|O 179|O ,|O and|O 248|O .|O 
In|O cases|O examined|O sequentially|O ,|O one|O had|O the|O same|O point|O mutation|O at|O codon|O 179|O at|O both|O diagnosis|O and|O relapse|O ,|O and|O another|O had|O the|O same|O p53|gene-rna gene|O mutation|O at|O codon|O 240|O both|O in|O leukemic|O cells|O at|O relapse|O and|O in|O a|O cell|O line|O derived|O at|O that|O time|O .|O 
The|O other|O case|O had|O no|O mutation|O at|O diagnosis|O but|O had|O the|O mutation|O at|O codon|O 177|O at|O relapse|O and|O cell|O lines|O derived|O from|O blast|O cells|O at|O diagnosis|O ,|O suggesting|O that|O a|O small|O number|O of|O leukemic|O cells|O with|O the|O p53|gene-rna gene|O mutation|O at|O diagnosis|O might|O have|O escaped|O PCR|O -|O SSCP|O analysis|O .|O 
In|O cell|O lines|O ,|O SCMC|O -|O L9|O had|O three|O point|O mutations|O in|O the|O p53|gene-rna gene|O at|O codons|O 175|O ,|O 248|O ,|O and|O 358|O ,|O whereas|O SCMC|O -|O L10|O had|O frame|O shift|O at|O codons|O 209|O -|O 211|O .|O 
One|O case|O had|O a|O rare|O polymorphism|O at|O codon|O 11|O .|O 
We|O found|O only|O one|O mutation|O of|O the|O N-ras|gene-rna gene|O that|O was|O a|O 2|O -|O bp|O substitution|O of|O GGT|O (|O Gly|O )|O to|O GTC|O (|O Val|O )|O at|O codon|O 13|O among|O 22|O t|O (|O 1|O ;|O 19|O )|O -|O ALL|O cases|O and|O five|O cell|O lines|O .|O 
This|O case|O showed|O no|O mutation|O of|O the|O p53|gene-rna gene|O and|O has|O had|O a|O good|O course|O .|O 
These|O results|O suggest|O that|O in|O t|O (|O 1|O ;|O 19|O )|O -|O ALL|O ,|O mutations|O of|O the|O p53|gene-rna and|O ras|gene-rna genes|O are|O infrequent|O at|O diagnosis|O and|O that|O p53|gene-rna gene|O alterations|O may|O be|O associated|O with|O relapse|O phase|O or|O progression|O of|O t|O (|O 1|O ;|O 19|O )|O -|O ALL|O .|O 
Mutational|O status|O of|O codons|O 12|O and|O 13|O of|O the|O N|gene-rna -|gene-rna and|O K|gene-rna -|gene-rna ras|gene-rna genes|O in|O tissue|O and|O cell|O lines|O derived|O from|O primary|O and|O metastatic|O prostate|O carcinomas|O .|O 
N|gene-rna -|gene-rna and|O K|gene-rna -|gene-rna ras|gene-rna mutations|O at|O codons|O 12|O and|O 13|O were|O investigated|O using|O oligonucleotide|O hybridization|O analysis|O after|O PCR|O amplification|O and|O subsequent|O sequence|O analysis|O of|O the|O amplified|O DNA|O from|O the|O region|O of|O interest|O in|O the|O following|O prostatic|O primary|O and|O metastatic|O (|O met|O )|O carcinoma|O -|O derived|O cell|O lines|O :|O 1013L|O (|O primary|O )|O ,|O PC3|O (|O bone|O met|O )|O ,|O DU145|O (|O brain|O met|O )|O ,|O and|O LNCaP|O (|O lymph|O node|O met|O )|O .|O 
We|O also|O examined|O fresh|O and|O archival|O primary|O and|O metastatic|O prostate|O tumor|O tissue|O and|O benign|O prostatic|O hypertrophy|O specimens|O .|O 
All|O prostatic|O cells|O and|O tissues|O examined|O contain|O at|O least|O one|O wild|O -|O type|O N|gene-rna -|gene-rna and|O K|gene-rna -|gene-rna ras|gene-rna allele|O with|O respect|O to|O codons|O 12|O and|O 13|O .|O 
No|O mutations|O were|O found|O at|O N-ras|gene-rna codon|O 13|O .|O 
The|O only|O mutation|O seen|O in|O the|O prostatic|O cell|O lines|O and|O tissues|O was|O a|O K-ras|gene-rna codon|O 12|O position|O II|O G|O -|O to|O -|O T|O transversion|O .|O 
Since|O these|O are|O established|O nonclonal|O cell|O lines|O that|O have|O adapted|O to|O tissue|O culture|O ,|O it|O is|O possible|O that|O this|O mutation|O does|O not|O represent|O the|O mutational|O state|O of|O prostatic|O carcinoma|O in|O vivo|O .|O 
However|O ,|O the|O lack|O of|O consistent|O mutation|O in|O the|O ras|gene-rna genes|O amplified|O directly|O from|O tumors|O suggests|O that|O when|O ras|gene-rna mutations|O occur|O during|O the|O progression|O of|O prostatic|O carcinoma|O ,|O they|O are|O late|O -|O stage|O events|O not|O directly|O involved|O in|O the|O initial|O development|O of|O disease|O .|O 
Immunoprecipitation|O studies|O using|O pan|gene-protein -|gene-protein ras|gene-protein antibodies|gene-protein revealed|O no|O evidence|O of|O altered|O expression|O of|O Ras|gene-protein proteins|O .|O 
Pattern|O of|O ras|gene-rna and|O gsp|gene-rna oncogene|O mutations|O in|O radiation|O -|O associated|O human|O thyroid|O tumors|O .|O 
The|O preferential|O activation|O of|O the|O Ki-ras|gene-rna oncogene|O in|O follicular|O radiation|O -|O associated|O human|O thyroid|O carcinomas|O ,|O has|O been|O suggested|O by|O Wright|O et|O al.|O (|O 1991|O )|O .|O 
However|O ,|O only|O 12|O thyroid|O tumors|O were|O analysed|O in|O this|O study|O .|O 
In|O order|O to|O confirm|O if|O radiation|O favours|O ,|O in|O human|O thyroid|O tumorigenesis|O ,|O the|O appearance|O of|O a|O particular|O molecular|O lesion|O ,|O we|O studied|O 33|O benign|O and|O malignant|O human|O radiation|O -|O associated|O thyroid|O tumors|O .|O 
We|O used|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O amplification|O and|O allele|O -|O specific|O hybridization|O with|O mutant|O -|O specific|O probes|O for|O the|O three|O ras|gene-rna genes|O and|O the|O gsp|gene-rna oncogene|O .|O 
Compared|O to|O 85|O '|O spontaneous|O '|O human|O thyroid|O tumors|O ,|O the|O radiation|O -|O associated|O cases|O :|O (1)|O show|O a|O similar|O overall|O frequency|O of|O ras|gene-rna and|O gsp|gene-rna mutations|O (|O about|O 30|O %|O and|O 6|O %|O respectively|O )|O ;|O (2)|O present|O a|O similar|O frequency|O of|O mutation|O of|O the|O three|O ras|gene-rna genes|O without|O any|O predominance|O in|O adenomas|O and|O papillary|O carcinomas|O and|O (3)|O all|O Ki-ras|gene-rna mutations|O were|O found|O in|O papillary|O carcinomas|O (|O 4|O /|O 15|O )|O .|O 
ras|gene-rna and|O gsp|gene-rna genes|O were|O never|O found|O mutated|O simultaneously|O ,|O suggesting|O an|O alternative|O role|O for|O both|O oncogenes|gene-rna in|O the|O thyroid|O tumorigenic|O radiation|O -|O associated|O process|O .|O 
Intratumor|O cellular|O heterogeneity|O and|O alterations|O in|O ras|gene-rna oncogene|O and|O p53|gene-rna tumor|O suppressor|O gene|O in|O human|O prostate|O carcinoma|O .|O 
To|O assess|O the|O potential|O role|O of|O ras|gene-rna oncogene|O activation|O and|O p53|gene-rna tumor|O suppressor|O gene|O mutations|O in|O the|O development|O of|O human|O prostate|O carcinoma|O ,|O nine|O cases|O of|O histologically|O heterogeneous|O prostate|O tumors|O obtained|O from|O total|O prostatectomies|O were|O probed|O for|O these|O specific|O events|O .|O 
Each|O tumor|O was|O divided|O into|O 5|O to|O 10|O areas|O according|O to|O different|O growth|O or|O histological|O patterns|O .|O 
Targeted|O DNA|O sequences|O coding|O for|O ras|gene-rna and|O p53|gene-rna were|O amplified|O by|O the|O polymerase|gene-protein chain|O reaction|O ,|O analyzed|O by|O single|O -|O strand|O conformational|O polymorphisms|O ,|O and|O confirmed|O by|O direct|O DNA|O sequencing|O .|O 
Point|O mutations|O of|O the|O ras|gene-rna gene|O were|O found|O in|O three|O of|O the|O nine|O tumors|O .|O 
Two|O contained|O K-ras|gene-rna codon|O 13|O and|O H-ras|gene-rna codon|O 61|O mutations|O ,|O found|O in|O only|O one|O and|O three|O areas|O of|O each|O lesion|O ,|O respectively|O .|O 
The|O third|O tumor|O contained|O two|O different|O point|O mutations|O in|O K-ras|gene-rna codons|O 13|O and|O 61|O in|O different|O foci|O of|O the|O sample|O .|O 
Loss|O of|O heterozygosity|O at|O the|O polymorphic|O codon|O 72|O in|O the|O p53|gene-rna gene|O was|O detected|O in|O two|O of|O four|O informative|O cases|O (|O 50|O %|O )|O showing|O fragment|O cleavage|O by|O restriction|O fragment|O length|O polymorphism|O analysis|O .|O 
Mutations|O in|O p53|gene-rna ,|O missense|O transversions|O ,|O single|O base|O insertions|O ,|O and|O two|O base|O deletions|O were|O also|O detected|O in|O three|O tumors|O .|O 
The|O present|O results|O reveal|O mutated|O ras|gene-rna and|O p53|gene-rna occasionally|O occurring|O in|O small|O foci|O of|O the|O tumor|O and|O that|O genetic|O mutations|O in|O p53|gene-rna ,|O as|O opposed|O to|O those|O in|O ras|gene-rna ,|O are|O more|O closely|O associated|O with|O invasive|O growth|O of|O heterogeneous|O prostate|O carcinoma|O .|O 
N|gene-rna -|gene-rna and|O K|gene-rna RAS|gene-rna mutations|O in|O primary|O testicular|O germ|O cell|O tumors|O :|O incidence|O and|O possible|O biological|O implications|O .|O 
Recently|O ,|O conflicting|O results|O have|O been|O reported|O on|O the|O incidence|O of|O RAS|gene-rna mutations|O in|O primary|O testicular|O germ|O cell|O tumors|O of|O adults|O (|O TGCTs|O )|O .|O 
In|O four|O studies|O a|O low|O incidence|O of|O mutations|O (|O less|O than|O 15|O %|O )|O in|O a|O variety|O of|O TGCTs|O or|O derived|O cell|O lines|O was|O found|O ,|O whereas|O in|O two|O other|O studies|O a|O high|O incidence|O of|O N|gene-rna -|gene-rna or|O K|gene-rna RAS|gene-rna mutations|O (|O over|O 40|O %|O )|O was|O shown|O .|O 
A|O total|O of|O 62|O testicular|O seminomas|O (|O SE|O )|O and|O 34|O nonseminomatous|O TGCTs|O (|O NS|O )|O were|O studied|O thus|O far|O .|O 
The|O largest|O series|O consisted|O of|O 42|O TGCTs|O ,|O studied|O on|O paraffin|O embedded|O tissue|O .|O 
We|O present|O the|O results|O of|O analysis|O for|O the|O presence|O of|O N|gene-rna -|gene-rna and|O K|gene-rna RAS|gene-rna mutations|O ,|O in|O codons|O 12|O ,|O 13|O ,|O and|O 61|O ,|O in|O snap|O frozen|O samples|O of|O 100|O primary|O TGCTs|O ,|O comprising|O 40|O SE|O and|O 60|O NS|O .|O 
Using|O the|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O and|O allele|O specific|O oligonucleotide|O hybridization|O (|O ASO|O )|O ,|O mutations|O were|O found|O in|O five|O SE|O (|O three|O in|O NRAS|gene-rna and|O two|O in|O KRAS|gene-rna ,|O all|O codon|O 12|O )|O ,|O and|O in|O one|O NS|O (|O KRAS|gene-rna ,|O codon|O 12|O )|O .|O 
To|O exclude|O underestimation|O of|O the|O incidence|O of|O RAS|gene-rna mutations|O in|O TGCTs|O due|O to|O the|O presence|O of|O an|O excess|O of|O wild|O type|O alleles|O in|O the|O analyzed|O sample|O ,|O a|O PCR|O technique|O preferentially|O amplifying|O KRAS|gene-rna alleles|O with|O a|O mutation|O in|O codon|O 12|O was|O applied|O to|O all|O SE|O .|O 
This|O approach|O ,|O allowing|O a|O 250|O times|O more|O sensitive|O assay|O ,|O resulted|O in|O the|O detection|O of|O only|O one|O additional|O SE|O with|O a|O mutation|O .|O 
Based|O on|O a|O critical|O analysis|O of|O published|O data|O and|O on|O our|O results|O from|O the|O largest|O series|O of|O frozen|O samples|O investigated|O thus|O far|O ,|O we|O conclude|O that|O N|gene-rna -|gene-rna or|O K|gene-rna RAS|gene-rna mutations|O are|O rare|O and|O apparently|O not|O essential|O for|O initiation|O or|O progression|O of|O TGCTs|O .|O 
Correlation|O of|O cytogenetic|O results|O with|O immunophenotype|O ,|O genotype|O ,|O clinical|O features|O ,|O and|O ras|gene-rna mutation|O in|O acute|O myeloid|O leukemia|O .|O 
A|O study|O of|O 235|O Chinese|O patients|O in|O Taiwan|O .|O 
Of|O 235|O consecutive|O patients|O with|O de|O novo|O acute|O myeloid|O leukemia|O (|O AML|O )|O ,|O clonal|O chromosomal|O abnormalities|O were|O detected|O in|O 151|O (|O 64|O %|O )|O of|O them|O .|O 
Twenty-four|O of|O the|O 71|O patients|O with|O M2|O AML|O had|O t|O (|O 8|O ;|O 21|O )|O ,|O 35|O of|O the|O 36|O M3|O patients|O had|O t|O (|O 15|O ;|O 17|O )|O ,|O and|O 11|O of|O the|O 45|O M4|O leukemia|O disclosed|O inv|O (|O 16|O )|O .|O 
Six|O of|O the|O eight|O patients|O with|O 11|O q|O 23|O abnormality|O had|O M4|O or|O M5|O subtype|O of|O leukemia|O .|O 
The|O incidence|O of|O t|O (|O 15|O ;|O 17|O )|O and|O t|O (|O 8|O ;|O 21|O )|O was|O higher|O in|O our|O patients|O than|O in|O patients|O from|O most|O Western|O countries|O .|O 
Immunophenotyping|O was|O performed|O on|O 197|O patients|O .|O 
Patients|O with|O t|O (|O 15|O ;|O 17|O )|O were|O associated|O with|O negativity|O to|O HLA|gene-protein -|gene-protein DR|gene-protein ,|O CD11b|gene-protein ,|O and|O CD34|gene-protein .|O 
Patients|O with|O t|O (|O 8|O ;|O 21|O )|O expressed|O CD13|gene-protein and|O CD33|gene-protein less|O frequently|O than|O other|O patients|O ,|O but|O all|O showed|O CD15|gene-protein positivity|O .|O 
Coexpression|O of|O lymphoid|gene-protein -|gene-protein associated|gene-protein antigens|gene-protein on|O the|O leukemic|O blasts|O was|O detected|O in|O 52|O patients|O (|O 26|O %|O )|O ,|O including|O all|O 7|O patients|O with|O t|O (|O 9|O ;|O 22|O )|O ,|O 3|O of|O the|O 8|O patients|O with|O t|O /|O del|O (|O 11|O )|O (|O q23|O )|O ,|O 2|O of|O the|O 25|O patients|O with|O t|O (|O 15|O ;|O 17|O )|O ,|O and|O 2|O of|O the|O 22|O patients|O with|O t|O (|O 8|O ;|O 21|O )|O .|O 
Seven|O (|O 35|O %|O )|O of|O the|O 20|O patients|O coexpressing|O lymphoid|O markers|O showed|O immunoglobulin|gene-rna heavy|gene-rna chain|gene-rna or|O T-cell|gene-rna receptor|gene-rna beta|gene-rna -|gene-rna chain|gene-rna gene|O rearrangements|O ,|O while|O only|O 2|O (|O 4|O %|O )|O of|O the|O 53|O patients|O without|O lymphoid|gene-protein antigen|gene-protein expression|O did|O so|O .|O 
Patients|O with|O inv|O (|O 16|O )|O ,|O t|O (|O 8|O ;|O 21|O )|O ,|O and|O t|O (|O 15|O ;|O 17|O )|O had|O a|O better|O prognosis|O than|O other|O patients|O .|O 
Of|O all|O surface|O antigens|O tested|O ,|O only|O CD15|gene-protein ,|O CD11b|gene-protein ,|O and|O HLA|gene-protein -|gene-protein DR|gene-protein were|O of|O prognostic|O value|O :|O CD15|gene-protein with|O a|O higher|O complete|O remission|O (|O CR|O )|O rate|O and|O CD11b|gene-protein or|O HLA|gene-protein -|gene-protein DR|gene-protein with|O a|O shorter|O CR|O duration|O .|O 
N-ras|gene-rna mutations|O were|O detected|O in|O 7|O (|O 18|O %|O )|O of|O the|O 40|O patients|O in|O the|O study|O ,|O including|O two|O of|O the|O three|O patients|O with|O inv|O (|O 16|O )|O .|O 
This|O study|O demonstrated|O differences|O in|O clinical|O features|O ,|O immunophenotypes|O ,|O and|O genotypes|O among|O different|O cytogenetic|O subgroups|O .|O 
Analysis|O of|O ras|gene-rna oncogenes|O in|O malignant|O melanoma|O and|O precursor|O lesions|O :|O correlation|O of|O point|O mutations|O with|O differentiation|O phenotype|O .|O 
This|O study|O examined|O noncultured|O and|O cultured|O melanomas|O and|O related|O precursor|O specimens|O for|O (i)|O mutated|O ras|gene-rna genes|O using|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O methodology|O ,|O (ii)|O correlation|O of|O mutated|O ras|gene-rna genes|O with|O differentiation|O related|O phenotypic|O characteristics|O ,|O (iii)|O expression|O of|O ras|gene-rna -|gene-protein encoded|gene-protein p21|gene-protein proteins|O in|O tissues|O by|O immunoperoxidase|gene-protein analysis|O ,|O (iv)|O quantitative|O expression|O of|O mutated|O and|O wild|O -|O type|O ras|gene-rna encoded|gene-protein p21|gene-protein proteins|O by|O flow|O cytometry|O ,|O and|O (v)|O correlation|O between|O p21|gene-protein expression|O ,|O the|O occurrence|O of|O ras|gene-rna mutations|O ,|O and|O cell|O cycle|O kinetics|O .|O 
The|O results|O of|O these|O studies|O are|O (1)|O 24|O %|O of|O cultured|O malignant|O melanomas|O have|O activated|O ras|gene-rna genes|O ,|O with|O N-ras|gene-rna being|O activated|O ten|O times|O as|O frequently|O as|O Harvey|gene-rna (|gene-rna Ha|gene-rna )|gene-rna -|gene-rna ras|gene-rna .|O 
Each|O example|O of|O an|O activated|O ras|gene-rna gene|O showed|O a|O mutation|O at|O the|O 61st|O codon|O of|O the|O protein|gene-protein ,|O with|O the|O exception|O of|O one|O melanoma|O which|O showed|O a|O mutation|O at|O codon|O 13|O of|O the|O N-ras|gene-rna gene|O ;|O (2)|O all|O the|O melanomas|O displaying|O an|O activated|O ras|gene-rna gene|O had|O a|O similar|O cell|O surface|O phenotype|O and|O appear|O to|O come|O from|O a|O similar|O phase|O of|O differentiation|O ;|O (3)|O 5|O -|O 6|O %|O of|O noncultured|O primary|O and|O metastatic|O melanomas|O have|O mutated|O ras|gene-rna genes|O ;|O (4)|O no|O ras|gene-rna gene|O mutations|O were|O found|O in|O any|O precursor|O lesion|O ,|O specifically|O normal|O nevi|O and|O dysplastic|O nevi|O ;|O (5)|O immunoperoxidase|gene-protein analysis|O of|O paraffin|O -|O embedded|O specimens|O indicated|O no|O quantitative|O or|O qualitative|O alterations|O in|O p21|gene-protein expression|O that|O correlate|O with|O tumor|O progression|O ;|O (6)|O there|O were|O no|O observable|O differences|O in|O p21|gene-protein expression|O between|O melanoma|O cells|O growing|O exponentially|O or|O in|O plateau|O phase|O ,|O or|O between|O melanoma|O cells|O with|O or|O without|O ras|gene-rna mutations|O ;|O nor|O were|O any|O cell|O kinetic|O differences|O found|O between|O cells|O with|O and|O without|O mutated|O ras|gene-rna genes|O .|O 
These|O studies|O suggest|O that|O the|O role|O of|O ras|gene-rna mutations|O may|O be|O limited|O to|O an|O indirect|O involvement|O in|O the|O transformation|O of|O a|O subset|O of|O melanomas|O .|O 
Activated|O ras|gene-rna genes|O in|O human|O seminoma|O :|O evidence|O for|O tumor|O heterogeneity|O .|O 
The|O incidence|O of|O mutations|O in|O cellular|O ras|gene-rna genes|O was|O determined|O in|O human|O seminoma|O ,|O a|O germ|O cell|O tumor|O of|O the|O testis|O ,|O with|O the|O aid|O of|O specific|O oligonucleotide|O probe|O hybridization|O .|O 
To|O eliminate|O the|O large|O number|O of|O nonneoplastic|O cells|O present|O in|O seminomas|O ,|O aneuploid|O tumor|O cell|O nuclei|O were|O isolated|O from|O the|O tumor|O tissue|O by|O flow|O sorting|O .|O 
Mutations|O were|O detected|O in|O 40|O %|O of|O the|O seminomas|O at|O codons|O 12|O or|O 61|O of|O either|O the|O Ki-ras|gene-rna or|O the|O N-ras|gene-rna gene|O .|O 
No|O correlation|O was|O found|O with|O histopathological|O or|O clinical|O features|O .|O 
In|O some|O seminomas|O the|O mutant|O gene|O was|O present|O in|O only|O a|O fraction|O of|O the|O tumor|O cell|O population|O ,|O suggesting|O tumor|O heterogeneity|O for|O ras|gene-rna gene|O mutations|O .|O 
Yet|O ,|O flow|O cytometric|O measurement|O of|O nuclear|O DNA|O contents|O and|O histological|O examination|O of|O tumor|O tissue|O did|O not|O reveal|O two|O different|O tumor|O cell|O populations|O .|O 
We|O conclude|O from|O these|O observations|O that|O ras|gene-rna mutation|O is|O probably|O not|O the|O initial|O genetic|O event|O in|O the|O development|O of|O seminoma|O .|O 
Analysis|O of|O ras|gene-rna gene|O mutations|O and|O methylation|O state|O in|O human|O leukemias|O .|O 
We|O have|O screened|O a|O large|O series|O of|O primary|O human|O leukemias|O for|O activating|O point|O mutations|O at|O codons|O 12|O ,|O 13|O and|O 61|O of|O the|O N-ras|gene-rna and|O K-ras|gene-rna proto|O -|O oncogenes|O and|O at|O codons|O 12|O and|O 61|O of|O the|O H-ras|gene-rna proto|O -|O oncogene|O by|O using|O panels|O of|O oligonucleotide|O probes|O in|O conjunction|O with|O polymerase|gene-protein chain|O reaction|O gene|O amplification|O .|O 
13|O of|O 64|O (|O 20|O %|O )|O acute|O lymphoblastic|O leukemia|O cases|O had|O ras|gene-rna gene|O mutations|O mostly|O involving|O N-ras|gene-rna codon|O 12|O /|O 13|O ,|O G|O -|O A|O (|O gly|O -|O asp|O )|O transitions|O .|O 
Consistent|O with|O previous|O studies|O ,|O a|O comparable|O pattern|O and|O frequency|O of|O ras|gene-rna mutation|O was|O found|O amongst|O 45|O cases|O of|O acute|O myeloid|O leukemia|O and|O myelodysplasia|O .|O 
By|O contrast|O ,|O of|O 30|O cases|O of|O mature|O B|O cell|O chronic|O lymphocytic|O leukemia|O ,|O only|O one|O in|O terminal|O prolymphocytoid|O transformation|O harboured|O an|O activated|O ras|gene-rna gene|O .|O 
These|O patterns|O of|O mutation|O did|O not|O correlate|O with|O ras|gene-rna gene|O methylation|O state|O ,|O a|O finding|O not|O obviously|O compatible|O with|O differential|O gene|O accessibility|O being|O an|O important|O determinant|O of|O ras|gene-rna gene|O mutation|O patterns|O in|O leukemogenesis|O .|O 
Our|O data|O suggest|O that|O activated|O ras|gene-rna is|O more|O important|O in|O tumourigenesis|O of|O immature|O than|O mature|O lymphocyte|O progenitors|O whilst|O similar|O mechanisms|O associated|O with|O aetiology|O and/or|O target|O cell|O susceptibility|O probably|O underlie|O the|O similar|O patterns|O of|O ras|gene-rna gene|O mutations|O seen|O in|O acute|O leukemias|O of|O both|O myeloid|O and|O lymphoid|O cell|O lineages|O .|O 
Ras|gene-rna oncogene|O mutations|O are|O rare|O late|O stage|O events|O in|O chronic|O myelogenous|O leukemia|O .|O 
DNA|O from|O bone|O marrow|O and|O peripheral|O blood|O samples|O of|O 44|O chronic|O myelogenous|O leukemia|O (|O CML|O )|O patients|O were|O analyzed|O for|O the|O presence|O of|O mutations|O of|O codons|O 12|O ,|O 13|O or|O 61|O of|O the|O N-ras|gene-rna ,|O H-ras|gene-rna ,|O or|O K-ras|gene-rna genes|O .|O 
In|O seven|O patients|O ,|O samples|O were|O available|O from|O both|O their|O chronic|O phase|O and|O blast|O crisis|O .|O 
A|O total|O of|O 29|O samples|O examined|O were|O at|O chronic|O phase|O and|O 22|O were|O at|O blast|O crisis|O (|O eight|O lymphoid|O ,|O eight|O myeloid|O ,|O and|O six|O undifferentiated|O )|O .|O 
No|O mutations|O were|O identified|O in|O N-ras|gene-rna or|O H-ras|gene-rna .|O 
Two|O patients|O in|O myeloid|O blast|O crisis|O had|O K-ras|gene-rna mutations|O ,|O one|O patient|O at|O codon|O 12|O ,|O the|O other|O at|O codon|O 13|O .|O 
In|O the|O former|O patient|O the|O mutation|O was|O not|O present|O and|O the|O latter|O patient|O was|O not|O tested|O in|O chronic|O phase|O .|O 
Our|O findings|O indicate|O ras|gene-rna mutations|O are|O an|O infrequent|O late|O stage|O event|O in|O CML|O that|O occur|O in|O myeloid|O blast|O crisis|O .|O 
Allele|O loss|O on|O chromosome|O 10|O and|O point|O mutation|O of|O ras|gene-rna oncogenes|O are|O infrequent|O in|O tumors|O of|O MEN|gene-rna 2A|gene-rna .|O 
The|O multiple|gene-rna endocrine|gene-rna neoplasia|gene-rna type|gene-rna 2A|gene-rna (|O MEN|gene-rna 2A|gene-rna )|O gene|O has|O been|O mapped|O to|O the|O centromeric|O region|O of|O chromosome|O 10|O by|O linkage|O analysis|O .|O 
We|O examined|O 36|O medullary|O thyroid|O carcinomas|O (|O MTCs|O )|O (|O 16|O hereditary|O and|O 20|O sporadic|O )|O and|O ten|O pheochromocytomas|O (|O eight|O hereditary|O and|O two|O sporadic|O )|O to|O detect|O loss|O of|O alleles|O on|O chromosome|O 10|O using|O seven|O polymorphic|O DNA|O markers|O mapped|O to|O this|O chromosome|O .|O 
Of|O 20|O informative|O cases|O ,|O only|O one|O (|O 5|O %|O )|O sporadic|O MTC|O showed|O loss|O of|O heterozygosity|O at|O the|O locus|O RBP3|O .|O 
Allele|O loss|O at|O the|O RBP3|O locus|O was|O not|O found|O in|O pheochromocytomas|O from|O six|O heterozygotes|O .|O 
All|O tumors|O retained|O constitutional|O heterozygosity|O at|O six|O other|O loci|O on|O chromosome|O 10|O (|O D10S17|O ,|O D10S34|O ,|O D10S24|O on|O the|O short|O arm|O ,|O D10S15|O in|O the|O pericentromeric|O region|O ,|O D10S20|O ,|O and|O D10S4|O on|O the|O long|O arm|O )|O .|O 
Our|O findings|O suggest|O that|O the|O second|O hit|O for|O tumorigenesis|O in|O MEN|gene-rna 2A|gene-rna may|O not|O be|O loss|O of|O function|O of|O the|O normal|O allele|O at|O the|O homologous|O locus|O on|O the|O other|O copy|O of|O chromosome|O 10|O .|O 
Mutated|O ras|gene-rna oncogene|O was|O found|O only|O in|O one|O of|O 18|O MTCs|O at|O the|O codon|O 61|O of|O H-ras|gene-rna .|O 
Low|O incidence|O of|O point|O mutation|O of|O c-Ki-ras|gene-rna and|O N-ras|gene-rna oncogenes|O in|O human|O hepatocellular|O carcinoma|O .|O 
We|O examined|O the|O incidence|O of|O point|O mutation|O in|O codons|O 12|O ,|O 13|O and|O 61|O of|O c-Ki-ras|gene-rna and|O N-ras|gene-rna genes|O in|O human|O hepatocellular|O carcinoma|O (|O HCC|O )|O using|O the|O polymerase|gene-protein chain|O reaction|O and|O oligonucleotide|O hybridization|O techniques|O .|O 
Among|O 34|O tissues|O specimens|O surgically|O resected|O from|O 30|O patients|O and|O 5|O cell|O lines|O of|O human|O HCC|O ,|O only|O two|O had|O ras|gene-rna point|O mutations|O ;|O in|O one|O case|O ,|O codon|O 12|O of|O c-Ki-ras|gene-rna was|O altered|O from|O GGT|O ,|O coding|O glycine|O ,|O to|O GTT|O ,|O coding|O valine|O ;|O in|O the|O other|O case|O ,|O codon|O 61|O of|O N-ras|gene-rna was|O altered|O from|O CAA|O ,|O coding|O glutamine|O ,|O to|O AAA|O ,|O coding|O lysine|O .|O 
Thus|O ,|O point|O -|O mutational|O activation|O of|O ras|gene-rna oncogenes|O is|O an|O uncommon|O event|O in|O human|O HCC|O .|O 
Hypereosinophilic|O syndrome|O with|O evolution|O to|O myeloproliferative|O disorder|O :|O temporal|O relationship|O to|O loss|O of|O Y|O chromosome|O and|O c-N-ras|gene-rna activation|O .|O 
A|O case|O of|O hypereosinophilic|O syndrome|O is|O presented|O in|O which|O the|O patient|O was|O serially|O observed|O for|O 4|O years|O .|O 
Transformation|O to|O a|O disorder|O resembling|O chronic|O myeloid|O leukemic|O (|O CML|O )|O occurred|O 36|O months|O after|O diagnosis|O ;|O at|O 42|O months|O ,|O blastic|O transformation|O and|O marrow|O failure|O ensued|O ,|O leading|O to|O death|O .|O 
Marrow|O examination|O for|O histopathologic|O ,|O cytogenetic|O ,|O and|O molecular|O biologic|O analyses|O were|O performed|O during|O the|O eosinophilic|O ,|O myeloproliferative|O ,|O and|O blastic|O stages|O .|O 
These|O demonstrated|O ras|gene-rna activation|O by|O virtue|O of|O a|O codon|O 12|O G|O to|O C|O transversion|O mutation|O ,|O predicting|O for|O substitution|O of|O glycine|O by|O alanine|O ;|O in|O addition|O ,|O we|O observed|O Y|O chromosome|O loss|O late|O in|O the|O natural|O history|O of|O this|O illness|O ,|O suggesting|O that|O these|O genetic|O lesions|O can|O play|O a|O role|O in|O the|O profound|O loss|O of|O myeloid|O differentiation|O characteristic|O of|O the|O accelerated|O phase|O commonly|O observed|O in|O myeloproliferative|O syndromes|O .|O 
N-ras|gene-rna mutations|O in|O adult|O de|O novo|O acute|O myelogenous|O leukemia|O :|O prevalence|O and|O clinical|O significance|O .|O 
Point|O mutations|O of|O the|O N-ras|gene-rna proto|O -|O oncogenes|O have|O been|O previously|O detected|O in|O 20|O %|O to|O 60|O %|O of|O samples|O of|O acute|O myelogenous|O leukemia|O (|O AML|O )|O ,|O but|O the|O clinical|O significance|O of|O these|O mutations|O is|O presently|O unclear|O .|O 
We|O directly|O sequenced|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O amplified|O N-ras|gene-rna fragments|O to|O determine|O the|O frequency|O of|O N-ras|gene-rna point|O mutations|O in|O 55|O adult|O patients|O with|O de|O novo|O AML|O .|O 
Mutations|O were|O present|O in|O 8|O of|O 55|O (|O 15|O %|O )|O patients|O .|O 
These|O mutations|O were|O usually|O in|O codon|O 12|O ,|O 13|O ,|O or|O 61|O ,|O but|O one|O patient|O had|O mutations|O in|O both|O codons|O 13|O and|O 61|O ,|O and|O another|O had|O an|O unusual|O point|O mutation|O in|O N-ras|gene-rna codon|O 60|O .|O 
A|O comparison|O of|O patients|O with|O and|O without|O N-ras|gene-rna mutations|O showed|O no|O statistically|O significant|O differences|O in|O pretreatment|O clinical|O variables|O ,|O response|O to|O induction|O therapy|O ,|O or|O survival|O ,|O except|O for|O a|O possibly|O higher|O percentage|O of|O FAB|O M4|O subtypes|O in|O patients|O with|O the|O N-ras|gene-rna mutation|O .|O 
These|O data|O together|O with|O previous|O reports|O suggest|O that|O the|O presence|O of|O N-ras|gene-rna point|O mutations|O do|O not|O clearly|O define|O a|O unique|O clinical|O or|O biologic|O subset|O of|O AML|O patients|O .|O 
Infrequent|O point|O mutations|O of|O ras|gene-rna oncogenes|O in|O gastric|O cancers|O .|O 
Adenocarcinomas|O of|O the|O proximal|O and|O distal|O stomach|O have|O significant|O clinical|O and|O biological|O differences|O .|O 
A|O study|O was|O undertaken|O to|O determine|O if|O a|O difference|O in|O the|O incidence|O of|O mutated|O ras|gene-rna oncogenes|O exists|O between|O proximal|O (|O gastroesophageal|O junction|O or|O cardia|O )|O and|O distal|O (|O body|O or|O antrum|O )|O gastric|O tumors|O ,|O and|O to|O assess|O the|O overall|O incidence|O in|O gastric|O cancers|O from|O non|O -|O Asian|O patients|O .|O 
Deoxyribonucleic|O acid|O from|O 28|O primary|O gastric|O adenocarcinomas|O were|O analyzed|O for|O point|O mutations|O in|O codons|O 12|O ,|O 13|O ,|O and|O 61|O of|O the|O Ha-ras|gene-rna ,|O Ki-ras|gene-rna ,|O and|O N-ras|gene-rna protooncogenes|O using|O polymerase|gene-protein -|O catalyzed|O chain|O reaction|O methodology|O .|O 
Twelve|O tumors|O were|O located|O at|O the|O gastroesophageal|O junction|O or|O cardia|O ,|O and|O 16|O in|O the|O body|O or|O antrum|O .|O 
Mutated|O ras|gene-rna genes|O were|O detected|O in|O 2|O of|O 28|O tumors|O for|O an|O overall|O incidence|O of|O 7|O %|O .|O 
The|O mutations|O occurred|O in|O codon|O 61|O of|O the|O N-ras|gene-rna gene|O in|O a|O proximal|O gastric|O cancer|O and|O in|O codon|O 12|O of|O the|O Ki-ras|gene-rna gene|O in|O a|O distal|O gastric|O cancer|O .|O 
These|O data|O indicate|O that|O mutations|O in|O ras|gene-rna genes|O are|O an|O uncommon|O event|O in|O primary|O gastric|O cancers|O and|O that|O there|O is|O no|O meaningful|O difference|O in|O the|O incidence|O of|O ras|gene-rna mutations|O in|O proximal|O and|O distal|O stomach|O cancers|O .|O 
Characterization|O of|O a|O transforming|O N-ras|gene-rna gene|O in|O the|O human|O hepatoma|O cell|O line|O Hep|O G2|O :|O additional|O evidence|O for|O the|O importance|O of|O c-myc|gene-rna and|O ras|gene-rna cooperation|O in|O hepatocarcinogenesis|O .|O 
The|O expression|O of|O the|O c-myc|gene-rna gene|O has|O previously|O been|O shown|O to|O be|O elevated|O and|O deregulated|O in|O the|O human|O hepatoma|O cell|O line|O Hep|O G2|O (|O B.|O E.|O Huber|O and|O S.|O S.|O Thorgeirsson|O ,|O Cancer|O Res.|O ,|O 47|O :|O 3414|O -|O 3420|O ,|O 1987|O )|O .|O 
We|O now|O report|O that|O the|O Hep|O G2|O N-ras|gene-rna gene|O is|O activated|O to|O a|O dominant|O -|O acting|O ,|O transforming|O gene|O by|O a|O missense|O mutation|O in|O codon|O 61|O .|O 
Hep|O G2|O DNA|O produced|O transformed|O foci|O when|O transfected|O into|O NIH|O 3T3|O cells|O .|O 
Subsequent|O to|O a|O secondary|O round|O of|O transfection|O ,|O Southern|O blot|O analysis|O of|O tumorigenic|O NIH|O 3T3|O foci|O demonstrated|O the|O presence|O of|O human|O N-ras|gene-rna sequences|O .|O 
Nucleotide|O sequence|O analysis|O of|O one|O Hep|O G2|O N-ras|O allele|O demonstrated|O that|O codons|O 12|O ,|O 13|O ,|O and|O 59|O were|O normal|O and|O that|O codon|O 61|O had|O a|O missense|O mutation|O (|O CAA|O to|O CTA|O )|O .|O 
This|O mutation|O results|O in|O the|O incorporation|O of|O leucine|O instead|O of|O glutamine|O at|O residue|O 61|O of|O the|O N-ras|gene-rna gene|O product|O ,|O p21|gene-protein .|O 
N-ras|gene-rna sequences|O were|O amplified|O by|O the|O polymerase|gene-protein chain|O reaction|O from|O both|O Hep|O G2|O genomic|O DNA|O and|O Hep|O G2|O complementary|O DNA|O .|O 
Analysis|O of|O the|O amplified|O sequences|O demonstrated|O that|O only|O one|O Hep|O G2|O N-ras|gene-rna allele|O exhibited|O the|O codon|O 61|O mutation|O and|O that|O both|O the|O mutant|O and|O normal|O alleles|O were|O transcribed|O .|O 
Northern|O blot|O analysis|O demonstrated|O equivalent|O steady|O -|O state|O levels|O of|O N-ras|gene-rna transcripts|gene-rna in|O Hep|O G2|O cells|O and|O normal|O human|O liver|O .|O 
The|O steady|O -|O state|O levels|O of|O N-ras|gene-rna and|O ornithine|gene-rna decarboxylase|gene-rna transcripts|gene-rna were|O positively|O correlated|O suggesting|O a|O positive|O relationship|O between|O N-ras|gene-rna expression|O and|O the|O replication|O rate|O of|O Hep|O G2|O cells|O .|O 
c-Ki-ras|gene-rna and|O c-Ha-ras|gene-rna transcripts|gene-rna were|O not|O detected|O in|O either|O Hep|O G2|O cells|O or|O normal|O human|O liver|O .|O 
Immunoprecipitation|O experiments|O using|O the|O monoclonal|gene-protein antibody|gene-protein Y13-259|gene-protein demonstrated|O the|O presence|O of|O p21|gene-protein in|O Hep|O G2|O cells|O .|O 
Expression|O of|O a|O dominant|O -|O acting|O ,|O transforming|O N-ras|gene-rna gene|O ,|O in|O conjunction|O with|O the|O altered|O regulation|O of|O the|O c-myc|gene-rna gene|O ,|O documents|O two|O important|O genetic|O lesions|O that|O could|O be|O responsible|O for|O the|O transformed|O phenotype|O of|O Hep|O G2|O cells|O .|O 
Analysis|O of|O ras|gene-rna gene|O mutations|O in|O childhood|O myeloid|O leukaemia|O .|O 
Previous|O studies|O have|O shown|O that|O approximately|O 30|O %|O of|O adult|O acute|O myeloid|O leukaemias|O and|O 20|O %|O of|O adult|O acute|O lymphoid|O leukaemias|O contain|O point|O mutated|O ras|gene-rna oncogenes|O .|O 
In|O order|O to|O assess|O whether|O ras|gene-rna oncogenes|O are|O also|O involved|O in|O childhood|O leukaemias|O ,|O we|O have|O used|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O amplification|O and|O synthetic|O oligonucleotide|O probes|O to|O study|O the|O nature|O and|O frequency|O of|O ras|gene-rna gene|O mutations|O in|O childhood|O leukaemias|O ,|O concentrating|O largely|O on|O the|O acute|O myeloid|O leukaemias|O (|O AML|O )|O .|O 
Thirty-four|O childhood|O presentation|O AML|O DNAs|O were|O screened|O for|O mutations|O in|O and|O around|O codons|O 12|O ,|O 61|O and|O 117|O of|O N|gene-rna -|gene-rna ,|O K|gene-rna -|gene-rna and|O H|gene-rna -|gene-rna ras|gene-rna .|O 
Eight|O of|O these|O samples|O (|O 24|O %|O )|O contained|O ras|gene-rna mutations|O .|O 
As|O in|O the|O adult|O disease|O ,|O the|O gene|O predominantly|O involved|O was|O N-ras|gene-rna (|O 6|O /|O 8|O )|O ,|O with|O occasional|O activation|O of|O K-ras|gene-rna (|O 2|O /|O 6|O )|O .|O 
The|O most|O common|O base|O change|O was|O a|O G|O ----|O A|O transition|O at|O codon|O 12|O or|O 13|O (|O 4|O /|O 8|O )|O .|O 
Of|O the|O patients|O with|O mutant|O ras|gene-rna ,|O 4|O /|O 8|O were|O diagnosed|O as|O AML|O FAB|O subtype|O M5|O .|O 
Five|O of|O the|O 34|O childhood|O AMLs|O analysed|O displayed|O abnormalities|O of|O chromosome|O 7|O .|O 
However|O ,|O none|O of|O these|O cases|O contained|O a|O mutant|O ras|gene-rna gene|O .|O 
One|O AML|O patient|O was|O studied|O at|O relapse|O ,|O 14|O months|O after|O initial|O presentation|O .|O 
The|O presentation|O mutation|O (|O N|gene-rna 61|O p3|gene-protein )|O was|O not|O detectable|O ,|O although|O a|O new|O mutation|O (|O N|gene-rna 13|O Cys|O )|O was|O readily|O identified|O .|O 
This|O observation|O extends|O our|O original|O finding|O with|O presentation|O and|O relapse|O samples|O of|O adult|O AML|O ,|O in|O which|O it|O was|O uncommon|O for|O the|O relapse|O sample|O to|O contain|O the|O same|O ras|gene-rna mutation|O as|O the|O presentation|O DNA|O .|O 
In|O addition|O ,|O two|O out|O of|O five|O patients|O diagnosed|O as|O juvenile|O CML|O ,|O were|O found|O to|O harbour|O mutant|O ras|gene-rna .|O 
Radiation|O -|O associated|O and|O '|O spontaneous|O '|O human|O thyroid|O carcinomas|O show|O a|O different|O pattern|O of|O ras|gene-rna oncogene|O mutation|O .|O 
Activated|O ras|gene-rna oncogenes|O in|O experimentally|O induced|O rodent|O tumours|O have|O been|O demonstrated|O to|O show|O specific|O patterns|O of|O oncogene|O activation|O which|O depend|O on|O the|O inducing|O agent|O ,|O with|O H-ras|gene-rna activation|O in|O nitrosomethylurea|O (|O NMU|O )|O induced|O tumours|O ,|O and|O K-ras|gene-rna activation|O in|O tumours|O induced|O by|O ionising|O radiation|O .|O 
We|O report|O a|O study|O of|O 12|O radiation|O -|O associated|O human|O thyroid|O tumours|O ,|O using|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O amplification|O of|O paraffin|O -|O embedded|O material|O and|O allele|O -|O specific|O hybridisation|O with|O mutant|O -|O specific|O probes|O for|O the|O 3|O ras|gene-rna oncogenes|O .|O 
Compared|O to|O 68|O '|O spontaneous|O '|O human|O thyroid|O tumours|O ,|O the|O radiation|O -|O associated|O cases|O show|O the|O same|O overall|O prevalence|O of|O ras|gene-rna mutation|O .|O 
However|O there|O is|O a|O significantly|O higher|O rate|O of|O K-ras|gene-rna mutation|O in|O radiation|O -|O associated|O follicular|O carcinomas|O than|O in|O '|O spontaneous|O '|O follicular|O carcinomas|O (|O 60|O %|O compared|O to|O 6|O %|O ,|O P|O less|O than|O 0.05|O )|O ,|O suggesting|O that|O radiation|O may|O preferentially|O activate|O K-ras|gene-rna in|O human|O as|O well|O as|O rodent|O tumours|O .|O 
Low|O frequency|O of|O ras|gene-rna gene|O mutations|O in|O neuroblastomas|O ,|O pheochromocytomas|O ,|O and|O medullary|O thyroid|O cancers|O .|O 
Little|O is|O known|O about|O the|O prevalence|O and|O significance|O of|O ras|gene-rna gene|O activation|O in|O neural|O crest|O tumors|O such|O as|O neuroblastomas|O ,|O pheochromocytomas|O ,|O and|O medullary|O thyroid|O cancers|O (|O MTCs|O )|O .|O 
Therefore|O ,|O we|O analyzed|O DNA|O from|O 10|O human|O neuroblastoma|O cell|O lines|O and|O 10|O primary|O human|O pheochromocytomas|O for|O activating|O mutations|O in|O N-ras|gene-rna ,|O H-ras|gene-rna ,|O and|O K-ras|gene-rna .|O 
We|O also|O studied|O DNA|O from|O 24|O primary|O neuroblastomas|O and|O 10|O MTCs|O for|O N-ras|gene-rna mutations|O .|O 
ras|gene-rna genes|O were|O analyzed|O by|O direct|O sequencing|O of|O specific|O DNA|O fragments|O amplified|O by|O the|O polymerase|gene-protein chain|O reaction|O .|O 
With|O the|O exception|O of|O the|O SK-N-SH|O cell|O line|O ,|O the|O examined|O ras|gene-rna gene|O sequences|O were|O normal|O in|O all|O the|O neuroblastomas|O ,|O pheochromocytomas|O ,|O and|O MTCs|O tested|O .|O 
A|O single|O point|O mutation|O was|O identified|O at|O codon|O 59|O (|O GCT|O (|O ala|O )|O ----|O ACT|O (|O thr|O )|O )|O in|O one|O N-ras|gene-rna allele|O in|O an|O SK-N-SH|O subline|O .|O 
Interestingly|O ,|O this|O mutation|O is|O different|O from|O the|O activating|O codon|O 61|O mutation|O which|O resulted|O in|O the|O initial|O identification|O of|O N-ras|gene-rna from|O SK-N-SH|O DNA|O .|O 
Therefore|O ,|O we|O analyzed|O the|O sequences|O of|O earlier|O passages|O and|O sublines|O of|O the|O SK-N-SH|O cell|O line|O ,|O but|O mutations|O at|O codon|O 59|O or|O 61|O were|O not|O detected|O ,|O suggesting|O that|O neither|O mutation|O was|O present|O in|O the|O primary|O tumor|O .|O 
Our|O results|O indicate|O that|O N-ras|gene-rna mutations|O may|O occur|O spontaneously|O during|O in|O vitro|O passage|O of|O cell|O lines|O but|O rarely|O ,|O if|O ever|O ,|O occur|O in|O primary|O neuroblastomas|O ,|O pheochromocytomas|O ,|O and|O MTCs|O .|O 
In|O addition|O ,|O we|O have|O not|O found|O H-ras|gene-rna or|O K-ras|gene-rna mutations|O in|O any|O neuroblastoma|O cell|O line|O or|O primary|O pheochromocytoma|O .|O 
Detection|O of|O transforming|O genes|O by|O transfection|O of|O DNA|O from|O primary|O soft|O -|O tissue|O tumours|O .|O 
A|O series|O of|O adult|O soft|O -|O tissue|O tumours|O were|O screened|O for|O the|O presence|O of|O activated|O oncogenes|O by|O transfecting|O tumour|O DNA|O into|O NIH3T3|O mouse|O fibroblasts|O .|O 
In|O these|O studies|O an|O activated|O K-ras|gene-rna gene|O that|O contained|O a|O mutation|O at|O the|O second|O position|O of|O codon|O 12|O (|O GGT|O ----|O GAT|O )|O was|O found|O in|O a|O leiomyosarcoma|O .|O 
In|O addition|O ,|O following|O transfection|O of|O DNA|O from|O a|O liposarcoma|O ,|O we|O identified|O an|O activated|O gene|O that|O failed|O to|O hybridize|O to|O probes|O prepared|O from|O 10|O known|O human|O oncogenes|O (|O K-ras|gene-rna ,|O H-ras|gene-rna ,|O N-ras|gene-rna ,|O ret|gene-rna ,|O met|gene-rna ,|O trk|gene-rna ,|O mas|gene-rna ,|O dbl|gene-rna ,|O raf|gene-rna and|O hst|gene-rna )|O that|O have|O previously|O been|O detected|O in|O DNA|O transfection|O experiments|O .|O 
BamHI|gene-protein -|O BamHI|gene-protein fragments|O of|O this|O activated|O gene|O of|O 3.5|O and|O 8.5|O kb|O were|O cloned|O from|O NIH3T3|O secondary|O transfectants|O using|O a|O probe|O that|O detects|O the|O human|O alu|O family|O of|O highly|O repetitive|O DNA|O sequences|O .|O 
Repeat|O -|O free|O subclones|O of|O these|O BamHI|gene-protein fragments|O were|O used|O to|O map|O this|O gene|O to|O human|O chromosome|O 19|O (|O p13.2|O -|O q13.3|O )|O .|O 
Our|O studies|O also|O demonstrate|O that|O a|O subclone|O from|O one|O of|O the|O BamHI|gene-protein fragments|O detects|O a|O 3.0|gene-rna kb|gene-rna transcript|gene-rna in|O primary|O and|O secondary|O transfectants|O .|O 
N-ras|gene-rna gene|O mutations|O in|O childhood|O acute|O non|O -|O lymphoblastic|O leukemia|O .|O 
In|O view|O of|O the|O potential|O role|O for|O ras|gene-rna activation|O in|O leukemogenesis|O ,|O we|O have|O screened|O a|O number|O of|O children|O with|O acute|O non|O -|O lymphoblastic|O leukemia|O (|O ANLL|O )|O for|O activating|O point|O mutations|O at|O codons|O 12|O ,|O 13|O and|O 61|O of|O the|O N-ras|gene-rna proto|O -|O oncogene|O using|O panels|O of|O oligonucleotide|O probes|O in|O conjunction|O with|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O gene|O amplification|O .|O 
In|O contrast|O to|O the|O frequent|O occurrence|O (|O approximately|O 30|O %|O )|O of|O N-ras|gene-rna mutation|O reported|O in|O adult|O ANLL|O ,|O 6|O of|O 46|O cases|O (|O 13|O %|O )|O at|O the|O time|O of|O diagnosis|O had|O N-ras|gene-rna mutations|O involving|O codons|O 12|O and|O 13|O .|O 
In|O these|O patients|O we|O also|O determine|O whether|O presenting|O clinical|O symptoms|O ,|O cellular|O pathology|O ,|O karyotype|O ,|O or|O eventual|O outcome|O distinguished|O them|O from|O the|O ras|gene-rna -|O negative|O group|O .|O 
N-ras|gene-rna activation|O tended|O to|O be|O associated|O with|O a|O higher|O white|O blood|O cell|O count|O at|O diagnosis|O (|O mean|O of|O 225,000|O /|O microliters|O vs|O 91,000|O /|O microliters|O )|O and|O fewer|O remissions|O obtained|O after|O 28|O days|O of|O therapy|O (|O 3|O /|O 6|O ,|O 50|O %|O vs|O 24|O /|O 32|O ,|O 75|O %|O )|O .|O 
It|O is|O possible|O that|O activation|O of|O N-ras|gene-rna oncogene|O may|O be|O involved|O in|O the|O progression|O of|O some|O cases|O of|O childhood|O ANLL|O .|O 
Multiple|O point|O mutation|O of|O N-ras|gene-rna and|O K-ras|gene-rna oncogenes|O in|O myelodysplastic|O syndrome|O and|O acute|O myelogenous|O leukemia|O .|O 
We|O analyzed|O activating|O mutations|O of|O N-ras|gene-rna and|O K-ras|gene-rna by|O the|O polymerase|gene-protein chain|O reaction|O and|O oligonucleotide|O hybridization|O in|O hematological|O disorders|O .|O 
Activating|O mutations|O of|O these|O codons|O were|O detected|O in|O 4|O of|O 20|O cases|O of|O myelodysplastic|O syndrome|O (|O MDS|O )|O and|O 15|O of|O 77|O cases|O of|O acute|O myelogenous|O leukemia|O (|O AML|O )|O .|O 
Our|O of|O 19|O cases|O of|O MDS|O and|O AML|O who|O carried|O active|O mutations|O ,|O 7|O cases|O were|O found|O to|O have|O two|O or|O more|O distinct|O mutations|O in|O activating|O codons|O of|O N-ras|gene-rna and|O K-ras|gene-rna .|O 
Ras|gene-rna mutation|O was|O found|O preferentially|O in|O progressive|O disease|O such|O as|O refractory|O anemia|O with|O excess|O of|O blasts|O (|O RAEB|O )|O of|O RAEB|O in|O transformation|O (|O RAEB-t|O )|O .|O 
A|O relatively|O high|O incidence|O of|O ras|gene-rna mutation|O was|O found|O in|O M5|O AML|O (|O 40|O %|O )|O .|O 
No|O ras|gene-rna mutations|O were|O found|O in|O other|O hematological|O disorders|O ,|O such|O as|O acute|O lymphoblastic|O leukemia|O and|O chronic|O myelogenous|O -|O leukemia|O .|O 
The|O most|O frequent|O amino|O acid|O substitution|O was|O that|O of|O an|O aspartate|O for|O glycine|O at|O codon|O 12|O of|O N-ras|gene-rna resulting|O from|O G|O to|O A|O mutation|O (|O 11|O /|O 35|O )|O .|O 
The|O survival|O of|O AML|O patients|O who|O carried|O ras|gene-rna mutations|O showed|O no|O significant|O differences|O from|O those|O without|O ras|gene-rna mutations|O calculated|O by|O Kaplan|O -|O Meier|O .|O 
Seven|O cases|O of|O MDS|O and|O 7|O cases|O of|O AML|O patients|O could|O be|O investigated|O at|O various|O points|O during|O their|O clinical|O course|O .|O 
Among|O these|O 14|O cases|O ,|O we|O found|O 2|O interesting|O cases|O of|O MDS|O .|O 
The|O first|O case|O lost|O multiple|O clones|O carrying|O ras|gene-rna mutations|O during|O disease|O progression|O ,|O the|O second|O case|O acquired|O mutation|O of|O the|O ras|gene-rna gene|O during|O disease|O progression|O .|O 
These|O results|O suggested|O that|O multiple|O point|O mutations|O of|O ras|gene-rna genes|O may|O not|O be|O initiating|O events|O but|O may|O contribute|O to|O a|O clonal|O evolution|O of|O MDS|O and|O AML|O .|O 
Point|O mutation|O at|O codon|O 12|O of|O the|O c-Ha-ras|gene-rna gene|O in|O human|O gastric|O cancers|O .|O 
The|O molecular|O mechanisms|O of|O the|O carcinogenic|O process|O of|O gastric|O cancer|O have|O not|O been|O fully|O understood|O yet|O .|O 
In|O order|O to|O know|O whether|O c-Ha-ras|gene-rna gene|O is|O being|O involved|O in|O the|O process|O of|O gastric|O carcinogenesis|O ,|O 8|O gastric|O cancer|O cell|O lines|O ,|O 8|O cases|O of|O gastric|O cancer|O and|O same|O number|O of|O adjacent|O dysplasia|O were|O analyzed|O for|O the|O presence|O of|O mutation|O at|O codon|O 12|O ,|O 13|O and|O 61|O of|O the|O c-Ha-ras|gene-rna gene|O by|O using|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O and|O mutant|O -|O specific|O oligonucleotide|O hybridization|O .|O 
Point|O mutations|O at|O codon|O 12|O of|O the|O c-Ha-ras|gene-rna gene|O were|O found|O in|O 2|O out|O of|O 8|O gastric|O cancer|O and|O dysplasia|O samples|O in|O one|O case|O ,|O but|O we|O found|O no|O mutation|O at|O codon|O 13|O or|O 61|O of|O the|O c-Ha-ras|gene-rna gene|O .|O 
These|O results|O suggest|O that|O the|O frequency|O of|O mutation|O of|O the|O c-Ha-ras|gene-rna gene|O detected|O by|O sensitive|O PCR|O technique|O is|O low|O indeed|O ,|O however|O it|O would|O be|O notable|O that|O such|O a|O genetic|O change|O has|O been|O detected|O in|O the|O dysplastic|O lesion|O of|O the|O gastric|O cancer|O patient|O .|O 
The|O p53|gene-rna tumor|O -|O suppressor|O gene|O and|O ras|gene-rna oncogene|O mutations|O in|O oral|O squamous|O -|O cell|O carcinoma|O .|O 
The|O frequencies|O of|O mutations|O in|O the|O p53|gene-rna tumor|O -|O suppressor|O gene|O and|O ras|gene-rna proto|O -|O oncogenes|O were|O investigated|O systematically|O in|O surgically|O resected|O oral|O squamous|O -|O cell|O carcinomas|O (|O SCCs|O )|O using|O single|O -|O strand|O conformation|O polymorphism|O (|O SSCP|O )|O and/or|O dot|O -|O blot|O hybridization|O analysis|O of|O DNA|O fragments|O which|O had|O been|O amplified|O by|O the|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O .|O 
p53|gene-rna gene|O mutations|O ,|O within|O the|O region|O of|O exons|O 5|O to|O 8|O ,|O were|O detected|O in|O 17|O out|O of|O 27|O (|O 63|O %|O )|O tumor|O specimens|O .|O 
The|O role|O of|O p53|gene-rna mutations|O in|O cell|O -|O line|O establishment|O was|O investigated|O .|O 
p53|gene-rna gene|O mutations|O were|O detected|O in|O 5|O out|O of|O 6|O tissue|O samples|O from|O which|O cell|O lines|O were|O established|O and|O in|O 4|O out|O of|O 5|O specimens|O from|O which|O cell|O lines|O could|O not|O be|O established|O ,|O suggesting|O that|O the|O presence|O of|O p53|gene-rna gene|O mutations|O is|O not|O by|O itself|O sufficient|O for|O cell|O -|O line|O establishment|O .|O 
Tumor|O samples|O were|O also|O analyzed|O for|O point|O mutational|O activation|O of|O the|O ras|gene-rna proto|O -|O oncogenes|O .|O 
One|O out|O of|O 30|O (|O 3|O %|O )|O tumors|O showed|O an|O activating|O point|O mutation|O in|O codon|O 12|O of|O H-ras|gene-rna ,|O this|O being|O consistent|O with|O reports|O from|O Europe|O and|O USA|O but|O not|O with|O any|O from|O India|O .|O 
Compared|O to|O frequencies|O of|O the|O other|O genetic|O changes|O so|O far|O reported|O for|O oral|O SCC|O ,|O the|O p53|gene-rna mutations|O have|O been|O observed|O most|O often|O to|O undergo|O genetic|O change|O .|O 
p53|gene-rna gene|O mutation|O is|O thus|O intimately|O involved|O in|O the|O genesis|O of|O oral|O SCC|O and|O consequently|O should|O be|O useful|O as|O a|O marker|O for|O the|O diagnosis|O of|O this|O neoplasm|O .|O 
Ras|gene-rna oncogene|O point|O mutation|O :|O an|O infrequent|O event|O in|O bronchioloalveolar|O cancer|O .|O 
Ras|gene-rna oncogene|O point|O mutation|O ,|O primarily|O activating|O the|O K-ras|gene-rna gene|O ,|O has|O been|O reported|O in|O approximately|O one|O third|O of|O lung|O adenocarcinomas|O .|O 
This|O identifies|O a|O subset|O of|O early|O stage|O tumors|O clinically|O associated|O with|O smoking|O and|O an|O aggressive|O clinical|O course|O .|O 
Because|O of|O these|O findings|O ,|O this|O study|O was|O undertaken|O to|O determine|O the|O occurrence|O of|O ras|gene-rna point|O mutations|O in|O bronchioloalveolar|O carcinoma|O .|O 
This|O uncommon|O form|O of|O lung|O adenocarcinoma|O is|O usually|O indolent|O but|O can|O sometimes|O present|O as|O a|O rapidly|O growing|O ,|O multifocal|O tumor|O .|O 
Twenty|O tumor|O samples|O obtained|O at|O thoracotomy|O were|O examined|O for|O H-ras|gene-rna ,|O K-ras|gene-rna ,|O and|O N-ras|gene-rna oncogene|O mutational|O activation|O involving|O codons|O 12|O ,|O 13|O ,|O or|O 61|O .|O 
This|O was|O performed|O by|O an|O oligonucleotide|O hybridization|O technique|O following|O polymerase|gene-protein chain|O reaction|O amplification|O of|O these|O specific|O sequences|O .|O 
K-ras|gene-rna point|O mutation|O involving|O codon|O 12|O was|O observed|O in|O two|O tumors|O ,|O but|O not|O in|O the|O adjacent|O histologically|O benign|O lung|O tissue|O .|O 
These|O mutations|O were|O confirmed|O by|O direct|O sequencing|O of|O these|O polymerase|gene-protein chain|O reaction|O products|O .|O 
Both|O patients|O were|O smokers|O ,|O had|O stage|O I|O tumors|O ,|O and|O remain|O disease|O -|O free|O at|O 27|O and|O 40|O months|O postoperatively|O .|O 
No|O H-ras|gene-rna or|O N-ras|gene-rna point|O mutations|O were|O found|O .|O 
These|O findings|O suggest|O that|O ras|gene-rna activation|O is|O an|O infrequent|O event|O in|O bronchioloalveolar|O carcinoma|O .|O 
We|O speculate|O that|O ras|gene-rna activation|O is|O not|O a|O common|O transformational|O event|O in|O this|O form|O of|O lung|O adenocarcinoma|O .|O 
Incidence|O of|O ras|gene-rna oncogene|O activation|O in|O lung|O carcinomas|O in|O Hong|O Kong|O .|O 
BACKGROUND|O .|O 
In|O Hong|O Kong|O ,|O lung|O carcinomas|O contribute|O to|O the|O majority|O of|O cancer|O deaths|O among|O Chinese|O .|O 
Point|O mutational|O activation|O of|O ras|gene-rna oncogenes|O has|O been|O observed|O in|O several|O populations|O .|O 
The|O incidence|O of|O these|O mutations|O in|O Hong|O Kong|O lung|O carcinomas|O was|O investigated|O .|O 
METHODS|O .|O 
Lung|O resections|O obtained|O from|O 52|O Chinese|O patients|O whose|O conditions|O were|O newly|O diagnosed|O as|O non|O -|O small|O cell|O lung|O cancer|O ,|O paraffin|O sections|O from|O 29|O Chinese|O patients|O with|O previously|O diagnosed|O adenocarcinoma|O of|O the|O lung|O ,|O and|O paraffin|O sections|O from|O 49|O squamous|O cell|O carcinomas|O were|O examined|O for|O the|O presence|O of|O point|O mutations|O in|O Ki-ras|gene-rna codon|O 12|O ,|O N-ras|gene-rna codon|O 61|O ,|O and|O Ha-ras|gene-rna codon|O 12|O oncogenes|O by|O allele|O -|O specific|O hybridization|O after|O specific|O amplification|O of|O appropriate|O regions|O of|O the|O DNA|O using|O the|O polymerase|gene-protein chain|O reaction|O .|O 
RESULTS|O .|O 
Among|O the|O 130|O lung|O carcinomas|O investigated|O ,|O Ki-ras|gene-rna point|O mutations|O were|O detected|O in|O seven|O cases|O ,|O of|O which|O six|O were|O adenocarcinomas|O and|O one|O a|O squamous|O cell|O carcinoma|O .|O 
No|O mutations|O were|O detected|O in|O the|O N-ras|gene-rna and|O Ha-ras|gene-rna codons|O .|O 
CONCLUSIONS|O .|O 
The|O incidence|O of|O Ki-ras|gene-rna codon|O 12|O point|O mutational|O activation|O in|O Chinese|O patients|O with|O adenocarcinomas|O was|O 6|O of|O 63|O (|O 9.5|O %|O )|O .|O 
The|O incidence|O of|O Ki-ras|gene-rna 12|O point|O mutational|O activation|O among|O men|O with|O lung|O adenocarcinomas|O in|O Hong|O Kong|O (|O 6|O of|O 32|O patients|O ,|O 18.8|O %|O )|O is|O significantly|O different|O from|O that|O in|O women|O in|O Hong|O Kong|O (|O 0|O of|O 31|O patients|O ,|O 0|O %|O )|O .|O 
Although|O ras|gene-rna oncogenes|O are|O implicated|O as|O having|O a|O role|O in|O the|O development|O of|O lung|O adenocarcinomas|O ,|O especially|O among|O smokers|O ,|O it|O is|O clear|O from|O these|O data|O that|O they|O are|O not|O associated|O with|O the|O unusually|O high|O incidence|O of|O lung|O adenocarcinomas|O among|O women|O in|O Hong|O Kong|O .|O 
Mutational|O spectrum|O of|O beta-catenin|gene-rna ,|O AXIN1|gene-rna ,|O and|O AXIN2|gene-rna in|O hepatocellular|O carcinomas|O and|O hepatoblastomas|O .|O 
Activation|O of|O Wnt|gene-generic signaling|O through|O beta-catenin|gene-rna mutations|O contributes|O to|O the|O development|O of|O hepatocellular|O carcinoma|O (|O HCC|O )|O and|O hepatoblastoma|O (|O HB|O )|O .|O 
To|O explore|O the|O contribution|O of|O additional|O Wnt|gene-rna pathway|O molecules|O to|O hepatocarcinogenesis|O ,|O we|O examined|O beta-catenin|gene-rna ,|O AXIN1|gene-rna and|O AXIN2|gene-rna mutations|O in|O 73|O HCCs|O and|O 27|O HBs|O .|O 
beta-catenin|gene-rna mutations|O were|O detected|O in|O 19.2|O %|O (|O 14|O out|O of|O 73|O )|O HCCs|O and|O 70.4|O %|O (|O 19|O out|O of|O 27|O )|O HBs|O .|O 
beta-catenin|gene-rna mutations|O in|O HCCs|O were|O primarily|O point|O mutations|O ,|O whereas|O more|O than|O half|O of|O the|O HBs|O had|O deletions|O .|O 
AXIN1|gene-rna mutations|O occurred|O in|O seven|O (|O 9.6|O %|O )|O HCCs|O and|O two|O (|O 7.4|O %|O )|O HBs|O .|O 
The|O AXIN1|gene-rna mutations|O included|O seven|O missense|O mutations|O ,|O a|O 1|O bp|O deletion|O ,|O and|O a|O 12|O bp|O insertion|O .|O 
The|O predominance|O of|O missense|O mutations|O found|O in|O the|O AXIN1|gene-rna gene|O is|O different|O from|O the|O small|O deletions|O or|O nonsense|O mutations|O described|O previously|O .|O 
Loss|O of|O heterozygosity|O at|O the|O AXIN1|gene-rna locus|O was|O present|O in|O four|O of|O five|O informative|O HCCs|O with|O AXIN1|gene-rna mutations|O ,|O suggesting|O a|O tumor|O suppressor|O function|O of|O this|O gene|gene-rna .|O 
AXIN2|gene-rna mutations|O were|O found|O in|O two|O (|O 2.7|O %|O )|O HCCs|O but|O not|O in|O HBs|O .|O 
Two|O HCCs|O had|O both|O AXIN1|gene-rna and|O beta-catenin|gene-rna mutations|O ,|O and|O one|O HCC|O had|O both|O AXIN2|gene-rna and|O beta-catenin|gene-rna mutations|O .|O 
About|O half|O the|O HCCs|O with|O AXIN1|gene-rna or|O AXIN2|gene-rna mutations|O showed|O beta-catenin|gene-protein accumulation|O in|O the|O nucleus|O ,|O cytoplasm|O or|O membrane|O .|O 
Overall|O ,|O these|O data|O indicate|O that|O besides|O the|O approximately|O 20|O %|O of|O HCCs|O and|O 80|O %|O of|O HBs|O with|O beta-catenin|gene-rna mutations|O contributing|O to|O hepatocarcinogenesis|O ,|O AXIN1|gene-rna and|O AXIN2|gene-rna mutations|O appear|O to|O be|O important|O in|O an|O additional|O 10|O %|O of|O HCCs|O and|O HBs|O .|O 
Molecular|O analysis|O of|O sulindac|O -|O resistant|O adenomas|O in|O familial|O adenomatous|O polyposis|O .|O 
PURPOSE|O :|O 
Sulindac|O causes|O the|O reduction|O of|O adenomas|O in|O familial|O adenomatous|O polyposis|O (|O FAP|O )|O patients|O ,|O but|O complete|O regression|O is|O unusual|O ,|O and|O breakthrough|O of|O colorectal|O carcinoma|O during|O sulindac|O treatment|O has|O been|O described|O .|O 
The|O molecular|O features|O related|O to|O sulindac|O resistance|O are|O unknown|O .|O 
Therefore|O ,|O we|O investigated|O molecular|O alterations|O in|O adenomas|O from|O FAP|O patients|O with|O complete|O adenoma|O regression|O on|O sulindac|O (|O responsive|O patients|O )|O and|O from|O FAP|O patients|O with|O sulindac|O -|O resistant|O adenomas|O (|O resistant|O patients|O )|O .|O 
DESIGN|O :|O 
Fourteen|O baseline|O adenomas|O (|O removed|O before|O sulindac|O treatment|O )|O from|O six|O responsive|O patients|O were|O studied|O .|O 
Also|O ,|O 9|O baseline|O adenomas|O and|O 34|O resistant|O adenomas|O (|O removed|O during|O sulindac|O treatment|O )|O from|O three|O resistant|O patients|O were|O analyzed|O .|O 
Using|O immunohistochemistry|O ,|O we|O evaluated|O the|O expression|O of|O beta-catenin|gene-generic ,|O cyclooxygenase-2|gene-generic (|O Cox-2|gene-generic )|O ,|O p53|gene-generic ,|O Bcl-2|gene-generic ,|O and|O Bax|gene-generic .|O 
K-ras|gene-rna codon|O 12|O mutations|O ,|O loss|O of|O heterozygosity|O at|O 5q|O (|O APC|gene-rna locus|O )|O ,|O and|O microsatellite|O instability|O were|O studied|O with|O PCR|O -|O based|O techniques|O .|O 
RESULTS|O :|O 
There|O were|O no|O significant|O differences|O between|O baseline|O adenomas|O from|O sulindac|O -|O responsive|O and|O -|O resistant|O patients|O (|O P|O >|O 0.05|O )|O .|O 
There|O was|O less|O loss|O of|O membranous|O beta-catenin|gene-protein staining|O and|O less|O nuclear|O beta-catenin|gene-protein accumulation|O in|O resistant|O adenomas|O compared|O with|O baseline|O adenomas|O from|O the|O same|O (|O sulindac|O -|O resistant|O )|O patients|O (|O P|O <|O 0.01|O )|O or|O baseline|O adenomas|O from|O responsive|O patients|O (|O P|O <|O 0.01|O )|O .|O 
Epithelial|O Cox-2|gene-generic expression|O was|O less|O ,|O though|O not|O significant|O ,|O in|O resistant|O adenomas|O compared|O with|O baseline|O adenomas|O from|O resistant|O patients|O ,|O but|O was|O significantly|O less|O in|O baseline|O adenomas|O from|O responsive|O patients|O (|O P|O <|O 0.01|O )|O .|O 
K-ras|gene-rna mutations|O were|O found|O in|O 8|O of|O 34|O resistant|O adenomas|O (|O 24|O %|O )|O and|O in|O none|O of|O the|O baseline|O adenomas|O (|O P|O <|O 0.05|O )|O .|O 
Stromal|O Cox-2|gene-generic expression|O ,|O staining|O of|O p53|gene-protein and|O Bcl-2|gene-protein ,|O and|O loss|O of|O heterozygosity|O at|O 5q|O were|O comparable|O in|O both|O groups|O .|O 
Loss|O of|O Bax|gene-protein staining|O and|O microsatellite|O instability|O were|O not|O found|O in|O any|O adenoma|O .|O 
CONCLUSIONS|O :|O 
Sulindac|O -|O resistant|O adenomas|O display|O less|O alteration|O in|O beta-catenin|gene-protein staining|O and|O less|O epithelial|O Cox-2|gene-rna expression|O when|O compared|O with|O adenomas|O removed|O before|O sulindac|O treatment|O .|O 
K-ras|gene-rna mutations|O may|O contribute|O to|O sulindac|O -|O resistance|O .|O 
Continued|O research|O is|O needed|O to|O investigate|O molecular|O alterations|O related|O to|O sulindac|O resistance|O .|O 
H|gene-rna -|gene-rna ,|O K|gene-rna -|gene-rna ,|O and|O N|gene-rna -|gene-rna ras|gene-rna gene|O mutation|O in|O atypical|O fibroxanthoma|O and|O malignant|O fibrous|O histiocytoma|O .|O 
Atypical|O fibroxanthoma|O (|O AFX|O )|O which|O is|O histologically|O similar|O to|O malignant|O fibrous|O histiocytoma|O (|O MFH|O )|O ,|O occurs|O in|O the|O sun|O -|O exposed|O skin|O .|O 
The|O presence|O of|O mutations|O at|O codons|O 12|O and|O 13|O of|O the|O H|gene-rna -|gene-rna and|O K|gene-rna -|gene-rna ras|gene-rna genes|O and|O in|O exons|O 1|O and|O 2|O ,|O which|O include|O codons|O 12|O ,|O 13|O ,|O and|O 61|O ,|O of|O the|O N-ras|gene-rna gene|O was|O studied|O in|O 8|O cases|O of|O AFX|O and|O 8|O cases|O of|O storiform|O -|O pleomorphic|O -|O type|O MFH|O using|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O -|O restriction|O fragment|O length|O polymorphism|O and|O PCR|O -|O single|O -|O conformation|O polymorphism|O .|O 
Two|O of|O the|O 8|O cases|O of|O MFH|O showed|O ras|gene-rna mutations|O in|O the|O H-ras|gene-rna gene|O at|O codon|O 12|O (|O GGC|O -|O AGC|O )|O and|O in|O the|O K-ras|gene-rna gene|O at|O codon|O 13|O (|O GGC|O -|O GAC|O )|O .|O 
H|gene-rna -|gene-rna and|O K|gene-rna -|gene-rna ras|gene-rna gene|O mutations|O were|O not|O seen|O in|O any|O of|O the|O cases|O of|O AFX|O (|O 0|O of|O 8|O )|O .|O 
N-ras|gene-rna gene|O mutation|O was|O not|O detected|O in|O either|O the|O AFX|O (|O 0|O of|O 8|O )|O or|O MFH|O (|O 0|O of|O 8|O )|O cases|O .|O 
In|O conclusion|O ,|O although|O the|O number|O of|O cases|O in|O this|O study|O was|O small|O ,|O H|gene-rna -|gene-rna and|O K|gene-rna -|gene-rna ras|gene-rna genes|O were|O present|O in|O some|O of|O the|O MFH|O cases|O and|O accordingly|O may|O play|O an|O important|O role|O in|O the|O pathogenesis|O of|O MFH|O .|O 
In|O addition|O ,|O the|O finding|O that|O H|gene-rna -|gene-rna ,|O K|gene-rna -|gene-rna ,|O and|O N|gene-rna -|gene-rna ras|gene-rna gene|O mutations|O are|O not|O present|O in|O AFX|O may|O indicate|O why|O AFX|O has|O a|O more|O favorable|O behavior|O than|O MFH|O .|O 
High|O frequency|O of|O beta-catenin|gene-rna mutations|O in|O hepatoblastoma|O .|O 
Hepatoblastoma|O (|O HB|O )|O is|O an|O embryonic|O neoplasm|O representing|O the|O most|O frequent|O malignant|O liver|O tumour|O in|O childhood|O .|O 
Its|O tumourigenesis|O at|O the|O molecular|O level|O is|O still|O poorly|O understood|O ,|O and|O candidate|O genes|O are|O yet|O to|O be|O identified|O .|O 
According|O to|O recent|O reports|O describing|O beta-catenin|gene-rna mutations|O (|O BCM|O )|O at|O hot|O -|O spot|O regions|O involving|O exon|O 3|O in|O several|O types|O of|O malignancies|O including|O HB|O ,|O we|O investigated|O BCM|O in|O 16|O HBs|O classified|O into|O different|O histological|O types|O .|O 
One|O tumour|O had|O been|O previously|O confirmed|O to|O harbour|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|O APC|gene-rna )|O mutations|O that|O exhibit|O a|O similar|O oncogenic|O effect|O to|O that|O of|O BCM|O .|O 
Mutations|O in|O both|O exon|O 3|O and|O its|O flanking|O region|O of|O the|O beta-catenin|gene-rna gene|O were|O investigated|O and|O determined|O .|O 
Twelve|O tumours|O (|O 75|O %|O )|O revealed|O pathogenic|O BCM|O ,|O including|O 5|O with|O missense|O mutations|O at|O codons|O 32|O ,|O 34|O ,|O or|O 37|O and|O 7|O with|O interstitial|O deletions|O that|O partially|O or|O totally|O affected|O exon|O 3|O .|O 
All|O 7|O deletions|O were|O in|O -|O frame|O deletions|O without|O frameshift|O .|O 
A|O single|O nucleotide|O change|O at|O codon|O 31|O regarded|O as|O non|O -|O pathogenic|O polymorphism|O was|O detected|O in|O the|O tumour|O possessing|O APC|gene-rna mutations|O .|O 
Therefore|O ,|O a|O total|O of|O 13|O tumours|O (|O 81|O %|O )|O were|O compromised|O by|O an|O enhanced|O beta-catenin|gene-rna -|O mediated|O transcription|O pathway|O .|O 
Mutations|O were|O observed|O in|O every|O histological|O type|O of|O HB|O .|O 
The|O very|O high|O frequency|O without|O correlation|O to|O histological|O type|O indicates|O that|O BCM|O are|O crucial|O events|O in|O the|O tumourigenesis|O of|O HB|O .|O 
Oncogenic|O potential|O of|O c-erbB-2|gene-rna and|O its|O association|O with|O c-K-ras|gene-rna in|O premalignant|O and|O malignant|O lesions|O of|O the|O human|O uterine|O endometrium|O .|O 
The|O aim|O of|O this|O study|O was|O to|O detect|O activated|O c-K-ras|gene-rna by|O gene|O point|O mutation|O and|O to|O find|O c-erbB-2|gene-rna gene|O amplification|O with|O p185|gene-protein expression|O in|O association|O with|O the|O c-K-ras|gene-rna gene|O product|O p21|gene-protein in|O the|O human|O endometrium|O .|O 
Specimens|O obtained|O from|O 25|O normal|O ,|O 31|O hyperplastic|O and|O 72|O malignant|O samples|O of|O the|O human|O endometrium|O were|O examined|O for|O point|O mutation|O in|O codons|O 12|O ,|O 13|O and|O 61|O of|O the|O c-K-ras|gene-rna by|O direct|O sequencing|O and|O c-erbB-2|gene-rna gene|O amplification|O with|O p185|gene-protein and|O p21|gene-protein expression|O by|O differential|O polymerase|gene-protein chain|O reaction|O (|O DPCR|O )|O and|O immunohistochemistry|O .|O 
Neither|O the|O normal|O endometrium|O nor|O endometrial|O hyperplasias|O were|O found|O to|O have|O mutations|O in|O the|O c-K-ras|gene-rna gene|O ,|O although|O a|O double|O mutation|O of|O codons|O 12|O and|O 13|O as|O a|O single|O -|O point|O mutation|O was|O observed|O in|O one|O case|O of|O endometrioid|O carcinoma|O (|O 2.8|O %|O )|O .|O 
In|O each|O of|O two|O other|O cases|O of|O endometrioid|O carcinoma|O (|O 2|O /|O 72|O )|O ,|O two|O single|O -|O point|O mutations|O of|O codon|O 13|O (|O 5.6|O %|O )|O were|O shown|O .|O 
Using|O DPCR|O ,|O we|O found|O c-erbB-2|gene-rna to|O be|O amplified|O in|O 15|O premalignant|O (|O 48|O %|O )|O and|O 45|O malignant|O (|O 63|O %|O )|O samples|O .|O 
We|O noticed|O that|O nonamplification|O of|O the|O c-erbB-2|gene-rna gene|O was|O associated|O with|O the|O absence|O of|O immunoreactivity|O .|O 
Our|O data|O indicate|O that|O ,|O while|O c-erbB-2|gene-rna plays|O a|O role|O in|O the|O early|O development|O of|O endometrioid|O carcinomas|O ,|O c-K-ras|gene-rna gene|O activation|O by|O point|O mutation|O does|O not|O .|O 
Ki-ras|gene-rna proto|O -|O oncogene|O mutations|O in|O sporadic|O colorectal|O adenomas|O :|O relationship|O to|O histologic|O and|O clinical|O characteristics|O .|O 
BACXKGROUND|O &|O AIMS|O :|O 
The|O goal|O of|O this|O study|O was|O to|O examine|O the|O relationship|O between|O Ki-ras|gene-rna mutations|O in|O colorectal|O adenomas|O and|O characteristics|O of|O both|O the|O subject|O (|O age|O ,|O gender|O ,|O and|O family|O /|O personal|O history|O of|O colonic|O neoplasia|O )|O and|O the|O adenoma|O (|O multiplicity|O ,|O size|O ,|O location|O ,|O and|O histologic|O features|O )|O .|O 
METHODS|O :|O 
Ki-ras|gene-rna mutations|O were|O detected|O by|O direct|O sequencing|O in|O 738|O adenomatous|O polyps|O removed|O at|O baseline|O from|O 639|O participants|O in|O a|O nutritional|O trial|O of|O adenoma|O recurrence|O .|O 
RESULTS|O :|O 
Ki-ras|gene-rna mutations|O were|O detected|O in|O 17.2|O %|O of|O the|O adenomas|O .|O 
Ki-ras|gene-rna mutations|O were|O unrelated|O to|O gender|O ,|O family|O ,|O or|O personal|O history|O of|O colonic|O neoplasia|O ,|O location|O within|O the|O colorectum|O ,|O or|O adenoma|O multiplicity|O ,|O but|O were|O more|O common|O in|O older|O subjects|O (|O P|O =|O 0.01|O for|O trend|O )|O ,|O in|O larger|O adenomas|O (|O P|O <|O 0.0001|O for|O trend|O )|O ,|O in|O adenomas|O with|O villous|O histology|O (|O odds|O ratio|O [|O OR|O ]|O ,|O 3.2|O ;|O 95|O %|O confidence|O interval|O [|O CI|O ]|O ,|O 2.1|O -|O 4.9|O vs.|O tubular|O )|O ,|O and|O in|O adenomas|O with|O high|O -|O grade|O dysplasia|O (|O 32.0|O %|O vs.|O 13.6|O %|O ;|O OR|O ,|O 3.0|O ;|O 95|O %|O CI|O ,|O 1.9|O -|O 4.6|O vs.|O low|O -|O grade|O dysplasia|O )|O .|O 
Multivariate|O analysis|O showed|O Ki-ras|gene-rna mutations|O to|O be|O independently|O associated|O with|O subject|O age|O (|O P|O =|O 0.01|O for|O trend|O )|O ,|O tubulovillous|O /|O villous|O histology|O (|O OR|O ,|O 2.3|O ;|O 95|O %|O CI|O ,|O 1.5|O -|O 3.7|O )|O ,|O and|O high|O -|O grade|O dysplasia|O (|O OR|O ,|O 1.9|O ;|O 95|O %|O CI|O ,|O 1.2|O -|O 3.1|O )|O .|O 
Adenoma|O size|O was|O not|O independently|O related|O to|O Ki-ras|gene-rna mutation|O .|O 
CONCLUSIONS|O :|O 
Ki-ras|gene-rna mutations|O are|O associated|O with|O the|O histologic|O features|O of|O adenoma|O progression|O (|O villous|O histology|O and|O high|O -|O grade|O dysplasia|O )|O rather|O than|O with|O adenoma|O growth|O .|O 
Frequent|O FGFR3|gene-rna mutations|O in|O papillary|O non|O -|O invasive|O bladder|O (|O pTa|O )|O tumors|O .|O 
We|O recently|O identified|O activating|O mutations|O of|O fibroblast|gene-rna growth|gene-rna factor|gene-rna receptor|gene-rna 3|gene-rna (|O FGFR3|gene-rna )|O in|O bladder|O carcinoma|O .|O 
In|O this|O study|O we|O assessed|O the|O incidence|O of|O FGFR3|gene-rna mutations|O in|O a|O series|O of|O 132|O bladder|O carcinomas|O :|O 20|O carcinoma|O in|O situ|O (|O CIS|O )|O ,|O 50|O pTa|O ,|O 19|O pT1|O ,|O and|O 43|O pT2-4|O .|O 
All|O 48|O mutations|O identified|O were|O identical|O to|O the|O germinal|O activating|O mutations|O that|O cause|O thanatophoric|O dysplasia|O ,|O a|O lethal|O form|O of|O dwarfism|O .|O 
The|O S|O 249|O C|O mutation|O ,|O found|O in|O 33|O of|O the|O 48|O mutated|O tumors|O ,|O was|O the|O most|O common|O .|O 
The|O frequency|O of|O mutations|O was|O higher|O in|O pTa|O tumors|O (|O 37|O of|O 50|O ,|O 74|O %|O )|O than|O in|O CIS|O (|O 0|O of|O 20|O ,|O 0|O %|O ;|O P|O <|O 0.0001|O )|O ,|O pT1|O (|O 4|O of|O 19|O ,|O 21|O %|O ;|O P|O <|O 0.0001|O )|O and|O pT2-4|O tumors|O (|O 7|O of|O 43|O ,|O 16|O %|O ;|O P|O <|O 0.0001|O )|O .|O 
FGFR3|gene-rna mutations|O were|O detected|O in|O 27|O of|O 32|O (|O 84|O %|O )|O G1|O ,|O 16|O of|O 29|O (|O 55|O %|O )|O G2|O ,|O and|O 5|O of|O 71|O (|O 7|O %|O )|O G3|O tumors|O .|O 
This|O association|O between|O FGFR3|gene-rna mutations|O and|O low|O grade|O was|O highly|O significant|O (|O P|O <|O 0.0001|O )|O .|O 
FGFR3|gene-rna is|O the|O first|O gene|O found|O to|O be|O mutated|O at|O a|O high|O frequency|O in|O pTa|O tumors|O .|O 
The|O absence|O of|O FGFR3|gene-rna mutations|O in|O CIS|O and|O the|O low|O frequency|O of|O FGFR3|gene-rna mutations|O in|O pT1|O and|O pT2-4|O tumors|O are|O consistent|O with|O the|O model|O of|O bladder|O tumor|O progression|O in|O which|O the|O most|O common|O precursor|O of|O pT1|O and|O pT2-4|O tumors|O is|O CIS|O .|O 
The|O fibroblast|gene-rna growth|gene-rna factor|gene-rna receptor|gene-rna 3|gene-rna (|O FGFR3|gene-rna )|O mutation|O is|O a|O strong|O indicator|O of|O superficial|O bladder|O cancer|O with|O low|O recurrence|O rate|O .|O 
We|O analyzed|O the|O possible|O prognostic|O value|O of|O the|O recently|O discovered|O fibroblast|gene-rna growth|gene-rna factor|gene-rna receptor|gene-rna 3|gene-rna (|O FGFR3|gene-rna )|O mutations|O in|O bladder|O cancer|O .|O 
A|O FGFR3|gene-rna mutation|O was|O found|O in|O 34|O of|O 53|O pTaG|O 1|O -|O 2|O bladder|O cancers|O ,|O whereas|O none|O of|O the|O 19|O higher|O -|O staged|O tumors|O had|O a|O mutation|O (|O P|O <|O 0.0001|O )|O .|O 
In|O 57|O patients|O with|O superficial|O disease|O followed|O prospectively|O by|O cystoscopy|O for|O 12|O months|O ,|O 14|O of|O 23|O patients|O in|O the|O wild|O -|O type|O FGFR3|gene-rna group|O developed|O recurrent|O bladder|O cancer|O compared|O with|O only|O 7|O of|O 34|O patients|O in|O the|O mutant|O group|O (|O P|O =|O 0.004|O )|O .|O 
The|O recurrence|O rate|O per|O year|O was|O 0.24|O for|O the|O FGFR3|gene-rna mutant|O tumors|O and|O 1.12|O for|O tumors|O with|O a|O wild|O -|O type|O FGFR3|gene-rna gene|O .|O 
In|O addition|O ,|O FGFR3|gene-rna mutation|O status|O was|O the|O strongest|O predictor|O of|O recurrence|O when|O compared|O with|O stage|O and|O grade|O (|O P|O =|O 0.008|O )|O .|O 
This|O is|O the|O first|O mutation|O in|O bladder|O cancer|O that|O selectively|O identifies|O patients|O with|O favorable|O disease|O characteristics|O .|O 
Our|O results|O suggest|O that|O the|O frequency|O of|O cystoscopic|O examinations|O can|O be|O reduced|O considerably|O in|O patients|O with|O FGFR3|gene-rna -|O positive|O tumors|O .|O 
Analysis|O of|O KIT|gene-rna mutation|O and|O protein|O expression|O in|O fine|O needle|O aspirates|O of|O gastrointestinal|O stromal|O /|O smooth|O muscle|O tumors|O .|O 
OBJECTIVE|O :|O 
To|O determine|O if|O sequencing|O the|O KIT|gene-rna gene|O could|O facilitate|O more|O definitive|O FNA|O diagnosis|O .|O 
STUDY|O DESIGN|O :|O 
Sixteen|O cases|O of|O gastrointestinal|O stromal|O /|O smooth|O muscle|O tumor|O (|O GIST|O )|O in|O which|O fine|O needle|O aspiration|O (|O FNA|O )|O was|O performed|O (|O mean|O age|O ,|O 67|O ;|O M|O /|O F|O =|O 12|O /|O 4|O )|O were|O studied|O .|O 
DNA|O was|O extracted|O from|O cytologic|O preparations|O from|O all|O patients|O (|O 15|O cell|O blocks|O ,|O 1|O alcohol|O -|O fixed|O smear|O )|O and|O seven|O subsequent|O resection|O specimens|O .|O 
DNA|O was|O amplified|O by|O polymerase|gene-protein chain|O reaction|O ,|O using|O primers|O designed|O to|O amplify|O a|O segment|O of|O the|O KIT|gene-rna gene|O exon|O 11|O and|O sequenced|O on|O an|O ABI|O Prism|O 377|O DNA|O sequence|O analyzer|O (|O Applied|O Biosystems|O ,|O Indianapolis|O ,|O Indiana|O ,|O U.S.A.|O )|O .|O 
Immunocytochemical|O staining|O for|O CD|gene-protein 117|gene-protein (|O the|O KIT|gene-rna gene|gene-protein product|gene-protein )|O was|O performed|O on|O sections|O from|O 12|O cell|O blocks|O and|O 7|O surgical|O resections|O .|O 
RESULTS|O :|O 
In|O -|O frame|O deletion|O of|O exon|O 11|O was|O detected|O in|O eight|O cases|O (|O 7|O monoalleic|O ,|O 1|O bialleic|O )|O ;|O a|O point|O mutation|O was|O found|O in|O one|O case|O .|O 
Mutation|O was|O found|O only|O in|O histologically|O malignant|O (|O 6|O of|O 10|O cases|O )|O and|O borderline|O GISTs|O (|O 3|O of|O 4|O cases|O )|O .|O 
No|O mutation|O was|O identified|O in|O benign|O tumors|O .|O 
In|O three|O cases|O ,|O scant|O cellularity|O or|O blood|O precluded|O sequencing|O .|O 
CD|gene-protein 117|gene-protein was|O expressed|O in|O 12|O of|O 15|O cases|O .|O 
CONCLUSION|O :|O 
Immunocytochemical|O staining|O for|O CD|gene-protein 117|gene-protein is|O useful|O in|O confirming|O a|O cytologic|O diagnosis|O of|O GIST|O but|O does|O not|O facilitate|O diagnosis|O of|O malignancy|O .|O 
FNA|O biopsy|O specimens|O are|O suitable|O for|O KIT|gene-rna gene|O sequencing|O ;|O detection|O of|O a|O KIT|gene-rna mutation|O favors|O a|O malignant|O diagnosis|O ,|O though|O absence|O of|O mutation|O does|O not|O preclude|O malignancy|O .|O 
Epstein|O -|O Barr|O virus|O associated|O B-cell|O lymphoma|O of|O brain|O developing|O in|O myelodysplastic|O syndrome|O with|O c-kit|gene-rna mutation|O (|O Try|O -|O 557|O -->|O stop|O )|O .|O 
The|O first|O case|O of|O B-cell|O lymphoma|O of|O brain|O in|O a|O patient|O with|O myelodysplastic|O syndrome|O (|O MDS|O )|O was|O reported|O .|O 
A|O 68|O -|O year|O -|O old|O man|O was|O admitted|O because|O of|O anemia|O ,|O fever|O ,|O and|O thrombocytopenia|O and|O was|O diagnosed|O as|O having|O MDS|O (|O refractory|O anemia|O with|O excess|O of|O blasts|O )|O on|O the|O basis|O of|O the|O findings|O of|O bone|O marrow|O aspiration|O and|O chromosomal|O analysis|O .|O 
The|O patient|O was|O followed|O up|O without|O chemotherapy|O ,|O but|O a|O brain|O tumor|O appeared|O after|O 3|O years|O .|O 
Histologic|O and|O immunohistologic|O examinations|O revealed|O diffuse|O large|O B-cell|O lymphoma|O .|O 
Mutations|O of|O the|O c-kit|gene-rna proto|O -|O oncogene|O (|O stem|gene-protein cell|gene-protein factor|gene-protein receptor|gene-protein )|O and|O the|O p53|gene-rna tumor|O -|O suppressor|O gene|O were|O examined|O in|O the|O MDS|O lesion|O and|O malignant|O lymphoma|O (|O ML|O )|O by|O the|O polymerase|gene-protein chain|O reaction|O -|O single|O -|O strand|O conformational|O polymorphism|O (|O PCR|O -|O SSCP|O )|O method|O followed|O by|O direct|O sequencing|O .|O 
The|O p53|gene-rna mutation|O was|O not|O found|O in|O either|O MDS|O or|O ML|O ,|O but|O a|O nonsense|O mutation|O (|O Try|O -|O 557|O -->|O stop|O )|O in|O exon|O 11|O of|O the|O c-kit|gene-rna ,|O which|O might|O lead|O to|O dysfunction|O of|O tyrosine|gene-protein kinase|gene-protein activity|O ,|O was|O detected|O in|O MDS|O .|O 
This|O is|O the|O first|O report|O of|O c-kit|gene-rna mutation|O in|O MDS|O .|O 
Epstein|O -|O Barr|O virus|O (|O EBV|O )|O genome|O was|O demonstrated|O in|O the|O nucleus|O of|O brain|O ML|O cells|O by|O in|O situ|O hybridization|O with|O EBV|O -|O encoded|O RNA-1|O probe|O .|O 
Immunohistochemistry|O showed|O that|O the|O tumor|O cells|O expressed|O latent|O infection|O gene|O products|O ,|O including|O EBV|gene-protein nuclear|gene-protein antigen-2|gene-protein and|O latent|gene-protein membrane|gene-protein protein-1|gene-protein .|O 
This|O pattern|O of|O latent|O gene|O expression|O was|O Lat|O III|O ,|O which|O is|O usually|O found|O in|O malignant|O lymphomas|O developing|O in|O immunocompromised|O hosts|O .|O 
These|O findings|O suggest|O that|O a|O profound|O pancytopenia|O in|O MDS|O resulted|O in|O an|O immunodeficient|O condition|O ,|O after|O which|O EBV|O -|O positive|O B-cell|O lymphoma|O of|O brain|O developed|O .|O 
Beta-catenin|gene-rna mutations|O are|O associated|O with|O a|O subset|O of|O low|O -|O stage|O hepatocellular|O carcinoma|O negative|O for|O hepatitis|O B|O virus|O and|O with|O favorable|O prognosis|O .|O 
To|O better|O understand|O the|O role|O of|O beta-catenin|gene-rna mutation|O in|O hepatocellular|O carcinoma|O (|O HCC|O )|O ,|O we|O correlated|O the|O gene|gene-rna mutation|O with|O hepatitis|O virus|O B|O (|O HBV|O )|O and|O hepatitis|O virus|O C|O (|O HCV|O )|O status|O and|O the|O clinicopathological|O features|O in|O 366|O patients|O with|O resected|O primary|O unifocal|O HCC|O .|O 
beta-Catenin|gene-rna mutations|O were|O also|O analyzed|O in|O 55|O patients|O with|O multifocal|O HCC|O (|O 68|O tumors|O )|O .|O 
Of|O the|O whole|O series|O ,|O 57|O (|O 13.1|O %|O )|O of|O 434|O tumors|O examined|O had|O beta-catenin|gene-rna mutations|O ,|O 34|O occurred|O at|O the|O serine|O /|O threonine|O residues|O of|O the|O GSK-3beta|gene-protein region|O of|O beta-catenin|gene-rna .|O 
Outside|O the|O GSK-3beta|gene-protein phosphorylation|O site|O ,|O codons|O 32|O and|O 34|O were|O two|O mutational|O hot|O spots|O (|O 17|O tumors|O )|O .|O 
The|O non|O -|O HBV|O -|O related|O HCC|O that|O was|O predominantly|O HCV|O related|O had|O a|O higher|O frequency|O of|O mutation|O (|O P|O :|O <|O 0.00001|O )|O and|O more|O frequent|O mutations|O at|O codon|O 45|O than|O HBV|O -|O related|O HCC|O .|O 
HBV|O -|O related|O HCC|O had|O a|O younger|O mean|O age|O (|O P|O :|O <|O 0.00001|O )|O ,|O and|O higher|O male|O -|O to|O -|O female|O ratio|O (|O P|O :|O <|O 0.003|O )|O and|O positive|O familial|O history|O of|O HCC|O (|O P|O :|O <|O 0.014|O )|O .|O 
Among|O 366|O unifocal|O HCCs|O selected|O for|O clinicopathological|O analysis|O ,|O beta-catenin|gene-rna mutations|O were|O associated|O with|O grade|O I|O (|O P|O :|O =|O 0.005|O )|O and|O stage|O I|O and|O II|O HCC|O (|O P|O :|O <|O 0.0001|O )|O ,|O and|O a|O better|O 5|O -|O year|O survival|O rate|O (|O P|O :|O =|O 0.|O 00003|O )|O .|O 
These|O findings|O suggest|O mechanisms|O for|O beta-catenin|gene-rna mutations|O differ|O between|O HBV|O -|O related|O and|O non|O -|O HBV|O -|O related|O HCCs|O ,|O and|O that|O beta-catenin|gene-rna mutation|O is|O a|O favorable|O prognostic|O factor|O related|O to|O low|O stage|O .|O 
beta-Catenin|gene-rna mutation|O was|O associated|O with|O nuclear|O expression|O of|O the|O protein|gene-protein (|O P|O :|O <|O 0.00001|O )|O ,|O but|O we|O failed|O to|O detect|O point|O or|O large|O fragment|O deletion|O mutation|O in|O 39|O HCCs|O with|O nuclear|O beta-catenin|gene-protein expression|O ,|O presumably|O wild|O -|O type|O protein|gene-protein .|O 
HCCs|O expressing|O mutant|O nuclear|O beta-catenin|gene-protein had|O a|O better|O 5|O -|O year|O survival|O rate|O (|O P|O :|O <|O 0.007|O )|O ,|O suggesting|O that|O mutant|O and|O wild|O -|O type|O nuclear|O beta-catenin|gene-protein proteins|O are|O not|O functionally|O equivalent|O and|O deserve|O more|O studies|O for|O further|O clarification|O .|O 
Application|O of|O the|O p53|gene-rna and|O K-ras|gene-rna gene|O mutation|O patterns|O for|O cytologic|O diagnosis|O of|O recurrent|O lung|O carcinomas|O .|O 
BACKGROUND|O :|O 
Cytologic|O specimens|O are|O one|O of|O the|O most|O important|O materials|O for|O lung|O carcinoma|O diagnosis|O ,|O because|O they|O can|O be|O used|O in|O mass|O screening|O for|O lung|O carcinoma|O and|O early|O detection|O of|O cancer|O recurrence|O by|O examination|O of|O sputum|O and|O pleural|O fluid|O .|O 
METHODS|O :|O 
To|O prove|O the|O potentiality|O of|O the|O cytologic|O specimens|O to|O be|O subjected|O to|O molecular|O detection|O of|O recurrent|O lung|O carcinomas|O ,|O the|O authors|O enrolled|O 16|O patients|O who|O had|O undergone|O surgical|O treatment|O for|O lung|O carcinoma|O with|O recurrence|O detected|O by|O malignant|O pleural|O fluid|O .|O 
First|O ,|O they|O examined|O K-ras|gene-rna gene|O and|O p53|gene-rna tumor|O suppressor|O gene|O abnormalities|O in|O resected|O tumors|O by|O polymerase|gene-protein chain|O reaction|O -|O based|O single|O -|O strand|O conformation|O polymorphism|O (|O PCR|O -|O SSCP|O )|O analysis|O .|O 
Next|O ,|O using|O a|O microdissection|O method|O ,|O they|O investigated|O the|O use|O of|O cytologic|O specimens|O such|O as|O pleural|O fluid|O for|O the|O detection|O of|O recurrence|O by|O finding|O the|O same|O mutations|O observed|O in|O the|O initially|O resected|O tumor|O .|O 
RESULTS|O :|O 
Seven|O abnormally|O shifted|O bands|O were|O detected|O among|O six|O patients|O by|O PCR|O -|O SSCP|O analysis|O of|O surgical|O materials|O .|O 
Five|O of|O 7|O abnormally|O shifted|O bands|O (|O 71.4|O %|O )|O also|O were|O detected|O from|O microdissected|O malignant|O cells|O in|O cytologic|O smears|O .|O 
In|O two|O cases|O ,|O they|O detected|O mutations|O by|O using|O single|O malignant|O cells|O in|O pleural|O fluid|O .|O 
CONCLUSIONS|O :|O 
The|O authors|O successfully|O detected|O the|O same|O mutations|O in|O recurrent|O cytologic|O specimens|O as|O those|O in|O the|O initially|O resected|O tumors|O by|O PCR|O -|O SSCP|O analysis|O .|O 
These|O findings|O suggest|O that|O the|O p53|gene-rna and|O K-ras|gene-rna gene|O mutation|O patterns|O are|O effective|O markers|O for|O the|O detection|O of|O recurrent|O lung|O carcinoma|O in|O cytologic|O specimens|O .|O 
Beta-catenin|gene-rna and|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|O APC|gene-rna )|O mutations|O in|O adenomas|O from|O hereditary|O non|O -|O polyposis|O colorectal|O cancer|O patients|O .|O 
To|O clarify|O the|O roles|O of|O the|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|O APC|gene-rna )|O and|O beta-catenin|gene-rna genes|O in|O hereditary|O nonpolyposis|O colorectal|O cancer|O (|O HNPCC|O )|O tumorigenesis|O ,|O we|O searched|O for|O their|O mutations|O in|O 14|O HNPCC|O adenomas|O with|O microsatellite|O instability|O (|O MSI|O )|O .|O 
Seven|O (|O 50|O %|O )|O adenomas|O exhibited|O somatic|O APC|gene-rna mutations|O ,|O five|O of|O which|O were|O frameshift|O mutations|O and|O the|O other|O two|O nonsense|O ones|O .|O 
However|O ,|O the|O APC|gene-rna mutational|O spectrum|O of|O these|O adenomas|O was|O similar|O to|O that|O of|O sporadic|O colorectal|O tumors|O .|O 
Two|O adenomas|O (|O 14.3|O %|O )|O with|O undetectable|O APC|gene-rna alterations|O showed|O missense|O mutations|O at|O codon|O 45|O (|O TCT|O to|O TTT|O or|O to|O CCT|O )|O in|O beta-catenin|gene-rna .|O 
The|O MSI|O frequency|O in|O adenomas|O with|O beta-catenin|gene-rna mutations|O was|O significantly|O higher|O than|O that|O with|O APC|gene-rna ones|O (|O P|O <|O 0.001|O )|O ,|O indicating|O that|O mutations|O of|O beta-catenin|gene-rna rather|O than|O APC|gene-rna are|O strongly|O associated|O with|O MSI|O .|O 
These|O data|O suggest|O that|O adenomas|O with|O beta-catenin|gene-rna activating|O mutations|O and|O some|O with|O APC|gene-rna inactivating|O mutations|O may|O be|O precursors|O of|O HNPCC|O colorectal|O cancers|O .|O 
Somatic|O mutations|O of|O beta-catenin|gene-rna play|O a|O crucial|O role|O in|O the|O tumorigenesis|O of|O sporadic|O hepatoblastoma|O .|O 
Hepatoblastoma|O (|O HB|O )|O is|O the|O most|O common|O malignant|O hepatic|O tumor|O during|O early|O childhood|O .|O 
Its|O molecular|O pathogenesis|O is|O still|O poorly|O understood|O .|O 
Mutations|O of|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|O APC|gene-rna )|O gene|O have|O been|O identified|O in|O sporadic|O cases|O and|O in|O individuals|O associated|O with|O familial|O adenomatous|O polyposis|O syndrome|O .|O 
beta-catenin|gene-generic is|O a|O key|O element|O in|O the|O cadherin|gene-protein -|O mediated|O cell|O adhesion|O system|O and|O Wnt|gene-rna /|O wingless|gene-rna pathway|O ,|O and|O is|O controlled|O by|O APC|gene-rna .|O 
APC|gene-rna affects|O the|O degradation|O of|O beta-catenin|gene-protein by|O its|O NH(2)|O -|O terminal|O phosphorylation|O on|O the|O serine|O /|O threonine|O residues|O of|O exon|O 3|O .|O 
Mutations|O of|O these|O phosphorylation|O sites|O are|O primary|O targets|O for|O activating|O mutations|O in|O several|O types|O of|O human|O cancer|O and|O lead|O to|O nuclear|O accumulation|O of|O beta-catenin|gene-protein protein|O .|O 
In|O this|O study|O ,|O we|O examined|O nine|O patients|O with|O HB|O using|O immunohistochemistry|O and|O direct|O DNA|O sequencing|O .|O 
All|O nine|O cases|O showed|O predominant|O nuclear|O expression|O of|O beta-catenin|gene-protein .|O 
Eight|O cases|O (|O 89|O %|O )|O showed|O mutations|O involving|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O ,|O including|O five|O with|O deletions|O and|O three|O with|O missense|O mutations|O .|O 
All|O five|O deletions|O were|O in|O -|O frame|O deletions|O without|O frameshift|O .|O 
The|O very|O high|O frequency|O of|O mutations|O in|O the|O beta-catenin|gene-rna gene|O suggests|O that|O beta-catenin|gene-rna mutations|O are|O crucial|O in|O the|O tumorigenesis|O of|O HB|O .|O 
AXIN1|gene-rna mutations|O in|O hepatocellular|O carcinomas|O ,|O and|O growth|O suppression|O in|O cancer|O cells|O by|O virus|O -|O mediated|O transfer|O of|O AXIN1|gene-rna .|O 
The|O Wnt|gene-rna signaling|O pathway|O is|O essential|O for|O development|O and|O organogenesis|O .|O 
Wnt|gene-rna signaling|O stabilizes|O beta-catenin|gene-protein ,|O which|O accumulates|O in|O the|O cytoplasm|O ,|O binds|O to|O 1-cell|O factor|O (|O TCF|gene-protein ;|O also|O known|O as|O lymphocyte|gene-protein enhancer|gene-protein -|gene-protein binding|gene-protein factor|gene-protein ,|O LEF|gene-protein )|O and|O then|O upregulates|O downstream|O genes|O .|O 
Mutations|O in|O CTNNB1|gene-rna (|O encoding|O beta-catenin|gene-protein )|O or|O APC|gene-rna (|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna )|O have|O been|O reported|O in|O human|O neoplasms|O including|O colon|O cancers|O and|O hepatocellular|O carcinomas|O (|O HCCs|O )|O .|O 
Because|O HCC5|O tend|O to|O show|O accumulation|O of|O beta-catenin|gene-protein more|O often|O than|O mutations|O in|O CTNNB1|gene-rna ,|O we|O looked|O for|O mutations|O in|O AXIN1|gene-rna ,|O encoding|O a|O key|O factor|O for|O Wnt|gene-rna signaling|O ,|O in|O 6|O HCC|O cell|O lines|O and|O 100|O primary|O HCC5|O .|O 
Among|O the|O 4|O cell|O lines|O and|O 87|O HCC5|O in|O which|O we|O did|O not|O detect|O CTNNB1|gene-rna mutations|O ,|O we|O identified|O AXIN1|gene-rna mutations|O in|O 3|O cell|O lines|O and|O 6|O mutations|O in|O 5|O of|O the|O primary|O HCCs|O .|O 
In|O cell|O lines|O containing|O mutations|O in|O either|O gene|O ,|O we|O observed|O increased|O DNA|O binding|O of|O TCF|gene-protein associated|O with|O beta-catenin|gene-protein in|O nuclei|O .|O 
Adenovirus|O mediated|O gene|O transfer|O of|O wild|O -|O type|O AXINI|gene-rna induced|O apoptosis|O in|O hepatocellular|O and|O colorectal|O cancer|O cells|O that|O had|O accumulated|O beta-catenin|gene-protein as|O a|O consequence|O of|O either|O APC|gene-rna ,|O CTNNB1|gene-rna or|O AXIN1|gene-rna mutation|O ,|O suggesting|O that|O axin|gene-protein may|O be|O an|O effective|O therapeutic|O molecule|O for|O suppressing|O growth|O of|O hepatocellular|O and|O colorectal|O cancers|O .|O 
Beta-catenin|gene-protein accumulation|O and|O mutation|O of|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O in|O hepatocellular|O carcinoma|O .|O 
A|O study|O was|O conducted|O to|O clarify|O the|O contribution|O of|O beta-catenin|gene-protein accumulation|O and|O mutation|O of|O the|O beta-catenin|gene-rna gene|O to|O hepatocarcinogenesis|O .|O 
Beta-catenin|gene-protein accumulation|O was|O examined|O immunohistochemically|O in|O 38|O paired|O samples|O of|O hepatocellular|O carcinoma|O (|O HCC|O )|O and|O corresponding|O non|O -|O cancerous|O liver|O tissue|O .|O 
Gene|O mutation|O was|O analyzed|O by|O polymerase|gene-protein chain|O reaction|O -|O single|O strand|O conformation|O polymorphism|O (|O PCR|O -|O SSCP|O )|O and|O direct|O sequencing|O using|O intronic|O primers|O encompassing|O exon|O 3|O .|O 
Neither|O accumulation|O nor|O mutation|O was|O detected|O in|O non|O -|O cancerous|O liver|O tissues|O that|O showed|O no|O remarkable|O histological|O features|O ,|O chronic|O hepatitis|O or|O liver|O cirrhosis|O .|O 
Accumulation|O of|O beta-catenin|gene-protein was|O seen|O in|O the|O nucleus|O ,|O cytoplasm|O or|O cell|O membrane|O in|O 15|O of|O 38|O (|O 39|O %|O )|O HCC|O samples|O ,|O and|O gene|O mutation|O was|O seen|O in|O 9|O of|O 38|O (|O 24|O %|O )|O HCC|O samples|O .|O 
Although|O there|O was|O a|O significant|O correlation|O between|O accumulation|O and|O mutation|O (|O P|O <|O 0.01|O )|O ,|O six|O HCCs|O without|O mutation|O also|O showed|O accumulation|O .|O 
Samples|O of|O early|O HCC|O showed|O neither|O accumulation|O nor|O mutation|O ,|O and|O accumulation|O and|O mutation|O were|O each|O correlated|O significantly|O with|O portal|O vein|O tumor|O involvement|O (|O P|O <|O 0.05|O )|O .|O 
The|O present|O results|O indicate|O that|O (1)|O mutation|O of|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O can|O lead|O to|O beta-catenin|gene-protein accumulation|O ,|O although|O other|O mechanisms|O of|O accumulation|O may|O also|O operate|O in|O HCC|O ,|O and|O (2)|O beta-catenin|gene-protein accumulation|O and|O mutation|O of|O the|O beta-catenin|gene-rna gene|O are|O not|O early|O events|O in|O hepatocarcinogenesis|O ,|O and|O may|O be|O associated|O with|O the|O malignant|O progression|O of|O HCC|O .|O 
K-ras2|gene-rna activation|O and|O genome|O instability|O increase|O proliferation|O and|O size|O of|O FAP|O adenomas|O .|O 
The|O possible|O role|O of|O K-ras2|gene-rna mutations|O and|O aneuploidy|O toward|O increase|O of|O proliferation|O and|O adenoma|O size|O in|O Familial|O Adenomatous|O Polyposis|O (|O FAP|O )|O adenomas|O is|O not|O known|O .|O 
The|O present|O study|O addresses|O these|O issues|O by|O investigating|O 147|O colorectal|O adenomas|O obtained|O from|O four|O FAP|O patients|O .|O 
The|O majority|O of|O adenomas|O had|O size|O lower|O than|O or|O equal|O to|O 10|O mm|O (|O 86|O %|O )|O ,|O low|O grade|O dysplasia|O (|O 63|O %|O )|O ,|O and|O were|O preferentially|O located|O in|O the|O right|O colon|O (|O 60|O %|O )|O .|O 
Normal|O mucosa|O samples|O were|O obtained|O from|O 19|O healthy|O donors|O .|O 
Three|O synchronous|O adenocarcinomas|O were|O also|O investigated|O .|O 
K-ras2|gene-rna mutation|O spectrum|O was|O analysed|O by|O PCR|O and|O Sequence|O Specific|O Oligonucleotide|O (|O SSO|O )|O hybridization|O ,|O while|O flow|O cytometry|O (|O FCM|O )|O was|O used|O for|O evaluating|O degree|O of|O DNA|O ploidy|O and|O S-phase|O fraction|O .|O 
Overall|O ,|O incidences|O of|O K-ras2|gene-rna mutations|O ,|O DNA|O aneuploidy|O and|O high|O S-phase|O values|O (|O >|O 7.2|O %|O )|O were|O 6.6|O %|O ,|O 5.4|O %|O and|O 10.5|O %|O ,|O respectively|O .|O 
In|O particular|O ,|O among|O the|O adenomas|O with|O size|O lower|O than|O 5|O mm|O ,|O K-ras2|gene-rna mutation|O and|O DNA|O aneuploidy|O frequencies|O were|O only|O slightly|O above|O 1|O %|O .|O 
Statistically|O significant|O correlations|O were|O found|O between|O K-ras2|gene-rna and|O size|O ,|O DNA|O ploidy|O and|O size|O and|O K-ras2|gene-rna and|O S-phase|O (|O p|O <|O 0.001|O )|O .|O 
In|O particular|O ,|O among|O the|O wild|O type|O K-ras2|gene-rna adenomas|O ,|O high|O S-phase|O values|O were|O detected|O in|O 8|O %|O of|O the|O cases|O versus|O 57|O %|O among|O the|O K-ras2|gene-rna mutated|O adenomas|O (|O p|O =|O 0.0005|O )|O .|O 
The|O present|O series|O of|O FAP|O adenomas|O indicates|O that|O K-ras2|gene-rna activation|O and|O gross|O genomic|O changes|O play|O a|O role|O toward|O a|O proliferative|O gain|O and|O tumour|O growth|O in|O size|O .|O 
K-ras|gene-rna mutations|O in|O DNA|O extracted|O from|O the|O plasma|O of|O patients|O with|O pancreatic|O carcinoma|O :|O diagnostic|O utility|O and|O prognostic|O significance|O .|O 
PURPOSE|O :|O 
Previous|O studies|O have|O demonstrated|O the|O presence|O of|O K-ras|gene-rna mutations|O in|O the|O plasma|O of|O patients|O with|O pancreatic|O carcinoma|O .|O 
However|O ,|O the|O diagnostic|O utility|O and|O the|O prognostic|O significance|O of|O this|O finding|O have|O never|O been|O addressed|O .|O 
PATIENTS|O AND|O METHODS|O :|O 
Forty-four|O consecutive|O patients|O with|O histologically|O confirmed|O primary|O pancreatic|O ductal|O adenocarcinoma|O were|O included|O .|O 
A|O control|O group|O of|O 37|O patients|O with|O chronic|O pancreatitis|O ,|O 10|O patients|O with|O other|O tumors|O of|O the|O pancreatic|O area|O ,|O nine|O patients|O with|O acute|O pancreatitis|O ,|O and|O four|O healthy|O volunteers|O was|O also|O included|O .|O 
Plasma|O DNA|O was|O isolated|O and|O K-ras|gene-rna codon|O -|O 12|O mutations|O were|O analyzed|O by|O means|O of|O restriction|O fragment|O length|O polymorphism|O -|O polymerase|gene-protein chain|O reaction|O and|O single|O -|O strand|O conformation|O polymorphism|O techniques|O .|O 
Patients|O were|O followed|O up|O to|O establish|O their|O clinical|O outcome|O .|O 
RESULTS|O :|O 
The|O mutant|O -|O type|O K-ras|gene-rna gene|O was|O found|O in|O plasma|O DNA|O samples|O of|O 12|O (|O 27|O %|O )|O of|O 44|O patients|O with|O pancreatic|O ductal|O adenocarcinoma|O ;|O this|O finding|O was|O related|O to|O the|O tumor|O stage|O (|O P|O =|O .05|O )|O ,|O mainly|O in|O the|O presence|O of|O distant|O metastases|O (|O P|O =|O .02|O )|O .|O 
In|O addition|O ,|O K-ras|gene-rna mutations|O were|O detected|O in|O the|O plasma|O DNA|O of|O two|O (|O 5|O %|O )|O of|O 37|O patients|O with|O chronic|O pancreatitis|O .|O 
In|O the|O subset|O of|O patients|O with|O pancreatic|O masses|O ,|O the|O sensitivity|O and|O specificity|O of|O plasma|O K-ras|gene-rna analysis|O for|O pancreatic|O adenocarcinoma|O were|O 27|O %|O and|O 100|O %|O ,|O respectively|O .|O 
Finally|O ,|O pancreatic|O carcinoma|O patients|O with|O the|O mutant|O -|O type|O K-ras|gene-rna gene|O in|O plasma|O DNA|O exhibited|O a|O shorter|O survival|O time|O than|O patients|O with|O the|O wild|O -|O type|O gene|gene-rna (|O P|O <|O .005|O )|O ,|O and|O plasma|O K-ras|gene-rna mutations|O were|O identified|O as|O the|O only|O independent|O prognostic|O factor|O (|O odds|O ratio|O ,|O 1.51|O ;|O 95|O %|O confidence|O interval|O ,|O 1.02|O to|O 2.23|O )|O .|O 
CONCLUSION|O :|O 
Plasma|O K-ras|gene-rna analysis|O is|O a|O highly|O specific|O ,|O low|O -|O sensitivity|O approach|O that|O has|O diagnostic|O and|O prognostic|O clinical|O implications|O in|O patients|O with|O pancreatic|O carcinoma|O .|O 
Alterations|O of|O the|O p53|gene-rna ,|O p21|gene-rna ,|O p16|gene-rna ,|O p15|gene-rna and|O RAS|gene-rna genes|O in|O childhood|O T-cell|O acute|O lymphoblastic|O leukemia|O .|O 
We|O investigated|O the|O alterations|O of|O the|O p53|gene-rna ,|O p21|gene-rna ,|O p16|gene-rna ,|O p15|gene-rna and|O RAS|gene-rna genes|O in|O childhood|O T-cell|O acute|O lymphoblastic|O leukemia|O (|O T-ALL|O )|O and|O T-ALL|O cell|O lines|O by|O polymerase|gene-protein chain|O reaction|O -|O single|O strand|O conformation|O polymorphism|O (|O PCR|O -|O SSCP|O )|O analysis|O and|O direct|O sequencing|O .|O 
Mutations|O of|O the|O p53|gene-rna gene|O were|O found|O in|O three|O of|O 57|O (|O 5|O %|O )|O patients|O at|O diagnosis|O ,|O one|O of|O 14|O (|O 7|O %|O )|O patients|O at|O relapse|O and|O in|O 12|O of|O 18|O (|O 67|O %|O )|O cell|O lines|O .|O 
In|O these|O 12|O cell|O lines|O ,|O four|O had|O more|O than|O two|O mutations|O of|O the|O p53|gene-rna gene|O .|O 
The|O p53|gene-rna mutations|O were|O found|O in|O four|O of|O five|O cell|O lines|O whose|O original|O fresh|O leukemic|O cells|O were|O simultaneously|O examined|O original|O fresh|O leukemic|O cells|O .|O 
However|O ,|O only|O one|O of|O the|O four|O fresh|O leukemic|O cells|O had|O the|O same|O mutation|O .|O 
All|O patients|O with|O p53|gene-rna mutations|O in|O the|O course|O of|O disease|O died|O .|O 
Mutations|O of|O the|O p21|gene-rna gene|O were|O not|O identified|O in|O 71|O fresh|O samples|O and|O in|O 18|O cell|O lines|O .|O 
N-RAS|gene-rna mutations|O were|O found|O in|O two|O of|O 57|O (|O 4|O %|O )|O fresh|O T-ALL|O patients|O at|O diagnosis|O ,|O and|O four|O of|O 18|O cell|O lines|O (|O 22|O %|O )|O ,|O whereas|O no|O mutations|O were|O detected|O in|O any|O samples|O at|O relapse|O .|O 
Alterations|O of|O the|O p16|gene-rna gene|O were|O found|O in|O 18|O of|O 47|O (|O 38|O %|O )|O patients|O at|O diagnosis|O and|O in|O seven|O of|O 14|O (|O 50|O %|O )|O at|O relapse|O .|O 
These|O differences|O were|O not|O statistically|O significant|O .|O 
There|O were|O no|O differences|O in|O the|O frequency|O of|O alteration|O of|O the|O p16|gene-rna and|O p15|gene-rna genes|O between|O event|O -|O free|O patients|O and|O the|O remaining|O patients|O .|O 
Furthermore|O ,|O we|O found|O the|O methylation|O of|O p16|gene-rna gene|O in|O three|O of|O seven|O patients|O lacking|O homozygous|O deletions|O ,|O suggesting|O higher|O frequency|O of|O p16|gene-rna inactivation|O than|O previous|O reports|O in|O T-ALL|O .|O 
Interestingly|O ,|O we|O found|O that|O one|O allele|O is|O inactivated|O by|O methylation|O and|O another|O allele|O had|O nonsense|O mutation|O in|O one|O cell|O line|O (|O KOPT-KI|O )|O ,|O resulting|O in|O loss|O of|O protein|O expression|O of|O p16|gene-rna .|O 
This|O type|O of|O p16|gene-rna inactivation|O has|O not|O been|O so|O far|O reported|O in|O leukemia|O .|O 
We|O conclude|O that|O ,|O (1)|O p53|gene-rna mutations|O are|O infrequent|O at|O diagnosis|O but|O tend|O to|O be|O associated|O with|O poor|O clinical|O outcome|O ;|O (2)|O RAS|gene-rna and|O p21|gene-rna mutations|O may|O not|O be|O involved|O in|O the|O pathogenesis|O of|O T-ALL|O ;|O (3)|O not|O only|O frequent|O alterations|O of|O p16|gene-rna and|O p15|gene-rna genes|O but|O also|O methylation|O of|O p16|gene-rna gene|O are|O involved|O in|O initiating|O the|O leukemogenesis|O of|O T-ALLs|O ,|O and|O (4)|O these|O 5|O genes|O are|O independently|O involved|O in|O T-ALL|O .|O 
Ki-ras|gene-rna codon|O 12|O point|O mutational|O activation|O in|O Hong|O Kong|O colorectal|O carcinoma|O patients|O .|O 
This|O study|O investigated|O the|O frequency|O and|O importance|O of|O Ki-ras|gene-rna codon|O 12|O mutations|O in|O 99|O Hong|O Kong|O Chinese|O colorectal|O carcinoma|O specimens|O by|O allele|O -|O specific|O oligonucleotide|O hybridization|O .|O 
The|O frequency|O of|O mutations|O detected|O was|O 30|O %|O and|O the|O most|O common|O mutation|O observed|O resulted|O in|O aspartic|O acid|O substitutions|O .|O 
Previous|O studies|O showed|O that|O specific|O Ki-ras|gene-rna mutations|O have|O been|O significantly|O associated|O with|O prognosis|O .|O 
Ki-ras|gene-rna codon|O 12|O point|O mutational|O activation|O in|O CRC|O was|O significantly|O associated|O with|O the|O differentiation|O status|O of|O tumors|O in|O this|O study|O .|O 
Ethnic|O differences|O in|O the|O patterns|O of|O Ki-ras|gene-rna codon|O 12|O point|O mutations|O were|O observed|O .|O 
Activating|O and|O dominant|O inactivating|O c-KIT|gene-rna catalytic|O domain|O mutations|O in|O distinct|O clinical|O forms|O of|O human|O mastocytosis|O .|O 
Human|O mastocytosis|O is|O characterized|O by|O increased|O mast|O cells|O .|O 
It|O usually|O occurs|O as|O a|O sporadic|O disease|O that|O is|O often|O transient|O and|O limited|O in|O children|O and|O persistent|O or|O progressive|O in|O adults|O .|O 
The|O c-KIT|gene-rna protooncogene|O encodes|O KIT|gene-protein ,|O a|O tyrosine|gene-protein kinase|gene-protein that|O is|O the|O receptor|gene-protein for|gene-protein mast|gene-protein cell|gene-protein growth|gene-protein factor|gene-protein .|O 
Because|O mutated|O KIT|gene-protein can|O transform|O cells|O ,|O we|O examined|O c-KIT|gene-rna in|O skin|O lesions|O of|O 22|O patients|O with|O sporadic|O mastocytosis|O and|O 3|O patients|O with|O familial|O mastocytosis|O .|O 
All|O patients|O with|O adult|O sporadic|O mastocytosis|O had|O somatic|O c-KIT|gene-rna mutations|O in|O codon|O 816|O causing|O substitution|O of|O valine|O for|O aspartate|O and|O spontaneous|O activation|O of|O mast|gene-protein cell|gene-protein growth|gene-protein factor|gene-protein receptor|gene-protein (|O P|O =|O 0.0001|O )|O .|O 
A|O subset|O of|O four|O pediatric|O onset|O cases|O with|O clinically|O unusual|O disease|O also|O had|O codon|O 816|O activating|O mutations|O substituting|O valine|O ,|O tyrosine|O ,|O or|O phenylalanine|O for|O aspartate|O .|O 
Typical|O pediatric|O patients|O lacked|O 816|O mutations|O ,|O but|O limited|O sequencing|O showed|O three|O of|O six|O had|O a|O novel|O dominant|O inactivating|O mutation|O substituting|O lysine|O for|O glutamic|O acid|O in|O position|O 839|O ,|O the|O site|O of|O a|O potential|O salt|O bridge|O that|O is|O highly|O conserved|O in|O receptor|gene-protein tyrosine|gene-protein kinases|gene-protein .|O 
No|O c-KIT|gene-rna mutations|O were|O found|O in|O the|O entire|O coding|O region|O of|O three|O patients|O with|O familial|O mastocytosis|O .|O 
We|O conclude|O that|O c-KIT|gene-rna somatic|O mutations|O substituting|O valine|O in|O position|O 816|O of|O KIT|gene-protein are|O characteristic|O of|O sporadic|O adult|O mastocytosis|O and|O may|O cause|O this|O disease|O .|O 
Similar|O mutations|O causing|O activation|O of|O the|O mast|gene-protein cell|gene-protein growth|gene-protein factor|gene-protein receptor|gene-protein are|O found|O in|O children|O apparently|O at|O risk|O for|O extensive|O or|O persistent|O disease|O .|O 
In|O contrast|O ,|O typical|O pediatric|O mastocytosis|O patients|O lack|O these|O mutations|O and|O may|O express|O inactivating|O c-KIT|gene-rna mutations|O .|O 
Familial|O mastocytosis|O ,|O however|O ,|O may|O occur|O in|O the|O absence|O of|O c-KIT|gene-rna coding|O mutations|O .|O 
Activating|O SRC|gene-generic mutation|O in|O a|O subset|O of|O advanced|O human|O colon|O cancers|O .|O 
The|O discovery|O of|O Rous|O sarcoma|O virus|O (|O RSV|O )|O led|O to|O the|O identification|O of|O cellular|O Src|gene-protein (|O c-Src|gene-protein )|O ,|O a|O non|gene-protein -|gene-protein receptor|gene-protein tyrosine|gene-protein kinase|gene-protein ,|O which|O has|O since|O been|O implicated|O in|O the|O development|O of|O numerous|O human|O cancers|O .|O 
c-Src|gene-protein has|O been|O found|O to|O be|O highly|O activated|O in|O colon|O cancers|O ,|O particularly|O in|O those|O metastatic|O to|O the|O liver|O .|O 
Studies|O of|O the|O mechanism|O of|O c-Src|gene-protein regulation|O have|O suggested|O that|O c-Src|gene-protein kinase|gene-protein activity|O is|O downregulated|O by|O phosphorylation|O of|O a|O critical|O carboxy|O -|O terminal|O tyrosine|O (|O Tyr|O 530|O in|O human|O c-Src|gene-protein ,|O equivalent|O to|O Tyr|O 527|O in|O chicken|O Src|gene-protein )|O and|O have|O implied|O the|O existence|O of|O activating|O mutations|O in|O this|O C-terminal|O regulatory|O region|O .|O 
We|O report|O here|O the|O identification|O of|O a|O truncating|O mutation|O in|O SRC|gene-generic at|O codon|O 531|O in|O 12|O %|O of|O cases|O of|O advanced|O human|O colon|O cancer|O tested|O and|O demonstrate|O that|O the|O mutation|O is|O activating|O ,|O transforming|O ,|O tumorigenic|O and|O promotes|O metastasis|O .|O 
These|O results|O provide|O ,|O for|O the|O first|O time|O ,|O genetic|O evidence|O that|O activating|O SRC|gene-generic mutations|O may|O have|O a|O role|O in|O the|O malignant|O progression|O of|O human|O colon|O cancer|O .|O 
Somatic|O mutations|O in|O the|O kinase|gene-protein domain|O of|O the|O Met|gene-rna /|O hepatocyte|gene-rna growth|gene-rna factor|gene-rna receptor|gene-rna gene|O in|O childhood|O hepatocellular|O carcinomas|O .|O 
The|O MET|gene-rna protooncogene|O encodes|O a|O transmembrane|O tyrosine|gene-protein kinase|gene-protein identified|O as|O the|O receptor|O of|O a|O polypeptide|O known|O as|O hepatocyte|gene-protein growth|gene-protein factor|gene-protein /|O scatter|gene-protein factor|gene-protein .|O 
We|O performed|O PCR|O -|O based|O single|O -|O strand|O conformational|O polymorphism|O and|O sequencing|O analysis|O of|O the|O tyrosine|gene-protein kinase|gene-protein domain|O of|O the|O MET|gene-rna gene|O (|O exon|O 15|O -|O 19|O )|O in|O 75|O primary|O liver|O cancers|O .|O 
Three|O missense|O mutations|O were|O detected|O exclusively|O in|O 10|O childhood|O hepatocellular|O carcinomas|O (|O HCCs|O )|O ,|O while|O no|O mutations|O were|O detected|O in|O 16|O adult|O HCCs|O ,|O 21|O cholangiocarcinomas|O ,|O or|O 28|O hepatoblastomas|O .|O 
The|O extremely|O short|O incubation|O period|O from|O hepatitis|O B|O virus|O infection|O to|O the|O genesis|O of|O childhood|O HCC|O as|O compared|O with|O the|O adult|O HCC|O suggests|O that|O there|O may|O be|O an|O additional|O mechanism|O that|O accelerates|O the|O carcinogenesis|O of|O childhood|O HCC|O .|O 
Our|O results|O indicate|O that|O mutations|O of|O the|O tyrosine|gene-protein kinase|gene-protein domain|O of|O the|O MET|gene-rna gene|O may|O be|O involved|O in|O the|O acceleration|O of|O the|O carcinogenesis|O in|O childhood|O HCC|O .|O 
Childhood|O hepatoblastomas|O frequently|O carry|O a|O mutated|O degradation|O targeting|O box|O of|O the|O beta-catenin|gene-rna gene|O .|O 
Hepatoblastomas|O (|O HBs|O )|O are|O embryonal|O tumors|O affecting|O young|O children|O and|O representing|O the|O most|O frequent|O malignant|O liver|O tumors|O in|O childhood|O .|O 
The|O molecular|O pathogenesis|O of|O HB|O is|O poorly|O understood|O .|O 
Although|O most|O cases|O are|O sporadic|O ,|O the|O incidence|O is|O highly|O elevated|O in|O patients|O with|O familial|O adenomatous|O polyposis|O coli|O .|O 
These|O patients|O carry|O germline|O mutations|O of|O the|O APC|gene-rna tumor|O suppressor|O gene|O .|O 
APC|gene-rna controls|O the|O degradation|O of|O the|O oncogene|O product|O beta-catenin|gene-protein after|O its|O NH2|O -|O terminal|O phosphorylation|O on|O serine|O /|O threonine|O residues|O .|O 
APC|gene-rna ,|O as|O well|O as|O beta-catenin|gene-protein ,|O has|O been|O found|O to|O be|O a|O central|O effector|O of|O the|O growth|O promoting|O wingless|gene-rna signaling|O pathway|O in|O development|O .|O 
To|O find|O out|O if|O this|O pathway|O is|O involved|O in|O the|O pathogenesis|O of|O sporadic|O HBs|O ,|O we|O examined|O 52|O biopsies|O and|O three|O cell|O lines|O from|O sporadic|O HBs|O for|O mutations|O in|O the|O APC|gene-rna and|O beta-catenin|gene-rna genes|O .|O 
Using|O single|O -|O strand|O conformational|O polymorphism|O analysis|O ,|O deletion|O screening|O by|O PCR|O ,|O and|O direct|O sequencing|O ,|O we|O found|O a|O high|O frequency|O of|O beta-catenin|gene-rna mutations|O in|O sporadic|O HBs|O (|O 48|O %|O )|O .|O 
The|O mutations|O affected|O exon|O 3|O encoding|O the|O degradation|O targeting|O box|O of|O beta-catenin|gene-rna leading|O to|O accumulation|O of|O intracytoplasmic|O and|O nuclear|O beta-catenin|gene-protein protein|O .|O 
The|O high|O frequency|O of|O activating|O mutations|O in|O the|O beta-catenin|gene-rna gene|O indicates|O an|O important|O role|O in|O the|O pathogenesis|O of|O HB|O .|O 
Gallbladder|O adenomas|O have|O molecular|O abnormalities|O different|O from|O those|O present|O in|O gallbladder|O carcinomas|O .|O 
Although|O most|O gallbladder|O carcinomas|O evolve|O from|O dysplasia|O and|O carcinoma|O in|O situ|O ,|O the|O role|O of|O gallbladder|O adenomas|O in|O the|O pathogenesis|O of|O gallbladder|O carcinoma|O is|O still|O controversial|O .|O 
A|O series|O of|O molecular|O changes|O including|O loss|O of|O heterozygosity|O (|O LOH|O )|O at|O 17p|O (|O TP53|gene-rna gene|O )|O ,|O 13q|O (|O RB|gene-rna gene|O )|O ,|O 18q|O (|O DCC|gene-rna gene|O )|O ,|O and|O 9p21|O (|O CDKN2a|gene-rna gene|O )|O chromosomal|O regions|O have|O been|O identified|O in|O dysplasias|O ,|O carcinomas|O in|O situ|O ,|O and|O invasive|O carcinomas|O of|O the|O gallbladder|O ,|O whereas|O mutations|O in|O K|gene-rna -|gene-rna and|O N|gene-rna -|gene-rna ras|gene-rna genes|O are|O rare|O .|O 
To|O determine|O whether|O the|O molecular|O abnormalities|O of|O adenomas|O are|O similar|O to|O those|O found|O in|O carcinomas|O ,|O we|O obtained|O extracted|O DNA|O from|O precisely|O microdissected|O tissue|O from|O 16|O gallbladder|O adenomas|O (|O 14|O pyloric|O and|O 2|O intestinal|O -|O type|O )|O .|O 
We|O determined|O the|O presence|O of|O mutations|O in|O TP53|gene-rna ,|O K|gene-rna -|gene-rna and|O N|gene-rna -|gene-rna ras|gene-rna genes|O ,|O and|O LOH|O at|O five|O chromosomal|O regions|O (|O 5q22|O APC|gene-rna -|O MCC|gene-rna region|O ,|O RB|gene-rna ,|O TP53|gene-rna ,|O DCC|gene-rna and|O 9p21|O -|O CDKN2a|gene-rna )|O .|O 
For|O the|O TP53|gene-rna mutation|O study|O ,|O single|O strand|O conformational|O polymorphism|O (|O SSCP|O )|O analysis|O in|O exons|O 4|O to|O 8|O were|O performed|O .|O 
K|gene-rna -|gene-rna and|O N|gene-rna -|gene-rna ras|gene-rna mutations|O detection|O was|O performed|O by|O designed|O restriction|O fragment|O length|O polymorphism|O (|O RFLP|O )|O method|O and|O sequencing|O .|O 
Only|O a|O single|O LOH|O (|O at|O 5q22|O )|O was|O detected|O in|O a|O gallbladder|O adenoma|O of|O intestinal|O type|O .|O 
No|O mutations|O at|O the|O TP53|gene-rna were|O detected|O .|O 
Four|O adenomas|O (|O 25|O %|O )|O showed|O K-ras|gene-rna mutations|O (|O two|O in|O codon|O 12|O and|O two|O in|O codon|O 61|O )|O .|O 
We|O conclude|O that|O gallbladder|O adenoma|O lacks|O the|O molecular|O changes|O frequently|O detected|O in|O dysplasia|O ,|O carcinoma|O in|O situ|O ,|O and|O invasive|O carcinoma|O of|O the|O gallbladder|O .|O 
Likewise|O the|O occurrence|O of|O K-ras|gene-rna mutations|O at|O codon|O 12|O and|O 61|O in|O 25|O %|O of|O adenomas|O strongly|O suggests|O that|O these|O lesions|O are|O not|O precursors|O of|O invasive|O gallbladder|O carcinoma|O .|O 
Mutations|O in|O exon|O 11|O of|O c-Kit|gene-rna occur|O preferentially|O in|O malignant|O versus|O benign|O gastrointestinal|O stromal|O tumors|O and|O do|O not|O occur|O in|O leiomyomas|O or|O leiomyosarcomas|O .|O 
Gastrointestinal|O stromal|O tumors|O (|O GISTs|O )|O comprise|O the|O largest|O subset|O of|O mesenchymal|O tumors|O of|O the|O gastrointestinal|O tract|O .|O 
These|O neoplasms|O differ|O histologically|O and|O immunohistochemically|O from|O typical|O leiomyomas|O and|O leiomyosarcomas|O .|O 
Most|O GISTs|O express|O CD34|gene-protein and|O CD117|gene-protein (|O c-kit|gene-protein protein|O )|O but|O not|O desmin|gene-protein .|O 
Recently|O ,|O gain|O -|O of|O -|O function|O mutations|O of|O c-kit|gene-rna proto|O -|O oncogene|O have|O been|O shown|O in|O five|O solitary|O GISTs|O and|O in|O tumors|O and|O leukocytes|O from|O a|O family|O with|O multiple|O GISTs|O .|O 
An|O in-frame|O deletion|O or|O a|O point|O mutation|O in|O exon|O 11|O of|O c-kit|gene-rna was|O detected|O in|O these|O cases|O .|O 
Stable|O transfection|O of|O the|O mutant|O c-kit|gene-rna complementary|O DNA|O was|O also|O shown|O to|O induce|O malignant|O transformation|O of|O murine|O lymphoid|O cells|O ,|O suggesting|O that|O the|O c-kit|gene-rna mutations|O contribute|O to|O tumor|O development|O .|O 
In|O this|O study|O ,|O we|O evaluated|O 43|O GISTs|O and|O 14|O smooth|O muscle|O tumors|O for|O mutations|O in|O the|O exon|O 11|O of|O c-kit|gene-rna by|O a|O PCR|O -|O assay|O .|O 
Half|O of|O the|O malignant|O GISTs|O (|O 12|O /|O 24|O )|O and|O only|O one|O benign|O GIST|O (|O 1|O /|O 19|O )|O revealed|O mutant|O bands|O .|O 
No|O mutant|O bands|O were|O found|O in|O 3|O leiomyomas|O and|O 11|O leiomyosarcomas|O .|O 
Sequence|O analysis|O confirmed|O the|O presence|O of|O an|O in-frame|O deletion|O of|O 3|O -|O 21|O bp|O in|O all|O 13|O GISTs|O with|O mutant|O bands|O .|O 
Wild|O -|O type|O bands|O from|O 8|O malignant|O and|O 11|O benign|O GISTs|O and|O 7|O smooth|O muscle|O tumors|O without|O mutant|O bands|O were|O cloned|O and|O sequenced|O .|O 
Additional|O mutations|O were|O found|O in|O 3|O malignant|O and|O 2|O benign|O GISTs|O .|O 
There|O were|O no|O mutations|O in|O 3|O leiomyomas|O and|O 4|O leiomyosarcomas|O .|O 
The|O mutation|O status|O of|O exon|O 11|O did|O not|O correlate|O with|O immunohistochemically|O detectable|O expression|O of|O the|O CD117|gene-protein ,|O as|O virtually|O all|O GISTs|O with|O or|O without|O such|O mutations|O showed|O CD117|gene-protein immunoreactivity|O .|O 
The|O c-kit|gene-rna mutations|O occur|O preferentially|O in|O malignant|O GISTs|O and|O might|O be|O a|O clinically|O useful|O adjunct|O marker|O in|O the|O evaluation|O of|O GISTs|O .|O 
The|O conservation|O of|O the|O c-kit|gene-rna mutation|O pattern|O ,|O observed|O in|O consecutive|O lesions|O from|O the|O same|O patients|O ,|O suggests|O that|O these|O mutations|O might|O be|O useful|O tumor|O markers|O in|O monitoring|O recurrence|O or|O minimal|O residual|O disease|O .|O 
Analysis|O of|O K-ras|gene-rna gene|O mutations|O in|O rare|O pancreatic|O and|O ampullary|O tumours|O .|O 
OBJECTIVE|O :|O 
Mutation|O of|O the|O K-ras|gene-rna oncogene|O is|O a|O frequent|O event|O in|O pancreatic|O ductal|O carcinogenesis|O and|O it|O is|O believed|O to|O occur|O at|O an|O early|O stage|O in|O the|O development|O of|O pancreatic|O cancer|O .|O 
However|O ,|O little|O is|O known|O of|O the|O role|O of|O K-ras|gene-rna mutations|O in|O rare|O pancreatic|O epithelial|O neoplasms|O ,|O endocrine|O tumours|O or|O other|O non|O -|O epithelial|O tumours|O of|O the|O pancreas|O .|O 
Furthermore|O ,|O limited|O data|O are|O available|O regarding|O the|O role|O of|O K-ras|gene-rna mutations|O in|O the|O pathogenesis|O of|O ampullary|O tumours|O .|O 
DESIGN|O AND|O METHODS|O :|O 
Using|O single|O -|O strand|O conformation|O polymorphism|O (|O SSCP|O )|O and|O direct|O sequencing|O of|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O -|O amplified|O fragments|O ,|O we|O analysed|O codons|O 12|O and|O 13|O for|O the|O presence|O of|O oncogenic|O mutations|O of|O the|O K-ras|gene-rna oncogene|O .|O 
Tissues|O were|O obtained|O from|O patients|O undergoing|O tumour|O resection|O for|O various|O rare|O pancreatic|O or|O ampullary|O neoplasms|O (|O number|O of|O cases|O in|O brackets|O )|O :|O ampullary|O adenoma|O (|O 1|O )|O ,|O neuro|O -|O endocrine|O tumour|O (|O 3|O )|O ,|O malignant|O fibrous|O histiocytoma|O of|O the|O pancreas|O (|O 1|O )|O ,|O pancreatic|O cystadenocarcinoma|O (|O 1|O )|O ,|O serous|O cystadenoma|O (|O 1|O )|O ,|O and|O primary|O and|O metastatic|O adenocarcinoma|O of|O the|O ampulla|O (|O 5|O )|O and|O pancreas|O (|O 3|O )|O .|O 
RESULTS|O :|O 
K-ras|gene-rna gene|O mutations|O at|O codon|O 12|O were|O detected|O in|O both|O pancreatic|O adenocarcinomas|O and|O in|O the|O metastatic|O lesion|O ,|O whereas|O two|O ampullary|O cancers|O harboured|O a|O point|O mutation|O at|O codon|O 13|O :|O GGC|O -->|O GGG|O and|O GGC|O -->|O GGT|O .|O 
None|O of|O the|O other|O tumours|O exhibited|O a|O K-ras|gene-rna gene|O mutation|O at|O codons|O 12|O or|O 13|O .|O 
CONCLUSION|O :|O 
Pancreatic|O tumours|O other|O than|O ductal|O adenocarcinoma|O of|O the|O pancreas|O do|O not|O harbour|O mutations|O of|O the|O K-ras|gene-rna oncogene|O .|O 
In|O addition|O ,|O ampullary|O adenocarcinomas|O may|O present|O with|O codon|O 13|O mutations|O ;|O however|O ,|O these|O mutations|O were|O not|O associated|O with|O amino|O acid|O substitution|O .|O 
Therefore|O ,|O K-ras|gene-rna gene|O mutations|O seem|O to|O be|O a|O specific|O genetic|O alteration|O contributing|O to|O the|O pathogenesis|O of|O pancreatic|O ductal|O adenocarcinoma|O .|O 
Oncogene|O profile|O of|O papillary|O thyroid|O carcinoma|O .|O 
BACKGROUND|O :|O 
Our|O purpose|O was|O to|O study|O the|O expression|O of|O multiple|O oncogenes|O in|O papillary|O thyroid|O cancer|O for|O possible|O interactions|O and|O prognostic|O significance|O .|O 
METHODS|O :|O 
Twenty|O papillary|O thyroid|O carcinomas|O were|O studied|O for|O expression|O /|O mutation|O of|O 3|O oncogenes|O :|O ras|gene-rna ,|O ret|gene-rna /|O PTC|gene-rna ,|O and|O erbB-2|gene-rna /|O neu|gene-rna .|O 
H|gene-rna ,|O N|gene-rna ,|O and|O K|gene-rna ras|gene-rna codons|O were|O examined|O by|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O ,|O single|O -|O stranded|O conformation|O polymorphism|O ,|O and|O sequencing|O .|O 
The|O thyroid|O oncogene|O ret|gene-rna /|O PTC|gene-rna was|O identified|O by|O reverse|O transcription|O (|O RT|O )|O -|O PCR|O .|O 
Gene|O amplification|O of|O erbB-2|gene-rna /|O neu|gene-rna was|O analyzed|O by|O differential|O PCR|O .|O 
The|O transmembrane|O domain|O of|O erbB-2|gene-rna /|O neu|gene-rna was|O sequenced|O for|O activating|O mutations|O .|O 
Quantitation|O of|O erbB-2|gene-rna /|O neu|gene-rna mRNA|O was|O evaluated|O by|O competitive|O RT|O -|O PCR|O ,|O and|O protein|O expression|O was|O determined|O by|O immunohistochemistry|O .|O 
RESULTS|O :|O 
Among|O 20|O tumors|O ,|O 3|O had|O insular|O /|O anaplastic|O dedifferentiation|O ,|O 13|O were|O intrathyroidal|O ,|O and|O 7|O were|O metastatic|O to|O cervical|O lymph|O nodes|O (|O 6|O )|O or|O lung|O (|O 1|O )|O .|O 
An|O H-ras|gene-rna 13|O mutation|O was|O found|O in|O 1|O metastatic|O tumor|O and|O an|O N-ras|gene-rna 61|O mutation|O in|O 1|O intrathyroidal|O tumor|O .|O 
ret|gene-rna /|O PTC|gene-rna was|O identified|O in|O 3|O intrathyroidal|O and|O 5|O metastatic|O tumors|O .|O 
No|O erbB-2|gene-rna /|O neu|gene-rna DNA|O amplification|O or|O mutations|O were|O identified|O ,|O although|O 4|O tumors|O had|O elevated|O erbB-2|gene-rna /|O neu|gene-rna mRNA|O levels|O .|O 
Three|O of|O 20|O patients|O had|O abnormalities|O detected|O in|O multiple|O oncogenes|O ;|O 2|O had|O elevated|O erbB-2|gene-rna /|O neu|gene-rna mRNA|O and|O ret|gene-rna /|O PTC|gene-rna rearrangements|O ,|O and|O 1|O of|O these|O had|O pulmonary|O metastasis|O .|O 
An|O intrathyroidal|O papillary|O cancer|O had|O an|O N|gene-rna 61|O ras|gene-rna mutation|O and|O a|O ret|gene-rna /|O PTC|gene-rna gene|O rearrangement|O .|O 
CONCLUSIONS|O :|O 
ret|gene-rna /|O PTC|gene-rna rearrangements|O are|O present|O in|O 40|O %|O of|O papillary|O thyroid|O carcinomas|O and|O may|O play|O a|O role|O in|O metastatic|O behavior|O .|O 
In|O contrast|O ,|O ras|gene-rna mutations|O are|O rare|O (|O 10|O %|O )|O .|O 
erbB-2|gene-rna /|O neu|gene-rna gene|O amplification|O and|O activating|O mutations|O are|O not|O detected|O ,|O although|O elevated|O mRNA|O levels|O were|O found|O in|O 20|O %|O of|O papillary|O carcinomas|O .|O 
The|O lack|O of|O correlation|O among|O the|O 3|O oncogenes|gene-rna in|O 17|O of|O 20|O (|O 85|O %|O )|O papillary|O thyroid|O carcinomas|O suggests|O that|O they|O were|O not|O cumulative|O factors|O in|O the|O pathogenesis|O of|O these|O tumors|O .|O 
KIT|gene-rna mutation|O portends|O poor|O prognosis|O in|O gastrointestinal|O stromal|O /|O smooth|O muscle|O tumors|O .|O 
Gastrointestinal|O stromal|O /|O smooth|O muscle|O tumors|O (|O GISTs|O )|O are|O uncommon|O neoplasms|O for|O which|O current|O criteria|O for|O the|O diagnosis|O of|O malignancy|O (|O location|O ,|O size|O ,|O and|O mitotic|O index|O )|O do|O not|O always|O reliably|O predict|O patient|O outcome|O .|O 
Recently|O ,|O mutation|O of|O KIT|gene-rna oncogene|gene-rna exon|O 11|O has|O been|O observed|O in|O some|O of|O these|O tumors|O ,|O but|O the|O relationship|O between|O mutation|O and|O clinical|O outcome|O has|O not|O yet|O been|O determined|O .|O 
DNA|O was|O obtained|O from|O the|O formalin|O -|O fixed|O ,|O paraffin|O -|O embedded|O tissue|O of|O 35|O gastric|O GISTs|O .|O 
A|O segment|O of|O exon|O 11|O was|O amplified|O by|O PCR|O and|O sequenced|O on|O an|O ABI|O 377|O sequencer|O .|O 
The|O relationship|O between|O the|O presence|O or|O absence|O of|O mutation|O ,|O tumor|O size|O ,|O and|O mitotic|O index|O was|O investigated|O using|O correlation|O analysis|O ,|O and|O the|O relationship|O between|O mutation|O and|O outcome|O was|O investigated|O using|O Kaplan|O -|O Meier|O plots|O ,|O the|O Cox|O -|O Mantel|O statistic|O ,|O and|O the|O Cox|O regression|O model|O .|O 
Exon|O 11|O deletion|O mutations|O were|O identified|O in|O 10|O cases|O ,|O and|O point|O mutations|O were|O identified|O in|O an|O additional|O 3|O cases|O ;|O 22|O cases|O demonstrated|O no|O KIT|gene-rna mutations|O .|O 
KIT|gene-rna mutation|O was|O associated|O with|O decreased|O survival|O (|O p|O =|O 0.001|O )|O ,|O with|O fewer|O than|O 30|O %|O of|O patients|O surviving|O more|O than|O 3|O years|O ,|O compared|O with|O over|O 65|O %|O survival|O for|O patients|O whose|O tumors|O did|O not|O bear|O the|O mutation|O .|O 
KIT|gene-rna mutation|O did|O not|O correlate|O with|O either|O the|O mitotic|O index|O or|O the|O tumor|O size|O .|O 
In|O conclusion|O ,|O KIT|gene-rna mutation|O is|O associated|O with|O poor|O prognosis|O in|O patients|O with|O gastrointestinal|O stromal|O tumors|O .|O 
Whether|O the|O KIT|gene-rna mutation|O will|O prove|O to|O be|O an|O independent|O prognostic|O factor|O awaits|O the|O completion|O of|O larger|O studies|O .|O 
Pancreatic|O endocrine|O tumours|O :|O evidence|O for|O a|O tumour|O suppressor|O pathogenesis|O and|O for|O a|O tumour|O suppressor|O gene|O on|O chromosome|O 17p|O .|O 
Two|O molecular|O pathways|O leading|O to|O cancer|O are|O known|O .|O 
Common|O -|O type|O cancers|O arise|O from|O the|O '|O tumour|O suppressor|O '|O pathway|O ,|O characterized|O by|O gross|O chromosomal|O changes|O and|O allelic|O losses|O (|O LOH|O )|O in|O an|O average|O of|O 25|O per|O cent|O or|O more|O of|O randomly|O chosen|O chromosomal|O loci|O .|O 
The|O '|O mutator|O pathway|O '|O has|O been|O recognized|O in|O a|O subset|O of|O cancers|O ,|O characterized|O by|O widespread|O microsatellite|O DNA|O instability|O and|O rarity|O of|O chromosomal|O losses|O .|O 
The|O present|O study|O has|O investigated|O 20|O pancreatic|O endocrine|O tumours|O (|O PETs|O )|O for|O loss|O of|O heterozygosity|O (|O LOH|O )|O at|O seven|O chromosomal|O loci|O (|O 3p14|O ,|O 7q|O 31|O -|O 32|O ,|O 11q13|O ,|O 13q14|O ,|O 18q21|O ,|O 17p13|O ,|O and|O 17q21|O )|O ;|O microsatellite|O instability|O ;|O and|O Ki-ras|gene-rna ,|O N-ras|gene-rna ,|O and|O p53|gene-rna gene|O mutations|O .|O 
LOH|O was|O found|O in|O an|O average|O of|O 24|O per|O cent|O of|O the|O chromosomal|O loci|O analysed|O .|O 
No|O tumour|O showed|O microsatellite|O instability|O .|O 
Ki-ras|gene-rna and|O p53|gene-rna mutations|O were|O each|O found|O in|O one|O case|O .|O 
The|O frequency|O of|O losses|O was|O higher|O in|O malignant|O (|O 40|O per|O cent|O )|O than|O in|O benign|O (|O 17|O per|O cent|O )|O tumours|O (|O p|O =|O 0.009|O )|O ,|O and|O the|O specific|O chromosome|O 17p13|O LOH|O was|O associated|O with|O extrapancreatic|O extension|O of|O disease|O (|O p|O =|O 0.007|O )|O ,|O high|O proliferative|O activity|O (|O p|O =|O 0.001|O )|O ,|O and|O absence|O of|O progesterone|gene-protein receptors|gene-protein (|O p|O =|O 0.01|O )|O .|O 
A|O common|O deleted|O region|O on|O chromosome|O 17p13|O and|O the|O rarity|O of|O p53|gene-rna gene|O mutations|O suggest|O the|O existence|O of|O a|O novel|O tumour|O suppressor|O gene|O involved|O in|O the|O pathogenesis|O of|O PETs|O in|O this|O chromosomal|O area|O .|O 
Accuracy|O of|O DNA|O amplification|O from|O archival|O hematological|O slides|O for|O use|O in|O genetic|O biomarker|O studies|O .|O 
Archival|O slides|O are|O a|O potentially|O useful|O source|O of|O DNA|O for|O mutation|O analyses|O in|O large|O population|O -|O based|O studies|O .|O 
However|O ,|O it|O is|O unknown|O whether|O specimen|O age|O or|O histological|O stains|O alter|O the|O accuracy|O of|O Taq|gene-protein polymerase|gene-protein or|O induce|O secondary|O mutations|O in|O sample|O DNA|O .|O 
To|O address|O this|O question|O ,|O we|O evaluated|O five|O methods|O for|O extraction|O of|O genomic|O DNA|O from|O archival|O bone|O marrow|O slides|O of|O 17|O leukemia|O patients|O and|O analyzed|O exons|O 1|O and|O 2|O of|O the|O N|gene-rna -|gene-rna and|O K|gene-rna -|gene-rna ras|gene-rna genes|O for|O the|O presence|O of|O mutations|O .|O 
Of|O the|O five|O methods|O ,|O optimal|O DNA|O purification|O was|O achieved|O by|O boiling|O and|O phenol|O :|O chloroform|O extraction|O .|O 
N|gene-rna -|gene-rna and|O K|gene-rna -|gene-rna ras|gene-rna exons|O 1|O and|O 2|O were|O independently|O amplified|O using|O 35|O cycles|O of|O PCR|O ,|O and|O 6|O -|O 12|O clones|O for|O each|O exon|O were|O isolated|O and|O individually|O sequenced|O for|O each|O patient|O .|O 
Mutations|O were|O confirmed|O by|O repeat|O extraction|O ,|O cloning|O ,|O and|O sequencing|O .|O 
Sixteen|O of|O 17|O patient|O samples|O were|O successfully|O amplified|O (|O 94|O %|O )|O ,|O including|O slides|O up|O to|O 29|O years|O old|O .|O 
Twelve|O slides|O had|O been|O stained|O with|O Wright|O -|O Giemsa|O ,|O I|O stained|O with|O toluidine|O blue|O ,|O and|O 4|O were|O unstained|O .|O 
A|O total|O of|O 16|O single|O -|O base|O mutations|O were|O identified|O of|O 33,840|O nucleotides|O sequenced|O .|O 
No|O insertions|O or|O deletions|O were|O identified|O .|O 
Six|O of|O 16|O single|O -|O base|O mutations|O were|O previously|O described|O activating|O mutations|O in|O codon|O 13|O of|O N-ras|gene-rna exon|O 1|O .|O 
The|O 10|O other|O mutations|O were|O in|O other|O regions|O of|O the|O N|gene-rna -|gene-rna and|O K|gene-rna -|gene-rna ras|gene-rna genes|O and|O were|O not|O reproduced|O after|O repeat|O extraction|O ,|O cloning|O ,|O and|O sequencing|O .|O 
The|O frequency|O of|O these|O other|O alterations|O was|O I|O of|O 3384|O bp|O .|O 
This|O value|O is|O comparable|O with|O the|O inherent|O error|O frequency|O for|O Taq|gene-protein polymerase|gene-protein .|O 
Our|O findings|O suggest|O that|O high|O fidelity|O DNA|O amplification|O can|O be|O achieved|O using|O archival|O hematological|O slides|O as|O old|O as|O 29|O years|O and|O can|O be|O reliably|O used|O in|O genetic|O analyses|O .|O 
Prevalences|O of|O Gs|gene-rna alpha|gene-rna ,|O ras|gene-rna ,|O p53|gene-rna mutations|O and|O ret|gene-rna /|O PTC|gene-rna rearrangement|O in|O differentiated|O thyroid|O tumours|O in|O a|O Korean|O population|O .|O 
OBJECTIVE|O :|O 
In|O thyroid|O tumours|O ,|O ras|gene-rna ,|O Gs|gene-rna alpha|gene-rna ,|O p53|gene-rna mutations|O and|O ret|gene-rna /|O PTC|gene-rna rearrangement|O have|O been|O reported|O with|O variable|O prevalences|O in|O different|O geographical|O regions|O .|O 
We|O studied|O the|O prevalence|O of|O these|O mutations|O and|O rearrangement|O in|O thyroid|O tumours|O in|O a|O Korean|O population|O .|O 
As|O MDM2|gene-protein and|O Bcl-1|gene-protein protein|O expressions|O have|O been|O suggested|O to|O be|O associated|O with|O p53|gene-protein protein|O ,|O we|O also|O studied|O possible|O relationships|O among|O them|O .|O 
PATIENTS|O AND|O DESIGN|O :|O 
Eleven|O cases|O of|O adenomatous|O goitre|O ,|O eight|O cases|O of|O follicular|O adenoma|O ,|O five|O cases|O of|O follicular|O carcinoma|O and|O 37|O cases|O of|O papillary|O carcinoma|O were|O included|O in|O this|O study|O .|O 
To|O find|O mutations|O and|O rearrangement|O ,|O RT|O -|O PCR|O ,|O SSCP|O and/or|O direct|O sequencing|O ,|O after|O subcloning|O if|O necessary|O ,|O were|O used|O ,|O and|O immunohistochemical|O stainings|O were|O performed|O for|O p53|gene-protein ,|O MDM2|gene-protein and|O Bcl-2|gene-protein proteins|O in|O cases|O of|O papillary|O carcinoma|O .|O 
RESULTS|O :|O 
We|O could|O not|O find|O any|O rearrangement|O for|O ret|gene-rna /|O PTC|gene-rna -|gene-rna 1|gene-rna ,|O -|gene-rna 2|gene-rna ,|O -|gene-rna 3|gene-rna and|O mutation|O of|O Gs|gene-rna alpha|gene-rna .|O 
For|O the|O ras|gene-rna oncogene|O ,|O K|gene-rna and|O H|gene-rna -|gene-rna ras|gene-rna mutations|O were|O not|O found|O ,|O but|O N-ras|gene-rna mutations|O ,|O point|O mutation|O of|O CAA|O to|O CGA|O in|O codon|O 61|O ,|O were|O detected|O in|O one|O follicular|O adenoma|O (|O 12.5|O %|O ,|O 1|O /|O 8|O )|O and|O one|O follicular|O carcinoma|O (|O 33|O %|O ,|O 1|O /|O 3|O )|O .|O 
p53|gene-rna mutations|O were|O detected|O in|O only|O one|O case|O of|O papillary|O carcinoma|O (|O 3|O %|O ,|O 1|O /|O 31|O :|O exon|O 8|O ,|O codon|O 266|O GGA|O -->|O GAA|O )|O .|O 
In|O 30|O cases|O of|O papillary|O carcinoma|O without|O p53|gene-rna mutation|O ,|O the|O prevalences|O of|O positive|O immunohistochemical|O staining|O were|O 13.3|O %|O for|O p53|gene-protein protein|O ,|O 53.3|O %|O for|O MDM2|gene-protein protein|O and|O 56.7|O %|O for|O Bcl-2|gene-protein protein|O .|O 
While|O over|O -|O expression|O of|O p53|gene-protein protein|O was|O not|O significantly|O related|O to|O that|O of|O MDM2|gene-protein and|O Bcl-2|gene-protein proteins|O ,|O over|O -|O expression|O of|O MDM2|gene-protein and|O Bcl-2|gene-protein in|O papillary|O carcinoma|O were|O associated|O .|O 
CONCLUSION|O :|O 
ret|gene-rna /|O PTC|gene-rna rearrangement|O ,|O Gs|gene-rna alpha|gene-rna ,|O ras|gene-rna and|O p53|gene-rna mutations|O are|O relatively|O rare|O in|O differentiated|O thyroid|O neoplasms|O from|O a|O Korean|O population|O ,|O which|O may|O reflect|O genetic|O and|O environmental|O differences|O from|O patients|O in|O countries|O with|O high|O prevalences|O .|O 
P53|gene-protein protein|O over|O -|O expression|O was|O noted|O in|O 13.3|O %|O of|O papillary|O carcinoma|O cases|O without|O p53|gene-rna mutation|O and|O was|O not|O significantly|O related|O to|O MDM2|gene-protein and|O Bcl-2|gene-protein expression|O .|O 
Second|O primary|O cancers|O after|O resection|O of|O lung|O adenocarcinoma|O with|O ras|gene-rna gene|O mutation|O .|O 
BACKGROUND|O :|O 
Ras|gene-rna gene|O mutations|O are|O associated|O with|O a|O poor|O prognosis|O in|O patients|O with|O adenocarcinoma|O of|O the|O lung|O .|O 
However|O ,|O the|O association|O between|O cases|O with|O ras|gene-rna gene|O mutation|O and|O an|O occurrence|O of|O second|O primary|O cancer|O is|O unknown|O .|O 
MATERIALS|O AND|O METHODS|O :|O 
We|O examined|O 89|O adenocarcinoma|O of|O the|O lung|O obtained|O from|O patients|O treated|O by|O curative|O resection|O ,|O and|O four|O second|O primary|O cancers|O ,|O for|O mutation|O at|O codons|O 12|O ,|O 13|O ,|O and|O 61|O of|O three|O ras|gene-rna oncogenes|O using|O polymerase|gene-protein chain|O reaction|O and|O oligonucleotide|O hybridization|O techniques|O .|O 
RESULTS|O :|O 
Ras|gene-rna gene|O mutations|O were|O detected|O in|O 13|O cases|O .|O 
Six|O patients|O died|O from|O recurrent|O disease|O within|O 3|O years|O .|O 
Of|O the|O seven|O patients|O who|O survived|O over|O 5|O years|O ,|O three|O patients|O demonstrated|O a|O metachronous|O second|O primary|O cancer|O after|O the|O operation|O for|O lung|O cancer|O ,|O and|O one|O patient|O had|O synchronous|O laryngeal|O cancer|O .|O 
Two|O of|O the|O cases|O with|O second|O primary|O cancer|O demonstrated|O the|O ras|gene-rna gene|O mutation|O .|O 
One|O had|O the|O same|O mutation|O as|O that|O of|O the|O primary|O lung|O cancer|O ,|O and|O the|O other|O had|O a|O different|O mutation|O from|O the|O first|O lung|O cancer|O .|O 
CONCLUSION|O :|O 
Ras|gene-rna gene|O mutations|O play|O an|O important|O role|O in|O tumor|O progression|O of|O lung|O adenocarcinoma|O and|O also|O might|O have|O an|O role|O in|O the|O carcinogenesis|O in|O respiratory|O tract|O cancer|O .|O 
Systemic|O mastocytosis|O associated|O with|O acute|O myeloid|O leukaemia|O :|O report|O of|O two|O cases|O and|O detection|O of|O the|O c-kit|gene-rna mutation|O Asp|O -|O 816|O to|O Val|O .|O 
A|O subset|O of|O patients|O with|O systemic|O mastocytosis|O (|O SM|O )|O develop|O acute|O myeloid|O leukaemia|O (|O AML|O )|O .|O 
However|O ,|O little|O is|O known|O about|O the|O biology|O of|O such|O leukaemias|O and|O their|O relationship|O to|O the|O mast|O cell|O (|O MC|O )|O lineage|O .|O 
We|O report|O on|O two|O female|O patients|O who|O suffered|O from|O SM|O and|O AML|O .|O 
According|O to|O FAB|O criteria|O ,|O the|O leukaemias|O were|O classified|O as|O AML-M4|O (|O patient|O 1|O )|O and|O AML-MO|O (|O patient|O 2|O )|O .|O 
The|O coexistence|O of|O the|O two|O distinct|O neoplasms|O (|O AML|O and|O SM|O )|O was|O demonstrable|O by|O immunostaining|O of|O serial|O bone|O marrow|O (|O BM|O )|O sections|O with|O monoclonal|gene-protein antibodies|gene-protein (|O mAb|gene-protein )|O .|O 
In|O particular|O ,|O the|O MC|O infiltrates|O were|O found|O to|O react|O with|O mAb|gene-protein against|O MC|O -|O tryptase|gene-protein and|O MC|gene-protein growth|gene-protein factor|gene-protein receptor|gene-protein c-kit|gene-protein (|O CD117|gene-protein )|O ,|O but|O not|O with|O mAb|gene-protein to|O CD15|gene-protein or|O CD34|gene-protein .|O 
In|O contrast|O ,|O the|O AML|O blasts|O were|O immunoreactive|O for|O CD15|gene-protein (|O patient|O 1|O )|O or|O CD34|gene-protein (|O patient|O 2|O )|O ,|O but|O did|O not|O express|O tryptase|gene-protein .|O 
The|O c-kit|gene-rna point|O mutation|O Asp|O -->|O Val|O at|O codon|O 816|O ,|O considered|O to|O play|O a|O role|O in|O the|O transformation|O of|O MC|O progenitors|O ,|O was|O detected|O in|O patient|O 1|O in|O a|O BM|O cell|O fraction|O containing|O 4|O %|O MC|O .|O 
However|O ,|O no|O c-kit|gene-rna mutation|O was|O found|O in|O pure|O AML|O blasts|O (|O <|O 1|O %|O MC|O )|O .|O 
These|O findings|O argue|O against|O an|O evolution|O of|O the|O AML|O clone|O from|O neoplastic|O MC|O or|O MC|O -|O committed|O progenitors|O .|O 
Identification|O of|O activating|O c-kit|gene-rna mutations|O in|O adult|O -|O ,|O but|O not|O in|O childhood|O -|O onset|O indolent|O mastocytosis|O :|O a|O possible|O explanation|O for|O divergent|O clinical|O behavior|O .|O 
Mastocytosis|O represents|O a|O mast|O cell|O proliferative|O disease|O that|O generally|O runs|O a|O benign|O clinical|O course|O ,|O with|O spontaneous|O remissions|O mostly|O by|O puberty|O in|O childhood|O -|O onset|O disease|O ,|O although|O rare|O forms|O ,|O particularly|O in|O adult|O -|O onset|O disease|O ,|O can|O be|O associated|O with|O (pre)malignant|O hematologic|O disorders|O and|O very|O rarely|O present|O as|O mast|O cell|O leukemia|O or|O malignant|O mastocytosis|O .|O 
Reasons|O for|O this|O divergent|O clinical|O behavior|O of|O childhood|O -|O versus|O adult|O -|O onset|O disease|O are|O unknown|O .|O 
Recently|O ,|O two|O activating|O mutations|O in|O the|O intracellular|O domain|O of|O the|O proto|O -|O oncogene|O c-kit|gene-rna ,|O which|O encodes|O a|O tyrosine|gene-protein kinase|gene-protein receptor|gene-protein for|O the|O mast|gene-protein cell|gene-protein growth|gene-protein factor|gene-protein stem|gene-protein cell|gene-protein factor|gene-protein ,|O have|O been|O detected|O in|O the|O human|O leukemic|O mast|O cell|O line|O HMC-1|O .|O 
We|O have|O therefore|O studied|O lesional|O skin|O biopsies|O from|O patients|O with|O adult|O -|O and|O childhood|O -|O onset|O indolent|O mastocytosis|O for|O the|O presence|O of|O these|O codon|O 560|O and|O 816|O mutations|O .|O 
C-kit|gene-rna coding|O DNA|O sequences|O were|O amplified|O and|O analyzed|O by|O mutation|O -|O specific|O restriction|O analyses|O ,|O and|O mutated|O polymerase|gene-protein chain|O reaction|O products|O were|O additionally|O cloned|O and|O sequenced|O .|O 
The|O codon|O 816|O mutation|O was|O found|O in|O all|O six|O samples|O from|O adult|O patients|O ,|O but|O not|O in|O any|O of|O the|O 11|O specimens|O from|O children|O .|O 
In|O addition|O ,|O the|O codon|O 560|O mutation|O could|O be|O demonstrated|O for|O the|O first|O time|O in|O indolent|O mastocytosis|O ,|O namely|O in|O two|O of|O four|O specimens|O from|O adult|O patients|O ,|O but|O not|O in|O those|O from|O two|O children|O .|O 
These|O data|O thus|O provide|O a|O possible|O explanation|O for|O the|O divergent|O clinical|O behavior|O of|O adult|O -|O versus|O childhood|O -|O onset|O indolent|O mastocytosis|O ,|O with|O the|O first|O being|O associated|O with|O an|O activating|O mutation|O ,|O possibly|O as|O part|O of|O a|O neoplastic|O process|O ,|O and|O the|O latter|O representing|O most|O likely|O a|O reactive|O process|O of|O an|O as|O yet|O unknown|O pathogenesis|O .|O 
Pancreatic|O cancer|O associated|O with|O granulocyte|gene-protein -|gene-protein colony|gene-protein stimulating|gene-protein factor|gene-protein production|O confirmed|O by|O immunohistochemistry|O .|O 
We|O report|O an|O 83|O -|O year|O -|O old|O man|O with|O pancreatic|O body|O cancer|O of|O 4.5|O cm|O in|O diameter|O .|O 
Peripheral|O leukocyte|O count|O was|O 15,700|O /|O microl|O and|O the|O serum|O concentration|O of|O granulocyte|gene-protein -|gene-protein colony|gene-protein stimulating|gene-protein factor|gene-protein (|O G-CSF|gene-protein )|O was|O 123|O pg|O /|O ml|O (|O normal|O ,|O 6.0|O -|O 21.9|O pg|O /|O ml|O )|O on|O admission|O .|O 
Furthermore|O ,|O not|O only|O K-ras|gene-rna codon|O 12|O (|O GGT|O -->|O GAT|O )|O but|O also|O p53|gene-rna at|O codon|O 247|O (|O CGG|O -->|O CCG|O )|O mutations|O were|O identified|O in|O the|O pancreatic|O juice|O aspirated|O endoscopically|O .|O 
We|O performed|O chemotherapy|O with|O two|O courses|O of|O 5-fluorouracil|O ,|O pirarubicin|O hydrochloride|O ,|O and|O mitomycin-C|O ,|O resulting|O in|O no|O beneficial|O effect|O .|O 
After|O the|O second|O course|O the|O patient|O developed|O interstitial|O pneumonia|O ,|O probably|O caused|O by|O anticancer|O drugs|O ,|O and|O died|O 4|O months|O after|O the|O tumor|O was|O detected|O .|O 
In|O the|O autopsy|O tissue|O ,|O the|O tumor|O macroscopically|O occupied|O the|O pancreas|O body|O and|O was|O 7|O x|O 6|O x|O 5|O cm|O in|O size|O .|O 
Histopathologic|O diagnosis|O of|O the|O tumor|O was|O poorly|O differentiated|O adenosquamous|O carcinoma|O .|O 
Immunohistochemical|O staining|O of|O the|O autopsy|O tissue|O showed|O that|O pancreatic|O cancer|O cells|O were|O positive|O for|O G-CSF|gene-protein .|O 
This|O is|O the|O first|O case|O report|O of|O G-CSF|gene-protein -|O positive|O pancreatic|O cancer|O confirmed|O by|O immunohistochemistry|O .|O 
Prognostic|O significance|O of|O proliferative|O activity|O ,|O DNA|O -|O ploidy|O ,|O p53|gene-rna and|O Ki-ras|gene-rna point|O mutations|O in|O colorectal|O liver|O metastases|O .|O 
Paired|O colorectal|O liver|O metastases|O (|O CLM|O )|O and|O normal|O tissue|O samples|O from|O a|O consecutive|O series|O of|O 36|O patients|O were|O studied|O prospectively|O .|O 
MIB-1|gene-protein expression|O was|O studied|O by|O immunohistochemistry|O on|O paraffin|O -|O embedded|O sections|O .|O 
DNA|O ploidy|O and|O S-phase|O fraction|O (|O SPF|O )|O measurements|O were|O performed|O by|O flow|O cytometry|O on|O frozen|O tissues|O .|O 
Mutations|O within|O the|O p53|gene-rna (|O exons|O 5|O -|O 8|O )|O and|O c-Ki-ras|gene-rna (|O codons|O 12|O and|O 13|O )|O genes|O were|O detected|O by|O PCR|O single|O -|O strand|O conformation|O polymorphism|O analysis|O followed|O by|O sequencing|O .|O 
A|O high|O correlation|O was|O observed|O between|O the|O MIB-1|gene-protein LI|O and|O SPF|O value|O (|O rho|O =|O 0.81|O ;|O P|O <|O 0.01|O )|O .|O 
Moreover|O ,|O p53|gene-rna gene|O mutations|O were|O associated|O with|O either|O high|O MIB-1|gene-protein LI|O and|O high|O SPF|O .|O 
In|O univariate|O analysis|O ,|O SPF|O and|O MIB-1|gene-protein levels|O were|O related|O to|O risk|O of|O death|O .|O 
The|O association|O between|O overall|O survival|O and|O DNA|O -|O ploidy|O or|O p53|gene-rna mutations|O did|O not|O reach|O statistical|O significance|O ,|O but|O a|O slightly|O better|O survival|O was|O observed|O for|O patients|O either|O with|O DNA|O -|O diploid|O tumours|O or|O without|O mutations|O (|O P|O =|O 0.05|O and|O P|O =|O 0.06|O ,|O respectively|O )|O .|O 
SPF|O was|O shown|O by|O multivariate|O Cox|O model|O analysis|O to|O be|O an|O independent|O prognostic|O variable|O and|O thus|O it|O might|O be|O a|O useful|O prognostic|O factor|O in|O patients|O with|O CLM|O .|O 
Different|O ras|gene-rna gene|O mutational|O frequencies|O in|O thyroid|O papillary|O carcinomas|O in|O Japan|O and|O Thailand|O .|O 
The|O incidence|O and|O pattern|O of|O ras|gene-rna oncogene|O mutations|O in|O human|O malignancies|O demonstrate|O geographic|O and|O racial|O differences|O .|O 
For|O example|O ,|O specificity|O of|O alterations|O is|O found|O in|O cholangiocellular|O carcinomas|O in|O Thai|O patients|O with|O a|O different|O etiology|O from|O those|O in|O Japanese|O patients|O .|O 
In|O the|O present|O study|O ,|O a|O comparison|O of|O ras|gene-rna gene|O mutations|O in|O thyroid|O papillary|O carcinomas|O from|O Japanese|O and|O Thai|O patients|O was|O performed|O using|O single|O -|O strand|O conformation|O polymorphism|O and|O direct|O sequencing|O analyses|O .|O 
The|O incidence|O of|O ras|gene-rna mutation|O differed|O markedly|O in|O Japanese|O (|O two|O of|O 24|O carcinomas|O ,|O 8.3|O %|O )|O and|O Thai|O (|O five|O of|O 10|O carcinomas|O ,|O 50|O %|O )|O patients|O .|O 
In|O addition|O ,|O all|O but|O one|O ras|gene-rna mutation|O occurred|O at|O codon|O 12|O of|O the|O K-ras|gene-rna gene|O in|O the|O Thai|O cases|O .|O 
These|O results|O suggest|O that|O thyroid|O cancers|O in|O Thailand|O may|O be|O due|O to|O specific|O genetic|O and/or|O environmental|O factors|O .|O 
Clinical|O correlates|O of|O the|O presence|O of|O the|O Asp|O 816|O Val|O c-kit|gene-rna mutation|O in|O the|O peripheral|O blood|O mononuclear|O cells|O of|O patients|O with|O mastocytosis|O .|O 
BACKGROUND|O :|O 
The|O Asp|O 816|O Val|O mutation|O in|O the|O catalytic|O domain|O of|O the|O c-kit|gene-protein receptor|gene-protein has|O been|O identified|O in|O patients|O with|O systemic|O mastocytosis|O .|O 
METHODS|O :|O 
To|O determine|O whether|O this|O mutation|O is|O associated|O with|O identifiable|O clinical|O patterns|O of|O disease|O and|O prognosis|O ,|O a|O total|O of|O 65|O patients|O with|O mastocytosis|O were|O screened|O for|O the|O presence|O of|O the|O Asp|O 816|O Val|O mutation|O in|O peripheral|O blood|O mononuclear|O cells|O (|O PBMCs|O )|O .|O 
RESULTS|O :|O 
By|O analysis|O of|O HinfI|gene-protein digestion|O products|O ,|O the|O authors|O found|O that|O the|O overall|O prevalence|O of|O this|O mutation|O in|O the|O current|O patient|O series|O was|O 25|O %|O .|O 
The|O presence|O of|O the|O Asp|O 816|O Val|O mutation|O in|O PBMCs|O was|O observed|O in|O 15|O adults|O (|O of|O 16|O Asp|O 816|O Val|O mutation|O positive|O patients|O )|O and|O 1|O infant|O ,|O but|O not|O in|O any|O children|O with|O mastocytosis|O .|O 
Patients|O whose|O PBMCs|O were|O positive|O for|O this|O mutation|O (|O category|O II|O and|O a|O subset|O of|O category|O Ib|O mastocytosis|O patients|O )|O manifested|O a|O more|O severe|O disease|O pattern|O ,|O with|O clinical|O features|O ranging|O in|O severity|O from|O early|O to|O advanced|O myelodysplastic|O or|O myeloproliferative|O syndromes|O .|O 
These|O patients|O more|O commonly|O had|O osteosclerotic|O bone|O involvement|O (|O a|O clinical|O feature|O primarily|O observed|O in|O mastocytosis|O patients|O with|O an|O associated|O hematologic|O disorder|O )|O as|O well|O as|O immunoglobulin|gene-protein dysregulation|O and|O peripheral|O blood|O abnormalities|O .|O 
Furthermore|O ,|O pedigree|O analysis|O of|O three|O families|O provided|O evidence|O that|O the|O mutation|O was|O somatic|O .|O 
CONCLUSIONS|O :|O 
Twenty-five|O percent|O of|O all|O patients|O with|O mastocytosis|O had|O the|O Asp|O 816|O Val|O mutation|O in|O PBMCs|O ;|O 56|O %|O of|O these|O patients|O had|O evidence|O of|O a|O myelodysplastic|O or|O myeloproliferative|O syndrome|O ,|O and|O 44|O %|O had|O been|O clinically|O placed|O in|O the|O indolent|O mastocytosis|O category|O ,|O suggesting|O that|O the|O current|O classification|O scheme|O used|O to|O assign|O prognosis|O may|O be|O inadequate|O .|O 
Therefore|O ,|O determination|O of|O the|O presence|O or|O absence|O of|O this|O mutation|O in|O PBMCs|O of|O mastocytosis|O patients|O offers|O a|O useful|O adjunct|O in|O determining|O the|O extent|O of|O workup|O and|O assigning|O prognosis|O in|O this|O complex|O and|O heterogeneous|O disease|O .|O 
[|O Analysis|O of|O genetic|O disorders|O of|O cancer|O of|O the|O rectum|O :|O differences|O in|O relation|O to|O cancer|O of|O the|O colon|O ]|O 
AIMS|O AND|O METHODS|O :|O 
We|O studied|O the|O mechanisms|O of|O colon|O and|O rectal|O carcinogenesis|O by|O analysing|O in|O a|O series|O of|O 83|O rectal|O tumors|O the|O prevalence|O of|O the|O two|O tumor|O types|O characteristic|O of|O colon|O cancer|O ,|O i.e.|O ,|O the|O LOH|O +|O type|O ,|O defined|O by|O p53|gene-rna and|O APC|gene-rna mutations|O (|O studied|O by|O DGGE|O and|O protein|O truncation|O assay|O )|O ,|O and|O the|O RER|O +|O type|O ,|O which|O is|O characterized|O by|O the|O instability|O of|O some|O mononucleotide|O repeat|O microsatellites|O (|O Bat|O 25|O and|O Bat|O 26|O )|O .|O 
Additionally|O ,|O we|O analyzed|O the|O occurrence|O of|O Ki-Ras|gene-rna mutations|O (|O direct|O sequencing|O )|O .|O 
RESULTS|O :|O 
Only|O one|O tumor|O turned|O out|O to|O be|O RER|O +|O .|O 
Moreover|O ,|O in|O 59|O %|O of|O the|O tumor|O cases|O mutations|O were|O found|O in|O p53|gene-rna ,|O essentially|O affecting|O codon|O 175|O .|O 
The|O APC|gene-rna and|O Ki-Ras|gene-rna genes|O were|O found|O to|O be|O mutated|O in|O 40|O and|O 26|O %|O of|O the|O rectal|O tumors|O ,|O respectively|O .|O 
In|O 18|O tumors|O (|O 21|O %|O )|O none|O of|O the|O genes|gene-rna studied|O were|O mutated|O .|O 
CONCLUSIONS|O :|O 
The|O RER|O +|O phenotype|O is|O rare|O among|O rectal|O tumors|O ,|O which|O are|O essentially|O LOH|O +|O .|O 
In|O these|O LOH|O +|O tumors|O the|O p53|gene-rna gene|O is|O more|O frequently|O mutated|O than|O in|O colorectal|O tumors|O with|O the|O same|O phenotype|O .|O 
Mutations|O in|O the|O APC|gene-rna and|O Ki-Ras|gene-rna genes|O ,|O on|O the|O other|O hand|O ,|O are|O less|O frequent|O in|O rectal|O tumors|O .|O 
Tumors|O with|O the|O RER|O -|O and|O LOH|O -|O phenotype|O may|O develop|O as|O a|O result|O of|O a|O third|O carcinogenesis|O model|O which|O must|O be|O defined|O .|O 
Detection|O of|O K-ras|gene-rna mutations|O in|O lung|O carcinomas|O :|O relationship|O to|O prognosis|O .|O 
The|O K-ras|gene-rna mutation|O is|O one|O of|O the|O most|O common|O genetic|O alterations|O found|O in|O human|O lung|O cancer|O .|O 
To|O evaluate|O the|O prognostic|O value|O of|O ras|gene-rna gene|O alterations|O in|O lung|O cancer|O in|O a|O U.S.|O population|O ,|O we|O have|O screened|O 173|O human|O lung|O tumors|O ,|O which|O included|O 127|O adenocarcinomas|O ,|O 37|O squamous|O carcinomas|O ,|O and|O 9|O adenosquamous|O carcinomas|O ,|O for|O mutations|O in|O the|O K-ras|gene-rna gene|O using|O the|O combination|O of|O the|O PCR|O and|O denaturing|O gradient|O gel|O electrophoresis|O .|O 
Forty-three|O tumors|O contained|O K-ras|gene-rna mutations|O .|O 
Of|O these|O ,|O 41|O were|O identified|O among|O the|O adenocarcinomas|O (|O 32|O %|O )|O ,|O 1|O among|O the|O squamous|O carcinomas|O (|O 2.7|O %|O )|O ,|O and|O 1|O among|O the|O adenosquamous|O carcinomas|O (|O 11|O %|O )|O .|O 
Forty|O of|O these|O mutations|O were|O found|O in|O codon|O 12|O and|O consisted|O of|O 24|O G|O to|O T|O transversions|O ,|O 12|O G|O to|O A|O transitions|O ,|O 2|O G|O to|O C|O transversions|O ,|O and|O 1|O double|O GG|O to|O TT|O mutation|O .|O 
Two|O other|O G|O to|O T|O transversions|O were|O found|O in|O codon|O 13|O ,|O and|O 1|O A|O to|O C|O transversion|O was|O found|O in|O codon|O 61|O .|O 
The|O data|O showed|O that|O gender|O did|O not|O seem|O to|O affect|O the|O incidence|O and|O the|O types|O of|O the|O K-ras|gene-rna mutations|O or|O amino|O acid|O changes|O .|O 
Examination|O of|O the|O mutations|O in|O adenocarcinomas|O in|O relation|O to|O overall|O survival|O showed|O no|O difference|O in|O adenocarcinomas|O with|O K-ras|gene-rna mutations|O compared|O with|O K-ras|gene-rna -|O negative|O adenocarcinomas|O .|O 
However|O ,|O the|O substitution|O of|O the|O wild|O -|O type|O GGT|O (|O glycine|O )|O at|O codon|O 12|O with|O a|O GTT|O (|O valine|O )|O or|O a|O CGT|O (|O arginine|O )|O showed|O a|O strong|O trend|O (|O P|O =|O 0.07|O )|O toward|O a|O poorer|O prognosis|O compared|O with|O wild|O -|O type|O or|O other|O amino|O acid|O substitutions|O .|O 
Substitution|O of|O the|O wild|O -|O type|O glycine|O for|O aspartate|O (|O GAT|O )|O showed|O a|O strong|O trend|O (|O P|O =|O 0.06|O )|O for|O a|O better|O outcome|O than|O the|O valine|O or|O arginine|O substitution|O .|O 
Although|O these|O trends|O will|O require|O larger|O patient|O populations|O for|O verification|O ,|O these|O data|O suggest|O that|O the|O prognostic|O significance|O of|O K-ras|gene-rna mutations|O may|O depend|O on|O the|O amino|O acid|O substitution|O in|O the|O p21(ras)|gene-protein protein|O .|O 
Analysis|O of|O K-ras|gene-rna gene|O mutations|O in|O lung|O carcinomas|O :|O correlation|O with|O gender|O ,|O histological|O subtypes|O ,|O and|O clinical|O outcome|O .|O 
PURPOSE|O :|O 
Lung|O cancer|O is|O respectively|O the|O leading|O and|O second|O -|O leading|O cause|O of|O cancer|O deaths|O among|O women|O and|O men|O in|O Taiwan|O .|O 
The|O commonest|O pathological|O type|O of|O lung|O carcinoma|O found|O in|O Taiwan|O is|O adenocarcinoma|O .|O 
and|O it|O has|O been|O documented|O that|O K-ras|gene-rna oncogene|O mutation|O occurs|O in|O a|O subset|O of|O lung|O adenocarcinoma|O .|O 
We|O therefore|O investigated|O the|O mutation|O spectrum|O and|O clinicopathological|O significance|O of|O K-ras|gene-rna oncogene|O mutations|O in|O lung|O cancer|O patients|O in|O Taiwan|O .|O 
METHODS|O :|O 
The|O lung|O tumors|O were|O surgically|O resected|O from|O 84|O lung|O cancer|O patients|O .|O 
DNA|O was|O isolated|O and|O the|O mutation|O spectrum|O was|O examined|O by|O direct|O sequencing|O .|O 
These|O data|O were|O also|O correlated|O with|O the|O clinicopathological|O characteristics|O of|O patients|O .|O 
RESULTS|O :|O 
K-ras|gene-rna gene|O mutations|O were|O detected|O in|O 5|O cases|O among|O the|O 84|O patients|O investigated|O (|O 6.0|O %|O )|O .|O 
The|O majority|O of|O mutations|O occurred|O in|O exon|O 1|O (|O 80|O %|O ,|O 4|O of|O 5|O )|O and|O were|O located|O mainly|O in|O codons|O 12|O and|O 13|O .|O 
Two|O patients|O had|O G|O x|O C|O -->|O T|O x|O A|O transversions|O and|O 2|O patients|O had|O G|O x|O C|O -->|O A|O x|O T|O transitions|O .|O 
Notably|O ,|O 1|O patient|O had|O a|O G|O x|O C|O base|O -|O pair|O deletion|O from|O the|O contiguous|O G|O x|O C|O base|O pairs|O located|O between|O codons|O 68|O and|O 69|O .|O 
All|O mutations|O occurred|O in|O male|O patients|O who|O were|O smokers|O .|O 
The|O incidences|O of|O K-ras|gene-rna gene|O mutation|O among|O male|O and|O female|O patients|O with|O adenocarcinoma|O were|O 13|O %|O and|O 0|O %|O respectively|O .|O 
Patients|O with|O K-ras|gene-rna gene|O mutation|O survived|O for|O shorter|O periods|O than|O those|O without|O mutations|O (|O P|O =|O 0.08|O ,|O by|O the|O log|O -|O rank|O test|O )|O .|O 
CONCLUSIONS|O :|O 
The|O incidence|O of|O K-ras|gene-rna gene|O mutations|O for|O male|O and|O female|O patients|O with|O adenocarcinoma|O was|O 13|O %|O and|O 0|O %|O respectively|O .|O 
Thus|O ,|O the|O role|O of|O K-ras|gene-rna in|O the|O development|O of|O lung|O adenocarcinoma|O among|O Chinese|O men|O who|O are|O predominantly|O smokers|O is|O not|O significantly|O different|O from|O that|O in|O other|O populations|O worldwide|O .|O 
However|O ,|O K-ras|gene-rna mutations|O may|O not|O be|O associated|O with|O adenocarcinoma|O among|O women|O in|O Taiwan|O ,|O who|O are|O virtually|O all|O nonsmokers|O .|O 
Bronchioloalveolar|O adenocarcinoma|O of|O lung|O :|O monoclonal|O origin|O for|O multifocal|O disease|O .|O 
In|O an|O attempt|O to|O understand|O the|O histogenesis|O and|O molecular|O pathogenesis|O of|O multifocal|O bronchioloalveolar|O lung|O carcinoma|O (|O BAC|O )|O we|O studied|O 28|O cases|O of|O BAC|O using|O a|O topographic|O genotyping|O approach|O for|O the|O presence|O of|O K-ras|gene-rna exon|O 1|O mutations|O and|O p53|gene-rna loss|O of|O heterozygosity|O (|O LOH|O )|O .|O 
This|O analytical|O approach|O demonstrated|O K-ras|gene-rna exon|O 1|O mutations|O in|O 12.5|O %|O of|O solitary|O BACs|O ,|O 40|O %|O of|O BACs|O with|O microscopic|O or|O macroscopic|O satellite|O lesions|O ,|O and|O 60|O %|O of|O BACs|O with|O intrathoracic|O metastases|O .|O 
In|O all|O cases|O with|O K-ras|gene-rna mutations|O ,|O the|O identical|O point|O mutation|O was|O present|O in|O the|O primary|O ,|O satellite|O ,|O and|O intrathoracic|O metastatic|O lesions|O .|O 
When|O p53|gene-rna LOH|O was|O demonstrated|O in|O the|O primary|O lesion|O ,|O it|O was|O also|O detected|O in|O the|O satellites|O and|O intrathoracic|O metastases|O .|O 
No|O significant|O association|O was|O noted|O between|O the|O presence|O of|O K-ras|gene-rna mutations|O and|O p53|gene-rna LOH|O .|O 
The|O results|O strongly|O support|O a|O monoclonal|O origin|O of|O multifocal|O BACs|O .|O 
Furthermore|O ,|O the|O findings|O support|O the|O theories|O explaining|O the|O origin|O of|O multifocal|O BAC|O by|O intraalveolar|O route|O of|O spread|O ,|O intrapulmonary|O lymphatic|O spread|O ,|O or|O aerosolization|O leading|O to|O implantation|O at|O different|O sites|O .|O 
A|O trend|O toward|O an|O increased|O frequency|O of|O K-ras|gene-rna mutations|O and|O p53|gene-rna LOH|O in|O BACs|O with|O satellites|O or|O metastases|O compared|O to|O solitary|O BACs|O was|O noted|O .|O 
N-ras|gene-rna mutations|O are|O common|O in|O melanomas|O from|O sun|O -|O exposed|O skin|O of|O humans|O but|O rare|O in|O mucosal|O membranes|O or|O unexposed|O skin|O .|O 
Ras|gene-rna mutations|O ,|O preferentially|O in|O codon|O 61|O of|O the|O N-ras|gene-rna oncogene|O ,|O are|O common|O in|O human|O cutaneous|O melanomas|O .|O 
In|O this|O study|O ,|O we|O questioned|O the|O association|O between|O ras|gene-rna mutations|O in|O primary|O melanomas|O and|O sun|O exposure|O .|O 
DNA|O was|O extracted|O from|O formalin|O -|O fixed|O primary|O melanomas|O :|O 28|O at|O chronically|O sun|O -|O exposed|O head|O and|O neck|O areas|O ,|O 18|O at|O sites|O subject|O to|O intermittent|O sun|O exposure|O ,|O and|O 28|O from|O unexposed|O mucosal|O membranes|O (|O vulva|O /|O vagina|O ,|O anus|O /|O rectum|O ,|O palate|O )|O .|O 
Mutations|O of|O both|O exons|O of|O H|gene-rna -|gene-rna ,|O K|gene-rna -|O ,|O and|O N|gene-rna -|gene-rna ras|gene-rna genes|O were|O examined|O by|O polymerase|gene-protein chain|O reaction|O /|O single|O -|O strand|O conformation|O polymorphism|O and|O by|O direct|O nucleotide|O sequencing|O of|O the|O polymerase|gene-protein chain|O reaction|O amplified|O exons|O .|O 
Thirty-two|O per|O cent|O of|O the|O head|O and|O neck|O melanomas|O and|O 11|O %|O of|O the|O melanomas|O from|O intermittently|O sun|O -|O exposed|O skin|O had|O N-ras|gene-rna codon|O 61|O mutations|O ;|O comparatively|O only|O 7|O %|O of|O the|O tumors|O from|O the|O unexposed|O areas|O had|O such|O mutations|O .|O 
One|O vulvar|O melanoma|O had|O an|O N-ras|gene-rna codon|O 12|O mutation|O .|O 
No|O H-ras|gene-rna or|O K-ras|gene-rna mutations|O were|O detected|O in|O any|O sample|O .|O 
The|O frequency|O of|O N-ras|gene-rna exon|O 2|O mutations|O in|O melanomas|O of|O typically|O sunbathed|O skin|O was|O compared|O for|O the|O first|O time|O with|O that|O in|O melanomas|O of|O areas|O completely|O protected|O from|O sun|O exposure|O .|O 
The|O significantly|O higher|O frequency|O (|O p|O =|O 0.04|O ,|O chi|O square|O exact|O test|O )|O of|O these|O N-ras|gene-rna mutations|O on|O the|O head|O and|O neck|O demonstrates|O their|O UV|O -|O light|O induction|O in|O a|O subset|O of|O melanomas|O explaining|O one|O of|O the|O molecular|O effects|O of|O UV|O light|O in|O human|O skin|O .|O 
K-ras|gene-rna gene|O mutations|O in|O the|O diagnosis|O of|O fine|O -|O needle|O aspirates|O of|O pancreatic|O masses|O :|O prospective|O study|O using|O two|O techniques|O with|O different|O detection|O limits|O .|O 
Detection|O of|O K-ras|gene-rna mutations|O may|O be|O useful|O in|O the|O evaluation|O of|O pancreatic|O cancer|O .|O 
The|O aim|O of|O this|O study|O was|O to|O assess|O ,|O in|O a|O prospective|O design|O ,|O the|O diagnostic|O utility|O of|O K-ras|gene-rna mutation|O analysis|O in|O 62|O consecutive|O fine|O -|O needle|O aspirates|O of|O pancreatic|O masses|O ,|O using|O two|O PCR|O -|O based|O techniques|O -|O standard|O and|O enriched|O -|O with|O detection|O limits|O of|O a|O mutant|O allele|O in|O the|O presence|O of|O 10(2)|O or|O 10(3)|O wild|O -|O type|O alleles|O ,|O respectively|O .|O 
Cytology|O alone|O offered|O a|O diagnostic|O sensitivity|O of|O 75|O %|O .|O 
The|O enriched|O higher|O sensitivity|O detection|O technique|O ,|O in|O combination|O with|O cytology|O ,|O offered|O a|O diagnostic|O sensitivity|O of|O 91|O %|O without|O false|O positives|O .|O 
The|O molecular|O analysis|O would|O have|O contributed|O to|O diagnosis|O in|O an|O additional|O 14|O cases|O of|O pancreatic|O cancer|O .|O 
The|O standard|O technique|O contributed|O to|O diagnosis|O in|O an|O additional|O 9|O cases|O .|O 
These|O results|O strongly|O support|O the|O use|O of|O the|O enriched|O method|O of|O detecting|O K-ras|gene-rna mutations|O as|O a|O complement|O to|O cytology|O in|O the|O evaluation|O of|O pancreatic|O masses|O .|O 
Oncogenic|O ras|gene-rna induces|O gastrin|gene-generic gene|O expression|O in|O colon|O cancer|O .|O 
BACKGROUND|O &|O AIMS|O :|O 
The|O expression|O of|O gastrin|gene-protein ,|O as|O a|O tumor|gene-protein growth|gene-protein factor|gene-protein ,|O is|O significantly|O increased|O in|O some|O colon|O cancers|O compared|O with|O the|O low|O levels|O found|O in|O normal|O mucosa|O .|O 
The|O aim|O of|O this|O study|O was|O to|O elucidate|O the|O transcriptional|O mechanisms|O of|O gastrin|gene-generic induction|O in|O colon|O cancer|O .|O 
METHODS|O :|O 
Gastrin|gene-rna messenger|O (|O mRNA|O )|O levels|O and|O K-ras|gene-rna genotype|O were|O determined|O in|O colon|O cancer|O cell|O lines|O and|O surgical|O specimens|O .|O 
Colon|O cancer|O cells|O were|O transfected|O with|O oncogenic|O ras|gene-rna expression|O vectors|O ,|O and|O transcriptional|O activity|O was|O assayed|O with|O gastrin|gene-rna -|O luciferase|gene-rna reporter|O genes|O .|O 
RESULTS|O :|O 
Colon|O cancer|O cell|O lines|O and|O tissues|O with|O K-ras|gene-rna mutations|O all|O had|O significantly|O higher|O gastrin|gene-rna mRNA|O levels|O than|O those|O that|O were|O ras|gene-rna wild|O type|O .|O 
Treatment|O of|O several|O ras|gene-rna mutant|O cell|O lines|O with|O PD98059|O ,|O an|O inhibitor|O of|O mitogen|gene-protein -|gene-protein activated|gene-protein protein|gene-protein kinase|gene-protein kinase|gene-protein ,|O resulted|O in|O a|O decrease|O in|O endogenous|O gastrin|gene-rna mRNA|O levels|O .|O 
The|O effects|O of|O ras|gene-rna on|O gastrin|gene-protein expression|O appeared|O to|O be|O mediated|O through|O the|O gastrin|gene-rna promoter|O because|O transfection|O of|O oncogenic|O ras|gene-rna and|O activated|O raf|gene-rna expression|O vectors|O both|O induced|O gastrin|gene-rna -|O promoter|O ,|O luciferase|gene-rna -|O reporter|O genes|O .|O 
The|O inductive|O effects|O of|O oncogenic|O ras|gene-rna could|O be|O blocked|O by|O the|O coexpression|O of|O dominant|O negative|O forms|O of|O raf|gene-generic and|O extracellular|O regulated|O kinase|gene-protein .|O 
CONCLUSIONS|O :|O 
Oncogenic|O ras|gene-rna induces|O gastrin|gene-rna gene|O expression|O through|O activation|O of|O the|O Raf|gene-rna -|O MEK|gene-rna -|O ERK|gene-rna signal|O transduction|O pathway|O .|O 
A|O novel|O gain|O -|O of|O -|O function|O mutation|O of|O c-kit|gene-rna gene|O in|O gastrointestinal|O stromal|O tumors|O .|O 
BACKGROUND|O &|O AIMS|O :|O 
The|O c-kit|gene-rna gene|O encodes|O a|O receptor|gene-protein tyrosine|gene-protein kinase|gene-protein (|O KIT|gene-protein )|O .|O 
Recently|O ,|O we|O found|O gain|O -|O of|O -|O function|O mutations|O of|O the|O c-kit|gene-rna gene|O in|O gastrointestinal|O stromal|O tumors|O (|O GISTs|O )|O .|O 
All|O mutations|O were|O confined|O within|O the|O 11|O amino|O acids|O (|O Lys-550|O to|O Val-560|O )|O in|O the|O juxtamembrane|O domain|O ,|O but|O one|O GIST|O showed|O a|O novel|O deletion|O -|O type|O mutation|O at|O codon|O 579|O (|O Asp|O )|O in|O the|O juxtamembrane|O domain|O .|O 
The|O aim|O of|O this|O study|O was|O to|O clarify|O whether|O the|O mutation|O is|O activating|O .|O 
METHODS|O :|O 
Mutant|O c-kit|gene-rna cDNA|O was|O transfected|O into|O an|O interleukin|gene-protein 3|gene-protein (|O IL-3|gene-protein )|O -|O dependent|O Ba|O /|O F3|O murine|O lymphoid|O cell|O line|O ,|O and|O the|O magnitude|O of|O autophosphorylation|O of|O the|O mutant|O KIT|gene-protein was|O examined|O with|O or|O without|O stem|gene-protein cell|gene-protein factor|gene-protein (|O SCF|gene-protein )|O ,|O a|O ligand|O of|O KIT|gene-protein .|O 
An|O in|O vitro|O kinase|gene-protein assay|O was|O also|O performed|O .|O 
The|O biological|O behavior|O of|O the|O transfectant|O was|O estimated|O by|O both|O an|O in|O vitro|O proliferation|O assay|O and|O in|O vivo|O transplantation|O to|O nude|O mice|O .|O 
RESULTS|O :|O 
The|O mutant|O KIT|gene-protein exhibited|O constitutive|O phosphorylation|O and|O strong|O kinase|gene-protein activity|O without|O SCF|gene-protein .|O 
The|O transfectant|O grew|O autonomously|O without|O IL-3|gene-protein and|O SCF|gene-protein ,|O and|O it|O formed|O tumors|O in|O nude|O mice|O .|O 
CONCLUSIONS|O :|O 
Deletion|O at|O codon|O 579|O (|O Asp|O )|O in|O the|O juxtamembrane|O domain|O of|O the|O c-kit|gene-rna gene|O is|O a|O novel|O gain|O -|O of|O -|O function|O mutation|O other|O than|O the|O region|O between|O Lys-550|O and|O Val-560|O .|O 
c-kit|gene-rna mutation|O and|O osteopetrosis|O -|O like|O osteopathy|O in|O a|O patient|O with|O systemic|O mast|O cell|O disease|O .|O 
We|O describe|O the|O case|O of|O a|O 69|O -|O year|O -|O old|O man|O with|O systemic|O mastocytosis|O and|O severe|O osteopetrosis|O who|O carries|O a|O somatic|O activating|O mutation|O in|O the|O c-kit|gene-rna proto|O -|O oncogene|O .|O 
The|O patient|O initially|O presented|O with|O urticaria|O pigmentosa|O ,|O progressing|O to|O systemic|O mast|O cell|O disease|O with|O severe|O anemia|O due|O to|O bone|O marrow|O involvement|O ,|O chronic|O diarrhea|O ,|O and|O hepatosplenomegaly|O .|O 
Direct|O sequencing|O using|O amplimers|O from|O reverse|gene-protein transcriptase|gene-protein -|O polymerase|gene-protein chain|O reactions|O (|O RT|O -|O PCR|O )|O from|O skin|O mast|O cell|O -|O derived|O RNA|O revealed|O a|O point|O mutation|O in|O the|O c-kit|gene-rna proto|O -|O oncogene|O at|O position|O 2468|O ,|O introducing|O a|O new|O recognition|O site|O for|O the|O restriction|O endonuclease|O HinfI|gene-protein .|O 
Treatment|O with|O interferon-alpha|gene-protein 2a|gene-protein ,|O prednisone|O ,|O and|O erythropoietin|gene-protein was|O initiated|O .|O 
Subsequently|O ,|O clinical|O symptoms|O improved|O significantly|O and|O hemoglobin|gene-protein levels|O are|O now|O stable|O at|O 13|O g|O /|O dl|O .|O 
Alterations|O of|O p53|gene-rna gene|O and|O Ha-ras|gene-rna gene|O are|O independent|O events|O in|O solar|O keratosis|O and|O squamous|O cell|O carcinoma|O .|O 
In|O order|O to|O clarity|O the|O multiple|O -|O step|O progression|O from|O solar|O keratosis|O to|O squamous|O cell|O carcinoma|O ,|O aberrations|O of|O the|O p53|gene-rna gene|O (|O exons|O 2|O -|O 11|O )|O and|O ras|gene-rna genes|O (|O exons|O 1|O and|O 2|O )|O in|O solar|O keratosis|O and|O squamous|O cell|O carcinoma|O were|O investigated|O by|O polymerase|gene-protein chain|O reaction|O and|O single|O -|O strand|O conformation|O polymorphism|O analysis|O .|O 
In|O a|O series|O of|O Japanese|O patients|O ,|O eight|O of|O 27|O (|O 30|O %|O )|O samples|O of|O solar|O keratosis|O and|O three|O of|O six|O (|O 50|O %|O )|O samples|O of|O squamous|O cell|O carcinoma|O showed|O structural|O abnormalities|O in|O the|O p53|gene-rna gene|O .|O 
Only|O one|O solar|O keratosis|O (|O 4|O %|O )|O showed|O a|O point|O mutation|O in|O the|O Ha-ras|gene-rna gene|O but|O not|O in|O the|O p53|gene-rna gene|O .|O 
Among|O these|O cases|O ,|O no|O mutation|O of|O ras|gene-rna genes|O could|O be|O detected|O in|O squamous|O cell|O carcinoma|O .|O 
Simultaneous|O mutation|O of|O ras|gene-rna genes|O and|O the|O p53|gene-rna gene|O was|O not|O detected|O in|O any|O cases|O of|O either|O solar|O keratosis|O or|O squamous|O cell|O carcinoma|O .|O 
It|O is|O concluded|O that|O aberrations|O of|O the|O p53|gene-rna gene|O and|O ras|gene-rna genes|O are|O induced|O through|O independent|O processes|O of|O ultraviolet|O irradiation|O in|O the|O course|O of|O carcinogenic|O change|O from|O solar|O keratosis|O to|O squamous|O cell|O carcinoma|O .|O 
Specific|O K-ras2|gene-rna mutations|O in|O human|O sporadic|O colorectal|O adenomas|O are|O associated|O with|O DNA|O near|O -|O diploid|O aneuploidy|O and|O inhibition|O of|O proliferation|O .|O 
Recent|O studies|O indicate|O that|O p21ras|gene-protein proteins|O mediate|O their|O multiple|O cell|O functions|O through|O interactions|O with|O multiple|O effectors|O and|O that|O the|O number|O of|O new|O effectors|O is|O growing|O .|O 
We|O recently|O reported|O that|O K-ras2|gene-rna mutations|O in|O human|O colorectal|O adenomas|O were|O associated|O with|O chromosome|O instability|O and|O proliferation|O changes|O .|O 
In|O the|O present|O study|O ,|O we|O extend|O these|O previous|O observations|O .|O 
Hereditary|O and|O multiple|O (|O n|O >|O or|O =|O 5|O )|O adenomas|O and|O adenomas|O with|O early|O cancer|O were|O excluded|O .|O 
Dysplasia|O was|O moderate|O in|O 91|O cases|O and|O high|O in|O 25|O ,|O and|O the|O median|O adenoma|O size|O was|O 1.5|O cm|O .|O 
K-ras2|gene-rna spectrum|O analysis|O was|O done|O by|O sequence|O -|O specific|O oligonucleotide|O hybridization|O using|O nuclear|O suspensions|O provided|O by|O analysis|O and|O sorting|O of|O multiparameter|O flow|O cytometry|O .|O 
In|O particular|O ,|O tissue|O inflammatory|O cells|O were|O separated|O for|O DNA|O diploid|O tumors|O ,|O whereas|O DNA|O aneuploid|O epithelial|O subclones|O were|O analyzed|O separately|O .|O 
K-ras2|gene-rna mutations|O and|O DNA|O aneuploidy|O were|O both|O detected|O in|O 29|O of|O 116|O (|O 25|O %|O )|O cases|O .|O 
DNA|O aneuploid|O index|O was|O in|O the|O near|O -|O diploid|O region|O in|O the|O majority|O of|O cases|O .|O 
DNA|O aneuploidy|O was|O strongly|O associated|O with|O G|O -->|O C|O /|O T|O transversions|O .|O 
An|O association|O was|O also|O found|O between|O low|O S-phase|O values|O and|O G|O -->|O A|O transitions|O .|O 
These|O findings|O were|O confirmed|O using|O multivariate|O logistic|O regression|O analysis|O to|O account|O for|O the|O effects|O of|O size|O ,|O dysplasia|O ,|O site|O ,|O type|O ,|O age|O ,|O and|O sex|O .|O 
These|O data|O suggest|O that|O specific|O K-ras2|gene-rna mutations|O in|O a|O subgroup|O of|O human|O sporadic|O colorectal|O adenomas|O play|O a|O role|O in|O chromosome|O instability|O and|O ,|O contrary|O to|O expectations|O ,|O are|O associated|O with|O inhibition|O of|O proliferation|O .|O 
Accumulated|O clonal|O genetic|O alterations|O in|O familial|O and|O sporadic|O colorectal|O carcinomas|O with|O widespread|O instability|O in|O microsatellite|O sequences|O .|O 
A|O subset|O of|O hereditary|O and|O sporadic|O colorectal|O carcinomas|O is|O defined|O by|O microsatellite|O instability|O (|O MSI|O )|O ,|O but|O the|O spectra|O of|O gene|O mutations|O have|O not|O been|O characterized|O extensively|O .|O 
Thirty-nine|O hereditary|O nonpolyposis|O colorectal|O cancer|O syndrome|O carcinomas|O (|O HNPCCa|O )|O and|O 57|O sporadic|O right|O -|O sided|O colonic|O carcinomas|O (|O SRSCCa|O )|O were|O evaluated|O .|O 
Of|O HNPCCa|O ,|O 95|O %|O (|O 37|O /|O 39|O )|O were|O MSI|O -|O positive|O as|O contrasted|O with|O 31|O %|O (|O 18|O /|O 57|O )|O of|O SRSCCa|O (|O P|O <|O 0.000001|O )|O ,|O but|O instability|O tended|O to|O be|O more|O widespread|O in|O SRSCCa|O (|O P|O =|O 0.08|O )|O .|O 
Absence|O of|O nuclear|gene-protein hMSH2|gene-protein mismatch|gene-protein repair|gene-protein gene|gene-protein product|gene-protein by|O immunohistochemistry|O was|O associated|O with|O germline|O hMSH2|gene-rna mutation|O (|O P|O =|O 0.0007|O )|O .|O 
The|O prevalence|O of|O K-ras|gene-rna proto|O -|O oncogene|O mutations|O was|O similar|O in|O HNPCCa|O and|O SRSCCa|O (|O 30|O %|O (|O 11|O /|O 37|O )|O and|O 30|O %|O (|O 16|O /|O 54|O )|O )|O ,|O but|O no|O HNPCCa|O from|O patients|O with|O germline|O hMSH2|gene-rna mutation|O had|O codon|O 13|O mutation|O (|O P|O =|O 0.02|O )|O ,|O and|O two|O other|O HNPCCa|O had|O multiple|O K-ras|gene-rna mutations|O attributable|O to|O subclones|O .|O 
18q|O allelic|O deletion|O and|O p53|gene-protein gene|gene-protein product|gene-protein overexpression|O were|O inversely|O related|O to|O MSI|O (|O P|O =|O 0.0004|O and|O P|O =|O 0.0001|O ,|O respectively|O )|O .|O 
Frameshift|O mutation|O of|O the|O transforming|O growth|gene-rna factor|gene-rna beta|gene-rna type|gene-rna II|gene-rna receptor|gene-rna gene|O was|O frequent|O in|O all|O MSI|O -|O positive|O cancers|O (|O 85|O %|O ,|O 46|O /|O 54|O )|O ,|O but|O mutation|O of|O the|O E2F-4|gene-rna transcription|gene-rna factor|gene-rna gene|O was|O more|O common|O in|O HNPCCa|O of|O patients|O with|O germline|O hMSH2|gene-rna mutation|O than|O in|O those|O with|O germline|O bMLH1|gene-rna mutation|O (|O 100|O %|O (|O 8|O /|O 8|O )|O versus|O 40|O %|O (|O 2|O /|O 5|O )|O ,|O P|O =|O 0.04|O )|O ,|O and|O mutation|O of|O the|O Bax|gene-rna proapoptotic|O gene|O was|O more|O frequent|O in|O HNPCCa|O than|O in|O MSI|O -|O positive|O SRSCCa|O (|O 55|O %|O (|O 17|O /|O 31|O )|O versus|O 13|O %|O (|O 2|O /|O 15|O )|O ,|O P|O =|O 0.01|O )|O .|O 
The|O most|O common|O combination|O of|O mutations|O occurred|O in|O only|O 23|O %|O (|O 8|O /|O 35|O )|O of|O evaluable|O MSI|O -|O positive|O cancers|O .|O 
Our|O findings|O suggest|O that|O the|O accumulation|O of|O specific|O genetic|O alterations|O in|O MSI|O -|O positive|O colorectal|O cancers|O is|O markedly|O heterogeneous|O ,|O because|O the|O occurrence|O of|O some|O mutations|O (|O eg|O ,|O ras|gene-rna ,|O E2F-4|gene-rna ,|O and|O Bax|gene-rna genes|O )|O ,|O but|O not|O others|O (|O eg|O ,|O transforming|gene-rna growth|gene-rna factor|gene-rna beta|gene-rna type|gene-rna II|gene-rna receptor|gene-rna gene|O )|O ,|O depends|O on|O the|O underlying|O basis|O of|O the|O mismatch|O repair|O deficiency|O .|O 
This|O genetic|O heterogeneity|O may|O contribute|O to|O the|O heterogeneous|O clinical|O and|O pathological|O features|O of|O MSI|O -|O positive|O cancers|O .|O 
Detection|O of|O a|O rare|O point|O mutation|O at|O codon|O 59|O and|O relatively|O high|O incidence|O of|O H-ras|gene-rna mutation|O in|O Indian|O oral|O cancer|O .|O 
Analysis|O of|O H|gene-rna -|gene-rna ,|O K|gene-rna -|gene-rna and|O N|gene-rna -|gene-rna ras|gene-rna genes|O for|O point|O mutations|O by|O PCR|O -|O SSCP|O and|O direct|O sequencing|O of|O 46|O oral|O SCCs|O that|O were|O previously|O analyzed|O for|O p53|gene-rna mutations|O revealed|O that|O 9|O (|O 20|O %|O )|O had|O point|O mutations|O in|O either|O the|O H-ras|gene-rna or|O the|O N-ras|gene-rna .|O 
A|O novel|O mutation|O at|O codon|O 59|O (|O GCC|O -|O ACC|O )|O of|O H-ras|gene-rna thus|O far|O reported|O only|O in|O v-H-ras|gene-rna of|O Harvey|O murine|O sarcoma|O virus|O was|O observed|O in|O a|O tumor|O of|O the|O cheek|O .|O 
Majority|O (|O 8|O /|O 9|O )|O of|O these|O mutations|O were|O observed|O in|O H-ras|gene-rna ,|O one|O in|O N-ras|gene-rna and|O none|O in|O K-ras|gene-rna .|O 
This|O study|O indicated|O that|O the|O ras|gene-rna gene|O mutation|O was|O relatively|O high|O in|O oral|O cancers|O associated|O with|O tobacco|O chewing|O and|O the|O ras|gene-rna and|O p53|gene-rna mutational|O events|O seem|O to|O be|O independent|O and|O mutually|O exclusive|O .|O 
K-ras|gene-rna mutations|O in|O stools|O and|O tissue|O samples|O from|O patients|O with|O malignant|O and|O nonmalignant|O pancreatic|O diseases|O .|O 
Mutant|O -|O enriched|O PCR|O and|O reverse|O dot|O blot|O hybridization|O in|O microplates|O were|O applied|O for|O examining|O K-ras|gene-rna status|O in|O stools|O and|O tissue|O samples|O from|O patients|O with|O pancreatic|O tumors|O and|O chronic|O pancreatitis|O .|O 
In|O tissue|O samples|O ,|O K-ras|gene-rna mutations|O were|O found|O in|O 32|O of|O 35|O cases|O of|O ductal|O adenocarcinoma|O ,|O in|O 5|O of|O 7|O periampullary|O cancers|O ,|O in|O 1|O cystadenocarcinoma|O ,|O and|O in|O 3|O of|O 5|O patients|O with|O chronic|O pancreatitis|O .|O 
In|O stools|O ,|O mutated|O K-ras|gene-rna was|O seen|O in|O 10|O of|O 25|O cases|O of|O ductal|O adenocarcinoma|O ,|O in|O 1|O case|O of|O cystadenocarcinoma|O ,|O and|O in|O 2|O of|O 6|O cases|O of|O chronic|O pancreatitis|O .|O 
These|O data|O indicate|O that|O the|O K-ras|gene-rna status|O of|O stool|O samples|O may|O help|O identify|O pancreatic|O carcinoma|O and|O persons|O at|O risk|O for|O cancer|O development|O ;|O however|O ,|O it|O does|O not|O allow|O discrimination|O of|O malignant|O from|O nonmalignant|O diseases|O .|O 
Detection|O of|O K-ras|gene-rna point|O mutations|O in|O sputum|O from|O patients|O with|O adenocarcinoma|O of|O the|O lung|O by|O point|O -|O EXACCT|O .|O 
PURPOSE|O :|O 
Kirsten|gene-rna ras|gene-rna (|O K-ras|gene-rna )|O point|O mutations|O are|O found|O in|O 30|O %|O to|O 56|O %|O of|O pulmonary|O adenocarcinomas|O by|O means|O of|O highly|O sensitive|O techniques|O .|O 
Recently|O ,|O the|O Point|O -|O EXACCT|O (|O point|O mutation|O detection|O using|O exonuclease|gene-protein amplification|O coupled|O capture|O technique|O )|O method|O was|O described|O ,|O which|O detected|O one|O cell|O with|O a|O mutation|O in|O 15,000|O normal|O cells|O .|O 
The|O aim|O of|O this|O study|O was|O to|O examine|O whether|O K-ras|gene-rna point|O mutations|O could|O be|O found|O with|O this|O rapid|O method|O in|O the|O sputum|O of|O patients|O with|O adenocarcinoma|O of|O the|O lung|O .|O 
PATIENTS|O AND|O METHODS|O :|O 
DNA|O from|O paraffin|O -|O embedded|O adenocarcinoma|O and|O corresponding|O sputum|O samples|O were|O analyzed|O for|O mutations|O of|O the|O K-ras|gene-rna gene|O .|O 
Twenty-eight|O biopsy|O specimens|O and|O 54|O sputum|O samples|O of|O 22|O patients|O were|O used|O for|O amplification|O and|O K-ras|gene-rna codon|O 12|O point|O mutation|O detection|O .|O 
RESULTS|O :|O 
In|O 11|O of|O 22|O patients|O (|O 50|O %|O )|O ,|O a|O mutation|O in|O K-ras|gene-rna codon|O 12|O was|O shown|O in|O the|O tumor|O sample|O .|O 
In|O five|O of|O 11|O patients|O (|O 45|O %|O )|O with|O a|O K-ras|gene-rna mutation|O in|O the|O tumor|O ,|O the|O same|O type|O of|O mutation|O was|O identified|O in|O at|O least|O one|O sputum|O sample|O .|O 
A|O mutation|O could|O not|O be|O detected|O in|O any|O of|O the|O sputum|O samples|O from|O patients|O with|O a|O K-ras|gene-rna -|O negative|O tumor|O .|O 
Time|O between|O K-ras|gene-rna point|O mutation|O detection|O in|O sputum|O and|O clinical|O diagnosis|O of|O lung|O cancer|O varied|O from|O 1|O month|O to|O almost|O 4|O years|O .|O 
In|O two|O of|O the|O five|O patients|O with|O K-ras|gene-rna -|O positive|O sputum|O specimens|O ,|O malignant|O cells|O were|O found|O with|O cytologic|O examination|O .|O 
CONCLUSION|O :|O 
Point|O -|O EXACCT|O is|O suitable|O for|O the|O detection|O of|O K-ras|gene-rna point|O mutations|O in|O sputum|O samples|O of|O patients|O with|O adenocarcinoma|O of|O the|O lung|O .|O 
This|O approach|O may|O be|O an|O important|O adjunct|O to|O cytology|O in|O the|O early|O diagnosis|O of|O lung|O cancer|O .|O 
Mutation|O analyses|O of|O KRAS|gene-rna exon|O 1|O comparing|O three|O different|O techniques|O :|O temporal|O temperature|O gradient|O electrophoresis|O ,|O constant|O denaturant|O capillary|O electrophoresis|O and|O allele|O specific|O polymerase|gene-protein chain|O reaction|O .|O 
Mutations|O in|O the|O KRAS|gene-rna gene|O is|O a|O key|O event|O in|O the|O carcinogenesis|O of|O many|O human|O cancers|O and|O may|O serve|O as|O a|O diagnostic|O marker|O and|O a|O target|O for|O therapeutic|O intervention|O .|O 
In|O this|O study|O we|O have|O applied|O three|O different|O techniques|O for|O mutation|O detection|O of|O KRAS|gene-rna exon|O 1|O mutations|O :|O Allele|O specific|O polymerase|gene-protein chain|O reaction|O (|O AS-PCR|O )|O ,|O temporal|O temperature|O gradient|O electrophoresis|O (|O TTGE|O )|O and|O constant|O denaturant|O capillary|O electrophoresis|O (|O CDCE|O )|O .|O 
Samples|O from|O 191|O sporadic|O colon|O carcinomas|O were|O analyzed|O .|O 
AS-PCR|O were|O performed|O with|O oligonucleotides|O specific|O for|O know|O mutations|O in|O codon|O 12|O and|O 13|O of|O the|O KRAS|gene-rna gene|O .|O 
In|O TTGE|O analyses|O ,|O linear|O ramping|O of|O the|O temperature|O were|O performed|O during|O electrophoresis|O in|O a|O constant|O denaturant|O gel|O .|O 
CDCE|O analyses|O were|O performed|O using|O fluorescin|O labeled|O PCR|O -|O products|O .|O 
Separation|O was|O achieved|O under|O constant|O denaturing|O conditions|O using|O high|O temperature|O in|O a|O gel|O -|O filled|O capillary|O followed|O by|O laser|O detection|O .|O 
A|O mutated|O KRAS|gene-rna gene|O was|O found|O in|O 42|O /|O 191|O (|O 22.0|O %|O )|O of|O the|O samples|O using|O AS-PCR|O ,|O in|O 62|O /|O 191|O (|O 32.5|O %|O )|O using|O TTGE|O and|O in|O 66|O /|O 191|O (|O 34.6|O %|O )|O of|O the|O samples|O using|O CDCE|O .|O 
In|O the|O TTGE|O and|O CDCE|O analyses|O the|O sequence|O of|O the|O mutant|O were|O determined|O by|O comparing|O the|O electrophoretic|O pattern|O to|O that|O of|O known|O mutations|O or|O by|O mixing|O the|O sample|O with|O known|O mutations|O prior|O to|O reanalysis|O .|O 
In|O a|O titration|O experiment|O mixing|O mutant|O and|O wild|O -|O type|O alleles|O prior|O to|O PCR|O ,|O the|O sensitivity|O for|O mutation|O detection|O was|O shown|O to|O be|O 10(-2)|O for|O TTGE|O and|O under|O optimized|O conditions|O 10(-3)|O for|O CDCE|O .|O 
Variability|O of|O Ha-ras|gene-rna (|O codon|O 12|O )|O proto|O -|O oncogene|O mutations|O in|O diverse|O thyroid|O cancers|O .|O 
Structural|O alterations|O to|O proto|O -|O oncogene|O sequences|O may|O be|O involved|O in|O the|O pathogenesis|O of|O human|O thyroid|O neoplasms|O .|O 
We|O studied|O 128|O thyroid|O tumours|O (|O 35|O benign|O and|O 93|O malignant|O )|O for|O ras|gene-rna gene|O point|O mutations|O in|O three|O different|O codons|O (|O 12|O ,|O 13|O and|O 61|O )|O using|O a|O restriction|O fragment|O length|O polymorphism|O technique|O and|O direct|O sequencing|O of|O double|O -|O stranded|O DNA|O on|O polymerase|gene-protein chain|O -|O reaction|O -|O amplified|O tumour|O DNA|O .|O 
We|O found|O a|O high|O frequency|O of|O ras|gene-rna mutation|O for|O the|O Ha-ras|gene-rna codon|O 12|O in|O follicular|O adenomas|O (|O 7|O of|O 35|O )|O ,|O particularly|O in|O atypical|O adenomas|O (|O 5|O of|O 17|O )|O ,|O in|O follicular|O carcinomas|O (|O 6|O of|O 19|O )|O ,|O with|O a|O high|O percentage|O for|O Hurthle|O cell|O carcinomas|O (|O 6|O of|O 11|O )|O ,|O and|O in|O papillary|O carcinomas|O (|O 4|O of|O 66|O )|O .|O 
Point|O mutations|O for|O other|O ras|gene-rna genes|O in|O different|O codons|O studied|O were|O weak|O to|O absent|O .|O 
No|O mutation|O was|O found|O in|O undifferentiated|O carcinomas|O (|O n|O =|O 8|O )|O .|O 
The|O predominant|O amino|O acid|O substitution|O both|O in|O the|O adenomas|O and|O in|O the|O differentiated|O tumours|O was|O glycine|O to|O valine|O (|O GGC|O to|O GTC|O )|O at|O position|O 12|O of|O the|O Ha-ras|gene-rna gene|O .|O 
Our|O results|O obtained|O on|O a|O large|O series|O confirm|O the|O frequent|O occurrence|O of|O Ha-ras|gene-rna codon|O 12|O gene|O mutations|O both|O in|O adenomas|O and|O in|O carcinomas|O .|O 
The|O frequency|O of|O ras|gene-rna mutations|O is|O linked|O to|O the|O geographical|O origin|O of|O the|O population|O studied|O and|O varies|O (|O 0|O -|O 85|O %|O )|O from|O one|O cancer|O type|O to|O another|O according|O to|O published|O data|O .|O 
Therefore|O ,|O these|O mutations|O are|O merely|O an|O expression|O of|O cellular|O transformation|O .|O 
Beta-catenin|gene-rna mutation|O in|O carcinoma|O of|O the|O uterine|O endometrium|O .|O 
Beta-catenin|gene-protein forms|O complexes|O with|O Tcf|gene-protein and|O Lef-1|gene-protein and|O functions|O as|O a|O transcriptional|O activator|O downstream|O of|O the|O Wnt|gene-rna signaling|O pathway|O .|O 
Activation|O of|O the|O pathway|O by|O stabilization|O of|O beta-catenin|gene-protein has|O been|O shown|O to|O be|O important|O in|O the|O development|O of|O colorectal|O carcinoma|O ,|O which|O is|O mainly|O caused|O by|O inactivating|O mutations|O of|O the|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna tumor|O suppressor|O gene|O or|O by|O activating|O mutations|O in|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O .|O 
Here|O ,|O we|O analyzed|O mutations|O in|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O in|O endometrial|O carcinoma|O cases|O in|O which|O loss|O of|O heterozygosity|O at|O the|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna tumor|O suppressor|O gene|O locus|O has|O been|O rarely|O reported|O .|O 
We|O found|O that|O 10|O of|O 76|O cases|O had|O beta-catenin|gene-rna gene|O mutations|O .|O 
All|O mutations|O identified|O were|O single|O -|O base|O missense|O mutations|O on|O serine|O /|O threonine|O residues|O (|O codons|O 33|O ,|O 37|O ,|O 41|O ,|O and|O 45|O )|O ,|O altering|O the|O glycogen|gene-protein synthase|gene-protein kinase|gene-protein -|gene-protein 3|gene-protein beta|gene-protein phosphorylation|O consensus|O motif|O ,|O which|O participates|O in|O the|O degradation|O of|O beta-catenin|gene-generic .|O 
To|O determine|O whether|O these|O beta-catenin|gene-rna mutations|O actually|O led|O to|O stabilization|O of|O this|O protein|gene-protein ,|O expression|O of|O beta-catenin|gene-protein was|O analyzed|O immunohistochemically|O ,|O and|O 9|O of|O 10|O cases|O with|O the|O beta-catenin|gene-rna mutation|O and|O 20|O of|O 66|O cases|O without|O it|O showed|O accumulation|O of|O beta-catenin|gene-protein in|O the|O cytoplasm|O and/or|O nucleus|O .|O 
In|O total|O ,|O 38|O %|O of|O cases|O showed|O accumulation|O of|O beta-catenin|gene-protein .|O 
These|O data|O indicate|O that|O stabilization|O of|O beta-catenin|gene-protein due|O to|O mutations|O in|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O and|O other|O mechanisms|O may|O have|O an|O important|O role|O in|O development|O of|O endometrial|O carcinomas|O .|O 
In|O vivo|O differentiation|O of|O mast|O cells|O from|O acute|O myeloid|O leukemia|O blasts|O carrying|O a|O novel|O activating|O ligand|O -|O independent|O C-kit|gene-rna mutation|O .|O 
The|O primary|O role|O of|O protooncogene|O c-kit|gene-rna in|O mast|O cell|O differentiation|O is|O supported|O by|O the|O development|O of|O mast|O cells|O from|O CD34|gene-protein +|O /|O CD117|gene-protein +|O (|O c-kit|gene-generic )|O myeloid|O precursors|O .|O 
Growth|gene-protein factor|gene-protein independence|O ,|O neoplastic|O transformation|O and|O differentiation|O of|O mast|O cells|O were|O found|O in|O association|O with|O c-kit|gene-rna activating|O mutations|O in|O both|O murine|O and|O human|O mastocytoma|O and|O mast|O cell|O diseases|O .|O 
We|O have|O identified|O a|O novel|O c-kit|gene-rna mutation|O (|O D|O 816|O Y|O )|O in|O peripheral|O blood|O mononuclear|O cells|O from|O a|O patient|O with|O AML|O (|O M2|O )|O ,|O massive|O presence|O of|O mast|O cells|O in|O bone|O marrow|O and|O rapid|O progression|O of|O the|O disease|O .|O 
The|O mutation|O ,|O a|O G|O -->|O T|O transversion|O at|O nt|O 2467|O of|O the|O c-kit|gene-rna gene|O resulting|O in|O Asp|O 816|O -->|O Tyr|O substitution|O ,|O corresponds|O to|O the|O D|O 814|O Y|O and|O D|O 817|O Y|O mutations|O identified|O and|O characterized|O in|O the|O murine|O P815|O mastocytoma|O and|O the|O rat|O RBL-2H3|O mast|O cell|O leukemia|O cell|O lines|O .|O 
The|O absence|O of|O SCF|gene-protein transcripts|O that|O we|O found|O by|O RTPCR|O in|O the|O patient|O 's|O blasts|O indicates|O that|O ,|O also|O in|O humans|O ,|O this|O activating|O mutation|O leads|O to|O SCF|gene-protein independent|O growth|O .|O 
The|O expression|O of|O the|O mutant|O allele|O on|O Kit|gene-generic signaling|O may|O be|O further|O enhanced|O by|O trisomy|O of|O chromosome|O 4|O (|O carrying|O the|O c-kit|gene-rna gene|O )|O in|O the|O patient|O 's|O blasts|O .|O 
From|O these|O findings|O it|O is|O concluded|O that|O mast|O cells|O could|O be|O generated|O from|O a|O leukemic|O CD34|gene-protein /|O CD117|gene-protein -|O positive|O clone|O ,|O that|O combines|O the|O antigenic|O expression|O of|O mast|O cell|O precursor|O to|O the|O growth|gene-protein and|gene-protein differentiation|gene-protein factor|gene-protein -|O independence|O which|O was|O derived|O by|O the|O c-kit|gene-rna D|O 816|O Y|O mutation|O .|O 
Detection|O of|O ras|gene-rna gene|O mutations|O in|O peripheral|O blood|O of|O carcinoma|O patients|O using|O CD45|gene-protein immunomagnetic|O separation|O and|O nested|O mutant|O allele|O specific|O amplification|O .|O 
We|O developed|O a|O sensitive|O technique|O of|O detecting|O circulating|O tumor|O cells|O in|O carcinoma|O patients|O ,|O using|O CD45|gene-protein immunomagnetic|O separation|O to|O isolate|O epithelial|O cells|O in|O blood|O samples|O and|O specific|O polymerase|gene-protein chain|O reaction|O analysis|O to|O identify|O point|O mutations|O of|O the|O K-ras|gene-rna gene|O .|O 
The|O method|O is|O based|O on|O the|O fact|O that|O the|O peripheral|O blood|O mononuclear|O cells|O (|O PBMC|O )|O that|O express|O CD45|gene-protein antigen|gene-protein are|O trapped|O with|O anti|O -|O CD45|gene-protein conjugated|O supramagnetic|O microbeads|O while|O the|O carcinoma|O cells|O that|O do|O not|O express|O CD45|gene-protein antigen|gene-protein are|O not|O trapped|O and|O pass|O through|O the|O magnetic|O fields|O .|O 
This|O method|O concentrated|O the|O number|O of|O carcinoma|O cells|O 3.3|O times|O .|O 
After|O this|O separation|O ,|O the|O modified|O method|O of|O mutant|O allele|O specific|O amplification|O was|O applied|O and|O this|O method|O was|O able|O to|O ten|O control|O carcinoma|O cells|O in|O a|O background|O of|O 107|O PBMC|O .|O 
A|O preliminary|O clinical|O study|O demonstrated|O that|O six|O cases|O of|O end|O -|O stage|O carcinoma|O with|O K-ras|gene-rna mutations|O in|O the|O primary|O tumor|O showed|O the|O same|O mutations|O in|O the|O peripheral|O blood|O samples|O ,|O while|O two|O cases|O without|O K-ras|gene-rna mutation|O in|O the|O primary|O tumor|O and|O 10|O healthy|O volunteers|O showed|O no|O mutation|O in|O the|O peripheral|O blood|O samples|O .|O 
The|O results|O suggest|O that|O this|O method|O may|O be|O very|O useful|O to|O detect|O circulating|O carcinoma|O cells|O in|O the|O patient|O whose|O primary|O tumor|O shows|O K-ras|gene-rna mutations|O .|O 
The|O type|O of|O K-ras|gene-rna mutation|O determines|O prognosis|O in|O colorectal|O cancer|O .|O 
BACKGROUND|O :|O 
Mutations|O involving|O the|O oncogene|O K-ras|gene-rna in|O colorectal|O cancer|O may|O be|O related|O to|O tumor|O aggressiveness|O .|O 
However|O ,|O the|O value|O of|O K-ras|gene-rna gene|O determination|O as|O a|O prognostic|O marker|O has|O not|O been|O clearly|O established|O .|O 
PATIENTS|O AND|O METHODS|O :|O 
The|O results|O from|O 98|O patients|O recruited|O in|O a|O prospective|O study|O analyzing|O the|O effect|O of|O a|O K-ras|gene-rna mutation|O as|O a|O prognostic|O factor|O in|O colorectal|O cancer|O are|O reported|O .|O 
RESULTS|O :|O 
Disease|O -|O free|O (|O P|O =|O 0.02|O )|O and|O overall|O survival|O (|O P|O =|O 0.03|O )|O were|O significantly|O reduced|O for|O patients|O harboring|O a|O K-ras|gene-rna mutation|O .|O 
Two|O specific|O mutations|O demonstrated|O a|O significantly|O increased|O risk|O of|O disease|O recurrence|O ,|O namely|O ,|O 12|O -|O TGT|O (|O P|O =|O 0.04|O )|O and|O 13|O -|O GAC|O substitutions|O (|O P|O =|O 0.002|O )|O .|O 
Patients|O with|O either|O of|O these|O substitutions|O had|O a|O 2|O -|O year|O disease|O -|O free|O survival|O rate|O of|O 37|O %|O compared|O with|O that|O of|O 67|O %|O for|O the|O group|O of|O patients|O harboring|O any|O other|O mutation|O type|O or|O a|O wild|O -|O type|O status|O (|O P|O =|O 0.01|O )|O .|O 
CONCLUSIONS|O :|O 
The|O results|O herein|O presented|O suggest|O that|O K-ras|gene-rna acts|O as|O a|O prognostic|O factor|O in|O colorectal|O cancer|O and|O that|O this|O effect|O is|O probably|O related|O to|O a|O limited|O number|O of|O defined|O mutations|O .|O 
Molecular|O pathogenesis|O of|O sporadic|O duodenal|O cancer|O .|O 
Whether|O duodenal|O adenocarcinoma|O should|O be|O considered|O as|O a|O gastrointestinal|O or|O as|O a|O peripancreatic|O cancer|O is|O a|O matter|O of|O debate|O ,|O as|O is|O the|O opportunity|O and|O type|O of|O treatment|O .|O 
We|O investigated|O 12|O such|O cancers|O for|O the|O genetic|O anomalies|O involved|O in|O the|O pathogenesis|O of|O gastrointestinal|O malignancies|O ,|O including|O (a)|O those|O occurring|O in|O common|O -|O type|O cancers|O -|O allelic|O losses|O at|O chromosomes|O 3p|O ,|O 5q|O ,|O 17p|O and|O 18q|O ,|O and|O Ki-ras|gene-rna and|O p53|gene-rna alterations|O ;|O and|O (b)|O those|O characteristic|O of|O mutator|O -|O phenotype|O cancers|O -|O microsatellite|O instability|O and|O TGF-betaRII|gene-rna gene|O mutations|O .|O 
We|O found|O Ki-ras|gene-rna and|O p53|gene-rna mutations|O in|O five|O (|O 42|O %|O )|O and|O eight|O cancers|O (|O 67|O %|O )|O ,|O respectively|O ;|O chromosome|O 3p|O ,|O 5q|O ,|O 17p|O and|O 18q|O allelic|O losses|O in|O two|O of|O nine|O (|O 22|O %|O )|O ,|O six|O of|O ten|O (|O 60|O %|O )|O ,|O six|O of|O nine|O (|O 67|O %|O )|O and|O three|O of|O ten|O (|O 30|O %|O )|O informative|O cancers|O ,|O respectively|O .|O 
Finally|O ,|O three|O cancers|O (|O 25|O %|O )|O showed|O widespread|O microsatellite|O instability|O and|O two|O of|O them|O had|O a|O TGF-betaRII|gene-rna gene|O mutation|O .|O 
Our|O data|O suggest|O that|O duodenal|O cancers|O may|O arise|O from|O either|O of|O the|O two|O known|O pathogenetic|O molecular|O pathways|O of|O gastric|O and|O colorectal|O cancers|O .|O 
The|O majority|O of|O our|O cases|O were|O highly|O aggressive|O cancers|O with|O frequent|O chromosomal|O changes|O and|O p53|gene-rna mutations|O as|O observed|O in|O the|O common|O -|O type|O gastrointestinal|O malignancies|O ,|O while|O widespread|O subtle|O alterations|O characteristic|O of|O mutator|O -|O phenotype|O cancers|O occurred|O in|O a|O minority|O ,|O which|O also|O showed|O a|O favourable|O long|O -|O term|O outcome|O .|O 
Irinotecan|O hydrochloride|O (|O CPT-11|O )|O resistance|O identified|O by|O K-ras|gene-rna mutation|O in|O patients|O with|O progressive|O colon|O cancer|O after|O treatment|O with|O 5-fluorouracil|O (|O 5-FU|O )|O .|O 
OBJECTIVE|O :|O 
To|O determine|O the|O prognostic|O role|O of|O a|O K-ras|gene-rna mutation|O in|O tumor|O tissue|O of|O patients|O with|O refractory|O colon|O cancer|O who|O received|O irinotecan|O hydrochloride|O (|O CPT-11|O )|O .|O 
METHODS|O :|O 
DNA|O was|O extracted|O from|O paraffin|O -|O stored|O tumor|O tissue|O of|O 35|O patients|O with|O progressive|O colon|O cancer|O failing|O treatment|O with|O 5-fluorouracil|O who|O subsequently|O received|O CPT-11|O (|O 100|O mg|O /|O m2|O i.v.|O per|O week|O x|O 4|O weeks|O with|O 2|O weeks|O off|O per|O course|O )|O .|O 
The|O first|O exon|O of|O the|O K-ras|gene-rna gene|O was|O amplified|O by|O polymerase|gene-protein chain|O reaction|O by|O using|O K-ras|gene-rna -|O specific|O primers|O followed|O by|O mutant|O enrichment|O sequencing|O .|O 
Survival|O differences|O of|O patients|O with|O a|O K-ras|gene-rna mutation|O were|O compared|O with|O those|O of|O patients|O with|O a|O normal|O K-ras|gene-rna status|O .|O 
RESULTS|O :|O 
A|O total|O of|O 21|O patients|O had|O a|O normal|O K-ras|gene-rna sequence|O and|O 14|O patients|O had|O a|O K-ras|gene-rna mutation|O [|O GAT|O ,|O n|O =|O 7|O ;|O TGT|O ,|O n|O =|O 3|O ;|O and|O GCT|O ,|O AGT|O ,|O GTT|O ,|O GAC|O (|O codon|O 13|O )|O ,|O n|O =|O 1|O each|O ]|O .|O 
Median|O survival|O of|O patients|O with|O a|O normal|O ras|gene-rna sequence|O from|O time|O of|O treatment|O with|O CPT-11|O was|O 332|O days|O compared|O with|O 169|O days|O for|O patients|O with|O a|O K-ras|gene-rna mutation|O (|O p|O =|O 0.0036|O )|O .|O 
No|O differences|O in|O age|O ,|O sex|O ,|O cancer|O stage|O ,|O surgical|O treatment|O ,|O or|O chemotherapy|O treatment|O were|O observed|O .|O 
CONCLUSION|O :|O 
Determination|O of|O the|O presence|O of|O a|O K-ras|gene-rna mutation|O may|O predict|O survival|O in|O patients|O with|O progressive|O colon|O cancer|O after|O treatment|O with|O 5-fluorouracil|O who|O receive|O CPT-11|O .|O 
p53|gene-rna and|O K-ras|gene-rna status|O in|O duodenal|O adenomas|O in|O familial|O adenomatous|O polyposis|O .|O 
BACKGROUND|O :|O 
The|O genetic|O alterations|O in|O patients|O with|O familial|O adenomatous|O polyposis|O (|O FAP|O )|O and|O duodenal|O adenomas|O are|O poorly|O characterized|O when|O compared|O with|O data|O relating|O to|O colorectal|O tumorigenesis|O in|O the|O same|O patients|O .|O 
METHODS|O :|O 
Point|O mutation|O of|O the|O K-ras|gene-rna oncogene|O and|O point|O mutation|O and|O overexpression|O of|O the|O TP53|gene-rna tumour|O suppressor|O gene|O were|O investigated|O in|O 32|O duodenal|O polyps|O (|O seven|O without|O mucosal|O pathology|O ,|O 23|O with|O mildly|O dysplastic|O adenomas|O and|O two|O with|O moderately|O dysplastic|O adenomas|O )|O from|O 21|O patients|O with|O FAP|O .|O 
RESULTS|O :|O 
K-ras|gene-rna mutation|O ,|O TP53|gene-rna mutation|O or|O positive|O p53|gene-protein staining|O were|O not|O found|O in|O duodenal|O polyps|O without|O histological|O abnormality|O .|O 
Of|O 25|O duodenal|O adenomas|O ,|O K-ras|gene-rna mutation|O was|O found|O in|O three|O (|O two|O mildly|O dysplastic|O ,|O one|O moderately|O dysplastic|O )|O ,|O 20|O showed|O positive|O p53|gene-protein immunostaining|O ,|O and|O mutation|O of|O the|O TP53|gene-rna gene|O was|O found|O in|O one|O moderately|O dysplastic|O adenoma|O .|O 
p53|gene-protein protein|O overexpression|O in|O duodenal|O adenomas|O was|O significantly|O more|O frequent|O than|O mutation|O of|O either|O K-ras|gene-rna or|O TP53|gene-rna (|O P|O <|O 0.01|O )|O .|O 
CONCLUSION|O :|O 
p53|gene-generic dysfunction|O is|O a|O hallmark|O of|O duodenal|O adenomas|O in|O patients|O with|O FAP|O .|O 
Overexpression|O may|O indicate|O DNA|O damage|O and|O thus|O an|O early|O step|O in|O tumorigenesis|O .|O 
Multiple|O hyperplastic|O polyps|O in|O the|O stomach|O :|O evidence|O for|O clonality|O and|O neoplastic|O potential|O .|O 
The|O origin|O and|O neoplastic|O potential|O of|O gastric|O epithelial|O polyps|O remains|O an|O area|O of|O great|O interest|O ,|O and|O treatment|O choices|O are|O a|O topic|O of|O controversy|O .|O 
This|O report|O describes|O a|O patient|O diagnosed|O with|O three|O concurrent|O hyperplastic|O gastric|O polyps|O that|O were|O studied|O for|O genetic|O alterations|O .|O 
The|O polyps|O were|O investigated|O for|O alterations|O in|O the|O K-ras|gene-rna oncogene|O and|O the|O p53|gene-rna tumor|O suppressor|O gene|O and|O for|O p21WAF1|gene-protein /|O Cip1|gene-protein and|O MDM2|gene-protein protein|O overexpression|O .|O 
In|O addition|O ,|O loss|O of|O heterozygosity|O at|O several|O loci|O that|O are|O frequently|O involved|O in|O human|O cancer|O was|O analyzed|O ,|O microsatellite|O instability|O ,|O a|O hallmark|O of|O the|O "|O mutator|O "|O phenotype|O ,|O was|O determined|O ,|O and|O Epstein|O -|O Barr|O virus|O infection|O was|O investigated|O .|O 
All|O separate|O areas|O from|O the|O three|O independent|O polyps|O harbored|O the|O same|O activating|O point|O mutation|O in|O codon|O 12|O of|O the|O K-ras|gene-rna oncogene|O ,|O indicating|O a|O clonal|O origin|O .|O 
DNA|O sequence|O alterations|O in|O p53|gene-rna were|O not|O found|O ,|O although|O high|O p53|gene-protein protein|O levels|O could|O be|O shown|O by|O immunohistochemistry|O in|O areas|O of|O carcinoma|O within|O the|O largest|O polyp|O .|O 
No|O alterations|O in|O any|O of|O the|O other|O molecular|O markers|O were|O observed|O .|O 
The|O results|O strongly|O favor|O a|O clonal|O origin|O of|O the|O three|O independent|O gastric|O polyps|O and|O support|O the|O notion|O that|O these|O hyperplastic|O polyps|O may|O carry|O a|O risk|O for|O malignancy|O .|O 
A|O possible|O role|O for|O human|O papillomaviruses|O and|O c-myc|gene-rna ,|O c-Ha-ras|gene-rna ,|O and|O p53|gene-rna gene|O alterations|O in|O malignant|O cutaneous|O lesions|O from|O renal|O transplant|O recipients|O .|O 
Several|O years|O after|O transplantation|O ,|O renal|O transplant|O recipients|O develop|O numerous|O cutaneous|O squamous|O cell|O carcinomas|O (|O SCC|O )|O ,|O in|O which|O human|O papillomaviruses|O (|O HPV|O )|O may|O be|O detected|O .|O 
Alterations|O in|O c-myc|gene-rna ,|O c-Ha-ras|gene-rna ,|O and|O p53|gene-rna genes|O were|O studied|O in|O 34|O SCC|O ,|O in|O correlation|O with|O the|O presence|O of|O HPV|O .|O 
In|O situ|O hybridization|O (|O ISH|O )|O and|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O showed|O that|O many|O SCC|O contained|O several|O HPV|O types|O infecting|O different|O foci|O of|O epithelial|O cells|O .|O 
Using|O Southern|O blot|O and|O ISH|O ,|O c-myc|gene-rna and/or|O c-Ha-ras|gene-rna gene|O amplification|O was|O detected|O in|O 7|O /|O 13|O SCC|O tested|O .|O 
With|O PCR|O and|O oligoprobe|O hybridization|O ,|O a|O GGC|O ->|O GAC|O mutation|O was|O found|O at|O codon|O 12|O of|O c-Ha-ras|gene-rna gene|O in|O 1|O /|O 21|O SCC|O tested|O ,|O while|O no|O mutation|O was|O detected|O at|O codon|O 61|O .|O 
Using|O immunohistochemistry|O ,|O p53|gene-protein protein|O expression|O was|O detected|O either|O along|O the|O basal|O cell|O layer|O or|O spotted|O in|O foci|O of|O basal|O cells|O .|O 
Our|O results|O show|O an|O abnormal|O distribution|O of|O HPV|O types|O in|O SCC|O from|O renal|O transplant|O recipients|O ,|O and|O alterations|O of|O c-myc|gene-rna ,|O c-Ha-ras|gene-rna ,|O and|O p53|gene-rna genes|O without|O any|O direct|O link|O with|O the|O presence|O of|O any|O studied|O HPV|O type|O .|O 
Thus|O ,|O viral|O infection|O and|O oncogene|O activation|O may|O represent|O factors|O involved|O in|O the|O etiology|O of|O skin|O SCC|O from|O transplant|O recipients|O .|O 
K-ras|gene-rna mutation|O in|O a|O tubular|O adenoma|O originating|O at|O an|O ileostomy|O in|O a|O familial|O adenomatous|O polyposis|O patient|O .|O 
Genetic|O alterations|O in|O a|O tubular|O adenoma|O with|O severe|O dysplasia|O arising|O in|O a|O Brooke|O ileostomy|O of|O a|O familial|O adenomatous|O polyposis|O patient|O were|O analyzed|O .|O 
Clinical|O and|O morphological|O characteristics|O suggest|O that|O ileal|O mucosa|O progressed|O to|O colonic|O metaplasia|O and|O then|O to|O dysplastic|O adenoma|O .|O 
Such|O changes|O at|O ileostomy|O sites|O are|O rare|O ,|O and|O little|O is|O known|O about|O the|O associated|O genetic|O alterations|O .|O 
To|O determine|O whether|O metaplastic|O epithelium|O progression|O to|O adenoma|O in|O the|O ileum|O is|O subject|O to|O the|O same|O mutations|O identified|O in|O colon|O carcinogenesis|O ,|O we|O evaluated|O somatic|O genetic|O alterations|O associated|O with|O sporadic|O colorectal|O cancer|O development|O .|O 
Sequences|O examined|O included|O mutation|O cluster|O regions|O of|O the|O p53|gene-rna tumor|O suppressor|O gene|O and|O the|O k-ras|gene-rna oncogene|O .|O 
Using|O polymerase|gene-protein chain|O reaction|O and|O DNA|O sequencing|O ,|O we|O identified|O a|O point|O mutation|O at|O codon|O 12|O of|O the|O K-ras|gene-rna oncogene|O .|O 
To|O our|O knowledge|O ,|O this|O is|O the|O first|O report|O of|O a|O ras|gene-rna mutation|O occurring|O in|O a|O tumor|O originating|O from|O ileal|O mucosa|O .|O 
Analysis|O of|O ras|gene-rna point|O mutations|O and|O human|O papillomavirus|O 16|O and|O 18|O in|O cervical|O carcinomata|O and|O their|O metastases|O .|O 
Paraffin|O -|O wax|O -|O embedded|O samples|O of|O normal|O cervical|O tissue|O and|O of|O primary|O cervical|O carcinomata|O and|O nodal|O metastases|O were|O obtained|O from|O each|O of|O 15|O patients|O .|O 
They|O were|O analyzed|O for|O the|O presence|O of|O ras|gene-rna point|O mutations|O and|O human|O papillomavirus|O (|O HPV|O )|O types|O 16|O and|O 18|O using|O the|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O and|O hybridization|O to|O oligomer|O probes|O .|O 
Only|O 1|O patient|O was|O found|O to|O have|O a|O ras|gene-rna mutation|O :|O a|O codon|O 13|O mutation|O of|O Ki-ras|gene-rna which|O was|O present|O in|O only|O two|O lymph|O node|O metastases|O ,|O but|O not|O in|O the|O primary|O tumor|O or|O in|O a|O third|O metastasis|O .|O 
These|O results|O suggest|O that|O ras|gene-rna point|O mutation|O is|O not|O a|O common|O factor|O in|O the|O development|O of|O primary|O or|O metastatic|O cervical|O cancer|O .|O 
HPV|O 16|O was|O detected|O in|O 7|O of|O the|O 15|O patients|O and|O was|O present|O in|O both|O primary|O and|O metastatic|O tumors|O in|O 6|O of|O these|O 7|O cases|O .|O 
HPV|O 18|O was|O not|O detected|O in|O any|O of|O the|O 15|O patients|O .|O 
These|O results|O do|O not|O suggest|O a|O role|O for|O HPVs|O 16|O and|O 18|O in|O producing|O metastatic|O behavior|O .|O 
Ras|gene-rna point|O mutations|O occur|O in|O acute|O myeloid|O leukemia|O with|O illegitimate|O T-cell|gene-rna receptor|gene-rna delta|gene-rna gene|O rearrangement|O .|O 
Mutations|O in|O the|O ras|gene-rna proto|O -|O oncogenes|O are|O the|O most|O frequently|O observed|O molecular|O alteration|O in|O acute|O myeloid|O leukemia|O (|O AML|O )|O .|O 
Whether|O ras|gene-rna mutations|O occur|O as|O late|O or|O relatively|O early|O events|O in|O the|O multistep|O process|O of|O myeloid|O transformation|O ,|O remains|O an|O open|O question|O .|O 
We|O previously|O described|O illegitimate|O T-cell|gene-rna receptor|gene-rna (|gene-rna TCR|gene-rna )|gene-rna -|gene-rna delta|gene-rna gene|O rearrangements|O in|O a|O subset|O of|O AML|O .|O 
These|O recombinations|O were|O detected|O in|O 9|O out|O of|O 100|O de|O novo|O AML|O cases|O .|O 
Southern|O blot|O analysis|O suggested|O the|O presence|O of|O these|O recombinations|O in|O the|O vast|O majority|O of|O AML|O cells|O and|O thus|O could|O be|O used|O as|O clonal|O markers|O .|O 
In|O order|O to|O more|O accurately|O define|O the|O role|O of|O ras|gene-rna proto|O -|O oncogene|O mutations|O in|O the|O multistep|O process|O of|O malignant|O transformation|O in|O myeloid|O leukemias|O ,|O we|O performed|O single|O strand|O conformation|O polymorphism|O (|O SSCP|O )|O assays|O ,|O slot|O blot|O and|O direct|O sequencing|O analysis|O on|O these|O nine|O cases|O with|O illegitimate|O TCR|gene-rna delta|gene-rna gene|O rearrangements|O .|O 
Ras|gene-rna proto|O -|O oncogene|O mutations|O were|O found|O in|O three|O of|O nine|O cases|O .|O 
Interestingly|O ,|O SSCP|O ,|O slot|O blot|O and|O sequencing|O suggested|O the|O presence|O of|O the|O respective|O mutations|O in|O most|O of|O the|O leukemic|O cells|O .|O 
Thus|O ,|O ras|gene-rna mutations|O presumably|O occurred|O early|O in|O the|O process|O of|O transformation|O in|O these|O three|O cases|O .|O 
Absence|O of|O N-ras|gene-rna mutations|O in|O myeloid|O and|O lymphoid|O blast|O crisis|O of|O chronic|O myeloid|O leukemia|O .|O 
Mutations|O within|O N-ras|gene-rna oncogene|O codons|O 12|O ,|O 13|O ,|O and|O 61|O occur|O in|O approximately|O 25|O -|O 30|O %|O of|O patients|O with|O acute|O nonlymphocytic|O leukemia|O and|O at|O a|O lower|O frequency|O (|O 6|O -|O 20|O %|O )|O in|O patients|O with|O acute|O lymphocytic|O leukemia|O .|O 
Moreover|O ,|O N-ras|gene-rna mutations|O have|O been|O described|O in|O patients|O with|O chronic|O myeloid|O leukemia|O (|O CML|O )|O in|O blast|O crisis|O but|O have|O not|O been|O observed|O during|O the|O chronic|O phase|O of|O the|O disease|O .|O 
In|O view|O of|O the|O morphological|O and|O clinical|O similarities|O between|O acute|O leukemia|O and|O the|O blast|O crisis|O of|O CML|O ,|O the|O question|O was|O raised|O whether|O the|O presence|O of|O N-ras|gene-rna mutations|O is|O associated|O with|O the|O phenotype|O of|O acute|O leukemia|O .|O 
We|O investigated|O leukemic|O cells|O from|O 100|O patients|O with|O CML|O for|O the|O presence|O of|O N-ras|gene-rna mutations|O in|O the|O mutational|O hot|O spot|O codons|O .|O 
The|O cases|O analyzed|O included|O 87|O diagnosed|O with|O different|O types|O of|O blast|O crisis|O and|O 13|O cases|O in|O accelerated|O or|O chronic|O phase|O of|O the|O disease|O .|O 
Fragments|O from|O N-ras|gene-rna exons|O I|O and|O II|O containing|O the|O codons|O of|O interest|O were|O amplified|O by|O polymerase|gene-protein chain|O reaction|O and|O analyzed|O for|O the|O presence|O of|O point|O mutations|O by|O three|O different|O technical|O approaches|O ,|O including|O specific|O oligonucleotide|O hybridization|O ,|O direct|O sequencing|O ,|O and|O single|O -|O strand|O conformation|O polymorphism|O analysis|O .|O 
N-ras|gene-rna mutations|O were|O not|O detected|O in|O any|O of|O the|O CML|O patients|O investigated|O .|O 
Only|O one|O patient|O ,|O in|O whom|O the|O initial|O diagnosis|O of|O CML|O -|O blast|O crisis|O had|O been|O revised|O to|O chronic|O myelomonocytic|O leukemia|O ,|O displayed|O an|O N-ras|gene-rna mutation|O within|O codon|O 13|O .|O 
Our|O data|O strongly|O suggest|O that|O N-ras|gene-rna mutations|O do|O not|O play|O a|O role|O in|O myeloid|O or|O lymphoid|O blast|O crisis|O of|O CML|O .|O 
N-ras|gene-rna mutation|O :|O an|O independent|O prognostic|O factor|O for|O aggressiveness|O of|O papillary|O thyroid|O carcinoma|O .|O 
BACKGROUND|O .|O 
The|O clinical|O importance|O of|O point|O mutations|O of|O ras|gene-rna oncogene|O in|O differentiated|O thyroid|O cancers|O has|O not|O been|O fully|O clarified|O .|O 
The|O purpose|O of|O this|O study|O is|O to|O determine|O the|O prognostic|O importance|O of|O ras|gene-rna mutation|O in|O papillary|O thyroid|O carcinoma|O .|O 
METHODS|O .|O 
Tumors|O of|O 91|O patients|O with|O papillary|O carcinoma|O were|O studied|O ;|O mean|O follow|O -|O up|O was|O 14.1|O years|O (|O range|O ,|O 1|O to|O 40|O years|O )|O .|O 
Patients|O were|O grouped|O as|O follows|O :|O class|O I|O ,|O intrathyroidal|O disease|O ,|O n|O =|O 21|O ;|O class|O II|O ,|O cervical|O node|O metastases|O ,|O n|O =|O 22|O ;|O class|O III|O ,|O extrathyroidal|O disease|O ,|O n|O =|O 19|O ;|O and|O class|O IV|O ,|O distant|O metastases|O ,|O n|O =|O 29|O .|O 
DNA|O was|O analyzed|O with|O polymerase|gene-protein chain|O reaction|O ,|O oligonucleotide|O hybridization|O ,|O and|O DNA|O sequence|O analysis|O techniques|O .|O 
RESULTS|O .|O 
Thirteen|O (|O 14.3|O %|O )|O of|O 91|O tumors|O showed|O an|O N-ras|gene-rna point|O mutation|O :|O 4.8|O %|O (|O 1|O of|O 21|O )|O patients|O in|O class|O I|O ;|O 4.5|O %|O (|O 1|O of|O 22|O )|O patients|O in|O class|O II|O ;|O 15.8|O %|O (|O 3|O of|O 19|O )|O patients|O in|O class|O III|O ;|O and|O 27.8|O %|O (|O 8|O of|O 29|O )|O patients|O in|O class|O IV|O .|O 
Each|O mutation|O changed|O codon|O 61|O from|O glutamine|O to|O arginine|O .|O 
Patients|O with|O distant|O metastases|O (|O 8|O of|O 29|O )|O had|O a|O significantly|O higher|O incidence|O of|O ras|gene-rna mutations|O than|O others|O (|O 5|O of|O 62|O ,|O p|O =|O 0.01|O )|O .|O 
Patients|O in|O classes|O III|O and|O IV|O also|O had|O a|O higher|O incidence|O of|O mutations|O (|O 11|O of|O 48|O )|O than|O patients|O in|O classes|O I|O and|O II|O (|O 2|O of|O 43|O ,|O p|O =|O 0.01|O )|O .|O 
The|O incidence|O of|O ras|gene-rna mutations|O was|O significantly|O higher|O in|O patients|O who|O died|O of|O papillary|O cancer|O (|O 5|O of|O 15|O ,|O 33.3|O %|O )|O than|O in|O patients|O who|O are|O still|O alive|O (|O 8|O of|O 76|O ,|O 10.5|O %|O )|O (|O p|O =|O 0.02|O )|O .|O 
Kaplan|O -|O Meier|O survival|O curves|O also|O showed|O a|O greater|O mortality|O from|O tumor|O (|O p|O <|O 0.05|O )|O and|O a|O higher|O recurrence|O rate|O (|O p|O <|O 0.01|O )|O in|O ras|gene-rna -|O positive|O tumors|O than|O in|O the|O ras|gene-rna -|O negative|O group|O .|O 
Finally|O ,|O in|O studies|O by|O multivariate|O analyses|O ,|O positive|O ras|gene-rna mutation|O and|O age|O were|O shown|O to|O be|O two|O independent|O prognostic|O factors|O for|O prediction|O of|O death|O from|O papillary|O cancer|O and|O recurrence|O of|O cancer|O .|O 
CONCLUSIONS|O .|O 
Mutation|O of|O N-ras|gene-rna gene|O at|O codon|O 61|O is|O an|O independent|O prognostic|O factor|O for|O aggressiveness|O of|O papillary|O thyroid|O carcinomas|O .|O 
Association|O of|O activated|O proto|O -|O oncogenes|O ras|gene-rna and|O myc|gene-rna in|O colorectal|O carcinomas|O .|O 
We|O have|O examined|O 60|O colorectal|O carcinomas|O for|O activation|O of|O two|O proto|O -|O oncogenes|O ,|O c-myc|gene-rna and|O c-Ki-ras|gene-rna .|O 
Over|O -|O expression|O of|O c-myc|gene-rna mRNA|O as|O determined|O by|O Northern|O analysis|O was|O found|O in|O 58|O %|O of|O cases|O (|O 35|O /|O 60|O )|O .|O 
Activation|O of|O the|O c-Ki-ras|gene-rna gene|O by|O point|O mutations|O in|O codons|O 12|O or|O 13|O as|O determined|O by|O mismatch|O specific|O oligonucleotide|O hybridisation|O was|O found|O in|O 35|O %|O (|O 21|O /|O 60|O )|O of|O cases|O .|O 
There|O was|O a|O statistically|O significant|O association|O between|O activation|O of|O c-Ki-ras|gene-rna and|O over|O -|O expression|O of|O c-myc|gene-generic (|O P|O =|O 0.03|O )|O ,|O with|O 76|O %|O of|O tumours|O with|O an|O activated|O c-Ki-ras|gene-rna proto|O -|O oncogene|O showing|O over|O -|O expression|O of|O c-myc|gene-generic .|O 
The|O association|O was|O significant|O in|O left-sided|O colorectal|O tumours|O (|O P|O =|O 0.03|O )|O but|O not|O right-sided|O (|O P|O =|O 0.5|O )|O .|O 
However|O ,|O whereas|O only|O 59|O %|O of|O left|O side|O tumours|O showed|O at|O least|O one|O of|O the|O two|O changes|O (|O ras|gene-rna activation|O only|O ,|O or|O myc|gene-rna activation|O only|O or|O both|O )|O ,|O 93|O %|O of|O right|O side|O tumours|O showed|O at|O least|O one|O of|O the|O changes|O (|O P|O =|O 0.01|O )|O .|O 
Twenty-two|O percent|O of|O left|O side|O tumours|O showed|O both|O changes|O compared|O with|O 35|O %|O of|O right|O side|O tumours|O ,|O although|O this|O result|O did|O not|O achieve|O significance|O (|O P|O =|O 0.2|O )|O .|O 
These|O results|O suggest|O that|O in|O left-sided|O colorectal|O tumours|O ras|gene-rna and|O myc|gene-rna cooperate|O ,|O as|O established|O in|O vitro|O ,|O to|O produce|O neoplastic|O transformation|O while|O different|O pathway(s)|O are|O involved|O in|O right-sided|O tumours|O .|O 
Co|O -|O incident|O N|gene-rna and|O K|gene-rna ras|gene-rna gene|O mutations|O in|O a|O case|O of|O AML|O ,|O restricted|O to|O differing|O cell|O lineages|O .|O 
Peripheral|O blood|O from|O a|O patient|O with|O acute|O myeloid|O leukaemia|O (|O AML|O )|O of|O M5|O FAB|O classification|O ,|O was|O shown|O to|O have|O mutations|O to|O both|O the|O N|gene-rna and|O K|gene-rna ras|gene-rna genes|O .|O 
Leucophoresed|O blood|O was|O separated|O on|O a|O discontinuous|O Percoll|O density|O gradient|O to|O provide|O fractions|O enriched|O for|O different|O cell|O lineages|O .|O 
DNA|O extracted|O from|O these|O fractions|O was|O amplified|O using|O the|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O technique|O ,|O and|O hybridized|O with|O oligonucleotide|O probes|O specific|O for|O the|O single|O base|O mutations|O previously|O demonstrated|O .|O 
The|O N-ras|gene-rna mutation|O was|O shown|O to|O be|O restricted|O to|O the|O blast|O and|O monocytic|O cell|O fractions|O ,|O concordant|O with|O the|O FAB|O subtype|O of|O M5|O .|O 
The|O K-ras|gene-rna mutation|O ,|O however|O ,|O was|O present|O in|O all|O fractions|O ,|O suggesting|O it|O had|O occurred|O in|O a|O multi|O -|O potential|O stem|O cell|O representing|O an|O earlier|O stage|O in|O the|O generation|O of|O the|O leukaemia|O ,|O or|O possibly|O an|O incidental|O background|O phenomenon|O .|O 
Presence|O of|O mutations|O in|O all|O three|O ras|gene-rna genes|O in|O human|O thyroid|O tumors|O .|O 
Polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O amplification|O followed|O by|O oligonucleotide|O probing|O was|O used|O to|O investigate|O the|O presence|O of|O ras|gene-rna genes|O mutations|O in|O human|O thyroid|O adenomas|O and|O carcinomas|O .|O 
The|O results|O confirm|O the|O frequent|O occurrence|O of|O mutations|O in|O all|O three|O ras|gene-rna genes|O in|O both|O adenomas|O and|O carcinomas|O ,|O in|O agreement|O with|O the|O hypothesis|O that|O the|O ras|gene-rna mutations|O may|O constitute|O early|O steps|O in|O thyroid|O tumorigenesis|O .|O 
No|O evident|O correlation|O between|O the|O frequency|O of|O ras|gene-rna mutations|O ,|O the|O identity|O of|O the|O mutated|O ras|gene-rna gene|O ,|O the|O position|O affected|O in|O the|O ras|gene-rna gene|O or|O the|O type|O of|O mutation|O and|O the|O pathological|O features|O is|O apparent|O .|O 
However|O ,|O definitive|O conclusion|O on|O this|O point|O is|O precluded|O because|O of|O the|O small|O number|O of|O tumors|O examined|O at|O the|O present|O time|O .|O 
Analysis|O of|O ras|gene-rna gene|O mutations|O in|O biliary|O and|O pancreatic|O tumors|O by|O polymerase|gene-protein chain|O reaction|O and|O direct|O sequencing|O .|O 
Ras|gene-rna gene|O is|O one|O of|O the|O oncogenes|O most|O commonly|O detected|O in|O human|O cancers|O and|O consists|O of|O three|O families|O (|O H-ras|gene-rna ,|O K-ras|gene-rna ,|O N-ras|gene-rna )|O that|O are|O converted|O to|O active|O oncogenes|O by|O point|O mutations|O occurring|O in|O codon|O 12|O ,|O 13|O ,|O or|O 61|O .|O 
The|O authors|O analyzed|O mutations|O of|O these|O codons|O in|O 12|O extrahepatic|O bile|O duct|O carcinomas|O ,|O nine|O gallbladder|O carcinomas|O ,|O and|O 20|O pancreatic|O tumors|O (|O 18|O pancreatic|O adenocarcinomas|O and|O two|O islet|O cell|O tumors|O )|O by|O a|O method|O to|O directly|O sequence|O nucleotides|O ,|O using|O polymerase|gene-protein chain|O reaction|O and|O a|O direct|O sequencing|O method|O .|O 
Point|O mutations|O at|O K-ras|gene-rna codon|O 12|O were|O found|O in|O all|O of|O 18|O pancreatic|O adenocarcinomas|O and|O in|O one|O bile|O duct|O carcinoma|O ,|O but|O there|O were|O no|O mutations|O in|O the|O remaining|O 11|O bile|O duct|O carcinomas|O ,|O in|O all|O of|O 9|O gallbladder|O carcinomas|O ,|O or|O in|O two|O islet|O cell|O tumors|O .|O 
A|O very|O high|O incidence|O of|O ras|gene-rna gene|O mutations|O may|O be|O used|O clinically|O for|O the|O diagnosis|O of|O debatable|O cases|O of|O pancreatic|O adenocarcinoma|O .|O 
Low|O frequency|O of|O ras|gene-rna oncogene|O mutations|O in|O Philadelphia|O -|O positive|O acute|O leukemia|O and|O report|O of|O a|O novel|O mutation|O H|gene-rna 61|O Leu|O in|O a|O single|O case|O .|O 
Activating|O ras|gene-rna mutations|O are|O frequent|O (|O 25|O -|O 60|O %|O )|O in|O chronic|O myelomonocytic|O leukemia|O (|O CMML|O )|O and|O in|O acute|O myeloid|O leukemia|O (|O AML|O )|O (|O 30|O %|O )|O ,|O in|O contrast|O to|O chronic|O myeloid|O leukemia|O (|O CML|O )|O in|O which|O the|O incidence|O is|O very|O low|O (|O 0|O -|O 3|O %|O )|O .|O 
This|O might|O reflect|O that|O the|O leukemic|O cell|O in|O CML|O is|O at|O a|O level|O of|O differentiation|O in|O which|O ras|gene-rna gene|O activation|O is|O not|O involved|O or|O ,|O alternatively|O ,|O might|O be|O due|O to|O the|O presence|O in|O CML|O of|O the|O bcr|gene-rna l|O abl|gene-rna fused|O gene|O .|O 
We|O have|O analyzed|O the|O presence|O of|O point|O mutations|O in|O codons|O 12|O ,|O 13|O ,|O 59|O ,|O 61|O and|O 63|O of|O N|gene-rna -|gene-rna ,|O K|gene-rna -|gene-rna ,|O and|O H|gene-rna -|gene-rna ras|gene-rna genes|O ,|O in|O 26|O cases|O of|O Philadelphia|O -|O chromosome|O -|O positive|O ,|O bcr|gene-rna l|O abl|gene-rna -|O positive|O acute|O leukemia|O (|O Ph|O +|O AL|O )|O ,|O and|O in|O eight|O CMML|O cases|O by|O using|O the|O polymerase|gene-protein chain|O reaction|O .|O 
Aberrant|O ras|gene-rna genes|O were|O detected|O in|O a|O single|O Ph|O +|O AL|O case|O ,|O and|O in|O four|O out|O of|O eight|O CMML|O patients|O .|O 
The|O Ph|O +|O AL|O showing|O altered|O ras|gene-rna allele|O had|O an|O unusual|O point|O mutation|O in|O H-ras|gene-rna gene|O ,|O substituting|O leucine|O for|O glutamine|O .|O 
This|O mutation|O has|O not|O been|O previously|O found|O in|O any|O hematological|O disease|O .|O 
Our|O findings|O suggest|O that|O ras|gene-rna mutations|O are|O probably|O not|O involved|O in|O the|O pathogenesis|O of|O those|O leukemias|O in|O which|O blast|O cells|O contain|O bcr|gene-rna l|O abl|gene-rna oncogene|O activation|O .|O 
ras|gene-rna oncogene|O activation|O and|O occupational|O exposures|O in|O acute|O myeloid|O leukemia|O .|O 
BACKGROUND|O :|O 
Epidemiologic|O studies|O of|O acute|O myeloid|O leukemias|O (|O AMLs|O )|O show|O small|O increases|O in|O risk|O of|O disease|O associated|O with|O certain|O occupations|O and|O chemical|O exposures|O .|O 
PURPOSE|O :|O 
This|O study|O was|O designed|O to|O determine|O whether|O the|O presence|O of|O mutationally|O activated|O ras|gene-rna oncogenes|O in|O AML|O are|O associated|O with|O occupational|O and|O chemical|O exposures|O .|O 
METHODS|O :|O 
We|O interviewed|O 62|O patients|O with|O newly|O diagnosed|O AML|O (|O or|O their|O next|O -|O of|O -|O kin|O )|O ,|O all|O of|O whom|O were|O enrolled|O in|O a|O national|O multicenter|O clinical|O trial|O ,|O and|O 630|O healthy|O control|O subjects|O .|O 
DNA|O extracted|O from|O patients|O '|O pretreatment|O bone|O marrow|O samples|O was|O amplified|O by|O using|O the|O polymerase|gene-protein chain|O reaction|O and|O probed|O with|O allele|O -|O specific|O oligonucleotides|O for|O activating|O point|O mutations|O at|O the|O 12th|O ,|O 13th|O ,|O and|O 61st|O codons|O of|O three|O protooncogenes|O :|O H-ras|gene-rna (|O also|O known|O as|O HRAS|gene-rna )|O ,|O K-ras|gene-rna (|O also|O known|O as|O KRAS2|gene-rna )|O ,|O and|O N-ras|gene-rna (|O also|O known|O as|O NRAS|gene-rna )|O .|O 
RESULTS|O :|O 
Patients|O with|O ras|gene-rna mutation|O -|O positive|O AML|O had|O a|O higher|O frequency|O (|O six|O of|O 10|O patients|O )|O of|O working|O 5|O or|O more|O years|O in|O an|O a|O priori|O high|O -|O risk|O occupation|O than|O did|O patients|O with|O ras|gene-rna mutation|O -|O negative|O AML|O (|O eight|O of|O 52|O ;|O odds|O ratio|O [|O OR|O ]|O =|O 6.8|O ;|O 95|O %|O confidence|O interval|O [|O CI|O ]|O =|O 1.3|O -|O 36|O )|O .|O 
Patients|O with|O ras|gene-rna mutation|O -|O positive|O AML|O were|O more|O likely|O than|O patients|O with|O ras|gene-rna mutation|O -|O negative|O AML|O to|O have|O breathed|O chemical|O vapor|O on|O the|O job|O (|O OR|O =|O 9.1|O ;|O 95|O %|O CI|O =|O 1.3|O -|O 64|O )|O or|O to|O have|O had|O skin|O contact|O with|O chemicals|O (|O OR|O =|O 6.9|O ;|O 95|O %|O CI|O =|O 1.3|O -|O 37|O )|O .|O 
When|O ras|gene-rna -|O positive|O patients|O were|O compared|O with|O healthy|O control|O subjects|O ,|O the|O ORs|O for|O occupation|O and|O occupational|O exposures|O remained|O elevated|O ,|O while|O patients|O with|O ras|gene-rna mutation|O -|O negative|O AML|O showed|O no|O increased|O risk|O when|O compared|O with|O control|O subjects|O .|O 
CONCLUSION|O :|O 
Activation|O of|O ras|gene-rna proto|O -|O oncogenes|O may|O identify|O an|O etiologic|O subgroup|O of|O AML|O caused|O by|O occupation|O and|O chemical|O exposure|O .|O 
IMPLICATION|O :|O 
Disease|O etiology|O may|O be|O better|O understood|O if|O epidemiologic|O measures|O of|O exposure|O are|O integrated|O with|O molecular|O assays|O of|O the|O genetic|O defects|O responsible|O for|O cancer|O initiation|O and|O promotion|O .|O 
N-RAS|gene-rna activation|O in|O the|O terminal|O stage|O of|O undifferentiated|O chronic|O myeloproliferative|O disease|O .|O 
The|O relationship|O between|O activation|O of|O the|O N-RAS|gene-rna gene|O and|O the|O leukemic|O progression|O of|O undifferentiated|O chronic|O myeloproliferative|O disease|O (|O UCMPD|O )|O was|O investigated|O in|O a|O 71|O -|O year|O -|O old|O male|O .|O 
Hematologically|O ,|O it|O was|O difficult|O to|O differentiate|O the|O UCMPD|O from|O chronic|O myelogenous|O leukemia|O .|O 
Chromosomal|O analysis|O revealed|O no|O Philadelphia|O chromosome|O (|O Ph1|O -|O )|O ,|O and|O DNA|O analysis|O revealed|O no|O BCR|gene-rna rearrangement|O (|O BCR|gene-rna -|O )|O either|O at|O the|O beginning|O or|O in|O the|O terminal|O stages|O of|O the|O disease|O .|O 
We|O performed|O a|O tumorigenicity|O assay|O ,|O using|O NIH3T3|O cells|O ,|O and|O molecular|O analysis|O ,|O using|O the|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O and|O direct|O sequencing|O .|O 
The|O DNA|O of|O leukemic|O cells|O at|O the|O beginning|O of|O the|O leukemic|O progression|O did|O not|O show|O any|O abnormalities|O ,|O but|O at|O the|O terminal|O stage|O of|O the|O disease|O the|O DNA|O showed|O a|O point|O mutation|O in|O codon|O 12|O (|O GGT|O ----|O GCT|O )|O of|O the|O N-RAS|gene-rna gene|O .|O 
Interestingly|O ,|O a|O codon|O 13|O mutation|O (|O GGT|O ----|O GTT|O )|O was|O also|O detected|O by|O tumorigenicity|O assay|O .|O 
These|O observations|O suggest|O that|O the|O activated|O N-RAS|gene-rna gene|O contributes|O to|O the|O hematologic|O progression|O of|O UCMPD|O .|O 
Na|O (|O +|O )|O -|O dependent|O AIB|O transport|O by|O neuroblastoma|O cells|O .|O 
Na|O (|O +|O )|O -|O dependent|O amino|O isobutyric|O acid|O transport|O by|O two|O neuroblastoma|O cell|O lines|O with|O and|O without|O amplification|O of|O the|O oncogene|O N-myc|gene-rna is|O studied|O .|O 
Surprisingly|O ,|O the|O contribution|O of|O system|O A|O is|O greater|O in|O the|O cell|O line|O showing|O no|O N-myc|gene-rna amplification|O .|O 
Preliminary|O data|O support|O a|O role|O for|O essential|O tyrosine|O and|O cysteine|O residues|O in|O the|O active|O center|O of|O the|O carriers|O ,|O mainly|O in|O system|O A|O .|O 
Brain|O ganglioglioma|O with|O large|O extension|O to|O subarachnoid|O space|O .|O 
A|O case|O of|O temporal|O ganglioglioma|O with|O large|O leptomeningeal|O growth|O is|O presented|O .|O 
This|O unusual|O spread|O has|O not|O been|O previously|O described|O in|O these|O tumors|O .|O 
[|O Right|O temporo|O -|O occipital|O ganglioglioma|O in|O a|O 10|O -|O year|O -|O old|O patient|O ]|O 
Authors|O describe|O an|O operated|O case|O of|O ganglioglioma|O of|O the|O right|O temporo|O -|O occipital|O region|O in|O a|O ten|O year|O old|O patient|O .|O 
After|O case|O presentation|O and|O an|O analysis|O of|O the|O literature|O ,|O the|O diagnostic|O pre|O -|O operative|O problems|O are|O discussed|O analysing|O the|O CT|O aspects|O of|O the|O lesion|O .|O 
Recommendations|O for|O reporting|O of|O tumors|O of|O the|O adrenal|O cortex|O and|O medulla|O .|O 
The|O Association|O of|O Directors|O of|O Anatomic|O and|O Surgical|O Pathology|O has|O developed|O recommendations|O for|O the|O surgical|O pathology|O report|O for|O common|O malignant|O tumors|O .|O 
The|O recommendations|O for|O tumors|O of|O the|O adrenal|O are|O reported|O herein|O .|O 
[|O P73|gene-rna :|O a|O kin|O to|O the|O p52|gene-rna tumor|O suppressor|O gene|O ]|O 
A|O gene|O with|O remarkable|O sequence|O homology|O with|O the|O tumour|O suppressor|O gene|O p53|gene-rna is|O located|O at|O the|O tip|O of|O the|O short|O arm|O of|O human|O chromosome|O 1|O which|O is|O often|O found|O to|O be|O deleted|O in|O neuroblastomas|O ,|O melanomas|O and|O breast|O cancers|O .|O 
Despite|O their|O structural|O and|O functional|O similarities|O ,|O p53|gene-rna and|O p73|gene-rna may|O have|O distinct|O roles|O in|O cell|O grow|O regulation|O .|O 
Regulation|O of|O the|O cholinergic|gene-rna gene|O locus|O .|O 
DNase|gene-protein I|gene-protein hypersensitive|O site|O mapping|O of|O the|O human|O cholinergic|gene-rna gene|O locus|O has|O been|O used|O to|O detect|O cholinergic|gene-rna specific|O potential|O regulatory|O sites|O .|O 
Analysis|O of|O mutant|O PC12|O cell|O lines|O provides|O evidence|O that|O protein|gene-protein kinase|gene-protein A|gene-protein II|gene-protein is|O required|O and|O coordinately|O regulates|O basal|O expression|O of|O both|O the|O ChAT|gene-rna and|O VAChT|gene-rna genes|O .|O 
The|O treatment|O of|O neuroblastoma|O .|O 
A|O protocol|O for|O the|O management|O of|O children|O with|O neuroblastoma|O is|O described|O .|O 
The|O appearance|O of|O peri|O -|O orbital|O ecchymosis|O and|O radiologically|O demonstrable|O skeletal|O metastases|O are|O of|O poor|O prognostic|O significance|O .|O 
The|O relatively|O infrequent|O occurrence|O of|O neuroblastoma|O in|O the|O Black|O population|O of|O Johannesburg|O is|O stressed|O .|O 
Cystic|O neuroblastoma|O with|O colonic|O fistula|O .|O 
Neuroblastoma|O is|O the|O most|O common|O malignant|O tumour|O in|O infancy|O originating|O in|O about|O 70|O %|O of|O cases|O in|O the|O adrenal|O gland|O .|O 
Haemorrhage|O and|O necrosis|O is|O often|O seen|O in|O neuroblastoma|O but|O cyst|O formation|O is|O uncommon|O .|O 
Fistulous|O communication|O between|O an|O adrenal|O cystic|O neuroblastoma|O and|O the|O large|O bowel|O has|O never|O to|O our|O knowledge|O been|O reported|O before|O .|O 
[|O Prognostic|O value|O of|O the|O N-myc|gene-rna oncogene|O in|O neuroblastoma|O ]|O 
Activation|O of|O cellular|O proto|O -|O oncogenes|O can|O be|O detected|O in|O several|O human|O cancers|O .|O 
In|O neuroblastoma|O ,|O amplification|O and|O overexpression|O of|O N-myc|gene-rna oncogene|O have|O been|O shown|O to|O be|O associated|O with|O advanced|O stages|O of|O disease|O and|O rapid|O tumor|O progression|O .|O 
These|O results|O suggest|O the|O clinical|O importance|O of|O the|O N-myc|gene-rna oncogene|O .|O 
Other|O oncogenes|O might|O also|O be|O activated|O in|O this|O cancer|O .|O 
The|O course|O of|O five|O -|O year|O survivors|O of|O cancer|O in|O childhood|O .|O 
A|O follow|O -|O up|O study|O was|O made|O of|O two|O independent|O series|O of|O 1,807|O and|O 425|O children|O who|O were|O alive|O five|O years|O after|O diagnosis|O of|O a|O malignant|O neoplasm|O .|O 
Over|O the|O subsequent|O 20|O years|O (|O 5|O to|O 24|O years|O after|O initial|O diagnosis|O )|O ,|O actuarial|O survival|O rates|O for|O the|O cohorts|O were|O 83|O %|O and|O 79|O %|O ,|O respectively|O ,|O compared|O to|O 97|O %|O for|O matched|O control|O subjects|O in|O the|O general|O population|O (|O P|O less|O than|O 0.01|O )|O .|O 
Cure|O was|O achieved|O in|O a|O large|O majority|O of|O the|O 5|O -|O year|O relapse|O -|O free|O survivors|O of|O cancer|O in|O this|O study|O .|O 
Axon|O guidance|O :|O GTPases|gene-protein help|O axons|O reach|O their|O targets|O .|O 
During|O development|O and|O regeneration|O of|O the|O nervous|O system|O ,|O axons|O must|O correctly|O navigate|O to|O their|O specific|O targets|O through|O a|O complex|O molecular|O environment|O .|O 
Recent|O work|O has|O shed|O light|O on|O how|O GTPases|gene-protein of|O the|O Ras|gene-generic family|O are|O involved|O in|O transducing|O extracellular|O signals|O into|O responses|O that|O lead|O to|O directed|O neurite|O outgrowth|O .|O 
Neurocristopathy|O in|O mother|O (|O ganglioneuroblastoma|O )|O and|O daughter|O (|O aganglionosis|O )|O :|O incidental|O or|O causal|O ?|O 
We|O report|O on|O a|O mother|O who|O had|O been|O treated|O for|O a|O ganglioneuroblastoma|O and|O her|O daughter|O who|O had|O a|O long|O segment|O aganglionosis|O .|O 
Review|O of|O the|O relevant|O literature|O and|O recent|O molecular|O findings|O warrant|O the|O conclusion|O that|O most|O likely|O ,|O there|O is|O a|O causal|O relation|O between|O these|O two|O neurocristopathies|O .|O 
Monoamine|gene-protein oxidase|gene-protein activity|O decreased|O in|O cells|O lacking|O hypoxanthine|gene-protein phosphoribosyltransferase|gene-protein activity|O .|O 
The|O Lesch|O -|O Nyhan|O syndrome|O in|O humans|O is|O characterized|O by|O lack|O of|O hypoxanthine|gene-protein phosphoribosyltransferase|gene-protein activity|O and|O neurologic|O abnormalities|O that|O suggest|O changes|O in|O catecholamine|O metabolism|O .|O 
Monoamine|gene-protein oxidase|gene-protein ,|O which|O degrades|O biogenic|O amines|O ,|O has|O decreased|O activity|O in|O noradrenergic|O murine|O neuroblastoma|O cell|O lines|O lacking|O hypoxanthine|gene-protein phosphoribosyltransferase|gene-protein activity|O and|O in|O skin|O fibroblasts|O from|O patients|O with|O the|O Lesch|O -|O Nyhan|O syndrome|O .|O 
[|O Guanyl|gene-protein cyclase|gene-protein activities|O in|O clonal|O lines|O of|O cultured|O astroblasts|O and|O neuroblasts|O ]|O 
Guanylate|gene-protein cyclase|gene-protein was|O found|O to|O be|O present|O in|O a|O number|O of|O astroblast|O and|O neuroblast|O clones|O .|O 
No|O correlations|O were|O observed|O between|O the|gene-protein enzyme|gene-protein activity|O and|O the|O nature|O of|O the|O clone|O .|O 
The|gene-protein enzyme|gene-protein shows|O a|O requirement|O for|O manganese|O ions|O and|O is|O stimulated|O by|O calcium|O .|O 
When|O the|O astroblast|O clone|O NN|O is|O cultured|O together|O with|O the|O neuroblast|O clone|O M1|O for|O two|O months|O and|O the|O astroblast|O cells|O again|O isolated|O ,|O a|O reduced|O guanylate|gene-protein cyclase|gene-protein activity|O was|O found|O .|O 
DNA|O regions|O supporting|O hippocalcin|gene-rna gene|O expression|O in|O cell|O lines|O .|O 
The|O rat|O hippocalcin|gene-rna gene|O -|O 3.2|O to|O +|O 0.6|O kb|O region|O activates|O reporter|gene-rna gene|O expression|O in|O the|O NG108-15|O and|O PC12|O neuronal|O cell|O lines|O ,|O but|O not|O in|O NIH3T3|O or|O HEK-293|O cells|O .|O 
Three|O fragments|O (|O -|O 3.2|O to|O -|O 2.6|O ,|O -|O 2.6|O to|O -|O 2.3|O and|O -|O 2.3|O to|O -|O 1.8|O kb|O )|O weakly|O activate|O transcription|O ,|O and|O "|O -|O 1.8|O to|O -|O 1.5|O "|O kb|O is|O a|O strong|O activator|O .|O 
Thus|O cell|O type|O -|O specific|O expression|O of|O the|O rat|O hippocalcin|gene-rna gene|O is|O regulated|O by|O distributed|O elements|O in|O the|O -|O 3.2|O to|O -|O 1.5|O kb|O region|O .|O 
[|O Neuroblastoma|O ;|O biology|O and|O prognostic|O factors|O ]|O 
Recently|O accumulated|O data|O on|O the|O biology|O of|O the|O tumors|O of|O neuroblastoma|O group|O are|O reviewed|O .|O 
Histopathological|O classification|O system|O developed|O by|O Shimada|O et|O al|O ,|O elevated|O levels|O of|O serum|O neuron|O -|O specific|O enolase|gene-protein and|O ferritin|gene-protein ,|O and|O gene|O abnormalities|O including|O partial|O deletion|O of|O the|O short|O arm|O of|O chromosome|O #|O 1|O and|O N-myc|gene-rna gene|O amplification|O are|O discussed|O as|O well|O as|O their|O prognostic|O significance|O .|O 
Also|O ,|O the|O current|O activities|O of|O CCSG|O (|O Childrens|O Cancer|O Study|O Group|O )|O neuroblastoma|O studies|O are|O briefly|O reported|O .|O 
Reassignment|O of|O MYCL1|gene-rna to|O human|O chromosome|O 1p34.3|O by|O fluorescence|O in|O situ|O hybridization|O .|O 
MYCL1|gene-rna has|O been|O previously|O mapped|O to|O 1p32|O .|O 
This|O position|O was|O in|O contradiction|O with|O our|O mapping|O data|O of|O 1p|O deletions|O in|O neuroblastoma|O cell|O lines|O .|O 
Using|O FISH|O on|O high|O resolution|O R|O -|O banded|O chromosomes|O with|O a|O YAC|O clone|O for|O MYCL1|gene-rna we|O were|O able|O to|O reassign|O the|O gene|O to|O subband|O 1p34.3|O .|O 
This|O new|O map|O position|O is|O of|O importance|O for|O the|O establishment|O of|O an|O integrated|O map|O for|O chromosome|O 1|O and|O the|O search|O for|O disease|O genes|O in|O this|O region|O .|O 
Multiple|O opiate|gene-protein receptors|gene-protein :|O alcohol|O selectively|O inhibits|O binding|O to|O delta|gene-protein receptors|gene-protein .|O 
The|O addition|O of|O ethanol|O or|O other|O aliphatic|O alcohols|O to|O rat|O brain|O membranes|O strongly|O inhibits|O binding|O of|O enkephalins|gene-protein at|O concentrations|O at|O which|O little|O inhibition|O of|O opiate|O alkaloids|O is|O seen|O .|O 
Inhibition|O is|O reversible|O ,|O and|O potency|O increases|O with|O chain|O length|O of|O the|O alcohol|O .|O 
The|O results|O suggest|O that|O delta|gene-protein receptors|gene-protein are|O considerably|O more|O sensitive|O to|O alcohols|O than|O mu|gene-protein receptors|gene-protein .|O 
This|O is|O the|O first|O demonstration|O of|O selective|O inhibition|O of|O one|O of|O the|O postulated|O classes|O of|O opiate|gene-protein receptors|gene-protein by|O a|O reagent|O that|O is|O not|O a|O ligand|O for|O the|O receptor|gene-protein .|O 
Solid|O tumors|O in|O children|O .|O 
A|O thorough|O understanding|O of|O the|O incidence|O ,|O clinical|O presentation|O ,|O treatment|O ,|O prognosis|O ,|O and|O psychosocial|O issues|O surrounding|O children|O with|O solid|O tumors|O enables|O the|O nurse|O to|O actively|O participate|O on|O the|O health|O care|O team|O .|O 
Although|O significant|O advances|O over|O the|O past|O two-and-a-half|O decades|O to|O improve|O the|O outcomes|O of|O children|O with|O cancer|O have|O occurred|O ,|O there|O remains|O room|O for|O continued|O improvement|O ,|O especially|O among|O children|O with|O advanced|O -|O stage|O nephroblastoma|O ,|O neuroblastoma|O ,|O HCC|O ,|O and|O teratoma|O .|O 
[|O Neuroblastoma|O ]|O 
The|O review|O deals|O with|O neuroblastoma|O ,|O its|O frequency|O ,|O localization|O ,|O features|O of|O its|O clinical|O course|O and|O microscopic|O patterns|O .|O 
The|O ability|O of|O neuroblastoma|O for|O maturation|O and|O sometimes|O for|O spontaneous|O regression|O as|O well|O as|O the|O relationship|O between|O tumors|O of|O the|O autonomous|O nervous|O system|O and|O the|O so|O -|O called|O neuroblastoma|O in|O situ|O and|O von|O Recklinghausen|O 's|O disease|O are|O discussed|O .|O 
Some|O light|O and|O electron|O microscope|O differential|O diagnostic|O criteria|O are|O given|O .|O 
An|O attempt|O is|O made|O to|O explain|O certain|O clinico|O -|O biological|O features|O of|O neuroblastoma|O from|O the|O point|O of|O view|O of|O current|O embryological|O data|O .|O 
Signaling|O pathways|O mediate|O the|O neuroprotective|O effects|O of|O GDNF|gene-protein .|O 
We|O show|O that|O the|O glial|gene-protein cell|gene-protein line|gene-protein -|gene-protein derived|gene-protein neurotrophic|gene-protein factor|gene-protein (|O GDNF|gene-protein )|O activates|O the|O PI3K|gene-protein /|O Akt|gene-protein -|O signaling|O pathway|O in|O human|O neuroblastoma|O cells|O that|O express|O functional|O Ret|gene-protein -|O receptor|O complexes|O .|O 
Consistent|O with|O this|O finding|O we|O show|O PI3K|gene-protein -|O dependent|O Bad|gene-protein -|O inactivation|O by|O binding|O to|O 14-3-3|gene-protein proteins|gene-protein in|O response|O to|O GDNF|gene-protein .|O 
Using|O differential|O display|O techniques|O we|O detected|O several|O cDNA|O clones|O differentially|O expressed|O after|O treatment|O with|O GDNF|gene-protein or|O 6-OHDA|O .|O 
Neuroblastoma|O in|O a|O patient|O with|O Sotos|O '|O syndrome|O .|O 
Sotos|O '|O syndrome|O ,|O or|O cerebral|O gigantism|O ,|O is|O a|O disorder|O of|O growth|O regulation|O .|O 
Tumours|O have|O occasionally|O been|O reported|O in|O children|O with|O Sotos|O '|O syndrome|O ,|O but|O it|O is|O uncertain|O whether|O this|O is|O a|O coincidence|O ,|O or|O whether|O it|O is|O aetiologically|O related|O to|O the|O underlying|O disorder|O of|O growth|O .|O 
We|O report|O a|O 15|O month|O old|O child|O with|O a|O paraspinal|O neuroblastoma|O and|O Sotos|O '|O syndrome|O and|O suggest|O that|O children|O with|O this|O condition|O may|O be|O at|O higher|O risk|O for|O developing|O tumours|O than|O the|O general|O population|O .|O 
[|O Clinical|O problems|O of|O radiotherapy|O in|O pediatric|O oncology|O ]|O 
The|O main|O principles|O of|O radiation|O therapy|O as|O well|O as|O the|O role|O of|O ratio|O Integral|O Dose|O /|O Total|O Dose|O in|O radiation|O treatment|O of|O malignant|O tumors|O in|O children|O are|O considered|O .|O 
Indications|O for|O radiation|O therapy|O of|O nephroblastomas|O and|O peculiarities|O of|O radiation|O treatment|O of|O haemangiomas|O are|O described|O .|O 
Expedience|O is|O proved|O of|O radiation|O of|O only|O the|O liver|O part|O affected|O by|O neuroblastoma|O .|O 
Tactics|O of|O radiation|O therapy|O of|O eosinophilic|O granuloma|O of|O bones|O in|O analyzed|O .|O 
Possibility|O of|O conservative|O therapy|O including|O radiation|O component|O in|O treatment|O of|O retinoblastoma|O in|O children|O is|O discussed|O .|O 
Heterologous|O biosynthesis|O and|O processing|O of|O preprovasopressin|gene-protein in|O Neuro2A|O neuroblastoma|O cells|O .|O 
To|O obtain|O a|O model|O for|O the|O sorting|O and|O processing|O of|O preprovasopressin|gene-protein (|O preproVP|gene-protein )|O ,|O rat|O VP|gene-rna cDNA|O was|O transfected|O in|O murine|O Neuro2A|O neuroblastoma|O cells|O ,|O which|O do|O not|O express|O VP|gene-protein .|O 
The|O precursor|O of|O VP|gene-protein was|O expressed|O and|O processed|O into|O the|O authentic|O VP|gene-rna gene|O products|O VP|gene-protein ,|O neurophysin|gene-protein (|O NP|gene-protein )|O and|O glycopeptide|gene-protein (|O GP|gene-protein )|O as|O determined|O with|O reversed|O phase|O HPLC|O and|O radioimmunoassay|O .|O 
In|O addition|O ,|O Neuro2A|O -|O specific|O forms|O of|O NP|gene-protein and|O GP|gene-protein were|O observed|O ,|O which|O may|O be|O produced|O in|O the|O constitutive|O secretory|O pathway|O in|O these|O cells|O .|O 
Phosphorus|O 31|O NMR|O of|O neuroblastoma|O clonal|O lines|O .|O 
Effect|O of|O cell|O confluency|O state|O and|O dibutyryl|O cyclic|O AMP|O .|O 
Phosphorus|O nuclear|O magnetic|O resonance|O is|O used|O to|O study|O changes|O in|O the|O levels|O of|O the|O major|O phosphate|O -|O containing|O intermediary|O metabolites|O concomitant|O with|O induced|O cellular|O differentiation|O in|O the|O N-18|O and|O C-46|O neuroblastoma|O clonal|O lines|O .|O 
The|O study|O reveals|O differences|O between|O the|O 31P|O -|O NMR|O profiles|O of|O the|O two|O clonal|O lines|O and|O also|O striking|O differences|O attendant|O to|O dibutyryl|O cAMP|O -|O mediated|O morphological|O differentiation|O in|O the|O N-18|O clone|O .|O 
Phosphorus|O -|O 31|O NMR|O would|O appear|O to|O provide|O a|O new|O technique|O with|O which|O to|O study|O genetic|O differentiation|O .|O 
Microviscosity|O changes|O during|O differentiation|O of|O neuroblastoma|O cells|O .|O 
Microviscosity|O (|O eta|O )|O of|O the|O plasma|O -|O membrane|O lipid|O matrix|O was|O measured|O in|O exponentially|O growing|O and|O differentiating|O C1300|O mouse|O neuroblastoma|O cells|O ,|O attached|O to|O a|O glass|O substratum|O ,|O by|O fluorescence|O polarisation|O of|O 1,6-diphenyl-1,3,5-hexatriene|O .|O 
Upon|O differentiation|O eta|O decreases|O progressively|O ,|O reaching|O values|O below|O those|O observed|O in|O the|O growth|O phase|O .|O 
Treatment|O of|O the|O cells|O with|O dipalmitoyl|O phosphatidylcholine|O vesicles|O reversibly|O inhibits|O morphological|O differentiation|O .|O 
The|O results|O show|O that|O a|O high|O membrane|O fluidity|O is|O a|O prerequisite|O for|O differentiation|O .|O 
Amplified|O MYCN|gene-rna in|O human|O neuroblastoma|O :|O paradigm|O for|O the|O translation|O of|O molecular|O genetics|O to|O clinical|O oncology|O .|O 
Increase|O in|O the|O dosage|O of|O cellular|O oncogenes|O by|O DNA|O amplification|O is|O a|O frequent|O genetic|O alteration|O of|O cancer|O cells|O .|O 
In|O neuroblastoma|O ,|O amplification|O of|O the|O gene|O MYCN|gene-rna has|O been|O associated|O with|O aggressively|O growing|O cancers|O and|O is|O an|O indicator|O for|O poor|O prognosis|O .|O 
MYCN|gene-rna amplification|O is|O of|O predictive|O value|O in|O identifying|O patients|O with|O neuroblastoma|O who|O require|O specific|O therapeutic|O regimens|O and|O those|O who|O do|O not|O benefit|O from|O chemotherapy|O .|O 
Synchronous|O neuroblastoma|O and|O von|O Recklinghausen|O 's|O disease|O :|O a|O review|O of|O the|O literature|O .|O 
We|O report|O an|O unusual|O case|O of|O progressive|O disseminated|O neuroblastoma|O occurring|O in|O a|O child|O with|O a|O family|O history|O and|O stigmata|O of|O von|O Recklinghausen|O 's|O disease|O .|O 
A|O review|O of|O the|O literature|O confirms|O the|O extreme|O rarity|O of|O finding|O these|O two|O neurocristopathies|O in|O a|O single|O individual|O and|O thus|O undermines|O the|O widely|O held|O notion|O of|O an|O association|O --|O genetic|O or|O otherwise|O --|O between|O these|O two|O entities|O .|O 
We|O propose|O that|O synchronous|O neuroblastoma|O and|O von|O Recklinghausen|O 's|O disease|O is|O accounted|O for|O by|O chance|O alone|O and|O therefore|O represents|O a|O randomly|O occurring|O phenomenon|O .|O 
Recurrence|O of|O neuroblastoma|O following|O prolonged|O remission|O .|O 
A|O 6|O -|O year|O -|O old|O girl|O with|O unresectable|O and|O metastatic|O neuroblastoma|O had|O a|O complete|O remission|O with|O irradiation|O to|O the|O primary|O tumor|O and|O systemic|O administration|O of|O cyclophosphamide|O .|O 
The|O patient|O was|O disease|O -|O free|O for|O 16|O years|O but|O had|O an|O explosive|O recurrence|O of|O tumor|O six|O weeks|O after|O a|O hysterectomy|O .|O 
Although|O no|O clear|O cause|O -|O and|O -|O effect|O relationship|O exists|O between|O the|O surgery|O and|O the|O recurrence|O ,|O this|O case|O illustrates|O that|O a|O recurrence|O is|O possible|O after|O a|O long|O disease|O -|O free|O interval|O .|O 
Diagnostic|O and|O therapeutic|O procedures|O in|O such|O patients|O should|O be|O undertaken|O with|O caution|O .|O 
Regulation|O of|O protein|gene-protein synthesis|O at|O the|O translational|O level|O in|O neuroblastoma|O cells|O .|O 
Protein|gene-protein synthesis|O in|O reuroblastoma|O cells|O has|O been|O studied|O in|O a|O cell|O -|O free|O system|O .|O 
The|O activity|O of|O lysates|O from|O cells|O grown|O in|O suspension|O and|O monolayer|O has|O been|O compared|O .|O 
A|O higher|O level|O of|O activity|O has|O been|O found|O in|O monolayer|O cells|O .|O 
The|O activity|O of|O some|O components|O of|O the|O lysate|O that|O are|O involved|O in|O protein|gene-protein synthesis|O has|O been|O analyzed|O .|O 
The|O data|O suggest|O that|O the|O controlling|O step|O of|O protein|gene-protein synthesis|O in|O this|O system|O might|O be|O in|O the|O initiation|O process|O .|O 
The|O correlation|O between|O activation|O of|O protein|gene-protein synthesis|O and|O neurite|O outgrowth|O in|O monolayer|O cultures|O is|O discussed|O .|O 
Three|O types|O of|O voltage|O -|O dependent|O calcium|O currents|O in|O cultured|O human|O neuroblastoma|O cells|O .|O 
The|O voltage|O -|O dependent|O calcium|O current|O (|O ICa|O )|O in|O cultured|O human|O neuroblastoma|O cells|O (|O NB-I|O )|O was|O studied|O by|O whole|O -|O cell|O recording|O .|O 
The|O low|O -|O threshold|O current|O (|O Il|O )|O ,|O the|O high|O -|O threshold|O ,|O fast|O inactivating|O current|O (|O Ih.f.|O )|O ,|O and|O the|O high|O -|O threshold|O ,|O slow|O inactivating|O current|O (|O Ih.s.|O )|O were|O identified|O .|O 
Il.|O was|O blocked|O by|O Ni2|O +|O .|O 
Ih.f.|O was|O blocked|O by|O omega-conotoxin|gene-protein GVIA|gene-protein .|O 
Ih.s.|O was|O blocked|O by|O nifedipine|O ,|O and|O enhanced|O by|O Bay|O K|O 8644|O .|O 
These|O characteristics|O indicate|O that|O Il|O ,|O Ih.f.|O and|O Ih.s.|O are|O consistent|O with|O the|O T|O -|O ,|O N|O -|O and|O L|O -|O type|O ICa|O ,|O respectively|O .|O 
Imaging|O of|O giant|O tumours|O involving|O the|O anterior|O skull|O base|O .|O 
Tumours|O involving|O the|O anterior|O skull|O base|O are|O a|O challenge|O in|O diagnosis|O and|O treatment|O .|O 
They|O may|O arise|O from|O the|O bony|O skull|O base|O itself|O ,|O intracranially|O or|O from|O the|O sinonasal|O tract|O and|O orbit|O .|O 
It|O is|O often|O difficult|O to|O determine|O the|O site|O of|O origin|O of|O giant|O tumours|O as|O anatomical|O boundaries|O are|O frequently|O breached|O .|O 
Accurate|O imaging|O evaluation|O is|O useful|O in|O planning|O treatment|O and|O may|O help|O in|O the|O differential|O diagnosis|O .|O 
We|O review|O those|O CT|O and|O MRI|O features|O of|O giant|O anterior|O cranial|O fossa|O tumours|O which|O may|O be|O helpful|O in|O identifying|O a|O pre|O -|O operative|O diagnosis|O .|O 
Potent|O blocking|O action|O of|O lead|O on|O voltage|O -|O activated|O calcium|O channels|O in|O human|O neuroblastoma|O cells|O SH-SY5Y|O .|O 
Human|O neuroblastoma|O cells|O (|O SH-SY5Y|O )|O have|O two|O types|O of|O voltage|O -|O activated|O calcium|O channels|O ,|O which|O are|O equivalent|O to|O the|O N|O and|O L|O types|O .|O 
Both|O types|O of|O calcium|O channels|O were|O equally|O blocked|O by|O lead|O in|O a|O concentration|O -|O dependent|O and|O reversible|O manner|O ,|O with|O Ki|O congruent|O to|O 1|O microM|O .|O 
This|O lead|O concentration|O is|O in|O the|O same|O order|O of|O magnitude|O as|O that|O found|O in|O the|O blood|O of|O children|O exhibiting|O neuropsychological|O disorders|O .|O 
Sodium|O and|O potassium|O channel|O currents|O were|O not|O significantly|O affected|O by|O lead|O at|O a|O concentration|O of|O 10|O microM|O .|O 
Subcellular|O localization|O of|O angiotensin|gene-protein -|gene-protein converting|gene-protein enzyme|gene-protein in|O cultured|O neuroblastoma|O cells|O .|O 
Angiotensin|gene-protein -|gene-protein converting|gene-protein enzyme|gene-protein (|O ACE|gene-protein )|O activity|O of|O Neuro-2A|O mouse|O neuroblastoma|O cells|O was|O found|O predominantly|O in|O particulate|O fractions|O .|O 
Density|O gradient|O centrifugation|O of|O the|O particulate|O fractions|O showed|O ACE|gene-protein activity|O in|O light|O fractions|O of|O the|O gradient|O ,|O a|O result|O suggesting|O a|O plasma|O membrane|O localization|O .|O 
This|O was|O confirmed|O using|O the|O aqueous|O two|O -|O phase|O polymer|O system|O of|O plasma|O membrane|O isolation|O .|O 
The|O rapid|O and|O energy|O -|O independent|O hydrolysis|O of|O exogenous|O substrate|O by|O ACE|gene-protein of|O intact|O cells|O and|O the|O sensitivity|O of|O the|O enzyme|O of|O intact|O cells|O to|O proteases|gene-protein indicate|O further|O that|O the|O active|O site|O of|O ACE|gene-protein is|O oriented|O extracellularly|O .|O 
Evidence|O that|O neutral|O sphingomyelinase|gene-protein of|O cultured|O murine|O neuroblastoma|O cells|O is|O oriented|O externally|O on|O the|O plasma|O membrane|O .|O 
The|O activity|O of|O the|O neutral|O ,|O Mg2|O +|O -|O stimulated|O sphingomyelinase|gene-protein of|O cultured|O neuroblastoma|O cells|O (|O N1E-115|O )|O is|O enriched|O in|O the|O plasma|O membrane|O fraction|O and|O is|O reduced|O following|O treatment|O of|O intact|O or|O broken|O cells|O with|O trypsin|gene-protein ,|O alpha-chymotrypsin|gene-protein ,|O papain|gene-protein ,|O and|O protease|gene-protein .|O 
Two|O protease|gene-protein -|gene-protein sensitive|gene-protein enzymes|gene-protein of|O the|O cell|O interior|O (|O lactate|gene-protein dehydrogenase|gene-protein and|O NADPH|gene-protein -|gene-protein cytochrome|gene-protein c|gene-protein reductase|gene-protein )|O are|O not|O affected|O by|O protease|gene-protein treatment|O of|O intact|O cells|O .|O 
These|O results|O indicate|O that|O the|O neutral|O ,|O Mg2|O +|O -|O stimulated|O sphingomyelinase|gene-protein is|O oriented|O externally|O on|O the|O plasma|O membrane|O of|O the|O cultured|O neuroblastoma|O cell|O .|O 
Glycosylation|O changes|O in|O membrane|gene-protein glycoproteins|gene-protein after|O transfection|O of|O NIH|O 3T3|O with|O human|O tumor|O DNA|O .|O 
Glycoproteins|gene-protein from|O NIH|O 3T3|O transformed|O by|O transfection|O with|O human|O tumor|O DNA|O had|O altered|O glycosylation|O .|O 
That|O is|O ,|O the|O glycoproteins|gene-protein have|O a|O decrease|O in|O biantennary|O oligosaccharides|O with|O a|O concomitant|O increase|O in|O tri|O -|O and|O tetra|O antennary|O oligosaccharides|O .|O 
After|O swainsonine|O treatment|O ,|O glycosylation|O of|O oncogene|O transfected|O NIH|O 3T3|O was|O more|O similar|O to|O the|O normal|O counterpart|O .|O 
Thus|O ,|O this|O inhibitor|O of|O glycoprotein|gene-protein processing|O is|O able|O to|O reverse|O at|O least|O one|O phenotypic|O expression|O of|O transformation|O ,|O the|O formation|O of|O more|O highly|O branched|O oligosaccharides|O .|O 
The|O mechanism|O may|O be|O by|O inhibition|O of|O a|O specific|O glycosyl|gene-protein transferase|gene-protein .|O 
Adriamycin|O in|O the|O treatment|O of|O childhood|O solid|O tumors|O .|O 
A|O Southwest|O Oncology|O Group|O study|O .|O 
Ninety-eight|O children|O with|O solid|O tumors|O resistant|O to|O conventional|O chemotherapy|O received|O adriamycin|O 90|O mg|O /|O m2|O ,|O either|O as|O a|O single|O intravenous|O injection|O or|O in|O 6|O divided|O doses|O administered|O every|O 6|O hours|O .|O 
Of|O the|O 88|O evaluable|O children|O ,|O 6|O (|O 7|O %|O )|O achieved|O a|O complete|O response|O and|O 26|O (|O 29|O %|O )|O achieved|O a|O partial|O response|O .|O 
Tumors|O which|O demonstrated|O significant|O response|O rates|O were|O :|O neuroblastoma|O (|O 9|O /|O 18|O )|O ,|O Wilms|O '|O tumor|O (|O 7|O /|O 13|O )|O ,|O rhabdomyosarcoma|O (|O 4|O /|O 11|O )|O ,|O and|O lymphoma|O (|O 4|O /|O 8|O )|O .|O 
The|O toxicities|O observed|O with|O this|O regimen|O included|O :|O alopecia|O ,|O leukopenia|O ,|O thrombocytopenia|O ,|O nausea|O ,|O vomiting|O ,|O stomatitis|O ,|O febrile|O episodes|O ,|O and|O ST|O -|O segment|O changes|O .|O 
New|O genetic|O loci|O in|O neuroblastoma|O .|O 
Neuroblastoma|O has|O been|O associated|O genetically|O with|O amplification|O of|O the|O MYCN|gene-rna gene|O and|O with|O alteration|O of|O the|O short|O arm|O of|O chromosome|O 1|O (|O 1p|O )|O .|O 
In|O pursuit|O of|O determining|O the|O spectrum|O of|O genetic|O loci|O damaged|O recurrently|O in|O neuroblastoma|O cells|O we|O have|O recently|O encountered|O two|O additional|O types|O of|O genomic|O abnormalities|O :|O i.)|O duplication|O of|O the|O MYCN|gene-rna gene|O on|O chromosome|O 2p24|O ;|O and|O ii.)|O amplification|O of|O the|O gene|O MDM2|gene-rna .|O 
These|O alterations|O extend|O the|O spectrum|O of|O genetic|O lesions|O in|O neuroblastoma|O cells|O ,|O although|O their|O incidence|O in|O primary|O tumor|O tissues|O has|O not|O been|O determined|O as|O yet|O .|O 
Concomitant|O p53|gene-rna mutation|O and|O MYCN|gene-rna amplification|O in|O neuroblastoma|O .|O 
The|O MYCN|gene-rna oncogene|O is|O amplified|O in|O 20|O %|O of|O childhood|O neuroblastoma|O and|O is|O associated|O independently|O with|O poor|O prognosis|O .|O 
Alteration|O of|O the|O p53|gene-rna tumor|gene-rna supressor|gene-rna gene|O ,|O in|O contrast|O ,|O occurs|O infrequently|O in|O these|O tumors|O .|O 
In|O this|O report|O ,|O we|O described|O a|O 3|O -|O year|O -|O old|O girl|O with|O stage|O IV|O neuroblastoma|O .|O 
Molecular|O analysis|O revealed|O ,|O both|O MYCN|gene-rna gene|O amplification|O and|O a|O point|O mutation|O of|O the|O p53|gene-rna tumor|gene-rna supressor|gene-rna gene|O .|O 
To|O our|O knowledge|O ,|O this|O is|O the|O first|O reported|O case|O of|O neuroblastoma|O with|O genetic|O alterations|O of|O both|O these|gene-rna genes|gene-rna .|O 
The|O 13p|O HSR|O in|O a|O human|O neuroblastoma|O cell|O line|O does|O not|O contain|O rRNA|gene-rna genes|O .|O 
We|O have|O studied|O a|O human|O neuroblastoma|O cell|O line|O containing|O a|O homogeneously|O staining|O region|O (|O HSR|O )|O on|O the|O short|O (|O p|O )|O arm|O of|O chromosome|O #|O 13|O .|O 
The|O HSRs|O are|O believed|O to|O represent|O sites|O of|O gene|O amplification|O ,|O containing|O multiple|O copies|O of|O one|O or|O a|O small|O number|O of|O genes|O .|O 
The|O 18S|gene-rna and|O 28S|gene-rna ribosomal|gene-rna RNA|gene-rna genes|O are|O the|O only|O structural|O genes|O so|O far|O assigned|O to|O the|O p|O arms|O of|O the|O human|O acrocentric|O chromosomes|O ,|O which|O include|O number|O #|O 13|O .|O 
Using|O two|O recombinant|O DNA|O probes|O specific|O for|O sequences|O in|O the|O 18S|gene-rna /|O 28S|gene-rna ribosomal|gene-rna RNA|gene-rna (|O rRNA|gene-rna )|O gene|O complex|O for|O in|O situ|O hybridization|O ,|O we|O have|O been|O able|O to|O establish|O that|O the|O 13p|O HSR|O in|O this|O line|O does|O not|O contain|O rRNA|gene-rna genes|O .|O 
Neuroepithelioma|O (|O neuroblastoma|O )|O arising|O in|O an|O adult|O .|O 
A|O case|O report|O .|O 
Cytogenetic|O studies|O on|O neuroblastomas|O arising|O in|O children|O have|O revealed|O consistent|O abnormalities|O of|O the|O short|O arm|O of|O chromosome|O number|O 1|O .|O 
Partly|O because|O of|O the|O rare|O occurrence|O of|O neuroblastomas|O in|O adults|O ,|O extensive|O cytogenetic|O studies|O in|O this|O group|O of|O patients|O have|O not|O been|O performed|O .|O 
We|O report|O a|O case|O of|O a|O neuroepithelioma|O (|O neuroblastoma|O )|O arising|O in|O a|O 50|O -|O year|O -|O old|O male|O patient|O .|O 
On|O chromosome|O analysis|O of|O a|O metastasis|O ,|O a|O stemline|O with|O karyotype|O 47|O ,|O X|O Y|O ,|O +|O der1|O (|O 1|O qter|O ---|O 1|O cen|O ::|O 1q21|O ---|O 1|O qter|O )|O was|O identified|O .|O 
The|O possible|O consequences|O of|O this|O result|O and|O those|O of|O results|O previously|O reported|O in|O the|O literature|O are|O discussed|O .|O 
Neuroblastoma|O in|O the|O first|O year|O of|O life|O :|O clinical|O and|O biologic|O factors|O influencing|O outcome|O .|O 
The|O survival|O for|O infants|O less|O than|O 1|O year|O of|O age|O with|O neuroblastoma|O is|O twice|O that|O of|O older|O children|O .|O 
This|O report|O describes|O 70|O babies|O with|O neuroblastoma|O who|O experienced|O an|O 84|O %|O survival|O .|O 
Survival|O was|O 100|O %|O for|O stages|O I|O ,|O II|O ,|O and|O III|O ,|O 81|O %|O for|O stage|O IV-S|O ,|O and|O 50|O %|O for|O stage|O IV|O .|O 
Most|O survivors|O had|O favorable|O biologic|O characteristics|O including|O spontaneous|O regression|O ,|O favorable|O Shimada|O histology|O ,|O normal|O first|O chromosome|O ,|O aneuploid|O tumors|O ,|O absent|O or|O low|O N-myc|gene-rna oncogene|O expression|O ,|O and|O normal|O serum|O ferritin|gene-protein levels|O .|O 
Low|O specificity|O of|O PGP9.5|gene-protein expression|O for|O detection|O of|O micrometastatic|O neuroblastoma|O .|O 
To|O determine|O the|O specificity|O of|O neuroendocrine|O protein|O gene|O product|O (|O PGP9.5|gene-protein )|O gene|O transcripts|O for|O detecting|O micrometastatic|O neuroblastoma|O ,|O we|O have|O used|O a|O highly|O sensitive|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O technique|O to|O evaluate|O expression|O of|O this|gene-rna gene|gene-rna in|O normal|O blood|O and|O bone|O marrow|O .|O 
While|O expression|O of|O the|O tyrosine|gene-protein hydroxylase|gene-protein gene|O was|O not|O detected|O in|O any|O normal|O sample|O ,|O low|O -|O level|O PGP9.5|gene-protein expression|O was|O detected|O in|O eight|O out|O of|O ten|O blood|O and|O seven|O of|O 12|O marrow|O samples|O .|O 
PGP9.5|gene-rna gene|O transcripts|O in|O normal|O tissues|O have|O the|O potential|O to|O interfere|O with|O the|O detection|O of|O micrometastatic|O neuroblastoma|O .|O 
Evaluation|O of|O cyclocytidine|O in|O children|O with|O advanced|O acute|O leukemia|O and|O solid|O tumors|O .|O 
Cyclocytidine|O ,|O a|O slow|O -|O release|O form|O of|O cytosine|O arabinoside|O ,|O was|O evaluated|O in|O 69|O children|O with|O advanced|O acute|O leukemia|O and|O solid|O tumors|O .|O 
One|O child|O with|O acute|O lymphocytic|O leukemia|O attained|O a|O complete|O remission|O .|O 
This|O child|O had|O received|O intrathecal|O cytosine|O arabinoside|O prior|O to|O the|O cyclocytidine|O .|O 
Eighteen|O of|O the|O 31|O patients|O with|O acute|O lymphocytic|O leukemia|O /|O acute|O undifferentiated|O leukemia|O who|O did|O not|O respond|O received|O two|O or|O more|O courses|O of|O the|O drug|O .|O 
There|O were|O no|O responses|O in|O 15|O children|O with|O acute|O myelogenous|O leukemia|O ,|O in|O 11|O children|O with|O neuroblastoma|O ,|O or|O in|O 11|O children|O with|O various|O solid|O tumors|O of|O childhood|O .|O 
A|O dose|O of|O 600|O ng|O /|O m2|O /|O day|O for|O 10|O consecutive|O days|O is|O tolerated|O in|O children|O .|O 
Effects|O of|O presenilin|gene-protein N|O -|O terminal|O fragments|O on|O production|O of|O amyloid|gene-protein beta|gene-protein peptide|gene-protein and|O accumulation|O of|O endogenous|O presenilins|gene-protein .|O 
To|O clarify|O the|O effects|O of|O the|O proteolytic|O cleavage|O of|O presenilin|gene-protein 1|gene-protein (|O PS1|gene-protein )|O and|O presenilin|gene-protein 2|gene-protein (|O PS2|gene-protein )|O proteins|O on|O their|O functions|O ,|O we|O established|O stable|O cell|O lines|O which|O expressed|O the|O physiologically|O cleaved|O N|O -|O terminal|O fragment|O (|O NTF|O )|O with|O or|O without|O mutations|O of|O familial|O Alzheimer|O 's|O disease|O (|O FAD|O )|O .|O 
We|O found|O that|O exogenous|O expression|O of|O the|O PS1|gene-protein -|O NTF|O or|O PS2|gene-protein -|O NTF|O harboring|O FAD|O mutations|O was|O insufficient|O for|O increased|O production|O of|O amyloidogenic|gene-protein A|gene-protein beta|gene-protein X-42|gene-protein peptide|O and|O that|O the|O overexpressed|O NTFs|O had|O no|O effect|O on|O the|O accumulation|O of|O endogenous|O presenilin|gene-protein fragments|O .|O 
Coamplification|O of|O the|O L-myc|gene-rna and|O N-myc|gene-rna oncogenes|O in|O a|O neuroblastoma|O cell|O line|O .|O 
The|O L-myc|gene-rna ,|O N-myc|gene-rna and|O c-myc|gene-rna genes|O are|O members|O of|O the|O myc|gene-rna oncogene|O family|O .|O 
In|O particular|O ,|O L-myc|gene-rna is|O novel|O ,|O and|O amplification|O of|O L-myc|gene-rna is|O still|O unknown|O except|O in|O small|O cell|O lung|O carcinoma|O .|O 
We|O examined|O L-myc|gene-rna amplification|O in|O 30|O human|O neuroblastomas|O using|O Southern|O blot|O hybridization|O ,|O and|O found|O that|O the|O L-myc|gene-rna gene|O was|O amplified|O approximately|O 5|O -|O fold|O in|O GOTO|O ,|O a|O human|O neuroblastoma|O cell|O line|O .|O 
The|O N-myc|gene-rna gene|O was|O also|O amplified|O approximately|O 60|O -|O fold|O and|O furthermore|O ,|O over|O -|O expression|O of|O L-myc|gene-rna and|O N-myc|gene-rna genes|O was|O observed|O in|O this|O cell|O line|O .|O 
In|O this|O report|O ,|O we|O describe|O the|O coamplification|O of|O the|O myc|gene-rna gene|O family|O in|O the|O GOTO|O neuroblastoma|O cell|O line|O .|O 
Transcription|O of|O N-myc|gene-rna and|O proliferation|O -|O related|O genes|O is|O linked|O in|O human|O neuroblastoma|O .|O 
A|O definite|O association|O between|O the|O transcription|O of|O N-myc|gene-rna oncogene|O and|O proliferation|O -|O related|O genes|O ,|O histone|gene-rna H3|gene-rna ,|O c-myc|gene-rna and|O p53|gene-rna ,|O was|O found|O in|O a|O set|O of|O 12|O primary|O untreated|O neuroblastomas|O and|O a|O metastasis|O of|O one|O of|O these|O at|O relapse|O .|O 
Molecular|O analysis|O allowed|O us|O to|O discriminate|O between|O actually|O proliferating|O and|O non|O -|O proliferating|O tumors|O ,|O and|O suggested|O a|O link|O between|O N-myc|gene-rna and|O proliferation|O .|O 
Flow|O cytometric|O analysis|O of|O DNA|O distribution|O was|O less|O reliable|O for|O assessing|O tumor|O proliferative|O activity|O .|O 
Our|O data|O also|O seem|O to|O indicate|O a|O down|O -|O regulation|O of|O c-myc|gene-rna by|O N-myc|gene-rna in|O human|O neuroblastoma|O .|O 
Tumors|O of|O the|O neuroblastoma|O group|O .|O 
The|O basic|O histologic|O changes|O associated|O with|O the|O maturational|O sequences|O of|O neuroblastoma|O tumors|O are|O reviewed|O .|O 
The|O author|O describes|O a|O histopathologic|O classification|O system|O developed|O for|O distinguishing|O favorable|O and|O unfavorable|O prognoses|O ,|O based|O on|O the|O combination|O of|O tumor|O morphology|O and|O patient|O 's|O age|O at|O diagnosis|O .|O 
Also|O discussed|O are|O the|O results|O of|O recent|O analyses|O of|O the|O biologically|O significant|O relationship|O between|O histologic|O findings|O and|O molecular|O markers|O ,|O such|O as|O amplification|O of|O the|O N-myc|gene-rna oncogene|O and|O expression|O of|O the|O nerve|gene-rna growth|gene-rna factor|gene-rna receptor|gene-rna gene|O .|O 
Clinical|O trials|O involving|O neuroblastoma|O tumors|O are|O briefly|O reviewed|O .|O 
Microwave|O radiation|O -|O induced|O calcium|O ion|O efflux|O from|O human|O neuroblastoma|O cells|O in|O culture|O .|O 
Monolayer|O cultures|O of|O human|O neuroblastoma|O cells|O were|O exposed|O to|O 915|O -|O MHz|O radiation|O ,|O with|O or|O without|O sinusoidal|O amplitude|O modulation|O (|O 80|O %|O )|O at|O 16|O Hz|O ,|O at|O specific|O absorption|O rates|O (|O SAR|O )|O for|O the|O culture|O medium|O and|O cells|O of|O 0.00|O ,|O 0.01|O ,|O 0.05|O ,|O 0.075|O ,|O 0.1|O ,|O 0.5|O ,|O 0.75|O ,|O 1.0|O ,|O 1.5|O ,|O 2|O ,|O or|O 5|O mW|O /|O g|O .|O 
A|O significant|O increase|O in|O the|O efflux|O of|O calcium|O ions|O (|O 45|O Ca2|O +|O )|O as|O compared|O to|O unexposed|O control|O cultures|O occurred|O at|O two|O SAR|O values|O :|O 0.05|O and|O 1|O mW|O /|O g|O .|O 
Increased|O efflux|O at|O 0.05|O mW|O /|O g|O was|O dependent|O on|O the|O presence|O of|O amplitude|O modulation|O at|O 16|O Hz|O but|O at|O the|O higher|O value|O it|O was|O not|O .|O 
These|O results|O indicate|O that|O human|O neuroblastoma|O cells|O are|O sensitive|O to|O extremely|O low|O levels|O of|O microwave|O radiation|O at|O certain|O narrow|O ranges|O of|O SAR|O .|O 
A|O tissue|O culture|O assay|O for|O tetrodotoxin|O ,|O saxitoxin|O and|O related|O toxins|O .|O 
In|O the|O presence|O of|O ouabain|O ,|O veratridine|O enhances|O sodium|O influx|O in|O the|O mouse|O neuroblastoma|O cell|O line|O Neuro-2A|O (|O ATCC|O ,|O CCL131|O )|O ,|O causing|O cellular|O swelling|O and|O subsequent|O death|O .|O 
Tetrodotoxin|O (|O puffer|O fish|O toxin|O )|O or|O saxitoxin|O (|O paralytic|O shellfish|O poison|O )|O ,|O both|O of|O which|O block|O the|O sodium|O channel|O of|O excitable|O membranes|O ,|O antagonize|O this|O effect|O ,|O enabling|O cell|O growth|O to|O continue|O .|O 
This|O phenomenon|O was|O used|O as|O the|O basis|O of|O a|O new|O assay|O for|O these|O toxins|O .|O 
It|O is|O also|O possible|O to|O estimate|O the|O quantity|O of|O TTX|O from|O the|O relationship|O between|O TTX|O concentration|O and|O percentage|O of|O living|O cells|O .|O 
This|O new|O method|O is|O simple|O ,|O inexpensive|O ,|O and|O sensitive|O ,|O and|O may|O replace|O the|O conventional|O mouse|O bioassay|O .|O 
Solid|O tumors|O of|O children|O :|O chromosome|O abnormalities|O and|O the|O development|O of|O cancer|O .|O 
Chromosome|O abnormalities|O in|O five|O solid|O tumors|O which|O occur|O predominantly|O in|O children|O and|O young|O adults|O are|O described|O .|O 
Four|O of|O the|O tumors|O are|O associated|O with|O rearrangements|O involving|O particular|O chromosome|O segments|O :|O deletion|O 13q14|O in|O retinoblastoma|O ,|O deletion|O 11p13|O in|O Wilms|O '|O tumor|O ,|O deletions|O /|O rearrangements|O of|O 1p|O (|O distal|O to|O band|O 1p31|O )|O in|O neuroblastoma|O ,|O and|O translocation|O 22|O /|O autosome|O in|O Ewing|O sarcoma|O .|O 
Though|O aneuploidy|O for|O a|O number|O of|O chromosomes|O may|O occur|O in|O the|O fifth|O tumor|O ,|O rhabdomyosarcoma|O ,|O it|O has|O yet|O to|O be|O associated|O with|O a|O consistent|O marker|O arrangement|O .|O 
A|O general|O classification|O of|O chromosome|O abnormalities|O in|O cancer|O is|O presented|O .|O 
Possible|O roles|O for|O the|O gene|O changes|O produced|O by|O each|O class|O of|O chromosome|O abnormality|O in|O the|O development|O of|O cancer|O are|O discussed|O .|O 
Prognostic|O value|O of|O different|O staging|O systems|O in|O neuroblastomas|O and|O completeness|O of|O tumour|O excision|O .|O 
Two|O hundred|O and|O fifty|O three|O patients|O were|O retrospectively|O assigned|O to|O eight|O different|O staging|O systems|O proposed|O for|O neuroblastomas|O ,|O and|O the|O prognostic|O value|O of|O each|O staging|O system|O was|O evaluated|O individually|O .|O 
The|O ability|O of|O each|O system|O to|O predict|O prognosis|O was|O compared|O with|O the|O others|O and|O the|O system|O proposed|O by|O Evans|O et|O al|O found|O to|O be|O the|O best|O predictor|O ,|O even|O better|O than|O the|O recently|O proposed|O Tumour|O -|O Nodes|O -|O Metastases|O staging|O system|O .|O 
This|O is|O probably|O due|O to|O the|O fact|O that|O factors|O other|O than|O the|O resectability|O of|O the|O tumour|O play|O a|O major|O role|O in|O the|O survival|O of|O these|O children|O .|O 
Age|O was|O found|O to|O have|O independent|O prognostic|O significance|O whatever|O staging|O system|O was|O used|O .|O 
Changes|O in|O microtubule|O -|O associated|O tau|gene-protein protein|O in|O human|O neuroblastoma|O cells|O after|O phencyclidine|O .|O 
1.|O 
A|O human|O neuroblastoma|O cell|O line|O ,|O SH-SY5Y|O ,|O was|O used|O to|O study|O the|O effects|O of|O phencyclidine|O (|O PCP|O )|O on|O microtubule|O -|O associated|O tau|gene-protein protein|O ,|O which|O acts|O in|O vivo|O chiefly|O to|O induce|O the|O assembly|O of|O tubulin|gene-protein and|O in|O vitro|O to|O promote|O microtubule|O polymerization|O .|O 
2.|O 
PCP|O (|O 1.0|O mM|O )|O decreased|O tau|gene-protein protein|O (|O 50|O kD|O )|O in|O the|O cytoplasmic|O (|O supernatant|O )|O fraction|O as|O well|O as|O in|O the|O membrane|O (|O pellet|O )|O fraction|O .|O 
3.|O 
These|O changes|O in|O tau|gene-protein protein|O were|O accompanied|O by|O decreases|O of|O 30|O -|O 95|O %|O in|O cell|O number|O after|O concentrations|O of|O PCP|O ,|O 0.25|O -|O 1.0|O mM|O ,|O respectively|O .|O 
4.|O 
After|O 0.5|O mM|O PCP|O cytoplasmic|O and|O membrane|O fractions|O of|O SH-SY5Y|O cells|O showed|O 100|O and|O 84|O %|O increases|O in|O total|O protein|O ,|O respectively|O .|O 
Conditional|O open|O and|O delay|O time|O histograms|O of|O sodium|O channels|O .|O 
Currents|O through|O single|O sodium|O channels|O were|O recorded|O in|O neuroblastoma|O cells|O .|O 
Open|O time|O histograms|O were|O constructed|O from|O openings|O which|O appeared|O between|O 2.0|O and|O 5.0|O ms|O after|O the|O onset|O of|O the|O depolarization|O .|O 
Histograms|O constructed|O from|O openings|O which|O were|O not|O preceded|O by|O other|O openings|O showed|O a|O maximum|O at|O t|O greater|O than|O 0|O in|O contrast|O to|O those|O ,|O which|O were|O preceded|O by|O other|O openings|O .|O 
Time|O constants|O of|O delay|O time|O histograms|O fitted|O by|O the|O sum|O of|O two|O exponentials|O were|O different|O for|O the|O first|O ,|O second|O and|O third|O records|O of|O runs|O .|O 
The|O results|O support|O the|O view|O that|O sodium|O channels|O have|O multiple|O open|O and|O closed|O states|O and|O the|O transition|O probabilities|O among|O the|O states|O depend|O on|O local|O conditions|O of|O the|O membrane|O .|O 
Cloning|O of|O a|O human|O cDNA|O encoding|O a|O putative|O nucleotide|gene-protein -|gene-protein binding|gene-protein protein|gene-protein related|O to|O Escherichia|O coli|O MinD|gene-protein .|O 
A|O novel|O human|O cDNA|O encoding|O a|O putative|O nucleotide|O -|O binding|O protein|O (|O NBP|gene-protein )|O was|O obtained|O by|O screening|O a|O human|O SHSY5Y|O neuroblastoma|O library|O .|O 
The|O deduced|O protein|O contains|O 320|O amino|O acids|O (|O aa|O )|O with|O a|O M(r)|O of|O 34,540|O .|O 
NBP|O displays|O sequence|O similarity|O with|O the|O product|O of|O the|O minD|gene-rna gene|O from|O Escherichia|O coli|O .|O 
MinD|gene-protein is|O involved|O in|O the|O proper|O placement|O of|O the|O division|O septum|O ,|O and|O has|O ATPase|gene-protein activity|O .|O 
NBP|gene-protein and|O MinD|gene-protein contain|O consensus|O nucleotide|O (|O nt|O )|O -|O binding|O domains|O .|O 
The|O NBP|gene-protein mRNA|O is|O approx.|O 1500|O nt|O in|O length|O and|O is|O expressed|O in|O several|O human|O cell|O lines|O and|O in|O all|O rat|O tissues|O examined|O ,|O with|O the|O highest|O levels|O in|O lung|O and|O testis|O .|O 
Coexpression|O of|O species|O -|O specific|O histone|gene-rna H1|gene-rna and|O H2B|gene-rna genes|O in|O mouse|O -|O rat|O hybrid|O cells|O .|O 
Five|O different|O clones|O of|O somatic|O hybrid|O cell|O lines|O between|O mouse|O and|O rat|O cells|O were|O examined|O for|O the|O expression|O of|O species|O -|O specific|O histone|gene-generic H1|gene-generic and|O H2B|gene-generic subtypes|O .|O 
It|O was|O found|O that|O one|O hybrid|O (|O 140-3|O )|O contained|O only|O mouse|O specific|O histones|gene-protein and|O the|O other|O four|O clones|O had|O both|O mouse|O and|O rat|O specific|O histones|gene-protein in|O various|O ratios|O .|O 
In|O three|O cases|O (|O 141-B|O ,|O NBr10A|O ,|O NBr20A|O )|O ,|O the|O relative|O amount|O of|O mouse|O and|O rat|O specific|O histones|gene-protein was|O correlated|O with|O the|O karyotype|O of|O the|O hybrids|O .|O 
However|O ,|O this|O was|O not|O true|O in|O one|O case|O (|O NG108-15|O )|O .|O 
The|O results|O indicate|O that|O a|O single|O mammalian|O hybrid|O clone|O can|O express|O both|O parental|O types|O of|O histones|gene-protein ,|O and|O the|O histone|gene-protein expression|O in|O these|O hybrids|O is|O not|O regulated|O by|O an|O allelic|O exclusion|O but|O may|O be|O expressed|O codominantly|O by|O gene|O dosage|O .|O 
Differential|O expression|O of|O the|O N-myc|gene-rna ,|O c-fos|gene-rna ,|O and|O smg|gene-rna p25A|gene-rna genes|O in|O human|O neuroblastoma|O cells|O during|O neuronal|O and|O Schwannian|O differentiation|O .|O 
We|O have|O examined|O expression|O of|O the|O N-myc|gene-rna ,|O c-fos|gene-rna and|O smg|gene-rna p25A|gene-rna genes|O in|O two|O human|O neuroblastoma|O cell|O lines|O during|O their|O differentiation|O .|O 
The|O decrease|O in|O the|O N-myc|gene-rna gene|O expression|O and|O the|O increase|O in|O the|O c-fos|gene-rna gene|O expression|O are|O observed|O during|O the|O differentiation|O of|O NB-1|O cells|O into|O neuronal|O cells|O and|O of|O GOTO|O cells|O into|O Schwann|O -|O type|O cells|O .|O 
On|O the|O other|O hand|O ,|O the|O smg|gene-protein p25A|gene-protein ,|O a|O ras|gene-protein p21|gene-protein -|O like|O small|O GTP|gene-protein -|gene-protein binding|gene-protein protein|O ,|O gene|O expression|O is|O increased|O in|O NB-1|O cells|O but|O not|O in|O GOTO|O cells|O during|O their|O differentiation|O ,|O suggesting|O that|O smg|gene-generic p25A|gene-generic is|O closely|O associated|O with|O the|O neuronal|O phenotype|O of|O neuroblastoma|O cells|O .|O 
Expression|O of|O mRNA|O encoding|O neurotrophic|gene-protein factors|gene-protein and|O its|O regulation|O in|O a|O hybrid|O neuronal|O cell|O line|O .|O 
In|O a|O cultured|O hybrid|O neuronal|O cell|O line|O (|O BIM|O )|O which|O was|O produced|O between|O human|O neuroblastoma|O cells|O (|O IMR32|O )|O and|O thymidine|O auxotrophs|O (|O B3T|O )|O of|O rat|O nerve|O -|O like|O cells|O (|O B103|O )|O ,|O the|O mRNAs|O encoding|O ciliary|gene-protein neurotrophic|gene-protein factor|gene-protein (|O CNTF|gene-protein )|O and|O neurotrophins|gene-protein were|O detected|O by|O the|O polymerase|gene-protein chain|O reaction|O method|O .|O 
The|O conditioned|O medium|O of|O BIM|O cells|O enhanced|O choline|gene-protein acetyltransferase|gene-protein (|O ChAT|gene-protein )|O activity|O in|O septal|O neurons|O and|O survival|O of|O ciliary|O ganglion|O neurons|O .|O 
The|O mRNA|O expression|O of|O CNTF|gene-protein and|O neurotrophins|gene-protein in|O BIM|O cells|O was|O differently|O regulated|O by|O the|O stimulation|O with|O cAMP|O ,|O FGF|gene-protein and|O retinoic|O acid|O .|O 
These|O data|O suggest|O multiple|O regulation|O and|O collaboration|O of|O neurotrophic|gene-protein factors|gene-protein .|O 
Embryonic|O chicken|O brain|O and|O mouse|O neuroblastoma|O cells|O N1E-115|O and|O N-18|O contain|O an|O inhibitor|O of|O acid|O deoxyribonuclease|gene-protein .|O 
Activity|O of|O a|O trypsin|gene-protein -|O sensitive|O acid|O deoxyribonuclease|gene-protein (|O DNase|gene-protein )|O inhibitor|O has|O been|O detected|O in|O 13|O -|O to|O 21|O -|O day|O -|O old|O embryonic|O chicken|O brains|O and|O in|O clonal|O lines|O of|O neuroblastoma|O cells|O (|O adrenergic|O ,|O N1E-115|O ,|O and|O neurotransmitter|O -|O inactive|O ,|O N-18|O )|O grown|O for|O 48|O hr|O after|O subculture|O .|O 
The|O activities|O of|O purified|O porcine|O and|O bovine|O spleen|O DNases|gene-protein were|O inhibited|O 60|O --|O 75|O %|O in|O the|O presence|O of|O the|O inhibitor|O ,|O whereas|O less|O than|O 10|O %|O inhibition|O was|O observed|O with|O purified|O pancreatic|gene-protein DNase|gene-protein .|O 
Activities|O of|O an|O acidic|O DNase|gene-protein and|O its|O inhibitor|O reached|O maxima|O in|O 21|O -|O day|O -|O old|O embryonic|O chicken|O brain|O .|O 
The|O proteins|O were|O separated|O by|O isoelectric|O focusing|O and|O affinity|O column|O chromatographic|O techniques|O .|O 
The|O pI|O values|O of|O the|O acid|O DNase|gene-protein and|O its|O inhibitor|O were|O 5.4|O and|O 4.2|O ,|O respectively|O .|O 
Bradykinin|gene-protein inhibits|O potassium|O (|O M|O )|O currents|O in|O N1E-115|O neuroblastoma|O cells|O .|O 
Responses|O resemble|O those|O in|O NG108-15|O neuroblastoma|O x|O glioma|O hybrid|O cells|O .|O 
Application|O of|O bradykinin|gene-protein to|O voltage|O -|O clamped|O N1E-115|O mouse|O neuroblastoma|O cells|O evoked|O sequential|O outward|O and|O inward|O membrane|O currents|O ,|O accompanied|O by|O an|O increase|O and|O decrease|O of|O membrane|O conductance|O ,|O respectively|O .|O 
Methacholine|O produced|O an|O inward|O current|O with|O a|O decreased|O conductance|O .|O 
The|O outward|O current|O response|O to|O bradykinin|gene-protein was|O imitated|O by|O intracellular|O inositol|O 1,4,5-trisphosphate|O (|O IP3|O )|O .|O 
Bath|O application|O of|O phorbol|O dibutyrate|O induced|O an|O inward|O current|O and|O potentiated|O the|O response|O to|O IP3|O .|O 
We|O conclude|O that|O the|O response|O of|O these|O cells|O to|O bradykinin|gene-protein is|O identical|O to|O that|O of|O NG108-15|O hybrid|O cells|O ,|O and|O therefore|O may|O be|O attributed|O to|O the|O dual|O effects|O of|O inositol|O trisphosphate|O and|O diacylglycerol|O formed|O by|O hydrolysis|O of|O phosphatidylinositide|O .|O 
Nucleolar|O localization|O of|O myc|gene-rna transcripts|gene-rna .|O 
In|O situ|O hybridization|O has|O revealed|O a|O striking|O subnuclear|O distribution|O of|O c-myc|gene-rna RNA|gene-rna transcripts|gene-rna .|O 
A|O major|O fraction|O of|O the|O sense|O -|O strand|O nuclear|O c-myc|gene-rna transcripts|gene-rna was|O localized|O to|O the|O nucleoli|O .|O 
myc|gene-rna intron|O 1|O -|O containing|O RNAs|O were|O noticeably|O absent|O from|O nucleoli|O ,|O accumulating|O instead|O in|O the|O nucleoplasm|O .|O 
The|O localization|O of|O myc|gene-rna RNA|O to|O nucleoli|O was|O shown|O to|O be|O common|O to|O a|O number|O of|O diverse|O cell|O types|O ,|O including|O primary|O Sertoli|O cells|O and|O several|O cell|O lines|O .|O 
Furthermore|O ,|O nucleolar|O localization|O was|O not|O restricted|O to|O c-myc|gene-rna and|O N-myc|gene-rna and|O myoD|gene-rna transcripts|gene-rna also|O displayed|O this|O phenomenon|O .|O 
In|O contrast|O ,|O gamma-actin|gene-rna or|O lactate|gene-rna dehydrogenase|gene-rna transcripts|gene-rna did|O not|O display|O nucleolar|O localization|O .|O 
These|O observations|O suggest|O a|O new|O role|O for|O the|O nucleolus|O in|O transport|O and/or|O turnover|O of|O potential|O mRNAs|O .|O 
Neurotrophin|gene-protein receptors|gene-protein ,|O tumor|O progression|O and|O tumor|O maturation|O .|O 
The|O nerve|gene-protein growth|gene-protein factor|gene-protein receptor|gene-protein TrkA|gene-protein was|O initially|O isolated|O as|O a|O transforming|O oncogene|O ,|O trk|gene-rna ,|O in|O which|O most|O of|O the|O extracellular|O receptor|O part|O is|O replaced|O by|O the|O coding|O sequence|O for|O a|O tropomyosin|gene-protein -|O encoding|O gene|O .|O 
The|O impact|O that|O the|O identification|O of|O the|O first|O neurotrophin|gene-protein receptor|gene-protein has|O made|O on|O the|O entire|O field|O of|O developmental|O neurobiology|O cannot|O be|O overstated|O .|O 
Following|O a|O brief|O introduction|O to|O the|O biology|O of|O neurotrophins|gene-protein and|O their|O receptors|O ,|O this|O review|O will|O focus|O on|O oncogenic|O Trk|gene-rna in|O human|O malignant|O disorders|O ,|O discuss|O putative|O tumorigenic|O involvement|O of|O Trk|gene-rna family|O members|O in|O the|O childhood|O malignancy|O neuroblastoma|O ,|O and|O point|O out|O potential|O neurotrophin|gene-protein -|O based|O treatment|O modalities|O for|O this|O and|O other|O neuroendocrine|O tumors|O .|O 
[|O Oncogenes|O and|O suppressor|O genes|O in|O the|O genesis|O and|O progression|O of|O solid|O tumors|O in|O children|O ]|O 
Molecular|O and|O genetic|O analyses|O of|O tumor|O cell|O show|O that|O cellular|O oncogenes|O and|O suppressor|O genes|O are|O involved|O in|O neoplastic|O transformation|O .|O 
In|O pediatric|O tumors|O oncogenes|O as|O N-myc|gene-rna play|O an|O important|O role|O in|O the|O tumor|O progression|O .|O 
In|O retinoblastoma|O ,|O neuroblastoma|O ,|O Wilms|O '|O tumor|O ,|O and|O rhabdomyosarcoma|O loss|O of|O heterozygosity|O for|O specific|O chromosome|O loci|O has|O been|O suggested|O to|O be|O a|O critical|O step|O in|O cancer|O development|O .|O 
Oncogene|O abnormalities|O can|O also|O be|O useful|O as|O a|O molecular|O tumor|O factor|O to|O foresee|O the|O prognosis|O of|O the|O disease|O .|O 
The|O present|O article|O is|O a|O review|O on|O the|O role|O of|O the|O oncogenes|O and|O suppressor|O genes|O in|O pediatric|O solid|O tumors|O .|O 
Ethanol|O exposure|O increases|O expression|O of|O c-jun|gene-rna and|O junD|gene-rna in|O human|O neuroblastoma|O cells|O .|O 
The|O aim|O of|O this|O study|O was|O to|O investigate|O the|O effect|O of|O ethanol|O exposure|O on|O the|O expression|O of|O fos|gene-rna and|O jun|gene-rna genes|O .|O 
Exposure|O of|O human|O neuroblastoma|O SH-SY5Y|O cells|O to|O ethanol|O for|O 2|O -|O 4|O days|O caused|O a|O dose|O -|O dependent|O increase|O in|O c-jun|gene-rna and|O junD|gene-rna mRNA|O levels|O ,|O whereas|O mRNAs|O for|O c-fos|gene-rna ,|O fosB|gene-rna and|O junB|gene-rna were|O not|O detectable|O in|O control|O or|O ethanol|O -|O treated|O cells|O .|O 
Four|O days|O of|O ethanol|O exposure|O also|O enhanced|O the|O AP-1|gene-protein binding|O activity|O .|O 
Experiments|O with|O actinomycin|O D|O demonstrated|O that|O ethanol|O did|O not|O influence|O the|O degradation|O of|O c-jun|gene-rna and|O junD|gene-rna mRNAs|O .|O 
These|O results|O demonstrate|O that|O long|O -|O term|O exposure|O to|O ethanol|O increases|O c-jun|gene-rna and|O junD|gene-rna expression|O .|O 
This|O effect|O may|O be|O one|O of|O the|O mechanisms|O through|O which|O ethanol|O influences|O the|O gene|O regulatory|O system|O in|O neuronal|O cells|O .|O 
A|O requirement|O for|O the|O POU|gene-protein transcription|gene-protein factor|gene-protein ,|O Brn-2|gene-protein ,|O in|O corticotropin|O -|O releasing|O hormone|O expression|O in|O a|O neuronal|O cell|O line|O .|O 
The|O expression|O of|O the|O endogenous|O CRF|gene-rna gene|O was|O examined|O in|O the|O human|O neuroblastoma|O cell|O line|O ,|O BE(2)-M17|O .|O 
In|O this|O cell|O line|O ,|O treatment|O with|O retinoic|O acid|O induces|O CRF|gene-rna mRNA|O transcription|O .|O 
We|O examined|O the|O requirement|O for|O the|O POU|gene-protein transcription|gene-protein factor|gene-protein ,|O Bm-2|gene-protein ,|O for|O this|O response|O .|O 
We|O confirmed|O that|O Bm-2|gene-protein is|O expressed|O in|O retinoic|O acid|O -|O induced|O BE(2)-M17|O cells|O .|O 
Expression|O of|O antisense|O Bm-2|gene-rna message|O aborted|O the|O retinoic|O acid|O -|O mediated|O induction|O of|O CRF|gene-rna transcription|O .|O 
However|O ,|O overexpression|O of|O Bm-2|gene-generic was|O not|O sufficient|O for|O CRF|gene-rna expression|O in|O the|O absence|O of|O retinoic|O acid|O .|O 
These|O experiments|O support|O the|O hypothesis|O that|O Bm-2|gene-generic is|O an|O intermediary|O for|O retinoic|O acid|O -|O induced|O CRF|gene-rna expression|O .|O 
The|O helix|O -|O loop|O -|O helix|O transcription|O factor|O USF|gene-protein interacts|O with|O the|O basal|O promoter|O of|O human|O amyloid|gene-rna precursor|gene-rna protein|gene-rna .|O 
Nuclear|O factors|O from|O HeLa|O ,|O PC12|O ,|O NG108-15|O and|O SK-N-SH|O cell|O lines|O recognized|O an|O oligonucleotide|O (|O -|O 56|O to|O -|O 37|O :|O APP|gene-rna -|O E1|O )|O containing|O an|O E|O box|O (|O CANNTG|O )|O which|O had|O previously|O been|O characterized|O as|O a|O DNase|gene-protein I|gene-protein -|O protected|O sequence|O in|O the|O basal|O promoter|O of|O the|O human|O amyloid|gene-rna precursor|gene-rna protein|gene-rna (|O APP|gene-rna )|O gene|O .|O 
Binding|O to|O APP|gene-rna -|O E1|O was|O competed|O with|O an|O oligonucleotide|O encompassing|O the|O recognition|O site|O of|O the|O transcription|O factor|O USF|gene-protein .|O 
Antibodies|gene-protein directed|O against|O USF|gene-protein interacted|O with|O the|O APP|gene-rna -|O E1|O -|O protein|O complex|O and|O in|O vitro|O synthesized|O USF|gene-protein could|O bind|O APP|gene-rna -|O E1|O .|O 
Co|O -|O expression|O of|O USF|gene-rna cDNA|O transactivated|O a|O human|O APP|gene-rna -|O reporter|gene-rna gene|gene-rna construct|O .|O 
These|O results|O suggest|O that|O USF|gene-protein may|O play|O a|O role|O in|O the|O expression|O of|O the|O APP|gene-rna gene|O .|O 
Biological|O characteristics|O of|O N-myc|gene-rna amplified|O neuroblastoma|O in|O patients|O over|O one|O year|O of|O age|O .|O 
1.|O 
A|O genomic|O amplification|O of|O N-myc|gene-rna of|O neuroblastoma|O was|O frequently|O observed|O in|O patients|O in|O the|O advanced|O stage|O of|O the|O disease|O ,|O in|O those|O with|O the|O tumor|O originating|O from|O the|O suprarenal|O region|O ,|O and|O in|O those|O with|O a|O histologically|O undifferentiated|O neuroblastoma|O .|O 
Thus|O ,|O N-myc|gene-rna may|O be|O one|O of|O the|O most|O pertinent|O prognostic|O factors|O of|O neuroblastoma|O in|O patients|O over|O one|O year|O of|O age|O .|O 
2.|O 
The|O neuroblastoma|O patient|O with|O 1|O -|O 10|O copies|O of|O N-myc|gene-rna responded|O to|O aggressive|O multidisciplinary|O therapy|O ,|O even|O those|O over|O one|O year|O of|O age|O .|O 
3.|O 
Rapid|O invasion|O and|O progression|O of|O the|O tumor|O was|O evident|O in|O children|O with|O more|O than|O 10|O copies|O of|O N-myc|gene-rna .|O 
4.|O 
N-myc|gene-rna amplification|O may|O correlate|O with|O immaturity|O of|O catecholamine|O metabolism|O of|O neuroblastoma|O .|O 
Desensitization|O of|O D1|gene-protein dopamine|gene-protein receptors|gene-protein down|O -|O regulates|O the|O Gs|gene-protein alpha|gene-protein subunit|O of|O G|gene-protein protein|gene-protein in|O SK-N-MC|O neuroblastoma|O cells|O .|O 
The|O effect|O of|O long|O -|O term|O (|O 72|O h|O )|O treatment|O with|O dopamine|gene-protein D1|gene-protein receptor|gene-protein agonists|O ,|O SKF|O 38393|O and|O dopamine|O on|O D1|gene-protein dopamine|gene-protein receptor|gene-protein and|O G-protein|gene-protein (|O Gs|gene-protein alpha|gene-protein )|O was|O investigated|O in|O SK-N-MC|O neuroblastoma|O cells|O .|O 
The|O prolonged|O treatment|O of|O cells|O with|O 10|O microM|O SKF|O 38393|O or|O 10|O microM|O dopamine|O resulted|O in|O a|O decrease|O in|O dopamine|gene-protein D1|gene-protein receptor|gene-protein by|O 41|O and|O 81|O %|O ,|O respectively|O ,|O as|O measured|O by|O specific|O antagonist|O [3H]SCH|O 23390|O binding|O .|O 
Similarly|O ,|O the|O prolonged|O treatment|O of|O SK-N-MC|O cells|O with|O 10|O microM|O SKF|O 38393|O or|O 10|O microM|O dopamine|O resulted|O in|O a|O reduction|O of|O the|O level|O of|O Gs|gene-protein alpha|gene-protein subunit|O of|O G-protein|gene-protein .|O 
The|O results|O indicate|O that|O agonist|O -|O induced|O down|O -|O regulation|O of|O D1|gene-protein dopamine|gene-protein receptor|gene-protein may|O also|O modulate|O G-proteins|gene-protein .|O 
Charged|O particle|O therapy|O to|O pediatric|O tumors|O of|O the|O retroperitoneal|O region|O :|O a|O possible|O indication|O .|O 
Despite|O a|O very|O successful|O interdisciplinary|O therapy|O regimen|O for|O pediatric|O solid|O tumors|O dominated|O by|O surgery|O and|O chemotherapy|O ,|O the|O role|O of|O radiotherapy|O might|O become|O again|O more|O important|O if|O new|O techniques|O will|O allow|O a|O better|O dose|O localization|O to|O the|O target|O volume|O combined|O with|O a|O better|O protection|O of|O the|O normal|O tissue|O .|O 
This|O characteristic|O is|O known|O for|O charged|O particle|O beams|O .|O 
In|O a|O field|O study|O based|O on|O German|O cooperative|O trials|O ,|O the|O possibility|O of|O a|O charged|O particle|O radiotherapy|O to|O retroperitoneal|O tumors|O of|O childhood|O will|O be|O discussed|O regarding|O indications|O in|O risk|O groups|O and|O recurrences|O .|O 
Absolute|O patient|O numbers|O are|O estimated|O from|O the|O clinical|O experiences|O and|O the|O incidences|O of|O the|O diseases|O .|O 
A|O stepwise|O introduction|O of|O this|O new|O therapy|O modality|O is|O proposed|O .|O 
Neuroblastoma|O ,|O retinoblastoma|O ,|O and|O brain|O tumors|O in|O children|O .|O 
Considerable|O progress|O has|O been|O made|O recently|O in|O the|O biologic|O understanding|O and|O the|O clinical|O management|O of|O pediatric|O tumors|O of|O the|O peripheral|O and|O central|O nervous|O system|O .|O 
Here|O we|O review|O important|O representative|O studies|O published|O primarily|O in|O the|O past|O 2|O years|O regarding|O neuroblastoma|O ,|O retinoblastoma|O ,|O and|O brain|O tumors|O in|O children|O .|O 
Highlights|O include|O 1)|O the|O importance|O of|O tumor|O DNA|O content|O ,|O N-myc|gene-rna amplification|O ,|O and|O chromosome|O 1|O deletion|O in|O predicting|O outcome|O of|O patients|O with|O neuroblastoma|O ;|O 2)|O the|O impact|O of|O mass|O screening|O for|O neuroblastoma|O in|O Japan|O and|O elsewhere|O ;|O 3)|O improvements|O in|O the|O clinical|O management|O of|O neuroblastoma|O ,|O retinoblastoma|O ,|O and|O brain|O tumors|O ;|O and|O 4)|O neurologic|O sequelae|O of|O these|O tumors|O and|O their|O treatment|O .|O 
Probability|O paper|O analysis|O of|O flow|O cytofluorometric|O measurements|O of|O cellular|O deoxyribonucleic|O acid|O content|O .|O 
A|O graphic|O analysis|O of|O cellular|O deoxyribonucleic|O acid|O (|O DNA|O )|O histograms|O obtained|O by|O flow|O cytofluorometry|O is|O described|O .|O 
This|O technique|O utilizes|O probability|O paper|O that|O graphs|O data|O in|O cumulative|O percentile|O form|O .|O 
From|O this|O graphic|O representation|O ,|O individual|O normal|O distributions|O contributing|O to|O the|O histogram|O may|O be|O isolated|O and|O statistically|O describe|O .|O 
G0G1|O and|O G2M|O distributions|O are|O independently|O described|O and|O S|O phase|O is|O fit|O to|O 1|O --|O 5|O overlapping|O normal|O distributions|O as|O dictated|O by|O the|O analysis|O results|O .|O 
This|O technique|O offers|O several|O advantages|O ,|O including|O relatively|O simple|O mathematical|O calculations|O and|O few|O assumptions|O or|O restraints|O placed|O on|O the|O analysis|O .|O 
It|O has|O proved|O to|O be|O useful|O in|O analyzing|O proliferating|O and|O nonproliferating|O populations|O as|O well|O as|O distributions|O with|O unusual|O findings|O such|O as|O debris|O or|O aberrant|O DNA|O contents|O .|O 
Truncated|O apoE|gene-protein forms|O tangle|O -|O like|O structures|O in|O a|O neuronal|O cell|O line|O .|O 
Apolipoprotein|gene-protein E|gene-protein is|O the|O predominant|O brain|O lipoprotein|O and|O polymorphic|O variation|O in|O the|O APOE|gene-rna gene|O the|O major|O genetic|O susceptibly|O factor|O for|O late|O onset|O Alzheimer|O 's|O disease|O (|O AD|O )|O .|O 
Recently|O it|O was|O reported|O that|O carboxyl|O -|O truncated|O ApoE|gene-protein fragments|O induce|O tangle|O -|O like|O structures|O in|O neurons|O .|O 
We|O confirm|O the|O finding|O :|O in|O mouse|O neuroblastoma|O cells|O truncated|O apoE|gene-protein fragments|O lacking|O the|O carboxyterminus|O induce|O structures|O that|O have|O the|O appearance|O of|O neurofibrillary|O tangles|O .|O 
However|O these|O tangles|O are|O not|O induced|O in|O non|O -|O neuronal|O cells|O even|O in|O the|O presence|O of|O co|O -|O expressed|O neurofilaments|O or|O tau|gene-protein .|O 
Further|O understanding|O of|O the|O basis|O of|O this|O cell|O specificity|O might|O add|O to|O understanding|O of|O the|O cell|O specificity|O of|O tangles|O in|O AD|O .|O 
Cyclic|gene-protein adenosine|gene-protein 3':5'-monophosphate|gene-protein -|gene-protein binding|gene-protein protein|gene-protein ,|O a|O biochemical|O marker|O of|O neuroblastoma|O differentiation|O .|O 
Mouse|O neuroblastoma|O tumors|O show|O reduced|O amounts|O of|O cyclic|gene-protein adenosine|gene-protein 3':5'-monophosphate|gene-protein (|gene-protein cAMP|gene-protein )|gene-protein binding|gene-protein protein|gene-protein .|O 
However|O ,|O the|O levels|O of|O cAMP|gene-protein -|gene-protein binding|gene-protein protein|gene-protein were|O increased|O by|O 2|O -|O fold|O when|O the|O tumor|O cells|O were|O established|O in|O tissue|O culture|O ,|O and|O these|O levels|O were|O comparable|O to|O that|O found|O in|O mouse|O brain|O .|O 
This|O binding|gene-protein protein|gene-protein is|O a|O free|O cAMP|gene-protein -|gene-protein binding|gene-protein protein|gene-protein that|O is|O not|O associated|O with|O protein|gene-protein kinase|gene-protein .|O 
The|O reduced|O amounts|O of|O free|O cAMP|gene-protein -|gene-protein binding|gene-protein protein|gene-protein in|O tumors|O are|O not|O a|O consequence|O of|O a|O defective|O gene|O ,|O but|O the|O synthesis|O of|O this|gene-protein protein|gene-protein is|O regulated|O at|O the|O transcriptional|O and/or|O translational|O levels|O .|O 
The|O free|O cAMP|gene-protein -|gene-protein binding|gene-protein protein|gene-protein like|O the|O neurotransmitter|gene-protein -|gene-protein synthesizing|gene-protein enzymes|gene-protein can|O be|O used|O as|O a|O biochemical|O marker|O of|O differentiation|O ,|O and|O this|gene-protein protein|gene-protein may|O play|O a|O role|O in|O neuronal|O differentiation|O .|O 
Cloning|O and|O expression|O of|O a|O human|O /|O mouse|O Polycomb|gene-rna group|gene-rna gene|O ,|O ENX-2|gene-rna /|O Enx-2|gene-rna .|O 
The|O Drosophila|gene-rna Polycomb|gene-rna group|gene-rna (|O Pc-G|gene-rna )|O genes|O encode|O transcriptional|O factors|O involved|O in|O development|O .|O 
Little|O is|O known|O about|O members|O of|O the|O vertebrate|O Pc-G|gene-rna genes|O .|O 
In|O this|O study|O ,|O we|O have|O isolated|O a|O cDNA|O encoding|O a|O human|O Pc-G|gene-protein protein|O and|O the|O mouse|O equivalent|O .|O 
The|O human|O and|O mouse|O genes|O ,|O which|O were|O named|O ENX-2|gene-rna and|O Enx-2|gene-rna ,|O encode|O 702|O and|O 750|O amino|O acids|O ,|O respectively|O .|O 
ENX-2|gene-protein /|O Enx-2|gene-protein protein|O exhibits|O a|O high|O homology|O (|O 53|O -|O 55|O %|O identity|O )|O to|O Drosophila|O Enhancer|gene-protein of|gene-protein zeste|gene-protein [|O E(z)|gene-protein ]|O protein|O belonging|O to|O the|O Pc-G|gene-generic .|O 
The|O expression|O of|O Enx-2|gene-generic was|O observed|O in|O mouse|O kidney|O ,|O adrenal|O gland|O ,|O testis|O and|O brain|O at|O high|O levels|O by|O Northern|O blot|O analysis|O .|O 
A|O cell|O line|O of|O mouse|O neuroblastoma|O ,|O Neuro-2a|O ,|O also|O expresses|O Enx-2|gene-rna mRNA|O and|O its|O level|O is|O elevated|O by|O induction|O of|O neuronal|O differentiation|O of|O the|O cell|O .|O 
Interleukin-6|gene-protein and|O corticotrophin|O -|O releasing|O hormone|O mRNA|O are|O modulated|O during|O differentiation|O of|O human|O neuroblastoma|O cells|O .|O 
Two|O cell|O clones|O [|O BE(2)-C|O and|O BE(2)-M17|O ]|O derived|O from|O the|O human|O neuroblastoma|O cell|O line|O SK-N-BE(2)|O express|O corticotrophin|O -|O releasing|O hormone|O as|O well|O as|O interleukin-6|gene-rna mRNA|O .|O 
Both|gene-rna genes|gene-rna are|O overexpressed|O ,|O although|O with|O a|O different|O time|O course|O ,|O following|O exposure|O to|O 5|O microM|O retinoic|O acid|O ,|O in|O parallel|O to|O the|O induction|O of|O neuroblastic|O differentiation|O .|O 
On|O the|O contrary|O ,|O we|O are|O unable|O to|O detect|O interleukin-1|gene-rna beta|gene-rna mRNA|O in|O these|O cell|O lines|O .|O 
Both|O cytokines|gene-protein are|O known|O to|O increase|O hypothalamic|O CRH|gene-rna mRNA|O .|O 
The|O production|O of|O cytokines|gene-protein and|O neuropeptides|gene-protein by|O neuroblastoma|O cells|O indicate|O a|O complex|O dialogue|O between|O tumour|O cells|O and|O anti|O -|O tumour|O immunity|O .|O 
Neocarzinostatin|O induces|O neuronal|O morphology|O of|O mouse|O neuroblastoma|O in|O culture|O .|O 
Neocarzinostatin|O ,|O an|O antineoplastic|O agent|O which|O consists|O of|O a|O chromophore|O noncovalently|O bound|O to|O a|O protein|O of|O approximately|O 10,000D|O MW|O ,|O induces|O the|O morphological|O differentiation|O of|O cells|O of|O the|O C1300|O murine|O neuroblastoma|O line|O in|O vitro|O .|O 
It|O also|O has|O antimitotic|O activity|O ,|O ascribed|O previously|O in|O other|O cell|O lines|O to|O the|O action|O of|O the|O chromophore|O upon|O DNA|O .|O 
The|O chromophore|O is|O antimitotic|O for|O neuroblastoma|O cells|O ,|O as|O well|O .|O 
The|O morphology|O -|O altering|O effect|O of|O neocarzinostatin|O can|O also|O be|O mimicked|O by|O chromophore|O alone|O .|O 
The|O morphology|O -|O altering|O effect|O becomes|O apparent|O at|O doses|O of|O the|O agent|O which|O decrease|O the|O culture|O growth|O rate|O to|O approximately|O 50|O %|O of|O control|O values|O .|O 
It|O appears|O that|O induction|O of|O morphological|O neural|O differentiation|O of|O neuroblastoma|O cells|O requires|O an|O increase|O in|O the|O doubling|O time|O above|O a|O critical|O value|O .|O 
The|O toxic|O effect|O of|O Alzheimer|gene-protein amyloid|gene-protein protein|gene-protein precursor|gene-protein overexpressed|O in|O the|O neuroblastoma|O cell|O line|O NB-1|O on|O neurite|O outgrowth|O .|O 
The|O neuroblastoma|O cell|O line|O NB-1|O is|O induced|O to|O start|O neurite|O outgrowth|O by|O dibutyryl|O cyclic|O AMP|O (|O Bt2cAMP|O )|O .|O 
To|O study|O the|O function|O of|O Alzheimer|gene-protein amyloid|gene-protein protein|gene-protein precursor|gene-protein (|O APP|gene-protein )|O ,|O a|O stable|O cell|O line|O overexpressing|O APP|gene-protein was|O established|O by|O cDNA|O transfection|O .|O 
The|O APP|gene-rna cDNA|O was|O driven|O by|O the|O cytomegalovirus|O early|O gene|O promoter|O .|O 
The|O transformant|O underwent|O degeneration|O as|O well|O as|O neurite|O outgrowth|O in|O the|O presence|O of|O Bt2cAMP|O ,|O which|O also|O increased|O the|O amount|O of|O APP|gene-rna mRNA|O and|O protein|gene-protein .|O 
The|O expressed|O APP|gene-protein was|O mainly|O processed|O in|O the|O secretory|O pathway|O and|O few|O amyloidogenic|O fragments|O were|O observed|O .|O 
Hence|O ,|O not|O only|O the|O beta|gene-protein /|O A4|gene-protein protein|O but|O also|O the|O overexpressed|O APP|gene-protein itself|O might|O be|O neurotoxic|O .|O 
Clinical|O response|O and|O toxicity|O with|O cis-dichlorodiammineplatinum(II)|O in|O children|O .|O 
cis-Dichlorodiammineplatinum(II)|O (|O DDP|O )|O was|O studied|O in|O 16|O children|O with|O far|O -|O advanced|O malignancies|O .|O 
Three|O dosage|O schedules|O were|O tried|O :|O regimen|O A|O ,|O 20|O mg|O /|O m2|O /|O day|O x|O 5|O days|O for|O 3|O -|O 4|O weeks|O (|O 11|O patients|O )|O ;|O regimen|O B|O ,|O 50|O mg|O /|O m2|O once|O a|O week|O (|O four|O patients|O )|O ;|O and|O regimen|O C|O ,|O 60|O mg|O /|O m2|O /|O day|O x|O 2|O days|O every|O 3|O -|O 4|O weeks|O (|O one|O patient|O )|O .|O 
Four|O of|O 16|O patients|O (|O 25|O %|O )|O showed|O partial|O response|O ,|O including|O one|O with|O osteogenic|O sarcoma|O ,|O one|O with|O neuroblastoma|O ,|O one|O with|O seminoma|O ,|O and|O one|O with|O medullary|O carcinoma|O of|O the|O thyroid|O .|O 
Two|O patients|O showed|O clinical|O improvement|O .|O 
The|O major|O toxic|O manifestations|O included|O nausea|O and|O vomiting|O (|O 16|O of|O 16|O )|O ,|O renal|O toxicity|O (|O three|O of|O 16|O )|O ,|O transient|O pancytopenia|O (|O six|O of|O 12|O )|O ,|O and|O hearing|O loss|O (|O two|O of|O 16|O )|O .|O 
It|O is|O apparent|O that|O DDP|O has|O activity|O in|O pediatric|O tumors|O ;|O however|O ,|O a|O more|O precise|O response|O rate|O must|O be|O delineated|O in|O a|O larger|O series|O of|O patients|O .|O 
Glial|gene-protein cell|gene-protein line|gene-protein -|gene-protein derived|gene-protein neurotrophic|gene-protein factor|gene-protein signals|O through|O the|O RET|gene-protein receptor|gene-protein and|O activates|O mitogen|gene-protein -|gene-protein activated|gene-protein protein|gene-protein kinase|gene-protein .|O 
Glial|gene-protein cell|gene-protein line|gene-protein -|gene-protein derived|gene-protein neurotrophic|gene-protein factor|gene-protein (|O GDNF|gene-protein )|O ,|O a|O member|O of|O the|O transforming|O growth|gene-protein factor|gene-protein -|gene-protein beta|gene-protein family|O of|O growth|O factors|O ,|O was|O first|O identified|O by|O its|O ability|O to|O promote|O the|O survival|O of|O midbrain|O dopaminergic|O neurons|O in|O culture|O .|O 
We|O demonstrate|O that|O GDNF|gene-protein treatment|O of|O several|O neuroblastoma|O cell|O lines|O leads|O to|O dose|O -|O dependent|O tyrosine|O phosphorylation|O of|O the|O RET|gene-protein receptor|gene-protein and|O that|O other|O transforming|O growth|gene-protein factor|gene-protein -|gene-protein beta|gene-protein family|O members|O are|O not|O able|O to|O activate|O the|O RET|gene-protein receptor|gene-protein .|O 
GDNF|gene-protein treatment|O of|O neuroblastoma|O cells|O also|O results|O in|O increased|O transcription|O of|O an|O Elk|gene-rna luciferase|gene-rna reporter|gene-rna gene|gene-rna ,|O suggesting|O that|O GDNF|gene-protein activates|O the|O mitogen|gene-protein -|gene-protein activated|gene-protein protein|gene-protein kinase|gene-protein signal|O transduction|O pathway|O .|O 
N-myc|gene-rna amplification|O and|O neuron|gene-protein -|gene-protein specific|gene-protein enolase|gene-protein production|O of|O a|O neuroblastoma|O cell|O line|O and|O germ|O cell|O tumor|O cell|O lines|O .|O 
N-myc|gene-rna gene|O amplification|O of|O the|O gynecological|O malignant|O tumor|O cell|O lines|O and|O a|O neuroblastoma|O cell|O line|O was|O studied|O by|O the|O Southern|O hybridization|O method|O along|O with|O the|O production|O of|O neuron|gene-protein -|gene-protein specific|gene-protein enolase|gene-protein (|O NSE|gene-protein )|O by|O these|O cell|O lines|O .|O 
N-myc|gene-rna amplification|O and|O NSE|gene-protein production|O were|O observed|O side|O by|O side|O in|O three|O cell|O lines|O :|O neuroblastoma|O cell|O line|O HSNB|O ,|O endodermal|O sinus|O tumor|O cell|O line|O HAEST|O ,|O and|O malignant|O teratoma|O cell|O line|O HUOT|O .|O 
However|O ,|O N-myc|gene-rna amplification|O and|O NSE|gene-protein production|O disappeared|O gradually|O following|O successive|O passages|O of|O the|O HAEST|O and|O HUOT|O lines|O .|O 
With|O respect|O to|O the|O HUOT|O line|O ,|O these|O parameters|O disappeared|O along|O with|O the|O cells|O of|O nervous|O origin|O .|O 
N-myc|gene-rna amplification|O and|O NSE|gene-protein production|O were|O not|O observed|O in|O nine|O other|O cell|O lines|O .|O 
I-131|O metaiodobenzylguanidine|O :|O diagnostic|O use|O in|O neuroblastoma|O patients|O in|O relapse|O .|O 
Metaiodobenzylguanidine|O (|O MIBG|O )|O has|O been|O used|O for|O the|O detection|O and|O treatment|O of|O neuroectodermal|O tumors|O ,|O including|O neuroblastoma|O .|O 
We|O report|O our|O experience|O with|O 131I-MIBG|O used|O diagnostically|O in|O neuroblastoma|O patients|O with|O relapse|O .|O 
Thirty-eight|O studies|O were|O performed|O in|O 26|O patients|O .|O 
There|O were|O 24|O children|O (|O range|O 3|O months|O -|O 14|O years|O )|O and|O two|O adults|O .|O 
While|O the|O study|O was|O found|O to|O be|O both|O sensitive|O and|O specific|O for|O the|O presence|O of|O disease|O ,|O there|O are|O instances|O of|O discordance|O .|O 
False|O -|O negative|O studies|O were|O found|O with|O a|O markedly|O anaplastic|O tumor|O and|O with|O two|O mature|O ganglioneuromas|O .|O 
A|O bone|O lesion|O was|O negative|O with|O 131I-MIBG|O ,|O but|O positive|O on|O bone|O scan|O .|O 
A|O biopsy|O confirmed|O the|O presence|O of|O neuroblastoma|O .|O 
Caution|O should|O be|O exercised|O when|O scanning|O pretreated|O patients|O ,|O and|O perhaps|O with|O newly|O diagnosed|O patients|O as|O well|O .|O 
A|O housekeeping|O type|O promoter|O ,|O located|O in|O the|O 3|O '|O region|O of|O the|O Duchenne|gene-rna muscular|gene-rna dystrophy|gene-rna gene|O ,|O controls|O the|O expression|O of|O Dp71|gene-protein ,|O a|O major|O product|O of|O the|gene-rna gene|gene-rna .|O 
The|O 70.8|O kDa|O protein|O product|O of|O the|O distal|O part|O of|O the|O giant|O Duchenne|gene-rna muscular|gene-rna dystrophy|gene-rna (|O DMD|gene-rna )|O gene|O ,|O Dp71|gene-protein ,|O is|O expressed|O in|O many|O cell|O types|O and|O tissues|O .|O 
Anchored|O PCR|O ,|O primer|O extension|O and|O functional|O analysis|O of|O transfected|O constructs|O were|O used|O to|O determine|O the|O 5|O '|O end|O of|O the|O mRNA|O and|O characterize|O the|O promoter|O of|O this|O major|O DMD|gene-rna gene|gene-protein product|gene-protein .|O 
The|O 5|O '|O untranslated|O region|O (|O 5'UTR|O )|O of|O Dp71|gene-protein is|O transcribed|O from|O a|O single|O exon|O ;|O the|O promoter|O does|O not|O contain|O a|O TATA|O box|O ,|O and|O has|O a|O very|O high|O GC|O content|O and|O several|O potential|O Sp1|O binding|O sites|O .|O 
It|O is|O located|O more|O than|O 2000|O kb|O 3|O '|O to|O the|O muscle|O and|O brain|O type|O dystrophin|O promoters|O and|O only|O 150|O kb|O from|O the|O 3|O '|O end|O of|O the|gene-rna gene|gene-rna ,|O suggesting|O that|O in|O most|O DMD|gene-rna patients|O the|O expression|O of|O Dp71|gene-protein is|O unaffected|O .|O 
The|O renin|gene-rna -|O angiotensin|gene-rna system|O in|O hybrid|O NG108-15|O cells|O .|O 
Renin|gene-rna gene|O is|O from|O mouse|O neuroblastoma|O ,|O angiotensinogen|gene-rna and|O angiotensin|gene-rna -|gene-rna converting|gene-rna enzyme|gene-rna genes|O are|O of|O rat|O glioma|O origin|O .|O 
Angiotensin|gene-protein II|gene-protein (|O Ang|gene-protein II|gene-protein )|O increases|O the|O level|O of|O tyrosine|gene-protein phosphorylation|O of|O several|O proteins|O in|O nondifferentiated|O NG108-15|O cells|O ,|O a|O hybrid|O derived|O from|O the|O fusion|O of|O mouse|O neuroblastoma|O and|O rat|O glioma|O cells|O .|O 
Conversely|O ,|O incubation|O of|O NG108-15|O cells|O with|O an|O angiotensin|gene-protein -|gene-protein converting|gene-protein enzyme|gene-protein (|O ACE|gene-protein )|O inhibitor|O decreased|O the|O basal|O level|O of|O tyrosine|gene-protein phosphorylation|O of|O proteins|O ,|O suggesting|O that|O locally|O secreted|O Ang|gene-protein II|gene-protein may|O act|O as|O an|O autocrine|O regulator|O .|O 
By|O RT|O -|O PCR|O ,|O we|O found|O that|O nondifferentiated|O NG108-15|O cells|O contained|O the|O mRNA|O transcript|O of|O the|O rat|O angiotensinogen|gene-rna ,|O mouse|O renin|gene-rna and|O rat|O ACE|gene-rna genes|O ,|O thus|O confirming|O that|O NG108-15|O cells|O contain|O all|O the|O elements|O of|O a|O local|O renin|gene-protein -|O angiotensin|gene-protein system|O .|O 
PKR|gene-protein is|O not|O required|O for|O interferon-gamma|gene-protein inhibition|O of|O VSV|gene-rna replication|O in|O neurons|O .|O 
In|O this|O report|O ,|O the|O contribution|O of|O PKR|gene-protein to|O the|O IFN-gamma|gene-protein mediated|O inhibition|O of|O VSV|gene-rna replication|O in|O neurons|O was|O examined|O .|O 
IFN-gamma|gene-protein treatment|O of|O NB41A3|O murine|O neuroblastoma|O cells|O resulted|O in|O the|O reduced|O expression|O of|O VSV|gene-protein protein|O during|O infection|O .|O 
PKR|gene-protein was|O found|O to|O be|O modestly|O upregulated|O in|O NB41A3|O cells|O following|O IFN-gamma|gene-protein treatment|O .|O 
The|O phosphorylation|O state|O of|O PKR|gene-protein and|O its|O downstream|O target|O ,|O eIF2alpha|gene-protein ,|O were|O unaffected|O by|O either|O IFN-gamma|gene-protein or|O VSV|gene-protein infection|O .|O 
Inhibition|O of|O PKR|gene-protein through|O the|O use|O of|O 2-aminopurine|O or|O the|O expression|O of|O the|O Influenza|gene-rna A|gene-rna NS1|gene-rna gene|O had|O no|O effect|O on|O the|O ability|O of|O IFN-gamma|gene-protein to|O inhibit|O the|O replication|O of|O VSV|gene-rna in|O vitro|O .|O 
These|O data|O indicate|O that|O endogenously|O expressed|O PKR|gene-protein is|O not|O required|O for|O the|O IFN-gamma|gene-protein mediated|O inhibition|O of|O VSV|gene-rna replication|O in|O NB41A3|O neuroblastoma|O cells|O .|O 
Constitutional|O 1p36|O deletion|O in|O a|O child|O with|O neuroblastoma|O .|O 
We|O describe|O a|O child|O with|O dysmorphic|O features|O ,|O as|O well|O as|O developmental|O and|O growth|O delay|O ,|O who|O developed|O neuroblastoma|O at|O 5|O mo|O of|O age|O .|O 
Cytogenetic|O analysis|O of|O blood|O lymphocytes|O revealed|O an|O interstitial|O deletion|O of|O 1p36.1|O -->|O 1p36.2|O ,|O which|O was|O apparent|O only|O with|O high|O -|O resolution|O banding|O .|O 
Molecular|O analysis|O with|O a|O collection|O of|O polymorphic|O DNA|O probes|O for|O 1p|O confirmed|O an|O interstitial|O deletion|O involving|O subbands|O of|O 1p36|O .|O 
Deletions|O of|O this|O region|O are|O a|O common|O finding|O in|O neuroblastoma|O cells|O from|O patients|O with|O advanced|O stages|O of|O disease|O .|O 
Therefore|O ,|O these|O results|O (a)|O suggest|O that|O constitutional|O deletion|O of|O this|O region|O predisposed|O the|O patient|O to|O the|O development|O of|O neuroblastoma|O and|O (b)|O support|O the|O localization|O of|O a|O neuroblastoma|O tumor|O -|O suppressor|O locus|O to|O 1p36|O .|O 
Comparison|O of|O fast|O responses|O to|O serotonin|O and|O 2-methyl-serotonin|O in|O voltage|O -|O clamped|O N1E-115|O neuroblastoma|O cells|O .|O 
The|O activation|O of|O 5-HT3|O receptors|O by|O 5-HT|O and|O 2-methyl-5-HT|O was|O studied|O with|O '|O concentration|O -|O jump|O '|O techniques|O in|O voltage|O -|O clamped|O N1E-115|O cells|O grown|O in|O culture|O .|O 
When|O applied|O to|O single|O cells|O with|O a|O fast|O perfusion|O technique|O ,|O both|O agonists|O induced|O currents|O the|O on|O -|O rate|O kinetics|O of|O which|O were|O concentration|O -|O dependent|O .|O 
Based|O on|O the|O time|O constants|O of|O current|O kinetics|O and|O subsequent|O estimates|O of|O agonist|O association|O and|O dissociation|O rates|O ,|O an|O apparent|O Kd|O of|O 1.3|O microM|O was|O determined|O for|O 5-HT|O ,|O a|O value|O in|O agreement|O with|O binding|O and|O functional|O studies|O .|O 
Receptor|O activation|O by|O 2-methyl-5-HT|O was|O slower|O ,|O consistent|O with|O its|O lower|O potency|O as|O compared|O to|O the|O parent|O compound|O .|O 
In|O addition|O ,|O the|O rise|O time|O of|O 2-methyl-5-HT|O -|O mediated|O currents|O was|O affected|O by|O hyperpolarizing|O membrane|O potential|O .|O 
The|O results|O show|O evidence|O of|O different|O molecular|O behaviors|O for|O the|O two|O agonists|O .|O 
Partial|O reversion|O of|O transformed|O phenotype|O of|O B104|O cancer|O cells|O by|O antisense|O nucleic|O acids|O .|O 
We|O used|O antisense|O RNA|O to|O inhibit|O the|O expression|O of|O oncogene|O neu|gene-rna and|O investigated|O the|O effects|O of|O diminished|O neu|gene-rna expression|O on|O the|O phenotypes|O of|O B104|O cells|O containing|O activated|O oncogene|O neu|gene-rna .|O 
Antisense|O MT-neu|gene-rna and|O pSV-neo|gene-rna plasmids|O were|O cotransfected|O into|O neuroblastoma|O B104|O cells|O .|O 
Southern|O analysis|O showed|O the|O integration|O of|O anti|gene-rna -|gene-rna neu|gene-rna DNA|O into|O B104|O cells|O .|O 
The|O expression|O of|O neu|gene-rna was|O inhibited|O up|O to|O 90|O %|O as|O quantitated|O by|O immunoprecipitation|O .|O 
The|O growth|O rate|O and|O the|O potential|O to|O differentiate|O in|O these|O transfectants|O were|O not|O affected|O as|O compared|O to|O the|O parental|O cell|O lines|O .|O 
The|O ability|O to|O grow|O in|O soft|O agar|O was|O inhibited|O more|O than|O 90|O %|O in|O these|O transfectants|O .|O 
Our|O results|O indicated|O that|O antisense|O -|O RNA|O against|O a|O specific|O oncogene|O can|O decrease|O the|O tumorigenicity|O of|O tumor|O cells|O but|O may|O not|O be|O able|O to|O revert|O it|O to|O normal|O cells|O completely|O .|O 
IGF2|gene-rna but|O not|O H19|gene-rna shows|O loss|O of|O imprinting|O in|O human|O glioma|O .|O 
Genomic|O imprinting|O is|O a|O gamete|O -|O specific|O modification|O resulting|O in|O the|O allele|O -|O specific|O expression|O of|O genes|O in|O somatic|O cells|O .|O 
A|O loss|O of|O imprinting|O (|O LOI|O )|O has|O been|O found|O in|O many|O embryonal|O and|O adult|O tumors|O ,|O suggesting|O that|O it|O plays|O a|O role|O in|O tumor|O development|O .|O 
The|O incidence|O of|O LOI|O ,|O however|O ,|O does|O not|O seem|O to|O be|O ubiquitous|O among|O tumors|O because|O neuroblastoma|O and|O colorectal|O cancer|O revealed|O no|O LOI|O .|O 
We|O examined|O the|O involvement|O of|O LOI|O of|O IGF2|gene-rna and|O H19|gene-rna genes|O in|O human|O gliomas|O .|O 
The|O two|gene-rna genes|gene-rna were|O imprinted|O in|O normal|O brain|O subcortex|O tissues|O .|O 
In|O glioma|O ,|O 8|O of|O 14|O informative|O cases|O (|O 57|O %|O )|O revealed|O LOI|O in|O IGF2|gene-rna .|O 
The|O frequency|O did|O not|O depend|O on|O the|O tumor|O grade|O .|O 
For|O H19|gene-rna ,|O in|O contrast|O ,|O all|O 13|O informative|O cases|O maintained|O imprinting|O .|O 
These|O results|O suggest|O that|O LOI|O of|O IGF2|gene-rna but|O not|O H19|gene-rna plays|O a|O role|O in|O the|O development|O of|O human|O glioma|O .|O 
Calcium|O buffering|O capacity|O of|O neuronal|O cell|O cytosol|O measured|O by|O flash|O photolysis|O of|O calcium|O buffer|O NP-EGTA|O .|O 
N1E-115|O mouse|O neuroblastoma|O cells|O were|O injected|O with|O a|O calcium|O buffer|O /|O indicator|O solution|O to|O allow|O both|O ratiometric|O measurement|O of|O free|O calcium|O concentration|O and|O the|O release|O of|O calcium|O ions|O upon|O UV|O flash|O .|O 
The|O solution|O contained|O sulforhodamine|O ,|O a|O marker|O dye|O used|O to|O estimate|O the|O volume|O injected|O ;|O fluo-3|O ,|O a|O calcium|O indicator|O ,|O and|O NP-EGTA|O ,|O a|O high|O affinity|O calcium|O -|O selective|O buffer|O that|O is|O converted|O by|O UV|O flash|O to|O products|O with|O negligible|O calcium|O affinity|O .|O 
The|O calcium|O increase|O recorded|O upon|O UV|O irradiation|O (|O Delta[Ca2+]i|O )|O was|O small|O for|O small|O injection|O volumes|O ,|O increased|O with|O larger|O injection|O volumes|O ,|O but|O approached|O a|O plateau|O at|O the|O largest|O injection|O volumes|O .|O 
From|O this|O relation|O we|O estimate|O the|O buffering|O capacity|O of|O the|O cytosol|O as|O 1700|O ions|O bound|O per|O ion|O free|O .|O 
DAP-5|gene-protein is|O involved|O in|O MycN|gene-protein /|O IFNgamma|gene-protein -|O induced|O apoptosis|O in|O human|O neuroblastoma|O cells|O .|O 
Death|gene-protein associated|gene-protein protein-5|gene-protein (|O DAP-5|gene-protein )|O is|O a|O ubiquitously|O expressed|O member|O of|O the|O translation|gene-protein initiation|gene-protein factor|gene-protein eIF4G|gene-protein family|O that|O lacks|O the|O eIF4E|gene-protein binding|O site|O .|O 
A|O dominant|O negative|O fragment|O of|O DAP-5|gene-protein protects|O HeLa|O cells|O from|O IFNgamma|gene-protein -|O induced|O cell|O death|O .|O 
By|O employing|O a|O functional|O approach|O we|O examined|O the|O role|O of|O DAP-5|gene-protein in|O human|O neuroblastoma|O cells|O that|O are|O sensitized|O for|O IFNgamma|gene-protein -|O induced|O apoptosis|O by|O tetracycline|O controlled|O MYCN|gene-generic expression|O .|O 
DAP-5|gene-protein fragment|O transcribed|O at|O high|O levels|O and|O translated|O into|O a|O functional|O miniprotein|O of|O 28|O kDa|O protected|O neuroblastoma|O cells|O from|O IFNgamma|gene-protein -|O induced|O apoptosis|O .|O 
Reduced|O serum|O levels|O were|O toxic|O to|O cells|O constitutively|O expressing|O DAP-5|gene-protein fragment|O suggesting|O that|O DAP-5|gene-protein protein|O is|O essential|O for|O both|O viability|O and|O death|O of|O human|O neuroblastoma|O cells|O .|O 
Immunoreactive|O thymopoietin|gene-protein in|O the|O mouse|O central|O nervous|O system|O .|O 
A|O thymopoietin|gene-protein -|O immunoreactive|O substance|O (|O TP|O -|O IRS|O )|O has|O been|O detected|O in|O homogenates|O of|O mouse|O spinal|O cord|O and|O brain|O using|O a|O radioimmunoassay|O ;|O levels|O were|O maximal|O at|O birth|O .|O 
TP|O -|O IRS|O was|O also|O detected|O in|O supernatants|O of|O mouse|O neuroblastoma|O (|O NIE-115|O )|O and|O primary|O spinal|O cord|O cultures|O but|O not|O human|O astrocytic|O and|O meningeal|O tumors|O or|O mouse|O primary|O astrocyte|O cultures|O .|O 
With|O affinity|O purified|O rabbit|O anti|gene-protein -|gene-protein TP|gene-protein globulin|gene-protein ,|O immunofluorescent|O staining|O was|O seen|O in|O mouse|O spinal|O cord|O cultures|O in|O association|O with|O nuclear|O membranes|O of|O neurons|O and|O ,|O to|O a|O lesser|O degree|O ,|O flat|O background|O cells|O .|O 
From|O supernatants|O of|O NIE-115|O cells|O grown|O in|O tritiated|O leucine|O and|O lysine|O ,|O proteins|O of|O approximately|O 8000|O and|O 4500|O Da|O were|O isolated|O by|O TP|O affinity|O chromatography|O (|O compared|O with|O 5562|O Da|O for|O thymic|gene-protein thymopoietin|gene-protein )|O .|O 
When|O injected|O into|O mice|O ,|O these|O neural|gene-protein proteins|gene-protein partially|O blocked|O neuromuscular|O transmission|O in|O a|O manner|O similar|O to|O thymic|gene-protein thymopoietin|gene-protein .|O 
Human|O ribosomal|gene-protein protein|gene-protein L37a|gene-protein :|O cloning|O of|O the|O cDNA|O and|O analysis|O of|O differential|O gene|O expression|O in|O tissues|O and|O cell|O lines|O .|O 
A|O cDNA|O corresponding|O to|O human|O ribosomal|gene-protein protein|gene-protein L37a|gene-protein (|O hL37a|gene-protein )|O was|O obtained|O by|O screening|O a|O SHSY5Y|O neuroblastoma|O library|O .|O 
The|O full|O -|O length|O cDNA|O contained|O 366|O nucleotides|O (|O nt|O )|O in|O addition|O to|O a|O poly(A)|O tail|O .|O 
The|O pyrimidine|O -|O rich|O sequence|O ,|O CTTTCT|O ,|O that|O is|O common|O to|O many|O ribosomal|O protein|O -|O encoding|O cDNAs|O was|O present|O at|O the|O 5|O '|O terminus|O .|O 
The|O nt|O sequence|O displayed|O 85|O %|O identity|O with|O rat|O L37a|gene-rna (|O rL37a|gene-rna )|O cDNA|O .|O 
The|O predicted|O protein|O contains|O 92|O amino|O acids|O with|O a|O M(r)|O of|O 10,277|O ,|O is|O highly|O basic|O ,|O and|O has|O 100|O %|O sequence|O identity|O with|O rL37a|gene-protein .|O 
A|O putative|O zinc|O -|O finger|O domain|O is|O present|O in|O the|O central|O region|O of|O the|O protein|O .|O 
Human|O lymphocytes|O and|O several|O human|O cell|O lines|O express|O hL37a|gene-rna mRNA|O at|O significantly|O higher|O levels|O than|O the|O rat|O cell|O lines|O and|O rat|O tissues|O tested|O .|O 
The|O hL37a|gene-rna gene|O does|O not|O contain|O introns|O .|O 
Regulation|O of|O retinoic|gene-protein acid|gene-protein receptor|gene-protein alpha|gene-protein expression|O in|O human|O neuroblastoma|O cell|O lines|O and|O tumor|O tissue|O .|O 
Human|O neuroblastoma|O (|O NB|O )|O cell|O lines|O treated|O with|O all|O -|O trans|O retinoic|O acid|O (|O RA|O )|O differentiate|O in|O culture|O ,|O forming|O neurites|O and|O exhibiting|O growth|O arrest|O .|O 
We|O treated|O 5|O human|O NB|O cell|O lines|O with|O RA|O ,|O and|O observed|O a|O 2|O -|O 5|O fold|O induction|O of|O retinoic|gene-rna acid|gene-rna receptor|gene-rna alpha|gene-rna (|O RAR|gene-rna alpha|gene-rna )|O mRNA|O expression|O in|O 4|O of|O the|O 5|O cell|O lines|O ,|O as|O an|O early|O cellular|O response|O .|O 
Induction|O of|O RAR|gene-generic alpha|gene-generic expression|O was|O specific|O for|O RA|O among|O several|O differentiating|O agents|O tested|O .|O 
RAR|gene-rna alpha|gene-rna mRNA|O expression|O in|O 13|O primary|O neuroblastoma|O tumor|O samples|O was|O 3|O fold|O higher|O in|O localised|O compared|O with|O advanced|O tumors|O (|O p|O <|O 0.05|O )|O .|O 
RAR|gene-generic alpha|gene-generic expression|O may|O be|O necessary|O for|O the|O effects|O of|O RA|O on|O NB|O cells|O in|O vitro|O and|O reduced|O expression|O of|O this|O gene|O in|O vivo|O may|O contribute|O to|O the|O process|O of|O NB|O tumorigenesis|O .|O 
Differentiation|O of|O neuroblastoma|O cells|O correlates|O with|O an|O altered|O splicing|O pattern|O of|O tau|gene-rna RNA|O .|O 
Morphological|O differentiation|O of|O N2A|O neuroblastoma|O cells|O is|O associated|O with|O an|O altered|O splicing|O of|O the|O gene|O of|O the|O microtubule|gene-protein -|gene-protein associated|gene-protein protein|gene-protein ,|O tau|gene-protein .|O 
Two|O populations|O of|O RNA|O (|O coding|O for|O tau|gene-protein proteins|O containing|O three|O or|O four|O tubulin|gene-protein -|O binding|O motifs|O )|O are|O present|O in|O a|O similar|O proportion|O in|O undifferentiated|O neuroblastoma|O cells|O while|O in|O differentiated|O cells|O the|O proportion|O is|O changed|O in|O favour|O of|O that|O population|O coding|O for|O tau|gene-protein protein|O containing|O four|O tubulin|gene-protein -|O binding|O motifs|O .|O 
An|O increase|O in|O a|O high|O molecular|O weight|O tau|gene-protein isoforms|gene-protein correlates|O with|O the|O increase|O in|O the|O RNA|O population|O coding|O for|O four|O tubulin|gene-protein -|O binding|O motifs|O .|O 
A|O possible|O consequence|O of|O expressing|O a|O higher|O proportion|O of|O the|O tau|gene-protein protein|O containing|O four|O tubulin|gene-protein -|O binding|O motifs|O could|O be|O an|O increase|O in|O microtubule|O stability|O of|O differentiated|O neuroblastoma|O cells|O .|O 
[|O Study|O Progress|O of|O p73|gene-rna Gene|O in|O Digestive|O System|O Carcinoma|O ]|O 
p73|gene-rna gene|O is|O a|O new|O member|O of|O the|O tumor|O suppressor|O gene|O p53|gene-rna family|O .|O 
They|O are|O similar|O in|O the|O structure|O and|O function|O of|O the|O coding|O protein|O ,|O but|O they|O also|O have|O notable|O distinctions|O in|O other|O aspects|O .|O 
Many|O studies|O have|O shown|O that|O the|O abnormal|O p73|gene-rna gene|O is|O associated|O with|O neuroblastoma|O ,|O malignant|O melanoma|O ,|O prostatic|O carcinoma|O ,|O and|O lung|O cancer|O ,|O et|O al|O .|O 
Recently|O ,|O many|O studies|O have|O demonstrated|O that|O p73|gene-rna gene|O may|O involve|O the|O occurrence|O and|O development|O of|O a|O portion|O of|O the|O digestive|O system|O carcinoma|O .|O 
This|O review|O summarized|O the|O present|O conditions|O of|O the|O p73|gene-rna gene|O and|O its|O correlation|O with|O the|O occurrence|O ,|O development|O ,|O prognosis|O ,|O and|O expression|O in|O the|O digestive|O system|O carcinoma|O .|O 
We|O suggested|O that|O the|O further|O study|O about|O the|O p73|gene-rna gene|O may|O be|O helpful|O to|O recognize|O the|O nature|O of|O the|O carcinoma|O and|O bring|O wish|O to|O overcome|O it|O finally|O .|O 
Isolation|O and|O purification|O of|O an|O epidermal|gene-protein growth|gene-protein factor|gene-protein receptor|gene-protein -|O related|O inhibitor|O of|O cell|O growth|O from|O cultured|O rat|O astrocytes|O .|O 
Astrocytes|O rarely|O undergo|O mitotic|O cell|O division|O in|O the|O developed|O adult|O .|O 
However|O ,|O following|O injury|O to|O the|O central|O nervous|O system|O (|O CNS|O )|O ,|O astrocytes|O undergo|O rapid|O cell|O division|O and|O reactive|O astrocytes|O encapsulate|O exposed|O areas|O of|O the|O CNS|O producing|O a|O glial|O scar|O .|O 
Studies|O indicate|O the|O existence|O of|O a|O family|O of|O epidermal|gene-protein growth|gene-protein factor|gene-protein receptor|gene-protein (|O EGFr|gene-protein )|O related|O glycosidic|O mitogen|O inhibitors|O with|O growth|O inhibiting|O properties|O for|O astrocytes|O .|O 
Here|O ,|O for|O the|O first|O time|O ,|O we|O describe|O the|O isolation|O of|O such|O a|O factor|O from|O cultured|O rat|O astrocytes|O by|O ion|O -|O exchange|O and|O immunoaffinity|O chromatography|O .|O 
The|O isolated|O factor|O is|O glycosidic|O in|O nature|O ,|O cross|O reacts|O with|O the|O anti|gene-protein -|gene-protein EGFr|gene-protein monoclonal|gene-protein antibody|gene-protein Clone|gene-protein 29.1|gene-protein ,|O and|O inhibits|O the|O growth|O of|O primary|O astrocytes|O and|O N2a|O neuroblastoma|O cells|O in|O vitro|O .|O 
S100|gene-protein beta|gene-protein stimulates|O calcium|O fluxes|O in|O glial|O and|O neuronal|O cells|O .|O 
The|O glial|O -|O derived|O protein|O S100|gene-protein beta|gene-protein can|O act|O as|O a|O mitogen|O or|O a|O neurotrophic|gene-protein factor|gene-protein ,|O stimulating|O proliferation|O of|O glial|O cells|O or|O differentiation|O of|O immature|O neurons|O .|O 
We|O report|O here|O that|O dimeric|O S100|gene-protein beta|gene-protein evokes|O increases|O in|O intracellular|O free|O calcium|O concentrations|O (|O [Ca2+]i|O )|O in|O both|O glial|O cells|O and|O neuronal|O cells|O .|O 
The|O [Ca2+]i|O increase|O exhibited|O a|O rapid|O transient|O component|O which|O was|O not|O affected|O by|O removal|O of|O extracellular|O calcium|O and|O a|O sustained|O component|O which|O appeared|O to|O require|O influx|O of|O extracellular|O calcium|O through|O Ni(2+)|O -|O sensitive|O channels|O .|O 
S100|gene-protein beta|gene-protein also|O stimulated|O hydrolysis|O of|O phosphoinositides|O ,|O suggesting|O a|O mobilization|O of|O calcium|O from|O intracellular|O stores|O .|O 
These|O data|O suggest|O that|O although|O the|O final|O biological|O responses|O of|O neuronal|O and|O glial|O cells|O to|O S100|gene-protein beta|gene-protein are|O different|O ,|O transduction|O of|O the|O S100|gene-protein beta|gene-protein signal|O in|O both|O cell|O types|O involves|O changes|O in|O [Ca2+]i|O .|O 
Anti|gene-protein -|gene-protein neurofilament|gene-protein protein|gene-protein antibodies|gene-protein in|O opsoclonus|O -|O myoclonus|O .|O 
Opsoclonus|O -|O myoclonus|O (|O OM|O )|O is|O a|O neurological|O disorder|O usually|O occurring|O in|O infancy|O ,|O clinically|O manifested|O by|O various|O involuntary|O movements|O .|O 
The|O pathogenesis|O of|O OM|O is|O unknown|O ,|O but|O since|O the|O disease|O often|O is|O associated|O with|O viral|O infection|O or|O with|O neuroblastoma|O ,|O an|O immunologic|O basis|O for|O OM|O has|O been|O postulated|O .|O 
We|O have|O studied|O two|O children|O with|O OM|O whose|O serum|O contained|O antibodies|gene-protein directed|O against|O the|O 210|gene-protein kDa|gene-protein neurofilament|gene-protein protein|gene-protein ;|O these|O antibodies|gene-protein were|O not|O seen|O in|O the|O serum|O of|O 21|O children|O with|O other|O neurological|O disorders|O .|O 
Neurofilament|gene-protein proteins|gene-protein ,|O which|O are|O found|O only|O in|O neurons|O ,|O may|O be|O of|O prime|O importance|O in|O neuronal|O function|O ,|O especially|O during|O development|O of|O the|O nervous|O system|O .|O 
Our|O findings|O suggest|O that|O generation|O of|O antibodies|gene-protein to|O the|O neurofilament|gene-protein proteins|gene-protein can|O occur|O in|O patients|O with|O opsoclonus|O -|O myoclonus|O ;|O the|O role|O of|O the|O anti|gene-protein -|gene-protein NF210K|gene-protein antibodies|gene-protein in|O the|O pathogenesis|O of|O OM|O ,|O however|O ,|O is|O uncertain|O .|O 
Nerve|gene-protein growth|gene-protein factor|gene-protein -|O induced|O differentiation|O in|O neuroblastoma|O cells|O expressing|O TrkA|gene-protein but|O lacking|O p75NGFR|gene-protein .|O 
Nerve|gene-protein growth|gene-protein factor|gene-protein (|O NGF|gene-protein )|O binds|O to|O two|O distinct|O cell|O surface|O receptors|O ,|O TrkA|gene-protein ,|O which|O is|O a|O receptor|gene-protein tyrosine|gene-protein kinase|gene-protein ,|O and|O p75NGFR|gene-protein ,|O whose|O role|O in|O NGF|gene-protein -|O induced|O signal|O transduction|O remains|O unclear|O .|O 
We|O have|O found|O that|O human|O neuroblastoma|O IMR-32|O cells|O express|O TrkA|gene-protein ,|O but|O p75NGFR|gene-protein expression|O was|O not|O detectable|O in|O these|O cells|O by|O northern|O blot|O analysis|O ,|O immunoblotting|O ,|O or|O chemical|O crosslinking|O experiments|O .|O 
Despite|O the|O lack|O of|O p75NGFR|gene-protein expression|O ,|O subnanomolar|O concentrations|O of|O recombinant|O human|O NGF|gene-protein induced|O neurite|O outgrowth|O ,|O tyrosine|O phosphorylation|O ,|O and|O immediate|O early|O gene|O expression|O in|O these|O cells|O .|O 
These|O results|O strongly|O suggest|O that|O NGF|gene-protein -|O induced|O neuronal|O differentiation|O in|O IMR-32|O cells|O is|O initiated|O through|O TrkA|gene-protein in|O the|O absence|O of|O p75NGFR|gene-protein .|O 
Thus|O ,|O IMR-32|O cells|O may|O provide|O a|O model|O for|O studying|O neurotrophic|O effects|O of|O NGF|gene-protein on|O adult|O striatal|O cholinergic|O neurons|O ,|O which|O also|O lack|O p75NGFR|gene-protein expression|O .|O 
Characterization|O of|O 5|O '|O flanking|O region|O of|O alpha|O isoform|O of|O rat|O Ca2+|gene-rna /|gene-rna calmodulin|gene-rna -|gene-rna dependent|gene-rna protein|gene-rna kinase|gene-rna II|gene-rna gene|O and|O neuronal|O cell|O type|O specific|O promoter|O activity|O .|O 
The|O 5|O '|O flanking|O region|O of|O the|O alpha|O isoform|O of|O the|O rat|O Ca2+|gene-rna /|gene-rna calmodulin|gene-rna -|gene-rna dependent|gene-rna protein|gene-rna kinase|gene-rna II|gene-rna (|O alpha|gene-rna CaM|gene-rna kinase|gene-rna II|gene-rna )|O gene|O was|O isolated|O in|O 2.3|O kbp|O of|O genomic|O sequence|O .|O 
Functional|O analysis|O of|O alpha|gene-rna CaM|gene-rna kinase|gene-rna II|gene-rna promoter|O deletion|O mutants|O fused|O to|O a|O reporter|O gene|O in|O neuroblastoma|O ,|O including|O N18TG2|O ,|O NG108-15|O ,|O and|O CAD|O cells|O revealed|O strong|O transcriptional|O activity|O localized|O 100|O -|O 145|O bp|O ,|O and|O a|O potent|O silencer|O 199|O -|O 275|O bp|O upstream|O of|O the|O transcription|O start|O site|O .|O 
The|O promoter|O is|O inactive|O in|O non|O -|O neuronal|O cells|O including|O BALB|O /|O c|O 3T3|O ,|O Chinese|O hamster|O ovary|O ,|O HT1080|O ,|O and|O C6|O glioma|O cells|O .|O 
These|O results|O indicated|O that|O the|O alpha|gene-rna CaM|gene-rna kinase|gene-rna II|gene-rna gene|O is|O transcribed|O from|O a|O tissue|O -|O specific|O promoter|O which|O is|O under|O intense|O negative|O control|O .|O 
Parkin|gene-protein is|O metabolized|O by|O the|O ubiquitin|gene-protein /|O proteosome|gene-protein system|O .|O 
Mutations|O in|O the|O parkin|gene-rna gene|O cause|O autosomal|O recessive|O juvenile|O parkinsonism|O .|O 
Immunostaining|O of|O substantia|O nigra|O sections|O from|O sporadic|O Parkinson|O 's|O disease|O (|O PD|O )|O cases|O shows|O that|O Parkin|O accumulates|O in|O axonal|O spheroids|O and|O in|O some|O Lewy|O bodies|O .|O 
Because|O ubiquitin|gene-protein is|O a|O major|O component|O of|O Lewy|O bodies|O and|O axonal|O spheroids|O ,|O we|O investigated|O whether|O Parkin|gene-protein is|O metabolized|O via|O the|O ubiquitin|gene-protein /|O proteosomal|O pathway|O .|O 
Treatment|O of|O BE-M17|O neuroblastoma|O cells|O with|O the|O proteosomal|O inhibitor|O ,|O MG132|O ,|O produced|O a|O band|O corresponding|O to|O di|O -|O ubiquitinated|O Parkin|gene-protein that|O was|O apparent|O by|O immunoblot|O using|O two|O different|O anti|gene-protein -|gene-protein Parkin|gene-protein antibodies|gene-protein .|O 
This|O higher|O mol.|O wt|O band|O also|O co|O -|O immunoprecipitated|O with|O Parkin|gene-protein .|O 
These|O data|O suggest|O that|O Parkin|gene-generic plays|O a|O role|O in|O the|O pathophysiology|O of|O sporadic|O PD|O ,|O and|O that|O Parkin|gene-protein is|O a|O substrate|O for|O ubiquitination|O that|O is|O degraded|O by|O the|O proteosomal|O complex|O .|O 
Anionic|O site|O interactions|O in|O human|O butyrylcholinesterase|gene-protein disrupted|O by|O two|O single|O point|O mutations|O .|O 
Structure|O -|O function|O relationships|O of|O recombinant|O human|O butyrylcholinesterase|gene-protein (|O CHE|gene-protein )|O variants|O were|O investigated|O by|O Xenopus|O oocyte|O microinjection|O .|O 
A|O Ser|O -|O 425|O to|O Pro|O -|O 425|O mutation|O failed|O to|O modify|O ligand|O binding|O properties|O .|O 
In|O contrast|O ,|O Asp|O -|O 70|O to|O Gly|O -|O 70|O substitution|O significantly|O reduced|O CHE|gene-protein binding|O capacity|O for|O succinylcholine|O and|O specific|O inhibitors|O ,|O demonstrating|O Asp|O -|O 70|O as|O a|O key|O anionic|O site|O component|O for|O certain|O ligands|O .|O 
Furthermore|O ,|O the|O presence|O of|O both|O mutations|O rendered|O CHE|gene-protein totally|O resistant|O to|O succinylcholine|O and|O dibucaine|O inhibition|O ,|O while|O all|O mutant|O proteins|O bound|O butyrylthiocholine|O ,|O benzoylcholine|O ,|O and|O propionylcholine|O normally|O .|O 
These|O findings|O imply|O structural|O interactions|O between|O the|O conserved|O Asp|O -|O 70|O and|O Ser|O -|O 425|O regions|O in|O cholinesterases|gene-protein and|O suggest|O the|O contribution|O of|O additional|O electronegative|O amino|O acids|O to|O anionic|O site|O binding|O .|O 
Significance|O of|O chromosome|O 1p|O loss|O of|O heterozygosity|O in|O neuroblastoma|O .|O 
We|O analyzed|O 156|O primary|O neuroblastoma|O tumor|O samples|O for|O loss|O of|O heterozygosity|O at|O the|O distal|O short|O arm|O of|O chromosome|O 1|O (|O 1p|O LOH|O )|O .|O 
We|O also|O compared|O 1p|O LOH|O with|O known|O clinical|O and|O genetic|O prognostic|O variables|O as|O well|O as|O patient|O outcome|O .|O 
1p|O LOH|O was|O detected|O in|O 30|O of|O 156|O tumors|O (|O 19|O %|O )|O and|O was|O strongly|O associated|O with|O adverse|O clinical|O and|O biological|O features|O .|O 
1p|O LOH|O was|O also|O strongly|O predictive|O of|O a|O poor|O outcome|O in|O univariate|O analyses|O (|O estimated|O 4|O -|O year|O survival|O ,|O 32|O +/-|O 10|O %|O SE|O versus|O 76|O +/-|O 5|O %|O SE|O ;|O P|O <|O 0.001|O )|O .|O 
However|O ,|O the|O prognostic|O value|O of|O 1p|O LOH|O was|O equivocal|O when|O stratified|O for|O amplification|O of|O the|O MYCN|gene-rna oncogene|O (|O P|O =|O 0.16|O )|O .|O 
We|O conclude|O that|O 1p|O LOH|O is|O an|O important|O component|O of|O a|O pattern|O of|O genetic|O abnormalities|O in|O neuroblastoma|O associated|O with|O an|O aggressive|O clinical|O course|O .|O 
Biological|O and|O clinical|O role|O of|O p73|gene-rna in|O neuroblastoma|O .|O 
The|O p73|gene-rna gene|O is|O a|O p53|gene-rna homologue|O localized|O at|O 1p36.3|O ,|O a|O chromosomal|O region|O frequently|O deleted|O in|O neuroblastoma|O .|O 
p73|gene-rna was|O originally|O considered|O an|O oncosuppressor|O gene|O .|O 
However|O ,|O it|O was|O soon|O realized|O that|O its|O mode|O of|O action|O did|O not|O resemble|O that|O of|O a|O classic|O anti|O -|O oncogene|O .|O 
The|O recent|O discovery|O of|O N|O -|O terminal|O truncated|O isoforms|O ,|O with|O oncogenic|O properties|O ,|O showed|O that|O p73|gene-rna has|O a|O '|O two|O in|O one|O '|O structure|O .|O 
Indeed|O ,|O the|O full|O -|O length|O variants|O are|O strong|O inducers|O of|O apoptosis|O while|O the|O truncated|O isoforms|O inhibit|O the|O pro|O -|O apoptotic|O activity|O of|O p53|gene-rna and|O of|O the|O full|O -|O length|O p73|gene-rna .|O 
This|O review|O summarizes|O some|O aspects|O of|O p73|gene-rna biology|O with|O particular|O reference|O to|O its|O possible|O role|O in|O neuroblastoma|O .|O 
Sequence|O and|O characterisation|O of|O the|O RET|gene-rna proto|O -|O oncogene|O 5|O '|O flanking|O region|O :|O analysis|O of|O retinoic|O acid|O responsiveness|O at|O the|O transcriptional|O level|O .|O 
The|O RET|gene-rna proto|O -|O oncogene|O encodes|O a|O receptor|gene-protein tyrosine|gene-protein kinase|gene-protein expressed|O during|O neural|O crest|O development|O .|O 
RET|gene-rna expression|O is|O enhanced|O in|O vitro|O by|O several|O differentiating|O agents|O ,|O including|O retinoic|O acid|O (|O RA|O )|O ,|O which|O up|O -|O regulates|O RET|gene-rna expression|O in|O neuroblastoma|O cell|O lines|O .|O 
In|O the|O present|O work|O we|O sequenced|O and|O analysed|O a|O 5|O kbp|O genomic|O fragment|O 5|O '|O to|O RET|gene-rna .|O 
Three|O deletion|O fragments|O of|O this|O region|O were|O tested|O for|O their|O RA|O inducibility|O in|O transient|O transfection|O assays|O and|O failed|O to|O support|O the|O hypothesis|O of|O a|O direct|O transcriptional|O activation|O .|O 
Finally|O ,|O our|O functional|O analysis|O of|O a|O candidate|O RA|O response|O element|O present|O in|O the|O RET|gene-rna promoter|O provides|O new|O hints|O for|O the|O understanding|O of|O the|O interaction|O between|O nuclear|O receptors|O and|O their|O specific|O recognition|O sites|O .|O 
Long|O term|O survival|O with|O early|O childhood|O intracerebral|O tumours|O .|O 
Three|O young|O adults|O are|O described|O who|O presented|O during|O early|O childhood|O with|O a|O seizure|O disorder|O due|O to|O an|O underlying|O intracerebral|O tumour|O .|O 
The|O tumours|O were|O excised|O incompletely|O 14|O -|O 19|O years|O later|O .|O 
The|O histological|O findings|O were|O those|O of|O a|O temporal|O lobe|O benign|O capillary|O haemangioblastoma|O (|O Case|O 1|O )|O ,|O parietal|O lobe|O subependymoma|O (|O Case|O 2|O )|O ,|O and|O parietal|O lobe|O ganglioglioma|O (|O Case|O 3|O )|O .|O 
After|O a|O mean|O period|O of|O follow|O -|O up|O of|O 22|O years|O (|O range|O 18|O -|O 26|O )|O ,|O only|O mild|O residual|O physical|O disabilities|O exist|O in|O each|O patient|O .|O 
These|O three|O cases|O illustrate|O (1)|O the|O need|O promptly|O to|O investigate|O children|O who|O present|O with|O focal|O seizures|O or|O whose|O EEG|O shows|O definite|O focal|O abnormalities|O ,|O (2)|O the|O relevant|O investigations|O should|O include|O cranial|O CT|O or|O MRI|O in|O such|O cases|O and|O (3)|O that|O certain|O supratentorial|O tumours|O have|O a|O favourable|O outcome|O due|O to|O their|O benign|O biological|O behaviour|O rather|O than|O their|O location|O .|O 
Distribution|O of|O disialoganglioside|gene-protein GD2|gene-protein -|gene-protein antigen|gene-protein and|O binding|O of|O anti|gene-protein -|gene-protein GD2|gene-protein antibodies|gene-protein on|O spheroids|O of|O neuroblastoma|O cell|O line|O .|O 
The|O ganglioside|O GD2|O is|O highly|O expressed|O on|O human|O tumors|O of|O neuroectodermal|O origin|O .|O 
We|O investigated|O by|O scanning|O electron|O microscopy|O the|O ganglioside|O GD2|O distribution|O on|O the|O surface|O of|O spheroids|O of|O the|O neuroblastoma|O cell|O line|O SK-N-LO|O .|O 
About|O 50|O %|O of|O cells|O showed|O GD2|O on|O the|O plasma|O membrane|O and|O the|O distribution|O of|O GD2|O on|O most|O of|O these|O cells|O was|O heterogeneous|O ,|O with|O more|O GD2|O at|O the|O contact|O sites|O of|O the|O cells|O .|O 
The|O binding|O kinetics|O of|O the|O chimeric|gene-protein anti|gene-protein -|gene-protein GD2|gene-protein antibody|gene-protein ch14.18|gene-protein labelled|O with|O I-125|O on|O spheroids|O (|O average|O diameter|O :|O 450|O microns|O )|O was|O determined|O by|O gamma|O counting|O .|O 
Over|O 4|O hours|O the|O antibody|O concentration|O was|O raised|O substantially|O but|O up|O to|O 24|O hours|O there|O was|O only|O a|O very|O slow|O further|O increase|O .|O 
A|O clustered|O pattern|O of|O bound|O chimeric|gene-protein anti|gene-protein -|gene-protein GD2|gene-protein antibody|gene-protein ch14.18|gene-protein was|O found|O on|O a|O cross|O -|O section|O of|O the|O spheroid|O by|O autoradiography|O .|O 
Melatonin|O regulation|O of|O antioxidant|gene-rna enzyme|gene-rna gene|O expression|O .|O 
Antioxidant|gene-protein enzymes|gene-protein (|O AOEs|gene-protein )|O are|O part|O of|O the|O primary|O cellular|O defense|O against|O free|O radicals|O induced|O by|O toxins|O and/or|O spontaneously|O formed|O in|O cells|O .|O 
Melatonin|O (|O MLT|O )|O has|O received|O much|O attention|O in|O recent|O years|O due|O to|O its|O direct|O free|O radical|O scavenging|O and|O antioxidant|O properties|O .|O 
In|O the|O present|O work|O we|O report|O that|O MLT|O ,|O at|O physiological|O serum|O concentrations|O (|O 1|O nM|O )|O ,|O increases|O the|O mRNA|O of|O both|O superoxide|gene-rna dismutases|gene-rna (|O SODs|gene-rna )|O and|O glutathione|gene-rna peroxidase|gene-rna (|O GPx|gene-rna )|O in|O two|O neuronal|O cell|O lines|O .|O 
The|O MLT|O effect|O on|O both|O SODs|gene-rna and|O GPx|gene-rna mRNA|O was|O mediated|O by|O a|O de|O novo|O synthesized|O protein|O .|O 
MLT|O alters|O mRNA|O stability|O for|O Cu-Zn|O SOD|gene-protein and|O GPx|gene-protein .|O 
Experiments|O with|O a|O short|O time|O treatment|O (|O pulse|O action|O )|O of|O MLT|O suggest|O that|O the|O regulation|O of|O AOE|gene-rna gene|O expression|O is|O likely|O to|O be|O receptor|O mediated|O ,|O because|O 1|O -|O h|O treatment|O with|O MLT|O results|O in|O the|O same|O response|O as|O a|O 24|O -|O h|O treatment|O .|O 
Expression|O of|O the|O ret|gene-rna proto|O -|O oncogene|O in|O human|O neuroblastoma|O cell|O lines|O and|O its|O increase|O during|O neuronal|O differentiation|O induced|O by|O retinoic|O acid|O .|O 
Previously|O we|O observed|O specific|O expression|O of|O the|O ret|gene-rna proto|O -|O oncogene|O (|O proto|gene-rna -|gene-rna ret|gene-rna )|O in|O human|O neuroblastoma|O cell|O lines|O .|O 
A|O neuronal|O subline|O and|O non|O -|O neuronal|O sublines|O were|O isolated|O from|O the|O SK-N-SH|O cell|O line|O ,|O which|O is|O composed|O of|O a|O heterogeneous|O cell|O population|O .|O 
Expression|O of|O proto|gene-rna -|gene-rna ret|gene-rna was|O detected|O in|O the|O neuronal|O subline|O ,|O named|O SH-4305|O ,|O but|O not|O in|O three|O non|O -|O neuronal|O sublines|O .|O 
Expression|O of|O proto|gene-rna -|gene-rna ret|gene-rna in|O the|O SH-4305|O cells|O increased|O markedly|O after|O treatment|O with|O retinoic|O acid|O for|O 1|O day|O ,|O with|O concomitant|O morphological|O change|O ,|O namely|O neurite|O outgrowth|O ,|O and|O induction|O of|O neurofilament|O mRNA|O expression|O .|O 
Induction|O of|O proto|gene-rna -|gene-rna ret|gene-rna expression|O seemed|O to|O be|O correlated|O with|O neurite|O outgrowth|O and|O increase|O of|O neurofilament|O mRNA|O expression|O .|O 
These|O data|O suggest|O that|O the|O proto|gene-rna -|gene-rna ret|gene-rna product|O plays|O a|O role|O in|O neuronal|O differentiation|O .|O 
A|O possible|O growth|O factor|O role|O of|O IL-6|gene-protein in|O neuroectodermal|O tumours|O .|O 
Preliminary|O data|O have|O shown|O that|O IL-6|gene-protein may|O act|O as|O an|O autocrine|O growth|O factor|O to|O control|O proliferation|O .|O 
We|O further|O characterised|O the|O role|O of|O IL-6|gene-protein in|O tumour|O growth|O as|O an|O autocrine|O /|O paracrine|O growth|O factor|O in|O neuroectodermal|O tumours|O .|O 
We|O evaluated|O the|O production|O and|O secretion|O of|O IL-6|gene-protein by|O seven|O human|O melanoma|O ,|O five|O neuroblastoma|O and|O one|O glioblastoma|O cell|O lines|O .|O 
Moreover|O ,|O we|O determined|O their|O IL-6|gene-protein -|O dependent|O growth|O in|O serum|O free|O -|O medium|O or|O under|O minimal|O growth|O -|O supplement|O conditions|O :|O IL-6|gene-protein dependent|O growth|O was|O observed|O in|O two|O non|O -|O IL-6|gene-protein producing|O melanoma|O and|O in|O one|O neuroblastoma|O cell|O lines|O .|O 
In|O addition|O ,|O expression|O of|O IL-6|gene-rna mRNA|O and|O peptide|O was|O increased|O by|O retinoic|O acid|O .|O 
The|O data|O support|O the|O hypothesis|O that|O IL-6|gene-protein contributes|O to|O neuroectodermal|O tumour|O growth|O ,|O even|O though|O it|O shows|O a|O less|O potent|O effect|O than|O other|O reported|O growth|O factor|O such|O as|O IGF-II|gene-protein .|O 
Response|O to|O nondepolarizing|O muscle|O relaxants|O in|O children|O with|O tumours|O .|O 
The|O rate|O of|O onset|O of|O action|O of|O d-tubocurarine|O (|O 64|O patients|O )|O or|O alcuronium|O (|O 36|O patients|O )|O was|O studied|O electromyographically|O in|O 100|O children|O who|O had|O abdominal|O ,|O bone|O or|O cerebral|O tumours|O .|O 
It|O was|O found|O that|O there|O was|O a|O significantly|O delayed|O onset|O (|O over|O three|O times|O longer|O than|O controls|O )|O or|O additional|O doses|O were|O required|O in|O patients|O with|O malignant|O liver|O ,|O renal|O and|O bone|O tumours|O who|O received|O d-tubocurarine|O .|O 
The|O onset|O of|O alcuronium|O blockade|O was|O also|O prolonged|O but|O to|O a|O lesser|O extent|O .|O 
When|O tumours|O with|O an|O abnormal|O prolongation|O of|O onset|O of|O relaxation|O were|O successfully|O treated|O by|O chemotherapy|O and/or|O surgery|O ,|O the|O response|O reverted|O to|O normal|O .|O 
Children|O with|O benign|O tumours|O or|O masses|O had|O normal|O responses|O .|O 
In|O contrast|O ,|O neuroblastomas|O were|O associated|O with|O little|O prolongation|O of|O onset|O .|O 
Cerebral|O tumours|O showed|O a|O variable|O response|O ,|O with|O the|O observed|O changes|O being|O unreliable|O indicators|O of|O degree|O of|O malignancy|O .|O 
Enhanced|O MYCN|gene-rna oncogene|O expression|O in|O human|O neuroblastoma|O cells|O is|O associated|O with|O altered|O FGF|gene-protein receptor|gene-protein expression|O and|O cellular|O growth|O response|O to|O basic|O FGF|gene-protein .|O 
We|O have|O examined|O the|O effect|O of|O human|O basic|gene-protein fibroblast|gene-protein growth|gene-protein factor|gene-protein (|O bFGF|gene-protein )|O on|O the|O proliferation|O of|O human|O neuroblastoma|O cells|O with|O normal|O and|O enhanced|O MYCN|gene-rna oncogene|O expression|O .|O 
bFGF|gene-protein stimulated|O the|O proliferation|O of|O the|O neuroblastoma|O cells|O with|O enhanced|O ,|O but|O not|O normal|O ,|O MYCN|gene-rna expression|O .|O 
Both|O cell|O species|O express|O FGFR-1|gene-protein ,|O but|O not|O FGFR-2|gene-protein ,|O receptors|gene-protein and|O both|O harbor|O FGF|gene-protein receptor|gene-protein species|O of|O Mr|O 145.000|O ,|O but|O they|O differ|O in|O their|O pattern|O of|O lower|O and|O higher|O -|O molecular|O weight|O FGF|gene-protein receptor|gene-protein species|O .|O 
Our|O results|O demonstrate|O that|O enhanced|O MYCN|gene-rna expression|O confers|O to|O neuroblastoma|O cells|O the|O ability|O to|O respond|O to|O bFGF|gene-protein ,|O possibly|O by|O inducing|O functional|O FGF|gene-protein receptors|gene-protein .|O 
This|O mechanism|O may|O contribute|O to|O the|O advanced|O malignant|O phenotype|O of|O human|O neuroblastomas|O with|O enhanced|O MYCN|gene-rna expression|O .|O 
Synergy|O between|O 5|O '|O and|O 3|O '|O flanking|O regions|O of|O the|O human|O tyrosine|gene-rna hydroxylase|gene-rna gene|O ensures|O specific|O ,|O high|O -|O level|O expression|O in|O neuroblastoma|O cells|O .|O 
Factors|O regulating|O tyrosine|gene-rna hydroxylase|gene-rna (|O TH|gene-rna )|O gene|O transcription|O are|O of|O major|O importance|O in|O the|O studies|O of|O malignant|O and|O degenerative|O diseases|O of|O catecholamine|O -|O synthesizing|O tissues|O .|O 
In|O this|O study|O ,|O we|O used|O transient|O transfection|O of|O a|O reporter|O gene|O to|O show|O that|O high|O -|O level|O ,|O tissue|O -|O specific|O TH|gene-rna expression|O was|O only|O achieved|O when|O the|O reporter|O gene|O was|O cloned|O between|O a|O 5|O '|O TH|gene-rna promoter|O sequence|O (|O -|O 513|O -|O +|O 1|O )|O ,|O and|O ,|O a|O 3|O '|O TH|gene-rna gene|O flanking|O sequence|O (|O end|O of|O exon|O 14|O -|O +|O 976|O )|O .|O 
We|O also|O show|O that|O TH|gene-rna mRNA|O expression|O level|O is|O closely|O linked|O to|O the|O expression|O level|O of|O the|O proto|O -|O oncogene|O ,|O MYCN|gene-rna in|O neuroblastoma|O tumor|O cell|O lines|O .|O 
Taken|O together|O our|O data|O indicate|O that|O MYCN|gene-rna may|O regulate|O TH|gene-rna expression|O in|O neuroblastoma|O cells|O ,|O but|O not|O through|O binding|O to|O the|O 5|O '|O or|O 3|O '|O TH|gene-rna gene|O flanking|O sequences|O used|O in|O our|O experiments|O .|O 
Cell|O -|O type|O -|O specific|O modulation|O of|O Hox|gene-rna gene|O expression|O by|O members|O of|O the|O TGF-beta|gene-protein superfamily|O :|O a|O comparison|O between|O human|O osteosarcoma|O and|O neuroblastoma|O cell|O lines|O .|O 
Homeobox|gene-rna gene|O expression|O in|O osteoblast|O -|O like|O cells|O was|O investigated|O using|O the|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O .|O 
A|O total|O of|O 13|O homeobox|gene-rna genes|O was|O detected|O in|O U-2|O OS|O (|O human|O osteosarcoma|O )|O and|O MC3T3-E1|O (|O mouse|O osteoblast|O )|O cells|O by|O sequencing|O cloned|O PCR|O products|O .|O 
Using|O specific|O primers|O ,|O a|O different|O pattern|O of|O Hox|gene-rna gene|O expression|O was|O shown|O for|O the|O neuroblastoma|O cell|O line|O SK-N-SH|O relative|O to|O U-2|O OS|O and|O MC3T3-E1|O .|O 
Additionally|O ,|O we|O showed|O that|O expression|O of|O HOXC6|gene-rna in|O U-2|O OS|O and|O SK-N-SH|O was|O differentially|O regulated|O by|O rhBMP-2|gene-protein ,|O TGF-beta|gene-protein and|O activin-A|gene-protein .|O 
This|O suggests|O that|O specific|O Hox|gene-rna genes|O may|O be|O target|O genes|O for|O TGF-beta|gene-protein superfamily|O members|O ,|O and|O allows|O us|O to|O further|O understand|O the|O complex|O functions|O of|O these|O growth|O factors|O and|O how|O they|O relate|O to|O growth|O and|O development|O .|O 
Natriuretic|gene-protein peptide|gene-protein receptors|gene-protein of|gene-protein type|gene-protein A|gene-protein in|O human|O neuroblastomas|O .|O 
Functional|O natriuretic|gene-protein peptide|gene-protein receptors|gene-protein of|gene-protein type|gene-protein A|gene-protein (|O NPR-A|gene-protein )|O were|O detected|O in|O the|O human|O neuroblastoma|O NB-OK-1|O ,|O SK-N-SH|O and|O SK-N-BE|O ,|O but|O not|O the|O SH-SY5Y|O ,|O cell|O lines|O .|O 
Also|O ,|O NPR-A|gene-rna mRNA|O was|O detected|O in|O 19|O of|O the|O 25|O tumor|O neuroblastoma|O samples|O tested|O in|O this|O study|O .|O 
Five|O of|O the|O eight|O tumor|O neuroblastoma|O samples|O that|O were|O assayed|O for|O atrial|gene-protein natriuretic|gene-protein peptide|gene-protein (|O ANP|gene-protein )|O binding|O revealed|O the|O presence|O of|O ANP|gene-protein -|O binding|O sites|O .|O 
In|O the|O human|O neuroblastoma|O NB-OK-1|O cell|O line|O ,|O [|O (3)H|O ]|O thymidine|O incorporation|O was|O increased|O in|O response|O to|O ANP|gene-protein ,|O decreased|O in|O response|O to|O pituitary|gene-protein adenylate|gene-protein cyclase|gene-protein -|gene-protein activating|gene-protein polypeptide|gene-protein (|O PACAP-27|gene-protein )|O ,|O and|O the|O stimulatory|O effect|O of|O ANP|gene-protein was|O inhibited|O by|O PACAP-27|gene-protein .|O 
Tissue|gene-protein transglutaminase|gene-protein activity|O was|O decreased|O by|O ANP|gene-protein and|O PACAP-27|gene-protein ,|O and|O their|O effects|O were|O additive|O .|O 
However|O ,|O neither|O cell|O cycle|O phases|O ,|O cell|O growth|O ,|O or|O cell|O apoptosis|O were|O modified|O by|O ANP|gene-protein or|O PACAP-27|gene-protein treatments|O .|O 
Phase|O I|O trial|O of|O trimetrexate|O in|O pediatric|O solid|O tumors|O :|O a|O Pediatric|O Oncology|O Group|O study|O .|O 
Trimetrexate|O (|O TMTX|O )|O ,|O a|O lipophilic|O antifol|O ,|O was|O evaluated|O in|O a|O Pediatric|O Oncology|O Group|O (|O POG|O )|O Phase|O I|O trial|O in|O children|O with|O refractory|O solid|O tumors|O .|O 
TMTX|O was|O administered|O intravenously|O daily|O x|O 5|O every|O three|O weeks|O .|O 
Starting|O dose|O was|O 6.4|O mg|O /|O m2|O /|O day|O .|O 
Dose|O was|O escalated|O by|O 20|O %|O until|O the|O maximal|O tolerated|O dose|O was|O reached|O .|O 
A|O total|O of|O 75|O courses|O were|O administered|O to|O 26|O children|O .|O 
The|O major|O toxicity|O was|O myelosuppression|O ,|O of|O which|O neutropenia|O and|O thrombocytopenia|O were|O most|O prominent|O .|O 
Rash|O ,|O mucositis|O ,|O and|O transient|O liver|gene-protein enzyme|gene-protein elevations|O were|O infrequently|O seen|O .|O 
Responses|O were|O observed|O in|O children|O with|O brainstem|O glioma|O ,|O neuroblastoma|O ,|O and|O renal|O cell|O carcinoma|O .|O 
The|O recommended|O Phase|O II|O dose|O using|O this|O schedule|O is|O 9.2|O -|O 11|O mg|O /|O m2|O /|O day|O depending|O on|O how|O heavily|O the|O patient|O has|O been|O treated|O prior|O to|O initiating|O this|O therapy|O .|O 
Up|O -|O regulation|O of|O Jun|gene-rna /|O AP-1|gene-rna during|O differentiation|O of|O N1E-115|O neuroblastoma|O cells|O .|O 
Neuroblastoma|O cell|O lines|O isolated|O from|O neuroblastoma|O tumors|O can|O be|O induced|O to|O differentiate|O into|O neuronal|O cell|O types|O by|O treatment|O with|O chemical|O agents|O ,|O such|O as|O dimethyl|O sulfoxide|O and|O retinoic|O acid|O .|O 
The|O molecular|O mechanisms|O underlying|O this|O differentiation|O process|O ,|O however|O ,|O are|O completely|O obscure|O .|O 
In|O this|O paper|O ,|O we|O show|O that|O neuronal|O differentiation|O of|O mouse|O N1E-115|O neuroblastoma|O cells|O by|O dimethyl|O sulfoxide|O is|O accompanied|O by|O a|O prolonged|O rise|O in|O c-jun|gene-rna ,|O junB|gene-rna ,|O and|O junD|gene-rna expression|O and|O AP-1|gene-rna activity|O .|O 
Multiple|O sequence|O elements|O in|O the|O Jun|gene-rna promoters|O are|O involved|O in|O this|O process|O .|O 
Furthermore|O ,|O we|O show|O that|O c-jun|gene-rna and|O junD|gene-rna ,|O but|O not|O junB|gene-rna ,|O are|O expressed|O at|O high|O levels|O in|O the|O neuronal|O cell|O types|O obtained|O after|O dimethyl|O sulfoxide|O treatment|O .|O 
These|O results|O suggest|O an|O important|O role|O for|O c-jun|gene-rna and|O junD|gene-rna in|O neuronal|O differentiation|O of|O N1E-115|O cells|O .|O 
Delivery|O of|O anti|gene-protein -|gene-protein GAP-43|gene-protein antibodies|gene-protein into|O neuroblastoma|O cells|O reduces|O growth|O cone|O size|O .|O 
We|O have|O previously|O demonstrated|O that|O antibodies|gene-protein to|O the|O growth|gene-protein -|gene-protein associated|gene-protein protein|gene-protein ,|O GAP-43|gene-protein ,|O introduced|O intracellularly|O using|O a|O lipid|O carrier|O inhibited|O neurite|O outgrowth|O in|O NB|O 2a|O /|O d1|O neuroblastoma|O cells|O ,|O and|O that|O culturing|O of|O these|O cells|O on|O adhesive|O substrates|O such|O as|O laminin|gene-protein or|O poly-L-lysine|gene-protein overcame|O this|O restriction|O .|O 
These|O findings|O suggest|O that|O GAP-43|gene-protein may|O facilitate|O neuritogenesis|O by|O increasing|O membrane|O adhesiveness|O .|O 
To|O address|O this|O issue|O ,|O in|O the|O present|O study|O we|O examined|O the|O effect|O of|O intracellular|O delivery|O of|O this|O antibody|gene-protein on|O growth|O cone|O size|O .|O 
A|O statistically|O significant|O percentage|O of|O those|O neurites|O that|O did|O elaborate|O following|O intracellular|O delivery|O of|O GAP-43|gene-protein exhibited|O either|O no|O observable|O growth|O cones|O or|O smaller|O growth|O cones|O versus|O cells|O receiving|O pre|gene-protein -|gene-protein immune|gene-protein IgG|gene-protein .|O 
These|O results|O support|O the|O hypothesis|O that|O the|O requirement|O for|O GAP-43|gene-protein in|O neuritogenesis|O may|O be|O related|O to|O growth|O cone|O formation|O and|O membrane|O adhesiveness|O .|O 
Magnetic|O resonance|O imaging|O in|O gangliogliomas|O and|O gangliocytomas|O of|O the|O nervous|O system|O .|O 
Gangliogliomas|O and|O gangliocytomas|O are|O rare|O and|O benign|O neuronal|O tumors|O which|O affect|O young|O subjects|O .|O 
This|O study|O concerns|O 3|O cases|O of|O ganglioglioma|O and|O 3|O cases|O of|O gangliocytoma|O explored|O by|O CT|O and|O MRI|O and|O confirmed|O by|O pathological|O examination|O .|O 
The|O most|O typical|O CT|O image|O was|O that|O of|O an|O often|O calcified|O contrast|O -|O enhanced|O cystic|O tumor|O .|O 
At|O MRI|O ,|O each|O tumor|O emitted|O a|O low|O -|O intensity|O signal|O on|O T1|O -|O weighted|O sequences|O and|O a|O high|O -|O intensity|O signal|O on|O T2|O -|O weighted|O sequences|O .|O 
Contrast|O enhancement|O after|O gadolinium|O injection|O was|O frequent|O .|O 
Neuroradiology|O is|O not|O specific|O ,|O and|O these|O tumors|O are|O usually|O diagnosed|O at|O pathology|O .|O 
However|O ,|O the|O diagnosis|O may|O be|O considered|O in|O young|O patients|O with|O a|O history|O of|O old|O ,|O drug|O -|O resistant|O partial|O epilepsy|O and|O having|O a|O contrast|O -|O enhanced|O ,|O calcified|O cystic|O lesion|O in|O the|O temporal|O lobe|O or|O the|O cerebellum|O .|O 
Human|O neuroblastoma|O cell|O differentiation|O requires|O protein|gene-protein kinase|gene-protein C-theta|gene-protein .|O 
Neuroblastoma|O LAN-5|O cells|O exposed|O to|O retinoic|O acid|O cease|O to|O multiply|O and|O extend|O neurite|O outgrowths|O acquiring|O a|O neuronal|O phenotype|O .|O 
We|O now|O report|O that|O protein|gene-protein kinase|gene-protein C-theta|gene-protein ;|O (|O PKC-theta|gene-protein ;|O )|O isozyme|gene-protein is|O involved|O in|O this|O differentiation|O process|O due|O to|O the|O following|O findings|O :|O (i)|O PKC-theta|gene-protein ;|O is|O expressed|O by|O LAN-5|O cells|O as|O a|O nuclear|O and|O perinuclear|O protein|O ;|O (ii)|O cell|O stimulation|O with|O retinoic|O acid|O promotes|O in|O a|O large|O increase|O in|O the|O expression|O level|O of|O the|O kinase|gene-protein and|O its|O intracellular|O redistribution|O ;|O and|O (iii)|O a|O PKC-theta|gene-protein ;|O antisense|O oligonucleotide|O reduces|O at|O the|O same|O time|O the|O expression|O level|O of|O the|O kinase|gene-protein and|O the|O cell|O response|O to|O retinoic|O acid|O .|O 
Altogether|O these|O data|O are|O consistent|O with|O a|O specific|O role|O played|O by|O PKC-theta|gene-protein ;|O in|O the|O differentiation|O program|O of|O neuronal|O cells|O .|O 
Recombinant|O derivatives|O of|O clostridial|O neurotoxins|O as|O delivery|O vehicles|O for|O proteins|O and|O small|O organic|O molecules|O .|O 
Clostridial|O neurotoxins|O are|O the|O most|O powerful|O toxins|O known|O .|O 
Nevertheless|O ,|O derivatives|O of|O these|O toxins|O may|O find|O broad|O applications|O both|O in|O science|O and|O medicine|O because|O of|O their|O unique|O abilities|O to|O recognize|O neurons|O and|O deliver|O small|O and|O large|O molecules|O into|O them|O .|O 
In|O this|O paper|O we|O describe|O the|O construction|O of|O two|O types|O of|O such|O derivatives|O .|O 
Proteins|O belonging|O to|O the|O first|O class|O were|O designed|O to|O allow|O direct|O conjugation|O with|O one|O or|O few|O molecules|O of|O interest|O .|O 
Proteins|O belonging|O to|O the|O second|O class|O contain|O biotin|O residue|O and|O therefore|O could|O be|O easily|O connected|O to|O streptavidin|gene-protein loaded|O with|O multiple|O molecules|O of|O interest|O .|O 
Only|O C|O -|O terminal|O regions|O of|O neurotoxin|O heavy|O chains|O were|O incorporated|O in|O the|O structure|O of|O recombinant|O proteins|O .|O 
Nevertheless|O ,|O recombinant|O proteins|O were|O found|O to|O be|O able|O to|O recognize|O specific|O neuronal|O receptors|O and|O target|O model|O molecules|O to|O rat|O synaptosomes|O and|O human|O neuroblastoma|O cells|O .|O 
Telomerase|gene-protein is|O a|O strong|O indicator|O for|O assessing|O the|O proneness|O to|O progression|O in|O neuroblastomas|O .|O 
BACKGROUND|O :|O 
As|O traditional|O parameters|O do|O not|O ensure|O completely|O accurate|O prognostic|O grouping|O in|O neuroblastoma|O (|O NB|O )|O ,|O new|O molecular|O markers|O are|O needed|O for|O assessing|O the|O individual|O patient|O 's|O prognosis|O more|O precisely|O .|O 
PROCEDURE|O ,|O RESULTS|O ,|O AND|O CONCLUSIONS|O :|O 
Based|O on|O 133|O NB|O ,|O we|O show|O that|O telomerase|gene-protein activity|O (|O TA|O )|O is|O a|O powerful|O ,|O independent|O prognostic|O marker|O for|O all|O stages|O and|O is|O capable|O of|O differentiating|O between|O good|O and|O poor|O outcome|O in|O putative|O '|O favorable|O '|O clinical|O or|O biological|O subgroups|O of|O NB|O patients|O .|O 
Analysis|O of|O gene|O and|O protein|O expression|O of|O telomerase|gene-protein subunits|O suggests|O that|O the|O presence|O or|O absence|O of|O TA|O in|O NB|O is|O strongly|O correlated|O with|O expression|O levels|O of|O both|O the|O catalytic|O subunit|O hTERT|gene-protein and|O the|O internal|O RNA|O component|O (|O hTR|gene-rna )|O .|O 
Cystic|O neuroblastoma|O with|O hepatic|O metastasis|O :|O report|O of|O one|O case|O .|O 
Neuroblastoma|O is|O the|O most|O common|O infant|O malignancy|O ,|O but|O cystic|O neuroblastoma|O is|O a|O rare|O presentation|O of|O this|O disease|O .|O 
There|O were|O only|O thirty-one|O reported|O cases|O in|O literature|O .|O 
Here|O we|O report|O another|O case|O .|O 
A|O 4|O -|O month|O -|O old|O female|O baby|O presented|O with|O a|O huge|O abdominal|O mass|O which|O was|O histologically|O proved|O to|O be|O a|O cystic|O neuroblastoma|O .|O 
Her|O urinary|O vanillylmandelic|O acid|O (|O VMA|O )|O was|O elevated|O .|O 
The|O image|O studies|O ,|O including|O abdominal|O sonography|O ,|O computed|O tomography|O ,|O and|O magnetic|O resonance|O image|O ,|O revealed|O a|O huge|O main|O mass|O with|O calcification|O and|O septa|O in|O the|O abdominal|O cavity|O ,|O and|O multiple|O metastatic|O nodules|O with|O septation|O in|O the|O liver|O .|O 
A|O three|O -|O layer|O fluid|O -|O fluid|O level|O was|O found|O in|O the|O main|O mass|O and|O also|O in|O the|O metastatic|O nodules|O .|O 
No|O previous|O report|O showed|O a|O three|O -|O layer|O fluid|O -|O fluid|O level|O in|O the|O cystic|O component|O of|O neuroblastoma|O like|O the|O case|O presented|O here|O .|O 
It|O may|O be|O evidence|O of|O easy|O hemorrhagic|O character|O of|O this|O tumor|O .|O 
Modulation|O of|O sodium|O -|O sensitive|O GTPase|gene-protein by|O partial|O opiate|O agonists|O .|O 
An|O explanation|O for|O the|O dual|O requirement|O for|O Na+|O and|O GTP|O in|O inhibitory|O regulation|O of|O adenylate|gene-protein cyclase|gene-protein .|O 
Opiates|O and|O opioid|O peptides|O inhibit|O adenylate|gene-protein cyclase|gene-protein and|O stimulate|O specific|O low|O Km|O GTPase|gene-protein activity|O in|O membranes|O from|O neuroblastoma|O x|O glioma|O NG108-15|O hybrid|O cells|O .|O 
The|O effects|O of|O opiate|O agonists|O on|O both|O enzymes|O are|O mediated|O by|O high|O affinity|O stereospecific|O receptors|O and|O require|O Mg2+|O ,|O GTP|O ,|O and|O Na+|O .|O 
In|O the|O presence|O of|O Mg2+|O ,|O Na+|O inhibits|O basal|O GTPase|gene-protein activity|O ;|O opiates|O stimulate|O GTP|O hydrolysis|O by|O antagonizing|O the|O Na+|O -|O induced|O inhibition|O .|O 
Activation|O of|O GTPase|gene-protein leads|O ,|O in|O turn|O ,|O to|O inactivation|O of|O GTP|O -|O stimulated|O adenylate|gene-protein cyclase|gene-protein activity|O .|O 
The|O intrinsic|O activities|O (|O or|O efficacies|O )|O of|O a|O series|O of|O opiates|O are|O identical|O for|O stimulation|O of|O GTPase|gene-protein and|O inhibition|O of|O adenylate|gene-protein cyclase|gene-protein .|O 
These|O results|O provide|O a|O mechanism|O for|O the|O dual|O requirement|O for|O Na+|O and|O GTP|O in|O the|O inhibitory|O coupling|O of|O opiate|gene-protein receptors|gene-protein to|O the|O adenylate|gene-protein cyclase|gene-protein system|O in|O these|O cells|O and|O may|O be|O of|O general|O significance|O to|O the|O action|O of|O other|O inhibitory|O hormones|O .|O 
Translocation|O junctions|O cluster|O at|O the|O distal|O short|O arm|O of|O chromosome|O 1|O (|O 1p36.1-2|O )|O in|O human|O neuroblastoma|O cells|O .|O 
Human|O neuroblastoma|O cells|O show|O at|O high|O frequency|O structural|O changes|O of|O the|O distal|O short|O arm|O of|O chromosome|O 1|O (|O 1p|O )|O .|O 
The|O commonly|O altered|O region|O has|O been|O identified|O in|O previous|O loss|O -|O of|O -|O heterozygosity|O (|O LOH|O )|O studies|O to|O involve|O deletion|O of|O 1p36.1-2|O .|O 
These|O bands|O are|O also|O the|O site|O of|O constitutional|O alterations|O in|O patients|O with|O neuroblastoma|O .|O 
In|O an|O approach|O to|O define|O the|O 1p36.1-2|O alterations|O in|O more|O detail|O we|O here|O employ|O four|O neuroblastoma|O cell|O lines|O to|O map|O translocation|O breaks|O involving|O 1p36.1-2|O by|O fluorescence|O in|O situ|O hybridization|O (|O FISH|O )|O .|O 
A|O chromosomal|O interval|O flanked|O by|O loci|O DIS96|O and|O DIS98|O contained|O translocation|O junctions|O in|O each|O of|O four|O lines|O .|O 
This|O analysis|O identifies|O in|O 1p|O a|O restricted|O genomic|O region|O as|O involved|O in|O chromosomal|O rearrangement|O in|O different|O neuroblastomas|O .|O 
The|O specificity|O of|O neuroblastoma|O translocation|O junctions|O at|O the|O molecular|O level|O implicates|O this|O genomic|O region|O in|O tumor|O development|O .|O 
Hypoxanthine|gene-rna -|gene-rna guanine|gene-rna phosphoribosyltransferase|gene-rna genes|O of|O mouse|O and|O Chinese|O hamster|O :|O construction|O and|O sequence|O analysis|O of|O cDNA|O recombinants|O .|O 
Recombinant|O plasmids|O containing|O DNA|O inserts|O complementary|O to|O mRNA|O coding|O for|O hypoxanthine|gene-protein -|gene-protein guanine|gene-protein phosphoribosyltransferase|gene-protein (|O HPRT|gene-protein )|O from|O mouse|O and|O Chinese|O hamster|O cell|O lines|O have|O been|O isolated|O from|O cDNA|O libraries|O and|O characterized|O by|O DNA|O sequence|O analysis|O .|O 
A|O total|O of|O 1292|O nucleotides|O of|O the|O mouse|O cDNA|O sequence|O and|O 1301|O nucleotides|O of|O the|O Chinese|O hamster|O cDNA|O sequence|O has|O been|O determined|O .|O 
Each|O of|O these|O sequences|O includes|O an|O open|O reading|O frame|O of|O 654|O nucleotides|O (|O 218|O amino|O acids|O )|O corresponding|O to|O the|O HPRT|gene-protein protein|O coding|O region|O .|O 
The|O deduced|O amino|O acid|O sequences|O for|O the|O mouse|O and|O Chinese|O hamster|O enzymes|O are|O presented|O and|O compared|O to|O that|O of|O human|O HPRT|gene-protein .|O 
At|O least|O 95|O %|O of|O the|O amino|O acids|O are|O conserved|O in|O the|O three|O species|O .|O 
In|O addition|O ,|O we|O present|O evidence|O that|O two|O species|O of|O HPRT|gene-rna mRNA|O ,|O which|O differ|O in|O the|O site|O of|O polyadenylation|O that|O is|O utilized|O during|O processing|O of|O the|O RNA|O transcripts|O ,|O exist|O in|O Chinese|O hamster|O cells|O .|O 
Coexpression|O of|O the|O myc|gene-rna gene|O family|O members|O in|O human|O neuroblastoma|O cell|O lines|O .|O 
Members|O of|O the|O myc|gene-rna oncogene|O family|O such|O as|O c|gene-rna ,|O N|gene-rna -|gene-rna ,|O and|O L|gene-rna -|gene-rna myc|gene-rna are|O expressed|O in|O many|O malignant|O tumors|O .|O 
Expression|O of|O c|gene-rna -|gene-rna ,|O N|gene-rna -|gene-rna ,|O and|O L|gene-rna -|gene-rna myc|gene-rna oncogenes|O in|O 7|O human|O neuroblastoma|O cell|O lines|O (|O GOTO|O ,|O IMR-32|O ,|O TGW|O ,|O SCCH-26|O ,|O TNB|O 9|O ,|O NBL-S|O ,|O and|O SK-N-SH|O )|O ,|O a|O human|O small|O cell|O lung|O carcinoma|O SBC-5|O cell|O line|O ,|O and|O a|O human|O monocytic|O leukemia|O THP-1-S|O cell|O line|O at|O mRNA|O and|O protein|O levels|O was|O studied|O to|O know|O the|O specificity|O of|O a|O newly|O developed|O antibody|O against|O homologous|O region|O at|O C-terminus|O of|O N-Myc|gene-protein ,|O designated|O as|O anti|gene-protein pan|gene-protein -|gene-protein Myc|gene-protein antibody|gene-protein .|O 
By|O RT|O -|O PCR|O and|O immunoblot|O analysis|O ,|O coexpression|O of|O three|O myc|gene-rna genes|O was|O detected|O in|O all|O neuroblastoma|O cell|O lines|O tested|O .|O 
c|gene-rna -|gene-rna and|O L|gene-rna -|gene-rna myc|gene-rna expression|O were|O observed|O that|O anti|gene-protein pan|gene-protein -|gene-protein Myc|gene-protein antibody|gene-protein recognizes|O c-Myc|gene-protein and|O N-Myc|gene-protein proteins|O but|O not|O L-Myc|gene-protein .|O 
These|O results|O indicate|O that|O neuroblastoma|O cells|O may|O acquire|O an|O aberrant|O transcriptional|O control|O system|O in|O myc|gene-rna family|O gene|O expression|O .|O 
Functional|O evidence|O for|O human|O tumour|gene-rna suppressor|gene-rna genes|gene-rna :|O chromosome|O and|O molecular|O genetic|O studies|O .|O 
There|O is|O now|O ample|O genetic|O and|O some|O functional|O evidence|O for|O the|O existence|O of|O tumour|gene-rna suppressor|gene-rna genes|gene-rna .|O 
Although|O much|O of|O the|O functional|O evidence|O has|O been|O derived|O from|O somatic|O cell|O hybrid|O and|O chromosome|O transfer|O studies|O ,|O it|O is|O critical|O that|O cloned|O candidate|O tumour|gene-rna suppressor|gene-rna genes|gene-rna be|O used|O in|O such|O functional|O assays|O .|O 
Our|O experience|O with|O RB|gene-rna and|O p53|gene-rna indicates|O that|O much|O will|O be|O learned|O about|O the|O control|O of|O the|O cell|O cycle|O from|O studies|O of|O tumour|gene-rna suppressor|gene-rna genes|gene-rna .|O 
However|O ,|O the|O handful|O of|O candidate|O genes|O cloned|O to|O date|O also|O indicates|O a|O variety|O of|O cellular|O localizations|O and|O cellular|O functions|O .|O 
Thus|O ,|O just|O as|O oncogenes|gene-rna seem|O to|O act|O to|O promote|O growth|O at|O many|O levels|O of|O metabolic|O control|O ,|O it|O would|O seem|O that|O tumour|gene-rna suppressor|gene-rna genes|gene-rna act|O in|O complementary|O ways|O to|O control|O cell|O proliferation|O .|O 
The|O molecular|O genetic|O study|O of|O cancer|O has|O truly|O entered|O an|O exciting|O phase|O .|O 
GQ1b|O ,|O a|O bioactive|O ganglioside|O that|O exhibits|O novel|O nerve|gene-protein growth|gene-protein factor|gene-protein (|O NGF|gene-protein )|O -|O like|O activities|O in|O the|O two|O neuroblastoma|O cell|O lines|O .|O 
To|O clarify|O the|O role|O of|O gangliosides|O in|O the|O morphological|O and|O biochemical|O differentiation|O of|O neuronal|O cell|O cultures|O ,|O the|O model|O cell|O culture|O system|O represented|O by|O two|O neuroblastoma|O cell|O lines|O ,|O GOTO|O and|O NB-1|O ,|O which|O were|O established|O from|O adrenal|O gland|O and|O metastatic|O neck|O lymph|O node|O ,|O respectively|O ,|O was|O examined|O .|O 
We|O found|O that|O the|O total|O ganglioside|O fraction|O from|O human|O brain|O had|O two|O remarkable|O effects|O on|O these|O cell|O lines|O ,|O which|O are|O similar|O to|O those|O of|O nerve|gene-protein growth|gene-protein factor|gene-protein (|O NGF|gene-protein )|O :|O (a)|O an|O increase|O in|O the|O cell|O number|O ,|O and|O (b)|O an|O increase|O in|O the|O neurite|O number|O and|O the|O total|O length|O of|O neurites|O .|O 
In|O these|O cases|O ,|O the|O genuine|O effector|O in|O total|O gangliosides|O could|O not|O be|O ascribed|O to|O a|O possibly|O contaminating|O NGF|gene-protein -|gene-protein like|gene-protein protein|gene-protein ,|O but|O rather|O to|O a|O particular|O molecular|O species|O of|O the|O gangliosides|O ,|O GQ1b|O ,|O which|O could|O completely|O replace|O the|O effector|O function|O not|O only|O qualitatively|O but|O also|O quantitatively|O .|O 
Our|O results|O provide|O direct|O evidence|O for|O the|O participation|O of|O gangliosides|O in|O such|O functions|O .|O 
[|O Deletion|O mutation|O of|O beta-amyloid|gene-protein precursor|gene-protein protein|gene-protein decreases|O the|O secretion|O of|O beta-amyloid|gene-protein in|O SH-SY5Y|O neuroblastoma|O cells|O ]|O 
OBJECTIVE|O :|O 
To|O explore|O the|O effect|O of|O A|gene-protein beta|gene-protein secretion|O lacking|O exons|O 2|O and|O 3|O of|O APP695|gene-rna (|O delta|gene-rna APP695|gene-rna )|O on|O SH-SY5Y|O neuroblastoma|O cells|O .|O 
METHODS|O :|O 
APP695|gene-rna cDNA|O and|O delta|gene-rna APP695|gene-rna cDNA|O eukaryotic|O expression|O vectors|O were|O constructed|O by|O gene|O recombination|O .|O 
Immunoprecipitation|O Western|O blotting|O was|O used|O to|O analyse|O the|O A|gene-protein beta|gene-protein secretion|O and|O MTT|O assay|O to|O observe|O the|O cell|O viability|O 's|O change|O after|O being|O stably|O transfected|O with|O the|O plasmids|O by|O lipofectamine|O method|O .|O 
RESULTS|O :|O 
Stable|O transfectants|O were|O selected|O in|O 0.6|O g|O .|O L-1|O G418|O .|O 
delta|gene-rna APP695|gene-rna cDNA|O construct|O transfection|O decreased|O significantly|O the|O production|O of|O beta|gene-protein amyloid|gene-protein in|O the|O SH-SY5Y|O compared|O with|O APP695|gene-rna cDNA|O construct|O .|O 
It|O did|O not|O affect|O the|O cell|O viability|O by|O MTT|O method|O .|O 
CONCLUSION|O :|O 
This|O result|O suggests|O that|O the|O alternative|O splicing|O of|O APP|gene-rna exons|O 2|O and|O 3|O modulates|O the|O secretion|O of|O A|gene-protein beta|gene-protein by|O influencing|O the|O processing|O of|O APP|gene-generic .|O 
In|O vitro|O neuroblastomal|O clump|O formations|O as|O an|O indicator|O of|O a|O bone|O marrow|O metastasis|O .|O 
In|O a|O long|O -|O term|O culture|O of|O bone|O marrow|O taken|O from|O a|O child|O with|O a|O suspected|O abdominal|O tumor|O ,|O a|O large|O number|O of|O globular|O in|O vitro|O clumps|O developed|O within|O 5|O days|O ,|O although|O the|O bone|O marrow|O used|O had|O tested|O negative|O to|O the|O presence|O of|O abnormal|O cells|O .|O 
Light|O microscopic|O and|O marker|O studies|O of|O these|O clumps|O provided|O evidence|O of|O neuroblastomal|O origin|O ,|O and|O the|O diagnosis|O of|O a|O neuroblastoma|O was|O confirmed|O by|O a|O subsequent|O cathecholamine|O assessment|O and|O the|O histological|O findings|O of|O the|O excised|O tumor|O .|O 
Of|O three|O in|O vitro|O culture|O methods|O tested|O ,|O i.e.|O ,|O a|O long|O -|O term|O bone|O marrow|O culture|O (|O LTBMC|O )|O ,|O a|O liquid|O culture|O ,|O and|O a|O methylcellulose|O clonal|O cell|O culture|O ,|O the|O LTBMC|O was|O found|O to|O be|O the|O most|O sensitive|O for|O detecting|O tumor|O cells|O .|O 
This|O LTBMC|O was|O considered|O to|O be|O useful|O for|O not|O only|O achieving|O a|O definitive|O neuroblastoma|O diagnosis|O but|O also|O the|O early|O detection|O of|O bone|O marrow|O metastasis|O in|O N-myc|gene-rna gene|O amplified|O neuroblastomas|O .|O 
Telomerase|gene-protein in|O brain|O tumors|O .|O 
INTRODUCTION|O :|O 
In|O recent|O years|O ,|O many|O scientists|O involved|O in|O cancer|O research|O have|O directed|O their|O attention|O to|O telomerase|gene-protein ,|O an|O enzymatic|O complex|O which|O is|O specifically|O involved|O in|O duplicating|O telomeres|O ,|O the|O very|O ends|O of|O linear|O chromosomes|O .|O 
The|O discovery|O that|O most|O immortal|O cell|O lines|O in|O vitro|O and|O human|O tumor|O cells|O in|O vivo|O have|O telomerase|gene-protein activity|O ,|O in|O contrast|O to|O telomerase|gene-protein -|O negative|O normal|O somatic|O cells|O ,|O has|O made|O telomerase|gene-protein a|O candidate|O for|O use|O as|O a|O molecular|O marker|O of|O malignancy|O and|O even|O as|O a|O target|O for|O anticancer|O therapies|O .|O 
Thus|O ,|O the|O assessment|O of|O the|O role|O of|O telomerase|gene-protein activity|O in|O neoplastic|O transformation|O has|O become|O a|O key|O issue|O in|O oncology|O ,|O as|O stated|O by|O the|O exponential|O increase|O of|O papers|O on|O telomerase|gene-protein in|O the|O last|O 5|O years|O .|O 
OBJECT|O :|O 
In|O this|O paper|O ,|O we|O review|O some|O recent|O data|O from|O the|O literature|O ,|O including|O our|O own|O studies|O ,|O on|O the|O regulation|O of|O telomerase|gene-protein activity|O in|O brain|O tumors|O .|O 
Pentoxifylline|O augments|O but|O does|O not|O antagonize|O TNF|gene-protein alpha|gene-protein -|O mediated|O neuroblastoma|O cell|O differentiation|O :|O modulation|O of|O calcium|O mobilization|O but|O not|O cAMP|O .|O 
We|O described|O here|O that|O pentoxifylline|O (|O PTX|O )|O ,|O which|O is|O well|O known|O to|O counteract|O tumor|gene-protein necrosis|gene-protein factor|gene-protein alpha|gene-protein (|O TNF|gene-protein alpha|gene-protein )|O -|O mediated|O inflammatory|O responses|O ,|O augmented|O TNF|gene-protein alpha|gene-protein -|O induced|O neuroblastoma|O cell|O differentiation|O in|O conjunction|O with|O growth|O inhibition|O and|O cell|O -|O cycle|O arrest|O in|O G1|O phase|O .|O 
PTX|O also|O enhanced|O TNF|gene-protein alpha|gene-protein -|O induced|O down|O -|O regulation|O of|O acetylcholine|O -|O mediated|O [Ca2+]i|O mobilization|O in|O neuroblastoma|O cells|O .|O 
Furthermore|O ,|O we|O found|O that|O addition|O of|O cAMP|O failed|O to|O induce|O neuroblastoma|O cell|O differentiation|O ,|O whereas|O blockade|O of|O [Ca2+]i|O mobilization|O by|O 8-(N,N-diethyl-amino)octyl-3,4,5-trimethoxybenzoate|O HCl|O (|O TMB-8|O ,|O 10|O microM|O )|O did|O induce|O neuroblastoma|O cell|O differentiation|O .|O 
Taken|O together|O ,|O these|O results|O indicated|O that|O PTX|O possessed|O a|O novel|O signal|O transduction|O ,|O down|O -|O regulation|O of|O [Ca2+]i|O mobilization|O ,|O to|O augment|O but|O not|O counteract|O TNF|gene-protein alpha|gene-protein -|O mediated|O functions|O .|O 
Inhibition|O of|O phospholipase|gene-protein C|gene-protein blocks|O opioid|gene-protein receptor|gene-protein -|O mediated|O activation|O of|O Gi|gene-protein proteins|gene-protein .|O 
Activation|O of|O phospholipase|gene-protein C|gene-protein (|O PLC|gene-protein )|O in|O response|O to|O stimulation|O of|O delta|gene-protein -|gene-protein opioid|gene-protein ,|O m4|gene-protein muscarinic|gene-protein and|O alpha2|gene-protein adrenergic|gene-protein receptors|gene-protein was|O observed|O in|O NG108-15|O cells|O .|O 
Treatment|O with|O PLC|gene-protein specific|O inhibitors|O ,|O U73122|O and|O ET-18-OCH3|O ,|O blocked|O delta|gene-protein -|gene-protein opioid|gene-protein receptor|gene-protein -|O mediated|O activation|O of|O G|gene-protein proteins|gene-protein with|O no|O effect|O on|O opioid|O binding|O to|O the|O receptors|gene-protein .|O 
U73122|O treatment|O also|O suppressed|O functional|O responses|O of|O m4|gene-protein muscarinic|gene-protein and|O alpha2|gene-protein adrenergic|gene-protein receptors|gene-protein in|O NG108-15|O cells|O .|O 
Furthermore|O ,|O the|O G|gene-protein protein|gene-protein activation|O mediated|O by|O mu|gene-protein -|gene-protein and|O delta|gene-protein -|gene-protein opioid|gene-protein receptors|gene-protein and|O opioid|gene-protein receptor|gene-protein -|gene-protein like|gene-protein receptor|gene-protein (|O ORL1|gene-protein )|O were|O abolished|O by|O U73122|O in|O SK-N-SH|O neuroblastoma|O cells|O .|O 
Inhibition|O of|O adenylyl|gene-protein cyclase|gene-protein induced|O by|O high|O concentrations|O of|O GTP|O was|O blocked|O by|O U73122|O ,|O suggesting|O that|O blockade|O is|O at|O the|O level|O of|O G|gene-protein proteins|gene-protein .|O 
Our|O results|O thus|O indicated|O that|O inhibition|O of|O PLC|gene-protein leads|O to|O blockade|O of|O Gi|gene-protein protein|gene-protein activation|O mediated|O by|O opioid|gene-protein receptors|gene-protein or|O other|O Gi|gene-protein -|gene-protein coupled|gene-protein receptors|gene-protein .|O 
Human|O granulocyte|gene-protein -|gene-protein macrophage|gene-protein colony|gene-protein -|gene-protein stimulating|gene-protein factor|gene-protein is|O a|O growth|gene-protein factor|gene-protein active|O on|O a|O variety|O of|O cell|O types|O of|O nonhemopoietic|O origin|O .|O 
Granulocyte|gene-protein -|gene-protein macrophage|gene-protein colony|gene-protein -|gene-protein stimulating|gene-protein factor|gene-protein (|O GM-CSF|gene-protein )|O is|O a|O member|O of|O a|O family|O of|O glycoprotein|gene-protein hormones|gene-protein that|O stimulate|O the|O proliferation|O and|O differentiation|O of|O hemopoietic|O cells|O in|O vitro|O and|O in|O vivo|O .|O 
We|O now|O report|O that|O human|O GM-CSF|gene-protein can|O also|O stimulate|O the|O proliferation|O of|O two|O osteogenic|O sarcoma|O cell|O lines|O ,|O a|O breast|O carcinoma|O cell|O line|O ,|O a|O simian|O virus|O 40|O -|O transformed|O marrow|O stromal|O cell|O line|O ,|O and|O normal|O marrow|O fibroblast|O precursors|O .|O 
These|O findings|O suggest|O a|O more|O general|O regulatory|O function|O of|O GM-CSF|gene-protein on|O nonhemopoietic|O cell|O types|O than|O previously|O anticipated|O .|O 
They|O also|O raise|O the|O possibility|O of|O adverse|O side|O effects|O of|O GM-CSF|gene-protein therapy|O in|O patients|O whose|O malignant|O cells|O may|O be|O directly|O stimulated|O by|O this|O molecule|O and|O suggest|O a|O previously|O unanticipated|O role|O of|O GM-CSF|gene-rna gene|O activation|O in|O the|O evolution|O of|O solid|O tumors|O and|O in|O the|O pathogenesis|O of|O myelofibrosis|O .|O 
Distinct|O subcellular|O localization|O of|O transiently|O expressed|O types|gene-protein 1|gene-protein and|O 2|gene-protein iodothyronine|gene-protein deiodinases|gene-protein as|O determined|O by|O immunofluorescence|O confocal|O microscopy|O .|O 
We|O compared|O the|O subcellular|O localization|O of|O FLAG|O -|O epitope|O tagged|O Types|gene-protein 1|gene-protein and|O 2|gene-protein deiodinases|gene-protein (|O D1|gene-protein and|O D2|gene-protein )|O transiently|O expressed|O in|O human|O embryonic|O kidney|O (|O HEK-293|O )|O and|O mouse|O neuroblastoma|O (|O NB2A|O )|O cells|O .|O 
D2|gene-protein is|O an|O integral|O membrane|O protein|O based|O on|O resistance|O to|O extraction|O at|O pH|O 11|O with|O the|O NH2|O terminus|O in|O the|O endoplasmic|O reticulum|O (|O ER|O )|O .|O 
Immunofluorescence|O confocal|O microscopy|O using|O anti|gene-protein -|gene-protein FLAG|gene-protein and|O anti|gene-protein -|gene-protein GRP78|gene-protein /|gene-protein BiP|gene-protein antibodies|gene-protein showed|O the|O FLAG|O -|O D1|gene-protein signal|O was|O found|O in|O the|O periphery|O of|O the|O cells|O and|O not|O co|O -|O localized|O with|O the|O ER|O specific|O marker|O GRP78|gene-protein /|gene-protein BiP|gene-protein .|O 
On|O the|O other|O hand|O ,|O FLAG|O -|O D2|gene-protein protein|O was|O found|O in|O the|O ER|O co|O -|O localized|O with|O the|O GRP78|gene-protein /|gene-protein BiP|gene-protein protein|O .|O 
These|O differential|O distribution|O patterns|O indicate|O subcellular|O sorting|O of|O D1|gene-protein and|O D2|gene-protein is|O determined|O by|O intrinsic|O protein|O sequence|O and|O can|O explain|O the|O ready|O access|O of|O D2|gene-protein -|O generated|O T3|gene-protein to|O the|O nucleus|O .|O 
Amplification|O of|O the|O MYCN|gene-rna oncogene|O and|O deletion|O of|O putative|O tumour|gene-rna suppressor|gene-rna gene|gene-rna in|O human|O neuroblastomas|O .|O 
Human|O neuroblastoma|O cells|O often|O carry|O non|O -|O random|O chromosomal|O abnormalities|O signalling|O genetic|O alterations|O .|O 
Quite|O frequent|O are|O '|O double|O minutes|O '|O (|O DMs|O )|O and|O homogeneously|O staining|O regions|O (|O HSRs|O )|O ,|O both|O cytogenetic|O manifestations|O of|O amplified|O DNA|O ,|O and|O chromosome|O 1p|O -|O deletions|O indicating|O loss|O of|O genetic|O information|O .|O 
With|O the|O identification|O of|O amplified|O MYCN|gene-rna and|O the|O demonstration|O of|O a|O consensus|O deletion|O spanning|O the|O chromosome|O 1p36.1-2|O region|O it|O appears|O now|O likely|O that|O both|O amplification|O of|O a|O cellular|O oncogene|O and|O loss|O of|O a|O tumour|gene-rna -|gene-rna suppressor|gene-rna gene|gene-rna play|O an|O important|O role|O in|O neuroblastoma|O .|O 
Amplification|O of|O MYCN|gene-rna is|O an|O indicator|O for|O poor|O prognosis|O ,|O even|O when|O classical|O morphological|O criteria|O would|O suggest|O a|O better|O outcome|O .|O 
Consequently|O ,|O patients|O with|O amplification|O are|O subjected|O to|O more|O intensive|O therapeutic|O regimens|O .|O 
Amplification|O of|O MYCN|gene-rna is|O a|O paradigm|O for|O the|O clinical|O use|O of|O an|O oncogene|O alteration|O .|O 
Glyceraldehyde-3-phosphate|gene-protein dehydrogenase|gene-protein ,|O the|O putative|O target|O of|O the|O antiapoptotic|O compounds|O CGP|O 3466|O and|O R-(-)-deprenyl|O .|O 
R-(-)-Deprenyl|O (|O Selegiline|O )|O represents|O one|O of|O the|O drugs|O currently|O used|O for|O the|O treatment|O of|O Parkinson|O 's|O disease|O .|O 
This|O compound|O was|O shown|O to|O protect|O neurons|O or|O glias|O from|O programmed|O cell|O death|O in|O a|O variety|O of|O models|O .|O 
The|O mechanism|O of|O action|O of|O neuroprotection|O as|O well|O as|O inhibition|O of|O apoptosis|O remains|O elusive|O .|O 
CGP|O 3466|O is|O a|O structurally|O related|O analog|O of|O R-(-)-deprenyl|O that|O exhibits|O virtually|O no|O monoamine|gene-protein oxidase|gene-protein type|gene-protein B|gene-protein inhibiting|O activity|O but|O is|O neuroprotective|O in|O the|O picomolar|O concentration|O range|O .|O 
We|O showed|O specific|O binding|O of|O CGP|O 3466|O to|O glyceraldehyde-3-phosphate|gene-protein dehydrogenase|gene-protein by|O affinity|O binding|O ,|O by|O affinity|O labeling|O ,|O and|O by|O means|O of|O BIAcore(R)|O technology|O .|O 
Apoptosis|O assays|O based|O on|O the|O human|O neuroblastoma|O cell|O line|O PAJU|O established|O the|O importance|O of|O this|O interaction|O for|O mediating|O drug|O -|O induced|O inhibition|O of|O programmed|O cell|O death|O .|O 
Caspase|gene-protein 8|gene-protein is|O deleted|O or|O silenced|O preferentially|O in|O childhood|O neuroblastomas|O with|O amplification|O of|O MYCN|gene-rna .|O 
Caspase|gene-protein 8|gene-protein is|O a|O cysteine|gene-protein protease|gene-protein regulated|O in|O both|O a|O death|O -|O receptor|O -|O dependent|O and|O -|O independent|O manner|O during|O apoptosis|O .|O 
Here|O ,|O we|O report|O that|O the|O gene|O for|O caspase|gene-protein 8|gene-protein is|O frequently|O inactivated|O in|O neuroblastoma|O ,|O a|O childhood|O tumor|O of|O the|O peripheral|O nervous|O system|O .|O 
The|O gene|O is|O silenced|O through|O DNA|O methylation|O as|O well|O as|O through|O gene|O deletion|O .|O 
Complete|O inactivation|O of|O CASP8|gene-rna occurred|O almost|O exclusively|O in|O neuroblastomas|O with|O amplification|O of|O the|O oncogene|O MYCN|gene-rna .|O 
Caspase|gene-protein 8|gene-protein -|O null|O neuroblastoma|O cells|O were|O resistant|O to|O death|O receptor|O -|O and|O doxorubicin|O -|O mediated|O apoptosis|O ,|O deficits|O that|O were|O corrected|O by|O programmed|O expression|O of|O the|O enzyme|O .|O 
Thus|O ,|O caspase|gene-protein 8|gene-protein acts|O as|O a|O tumor|O suppressor|O in|O neuroblastomas|O with|O amplification|O of|O MYCN|gene-rna .|O 
The|O N-myc|gene-rna paradox|O :|O N-myc|gene-rna overexpression|O in|O neuroblastomas|O is|O associated|O with|O sensitivity|O as|O well|O as|O resistance|O to|O apoptosis|O .|O 
Neuroblastomas|O are|O characterized|O by|O defects|O in|O tumor|gene-protein necrosis|gene-protein factor|gene-protein -|gene-protein related|gene-protein apoptosis|gene-protein inducing|gene-protein ligand|gene-protein (|O TRAIL|gene-protein )|O induced|O apoptosis|O ,|O especially|O down|O -|O regulation|O and|O methylation|O of|O Caspase-8|gene-protein (|O CASP8|gene-protein )|O .|O 
This|O defect|O is|O associated|O with|O amplification|O of|O N-myc|gene-rna .|O 
However|O ,|O N-myc|gene-rna has|O also|O been|O implicated|O in|O induction|O of|O apoptosis|O ,|O especially|O activation|O of|O CASP9|gene-generic mediated|O apoptosis|O .|O 
Here|O we|O found|O that|O ectopic|O N-myc|gene-rna expression|O induces|O TRAIL|gene-protein susceptibility|O ,|O both|O by|O CASP8|gene-protein and|O CASP9|gene-protein mediated|O apoptosis|O .|O 
N-myc|gene-rna did|O not|O modify|O CASP8|gene-protein expression|O and|O methylation|O .|O 
CASP8|gene-protein defects|O therefore|O represent|O an|O independent|O event|O in|O neuroblastoma|O ,|O counteracting|O the|O N-myc|gene-rna induced|O susceptibility|O to|O apoptosis|O .|O 
Analysis|O of|O the|O CASP9|gene-protein mediated|O route|O in|O a|O series|O of|O neuroblastoma|O cell|O lines|O ,|O we|O found|O normal|O expression|O and|O no|O aberrant|O methylation|O of|O four|O apoptotic|O intermediates|O ,|O including|O CASP9|gene-protein itself|O .|O 
Targeted|O cytokines|gene-protein for|O cancer|O immunotherapy|O .|O 
Targeting|O of|O cytokines|gene-protein into|O the|O tumor|O microenvironment|O using|O antibody|gene-protein -|gene-protein cytokine|gene-protein fusion|gene-protein proteins|gene-protein ,|O called|O immunocytokines|gene-protein ,|O represents|O a|O novel|O approach|O in|O cancer|O immunotherapy|O .|O 
This|O article|O summarizes|O therapeutic|O efficacy|O and|O immune|O mechanisms|O involved|O in|O targeting|O interleukin-2|gene-protein (|O IL-2|gene-protein )|O to|O neuroectodermal|O tumors|O using|O ganglioside|gene-protein GD2|gene-protein -|gene-protein specific|gene-protein antibody-IL-2|gene-protein fusion|gene-protein protein|gene-protein (|O ch14.18-IL-2|gene-protein )|O .|O 
Treatment|O of|O established|O melanoma|O metastases|O with|O ch14.18-IL-2|gene-protein resulted|O in|O eradication|O of|O disease|O followed|O by|O a|O vaccination|O effect|O protecting|O mice|O from|O lethal|O challenges|O with|O wild|O -|O type|O tumor|O calls|O .|O 
In|O a|O syngeneic|O neuroblastoma|O model|O ,|O targeted|O IL-2|gene-protein was|O effective|O in|O the|O amplification|O of|O a|O weak|O memory|O immune|O response|O previously|O induced|O by|O IL-12|gene-rna gene|O therapy|O using|O an|O engineered|O linear|O version|O of|O this|O heterodimeric|O cytokine|gene-protein .|O 
These|O findings|O show|O that|O targeted|O IL-2|gene-protein may|O provide|O an|O effective|O tool|O in|O cancer|O immunotherapy|O and|O establish|O the|O missing|O link|O between|O T|O cell|O -|O mediated|O vaccination|O and|O objective|O clinical|O responses|O .|O 
Staurosporine|O induces|O a|O neuronal|O phenotype|O in|O SH-SY5Y|O human|O neuroblastoma|O cells|O that|O resembles|O that|O induced|O by|O the|O phorbol|O ester|O 12-O-tetradecanoyl|O phorbol-13|O acetate|O (|O TPA|O )|O .|O 
Treatment|O of|O SH-SY5Y|O human|O neuroblastoma|O cells|O with|O the|O protein|O kinase|gene-protein inhibitor|O staurosporine|O ,|O induced|O both|O morphological|O and|O functional|O differentiation|O in|O these|O cells|O .|O 
The|O effects|O of|O staurosporine|O were|O comparable|O to|O those|O induced|O by|O the|O protein|gene-protein kinase|gene-protein C|gene-protein (|O PKC|gene-protein )|O activator|O ,|O 12-O-tetradecanoyl|O phorbol|O 13-acetate|O (|O TPA|O )|O ,|O with|O respect|O to|O induction|O of|O neuronal|O differentiation|O ,|O i.e.|O neurite|O outgrowth|O ,|O inhibition|O of|O DNA|O synthesis|O ,|O induction|O and|O down|O -|O regulation|O of|O c-myc|gene-protein protein|O expression|O ,|O induction|O of|O mRNA|O for|O both|O neuropeptide|O Y|O (|O NPY|O )|O and|O growth|gene-protein associated|gene-protein protein|gene-protein 43|gene-protein (|O GAP-43|gene-protein )|O and|O stimulation|O of|O tyrosine|gene-protein hydroxylase|gene-protein expression|O .|O 
Staurosporine|O failed|O to|O translocate|O PKC|gene-protein to|O the|O membrane|O fraction|O or|O to|O stimulate|O phosphorylation|O of|O the|O endogenous|O PKC|gene-protein substrate|O M(r)|O 80,000|O (|O p80|gene-protein )|O .|O 
Instead|O ,|O staurosporine|O inhibited|O TPA|O -|O induced|O phosphorylation|O of|O p80|gene-protein .|O 
Reduction|O of|O N-myc|gene-rna expression|O by|O antisense|O RNA|O is|O amplified|O by|O interferon|gene-protein :|O possible|O involvement|O of|O the|O 2-5A|O system|O .|O 
Expression|O of|O myc-box|gene-rna genes|O can|O be|O reduced|O by|O Interferon|gene-protein (|O c-myc|gene-rna in|O Daudi|O cells|O )|O or|O Retinoic|O acid|O (|O N-myc|gene-rna in|O neuroblastoma|O cells|O )|O .|O 
Interferon|gene-protein did|O not|O reduce|O N-myc|gene-rna expression|O in|O neuroblastoma|O cells|O .|O 
However|O ,|O after|O transfection|O of|O the|O human|O neuroblastoma|O cell|O line|O LS|O with|O a|O vector|O ,|O providing|O the|O Cadmium|O inducible|O expression|O of|O an|O antisense|O N-myc|gene-rna transcript|O ,|O drastic|O reduction|O of|O N-myc|gene-rna RNA|O was|O achieved|O in|O these|O cells|O by|O incubation|O with|O Cadmium|O and|O Interferon|gene-protein .|O 
Treatment|O with|O Cadmium|O alone|O resulted|O in|O a|O comparably|O small|O reduction|O of|O N-myc|gene-rna transcripts|O in|O these|O cells|O .|O 
Interferon|gene-protein alone|O did|O not|O appreciably|O affect|O N-myc|gene-rna expression|O .|O 
Reduction|O of|O N-myc|gene-rna was|O accompanied|O with|O reduced|O cell|O proliferation|O and|O morphological|O differentiation|O .|O 
It|O is|O assumed|O that|O most|O of|O the|O inhibitory|O effects|O observed|O are|O mediated|O by|O the|O Interferon|gene-protein inducible|O 2-5A|O system|O .|O 
Irreversible|O modification|O of|O measles|O virus|O RNA|O in|O vitro|O by|O nuclear|O RNA|O -|O unwinding|O activity|O in|O human|O neuroblastoma|O cells|O .|O 
The|O matrix|gene-rna (|O M|gene-rna )|O gene|O of|O a|O measles|O virus|O (|O MV|O )|O variant|O passaged|O in|O IMR-32|O human|O neuroblastoma|O cells|O displays|O numerous|O uridine|O -|O to|O -|O cytosine|O transitions|O called|O biased|O hypermutation|O .|O 
Using|O an|O in|O vitro|O assay|O ,|O we|O show|O that|O IMR-32|O cells|O contain|O high|O levels|O of|O an|O activity|O which|O unwinds|O and|O irreversibly|O alters|O the|O base|O pairing|O of|O double|O -|O stranded|O RNA|O synthesized|O from|O the|O M|gene-rna gene|O of|O MV|O .|O 
This|O activity|O is|O found|O exclusively|O in|O the|O cellular|O nucleus|O and|O is|O present|O at|O a|O lower|O level|O in|O African|O green|O monkey|O kidney|O Vero|O cells|O .|O 
Experiments|O with|O mixed|O cell|O extracts|O suggest|O that|O the|O low|O activity|O in|O Vero|O cells|O is|O not|O due|O to|O inhibitory|O factors|O .|O 
These|O findings|O support|O the|O hypothesis|O that|O this|O RNA|O -|O modifying|O and|O -|O unwinding|O activity|O is|O responsible|O for|O biased|O hypermutation|O of|O MV|O strains|O that|O infect|O the|O central|O nervous|O system|O .|O 
Possible|O functions|O of|O this|O neural|O cell|O activity|O and|O implications|O for|O central|O nervous|O system|O disorders|O are|O discussed|O .|O 
Loss|O of|O allelic|O heterozygosity|O on|O distal|O chromosome|O 1p|O in|O Merkel|O cell|O carcinoma|O .|O 
A|O marker|O of|O neural|O crest|O origins|O ?|O 
The|O location|O of|O genes|O involved|O in|O tumor|O evolution|O has|O been|O inferred|O from|O experiments|O in|O which|O loss|O of|O constitutional|O heterozygosity|O has|O been|O detected|O in|O tumor|O DNA|O at|O high|O frequency|O in|O specific|O chromosome|O regions|O .|O 
For|O example|O ,|O cytogenetic|O and|O molecular|O abnormalities|O on|O chromosome|O 1p|O have|O been|O reported|O in|O tumors|O such|O as|O malignant|O melanoma|O and|O neuroblastoma|O which|O arise|O in|O cells|O derived|O from|O embryonic|O neural|O crest|O tissue|O .|O 
To|O extend|O these|O observations|O ,|O we|O have|O examined|O tumor|O DNA|O from|O three|O cases|O of|O Merkel|O cell|O carcinoma|O for|O evidence|O of|O loss|O of|O constitutional|O heterozygosity|O on|O the|O short|O arm|O of|O chromosome|O 1|O .|O 
In|O all|O three|O cases|O ,|O heterozygous|O allelic|O deletions|O of|O varying|O extent|O on|O distal|O chromosome|O 1p|O were|O detected|O in|O tumor|O DNA|O .|O 
Comparisons|O with|O neural|O crest|O tumors|O suggest|O that|O loss|O of|O heterozygosity|O on|O distal|O chromosome|O 1p|O in|O Merkel|O cell|O tumors|O may|O be|O a|O marker|O of|O neural|O crest|O origin|O .|O 
N-myc|gene-rna oncogene|O RNA|O expression|O in|O neuroblastoma|O .|O 
Tumor|O specimens|O from|O 33|O patients|O with|O neuroblastoma|O were|O assayed|O for|O amplification|O of|O the|O N-myc|gene-rna oncogene|O and|O RNA|O expression|O to|O determine|O whether|O N-myc|gene-rna RNA|O expression|O levels|O correlated|O with|O N-myc|gene-rna gene|O amplification|O and|O clinical|O outcome|O .|O 
N-myc|gene-rna gene|O amplification|O was|O detected|O in|O one|O stage|O II|O tumor|O ,|O one|O stage|O IV-S|O tumor|O ,|O and|O seven|O stage|O III|O or|O IV|O tumors|O .|O In|O each|O case|O ,|O N-myc|gene-rna RNA|O expression|O roughly|O paralleled|O N-myc|gene-rna gene|O amplification|O .|O 
However|O ,|O enhanced|O N-myc|gene-rna RNA|O expression|O was|O not|O confined|O to|O tumors|O with|O N-myc|gene-rna gene|O amplification|O :|O all|O of|O the|O early|O (|O stage|O I|O and|O II|O )|O tumors|O ,|O five|O stage|O IV-S|O tumors|O ,|O and|O 12|O advanced|O (|O stage|O III|O and|O IV|O )|O tumors|O had|O levels|O of|O N-myc|gene-rna RNA|O that|O were|O elevated|O up|O to|O 50|O -|O fold|O .|O 
While|O N-myc|gene-rna gene|O amplification|O correlated|O with|O prognosis|O ,|O there|O was|O no|O such|O correlation|O with|O levels|O of|O N-myc|gene-rna RNA|O expression|O .|O 
The|O precise|O role|O of|O the|O N-myc|gene-rna gene|O in|O the|O pathogenesis|O of|O neuroblastoma|O remains|O unclear|O .|O 
Differential|O expression|O in|O an|O antisense|O MYCN|gene-rna neuroblastoma|O model|O .|O 
BACKGROUND|O :|O 
A|O previously|O published|O antisense|O MYCN|gene-rna -|O expressing|O model|O system|O was|O utilized|O to|O identify|O genes|O whose|O expression|O is|O altered|O by|O the|O down|O -|O regulation|O of|O MYCN|gene-rna by|O AS|O MYCN|gene-rna .|O 
RESULTS|O :|O 
Differential|O display|O comparing|O nontransfected|O human|O NB|O NBL-S|O cells|O to|O three|O AS|O MYCN|gene-rna -|O expressing|O cell|O lines|O (|O NBAS|O -|O 4|O ,|O -|O 5|O ,|O and|O -|O 6|O )|O yielded|O nine|O differentially|O expressed|O cDNAs|O designated|O NDDE|gene-rna :|gene-rna 1|gene-rna -|gene-rna 9|gene-rna ,|O for|O MYCN|gene-rna -|gene-rna dependent|gene-rna differential|O expression|gene-rna genes|O .|O 
A|O GenBank|O search|O revealed|O matches|O for|O seven|O of|O the|O nine|O cDNAs|O .|O 
Differential|O expression|O was|O confirmed|O for|O five|O of|O the|O cDNAs|O by|O Northern|O blot|O analysis|O .|O 
RESULTS|O :|O 
NDDE|gene-rna :|gene-rna 8|gene-rna is|O up|O -|O regulated|O in|O the|O AS|O MYCN|gene-rna -|O expressing|O clones|O and|O shares|O homology|O with|O the|O EB1|gene-rna clone|gene-rna p53|gene-rna -|gene-rna induced|gene-rna gene|gene-rna (|O PRG3|gene-rna )|O .|O 
NDDE|gene-rna :|gene-rna 2|gene-rna is|O up|O -|O regulated|O in|O the|O high|O -|O expressing|O N-myc|gene-protein protein|O NBL-S|O cells|O and|O shares|O homology|O with|O a|O 27|O kD|O heat|O shock|O protein|O PAN1|gene-protein clone|O .|O 
Further|O analysis|O of|O all|O five|O cDNAs|O might|O further|O elucidate|O the|O targets|O of|O MYCN|gene-protein in|O NB|O .|O 
A|O product|O of|O DAN|gene-rna ,|O a|O novel|O candidate|O tumour|O suppressor|O gene|O ,|O is|O secreted|O into|O culture|O medium|O and|O suppresses|O DNA|O synthesis|O .|O 
Our|O previous|O studies|O have|O shown|O that|O the|O DAN|gene-protein gene|O product|O possesses|O an|O ability|O to|O revert|O phenotypes|O of|O transformed|O rat|O fibroblasts|O and|O represents|O a|O candidate|O tumour|O suppressor|O gene|O for|O neuroblastoma|O .|O 
In|O the|O present|O study|O ,|O characterisation|O of|O DAN|gene-protein was|O carried|O out|O using|O rat|O fibroblast|O 3Y1|O cells|O and|O their|O DAN|gene-rna -|O overexpressor|O counterparts|O (|O S-9|O )|O .|O 
The|O N|O -|O terminal|O region|O of|O DAN|gene-protein (|O amino|O acids|O 1|O -|O 24|O )|O was|O highly|O hydrophobic|O and|O DAN|gene-protein protein|O was|O found|O to|O be|O secreted|O into|O the|O culture|O medium|O .|O 
When|O DAN|gene-protein was|O treated|O with|O PNGase|gene-protein F|gene-protein ,|O a|O enzyme|O that|O cleaves|O most|O N|O -|O linked|O carbohydrate|O residues|O ,|O the|O mobility|O of|O both|O cytoplasmic|O and|O secreted|O DAN|gene-protein was|O increased|O in|O SDS|O -|O polyacrylamide|O gel|O electrophoresis|O ,|O suggesting|O DAN|gene-protein is|O N-glycosylated|O ,|O irrespective|O of|O its|O localisation|O .|O 
When|O partially|O purified|O ,|O DAN|gene-protein was|O able|O ,|O when|O added|O to|O the|O culture|O ,|O to|O suppress|O DNA|O synthesis|O of|O Rous|O sarcoma|O virus|O -|O transformed|O 3Y1|O cells|O ,|O which|O lack|O the|O expression|O of|O DAN|gene-protein .|O 
p73|gene-rna mutations|O are|O not|O detected|O in|O sporadic|O and|O hereditary|O breast|O cancer|O .|O 
Recently|O ,|O a|O novel|O tumor|O suppressor|O gene|O ,|O p73|gene-rna ,|O was|O isolated|O and|O mapped|O to|O chromosome|O 1p36|O ,|O a|O region|O commonly|O associated|O with|O loss|O of|O heterozygosity|O in|O neuroblastoma|O and|O other|O human|O malignancies|O ,|O including|O breast|O cancer|O .|O 
The|O p73|gene-rna gene|O shares|O considerable|O homology|O with|O the|O common|O tumor|O suppressor|O gene|O p53|gene-rna ,|O both|O in|O composition|O and|O function|O .|O 
This|O study|O examines|O the|O potential|O participation|O of|O p73|gene-rna in|O the|O pathogenesis|O of|O sporadic|O and|O hereditary|O breast|O cancers|O .|O 
Mutation|O analysis|O of|O 29|O hereditary|O breast|O cancer|O cases|O revealed|O five|O independent|O silent|O mutations|O in|O the|O hereditary|O cases|O that|O are|O unlikely|O to|O play|O a|O role|O in|O tumor|O development|O .|O 
Mutation|O analysis|O of|O 48|O sporadic|O breast|O tumors|O did|O not|O identify|O any|O unique|O variants|O .|O 
Eleven|O common|O polymorphisms|O scattered|O throughout|O the|O gene|O were|O also|O detected|O .|O 
Thus|O ,|O mutations|O in|O the|O p73|gene-rna gene|O appear|O to|O play|O little|O if|O any|O role|O in|O hereditary|O or|O sporadic|O breast|O cancer|O .|O 
Endogenous|O opioid|gene-protein receptor|gene-protein -|gene-protein like|gene-protein receptor|gene-protein in|O human|O neuroblastoma|O SK-N-SH|O cells|O :|O activation|O of|O inhibitory|O G|gene-protein protein|gene-protein and|O homologous|O desensitization|O .|O 
Endogenous|O expression|O of|O opioid|gene-protein receptor|gene-protein -|gene-protein like|gene-protein receptor|gene-protein (|O ORL1|gene-protein )|O ,|O in|O human|O neuroblastoma|O SK-N-SH|O cells|O was|O demonstrated|O by|O binding|O with|O nociceptin|gene-protein /|O orphanin|gene-protein FQ|gene-protein (|O N|gene-protein /|O OFQ|gene-protein )|O .|O 
Scatchard|O analysis|O of|O [3H]|O N|gene-protein /|O OFQ|gene-protein saturation|O binding|O data|O gave|O Kd|O =|O 1.3|O +/-|O 0.1|O nM|O and|O Bmax|O =|O 1.58|O +/-|O 2.5|O fmol|O /|O mg|O protein|O .|O 
N|gene-protein /|O OFQ|gene-protein stimulation|O increased|O [35S]GTP|O gamma|O S|O binding|O to|O cell|O membranes|O and|O attenuated|O forskolin|O -|O induced|O cAMP|O accumulation|O in|O a|O concentration|O -|O dependent|O manner|O .|O 
The|O effects|O of|O N|gene-protein /|O OFQ|gene-protein were|O eliminated|O by|O the|O pretreatment|O of|O pertussis|gene-protein toxin|gene-protein (|O PTX|gene-protein )|O but|O not|O by|O the|O antagonists|O of|O opioid|gene-protein receptors|gene-protein ,|O revealing|O mediation|O of|O N|gene-protein /|O OFQ|gene-protein signal|O transduction|O by|O ORL1|gene-protein receptor|gene-protein and|O PTX|gene-protein sensitive|O G|gene-protein protein(s)|gene-protein .|O 
The|O ability|O of|O N|gene-protein /|O OFQ|gene-protein to|O inhibit|O cAMP|O production|O was|O greatly|O reduced|O after|O prechallenging|O with|O N|gene-protein /|O OFQ|gene-protein ,|O indicating|O that|O ORL1|gene-protein undergoes|O homologous|O desensitization|O in|O neuronal|O cells|O .|O 
Long|O -|O term|O morphine|O treatment|O increases|O Ku|gene-protein protein|O DNA|O end|O -|O binding|O activity|O .|O 
Human|O neuroblastoma|O SH-SY5Y|O and|O small|O -|O cell|O lung|O carcinoma|O U1690|O cells|O of|O neuroendocrine|O origin|O were|O exposed|O to|O morphine|O for|O 1|O h|O ,|O 3|O h|O or|O 5|O days|O .|O 
These|O treatments|O did|O not|O alter|O activities|O of|O AP-1|gene-protein ,|O NF-kappa|gene-protein B|gene-protein and|O YY1|gene-protein transcription|O factors|O in|O SH-SY5Y|O cells|O or|O NF-kappa|gene-protein B|gene-protein and|O YY1|gene-protein in|O U1690|O cells|O .|O 
Five|O -|O day|O morphine|O treatment|O ,|O however|O ,|O caused|O a|O twofold|O increase|O in|O the|O activity|O of|O a|O sequence|O -|O non|O -|O specific|O ,|O spermidine|gene-protein -|gene-protein activated|gene-protein DNA|gene-protein -|gene-protein binding|gene-protein factor|gene-protein in|O U1690|O cells|O .|O 
The|O morphine|O effect|O was|O prevented|O by|O the|O antagonist|O naloxone|O .|O 
The|O DNA|O -|O binding|O factor|O bound|O preferentially|O to|O double|O -|O stranded|O DNA|O ends|O .|O 
This|O fact|O and|O data|O on|O subunit|O composition|O ,|O molecular|O masses|O of|O subunits|O ,|O and|O supershift|O /|O inhibition|O by|O specific|O antibodies|O in|O a|O band|O shift|O assay|O ,|O show|O the|O spermidine|gene-protein -|gene-protein activated|gene-protein factor|gene-protein to|O be|O identical|O with|O the|O Ku|gene-protein protein|O ,|O the|O DNA|O -|O binding|O subunit|O of|O DNA|gene-protein -|gene-protein dependent|gene-protein protein|gene-protein kinase|gene-protein .|O 
The|O effect|O observed|O may|O be|O one|O of|O the|O mechanisms|O through|O which|O opioids|O influence|O gene|O regulation|O .|O 
Parc|gene-protein :|O a|O cytoplasmic|O anchor|O for|O p53|gene-protein .|O 
Nuclear|O localization|O of|O p53|gene-protein is|O essential|O for|O its|O tumor|O suppressor|O function|O .|O 
Here|O ,|O we|O have|O identified|O Parc|gene-protein ,|O a|O Parkin|gene-protein -|gene-protein like|gene-protein ubiquitin|gene-protein ligase|gene-protein ,|O as|O a|O cytoplasmic|O anchor|O protein|O in|O p53|gene-protein -|O associated|O protein|O complexes|O .|O 
Parc|gene-protein directly|O interacts|O and|O forms|O a|O approximately|O 1|O MDa|O complex|O with|O p53|gene-protein in|O the|O cytoplasm|O of|O unstressed|O cells|O .|O 
In|O the|O absence|O of|O stress|O ,|O inactivation|O of|O Parc|gene-protein induces|O nuclear|O localization|O of|O endogenous|O p53|gene-protein and|O activates|O p53|gene-protein -|O dependent|O apoptosis|O .|O 
Overexpression|O of|O Parc|gene-protein promotes|O cytoplasmic|O sequestration|O of|O ectopic|O p53|gene-protein .|O 
Furthermore|O ,|O abnormal|O cytoplasmic|O localization|O of|O p53|gene-protein was|O observed|O in|O a|O number|O of|O neuroblastoma|O cell|O lines|O ;|O RNAi|O -|O mediated|O reduction|O of|O endogenous|O Parc|gene-protein significantly|O sensitizes|O these|O neuroblastoma|O cells|O in|O the|O DNA|O damage|O response|O .|O 
These|O results|O reveal|O that|O Parc|gene-protein is|O a|O critical|O regulator|O in|O controlling|O p53|gene-protein subcellular|O localization|O and|O subsequent|O function|O .|O 
Generation|O of|O immortalized|O murine|O forebrain|O cell|O lines|O expressing|O an|O alpha|gene-protein isoform|gene-protein of|gene-protein Ca2+|gene-protein /|gene-protein calmodulin|gene-protein -|gene-protein dependent|gene-protein protein|gene-protein kinase|gene-protein II|gene-protein .|O 
Immortalized|O hybrid|O cells|O were|O generated|O by|O the|O somatic|O fusion|O of|O the|O cells|O from|O the|O forebrain|O of|O embryonic|O mouse|O with|O N18TG2|O neuroblastoma|O cells|O .|O 
Three|O monoclonal|O hybrid|O cell|O lines|O ,|O designated|O NF26|O ,|O NF81|O ,|O and|O NF83|O (|O neuroblastoma|O forebrain|O hybrid|O cells|O )|O ,|O expressing|O an|O alpha|gene-protein isoform|gene-protein of|gene-protein Ca2+|gene-protein /|gene-protein calmodulin|gene-protein -|gene-protein dependent|gene-protein protein|gene-protein kinase|gene-protein II|gene-protein (|O CaM|gene-protein kinase|gene-protein II|gene-protein )|O were|O isolated|O ,|O and|O their|O expression|O was|O demonstrated|O by|O immunoblotting|O and|O immunocytochemistry|O using|O a|O monoclonal|gene-protein antibody|gene-protein specific|O to|O the|O a|O isoform|O of|O the|O enzyme|O .|O 
The|O kinase|gene-protein activity|O of|O the|O hybrid|O cells|O was|O 2|O -|O to|O 3|O -|O fold|O higher|O than|O that|O of|O the|O parent|O neuroblastoma|O line|O N18TG2|O cells|O .|O 
The|O neuronal|O origin|O of|O these|O lines|O was|O shown|O by|O their|O immunoreactivity|O to|O neurofilament|gene-protein protein|gene-protein ,|O a|O neuron|O specific|O marker|O .|O 
Lines|O NF26|O ,|O NF81|O ,|O and|O NF83|O are|O the|O first|O cell|O lines|O to|O express|O the|O gene|O of|O the|O alpha|gene-protein isoform|gene-protein of|gene-protein CaM|gene-protein kinase|gene-protein II|gene-protein in|O the|O brain|O .|O 
Use|O of|O gene|O marking|O in|O bone|O marrow|O transplantation|O .|O 
We|O have|O used|O gene|O marking|O to|O investigate|O the|O mechanism|O of|O relapse|O and|O biology|O of|O reconstitution|O following|O bone|O marrow|O transplantation|O (|O BMT|O )|O .|O 
The|O rationale|O for|O our|O initial|O protocols|O was|O to|O learn|O if|O residual|O malignant|O cells|O in|O autologous|O marrow|O contribute|O to|O subsequent|O relapse|O .|O 
Marked|O malignant|O cells|O were|O found|O at|O the|O time|O of|O relapse|O in|O 6|O /|O 8|O patients|O relapsing|O after|O autologous|O BMT|O for|O AML|O or|O neuroblastoma|O showing|O the|O infused|O marrow|O contributed|O to|O disease|O recurrence|O .|O 
Modifications|O of|O this|O marker|O approach|O with|O two|O distinguishable|O vectors|O are|O now|O being|O used|O to|O compare|O the|O efficacy|O of|O purging|O techniques|O .|O 
We|O were|O also|O able|O to|O evaluate|O gene|O transfer|O to|O normal|O progenitors|O and|O demonstrated|O that|O the|O marker|O gene|O was|O expressed|O for|O up|O to|O 36|O months|O .|O 
Gene|O marking|O is|O also|O being|O used|O to|O trace|O the|O fate|O of|O EBV|O -|O specific|O CTLs|O that|O we|O are|O administering|O to|O recipients|O of|O allogeneic|O BMT|O and|O has|O provided|O evidence|O of|O persistence|O of|O adoptively|O transferred|O CTL|O for|O up|O to|O 10|O months|O .|O 
Surgical|O treatment|O of|O anterior|O callosal|O tumors|O .|O 
OBJECTIVE|O :|O Thirteen|O patients|O with|O neoplasm|O of|O anterior|O corpus|O callosum|O have|O undergone|O our|O observation|O during|O the|O last|O two|O years|O .|O 
METHODS|O :|O For|O the|O diagnosis|O ,|O all|O the|O patients|O underwent|O TC|O ,|O NMR|O and|O stereotactic|O biopsy|O .|O In|O 6|O cases|O with|O glioblastomas|O ,|O a|O radiation|O treatment|O was|O adopted|O .|O 
The|O other|O 7|O patients|O underwent|O total|O surgical|O treatment|O in|O 5|O cases|O ,|O and|O partial|O in|O 2|O cases|O ,|O as|O documented|O by|O postoperative|O contrast|O -|O enhanced|O CT|O scanning|O .|O 
Histologically|O ,|O there|O were|O :|O 3|O glioblastomas|O ,|O 1|O grade|O III|O astrocytoma|O ,|O 1|O neuroblastoma|O (|O PNET|O )|O ,|O 2|O pilocytic|O astrocytomas|O .|O 
RESULTS|O :|O Neuropsychological|O tests|O carried|O out|O on|O the|O 5|O patients|O still|O living|O showed|O persistent|O disturbances|O of|O verbal|O memory|O in|O all|O five|O and|O disturbances|O of|O verbal|O phonological|O fluency|O in|O 3|O cases|O .|O 
No|O patient|O presented|O apraxia|O ,|O dysgraphia|O and|O dyslexia|O .|O 
CONCLUSIONS|O :|O Thus|O ,|O no|O severe|O neuropsychological|O deficits|O developed|O after|O surgical|O treatment|O of|O anterior|O callosal|O tumors|O .|O 
Nitric|O oxide|O donor|O -|O induced|O p53|gene-protein -|O sensitive|O cell|O death|O is|O enhanced|O by|O Bcl-2|gene-protein reduction|O in|O human|O neuroblastoma|O cells|O .|O 
In|O human|O neuroblastoma|O SH-SY5Y|O cells|O ,|O S-nitroso-N-acetylpenicillamine|O (|O SNAP|O )|O ,|O a|O nitric|O oxide|O (|O NO|O )|O -|O donor|O ,|O caused|O cell|O death|O accompanying|O p53|gene-protein expression|O ,|O nucleosomal|O DNA|O fragmentation|O and|O cell|O death|O .|O 
In|O addition|O ,|O SNAP|O -|O induced|O cell|O death|O and|O DNA|O fragmentation|O were|O enhanced|O by|O pretreatment|O for|O 4|O days|O with|O N6,2'-O-dibutyryl|O cyclic|O AMP|O (|O diBu-cAMP|O )|O or|O staurosporine|O ,|O while|O those|O were|O not|O changed|O by|O pretreatment|O with|O phorbol|O 12-myristate|O 13-acetate|O (|O PMA|O )|O .|O 
Protein|O level|O of|O Bcl-2|gene-protein was|O decreased|O by|O pretreatment|O with|O diBu-cAMP|O or|O staurosporine|O ,|O and|O ,|O on|O the|O contrary|O ,|O the|O level|O was|O increased|O by|O pretreatment|O with|O PMA|O .|O 
However|O ,|O these|O pretreatments|O did|O not|O change|O Bax|gene-protein protein|O level|O and|O SNAP|O -|O induced|O p53|gene-protein expression|O .|O 
However|O ,|O SNAP|O -|O treatment|O did|O not|O change|O protein|O levels|O of|O Bcl-2|gene-protein and|O Bax|gene-protein .|O 
These|O results|O suggest|O that|O SNAP|O -|O induced|O p53|gene-protein -|O sensitive|O apoptosis|O is|O enhanced|O by|O Bcl-2|gene-protein reduction|O ,|O and|O that|O Bcl-2|gene-protein and|O Bax|gene-protein may|O act|O downstream|O of|O p53|gene-protein in|O SH-SY5Y|O cells|O .|O 
L-cysteine|O increases|O glucose|O uptake|O in|O mouse|O soleus|O muscle|O and|O SH-SY5Y|O cells|O .|O 
Previous|O investigation|O demonstrated|O the|O potential|O of|O L-cysteine|O (|O L-Cys|O )|O at|O high|O concentrations|O to|O cause|O hypoglycemia|O in|O mice|O totally|O deprived|O of|O insulin|gene-protein .|O 
For|O further|O elucidation|O of|O the|O glucose|O -|O lowering|O mechanism|O ,|O glucose|O uptake|O and|O quantity|O of|O glucose|gene-protein transporters|gene-protein (|O GLUTs|gene-protein 3|gene-protein and|O 4|gene-protein )|O in|O mouse|O soleus|O muscle|O and|O C2C12|O muscle|O cells|O ,|O as|O well|O as|O in|O human|O SH-SY5Y|O neuroblastoma|O cells|O ,|O were|O investigated|O .|O 
A|O marked|O enhancement|O of|O glucose|O uptake|O was|O demonstrated|O ,|O peaking|O at|O 5.0|O mM|O L-Cys|O in|O soleus|O muscle|O (|O P|O <|O 0.05|O )|O and|O SH-SY5Y|O cells|O (|O P|O <|O 0.001|O )|O ,|O respectively|O .|O 
In|O contrast|O ,|O glucose|O uptake|O was|O not|O affected|O in|O the|O C2C12|O muscle|O cells|O .|O 
Kinetic|O analysis|O of|O the|O SH-SY5Y|O glucose|O uptake|O showed|O a|O 2.5|O -|O fold|O increase|O in|O maximum|O transport|O velocity|O compared|O with|O controls|O (|O P|O <|O 0.001|O )|O .|O 
In|O addition|O ,|O both|O GLUT3|gene-protein and|O GLUT4|gene-protein levels|O were|O increased|O following|O exposure|O to|O L-Cys|O .|O Our|O findings|O point|O to|O a|O possible|O hypoglycemic|O effect|O of|O L-Cys|O .|O 
Covalent|O crosslinking|O analysis|O of|O angiotensin|gene-protein receptors|gene-protein on|O differentiated|O NG108-15|O cells|O .|O 
Neuroblastoma|O x|O glioma|O hybrid|O cells|O (|O NG108-15|O )|O were|O used|O as|O a|O model|O system|O to|O characterize|O neuronal|gene-protein -|gene-protein glial|gene-protein type|gene-protein angiotensin|gene-protein (|gene-protein ANG|gene-protein )|gene-protein receptors|gene-protein by|O covalent|O crosslinking|O analysis|O .|O 
After|O differentiation|O with|O 1.5|O %|O DMSO|O and|O 0.5|O %|O fetal|O bovine|O serum|O for|O four|O to|O five|O days|O ,|O saturation|O analysis|O revealed|O a|O single|O high|O affinity|O site|O with|O a|O Kd|O =|O 1.35|O +/-|O 0.42|O nM|O and|O a|O Bmax|O =|O 468|O +/-|O 106|O fmol|O /|O mg|O protein|O .|O 
Using|O the|O homobifunctional|O crosslinking|O reagent|O bis(sulfosuccinimidyl)|O suberate|O (|O BS3|O )|O ,|O a|O site|O with|O an|O estimated|O Mr|O of|O 78|O kDa|O was|O specifically|O labeled|O with|O 125I|O -|O ANG|gene-protein II|gene-protein as|O determined|O by|O SDS-polyacrylamide|O gel|O electrophoresis|O .|O 
Both|O ANG|gene-protein II|gene-protein and|O ANG|gene-protein III|gene-protein (|O 10(-6)|O M|O )|O inhibited|O specific|O labeling|O .|O 
The|O Ki|O for|O ANG|gene-protein III|gene-protein binding|O was|O similar|O by|O both|O pharmacologic|O (|O Ki|O =|O 3.33|O +/-|O 0.98|O nM|O )|O and|O gel|O densitometric|O (|O Ki|O =|O 2.65|O +/-|O 0.32|O nM|O )|O analyses|O .|O 
We|O conclude|O that|O the|O 78|O kDa|O protein|O represents|O a|O high|O affinity|O ANG|gene-protein binding|O site|O with|O similar|O affinities|O for|O both|O ANG|gene-protein II|gene-protein and|O ANG|gene-protein III|gene-protein .|O 
Procholecystokinin|gene-rna and|O proenkephalin|gene-rna A|gene-rna mRNA|O expression|O is|O modulated|O by|O cyclic|O AMP|O and|O noradrenaline|O .|O 
Regulation|O of|O the|O expression|O of|O procholecystokinin|gene-rna (|O proCCK|gene-rna )|O and|O proenkephalin|gene-rna A|gene-rna mRNA|O was|O studied|O in|O the|O human|O neuroblastoma|O cell|O line|O SK-N-MC|O .|O 
Cells|O were|O treated|O with|O dibutyryl-3',5'-cyclic|O AMP|O (|O dbcAMP|O )|O ,|O noradrenaline|O or|O isoproterenol|O ,|O a|O beta-adrenoceptor|gene-protein agonist|O .|O 
Levels|O of|O proCCK|gene-rna and|O proenkephalin|gene-rna A|gene-rna mRNA|O were|O determined|O by|O Northern|O blot|O analysis|O with|O proCCK|gene-rna -|O and|O proenkephalin|gene-rna A|gene-rna -|O specific|O cRNA|O hybridization|O probes|O 9|O h|O after|O drug|O treatments|O .|O 
ProCCK|gene-rna and|O proenkephalin|gene-rna A|gene-rna mRNA|O were|O co|O -|O expressed|O in|O SK-N-MC|O cells|O .|O 
ProCCK|gene-rna mRNA|O levels|O were|O increased|O 1.5|O -|O 2.5|O times|O by|O dbcAMP|O ,|O noradrenaline|O and|O isoproterenol|O when|O compared|O with|O controls|O .|O 
The|O level|O of|O proenkephalin|gene-rna A|gene-rna mRNA|O increased|O approximately|O two|O to|O three|O times|O under|O the|O same|O drug|O conditions|O ,|O whereas|O the|O level|O of|O N-myc|gene-rna mRNA|O did|O not|O change|O significantly|O .|O 
These|O results|O suggest|O that|O expression|O of|O proCCK|gene-rna and|O proenkephalin|gene-rna A|gene-rna mRNA|O may|O be|O regulated|O by|O a|O similar|O cAMP|O -|O dependent|O mechanism|O in|O the|O SK-N-MC|O cell|O line|O .|O 
Double|O minute|O chromosomes|O .|O 
A|O bone|O marrow|O indicator|O of|O neuroblastoma|O metastasis|O and|O relapse|O :|O two|O case|O reports|O .|O 
Two|O cases|O of|O childhood|O neuroblastoma|O are|O presented|O .|O 
Case|O 1|O was|O diagnosed|O as|O Stage|O IV|O with|O metastasis|O to|O the|O bone|O marrow|O .|O 
During|O remission|O ,|O histologic|O studies|O of|O bone|O marrow|O aspirate|O and|O biopsy|O showed|O a|O normocellular|O marrow|O with|O no|O evidence|O of|O malignant|O cells|O .|O 
Concurrent|O cytogenetic|O studies|O of|O the|O bone|O marrow|O showed|O the|O majority|O of|O the|O cells|O to|O contain|O double|O minute|O chromosomes|O (|O DM|O )|O .|O 
The|O chromosome|O findings|O indicated|O the|O presence|O of|O neuroblastoma|O cells|O in|O the|O marrow|O prior|O to|O histologic|O evidence|O of|O relapse|O .|O 
Case|O 2|O was|O diagnosed|O as|O Stage|O I|O neuroblastoma|O with|O no|O metastasis|O to|O the|O bone|O marrow|O .|O 
Subsequent|O cytogenetic|O studies|O showed|O DM|O present|O in|O a|O small|O number|O of|O cells|O and|O a|O deletion|O of|O chromosome|O 1|O (|O 1p|O -|O )|O in|O a|O single|O cell|O .|O 
The|O chromosome|O findings|O indicated|O an|O advanced|O stage|O of|O malignancy|O which|O was|O not|O evident|O with|O histologic|O techniques|O .|O 
These|O findings|O suggest|O that|O cytogenetic|O analysis|O of|O bone|O marrow|O can|O be|O a|O valuable|O aid|O to|O the|O early|O diagnosis|O ,|O prognosis|O ,|O and|O treatment|O of|O neuroblastoma|O .|O 
Hirschsprung|O associated|O GDNF|gene-rna mutations|O do|O not|O prevent|O RET|gene-rna activation|O .|O 
Hirschsprung|O disease|O (|O HSCR|O )|O is|O a|O complex|O disorder|O characterised|O by|O aganglia|O of|O distal|O gastrointestinal|O tracts|O .|O 
The|O highest|O proportion|O of|O both|O familial|O and|O sporadic|O cases|O is|O due|O to|O mutations|O of|O the|O RET|gene-rna proto|O -|O oncogene|O .|O 
Five|O germline|O mutations|O in|O the|O glial|gene-rna cell|gene-rna -|gene-rna line|gene-rna -|gene-rna derived|gene-rna neurotrophic|gene-rna factor|gene-rna (|O GDNF|gene-rna )|O gene|O ,|O one|O of|O the|O RET|gene-rna ligands|O ,|O have|O been|O detected|O in|O HSCR|O patients|O .|O 
Pedigrees|O analysis|O and|O the|O observed|O association|O between|O these|O GDNF|gene-rna alterations|O and|O RET|gene-rna variants|O in|O the|O same|O patients|O raised|O the|O question|O of|O whether|O the|O GDNF|gene-rna gene|O plays|O any|O causative|O /|O predisposing|O role|O in|O HSCR|O pathogenesis|O .|O 
In|O the|O present|O work|O ,|O we|O have|O studied|O the|O ability|O of|O GDNF|gene-protein proteins|gene-protein ,|O each|O bearing|O one|O of|O the|O reported|O mutations|O ,|O to|O activate|O RET|gene-rna by|O performing|O a|O functional|O test|O in|O cultured|O neuroblastoma|O cells|O .|O 
Consistently|O with|O the|O lack|O of|O genotype|O /|O phenotype|O correlation|O in|O human|O subjects|O ,|O our|O results|O indicate|O absence|O of|O detectable|O alterations|O of|O mutant|O GDNF|gene-rna induced|O RET|gene-rna activation|O .|O 
dbl|gene-rna oncogene|O expression|O in|O childhood|O tumors|O and|O tumor|O cell|O lines|O .|O 
We|O studied|O the|O expression|O of|O the|O dbl|gene-rna oncogene|O in|O the|O total|O RNA|O obtained|O from|O a|O wide|O spectrum|O of|O childhood|O tumors|O ,|O including|O Ewing|O 's|O sarcomas|O ,|O peripheral|O neuroectodermal|O tumors|O (|O PNET|O )|O ,|O esthesioneuroblastomas|O ,|O neuroblastomas|O ,|O retinoblastomas|O ,|O rhabdomyosarcomas|O ,|O osteosarcomas|O ,|O and|O synovial|O sarcomas|O .|O 
Material|O was|O obtained|O from|O primary|O tumors|O ,|O nude|O mice|O xenografts|O ,|O and|O tumor|O cell|O lines|O .|O 
Following|O the|O Northern|O blot|O technique|O ,|O a|O single|O band|O of|O 2.8|O kb|O was|O found|O in|O each|O analyzed|O case|O .|O 
Induction|O of|O neural|O differentiation|O in|O Ewing|O 's|O sarcoma|O ,|O peripheral|O PNET|O ,|O and|O neuroblastoma|O cell|O lines|O with|O dibutyryl|O cyclic|O AMP|O did|O not|O change|O the|O expression|O of|O the|O dbl|gene-rna oncogene|O .|O 
We|O conclude|O that|O the|O wide|O expression|O of|O the|O dbl|gene-rna oncogene|O in|O these|O childhood|O tumors|O reduces|O its|O value|O as|O a|O molecular|O marker|O for|O their|O differential|O diagnosis|O ;|O on|O the|O other|O hand|O ,|O the|O dbl|gene-rna oncogene|O does|O not|O appear|O to|O be|O an|O essential|O molecular|O factor|O in|O the|O process|O of|O neuroectodermal|O differentiation|O of|O small|O round|O cell|O tumors|O of|O childhood|O .|O 
Targeted|O expression|O of|O MYCN|gene-rna causes|O neuroblastoma|O in|O transgenic|O mice|O .|O 
The|O proto|O -|O oncogene|O MYCN|gene-rna is|O often|O amplified|O in|O human|O neuroblastomas|O .|O 
The|O assumption|O that|O the|O amplification|O contributes|O to|O tumorigenesis|O has|O never|O been|O tested|O directly|O .|O 
We|O have|O created|O transgenic|O mice|O that|O overexpress|O MYCN|gene-rna in|O neuroectodermal|O cells|O and|O develop|O neuroblastoma|O .|O 
Analysis|O of|O tumors|O by|O comparative|O genomic|O hybridization|O revealed|O gains|O and|O losses|O of|O at|O least|O seven|O chromosomal|O regions|O ,|O all|O of|O which|O are|O syntenic|O with|O comparable|O abnormalities|O detected|O in|O human|O neuroblastomas|O .|O 
In|O addition|O ,|O we|O have|O shown|O that|O increases|O in|O MYCN|gene-rna dosage|O or|O deficiencies|O in|O either|O of|O the|O tumor|O suppressor|O genes|O NF1|gene-rna or|O RB1|gene-rna can|O augment|O tumorigenesis|O by|O the|O transgene|O .|O 
Our|O results|O provide|O direct|O evidence|O that|O MYCN|gene-rna can|O contribute|O to|O the|O genesis|O of|O neuroblastoma|O ,|O suggest|O that|O the|O genetic|O events|O involved|O in|O the|O genesis|O of|O neuroblastoma|O can|O be|O tumorigenic|O in|O more|O than|O one|O chronological|O sequence|O ,|O and|O offer|O a|O model|O for|O further|O study|O of|O the|O pathogenesis|O and|O therapy|O of|O neuroblastoma|O .|O 
Synapse|O -|O competence|O of|O LA-N-2|O human|O neuroblastoma|O cells|O in|O coculture|O with|O rat|O striated|O muscle|O cells|O .|O 
The|O purpose|O of|O this|O study|O was|O to|O determine|O whether|O cells|O of|O the|O human|O neuroblastoma|O line|O ,|O LA-N-2|O ,|O are|O capable|O of|O establishing|O functional|O synapses|O in|O culture|O .|O 
We|O used|O a|O coculture|O system|O in|O which|O striated|O muscle|O cells|O from|O the|O rat|O served|O as|O postsynaptic|O targets|O for|O the|O cholinergic|O LA-N-2|O cells|O .|O 
By|O recording|O postsynaptic|O responses|O from|O muscle|O cells|O ,|O differentiated|O LA-N-2|O cells|O were|O found|O to|O innervate|O muscle|O cells|O ,|O releasing|O acetylcholine|O spontaneously|O at|O LA-N-2|O -|O muscle|O synapses|O .|O 
A|O subpopulation|O of|O the|O LA-N-2|O cells|O forming|O synapses|O with|O the|O muscle|O cells|O also|O developed|O the|O ability|O to|O release|O acetylcholine|O in|O response|O to|O stimulation|O .|O 
This|O ,|O coupled|O with|O results|O obtained|O from|O experiments|O examining|O the|O time|O course|O of|O synapse|O formation|O ,|O led|O us|O to|O propose|O that|O the|O extent|O to|O which|O LA-N-2|O cells|O in|O our|O coculture|O system|O are|O differentiated|O may|O vary|O and|O that|O this|O variation|O may|O underlie|O the|O degree|O to|O which|O they|O express|O neuron|O -|O like|O transmission|O properties|O .|O 
Effect|O of|O lipopolysaccharide|O on|O the|O gene|O expression|O of|O the|O enzymes|O involved|O in|O tetrahydrobiopterin|O de|O novo|O biosynthesis|O in|O murine|O neuroblastoma|O cell|O line|O N1E-115|O .|O 
The|O amounts|O of|O messenger|O RNA|O for|O three|O enzymes|O ,|O namely|O guanosine|gene-protein triphosphate|gene-protein (|gene-protein GTP|gene-protein )|gene-protein cyclohydrolase|gene-protein 1,6-pyruvoyltetrahydropterin|gene-protein synthase|gene-protein ,|O and|O sepiapterin|gene-protein reductase|gene-protein ,|O all|O of|O which|O are|O involved|O in|O the|O de|O novo|O biosynthesis|O of|O (6R)-L-erythrodihydroxypropyl-2-amino-4-hydroxy-5,6,7,8-tetrahydro|O pteridine|O (|O BH4|O )|O from|O GTP|O ,|O were|O measured|O quantitatively|O in|O murine|O neuroblastoma|O cell|O line|O N1E-115|O by|O the|O competitive|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O technique|O after|O reverse|O transcription|O using|O a|O heterologous|O DNA|O fragment|O as|O an|O internal|O standard|O .|O 
Twenty-four|O hour|O activation|O of|O this|O cell|O line|O with|O 1|O microg|O /|O ml|O lipopolysaccharide|O resulted|O in|O statistically|O significant|O increases|O in|O the|O amounts|O of|O the|O messages|O of|O all|gene-protein three|gene-protein enzymes|gene-protein .|O 
Our|O data|O suggest|O that|O lipopolysaccharide|O can|O activate|O the|O intrinsic|O pathway|O resulting|O in|O the|O enhanced|O gene|O expression|O of|O these|gene-protein three|gene-protein enzymes|gene-protein in|O neuron|O -|O derived|O cells|O such|O as|O N1E-115|O .|O 
Insulin|gene-protein -|gene-protein like|gene-protein growth|gene-protein factor|gene-protein II|gene-protein in|O the|O pathogenesis|O of|O human|O neuroblastoma|O .|O 
Insulin|gene-protein -|gene-protein like|gene-protein growth|gene-protein factor|gene-protein II|gene-protein (|O IGF-II|gene-protein )|O acts|O as|O an|O autocrine|gene-protein growth|gene-protein factor|gene-protein for|O many|O in|O vitro|O tumor|O cell|O lines|O including|O neuroblastoma|O .|O 
To|O examine|O the|O role|O of|O IGF-II|gene-protein in|O tumor|O biology|O we|O have|O analyzed|O a|O total|O of|O 56|O primary|O neuroblastoma|O tumor|O samples|O for|O the|O presence|O of|O IGF-II|gene-protein using|O a|O combination|O of|O mRNA|O and|O protein|O analysis|O .|O 
A|O group|O of|O 21|O samples|O was|O examined|O for|O the|O presence|O of|O IGF-II|gene-rna mRNA|O by|O slot|O blot|O and|O a|O separate|O group|O of|O 37|O samples|O was|O examined|O for|O IGF-II|gene-protein immunoreactivity|O .|O 
IGF-II|gene-protein was|O detected|O in|O 48|O %|O of|O the|O total|O tumor|O specimens|O analyzed|O .|O 
IGF-II|gene-protein immunoreactivity|O was|O observed|O in|O cells|O resembling|O developing|O neuroblasts|O and|O was|O confined|O to|O the|O cytoplasm|O and|O proximal|O neurites|O .|O 
The|O appearance|O of|O IGF-II|gene-rna mRNA|O and|O protein|O did|O not|O correlate|O with|O tumor|O prognostic|O features|O including|O stage|O ,|O histology|O ,|O or|O N-myc|gene-rna amplification|O .|O 
These|O data|O suggest|O that|O the|O expression|O of|O IGF-II|gene-protein is|O not|O confined|O to|O a|O specific|O stage|O of|O the|O disease|O but|O may|O have|O a|O broader|O role|O in|O the|O pathogenesis|O of|O neuroblastoma|O .|O 
Biological|O properties|O of|O a|O tumour|O cell|O line|O (|O NB1-G|O )|O derived|O from|O human|O neuroblastoma|O .|O 
The|O properties|O of|O a|O new|O tumour|O cell|O line|O (|O NB1-G|O )|O derived|O from|O human|O neuroblastoma|O by|O xenografting|O in|O nude|O rats|O followed|O by|O adaptation|O to|O tissue|O culture|O are|O described|O .|O 
Studies|O using|O a|O panel|O of|O monoclonal|gene-protein antibodies|gene-protein demonstrate|O the|O neuro|O -|O ectodermal|O nature|O of|O the|O cells|O and|O support|O the|O diagnosis|O of|O the|O primary|O tumour|O as|O neuroblastoma|O .|O 
Cytogenetic|O studies|O have|O revealed|O a|O human|O karyotype|O with|O several|O chromosomal|O abnormalities|O .|O 
Genetic|O analysis|O by|O in|O situ|O DNA|O hybridization|O has|O demonstrated|O the|O presence|O of|O multiple|O copies|O of|O the|O N-myc|gene-rna gene|O .|O 
Approximately|O 20|O -|O 30|O fold|O amplification|O of|O the|gene-rna gene|gene-rna is|O observed|O on|O Southern|O blot|O analysis|O .|O 
The|O cell|O line|O has|O been|O adapted|O to|O growth|O as|O multicellular|O tumour|O spheroids|O as|O well|O as|O monolayer|O culture|O .|O 
Radiobiological|O studies|O on|O spheroids|O show|O the|O cells|O to|O be|O radiosensitive|O with|O low|O capacity|O for|O sub|O -|O lethal|O damage|O accumulation|O and|O repair|O .|O 
The|O cell|O line|O should|O be|O useful|O for|O fundamental|O studies|O of|O human|O neuroblastoma|O as|O well|O as|O experimental|O therapy|O in|O vitro|O .|O 
N-myc|gene-protein protein|O expression|O in|O human|O breast|O carcinoma|O :|O prognostic|O implications|O .|O 
The|O overexpression|O of|O N-myc|gene-rna gene|O and|O its|gene-protein protein|gene-protein products|gene-protein has|O been|O thought|O to|O be|O limited|O to|O cases|O of|O neuroblastoma|O ,|O retinoblastoma|O and|O small|O cell|O lung|O carcinoma|O ,|O but|O there|O is|O increasing|O evidence|O of|O its|O wider|O distribution|O in|O human|O tumors|O .|O 
This|O study|O showed|O that|O the|gene-protein protein|gene-protein of|O N-myc|gene-rna gene|O is|O associated|O in|O normal|O ,|O benign|O and|O malignant|O human|O breast|O tissues|O .|O 
We|O found|O that|O N-myc|gene-protein oncoprotein|O is|O overexpressed|O in|O most|O breast|O carcinomas|O and|O that|O N-myc|gene-protein overexpression|O is|O significantly|O correlated|O with|O clinical|O stage|O ,|O and|O histological|O grading|O of|O the|O tumors|O ,|O and|O ,|O more|O importantly|O with|O the|O clinical|O outcome|O of|O the|O patients|O .|O 
Analysis|O of|O DNA|O ,|O mRNA|O and|O protein|O levels|O suggested|O that|O the|O high|O N-myc|gene-generic expression|O in|O breast|O cancer|O occurs|O without|O concomitant|O gene|O amplification|O .|O 
The|O finding|O of|O a|O direct|O inverse|O correlation|O between|O N-myc|gene-generic overexpression|O and|O the|O prognosis|O of|O patients|O with|O breast|O carcinoma|O suggests|O that|O N-myc|gene-generic expression|O may|O be|O useful|O as|O a|O prognostic|O factor|O in|O human|O breast|O cancer|O .|O 
Structure|O of|O the|O human|O M(2)|gene-rna muscarinic|gene-rna acetylcholine|gene-rna receptor|gene-rna gene|O and|O its|O promoter|O .|O 
The|O M(2)|gene-protein muscarinic|gene-protein receptor|gene-protein inhibits|O the|O release|O of|O acetylcholine|O from|O cholinergic|O fibers|O in|O the|O lungs|O and|O elsewhere|O .|O 
In|O airway|O parasympathetic|O neurons|O ,|O M(2)|gene-generic receptor|gene-generic expression|O is|O decreased|O by|O viral|O infections|O and|O by|O interferon|gene-protein -|gene-protein gamma|gene-protein ,|O increasing|O actylcholine|O release|O .|O 
Dexamethasone|O increases|O M(2)|gene-generic receptor|gene-generic expression|O ,|O decreasing|O acetylcholine|O release|O .|O 
We|O carried|O out|O 5|O '|O rapid|O amplification|O of|O cDNA|O ends|O beginning|O with|O mRNA|O from|O human|O heart|O and|O IMR32|O human|O neuroblastoma|O cells|O .|O 
This|O demonstrated|O a|O 5|O '|O UTR|O of|O 100|O BP|O ,|O corresponding|O to|O two|O sequences|O on|O chromosome|O 7|O ,|O separated|O by|O a|O 22.6|O kB|O intron|O .|O 
The|O splice|O acceptor|O site|O is|O at|O -|O 45|O relative|O to|O the|O initiating|O atg|O .|O 
The|O 3000|O BP|O upstream|O of|O 5|O '|O RACE|O product|O were|O subcloned|O into|O a|O pGL3|O luciferase|O reporter|O vector|O .|O 
Deletional|O constructs|O were|O expressed|O in|O IMR32|O cells|O .|O 
These|O demonstrated|O that|O 412|O BP|O provided|O full|O expression|O of|O the|O reporter|O gene|O ,|O and|O suggested|O a|O repressor|O element|O between|O -|O 1848|O and|O -|O 1510|O .|O 
Expression|O of|O a|O 260|O kDa|O neuroblastoma|O surface|O antigen|O ,|O the|O target|O of|O cytotoxic|O natural|O human|O IgM|gene-protein :|O correlation|O to|O MYCN|gene-rna amplification|O and|O effects|O of|O retinoic|O acid|O .|O 
Human|O neuroblastoma|O cells|O contain|O a|O 260|O kDa|O surface|O -|O associated|O antigen|O (|O NB-p260|gene-protein )|O that|O is|O recognised|O by|O natural|O cytotoxic|O IgM|gene-protein antibodies|gene-protein .|O 
In|O this|O study|O we|O demonstrate|O that|O NB-p260|gene-protein is|O expressed|O in|O vivo|O in|O a|O neuroblastoma|O tumour|O specimen|O but|O not|O in|O normal|O human|O tissues|O of|O neuronal|O origin|O .|O 
Since|O MYCN|gene-rna amplification|O is|O a|O clinical|O marker|O of|O neuroblastoma|O disease|O progression|O ,|O we|O analysed|O the|O expression|O of|O NB-p260|gene-protein in|O human|O neuroblastoma|O cell|O lines|O with|O different|O MYCN|gene-rna amplification|O status|O .|O 
However|O ,|O both|O amplified|O and|O non|O -|O amplified|O neuroblastoma|O cell|O lines|O exhibited|O comparable|O NB-p260|gene-protein expression|O .|O 
Treatment|O of|O neuroblastoma|O cells|O with|O the|O differentiation|O -|O inducing|O agent|O retinoic|O acid|O (|O RA|O )|O also|O had|O no|O effect|O on|O the|O expression|O of|O NB-p260|gene-protein .|O 
Collectively|O ,|O the|O data|O suggest|O that|O expression|O of|O NB-p260|gene-protein on|O human|O neuroblastoma|O cells|O is|O independent|O of|O malignancy|O and|O differentiation|O status|O of|O neuroblastoma|O .|O 
Retinoic|O acid|O and|O forskolin|O activate|O the|O human|O MDR1|gene-rna gene|O promoter|O in|O differentiated|O neuroblasts|O .|O 
To|O determine|O whether|O over|O -|O expression|O of|O the|O MDR1|gene-rna gene|O may|O result|O from|O activation|O of|O its|O promoter|O by|O differentiating|O agents|O ,|O the|O activity|O of|O the|O human|O MDR1|gene-rna proximal|O promoter|O (|O MDR1|gene-rna pp|O )|O transfected|O to|O 2|O neuroblastoma|O lines|O treated|O with|O retinoic|O acid|O and|O forskolin|O was|O first|O measured|O using|O transient|O expression|O assays|O while|O the|O MDR1|gene-rna mRNA|O levels|O were|O measured|O by|O Northern|O blots|O .|O 
The|O results|O indicate|O that|O retinoic|O acid|O and|O forskolin|O were|O able|O to|O activate|O the|O human|O MDR1|gene-rna pp|O in|O a|O dose|O dependent|O manner|O after|O transfection|O of|O the|O MDR1|gene-rna pp|O -|O CAT|gene-rna constructs|O in|O the|O 2|O cell|O models|O tested|O ,|O i.e.|O ,|O SK-N-SH|O and|O IGR-N-91|O ,|O a|O new|O human|O neuroblastoma|O cell|O line|O .|O 
A|O significant|O increase|O in|O MDR1|gene-rna gene|O transcript|O levels|O was|O observed|O upon|O treatment|O with|O differentiation|O inducers|O in|O SK-N-SH|O but|O not|O in|O IGR-N-91|O neuroblasts|O .|O 
These|O results|O suggest|O that|O the|O induction|O of|O the|O MDR1|gene-rna gene|O promoter|O is|O necessary|O but|O not|O sufficient|O to|O lead|O to|O an|O increase|O in|O MDR1|gene-rna gene|O transcript|O levels|O ,|O according|O to|O the|O neuroblast|O cell|O line|O considered|O .|O 
[|O Oncogenes|O and|O their|O significance|O for|O head|O and|O neck|O cancers|O ]|O 
During|O the|O past|O few|O decades|O medical|O science|O has|O accepted|O the|O concept|O that|O cancer|O is|O a|O fundamental|O disorder|O of|O cellular|O growth|O control|O .|O 
A|O disorder|O can|O originate|O in|O some|O cells|O through|O changes|O in|O genes|O (|O DNA|O level|O :|O gene|O amplification|O ,|O mutation|O and|O rearrangement|O )|O or|O their|O expression|O (|O RNA|O and|O protein|O levels|O )|O ,|O and|O stimulates|O growth|O in|O contrast|O to|O surrounding|O cells|O .|O 
Over|O the|O last|O decade|O genes|O affected|O in|O the|O cancer|O cell|O have|O been|O identified|O as|O well|O as|O the|O nature|O of|O changes|O undergone|O .|O 
Only|O a|O few|O of|O the|O known|O oncogenes|O play|O a|O role|O in|O head|O and|O neck|O cancer|O .|O 
These|O are|O epidermal|gene-protein growth|gene-protein factor|gene-protein receptor|gene-protein ,|O c-myc|gene-generic ,|O the|O ras|gene-rna gene|O family|O ,|O int-2|gene-rna ,|O hst-1|gene-rna and|O bcl-1|gene-rna .|O 
In|O some|O clinical|O disorders|O ,|O such|O as|O childhood|O neuroblastoma|O and|O breast|O cancer|O ,|O oncogenes|O have|O been|O shown|O to|O play|O an|O important|O role|O in|O tumor|O staging|O or|O as|O a|O prognostic|O parameter|O .|O 
The|O aim|O for|O future|O therapy|O is|O the|O effective|O application|O of|O oncogenes|O (|O or|O "|O gene|O therapy|O "|O )|O in|O clinical|O practice|O .|O 
Sigma|gene-protein and|O opioid|gene-protein receptors|gene-protein in|O human|O brain|O tumors|O .|O 
Human|O brain|O tumors|O (|O obtained|O as|O surgical|O specimens|O )|O and|O nude|O mouse|O -|O borne|O human|O neuroblastomas|O and|O gliomas|O were|O analyzed|O for|O sigma|gene-protein and|O opioid|gene-protein receptor|gene-protein content|O .|O 
Sigma|gene-protein binding|O was|O assessed|O using|O [3H]1,3-di-o-tolylguanidine|O (|O DTG|O )|O ,|O whereas|O opoid|gene-protein receptor|gene-protein subtypes|O were|O measured|O with|O tritiated|O forms|O of|O the|O following|O :|O mu|gene-protein ,|O [D-ala2,mePhe4,gly-ol5]enkephalin|gene-protein (|O DAMGE|gene-protein )|O ;|O kappa|gene-protein ,|O ethylketocyclazocine|O (|O EKC|O )|O or|O U69,593|O ;|O delta|gene-protein ,|O [D-pen2,D-pen5]enkephalin|gene-protein (|O DPDPE|gene-protein )|O or|O [D-ala2,D-leu5]enkephalin|gene-protein (|O DADLE|gene-protein )|O with|O mu|gene-protein suppressor|gene-protein present|O .|O 
Binding|O parameters|O were|O estimated|O by|O homologous|O displacement|O assays|O followed|O by|O analysis|O using|O the|O LIGAND|O program|O .|O 
Sigma|gene-protein binding|O was|O detected|O in|O 15|O of|O 16|O tumors|O examined|O with|O very|O high|O levels|O (|O pmol|O /|O mg|O protein|O )|O found|O in|O a|O brain|O metastasis|O from|O an|O adenocarcinoma|O of|O lung|O and|O a|O human|O neuroblastoma|O (|O SK-N-MC|O )|O passaged|O in|O nude|O mice|O .|O 
kappa|gene-protein opioid|gene-protein receptor|gene-protein binding|O was|O detected|O in|O 4|O of|O 4|O glioblastoma|O multiforme|O specimens|O and|O 2|O of|O 2|O human|O astrocytoma|O cell|O lines|O tested|O but|O not|O in|O the|O other|O brain|O tumors|O analyzed|O .|O 
Etr-r3|gene-rna /|O mNapor|gene-rna ,|O encoding|O an|O ELAV|gene-protein -|gene-protein type|gene-protein RNA|gene-protein binding|gene-protein protein|gene-protein ,|O is|O expressed|O in|O differentiating|O cells|O in|O the|O developing|O rodent|O forebrain|O .|O 
The|O gene|O encoding|O human|O neuroblastoma|O apoptosis|gene-protein -|gene-protein related|gene-protein RNA|gene-protein binding|gene-protein protein|gene-protein (|O NAPOR|gene-protein )|O has|O rat|O and|O mouse|O homologues|O ,|O Etr-r3|gene-rna and|O mNapor|gene-rna ,|O cloned|O recently|O by|O ourselves|O and|O others|O .|O 
Etr-r3|gene-rna /|O mNapor|gene-rna is|O transcribed|O in|O embryonic|O brain|O but|O its|O detailed|O expression|O patterns|O are|O unknown|O .|O 
It|O has|O been|O hypothesised|O that|O its|O expression|O coincides|O with|O the|O occurrence|O of|O programmed|O cell|O death|O ,|O but|O existing|O expression|O data|O are|O insufficient|O to|O evaluate|O this|O possibility|O .|O 
We|O used|O northern|O blots|O and|O in|O situ|O hybridisation|O to|O show|O that|O Etr-r3|gene-rna /|O mNapor|gene-rna is|O expressed|O by|O most|O postmitotic|O differentiating|O cells|O throughout|O the|O forebrain|O during|O embryogenesis|O and|O the|O first|O weeks|O of|O postnatal|O life|O .|O 
Expression|O is|O particularly|O high|O in|O the|O developing|O cerebral|O cortex|O ,|O in|O nuclei|O of|O the|O ventral|O telencephalon|O ,|O in|O dorsal|O thalamus|O and|O in|O hypothalamus|O .|O 
In|O contrast|O ,|O Etr-r3|gene-rna /|O mNapor|gene-rna is|O expressed|O by|O very|O few|O cells|O in|O proliferative|O regions|O ,|O where|O cell|O death|O rates|O are|O highest|O .|O 
Basic|gene-protein fibroblast|gene-protein growth|gene-protein factor|gene-protein enhances|O nerve|gene-rna growth|gene-rna factor|gene-rna receptor|gene-rna gene|O promoter|O activity|O in|O human|O neuroblastoma|O cell|O line|O CHP100|O .|O 
The|O human|O neuroblastoma|O cell|O line|O CHP100|O provides|O a|O useful|O model|O system|O in|O which|O to|O study|O the|O molecular|O mechanisms|O of|O transcriptional|O regulation|O of|O the|O low|O -|O affinity|O nerve|gene-rna growth|gene-rna factor|gene-rna receptor|gene-rna (|O NGFR|gene-rna )|O gene|O during|O neuronal|O development|O .|O 
Basic|gene-protein fibroblast|gene-protein growth|gene-protein factor|gene-protein (|O bFGF|gene-protein )|O induced|O morphological|O changes|O in|O CHP100|O cells|O ,|O including|O flattening|O of|O cell|O bodies|O and|O neurite|O outgrowth|O .|O 
bFGF|gene-protein also|O increased|O p75NGFR|gene-protein immunoreactivity|O ,|O as|O assessed|O by|O immunocytochemistry|O ,|O and|O increased|O p75NGFR|gene-rna mRNA|O levels|O ,|O as|O assessed|O by|O Northern|O (|O RNA|O )|O blot|O analysis|O .|O 
A|O chimeric|O gene|O consisting|O of|O 6.7|O kb|O of|O the|O 5|O '|O -|O flanking|O region|O of|O the|O human|O NGFR|gene-rna gene|O linked|O to|O the|O chloramphenicol|gene-rna acetyltransferase|gene-rna gene|O was|O constructed|O .|O 
In|O stable|O transformants|O of|O CHP100|O cells|O ,|O 10|O ng|O of|O bFGF|gene-protein per|O ml|O induced|O an|O eightfold|O increase|O in|O chloramphenicol|gene-protein acetyltransferase|gene-protein activity|O .|O 
These|O results|O indicate|O that|O upstream|O elements|O of|O the|O NGFR|gene-rna gene|O mediate|O transcriptional|O regulation|O by|O bFGF|gene-protein .|O 
Tau|gene-protein blocks|O traffic|O of|O organelles|O ,|O neurofilaments|O ,|O and|O APP|gene-protein vesicles|O in|O neurons|O and|O enhances|O oxidative|O stress|O .|O 
We|O studied|O the|O effect|O of|O microtubule|O -|O associated|O tau|gene-protein protein|O on|O trafficking|O of|O vesicles|O and|O organelles|O in|O primary|O cortical|O neurons|O ,|O retinal|O ganglion|O cells|O ,|O and|O neuroblastoma|O cells|O .|O 
Tau|gene-protein inhibits|O kinesin|gene-protein -|O dependent|O transport|O of|O peroxisomes|O ,|O neurofilaments|O ,|O and|O Golgi|O -|O derived|O vesicles|O into|O neurites|O .|O 
Loss|O of|O peroxisomes|O makes|O cells|O vulnerable|O to|O oxidative|O stress|O and|O leads|O to|O degeneration|O .|O 
In|O particular|O ,|O tau|gene-protein inhibits|O transport|O of|O amyloid|gene-protein precursor|gene-protein protein|gene-protein (|O APP|gene-protein )|O into|O axons|O and|O dendrites|O ,|O causing|O its|O accumulation|O in|O the|O cell|O body|O .|O 
APP|gene-protein tagged|O with|O yellow|gene-protein fluorescent|gene-protein protein|gene-protein and|O transfected|O by|O adenovirus|O associates|O with|O vesicles|O moving|O rapidly|O forward|O in|O the|O axon|O (|O approximately|O 80|O %|O )|O and|O slowly|O back|O (|O approximately|O 20|O %|O )|O .|O 
Both|O movements|O are|O strongly|O inhibited|O by|O cotransfection|O with|O fluorescently|O tagged|O tau|gene-protein (|O cyan|gene-protein fluorescent|gene-protein protein|gene-protein -|O tau|gene-protein )|O as|O seen|O by|O two|O -|O color|O confocal|O microscopy|O .|O 
The|O data|O suggests|O a|O linkage|O between|O tau|gene-protein and|O APP|gene-protein trafficking|O ,|O which|O may|O be|O significant|O in|O Alzheimer|O 's|O disease|O .|O 
PrP|gene-rna (|O prion|gene-rna )|O gene|O expression|O in|O sheep|O may|O be|O modulated|O by|O alternative|O polyadenylation|O of|O its|O messenger|O RNA|O .|O 
Scrapie|O -|O associated|O fibrils|O and|O their|O major|O protein|O component|O ,|O PrP|gene-protein or|O prion|gene-protein protein|O ,|O accumulate|O in|O the|O brains|O and|O some|O other|O tissues|O of|O all|O species|O affected|O by|O transmissible|O spongiform|O encephalopathies|O or|O prion|gene-protein diseases|O .|O 
To|O investigate|O the|O role|O of|O PrP|gene-rna gene|O expression|O in|O the|O hosts|O of|O these|O diseases|O ,|O we|O have|O analysed|O some|O characteristics|O of|O PrP|gene-rna gene|O RNA|O transcripts|O in|O sheep|O and|O cattle|O tissues|O and|O made|O comparisons|O with|O PrP|gene-rna RNA|O transcripts|O in|O human|O and|O mouse|O tissues|O .|O 
Two|O PrP|gene-rna messenger|O RNAs|O of|O 4.6|O kb|O and|O 2.1|O kb|O ,|O the|O result|O of|O alternative|O polyadenylation|O ,|O were|O found|O first|O in|O sheep|O peripheral|O tissues|O and|O also|O occurred|O at|O low|O levels|O in|O sheep|O brain|O and|O bovine|O tissues|O ,|O but|O not|O in|O human|O and|O mouse|O tissues|O .|O 
Our|O results|O from|O transfection|O assays|O of|O murine|O neuroblastoma|O cells|O with|O constructs|O expressing|O different|O regions|O of|O ovine|O PrP|gene-rna messenger|O RNA|O revealed|O the|O presence|O of|O sequences|O in|O the|O 3|O '|O untranslated|O region|O of|O the|O gene|O that|O modulate|O protein|O synthesis|O .|O 
Human|O galanin|gene-protein :|O molecular|O cloning|O reveals|O a|O unique|O structure|O .|O 
Galanin|gene-protein ,|O a|O novel|O neuropeptide|O /|O hypothalamic|O hormone|O originally|O identified|O and|O isolated|O by|O virtue|O of|O its|O carboxy|O -|O terminal|O amide|O group|O ,|O has|O recently|O been|O shown|O to|O have|O a|O diverse|O range|O of|O biological|O activities|O ,|O including|O potent|O effects|O on|O the|O secretion|O of|O insulin|gene-protein and|O growth|gene-protein hormone|gene-protein .|O 
The|O physiological|O role|O of|O galanin|gene-protein remains|O unclear|O ,|O with|O different|O effects|O being|O observed|O when|O porcine|O and|O rat|O galanin|gene-protein have|O been|O used|O in|O various|O animal|O model|O systems|O and|O in|O human|O studies|O .|O 
Molecular|O cloning|O of|O cDNA|O encoding|O human|O galanin|gene-protein and|O galanin|gene-protein mRNA|gene-protein associated|gene-protein peptide|gene-protein (|O GMAP|gene-protein )|O from|O both|O pituitary|O and|O neuroblastoma|O sources|O has|O revealed|O a|O unique|O and|O unexpected|O structure|O .|O 
In|O contrast|O to|O porcine|O ,|O bovine|O and|O rodent|O galanin|gene-protein ,|O human|O galanin|gene-protein lacks|O a|O carboxy|O -|O terminal|O amide|O .|O 
By|O analogy|O to|O other|O neurohormones|O ,|O the|O absence|O of|O carboxy|O -|O terminal|O amidation|O would|O be|O expected|O to|O have|O significant|O effects|O on|O functional|O properties|O such|O as|O affinity|O for|O different|O receptor|O subtypes|O and|O physiological|O half|O life|O ,|O and|O may|O be|O responsible|O for|O the|O species|O specificity|O observed|O in|O the|O action|O of|O galanin|gene-protein .|O 
Anti|O -|O beta|O 2|O subunit|O antisense|O oligonucleotides|O modulate|O the|O surface|O expression|O of|O the|O alpha|O 1|O subunit|O of|O N|O -|O type|O omega-CTX|gene-protein sensitive|O Ca2+|gene-protein channels|gene-protein in|O IMR|O 32|O human|O neuroblastoma|O cells|O .|O 
High|O voltage|O activated|O Ca2+|gene-protein channels|gene-protein are|O heteropolymeric|O complexes|O in|O which|O the|O alpha|O 1|O subunit|O forms|O the|O channel|O ,|O while|O the|O alpha|O 2|O -|O delta|O and|O beta|O subunits|O are|O important|O for|O the|O assembly|O and|O regulation|O of|O the|O biophysical|O properties|O of|O the|O channel|O .|O 
We|O have|O tested|O the|O role|O of|O the|O beta|O 2|O subunit|O on|O the|O expression|O and|O electrophysiological|O properties|O of|O the|O omega-conotoxin|gene-protein GVIA|O -|O sensitive|O Ca2+|gene-protein channel|gene-protein expressed|O in|O the|O IMR|O 32|O human|O neuroblastoma|O cell|O line|O .|O 
Anti|O -|O beta|O 2|O subunit|O antisense|O oligonucleotides|O supplied|O to|O the|O cells|O in|O culture|O induced|O a|O time|O -|O dependent|O increase|O in|O the|O number|O of|O [125I]|O -omega-conotoxin|gene-protein binding|O sites|O on|O the|O cell|O surface|O ,|O which|O was|O not|O paralleled|O by|O an|O increase|O in|O current|O amplitude|O .|O 
We|O suggest|O that|O a|O reduction|O in|O the|O expression|O of|O beta|O 2|O stimulates|O the|O transport|O to|O the|O plasma|O membrane|O of|O non|O -|O functioning|O Ca2+|gene-protein channels|gene-protein and|O ,|O in|O particular|O ,|O of|O the|O alpha|O 1|O omega-conotoxin|gene-protein binding|O subunit|O .|O 
A|O human|O modifier|O of|O methylation|O for|O class|gene-rna I|gene-rna HLA|gene-rna genes|O (|O MEMO-1|gene-rna )|O maps|O to|O chromosomal|O bands|O 1p|O 35|O -|O 36.1|O .|O 
Class|gene-rna I|gene-rna HLA|gene-rna genes|O are|O expressed|O in|O almost|O all|O tissues|O ,|O but|O expression|O is|O low|O or|O undetectable|O in|O many|O neuroblastomas|O .|O 
We|O analysed|O class|gene-rna I|gene-rna HLA|gene-rna methylation|O in|O normal|O tissues|O and|O in|O 28|O neuroectodermal|O tumour|O cell|O lines|O .|O 
HLA-C|gene-rna is|O hypermethylated|O in|O normal|O adult|O tissues|O and|O 13|O cell|O lines|O ,|O while|O 15|O cell|O lines|O show|O the|O hypomethylated|O phenotype|O .|O 
Hypomethylation|O of|O HLA-C|gene-rna strongly|O correlates|O with|O hemizygous|O deletion|O of|O a|O 9|O cM|O interval|O on|O 1p|O 35|O -|O 36.1|O ,|O suggesting|O that|O this|O region|O encodes|O a|O modifier|O of|O methylation|O for|O HLA-C|gene-rna .|O 
To|O test|O whether|O hypomethylation|O of|O class|gene-rna I|gene-rna HLA|gene-rna genes|O results|O from|O loss|O of|O a|O modifier|O gene|O ,|O we|O fused|O a|O hypomethylating|O neuroblastoma|O cell|O line|O with|O a|O hypermethylating|O cell|O line|O .|O 
Methylation|O of|O class|gene-rna I|gene-rna HLA|gene-rna genes|O was|O induced|O in|O the|O hybrids|O .|O 
Furthermore|O ,|O methylation|O of|O HLA|gene-rna -|gene-rna C|gene-rna ,|O -|gene-rna E|gene-rna and|O -|gene-rna A|gene-rna genes|O ,|O which|O are|O encoded|O in|O a|O 1.4|O Mb|O region|O on|O 6p21|O ,|O is|O correlated|O in|O most|O cell|O lines|O .|O 
Our|O results|O suggest|O that|O 1p|O 35|O -|O 36.1|O encodes|O a|O modifier|O of|O methylation|O for|O class|gene-rna I|gene-rna HLA|gene-rna genes|O ,|O that|O is|O deleted|O in|O many|O neuroblastomas|O .|O 
The|O adaptor|O protein|O Nck-1|gene-protein couples|O the|O netrin-1|gene-protein receptor|gene-protein DCC|gene-protein (|O deleted|O in|O colorectal|O cancer|O )|O to|O the|O activation|O of|O the|O small|O GTPase|gene-protein Rac1|gene-protein through|O an|O atypical|O mechanism|O .|O 
Netrins|gene-protein are|O a|O family|O of|O secreted|O proteins|O that|O guide|O the|O migration|O of|O cells|O and|O axonal|O growth|O cones|O during|O development|O .|O 
DCC|gene-protein (|O deleted|O in|O colorectal|O cancer|O )|O is|O a|O receptor|O for|O netrin-1|gene-protein implicated|O in|O mediating|O these|O responses|O .|O 
Here|O ,|O we|O show|O that|O DCC|gene-protein interacts|O constitutively|O with|O the|O SH3|O /|O SH2|O adaptor|O Nck|gene-protein in|O commissural|O neurons|O .|O 
This|O interaction|O is|O direct|O and|O requires|O the|O SH3|O but|O not|O SH2|O domains|O of|O Nck-1|gene-protein .|O 
Moreover|O ,|O both|O DCC|gene-protein and|O Nck-1|gene-protein associate|O with|O the|O actin|gene-protein cytoskeleton|O ,|O and|O this|O association|O is|O mediated|O by|O DCC|gene-protein .|O 
A|O dominant|O negative|O Nck-1|gene-protein inhibits|O the|O ability|O of|O DCC|gene-protein to|O induce|O neurite|O outgrowth|O in|O N1E-115|O cells|O and|O to|O activate|O Rac1|gene-protein in|O fibroblasts|O in|O response|O to|O netrin-1|gene-protein .|O 
These|O studies|O provide|O evidence|O for|O an|O important|O role|O of|O mammalian|O Nck-1|gene-protein in|O a|O novel|O signaling|O pathway|O from|O an|O extracellular|O guidance|O cue|O to|O changes|O in|O the|O actin|gene-protein -|O based|O cytoskeleton|O responsible|O for|O axonal|O guidance|O .|O 
Gene|O expression|O in|O mouse|O neuroblastoma|O cells|O :|O properties|O of|O the|O genome|O .|O 
Chromatin|O was|O prepared|O from|O isolated|O nuclei|O of|O proliferating|O and|O differentiated|O cultures|O of|O C1300|O mouse|O neuroblastoma|O cells|O .|O 
Differentiation|O was|O induced|O by|O serum|O withdrawal|O or|O treatment|O with|O dibutyryl|O cyclic|O AMP|O .|O 
The|O ability|O to|O support|O DNA|O -|O dependent|O RNA|O synthesis|O when|O assayed|O in|O a|O cell|O -|O free|O system|O is|O three|O times|O greater|O for|O chromatin|O from|O proliferating|O cells|O .|O 
Histones|gene-protein isolated|O from|O proliferating|O and|O differentiated|O cells|O were|O fractionated|O electrophoretically|O .|O 
The|O relative|O amounts|O of|O proteins|O present|O in|O the|O five|O major|O histone|gene-protein fractions|O were|O similar|O .|O 
In|O contrast|O ,|O there|O were|O significant|O differences|O in|O the|O nonhistone|O chromosomal|O proteins|O synthesized|O and|O associated|O with|O the|O genome|O of|O proliferating|O and|O differentiating|O neuroblastoma|O cells|O .|O 
Such|O differences|O are|O reflected|O by|O modifications|O in|O the|O electrophoretic|O banding|O patterns|O and|O in|O incorporation|O of|O [3H]tryptophan|O into|O various|O molecular|O weight|O classes|O of|O nonhistone|O chromosomal|O polypeptides|O .|O 
A|O functional|O relationship|O between|O changes|O in|O the|O nonhistone|O chromosomal|O proteins|O and|O variations|O in|O the|O transcriptional|O activity|O accompanying|O differentiation|O of|O neuroblastoma|O cells|O may|O exist|O .|O 
cDNA|O subtraction|O hybridization|O :|O a|O review|O and|O an|O application|O to|O neuroblastoma|O .|O 
Recent|O advances|O in|O molecular|O biological|O techniques|O have|O increased|O our|O capability|O to|O distinguish|O the|O small|O differences|O in|O gene|O expression|O between|O subpopulations|O of|O cells|O found|O within|O specific|O tissues|O or|O tumor|O isolates|O .|O 
We|O use|O subtractive|O hybridization|O or|O subtractive|O cloning|O to|O generate|O information|O regarding|O genes|O that|O direct|O various|O aspects|O of|O mammalian|O embryonic|O development|O .|O 
The|O technique|O also|O is|O used|O to|O identify|O genes|O with|O specificity|O for|O particular|O tissues|O or|O cell|O types|O or|O those|O that|O regulate|O various|O processes|O in|O the|O cell|O .|O 
Also|O ,|O subject|O to|O analysis|O is|O the|O aberrant|O expression|O of|O genes|O involved|O in|O tumorigenesis|O .|O 
Another|O use|O is|O analysis|O of|O subpopulations|O of|O cell|O types|O previously|O identified|O within|O individual|O solid|O tumors|O .|O 
We|O used|O subtractive|O cloning|O in|O the|O analysis|O of|O cell|O line|O subpopulations|O derived|O from|O the|O human|O pediatric|O tumor|O neuroblastoma|O .|O 
This|O has|O resulted|O in|O the|O identification|O of|O novel|O genes|O that|O may|O be|O useful|O in|O the|O study|O of|O this|O disease|O .|O 
Effects|O of|O a|O peptide|O analogue|O of|O the|O amphiphilic|O domain|O of|O the|O common|O neurotrophin|gene-protein receptor|gene-protein on|O nerve|gene-protein growth|gene-protein factor|gene-protein -|O mediated|O motility|O of|O human|O neuroblastoma|O cells|O .|O 
Exposure|O of|O human|O neuroblastoma|O cells|O (|O IMR-32|O )|O to|O a|O peptide|O mimic|O of|O the|O cytoplasmic|O amphiphilic|O domain|O of|O the|O common|O neurotrophin|gene-protein receptor|gene-protein (|O p75NTR|gene-protein 367|O -|O 379|O )|O resulted|O in|O enhanced|O nerve|gene-protein growth|gene-protein factor|gene-protein (|O NGF|gene-protein )|O -|O mediated|O inhibition|O of|O cell|O invasion|O in|O vitro|O .|O 
The|O peptide|O also|O enhanced|O NGF|gene-protein -|O mediated|O neurite|O extension|O and|O GAP-43|gene-rna gene|O expression|O but|O had|O no|O effect|O on|O NGF|gene-protein -|O mediated|O cell|O survival|O .|O 
These|O latter|O functional|O effects|O mimicked|O influences|O on|O NGF|gene-protein -|O mediated|O neurite|O growth|O in|O other|O trkA|gene-generic -|O positive|O cells|O as|O reported|O previously|O .|O 
NGF|gene-protein -|O dependent|O trkA|gene-generic phosphorylation|O was|O significantly|O enhanced|O by|O the|O presence|O of|O the|O peptide|O ,|O whereas|O high|O -|O affinity|O binding|O of|O 125I-|O NGF|gene-protein ,|O both|O NGF|gene-rna receptors|gene-rna mRNA|O and|O protein|O expression|O ,|O and|O trkA|gene-protein dimer|O /|O monomer|O ratios|O were|O not|O influenced|O .|O 
The|O studies|O suggest|O that|O ligand|O -|O mediated|O trkA|gene-generic activation|O has|O differential|O effects|O on|O cell|O motility|O phenomena|O and|O that|O the|O amphiphilic|O domain|O of|O p75NTR|gene-protein has|O a|O role|O in|O this|O differential|O signaling|O .|O 
Bcl-2|gene-generic and|O M-Myc|gene-generic coexpression|O increases|O IGF-IR|gene-protein and|O features|O of|O malignant|O growth|O in|O neuroblastoma|O cell|O lines|O .|O 
The|O bcl-2|gene-rna and|O c-myc|gene-rna oncogenes|O cooperate|O to|O transform|O multiple|O cell|O types|O .|O 
In|O the|O pediatric|O malignancy|O NB(2)|O ,|O Bcl-2|gene-protein is|O highly|O expressed|O .|O In|O tumors|O with|O a|O poor|O prognosis|O ,|O N-Myc|gene-protein ,|O a|O protein|O homologous|O to|O c-Myc|gene-protein ,|O is|O overexpressed|O as|O a|O result|O of|O gene|O amplification|O .|O 
The|O present|O study|O was|O designed|O to|O determine|O whether|O Bcl-2|gene-protein cooperates|O with|O N-Myc|gene-protein to|O bestow|O a|O tumorigenic|O phenotype|O to|O neuroblastoma|O (|O NB|O )|O cells|O .|O 
NB|O cell|O lines|O that|O at|O baseline|O express|O neither|O Bcl-2|gene-protein nor|O N-Myc|gene-protein were|O stably|O transfected|O to|O express|O these|O gene|O products|O .|O 
In|O this|O model|O ,|O we|O found|O Bcl-2|gene-protein rescues|O N-Myc|gene-protein -|O expressing|O cells|O from|O apoptosis|O induced|O by|O serum|O withdrawal|O .|O 
Coexpression|O of|O Bcl-2|gene-protein and|O N-Myc|gene-protein supports|O growth|O in|O low|O serum|O conditions|O and|O anchorage|O -|O independent|O growth|O in|O soft|O agar|O .|O 
Similarly|O ,|O in|O vivo|O tumorigenic|O and|O angiogenic|O activity|O was|O dependent|O on|O coexpression|O .|O 
Our|O data|O further|O suggests|O that|O the|O mechanism|O underlying|O these|O changes|O involves|O the|O receptor|gene-protein for|gene-protein insulin|gene-protein growth|gene-protein factor|gene-protein type|gene-protein I|gene-protein (|O IGF-IR|gene-protein )|O .|O 
Neuroblastoma|O :|O induction|O of|O differentiation|O (|O Part|O I|O )|O .|O 
Basical|O science|O in|O pediatric|O surgery|O .|O 
Neuroblastoma|O is|O the|O second|O -|O most|O common|O solid|O tumor|O in|O childhood|O .|O 
The|O majority|O of|O patients|O have|O a|O very|O poor|O outcome|O due|O to|O aggressive|O growth|O and|O metastatic|O spread|O .|O 
In|O contrast|O ,|O in|O rare|O cases|O ,|O spontaneous|O regression|O or|O differentiation|O towards|O a|O benign|O ganglioneuroma|O are|O observed|O .|O 
The|O mechanism|O leading|O to|O differentiation|O of|O neuroblastoma|O is|O of|O particular|O therapeutic|O interest|O .|O 
In|O this|O paper|O we|O report|O the|O results|O of|O our|O attempts|O to|O induce|O the|O expression|O of|O genes|O necessary|O for|O differentiation|O of|O neuroblastoma|O cells|O .|O 
TrkA|gene-rna codes|O for|O the|O high|O affinity|O receptor|gene-protein of|gene-protein NGF|gene-protein ,|O a|O neurotrophin|gene-protein known|O to|O promote|O differentiation|O .|O 
Treatment|O with|O retinoic|O acid|O caused|O a|O 3|O -|O fold|O increase|O of|O the|O trkA|gene-generic expression|O in|O neuroblastoma|O cell|O lines|O .|O 
Neurofibromin|gene-protein ,|O the|O gene|O product|O of|O the|O NF-1|gene-rna gene|O ,|O is|O involved|O in|O downregulation|O of|O the|O activity|O of|O ras|gene-protein -|O proteins|O .|O 
In|O contrast|O to|O immature|O neuronal|O tissues|O in|O mature|O brain|O ,|O the|O type|gene-protein II|gene-protein isoform|gene-protein of|gene-protein neurofibromin|gene-protein is|O predominantly|O expressed|O .|O 
Retinoic|O acid|O was|O able|O to|O raise|O the|O proportion|O of|O type|gene-protein II|gene-protein NF-1|gene-protein expressed|O in|O neuroblastoma|O cells|O .|O 
Isolation|O and|O analysis|O of|O a|O human|O cDNA|O highly|O homologous|O to|O the|O yeast|O gene|O encoding|O L17A|gene-protein ribosomal|O protein|O .|O 
A|O cDNA|O from|O human|O brain|O poly(A)|O +|O RNA|O with|O significant|O similarity|O to|O the|O gene|O encoding|O yeast|O L17A|gene-protein large|gene-protein subunit|gene-protein ribosomal|gene-protein (|gene-protein r|gene-protein )|gene-protein protein|gene-protein (|O L17A|gene-protein )|O was|O isolated|O using|O the|O polymerase|gene-protein chain|O reaction|O .|O 
The|O deduced|O amino|O acid|O (|O aa|O )|O sequence|O of|O 140|O aa|O (|O calculated|O pI|O of|O 10.79|O )|O exhibits|O a|O 78|O %|O similarity|O to|O that|O of|O the|O yeast|O L17A|gene-protein r|gene-protein protein|gene-protein (|O 88|O %|O when|O conservative|O aa|O replacements|O are|O considered|O as|O well|O )|O .|O 
This|O indicates|O that|O L17A|gene-protein is|O one|O of|O the|O best|O conserved|O r|gene-protein -|gene-protein proteins|gene-protein and|O therefore|O may|O play|O a|O critical|O role|O in|O ribosome|O function|O .|O 
In|O contrast|O to|O its|O eubacterial|O and|O chloroplast|O counterparts|O ,|O human|O L17A|gene-protein contains|O an|O N|O -|O terminal|O extension|O of|O 19|O aa|O which|O may|O be|O involved|O in|O nuclear|O targeting|O of|O the|O r|gene-protein -|gene-protein protein|gene-protein .|O 
Approximately|O five|O to|O seven|O genes|O in|O mammalian|O genomes|O give|O strong|O hybridization|O signals|O when|O probed|O with|O the|O human|O L17A|gene-rna homologue|O cDNA|O .|O 
Whereas|O the|O L17A|gene-rna homologue|O was|O found|O to|O be|O expressed|O at|O similar|O levels|O in|O several|O human|O tissues|O as|O a|O transcript|O of|O 600|O nucleotides|O ,|O a|O several|O -|O fold|O higher|O transcript|O level|O was|O detected|O in|O the|O rapidly|O growing|O neuroblastoma|O cell|O line|O ,|O SK-N-BE|O .|O 
Shedding|O of|O GD2|O ganglioside|O by|O human|O neuroblastoma|O .|O 
Substantial|O concentrations|O of|O the|O cell|O -|O surface|O glycosphingolipid|O ,|O the|O disialoganglioside|O GD2|O ,|O are|O uniformly|O present|O in|O human|O neuroblastoma|O tumors|O .|O 
This|O ganglioside|O can|O also|O be|O detected|O in|O the|O plasma|O of|O patients|O with|O neuroblastoma|O by|O direct|O thin|O -|O layer|O chromatographic|O analysis|O .|O 
Among|O 32|O neuroblastoma|O patients|O in|O all|O clinical|O stages|O studied|O prior|O to|O the|O initiation|O of|O treatment|O ,|O 27|O (|O 84|O %|O )|O showed|O measurably|O elevated|O plasma|O concentrations|O of|O GD2|O (|O greater|O than|O or|O equal|O to|O 50|O pmol|O /|O ml|O )|O .|O 
The|O mean|O level|O (|O 545|O +/-|O 108|O pmol|O /|O ml|O )|O was|O more|O than|O 50|O times|O the|O normal|O plasma|O GD2|O concentration|O of|O less|O than|O or|O equal|O to|O 10|O pmol|O /|O ml|O .|O 
Circulating|O GD2|O was|O not|O detected|O in|O the|O plasma|O of|O patients|O with|O the|O related|O ,|O more|O differentiated|O tumors|O ,|O ganglioneuroblastoma|O and|O ganglioneuroma|O ,|O indicating|O an|O association|O of|O the|O shedding|O of|O this|O ganglioside|O with|O the|O undifferentiated|O phenotype|O .|O 
Circulating|O GD2|O diminished|O in|O patients|O in|O response|O to|O therapy|O ,|O and|O reappeared|O in|O patients|O whose|O disease|O recurred|O .|O 
The|O results|O suggest|O that|O the|O sequential|O determination|O of|O circulating|O GD2|O will|O be|O of|O value|O in|O monitoring|O individual|O patients|O with|O neuroblastoma|O .|O 
Neurotrophic|O protein|O S100|gene-protein beta|gene-protein stimulates|O glial|O cell|O proliferation|O .|O 
Nervous|O system|O development|O involves|O a|O coordinated|O series|O of|O events|O ,|O including|O regulation|O of|O cell|O proliferation|O and|O differentiation|O by|O specific|O extracellular|O factors|O .|O 
S100|gene-protein beta|gene-protein is|O a|O neurotrophic|O protein|O that|O has|O been|O implicated|O in|O regulation|O of|O cellular|O proliferation|O ,|O but|O direct|O evidence|O was|O lacking|O .|O 
In|O this|O report|O ,|O nanomolar|O concentrations|O of|O S100|gene-protein beta|gene-protein are|O shown|O to|O stimulate|O proliferation|O of|O rat|O C6|O glioma|O cells|O and|O primary|O astrocytes|O .|O 
An|O S100|gene-protein mutant|O with|O a|O single|O amino|O acid|O change|O was|O inactive|O .|O 
S100|gene-protein beta|gene-protein also|O stimulated|O increases|O in|O the|O steady|O -|O state|O levels|O of|O c-myc|gene-rna and|O c-fos|gene-rna protooncogene|O mRNAs|O and|O complemented|O the|O effects|O of|O platelet|gene-protein -|gene-protein derived|gene-protein growth|gene-protein factor|gene-protein .|O 
Two|O neuroblastoma|O cell|O lines|O did|O not|O proliferate|O in|O response|O to|O S100|gene-protein beta|gene-protein ,|O suggesting|O that|O the|O mitogenic|O activity|O of|O S100|gene-protein beta|gene-protein is|O selective|O for|O astroglial|O cells|O .|O 
These|O results|O suggest|O that|O S100|gene-protein beta|gene-protein may|O be|O involved|O in|O the|O coordinate|O development|O and|O maintenance|O of|O the|O central|O nervous|O system|O by|O synchronously|O stimulating|O the|O differentiation|O of|O neurons|O and|O the|O proliferation|O of|O astroglia|O .|O 
Herpes|O simplex|O virus|O persistence|O in|O mouse|O neuroblastoma|O (|O C|O 1300|O )|O cell|O cultures|O :|O role|O of|O interferon|gene-protein .|O 
The|O Mp|O strain|O of|O herpes|O simplex|O virus|O type|O 1|O (|O HSV1|O )|O induced|O a|O persistent|O infection|O in|O the|O mouse|O C|O 1300|O neuronal|O cell|O line|O (|O clone|O N|O 115|O )|O .|O 
C|O 1300|O cultures|O infected|O at|O an|O MOI|O of|O 0.01|O or|O 0.001|O survived|O the|O initial|O infection|O and|O continued|O to|O produce|O infectious|O virus|O and|O viral|gene-protein antigens|gene-protein for|O 185|O days|O and|O 31|O days|O ,|O respectively|O .|O 
Viral|gene-protein antigens|gene-protein were|O not|O detected|O in|O cultures|O no|O longer|O producing|O infectious|O virus|O ;|O these|O "|O cured|O "|O cultures|O had|O comparable|O susceptibility|O to|O reinfection|O with|O HSV|O as|O previously|O uninfected|O C|O 1300|O cells|O .|O 
While|O significant|O amounts|O of|O interferon|gene-protein were|O produced|O by|O C|O 1300|O cells|O when|O challenged|O with|O Newcastle|O Disease|O Virus|O (|O NDV|O )|O or|O when|O treated|O with|O poly|O I|O :|O C|O ,|O HSV|O -|O induced|O interferon|gene-protein could|O not|O be|O detected|O in|O either|O the|O acutely|O or|O persistently|O infected|O cell|O lines|O .|O 
The|O persistent|O state|O was|O not|O significantly|O altered|O by|O the|O addition|O of|O 1,000|O units|O /|O ml|O of|O murine|O interferon|gene-protein alpha|gene-protein plus|O beta|gene-protein (|O MuIFN|gene-protein alpha|gene-protein +|O beta|gene-protein )|O ,|O nor|O was|O it|O affected|O by|O the|O addition|O of|O antibody|gene-protein to|O MuIFN|gene-protein .|O 
It|O appears|O that|O IFN|gene-protein does|O not|O play|O an|O important|O role|O in|O the|O establishment|O and/or|O maintenance|O of|O viral|O persistence|O in|O this|O neuronal|O system|O .|O 
Cyclic|gene-protein AMP|gene-protein responsive|gene-protein element|gene-protein binding|gene-protein protein|gene-protein phosphorylation|O and|O DNA|O binding|O is|O decreased|O by|O chronic|O lithium|O but|O not|O valproate|O treatment|O of|O SH-SY5Y|O neuroblastoma|O cells|O .|O 
Mood|O stabilizing|O drugs|O decrease|O central|O nervous|O system|O cyclic|O AMP|O signaling|O .|O 
We|O report|O here|O that|O chronic|O ,|O but|O not|O acute|O treatment|O with|O lithium|O chloride|O in|O human|O neuroblastoma|O SH-SY5Y|O cells|O ,|O inhibits|O phosphorylation|O of|O cyclic|gene-protein AMP|gene-protein responsive|gene-protein element|gene-protein binding|gene-protein protein|gene-protein and|O cyclic|O AMP|O responsive|O element|O DNA|O binding|O induced|O by|O the|O adenylyl|gene-protein cyclase|gene-protein activator|O forskolin|O ,|O but|O has|O no|O effect|O on|O constitutive|O expression|O of|O cyclic|gene-protein AMP|gene-protein responsive|gene-protein element|gene-protein binding|gene-protein protein|gene-protein .|O 
These|O results|O are|O consistent|O with|O an|O effect|O of|O lithium|O to|O blunt|O the|O cyclic|O AMP|O signal|O transduction|O pathway|O .|O 
Such|O an|O effect|O is|O not|O shared|O by|O the|O other|O commonly|O prescribed|O mood|O stabilizer|O ,|O sodium|O valproate|O .|O 
Our|O results|O suggest|O that|O cyclic|gene-protein AMP|gene-protein responsive|gene-protein element|gene-protein binding|gene-protein protein|gene-protein regulated|O gene|O expression|O may|O be|O relevant|O to|O the|O long|O -|O term|O prophylactic|O effect|O of|O lithium|O .|O 
Furthermore|O ,|O sodium|O valproate|O ,|O which|O is|O also|O effective|O in|O bipolar|O disorder|O ,|O would|O appear|O to|O act|O on|O other|O pathways|O to|O bring|O about|O its|O therapeutic|O effects|O .|O 
Immunohistology|O of|O neuroendocrine|O and|O neuroectodermal|O tumors|O .|O 
Neuroendocrine|O and|O neuroectodermal|O tumors|O are|O interrelated|O ,|O and|O comprise|O a|O neoplastic|O family|O including|O lesions|O formerly|O termed|O "|O carcinoid|O ,|O "|O "|O atypical|O carcinoid|O ,|O "|O "|O small|O cell|O undifferentiated|O carcinoma|O ,|O "|O "|O primitive|O neuroepithelioma|O ,|O "|O "|O chemodectoma|O ,|O "|O and|O "|O neuroblastoma|O ,|O "|O to|O name|O but|O a|O few|O entities|O .|O 
The|O nosology|O of|O these|O neoplasms|O has|O been|O simplified|O recently|O ,|O in|O part|O as|O a|O result|O of|O a|O better|O understanding|O of|O their|O immunophenotypes|O and|O molecular|O biological|O attributes|O .|O 
This|O review|O considers|O those|O immunohistochemical|O markers|O that|O are|O now|O generally|O available|O for|O diagnostic|O evaluation|O of|O neuroendocrine|O and|O neuroectodermal|O differentiation|O ,|O and|O provides|O information|O on|O the|O relative|O sensitivity|O and|O specificity|O of|O each|O of|O them|O .|O 
Intermediate|gene-protein filament|gene-protein proteins|gene-protein ,|O chromogranins|gene-protein ,|O synaptophysin|gene-protein ,|O CD56|gene-protein ,|O CD57|gene-protein ,|O CD99|gene-protein ,|O neuron|gene-protein -|gene-protein specific|gene-protein (|gene-protein gamma-dimer|gene-protein )|gene-protein enolase|gene-protein ,|O protein|O gene|gene-protein product|gene-protein 9.5|gene-protein ,|O and|O specific|O neuropeptide|gene-protein products|O are|O discussed|O .|O 
The|O application|O of|O such|O determinants|O in|O regional|O differential|O diagnosis|O is|O also|O summarized|O .|O 
Incidentally|O discovered|O adrenal|O masses|O .|O 
This|O report|O describes|O a|O retrospective|O study|O of|O 23|O patients|O with|O incidentally|O discovered|O adrenal|O masses|O .|O 
Two|O patients|O with|O subclinical|O cortisol|O secretion|O developed|O adrenal|O insufficiency|O after|O removal|O of|O benign|O adenomas|O .|O 
Another|O patient|O ,|O who|O probably|O harbors|O an|O asymptomatic|O pheochromocytoma|O ,|O developed|O a|O hypertensive|O crisis|O when|O a|O mass|O was|O palpated|O during|O aortic|O vascular|O surgery|O .|O 
Twelve|O patients|O underwent|O surgery|O .|O 
Seven|O benign|O adenomas|O ,|O an|O angiomyolipoma|O ,|O and|O a|O cyst|O were|O removed|O .|O 
Three|O patients|O had|O malignant|O masses|O that|O include|O an|O angiosarcoma|O ,|O an|O adrenal|O adenocarcinoma|O ,|O and|O a|O congenital|O neuroblastoma|O .|O 
We|O conclude|O that|O hormones|O ,|O especially|O cortisol|O ,|O may|O be|O secreted|O in|O subclinical|O amounts|O by|O incidentally|O discovered|O masses|O .|O 
We|O recommend|O a|O concise|O laboratory|O evaluation|O that|O includes|O an|O overnight|O dexamethasone|O suppression|O test|O .|O 
Based|O on|O our|O interpretation|O of|O the|O literature|O ,|O we|O believe|O masses|O greater|O than|O 3|O cm|O in|O size|O should|O be|O removed|O .|O 
Patients|O who|O do|O not|O undergo|O surgery|O should|O have|O computed|O tomographic|O scans|O repeated|O for|O one|O year|O and|O should|O be|O reassessed|O periodically|O for|O the|O development|O of|O hormone|O secretion|O .|O 
Alternative|O processing|O of|O RNA|O transcribed|O from|O NMYC|gene-rna .|O 
NMYC|gene-rna is|O a|O gene|O whose|O amplification|O and|O overexpression|O have|O been|O implicated|O in|O the|O generation|O of|O certain|O human|O malignancies|O .|O 
Little|O is|O known|O of|O how|O the|O expression|O of|O NMYC|gene-rna is|O normally|O controlled|O .|O 
We|O have|O therefore|O characterized|O transcription|O from|O the|O gene|O and|O the|O structure|O and|O stability|O of|O the|O resulting|O mRNAs|O .|O 
Transcription|O from|O NMYC|gene-rna is|O exceptionally|O complex|O :|O it|O initiates|O at|O numerous|O sites|O that|O may|O be|O grouped|O under|O the|O control|O of|O two|O promoters|O ,|O and|O the|O multiplicity|O of|O initiation|O sites|O combines|O with|O alternative|O splicing|O to|O engender|O two|O forms|O of|O mRNA|O .|O 
The|O mRNAs|O have|O different|O 5|O '|O leader|O sequences|O (|O alternative|O first|O exons|O of|O the|O gene|O )|O but|O identical|O bodies|O (|O the|O second|O and|O third|O exons|O of|O the|O gene|O )|O .|O 
Both|O forms|O of|O mRNA|O are|O unstable|O ,|O with|O half|O -|O lives|O of|O ca.|O 15|O min|O .|O 
Both|O encode|O the|O previously|O identified|O 65,000|O and|O 67,000|O -|O dalton|O products|O of|O NMYC|gene-rna .|O 
However|O ,|O the|O alternative|O first|O exons|O contain|O distinctive|O open|O reading|O frames|O that|O may|O diversify|O the|O coding|O potential|O of|O NMYC|gene-rna .|O 
The|O complexities|O in|O transcription|O of|O NMYC|gene-rna expand|O the|O means|O by|O which|O expression|O of|O the|O gene|O might|O be|O controlled|O .|O 
Toxicity|O of|O single|O -|O day|O high|O -|O dose|O vincristine|O ,|O melphalan|O ,|O etoposide|O and|O carboplatin|O consolidation|O with|O autologous|O bone|O marrow|O rescue|O in|O advanced|O neuroblastoma|O .|O 
16|O unselected|O patients|O with|O advanced|O neuroblastoma|O were|O given|O high|O -|O dose|O consolidation|O chemotherapy|O with|O vincristine|O ,|O melphalan|O ,|O etoposide|O and|O carboplatin|O over|O 5|O h|O followed|O by|O autologous|O bone|O marrow|O rescue|O .|O 
3|O patients|O died|O from|O treatment|O -|O related|O toxicity|O ,|O 2|O from|O disease|O ,|O 1|O is|O alive|O with|O disease|O and|O 10|O are|O alive|O and|O disease|O -|O free|O a|O median|O of|O 12.5|O months|O (|O range|O 2|O -|O 38|O months|O )|O after|O bone|O marrow|O rescue|O .|O 
All|O had|O bone|O marrow|O toxicity|O ,|O most|O mucositis|O and|O 6|O had|O seizures|O .|O 
Renal|O failure|O was|O unexpectedly|O severe|O .|O 
In|O the|O last|O 3|O patients|O ,|O administration|O of|O carboplatin|O was|O delayed|O by|O 18|O h|O in|O an|O attempt|O to|O reduce|O renal|O damage|O .|O 
The|O results|O show|O that|O this|O regimen|O produces|O significant|O morbidity|O and|O has|O a|O high|O mortality|O .|O 
Although|O the|O overall|O outcome|O is|O encouraging|O ,|O too|O few|O patients|O have|O been|O studied|O to|O gauge|O its|O efficacy|O .|O 
Whether|O such|O aggressive|O consolidation|O is|O necessary|O in|O heavily|O pretreated|O children|O with|O neuroblastoma|O remains|O unknown|O .|O 
Chemotherapy|O -|O induced|O expression|O of|O alpha|gene-protein B-crystallin|gene-protein in|O neuroblastoma|O .|O 
Since|O alpha|gene-protein B-crystallin|gene-protein is|O known|O to|O be|O expressed|O in|O glial|O tissues|O of|O human|O brain|O and|O neuroectodermal|O tumors|O ,|O the|O alpha|gene-protein B-crystallin|gene-protein content|O of|O neuroblastomas|O ,|O may|O be|O related|O to|O the|O degree|O of|O glial|O or|O neuronal|O differentiation|O .|O 
The|O alpha|gene-protein B-crystallin|gene-protein content|O of|O 73|O neuroblastomas|O ,|O was|O determined|O by|O enzyme|O immunoassay|O .|O 
The|O concentration|O of|O alpha|gene-protein B-crystallin|gene-protein was|O examined|O in|O light|O of|O neuroblastoma|O prognostic|O factors|O .|O 
Neuroblastomas|O from|O patients|O who|O received|O chemotherapy|O (|O n|O =|O 23|O )|O contained|O higher|O concentrations|O of|O alpha|gene-protein B-crystallin|gene-protein than|O those|O from|O patients|O who|O did|O not|O receive|O chemotherapy|O (|O n|O =|O 50|O )|O (|O P|O >|O 0.05|O )|O .|O 
There|O was|O a|O statistically|O significant|O difference|O in|O alpha|gene-protein B-crystallin|gene-protein concentrations|O in|O advanced|O stage|O patients|O who|O received|O preoperative|O chemotherapy|O (|O P|O <|O 0.01|O )|O .|O 
Immunohistochemistry|O demonstrated|O alpha|gene-protein B-crystallin|gene-protein expression|O in|O the|O nerve|O -|O like|O fibers|O and|O a|O few|O ganglion|O -|O like|O cells|O .|O 
Staining|O was|O not|O apparent|O in|O the|O less|O differentiated|O cells|O in|O the|O tumor|O cell|O nest|O .|O 
alpha|gene-protein B-crystallin|gene-protein may|O play|O a|O role|O in|O the|O response|O to|O cellular|O stress|O in|O neuroblastoma|O .|O 
Modulation|O of|O the|O proteolytic|O balance|O plasminogen|gene-protein activator|gene-protein /|O plasminogen|gene-protein activator|gene-protein inhibitor|gene-protein by|O enhanced|O N-myc|gene-rna oncogene|O expression|O or|O application|O of|O genistein|O .|O 
The|O aim|O of|O this|O study|O was|O to|O determine|O whether|O enhanced|O expression|O of|O N-myc|gene-rna in|O a|O neuroblastoma|O cell|O line|O affects|O the|O balance|O of|O plasminogen|gene-protein activator|gene-protein /|O plasminogen|gene-protein activator|gene-protein inhibitor|gene-protein (|O PA|gene-protein /|O PAI|gene-protein )|O ,|O a|O shift|O towards|O proteolysis|O having|O been|O observed|O in|O other|O malignant|O tissues|O .|O 
Two|O transfected|O neuroblastoma|O cell|O lines|O with|O (|O WAC2|O cells|O )|O or|O without|O (|O SH-EP007|O cells|O )|O enhanced|O expression|O of|O the|O N-myc|gene-rna oncogene|O were|O examined|O by|O zymography|O and|O RNA|O extraction|O to|O determine|O UPA|gene-protein and|O PAI|gene-protein enzyme|O activity|O and|O uPA|gene-rna RNA|O and|O PAI|gene-rna RNA|O expression|O ,|O respectively|O .|O 
The|O effect|O of|O genistein|O ,|O an|O inhibitor|O of|O tyrosine|gene-protein protein|gene-protein kinase|gene-protein ,|O on|O uPA|gene-protein /|O PAI|gene-protein was|O also|O investigated|O .|O 
Both|O the|O uPA|gene-rna /|O PAI-1|gene-rna ratio|O at|O mRNA|O level|O and|O the|O PA|gene-protein /|O PAI|gene-protein ratio|O at|O protein|O activity|O level|O were|O higher|O in|O the|O more|O malignant|O ,|O WAC2|O cell|O line|O .|O 
Genistein|O attenuated|O uPA|gene-protein activity|O and|O stimulated|O PAI|gene-protein activity|O in|O both|O cell|O lines|O ,|O leading|O to|O a|O decrease|O in|O the|O PA|gene-protein /|O PAI|gene-protein ratio|O .|O 
This|O effect|O was|O more|O pronounced|O in|O the|O more|O malignant|O ,|O WAC2|O cell|O line|O .|O 
Neuron|O -|O specific|O splicing|O of|O the|O Alzheimer|gene-rna amyloid|gene-rna precursor|gene-rna protein|gene-rna gene|O in|O a|O mini|O -|O gene|O system|O .|O 
Several|O forms|O of|O Alzheimer|gene-rna amyloid|gene-rna precursor|gene-rna protein|gene-rna (|O APP|gene-rna )|O mRNA|O are|O generated|O by|O alternative|O splicing|O .|O 
Among|O them|O ,|O the|O APP695|gene-rna mRNA|O skipping|O the|O exon|O 7|O and|O 8|O is|O expressed|O specifically|O in|O neurons|O ,|O suggesting|O that|O this|O alternative|O splicing|O is|O regulated|O in|O a|O neuron|O -|O specific|O manner|O .|O 
As|O the|O first|O step|O for|O investigating|O the|O mechanism|O of|O the|O neuron|O -|O specific|O splicing|O ,|O a|O mini|O -|O gene|O system|O was|O developed|O ,|O in|O which|O mini|O -|O APP|gene-rna genes|O consisting|O of|O the|O exon|O 6|O ,|O 7|O ,|O 8|O ,|O 9|O and|O their|O flanking|O regions|O were|O introduced|O into|O neuronal|O and|O nonneuronal|O cultured|O cell|O lines|O to|O see|O their|O expression|O profiles|O .|O 
In|O the|O system|O the|O exon|O 7|O and|O 8|O of|O the|O mini|O -|O gene|O were|O significantly|O skipped|O in|O the|O neuronal|O cell|O ,|O and|O the|O deletion|O study|O indicated|O that|O cis|O -|O acting|O elements|O for|O skipping|O the|O exons|O existed|O in|O the|O corresponding|O skipped|O -|O exon|O and|O its|O flanking|O regions|O .|O 
A|O small|O deletion|O upstream|O of|O the|O exon|O 8|O suppressed|O the|O skipping|O of|O the|O exon|O 8|O in|O the|O neuronal|O cell|O ,|O suggesting|O that|O one|O of|O the|O regulatory|O sequence(s)|O for|O the|O exon|O skipping|O exists|O in|O a|O small|O region|O upstream|O of|O the|O skipped|O exon|O .|O 
Hypoxanthine|gene-protein -|gene-protein guanine|gene-protein phosphoribosyltransferase|gene-protein -|O deficiency|O produces|O aberrant|O neurite|O outgrowth|O of|O rodent|O neuroblastoma|O used|O to|O model|O the|O neurological|O disorder|O Lesch|O Nyhan|O syndrome|O .|O 
Lesch|O Nyhan|O syndrome|O (|O LNS|O )|O manifests|O in|O bizarre|O and|O horrific|O neurological|O symptoms|O ,|O the|O primary|O cause|O being|O a|O deficiency|O of|O the|O purine|O salvage|O enzyme|O ,|O hypoxanthine|gene-protein -|gene-protein guanine|gene-protein phosphoribosyltransferase|gene-protein (|O HGPRT|gene-protein )|O .|O 
How|O and|O why|O this|O enzyme|O deficiency|O leads|O to|O abnormal|O brain|O development|O is|O unknown|O .|O 
To|O investigate|O this|O phenomenon|O the|O present|O study|O was|O designed|O to|O examine|O if|O the|O growth|O of|O two|O HGPRT|gene-protein -|O deficient|O neuroblastomas|O ,|O mouse|O N2aTG|O and|O rat|O B103-4C|O was|O different|O with|O respect|O to|O their|O corresponding|O control|O cell|O lines|O ,|O N2a|O and|O B103|O .|O 
Data|O is|O provided|O showing|O that|O compared|O to|O control|O cell|O lines|O ,|O HGPRT|gene-protein -|O deficient|O cells|O proliferated|O less|O and|O exhibited|O greater|O morphological|O complexity|O .|O 
If|O these|O abnormalities|O occur|O during|O neurogenesis|O of|O human|O HGPRT|gene-protein -|O deficient|O brain|O neurones|O ,|O they|O could|O profoundly|O influence|O central|O nervous|O system|O development|O and|O thus|O ,|O may|O form|O the|O aetiological|O basis|O for|O the|O symptoms|O of|O LNS|O .|O 
Induction|O of|O morphological|O differentiation|O of|O human|O neuroblastoma|O cells|O is|O accompanied|O by|O induction|O of|O tissue|gene-protein -|gene-protein type|gene-protein plasminogen|gene-protein activator|gene-protein .|O 
Human|O SH-SY5Y|O neuroblastoma|O cells|O treated|O with|O retinoic|O acid|O ,|O 12-O-tetradecanoyl-phorbol-13-acetate|O (|O TPA|O )|O or|O nerve|gene-protein growth|gene-protein factor|gene-protein differentiated|O morphologically|O to|O neuronlike|O cells|O with|O increased|O amounts|O of|O neurofilament|O protein|O and|O mRNA|O .|O 
All|O three|O effectors|O induced|O an|O increase|O in|O the|O amount|O of|O relative|O molecular|O weight|O (|O Mr|O )|O 70,000|O tissue|gene-protein -|gene-protein type|gene-protein plasminogen|gene-protein activator|gene-protein (|O t-PA|gene-protein )|O and|O its|O mRNA|O ,|O as|O determined|O by|O immunocapture|O ,|O enzyme|O activity|O ,|O and|O Northern|O blotting|O analyses|O .|O 
About|O 90|O %|O of|O the|O t-PA|gene-protein activity|O was|O secreted|O to|O the|O culture|O medium|O .|O 
In|O contrast|O ,|O of|O the|O three|O effectors|O studied|O ,|O only|O TPA|O induced|O transcription|O of|O the|O proto|O -|O oncogene|O c-fos|gene-rna ,|O studied|O as|O a|O control|O gene|O responsive|O to|O various|O stimuli|O ,|O and|O induced|O a|O rapid|O increase|O in|O urokinase|gene-protein -|gene-protein type|gene-protein PA|gene-protein (|O u-PA|gene-protein )|O .|O 
Most|O of|O the|O u-PA|gene-protein activity|O induced|O by|O TPA|O remained|O cell|O -|O associated|O .|O 
Because|O induction|O of|O differentiation|O correlated|O closely|O with|O induction|O of|O t-PA|gene-protein ,|O and|O not|O u-PA|gene-protein ,|O the|O authors|O propose|O that|O t-PA|gene-protein may|O have|O a|O functional|O role|O in|O the|O morphological|O differentiation|O of|O neuronal|O cells|O .|O 
Purification|O of|O a|O growth|gene-protein factor|gene-protein related|O to|O platelet|gene-protein -|gene-protein derived|gene-protein growth|gene-protein factor|gene-protein and|O a|O type|gene-protein beta|gene-protein transforming|gene-protein growth|gene-protein factor|gene-protein secreted|O by|O mouse|O neuroblastoma|O cells|O .|O 
A|O general|O strategy|O for|O the|O purification|O of|O basic|O polypeptide|O growth|gene-protein factors|gene-protein .|O 
A|O general|O strategy|O was|O developed|O for|O the|O purification|O of|O basic|O polypeptide|O growth|gene-protein factors|gene-protein .|O 
This|O method|O is|O a|O combination|O of|O gel|O filtration|O ,|O weak|O -|O cation|O -|O exchange|O h.p.l.c.|O and|O reverse|O -|O phase|O h.p.l.c.|O ,|O separating|O the|O proteins|O according|O to|O size|O ,|O charge|O and|O hydrophobicity|O respectively|O .|O 
All|O steps|O are|O carried|O out|O at|O low|O pH|O with|O exclusively|O volatile|O acidic|O buffer|O solutions|O .|O 
The|O sterile|O conditions|O and|O easy|O removal|O of|O salt|O by|O freeze|O -|O drying|O facilitate|O the|O detection|O of|O the|O growth|gene-protein factors|gene-protein by|O biological|O assays|O .|O 
By|O using|O this|O method|O ,|O homogeneous|O preparations|O of|O two|O basic|O growth|gene-protein factors|gene-protein were|O purified|O in|O high|O yield|O from|O mouse|O -|O neuroblastoma|O -|O Neuro|O -|O 2A|O -|O cell|O -|O conditioned|O medium|O .|O 
It|O is|O shown|O that|O these|O purified|O factors|gene-protein are|O biochemically|O and|O immunologically|O related|O to|O platelet|gene-protein -|gene-protein derived|gene-protein growth|gene-protein factor|gene-protein and|O type|gene-protein beta|gene-protein transforming|gene-protein growth|gene-protein factor|gene-protein from|O human|O platelets|O .|O 
Progressive|O growth|O of|O transplanted|O tumors|O is|O accompanied|O by|O increasing|O serum|O concentrations|O of|O murine|O gamma|gene-protein fetal|gene-protein antigen|gene-protein .|O 
BALB/c|O mice|O bearing|O growing|O Meth|O A|O sarcomas|O developed|O gradually|O increasing|O serum|O concentrations|O of|O the|O tumor|O -|O associated|O murine|O gamma|gene-protein fetal|gene-protein antigen|gene-protein (|O gamma-FA|gene-protein )|O ,|O a|O trend|O which|O could|O be|O reversed|O by|O surgical|O excision|O of|O the|O tumor|O tissue|O .|O 
This|O antigen|gene-protein was|O not|O detected|O in|O the|O sera|O of|O normal|O adult|O mice|O or|O in|O the|O sera|O of|O animals|O with|O non|O -|O neoplastic|O proliferative|O condition|O .|O 
Although|O gamma-FA|gene-protein occurs|O in|O splenic|O tissue|O ,|O its|O concentration|O in|O tumor|O -|O bearer|O serum|O was|O unaffected|O by|O splenectomy|O suggesting|O that|O gamma-FA|gene-protein is|O not|O released|O by|O the|O spleen|O in|O response|O to|O tumor|O growth|O .|O 
Agar|O gel|O precipitin|gene-protein and|O radioimmunoprecipitation|O assays|O ,|O using|O antisera|O prepared|O to|O the|O major|O internal|O protein|O (|O P|gene-protein 30|gene-protein )|O and|O external|O glycoprotein|O (|O gp|gene-protein 70|gene-protein )|O of|O Rauscher|O murine|O leukemia|O virus|O and|O to|O the|O secondary|O glycoprotein|O (|O gp|gene-protein 34|gene-protein )|O of|O mouse|O mammary|O tumor|O virus|O ,|O indicated|O that|O gamma-FA|gene-protein is|O not|O a|O major|O structural|O component|O of|O the|O more|O wide|O -|O spread|O murine|O retroviruses|O .|O 
The|O appearance|O of|O gamma-FA|gene-protein in|O the|O sera|O of|O tumor|O -|O bearing|O mice|O may|O reflect|O the|O ectopic|O activation|O of|O a|O specific|O cellular|O gene|O ,|O the|O expression|O of|O which|O bears|O some|O relationship|O to|O neoplastic|O transformation|O .|O 
Disordered|O differentiation|O as|O a|O target|O for|O novel|O approaches|O to|O the|O treatment|O of|O neuroblastoma|O .|O 
Some|O childhood|O malignant|O neoplasms|O are|O thought|O to|O arise|O in|O embryonic|O tissues|O .|O 
These|O tumors|O present|O unique|O opportunities|O for|O studying|O the|O maturation|O of|O specific|O cellular|O lineages|O and|O examining|O the|O possible|O role|O of|O alterations|O in|O the|O regulation|O of|O differentiation|O in|O tumor|O development|O .|O 
Several|O features|O of|O neuroblastoma|O ,|O a|O tumor|O thought|O to|O arise|O in|O cells|O originating|O in|O the|O embryonic|O neural|O crest|O ,|O suggest|O that|O it|O may|O be|O particularly|O useful|O in|O this|O regard|O .|O 
The|O identification|O of|O a|O series|O of|O markers|O that|O characterize|O the|O various|O cell|O types|O of|O the|O peripheral|O nervous|O system|O that|O are|O detectable|O in|O neuroblastoma|O tumor|O tissues|O has|O made|O it|O possible|O to|O recognize|O that|O the|O cells|O of|O neuroblastoma|O tumor|O cell|O lines|O and|O tissues|O correspond|O to|O specific|O stages|O of|O adrenal|O gland|O development|O .|O 
Experiments|O directed|O at|O understanding|O the|O cellular|O signals|O by|O which|O neural|O crest|O cell|O maturation|O is|O mediated|O may|O provide|O insights|O of|O therapeutic|O import|O because|O neuroblastoma|O tumors|O corresponding|O to|O some|O stages|O of|O differentiation|O respond|O very|O differently|O to|O nonspecific|O cytotoxic|O therapies|O than|O tumors|O corresponding|O to|O other|O stages|O .|O 
Bull|O 's|O eye|O (|O target|O )|O inclusions|O in|O neoplastic|O cells|O in|O malignant|O serous|O effusions|O .|O 
A|O study|O of|O 289|O cases|O .|O 
OBJECTIVE|O :|O 
To|O study|O the|O prevalence|O and|O significance|O of|O bull|O 's|O eye|O (|O target|O )|O inclusions|O in|O neoplastic|O cells|O in|O malignant|O serous|O effusions|O .|O 
STUDY|O DESIGN|O :|O 
We|O reviewed|O malignant|O pleural|O ,|O peritoneal|O and|O pericardial|O effusions|O from|O 289|O patients|O who|O had|O proven|O cancer|O at|O known|O primary|O sites|O .|O 
The|O ages|O of|O the|O patients|O ranged|O from|O 5|O to|O 72|O years|O ;|O 166|O were|O male|O and|O 123|O female|O .|O 
RESULTS|O :|O 
Bull|O 's|O eye|O inclusions|O are|O an|O uncommon|O finding|O and|O appeared|O in|O only|O 13|O cases|O of|O metastatic|O adenocarcinoma|O of|O the|O breast|O ,|O stomach|O ,|O colon|O ,|O lung|O ,|O ovary|O ,|O pancreas|O and|O urinary|O bladder|O .|O 
They|O were|O positively|O stained|O with|O periodic|O acid|O -|O Schiff|O stain|O with|O diastase|gene-protein .|O 
The|O inclusions|O were|O not|O seen|O in|O cells|O of|O nonadenocarcinomatous|O neoplasms|O ,|O such|O as|O squamous|O cell|O carcinoma|O ,|O oat|O cell|O (|O small|O cell|O )|O carcinoma|O ,|O neuroblastoma|O ,|O lymphoma|O and|O germ|O cell|O tumors|O .|O 
CONCLUSION|O :|O 
Bull|O 's|O eye|O inclusions|O are|O found|O in|O about|O 5|O %|O of|O malignant|O serous|O effusions|O containing|O cells|O of|O metastatic|O adenocarcinoma|O .|O 
The|O primary|O site|O of|O an|O adenocarcinoma|O cannot|O be|O deduced|O on|O the|O basis|O of|O the|O presence|O of|O inclusions|O .|O 
Bilateral|O retinoblastoma|O with|O ectopic|O intracranial|O retinoblastoma|O :|O trilateral|O retinoblastoma|O .|O 
In|O 11|O patients|O ,|O bilateral|O retinoblastoma|O presented|O at|O a|O mean|O age|O of|O 6|O months|O and|O pineoblastoma|O at|O 4|O years|O .|O 
We|O suggest|O that|O the|O hereditary|O multicentric|O retinoblastoma|O arose|O in|O vestigeal|O photoreceptors|O in|O the|O pineal|O as|O well|O as|O in|O the|O hypothetical|O retinoblasts|O of|O the|O retina|O .|O 
In|O certain|O lower|O animals|O ,|O the|O pineal|O functions|O as|O a|O photoreceptor|O organ|O ,|O resembles|O the|O retina|O histologically|O ,|O and|O is|O described|O as|O a|O "|O third|O eye|O .|O "|O 
Hence|O ,|O the|O patients|O we|O describe|O may|O be|O considered|O as|O having|O "|O trilateral|O retinoblastoma|O .|O "|O 
Two|O possible|O variants|O of|O this|O entity|O were|O also|O noted|O :|O (1)|O three|O children|O without|O retinoblastoma|O with|O rosettes|O and|O photoreceptor|O differentiation|O characteristic|O of|O retinoblastoma|O ,|O and|O (2)|O three|O additional|O cases|O involving|O children|O who|O presented|O with|O retinoblastoma|O -|O like|O tumors|O in|O the|O suprasellar|O or|O parasellar|O region|O 2|O to|O 6|O months|O before|O the|O discovery|O of|O intraocular|O retinoblastoma|O .|O 
These|O observations|O suggest|O that|O the|O retinoblastoma|gene-rna gene|O confers|O a|O previously|O unappreciated|O susceptibility|O to|O a|O narrow|O spectrum|O of|O neuroblastic|O tumors|O ,|O which|O usually|O present|O in|O the|O retina|O but|O which|O can|O also|O occur|O ectopically|O .|O 
Inhibition|O of|O plasma|gene-protein membrane|gene-protein Ca(2+)-ATPase|gene-protein pump|O activity|O in|O cultured|O C6|O glioma|O cells|O by|O halothane|O and|O xenon|O .|O 
We|O have|O compared|O the|O effect|O of|O two|O inhalational|O anesthetics|O ,|O halothane|O and|O xenon|O ,|O on|O Ca(2+)-ATPase|gene-protein (|O PMCA|gene-protein )|O pumping|O activity|O in|O plasma|O membrane|O vesicles|O prepared|O from|O cultured|O rat|O C6|O glioma|O cells|O .|O 
Halothane|O ,|O at|O concentrations|O ranging|O from|O 0.5|O to|O 1.75|O vol|O %|O (|O equivalent|O to|O 0.5|O to|O 1.6|O MAC|O )|O ,|O significantly|O inhibited|O Ca2+|O uptake|O (|O transport|O )|O by|O plasma|O membrane|O vesicles|O in|O a|O dose|O -|O related|O fashion|O .|O 
Xenon|O ,|O at|O partial|O pressures|O ranging|O from|O 0.5|O to|O 1.5|O atm|O (|O equivalent|O to|O 0.5|O to|O 1.6|O MAC|O )|O ,|O similarly|O inhibited|O PMCA|gene-protein pumping|O activity|O .|O 
Additive|O effects|O on|O suppression|O of|O PMCA|gene-protein pump|O activity|O were|O observed|O when|O C6|O cell|O plasma|O membrane|O vesicles|O were|O exposed|O to|O increasing|O partial|O pressures|O of|O xenon|O in|O the|O presence|O of|O halothane|O (|O 1|O vol|O %|O )|O .|O 
Halothane|O also|O inhibited|O PMCA|gene-protein pumping|O in|O cells|O from|O two|O other|O lines|O of|O neural|O origin|O ,|O B104|O (|O rat|O neuroblastoma|O )|O and|O PC12|O (|O rat|O pheochromocytoma|O )|O .|O 
Studies|O described|O in|O this|O report|O support|O the|O thesis|O that|O PMCA|gene-protein in|O cells|O of|O neural|O origin|O is|O inhibited|O by|O quite|O different|O inhalational|O anesthetics|O at|O clinically|O relevant|O concentrations|O .|O 
Characterization|O of|O a|O putative|O calcitonin|gene-protein receptor|gene-protein in|O IMR|O 32|O human|O neuroblastoma|O cells|O .|O 
In|O this|O study|O we|O characterized|O calcitonin|gene-protein (|gene-protein CT|gene-protein )|gene-protein receptors|gene-protein in|O human|O neuroblastoma|O IMR|O 32|O cells|O .|O 
Saturation|O binding|O assays|O indicated|O that|O [125I]|O -|O human|O CT|gene-protein bound|O with|O high|O affinity|O to|O IMR|O 32|O cell|O membranes|O (|O K(d)|O =|O 253.6|O pM|O ;|O Bmax|O =|O 3.84|O fmol|O /|O mg|O protein|O )|O .|O 
In|O competition|O binding|O studies|O ,|O human|O adrenomedullin|gene-protein displayed|O high|O affinity|O for|O these|O sites|O (|O IC50|O =|O 30|O nM|O )|O whereas|O human|O alpha|gene-protein calcitonin|gene-protein -|gene-protein gene|gene-protein related|gene-protein peptide|gene-protein (|O alphaCGRP|gene-protein ;|O IC50|O =|O 145|O nM|O )|O and|O human|O amylin|gene-protein (|O IC50|O =|O 415|O nM|O )|O showed|O lower|O affinity|O .|O 
These|O peptides|O increased|O cAMP|O levels|O in|O viable|O cells|O ;|O the|O relative|O potencies|O were|O :|O human|O CT|gene-protein >|O human|O adrenomedullin|gene-protein >|O human|O cCGRP|gene-protein >|O or|O =|O human|O amylin|gene-protein .|O 
The|O expression|O of|O mRNA|O coding|O for|O the|O published|O sequences|O of|O the|O human|O calcitonin|gene-protein receptor|gene-protein and|O of|O the|O human|O calcitonin|gene-protein receptor|gene-protein -|O like|O receptor|O was|O evaluated|O by|O reverse|gene-protein transcriptase|gene-protein -|O polymerase|gene-protein chain|O reaction|O .|O 
Electrophoretic|O analysis|O did|O not|O confirm|O the|O occurrence|O of|O mRNA|O coding|O for|O the|O above|O mentioned|O receptors|O in|O these|O cells|O .|O 
This|O study|O suggests|O the|O presence|O of|O a|O novel|O ,|O putative|O CT|gene-protein receptor|gene-protein in|O IMR|O 32|O cells|O .|O 
Identification|O of|O a|O 1-megabase|O consensus|O region|O of|O deletion|O at|O 1p36.3|O in|O primary|O neuroblastomas|O .|O 
BACKGROUND|O :|O 
Deletion|O of|O the|O distal|O short|O arm|O of|O chromosome|O 1|O occurs|O frequently|O in|O neuroblastoma|O .|O 
In|O addition|O ,|O neuroblastoma|O has|O been|O described|O in|O children|O with|O constitutional|O deletions|O within|O 1p36|O ,|O supporting|O the|O existence|O of|O one|O or|O more|O neuroblastoma|gene-rna suppressor|gene-rna genes|gene-rna within|O this|O region|O .|O 
PROCEDURE|O :|O 
We|O have|O pursued|O a|O 1p36|gene-rna tumor|gene-rna suppressor|gene-rna gene|gene-rna identification|O strategy|O that|O has|O included|O deletion|O mapping|O of|O 566|O primary|O neuroblastomas|O and|O 46|O neuroblastoma|O -|O derived|O cell|O lines|O ,|O and|O have|O determined|O the|O parental|O origin|O of|O the|O deleted|O 1p|O homologue|O in|O 44|O cases|O to|O determine|O whether|O there|O is|O evidence|O for|O genomic|O imprinting|O within|O this|O region|O .|O 
RESULTS|O AND|O CONCLUSIONS|O :|O 
We|O have|O identified|O a|O 1-Mb|O consensus|O region|O of|O deletion|O within|O 1p36.3|O defined|O by|O primary|O tumor|O deletions|O ,|O constructed|O a|O physical|O map|O of|O the|O region|O that|O is|O being|O sequenced|O to|O completion|O ,|O and|O have|O identified|O and|O prioritized|O candidate|O genes|O within|O this|O region|O for|O further|O analyses|O .|O 
Expression|O of|O the|O estrogen|O -|O regulated|O gene|O Nip2|gene-rna during|O rat|O brain|O maturation|O .|O 
The|O present|O study|O stems|O from|O previous|O observations|O demonstrating|O that|O in|O the|O neuroblastoma|O cell|O line|O SK-ER3|O the|O mRNA|O content|O of|O the|O pro|O -|O apoptotic|O gene|O Nip2|gene-rna is|O decreased|O following|O treatment|O with|O estradiol|O .|O 
We|O investigate|O the|O content|O of|O Nip2|gene-rna mRNA|O during|O the|O maturation|O of|O rat|O embryo|O brain|O and|O we|O show|O that|O Nip2|gene-rna mRNA|O is|O very|O low|O at|O embryo|O day|O 15|O and|O steadily|O increases|O up|O to|O day|O 20|O .|O 
At|O day|O 21|O Nip2|gene-rna mRNA|O is|O decreased|O almost|O to|O the|O low|O levels|O observed|O in|O the|O mature|O brain|O .|O 
Studies|O in|O neurons|O from|O rat|O embryo|O at|O day|O 18|O show|O that|O Nip2|gene-rna mRNA|O content|O is|O significantly|O decreased|O by|O exposure|O to|O estradiol|O at|O 1|O nM|O concentration|O demonstrating|O that|O the|O observations|O previously|O done|O in|O the|O SK-ER3|O neuroblastoma|O cell|O line|O can|O be|O reproduced|O in|O neurons|O in|O culture|O .|O 
The|O finding|O that|O estrogens|O may|O modulate|O the|O activity|O of|O Nip2|gene-rna gene|O activity|O may|O be|O of|O relevance|O not|O only|O with|O regard|O to|O the|O effects|O of|O estradiol|O on|O brain|O maturation|O ,|O but|O also|O for|O the|O understanding|O of|O the|O neuroprotective|O effects|O recently|O described|O for|O this|O hormone|O .|O 
Alzheimer|O 's|O associated|O variant|O ubiquitin|gene-protein causes|O inhibition|O of|O the|O 26S|gene-protein proteasome|gene-protein and|O chaperone|gene-protein expression|O .|O 
Intracellular|O protein|O inclusions|O in|O Alzheimer|O 's|O disease|O and|O progressive|O supranuclear|O palsy|O contain|O UBB+1|gene-protein ,|O a|O variant|O ubiquitin|gene-protein .|O 
UBB+1|gene-protein is|O able|O block|O the|O 26S|gene-protein proteasome|gene-protein in|O cell|O lines|O .|O 
Proteasome|gene-protein inhibition|O by|O drug|O action|O has|O previously|O been|O shown|O to|O induce|O a|O heat|O -|O shock|O response|O and|O render|O protection|O against|O stress|O .|O 
We|O investigated|O UBB+1|gene-protein by|O developing|O a|O stable|O ,|O conditional|O expression|O model|O in|O SH-SY5Y|O human|O neuroblastoma|O cells|O .|O 
Induction|O of|O UBB+1|gene-protein expression|O caused|O proteasome|gene-protein inhibition|O as|O was|O confirmed|O by|O reduced|O ability|O to|O process|O misfolded|O canavanyl|gene-protein proteins|gene-protein ,|O accumulation|O of|O GFPu|gene-protein ,|O a|O proteasome|gene-protein substrate|O ,|O and|O reduced|O cleavage|O of|O a|O fluorogenic|O substrate|O .|O 
We|O show|O that|O expression|O of|O UBB+1|gene-protein induces|O expression|O of|O heat|gene-protein -|gene-protein shock|gene-protein proteins|gene-protein .|O 
This|O priming|O of|O the|O chaperone|gene-protein system|O in|O these|O cells|O promotes|O a|O subsequent|O resistance|O to|O tert-butyl|O hydroperoxide|O -|O mediated|O oxidative|O stress|O .|O 
We|O conclude|O that|O although|O UBB+1|gene-protein -|gene-protein expressing|O cells|O have|O a|O compromised|O ubiquitin|gene-protein -|O proteasome|gene-protein system|O ,|O they|O are|O protected|O against|O oxidative|O stress|O conditions|O .|O 
Expression|O of|O transfected|O human|O CuZn|gene-rna superoxide|gene-rna dismutase|gene-rna gene|O in|O mouse|O L|O cells|O and|O NS20Y|O neuroblastoma|O cells|O induces|O enhancement|O of|O glutathione|gene-protein peroxidase|gene-protein activity|O .|O 
The|O human|O CuZn|gene-protein superoxide|gene-protein dismutase|gene-protein (|O superoxide|gene-protein dismutase|gene-protein 1|gene-protein )|O a|O key|O enzyme|O in|O the|O metabolism|O of|O oxygen|O free|O -|O radicals|O ,|O is|O encoded|O by|O a|O gene|O located|O on|O chromosome|O 21|O in|O the|O region|O 21|O q|O 22.1|O known|O to|O be|O involved|O in|O Down|O 's|O syndrome|O .|O 
A|O gene|O dosage|O effect|O for|O this|O enzyme|O has|O been|O reported|O in|O trisomy|O 21|O .|O 
To|O assess|O the|O biological|O consequences|O of|O superoxide|gene-protein dismutase|gene-protein 1|gene-protein overproduction|O within|O cells|O ,|O the|O human|O superoxide|gene-rna dismutase|gene-rna 1|gene-rna gene|O and|O a|O human|O superoxide|gene-rna dismutase|gene-rna 1|gene-rna cDNA|O were|O introduced|O into|O mouse|O L|O cells|O and|O NS20Y|O neuroblastoma|O cells|O .|O 
Both|O cell|O types|O expressed|O elevated|O levels|O (|O up|O to|O 3|O -|O fold|O )|O of|O enzymatically|O active|O human|O superoxide|gene-protein dismutase|gene-protein 1|gene-protein .|O 
These|O human|O superoxide|gene-protein dismutase|gene-protein 1|gene-protein overproducers|O ,|O especially|O neuronal|O cell|O lines|O ,|O showed|O an|O increased|O activity|O in|O the|O selenodependent|O glutathione|gene-protein peroxidase|gene-protein .|O 
These|O data|O are|O consistent|O with|O the|O possibility|O that|O gene|O dosage|O of|O superoxide|gene-generic dismutase|gene-generic 1|gene-generic contributes|O to|O oxygen|O metabolism|O modifications|O previously|O described|O in|O Down|O 's|O syndrome|O .|O 
Enhanced|O expression|O of|O the|O human|O gene|O N-myc|gene-rna consequent|O to|O amplification|O of|O DNA|O may|O contribute|O to|O malignant|O progression|O of|O neuroblastoma|O .|O 
Previous|O studies|O had|O revealed|O that|O DNA|O with|O partial|O similarity|O to|O the|O myc|gene-rna oncogene|O (|O N-myc|gene-rna )|O is|O frequently|O amplified|O in|O human|O neuroblastoma|O cell|O lines|O and|O neuroblastoma|O tumors|O .|O 
We|O show|O here|O for|O one|O patient|O that|O N-myc|gene-rna amplification|O is|O confined|O to|O the|O neuroblastoma|O tumor|O and|O is|O not|O present|O in|O normal|O tissue|O .|O 
N-myc|gene-rna mRNA|O approximately|O equal|O to|O 4.0|O kilobases|O in|O size|O is|O detectable|O in|O neuroblastoma|O cell|O lines|O and|O tumors|O and|O in|O a|O retinoblastoma|O cell|O line|O .|O 
By|O contrast|O ,|O appreciable|O amounts|O of|O this|O RNA|O were|O not|O present|O in|O a|O number|O of|O cell|O lines|O derived|O from|O other|O human|O tumors|O and|O in|O fibroblasts|O from|O a|O normal|O individual|O and|O from|O a|O neuroblastoma|O patient|O .|O 
Low|O levels|O of|O N-myc|gene-rna RNA|O were|O found|O in|O human|O and|O murine|O neuroblastoma|O cell|O lines|O lacking|O amplification|O of|O this|O gene|O ,|O up|O to|O 80|O -|O fold|O greater|O levels|O in|O all|O cell|O lines|O carrying|O amplified|O N-myc|gene-rna .|O 
In|O situ|O hybridization|O to|O sections|O of|O neuroblastoma|O tumors|O revealed|O high|O expression|O of|O N-myc|gene-rna predominantly|O in|O undifferentiated|O neuroblasts|O .|O 
We|O hypothesize|O that|O amplification|O and|O consequent|O elevated|O expression|O of|O N-myc|gene-rna may|O be|O related|O to|O malignant|O progression|O .|O 
Increased|O glucocorticoid|gene-rna receptor|gene-rna gene|O promoter|O activity|O after|O antidepressant|O treatment|O .|O 
We|O have|O tested|O the|O hypothesis|O that|O antidepressants|O affect|O the|O expression|O of|O the|O glucocorticoid|gene-rna receptor|gene-rna gene|O ,|O by|O looking|O at|O glucocorticoid|gene-rna receptor|gene-rna gene|O promoter|O activity|O ,|O glucocorticoid|gene-rna receptor|gene-rna mRNA|O levels|O ,|O and|O glucocorticoid|O -|O binding|O activity|O after|O treatment|O of|O different|O cell|O lines|O with|O desipramine|O .|O 
Treatment|O of|O LTK|O -|O cells|O or|O Neuro|O 2A|O cells|O with|O desipramine|O produced|O a|O 50|O -|O 200|O %|O increase|O in|O chloramphenicol|gene-protein acetyltransferase|gene-protein activity|O transcribed|O from|O a|O 2.7|O -|O kilobase|O glucocorticoid|gene-rna receptor|gene-rna gene|O promoter|O region|O .|O 
In|O cell|O lines|O derived|O from|O both|O neuronal|O and|O non|O -|O neuronal|O sources|O ,|O glucocorticoid|gene-rna receptor|gene-rna mRNA|O concentration|O doubled|O after|O desipramine|O treatment|O ,|O and|O this|O was|O associated|O with|O a|O 2|O -|O fold|O higher|O functional|O glucocorticoid|O binding|O capacity|O and|O increased|O glucocorticoid|O sensitivity|O ,|O as|O measured|O with|O the|O reporter|O plasmid|O pMMTVCAT|gene-rna .|O 
Antidepressant|O -|O induced|O increases|O in|O glucocorticoid|gene-rna receptor|gene-rna gene|O promoter|O activity|O ,|O glucocorticoid|gene-rna receptor|gene-rna mRNA|O levels|O ,|O and|O functional|O glucocorticoid|O binding|O activity|O suggest|O a|O novel|O mechanism|O of|O action|O for|O these|O drugs|O on|O the|O hypothalamic|O -|O pituitary|O -|O adrenal|O axis|O .|O 
Coordinate|O alteration|O of|O pp60c-src|gene-protein abundance|O and|O c-src|gene-rna RNA|O expression|O in|O human|O neuroblastoma|O variants|O .|O 
We|O examined|O the|O expression|O ,|O abundance|O ,|O and|O protein|gene-protein kinase|gene-protein activity|O of|O pp60c-src|gene-protein in|O two|O different|O pairs|O of|O genetically|O indistinguishable|O cloned|O human|O neuroblastoma|O cell|O variants|O which|O display|O altered|O phenotypes|O as|O the|O result|O of|O conversion|O from|O a|O neuronal|O to|O a|O non|O -|O neuronal|O phenotype|O .|O 
The|O results|O demonstrate|O that|O cells|O which|O exhibit|O the|O neuroblastic|O (|O N-type|O )|O phenotype|O possess|O high|O levels|O of|O pp60c-src|gene-protein protein|O and|O that|O one|O of|O the|O two|O N-type|O cell|O lines|O is|O capable|O of|O expressing|O the|O neuronal|O -|O specific|O isoenzyme|gene-protein of|gene-protein pp60c-src|gene-protein .|O 
In|O contrast|O ,|O cells|O which|O display|O the|O substrate|O -|O adherent|O (|O S-type|O )|O phenotype|O have|O low|O levels|O of|O pp60c-src|gene-protein protein|O and|O express|O exclusively|O the|O non|O -|O neuronal|O isoenzyme|gene-protein of|gene-protein pp60c-src|gene-protein .|O 
In|O all|O cells|O examined|O the|O abundance|O of|O pp60c-src|gene-protein was|O found|O to|O be|O proportional|O to|O the|O steady|O -|O state|O level|O of|O c-src|gene-rna RNA|O .|O 
In|O each|O case|O the|O protein|gene-protein kinase|gene-protein activity|O of|O pp60c-src|gene-protein was|O found|O to|O be|O proportional|O to|O the|O abundance|O of|O the|O protein|O and|O independent|O of|O the|O ratio|O of|O neuronal|O to|O non|O -|O neuronal|O species|O of|O pp60c-src|gene-protein .|O 
High|O levels|O of|O expression|O and|O nuclear|O localization|O of|O interleukin-1|gene-protein beta|gene-protein converting|gene-protein enzyme|gene-protein (|O ICE|gene-protein )|O and|O CPP32|gene-protein in|O favorable|O human|O neuroblastomas|O .|O 
Neuroblastomas|O frequently|O show|O spontaneous|O regression|O and|O differentiation|O ,|O which|O may|O at|O least|O partly|O be|O regulated|O by|O signaling|O through|O nerve|gene-protein growth|gene-protein factor|gene-protein and|O its|O receptors|O ,|O TRK-A|gene-protein and|O p75LNTR|gene-protein .|O 
We|O studied|O 52|O neuroblastic|O tumors|O to|O test|O whether|O the|O cell|O death|O -|O related|O proteases|gene-protein ,|O interleukin-1|gene-protein beta|gene-protein converting|gene-protein enzyme|gene-protein (|O ICE|gene-protein )|O ,|O CPP32|gene-protein ,|O and|O Ich-1|gene-protein ,|O were|O involved|O in|O the|O regression|O of|O the|O tumors|O .|O 
High|O levels|O of|O expression|O of|O ICE|gene-protein and|O CPP32|gene-protein were|O significantly|O correlated|O with|O a|O high|O level|O of|O TRK-A|gene-protein expression|O ,|O single|O copy|O of|O N-myc|gene-rna ,|O younger|O age|O ,|O lower|O stages|O ,|O and|O better|O prognosis|O .|O 
The|O immunohistochemical|O studies|O and|O Western|O analyses|O as|O well|O as|O the|O terminal|O dUTP-|O biotin|gene-protein nick|O end|O labeling|O (|O TUNEL|O )|O method|O revealed|O that|O both|O ICE|gene-protein and|O CPP32|gene-protein were|O translocated|O from|O the|O cytoplasm|O into|O the|O nuclei|O in|O regressing|O ,|O apoptotic|O tumor|O cells|O .|O 
Our|O results|O suggest|O that|O ICE|gene-protein and|O CPP32|gene-protein cysteine|gene-protein proteases|gene-protein may|O play|O an|O important|O role|O in|O regulating|O the|O apoptotic|O process|O of|O the|O favorable|O neuroblastomas|O .|O 
Loss|O of|O heterozygosity|O at|O chromosome|O 9p21|O in|O primary|O neuroblastomas|O :|O evidence|O for|O two|O deleted|O regions|O .|O 
The|O genes|O responsible|O for|O the|O development|O of|O neuroblastoma|O following|O in|O vivo|O deletion|O or|O mutation|O are|O largely|O unknown|O .|O 
We|O have|O performed|O loss|O of|O heterozygosity|O studies|O on|O a|O series|O of|O 24|O Portuguese|O primary|O neuroblastomas|O using|O 6|O polymorphic|O markers|O located|O at|O chromosome|O 9p21|O spanning|O the|O p16|gene-rna /|O MTS1|gene-rna /|O CDKN2|gene-rna ,|O p15|gene-rna /|O MTS2|gene-rna /|O CDKN2B|gene-rna ,|O and|O the|O interferon|gene-rna alpha|gene-rna and|O beta|gene-rna genes|O .|O 
Loss|O of|O heterozygosity|O was|O observed|O in|O 4|O of|O the|O 24|O tumors|O (|O 17|O %|O )|O ,|O a|O somewhat|O lower|O percentage|O than|O a|O previous|O study|O that|O identified|O patients|O by|O a|O mass|O screening|O program|O .|O 
A|O correlation|O was|O also|O observed|O between|O 9p21|O LOH|O and|O 1p36|O LOH|O in|O our|O group|O of|O tumors|O .|O 
Two|O distinct|O regions|O of|O 9p21|O deletion|O were|O observed|O :|O one|O located|O in|O the|O region|O adjacent|O to|O the|O markers|O D9S162|O and|O D9S1747|O and|O a|O second|O located|O centromerically|O of|O the|O p16|gene-rna gene|O near|O the|O D9S171|O marker|O .|O 
The|O latter|O region|O is|O exclusive|O of|O the|O p16|gene-rna gene|O .|O 
This|O result|O suggests|O the|O presence|O of|O at|O least|O one|O other|O tumor|O suppressor|O gene|O at|O 9p21|O ,|O apart|O from|O the|O p16|gene-rna and|O p15|gene-rna genes|O ,|O which|O may|O be|O of|O importance|O to|O the|O development|O of|O neuroblastoma|O .|O 
Subunit|O -|O dependent|O action|O of|O lead|O on|O neuronal|gene-protein nicotinic|gene-protein acetylcholine|gene-protein receptors|gene-protein expressed|O in|O Xenopus|O oocytes|O .|O 
1.|O 
Pb2+|O affects|O neuronal|gene-protein nicotinic|gene-protein acetylcholine|gene-protein receptors|gene-protein (|O nAChR|gene-protein )|O in|O N1E-115|O neuroblastoma|O cells|O in|O a|O dual|O manner|O .|O 
At|O nanomolar|O concentrations|O a|O blockade|O is|O observed|O ,|O while|O at|O submillimolar|O concentrations|O this|O blocking|O effect|O is|O reversed|O .|O 
2.|O 
The|O Xenopus|O oocyte|O expression|O system|O was|O used|O to|O examine|O whether|O the|O dual|O effect|O of|O Pb2+|O is|O related|O to|O a|O differential|O action|O on|O nAChR|gene-protein subtypes|O .|O 
Effects|O of|O Pb2+|O were|O investigated|O in|O oocytes|O expressing|O nAChR|gene-protein after|O co|O -|O injection|O of|O alpha|gene-rna 3|gene-rna and|O beta|gene-rna 2|gene-rna or|O alpha|gene-rna 3|gene-rna and|O beta|gene-rna 4|gene-rna cDNA|O .|O 
3.|O 
At|O 1|O -|O 250|O mumol|O /|O L|O ,|O Pb2+|O causes|O a|O 10|O -|O 1000|O %|O increase|O of|O the|O response|O mediated|O by|O the|O alpha|gene-protein 3|gene-protein beta|gene-protein 2|gene-protein nAChR|gene-protein .|O 
4.|O 
Pb2+|O blocks|O ACh|O -|O induced|O inward|O currents|O mediated|O by|O alpha|gene-protein 3|gene-protein beta|gene-protein 4|gene-protein nAChR|gene-protein .|gene-protein 
The|O inhibitory|O potency|O of|O Pb2+|O greatly|O varies|O between|O cells|O .|O 
In|O 50|O %|O of|O the|O cells|O concentrations|O <|O or|O =|O 1|O mumol|O /|O L|O Pb2+|O blocked|O the|O nicotinic|O response|O by|O 31|O -|O 93|O %|O .|O 
In|O the|O other|O cells|O even|O at|O higher|O concentrations|O Pb2+|O caused|O only|O 0|O -|O 65|O %|O inhibition|O .|O 
5.|O 
These|O results|O show|O that|O Pb2+|O may|O both|O potentiate|O and|O block|O nAChR|gene-protein ,|O depending|O on|O the|O type|O of|O nAChR|gene-protein subunit|O expressed|O .|O 
Decline|O of|O childhood|O cancer|O mortality|O in|O Italy|O ,|O 1955|O -|O 1980|O .|O 
The|O decline|O in|O childhood|O cancer|O mortality|O in|O Italy|O from|O 1955|O to|O 1980|O has|O been|O evaluated|O through|O (1)|O comparison|O of|O age|O -|O specific|O and|O age|O -|O standardized|O (|O 0|O -|O 14|O years|O )|O rates|O for|O the|O periods|O 1955|O -|O 1960|O and|O 1979|O -|O 1980|O and|O (2)|O computation|O of|O expected|O numbers|O of|O deaths|O by|O application|O of|O the|O age|O -|O specific|O rates|O for|O the|O period|O 1955|O -|O 1960|O to|O the|O population|O structure|O of|O subsequent|O periods|O .|O 
Certified|O mortality|O fell|O by|O 35|O %|O for|O leukaemias|O ,|O 90|O %|O for|O Hodgkin|O 's|O disease|O ,|O 30|O %|O for|O non|O -|O Hodgkin|O 's|O lymphomas|O ,|O 40|O %|O for|O bone|O sarcomas|O ,|O 30|O %|O for|O kidney|O (|O Wilms|O '|O )|O tumours|O ,|O 65|O %|O for|O retinoblastoma|O .|O 
No|O clear|O trend|O was|O reported|O for|O other|O neoplasms|O ,|O including|O neuroblastoma|O .|O 
About|O 300|O cancer|O deaths|O per|O year|O were|O avoided|O in|O the|O period|O 1979|O -|O 1980|O compared|O with|O the|O expected|O number|O based|O on|O the|O 1955|O -|O 1960|O rates|O (|O 170|O for|O leukaemias|O alone|O )|O .|O 
Although|O clearly|O encouraging|O ,|O these|O trends|O are|O substantially|O less|O favourable|O than|O those|O from|O several|O other|O developed|O countries|O .|O 
It|O is|O therefore|O likely|O that|O several|O dozen|O other|O deaths|O from|O childhood|O cancer|O could|O be|O avoided|O each|O year|O through|O earlier|O (|O or|O more|O accurate|O )|O application|O of|O effective|O therapies|O ,|O particularly|O for|O neoplasms|O requiring|O radiotherapy|O or|O surgical|O treatment|O .|O 
Trigonelline|O -|O induced|O neurite|O outgrowth|O in|O human|O neuroblastoma|O SK-N-SH|O cells|O .|O 
Extension|O of|O dendrites|O and|O axons|O in|O neurons|O may|O compensate|O and|O rescue|O damaged|O neuronal|O networks|O in|O the|O dementia|O brain|O .|O 
Our|O aim|O is|O to|O isolate|O and|O identify|O constituents|O of|O coffee|O beans|O exhibiting|O neurite|O outgrowth|O activity|O .|O 
Among|O the|O extracts|O of|O raw|O and|O roasted|O coffee|O beans|O ,|O a|O methanol|O fraction|O of|O the|O ethanol|O extract|O (|O 1|O microg|O /|O ml|O )|O of|O raw|O beans|O increased|O significantly|O the|O percentage|O of|O cells|O with|O neurites|O in|O human|O neuroblastoma|O SK-N-SH|O cells|O .|O 
Among|O subfractions|O of|O this|O methanol|O fraction|O was|O a|O basic|O fraction|O (|O 5|O microg|O /|O ml|O )|O which|O exhibited|O significant|O neurite|O outgrowth|O activity|O .|O 
Finally|O ,|O trigonelline|O in|O the|O basic|O fraction|O was|O identified|O to|O be|O active|O as|O far|O neurite|O extension|O was|O concerned|O .|O 
Treatment|O with|O trigonelline|O (|O 30|O microM|O )|O increased|O the|O percentage|O of|O cells|O with|O neurites|O at|O 3|O and|O 6|O d|O after|O treatment|O .|O 
In|O addition|O ,|O the|O number|O of|O neurites|O reacting|O positively|O to|O phosphorylated|O neurofilament-H|O was|O increased|O by|O treatment|O with|O 30|O microM|O trigonelline|O for|O 6|O d|O ,|O suggesting|O enhancement|O of|O axonal|O extension|O .|O 
These|O results|O show|O that|O trigonelline|O promotes|O functional|O neurite|O outgrowth|O .|O 
Antibody|gene-protein -|O dependent|O transcriptional|O regulation|O of|O measles|O virus|O in|O persistently|O infected|O neural|O cells|O .|O 
Application|O of|O neutralizing|O anti|gene-protein -|gene-protein hemagglutinin|gene-protein antibodies|gene-protein to|O mouse|O neuroblastoma|O cells|O (|O NS20Y|O /|O MS|O )|O persistently|O infected|O with|O measles|O virus|O (|O MV|O )|O leads|O to|O a|O significant|O reduction|O of|O viral|O structural|O proteins|O within|O 6|O days|O .|O 
While|O the|O transcriptional|O gradient|O for|O MV|gene-rna -|gene-rna specific|gene-rna mRNAs|O remained|O unaffected|O upon|O antibody|gene-protein treatment|O ,|O the|O total|O amount|O of|O MV|gene-rna -|gene-rna specific|gene-rna transcripts|O dropped|O by|O 80|O %|O after|O 24|O h|O .|O 
The|O expression|O of|O genomic|O RNA|O was|O affected|O similarly|O ,|O with|O slightly|O slower|O time|O kinetics|O .|O 
Both|O transcription|O and|O expression|O of|O the|O viral|O structural|O proteins|O could|O be|O completely|O reactivated|O when|O viral|O antibodies|gene-protein were|O removed|O from|O the|O tissue|O culture|O .|O 
The|O same|O findings|O could|O be|O obtained|O in|O rat|O glioma|O cells|O persistently|O infected|O with|O subacute|O sclerosing|O panencephalitis|O virus|O (|O C6|O /|O SSPE|O )|O but|O not|O in|O cells|O of|O nonneural|O origin|O .|O 
The|O data|O indicate|O that|O antibody|gene-protein -|O induced|O antigenic|O modulation|O affects|O the|O early|O stages|O of|O viral|O transcription|O within|O a|O few|O hours|O after|O the|O addition|O of|O antibodies|gene-protein and|O leads|O to|O an|O almost|O complete|O repression|O of|O viral|O gene|O expression|O in|O cells|O of|O neural|O origin|O .|O 
Biochemical|O analysis|O of|O cybrids|O expressing|O mitochondrial|O DNA|O from|O Contursi|O kindred|O Parkinson|O 's|O subjects|O .|O 
Complex|O I|O activity|O is|O reduced|O in|O cytoplasmic|O hybrid|O (|O cybrid|O )|O cell|O lines|O that|O contain|O mitochondrial|gene-rna DNA|gene-rna (|O mtDNA|gene-rna )|O from|O sporadic|O Parkinson|O 's|O disease|O (|O PD|O )|O patients|O .|O 
This|O implies|O that|O mtDNA|gene-rna aberration|O occurs|O in|O sporadic|O PD|O .|O 
To|O assess|O the|O integrity|O of|O mtDNA|gene-rna in|O autosomal|O dominant|O PD|O arising|O from|O mutation|O of|O the|O alpha-synuclein|gene-rna gene|O ,|O we|O transferred|O mitochondrial|O genes|O from|O PD|O -|O affected|O members|O of|O the|O Italian|O -|O American|O Contursi|O kindred|O to|O cells|O previously|O depleted|O of|O their|O endogenous|O mtDNA|gene-rna .|O 
Unlike|O cybrid|O cell|O lines|O expressing|O mtDNA|gene-rna from|O persons|O with|O sporadic|O or|O maternally|O inherited|O PD|O ,|O the|O resultant|O Contursi|O cybrid|O lines|O did|O not|O manifest|O complex|O I|O deficiency|O ,|O indicating|O that|O in|O Contursi|O PD|O mtDNA|gene-rna integrity|O is|O relatively|O preserved|O .|O 
Compared|O to|O control|O cybrids|O ,|O however|O ,|O Contursi|O cybrid|O lines|O did|O show|O some|O evidence|O of|O oxidative|O stress|O .|O 
For|O reasons|O that|O are|O unclear|O ,|O at|O least|O a|O limited|O amount|O of|O mtDNA|gene-rna damage|O may|O nevertheless|O develop|O in|O PD|O patients|O with|O alpha-synuclein|gene-rna mutation|O .|O 
Fc|gene-protein gamma|gene-protein receptors|gene-protein are|O expressed|O on|O human|O neuroblastoma|O cell|O lines|O :|O lack|O of|O correlation|O with|O N-myc|gene-rna oncogene|O activity|O .|O 
FcRs|gene-protein (|O Fc|gene-protein Receptors|gene-protein )|O have|O been|O detected|O on|O the|O cell|O surface|O of|O two|O human|O neuroblastoma|O cell|O lines|O ;|O IMR|O 32|O and|O SK-N-SH|O ,|O by|O immunocytochemistry|O and|O flow|O cytometric|O analysis|O ,|O using|O a|O previously|O characterized|O polyclonal|O antiserum|O raised|O against|O the|O Fc|gene-protein gamma|gene-protein R|gene-protein isolated|O from|O a|O human|O CLL|O line|O (|O Gorini|O ,|O Medgyesi|O ,|O Garavini|O ,|O Dorrington|O and|O Down|O ,|O 1987|O ;|O Rozsnay|O ,|O Sarmay|O ,|O Szabo|O ,|O Medgyesi|O ,|O Gorini|O and|O Gergely|O ,|O 1990|O )|O .|O 
FcR|gene-protein is|O expressed|O on|O all|O the|O cells|O of|O both|O lines|O at|O least|O at|O the|O same|O level|O as|O on|O the|O HL60|O promyelocyte|O cell|O line|O used|O as|O positive|O control|O .|O 
Two|O electrophoretic|O components|O displaying|O apparent|O molecular|O masses|O of|O 70|O and|O 43|O kDa|O respectively|O have|O been|O identified|O by|O SDS-PAGE|O followed|O by|O Western|O blotting|O analysis|O of|O crude|O cell|O membranes|O .|O 
In|O addition|O ,|O "|O in|O situ|O "|O hybridization|O experiments|O seem|O to|O exclude|O a|O correlation|O between|O FcR|gene-protein expression|O and|O N-myc|gene-rna oncogene|O activity|O .|O 
The|O presence|O of|O FcR|gene-protein in|O neuroblastoma|O could|O be|O related|O to|O a|O possible|O functional|O role|O even|O on|O these|O cells|O which|O do|O not|O belong|O to|O the|O immune|O system|O ;|O moreover|O ,|O they|O could|O also|O be|O exploited|O for|O a|O diagnostic|O characterization|O of|O this|O tumor|O .|O 
Nuclear|gene-protein localization|gene-protein signal|gene-protein peptides|O enhance|O cationic|O liposome|O -|O mediated|O gene|O therapy|O .|O 
The|O use|O of|O genes|O as|O therapeutic|O drugs|O will|O likely|O involve|O non|O -|O viral|O delivery|O systems|O .|O 
While|O traditionally|O less|O effective|O for|O gene|O expression|O ,|O the|O advantages|O of|O a|O non|O -|O viral|O delivery|O system|O include|O ease|O of|O production|O ,|O lower|O toxicity|O ,|O and|O no|O risk|O of|O infection|O .|O 
However|O ,|O most|O non|O -|O viral|O systems|O do|O not|O incorporate|O a|O mechanism|O for|O gene|O transport|O into|O the|O nucleus|O .|O 
Nuclear|gene-protein localization|gene-protein signal|gene-protein peptides|O can|O combine|O the|O increased|O expression|O of|O viral|O delivery|O systems|O with|O the|O safety|O and|O ease|O of|O preparation|O of|O non|O -|O viral|O delivery|O systems|O .|O 
A|O novel|O non|O -|O viral|O delivery|O vehicle|O consisting|O of|O a|O conglomerate|O of|O a|O synthetic|O nuclear|gene-protein localization|gene-protein signal|gene-protein peptide|O derived|O from|O the|O SV40|O virus|O ,|O a|O luciferase|gene-protein encoding|O PGL3|O plasmid|O ,|O and|O a|O cationic|O lipid|O DOTAP|O :|O DOPE|O (|O 1|O :|O 1|O w|O /|O w|O )|O liposome|O was|O transfected|O into|O SKnSH|O mammalian|O neuroblastoma|O cells|O .|O 
A|O three|O -|O fold|O increase|O in|O luciferase|gene-protein expression|O was|O seen|O with|O the|O delivery|O system|O containing|O a|O NLS|gene-protein peptide|O over|O cationic|O liposome|O controls|O .|O 
Examination|O of|O the|O factors|O that|O limit|O the|O rate|O of|O transgene|O expression|O can|O potentially|O lead|O to|O the|O discovery|O of|O new|O ways|O to|O improve|O the|O efficiency|O and|O efficacy|O of|O nonviral|O methods|O of|O gene|O therapy|O .|O 
Immunomodulatory|O effects|O of|O human|O neuroblastoma|O cells|O transduced|O with|O a|O retroviral|O vector|O encoding|O interleukin-2|gene-generic .|O 
We|O have|O investigated|O whether|O retroviral|O mediated|O transfer|O of|O the|O IL-2|gene-rna gene|O renders|O human|O neuroblastoma|O cells|O immunogenic|O ,|O justifying|O their|O use|O in|O a|O clinical|O tumor|O immunization|O study|O .|O 
Fourteen|O neuroblastoma|O cell|O lines|O were|O established|O from|O patients|O with|O disseminated|O neuroblastoma|O and|O transduced|O with|O the|O vector|O G1Ncvl2|O ,|O which|O contains|O the|O neomycin|gene-rna phosphotransferase|gene-rna gene|O and|O the|O cDNA|O of|O the|O human|O interleukin-2|gene-rna gene|O .|O 
Clones|O secreting|O >|O 150|O pg|O /|O 10(6)|O cells|O /|O 24|O h|O of|O IL-2|O were|O selected|O for|O further|O study|O .|O 
Secretion|O of|O IL-2|O was|O maintained|O for|O at|O least|O 3|O weeks|O in|O nonselective|O media|O ,|O implying|O that|O production|O of|O the|O cytokine|O would|O continue|O under|O in|O vivo|O conditions|O .|O 
Co|O -|O culture|O of|O IL-2|O transduced|O cell|O lines|O with|O patient|O lymphocytes|O induced|O potent|O cytotoxic|O activity|O against|O both|O transduced|O and|O parental|O neuroblastoma|O cell|O lines|O .|O 
This|O activity|O was|O HLA|gene-generic unrestricted|O ,|O and|O predominantly|O mediated|O by|O CD16|gene-protein +|O or|O CD56|gene-protein +|O and|O CD8|gene-protein -|O lymphocytes|O .|O 
These|O data|O form|O the|O preclinical|O justification|O for|O our|O current|O immunization|O protocol|O for|O patients|O with|O relapsed|O or|O resistant|O neuroblastoma|O .|O 
Insulin|gene-protein -|gene-protein like|gene-protein growth|gene-protein factor|gene-protein I|gene-protein shifts|O from|O promoting|O cell|O division|O to|O potentiating|O maturation|O during|O neuronal|O differentiation|O .|O 
SH-SY5Y|O neuroblastoma|O cells|O undergo|O neuronal|O differentiation|O and|O their|O proliferation|O is|O inhibited|O when|O they|O are|O treated|O with|O phorbol|O 12-myristate|O 13-acetate|O (|O PMA|O )|O .|O 
Insulin|gene-protein and|O insulin|gene-protein -|gene-protein like|gene-protein growth|gene-protein factor|gene-protein I|gene-protein (|O IGF-I|gene-protein )|O are|O mitogens|O for|O the|O nontreated|O SH-SY5Y|O cells|O ,|O whereas|O the|O proliferative|O response|O to|O such|O factor|O stimulation|O is|O lost|O upon|O differentiation|O ,|O in|O spite|O of|O the|O fact|O that|O the|O receptors|O for|O insulin|gene-protein and|O IGF-I|gene-protein remain|O expressed|O and|O functional|O in|O the|O differentiated|O cells|O .|O 
Here|O we|O show|O that|O the|O PMA|O -|O induced|O differentiation|O of|O SH-SY5Y|O cells|O grown|O in|O a|O serum|O -|O free|O medium|O is|O strongly|O potentiated|O by|O nanomolar|O concentrations|O of|O IGF-I|gene-protein ,|O as|O judged|O by|O morphology|O and|O markers|O for|O neuronal|O differentiation|O --|O e.g.|O ,|O neuropeptide|O tyrosine|O and|O growth|gene-protein -|gene-protein associated|gene-protein protein|gene-protein 43|gene-protein .|O 
Also|O ,|O insulin|gene-protein and|O IGF-II|gene-protein potentiated|O the|O phorbol|O ester|O -|O induced|O differentiation|O ,|O although|O less|O efficiently|O than|O IGF-I|gene-protein .|O 
Using|O blocking|O anti|O -|O receptor|O antibodies|gene-protein ,|O it|O could|O be|O shown|O that|O the|O differentiation|O induced|O by|O these|O factors|O ,|O in|O combination|O with|O PMA|O ,|O was|O primarily|O mediated|O through|O the|O IGF-I|gene-protein receptor|gene-protein .|O 
HEN1|gene-rna and|O HEN2|gene-rna :|O a|O subgroup|O of|O basic|gene-rna helix|gene-rna -|gene-rna loop|gene-rna -|gene-rna helix|gene-rna genes|O that|O are|O coexpressed|O in|O a|O human|O neuroblastoma|O .|O 
An|O important|O family|O of|O regulatory|O molecules|O is|O made|O up|O of|O proteins|O that|O possess|O the|O DNA|O -|O binding|O and|O dimerization|O motif|O known|O as|O the|O basic|O helix|O -|O loop|O -|O helix|O (|O bHLH|O )|O domain|O .|O 
The|O bHLH|gene-protein family|O includes|O subgroups|O of|O closely|O related|O proteins|O that|O share|O common|O functional|O properties|O and|O overlapping|O patterns|O of|O expression|O (|O e.g.|O ,|O the|O MyoD1|O and|O achaete|O -|O scute|O subgroups|O )|O .|O 
In|O this|O report|O we|O describe|O HEN1|gene-rna and|O HEN2|gene-rna ,|O mammalian|O genes|O that|O encode|O a|O distinct|O subgroup|O of|O bHLH|gene-protein proteins|O .|O 
The|O HEN1|gene-rna gene|O was|O identified|O on|O the|O basis|O of|O cross|O -|O hybridization|O with|O TAL1|gene-rna ,|O a|O known|O bHLH|gene-rna gene|O implicated|O in|O T-cell|O acute|O lymphoblastic|O leukemia|O .|O 
In|O situ|O fluorescence|O hybridization|O was|O used|O to|O localize|O the|O human|O HEN1|gene-rna gene|O to|O chromosome|O band|O 1q22|O .|O 
HEN1|gene-rna and|O HEN2|gene-rna are|O coexpressed|O in|O the|O IMR-32|O human|O neuroblastoma|O cell|O line|O ,|O and|O they|O encode|O highly|O related|O proteins|O of|O 133|O and|O 135|O residues|O ,|O respectively|O ,|O that|O share|O 98|O %|O amino|O acid|O identity|O in|O their|O hHLH|O domains|O .|O 
These|O data|O imply|O that|O the|O bHLH|gene-protein protein|O subgroup|O encoded|O by|O HEN1|gene-rna and|O HEN2|gene-rna may|O serve|O important|O regulatory|O functions|O in|O the|O developing|O nervous|O system|O .|O 
Modulation|O of|O neuritogenesis|O by|O ganglioside|O -|O specific|O sialidase|gene-protein (|O Neu|gene-protein 3|gene-protein )|O in|O human|O neuroblastoma|O NB-1|O cells|O .|O 
Plasma|O membrane|O -|O associated|O sialidase|gene-protein (|O Neu|gene-protein 3|gene-protein )|O ,|O which|O specifically|O hydrolyzes|O gangliosides|O ,|O is|O relatively|O abundantly|O present|O in|O the|O nervous|O system|O .|O 
To|O understand|O the|O role|O of|O Neu|gene-protein 3|gene-protein in|O neuronal|O differentiation|O ,|O we|O studied|O the|O relationship|O between|O neurite|O outgrowth|O and|O Neu|gene-protein 3|gene-protein expression|O in|O human|O neuroblastoma|O NB-1|O cells|O .|O 
The|O expression|O of|O Neu|gene-protein 3|gene-protein in|O NB-1|O cells|O increased|O when|O neurite|O outgrowth|O in|O these|O cells|O was|O induced|O by|O dibutyryl|O cAMP|O .|O 
While|O treatment|O with|O dibutyryl|O cAMP|O alone|O enhanced|O the|O outgrowth|O of|O dendrite|O -|O like|O processes|O ,|O transfection|O of|O the|O Neu|gene-protein 3|gene-protein gave|O rise|O to|O a|O more|O prominent|O outgrowth|O of|O neurites|O with|O axon|O -|O like|O characteristics|O ,|O even|O in|O the|O absence|O of|O dibutyryl|O cAMP|O .|O 
Neu|gene-protein 3|gene-protein induction|O by|O dibutyryl|O cAMP|O is|O probably|O attributable|O ,|O in|O part|O ,|O to|O transactivation|O of|O the|O Neu|gene-rna 3|gene-rna gene|O through|O cAMP|O responsive|O elements|O in|O the|O 5|O '|O -|O upstream|O region|O ,|O as|O revealed|O by|O the|O promotor|O activity|O assay|O using|O Neu|gene-protein 3|gene-protein promotor|O expression|O plasmid|O .|O 
These|O results|O indicate|O that|O Neu|gene-generic 3|gene-generic regulates|O neurite|O formation|O in|O NB-1|O cells|O ,|O and|O suggest|O that|O this|O effect|O may|O be|O enhanced|O by|O dibutyryl|O cAMP|O via|O a|O cAMP|O -|O dependent|O pathway|O .|O 
Duplication|O of|O N-MYC|gene-rna at|O its|O resident|O site|O 2p24|O may|O be|O a|O mechanism|O of|O activation|O alternative|O to|O amplification|O in|O human|O neuroblastoma|O cells|O .|O 
Amplification|O of|O the|O human|O N-MYC|gene-rna proto|O -|O oncogene|O is|O frequently|O seen|O either|O in|O extrachromosomal|O double|O minutes|O or|O in|O homogeneously|O staining|O regions|O of|O aggressively|O growing|O neuroblastomas|O .|O 
N-MYC|gene-rna maps|O to|O chromosome|O 2|O band|O p|O 23|O -|O 24|O ,|O but|O homogeneously|O staining|O regions|O have|O never|O been|O observed|O at|O this|O band|O ,|O suggesting|O transposition|O of|O N-MYC|gene-rna during|O amplification|O .|O 
Previous|O studies|O had|O suggested|O that|O in|O cells|O with|O amplified|O N-MYC|gene-rna the|O chromosomes|O 2|O appear|O to|O be|O unaltered|O and|O to|O carry|O one|O apparently|O normal|O copy|O of|O N-MYC|gene-rna each|O .|O 
In|O contrast|O ,|O the|O contribution|O of|O N-MYC|gene-rna to|O tumors|O which|O lack|O amplification|O has|O been|O unclear|O .|O 
We|O here|O show|O ,|O by|O fluorescence|O in|O situ|O hybridization|O ,|O that|O N-MYC|gene-rna is|O occasionally|O duplicated|O at|O its|O resident|O site|O in|O neuroblastoma|O cell|O lines|O previously|O thought|O to|O have|O a|O single|O copy|O gene|O .|O 
Additionally|O ,|O we|O detected|O duplication|O in|O a|O neuroblastoma|O cell|O line|O carrying|O amplification|O .|O 
Our|O results|O raise|O the|O possibility|O that|O duplication|O may|O ,|O in|O some|O neuroblastomas|O ,|O either|O be|O a|O prelude|O to|O amplification|O or|O an|O alternative|O pathway|O by|O which|O N-MYC|gene-rna becomes|O activated|O .|O 
Homozygous|O inactivation|O of|O NF1|gene-rna gene|O in|O a|O patient|O with|O familial|O NF1|O and|O disseminated|O neuroblastoma|O .|O 
Neurofibromatosis|O type|O 1|O (|O NF1|O )|O patients|O are|O susceptible|O to|O tumor|O development|O .|O 
In|O the|O present|O study|O we|O describe|O a|O child|O with|O NF1|O and|O disseminated|O neuroblastoma|O whose|O death|O resulted|O from|O disease|O progression|O .|O 
The|O mother|O had|O cafe|O -|O au|O -|O lait|O spots|O suggesting|O a|O familial|O NF1|O .|O 
Neuroblastoma|O cells|O showed|O MYCN|gene-rna amplification|O and|O chromosome|O 1p36|O deletion|O ,|O common|O features|O associated|O with|O tumor|O progression|O in|O this|O malignancy|O .|O 
The|O NF1|gene-rna gene|O displayed|O a|O germline|O T|O -->|O C|O transition|O of|O intron|O 14|O in|O both|O the|O proband|O and|O mother|O DNA|O .|O 
This|O mutation|O ,|O not|O yet|O previously|O described|O ,|O occurs|O in|O a|O splicing|O donor|O site|O and|O produces|O a|O new|O mRNA|O variant|O observed|O together|O with|O normal|O NF1|gene-rna mRNA|O .|O 
Furthermore|O ,|O the|O SSCP|O analysis|O of|O the|O NF1|gene-rna gene|O in|O tumor|O cells|O showed|O a|O somatic|O deletion|O encompassing|O the|O intron|O 26|O and|O 27|O b|O of|O the|O paternal|O NF1|gene-rna allele|O .|O 
Hence|O ,|O neuroblastoma|O cells|O displayed|O both|O somatic|O and|O germline|O mutation|O of|O the|O NF1|gene-rna gene|O .|O 
Our|O data|O suggest|O that|O ,|O although|O rare|O ,|O neuroblastoma|O in|O patients|O with|O NF1|O may|O display|O homozygous|O gene|O inactivation|O .|O 
Detection|O of|O N-myc|gene-rna oncogene|O expression|O in|O human|O neuroblastoma|O by|O in|O situ|O hybridization|O and|O blot|O analysis|O :|O relationship|O to|O clinical|O outcome|O .|O 
We|O studied|O N-myc|gene-rna oncogene|O expression|O in|O 13|O human|O neuroectodermal|O tumors|O and|O one|O teratoma|O by|O in|O situ|O hybridization|O .|O 
In|O four|O of|O six|O neuroblastomas|O ,|O there|O was|O increased|O N-myc|gene-rna expression|O (|O 15|O to|O 49|O %|O of|O the|O cells|O )|O .|O 
Many|O of|O the|O primitive|O neuroblastic|O cells|O had|O an|O increase|O of|O N-myc|gene-rna RNA|O not|O observed|O in|O the|O larger|O ,|O more|O differentiated|O cells|O .|O 
Two|O neuroblastomas|O matured|O to|O ganglioneuromas|O ;|O no|O biopsies|O performed|O during|O this|O progression|O expressed|O increased|O N-myc|gene-rna RNA|O .|O 
Three|O ganglioneuroblastomas|O ,|O two|O tumors|O presenting|O as|O ganglioneuromas|O ,|O a|O cerebral|O neuroectodermal|O tumor|O ,|O a|O neurofibrosarcoma|O ,|O and|O the|O teratoma|O did|O not|O have|O increased|O N-myc|gene-rna expression|O .|O 
The|O data|O obtained|O by|O in|O situ|O hybridization|O correlated|O well|O with|O data|O obtained|O by|O blot|O analysis|O .|O 
Neuroblastomas|O /|O ganglioneuroblastomas|O with|O a|O favorable|O course|O did|O not|O have|O appreciable|O elevation|O of|O N-myc|gene-rna expression|O over|O 10|O to|O 77|O mo|O of|O follow|O -|O up|O ;|O thus|O N-myc|gene-rna may|O not|O be|O involved|O in|O the|O maintenance|O of|O the|O neoplastic|O state|O .|O 
However|O ,|O such|O tumors|O with|O a|O fatal|O outcome|O 2|O to|O 14|O mo|O after|O diagnosis|O usually|O had|O elevated|O N-myc|gene-rna expression|O .|O 
These|O findings|O suggest|O a|O relationship|O between|O elevated|O levels|O of|O N-myc|gene-rna RNA|O and|O poor|O prognosis|O .|O 
Sp1|gene-protein and|O Sp3|gene-protein activate|O the|O rat|O connexin40|gene-protein proximal|O promoter|O .|O 
The|O rat|O gap|O junction|O protein|O connexin40|gene-protein (|O rCx40|gene-protein )|O has|O a|O characteristic|O developmental|O and|O regional|O expression|O pattern|O ,|O for|O which|O the|O exact|O regulatory|O mechanisms|O are|O not|O known|O .|O 
To|O identify|O the|O molecular|O factors|O controlling|O Cx40|gene-protein expression|O ,|O its|O proximal|O promoter|O was|O characterized|O .|O 
The|O proximal|O rCx40|gene-protein promoter|O is|O the|O most|O conserved|O noncoding|O region|O within|O the|O Cx40|gene-rna -|O gene|O known|O thus|O far|O and|O contains|O five|O potential|O binding|O sites|O for|O Sp|gene-protein -|gene-protein family|gene-protein transcription|gene-protein factors|gene-protein .|O 
The|O binding|O of|O both|O Sp1|gene-protein and|O Sp3|gene-protein to|O each|O of|O these|O DNA|O elements|O was|O demonstrated|O by|O EMSA|O .|O 
Luciferase|gene-protein assays|O of|O the|O natural|O rCx40|gene-protein proximal|O promoter|O or|O mutated|O derivatives|O in|O Cx40|gene-generic -|O expressing|O (|O NCM|O ,|O primary|O rat|O neonatal|O cardiomyocytes|O and|O A7r5|O ,|O rat|O smooth|O muscle|O embryonic|O thoracic|O aorta|O cells|O )|O and|O -|O nonexpressing|O cells|O (|O N2A|O ,|O mouse|O neuroblastoma|O cells|O )|O revealed|O that|O all|O sites|O are|O contributing|O to|O basal|O promoter|O activity|O .|O 
Trans|O -|O activation|O assays|O in|O Drosophila|O Schneider|O line|O 2|O cells|O demonstrated|O that|O Sp1|gene-protein and|O Sp3|gene-protein activate|O the|O rCx40|gene-protein proximal|O promoter|O in|O a|O dose|O -|O dependent|O and|O additive|O manner|O .|O 
Heat|gene-rna shock|gene-rna gene|O expression|O and|O cytoskeletal|O alterations|O in|O mouse|O neuroblastoma|O cells|O .|O 
The|O cytoskeleton|O of|O neuroblastoma|O cells|O ,|O clone|O Neuro|O 2A|O ,|O is|O altered|O by|O two|O stress|O conditions|O :|O heat|O shock|O and|O arsenite|O treatment|O .|O 
Microtubules|O are|O reorganized|O ,|O intermediate|O filaments|O are|O aggregated|O around|O the|O nucleus|O ,|O and|O the|O number|O of|O stress|O fibers|O is|O reduced|O .|O 
Since|O both|O stress|O modalities|O induce|O similar|O cytoskeletal|O alterations|O ,|O no|O thermic|O denaturation|O of|O one|O or|O more|O cytoskeletal|O components|O can|O be|O involved|O in|O this|O process|O .|O 
Heat|gene-protein shock|gene-protein proteins|O are|O induced|O both|O by|O heat|O and|O by|O arsenite|O .|O 
However|O ,|O cells|O treated|O with|O arsenite|O synthesize|O hsp28|gene-protein which|O is|O not|O detected|O in|O heat|O -|O treated|O cells|O .|O 
Synthesis|O of|O all|O hsps|gene-protein is|O prevented|O by|O addition|O of|O actinomycin|gene-protein D|gene-protein or|O cycloheximide|O .|O 
Under|O these|O conditions|O no|O alterations|O are|O observed|O in|O the|O organization|O of|O microtubules|O and|O intermediate|O filaments|O during|O heat|O or|O arsenite|O treatment|O .|O 
However|O ,|O these|O drugs|O are|O not|O able|O to|O prevent|O the|O rapid|O loss|O of|O stress|O fibers|O .|O 
A|O re|O -|O formation|O of|O the|O cytoskeleton|O during|O the|O recovery|O period|O proceeds|O within|O 3|O h|O and|O is|O also|O found|O to|O occur|O in|O the|O presence|O of|O a|O protein|O synthesis|O inhibitor|O .|O 
These|O data|O suggest|O that|O reorganization|O of|O microtubules|O and|O intermediate|O filaments|O during|O a|O stress|O treatment|O requires|O the|O synthesis|O of|O a|O new|O protein(s)|O ,|O probably|O hsp(s)|gene-protein .|O 
Spontaneous|O regeneration|O of|O free|O muscarinic|gene-protein receptor|gene-protein after|O alkylation|O by|O BM|O 123|O .|O 
I.|O Recovery|O in|O vivo|O and|O in|O cell|O culture|O .|O 
The|O recovery|O of|O rat|O muscarinic|gene-protein receptor|gene-protein number|O from|O the|O effects|O of|O a|O specific|O alkylating|O ligand|O ,|O N-[4-(2-chloroethylmethylamino)-2-butynyl]-2-pyrrolidone|O (|O BM|O 123|O )|O ,|O in|O three|O tissues|O is|O presented|O as|O an|O exponential|O function|O of|O time|O .|O 
No|O significant|O difference|O was|O found|O in|O the|O recovery|O rate|O constants|O derived|O from|O analysis|O of|O recovery|O time|O courses|O in|O corpus|O striatum|O ,|O cerebral|O cortex|O and|O ileal|O longitudinal|O muscle|O .|O 
The|O single|O rate|O constant|O (|O 0.021|O /|O hr|O )|O was|O also|O independent|O of|O amount|O and|O duration|O of|O BM|O 123|O dose|O .|O 
Additional|O analysis|O of|O agonist|O -|O defined|O high|O and|O low|O affinity|O subsites|O in|O cortex|O revealed|O that|O recovery|O of|O these|O populations|O also|O followed|O similar|O time|O courses|O although|O the|O alkylation|O proceeds|O more|O slowly|O for|O the|O high|O affinity|O sites|O .|O 
The|O rate|O constant|O for|O recovery|O of|O both|O subsites|O was|O 0.029|O /|O hr|O .|O 
Recovery|O from|O BM|O 123|O alkylation|O occurred|O in|O NG108-15|O neuroblastoma|O X|O glioma|O cells|O .|O 
The|O presence|O of|O cycloheximide|O in|O the|O recovery|O medium|O did|O not|O significantly|O inhibit|O this|O recovery|O process|O in|O the|O clonal|O cell|O line|O ,|O suggesting|O that|O de|O novo|O receptor|O synthesis|O is|O unnecessary|O for|O regeneration|O of|O unalkylated|O receptors|O .|O 
Familial|O Alzheimer|O 's|O disease|O -|O linked|O presenilin|gene-rna 1|gene-rna variants|O elevate|O Abeta|gene-protein 1|gene-protein -|gene-protein 42|gene-protein /|O 1|gene-protein -|gene-protein 40|gene-protein ratio|O in|O vitro|O and|O in|O vivo|O .|O 
Mutations|O in|O the|O presenilin|gene-rna 1|gene-rna (|O PS1|gene-rna )|O and|O presenilin|gene-rna 2|gene-rna genes|O cosegregate|O with|O the|O majority|O of|O early|O -|O onset|O familial|O Alzheimer|O 's|O disease|O (|O FAD|O )|O pedigrees|O .|O 
We|O now|O document|O that|O the|O Abeta|gene-protein 1|gene-protein -|gene-protein 42|gene-protein (|gene-protein 43|gene-protein )|gene-protein /|O Abeta|gene-protein 1|gene-protein -|gene-protein 40|gene-protein ratio|O in|O the|O conditioned|O media|O of|O independent|O N2a|O cell|O lines|O expressing|O three|O FAD|O -|O linked|O PS1|gene-rna variants|O is|O uniformly|O elevated|O relative|O to|O cells|O expressing|O similar|O levels|O of|O wild|O -|O type|O PS1|gene-rna .|O 
Similarly|O ,|O the|O Abeta|gene-protein 1|gene-protein -|gene-protein 42|gene-protein (|gene-protein 43|gene-protein )|gene-protein /|O Abeta|gene-protein 1|gene-protein -|gene-protein 40|gene-protein ratio|O is|O elevated|O in|O the|O brains|O of|O young|O transgenic|O animals|O coexpressing|O a|O chimeric|O amyloid|gene-protein precursor|gene-protein protein|gene-protein (|O APP|gene-protein )|O and|O an|O FAD|O -|O linked|O PS1|gene-rna variant|O compared|O with|O brains|O of|O transgenic|O mice|O expressing|O APP|gene-protein alone|O or|O transgenic|O mice|O coexpressing|O wild|O -|O type|O human|O PS1|gene-rna and|O APP|gene-generic .|O 
These|O studies|O provide|O compelling|O support|O for|O the|O view|O that|O one|O mechanism|O by|O which|O these|O mutant|O PS1|gene-rna cause|O AD|O is|O by|O increasing|O the|O extracellular|O concentration|O of|O Abeta|gene-protein peptides|O terminating|O at|O 42|O (|O 43|O )|O ,|O species|O that|O foster|O Abeta|gene-protein deposition|O .|O 
Duplication|O of|O the|O DR3|gene-rna gene|O on|O human|O chromosome|O 1p36|O and|O its|O deletion|O in|O human|O neuroblastoma|O .|O 
The|O human|O DR3|gene-rna gene|O ,|O whose|O product|O is|O also|O known|O as|O Wsl-1|gene-protein /|O APO-3|gene-protein /|O TRAMP|gene-protein /|O LARD|gene-protein ,|O encodes|O a|O tumor|gene-protein necrosis|gene-protein factor|gene-protein -|gene-protein related|gene-protein receptor|gene-protein that|O is|O expressed|O primarily|O on|O the|O surface|O of|O thymocytes|O and|O lymphocytes|O .|O 
DR3|gene-rna is|O capable|O of|O inducing|O both|O NF-kappa|gene-protein B|gene-protein activation|O and|O apoptosis|O when|O overexpressed|O in|O mammalian|O cells|O ,|O although|O its|O ligand|O has|O not|O yet|O been|O identified|O .|O 
We|O report|O here|O that|O the|O DR3|gene-rna gene|O locus|O is|O tandemly|O duplicated|O on|O human|O chromosome|O band|O 1|O p36.2|O -|O p36.3|O and|O that|O these|O genes|O are|O hemizygously|O deleted|O and/or|O translocated|O to|O another|O chromosome|O in|O neuroblastoma|O (|O NB|O )|O cell|O lines|O with|O amplified|O MYCN|gene-rna .|O 
Duplication|O of|O at|O least|O a|O portion|O of|O the|O DR3|gene-rna gene|O ,|O including|O the|O extracellular|O and|O transmembrane|O regions|O but|O not|O the|O cytoplasmic|O domain|O ,|O was|O demonstrated|O by|O both|O fluorescence|O in|O situ|O hybridization|O and|O genomic|O Southern|O blotting|O .|O 
In|O most|O NB|O cell|O lines|O ,|O both|O the|O DR3|gene-rna and|O the|O DR3L|gene-rna sequences|O are|O simultaneously|O deleted|O and/or|O translocated|O to|O another|O chromosome|O .|O 
Finally|O ,|O DR3|gene-protein /|O Wsl-1|gene-protein protein|O expression|O is|O quite|O variable|O among|O these|O NB|O cell|O lines|O ,|O with|O very|O low|O or|O undetectable|O levels|O in|O 7|O of|O 17|O NB|O cell|O lines|O .|O 
Efficient|O DNA|O transfection|O in|O neuronal|O and|O astrocytic|O cell|O lines|O .|O 
We|O have|O studied|O different|O parameters|O for|O efficient|O DNA|O transfection|O in|O various|O cell|O types|O and|O with|O different|O size|O of|O the|O promoter|O .|O 
Here|O we|O report|O that|O the|O optimum|O condition|O for|O DNA|O transfection|O by|O electroporation|O is|O 350|O V|O /|O 960|O microF|O for|O PC12|O ,|O 450|O V|O /|O 960|O microF|O C6|O cells|O ,|O and|O 250|O V|O /|O 500|O microF|O for|O COS-1|O cells|O .|O 
For|O the|O human|O neuroblastoma|O (|O SK-N-SH|O )|O cells|O the|O optimum|O condition|O for|O DNA|O transfection|O is|O by|O the|O calcium|O phosphate|O method|O .|O 
In|O promoter|O mapping|O studies|O ,|O a|O serial|O deletion|O approach|O is|O commonly|O used|O .|O 
To|O optimize|O transfection|O we|O have|O selected|O three|O DNA|O constructs|O that|O varied|O in|O size|O from|O 4.5|O to|O 12.4|O kilobases|O (|O kb|O )|O .|O 
We|O measured|O the|O promoter|O activity|O of|O these|O constructs|O under|O conditions|O of|O '|O equal|O amount|O '|O ,|O '|O equimolar|O '|O ,|O and|O '|O equimolar|O plus|O carrier|O DNA|O to|O make|O it|O equal|O amount|O '|O .|O 
We|O recommend|O that|O for|O comparative|O purpose|O ,|O transfection|O should|O be|O carried|O out|O under|O '|O equimolar|O condition|O '|O without|O a|O need|O to|O adjust|O the|O total|O amount|O of|O DNA|O by|O carrier|O DNA|O .|O 
Taken|O together|O ,|O our|O results|O suggest|O that|O efficient|O methods|O for|O DNA|O transfection|O are|O important|O to|O study|O gene|O regulation|O by|O devising|O better|O ways|O to|O deliver|O DNA|O into|O the|O mammalian|O cells|O .|O 
Suprarenal|O haematoma|O versus|O neuroblastoma|O complicated|O by|O haemorrhage|O .|O 
A|O diagnostic|O dilemma|O in|O the|O newborn|O .|O 
Concomitant|O neonatal|O suprarenal|O haemorrhage|O and|O neuroblastoma|O is|O rare|O .|O 
The|O clinical|O and|O radiologic|O manifestations|O recorded|O in|O 11|O patients|O with|O this|O entity|O are|O compared|O with|O the|O findings|O in|O 32|O cases|O with|O simple|O adrenal|O haemorrhage|O .|O 
Because|O of|O the|O many|O similarities|O in|O presentation|O the|O combined|O lesion|O must|O always|O be|O considered|O when|O a|O neonate|O is|O found|O to|O have|O a|O retroperitoneal|O ,|O extra|O -|O renal|O mass|O .|O 
Our|O present|O approach|O to|O the|O investigation|O includes|O conventional|O chest|O and|O abdominal|O radiography|O aimed|O to|O demonstrate|O possible|O paravertebral|O widening|O .|O 
Serial|O ultrasonographies|O are|O easy|O to|O carry|O out|O and|O indispensable|O .|O 
The|O low|O specificity|O of|O urography|O makes|O us|O refrain|O from|O this|O modality|O as|O a|O routine|O .|O 
Scintigraphy|O ,|O in|O infants|O and|O children|O considered|O useful|O in|O demonstrating|O extent|O and|O spread|O of|O neuroblastoma|O ,|O has|O hardly|O been|O employed|O in|O neonates|O .|O 
The|O true|O value|O of|O the|O modality|O in|O this|O particular|O age|O group|O remains|O to|O be|O settled|O .|O 
CT|O scanning|O does|O not|O seem|O to|O provide|O essential|O information|O additional|O to|O that|O of|O sonography|O and|O may|O therefore|O be|O excluded|O from|O the|O protocol|O .|O 
Determination|O of|O urinary|O excretion|O of|O catecholamine|O metabolites|O is|O of|O crucial|O significance|O and|O a|O compulsory|O part|O of|O the|O investigation|O .|O 
Cytopathogenicity|O of|O Naegleria|O fowleri|O and|O Naegleria|O gruberi|O for|O established|O mammalian|O cell|O cultures|O .|O 
Amebae|O of|O Naegleria|O fowleri|O and|O Naegleria|O gruberi|O were|O cytopathic|O for|O nine|O established|O mammalian|O cell|O cultures|O ,|O including|O mouse|O and|O human|O fibroblasts|O ,|O rabbit|O and|O monkey|O kidney|O cells|O ,|O rat|O and|O mouse|O neuroblastoma|O cells|O ,|O baby|O hamster|O kidney|O cells|O ,|O and|O human|O epithelioma|O and|O carcinoma|O cells|O .|O 
Nine|O strains|O of|O N.|O fowleri|O were|O equally|O cytopathic|O for|O rodent|O neuroblastoma|O cells|O .|O 
As|O few|O as|O one|O ameba|O per|O million|O neuroblastoma|O cells|O destroyed|O the|O mammalian|O target|O cells|O after|O 9|O days|O .|O 
The|O N.|O fowleri|O grew|O and|O destroyed|O rat|O neuroblastoma|O cells|O at|O 30|O to|O 37|O C|O whereas|O N.|O gruberi|O grew|O and|O destroyed|O the|O target|O cells|O at|O 25|O to|O 30|O C|O .|O 
Both|O N.|O fowleri|O and|O N.|O gruberi|O attached|O efficiently|O to|O the|O target|O cells|O at|O 30|O to|O 37|O C|O ;|O N.|O gruberi|O but|O not|O N.|O fowleri|O attached|O efficiently|O at|O 25|O C|O .|O 
Electron|O microscopic|O observations|O of|O mixed|O cultures|O of|O N.|O fowleri|O and|O neuroblastoma|O cells|O established|O that|O the|O amebae|O ,|O after|O 12|O hr|O ,|O had|O ingested|O portions|O of|O the|O neuroblastoma|O target|O cells|O without|O causing|O cell|O lysis|O .|O 
Conversely|O ,|O N.|O gruberi|O amebae|O ,|O after|O attaching|O to|O target|O cells|O ,|O disrupted|O the|O plasma|O membrane|O and|O cytoplasm|O of|O the|O target|O cells|O although|O the|O target|O cell|O nucleus|O remained|O intact|O .|O 
The|O amebae|O then|O ingested|O the|O target|O cell|O debris|O .|O 
Detection|O of|O MYCN|gene-rna amplification|O in|O three|O neuroblastoma|O cell|O lines|O by|O non|O -|O radioactive|O chromosomal|O in|O situ|O hybridization|O .|O 
A|O non|O -|O radioactive|O chromosomal|O in|O situ|O hybridization|O technique|O utilizing|O a|O biotin|O -|O streptavidin|gene-protein -|O polyalkaline|O -|O phosphatase|gene-protein complex|O was|O successfully|O applied|O to|O three|O neuroblastoma|O cell|O lines|O for|O detection|O of|O MYCN|gene-rna amplification|O .|O 
These|O cell|O lines|O ,|O designated|O PER-106|O ,|O PER-107|O ,|O and|O PER-108|O ,|O were|O derived|O from|O consecutive|O bone|O marrow|O samples|O taken|O from|O a|O patient|O with|O stage|O IV|O neuroblastoma|O .|O 
The|O cell|O line|O derived|O at|O diagnosis|O (|O PER-106|O )|O exhibited|O MYCN|gene-rna amplification|O in|O the|O form|O of|O variable|O numbers|O of|O double|O -|O minute|O chromosomes|O ,|O small|O fragments|O ,|O and|O rings|O of|O varying|O sizes|O .|O 
This|O observed|O variability|O of|O MYCN|gene-rna amplification|O may|O explain|O the|O reported|O heterogeneity|O of|O both|O MYCN|gene-rna mRNA|O and|O protein|O expression|O among|O individual|O cells|O of|O some|O neuroblastomas|O .|O 
The|O cell|O lines|O derived|O from|O subsequent|O samples|O (|O PER-107|O and|O PER-108|O )|O contained|O amplified|O MYCN|gene-rna as|O two|O consistent|O homogeneously|O staining|O regions|O in|O every|O cell|O .|O 
These|O were|O located|O on|O the|O short|O arms|O of|O chromosomes|O 6|O and|O 14|O .|O 
Thus|O ,|O amplified|O MYCN|gene-rna was|O identified|O in|O each|O cell|O line|O and|O demonstrated|O the|O concurrent|O evolution|O of|O amplification|O with|O cytogenetic|O abnormalities|O .|O 
Functional|O phage|O display|O of|O ciliary|gene-protein neurotrophic|gene-protein factor|gene-protein .|O 
We|O report|O the|O display|O of|O human|O ciliary|gene-protein neurotrophic|gene-protein factor|gene-protein (|O hCNTF|gene-protein )|O ,|O a|O survival|O factor|O for|O neuronal|O cells|O belonging|O to|O the|O alpha-helical|gene-protein cytokine|gene-protein superfamily|O ,|O on|O the|O surface|O of|O the|O filamentous|O bacteriophage|O fd|O .|O 
The|O hCNTF|gene-rna cDNA|O was|O fused|O to|O a|O DNA|O sequence|O encoding|O the|O C|O -|O terminal|O domain|O of|O pIII|gene-protein ,|O a|O minor|O coat|O protein|O exposed|O at|O one|O end|O of|O fd|O .|O 
Gene|O fusions|O were|O cloned|O into|O a|O plasmid|O containing|O the|O ColE1|O plasmid|O and|O fd|O origins|O of|O replication|O ,|O and|O were|O packaged|O into|O phagemid|O particles|O upon|O superinfection|O with|O M13KO7|O helper|O phage|O .|O 
The|O resulting|O fusion|O phage|O bound|O specifically|O to|O anti|gene-protein -|gene-protein CNTF|gene-protein antibodies|gene-protein and|O to|O the|O recombinant|O soluble|O CNTF|gene-protein alpha|gene-protein -|gene-protein receptor|gene-protein .|O 
Moreover|O ,|O phage|O -|O displayed|O hCNTF|gene-protein was|O found|O to|O possess|O biological|O activity|O at|O concentrations|O comparable|O to|O those|O of|O the|O soluble|O cytokine|gene-protein .|O 
These|O results|O demonstrate|O that|O CNTF|gene-protein can|O be|O displayed|O on|O phage|O in|O a|O correctly|O folded|O and|O functionally|O active|O form|O .|O 
Binding|O of|O fusion|O phage|O to|O immobilized|O CNTF|gene-protein alpha|gene-protein -|gene-protein receptor|gene-protein and|O subsequent|O elution|O at|O low|O pH|O resulted|O in|O affinity|O purification|O of|O CNTF|gene-protein -|O displaying|O virions|O .|O 
Utilization|O of|O this|O technology|O should|O enable|O the|O selection|O of|O high|O -|O affinity|O variants|O from|O libraries|O of|O CNTF|gene-protein mutants|O displayed|O on|O phage|O .|O 
Differences|O in|O the|O expression|O of|O neurokinin|gene-protein receptor|gene-protein in|O neural|O and|O bone|O marrow|O mesenchymal|O cells|O :|O implications|O for|O neuronal|O expansion|O from|O bone|O marrow|O cells|O .|O 
The|O neurokinin-1|gene-protein (|O NK-1|gene-protein )|O receptor|gene-protein interacts|O with|O peptides|O that|O belong|O to|O the|O tachykinin|gene-protein family|O .|O 
NK-1|gene-protein is|O inducible|O in|O bone|O marrow|O (|O BM|O )|O stroma|O .|O 
In|O neural|O cells|O ,|O its|O expression|O is|O high|O to|O constitutive|O .|O 
Screening|O of|O three|O cDNA|O libraries|O indicated|O that|O this|O different|O in|O NK-1|gene-protein expression|O in|O neural|O and|O BM|O cells|O could|O not|O be|O explained|O by|O differences|O in|O the|O cDNA|O sequence|O .|O 
Analyses|O the|O 5|O '|O flanking|O sequence|O in|O BM|O stroma|O and|O three|O neural|O cell|O lines|O indicated|O that|O sequence|O +|O 1|O /|O +|O 358|O relative|O to|O the|O transcription|O start|O (|O TS|O )|O site|O could|O account|O for|O the|O differences|O in|O NK-1|gene-protein expression|O .|O 
Particular|O cytokines|gene-protein could|O reverse|O the|O repressive|O effects|O of|O region|O +|O 1|O /|O +|O 358|O in|O BM|O stroma|O .|O 
The|O effects|O of|O NF-kappa|gene-protein B|gene-protein and|O cAMP|O activators|O were|O studied|O in|O stromal|O cells|O using|O a|O dominant|O negative|O inhibitor|O of|O NF-kappa|gene-protein B|gene-protein (|O I|gene-protein kappa|gene-protein B|gene-protein )|O or|O a|O repressor|O of|O CRE|gene-protein activators|O (|O ICERII|gene-protein gamma|gene-protein )|O .|O 
The|O results|O showed|O that|O their|O effects|O of|O these|O transcription|O factors|O depended|O on|O the|O stimulating|O cytokine|O .|O 
This|O study|O provides|O insight|O into|O the|O tissue|O -|O specific|O differences|O in|O the|O expression|O of|O the|O NK-1|gene-rna gene|O .|O 
Cytotoxicity|O of|O the|O cocaine|O metabolite|O benzoylecgonine|O .|O 
The|O NG108-15|O and|O C6|O cell|O lines|O were|O used|O in|O the|O present|O study|O as|O neuronal|O and|O glial|O models|O ,|O respectively|O ,|O to|O examine|O the|O cytotoxicity|O of|O the|O major|O metabolite|O of|O cocaine|O ,|O benzoylecgonine|O (|O BE|O )|O .|O 
Exposure|O of|O both|O cell|O types|O to|O varying|O concentrations|O of|O BE|O resulted|O in|O a|O loss|O of|O cells|O from|O the|O growth|O surface|O .|O 
Analysis|O of|O the|O unattached|O cells|O after|O such|O exposure|O ,|O using|O a|O variety|O of|O techniques|O ,|O revealed|O that|O these|O cells|O were|O not|O viable|O .|O 
Therefore|O ,|O this|O effect|O could|O not|O be|O ascribed|O to|O BE|O interfering|O with|O cell|O -|O substratum|O interactions|O .|O 
The|O early|O events|O in|O BE|O cytotoxicity|O were|O examined|O by|O observing|O cells|O cultivated|O on|O the|O stage|O of|O an|O inverted|O microscope|O ,|O using|O differential|O interference|O contrast|O (|O Nomarski|O )|O optics|O .|O 
Upon|O exposure|O of|O either|O cell|O type|O to|O 10|O microM|O BE|O a|O retraction|O of|O cellular|O processes|O could|O be|O observed|O within|O 30|O min|O .|O 
Within|O 6|O h|O cell|O death|O was|O apparent|O .|O 
Similar|O analyses|O using|O 50|O microM|O BE|O in|O the|O growth|O medium|O resulted|O in|O similar|O results|O ,|O except|O that|O process|O retraction|O could|O be|O observed|O as|O early|O as|O 15|O min|O after|O exposure|O .|O 
These|O results|O demonstrate|O that|O the|O major|O metabolite|O of|O cocaine|O ,|O benzoylecgonine|O ,|O is|O cytotoxic|O to|O in|O vitro|O models|O of|O neuronal|O and|O glial|O cells|O .|O 
Characterization|O of|O the|O 5|O '|O -|O sequence|O of|O the|O mouse|O fatty|gene-protein acid|gene-protein amide|gene-protein hydrolase|gene-protein .|O 
Fatty|gene-protein acid|gene-protein amide|gene-protein hydrolase|gene-protein (|O FAAH|gene-protein )|O is|O critical|O for|O degradation|O of|O several|O important|O fatty|O acid|O amides|O including|O anandamide|O ,|O an|O endocannabinoid|O ,|O as|O well|O as|O oleamide|O ,|O a|O sleep|O -|O inducing|O factor|O .|O 
These|O compounds|O play|O roles|O in|O diverse|O physiological|O processes|O ranging|O from|O memory|O and|O learning|O to|O the|O regulation|O of|O blood|O pressure|O .|O 
The|O mechanisms|O that|O regulate|O FAAH|gene-protein expression|O have|O not|O been|O characterized|O .|O 
A|O 5|O '|O -|O region|O of|O the|O mouse|O FAAH|gene-rna with|O promoter|O activity|O was|O isolated|O from|O 1.8|O kbp|O of|O genomic|O sequence|O .|O 
Characterization|O of|O +|O 1|O of|O transcription|O of|O FAAH|gene-rna by|O RNA|gene-protein ligase|gene-protein mediated|O -|O rapid|O amplification|O of|O cDNA|O ends|O showed|O that|O FAAH|gene-rna mRNA|O is|O transcribed|O from|O multiple|O transcription|O start|O sites|O lacking|O a|O TATA|O -|O box|O element|O .|O 
Functional|O analysis|O of|O the|O FAAH|gene-rna upstream|O sequence|O fused|O to|O a|O luciferase|gene-rna reporter|gene-rna gene|O revealed|O a|O FAAH|gene-rna -|O promoter|O construct|O with|O tissue|O specific|O activity|O .|O 
A|O 674|O -|O bp|O FAAH|gene-rna -|O promoter|O construct|O was|O active|O in|O N18TG2|O (|O N18|O )|O neuroblastoma|O cells|O and|O C6|O glioma|O cells|O ,|O lines|O that|O have|O endogenous|O FAAH|gene-protein activity|O .|O 
The|O same|O 674|O -|O bp|O FAAH|gene-rna -|O promoter|O construct|O was|O not|O active|O in|O C2C12|O or|O L6|O myogenic|O cells|O ,|O two|O lines|O that|O do|O not|O have|O FAAH|gene-protein activity|O .|O 
Characterization|O of|O a|O cell|O type|O -|O specific|O enhancer|O found|O in|O the|O human|O papilloma|O virus|O type|O 18|O genome|O .|O 
We|O have|O previously|O isolated|O long|O -|O range|O acting|O enhancer|O elements|O from|O the|O HeLa|O genome|O by|O functional|O selection|O .|O 
In|O this|O report|O ,|O the|O structural|O and|O functional|O characteristics|O of|O one|O (|O GA1|O )|O of|O the|O enhancers|O are|O reported|O .|O 
By|O cloning|O various|O restriction|O fragments|O and|O by|O deletion|O mutagenesis|O ,|O the|O activity|O of|O GA1|O was|O located|O in|O a|O 230|O -|O bp|O region|O .|O 
The|O nucleotide|O sequence|O of|O GA1|O and|O genomic|O Southern|O blot|O analysis|O indicated|O that|O GA1|O is|O derived|O from|O human|O papilloma|O virus|O (|O HPV|O )|O 18|O DNA|O that|O had|O been|O integrated|O into|O the|O HeLa|O genome|O .|O 
The|O enhancer|O is|O located|O in|O the|O non|O -|O coding|O region|O of|O the|O HPV|O 18|O genome|O .|O 
The|O HPV|O 18|O enhancer|O consists|O of|O two|O functional|O domains|O ,|O both|O of|O which|O have|O full|O enhancer|O activity|O in|O HeLa|O cells|O .|O 
The|O enhancer|O does|O not|O contain|O enhancer|O core|O sequences|O but|O contains|O several|O blocks|O of|O potential|O Z-DNA|O sequence|O .|O 
Like|O SV40|O and|O polyoma|O virus|O enhancers|O ,|O the|O activity|O of|O the|O HPV|O 18|O enhancer|O was|O repressed|O by|O adenovirus|O E1a|O products|O .|O 
The|O HPV|O 18|O enhancer|O shows|O a|O narrow|O cell|O type|O specificity|O :|O it|O is|O active|O in|O some|O cervical|O carcinoma|O cell|O lines|O ,|O but|O inactive|O in|O all|O non|O -|O cervical|O cells|O except|O for|O one|O neuroblastoma|O cell|O line|O .|O 
These|O results|O suggest|O that|O the|O HPV|O 18|O enhancer|O plays|O an|O important|O role|O in|O regulation|O of|O the|O viral|O genes|O .|O 
Expression|O of|O Fas|gene-protein (|O APO-1|gene-generic /|O CD95|gene-generic )|O and|O Fas|gene-protein ligand|gene-protein (|O FasL|gene-protein )|O in|O human|O neuroblastoma|O .|O 
BACKGROUND|O AND|O PROCEDURE|O :|O To|O determine|O the|O possible|O role|O of|O Fas|gene-protein /|O FasL|gene-protein system|O in|O the|O particularly|O heterogeneous|O behaviour|O of|O neuroblastoma|O (|O NB|O )|O ,|O we|O have|O measured|O the|O functional|O expression|O of|O Fas|gene-protein and|O its|O ligand|O ,|O FasL|gene-protein ,|O in|O primary|O neuroblastoma|O samples|O and|O cell|O lines|O by|O immunohistochemistry|O and|O flow|O cytometry|O .|O 
RESULTS|O :|O Our|O results|O reveal|O that|O while|O Fas|gene-protein expression|O is|O associated|O with|O low|O stage|O and|O more|O mature|O tumors|O ,|O heterogeneous|O FasL|gene-protein expression|O was|O mostly|O detected|O in|O high|O stage|O tumors|O ,|O with|O our|O apparent|O correlation|O to|O MYCN|gene-rna amplification|O .|O 
Flow|O cytometric|O analysis|O of|O cell|O lines|O demonstrated|O a|O high|O expression|O of|O Fas|gene-protein in|O epithelial|O -|O type|O ,|O HLA|gene-protein class|gene-protein I|gene-protein positive|O cell|O lines|O ,|O which|O was|O lost|O upon|O activation|O with|O phorbol|O esters|O .|O 
In|O contrast|O ,|O Fas|gene-protein ligand|gene-protein was|O detected|O in|O only|O a|O small|O subset|O of|O cell|O lines|O .|O 
CONCLUSIONS|O :|O In|O some|O cell|O lines|O ,|O cytotoxic|O assays|O revealed|O the|O ability|O of|O NB|O -|O associated|O Fas|gene-protein receptor|gene-protein to|O transduce|O an|O apoptotic|O signal|O upon|O triggering|O .|O 
The|O pattern|O of|O functional|O Fas|gene-protein /|O FasL|gene-protein expression|O in|O tumours|O and|O cell|O lines|O suggests|O that|O this|O system|O may|O be|O involved|O in|O the|O evasion|O of|O highly|O malignant|O neuroblastoma|O cells|O to|O host|O immune|O response|O .|O 
Biochemical|O and|O genetic|O characterization|O of|O the|O HBA71|gene-protein Ewing|O 's|O sarcoma|O cell|O surface|O antigen|O .|O 
Monoclonal|gene-protein antibody|gene-protein HBA71|gene-protein detects|O a|O cell|O surface|O antigen|O of|O human|O Ewing|O 's|O sarcomas|O and|O peripheral|O neuroepitheliomas|O that|O distinguishes|O these|O tumors|O from|O other|O small|O round|O cell|O tumors|O of|O childhood|O and|O adolescence|O .|O 
In|O the|O present|O study|O ,|O we|O show|O that|O monoclonal|gene-protein antibody|gene-protein HBA71|gene-protein reacts|O with|O polypeptides|O of|O Mr|O 32,000|O and|O 30,000|O and|O that|O the|O HBA71|gene-protein -|O coding|O gene|O segregates|O with|O human|O chromosomes|O X|O and|O Y|O in|O rodent|O -|O human|O hybrids|O .|O 
Therefore|O ,|O we|O compared|O HBA71|gene-protein to|O the|O T-cell|O leukemia|O antigen|O 12E7|gene-protein ,|O which|O is|O encoded|O by|O the|O pseudoautosomal|O region|O of|O chromosomes|O X|O and|O Y|O .|O 
We|O show|O that|O monoclonal|gene-protein antibodies|gene-protein HBA71|gene-protein and|O 12E7|gene-protein (a)|O detect|O polypeptides|O of|O identical|O size|O ,|O (b)|O react|O with|O mouse|O cells|O transfected|O with|O complementary|O DNA|O corresponding|O to|O the|O 12E7|gene-protein -|O coding|O gene|O ,|O MIC2|gene-rna ,|O and|O (c)|O give|O similar|O patterns|O of|O reactivity|O with|O human|O tumor|O cell|O lines|O and|O small|O round|O cell|O tumor|O tissues|O .|O 
Thus|O ,|O HBA71|gene-protein and|O 12E7|gene-protein are|O identical|O or|O closely|O related|O antigens|O and|O the|O available|O MIC2|gene-generic probes|O will|O facilitate|O analysis|O of|O the|O molecular|O mechanisms|O that|O determine|O differential|O HBA71|gene-protein expression|O in|O small|O round|O cell|O tumors|O of|O childhood|O and|O adolescence|O .|O 
myc|gene-rna gene|O amplification|O and|O expression|O in|O primary|O human|O neuroblastoma|O .|O 
Although|O N-myc|gene-rna amplification|O in|O neuroblastomas|O correlates|O with|O poor|O prognosis|O ,|O not|O all|O neuroblastomas|O which|O fail|O to|O respond|O to|O therapy|O have|O N-myc|gene-rna amplification|O .|O 
To|O determine|O whether|O other|O modes|O of|O myc|gene-rna gene|O activation|O underlie|O progression|O of|O some|O neuroblastomas|O ,|O 45|O were|O analyzed|O for|O amplification|O of|O N-myc|gene-rna ,|O c-myc|gene-rna and|O L-myc|gene-rna and|O 26|O were|O studied|O for|O transcription|O of|O these|O oncogenes|O .|O 
N-myc|gene-rna amplification|O was|O found|O in|O 6|O of|O 45|O tumors|O ;|O no|O tumor|O had|O amplification|O of|O c-myc|gene-rna or|O L-myc|gene-rna .|O 
Transcription|O of|O both|O N-myc|gene-rna and|O c-myc|gene-rna occurred|O in|O 21|O of|O 26|O neuroblastomas|O .|O 
No|O tumor|O without|O N-myc|gene-rna amplification|O had|O a|O level|O of|O N-myc|gene-rna expression|O near|O that|O of|O a|O tumor|O or|O cell|O line|O with|O amplification|O .|O 
One|O tumor|O with|O N-myc|gene-rna amplification|O was|O the|O only|O specimen|O with|O N-myc|gene-rna but|O not|O c-myc|gene-rna expression|O .|O 
Five|O samples|O had|O c-myc|gene-rna but|O not|O N-myc|gene-rna expression|O ;|O all|O had|O histological|O features|O of|O ganglioneuroma|O .|O 
DNA|O index|O did|O not|O correlate|O with|O myc|gene-rna gene|O amplification|O or|O expression|O .|O 
It|O is|O concluded|O that|O N-myc|gene-rna and|O c-myc|gene-rna are|O commonly|O expressed|O in|O primary|O untreated|O neuroblastomas|O ,|O but|O in|O the|O absence|O of|O N-myc|gene-rna amplification|O ,|O expression|O of|O these|O genes|O does|O not|O appear|O to|O correlate|O with|O disease|O progression|O .|O 
Depletion|O of|O glutathione|O by|O buthionine|O sulfoxine|O is|O cytotoxic|O for|O human|O neuroblastoma|O cell|O lines|O via|O apoptosis|O .|O 
Buthionine|O sulfoximine|O (|O BSO|O )|O selectively|O inhibits|O glutathione|O (|O GSH|O )|O synthesis|O and|O has|O been|O used|O to|O sensitize|O tumor|O cells|O to|O alkylating|O agents|O ,|O but|O has|O minimal|O single|O -|O agent|O cytotoxicity|O for|O most|O cell|O types|O .|O 
We|O determined|O the|O cytotoxicity|O of|O BSO|O for|O 18|O (|O 12|O MYCN|gene-rna amplified|O ;|O 6|O MYCN|gene-rna nonamplified|O )|O human|O neuroblastoma|O cell|O lines|O using|O DIMSCAN|O ,|O a|O digital|O image|O microscopy|O cytotoxicity|O assay|O .|O 
D-L(R:S)|O BSO|O was|O highly|O cytotoxic|O (|O >|O 3|O logs|O of|O cell|O kill|O )|O for|O most|O neuroblastoma|O cell|O lines|O ,|O with|O 17|O /|O 18|O cell|O lines|O having|O IC90|O values|O (|O range|O 2.|O 1|O ->|O 1000|O microM|O )|O below|O equivalent|O steady|O state|O plasma|O levels|O of|O L(R:S)|O BSO|O reported|O in|O adult|O human|O trials|O .|O 
Cell|O lines|O with|O genomic|O amplification|O of|O MYCN|gene-rna were|O more|O sensitive|O to|O BSO|O than|O MYCN|gene-rna nonamplified|O cell|O lines|O (|O P|O =|O 0.04|O )|O .|O 
D-L(R:S)|O BSO|O (|O 500|O microM|O for|O 72|O h|O )|O induced|O apoptosis|O as|O detected|O by|O DNA|O laddering|O ,|O nuclear|O morphology|O ,|O and|O TUNEL|O staining|O of|O DNA|O fragments|O using|O flow|O cytometry|O .|O 
Maximal|O cell|O killing|O occurred|O within|O 48|O h|O and|O was|O antagonized|O by|O ic|O value|O in|O neuroblastoma|O .|O 
p27Kip1|gene-protein :|O a|O key|O mediator|O of|O retinoic|O acid|O induced|O growth|O arrest|O in|O the|O SMS-KCNR|O human|O neuroblastoma|O cell|O line|O .|O 
Retinoic|O acid|O (|O RA|O )|O treatment|O of|O SMS-KCNR|O neuroblastoma|O (|O NB|O )|O cells|O leads|O to|O G1|O growth|O arrest|O and|O neuronal|O differentiation|O .|O 
To|O investigate|O the|O molecular|O mechanisms|O by|O which|O RA|O alters|O cell|O growth|O ,|O we|O analysed|O the|O expression|O and|O activity|O of|O components|O of|O the|O cell|O cycle|O machinery|O after|O culture|O in|O RA|O .|O 
Within|O 2|O days|O of|O RA|O treatment|O and|O prior|O to|O the|O arrest|O of|O NB|O cells|O in|O the|O G1|O phase|O of|O the|O cell|O cycle|O ,|O there|O is|O a|O complete|O downregulation|O of|O G1|gene-protein cyclin|gene-protein /|O Cdk|gene-protein activities|O .|O 
Protein|O levels|O for|O the|O G1|gene-protein cyclin|gene-protein /|O Cdks|gene-protein were|O essentially|O unchanged|O during|O this|O time|O although|O there|O was|O a|O decrease|O in|O the|O steady|O -|O state|O levels|O of|O p67N-Myc|gene-protein and|O hyperphosphorylated|O Rb|gene-protein proteins|O .|O 
The|O Cdk|gene-protein inhibitors|O ,|O p21Cip1|gene-protein and|O p27Kip1|gene-protein were|O constitutively|O expressed|O in|O KCNR|O while|O p15INK4B|gene-protein and|O p16INK4A|gene-protein were|O not|O detected|O .|O 
RA|O induced|O an|O increase|O in|O the|O expression|O of|O p27Kip1|gene-protein but|O not|O p21Cip1|gene-protein .|O 
Furthermore|O ,|O coincident|O with|O the|O decrease|O in|O kinase|gene-protein activity|O there|O was|O an|O increase|O in|O G1|gene-protein cyclin|gene-protein /|O Cdk|gene-protein bound|O p27Kip1|gene-protein .|O 
These|O results|O indicate|O that|O changes|O in|O the|O level|O of|O p27Kip1|gene-protein and|O its|O binding|O to|O G1|gene-protein cyclin|gene-protein /|O Cdks|gene-protein may|O play|O a|O key|O role|O in|O RA|O induced|O growth|O arrest|O of|O NB|O cells|O .|O 
Id2|gene-protein is|O critical|O for|O cellular|O proliferation|O and|O is|O the|O oncogenic|O effector|O of|O N-myc|gene-rna in|O human|O neuroblastoma|O .|O 
Perturbation|O of|O the|O function|O of|O the|O retinoblastoma|gene-protein (|O Rb|gene-protein )|O protein|O is|O found|O in|O most|O human|O tumors|O .|O 
Id2|gene-protein is|O a|O natural|O target|O of|O the|O Rb|gene-protein protein|O that|O is|O recruited|O by|O Myc|gene-protein oncoproteins|O to|O bypass|O the|O tumor|O suppressor|O function|O of|O Rb|gene-protein .|O 
Here|O we|O report|O that|O an|O "|O N-Myc|gene-rna -|O Id2|gene-protein pathway|O "|O persists|O during|O late|O development|O of|O the|O nervous|O system|O and|O parallels|O the|O rising|O levels|O of|O active|O Rb|gene-protein in|O neuronal|O precursors|O withdrawing|O from|O the|O cell|O cycle|O .|O 
An|O immunohistochemical|O analysis|O of|O primary|O neuroblastoma|O from|O 47|O patients|O shows|O that|O expression|O of|O Id2|gene-protein is|O strongly|O predictive|O of|O poor|O outcome|O ,|O irrespective|O of|O other|O clinical|O and|O biological|O variables|O .|O 
Overexpression|O of|O Id2|gene-protein mediates|O cellular|O transformation|O and|O is|O required|O to|O maintain|O the|O malignant|O behavior|O of|O neuroblastoma|O cells|O .|O 
Correspondingly|O ,|O embryonic|O fibroblasts|O from|O Id2|gene-protein -|gene-protein null|O mice|O display|O impaired|O ability|O to|O proliferate|O .|O 
We|O suggest|O that|O Id2|gene-protein overexpression|O may|O be|O a|O better|O prognostic|O indicator|O than|O N-myc|gene-rna gene|O amplification|O in|O neuroblastoma|O .|O 
Thus|O ,|O disrupting|O Id2|gene-protein function|O may|O lead|O to|O new|O and|O useful|O therapeutic|O strategies|O for|O cancer|O patients|O .|O 
Dermorphins|gene-protein ,|O opioid|gene-protein peptides|gene-protein from|O amphibian|O skin|O ,|O act|O on|O opioid|gene-protein receptors|gene-protein of|O mouse|O neuroblastoma|O x|O rat|O glioma|O hybrid|O cells|O .|O 
Dermorphin|gene-protein and|O its|O Hyp6|gene-protein analogue|O are|O opiate|O -|O like|O heptapeptides|O originally|O discovered|O in|O frog|O skin|O and|O characterized|O by|O the|O presence|O of|O a|O D-Ala2|O residue|O in|O their|O sequence|O .|O 
They|O were|O assayed|O for|O their|O capacity|O to|O compete|O with|O [3H]Leu|O -|O enkephalin|gene-protein for|O binding|O to|O opioid|gene-protein receptors|gene-protein in|O membranes|O of|O neuroblastoma|O x|O glioma|O hybrid|O cells|O .|O 
In|O the|O presence|O of|O 7|O nM|O -|O [3H]Leu|O -|O enkephalin|gene-protein ,|O the|O concentrations|O at|O which|O they|O caused|O 50|O %|O inhibition|O of|O [3H]|O enkephalin|gene-protein binding|O (|O IC50|O values|O )|O are|O 0.1|O micro|O M|O and|O 0.3|O micro|O M|O ,|O respectively|O .|O 
In|O contrast|O ,|O the|O synthetic|O L-Ala2|O -|O dermorphin|gene-protein shows|O very|O low|O affinity|O for|O the|O opioid|gene-protein receptors|gene-protein .|O 
In|O addition|O ,|O like|O other|O opioid|gene-protein peptides|gene-protein ,|O dermorphin|gene-protein and|O hyp6-dermorphin|gene-protein inhibit|O the|O elevation|O by|O prostaglandin|O E1|O (|O PGE1|O )|O of|O the|O level|O of|O adenosine|O 3':5'-cyclic|O monophosphate|O (|O cyclic|O AMP|O )|O (|O IC50|O values|O 0.2|O micro|O M|O and|O 0.4|O micro|O M|O ,|O respectively|O )|O .|O 
The|O inhibition|O is|O prevented|O by|O the|O opiate|O antagonist|O naloxone|O ,|O L-Ala2|O -|O dermorphin|gene-protein is|O at|O least|O three|O orders|O of|O magnitude|O less|O potent|O in|O inhibiting|O the|O PGE1|O -|O evoked|O increase|O in|O the|O level|O of|O cyclic|O AMP|O .|O 
The|O results|O show|O that|O peptides|O with|O an|O amino|O acid|O sequence|O quite|O different|O from|O that|O of|O the|O enkephalins|gene-protein can|O bind|O to|O opioid|gene-protein receptors|gene-protein of|O the|O hybrid|O cells|O .|O 
Differential|O expression|O of|O neuron|O -|O specific|O enolase|gene-rna mRNA|O in|O mouse|O neuroblastoma|O cells|O in|O response|O to|O differentiation|O inducing|O agents|O .|O 
1.|O 
The|O mouse|O neuroblastoma|O cell|O line|O N-115|O was|O used|O as|O a|O model|O system|O to|O study|O neuronal|O differentiation|O induced|O by|O treatment|O of|O cells|O with|O different|O agents|O .|O 
2.|O 
The|O extent|O of|O morphological|O differentiation|O obtained|O with|O dibutyryl|O cyclic|O AMP|O (|O dbc-AMP|O )|O ,|O dimethyl|O sulfoxide|O (|O DMSO|O )|O ,|O retinoic|O acid|O (|O RA|O )|O ,|O and|O serum|O -|O free|O medium|O was|O correlated|O to|O the|O expression|O of|O the|O mRNA|O for|O the|O gamma|O isoform|O of|O the|O glycolytic|O enzyme|O enolase|gene-protein ,|O a|O recognized|O neuron|O -|O specific|O marker|O .|O 
3.|O 
A|O 4|O -|O day|O treatment|O of|O the|O cells|O with|O any|O of|O the|O differentiation|O inducing|O agents|O used|O in|O this|O study|O resulted|O in|O the|O extension|O of|O long|O neurites|O ,|O though|O differences|O in|O cell|O body|O shape|O were|O observed|O depending|O on|O the|O agent|O used|O .|O 
4.|O 
Northern|O blot|O analysis|O revealed|O that|O changes|O in|O the|O level|O of|O gamma|gene-rna enolase|gene-rna -|O specific|O mRNA|O correlate|O with|O the|O extent|O of|O morphological|O differentiation|O ,|O with|O a|O 5|O -|O to|O 20|O -|O fold|O increase|O depending|O on|O the|O differentiation|O inducing|O agent|O used|O .|O 
5.|O 
Finally|O ,|O we|O found|O that|O a|O high|O cell|O density|O causes|O a|O significative|O increase|O in|O the|O level|O of|O the|O gamma|gene-generic enolase|gene-generic -|O specific|O message|O in|O cells|O maintained|O in|O growing|O conditions|O .|O 
Scrapie|O -|O infected|O mice|O and|O PrP|gene-rna knockout|O mice|O share|O abnormal|O localization|O and|O activity|O of|O neuronal|gene-protein nitric|gene-protein oxide|gene-protein synthase|gene-protein .|O 
PrP(Sc)|gene-protein ,|O the|O only|O identified|O component|O of|O the|O scrapie|gene-protein prion|gene-protein ,|O is|O a|O conformational|O isoform|O of|O PrPc|gene-protein .|O 
The|O physiological|O role|O of|O PrPc|gene-protein ,|O a|O glycolipid|O -|O anchored|O glycoprotein|O ,|O is|O still|O unknown|O .|O 
We|O have|O shown|O previously|O that|O neuronal|gene-protein nitric|gene-protein oxide|gene-protein synthase|gene-protein (|O nNOS|gene-protein )|O activity|O is|O impaired|O in|O the|O brains|O of|O mice|O sick|O with|O experimental|O scrapie|O as|O well|O as|O in|O scrapie|O -|O infected|O neuroblastoma|O cells|O .|O 
In|O this|O work|O we|O investigated|O the|O cell|O localization|O of|O nNOS|gene-protein in|O brains|O of|O wild|O -|O type|O and|O scrapie|O -|O infected|O mice|O as|O well|O as|O in|O mice|O in|O which|O the|O PrP|gene-rna gene|O was|O ablated|O .|O 
We|O now|O report|O that|O whereas|O in|O wild|O -|O type|O mice|O ,|O nNOS|gene-protein ,|O like|O PrPc|gene-protein ,|O is|O associated|O with|O detergent|O -|O insoluble|O cholesterol|O -|O rich|O membranous|O microdomains|O (|O rafts|O )|O ,|O this|O is|O not|O the|O case|O in|O brains|O of|O scrapie|O -|O infected|O or|O in|O those|O of|O adult|O PrP|gene-rna (|O 0|O /|O 0|O )|O mice|O .|O 
Also|O ,|O adult|O PrP|gene-rna (|O 0|O /|O 0|O )|O ,|O like|O scrapie|O -|O infected|O mice|O ,|O show|O reduced|O nNOS|gene-protein activity|O .|O 
We|O suggest|O that|O PrPc|gene-protein may|O play|O a|O role|O in|O the|O targeting|O of|O nNOS|gene-protein to|O its|O proper|O subcellular|O localization|O .|O 
Detailed|O deletion|O mapping|O of|O chromosome|O band|O 14q32|O in|O human|O neuroblastoma|O defines|O a|O 1.1|O -|O Mb|O region|O of|O common|O allelic|O loss|O .|O 
Neuroblastoma|O (|O NB|O )|O is|O a|O well|O -|O known|O malignant|O disease|O in|O infants|O ,|O but|O its|O molecular|O mechanisms|O have|O not|O yet|O been|O fully|O elucidated|O .|O 
To|O investigate|O the|O genetic|O contribution|O of|O abnormalities|O on|O the|O long|O arm|O of|O chromosome|O 14|O (|O 14q|O )|O in|O NB|O ,|O we|O analysed|O loss|O of|O heterozygosity|O (|O LOH|O )|O in|O 54|O primary|O NB|O samples|O using|O 12|O microsatellite|O markers|O on|O 14q32|O .|O 
Seventeen|O (|O 31|O %|O )|O of|O 54|O tumours|O showed|O LOH|O at|O one|O or|O more|O of|O the|O markers|O analysed|O ,|O and|O the|O smallest|O common|O region|O of|O allelic|O loss|O was|O identified|O between|O D14S62|O and|O D14S987|O .|O 
This|O region|O was|O estimated|O to|O be|O 1|O -|O cM|O long|O from|O the|O linkage|O map|O .|O 
Fluorescence|O in|O situ|O hybridization|O also|O confirmed|O the|O loss|O .|O 
There|O was|O no|O statistical|O correlation|O between|O LOH|O and|O any|O clinicopathologic|O features|O ,|O including|O age|O ,|O stage|O ,|O amplification|O of|O MYCN|gene-rna and|O ploidy|O .|O 
We|O further|O constructed|O a|O contig|O spanning|O the|O lost|O region|O using|O bacterial|O artificial|O chromosome|O and|O estimated|O this|O region|O to|O be|O approximately|O 1.1|O -|O Mb|O by|O pulsed|O -|O field|O gel|O electrophoresis|O .|O 
Our|O results|O will|O contribute|O to|O cloning|O and|O characterizing|O the|O putative|O tumour|O -|O associated|O gene(s)|O in|O 14q32|O in|O NB|O .|O 
BCL-2|gene-rna is|O upregulated|O in|O human|O SH-SY5Y|O neuroblastoma|O cells|O differentiated|O by|O overexpression|O of|O fibroblast|gene-protein growth|gene-protein factor|gene-protein 1|gene-protein .|O 
Fibroblast|gene-protein growth|gene-protein factor|gene-protein 1|gene-protein (|O FGF1|gene-protein )|O is|O a|O multipotent|O factor|O in|O the|O development|O and|O differentiation|O of|O the|O central|O nervous|O system|O .|O 
Recent|O studies|O in|O PC12|O cells|O attribute|O these|O effects|O to|O high|O endogenous|O FGF1|gene-protein expression|O .|O 
To|O examine|O the|O differentiation|O mechanisms|O induced|O by|O FGF1|gene-protein ,|O we|O performed|O studies|O in|O SH-SY5Y|O human|O neuroblastoma|O cells|O .|O 
We|O monitored|O the|O impact|O of|O FGF1|gene-protein overexpression|O in|O SH-SY5Y|O either|O after|O addition|O of|O exogenous|O FGF1|gene-protein and|O heparin|O or|O after|O stable|O transfection|O with|O the|O FGF1|gene-generic eukaryotic|O expression|O vector|O .|O 
Under|O both|O conditions|O ,|O the|O FGF1|gene-protein endogenous|O rise|O caused|O SH-SY5Y|O cell|O differentiation|O with|O morphological|O changes|O (|O appearance|O of|O neuritic|O extensions|O )|O ,|O increased|O GAP-43|gene-rna gene|O expression|O ,|O decreased|O of|O N-myc|gene-rna gene|O expression|O ,|O and|O prolonged|O long|O -|O term|O survival|O in|O serum|O -|O free|O media|O .|O 
These|O modifications|O were|O correlated|O with|O Bcl-2|gene-rna upregulation|O .|O 
These|O results|O suggest|O that|O there|O is|O a|O link|O between|O the|O endogenous|O FGF1|gene-generic signaling|O pathway|O and|O Bcl-2|gene-rna in|O neuronal|O survival|O modulation|O .|O 
Modulation|O of|O the|O N|gene-rna -|gene-rna type|gene-rna calcium|gene-rna channel|gene-rna gene|O expression|O by|O the|O alpha|gene-protein subunit|gene-protein of|gene-protein Go|gene-protein .|O 
Go|gene-protein ,|O a|O heterotrimeric|O G|gene-protein -|gene-protein protein|gene-protein ,|O is|O enriched|O in|O brain|O and|O neuronal|O growth|O cones|O .|O 
Although|O several|O reports|O suggest|O that|O Go|gene-protein may|O be|O involved|O in|O modulation|O of|O neuronal|O differentiation|O ,|O the|O precise|O role|O of|O Go|gene-protein is|O not|O clear|O .|O 
To|O investigate|O the|O function|O of|O Go|gene-protein in|O neuronal|O differentiation|O ,|O we|O determined|O the|O effect|O of|O Goalpha|gene-protein ,|O the|O alpha|gene-protein subunit|gene-protein of|gene-protein Go|gene-protein ,|O on|O the|O expression|O of|O Ca(v)2.2|gene-rna ,|O the|O pore|O -|O forming|O unit|O of|O N|gene-protein -|gene-protein type|gene-protein calcium|gene-protein channels|gene-protein ,|O at|O the|O transcription|O level|O .|O 
Treatment|O with|O cyclic|O AMP|O (|O cAMP|O )|O ,|O which|O triggers|O neurite|O outgrowth|O in|O neuroblastoma|O F11|O cells|O ,|O increased|O the|O mRNA|O level|O and|O the|O promoter|O activity|O of|O the|O Ca(v)2.2|gene-rna gene|O .|O 
Overexpression|O of|O Goalpha|gene-protein inhibited|O neurite|O extension|O in|O F11|O cells|O and|O simultaneously|O repressed|O the|O stimulatory|O effect|O of|O cAMP|O on|O the|O Ca(v)2.2|gene-rna gene|O expression|O to|O the|O basal|O level|O .|O 
Targeted|O mutation|O of|O the|O Goalpha|gene-rna gene|O also|O increased|O the|O level|O of|O Ca(v)2.2|gene-generic in|O the|O brain|O .|O 
These|O results|O suggest|O that|O Go|gene-protein may|O regulate|O neuronal|O differentiation|O through|O modulation|O of|O gene|O expression|O of|O target|O genes|O such|O as|O N|gene-rna -|gene-rna type|gene-rna calcium|gene-rna channels|gene-rna .|O 
Retinoic|O acid|O -|O induced|O differentiation|O of|O cultured|O human|O neuroblastoma|O cells|O :|O a|O comparison|O with|O phorbolester|O -|O induced|O differentiation|O .|O 
Cultured|O human|O SH-SY5Y|O neuroblastoma|O cells|O differentiated|O in|O the|O presence|O of|O retinoic|O acid|O (|O RA|O )|O or|O 12-0-tetradecanoyl-phorbol-13-acetate|O (|O TPA|O )|O .|O 
In|O both|O cases|O ,|O the|O cells|O acquired|O long|O cell|O processes|O and|O the|O cell|O growth|O was|O partially|O inhibited|O .|O 
Treatment|O with|O RA|O or|O TPA|O resulted|O in|O an|O increased|O neuron|O -|O specific|O enolase|gene-protein activity|O ,|O relative|O to|O the|O total|O cellular|O enolase|gene-protein activity|O .|O 
At|O the|O optimal|O concentration|O ,|O TPA|O induced|O a|O 200|O -|O fold|O increase|O in|O the|O concentration|O of|O noradrenalin|O ,|O whereas|O in|O RA|O -|O treated|O cells|O the|O corresponding|O increase|O was|O only|O fourfold|O .|O 
Cells|O treated|O with|O a|O combination|O of|O RA|O and|O TPA|O were|O morphologically|O differentiated|O and|O growth|O inhibited|O and|O had|O a|O high|O relative|O activity|O of|O neuron|O -|O specific|O enolase|gene-protein .|O 
The|O increase|O in|O the|O concentration|O of|O noradrenalin|O induced|O by|O TPA|O was|O inhibited|O by|O RA|O in|O a|O concentration|O -|O dependent|O fashion|O .|O 
However|O ,|O despite|O this|O result|O there|O seemed|O to|O be|O no|O general|O antagonistic|O effect|O of|O RA|O on|O the|O TPA|O -|O induced|O differentiation|O .|O 
The|O phenotypes|O of|O the|O cells|O treated|O by|O RA|O ,|O TPA|O ,|O or|O the|O combination|O of|O RA|O and|O TPA|O ,|O did|O ,|O on|O the|O other|O hand|O ,|O differ|O from|O each|O other|O .|O 
Our|O results|O suggest|O that|O RA|O and|O TPA|O induce|O the|O SH-SY5Y|O cells|O to|O differentiate|O along|O different|O pathways|O .|O 
SPECT|O quantitation|O of|O iodine-131|O concentration|O in|O phantoms|O and|O human|O tumors|O .|O 
The|O validity|O of|O SPECT|O measurement|O of|O iodine-131|O (|O 131I|O )|O concentration|O was|O tested|O in|O vitro|O in|O phantoms|O and|O in|O vivo|O by|O measuring|O bladder|O urine|O concentrations|O .|O 
Phantom|O studies|O comparing|O known|O and|O SPECT|O measured|O concentrations|O showed|O a|O good|O correlation|O for|O 131I|O (|O r|O =|O 0.98|O ,|O s.e.e.|O =|O 20.94|O counts|O /|O voxel|O )|O for|O phantoms|O of|O 25|O to|O 127|O cc|O and|O concentrations|O of|O 0.13|O to|O 9.5|O microCi|O /|O cc|O .|O 
The|O in|O vivo|O ,|O in|O vitro|O correlation|O of|O 131I|O concentrations|O in|O the|O urine|O was|O also|O good|O (|O r|O =|O 0.98|O ,|O s.e.e.|O =|O 0.677|O microCi|O /|O cc|O )|O .|O 
Quantitative|O SPECT|O was|O used|O to|O calculate|O the|O effective|O half|O -|O life|O and|O dosimetry|O of|O radioiodine|O in|O 12|O sites|O of|O thyroid|O carcinoma|O in|O seven|O patients|O .|O 
SPECT|O was|O also|O used|O to|O determine|O the|O dosimetry|O of|O [131I]MIBG|O (|O metaiodobenzylguanidine|O )|O in|O two|O patients|O with|O carcinoid|O ,|O two|O with|O neuroblastoma|O ,|O and|O one|O with|O pheochromocytoma|O .|O 
The|O radiation|O dose|O for|O thyroid|O carcinoma|O metastases|O varied|O between|O 6.3|O and|O 276.9|O rad|O /|O mCi|O .|O 
The|O dose|O from|O MIBG|O varied|O between|O 13.4|O and|O 57.8|O rad|O /|O mCi|O .|O 
These|O results|O indicate|O the|O validity|O of|O quantitative|O SPECT|O for|O in|O vivo|O measurement|O of|O 131I|O and|O the|O need|O to|O measure|O the|O concentration|O of|O 131I|O in|O individual|O human|O tumor|O sites|O .|O 
Neuroblastoma|O :|O inhibition|O of|O progression|O (|O Part|O II|O )|O .|O 
Basic|O science|O in|O pediatric|O surgery|O .|O 
In|O neuroblastoma|O ,|O amplification|O of|O the|O protooncogene|O N-myc|gene-rna is|O the|O most|O important|O molecular|O characteristic|O predicting|O a|O bad|O outcome|O for|O the|O patients|O .|O 
Despite|O the|O importance|O of|O the|O N-myc|gene-rna gene|O ,|O little|O is|O known|O about|O the|O mechanisms|O regulating|O its|O expression|O .|O 
We|O found|O evidence|O that|O insulin|gene-protein -|gene-protein like|gene-protein growth|gene-protein factor|gene-protein II|gene-protein stimulates|O the|O growth|O of|O neuroblastoma|O in|O a|O paracrine|O fashion|O .|O 
Two|O neuroblastoma|O cell|O lines|O predominantly|O expressed|O IGF-II|gene-protein whereas|O two|O other|O cell|O lines|O expressed|O the|O IGF|gene-protein -|gene-protein receptor|gene-protein .|O 
In|O a|O receptor|O -|O positive|O cell|O line|O ,|O N-myc|gene-rna expression|O was|O enhanced|O by|O stimulation|O with|O IGF-II|gene-protein .|O 
As|O the|O growth|O -|O stimulating|O signals|O of|O the|O IGF|gene-protein receptor|gene-protein are|O transmitted|O via|O Ras|gene-protein proteins|O ,|O inactivation|O of|O Ras|gene-protein is|O one|O promising|O tool|O to|O prevent|O the|O induction|O of|O N-myc|gene-rna expression|O by|O IGF-II|gene-protein .|O 
Treatment|O of|O neuroblastoma|O cells|O with|O an|O inhibitor|O of|O the|O farnesyl|gene-protein -|gene-protein protein|gene-protein -|gene-protein transferase|gene-protein (|O FPTase|gene-protein )|O inactivated|O H-ras|gene-protein protein|O completely|O and|O N-ras|gene-protein protein|O by|O more|O than|O 50|O %|O .|O 
Cell|O growth|O of|O neuroblastoma|O cells|O in|O serum|O containing|O medium|O was|O clearly|O diminished|O by|O inhibition|O of|O FPTase|gene-protein .|O 
The|O growth|O -|O promoting|O effect|O of|O IGF-II|gene-protein was|O reduced|O to|O exactly|O half|O the|O amount|O observed|O in|O non|O -|O inhibited|O cells|O .|O 
Autologous|O bone|O marrow|O transplantation|O in|O children|O with|O advanced|O neuroblastoma|O .|O 
BACKGROUND|O .|O 
Encouraging|O results|O have|O been|O reported|O with|O high|O dose|O chemotherapy|O and|O total|O body|O radiation|O followed|O by|O bone|O marrow|O autotransplantation|O in|O children|O with|O advanced|O neuroblastoma|O ;|O however|O ,|O relapse|O remains|O a|O significant|O problem|O .|O 
METHODS|O .|O 
The|O authors|O treated|O 22|O children|O with|O advanced|O neuroblastoma|O with|O high|O dose|O chemotherapy|O ,|O surgery|O ,|O intraoperative|O radiation|O ,|O and|O a|O bone|O marrow|O autotransplant|O (|O treated|O in|O vitro|O to|O remove|O tumor|O cells|O )|O followed|O by|O 13-cis-retinoic|O acid|O .|O 
RESULTS|O .|O 
The|O 3|O -|O year|O relapse|O rate|O was|O 25|O %|O (|O 95|O %|O confidence|O interval|O [|O CI|O ]|O ,|O 6|O -|O 44|O %|O )|O .|O 
The|O 3|O -|O year|O disease|O free|O survival|O rate|O was|O 72|O %|O (|O 95|O %|O CI|O ,|O 52|O -|O 92|O %|O )|O .|O 
Toxicities|O included|O hemolytic|O uremic|O syndrome|O ,|O herpes|O infection|O ,|O and|O hepatic|O venoocclusive|O disease|O .|O 
CONCLUSION|O .|O 
These|O data|O suggest|O that|O this|O treatment|O strategy|O offers|O an|O increased|O rate|O of|O 3|O -|O year|O disease|O free|O survival|O .|O 
The|O nonrandomized|O nature|O of|O this|O study|O and|O its|O use|O of|O multiple|O modalities|O precludes|O the|O analysis|O of|O the|O specific|O contribution|O of|O each|O treatment|O component|O and|O comparison|O with|O conventional|O therapy|O .|O 
Aberrations|O of|O p16INK4A|gene-rna ,|O p14ARF|gene-rna and|O p15INK4B|gene-rna genes|O in|O pediatric|O solid|O tumors|O .|O 
Expression|O of|O the|O p16INK4A|gene-rna (|O p16|gene-rna )|O ,|O p15INK4B|gene-rna (|O p15|gene-rna )|O ,|O and|O p14ARF|gene-rna genes|O ,|O located|O at|O 9p21|O ,|O was|O examined|O in|O pediatric|O neuroblastoma|O (|O NB|O )|O ,|O Ewing|O 's|O sarcoma|O (|O ES|O )|O ,|O and|O rhabdomyosarcoma|O (|O RMS|O )|O .|O 
p16|gene-rna expression|O was|O absent|O in|O 4|O of|O 5|O ESs|O ,|O and|O 2|O of|O these|O 4|O cases|O died|O .|O 
p16|gene-rna expression|O was|O reduced|O or|O absent|O in|O 10|O of|O 12|O RMSs|O ,|O and|O 4|O of|O these|O 10|O cases|O died|O .|O 
These|O results|O suggested|O the|O possibility|O that|O p16|gene-rna expression|O was|O associated|O with|O the|O progression|O of|O ES|O and|O RMS|O .|O 
There|O has|O been|O no|O previous|O report|O on|O p14ARF|gene-rna in|O NB|O .|O 
Our|O investigation|O might|O indicate|O that|O abnormal|O expression|O of|O the|O p16|gene-rna and|O p14ARF|gene-rna was|O associated|O with|O a|O poor|O prognosis|O in|O NB|O ,|O although|O in|O some|O cases|O of|O NB|O normal|O p16|gene-rna and|O abnormal|O p14ARF|gene-rna expression|O was|O seen|O .|O 
These|O findings|O suggest|O an|O important|O role|O of|O p14ARF|gene-rna gene|O in|O the|O tumorigenesis|O of|O NB|O .|O 
The|O different|O incidence|O of|O expression|O of|O the|O p16|gene-rna ,|O p15|gene-rna ,|O and|O p14ARF|gene-rna genes|O in|O these|O 3|O tumor|O types|O may|O reflect|O differences|O of|O the|O molecular|O process|O through|O which|O the|O 3|O tumors|O develop|O .|O 
Our|O results|O suggest|O that|O abnormal|O expression|O of|O the|O p16|gene-rna and/or|O p14ARF|gene-rna may|O be|O associated|O with|O a|O poor|O prognosis|O in|O these|O 3|O tumors|O .|O 
Genome|O -|O wide|O screen|O for|O allelic|O imbalance|O in|O a|O mouse|O model|O for|O neuroblastoma|O .|O 
We|O have|O used|O the|O rat|O tyrosine|gene-rna hydroxylase|gene-rna promotor|O to|O overexpress|O MYCN|gene-rna in|O the|O neural|O crest|O of|O transgenic|O mice|O ,|O resulting|O in|O a|O mouse|O model|O for|O neuroblastoma|O .|O 
Using|O PCR|O analysis|O of|O microsatellite|O markers|O ,|O we|O conducted|O a|O genome|O -|O wide|O analysis|O in|O tumors|O from|O these|O animals|O .|O 
Regions|O of|O chromosomes|O 1|O ,|O 3|O ,|O 10|O ,|O 11|O ,|O 14|O ,|O and|O 18|O were|O affected|O in|O 20|O -|O 50|O %|O of|O tumors|O .|O 
Analysis|O of|O a|O subset|O of|O these|O tumors|O by|O comparative|O genomic|O hybridization|O was|O consistent|O with|O the|O microsatellite|O data|O .|O 
The|O changes|O on|O mouse|O chromosomes|O 1|O ,|O 11|O ,|O 14|O ,|O and|O 18|O were|O syntenic|O with|O corresponding|O regions|O of|O loss|O of|O heterozygosity|O in|O human|O neuroblastoma|O ,|O suggesting|O that|O genes|O implicated|O in|O the|O mouse|O tumors|O may|O also|O play|O a|O role|O in|O the|O pathogenesis|O of|O the|O human|O disease|O .|O 
One|O -|O third|O of|O the|O mouse|O tumors|O shared|O abnormalities|O on|O chromosomes|O 1|O ,|O 3|O ,|O and|O 10|O ,|O whereas|O the|O remainder|O of|O tumors|O did|O not|O show|O this|O combination|O .|O 
These|O data|O suggest|O that|O genetic|O mutations|O on|O chromosomes|O 1|O ,|O 3|O ,|O and|O 10|O cooperate|O in|O the|O pathogenesis|O of|O neuroblastoma|O and|O that|O neuroblastoma|O in|O the|O mouse|O arises|O from|O at|O least|O two|O distinct|O genetic|O pathways|O ,|O one|O of|O which|O is|O dependent|O on|O lesions|O in|O chromosomes|O 1|O ,|O 3|O ,|O and|O 10|O ,|O the|O other|O of|O which|O is|O not|O .|O 
Modulation|O of|O cholecystokinin|gene-rna (|O CCK|gene-rna )|O gene|O -|O expression|O in|O a|O human|O neuroblastoma|O cell|O line|O :|O effects|O of|O serum|O on|O enhanced|O CCK|gene-rna and|O c-fos|gene-rna mRNA|O expression|O .|O 
The|O effect|O of|O fetal|O -|O calf|O serum|O (|O FCS|O )|O and|O Forskolin|O (|O FKN|O )|O on|O cholecystokinin|gene-rna (|O CCK|gene-rna )|O and|O proto|O -|O oncogene|O c-fos|gene-rna mRNA|O expression|O in|O the|O human|O neuroblastoma|O cell|O line|O SK-N-MC|O ,|O cultured|O in|O serum|O free|O medium|O was|O studied|O by|O Northern|O blot|O analysis|O and|O nuclear|O run|O -|O off|O transcription|O analysis|O .|O 
Addition|O of|O FCS|O or|O FKN|O gradually|O increased|O the|O basal|O CCK|gene-rna mRNA|O level|O approximately|O four|O to|O six|O -|O fold|O after|O 2|O -|O 4|O h|O .|O 
In|O contrast|O ,|O a|O strong|O and|O transient|O increase|O of|O the|O c-fos|gene-rna mRNA|O -|O level|O was|O observed|O ,|O approximately|O forty|O to|O fifty|O -|O fold|O after|O 50|O -|O 60|O min|O over|O unstimulated|O cells|O .|O 
Nuclear|O run|O -|O off|O transcription|O analysis|O indicates|O that|O c-fos|gene-rna mRNA|O is|O constitutively|O expressed|O and|O transcription|O may|O be|O further|O stimulated|O by|O FCS|O and|O FKN|O .|O 
Moreover|O ,|O in|O SK-N-MC|O nuclei|O ,|O transcription|O of|O the|O c-fos|gene-rna gene|O clearly|O precedes|O stimulated|O CCK|gene-rna -|O mRNA|O expression|O .|O 
This|O suggests|O that|O FOS|gene-generic ,|O which|O is|O known|O to|O form|O a|O AP-1|O heterodimer|O transcription|O complex|O with|O the|O proto|O -|O oncogen|O product|O ,|O Jun|gene-protein ,|O may|O bind|O to|O the|O tentative|O AP-1|O binding|O site|O ,|O found|O within|O the|O human|O CCK|gene-rna promoter|O and|O thereby|O modulates|O basal|O and|O enhanced|O CCK|gene-rna -|O mRNA|O expression|O in|O SK-N-MC|O cells|O .|O 
Tissue|O -|O and|O developmental|O stage|O -|O specific|O forms|O of|O a|O neural|O cell|O surface|O antigen|O linked|O to|O differences|O in|O glycosylation|O of|O a|O common|O polypeptide|O .|O 
We|O have|O previously|O identified|O a|O cell|O surface|O glycoprotein|O of|O the|O mouse|O nervous|O system|O named|O brain|gene-protein cell|gene-protein surface|gene-protein protein-2|gene-protein (|O BSP-2|gene-protein )|O .|O 
Here|O we|O report|O that|O this|O antigen|O is|O not|O a|O single|O ,|O discrete|O entity|O ,|O but|O a|O family|O of|O antigenically|O and|O structurally|O related|O molecules|O .|O 
Three|O components|O of|O 180|O ,|O 140|O ,|O and|O 120|O K|O were|O characteristic|O for|O more|O mature|O nervous|O tissues|O .|O 
Adult|O cerebral|O cortex|O contained|O the|O 140|O -|O K|O and|O 120|O -|O K|O antigens|O ,|O adult|O spinal|O cord|O only|O the|O 120|O -|O K|O ,|O and|O dorsal|O root|O ganglia|O from|O young|O mice|O mainly|O the|O 180|O -|O K|O component|O .|O 
Very|O different|O forms|O of|O the|O antigen|O that|O migrated|O as|O a|O diffuse|O zone|O from|O 180|O -|O 250|O -|O K|O in|O SDS-polyacrylamide|O gels|O were|O found|O in|O immature|O nervous|O tissues|O .|O 
A|O molecule|O different|O from|O the|O previous|O ones|O was|O found|O in|O a|O neuroblastoma|O line|O .|O 
Evidence|O is|O presented|O that|O the|O structural|O diversity|O of|O BSP-2|gene-protein is|O due|O to|O differences|O in|O glycosylation|O .|O 
This|O result|O indicates|O that|O cell|O type|O -|O and|O developmental|O stage|O -|O specific|O glycoprotein|O patterns|O previously|O found|O in|O the|O nervous|O system|O may|O in|O part|O be|O due|O to|O different|O glycosylation|O of|O identical|O polypeptides|O .|O 
The|O finding|O that|O a|O neural|O cell|O surface|O protein|O may|O be|O glycosylated|O in|O different|O ways|O has|O important|O implications|O for|O the|O generation|O of|O cell|O surface|O specificity|O .|O 
Binding|O of|O scorpion|O neurotoxins|O to|O chick|O embryonic|O heart|O cells|O in|O culture|O and|O relationship|O to|O calcium|O uptake|O and|O membrane|O potential|O .|O 
Stimulation|O of|O 45Ca|O uptake|O by|O scorpion|O neurotoxins|O in|O cultured|O chick|O embryonic|O heart|O cells|O has|O been|O shown|O to|O be|O directly|O linked|O to|O their|O effect|O on|O sodium|O channels|O .|O 
This|O property|O was|O used|O to|O compare|O the|O activity|O of|O 15|O neurotoxins|O from|O five|O different|O species|O to|O their|O lethal|O effect|O in|O the|O mouse|O and|O immunological|O properties|O .|O 
As|O scorpion|O neurotoxins|O ,|O the|O alkaloid|O neurotoxin|O veratridine|O enhanced|O 45Ca|O uptake|O ,|O and|O an|O apparent|O positive|O cooperativity|O between|O the|O two|O drugs|O was|O observed|O .|O 
125I|O -|O Labeled|O toxin|O II|O from|O the|O scorpion|O Androctonus|O australis|O Hector|O was|O shown|O to|O bind|O to|O chick|O heart|O cells|O specifically|O ,|O saturably|O ,|O and|O reversibly|O with|O high|O affinity|O (|O KD|O =|O 1|O --|O 3|O nM|O in|O sodium|O -|O free|O medium|O )|O and|O low|O capacity|O (|O 10|O --|O 20|O fmol|O /|O mg|O cell|O protein|O )|O .|O 
As|O shown|O by|O 45Ca|O uptake|O and|O radioactive|O toxin|O binding|O experiments|O ,|O the|O affinity|O of|O scorpion|O neurotoxin|O to|O heart|O cell|O receptors|O was|O dependent|O on|O external|O K+|O concentration|O .|O 
Toxin|O binding|O was|O lowered|O by|O increasing|O Na+|O concentration|O in|O the|O medium|O and|O was|O abolished|O by|O veratridine|O in|O a|O sodium|O (|O 140|O mM|O )|O containing|O medium|O .|O 
As|O previously|O reported|O for|O neuroblastoma|O cells|O ,|O all|O these|O results|O are|O in|O agreement|O with|O the|O membrane|O potential|O dependence|O of|O scorpion|O neurotoxin|O affinity|O for|O its|O membrane|O receptor|O .|O 
Alterations|O of|O anaphase|gene-rna -|gene-rna promoting|gene-rna complex|gene-rna genes|O in|O human|O colon|O cancer|O cells|O .|O 
Ubiquitin|gene-protein -|O mediated|O proteolysis|O of|O cell|O cycle|O regulators|O is|O a|O major|O element|O of|O the|O cell|O cycle|O control|O .|O 
The|O anaphase|gene-protein -|gene-protein promoting|gene-protein complex|gene-protein (|O APC|gene-protein /|gene-protein C|gene-protein )|O is|O a|O large|O multisubunit|O ubiquitin|gene-protein -|gene-protein protein|gene-protein ligase|gene-protein required|O for|O the|O ubiquitination|O and|O degradation|O of|O G1|O and|O mitotic|O checkpoint|O regulators|O .|O 
APC|gene-protein /|gene-protein C|gene-protein -|O dependent|O proteolysis|O regulates|O cyclin|gene-protein levels|O in|O G1|O ,|O and|O triggers|O the|O separation|O of|O sister|O chromatids|O at|O the|O metaphase|O -|O anaphase|O transition|O and|O the|O destruction|O of|O mitotic|O cyclins|gene-protein at|O the|O end|O of|O mitosis|O .|O 
Furthermore|O ,|O it|O was|O recently|O shown|O that|O APC|gene-protein /|gene-protein C|gene-protein regulates|O the|O degradation|O of|O crucial|O regulators|O of|O signal|O transduction|O pathways|O .|O 
We|O report|O here|O gene|O alterations|O in|O several|O components|O of|O this|O complex|O in|O human|O colon|O cancer|O cells|O ,|O including|O APC6|gene-generic /|O CDC16|gene-generic and|O APC8|gene-generic /|O CDC23|gene-generic which|O are|O known|O to|O be|O key|O function|O elements|O .|O 
The|O experimental|O expression|O of|O a|O truncation|O mutant|O of|O APC8|gene-generic /|O CDC23|gene-generic subunit|O (|O CDC23DeltaTPR|gene-protein )|O leads|O to|O abnormal|O levels|O of|O APC|gene-protein /|gene-protein C|gene-protein targets|O such|O as|O cyclin|gene-protein B1|gene-protein and|O disturbs|O the|O cell|O cycle|O progression|O of|O colon|O epithelial|O cells|O through|O mitosis|O .|O 
Overall|O ,|O these|O data|O support|O the|O hypothesis|O of|O a|O deleterious|O role|O of|O these|O mutations|O during|O colorectal|O carcinogenesis|O .|O 
Morphologic|O and|O molecular|O cytogenetics|O in|O neuroblastoma|O .|O 
BACKGROUND|O :|O 
Some|O genetic|O alterations|O have|O been|O shown|O to|O have|O prognostic|O implication|O for|O patients|O with|O neuroblastoma|O :|O MYCN|gene-rna oncogene|O amplification|O ,|O deletion|O of|O the|O short|O arm|O of|O chromosome|O 1|O and|O di|O -|O or|O tetra|O ploidy|O .|O 
The|O goal|O of|O this|O study|O was|O to|O analyze|O these|O factors|O in|O children|O with|O neuroblastoma|O .|O 
METHODS|O :|O 
Twenty|O neuroblastoma|O samples|O were|O analyzed|O with|O morphologic|O cytogenetics|O ,|O and|O each|O of|O them|O was|O compared|O with|O MYCN|gene-rna amplification|O status|O by|O Southern|O blot|O and|O fluorescent|O in|O situ|O hybridization|O (|O FISH|O )|O with|O a|O genomic|O probe|O .|O 
RESULTS|O :|O 
A|O complete|O karyotype|O was|O obtained|O for|O 14|O children|O .|O 
A|O diploid|O or|O tetraploid|O mode|O and|O a|O 1p|O deletion|O were|O found|O in|O most|O children|O with|O advanced|O stages|O .|O 
MYCN|gene-rna amplification|O status|O was|O totally|O concordant|O with|O both|O methods|O in|O all|O patients|O ,|O even|O in|O a|O case|O with|O low|O level|O amplification|O .|O 
A|O wide|O intercellular|O variation|O in|O the|O amplification|O level|O in|O each|O MYCN|gene-rna amplified|O sample|O was|O shown|O .|O 
CONCLUSION|O :|O 
The|O use|O of|O FISH|O to|O assess|O MYCN|gene-rna amplification|O rapidly|O in|O neuroblastoma|O is|O recommended|O .|O 
This|O method|O could|O be|O very|O useful|O in|O future|O therapeutic|O protocols|O in|O which|O treatment|O is|O based|O on|O MYCN|gene-rna status|O (|O and|O especially|O for|O infants|O and|O children|O with|O localized|O tumor|O )|O .|O 
Fine|O needle|O aspiration|O cytology|O of|O metastatic|O olfactory|O neuroblastoma|O :|O a|O case|O report|O .|O 
BACKGROUND|O :|O 
Olfactory|O neuroblastoma|O (|O ONB|O )|O is|O an|O uncommon|O tumor|O ,|O presenting|O as|O a|O polypoid|O mass|O arising|O from|O the|O upper|O nasal|O cavity|O .|O 
This|O tumor|O has|O been|O seldom|O diagnosed|O by|O direct|O fine|O needle|O aspiration|O (|O FNA|O )|O .|O 
CASE|O :|O 
Metastatic|O ONB|O was|O diagnosed|O by|O FNA|O .|O 
The|O patient|O was|O a|O 40|O -|O year|O -|O old|O female|O with|O a|O polypoid|O mass|O in|O the|O nasal|O cavity|O and|O ipsilateral|O cervical|O lymphadenopathy|O .|O 
The|O punch|O biopsy|O of|O the|O nasal|O tumor|O revealed|O a|O smudged|O small|O round|O cell|O neoplasm|O with|O neuroendocrine|O differentiation|O ,|O consistent|O with|O ONB|O .|O 
In|O FNA|O smears|O from|O the|O cervical|O lymph|O node|O ,|O there|O were|O well|O -|O preserved|O ,|O small|O ,|O monotonous|O cells|O with|O hyperchromatic|O nuclei|O ,|O fibrillary|O cytoplasm|O and|O indistinct|O cell|O borders|O .|O 
Also|O noteworthy|O were|O occasional|O pseudorosettes|O as|O well|O as|O rare|O true|O rosettes|O .|O 
By|O immunocytochemistry|O ,|O tumor|O cells|O were|O positive|O for|O cytokeratin|gene-protein ,|O chromogranin|gene-protein and|O synaptophysin|gene-protein .|O 
CONCLUSION|O :|O 
ONB|O ,|O like|O adrenal|O neuroblastoma|O ,|O shows|O distinctive|O cytologic|O features|O ,|O including|O a|O rosette|O or|O pseudorosette|O and|O fibrillary|O network|O .|O 
FNA|O can|O accurately|O demonstrate|O these|O characteristic|O findings|O ,|O and|O in|O some|O cases|O it|O may|O be|O a|O better|O diagnostic|O modality|O than|O incisional|O biopsy|O .|O 
Conversion|O of|O lytic|O to|O persistent|O alphavirus|O infection|O by|O the|O bcl-2|gene-rna cellular|O oncogene|O .|O 
Little|O is|O known|O about|O virus|O -|O host|O cell|O interactions|O that|O regulate|O the|O lytic|O potential|O of|O viruses|O during|O productive|O replication|O .|O 
Sindbis|O virus|O (|O SV|O )|O ,|O a|O single|O -|O stranded|O positive|O -|O sense|O RNA|O virus|O in|O the|O alphavirus|O genus|O (|O family|O Togaviridae|O )|O ,|O results|O in|O lytic|O infection|O in|O most|O vertebrate|O cell|O lines|O ,|O but|O persistent|O productive|O infection|O in|O post|O -|O mitotic|O neurons|O .|O 
The|O cellular|O oncogene|O bcl-2|gene-rna ,|O which|O encodes|O an|O inner|O mitochondrial|O membrane|O protein|O of|O M(r)|O 26,000|O (|O ref.|O 2|O )|O ,|O blocks|O programmed|O cell|O death|O (|O apoptosis|O )|O in|O neurons|O .|O 
We|O therefore|O investigated|O whether|O SV|O infection|O induces|O programmed|O cell|O death|O in|O non|O -|O neuronal|O cells|O ,|O and|O if|O so|O ,|O whether|O virus|O -|O induced|O programmed|O cell|O death|O can|O be|O blocked|O by|O transfection|O with|O bcl-2|gene-rna .|gene-rna 
We|O demonstrate|O that|O SV|O infection|O of|O baby|O hamster|O kidney|O (|O BHK-2|O )|O ,|O mouse|O neuroblastoma|O (|O N18|O )|O ,|O and|O rat|O prostatic|O adenocarcinoma|O (|O AT-3|O )|O cells|O results|O in|O programmed|O cell|O death|O ,|O whereas|O SV|O infection|O of|O bcl-2|gene-rna -|O transfected|O AT-3|O cells|O results|O in|O long|O -|O term|O persistent|O productive|O infection|O .|O 
Thus|O cellular|O bcl-2|gene-rna oncogene|O expression|O plays|O a|O role|O in|O the|O establishment|O of|O persistent|O viral|O infection|O by|O blocking|O virus|O -|O induced|O programmed|O cell|O death|O .|O 
Expression|O of|O multidrug|O resistance|O -|O related|O P-glycoprotein|gene-protein shows|O good|O prognosis|O in|O neuroblastoma|O .|O 
Expression|O of|O P-glycoprotein|gene-protein was|O studied|O in|O formalin|O -|O fixed|O tissue|O sections|O from|O 75|O materials|O with|O an|O immunoperoxidase|gene-protein (|O ABC|O )|O method|O using|O the|O monoclonal|O antibody|O MRK-16|gene-protein .|O 
Specimens|O examined|O were|O from|O three|O monkey|O fetuses|O ,|O eight|O autopsy|O cases|O ,|O and|O 64|O neuroblastoma|O patients|O ,|O 25|O of|O whom|O were|O underwent|O mass|O screening|O for|O diagnosis|O .|O 
P-glycoprotein|gene-protein test|O results|O were|O positive|O in|O fetal|O lung|O alveolar|O tissue|O and|O in|O the|O adrenal|O medulla|O of|O three|O of|O seven|O adult|O autopsy|O cases|O .|O 
Expression|O of|O P-glycoprotein|gene-protein was|O demonstrated|O in|O 22|O of|O 35|O cases|O (|O 63|O %|O )|O in|O a|O group|O of|O neuroblastoma|O patients|O younger|O than|O 12|O months|O of|O age|O ,|O as|O compared|O with|O 9|O of|O 20|O (|O 31|O %|O )|O who|O were|O older|O than|O 12|O months|O of|O age|O at|O diagnosis|O .|O 
P-glycoprotein|gene-protein positivity|O was|O higher|O in|O patients|O who|O were|O alive|O (|O 25|O of|O 40|O ,|O 63|O %|O )|O than|O in|O those|O who|O had|O died|O (|O 6|O of|O 24|O ,|O 25|O %|O )|O .|O 
Previous|O studies|O on|O P-glycoprotein|gene-protein expression|O in|O neuroblastoma|O were|O carried|O out|O using|O specimens|O mainly|O from|O older|O children|O ,|O and|O the|O results|O were|O not|O analyzed|O with|O reference|O to|O the|O findings|O in|O normal|O tissues|O .|O 
The|O present|O study|O has|O clearly|O shown|O that|O positive|O P-glycoprotein|gene-protein expression|O in|O neuroblastoma|O patients|O should|O be|O evaluated|O carefully|O in|O infant|O cases|O because|O it|O stains|O frequently|O in|O normal|O adrenal|O glands|O .|O 
Influence|O of|O cisplatin|O and|O doxorubicin|O on|O 125I-meta-iodobenzylguanidine|O uptake|O in|O human|O neuroblastoma|O cell|O lines|O .|O 
The|O combination|O of|O 131I-meta-iodobenzylguanidine|O (|O MIBG|O )|O with|O chemotherapy|O has|O recently|O been|O employed|O in|O the|O treatment|O of|O advanced|O stage|O neuroblastoma|O with|O encouraging|O results|O .|O 
However|O ,|O the|O mechanisms|O underlying|O the|O interaction|O between|O these|O two|O different|O modalities|O of|O treatment|O have|O not|O yet|O been|O explored|O .|O 
In|O this|O study|O ,|O human|O neuroblastoma|O cell|O lines|O pretreatment|O with|O cisplatin|O and|O doxorubicin|O increased|O cellular|O 125I-MIBG|O accumulation|O in|O a|O dose|O -|O dependent|O manner|O .|O 
Cell|O cycle|O analysis|O showed|O that|O increased|O 125I-MIBG|O accumulation|O correlated|O with|O the|O drug|O -|O induced|O G2/M|O phase|O block|O .|O 
Northern|O blot|O analysis|O demonstrated|O an|O increase|O in|O gene|O expression|O of|O the|O noradrenaline|gene-generic transporter|gene-generic induced|O by|O doxorubicin|O ,|O but|O not|O by|O cisplatin|O treatment|O .|O 
Increased|O 125I-MIBG|O accumulation|O was|O also|O observed|O in|O murine|O xenografts|O of|O the|O human|O neuroblastoma|O cell|O line|O SK-N-DZ|O or|O BE(2)M17|O treated|O intraperitoneally|O (|O i.p.|O )|O with|O cisplatin|O or|O doxorubicin|O ,|O respectively|O .|O 
These|O results|O suggest|O that|O the|O combination|O of|O 131I-MIBG|O and|O these|O drugs|O could|O selectively|O increase|O radiation|O doses|O delivered|O to|O neuroblastomas|O .|O 
The|O transcription|O of|O the|O human|O fructose|gene-rna -|gene-rna bisphosphate|gene-rna aldolase|gene-rna C|gene-rna gene|O is|O activated|O by|O nerve|gene-protein -|gene-protein growth|gene-protein -|gene-protein factor|gene-protein -|gene-protein induced|gene-protein B|gene-protein factor|gene-protein in|O human|O neuroblastoma|O cells|O .|O 
A|O DNA|O region|O located|O at|O around|O -|O 200|O bp|O in|O the|O 5|O '|O flanking|O region|O (|O region|O D|O )|O of|O the|O human|O brain|O -|O type|O fructose|gene-rna -|gene-rna bisphosphate|gene-rna aldolase|gene-rna (|O aldolase|gene-rna C|gene-rna )|O gene|O has|O been|O analysed|O .|O 
We|O show|O by|O transient|O transfection|O assay|O and|O electrophoretic|O -|O mobility|O -|O shift|O assay|O (|O EMSA|O )|O that|O the|O binding|O of|O transcriptional|O activators|O to|O region|O D|O is|O much|O more|O efficient|O (|O 80|O %|O versus|O 30|O %|O )|O in|O human|O neuroblastoma|O cells|O (|O SKNBE|O )|O than|O in|O the|O non|O -|O neuronal|O cell|O line|O A1251|O ,|O which|O contains|O low|O levels|O of|O aldolase|gene-rna C|gene-rna mRNA|O .|O 
The|O sequence|O of|O region|O D|O ,|O CAAGGTCA|O ,|O is|O very|O similar|O to|O the|O AAAGGTCA|O motif|O present|O in|O the|O mouse|O steroid|O 21-hydroxylase|gene-rna gene|O ;|O the|O latter|O motif|O binds|O nerve|gene-protein -|gene-protein growth|gene-protein -|gene-protein factor|gene-protein -|gene-protein induced|gene-protein B|gene-protein factor|gene-protein (|O NGFI-B|gene-protein )|O ,|O which|O is|O a|O member|O of|O the|O thyroid|gene-rna /|O steroid|gene-rna /|O retinoid|gene-rna nuclear|gene-rna receptor|gene-rna gene|gene-rna family|O .|O 
Competition|O experiments|O in|O EMSA|O and|O antibody|O -|O directed|O supershift|O experiments|O showed|O that|O NGFI-B|gene-protein is|O involved|O in|O the|O binding|O to|O region|O D|O of|O the|O human|O aldolase|gene-rna C|gene-rna gene|O .|O 
Furthermore|O ,|O the|O regulation|O of|O the|O aldolase|gene-rna C|gene-rna gene|O (|O which|O is|O the|O second|O known|O target|O of|O NGFI-B|gene-protein )|O expression|O during|O development|O parallels|O that|O of|O NGFI-B|gene-protein .|O 
Weak|O HLA|gene-protein and|O beta|gene-protein 2-microglobulin|gene-protein expression|O of|O neuronal|O cell|O lines|O can|O be|O modulated|O by|O interferon|gene-protein .|O 
Previous|O work|O showed|O that|O each|O of|O four|O human|O neuronal|O cell|O lines|O expresses|O less|O than|O or|O equal|O to|O 0.5|O %|O of|O the|O HLA|gene-protein -|gene-protein A|gene-protein ,|O B|gene-protein ,|O C|gene-protein and|O beta|gene-protein 2-microglobulin|gene-protein seen|O in|O glial|O ,|O lymphoid|O ,|O and|O other|O cell|O types|O ,|O and|O there|O is|O a|O corresponding|O weak|O expression|O in|O neuroblastoma|O tumor|O and|O adult|O brain|O .|O 
Here|O ,|O we|O probe|O the|O genetic|O basis|O of|O this|O weak|O expression|O .|O 
For|O each|O of|O three|O neuroblastoma|O cell|O lines|O ,|O we|O show|O that|O HLA|gene-protein -|gene-protein A|gene-protein ,|O B|gene-protein ,|O C|gene-protein and|O beta|gene-protein 2-microglobulin|gene-protein can|O be|O induced|O by|O interferon|gene-protein and|O that|O the|O induction|O occurs|O within|O every|O cell|O of|O the|O population|O .|O 
Class|O II|O (|O Ia|O )|O molecules|O are|O not|O detected|O .|O 
Microscopic|O assay|O and|O radioimmunoassay|O of|O intact|O cells|O suggest|O that|O the|O induced|O antigen|O appears|O at|O the|O cell|O surface|O as|O well|O as|O within|O each|O cell|O .|O 
Immunoblot|O analysis|O confirms|O that|O the|O induced|O proteins|O have|O the|O structure|O of|O class|O I|O molecules|O .|O 
Thus|O ,|O the|O normal|O weak|O HLA|gene-protein and|O beta|gene-protein 2-microglobulin|gene-protein expression|O of|O these|O cell|O lines|O appears|O to|O reflect|O a|O regulatory|O control|O rather|O than|O a|O primary|O genetic|O lesion|O .|O 
According|O to|O current|O theory|O ,|O lack|O of|O HLA|gene-protein -|gene-protein A|gene-protein ,|O B|gene-protein ,|O C|gene-protein should|O protect|O transformed|O ,|O infected|O ,|O or|O damaged|O neurons|O --|O but|O also|O neurons|O in|O neural|O transplants|O --|O from|O T-cell|O -|O mediated|O immunosurveillance|O .|O 
The|O possibility|O that|O neuronal|O HLA|gene-protein -|gene-protein A|gene-protein ,|O B|gene-protein ,|O C|gene-protein expression|O may|O be|O under|O regulatory|O control|O is|O of|O importance|O in|O this|O context|O .|O 
Mitochondrial|O localization|O of|O mutant|O superoxide|gene-protein dismutase|gene-protein 1|gene-protein triggers|O caspase|gene-protein -|O dependent|O cell|O death|O in|O a|O cellular|O model|O of|O familial|O amyotrophic|O lateral|O sclerosis|O .|O 
The|O mutations|O in|O superoxide|gene-protein dismutase|gene-protein 1|gene-protein (|O SOD1|gene-protein )|O cause|O approximately|O 20|O %|O of|O familial|O amyotrophic|O lateral|O sclerosis|O cases|O .|O 
A|O toxic|O gain|O of|O function|O has|O been|O considered|O to|O be|O the|O cause|O of|O the|O disease|O ,|O but|O its|O molecular|O mechanism|O remains|O uncertain|O .|O 
To|O determine|O whether|O the|O subcellular|O localization|O of|O mutant|O SOD1|gene-protein is|O crucial|O to|O mutant|O SOD1|gene-protein -|O mediated|O cell|O death|O ,|O we|O produced|O neuronal|O cell|O models|O with|O accumulation|O of|O SOD1|gene-protein in|O each|O subcellular|O fraction|O /|O organelle|O ,|O such|O as|O the|O cytosol|O ,|O nucleus|O ,|O endoplasmic|O reticulum|O ,|O and|O mitochondria|O .|O 
We|O showed|O that|O the|O localization|O of|O mutant|O SOD1|gene-protein in|O the|O mitochondria|O triggered|O the|O release|O of|O mitochondrial|O cytochrome|gene-protein c|gene-protein followed|O by|O the|O activation|O of|O caspase|gene-protein cascade|O and|O induced|O neuronal|O cell|O death|O without|O cytoplasmic|O mutant|O SOD1|gene-protein aggregate|O formation|O .|O 
Nuclear|O and|O endoplasmic|O reticulum|O localization|O of|O mutant|O SOD1|gene-protein did|O not|O induce|O cell|O death|O .|O 
These|O results|O suggest|O that|O the|O localization|O of|O mutant|O SOD1|gene-protein in|O the|O mitochondria|O is|O critical|O in|O the|O pathogenesis|O of|O mutant|O SOD1|gene-protein -|O associated|O familial|O amyotrophic|O lateral|O sclerosis|O .|O 
Development|O of|O resistance|O to|O acyclovir|O during|O chronic|O infection|O with|O the|O Oka|O vaccine|O strain|O of|O varicella|O -|O zoster|O virus|O ,|O in|O an|O immunosuppressed|O child|O .|O 
A|O 1|O -|O year|O -|O old|O boy|O was|O vaccinated|O with|O the|O Oka|O strain|O of|O varicella|O just|O prior|O to|O the|O discovery|O of|O a|O tumor|O that|O required|O intensive|O antitumor|O therapy|O .|O 
Three|O months|O later|O he|O developed|O herpes|O zoster|O ,|O which|O developed|O into|O chronic|O verrucous|O lesions|O that|O were|O refractory|O to|O treatment|O with|O acyclovir|O and|O which|O subsequently|O disseminated|O .|O 
DNA|O from|O a|O biopsy|O specimen|O of|O a|O chronic|O herpes|O -|O zoster|O lesion|O indicated|O that|O the|O Oka|O vaccine|O strain|O of|O the|O the|O virus|O caused|O this|O severe|O complication|O .|O 
Analysis|O of|O this|O viral|O DNA|O demonstrated|O a|O mutation|O in|O the|O viral|O thymidine|gene-rna kinase|gene-rna gene|O .|O 
Plasmids|O containing|O this|O altered|O gene|O were|O unable|O to|O produce|O functional|O thymidine|gene-protein kinase|gene-protein in|O an|O in|O vitro|O translation|O system|O .|O 
The|O presence|O of|O this|O mutation|O would|O explain|O the|O clinical|O resistance|O to|O acyclovir|O .|O 
This|O is|O the|O first|O report|O of|O Oka|O -|O strain|O varicella|O virus|O causing|O severe|O disease|O after|O reactivation|O and|O of|O resistance|O to|O acyclovir|O during|O an|O infection|O caused|O by|O this|O virus|O .|O 
Cytogenetics|O and|O tissue|O culture|O of|O small|O round|O cell|O tumors|O of|O bone|O and|O soft|O tissue|O .|O 
The|O variety|O of|O tumor|O -|O specific|O cytogenetic|O and|O genetic|O alterations|O among|O small|O round|O cell|O tumors|O (|O Ewing|O family|O of|O tumors|O ,|O rhabdomyosarcoma|O ,|O neuroblastoma|O ,|O and|O lymphoma|O )|O increases|O the|O possibility|O of|O genotypic|O diagnosis|O of|O them|O .|O 
In|O Ewing|O 's|O sarcoma|O and|O related|O peripheral|O primitive|O neuroectodermal|O tumors|O ,|O a|O (|O 11|O ;|O 22|O )|O (|O q24|O ;|O q12|O )|O translocation|O is|O associated|O with|O hybrid|O transcripts|O of|O the|O EWS|gene-rna gene|O with|O the|O FLIl|gene-rna gene|O .|O 
In|O alveolar|O rhabdomyosarcoma|O ,|O a|O (|O 2|O ;|O 13|O )|O (|O q35|O ;|O qt4|O )|O translocation|O is|O associated|O with|O a|O chimeric|O gene|O between|O PAX3|gene-rna and|O FKHR|gene-rna .|O 
Specific|O genetic|O alterations|O of|O the|O short|O arm|O of|O chromosome|O 1|O and|O amplification|O of|O the|O MYCN|gene-rna gene|O are|O diagnostically|O useful|O in|O neuroblastomas|O as|O the|O immunoglobulin|gene-rna or|O T-cell|gene-rna receptor|gene-rna gene|O rearrangements|O and|O chromosome|O translocations|O in|O lymphomas|O .|O 
Thus|O ,|O cytogenetics|O and|O genetics|O provide|O an|O essential|O adjunct|O to|O diagnostic|O surgical|O pathology|O in|O the|O case|O of|O small|O round|O cell|O tumors|O ,|O which|O often|O present|O substantial|O diagnostic|O challenges|O .|O 
Likewise|O ,|O in|O vitro|O culture|O studies|O represent|O another|O approach|O in|O determining|O histogenetic|O origin|O ,|O novel|O genes|O ,|O novel|O mechanisms|O of|O gene|O dysregulation|O ,|O and|O the|O biological|O characteristics|O of|O small|O round|O cell|O tumors|O .|O 
Long|O -|O term|O exposure|O to|O retinoic|O acid|O induces|O the|O expression|O of|O IRK1|gene-protein channels|gene-protein in|O HERG|gene-protein channel|gene-protein -|O endowed|O neuroblastoma|O cells|O .|O 
The|O modulation|O of|O inward|O K+|O conductances|O was|O studied|O during|O neuronal|O differentiation|O of|O human|O SH-SY5Y|O neuroblastoma|O cells|O .|O 
Under|O standard|O culture|O conditions|O ,|O these|O cells|O express|O the|O herg|gene-rna gene|O ,|O and|O the|O HERG|gene-protein current|O is|O the|O main|O inward|O K+|O current|O regulating|O their|O Vrest|O .|O 
After|O 10|O -|O 20|O days|O exposure|O to|O Retinoic|O Acid|O (|O RA|O )|O ,|O SH-SY5Y|O cells|O showed|O ,|O in|O addition|O to|O HERG|gene-protein currents|O ,|O a|O novel|O current|O characterized|O by|O inward|O rectification|O ,|O dependence|O on|O the|O extracellular|O K+|O concentration|O ,|O and|O blockade|O by|O Cs+|O and|O Ba2+|O ,|O the|O main|O features|O of|O the|O IRK1|gene-protein current|O .|O 
The|O appearance|O of|O this|O current|O is|O accompanied|O by|O a|O strong|O hyperpolarisation|O of|O Vrest|O .|O 
RT|O -|O PCR|O experiments|O confirmed|O that|O a|O transcript|O of|O the|O IRK1|gene-rna (|O Kir|gene-rna 2.1|gene-rna )|O gene|O actually|O appears|O in|O SH-SY5Y|O cells|O treated|O for|O 10|O -|O 20|O days|O with|O RA|O .|O 
On|O the|O whole|O ,|O data|O here|O presented|O demonstrate|O that|O RA|O -|O induced|O neuronal|O differentiation|O of|O neuroblastoma|O cells|O is|O accompanied|O by|O the|O switch|O from|O a|O HERG|gene-generic -|O driven|O to|O a|O IRK1|gene-generic -|O driven|O control|O of|O Vrest|O ,|O similarly|O to|O what|O happens|O in|O normal|O differentiating|O neurons|O ;|O however|O ,|O in|O tumor|O cells|O ,|O this|O switch|O does|O not|O imply|O the|O abolition|O of|O HERG|gene-protein channel|gene-protein expression|O .|O 
Adrenomedullin|gene-protein mediates|O vasodilation|O via|O CGRP1|gene-protein receptors|gene-protein .|O 
Adrenomedullin|gene-protein is|O a|O recently|O discovered|O 52|O amino|O acid|O polypeptide|O with|O potent|O hypotensive|O activity|O .|O 
The|O peptide|O possesses|O 21|O %|O homology|O with|O the|O amino|O acid|O sequence|O of|O human|O calcitonin|gene-protein gene|gene-protein -|gene-protein related|gene-protein peptide-alpha|gene-protein (|O hCGRP-alpha|gene-protein )|O .|O 
In|O 125I-hCGRP-alpha|gene-protein receptor|gene-protein binding|O experiments|O using|O membranes|O from|O human|O neuroblastoma|O cells|O (|O SK-N-MC|O )|O adrenomedullin|gene-protein is|O a|O potent|O competitor|O with|O a|O Ki|O of|O 0.37|O nM|O .|O In|O SK-N-MC|O cells|O hCGRP-alpha|gene-protein and|O adrenomedullin|gene-protein concentration|O -|O dependently|O increase|O cAMP|O levels|O with|O -logEC50|O values|O of|O 9.65|O and|O 7.75|O ,|O respectively|O .|O 
Both|O responses|O were|O attenuated|O in|O the|O presence|O of|O 30|O nM|O CGRP[8-37]|O ,|O a|O CGRP1|gene-protein receptor|gene-protein antagonist|O .|O 
In|O isolated|O rat|O hearts|O ,|O perfused|O at|O constant|O flow|O ,|O bolus|O infusion|O of|O adrenomedullin|gene-protein (|O 1|O to|O 100|O nM|O )|O resulted|O in|O a|O concentration|O -|O dependent|O ,|O pronounced|O and|O long|O -|O lasting|O vasodilation|O with|O an|O approximate|O EC50|O of|O about|O 3|O nM|O .|O 
This|O effect|O was|O markedly|O attenuated|O in|O the|O presence|O of|O 100|O nM|O CGRP[8-37]|O .|O 
In|O this|O model|O ,|O bolus|O infusion|O of|O hCGRP-alpha|gene-protein (|O 0.01|O to|O 100|O nM|O )|O evoked|O a|O comparable|O vasodilation|O with|O an|O approximate|O EC50|O of|O 0.5|O nM|O .|O 
This|O effect|O was|O also|O potently|O inhibited|O in|O the|O presence|O of|O CGRP[8-37]|O .|O These|O results|O suggest|O that|O adrenomedullin|gene-protein -|O mediated|O vasodilation|O is|O linked|O to|O the|O activation|O of|O CGRP1|gene-protein receptors|gene-protein in|O the|O coronary|O vascular|O system|O .|O 
The|O role|O of|O the|O MEIS|gene-rna homeobox|gene-rna genes|gene-rna in|O neuroblastoma|O .|O 
Department|O of|O Human|O Genetics|O M1-159|O ,|O Academic|O Medical|O Centre|O ,|O University|O of|O Amsterdam|O ,|O Amsterdam|O ,|O The|O Netherlands|O .|O d.geerts@amc.uva.nl|O 
We|O recently|O found|O amplification|O of|O the|O TALE|gene-rna homeobox|gene-rna gene|gene-rna MEIS1|gene-rna in|O the|O IMR32|O neuroblastoma|O cell|O line|O .|O 
We|O now|O demonstrate|O high|O -|O level|O expression|O of|O the|O MEIS1|gene-rna and|O MEIS2|gene-rna genes|O ,|O as|O well|O as|O efficient|O expression|O of|O most|O other|O TALE|gene-rna family|gene-rna member|gene-rna genes|gene-rna in|O a|O panel|O of|O neuroblastoma|O cell|O lines|O .|O 
Stable|O transfection|O of|O MEIS1|gene-rna -|O expressing|O cell|O lines|O with|O cDNA|O encoding|O a|O naturally|O occurring|O dominant|O -|O negative|O splice|O variant|O of|O MEIS1|gene-rna (|O MEIS1E|gene-rna )|O yielded|O clones|O with|O impaired|O cell|O proliferation|O ,|O gain|O of|O differentiated|O phenotype|O ,|O and|O increased|O contact|O inhibition|O and|O cell|O death|O .|O 
This|O indicated|O a|O relevance|O of|O MEIS|gene-rna expression|O for|O neuroblastoma|O cell|O growth|O and|O proliferation|O .|O 
We|O therefore|O determined|O the|O gene|O expression|O profiles|O of|O several|O MEIS1E|gene-rna transfectants|O using|O serial|O analysis|O of|O gene|O expression|O (|O SAGE|O )|O .|O 
A|O large|O number|O of|O genes|O showed|O differential|O expression|O as|O a|O result|O of|O MEIS1E|gene-rna expression|O .|O 
These|O include|O genes|O involved|O in|O developmental|O signalling|O pathways|O ,|O chromatin|O binding|O ,|O cell|O cycle|O control|O ,|O proliferation|O ,|O and|O apoptosis|O .|O 
The|O results|O presented|O provide|O important|O clues|O for|O the|O oncogenic|O function|O of|O MEIS1|gene-rna in|O neuroblastoma|O .|O 
Down|O -|O regulation|O of|O c-myc|gene-rna oncogene|O during|O NGF|gene-protein -|O induced|O differentiation|O of|O neuroblastoma|O cell|O lines|O .|O 
There|O may|O be|O a|O close|O relationship|O between|O myc|gene-rna oncogenes|O and|O carcinogenesis|O of|O human|O neuroblastoma|O .|O 
In|O previous|O studies|O ,|O we|O were|O able|O to|O induce|O differentiation|O of|O certain|O neuroblastoma|O cell|O lines|O with|O NGF|gene-protein .|O 
In|O order|O to|O study|O gene|O regulation|O during|O differentiation|O ,|O N-myc|gene-rna and|O c-myc|gene-rna cDNA|O probes|O were|O hybridized|O with|O RNA|O extracted|O from|O different|O cell|O lines|O before|O and|O after|O NGF|gene-protein treatment|O .|O 
It|O was|O found|O that|O cell|O lines|O which|O expressed|O N-myc|gene-rna did|O not|O express|O c-myc|gene-rna while|O those|O with|O c-myc|gene-rna did|O not|O express|O N-myc|gene-rna except|O for|O SHEP|O cell|O line|O which|O had|O neither|O c-myc|gene-rna nor|O N-myc|gene-rna expression|O .|O 
In|O NGF|gene-protein -|O induced|O differentiated|O neuroblastoma|O cells|O ,|O c-myc|gene-rna oncogene|O was|O down|O -|O regulated|O in|O comparison|O with|O the|O control|O samples|O .|O 
The|O time|O course|O of|O c-myc|gene-rna down|O -|O regulation|O was|O concomitant|O with|O the|O appearance|O of|O morphological|O differentiation|O .|O 
In|O situ|O hybridization|O also|O showed|O remarkable|O reduction|O of|O c-myc|gene-rna oncogene|O expression|O in|O NGF|gene-protein -|O induced|O differentiated|O cells|O as|O compared|O with|O the|O untreated|O control|O cells|O .|O 
These|O results|O indicate|O that|O down|O -|O regulation|O of|O c-myc|gene-rna oncogene|O may|O be|O a|O key|O event|O during|O NGF|gene-protein -|O induced|O differentiation|O and|O over|O -|O expression|O of|O c-myc|gene-rna oncogene|O may|O ,|O at|O least|O partially|O ,|O be|O responsible|O for|O the|O genesis|O of|O neuroblastoma|O .|O 
Activation|O of|O the|O human|O MDR1|gene-rna gene|O promoter|O in|O differentiated|O neuroblasts|O .|O 
When|O treated|O in|O vitro|O with|O retinoic|O acid|O ,|O many|O neuroblastoma|O cell|O lines|O undergo|O neuronal|O differentiation|O and|O show|O a|O significant|O increase|O in|O human|O multi|gene-rna -|gene-rna drug|gene-rna resistance|gene-rna gene|gene-rna (|O MDRI|gene-rna )|O transcript|O levels|O .|O 
To|O determine|O whether|O over|O -|O expression|O of|O the|O gene|O may|O result|O from|O activation|O of|O its|O promoter|O by|O differentiating|O agents|O ,|O the|O activity|O of|O the|O human|O MDRI|gene-rna proximal|O promoter|O (|O MDRI|gene-rna pp|O )|O transfected|O to|O 2|O neuroblastoma|O lines|O treated|O with|O retinoic|O acid|O and|O forskolin|O was|O first|O measured|O using|O transient|O expression|O assays|O .|O 
The|O MDRI|gene-rna gene|O transcript|O levels|O of|O these|O 2|O lines|O were|O then|O measured|O by|O Northern|O blots|O .|O 
The|O results|O indicate|O that|O retinoic|O acid|O and|O forskolin|O were|O able|O to|O activate|O the|O human|O MDRI|gene-rna pp|gene-rna in|O a|O dose|O -|O dependent|O manner|O after|O transfection|O of|O the|O MDRI|gene-rna pp|gene-rna -|O CAT|gene-rna constructs|O in|O the|O 2|O cell|O models|O tested|O ,|O i.e.|O ,|O SK-N-SH|O and|O IGR-N-91|O ,|O a|O new|O human|O neuroblastoma|O cell|O line|O .|O 
A|O significant|O increase|O in|O MDRI|gene-rna gene|O transcript|O levels|O was|O observed|O upon|O treatment|O with|O differentiation|O inducers|O in|O SK-N-SH|O but|O not|O in|O IGR-N-91|O neuroblasts|O .|O 
These|O results|O suggest|O that|O the|O induction|O of|O the|O MDRI|gene-rna gene|O promoter|O is|O necessary|O but|O not|O sufficient|O to|O lead|O to|O an|O increase|O in|O MDRI|gene-rna gene|O transcript|O levels|O ,|O according|O to|O the|O neuroblast|O cell|O line|O considered|O .|O 
A|O quantitative|O analysis|O of|O the|O role|O of|O K+|gene-protein channels|gene-protein in|O mitogenesis|O of|O neuroblastoma|O cells|O .|O 
The|O role|O of|O K+|gene-protein channels|gene-protein in|O mitogenesis|O was|O studied|O on|O mouse|O neuroblastoma|O cells|O by|O analysing|O the|O effects|O of|O various|O chemical|O agents|O on|O the|O whole|O -|O cell|O K+|O current|O and|O the|O cell|O proliferation|O .|O 
The|O outward|O current|O recorded|O during|O depolarizations|O on|O undifferentiated|O cells|O was|O made|O up|O of|O a|O small|O and|O slow|O inactivating|O K+|O current|O .|O 
Foetal|O calf|O serum|O ,|O which|O is|O mitogen|O for|O neuroblastoma|O cells|O ,|O shifted|O in|O opposite|O directions|O by|O 7|O -|O 10|O mV|O peak|O activation|O and|O steady|O -|O state|O inactivation|O -|O voltage|O curves|O of|O the|O K+|O current|O .|O 
The|O resulting|O effect|O was|O an|O increase|O in|O K+|O conductance|O .|O 
The|O effect|O on|O the|O resting|O K+|O flux|O of|O the|O classical|O K+|gene-protein channel|gene-protein blockers|O tetraethylammonium|O ,|O 4-aminopyridine|O and|O capsaicin|O ,|O the|O anticancer|O agent|O tamoxifen|O ,|O the|O heat|O inactivated|O serum|O and|O the|O increase|O in|O external|O K+|O concentration|O were|O estimated|O from|O their|O effects|O on|O the|O K+|O current|O .|O 
The|O cell|O proliferation|O was|O determined|O under|O the|O same|O conditions|O .|O 
The|O results|O indicate|O that|O cell|O proliferation|O is|O correlated|O to|O the|O resulting|O K+|O flux|O .|O 
It|O is|O supposed|O that|O mitogenesis|O is|O controlled|O by|O the|O intracellular|O Na+|O concentration|O which|O ,|O via|O a|O cell|O volume|O regulation|O ,|O is|O a|O function|O of|O the|O K+|O flux|O .|O 
A|O quantitative|O model|O is|O developed|O on|O the|O basis|O of|O these|O hypotheses|O .|O 
A|O new|O scorpion|O toxin|O with|O a|O very|O high|O affinity|O for|O sodium|O channels|O .|O 
An|O electrophysiological|O study|O .|O 
The|O neurotoxic|O action|O of|O toxin|O gamma|O from|O the|O venom|O of|O the|O Brazilian|O scorpion|O Tityus|O serrulatus|O (|O TiTx|O gamma|O )|O has|O been|O investigated|O in|O cultured|O mouse|O neuroblastoma|O cells|O (|O N1E115|O )|O using|O the|O suction|O pipette|O technique|O .|O 
Addition|O of|O 14|O to|O 53|O nM|O TiTx|O gamma|O to|O the|O external|O solution|O causes|O nerve|O cell|O membrane|O depolarization|O ,|O membrane|O potential|O oscillations|O and|O spontaneous|O action|O potentials|O within|O 10|O min|O .|O 
None|O of|O these|O effects|O were|O observed|O within|O 15|O min|O after|O application|O of|O 1|O microM|O toxin|O IV|O from|O Centruroides|O sculpturatus|O venom|O .|O 
Under|O voltage|O clamp|O the|O amplitude|O of|O the|O sodium|O current|O evoked|O by|O test|O pulses|O to|O potentials|O more|O positive|O than|O -|O 30|O mV|O is|O reversibly|O reduced|O by|O 50|O %|O after|O 17|O to|O 105|O nM|O TiTx|O gamma|O .|O 
On|O the|O other|O hand|O ,|O a|O sodium|O current|O component|O appears|O after|O TiTx|O gamma|O at|O test|O pulse|O potentials|O between|O -|O 70|O and|O -|O 40|O mV|O ,|O for|O which|O no|O sodium|O current|O is|O observed|O in|O the|O control|O experiment|O .|O 
The|O outward|O potassium|O current|O is|O not|O significantly|O affected|O by|O the|O highest|O TiTx|O gamma|O concentrations|O used|O .|O 
The|O potential|O -|O dependence|O of|O inactivation|O of|O the|O sodium|O current|O component|O that|O is|O induced|O by|O TiTx|O gamma|O is|O shifted|O by|O -|O 30|O mV|O with|O respect|O to|O control|O values|O .|O 
The|O local|O anaesthetic|O procain|O at|O 1|O mM|O discriminates|O between|O the|O two|O populations|O of|O sodium|O channels|O observed|O in|O the|O presence|O of|O TiTx|O gamma|O .|O 
Cdk5|gene-protein phosphorylates|O p53|gene-protein and|O regulates|O its|O activity|O .|O 
Cyclin|gene-protein dependent|gene-protein kinase|gene-protein 5|gene-protein (|O Cdk5|gene-protein )|O is|O a|O proline|O -|O direct|O protein|O kinase|gene-protein that|O is|O most|O active|O in|O the|O CNS|O ,|O and|O has|O been|O implicated|O as|O a|O contributing|O factor|O in|O certain|O neurodegenerative|O diseases|O .|O 
Further|O ,|O there|O is|O evidence|O to|O suggest|O that|O Cdk5|gene-protein may|O facilitate|O the|O progression|O of|O apoptosis|O .|O 
However|O ,|O the|O mechanisms|O involved|O have|O not|O been|O elucidated|O .|O 
The|O tumor|O suppressor|O protein|O p53|gene-protein ,|O a|O transcription|O factor|O that|O is|O regulated|O by|O phosphorylation|O ,|O increases|O the|O expression|O of|O genes|O that|O control|O growth|O arrest|O or|O cell|O death|O .|O 
To|O understand|O how|O Cdk5|gene-protein could|O facilitate|O apoptosis|O ,|O the|O effects|O of|O Cdk5|gene-protein on|O p53|gene-protein activity|O were|O examined|O .|O 
In|O the|O present|O study|O it|O is|O shown|O that|O in|O apoptotic|O PC12|O cells|O the|O levels|O of|O p53|gene-protein and|O Cdk5|gene-protein increase|O concomitantly|O .|O 
Further|O ,|O Cdk5|gene-protein /|O p25|gene-protein effectively|O phosphorylates|O recombinant|O p53|gene-protein in|O vitro|O .|O 
Transient|O transfection|O of|O Cdk5|gene-protein /|O p25|gene-protein into|O cells|O results|O in|O an|O increase|O in|O p53|gene-protein levels|O ,|O as|O well|O as|O the|O expression|O of|O the|O p53|gene-protein -|O responsive|O genes|O p21|gene-rna and|O Bax|gene-rna .|O 
Furthermore|O ,|O evidence|O is|O provided|O that|O increased|O Cdk5|gene-protein activity|O increases|O p53|gene-protein transcriptional|O activity|O significantly|O ,|O suggesting|O that|O p53|gene-protein is|O modulated|O in|O situ|O by|O Cdk5|gene-protein .|O 
This|O is|O the|O first|O demonstration|O that|O p53|gene-protein is|O a|O substrate|O of|O Cdk5|gene-protein ,|O and|O that|O Cdk5|gene-protein can|O modulate|O p53|gene-protein levels|O and|O activity|O .|O 
Immunomagnetic|O microsphere|O mediated|O purging|O of|O cALLa|gene-protein positive|O leukemic|O cells|O from|O bone|O marrow|O for|O autologous|O reinfusion|O .|O 
Bone|O marrow|O from|O sixteen|O patients|O with|O cALLa|gene-protein positive|O ALL|O have|O been|O treated|O with|O a|O monoclonal|gene-protein antibody|gene-protein (|O MoAb|gene-protein )|O cocktail|O which|O includes|O DuALL-1|gene-protein (|O CD9|gene-protein )|O ,|O WCMH15.14|gene-protein (|O CD10|gene-protein )|O and|O HD-37|gene-protein (|O CD19|gene-protein )|O .|O 
Following|O antibody|gene-protein treatment|O ,|O marrows|O were|O incubated|O (|O 30|O minutes|O )|O with|O anti|gene-protein -|gene-protein murine|gene-protein -|gene-protein IgG1|gene-protein (|O Fc|gene-protein )|O coated|O magnetic|O microbeads|O and|O passed|O through|O a|O graded|O magnetic|O field|O chamber|O .|O 
Two|O problems|O have|O had|O to|O be|O addressed|O :|O (1)|O More|O marrow|O cells|O must|O be|O processed|O than|O in|O marrows|O from|O patients|O with|O neuroblastoma|O ,|O for|O which|O the|O separation|O chamber|O was|O originally|O developed|O ,|O requiring|O the|O use|O of|O more|O beads|O ,|O causing|O occlusion|O of|O the|O chamber|O 's|O collection|O surface|O .|O 
This|O has|O been|O corrected|O by|O using|O a|O large|O surface|O area|O pre|O -|O magnet|O for|O the|O elimination|O of|O excess|O microbeads|O prior|O to|O processing|O in|O the|O main|O chamber|O ;|O (2)|O Up|O -|O modulation|O (|O up|O to|O 40|O %|O positive|O cells|O )|O of|O the|O CD9|gene-protein associated|O antigen|O has|O been|O detected|O .|O 
To|O avoid|O difficulty|O ,|O marrows|O are|O being|O routinely|O screened|O prior|O to|O harvest|O for|O purging|O ,|O and|O purging|O is|O delayed|O for|O patients|O with|O elevated|O CD9|gene-protein levels|O .|O 
Eight|O patients|O have|O been|O reinfused|O ,|O with|O no|O morbidity|O or|O mortality|O associated|O with|O the|O purging|O or|O other|O ex|O vivo|O handling|O of|O the|O marrow|O .|O 
[|O DAN|gene-rna gene|O ]|O 
DAN|gene-rna gene|O has|O been|O isolated|O by|O means|O of|O differential|O screening|O method|O between|O rat|O fibroblast|O 3Y1|O and|O Rous|O sarcoma|O virus|O -|O transformed|O 3Y1|O (|O SR-Y1|O )|O cells|O .|O 
DAN|gene-rna expression|O was|O suppressed|O in|O some|O of|O the|O transformed|O cells|O and|O its|O re|O -|O expression|O reverted|O the|O various|O transformed|O phenotypes|O such|O as|O colony|O formation|O in|O soft|O agar|O and|O tumor|O formation|O in|O mice|O .|O 
When|O DAN|gene-rna was|O overexpressed|O in|O 3Y1|O cells|O ,|O these|O cell|O showed|O the|O retardation|O of|O the|O entry|O into|O the|O S|O phase|O .|O 
DAN|gene-rna cDNA|O encodes|O a|O 27|O -|O kD|O protein|O which|O consists|O of|O 178|O amino|O acids|O .|O 
The|O deduced|O amino|O acid|O sequence|O has|O no|O homology|O with|O known|O proteins|O .|O 
The|O amino|O terminal|O of|O DAN|gene-generic is|O highly|O hydrophobic|O and|O DAN|gene-generic is|O indeed|O secreted|O into|O the|O culture|O medium|O .|O 
This|O secreted|O DAN|gene-generic ,|O when|O added|O to|O the|O culture|O of|O SR-3Y1|O cells|O ,|O suppressed|O DNA|O synthesis|O .|O 
Human|O DAN|gene-rna is|O mapped|O to|O 1|O p36.11|O -|O p36.13|O ,|O a|O region|O known|O to|O have|O highly|O significant|O linkage|O with|O the|O genesis|O and/or|O progression|O of|O human|O neuroblastoma|O .|O 
Aberrant|O bands|O on|O Southern|O blot|O were|O detected|O in|O some|O of|O the|O neuroblastoma|O cases|O .|O 
Rat|O and|O human|O genomic|O DANs|gene-rna were|O isolated|O .|O 
CAT|O and|O the|O electrophoretic|O mobility|O shift|O assays|O revealed|O the|O presence|O of|O possible|O positive|O and|O negative|O regulatory|O elements|O at|O -|O 57|O approximately|O +|O 118|O and|O -|O 1,232|O approximately|O -|O 987|O of|O rat|O genome|O ,|O respectively|O .|O 
The|O 37|O kDa|O /|O 67|O kDa|O laminin|gene-protein receptor|gene-protein is|O required|O for|O PrP(Sc)|gene-protein propagation|O in|O scrapie|O -|O infected|O neuronal|O cells|O .|O 
The|O accumulation|O of|O PrP(Sc)|gene-protein in|O scrapie|O -|O infected|O neuronal|O cells|O has|O been|O prevented|O by|O three|O approaches|O :|O (i)|O transfection|O of|O ScMNB|O cells|O with|O an|O antisense|O laminin|gene-rna receptor|gene-rna precursor|gene-rna (|O LRP|gene-rna )|O RNA|O -|O expression|O plasmid|O ,|O (ii)|O transfection|O of|O ScN2a|O cells|O and|O ScGT1|O cells|O with|O small|O interfering|O RNAs|O (|O siRNAs|O )|O specific|O for|O the|O LRP|gene-rna mRNA|O ,|O and|O (iii)|O incubation|O of|O ScN2a|O cells|O with|O an|O anti|gene-protein -|gene-protein LRP|gene-protein /|gene-protein LR|gene-protein antibody|gene-protein .|O 
LRP|gene-rna antisense|gene-rna RNA|O and|O LRP|gene-rna siRNAs|O reduced|O LRP|gene-protein /|gene-protein LR|gene-protein expression|O and|O inhibited|O the|O accumulation|O of|O PrP(Sc)|gene-protein in|O these|O cells|O .|O 
The|O treatments|O also|O reduced|O PrP(c)|gene-protein levels|O .|O 
The|O anti|gene-protein -|gene-protein LRP|gene-protein /|gene-protein LR|gene-protein antibody|gene-protein ,|O W3|gene-protein ,|O abolished|O PrP(Sc)|gene-protein accumulation|O and|O reduced|O PrP(c)|gene-protein levels|O after|O seven|O days|O of|O incubation|O .|O 
Cells|O remained|O free|O of|O PrP(Sc)|gene-protein after|O being|O cultured|O for|O 14|O additional|O days|O without|O the|O antibody|O ,|O whereas|O the|O PrP(c)|gene-protein level|O was|O restored|O .|O 
Our|O results|O demonstrate|O the|O necessity|O of|O the|O laminin|gene-protein receptor|gene-protein (|O LRP|gene-protein /|gene-protein LR|gene-protein )|O for|O PrP(Sc)|gene-protein propagation|O in|O cultured|O cells|O and|O suggest|O that|O LRP|gene-protein /|gene-protein LR|gene-protein -|gene-protein specific|gene-protein antibodies|gene-protein could|O be|O used|O as|O powerful|O therapeutic|O tools|O in|O the|O treatment|O of|O transmissible|O spongiform|O encephalopathies|O .|O 
Neuroblastoma|O .|O Correlation|O of|O neuropeptide|O expression|O in|O tumor|O tissue|O with|O other|O prognostic|O factors|O .|O 
BACKGROUND|O .|O 
The|O neuropeptide|O contents|O in|O neuroblastomas|O were|O quantified|O by|O radioimmunoassay|O (|O RIA|O )|O to|O assess|O their|O possible|O biologic|O significance|O .|O 
METHODS|O .|O 
Neuroblastoma|O tumor|O tissue|O was|O obtained|O from|O the|O primary|O tumor|O site|O before|O therapy|O in|O 16|O patients|O with|O newly|O diagnosed|O neuroblastoma|O and|O in|O 7|O patients|O with|O central|O nervous|O system|O medulloblastomas|O or|O gliomas|O .|O 
RESULTS|O .|O 
The|O tumor|O tissue|O was|O assayed|O for|O vasoactive|gene-protein intestinal|gene-protein peptide|gene-protein (|O VIP|gene-protein )|O ,|O somatostatin|gene-protein (|O SRIF|gene-protein )|O ,|O substance|gene-protein P|gene-protein ,|O and|O neurotensin|gene-protein by|O both|O immunostaining|O and|O RIA|O techniques|O .|O 
Increased|O VIP|gene-protein levels|O of|O 1.2|O pg|O /|O micrograms|O DNA|O or|O more|O correlated|O significantly|O with|O cellular|O differentiation|O (|O P|O =|O 0.003|O )|O and|O favorable|O disease|O stage|O (|O P|O =|O 0.002|O )|O in|O neuroblastomas|O .|O 
Increased|O SRIF|gene-protein contents|O (|O greater|O than|O 1.3|O pg|O /|O micrograms|O DNA|O )|O correlated|O with|O differentiation|O of|O the|O tumor|O (|O P|O =|O 0.002|O )|O .|O 
Increased|O VIP|gene-protein and|O SRIF|gene-protein content|O did|O not|O correlate|O with|O N-myc|gene-rna oncogene|O expression|O or|O ras|gene-rna oncogene|O protein|O immunostaining|O .|O 
No|O VIP|gene-protein was|O detectable|O in|O brain|O tumors|O ,|O and|O other|O neuropeptides|O were|O variable|O in|O content|O .|O 
CONCLUSIONS|O .|O 
RIA|O of|O VIP|gene-protein and|O SRIF|gene-protein levels|O in|O primary|O tumor|O tissue|O may|O offer|O an|O independent|O objective|O assay|O of|O biologic|O behavior|O in|O neuroblastoma|O biopsy|O specimens|O .|O 
Acid|gene-protein :|gene-protein coenzyme|gene-protein A|gene-protein ligase|gene-protein in|O brain|O :|O fatty|O acid|O specificity|O in|O cellular|O and|O subcellular|O fractions|O .|O 
We|O measured|O long|gene-protein -|gene-protein chain|gene-protein fatty|gene-protein acid|gene-protein :|gene-protein coenzyme|gene-protein A|gene-protein (|gene-protein CoA|gene-protein )|gene-protein ligase|gene-protein (|O EC|O 6.2.1.3|O )|O activity|O with|O four|O fatty|O acids|O in|O brain|O homogenates|O ,|O and|O cellular|O and|O subcellular|O fractions|O to|O determine|O whether|O there|O are|O differences|O in|O activity|O that|O could|O be|O correlated|O with|O differences|O in|O fatty|O acid|O composition|O and|O metabolism|O .|O 
In|O rat|O brain|O homogenates|O ,|O ligase|gene-protein activity|O varied|O appreciably|O with|O the|O four|O acids|O ,|O with|O 18|O :|O 2|O greater|O than|O 18|O :|O 1|O greater|O than|O 16|O :|O 0|O greater|O than|O 22|O :|O 1|O (|O nmol|O acyl-CoA|O formed|O /|O min|O /|O mg|O protein|O :|O 1.46|O ,|O 1.20|O ,|O 0.96|O ,|O and|O 0.57|O ,|O respectively|O )|O .|O 
This|O order|O was|O similar|O under|O all|O incubation|O conditions|O tested|O ,|O including|O variable|O pH|O and|O fatty|O acid|O concentrations|O .|O 
The|O relative|O specific|O activities|O (|O RSA|O ,|O 16|O :|O 0|O =|O 1.0|O )|O with|O the|O four|O substrates|O were|O similar|O in|O rat|O brain|O homogenate|O ,|O mitochondria|O ,|O and|O microsomes|O ,|O with|O the|O highest|O specific|O activities|O in|O the|O latter|O fraction|O .|O 
The|O RSA|O were|O also|O similar|O in|O ox|O brain|O homogenates|O ,|O in|O rabbit|O brain|O microsomes|O prepared|O from|O gray|O and|O white|O matter|O ,|O in|O neurons|O isolated|O from|O rat|O brain|O ,|O and|O in|O cultured|O neuroblastoma|O cells|O .|O 
Rat|O liver|O homogenates|O had|O a|O significantly|O different|O pattern|O of|O RSA|O .|O 
These|O results|O indicate|O that|O the|O ligase(s)|gene-protein has|O a|O preference|O for|O certain|O fatty|O acids|O ,|O but|O suggest|O that|O the|O major|O control|O of|O fatty|O acid|O composition|O and|O metabolism|O is|O a|O function|O of|O subsequent|O metabolic|O steps|O .|O 
Potent|O antitumor|O effects|O of|O an|O antitumor|gene-protein endothelial|gene-protein cell|gene-protein immunotoxin|gene-protein in|O a|O murine|O vascular|O targeting|O model|O .|O 
Immunotoxins|gene-protein and|O other|O antibody|O -|O based|O therapeutic|O reagents|O have|O proved|O effective|O agonist|O lymphomas|O and|O leukemias|O ,|O but|O results|O with|O carcinomas|O and|O other|O solid|O tumors|O have|O thus|O far|O been|O less|O impressive|O .|O 
A|O major|O reason|O for|O this|O difference|O is|O that|O macromolecules|O penetrate|O poorly|O and|O unevenly|O into|O solid|O tumors|O .|O 
A|O solution|O to|O this|O problem|O would|O be|O to|O attack|O the|O endothelial|O cells|O of|O the|O tumor|O vascular|O bed|O rather|O than|O the|O tumor|O cells|O themselves|O .|O 
We|O have|O developed|O a|O murine|O model|O of|O this|O vascular|O targeting|O approach|O where|O transfection|O of|O the|O tumor|O cells|O with|O a|O cytokine|gene-rna gene|O causes|O them|O to|O induce|O the|O expression|O of|O an|O experimental|O marker|O (|O MHC|gene-protein Class|gene-protein II|gene-protein )|O on|O tumor|O endothelium|O .|O 
In|O this|O report|O we|O show|O that|O an|O anti|gene-protein -|gene-protein Class|gene-protein II|gene-protein -|gene-protein deglycosylated|gene-protein Ricin|gene-protein A|gene-protein -|gene-protein chain|gene-protein immunotoxin|gene-protein kills|O IFN-gamma|gene-protein -|O activated|O endothelial|O cells|O in|O culture|O and|O ,|O when|O injected|O into|O tumor|O -|O bearing|O Balb|O /|O c|O nude|O mice|O ,|O causes|O complete|O thrombosis|O of|O the|O tumor|O vasculature|O ,|O widespread|O infarction|O ,|O and|O dramatic|O regressions|O of|O large|O solid|O tumors|O .|O 
These|O findings|O suggest|O that|O immunoconjugates|O prepared|O with|O recently|O described|O antibodies|O against|O human|O tumor|O endothelium|O could|O provide|O a|O broad|O -|O based|O therapy|O for|O variety|O of|O solid|O cancers|O in|O humans|O .|O 
HMGB1|gene-protein ,|O an|O architectural|gene-protein chromatin|gene-protein protein|O and|O extracellular|O signalling|O factor|O ,|O has|O a|O spatially|O and|O temporally|O restricted|O expression|O pattern|O in|O mouse|O brain|O .|O 
HMGB1|gene-protein is|O an|O abundant|O chromatin|O component|O ,|O so|O far|O considered|O ubiquitous|O .|O 
HMGB1|gene-protein also|O has|O an|O extracellular|O signalling|O role|O :|O when|O passively|O released|O by|O necrotic|O cells|O ,|O it|O triggers|O inflammation|O ;|O moreover|O ,|O it|O can|O be|O actively|O secreted|O by|O myeloid|O cells|O ,|O neurons|O and|O neuronal|O cancer|O cells|O .|O 
We|O show|O here|O that|O HMGB1|gene-protein protein|O is|O undetectable|O in|O most|O cells|O in|O adult|O mouse|O brain|O ,|O and|O is|O present|O in|O a|O subset|O of|O brain|O cells|O during|O development|O ,|O with|O a|O very|O complex|O temporal|O ,|O spatial|O and|O subcellular|O expression|O pattern|O .|O 
HMGB1|gene-protein is|O expressed|O in|O the|O cortical|O plate|O of|O E14.5|O embryos|O ,|O predominantly|O in|O the|O nucleus|O ,|O although|O roughly|O 1|O %|O of|O cells|O show|O a|O cytoplasmic|O localization|O as|O well|O .|O 
In|O E16|O embryos|O ,|O HMGB1|gene-protein is|O nuclearly|O expressed|O in|O scattered|O cells|O apparently|O moving|O from|O the|O ventricular|O zone|O to|O the|O cortical|O plate|O .|O 
HMGB1|gene-protein expression|O is|O strongly|O down|O -|O regulated|O at|O later|O developmental|O stages|O ;|O in|O adult|O mice|O significant|O expression|O is|O maintained|O only|O in|O areas|O of|O continuing|O neurogenesis|O .|O 
Finally|O ,|O HMGB1|gene-protein subcellular|O localization|O changes|O during|O retinoic|O acid|O induced|O differentiation|O of|O P19|O neuroblastoma|O cells|O .|O 
Prognostic|O indicators|O for|O neuroblastoma|O :|O stage|O ,|O grade|O ,|O DNA|O ploidy|O ,|O MIB-1|gene-protein -|O proliferation|O index|O ,|O p53|gene-protein ,|O HER-2|gene-protein /|O neu|gene-protein and|O EGFr|gene-protein --|O a|O survival|O study|O .|O 
Neuroblastoma|O ,|O a|O tumor|O of|O the|O sympathetic|O nervous|O system|O ,|O is|O one|O of|O the|O most|O common|O solid|O malignancies|O in|O infants|O and|O represents|O 7|O %|O of|O all|O cases|O of|O childhood|O cancer|O outside|O of|O the|O central|O nervous|O system|O .|O 
Thirty-five|O samples|O of|O neuroblastoma|O from|O 31|O patients|O were|O obtained|O from|O Duke|O University|O Medical|O Center|O between|O 1979|O and|O 1991|O and|O studied|O to|O determine|O the|O relative|O prognostic|O value|O of|O a|O number|O of|O clinical|O ,|O histologic|O ,|O nuclear|O ,|O and|O oncogenic|O features|O .|O 
The|O features|O studied|O were|O :|O stage|O ,|O Shimada|O classification|O ,|O DNA|O ploidy|O ,|O MIB-1|gene-protein -|O proliferation|O index|O and|O status|O for|O HER-2|gene-protein /|O neu|gene-protein ,|O p53|gene-protein and|O epidermal|gene-protein growth|gene-protein factor|gene-protein receptor|gene-protein (|O EGFr|gene-protein )|O .|O Only|O age|O (|O P|O =|O .03|O )|O ,|O HER-2|gene-protein /|O neu|gene-protein (|O P|O =|O .01|O )|O ,|O and|O p53|gene-protein (|O P|O =|O .02|O )|O reached|O statistical|O significance|O as|O prognostic|O indicators|O .|O 
The|O median|O survival|O for|O patients|O with|O HER-2|gene-protein /|O neu|gene-protein expression|O was|O 12|O months|O ;|O median|O survival|O for|O patients|O with|O no|O HER-2|gene-protein /|O neu|gene-protein expression|O was|O 138|O months|O .|O 
Similarly|O ,|O the|O median|O survival|O for|O patients|O with|O p53|gene-protein expression|O was|O 12|O months|O ;|O patients|O with|O no|O p53|gene-protein expression|O had|O a|O median|O survival|O was|O 144|O months|O .|O 
The|O combination|O of|O either|O HER-2|gene-protein /|O neu|gene-protein or|O p53|gene-protein positivity|O was|O especially|O strong|O as|O a|O prognostic|O indicator|O (|O P|O =|O .002|O )|O .|O 
MYCN|gene-rna gene|O amplification|O in|O rhabdomyosarcoma|O .|O 
BACKGROUND|O .|O 
Amplification|O of|O the|O MYCN|gene-rna oncogene|O ,|O formerly|O known|O as|O N-myc|gene-rna ,|O has|O been|O seen|O in|O several|O malignant|O tumors|O ,|O particularly|O neuroblastoma|O ,|O where|O its|O association|O with|O a|O poor|O clinical|O outcome|O is|O the|O clearest|O example|O of|O a|O clinically|O relevant|O oncogene|O mutation|O in|O any|O human|O cancer|O .|O 
METHODS|O .|O 
The|O incidence|O and|O clinical|O significance|O of|O MYCN|gene-rna amplification|O in|O rhabdomyosarcoma|O (|O RMS|O )|O was|O assessed|O by|O Southern|O blot|O analysis|O in|O this|O retrospective|O study|O of|O seven|O alveolar|O RMS|O and|O six|O embryonal|O RMS|O .|O 
RESULTS|O .|O 
MYCN|gene-rna amplification|O (|O 4|O -|O to|O 13|O -|O fold|O )|O was|O present|O in|O three|O of|O seven|O alveolar|O RMS|O (|O 42.9|O %|O )|O but|O in|O none|O of|O the|O embryonal|O RMS|O .|O 
There|O was|O no|O significant|O difference|O between|O the|O clinical|O behavior|O of|O the|O MYCN|gene-rna -|O amplified|O and|O unamplified|O tumors|O ,|O and|O no|O correlation|O was|O found|O with|O the|O light|O microscopic|O appearances|O of|O the|O tumors|O or|O with|O desmin|gene-protein immunoreactivity|O .|O 
CONCLUSIONS|O .|O 
The|O findings|O are|O compatible|O with|O previous|O studies|O that|O demonstrated|O cytogenetic|O evidence|O of|O gene|O amplification|O in|O RMS|O ,|O and|O help|O to|O clarify|O conflicting|O reports|O in|O the|O literature|O about|O MYCN|gene-rna amplification|O in|O alveolar|O and|O embryonal|O RMS|O .|O 
The|O results|O raise|O the|O possibility|O of|O important|O biologic|O differences|O between|O these|O subtypes|O of|O RMS|O ,|O differences|O that|O warrant|O further|O investigation|O .|O 
Expression|O of|O endothelin|gene-protein -|gene-protein converting|gene-protein enzyme|gene-protein in|O both|O neuroblastoma|O and|O glial|O cell|O lines|O and|O its|O localization|O in|O rat|O hippocampus|O .|O 
Endothelin|gene-protein -|gene-protein converting|gene-protein enzyme|gene-protein is|O a|O phosphoramidon|O -|O sensitive|O metalloprotease|gene-protein that|O cleaves|O big|O endothelin|gene-protein to|O the|O potent|O vasoconstrictor|O peptide|O ,|O endothelin|gene-protein .|O 
The|O converting|gene-protein enzyme|gene-protein is|O expressed|O in|O endothelial|O cells|O in|O a|O variety|O of|O tissues|O and|O in|O some|O secretory|O cells|O .|O 
In|O the|O present|O study|O ,|O phosphoramidon|gene-protein -|O sensitive|O endothelin|gene-protein -|gene-protein converting|gene-protein enzyme|gene-protein activity|O has|O been|O demonstrated|O by|O radioimmunoassay|O in|O the|O neuroblastoma|O cell|O line|O ,|O SH-SY5Y|O ,|O and|O in|O Bu17|O and|O C6|O glioma|O lines|O .|O 
The|O identity|O of|O the|O activity|O was|O confirmed|O by|O immunoblotting|O ,|O revealing|O a|O polypeptide|O of|O approximately|O 120|O kDa|O in|O each|O of|O these|O lines|O ,|O in|O D384|O glioma|O cells|O ,|O and|O in|O primary|O astrocytes|O .|O 
Immunofluorescence|O revealed|O the|O cell|O -|O surface|O location|O of|O endothelin|gene-protein -|gene-protein converting|gene-protein enzyme|gene-protein in|O the|O neuronal|O and|O glial|O cell|O lines|O and|O in|O primary|O astrocytes|O .|O 
Pretreatment|O of|O SH-SY5Y|O and|O Bu17|O cells|O with|O phosphoramidon|O resulted|O in|O an|O apparent|O concentration|O of|O the|O enzyme|O protein|O in|O an|O intracellular|O compartment|O .|O 
Immunoperoxidase|gene-protein -|O staining|O of|O rat|O brain|O sections|O located|O this|O metalloprotease|gene-protein to|O the|O pyramidal|O cells|O of|O the|O hippocampus|O .|O 
Endothelin|gene-protein -|gene-protein converting|gene-protein enzyme|gene-protein -|gene-protein 1|gene-protein was|O revealed|O by|O in|O situ|O hybridisation|O in|O the|O neuronal|O and|O glial|O cell|O lines|O .|O 
Expression|O of|O the|O human|O Achaete|gene-rna -|gene-rna scute|gene-rna 1|gene-rna gene|O in|O olfactory|O neuroblastoma|O (|O esthesioneuroblastoma|O )|O .|O 
Olfactory|O neuroblastoma|O (|O ONB|O )|O is|O a|O rare|O neuronal|O malignancy|O of|O the|O olfactory|O mucosal|O .|O 
Markers|O used|O in|O the|O diagnosis|O of|O ONB|O do|O not|O distinguish|O ONB|O from|O other|O neuronal|O tumors|O or|O tumors|O with|O neuroendocrine|O features|O thus|O making|O the|O diagnosis|O of|O ONB|O difficult|O .|O 
Using|O a|O modified|O RT|O -|O PCR|O technique|O ,|O we|O show|O that|O the|O human|O homologue|O of|O the|O Drosophila|O achaete|gene-rna -|gene-rna scute|gene-rna gene|O HASH1|gene-rna is|O expressed|O in|O 6|O primary|O and|O one|O metastatic|O ONB|O specimens|O ,|O whereas|O Olfactory|gene-protein Marker|gene-protein Protein|gene-protein (|O OMP|gene-protein )|O is|O not|O .|O 
Previous|O studies|O have|O shown|O that|O HASH1|gene-rna is|O expressed|O in|O immature|O olfactory|O neurons|O and|O is|O required|O for|O their|O development|O .|O 
OMP|gene-protein ,|O whose|O function|O is|O unknown|O ,|O is|O expressed|O exclusively|O in|O mature|O olfactory|O neurons|O .|O 
Together|O ,|O these|O data|O suggest|O that|O ONB|O is|O derived|O from|O immature|O olfactory|O neurons|O of|O neuroectodermal|O origin|O .|O 
Analysis|O of|O RNA|O expression|O in|O primary|O tumor|O specimens|O and|O in|O an|O established|O cell|O line|O make|O this|O an|O ideal|O system|O to|O study|O olfactory|O growth|O and|O differentiation|O .|O 
Furthermore|O ,|O these|O studies|O represent|O the|O first|O molecular|O genetic|O analysis|O of|O this|O rare|O and|O unusual|O neuronal|O tumor|O .|O 
Survival|gene-protein motor|gene-protein neuron|gene-protein protein|O in|O the|O nucleolus|O of|O mammalian|O neurons|O .|O 
Spinal|O muscular|O atrophy|O (|O SMA|O )|O is|O an|O inherited|O motor|O neuron|O disease|O caused|O by|O mutations|O in|O the|O survival|gene-rna motor|gene-rna neuron|gene-rna gene|O (|O SMN1|gene-rna )|O .|O 
While|O it|O has|O been|O shown|O that|O the|O SMN|gene-protein protein|O is|O involved|O in|O spliceosome|O biogenesis|O and|O pre|O -|O mRNA|O splicing|O ,|O there|O is|O increasing|O evidence|O indicating|O that|O SMN|gene-protein may|O also|O perform|O important|O functions|O in|O the|O nucleolus|O .|O 
We|O demonstrate|O here|O through|O the|O use|O of|O a|O previously|O characterized|O polyclonal|O anti|gene-protein -|gene-protein SMN|gene-protein antibody|gene-protein ,|O abSMN|gene-protein ,|O that|O the|O SMN|gene-protein protein|O shows|O a|O striking|O colocalization|O with|O the|O nucleolar|O protein|O ,|O fibrillarin|gene-protein ,|O in|O both|O nucleoli|O and|O Cajal|O bodies|O /|O gems|O of|O primary|O neurons|O .|O 
Immunoblot|O analysis|O with|O antifibrillarin|gene-protein and|O two|O different|O anti|gene-protein -|gene-protein SMN|gene-protein antibodies|gene-protein reveals|O that|O SMN|gene-protein and|O fibrillarin|gene-protein also|O cofractionate|O in|O the|O insoluble|O protein|O fraction|O of|O cultured|O cell|O lysates|O .|O 
Immunoprecipitation|O experiments|O using|O whole|O cell|O extracts|O of|O HeLa|O cells|O and|O cultured|O neurons|O revealed|O that|O abSMN|gene-protein coprecipitated|O small|O amounts|O of|O the|O U3|gene-rna small|gene-rna nucleolar|gene-rna RNA|gene-rna (|O snoRNA|gene-rna )|O previously|O shown|O to|O be|O associated|O with|O fibrillarin|gene-protein in|O vivo|O .|O 
These|O studies|O raise|O the|O possibility|O that|O SMN|gene-protein may|O serve|O a|O function|O in|O rRNA|O maturation|O /|O ribosome|O synthesis|O similar|O to|O its|O role|O in|O spliceosome|O biogenesis|O .|O 
Ganglioglioma|O in|O children|O .|O 
A|O review|O of|O 32|O cases|O at|O the|O University|O of|O Florida|O .|O 
The|O entity|O ganglioglioma|O in|O children|O seems|O to|O be|O an|O increasingly|O more|O common|O tumor|O .|O 
Most|O of|O these|O lesions|O are|O pathologically|O and|O clinically|O benign|O but|O have|O a|O pathological|O and|O clinical|O continuum|O in|O their|O behavior|O .|O 
Gross|O total|O resection|O ,|O especially|O involving|O the|O lesions|O in|O the|O supratentorial|O compartment|O ,|O is|O often|O curative|O .|O 
The|O most|O common|O symptom|O ,|O seizures|O ,|O in|O this|O group|O of|O lesions|O ,|O can|O often|O be|O alleviated|O with|O removal|O of|O the|O tumor|O .|O 
This|O may|O be|O enhanced|O with|O the|O use|O of|O corticography|O at|O the|O initial|O surgery|O .|O 
The|O group|O of|O lesions|O located|O in|O the|O brainstem|O are|O more|O difficult|O to|O control|O and|O may|O require|O multiple|O operations|O and|O other|O therapies|O including|O radiation|O and|O chemotherapy|O for|O optimum|O outcome|O .|O 
Malignant|O lesions|O in|O the|O ganglioglioma|O series|O are|O rare|O and|O optimum|O therapy|O for|O these|O tumors|O is|O not|O well|O defined|O at|O this|O time|O .|O 
Pathologically|O ,|O this|O group|O of|O tumors|O needs|O better|O definition|O for|O designing|O the|O best|O therapy|O .|O 
We|O are|O planning|O a|O survey|O both|O retrospectively|O and|O prospectively|O with|O flow|O cytometry|O and|O the|O use|O of|O various|O makers|O such|O as|O the|O K167|gene-protein proliferation|gene-protein antigen|gene-protein to|O better|O define|O potential|O biological|O behavior|O .|O 
Clearly|O ,|O a|O broader|O discussion|O with|O the|O patient|O and|O family|O is|O indicated|O when|O one|O of|O these|O tumors|O is|O discovered|O and|O operated|O .|O 
Inverse|O correlation|O between|O expression|O of|O multidrug|gene-rna resistance|gene-rna gene|O and|O N-myc|gene-rna oncogene|O in|O human|O neuroblastomas|O .|O 
Genomic|O amplification|O of|O N-myc|gene-rna is|O an|O important|O prognostic|O indicator|O in|O neuroblastoma|O .|O 
The|O tumors|O with|O amplified|O N-myc|gene-rna are|O initially|O sensitive|O to|O chemotherapy|O but|O often|O acquire|O resistance|O to|O therapy|O ,|O recur|O ,|O and|O ultimately|O kill|O the|O patients|O .|O 
We|O measured|O amplification|O and|O expression|O of|O N-myc|gene-rna and|O expression|O of|O mdr-1|gene-rna in|O 35|O surgically|O resected|O neuroblastomas|O ,|O before|O acquisition|O of|O drug|O resistance|O and|O in|O 4|O recurrent|O tumors|O resistant|O to|O chemotherapy|O .|O 
The|O mdr-1|gene-rna mRNA|O expression|O was|O found|O to|O be|O inversely|O correlated|O with|O the|O N-myc|gene-rna expression|O .|O 
The|O mdr-1|gene-rna gene|O expression|O was|O at|O a|O low|O level|O in|O advanced|O stage|O and|O histologically|O undifferentiated|O neuroblastomas|O ,|O the|O same|O group|O of|O tumors|O in|O which|O N-myc|gene-rna expression|O is|O elevated|O .|O 
A|O significantly|O better|O prognosis|O was|O noted|O in|O those|O patients|O whose|O tumors|O had|O a|O high|O level|O of|O mdr-1|gene-rna expression|O and|O a|O low|O level|O of|O N-myc|gene-rna expression|O .|O 
The|O role|O ,|O if|O any|O ,|O of|O increased|O expression|O of|O mdr-1|gene-rna in|O the|O acquisition|O of|O multidrug|O resistance|O in|O neuroblastoma|O remains|O unclear|O .|O 
However|O ,|O the|O aggressive|O clinical|O behavior|O associated|O with|O N-myc|gene-rna amplification|O and/or|O expression|O appears|O to|O be|O linked|O to|O down|O -|O regulation|O of|O mdr-1|gene-rna expression|O .|O 
Enhancement|O of|O B-MYB|gene-protein transcriptional|O activity|O by|O ZPR9|gene-protein ,|O a|O novel|O zinc|gene-protein finger|gene-protein protein|gene-protein .|O 
By|O using|O the|O yeast|O two|O -|O hybrid|O system|O ,|O the|O zinc|gene-protein finger|gene-protein protein|gene-protein ZPR9|gene-protein was|O identified|O as|O one|O of|O the|O B-MYB|gene-protein interacting|O proteins|O that|O associates|O with|O the|O carboxyl|O -|O terminal|O conserved|O region|O of|O B-MYB|gene-protein .|O 
ZPR9|gene-protein was|O found|O to|O form|O in|O vivo|O complexes|O with|O B-MYB|gene-protein ,|O as|O demonstrated|O by|O in|O vivo|O binding|O assay|O and|O coimmunoprecipitation|O experiments|O of|O the|O endogenously|O and|O exogenously|O expressed|O proteins|O .|O 
Deletion|O analysis|O revealed|O that|O this|O binding|O was|O mediated|O by|O all|O three|O functional|O domains|O ,|O an|O amino|O -|O terminal|O DNA|O -|O binding|O domain|O ,|O a|O transactivation|O domain|O ,|O and|O a|O carboxyl|O -|O terminal|O conserved|O region|O of|O B-MYB|gene-protein .|O 
We|O show|O that|O the|O interaction|O of|O ZPR9|gene-protein with|O B-MYB|gene-protein is|O functional|O because|O cotransfection|O of|O ZPR9|gene-protein significantly|O up|O -|O regulates|O B-MYB|gene-protein transcriptional|O activity|O in|O a|O dose|O -|O dependent|O manner|O .|O 
In|O addition|O ,|O coexpression|O of|O ZPR9|gene-protein with|O B-MYB|gene-protein caused|O the|O accumulation|O of|O B-MYB|gene-protein ,|O as|O well|O as|O ZPR9|gene-protein ,|O in|O the|O nucleus|O .|O 
Furthermore|O ,|O constitutive|O expression|O of|O ZPR9|gene-protein in|O human|O neuroblastoma|O cells|O induces|O apoptosis|O in|O the|O presence|O of|O retinoic|O acid|O .|O 
These|O results|O strongly|O suggest|O that|O ZPR9|gene-protein plays|O an|O important|O role|O in|O modulation|O of|O the|O transactivation|O by|O B-MYB|gene-protein and|O cellular|O growth|O of|O neuroblastoma|O cells|O .|O 
Signalling|O pathways|O for|O insulin|gene-protein -|gene-protein like|gene-protein growth|gene-protein factor|gene-protein type|gene-protein 1|gene-protein -|O mediated|O expression|O of|O uncoupling|gene-protein protein|gene-protein 3|gene-protein .|O 
Uncoupling|gene-protein protein|gene-protein 3|gene-protein (|O UCP3|gene-protein )|O is|O a|O mitochondrial|O protein|O with|O antioxidant|O properties|O and|O its|O regulation|O by|O factors|O promoting|O cell|O -|O survival|O may|O be|O important|O for|O protection|O of|O ,|O for|O instance|O ,|O neurons|O in|O states|O of|O oxidative|O stress|O .|O 
In|O the|O present|O study|O ,|O we|O investigated|O regulatory|O pathways|O for|O UCP3|gene-protein expression|O mediated|O by|O the|O neuroprotective|O hormone|O insulin|gene-protein -|gene-protein like|gene-protein growth|gene-protein factor|gene-protein type|gene-protein 1|gene-protein (|O IGF-1|gene-protein )|O in|O human|O neuroblastoma|O SH-SY5Y|O cells|O .|O 
Northern|O blot|O analysis|O and|O RT|O -|O PCR|O showed|O that|O treatment|O with|O 10|O nm|O IGF-1|gene-protein increased|O the|O UCP3|gene-rna mRNA|O levels|O 2.5|O -|O fold|O after|O 5|O h|O .|O 
Co|O -|O incubation|O with|O the|O phosphatidylinositol|gene-protein 3|gene-protein (|gene-protein PI3|gene-protein )|gene-protein -|gene-protein kinase|gene-protein inhibitor|O LY294002|O prohibited|O IGF-1|gene-protein -|O mediated|O induction|O of|O both|O UCP3|gene-rna mRNA|O and|O protein|O in|O a|O concentration|O -|O dependent|O manner|O ,|O with|O a|O complete|O blockage|O at|O 1|O microm|O ,|O as|O shown|O by|O RT|O -|O PCR|O and|O western|O blot|O analyses|O .|O 
The|O mitogen|gene-protein -|gene-protein activated|gene-protein protein|gene-protein (|gene-protein MAP|gene-protein )|gene-protein kinase|gene-protein kinase|gene-protein 1|gene-protein (|O MKK1|gene-protein or|O MEK|gene-protein )|O inhibitor|O PD98059|O also|O decreased|O the|O UCP3|gene-rna mRNA|O expression|O at|O 10|O microm|O ,|O however|O ,|O this|O concentration|O only|O partly|O inhibited|O the|O protein|O expression|O .|O 
We|O conclude|O that|O IGF-1|gene-protein enhanced|O UCP3|gene-protein expression|O at|O transcriptional|O level|O ,|O primarily|O through|O the|O PI3|gene-protein -|gene-protein kinase|gene-protein -|O dependent|O pathway|O and|O partly|O through|O the|O MAP|gene-protein kinase|gene-protein pathway|O .|O 
Synergism|O of|O buthionine|O sulfoximine|O and|O melphalan|O against|O neuroblastoma|O cell|O lines|O derived|O after|O disease|O progression|O .|O 
BACKGROUND|O :|O 
Despite|O intensive|O -|O alkylator|O based|O regimens|O ,|O >|O 50|O %|O of|O patients|O with|O high|O -|O risk|O neuroblastoma|O (|O NB|O )|O die|O from|O recurrent|O disease|O that|O is|O probably|O due|O ,|O in|O part|O ,|O to|O acquired|O alkylator|O resistance|O .|O 
PROCEDURE|O :|O 
Using|O buthionine|O sulfoximine|O (|O BSO|O )|O -|O mediated|O ,|O glutathione|O (|O GSH|O )|O depletion|O to|O modulate|O melphalan|O (|O L-PAM|O )|O resistance|O ,|O we|O examined|O six|O NB|O cell|O lines|O established|O after|O progressive|O disease|O following|O either|O standard|O chemotherapy|O ,|O BSO|O /|O L-PAM|O therapy|O ,|O or|O myeloablative|O therapy|O and|O autologous|O hematopoietic|O stem|O cell|O transplant|O (|O AHSCT|O )|O .|O 
RESULTS|O :|O 
Four|O of|O the|O six|O cell|O lines|O (|O three|O p53|gene-generic -|O nonfunctional|O and|O one|O p53|gene-generic -|O functional|O )|O showed|O high|O -|O level|O L-PAM|O resistance|O .|O 
CONCLUSIONS|O :|O 
Fixed|O ratio|O analysis|O demonstrated|O BSO|O /|O L-PAM|O synergy|O (|O combination|O index|O >|O 1|O )|O for|O all|O cell|O lines|O tested|O .|O 
In|O L-PAM|O -|O resistant|O cell|O lines|O ,|O the|O minimal|O cytotoxicity|O observed|O for|O BSO|O combined|O with|O nonmyeloablative|O concentrations|O of|O L-PAM|O was|O markedly|O enhanced|O (|O >|O 4|O logs|O total|O cell|O kill|O )|O when|O BSO|O was|O combined|O with|O myeloablative|O concentrations|O of|O L-PAM|O .|O In|O alkylator|O -|O resistant|O NB|O ,|O the|O optimal|O use|O of|O BSO|O may|O require|O dose|O escalation|O of|O L-PAM|O to|O levels|O requiring|O AHSCT|O .|O 
Multi|O -|O modality|O megatherapy|O with|O [131I]meta-iodobenzylguanidine|O ,|O high|O dose|O melphalan|O and|O total|O body|O irradiation|O with|O bone|O marrow|O rescue|O :|O feasibility|O study|O of|O a|O new|O strategy|O for|O advanced|O neuroblastoma|O .|O 
New|O therapeutic|O approaches|O are|O needed|O for|O advanced|O neuroblastoma|O as|O few|O patients|O are|O currently|O curable|O .|O 
We|O describe|O an|O innovative|O strategy|O combining|O [131I]meta-iodobenzylguanidine|O (|O [131I]mIBG|O )|O therapy|O with|O high|O dose|O chemotherapy|O and|O total|O body|O irradiation|O .|O 
The|O aim|O of|O combining|O these|O treatments|O is|O to|O overcome|O the|O specific|O limitations|O of|O each|O when|O used|O alone|O to|O maximise|O killing|O of|O neuroblastoma|O cells|O .|O 
Five|O children|O received|O combined|O therapy|O with|O [131I]mIBG|O followed|O by|O high|O dose|O melphalan|O and|O fractionated|O total|O body|O irradiation|O .|O 
Autologous|O bone|O marrow|O transplantation|O was|O undertaken|O in|O 3|O patients|O and|O allogeneic|O in|O 2|O patients|O .|O 
One|O patient|O received|O additional|O localised|O radiotherapy|O to|O residual|O bulk|O disease|O .|O 
One|O patient|O is|O alive|O without|O relapse|O 32|O months|O after|O treatment|O .|O 
4|O patients|O relapsed|O after|O remissions|O of|O 9|O ,|O 10|O ,|O 14|O and|O 21|O months|O .|O 
These|O results|O indicate|O that|O this|O combined|O modality|O approach|O is|O feasible|O and|O safe|O ,|O but|O further|O evaluation|O is|O necessary|O to|O establish|O whether|O it|O has|O advantages|O over|O conventional|O megatherapy|O using|O melphalan|O alone|O .|O 
Mu|O and|O delta|O opioids|O but|O not|O kappa|O opioid|O inhibit|O voltage|O -|O activated|O Ba2+|O currents|O in|O neuronal|O F-11|O cell|O .|O 
Whole|O -|O cell|O patch|O -|O clamp|O recordings|O were|O used|O to|O study|O Ba2+|O currents|O through|O voltage|O -|O dependent|O Ca2+|O channels|O in|O dorsal|O root|O ganglion|O x|O mouse|O neuroblastoma|O hybrid|O (|O F-11|O )|O cells|O .|O 
Opioid|O agonists|O selective|O for|O either|O mu|gene-protein (|O Tyr-D-Ala-Gly-Mephe-Gly-ol|O ;|O DAMGO|gene-protein )|O or|O delta|gene-protein (|O Tyr-D-Pen-Gly-Phe-D-Pen-OH|O ;|O DPDPE|gene-protein )|O receptors|gene-protein inhibited|O high|O -|O threshold|O Ba2+|O currents|O .|O 
The|O inhibition|O was|O reversible|O ,|O naloxone|O -|O sensitive|O ,|O and|O dose|O -|O dependent|O .|O 
The|O inhibitory|O effects|O of|O both|O DAMGO|gene-protein and|O DPDPE|gene-protein were|O blocked|O by|O pretreatment|O of|O the|O cells|O with|O pertussis|gene-protein toxin|gene-protein (|O PTX|gene-protein )|O as|O well|O as|O by|O brief|O exposure|O to|O the|O sulfhydryl|O alkylating|O agent|O ,|O N-ethylmaleimide|O (|O NEM|O )|O .|O 
The|O N|O -|O type|O Ca2+|O channel|O antagonist|O omega-conotoxin|gene-protein GVIA|gene-protein (|O omega-CTX|gene-protein GVIA|gene-protein )|O irreversibly|O inhibited|O high|O threshold|O Ba2+|O currents|O by|O 66|O %|O and|O blocked|O the|O inhibitory|O effect|O of|O DAMGO|gene-protein or|O DPDPE|gene-protein .|O 
In|O contrast|O ,|O the|O L|O -|O type|O Ca2+|O channel|O blocker|O nifedipine|O inhibited|O high|O threshold|O Ba2+|O currents|O by|O 15|O %|O and|O failed|O to|O block|O the|O inhibitory|O effect|O of|O DAMGO|gene-protein or|O DPDPE|gene-protein .|O 
These|O results|O demonstrate|O that|O mu|gene-protein and|O delta|gene-protein opioid|gene-protein receptors|gene-protein are|O negatively|O coupled|O to|O N|O -|O type|O Ca2+|O channels|O via|O PTX|gene-protein -|O and|O NEM|O -|O sensitive|O GTP|gene-protein -|gene-protein binding|gene-protein proteins|gene-protein in|O F-11|O cells|O .|O 
A|O novel|O method|O of|O generating|O neuronal|O cell|O lines|O from|O gene|O -|O knockout|O mice|O to|O study|O prion|gene-protein protein|O membrane|O orientation|O .|O 
The|O technology|O of|O gene|O knockout|O and|O transgenic|O mice|O has|O allowed|O the|O study|O of|O the|O role|O of|O genes|O and|O their|O proteins|O in|O animal|O physiology|O and|O metabolism|O .|O 
However|O ,|O these|O techniques|O have|O often|O been|O found|O to|O be|O limited|O in|O that|O some|O genetic|O manipulations|O of|O mice|O led|O either|O to|O a|O fatal|O phenotype|O or|O to|O compensations|O that|O mask|O the|O loss|O of|O function|O of|O the|O target|O protein|O .|O 
The|O experimentation|O on|O neurons|O from|O transgenic|O mice|O is|O particularly|O critical|O in|O the|O study|O of|O key|O proteins|O that|O may|O be|O involved|O in|O neurodegeneration|O .|O 
The|O cell|O fusion|O technique|O has|O been|O implemented|O as|O a|O novel|O way|O to|O generate|O cell|O lines|O from|O prion|gene-protein protein|O knockout|O mice|O .|O 
Fusion|O between|O neonatal|O mouse|O neurons|O and|O a|O neuroblastoma|O cell|O line|O have|O led|O to|O a|O Prnp|O degrees|O /|O degrees|O cell|O line|O that|O facilitates|O the|O study|O of|O the|O knockout|O phenotype|O .|O 
These|O cells|O are|O readily|O transfectable|O and|O allowed|O us|O to|O study|O the|O expression|O of|O prion|gene-protein protein|O mutants|O on|O a|O PrP|gene-protein -|O knockout|O background|O .|O 
Using|O this|O cell|O line|O we|O have|O examined|O the|O effect|O of|O PrP|gene-protein mutations|O reported|O to|O alter|O PrPc|gene-protein to|O a|O transmembrane|O form|O .|O 
Our|O results|O suggest|O that|O these|O mutations|O do|O not|O create|O transmembrane|O forms|O of|O the|O protein|O ,|O but|O block|O normal|O transport|O of|O PrP|gene-protein to|O the|O cell|O membrane|O .|O 
The|O effects|O of|O gamma|gene-protein interferon|gene-protein on|O the|O natural|O killer|O and|O tumor|O cells|O of|O children|O with|O neuroblastoma|O .|O 
A|O preliminary|O report|O .|O 
Human|O neuroblastoma|O cells|O lack|O HLA|gene-protein -|gene-protein A|gene-protein ,|O -|gene-protein B|gene-protein ,|O -|gene-protein C|gene-protein molecules|O which|O can|O be|O induced|O in|O vitro|O by|O gamma|gene-protein interferon|gene-protein (|O gamma|gene-protein IFN|gene-protein )|O .|O 
To|O test|O the|O hypothesis|O that|O the|O same|O induction|O would|O occur|O in|O vivo|O leading|O to|O tumor|O regression|O ,|O a|O Phase|O I|O study|O was|O initiated|O .|O 
Seven|O patients|O with|O neuroblastoma|O were|O entered|O on|O a|O Phase|O I|O study|O of|O recombinant|O gamma|gene-protein IFN|gene-protein in|O children|O .|O 
Three|O received|O 0.05|O mg|O /|O m2|O intravenously|O (|O IV|O )|O three|O times|O a|O week|O ,|O three|O received|O 0.1|O mg|O /|O m2|O for|O 4|O weeks|O ,|O and|O one|O patient|O withdrew|O from|O study|O before|O receiving|O adequate|O treatment|O for|O evaluation|O .|O 
No|O significant|O clinical|O response|O was|O seen|O .|O 
The|O side|O effects|O were|O fever|O and|O chills|O ,|O and|O no|O serious|O toxicity|O occurred|O .|O 
Natural|O killer|O (|O NK|O )|O and|O lymphocyte|O activated|O killer|O (|O LAK|O )|O precursor|O activity|O of|O peripheral|O blood|O mononuclear|O cells|O was|O determined|O before|O and|O during|O treatment|O ,|O and|O expression|O of|O HLA|gene-protein -|gene-protein A|gene-protein ,|O B|gene-protein ,|O C|gene-protein molecules|O was|O looked|O for|O on|O the|O tumor|O cells|O in|O the|O bone|O marrow|O of|O five|O patients|O .|O 
The|O NK|O activity|O initially|O low|O ,|O reached|O control|O levels|O in|O six|O patients|O ,|O but|O the|O increase|O was|O transient|O .|O 
The|O LAK|O precursor|O activity|O remained|O normal|O .|O 
Expression|O of|O HLA|gene-protein -|gene-protein A|gene-protein ,|O B|gene-protein ,|O C|gene-protein ,|O initially|O absent|O ,|O was|O induced|O on|O the|O neuroblastoma|O cells|O in|O four|O of|O six|O patients|O .|O 
Cerebellar|gene-protein degeneration|gene-protein -|gene-protein related|gene-protein antigen|gene-protein :|O a|O highly|O conserved|O neuroectodermal|O marker|O mapped|O to|O chromosomes|O X|O in|O human|O and|O mouse|O .|O 
Cerebellar|gene-protein degeneration|gene-protein -|gene-protein related|gene-protein antigen|gene-protein (|O designated|O CDR34|gene-protein )|O was|O previously|O cloned|O by|O antibody|O screening|O of|O a|O cDNA|O library|O and|O was|O shown|O to|O be|O one|O of|O the|O target|O molecules|O recognized|O by|O autoantibodies|gene-protein in|O patients|O with|O paraneoplastic|O cerebellar|O degeneration|O .|O 
This|O molecule|O is|O distinctive|O in|O that|O it|O contains|O a|O tandem|O hexapeptide|O repetitive|O structure|O ,|O presumably|O the|O basis|O for|O its|O high|O immunogenicity|O .|O 
In|O this|O study|O ,|O we|O cloned|O the|O human|O CDR34|gene-rna gene|O and|O proved|O that|O the|O entire|O repetitive|O sequence|O is|O encoded|O by|O a|O single|O exon|O without|O introns|O .|O 
We|O also|O showed|O that|O the|O nucleotide|O repeats|O are|O preserved|O only|O in|O the|O protein|O -|O coding|O sequences|O ,|O suggesting|O evolutionary|O constraint|O in|O this|O region|O of|O the|O gene|O .|O 
Corresponding|O mouse|O cDNA|O clones|O were|O also|O isolated|O ,|O which|O encoded|O a|O larger|O molecule|O with|O very|O similar|O hexapeptide|O repeating|O units|O .|O 
Comparison|O of|O the|O human|O and|O mouse|O repeats|O revealed|O a|O highly|O conserved|O Glu|O -|O Asp|O core|O in|O each|O unit|O ,|O implicating|O the|O functional|O significance|O of|O this|O motif|O .|O 
Chromosomal|O mapping|O by|O somatic|O cell|O hybrid|O analysis|O mapped|O CDR34|gene-rna to|O both|O human|O and|O mouse|O chromosomes|O X|O ,|O and|O in|O situ|O hybridization|O further|O assigned|O CDR34|gene-rna to|O human|O X|O q24|O -|O q27|O .|O 
Inhibitors|O of|O endocytosis|O perturb|O phospholipid|O metabolism|O in|O rabbit|O neutrophils|O and|O other|O cells|O .|O 
Dansylcadaverine|O ,|O amantadine|O ,|O and|O rimantadine|O ,|O which|O have|O been|O shown|O to|O inhibit|O the|O endocytosis|O of|O alpha|gene-protein 2-macroglobulin|gene-protein ,|O epidermal|gene-protein growth|gene-protein factor|gene-protein ,|O and|O vesicular|O stomatitis|O virus|O [|O Schlegel|O ,|O R.|O ,|O Dickson|O ,|O R.|O B.|O ,|O Willingham|O ,|O M.|O C.|O &|O Pastan|O ,|O I.|O (|O 1982|O )|O Proc.|O Natl.|O Acad.|O Sci.|O USA|O 79|O ,|O 2291|O -|O 2295|O ]|O ,|O were|O found|O to|O decrease|O phosphatidylcholine|O synthesis|O ,|O chemotaxis|O ,|O and|O internalization|O of|O a|O formylated|O peptide|O but|O to|O stimulate|O the|O incorporation|O of|O inositol|O into|O phosphatidylinositol|O in|O rabbit|O neutrophils|O .|O 
Dansylcadaverine|O decreased|O phosphatidylcholine|O synthesis|O by|O both|O the|O CDP|O -|O choline|O and|O transmethylation|O pathways|O and|O also|O inhibited|O the|O synthesis|O of|O phosphatidylethanolamine|O by|O the|O CDP|O -|O ethanolamine|O pathway|O .|O 
Dansylcadaverine|O had|O no|O effect|O on|O the|O phosphocholine|O ,|O CDP|O -|O choline|O ,|O or|O S-adenosyl-L-homocysteine|O pools|O but|O increased|O 2|O -|O fold|O the|O S-adenosyl-L-methionine|O pool|O .|O 
These|O results|O suggest|O that|O dansylcadaverine|O in|O some|O manner|O inhibited|O the|O condensation|O of|O CDP|O -|O choline|O with|O diacylglycerol|O to|O form|O phosphatidylcholine|O .|O 
Dansylcadaverine|O also|O inhibited|O phosphatidylcholine|O synthesis|O in|O human|O neutrophils|O ,|O human|O fibroblasts|O ,|O chicken|O embryo|O fibroblasts|O ,|O rat|O hepatocytes|O ,|O osteosarcoma|O cells|O ,|O and|O neuroblastoma|O cells|O .|O 
It|O did|O not|O stimulate|O phosphatidylinositol|O synthesis|O in|O chicken|O embryo|O fibroblasts|O .|O 
The|O expression|O of|O the|O developmentally|O regulated|O proto|O -|O oncogene|O Pax-3|gene-rna is|O modulated|O by|O N-Myc|gene-rna .|O 
N-Myc|gene-generic is|O a|O member|O of|O the|O Myc|gene-generic family|O of|O transcription|O factors|O that|O have|O been|O shown|O to|O play|O a|O pivotal|O role|O in|O cell|O proliferation|O and|O differentiation|O .|O 
In|O this|O report|O ,|O we|O have|O investigated|O the|O relationship|O between|O N-Myc|gene-generic and|O the|O developmental|O control|O gene|O Pax-3|gene-rna .|O 
Using|O transient|O transfection|O assays|O ,|O we|O show|O that|O the|O Pax-3|gene-rna promoter|O is|O activated|O by|O both|O N-Myc-Max|gene-generic and|O c-Myc-Max|gene-generic .|O 
Moreover|O ,|O we|O show|O that|O Myc|gene-generic regulation|O of|O Pax-3|gene-rna promoter|O activity|O is|O dependent|O upon|O a|O noncanonical|O E|O box|O site|O in|O the|O 5|O '|O promoter|O region|O of|O Pax-3|gene-rna .|O 
In|O addition|O ,|O we|O show|O that|O ectopic|O expression|O of|O both|O N-Myc|gene-generic and|O c-Myc|gene-generic leads|O to|O increased|O expression|O of|O Pax-3|gene-rna mRNA|O .|O 
Furthermore|O ,|O we|O show|O that|O Pax-3|gene-rna mRNA|O expression|O is|O cell|O cycle|O -|O regulated|O and|O that|O the|O 5|O '|O promoter|O region|O of|O Pax-3|gene-rna (|O bp|O -|O 1578|O to|O +|O 56|O )|O can|O direct|O cell|O cycle|O -|O dependent|O gene|O expression|O with|O kinetics|O similar|O to|O that|O of|O the|O endogenous|O transcript|O .|O 
Site|O -|O directed|O mutagenesis|O of|O the|O E|O box|O site|O within|O the|O Pax-3|gene-rna promoter|O significantly|O altered|O the|O pattern|O of|O expression|O through|O the|O cell|O cycle|O .|O 
These|O results|O suggest|O that|O the|O Myc|gene-generic family|O of|O transcription|O factors|O may|O modulate|O Pax-3|gene-rna expression|O in|O vivo|O .|O 
Immunohistology|O ,|O cytogenetics|O ,|O and|O molecular|O studies|O of|O small|O round|O cell|O tumors|O of|O childhood|O .|O 
A|O review|O .|O 
Malignancies|O of|O childhood|O include|O a|O well|O -|O defined|O spectrum|O of|O hematolymphoid|O ,|O organ|O specific|O (|O adrenal|O ,|O kidney|O ,|O liver|O )|O ,|O soft|O tissue|O ,|O bone|O ,|O and|O nervous|O system|O (|O central|O and|O peripheral|O )|O neoplasms|O with|O variable|O biology|O .|O 
Small|O round|O cell|O neoplasms|O ,|O a|O subset|O of|O childhood|O malignancies|O ,|O are|O histologically|O similar|O but|O differ|O markedly|O in|O their|O histogenesis|O ,|O therapy|O ,|O and|O prognosis|O .|O 
Traditionally|O ,|O clinical|O information|O and|O light|O microscopy|O ,|O with|O the|O aid|O of|O histochemistry|O and|O ultrastructural|O evaluation|O ,|O establish|O a|O diagnosis|O or|O at|O least|O narrow|O the|O differential|O diagnosis|O .|O 
Additionally|O ,|O immunohistology|O ,|O cytogenetics|O ,|O and|O molecular|O studies|O have|O become|O important|O in|O diagnosis|O and|O in|O defining|O phenotype|O /|O genotype|O ,|O patient|O treatment|O modalities|O ,|O and|O prognosis|O in|O specific|O cases|O .|O 
The|O 11|O ;|O 22|O chromosomal|O translocation|O typifies|O Ewing|O 's|O sarcoma|O ,|O primitive|O neuroectodermal|O tumor|O ,|O and|O Askin|O 's|O tumor|O ,|O as|O does|O the|O resultant|O chimeric|O transcript|O ,|O while|O expression|O and|O amplification|O of|O N-myc|gene-rna oncogene|O are|O predictive|O of|O the|O prognosis|O in|O neuroblastoma|O .|O 
Furthermore|O ,|O studies|O of|O genes|O and|O gene|O products|O are|O elucidating|O mechanisms|O of|O oncogenesis|O and|O tumor|O progression|O .|O 
Huntingtin|gene-protein is|O a|O cytoplasmic|O protein|O associated|O with|O vesicles|O in|O human|O and|O rat|O brain|O neurons|O .|O 
The|O gene|O defective|O in|O Huntington|O 's|O disease|O encodes|O a|O protein|O ,|O huntingtin|gene-protein ,|O with|O unknown|O function|O .|O 
Antisera|O generated|O against|O three|O separate|O regions|O of|O huntingtin|gene-protein identified|O a|O single|O high|O molecular|O weight|O protein|O of|O approximately|O 320|O kDa|O on|O immunoblots|O of|O human|O neuroblastoma|O extracts|O .|O 
The|O same|O protein|O species|O was|O detected|O in|O human|O and|O rat|O cortex|O synaptosomes|O and|O in|O sucrose|O density|O gradients|O of|O vesicle|O -|O enriched|O fractions|O ,|O where|O huntingtin|gene-protein immunoreactivity|O overlapped|O with|O the|O distribution|O of|O vesicle|O membrane|O proteins|O (|O SV2|gene-protein ,|O transferrin|gene-protein receptor|gene-protein ,|O and|O synaptophysin|gene-protein )|O .|O 
Immunohistochemistry|O in|O human|O and|O rat|O brain|O revealed|O widespread|O cytoplasmic|O labeling|O of|O huntingtin|gene-protein within|O neurons|O ,|O particularly|O cell|O bodies|O and|O dendrites|O ,|O rather|O than|O the|O more|O selective|O pattern|O of|O axon|O terminal|O labeling|O characteristic|O of|O many|O vesicle|gene-protein -|gene-protein associated|gene-protein proteins|gene-protein .|O 
At|O the|O ultrastructural|O level|O ,|O immunoreactivity|O in|O cortical|O neurons|O was|O detected|O in|O the|O matrix|O of|O the|O cytoplasm|O and|O around|O the|O membranes|O of|O the|O vesicles|O .|O 
The|O ubiquitous|O cytoplasmic|O distribution|O of|O huntingtin|gene-protein in|O neurons|O and|O its|O association|O with|O vesicles|O suggest|O that|O huntingtin|gene-protein may|O have|O a|O role|O in|O vesicle|O trafficking|O .|O 
Differential|O gene|O regulation|O by|O 9-cis|O and|O all|O -|O trans|O retinoic|O acid|O in|O neuroblastoma|O cells|O .|O 
BACKGROUND|O :|O 9-cis|O retinoic|O acid|O (|O RA|O )|O is|O more|O effective|O than|O all|O -|O trans|O RA|O at|O inducing|O neuroblastoma|O differentiation|O in|O vitro|O ,|O and|O has|O distinct|O biological|O properties|O with|O respect|O to|O its|O ability|O to|O promote|O apoptosis|O in|O N-type|O neuroblastoma|O cells|O .|O 
The|O cellular|O effects|O of|O 9-cis|O RA|O may|O ,|O in|O part|O ,|O result|O from|O activation|O of|O retinoid|gene-protein X|gene-protein receptor|gene-protein (|O RXR|gene-protein )|O homodimers|O .|O 
If|O this|O hypothesis|O is|O correct|O ,|O 9-cis|O RA|O may|O control|O the|O expression|O of|O a|O different|O subset|O of|O retinoid|O -|O regulated|O genes|O compared|O to|O all|O -|O trans|O RA|O .|O 
PROCEDURE|O :|O We|O have|O therefore|O used|O differential|O mRNA|O display|O to|O identify|O genes|O differentially|O expressed|O in|O neuroblastoma|O cells|O in|O response|O to|O all|O -|O trans|O and|O 9-cis|O RA|O .|O 
RESULTS|O :|O The|O majority|O of|O cDNAs|O differentially|O expressed|O in|O response|O to|O all|O -|O trans|O or|O 9-cis|O RA|O matched|O to|O nonredundant|O Genbank|O sequences|O or|O EST|O database|O sequences|O .|O 
Differential|O -|O display|O profiles|O were|O similar|O in|O SH|O SY|O 5Y|O and|O SH|O S|O EP|O cells|O ,|O clonal|O derivatives|O of|O the|O mixed|O neuroblastoma|O cell|O line|O SK|O N|O SH|O ,|O although|O there|O were|O apparent|O differences|O between|O these|O cell|O lines|O with|O respect|O to|O the|O retinoid|O -|O regulation|O of|O specific|O RT|O -|O PCR|O cDNA|O fragments|O .|O 
CONCLUSIONS|O :|O These|O data|O support|O the|O view|O that|O 9-cis|O and|O all|O -|O trans|O RA|O act|O via|O different|O receptor|O mechanisms|O .|O 
Mutations|O in|O tau|gene-rna gene|O exon|O 10|O associated|O with|O FTDP-17|gene-protein alter|O the|O activity|O of|O an|O exonic|O splicing|O enhancer|O to|O interact|O with|O Tra2|gene-protein beta|gene-protein .|O 
Mutations|O in|O the|O human|O tau|gene-rna gene|O leading|O to|O aberrant|O splicing|O have|O been|O identified|O in|O FTDP-17|gene-protein ,|O an|O autosomal|O dominant|O hereditary|O neurodegenerative|O disorder|O .|O 
Molecular|O mechanisms|O by|O which|O such|O mutations|O cause|O tau|gene-rna aberrant|O splicing|O were|O not|O understood|O .|O 
We|O characterized|O two|O mutations|O in|O exon|O 10|O of|O the|O tau|gene-rna gene|O ,|O N|O 279|O K|O and|O Del|O 280|O K|O .|O Our|O results|O revealed|O an|O exonic|O splicing|O enhancer|O element|O located|O in|O exon|O 10|O .|O 
The|O activity|O of|O this|O AG|O -|O rich|O splicing|O enhancer|O was|O altered|O by|O N|O 279|O K|O and|O Del|O 280|O K|O mutations|O .|O 
This|O exonic|O enhancer|O element|O interacts|O with|O human|O Tra2|gene-protein beta|gene-protein protein|O .|O 
The|O interaction|O between|O Tra2|gene-protein beta|gene-protein and|O the|O exonic|O splicing|O enhancer|O correlates|O with|O the|O activity|O of|O this|O enhancer|O element|O in|O stimulating|O splicing|O .|O 
Biochemical|O studies|O including|O in|O vitro|O splicing|O and|O RNA|O interference|O experiments|O in|O transfected|O cells|O support|O a|O role|O for|O Tra2|gene-protein beta|gene-protein protein|O in|O regulating|O alternative|O splicing|O of|O human|O tau|gene-rna gene|O .|O 
Our|O results|O implicate|O the|O human|O tau|gene-rna gene|O as|O a|O target|O gene|O for|O the|O alternative|O splicing|O regulator|O Tra2|gene-protein beta|gene-protein ,|O suggesting|O that|O Tra2|gene-protein beta|gene-protein may|O play|O a|O role|O in|O aberrant|O tau|gene-rna exon|O 10|O alternative|O splicing|O and|O in|O the|O pathogenesis|O of|O tauopathies|O .|O 
Cloned|O murine|O bradykinin|gene-protein receptor|gene-protein exhibits|O a|O mixed|O B1|gene-protein and|O B2|gene-protein pharmacological|O selectivity|O .|O 
We|O have|O isolated|O DNA|O clones|O encoding|O functional|O bradykinin|gene-protein receptors|gene-protein from|O human|O ,|O rat|O ,|O and|O mouse|O sources|O .|O 
Genomic|O bradykinin|gene-protein receptor|gene-protein clones|O have|O been|O isolated|O from|O mouse|O and|O human|O cosmid|O libraries|O and|O cDNA|O clones|O have|O been|O isolated|O from|O the|O human|O lung|O fibroblast|O cell|O line|O W138|O ,|O from|O the|O neuroblastoma|O /|O glioma|O hybrid|O NG108-15|O ,|O and|O from|O rat|O dorsal|O root|O ganglion|O cells|O .|O 
The|O receptor|O protein|O is|O encoded|O by|O an|O intronless|O region|O of|O the|O gene|O in|O both|O mouse|O and|O human|O .|O 
There|O is|O evidence|O of|O a|O splice|O acceptor|O site|O 8|O bases|O upstream|O from|O the|O initiation|O codon|O in|O all|O three|O species|O .|O 
The|O function|O of|O the|O expressed|O receptor|O proteins|O from|O mouse|O ,|O rat|O ,|O and|O human|O was|O tested|O by|O electrophysiological|O assays|O after|O injection|O of|O cRNA|O into|O Xenopus|O laevis|O oocytes|O and|O also|O by|O binding|O assays|O with|O membranes|O from|O COS-7|O cells|O transfected|O with|O cloned|O receptor|O -|O encoding|O DNA|O .|O 
The|O receptors|O from|O human|O and|O rat|O showed|O the|O pharmacological|O properties|O of|O B2|gene-protein receptors|gene-protein in|O both|O expression|O systems|O when|O tested|O with|O a|O variety|O of|O bradykinin|gene-protein analogues|O ,|O but|O receptors|O from|O mouse|O divided|O into|O two|O populations|O ,|O one|O population|O with|O pharmacological|O properties|O of|O B1|gene-protein -|gene-protein like|gene-protein receptors|gene-protein and|O another|O ,|O larger|O ,|O population|O with|O properties|O of|O B2|gene-protein receptors|gene-protein .|O 
Association|O of|O multiple|O copies|O of|O the|O N-myc|gene-rna oncogene|O with|O rapid|O progression|O of|O neuroblastomas|O .|O 
Eighty-nine|O patients|O with|O untreated|O primary|O neuroblastomas|O were|O studied|O to|O determine|O the|O relation|O between|O the|O number|O of|O copies|O of|O the|O N-myc|gene-rna oncogene|O and|O survival|O without|O disease|O progression|O .|O 
Genomic|O amplification|O (|O 3|O to|O 300|O copies|O )|O of|O N-myc|gene-rna was|O detected|O in|O 2|O of|O 16|O tumors|O in|O Stage|O II|O ,|O 13|O of|O 20|O in|O Stage|O III|O ,|O and|O 19|O of|O 40|O in|O Stage|O IV|O ;|O in|O contrast|O ,|O 8|O Stage|O I|O and|O 5|O Stage|O IV-S|O tumors|O all|O had|O 1|O copy|O of|O the|O gene|O (|O P|O less|O than|O 0.01|O )|O .|O 
Analysis|O of|O progression|O -|O free|O survival|O in|O all|O patients|O revealed|O that|O amplification|O of|O N-myc|gene-rna was|O associated|O with|O the|O worst|O prognosis|O (|O P|O less|O than|O 0.0001|O )|O ;|O the|O estimated|O progression|O -|O free|O survival|O at|O 18|O months|O was|O 70|O per|O cent|O ,|O 30|O per|O cent|O ,|O and|O 5|O per|O cent|O for|O patients|O whose|O tumors|O had|O 1|O ,|O 3|O to|O 10|O ,|O or|O more|O than|O 10|O N-myc|gene-rna copies|O ,|O respectively|O .|O 
Of|O 16|O Stage|O II|O tumors|O ,|O 2|O with|O amplification|O metastasized|O ,|O whereas|O only|O 1|O of|O 14|O without|O amplification|O did|O so|O (|O P|O =|O 0.03|O )|O .|O 
Stage|O IV|O tumors|O with|O amplification|O progressed|O most|O rapidly|O :|O nine|O months|O after|O diagnosis|O the|O estimated|O progression|O -|O free|O survival|O was|O 61|O per|O cent|O ,|O 47|O per|O cent|O ,|O and|O 0|O per|O cent|O in|O patients|O whose|O tumors|O had|O 1|O ,|O 3|O to|O 10|O ,|O or|O more|O than|O 10|O copies|O ,|O respectively|O (|O P|O less|O than|O 0.0001|O )|O .|O 
These|O results|O suggest|O that|O genomic|O amplification|O of|O N-myc|gene-rna may|O have|O a|O key|O role|O in|O determining|O the|O aggressiveness|O of|O neuroblastomas|O .|O 
Induction|O of|O peptidylglycine|gene-protein alpha-amidating|gene-protein monooxygenase|gene-protein in|O N(18)TG(2)|O cells|O :|O a|O model|O for|O studying|O oleamide|O biosynthesis|O .|O 
The|O fatty|O -|O acid|O primary|O amide|O ,|O oleamide|O ,|O is|O a|O novel|O signaling|O molecule|O whose|O mechanism|O of|O biosynthesis|O is|O unknown|O .|O 
Recently|O ,|O the|O N(18)TG(2)|O cell|O line|O was|O shown|O to|O synthesize|O oleamide|O from|O oleic|O acid|O ,|O thereby|O demonstrating|O that|O these|O cells|O contain|O the|O necessary|O catalytic|O activities|O for|O generating|O the|O fatty|O -|O acid|O primary|O amide|O .|O 
The|O ability|O of|O peptide|gene-protein alpha-amidating|gene-protein enzyme|gene-protein ,|O peptidylglycine|gene-protein -|gene-protein alpha-amidating|gene-protein monooxygenase|gene-protein (|O PAM|gene-protein ;|O EC|O 1.14.17.3|O )|O ,|O to|O catalyze|O the|O formation|O of|O oleamide|O from|O oleoylglycine|O in|O vitro|O suggests|O this|O as|O a|O function|O for|O the|O enzyme|O in|O vivo|O .|O 
This|O investigation|O shows|O that|O N(18)TG(2)|O cells|O ,|O in|O fact|O ,|O express|O PAM|gene-protein and|O that|O cellular|O differentiation|O dramatically|O increases|O this|O expression|O .|O 
PAM|gene-protein expression|O was|O confirmed|O by|O the|O detection|O of|O PAM|gene-rna mRNA|O ,|O PAM|gene-protein protein|O ,|O and|O enzymatic|O activity|O that|O exhibits|O the|O functional|O characteristics|O of|O PAM|gene-protein isolated|O from|O mammalian|O neuroendocrine|O tissues|O .|O 
The|O regulated|O expression|O of|O PAM|gene-protein in|O N(18)TG(2)|O cells|O is|O consistent|O with|O the|O proposed|O role|O of|O PAM|gene-protein in|O the|O biosynthesis|O of|O fatty|O -|O acid|O primary|O amides|O and|O further|O establishes|O this|O cell|O line|O as|O a|O model|O for|O studying|O the|O pathway|O .|O 
N-myc|gene-rna genomic|O content|O and|O DNA|O ploidy|O in|O stage|O IVS|O neuroblastoma|O .|O 
DNA|O ploidy|O and|O N-myc|gene-rna genomic|O content|O were|O analyzed|O in|O a|O series|O of|O stage|O IVS|O neuroblastomas|O by|O flow|O cytometry|O and|O Southern|O blot|O hybridization|O ,|O respectively|O .|O 
Of|O the|O 12|O stage|O IVS|O neuroblastomas|O studied|O ,|O nine|O were|O aneuploid|O (|O DNA|O index|O [|O DI|O ]|O greater|O than|O 1|O )|O ,|O two|O were|O diploid|O (|O DI|O =|O 1|O )|O ,|O and|O one|O was|O not|O assessable|O for|O DNA|O content|O due|O to|O insufficient|O tumor|O material|O .|O 
N-myc|gene-rna gene|O amplification|O was|O present|O in|O two|O of|O 12|O tumors|O .|O 
None|O of|O the|O aneuploid|O tumors|O exhibited|O N-myc|gene-rna amplification|O .|O 
Among|O the|O aneuploid|O neuroblastomas|O ,|O the|O DIs|O were|O between|O 1.27|O and|O 1.60|O ,|O ie|O ,|O in|O the|O near|O -|O triploid|O range|O .|O 
The|O follow|O -|O up|O from|O diagnosis|O ranged|O from|O 1|O to|O 41|O months|O (|O mean|O ,|O 20|O months|O )|O .|O 
The|O nine|O neuroblastomas|O with|O near|O -|O triploid|O DNA|O content|O were|O free|O of|O disease|O at|O the|O end|O of|O the|O follow|O -|O up|O period|O .|O 
In|O contrast|O ,|O a|O rapid|O and|O fatal|O tumor|O progression|O was|O observed|O for|O the|O three|O neuroblastomas|O with|O N-myc|gene-rna amplification|O and/or|O diploidy|O .|O 
Although|O involving|O only|O a|O limited|O series|O ,|O these|O results|O strongly|O suggest|O that|O the|O combined|O analysis|O of|O DNA|O ploidy|O and|O N-myc|gene-rna genomic|O content|O could|O predict|O clinical|O outcome|O in|O stage|O IVS|O neuroblastoma|O and|O should|O help|O to|O identify|O patients|O for|O whom|O a|O more|O aggressive|O therapy|O is|O required|O .|O 
The|O human|O fibroblast|gene-rna growth|gene-rna factor|gene-rna receptor|gene-rna genes|O :|O a|O common|O structural|O arrangement|O underlies|O the|O mechanisms|O for|O generating|O receptor|O forms|O that|O differ|O in|O their|O third|O immunoglobulin|O domain|O .|O 
To|O determine|O the|O mechanisms|O by|O which|O multiple|O forms|O of|O fibroblast|gene-protein growth|gene-protein factor|gene-protein (|gene-protein FGF|gene-protein )|gene-protein receptors|gene-protein are|O generated|O ,|O we|O have|O mapped|O the|O arrangement|O of|O exons|O and|O introns|O in|O the|O human|O FGF|gene-rna receptor|gene-rna 1|gene-rna (|O FGFR|gene-rna 1|gene-rna )|O gene|O (|O flg|gene-rna )|O .|O 
We|O found|O three|O alternative|O exons|O encoding|O a|O portion|O of|O the|O third|O immunoglobulin|gene-protein (|O Ig|gene-protein )|O -|O like|O domain|O of|O the|gene-protein receptor|gene-protein .|O 
One|O of|O these|O alternatives|O encodes|O a|O sequence|O that|O is|O part|O of|O a|O secreted|O form|O of|O FGFR|gene-protein 1|gene-protein .|O 
The|O other|O two|O encode|O sequences|O that|O are|O likely|O part|O of|O transmembrane|O forms|O of|O FGFR|gene-protein 1|gene-protein .|O 
One|O of|O these|O forms|O has|O not|O been|O previously|O reported|O in|O published|O cDNAs|O .|O 
Also|O ,|O we|O have|O determined|O the|O structural|O organization|O of|O a|O portion|O of|O the|O human|O FGFR|gene-rna 2|gene-rna gene|O (|O bek|gene-rna )|O and|O found|O a|O similar|O arrangement|O of|O alternative|O exons|O for|O the|O third|O Ig|gene-protein -|O like|O domain|O .|O 
The|O arrangement|O of|O these|O genes|O suggests|O that|O there|O are|O conserved|O mechanisms|O governing|O the|O expression|O of|O secreted|O FGF|gene-protein receptors|gene-protein as|O well|O as|O the|O expression|O of|O at|O least|O two|O distinct|O membrane|O -|O spanning|O forms|O of|O the|O FGF|gene-protein receptors|gene-protein .|O 
The|O diverse|O forms|O appear|O to|O be|O generated|O by|O alternative|O splicing|O of|O mRNA|O and|O selective|O use|O of|O polyadenylation|O signals|O .|O 
Paucity|O of|O beta|gene-protein 2-microglobulin|gene-protein expression|O on|O small|O cell|O lung|O cancer|O ,|O bronchial|O carcinoids|O and|O certain|O other|O neuroendocrine|O tumors|O .|O 
Cell|O lines|O established|O from|O small|O cell|O lung|O cancer|O (|O SCLC|O )|O ,|O a|O neuroendocrine|O tumor|O ,|O have|O low|O or|O absent|O expression|O of|O class|gene-protein I|gene-protein major|gene-protein histocompatibility|gene-protein complex|gene-protein antigens|gene-protein .|O 
To|O determine|O whether|O this|O phenomenon|O occurs|O also|O in|O vivo|O ,|O 244|O routine|O paraffin|O -|O embedded|O tumors|O including|O 32|O SCLC|O and|O 79|O non|O -|O SCLC|O (|O NSCLC|O )|O lung|O cancers|O were|O studied|O for|O expression|O of|O beta|gene-protein 2-microglobulin|gene-protein (|O beta|gene-protein 2m|gene-protein )|O by|O an|O avidin|gene-protein -|O biotin|O coupled|O immunoperoxidase|O technique|O .|O 
The|O majority|O of|O SCLC|O tumors|O lacked|O beta|gene-protein 2m|gene-protein expression|O ,|O while|O some|O had|O weak|O ,|O focal|O expression|O .|O 
In|O contrast|O ,|O most|O NSCLC|O expressed|O beta|gene-protein 2m|gene-protein ,|O often|O strongly|O .|O 
The|O difference|O between|O SCLC|O and|O NSCLC|O was|O highly|O significant|O statistically|O ,|O suggesting|O that|O beta|gene-protein 2m|gene-protein can|O be|O used|O as|O a|O clinical|O immunodiagnostic|O marker|O for|O distinguishing|O NSCLC|O from|O SCLC|O .|O 
In|O addition|O ,|O certain|O other|O neuroendocrine|O tumors|O (|O neuroblastoma|O ,|O bronchial|O and|O midgut|O carcinoid|O tumors|O )|O lacked|O beta|gene-protein 2m|gene-protein expression|O ,|O whereas|O some|O (|O pheochromocytoma|O ,|O medullary|O thyroid|O carcinoma|O ,|O and|O peripheral|O neuroectodermal|O tumors|O )|O usually|O stained|O positively|O .|O 
Such|O non|O -|O neuroendocrine|O tumors|O as|O colon|O ,|O breast|O ,|O and|O prostate|O carcinomas|O showed|O moderate|O to|O high|O expression|O of|O beta|gene-protein 2m|gene-protein .|O 
Selective|O absence|O of|O beta|gene-protein 2m|gene-protein expression|O by|O certain|O neuroendocrine|O tumors|O appears|O to|O be|O a|O phenomenon|O of|O biological|O and|O diagnostic|O importance|O .|O 
Expression|O of|O members|O of|O the|O chromogranin|gene-protein family|O in|O primary|O neuroblastomas|O .|O 
Expression|O of|O the|O members|O of|O the|O chromogranin|gene-protein family|O [|O i.e.|O ,|O chromogranin|gene-protein A|gene-protein (|O CgA|gene-protein )|O ,|O chromogranin|gene-protein B|gene-protein ,|O and|O secretogranin|gene-protein II|gene-protein (|O SgII|gene-protein )|O ]|O ,|O the|O acidic|O proteins|O of|O the|O matrix|O of|O the|O chromaffin|O granules|O presently|O regarded|O as|O specific|O neuroendocrine|O markers|O ,|O was|O investigated|O at|O gene|O and|O protein|O levels|O in|O a|O series|O of|O 14|O cases|O of|O primary|O untreated|O neuroblastomas|O .|O 
Oligonucleotides|O and|O cRNA|O probes|O were|O employed|O for|O hybridization|O analysis|O of|O specific|O mRNAs|O (|O both|O by|O Northern|O blots|O and|O nonradioactive|O in|O situ|O hybridization|O )|O ;|O proteins|O were|O localized|O by|O immunocytochemistry|O .|O 
Expression|O of|O different|O amounts|O of|O each|O type|O of|O chromogranin|gene-protein was|O determined|O in|O all|O tumors|O .|O 
Cases|O found|O immunocytochemically|O negative|O were|O all|O positive|O by|O Northern|O blot|O and|O in|O situ|O hybridization|O .|O 
A|O better|O prognosis|O was|O associated|O with|O a|O higher|O relative|O expression|O of|O SgII|gene-protein ;|O on|O the|O contrary|O ,|O a|O worse|O outcome|O was|O observed|O in|O cases|O with|O a|O higher|O expression|O of|O CgA|gene-protein .|O 
These|O findings|O are|O consistent|O with|O the|O hypothesis|O that|O SgII|gene-protein is|O preferentially|O expressed|O in|O neuroblastomas|O undergoing|O neuronal|O differentiation|O .|O 
In|O cases|O of|O neuroblastomas|O ,|O determination|O of|O expression|O levels|O of|O the|O different|O chromogranins|gene-protein in|O the|O tissues|O (|O and|O in|O the|O serum|O )|O can|O provide|O parameters|O of|O high|O diagnostic|O and|O prognostic|O value|O .|O 
Induction|O of|O glia|gene-protein -|gene-protein derived|gene-protein nexin|gene-protein after|O lesion|O of|O a|O peripheral|O nerve|O .|O 
Glia|gene-protein -|gene-protein derived|gene-protein nexin|gene-protein (|O GDN|gene-protein )|O ,|O also|O known|O as|O protease|gene-protein nexin|gene-protein I|gene-protein ,|O is|O a|O serine|gene-protein protease|gene-protein inhibitor|O of|O deduced|O relative|O molecular|O mass|O 41,700|O ,|O identified|O in|O conditioned|O media|O of|O glioma|O cells|O by|O its|O neurite|O -|O promoting|O activity|O .|O 
GDN|gene-protein can|O promote|O neurite|O outgrowth|O in|O vitro|O from|O neuroblastoma|O cells|O ,|O sympathetic|O neurons|O and|O hippocampal|O neurons|O (|O L.|O Farmer|O et|O al.|O ,|O manuscript|O in|O preparation|O )|O .|O 
In|O vivo|O ,|O GDN|gene-protein is|O constitutively|O expressed|O in|O all|O parts|O of|O the|O olfactory|O system|O ,|O where|O axonal|O regeneration|O and|O neurogenesis|O occur|O continuously|O throughout|O life|O .|O 
This|O observation|O indicates|O that|O GDN|gene-protein could|O be|O important|O for|O axonal|O regeneration|O in|O vivo|O .|O 
To|O investigate|O this|O possibility|O ,|O we|O have|O taken|O advantage|O of|O the|O fact|O that|O damage|O to|O nerves|O in|O the|O peripheral|O nervous|O system|O leads|O to|O their|O regeneration|O ,|O whereas|O in|O the|O central|O nervous|O system|O no|O such|O regeneration|O can|O occur|O .|O 
Here|O we|O report|O that|O after|O lesion|O of|O the|O rat|O sciatic|O nerve|O there|O is|O a|O large|O transient|O increase|O in|O the|O amount|O of|O GDN|gene-rna messenger|O RNA|O and|O of|O released|O GDN|gene-protein .|O 
The|O cells|O showing|O GDN|gene-protein immunoreactivity|O are|O mainly|O localized|O distal|O to|O the|O lesion|O site|O .|O 
These|O results|O further|O support|O the|O suggestion|O that|O GDN|gene-protein is|O important|O for|O axonal|O regeneration|O in|O vivo|O ,|O and|O indicate|O that|O protease|gene-protein inhibitors|O could|O have|O a|O role|O in|O Wallerian|O degeneration|O and|O peripheral|O nerve|O regeneration|O .|O 
Induction|O of|O apoptosis|O by|O p75|gene-protein neurotrophin|gene-protein receptor|gene-protein in|O human|O neuroblastoma|O cells|O .|O 
The|O low|O -|O affinity|O nerve|gene-protein growth|gene-protein factor|gene-protein receptor|gene-protein p75NTR|gene-protein belongs|O to|O a|O membrane|O receptor|O superfamily|O whose|O members|O ,|O in|O certain|O cell|O types|O ,|O are|O able|O to|O transduce|O an|O apoptotic|O signal|O .|O 
To|O investigate|O the|O effect|O of|O p75NTR|gene-protein expression|O in|O neuroblastoma|O cells|O ,|O we|O transfected|O the|O p75NTR|gene-rna cDNA|O into|O SK-N-BE|O cells|O ,|O a|O neuroblastoma|O cell|O line|O that|O lacks|O expression|O of|O both|O p75NTR|gene-protein and|O TrkA|gene-protein .|O 
Cell|O clones|O expressing|O elevated|O levels|O of|O p75NTR|gene-protein showed|O a|O high|O degree|O of|O cell|O death|O by|O apoptosis|O ,|O even|O in|O serum|O -|O supplemented|O medium|O .|O 
Moreover|O ,|O the|O level|O of|O apoptosis|O correlated|O directly|O with|O the|O expression|O level|O of|O the|O receptor|O ,|O indicating|O that|O p75NTR|gene-protein could|O activate|O the|O cell|O death|O program|O by|O itself|O .|O 
Clones|O expressing|O p75NTR|gene-protein showed|O a|O dramatic|O increase|O of|O cell|O death|O when|O switched|O into|O serum|O -|O free|O medium|O ;|O these|O cultures|O rapidly|O extinguished|O .|O 
This|O apoptotic|O effect|O was|O greatly|O inhibited|O by|O NGF|gene-protein treatment|O .|O 
Our|O results|O support|O the|O hypothesis|O that|O p75NTR|gene-protein ,|O when|O it|O is|O not|O bound|O by|O NGF|gene-protein ,|O may|O play|O a|O role|O in|O neuronal|O selection|O during|O embryonic|O development|O and|O suggest|O that|O neuroblastomas|O may|O arise|O from|O immature|O neuroblasts|O that|O escape|O programmed|O cell|O death|O .|O 
Therefore|O ,|O the|O loss|O of|O p75NTR|gene-protein expression|O in|O developing|O neural|O crest|O cells|O might|O be|O a|O primary|O event|O in|O the|O genesis|O of|O neuroblastoma|O .|O 
Suppression|O of|O an|O actin|gene-protein -|gene-protein binding|gene-protein protein|gene-protein ,|O drebrin|gene-protein ,|O by|O antisense|O transfection|O attenuates|O neurite|O outgrowth|O in|O neuroblastoma|O B104|O cells|O .|O 
Drebrins|gene-protein ,|O actin|gene-protein -|gene-protein binding|gene-protein proteins|gene-protein ,|O are|O dominantly|O expressed|O during|O embryogenesis|O and|O accumulated|O in|O neurite|O processes|O of|O postmigratory|O neurons|O .|O 
While|O the|O cytoskeletal|gene-protein proteins|gene-protein are|O the|O important|O factors|O for|O regulating|O neurite|O outgrowth|O ,|O the|O cellular|O mechanism|O in|O neurons|O is|O still|O unclear|O .|O 
To|O address|O the|O role|O of|O drebrins|gene-protein in|O the|O neurite|O outgrowth|O ,|O we|O have|O studied|O the|O effect|O of|O suppression|O of|O drebrin|gene-protein on|O a|O rat|O neuroblastoma|O B104|O cell|O line|O ,|O which|O constitutively|O expresses|O drebrin|gene-protein .|O 
Deprivation|O of|O serum|O or|O addition|O of|O gangliosides|O in|O the|O culture|O medium|O induced|O remarkable|O neurite|O outgrowth|O of|O B104|O cells|O .|O 
We|O transfected|O B104|O cells|O with|O an|O antisense|O construct|O of|O human|O drebrin|gene-rna E|gene-rna cDNA|O and|O found|O that|O the|O drebrin|gene-protein expression|O was|O significantly|O reduced|O in|O the|O stable|O antisense|O cell|O lines|O .|O 
In|O response|O to|O serum|O deprivation|O and|O gangliosides|O treatment|O ,|O their|O ability|O to|O extend|O neurite|O processes|O was|O significantly|O attenuated|O .|O 
In|O contrast|O ,|O the|O cell|O proliferation|O of|O the|O antisense|O transfectants|O was|O arrested|O by|O serum|O deprivation|O similar|O to|O control|O B104|O cells|O .|O 
These|O data|O suggest|O that|O the|O drebrins|gene-protein are|O required|O for|O neurite|O outgrowth|O in|O neuronal|O cells|O .|O 
Prognostic|O significance|O of|O cell|O proliferation|O in|O human|O neuroblastoma|O :|O comparison|O with|O other|O prognostic|O factors|O .|O 
Peripheral|O neuroblastic|O tumors|O (|O PNT|O )|O ,|O are|O heterogeneous|O neoplasms|O that|O include|O neuroblastoma|O (|O NB|O )|O ,|O ganglioneuroblastoma|O (|O GNB|O )|O and|O ganglioneuroma|O (|O GN|O )|O and|O present|O great|O biological|O heterogeneity|O .|O 
There|O are|O few|O reports|O analyzing|O PCNA|gene-protein and|O Ki-67|gene-protein expression|O in|O PNT|O ;|O however|O ,|O controversy|O exists|O concerning|O the|O specificity|O of|O PCNA|gene-protein as|O a|O real|O proliferative|O marker|O .|O 
The|O objective|O of|O our|O study|O was|O to|O determine|O which|O of|O these|O cellular|O proliferation|O markers|O is|O more|O specific|O on|O cellular|O cycle|O and|O could|O contribute|O with|O more|O information|O on|O the|O cell|O cycle|O .|O 
We|O found|O that|O PCNA|gene-protein was|O expressed|O in|O NB|O unfavourable|O cases|O ,|O with|O MYCN|gene-rna amplification|O and|O high|O mitosis|O -|O karyorrhexis|O -|O index|O (|O MKI|O )|O .|O 
Whereas|O ,|O Ki-67|gene-protein showed|O statistical|O significance|O regarding|O cases|O unfavourable|O with|O intermediate|O and|O high|O MKI|O ,|O aneuploid|O and|O stages|O 3|O and|O 4|O .|O 
Survival|O showed|O that|O patients|O with|O tumor|O not|O expressing|O Ki-67|gene-protein (|O MIB1|gene-protein )|O lived|O longer|O than|O those|O without|O PCNA|gene-protein (|O 88.93|O vs|O 74.05|O %|O )|O .|O 
We|O conclude|O that|O Ki-67|gene-protein expression|O permits|O reliable|O detection|O of|O the|O cellular|O proliferation|O neuroblastoma|O fraction|O and|O provides|O useful|O prognostic|O information|O when|O associated|O with|O other|O biological|O factors|O .|O 
Calcium|O modulation|O of|O inositol|O 1,4,5-trisphosphate|O -|O induced|O calcium|O release|O from|O neuroblastoma|O x|O glioma|O hybrid|O (|O NG108-15|O )|O microsomes|O .|O 
Subcellular|O fractions|O of|O neuroblastoma|O x|O glioma|O (|O NG108-15|O )|O hybrid|O cells|O were|O used|O to|O study|O the|O mechanism|O of|O inositol|O 1,4,5-trisphosphate|O -|O induced|O calcium|O release|O .|O 
A|O microsomal|O fraction|O ,|O enriched|O in|O endoplasmic|O reticulum|O and|O plasma|O membranes|O and|O almost|O devoid|O of|O mitochondria|O ,|O was|O the|O most|O active|O in|O inositol|O trisphosphate|O -|O or|O GTP|O -|O dependent|O release|O of|O calcium|O .|O 
Neither|O GTP|O nor|O inositol|O 1,4,5-trisphosphate|O affected|O the|O calcium|O efflux|O mediated|O by|O the|O other|O reagent|O ,|O suggesting|O that|O inositol|O trisphosphate|O and|O GTP|O act|O on|O different|O calcium|O -|O sequestrating|O vesicles|O .|O 
The|O stimulation|O of|O calcium|O release|O by|O GTP|O was|O relatively|O slow|O (|O t|O 1|O /|O 2|O =|O 90|O s|O )|O ,|O dependent|O on|O polyethyleneglycol|O ,|O and|O greater|O at|O 2|O X|O 10(-5)|O M|O calcium|O (|O 5|O nmol|O X|O min-1|O X|O mg-1|O )|O than|O at|O 10(-6)|O M|O calcium|O (|O 0.8|O nmol|O X|O min-1|O X|O mg-1|O )|O .|O 
The|O inositol|O trisphosphate|O -|O induced|O calcium|O efflux|O was|O not|O mimicked|O by|O inositol|O monophosphate|O ;|O it|O was|O fast|O (|O t|O 1|O /|O 2|O less|O than|O 10|O s|O )|O and|O unaffected|O by|O 3|O %|O polyethyleneglycol|O .|O 
The|O amount|O of|O calcium|O released|O by|O inositol|O trisphosphate|O was|O greatest|O at|O 10(-6)|O M|O external|O calcium|O (|O 1|O nmol|O X|O min-1|O X|O mg-1|O )|O and|O it|O was|O undetectable|O at|O 2|O X|O 10(-5)|O M|O calcium|O .|O 
A|O feedback|O inhibition|O of|O the|O inositol|O trisphosphate|O -|O induced|O calcium|O release|O by|O cytoplasmic|O calcium|O provides|O a|O safety|O mechanism|O preventing|O deleterious|O effects|O of|O abnormally|O high|O calcium|O levels|O .|O 
Regulation|O of|O viral|O and|O cellular|O genes|O in|O a|O human|O neuroblastoma|O cell|O line|O latently|O infected|O with|O herpes|O simplex|O virus|O type|O 2|O .|O 
A|O latent|O state|O of|O the|O herpes|O simplex|O virus|O type|O 2|O genome|O was|O established|O in|O a|O human|O neuroblastoma|O cell|O line|O (|O SMS-KCNR|O )|O to|O initiate|O studies|O on|O the|O mechanism|O by|O which|O host|O cells|O interact|O and|O regulate|O latent|O viral|O genes|O .|O 
To|O establish|O viral|O latency|O ,|O it|O was|O necessary|O to|O prevent|O virus|O replication|O by|O briefly|O exposing|O the|O infected|O cells|O to|O antiherpetic|O acycloguanosine|O (|O 20|O microM|O )|O and|O human|O interferon|gene-protein (|O 120|O U|O /|O ml|O )|O .|O 
Subsequently|O however|O ,|O these|O cells|O could|O be|O propagated|O without|O any|O antiherpetic|O agents|O and|O almost|O 60|O %|O of|O the|O cell|O population|O contained|O viral|O genome|O .|O 
While|O these|O cells|O did|O not|O produce|O any|O infectious|O virus|O ,|O immunoblot|O analysis|O revealed|O two|O intracellular|O polypeptides|O with|O molecular|O weights|O of|O 87.5|O kDa|O and|O 67|O kDa|O ,|O respectively|O ,|O that|O interacted|O with|O hyperimmune|O anti|O -|O HSV2|O rabbit|O serum|O .|O 
Two|O cellular|O enzymes|O ,|O acetylcholinesterase|gene-protein and|O choline|gene-protein acetyltransferase|gene-protein ,|O involved|O in|O metabolism|O of|O neurotransmitters|O were|O expressed|O at|O a|O higher|O level|O in|O the|O latently|O infected|O cells|O than|O in|O the|O mock|O -|O infected|O control|O cells|O .|O 
Infectious|O HSV-2|O could|O be|O reactivated|O from|O these|O cells|O only|O after|O the|O cells|O had|O undergone|O massive|O morphological|O differentiation|O and|O maturation|O to|O flat|O cell|O types|O by|O extensive|O treatment|O with|O 20|O micron|O bromodeoxyuridine|O .|O 
DR-nm23|gene-protein expression|O affects|O neuroblastoma|O cell|O differentiation|O ,|O integrin|gene-protein expression|O ,|O and|O adhesion|O characteristics|O .|O 
BACKGROUND|O AND|O PROCEDURE|O :|O 
Nm23|gene-rna gene|O family|O has|O been|O associated|O with|O metastasis|O suppression|O and|O differentiation|O .|O 
We|O studied|O DR-nm23|gene-protein during|O neuroblastoma|O cells|O differentiation|O .|O 
DR-nm23|gene-protein expression|O increased|O after|O retinoic|O acid|O induction|O of|O differentiation|O in|O human|O cell|O lines|O SK-N-SH|O and|O LAN-5|O .|O 
RESULTS|O :|O 
In|O several|O cell|O lines|O ,|O overexpression|O of|O DR-nm23|gene-protein was|O associated|O with|O more|O differentiated|O phenotypes|O .|O 
SK-N-SH|O cells|O increased|O vimentin|gene-protein expression|O ,|O increased|O deposition|O of|O collagen|gene-protein type|gene-protein IV|gene-protein ,|O modulated|O integrin|gene-protein expression|O ,|O and|O underwent|O growth|O arrest|O ;|O the|O murine|O neuroblastoma|O cell|O line|O N1E-115|O showed|O neurite|O outgrowth|O and|O a|O striking|O enhancement|O of|O beta1|gene-protein integrin|gene-protein expression|O .|O 
Up|O -|O regulation|O of|O beta1|gene-protein integrin|gene-protein was|O specifically|O responsible|O for|O the|O increase|O in|O the|O adhesion|O to|O collagen|gene-protein type|gene-protein I|gene-protein -|O coated|O plates|O .|O 
Finally|O ,|O cells|O overexpressing|O DR-nm23|gene-protein were|O unable|O to|O growth|O in|O soft|O agar|O .|O 
CONCLUSIONS|O :|O 
In|O conclusion|O ,|O DR-nm23|gene-protein expression|O is|O directly|O involved|O in|O differentiation|O of|O neuroblastoma|O cells|O ,|O and|O its|O ability|O to|O affects|O the|O adhesion|O to|O extracellular|O substrates|O and|O to|O inhibit|O growth|O in|O soft|O agar|O suggests|O an|O involvement|O in|O the|O metastatic|O potential|O of|O neuroblastoma|O .|O 
Induced|O HMGA1a|gene-protein expression|O causes|O aberrant|O splicing|O of|O Presenilin-2|gene-rna pre|O -|O mRNA|O in|O sporadic|O Alzheimer|O 's|O disease|O .|O 
The|O aberrant|O splicing|O isoform|O (|O PS2V|O )|O ,|O generated|O by|O exon|O 5|O skipping|O of|O the|O Presenilin-2|gene-rna (|O PS2|gene-rna )|O gene|O transcript|O ,|O is|O a|O diagnostic|O feature|O of|O sporadic|O Alzheimer|O 's|O disease|O (|O AD|O )|O .|O 
We|O found|O PS2V|O is|O hypoxia|O -|O inducible|O in|O human|O neuroblastoma|O SK-N-SH|O cells|O .|O 
We|O purified|O a|O responsible|O trans|O -|O acting|O factor|O based|O on|O its|O binding|O to|O an|O exon|O 5|O fragment|O .|O 
The|O factor|O was|O identified|O as|O the|O high|O mobility|O group|O A1a|gene-protein protein|O (|O HMGA1a|gene-protein ;|O formerly|O HMG-I|gene-protein )|O .|O 
HMGA1a|gene-protein bound|O to|O a|O specific|O sequence|O on|O exon|O 5|O ,|O located|O upstream|O of|O the|O 5|O '|O splice|O site|O .|O 
HMGA1a|gene-protein expression|O was|O induced|O by|O hypoxia|O and|O the|O protein|O was|O accumulated|O in|O the|O nuclear|O speckles|O with|O the|O endogenous|O splicing|O factor|O SC35|gene-protein .|O 
Overexpression|O of|O HMGA1a|gene-protein generated|O PS2V|O ,|O but|O PS2V|O was|O repressed|O by|O cotransfection|O with|O the|O U1|gene-protein snRNP|gene-protein 70|O K|O protein|O that|O has|O a|O strong|O affinity|O to|O HMGA1a|gene-protein .|O 
HMGA1a|gene-protein could|O interfere|O with|O U1|gene-protein snRNP|gene-protein binding|O to|O the|O 5|O '|O splice|O site|O and|O caused|O exon|O 5|O skipping|O .|O 
HMGA1a|gene-protein levels|O were|O significantly|O increased|O in|O the|O brain|O tissue|O from|O sporadic|O AD|O patients|O .|O 
We|O propose|O a|O novel|O mechanism|O of|O sporadic|O AD|O that|O involves|O HMGA1a|gene-protein -|O induced|O aberrant|O splicing|O of|O PS2|gene-rna pre|O -|O mRNA|O in|O the|O absence|O of|O any|O mutations|O .|O 
Regulation|O of|O methionine|gene-protein adenosyltransferase|gene-protein catalytic|O activity|O and|O messenger|O RNA|O in|O SH-SY5Y|O human|O neuroblastoma|O cells|O .|O 
The|O human|O neuroblastoma|O cell|O line|O SH-SY5Y|O was|O used|O to|O study|O the|O regulation|O of|O methionine|gene-protein adenosyltransferase|gene-protein (|O MAT|gene-protein II|gene-protein ;|O E.C.2.5.1.6.|O )|O catalytic|O activity|O and|O transcript|O levels|O in|O cells|O of|O neuronal|O origin|O .|O 
The|O cells|O were|O exposed|O for|O 24|O hr|O to|O a|O medium|O containing|O different|O concentrations|O of|O methionine|O (|O MAT|gene-protein substrate|O )|O as|O well|O as|O medium|O deficient|O of|O methionine|O .|O 
Furthermore|O ,|O cells|O were|O treated|O with|O hydroxycobalamin|O ,|O SAM|O ,|O and|O the|O competitive|O MAT|gene-protein inhibitor|O cycloleucine|O .|O 
The|O MAT|gene-protein catalytic|O activity|O was|O inversely|O correlated|O to|O methionine|O concentrations|O ,|O e.g.|O MAT|gene-protein Vmax|O increased|O 2|O -|O fold|O in|O cells|O grown|O in|O methionine|O -|O deficient|O medium|O as|O compared|O with|O cells|O cultured|O under|O standard|O conditions|O .|O 
Interestingly|O ,|O MAT|gene-protein Km|O also|O increased|O from|O 9.04|O +/-|O 0.44|O to|O 12.08|O +/-|O 0.83|O in|O the|O methionine|O -|O deficient|O medium|O .|O 
Hydroxycobalamin|O caused|O an|O increase|O in|O activity|O at|O 40|O microM|O while|O a|O decrease|O was|O observed|O at|O higher|O concentrations|O (|O 100|O ,|O 200|O ,|O and|O 400|O microM|O )|O .|O 
Cycloleucine|O caused|O a|O significant|O inhibition|O of|O MAT|gene-protein catalytic|O activity|O ,|O i.e.|O the|O inhibition|O was|O approximately|O 50|O %|O in|O the|O presence|O of|O 4|O mM|O cycloleucine|O .|O 
The|O relevance|O of|O these|O results|O for|O the|O understanding|O of|O observations|O on|O MAT|gene-protein catalytic|O activity|O in|O brains|O of|O patients|O with|O Alzheimer|O 's|O disease|O is|O discussed|O .|O 
Lack|O of|O HLA|gene-protein -|gene-protein class|gene-protein I|gene-protein antigens|gene-protein in|O human|O neuroblastoma|O cells|O :|O analysis|O of|O its|O relationship|O to|O TAP|gene-protein and|O tapasin|gene-protein expression|O .|O 
We|O studied|O the|O constitutive|O and|O the|O interferon|gene-protein (|gene-protein IFN|gene-protein )|gene-protein -|gene-protein gamma|gene-protein -|O induced|O expression|O of|O HLA|gene-protein class|gene-protein I|gene-protein antigen|gene-protein heavy|O chain|O ,|O beta2|gene-protein -|gene-protein microglobulin|gene-protein (|O beta2m|gene-protein )|O ,|O TAP-1|gene-protein ,|O TAP-2|gene-protein and|O tapasin|gene-protein in|O a|O panel|O of|O eleven|O neuroblastoma|O cell|O lines|O .|O 
Surface|O expression|O of|O HLA|gene-protein class|gene-protein I|gene-protein antigens|gene-protein was|O low|O in|O eight|O out|O of|O eight|O neuroblastoma|O cell|O lines|O bearing|O MYC-N|gene-rna amplification|O and/or|O 1p|O deletion|O ,|O while|O two|O out|O of|O three|O neuroblastoma|O cell|O lines|O lacking|O these|O genetic|O alterations|O showed|O normal|O expression|O .|O 
IFN-gamma|gene-protein treatment|O restored|O HLA|gene-protein class|gene-protein I|gene-protein antigen|gene-protein surface|O expression|O in|O all|O neuroblastoma|O cell|O lines|O .|O 
Eight|O out|O of|O 11|O neuroblastoma|O cell|O lines|O did|O not|O express|O TAP-1|gene-rna mRNA|O and|O three|O of|O them|O also|O lacked|O TAP-2|gene-rna mRNA|O .|O 
beta2|gene-rna m|gene-rna mRNA|O was|O barely|O detectable|O or|O absent|O in|O five|O neuroblastoma|O cell|O lines|O ,|O while|O tapasin|gene-rna mRNA|O was|O always|O expressed|O .|O 
IFN-gamma|gene-protein upregulated|O the|O expression|O of|O HLA|gene-protein class|gene-protein I|gene-protein heavy|O chain|O ,|O beta2|gene-protein m|gene-protein ,|O TAP-1|gene-protein ,|O TAP-2|gene-protein and|O tapasin|gene-protein ,|O as|O detected|O at|O mRNA|O or|O protein|O level|O .|O 
Post|O -|O transcriptional|O events|O were|O involved|O in|O altered|O TAP-1|gene-generic and|O beta2|gene-generic m|gene-generic expression|O in|O one|O peculiar|O neuroblastoma|O cell|O line|O .|O 
These|O data|O indicate|O that|O multiple|O mechanisms|O play|O a|O role|O in|O the|O HLA|gene-protein class|gene-protein I|gene-protein antigen|gene-protein -|O deficient|O phenotype|O of|O human|O neuroblastoma|O .|O 
Genetic|O changes|O associated|O with|O primary|O Merkel|O cell|O carcinoma|O .|O 
Merkel|O cell|O carcinoma|O (|O MCC|O )|O is|O a|O malignant|O tumor|O of|O the|O skin|O with|O a|O well|O -|O established|O neuroendocrine|O phenotype|O but|O an|O unknown|O histogenetic|O origin|O .|O 
Cytogenetic|O and|O molecular|O studies|O have|O shown|O evidence|O for|O genetic|O changes|O on|O the|O distal|O portion|O of|O chromosome|O 1p|O in|O different|O tumors|O with|O well|O -|O established|O neuroendocrine|O origins|O ,|O specifically|O neuroblastomas|O ,|O malignant|O melanomas|O ,|O and|O pheochromocytomas|O .|O 
Involvement|O of|O chromosome|O 1|O in|O MCC|O recently|O has|O been|O demonstrated|O by|O cytogenetic|O analysis|O and|O analysis|O of|O loss|O of|O heterozygosity|O (|O LOH|O )|O in|O metastatic|O tumor|O tissue|O .|O 
We|O performed|O analysis|O of|O LOH|O of|O the|O distal|O portion|O of|O chromosome|O 1p|O in|O paraffin|O material|O of|O 10|O primary|O MCCs|O after|O tissue|O microdissection|O ,|O using|O the|O polymorphic|O markers|O D1S160|O ,|O D1S243|O ,|O D1S468|O ,|O D1S1646|O ,|O and|O D1S1598|O .|O 
Seven|O of|O 10|O analyzed|O MCCs|O shared|O a|O distal|O deletion|O involving|O 1p35-36|O .|O 
None|O of|O the|O cases|O showed|O 1p|O involvement|O proximal|O to|O 1p35|O .|O 
The|O findings|O are|O similar|O to|O those|O described|O for|O malignant|O melanoma|O ,|O pheochromocytoma|O ,|O and|O neuroblastoma|O ,|O tumors|O known|O to|O originate|O from|O neural|O crest|O cells|O .|O 
In|O conjunction|O with|O previous|O cytogenetic|O data|O ,|O we|O conclude|O that|O Merkel|O cell|O carcinogenesis|O shares|O pathogenetic|O mechanisms|O with|O other|O neoplasms|O of|O neural|O crest|O derivation|O .|O 
Active|O repression|O of|O major|gene-rna histocompatibility|gene-rna complex|gene-rna class|gene-rna I|gene-rna genes|O in|O a|O human|O neuroblastoma|O cell|O line|O .|O 
Human|O neuronal|O cells|O express|O neither|O major|O histocompatibility|gene-rna complex|gene-rna (|gene-rna MHC|gene-rna )|gene-rna class|gene-rna I|gene-rna RNA|O nor|O cell|O surface|O molecules|O but|O can|O be|O induced|O to|O do|O so|O by|O various|O cytokines|gene-protein .|O 
In|O the|O present|O studies|O ,|O we|O report|O that|O expression|O of|O MHC|gene-generic class|gene-generic I|gene-generic in|O a|O neuroblastoma|O cell|O line|O ,|O CHP-126|O ,|O is|O actively|O repressed|O .|O 
This|O repression|O is|O mediated|O by|O the|O combined|O effects|O of|O a|O series|O of|O upstream|O silencer|O elements|O .|O 
Removal|O of|O the|O silencers|O reveals|O not|O only|O an|O active|O promoter|O element|O but|O also|O the|O presence|O of|O an|O active|O enhancer|O .|O 
Four|O silencers|O have|O been|O identified|O and|O shown|O to|O have|O distinct|O sequences|O ,|O binding|O factors|O ,|O and|O patterns|O of|O function|O .|O 
One|O element|O is|O located|O between|O -|O 724|O and|O -|O 697|O base|O pairs|O (|O bp|O )|O and|O corresponds|O to|O a|O silencer|O involved|O in|O tissue|O -|O specific|O regulation|O of|O class|gene-rna I|gene-rna gene|O expression|O .|O 
Three|O additional|O elements|O occur|O between|O -|O 503|O and|O -|O 402|O bp|O .|O 
One|O of|O these|O corresponds|O to|O a|O c-jun|gene-rna responsive|O element|O .|O 
Neither|O of|O the|O remaining|O elements|O corresponds|O to|O DNA|O sequences|O known|O to|O regulate|O expression|O of|O other|O genes|O .|O 
These|O data|O demonstrate|O that|O MHC|gene-rna class|gene-rna I|gene-rna expression|O normally|O is|O actively|O repressed|O in|O neuronal|O cells|O and|O suggest|O a|O model|O of|O rapid|O and|O specific|O triggering|O of|O class|gene-rna I|gene-rna in|O neuronal|O cells|O in|O response|O to|O infection|O .|O 
Identification|O of|O a|O human|O cDNA|O encoding|O a|O kinase|gene-protein -|O defective|O cdk5|gene-protein isoform|O .|O 
The|O cyclin|gene-protein -|gene-protein dependent|gene-protein kinase|gene-protein 5|gene-protein (|O Cdk5|gene-protein )|O catalytic|O subunit|O is|O expressed|O in|O both|O cycling|O and|O noncycling|O cells|O and|O is|O present|O in|O many|O tissues|O .|O 
Neuronal|O and|O muscle|O cells|O contain|O the|O highest|O amount|O of|O this|O protein|O .|O 
The|O p35|gene-protein protein|O ,|O which|O is|O expressed|O solely|O in|O the|O brain|O ,|O activates|O Cdk5|gene-protein .|O 
Cdk5|gene-protein activity|O is|O involved|O in|O terminal|O differentiation|O of|O neurons|O and|O muscle|O cells|O .|O 
We|O attempted|O to|O clone|O cdk5|gene-rna by|O PCR|O from|O a|O human|O fetal|O brain|O cDNA|O library|O .|O 
Surprisingly|O ,|O we|O amplified|O two|O forms|O of|O the|O cdk5|gene-rna gene|O ,|O the|O wild|O type|O and|O a|O cdk5|gene-rna variant|O that|O lacks|O the|O complete|O kinase|gene-protein domain|O VI|O .|O 
The|O variant|O is|O also|O found|O in|O SH-SY-5Y|O neuroblastoma|O cells|O but|O not|O in|O T|O -|O cells|O ,|O HeLa|O cells|O ,|O the|O thymus|O ,|O and|O placental|O tissue|O .|O 
The|O protein|O encoded|O by|O the|O cdk5|gene-rna variant|O ,|O the|O Cdk5|gene-protein isoform|gene-protein (|O Cdk5i|gene-protein )|O ,|O purifies|O with|O p35|gene-protein when|O coexpressed|O in|O insect|O cells|O .|O 
The|O activity|O associated|O with|O the|O heterodimer|O Cdk5i|gene-protein /|O p35|gene-protein is|O found|O to|O be|O appreciably|O weaker|O than|O the|O wild|O -|O type|O Cdk5|gene-protein /|O p35|gene-protein kinase|gene-protein .|O 
Moreover|O ,|O Cdk5i|gene-protein /|O p35|gene-protein cannot|O autophosphorylate|O its|O two|O subunits|O as|O with|O Cdk5|gene-protein /|O p35|gene-protein .|O 
Interestingly|O ,|O kinase|gene-protein -|O defective|O Cdk5i|gene-protein can|O abolish|O the|O activity|O of|O wild|O -|O type|O Cdk5|gene-protein when|O both|O are|O coexpressed|O with|O p35|gene-protein in|O insect|O cells|O ,|O suggesting|O that|O Cdk5i|gene-protein may|O have|O a|O function|O in|O regulating|O Cdk5|gene-protein activity|O in|O human|O cells|O too|O .|O 
Differential|O effect|O of|O p53|gene-generic on|O the|O promoters|O of|O mouse|O DNA|gene-rna polymerase|gene-rna beta|gene-rna gene|O and|O proliferating|gene-rna -|gene-rna cell|gene-rna -|gene-rna nuclear|gene-rna -|gene-rna antigen|gene-rna gene|O .|O 
A|O plasmid|O carrying|O the|O 5|O '|O flanking|O region|O of|O the|O mouse|O proliferating|gene-rna -|gene-rna cell|gene-rna -|gene-rna nuclear|gene-rna -|gene-rna antigen|gene-rna (|O PCNA|gene-rna )|O gene|O or|O DNA|gene-rna polymerase|gene-rna beta|gene-rna gene|O was|O fused|O with|O the|O chloramphenicol|gene-rna acetyltransferase|gene-rna (|O CAT|gene-rna )|O gene|O ,|O then|O cotransfected|O into|O mouse|O N18TG2|O cells|O with|O the|O expression|O plasmid|O for|O the|O p53|gene-rna gene|O .|O 
Expression|O of|O the|O wild|O -|O type|O p53|gene-generic repressed|O the|O CAT|gene-rna expression|O directed|O by|O the|O PCNA|gene-rna gene|O promoter|O ,|O while|O it|O had|O little|O effect|O on|O the|O DNA|gene-rna polymerase|gene-rna beta|gene-rna gene|O promoter|O .|O 
RNase|gene-protein protection|O analysis|O revealed|O that|O the|O repression|O of|O the|O PCNA|gene-rna gene|O promoter|O by|O p53|gene-generic was|O at|O the|O transcription|O step|O .|O 
Analysis|O with|O various|O deletion|O mutants|O in|O the|O PCNA|gene-rna gene|O promoter|O revealed|O that|O a|O specific|O sequence|O is|O not|O required|O for|O the|O repression|O ,|O suggesting|O that|O p53|gene-generic represses|O the|O PCNA|gene-rna gene|O promoter|O by|O interacting|O with|O some|O components|O of|O the|O basic|O transcription|O machinery|O .|O 
By|O analysis|O with|O various|O deletion|O mutants|O in|O the|O DNA|gene-rna polymerase|gene-rna beta|gene-rna gene|O promoter|O ,|O we|O identified|O the|O unique|O 10|O -|O bp|O palindromic|O sequence|O (|O -|O 24|O to|O -|O 15|O )|O ,|O in|O the|O presence|O of|O which|O p53|gene-generic was|O not|O able|O to|O repress|O the|O promoter|O activity|O .|O 
This|O sequence|O conferred|O resistance|O to|O p53|gene-generic repression|O onto|O the|O PCNA|gene-rna gene|O promoter|O ,|O when|O it|O was|O placed|O 21|O -|O bp|O upstream|O from|O the|O transcription|O -|O initiation|O site|O .|O 
Differential|O collagen|gene-protein biosynthesis|O by|O human|O neuroblastoma|O cell|O variants|O .|O 
Two|O morphologically|O distinct|O types|O of|O cells|O have|O been|O observed|O in|O cultures|O of|O human|O neuroblastoma|O cells|O .|O 
One|O ,|O designated|O N|O -|O type|O ,|O is|O composed|O of|O small|O neuroblast|O -|O like|O cells|O ;|O the|O other|O ,|O designated|O S|O -|O type|O ,|O is|O composed|O of|O large|O ,|O substrate|O -|O adherent|O cells|O .|O 
To|O obtain|O additional|O information|O on|O the|O nature|O of|O these|O two|O phenotypes|O ,|O we|O have|O investigated|O the|O collagen|gene-protein biosynthesis|O in|O several|O clones|O of|O human|O neuroblastoma|O cells|O with|O N|O -|O type|O ,|O S|O -|O type|O ,|O or|O mixed|O morphology|O ,|O using|O acrylamide|O gel|O electrophoresis|O ,|O ion|O exchange|O chromatography|O ,|O and|O Northern|O and|O Southern|O blots|O .|O 
A|O direct|O correlation|O between|O the|O proportion|O of|O cells|O with|O S|O -|O type|O morphology|O and|O the|O amount|O of|O collagen|gene-protein secreted|O was|O observed|O ,|O with|O the|O largest|O amount|O of|O collagen|gene-protein being|O produced|O by|O clones|O composed|O exclusively|O of|O S|O -|O type|O cells|O .|O 
Type|gene-protein I|gene-protein trimer|gene-protein and|O type|gene-protein III|gene-protein collagens|gene-protein were|O the|O two|O major|O isotypes|O secreted|O by|O these|O cells|O .|O 
The|O absence|O of|O secretion|O of|O the|O alpha|gene-protein 2|gene-protein (|gene-protein I|gene-protein )|gene-protein collagen|gene-protein chain|O was|O associated|O with|O absence|O of|O RNA|O coding|O for|O this|O protein|O chain|O .|O 
The|O pro|gene-rna -|gene-rna alpha|gene-rna 2|gene-rna gene|O of|O type|gene-protein I|gene-protein collagen|gene-protein was|O found|O highly|O methylated|O in|O these|O cells|O .|O 
Our|O data|O indicate|O that|O the|O presence|O of|O S|O -|O type|O cells|O in|O neuroblastoma|O cultures|O represents|O a|O differentiation|O of|O these|O neural|O crest|O -|O derived|O neuroblastic|O cells|O into|O glial|O cells|O such|O as|O Schwann|O cells|O .|O 
Traditional|O and|O emerging|O molecular|O markers|O in|O neuroblastoma|O prognosis|O :|O the|O good|O ,|O the|O bad|O and|O the|O ugly|O .|O 
BACKGROUND|O :|O 
Neuroblastomas|O (|O NB|O )|O are|O a|O heterogeneous|O group|O of|O childhood|O tumours|O with|O a|O wide|O range|O of|O likelihood|O for|O tumour|O progression|O .|O 
As|O traditional|O parameters|O do|O not|O ensure|O completely|O accurate|O prognostic|O grouping|O ,|O new|O molecular|O markers|O are|O needed|O for|O assessing|O the|O individual|O patient|O 's|O prognosis|O more|O precisely|O .|O 
PATIENTS|O AND|O METHODS|O :|O 
133|O NB|O of|O all|O stages|O were|O analysed|O in|O blind|O -|O trial|O fashion|O for|O telomerase|gene-protein activity|O (|O TA|O )|O ,|O expression|O of|O surviving|O ,|O and|O MYCN|gene-rna status|O .|O 
These|O data|O were|O correlated|O with|O other|O traditional|O prognostic|O indicators|O and|O disease|O outcome|O .|O 
RESULTS|O AND|O CONCLUSIONS|O :|O 
TA|O is|O a|O powerful|O independent|O prognostic|O marker|O for|O all|O stages|O and|O is|O capable|O of|O differentiating|O between|O good|O and|O poor|O outcome|O in|O putative|O "|O favourable|O "|O clinical|O or|O biological|O subgroups|O of|O NB|O patients|O .|O 
High|O surviving|O expression|O is|O associated|O with|O an|O adverse|O outcome|O ,|O but|O is|O more|O difficult|O to|O interprete|O than|O TA|O because|O survivin|gene-protein expression|O needs|O to|O be|O accurately|O quantified|O to|O be|O of|O predictive|O value|O .|O 
We|O propose|O an|O extended|O progression|O model|O for|O NB|O including|O emerging|O prognostic|O markers|O ,|O with|O emphasis|O on|O telomerase|gene-protein activity|O .|O 
Phorbol|O 12-myristate-13-acetate|O (|O PMA|O )|O stimulates|O a|O differential|O expression|O of|O cholecystokinin|gene-rna (|O CCK|gene-rna )|O and|O c-fos|gene-rna mRNA|O in|O a|O human|O neuroblastoma|O cell|O line|O .|O 
Regulation|O of|O cholecystokinin|gene-rna (|O CCK|gene-rna )|O and|O the|O proto|O -|O oncogene|O c-fos|gene-rna mRNA|O expression|O was|O studied|O in|O the|O human|O neuroblastoma|O cell|O line|O SK-N-MC|O .|O 
Cells|O were|O treated|O either|O with|O the|O tumor|O promoting|O phorbol-ester|O phorbol-12-myristate-13-acetate|O (|O PMA|O )|O ,|O the|O phosphodiesterase|gene-protein inhibitor|O isobutyl-methylxanthine|O (|O IBMX|O )|O ,|O which|O results|O in|O an|O elevated|O intracellular|O cyclic|O AMP|O (|O cAMP|O )|O level|O ,|O or|O with|O a|O combination|O of|O PMA|O and|O IBMX|O .|O 
The|O level|O of|O CCK|gene-rna and|O c-fos|gene-rna mRNA|O was|O determined|O by|O Northern|O -|O blot|O analysis|O with|O CCK|gene-rna and|O c-fos|gene-rna specific|O antisense|O RNA|O probes|O after|O 4|O -|O 24|O h|O of|O drug|O treatment|O .|O 
Treatment|O with|O PMA|O and|O IBMX|O for|O 4|O -|O 24|O hours|O transiently|O raised|O the|O CCK|gene-rna mRNA|O level|O approximately|O 1.5|O -|O 3.5|O times|O compared|O to|O the|O controls|O ,|O and|O the|O combination|O PMA|O and|O IBMX|O had|O an|O additive|O effect|O and|O elevated|O CCK|gene-rna mRNA|O abundance|O 1.5|O -|O 6.5|O times|O .|O 
Under|O the|O same|O experimental|O conditions|O ,|O both|O PMA|O and|O IBMX|O elevated|O the|O c-fos|gene-rna mRNA|O level|O approximately|O 3|O -|O 5.5|O times|O .|O 
The|O drug|O combination|O showed|O a|O pronounced|O synergistic|O effect|O and|O raised|O the|O c-fos|gene-rna mRNA|O level|O approximately|O 3|O -|O 20|O times|O as|O compared|O to|O controls|O .|O 
Apparently|O ,|O CCK|gene-rna and|O c-fos|gene-rna mRNA|O expression|O appears|O to|O be|O regulated|O by|O similar|O protein|gene-protein kinase|gene-protein C|gene-protein (|O PKC|gene-protein )|O and|O cAMP|O -|O dependent|O mechanisms|O in|O SK-N-MC|O cells|O .|O 
Expression|O of|O genes|O on|O human|O chromosome|O 21|O .|O 
Gene|O sequences|O were|O isolated|O from|O a|O lambda|O library|O containing|O inserts|O originating|O from|O human|O chromosome|O 21|O .|O 
One|O phage|O ,|O CP21G1|O ,|O had|O been|O selected|O on|O the|O basis|O of|O its|O lack|O of|O middle|O -|O repetitive|O sequences|O and|O its|O ability|O to|O hybridize|O with|O 32P|O -|O labeled|O cDNA|O synthesized|O from|O the|O cytoplasmic|O poly|O A+|O RNA|O of|O cultured|O fibroblasts|O .|O 
Further|O experiments|O revealed|O that|O the|O human|O insert|O in|O this|O phage|O is|O unique|O -|O sequence|O DNA|O ,|O maps|O to|O the|O long|O arm|O of|O chromosome|O 21|O ,|O and|O is|O expressed|O in|O fibroblasts|O and|O T|O cells|O .|O 
A|O panel|O of|O 127|O "|O unique|O -|O sequence|O "|O phage|O were|O also|O selected|O from|O the|O lambda|O library|O and|O were|O tested|O for|O hybridization|O to|O 32P|O -|O labeled|O cDNA|O synthesized|O from|O the|O cytoplasmic|O poly|O A+|O RNA|O of|O CCRF-HSB-2|O ,|O a|O T-blast|O leukemic|O line|O .|O 
Seventeen|O recombinants|O hybridized|O to|O the|O probe|O .|O 
One|O of|O these|O phages|O ,|O CP8|O ,|O contains|O a|O human|O unique|O -|O sequence|O DNA|O expressed|O in|O T|O cells|O and|O neuroblastoma|O cells|O .|O 
One|O phage|O (|O CP5|O )|O in|O the|O "|O unique|O -|O sequence|O "|O panel|O that|O had|O not|O hybridized|O to|O cDNA|O from|O T|O -|O cell|O RNA|O was|O found|O to|O carry|O a|O low|O -|O repeat|O sequence|O and|O to|O hybridize|O specifically|O to|O RNA|O from|O a|O neuroblastoma|O line|O .|O 
This|O phage|O appears|O to|O carry|O a|O brain|O -|O specific|O gene|O .|O 
Many|O of|O the|O genomic|O sequences|O related|O to|O the|O low|O -|O repeat|O sequence|O contained|O in|O CP5|O map|O to|O the|O short|O arm|O of|O chromosome|O 21|O .|O 
The|O cloned|O genes|O described|O here|O represent|O new|O markers|O for|O the|O detailed|O mapping|O of|O human|O chromosome|O 21|O and|O may|O prove|O valuable|O in|O studying|O tissue|O -|O specific|O gene|O regulation|O .|O 
Specific|O inhibition|O of|O pathological|O prion|gene-protein protein|O accumulation|O by|O small|O interfering|O RNAs|O .|O 
Development|O of|O transmissible|O spongiform|O encephalopathies|O (|O TSEs|O )|O pathogenesis|O requires|O the|O presence|O of|O both|O the|O normal|O host|O prion|gene-protein protein|O (|O PrP-sen|gene-protein )|O and|O the|O abnormal|O pathological|O proteinase-K|gene-protein resistant|gene-protein isoform|gene-protein (|O PrP-res|gene-protein )|O .|O 
PrP-res|gene-protein forms|O highly|O insoluble|O aggregates|O ,|O with|O self|O -|O perpetuating|O properties|O ,|O by|O binding|O and|O converting|O PrP-sen|gene-protein molecules|O into|O a|O likeness|O of|O themselves|O .|O 
In|O the|O present|O report|O ,|O we|O show|O that|O small|O interfering|O RNA|O (|O siRNA|O )|O duplexes|O trigger|O specific|O Prnp|gene-rna gene|O silencing|O in|O scrapie|O -|O infected|O neuroblastoma|O cells|O .|O 
A|O non|O -|O passaged|O ,|O scrapie|O -|O infected|O culture|O transfected|O with|O siRNA|O duplexes|O is|O depleted|O of|O PrP-sen|gene-protein and|O rapidly|O loses|O its|O PrP-res|gene-protein content|O .|O 
The|O use|O of|O different|O murine|O -|O adapted|O scrapie|O strains|O and|O host|O cells|O did|O not|O influence|O the|O siRNA|O -|O induced|O gene|O silencing|O efficiency|O .|O 
More|O than|O 80|O %|O of|O transfected|O cells|O were|O positive|O for|O the|O presence|O of|O fluorescein|O -|O labeled|O siRNA|O duplexes|O .|O 
No|O cytotoxicity|O associated|O with|O the|O use|O of|O siRNA|O was|O observed|O during|O the|O time|O course|O of|O these|O experiments|O .|O 
Despite|O a|O transient|O abrogation|O of|O PrP-res|gene-protein accumulation|O ,|O our|O results|O suggest|O that|O the|O use|O of|O siRNA|O may|O provide|O a|O new|O and|O promising|O therapeutic|O approach|O against|O prion|gene-protein diseases|O .|O 
Familial|O neuroendocrine|O tumors|O as|O a|O model|O of|O hereditary|O cancer|O .|O 
Familial|O neuroendocrine|O tumors|O are|O reviewed|O .|O 
The|O most|O dramatic|O advances|O have|O been|O in|O the|O application|O of|O molecular|O genetic|O techniques|O to|O define|O the|O affected|O genes|O and|O to|O develop|O predictive|O testing|O for|O patients|O with|O multiple|O endocrine|O neoplasia|O syndromes|O .|O 
Germline|O mutations|O at|O specific|O loci|O of|O the|O RET|gene-rna proto|O -|O oncogene|O have|O been|O demonstrated|O in|O patients|O with|O multiple|O endocrine|O neoplasia|O types|O IIA|O ,|O IIB|O ,|O and|O familial|O medullary|O thyroid|O carcinoma|O not|O associated|O with|O multiple|O endocrine|O neoplasia|O .|O 
This|O has|O led|O to|O direct|O DNA|O testing|O for|O these|O mutations|O in|O patients|O at|O risk|O for|O these|O syndromes|O .|O 
The|O approach|O to|O predictive|O testing|O ,|O diagnosis|O ,|O and|O early|O treatment|O of|O these|O patients|O is|O discussed|O as|O a|O model|O for|O the|O approach|O to|O hereditary|O cancers|O .|O 
Linkage|O testing|O with|O DNA|O markers|O is|O still|O required|O for|O patients|O with|O multiple|O endocrine|O neoplasia|O type|O I|O because|O the|O responsible|O gene|O has|O not|O yet|O been|O isolated|O .|O 
Efforts|O to|O clarify|O the|O etiologies|O of|O other|O familial|O neuroendocrine|O tumors|O not|O associated|O with|O multiple|O endocrine|O neoplasia|O continue|O .|O 
Familial|O pheochromocytoma|O ,|O neuroblastoma|O ,|O and|O carcinoid|O also|O are|O reviewed|O .|O 
The|O use|O of|O molecular|O genetic|O techniques|O as|O a|O powerful|O tool|O for|O the|O early|O identification|O and|O treatment|O of|O susceptible|O individuals|O is|O emphasized|O .|O 
Identification|O and|O characterization|O of|O neogenin|gene-rna ,|O a|O DCC|gene-rna -|O related|O gene|O .|O 
DCC|gene-rna (|O deleted|O in|O colorectal|O cancer|O )|O ,|O a|O candidate|O tumor|O suppressor|O gene|O located|O in|O chromosome|O band|O 18q21.2|O ,|O encodes|O a|O transmembrane|O protein|O of|O 1447|O amino|O acids|O .|O 
Neogenin|gene-protein ,|O a|O protein|O with|O nearly|O 50|O %|O amino|O acid|O identity|O to|O DCC|gene-protein ,|O was|O recently|O identified|O because|O of|O its|O dynamic|O expression|O in|O the|O developing|O nervous|O system|O and|O gastrointestinal|O tract|O of|O the|O chicken|O .|O 
To|O explore|O a|O role|O for|O the|O human|O neogenin|gene-rna (|O NGN|gene-rna )|O gene|O in|O cancer|O ,|O we|O have|O isolated|O cDNAs|O for|O two|O alternatively|O spliced|O forms|O of|O NGN|gene-rna ,|O encoding|O proteins|O of|O 1461|O and|O 1408|O amino|O acids|O .|O 
Fluorescence|O in|O situ|O hybridization|O studies|O (|O FISH|O )|O localized|O NGN|gene-rna in|O chromosome|O band|O 15q22|O ,|O a|O region|O infrequently|O affected|O by|O alterations|O in|O cancer|O .|O 
NGN|gene-rna transcripts|O of|O about|O 7.5|O and|O 5.5|O kb|O were|O detected|O in|O all|O adult|O tissues|O studied|O .|O 
In|O contrast|O to|O the|O frequent|O loss|O of|O DCC|gene-rna expression|O ,|O no|O alterations|O in|O NGN|gene-rna expression|O were|O observed|O in|O more|O than|O 50|O cancers|O studied|O ,|O including|O glioblastoma|O ,|O medulloblastoma|O ,|O neuroblastoma|O ,|O colorectal|O ,|O breast|O ,|O cervical|O and|O pancreatic|O cancer|O cell|O lines|O and|O xenografts|O .|O 
Based|O on|O their|O sequence|O conservation|O and|O similar|O expression|O during|O development|O ,|O DCC|gene-rna and|O NGN|gene-rna may|O have|O related|O functions|O .|O 
However|O ,|O the|O chromosomal|O location|O and|O ubiquitous|O expression|O of|O NGN|gene-rna in|O various|O human|O tumors|O suggest|O it|O is|O infrequently|O altered|O in|O cancer|O .|O 
ApoE|gene-protein synthesis|O in|O human|O neuroblastoma|O cells|O .|O 
Apolipoprotein|gene-protein E|gene-protein (|O apoE|gene-protein )|O is|O associated|O with|O the|O two|O hallmarks|O of|O Alzheimer|O 's|O disease|O :|O A|gene-protein beta|gene-protein deposits|O and|O neurofibrillary|O tangles|O .|O 
ApoE|gene-protein synthesis|O was|O detected|O in|O astrocytes|O by|O in|O situ|O hybridization|O but|O was|O not|O detected|O in|O neurons|O .|O 
Nevertheless|O ,|O different|O studies|O on|O apoE|gene-protein immunoreactivity|O reported|O the|O presence|O of|O apoE|gene-protein in|O neurons|O of|O Alzheimer|O ,|O control|O ,|O and|O necrosis|O pontisubicular|O brains|O .|O 
In|O this|O study|O ,|O we|O addressed|O the|O question|O of|O potential|O synthesis|O of|O apoE|gene-protein in|O neurons|O and|O its|O possible|O involvement|O in|O or|O in|O response|O to|O pathological|O conditions|O .|O 
To|O this|O purpose|O ,|O we|O have|O studied|O human|O neuronal|O cell|O lines|O (|O SY|O 5Y|O and|O Kelly|O cells|O )|O originating|O from|O neuroblastoma|O .|O 
Using|O monoclonal|gene-protein and|O polyclonal|gene-protein antibodies|gene-protein ,|O a|O 32|O -|O kDa|O band|O was|O detected|O in|O SY|O 5Y|O and|O Kelly|O cells|O ,|O before|O and|O after|O NGF|gene-protein differentiation|O .|O 
Two|O -|O dimensional|O gel|O electrophoresis|O analysis|O showed|O a|O typical|O profile|O of|O apoE|gene-protein spots|O resolved|O to|O the|O exact|O isoelectric|O points|O .|O 
By|O reverse|O transcription|O -|O polymerase|gene-protein chain|O reaction|O experiments|O ,|O we|O demonstrated|O the|O presence|O of|O apoE|gene-rna mRNA|O in|O these|O cell|O lines|O .|O 
SY|O 5Y|O cells|O synthesized|O the|O apoE3|gene-protein variant|O ,|O whereas|O Kelly|O cells|O expressed|O both|O apoE3|gene-protein and|O apoE4|gene-protein isoforms|O ,|O corroborating|O the|O two|O -|O dimensional|O gel|O results|O .|O 
These|O results|O suggested|O that|O apoE|gene-protein synthesis|O could|O occur|O in|O human|O neuronal|O cell|O lines|O under|O certain|O conditions|O .|O 
Internalization|O of|O beta-amyloid|gene-protein causes|O downregulation|O of|O apolipoprotein|gene-rna E|gene-rna mRNA|O expression|O in|O neuroblastoma|O cells|O .|O 
Apolipoprotein|gene-protein (|O apo|gene-protein )|O E|gene-protein ,|gene-protein like|O beta-amyloid|gene-protein (|O Abeta|gene-protein )|O ,|O is|O a|O key|O component|O of|O the|O senile|O plaques|O that|O characterize|O Alzheimer|O 's|O disease|O (|O AD|O )|O .|O 
Understanding|O how|O apoE|gene-protein participates|O in|O the|O formation|O of|O senile|O plaques|O is|O necessary|O to|O clarify|O the|O pathogenesis|O of|O AD|O ;|O however|O ,|O the|O mechanism|O remains|O unknown|O .|O 
In|O this|O study|O ,|O we|O investigated|O the|O changes|O of|O cellular|O apoE|gene-protein and|O its|O mRNA|O level|O induced|O by|O addition|O of|O extracellular|O Abeta|gene-protein to|O neuroblastoma|O cells|O .|O 
The|O presence|O of|O >|O or|O =|O 1.0|O micromol|O /|O L|O of|O Abeta|gene-protein induced|O a|O decrease|O of|O apoE|gene-rna mRNA|O expression|O and|O an|O increase|O in|O the|O immunofluorescence|O reactivity|O for|O intracellular|O apoE|gene-protein .|O 
Both|O Abeta|gene-protein and|O apoE|gene-protein were|O observed|O by|O electron|O -|O microscopy|O to|O be|O localized|O within|O lysosomes|O .|O 
The|O levels|O of|O intracellular|O apoE|gene-protein and|O its|O mRNA|O returned|O to|O the|O steady|O state|O time|O -|O dependently|O .|O 
These|O changes|O were|O attenuated|O by|O treatments|O with|O heparinase|gene-protein I|gene-protein or|O receptor|O -|O associated|O protein|O .|O 
These|O findings|O suggest|O that|O the|O internalized|O Abeta|gene-protein ,|O along|O with|O cellular|O apoE|gene-protein ,|O induces|O downregulation|O of|O apoE|gene-rna mRNA|O via|O a|O pathway|O possibly|O mediated|O by|O apoE|gene-protein receptors|gene-protein and|O heparin|gene-protein sulfate|gene-protein proteoglycans|gene-protein .|O 
A|O disorder|O of|O this|O physiological|O response|O could|O be|O linked|O to|O the|O development|O of|O AD|O .|O 
Sympathetic|O hyperplasia|O and|O neuroblastomas|O in|O transgenic|O mice|O expressing|O polyoma|gene-protein middle|gene-protein T|gene-protein antigen|gene-protein .|O 
Transgenic|O mice|O carrying|O a|O cDNA|O to|O the|O polyoma|O virus|O middle|gene-protein T|gene-protein (|gene-protein mT|gene-protein )|gene-protein antigen|gene-protein linked|O to|O the|O thymidine|gene-rna kinase|gene-rna promoter|O were|O generated|O to|O study|O the|O consequences|O of|O deregulated|O expression|O of|O mT|gene-protein -|gene-protein associated|gene-protein tyrosine|gene-protein kinase|gene-protein activity|O in|O a|O wide|O variety|O of|O tissues|O .|O 
Four|O independent|O transgenic|O founder|O animals|O were|O obtained|O ,|O from|O one|O of|O which|O was|O established|O a|O transgenic|O line|O .|O 
This|O mouse|O and|O all|O its|O offspring|O developed|O multiple|O neuroblastomas|O between|O 2|O and|O 3|O months|O of|O age|O .|O 
Expression|O of|O the|O transgene|O (|O assayed|O by|O tyrosine|gene-protein kinase|gene-protein assay|O and|O in|O situ|O hybridization|O )|O was|O restricted|O to|O the|O neurons|O of|O the|O central|O and|O peripheral|O nervous|O tissue|O ,|O probably|O because|O of|O a|O positional|O effect|O of|O the|O transgene|O integration|O .|O 
Characteristic|O preneoplastic|O lesions|O in|O the|O sympathetic|O ganglia|O and|O in|O the|O adrenal|O medulla|O were|O identified|O from|O which|O the|O neuroblastomas|O originated|O .|O 
The|O tumors|O arising|O in|O these|O mice|O show|O striking|O analogies|O to|O human|O neuroblastomas|O ,|O including|O the|O sites|O of|O development|O of|O the|O tumors|O ,|O their|O histological|O and|O ultrastructural|O appearance|O ,|O and|O the|O expression|O of|O diagnostic|O markers|O ,|O such|O as|O synaptophysin|gene-protein ,|O and|O high|O expression|O of|O the|O N-myc|gene-rna oncogene|O .|O 
This|O animal|O model|O thus|O provides|O a|O unique|O tool|O for|O studying|O growth|O control|O in|O sympathetic|O neuroblasts|O and|O the|O pathogenesis|O of|O neuroblastoma|O .|O 
Brain|O specific|O human|O genes|O ,|O NELL1|gene-rna and|O NELL2|gene-rna ,|O are|O predominantly|O expressed|O in|O neuroblastoma|O and|O other|O embryonal|O neuroepithelial|O tumors|O .|O 
NELL1|gene-rna and|O NELL2|gene-rna encode|O cysteine|O -|O rich|O amino|O acid|O sequences|O including|O six|O epidermal|gene-protein growth|gene-protein factor|gene-protein -|O like|O motifs|O ,|O which|O contain|O signal|O peptides|O at|O the|O N|O -|O terminals|O .|O 
The|O deduced|O amino|O acid|O sequences|O of|O both|O genes|O are|O 55|O %|O identical|O and|O their|O cysteine|O stretch|O structures|O are|O conserved|O .|O 
NELL1|gene-rna is|O expressed|O in|O the|O brain|O and|O kidney|O ,|O whereas|O NELL2|gene-rna is|O expressed|O specifically|O in|O the|O brain|O .|O 
The|O cell|O lineage|O expressing|O NELLs|gene-rna in|O the|O nervous|O system|O was|O investigated|O in|O established|O cell|O lines|O and|O central|O nervous|O system|O tumor|O tissues|O obtained|O from|O patients|O by|O Northern|O blot|O and|O reverse|O transcriptase|gene-protein -|O polymerase|gene-protein chain|O reaction|O analyses|O .|O 
NELL1|gene-rna and|O NELL2|gene-rna were|O predominantly|O expressed|O in|O neuroblastoma|O cell|O lines|O and|O little|O expressed|O in|O glioblastoma|O cell|O lines|O .|O 
NELL1|gene-rna and|O NELL2|gene-rna were|O also|O expressed|O in|O central|O neurocytoma|O ,|O medulloblastoma|O ,|O and|O some|O astrocytic|O tumors|O .|O 
Immunohistochemical|O analysis|O revealed|O that|O NELL2|gene-protein protein|O was|O localized|O in|O the|O cytoplasm|O of|O neurons|O .|O 
These|O results|O suggest|O that|O NELL2|gene-rna is|O predominantly|O expressed|O in|O the|O neuronal|O cell|O lineage|O in|O the|O human|O nervous|O system|O .|O 
NELL1|gene-rna is|O expressed|O mainly|O in|O tumors|O in|O the|O neuronal|O cell|O lineage|O .|O 
Transcriptional|O activation|O of|O the|O mouse|O peripherin|gene-rna gene|O by|O leukemia|O inhibitory|gene-protein factor|gene-protein :|O involvement|O of|O STAT|gene-protein proteins|O .|O 
Peripherin|gene-protein is|O a|O neuron|O -|O specific|O intermediate|O filament|O protein|O whose|O expression|O is|O activated|O in|O vitro|O by|O the|O neuropoietic|gene-protein cytokines|gene-protein leukemia|O inhibitory|gene-protein factor|gene-protein (|O LIF|gene-protein )|O and|O interleukin-6|gene-protein .|O 
We|O have|O studied|O the|O mechanisms|O of|O transcriptional|O activation|O of|O the|O peripherin|gene-rna gene|O by|O LIF|gene-protein .|O 
In|O particular|O ,|O we|O have|O identified|O a|O 70|O -|O bp|O element|O [|O peripherin|gene-protein cytokine|gene-protein -|O responsive|O element|O (|O Pe-CyRE|O )|O ]|O within|O the|O 5|O '|O -|O flanking|O sequences|O of|O the|O mouse|O peripherin|gene-rna gene|O (|O between|O -|O 930|O and|O -|O 860|O )|O that|O enhances|O transcription|O in|O two|O neuroblastoma|O cell|O lines|O ,|O NBFL|O and|O LA-N-2|O ,|O in|O response|O to|O LIF|gene-protein treatment|O .|O 
We|O have|O also|O shown|O by|O DNA|O mobility|O shift|O assays|O that|O treatment|O of|O cells|O by|O LIF|gene-protein induces|O the|O binding|O of|O protein|O complexes|O composed|O of|O at|O least|O two|O members|O of|O the|O signal|gene-protein transducers|gene-protein and|gene-protein activators|gene-protein of|gene-protein transcription|gene-protein (|gene-protein STAT|gene-protein )|gene-protein factor|gene-protein family|O to|O a|O cis|O element|O (|O Pe-APRE2|O )|O within|O Pe-CyRE|O .|O 
Furthermore|O ,|O the|O entire|O Pe-CyRE|O ,|O as|O well|O as|O Pe-APRE2|O ,|O conferred|O responsiveness|O onto|O a|O heterologous|O thymidine|gene-rna kinase|gene-rna promoter|O .|O 
However|O ,|O the|O response|O amplitude|O of|O the|O heterologous|O promoter|O to|O LIF|gene-protein was|O lower|O than|O that|O observed|O with|O the|O 5|O '|O -|O flanking|O sequences|O of|O the|O peripherin|gene-rna promoter|O ,|O suggesting|O that|O cooperative|O interactions|O with|O surrounding|O sequences|O of|O the|O peripherin|gene-rna gene|O are|O required|O for|O a|O full|O transcriptional|O activation|O .|O 
N-myc|gene-rna oncogene|O expression|O in|O histopathologically|O unrelated|O bilateral|O pediatric|O renal|O tumors|O .|O 
Renal|O tumors|O of|O childhood|O occasionally|O exhibit|O histopathologic|O and|O clinical|O features|O that|O preclude|O accurate|O diagnosis|O .|O 
Molecular|O and|O cell|O culture|O techniques|O may|O be|O helpful|O in|O better|O characterizing|O these|O cases|O .|O 
This|O approach|O was|O used|O to|O examine|O unusual|O bilateral|O renal|O tumors|O from|O a|O young|O boy|O .|O 
The|O left|O kidney|O tumor|O was|O an|O undifferentiated|O neoplasm|O with|O light|O microscopic|O features|O suggestive|O of|O both|O Wilms|O '|O tumor|O and|O neuroblastoma|O ,|O and|O the|O right|O kidney|O tumor|O was|O identified|O as|O multilocular|O cystic|O nephroma|O (|O MLCN|O )|O .|O 
In|O vitro|O tissue|O culture|O of|O tumor|O cells|O and|O hybridization|O experiments|O with|O an|O N-myc|gene-rna oncogene|O DNA|O probe|O contributed|O to|O a|O revised|O diagnosis|O of|O intrarenal|O neuroblastoma|O of|O the|O left|O kidney|O .|O 
A|O cell|O line|O established|O from|O the|O left|O tumor|O exhibited|O neurite|O outgrowth|O and|O was|O positive|O for|O neuron|O -|O specific|O enolase|gene-protein and|O synaptophysin|gene-protein .|O 
N-myc|gene-rna was|O greater|O than|O ten|O -|O fold|O amplified|O in|O chromosomal|O DNA|O from|O the|O left|O kidney|O tumor|O .|O 
Measurement|O of|O N-myc|gene-rna RNA|O expression|O enabled|O distinction|O between|O benign|O and|O malignant|O tumor|O tissue|O .|O 
The|O detection|O of|O N-myc|gene-rna gene|O amplification|O predicted|O a|O poor|O prognosis|O which|O was|O confirmed|O by|O the|O patient|O 's|O subsequent|O clinical|O course|O .|O 
Differential|O expression|O of|O N-myc|gene-rna and|O c-src|gene-rna proto|O -|O oncogenes|O during|O neuronal|O and|O schwannian|O differentiation|O of|O human|O neuroblastoma|O cells|O .|O 
Neuroblastoma|O (|O NB|O )|O cells|O can|O be|O induced|O to|O differentiate|O bidirectionally|O into|O either|O neuronal|O or|O schwannian|O cells|O by|O different|O inducers|O .|O 
However|O ,|O the|O underlying|O mechanisms|O are|O poorly|O understood|O .|O 
We|O examined|O the|O expression|O of|O N-myc|gene-rna and|O c-src|gene-rna genes|O in|O 3|O human|O NB|O -|O cell|O lines|O during|O either|O neuronal|O or|O schwannian|O differentiation|O in|O vitro|O ,|O since|O proto|O -|O oncogenes|O are|O considered|O to|O play|O a|O pivotal|O role|O in|O regulating|O cell|O proliferation|O and|O differentiation|O .|O 
Decreased|O N-myc|gene-rna expression|O and|O increased|O c-src|gene-rna expression|O were|O observed|O during|O neuronal|O differentiation|O by|O retinoic|O acid|O ,|O polyprenoic|O acid|O (|O E5166|O )|O and|O dibutyryl|O cyclic|O AMP|O ,|O whereas|O the|O expression|O of|O N-myc|gene-rna and|O c-src|gene-rna genes|O was|O considerably|O reduced|O during|O schwannian|O differentiation|O by|O bromodeoxyuridine|O ,|O demonstrating|O that|O the|O expression|O of|O N-myc|gene-rna and|O c-src|gene-rna genes|O was|O regulated|O independently|O in|O the|O bipolar|O differentiation|O processes|O of|O NB|O cells|O .|O 
Our|O results|O suggest|O that|O enhanced|O N-myc|gene-rna expression|O might|O be|O closely|O linked|O to|O the|O undifferentiated|O phenotypes|O of|O NB|O cells|O ,|O that|O c-src|gene-rna expression|O might|O be|O related|O to|O the|O neuronal|O differentiation|O of|O NB|O cells|O ,|O and|O that|O N-myc|gene-rna and|O c-src|gene-rna genes|O might|O be|O regulated|O independently|O in|O the|O determination|O of|O the|O bipolar|O differentiation|O of|O NB|O cells|O .|O 
Clinical|O relevance|O of|O TRKA|gene-protein expression|O on|O neuroblastoma|O :|O comparison|O with|O N-MYC|gene-rna amplification|O and|O CD44|gene-protein expression|O .|O 
TRKA|gene-rna expression|O was|O evaluated|O on|O 122|O untreated|O neuroblastomas|O by|O immunohistochemistry|O using|O an|O antibody|O with|O predetermined|O specificity|O .|O 
This|O procedure|O is|O simple|O and|O reliable|O for|O protein|O detection|O at|O cellular|O level|O in|O a|O routine|O clinical|O setting|O .|O 
Fourteen|O tumours|O were|O classified|O as|O benign|O ganglioneuroma|O with|O a|O restricted|O expression|O of|O TRKA|gene-protein on|O ganglion|O cells|O ;|O these|O patients|O were|O excluded|O from|O the|O following|O analysis|O .|O 
A|O total|O of|O 108|O tumours|O were|O classified|O as|O neuroblastoma|O or|O ganglioneuroblastoma|O ;|O 74|O expressed|O TRKA|gene-protein protein|O ,|O which|O strongly|O correlated|O with|O low|O stage|O ,|O absence|O of|O N-MYC|gene-rna amplification|O ,|O age|O (|O <|O 1|O year|O )|O ,|O CD44|gene-protein expression|O and|O favourable|O clinical|O outcome|O .|O 
In|O a|O univariate|O analysis|O including|O tumour|O stage|O ,|O age|O ,|O histology|O ,|O N-MYC|gene-rna amplification|O ,|O CD44|gene-protein and|O TRKA|gene-protein expression|O ,|O all|O parameters|O had|O significant|O prognostic|O value|O .|O 
The|O absence|O of|O TRKA|gene-protein expression|O on|O CD44|gene-protein -|O positive|O or|O N-MYC|gene-rna non|O -|O amplified|O tumours|O permits|O the|O characterization|O of|O a|O subgroup|O of|O patients|O with|O intermediate|O prognosis|O .|O 
However|O ,|O in|O a|O multivariate|O analysis|O taking|O into|O consideration|O the|O prognostic|O factors|O mentioned|O above|O ,|O CD44|gene-protein and|O tumour|O stage|O were|O the|O only|O independent|O prognostic|O factors|O for|O the|O prediction|O of|O patients|O '|O event|O -|O free|O survival|O .|O 
Variable|O expression|O and|O absence|O of|O mutations|O in|O p73|gene-rna in|O primary|O neuroblastoma|O tumors|O argues|O against|O a|O role|O in|O neuroblastoma|O development|O .|O 
In|O neuroblastoma|O ,|O a|O childhood|O tumor|O of|O neural|O crest|O ,|O a|O tumor|gene-rna suppressor|gene-rna gene|gene-rna located|O at|O 1p36|O has|O been|O implicated|O to|O play|O a|O major|O role|O in|O tumor|O aggressiveness|O and|O clinical|O prognosis|O .|O 
We|O have|O examined|O 30|O different|O staged|O primary|O neuroblastoma|O tumors|O using|O RT|O -|O PCR|O ,|O for|O expression|O of|O the|O p73|gene-rna gene|O located|O at|O 1p36.3|O ,|O and|O its|O correlation|O to|O other|O clinical|O and|O biological|O features|O of|O these|O tumors|O .|O 
No|O correlation|O between|O expression|O of|O p73|gene-rna and|O MYCN|gene-rna -|O amplification|O or|O 1p|O -|O deletion|O could|O be|O found|O ,|O five|O of|O ten|O 1p|O -|O deleted|O tumors|O showed|O detectable|O levels|O of|O p73|gene-rna ,|O and|O no|O mutations|O could|O be|O detected|O ,|O neither|O in|O the|O retained|O alleles|O nor|O in|O any|O other|O parts|O of|O the|O material|O .|O 
In|O five|O 1p|O -|O deleted|O cases|O the|O origin|O of|O deletion|O were|O determined|O ,|O two|O were|O of|O maternal|O and|O three|O of|O paternal|O origin|O .|O 
Both|O tumors|O with|O maternal|O 1p|O -|O loss|O showed|O detectable|O levels|O of|O p73|gene-rna ,|O whereas|O the|O three|O with|O paternal|O loss|O did|O not|O .|O 
This|O suggests|O that|O p73|gene-rna is|O expressed|O from|O the|O paternal|O allele|O only|O in|O advanced|O staged|O neuroblastoma|O tumors|O .|O 
Furthermore|O ,|O it|O suggests|O absence|O of|O correlation|O between|O p73|gene-rna -|O expression|O and|O stage|O in|O these|O tumors|O .|O 
In|O conclusion|O ,|O we|O could|O find|O no|O evidence|O for|O p73|gene-rna being|O the|O neuroblastoma|O tumor|gene-rna suppressor|gene-rna gene|gene-rna in|O 1p36|O .|O 
Synthesis|O and|O cytotoxic|O profile|O of|O a|O diphtheria|gene-protein toxin|gene-protein -|O neurotrophin-4|gene-protein chimera|O .|O 
A|O diphtheria|gene-protein toxin|gene-protein -|O neurotrophin-4/5|gene-protein (|O NT-4/5|gene-protein )|O chimera|O (|O DAB389-NT4|O )|O ,|O in|O which|O the|O native|O receptor|O binding|O domain|O of|O diphtheria|gene-protein toxin|gene-protein was|O replaced|O with|O a|O synthetic|O gene|O encoding|O rat|O NT-4/5|gene-protein ,|O was|O expressed|O ,|O refolded|O ,|O and|O purified|O .|O 
This|O fusion|O toxin|O has|O a|O deduced|O molecular|O mass|O of|O 60,163|O and|O is|O formed|O by|O joining|O the|O first|O 389|O amino|O acids|O of|O diptheria|gene-protein toxin|gene-protein to|O amino|O acids|O 1|O -|O 130|O of|O mature|O rat|O NT-4/5|gene-protein ,|O using|O an|O NH2|O -|O terminal|O bridge|O of|O 33|O additional|O amino|O acids|O including|O six|O consecutive|O histidines|O .|O 
Neural|O cell|O types|O expressing|O only|O p75LNGFR|gene-protein or|O p75LNGFR|gene-protein and|O full|O -|O length|O or|O truncated|O TrkB|gene-protein were|O used|O to|O evaluate|O the|O cytotoxic|O efficacy|O of|O DAB389-NT4|gene-protein .|O 
The|O fusion|O toxin|O produced|O a|O concentration|O -|O dependent|O killing|O of|O all|O cell|O populations|O ,|O with|O LC50|O values|O that|O largely|O reflected|O the|O known|O NT-4/5|gene-protein binding|O affinities|O for|O these|O receptor|O proteins|O .|O 
Mean|O LC50|O values|O ranged|O from|O 2,960|O pM|O in|O p75LNGFR|gene-protein -|O expressing|O neuro-2a|O neuroblastoma|O cells|O to|O 1,075|O and|O 70|O pM|O ,|O respectively|O ,|O in|O hippocampal|O astrocytes|O (|O p75LNGFR|gene-protein +|O /|O truncated|O TrkB|gene-protein +|O )|O and|O cerebellar|O granule|O cells|O (|O p75LNGFR|gene-protein +|O /|O TrkB|gene-protein +|O )|O .|O 
The|O LC50|O for|O DAB389-NT4|gene-protein in|O receptor|O -|O negative|O 3T3|O fibroblasts|O was|O 20|O nM|O .|O 
NT-4/5|gene-protein and|O brain|gene-protein -|gene-protein derived|gene-protein neurotrophic|gene-protein factor|gene-protein but|O not|O ciliary|gene-protein neurotrophic|gene-protein factor|gene-protein added|O in|O excess|O neutralized|O DAB389-NT4|gene-protein cytotoxicity|O .|O 
NT-4/5|gene-protein ,|O however|O ,|O did|O not|O reduce|O the|O cytotoxicity|O of|O intact|O diphtheria|gene-protein toxin|gene-protein .|O 
Ara-C|O induces|O apoptosis|O in|O monkey|O fibroblast|O cells|O .|O 
The|O effect|O of|O cytosine|O arabinoside|O (|O Ara-C|O )|O on|O cell|O viability|O has|O been|O studied|O in|O African|O green|O monkey|O kidney|O fibroblasts|O (|O CV1-P|O )|O .|O 
It|O has|O been|O shown|O previously|O that|O Ara-C|O -|O induced|O cell|O death|O in|O neurons|O is|O mediated|O by|O apoptosis|O .|O 
We|O investigated|O whether|O Ara-C|O can|O induce|O apoptosis|O also|O in|O CV1-P|O cells|O ,|O and|O if|O the|O apoptosis|O is|O p53|gene-protein -|O associated|O .|O 
For|O comparison|O ,|O human|O neuroblastoma|O cells|O (|O SH-SY5Y|O )|O were|O studied|O as|O a|O model|O of|O human|O neuronal|O cells|O .|O 
SYTO13|O /|O propidium|O iodide|O staining|O revealed|O condensed|O and|O fragmented|O nuclei|O in|O both|O cell|O lines|O .|O 
Ara-C|O treatment|O for|O 48|O h|O induced|O approximately|O 24|O %|O apoptosis|O in|O CV1-P|O cells|O whereas|O approximately|O 55|O %|O of|O SH-SY5Y|O cells|O were|O apoptotic|O .|O 
Ara-C|O increased|O the|O level|O of|O p53|gene-protein in|O both|O CV1-P|O and|O SH-SY5Y|O cells|O compared|O to|O control|O .|O 
The|O maximum|O level|O of|O p53|gene-protein in|O SH-SY5Y|O cells|O was|O reached|O at|O 12|O h|O and|O this|O then|O rapidly|O faded|O whereas|O CV1-P|O cells|O p53|gene-protein levels|O remained|O elevated|O after|O reaching|O their|O maximum|O .|O 
Caspase-3|gene-protein activity|O was|O 5|O -|O fold|O higher|O in|O human|O neuroblastoma|O cells|O than|O in|O monkey|O fibroblasts|O ,|O this|O reflected|O the|O decreased|O cell|O viability|O .|O 
Our|O results|O prove|O that|O Ara-C|O -|O induced|O apoptosis|O in|O CV1-P|O cells|O is|O associated|O with|O an|O increase|O of|O p53|gene-protein and|O activation|O of|O caspase-3|gene-protein .|O 
Ara-C|O -|O induced|O toxicity|O in|O CV1-P|O cells|O is|O modest|O compared|O to|O that|O seen|O in|O neuronal|O cells|O .|O 
Down|O -|O regulation|O of|O protein|gene-protein kinase|gene-protein C|gene-protein alpha|gene-protein and|O gamma|gene-protein and|O enhanced|O TPA|O -|O induced|O neurite|O formation|O in|O DAN|gene-rna -|O transfected|O neuroblastoma|O cells|O .|O 
DAN|gene-rna gene|O was|O first|O isolated|O by|O differential|O screening|O between|O rat|O 3Y1|O and|O v-src|gene-rna -|O transformed|O 3Y1|O cells|O and|O showed|O a|O tumor|O -|O suppressive|O activity|O toward|O v-src|gene-rna -|O transformed|O 3Y1|O cells|O .|O 
When|O DAN|gene-rna -|O transfected|O neuroblastoma|O cells|O were|O treated|O with|O a|O tumor|O promoter|O phorbol|O ester|O ,|O TPA|O ,|O neurite|O -|O like|O processes|O appeared|O within|O 2|O h|O whereas|O no|O apparent|O change|O was|O observed|O in|O the|O parent|O and|O vector|O -|O transfected|O cells|O up|O to|O 8|O h|O .|O 
This|O suggests|O some|O difference|O in|O TPA|gene-protein -|gene-protein receptor|gene-protein ,|O protein|gene-protein kinase|gene-protein C|gene-protein (|O PKC|gene-protein )|O ,|O between|O DAN|gene-rna -|O transfectants|O and|O the|O control|O cells|O .|O 
DAN|gene-rna -|O transfected|O SH-SY5Y|O cells|O showed|O complete|O loss|O in|O PKCalpha|gene-protein and|O a|O large|O decrease|O in|O PKCgamma|gene-protein .|O 
Similar|O down|O -|O regulation|O in|O PKCalpha|gene-protein and|O PKCgamma|gene-protein was|O also|O observed|O in|O DAN|gene-rna -|O transfected|O Ha-ras|gene-rna -|O transformed|O NIH|O 3T3|O cells|O .|O 
The|O decreased|O level|O of|O PKCalpha|gene-protein was|O partially|O recovered|O after|O treatment|O with|O a|O calpain|gene-protein inhibitor|O ,|O ZLLH|O .|O 
A|O 150|O -|O kDa|O proteolytic|O product|O of|O a|O calpain|gene-protein -|O specific|O substrate|O ,|O non|O -|O erythroid|O alpha-spectrin|gene-protein ,|O was|O detectable|O in|O DAN|gene-rna -|O transfected|O SH-SY5Y|O cells|O but|O not|O in|O the|O parent|O or|O vector|O -|O transfected|O control|O cells|O .|O 
This|O suggests|O that|O DAN|gene-rna -|O transfected|O cells|O contain|O activated|O calpain|gene-protein which|O may|O cause|O down|O -|O regulation|O of|O PKC|gene-protein and|O hence|O induce|O the|O altered|O TPA|O response|O .|O 
Retinoic|O acid|O regulates|O insulin|gene-protein -|gene-protein like|gene-protein growth|gene-protein factor|gene-protein II|gene-protein expression|O in|O a|O neuroblastoma|O cell|O line|O .|O 
Insulin|gene-protein -|gene-protein like|gene-protein growth|gene-protein factors|gene-protein (|O IGF-I|gene-protein and|O IGF-II|gene-protein )|O are|O mitogenic|O polypeptides|O that|O play|O an|O important|O role|O in|O normal|O growth|O and|O development|O .|O 
IGF-II|gene-protein has|O been|O shown|O to|O stimulate|O the|O growth|O of|O neuroblastoma|O tumors|O in|O an|O autocrine|O and|O paracrine|O fashion|O .|O 
Critical|O in|O determining|O the|O role|O of|O IGF-II|gene-protein in|O tumorigenesis|O is|O the|O necessity|O to|O delineate|O factors|O affecting|O the|O transcription|O of|O IGF-II|gene-protein in|O normal|O and|O tumor|O tissues|O .|O 
To|O date|O such|O factors|O are|O poorly|O characterized|O .|O 
In|O this|O study|O we|O find|O that|O retinoic|O acid|O (|O RA|O )|O ,|O a|O naturally|O occurring|O morphogen|O ,|O that|O has|O been|O shown|O to|O be|O indispensable|O in|O the|O development|O of|O the|O chick|O limb|O bud|O ,|O stimulates|O an|O increase|O in|O IGF-II|gene-rna messenger|O RNA|O (|O mRNA|O )|O in|O the|O Lan-1-15N|O neuroblastoma|O cell|O line|O .|O 
This|O increase|O in|O IGF-II|gene-protein is|O coincident|O with|O RA|O mediated|O inhibition|O of|O DNA|O synthesis|O .|O 
An|O increase|O in|O the|O steady|O state|O levels|O of|O IGF-II|gene-rna mRNA|O is|O detectable|O within|O 2|O h|O of|O RA|O treatment|O and|O maximal|O by|O 24|O h|O .|O 
In|O RA|O -|O treated|O Lan-1-15N|O cells|O ,|O IGF-II|gene-rna mRNA|O levels|O are|O regulated|O at|O the|O level|O of|O new|O gene|O transcription|O and|O result|O in|O an|O increase|O in|O IGF-II|gene-protein protein|O in|O the|O culture|O supernatant|O .|O 
These|O studies|O suggest|O one|O mechanism|O affecting|O the|O production|O of|O IGF-II|gene-protein in|O vivo|O may|O be|O mediated|O by|O RA|O and|O detail|O a|O model|O system|O by|O which|O transcriptional|O regulation|O of|O IGF-II|gene-rna mRNA|O can|O be|O analyzed|O .|O 
Cyclooxygenase-2|gene-protein stimulates|O production|O of|O amyloid|gene-protein beta-peptide|gene-protein in|O neuroblastoma|O x|O glioma|O hybrid|O NG108-15|O cells|O .|O 
Cyclooxygenase|gene-protein (|O COX|gene-protein )|O synthesizes|O bioactive|O prostaglandins|O from|O arachidonic|O acid|O ,|O and|O there|O are|O COX-1|gene-protein and|O COX-2|gene-protein isoforms|O with|O distinct|O pathophysiological|O functions|O .|O 
Recent|O studies|O demonstrated|O that|O COX-2|gene-protein expression|O was|O up|O -|O regulated|O in|O the|O brain|O of|O patients|O with|O Alzheimer|O 's|O disease|O .|O 
We|O established|O mouse|O neuroblastoma|O x|O rat|O glioma|O hybrid|O NG108-15|O cells|O stably|O expressing|O human|O COX-2|gene-protein .|O 
The|O COX-2|gene-protein -|O expressing|O cells|O showed|O 3|O -|O to|O 4|O -|O fold|O increases|O in|O both|O COX|gene-protein activity|O and|O prostaglandin|O E(2)|O production|O .|O 
The|O mRNA|O level|O of|O amyloid|gene-rna precursor|gene-rna protein|gene-rna (|O APP|gene-rna )|O was|O elevated|O by|O approximately|O 2|O -|O fold|O in|O the|O COX-2|gene-protein -|O expressing|O cells|O compared|O with|O mock|O -|O transfected|O cells|O .|O 
Amyloid|gene-protein beta-peptide|gene-protein and|O a|O secreted|O form|O of|O APP|gene-protein ,|O both|O derived|O from|O APP|gene-protein by|O proteolysis|O was|O also|O increased|O .|O 
Interestingly|O ,|O neurite|O outgrowth|O was|O stimulated|O in|O the|O COX-2|gene-protein -|O expressing|O cells|O with|O concomitant|O reduction|O of|O the|O cell|O proliferation|O rate|O .|O 
A|O selective|O COX-2|gene-protein inhibitor|O (|O JTE-522|O )|O and|O a|O nonselective|O COX|gene-protein inhibitor|O (|O indomethacin|O )|O suppressed|O production|O of|O amyloid|gene-protein beta-peptide|gene-protein and|O a|O secreted|O form|O of|O APP|gene-protein by|O inhibition|O of|O APP|gene-rna mRNA|O level|O ,|O suggesting|O that|O COX-2|gene-protein plays|O important|O roles|O in|O the|O neurodegenerative|O processes|O of|O Alzheimer|O 's|O disease|O .|O 
Identification|O and|O characterization|O of|O a|O retinoic|O acid|O -|O regulated|O human|O homologue|O of|O the|O unc-33|gene-rna -|gene-rna like|gene-rna phosphoprotein|gene-rna gene|O (|O hUlip|gene-rna )|O from|O neuroblastoma|O cells|O .|O 
A|O cDNA|O ,|O 7G1|gene-rna ,|O was|O isolated|O from|O retinoic|O acid|O (|O RA|O )|O differentiated|O neuroblastoma|O cells|O whose|O expression|O was|O high|O in|O human|O fetal|O brain|O and|O spinal|O cord|O mRNA|O but|O undetectable|O in|O adult|O brain|O or|O non|O -|O neuronal|O tissues|O .|O 
Sequence|O analysis|O indicates|O that|O 7G1|gene-rna is|O homologous|O to|O the|O Caenorhabditis|O elegans|O gene|O unc-33|gene-rna .|O 
A|O 5.5|O -|O kilobase|O pair|O full|O -|O length|O cDNA|O from|O a|O human|O fetal|O brain|O cDNA|O library|O contains|O an|O 1710|O -|O base|O pair|O open|O reading|O frame|O .|O 
Because|O the|O predicted|O 570|O amino|O acid|O sequence|O of|O 7G1|O shares|O 98|O %|O identity|O with|O the|O murine|O Ulip|gene-rna gene|O product|O ,|O an|O unc-33|gene-protein -|gene-protein like|gene-protein -|gene-protein phosphoprotein|gene-protein ,|O we|O refer|O to|O 7G1|gene-generic as|O the|O human|O Ulip|gene-generic (|O hUlip|gene-generic )|O .|O 
hUlip|gene-protein is|O also|O similar|O to|O the|O bacterial|O enzyme|O D-hydantoinase|gene-protein and|O the|O recently|O described|O vertebrate|O gene|O products|O CRMP62|gene-protein ,|O TOAD-64|gene-protein ,|O CRMP1|gene-protein ,|O CRMP2|gene-protein ,|O and|O mUNC|gene-protein .|O 
RA|O stimulates|O an|O increase|O in|O hUlip|gene-rna mRNA|O that|O is|O transcriptionally|O regulated|O .|O 
RA|O stimulates|O an|O increase|O in|O polypeptides|O of|O 58|O ,|O 60|O ,|O 65|O ,|O and|O 70|O kDa|O with|O the|O 58|O -|O and|O 65|O -|O kDa|O species|O being|O dephosphorylated|O forms|O of|O the|O 60|O -|O and|O 70|O -|O kDa|O species|O .|O 
This|O study|O presents|O a|O model|O in|O which|O to|O study|O the|O regulation|O and|O expression|O of|O the|O hUlip|gene-rna gene|O ,|O a|O member|O of|O an|O emerging|O family|O of|O molecules|O that|O potentially|O mediates|O signals|O involved|O in|O axonal|O outgrowth|O .|O 
Morphological|O and|O cytogenetic|O characterization|O and|O N-myc|gene-rna oncogene|O analysis|O of|O a|O newly|O established|O neuroblastoma|O cell|O line|O .|O 
A|O permanent|O cell|O line|O established|O from|O a|O xenograft|O of|O neuroblastoma|O which|O occurred|O in|O a|O 5|O -|O year|O -|O old|O girl|O was|O investigated|O for|O its|O morphological|O and|O biological|O characteristics|O .|O 
The|O cultured|O cells|O were|O tumorigenic|O in|O nude|O mice|O .|O 
Microscopically|O ,|O each|O tumor|O consisted|O of|O small|O round|O to|O polygonal|O cells|O with|O irregular|O nuclei|O and|O prominent|O nucleoli|O ,|O corresponding|O to|O the|O features|O of|O the|O primary|O and|O xenografted|O tumor|O cells|O .|O 
Electron|O microscopic|O examination|O revealed|O that|O both|O the|O transplanted|O tumor|O cells|O and|O the|O cultured|O cells|O contained|O scanty|O microtubules|O and|O dense|O -|O core|O neurosecretory|O granules|O .|O 
Chromosome|O analysis|O of|O this|O cell|O line|O showed|O monosomy|O for|O chromosomes|O 1|O ,|O 10|O ,|O 19|O and|O X|O ,|O and|O structural|O rearrangements|O involving|O chromosomes|O 8|O ,|O 17|O and|O 20|O ,|O in|O addition|O to|O numerous|O double|O minutes|O .|O 
The|O N-myc|gene-rna oncogene|O was|O found|O to|O be|O amplified|O 40|O -|O to|O 80|O -|O fold|O in|O the|O transplanted|O and|O cultured|O tumor|O cells|O ,|O as|O well|O as|O in|O the|O primary|O tumor|O cells|O .|O 
In|O situ|O hybridization|O with|O a|O digoxigenin|O -|O labeled|O uridine-triphosphate|O N-myc|gene-rna RNA|O probe|O detected|O abundant|O mRNA|O in|O the|O tumor|O cells|O .|O 
This|O neuroblastoma|O line|O may|O become|O a|O valuable|O in|O vitro|O experimental|O model|O system|O for|O studies|O aimed|O at|O better|O characterization|O of|O neuroblastoma|O .|O 
Rit|gene-protein promotes|O MEK|gene-protein -|O independent|O neurite|O branching|O in|O human|O neuroblastoma|O cells|O .|O 
Rit|gene-protein ,|O by|O sequence|O homology|O ,|O is|O a|O member|O of|O the|O Ras|gene-protein subfamily|O of|O small|gene-protein guanine|gene-protein triphosphatases|gene-protein (|O GTPases|gene-protein )|O .|O 
In|O PC6|O cells|O ,|O Rit|gene-protein signals|O through|O pathways|O both|O common|O to|O and|O different|O from|O those|O activated|O by|O Ras|gene-protein to|O promote|O cell|O survival|O and|O neurite|O outgrowth|O .|O 
However|O ,|O the|O specific|O morphological|O changes|O induced|O by|O Rit|gene-protein in|O human|O cells|O are|O not|O known|O .|O 
Here|O ,|O we|O show|O in|O a|O human|O neuronal|O model|O that|O Rit|gene-protein increases|O neurite|O outgrowth|O and|O branching|O through|O MEK|gene-protein -|O dependent|O and|O MEK|gene-protein -|O independent|O signaling|O mechanisms|O ,|O respectively|O .|O 
Adenoviral|O expression|O of|O wild|O -|O type|O or|O constitutively|O active|O Rit|gene-protein increased|O neurite|O initiation|O ,|O elongation|O and|O branching|O on|O endogenous|O matrix|O or|O a|O purified|O laminin-1|gene-protein substratum|O of|O SH-SY5Y|O cells|O as|O assessed|O using|O image|O analysis|O .|O 
This|O outgrowth|O was|O morphologically|O distinct|O from|O that|O promoted|O by|O constitutively|O active|O Ras|gene-protein or|O Raf|gene-protein (|O evidenced|O by|O increased|O branching|O and|O elongation|O )|O .|O 
Constitutively|O active|O Rit|gene-protein increased|O phosphorylation|O of|O ERK|gene-protein 1|gene-protein /|O 2|gene-protein ,|O but|O not|O Akt|gene-protein ,|O and|O the|O MEK|gene-protein inhibitor|O PD|O 098059|O blocked|O constitutively|O active|O Rit|gene-protein -|O induced|O neurite|O initiation|O but|O not|O elongation|O or|O branching|O .|O 
These|O results|O suggest|O that|O Rit|gene-protein plays|O a|O key|O role|O in|O human|O neuronal|O development|O and|O regeneration|O through|O activating|O both|O known|O and|O as|O yet|O undefined|O signaling|O pathways|O .|O 
Insulin|gene-generic -|gene-generic like|gene-generic growth|gene-generic factor|gene-generic I|gene-generic expression|O by|O tumors|O of|O neuroectodermal|O origin|O with|O the|O t|O (|O 11|O ;|O 22|O )|O chromosomal|O translocation|O .|O 
A|O potential|O autocrine|gene-protein growth|gene-protein factor|gene-protein .|O 
Expression|O of|O insulin|gene-rna -|gene-rna like|gene-rna growth|gene-rna factor|gene-rna I|gene-rna (|O IGF-I|gene-rna )|O mRNA|O by|O some|O tumor|O cell|O lines|O of|O neuroectodermal|O origin|O has|O been|O described|O .|O 
To|O further|O explore|O the|O significance|O of|O IGF-I|gene-rna mRNA|O expression|O in|O these|O tumors|O ,|O a|O more|O extensive|O analysis|O was|O performed|O .|O 
Most|O (|O 9|O of|O 10|O )|O neuroectodermal|O tumor|O cell|O lines|O with|O a|O t|O (|O 11|O ;|O 22|O )|O translocation|O (|O primitive|O neuroectodermal|O tumor|O [|O PNET|O ]|O ,|O Ewing|O 's|O sarcoma|O ,|O esthesioneuroblastoma|O )|O expressed|O IGF-I|gene-rna mRNA|O ,|O whereas|O 0|O of|O 15|O cell|O lines|O without|O the|O translocation|O (|O PNET|O ,|O neuroblastoma|O )|O expressed|O IGF-I|gene-generic .|O 
Furthermore|O ,|O inasmuch|O as|O all|O neuroblastoma|O (|O 12|O of|O 12|O )|O cell|O lines|O examined|O expressed|O IGF-II|gene-rna RNA|O ,|O the|O pattern|O of|O IGF|gene-generic expression|O could|O distinguish|O between|O these|O closely|O related|O tumors|O .|O 
CHP-100|O ,|O a|O PNET|O cell|O line|O with|O the|O t|O (|O 11|O ;|O 22|O )|O translocation|O ,|O was|O shown|O to|O secrete|O both|O IGF-I|gene-protein protein|O and|O an|O IGF|gene-protein binding|O protein|O ,|O IGFBP-2|gene-protein .|O 
This|O cell|O line|O also|O expressed|O the|O type|gene-rna I|gene-rna IGF|gene-rna receptor|gene-rna mRNA|O ,|O and|O blockade|O of|O this|O receptor|O by|O a|O monoclonal|O antibody|O (|O alpha|gene-protein IR3|gene-protein )|O inhibited|O serum|O -|O free|O growth|O .|O 
These|O data|O demonstrate|O that|O IGF-I|gene-generic expression|O is|O a|O property|O of|O neuroectodermal|O tumors|O with|O a|O t|O (|O 11|O ;|O 22|O )|O translocation|O and|O that|O interruption|O of|O an|O IGF-I|gene-generic autocrine|O loop|O inhibits|O the|O growth|O of|O these|O tumor|O cells|O .|O 
Applications|O of|O gene|O transfer|O to|O targeted|O radiotherapy|O .|O 
r.mairs@beatson.gla.ac.uk|O 
For|O targeted|O radionuclide|O therapy|O to|O succeed|O as|O a|O single|O modality|O treatment|O ,|O schemes|O must|O be|O devised|O which|O will|O enable|O the|O deposition|O in|O malignant|O cells|O of|O sterilising|O doses|O of|O radiation|O .|O 
Until|O such|O methods|O have|O been|O perfected|O ,|O it|O is|O necessary|O to|O combine|O targeted|O radiotherapy|O in|O a|O rational|O manner|O with|O conventional|O anti|O -|O cancer|O treatments|O .|O 
Several|O means|O of|O delivery|O of|O therapeutic|O radionuclides|O are|O being|O evaluated|O but|O none|O of|O these|O yet|O appears|O to|O be|O as|O powerful|O as|O the|O simplest|O and|O most|O effective|O example|O ,|O viz|O :|O sodium|O [131I]iodide|O treatment|O of|O disseminated|O thyroid|O carcinoma|O .|O 
The|O radiopharmaceutical|O [131I]meta-iodobenzylguanidine|O (|O [131I]MIBG|O )|O is|O an|O effective|O single|O agent|O for|O the|O treatment|O of|O neuroblastoma|O .|O 
However|O ,|O uptake|O of|O the|O drug|O in|O malignant|O sites|O is|O heterogeneous|O ,|O suggesting|O that|O this|O therapy|O alone|O is|O unlikely|O to|O cure|O disease|O .|O 
A|O growing|O body|O of|O experimental|O evidence|O indicates|O exciting|O possibilities|O for|O the|O integration|O of|O gene|O transfer|O with|O radionuclide|O targeting|O .|O 
This|O review|O covers|O aspects|O of|O the|O combination|O of|O gene|O manipulation|O and|O targeted|O radiotherapy|O ,|O emphasising|O the|O potential|O of|O gene|O transfer|O to|O facilitate|O tumour|O targeting|O with|O low|O molecular|O weight|O radiopharmaceuticals|O .|O 
Reverse|O -|O phase|O high|O -|O performance|O liquid|O chromatography|O of|O nerve|gene-protein growth|gene-protein factor|gene-protein receptor|gene-protein -|gene-protein like|gene-protein proteins|gene-protein identified|O with|O monoclonal|gene-protein antibodies|gene-protein .|O 
Human|O neuroblastoma|O SK-N-SH-SY5Y|O (|O SY5Y|O )|O and|O rat|O pheochromocytoma|O PC12|O cells|O are|O model|O cell|O lines|O used|O in|O the|O study|O of|O nerve|gene-protein growth|gene-protein factor|gene-protein (|O NGF|gene-protein )|O effect|O .|O 
The|O effects|O of|O NGF|gene-protein are|O initiated|O by|O binding|O to|O cell|gene-protein surface|gene-protein receptors|gene-protein (|O NGFR|gene-protein )|O .|O 
The|O amino|O acid|O sequence|O for|O NGFR|gene-protein has|O been|O deduced|O based|O on|O the|O identification|O of|O a|O single|O gene|O for|O NGFR|gene-protein .|O 
However|O ,|O there|O are|O two|O kinds|O of|O NGF|gene-protein binding|O activities|O and|O several|O reported|O molecular|O weights|O of|O NGFR|gene-protein .|O 
We|O report|O here|O on|O the|O demonstration|O of|O NGFR|gene-protein -|gene-protein like|gene-protein proteins|gene-protein from|O PC12|O and|O SY5Y|O cells|O by|O sequential|O lectin|gene-protein chromatography|O ,|O reverse|O -|O phase|O HPLC|O ,|O and|O SDS-PAGE|O analysis|O of|O immunoprecipitates|O obtained|O with|O NGFR|gene-protein -|gene-protein specific|gene-protein monoclonal|gene-protein antibodies|gene-protein .|O 
For|O both|O human|O and|O rodent|O NGFR|gene-protein ,|O there|O was|O a|O tendency|O for|O the|O higher|O molecular|O -|O weight|O species|O of|O NGFR|gene-protein -|gene-protein like|gene-protein proteins|gene-protein to|O be|O eluted|O in|O more|O hydrophobic|O fractions|O .|O 
Also|O ,|O the|O expression|O of|O different|O species|O of|O NGFR|gene-protein could|O be|O modified|O by|O treatment|O with|O retinoic|O acid|O (|O RA|O )|O .|O 
These|O results|O are|O consistent|O with|O the|O hypothesis|O that|O the|O different|O molecular|O species|O of|O NGFR|gene-protein may|O result|O from|O the|O generation|O of|O a|O truncated|O form|O of|O NGFR|gene-protein ,|O the|O presence|O of|O sugar|O residues|O on|O the|O NGFR|gene-protein protein|O ,|O dimer|O formation|O between|O NGFR|gene-protein ,|O or|O the|O association|O of|O NGFR|gene-protein with|O a|O receptor|gene-protein -|gene-protein associated|gene-protein protein|gene-protein .|O 
The|O transcription|O factor|O Sox10|gene-protein is|O a|O key|O regulator|O of|O peripheral|O glial|O development|O .|O 
The|O molecular|O mechanisms|O that|O determine|O glial|O cell|O fate|O in|O the|O vertebrate|O nervous|O system|O have|O not|O been|O elucidated|O .|O 
Peripheral|O glial|O cells|O differentiate|O from|O pluripotent|O neural|O crest|O cells|O .|O 
We|O show|O here|O that|O the|O transcription|O factor|O Sox10|gene-protein is|O a|O key|O regulator|O in|O differentiation|O of|O peripheral|O glial|O cells|O .|O 
In|O mice|O that|O carry|O a|O spontaneous|O or|O a|O targeted|O mutation|O of|O Sox10|gene-protein ,|O neuronal|O cells|O form|O in|O dorsal|O root|O ganglia|O ,|O but|O Schwann|O cells|O or|O satellite|O cells|O are|O not|O generated|O .|O 
At|O later|O developmental|O stages|O ,|O this|O lack|O of|O peripheral|O glial|O cells|O results|O in|O a|O severe|O degeneration|O of|O sensory|O and|O motor|O neurons|O .|O 
Moreover|O ,|O we|O show|O that|O Sox10|gene-protein controls|O expression|O of|O ErbB3|gene-rna in|O neural|O crest|O cells|O .|O 
ErbB3|gene-rna encodes|O a|O Neuregulin|gene-protein receptor|gene-protein ,|O and|O down|O -|O regulation|O of|O ErbB3|gene-rna accounts|O for|O many|O changes|O in|O development|O of|O neural|O crest|O cells|O observed|O in|O Sox10|gene-protein mutant|O mice|O .|O 
Sox10|gene-protein also|O has|O functions|O not|O mediated|O by|O ErbB3|gene-rna ,|O for|O instance|O in|O the|O melanocyte|O lineage|O .|O 
Phenotypes|O observed|O in|O heterozygous|O mice|O that|O carry|O a|O targeted|O Sox10|gene-protein null|O allele|O reproduce|O those|O observed|O in|O heterozygous|O Sox10|gene-protein (|O Dom|O )|O mice|O .|O 
Haploinsufficiency|O of|O Sox10|gene-protein can|O thus|O cause|O pigmentation|O and|O megacolon|O defects|O ,|O which|O are|O also|O observed|O in|O Sox10|gene-protein (|O Dom|O )|O /|O +|O mice|O and|O in|O patients|O with|O Waardenburg|O -|O Hirschsprung|O disease|O caused|O by|O heterozygous|O SOX10|gene-protein mutations|O .|O 
Effects|O of|O inhibitors|O of|O ornithine|gene-protein decarboxylase|gene-protein on|O the|O differentiation|O of|O mouse|O neuroblastoma|O cells|O .|O 
(R,S)-alpha-Fluoromethylornithine|O (|O alpha-FMO|O )|O ,|O a|O catalytic|O irreversible|O inhibitor|O of|O ornithine|gene-protein decarboxylase|gene-protein (|O L-ornithine|gene-protein carboxy-lyase|gene-protein ,|O EC|O 4.1.1.17|O )|O ,|O induced|O the|O differentiation|O of|O N2a|O mouse|O neuroblastoma|O cells|O .|O 
The|O effect|O of|O alpha-FMO|O was|O concentration|O dependent|O ;|O approximately|O 50|O %|O of|O the|O cell|O population|O exhibited|O neurite|O outgrowth|O in|O the|O presence|O of|O 1|O mM|O alpha-FMO|O ,|O while|O higher|O concentrations|O caused|O severe|O growth|O inhibition|O and|O cell|O death|O .|O 
The|O effect|O of|O 1|O mM|O alpha-FMO|O on|O neuroblastoma|O differentiation|O was|O potentiated|O greatly|O by|O 0.1|O to|O 0.2|O mM|O N6,O2'-dibutyryl|O adenosine|O cyclic|O 3':5'-monophosphate|O (|O Bt2cAMP|O )|O causing|O more|O than|O 90|O %|O of|O the|O cell|O population|O to|O differentiate|O morphologically|O with|O thick|O and|O long|O processes|O ;|O 0.1|O to|O 0.2|O mM|O Bt2cAMP|O ,|O by|O itself|O ,|O had|O no|O effect|O on|O cell|O growth|O and|O did|O not|O induce|O neurite|O outgrowth|O .|O 
The|O effect|O of|O alpha-FMO|O ,|O either|O by|O itself|O or|O in|O combination|O with|O 0.1|O to|O 0.2|O mM|O Bt2cAMP|O ,|O on|O the|O morphological|O differentiation|O of|O mouse|O neuroblastoma|O cells|O was|O reversed|O by|O the|O addition|O of|O exogenous|O putrescine|O or|O spermidine|O .|O 
The|O morphological|O differentiation|O of|O mouse|O neuroblastoma|O cells|O induced|O by|O 1|O mM|O alpha-FMO|O plus|O 0.2|O mM|O Bt2cAMP|O was|O accompanied|O by|O increases|O of|O the|O regulatory|O subunit|O of|O the|O type|gene-protein I|gene-protein cAMP|gene-protein -|gene-protein binding|gene-protein protein|gene-protein and|O acetylcholinesterase|gene-protein activity|O .|O 
These|O results|O indicate|O that|O the|O modulation|O of|O cellular|O polyamine|O contents|O may|O be|O important|O in|O neuroblastoma|O cell|O differentiation|O .|O 
CNTF|gene-protein up|O -|O regulation|O of|O TIMP-2|gene-rna in|O neuroblastoma|O cells|O .|O 
The|O ciliary|gene-protein neurotrophic|gene-protein factor|gene-protein (|O CNTF|gene-protein )|O can|O regulate|O survival|O and|O differentiation|O of|O many|O types|O of|O developing|O and|O adult|O neurons|O ;|O in|O metastatic|O SK-N-BE|O neuroblastoma|O cells|O ,|O it|O promotes|O differentiation|O and|O neurite|O outgrowth|O .|O 
The|O expression|O of|O Gelatinase|gene-protein A|gene-protein (|O MMP-2|gene-protein )|O and|O its|O specific|gene-protein tissue|gene-protein inhibitor|gene-protein (|O TIMP-2|gene-protein )|O ,|O a|O degradative|O system|O whose|O balance|O is|O involved|O in|O matrix|O invasion|O and|O metastasis|O ,|O was|O investigated|O in|O SK-N-BE|O cells|O cultured|O with|O and|O without|O CNTF|gene-protein or|O NGF|gene-protein .|O 
Zymographic|O analysis|O of|O conditioned|O media|O revealed|O that|O the|O cells|O constitutively|O secrete|O two|O gelatinases|gene-protein ,|O mainly|O pro|gene-protein -|gene-protein MMP-2|gene-protein but|O also|O traces|O of|O pro|gene-protein -|gene-protein MMP-9|gene-protein .|O 
In|O a|O time|O -|O course|O experiment|O in|O the|O presence|O of|O 25|O ng|O /|O ml|O of|O CNTF|gene-protein ,|O the|O MMP-2|gene-rna mRNA|O expression|O showed|O no|O significant|O modulation|O ,|O while|O TIMP-2|gene-rna mRNA|O up|O -|O regulated|O to|O >|O 2|O -|O fold|O after|O 48|O h|O and|O then|O fell|O dramatically|O .|O 
At|O the|O same|O concentrations|O ,|O NGF|gene-protein showed|O no|O effect|O .|O 
TIMP-2|gene-rna mRNA|O expression|O showed|O a|O dose|O -|O dependent|O increase|O of|O up|O to|O 8|O -|O fold|O from|O 1|O to|O 250|O ng|O /|O ml|O of|O CNTF|gene-protein and|O increased|O secretion|O of|O TIMP-2|gene-protein was|O confirmed|O by|O Western|O blotting|O .|O 
MMP-2|gene-protein was|O only|O slightly|O over|O -|O expressed|O under|O the|O same|O conditions|O ,|O at|O either|O mRNA|O or|O protein|O level|O ,|O with|O no|O correlation|O with|O neurocytokine|O concentration|O .|O 
These|O results|O suggest|O that|O boosting|O the|O expression|O of|O TIMP-2|gene-rna by|O CNTF|gene-protein could|O restrain|O both|O matrix|O degradation|O following|O nervous|O system|O injury|O and|O neuroblastoma|O aggressiveness|O .|O 
Regulation|O of|O tyrosine|gene-rna hydroxylase|gene-rna gene|O expression|O in|O IMR-32|O neuroblastoma|O cells|O by|O basic|gene-protein fibroblast|gene-protein growth|gene-protein factor|gene-protein and|O ciliary|gene-protein neurotrophic|gene-protein factor|gene-protein .|O 
The|O actions|O of|O basic|gene-protein fibroblast|gene-protein growth|gene-protein factor|gene-protein (|O bFGF|gene-protein )|O and|O ciliary|gene-protein neurotrophic|gene-protein factor|gene-protein (|O CNTF|gene-protein )|O on|O tyrosine|gene-rna hydroxylase|gene-rna (|O TH|gene-rna )|O gene|O expression|O were|O studied|O using|O IMR-32|O neuroblastoma|O cells|O .|O 
Treatment|O of|O these|O cells|O with|O bFGF|gene-protein for|O 3|O days|O induced|O the|O expression|O of|O detectable|O levels|O of|O immunoreactive|O TH|gene-protein protein|O and|O TH|gene-rna mRNA|O .|O 
In|O contrast|O ,|O CNTF|gene-protein did|O not|O affect|O TH|gene-generic expression|O unless|O bFGF|gene-protein was|O present|O .|O 
In|O the|O presence|O of|O saturating|O amounts|O of|O bFGF|gene-protein ,|O CNTF|gene-protein increased|O TH|gene-protein protein|O and|O mRNA|O levels|O of|O TH|gene-rna two|O -|O to|O three|O fold|O over|O those|O found|O in|O bFGF|gene-protein -|O treated|O cultures|O .|O 
The|O effects|O of|O CNTF|gene-protein on|O TH|gene-generic expression|O diminished|O with|O increasing|O culture|O time|O ,|O and|O after|O 6|O days|O of|O incubation|O CNTF|gene-protein no|O longer|O enhanced|O TH|gene-generic levels|O .|O 
The|O requirement|O for|O bFGF|gene-protein as|O cofactor|O in|O the|O effects|O of|O CNTF|gene-protein on|O TH|gene-generic was|O specific|O ,|O as|O CNTF|gene-protein did|O not|O affect|O TH|gene-generic when|O it|O was|O coadministered|O with|O 8-(4-chlorophenylthio)-cyclic|O AMP|O ,|O another|O agent|O that|O stimulates|O TH|gene-generic development|O in|O this|O cell|O line|O ,|O and|O bFGF|gene-protein was|O not|O required|O for|O CNTF|gene-protein to|O stimulate|O the|O development|O of|O choline|gene-protein acetyltransferase|gene-protein .|O 
Moreover|O ,|O cotreatment|O with|O bFGF|gene-protein reduced|O the|O ability|O of|O CNTF|gene-protein to|O enhance|O choline|gene-protein acetyltransferase|gene-protein .|O 
These|O results|O demonstrate|O that|O bFGF|gene-protein and|O CNTF|gene-protein can|O enhance|O expression|O of|O TH|gene-generic and|O that|O bFGF|gene-protein can|O modify|O the|O effects|O of|O CNTF|gene-protein on|O neurotransmitter|O phenotype|O .|O 
Transcriptional|O regulation|O of|O the|O N-myc|gene-rna gene|O :|O identification|O of|O positive|O regulatory|O element|O and|O its|O double|O -|O and|O single|O -|O stranded|O DNA|O binding|O proteins|O .|O 
The|O N-myc|gene-rna gene|O is|O amplified|O and|O overexpressed|O in|O neuroblastoma|O ,|O retinoblastoma|O and|O small|O cell|O lung|O carcinoma|O ,|O and|O is|O considered|O to|O be|O related|O to|O cell|O proliferation|O and/or|O differentiation|O .|O 
The|O transcriptional|O regulatory|O sequences|O of|O the|O c-myc|gene-rna gene|O have|O been|O already|O identified|O ,|O while|O those|O of|O N-myc|gene-rna have|O remained|O obscure|O for|O a|O long|O time|O .|O 
In|O this|O report|O ,|O we|O have|O identified|O several|O positive|O and|O negative|O transcriptional|O regulatory|O elements|O in|O the|O upstream|O region|O of|O the|O mouse|O N-myc|gene-rna gene|O .|O 
Among|O them|O ,|O an|O activating|O sequence|O spanning|O -|O 860|O to|O -|O 797|O bp|O (|O 63|O bp|O )|O could|O be|O reduced|O to|O a|O functional|O core|O of|O 21|O bp|O from|O -|O 846|O to|O -|O 826|O .|O 
This|O sequence|O ,|O termed|O N21|O box|O ,|O worked|O as|O a|O positive|O transcriptional|O element|O when|O linked|O directly|O upstream|O (|O but|O not|O downstream|O )|O of|O the|O putative|O N-myc|gene-rna promoter|O in|O HeLa|O ,|O not|O in|O IMR32|O cells|O .|O 
At|O least|O two|O proteins|O ,|O of|O 42|O kDa|O and|O 100|O kDa|O ,|O bound|O to|O the|O double|O -|O stranded|O N21|O box|O ,|O and|O were|O expressed|O in|O HeLa|O as|O well|O as|O in|O IMR32|O cells|O .|O 
Moreover|O ,|O the|O plus|O strand|O of|O N21|O box|O could|O be|O specifically|O bound|O by|O a|O species|O of|O 42|O kDa|O from|O either|O cell|O type|O and|O by|O a|O 37|O kDa|O protein|O found|O only|O in|O HeLa|O cells|O .|O 
These|O proteins|O may|O be|O factors|O binding|O to|O positive|O transcriptional|O regulatory|O elements|O and|O may|O have|O a|O role|O in|O the|O regulation|O of|O N-myc|gene-rna expression|O .|O 
Regulation|O of|O neuronal|O proliferation|O and|O differentiation|O by|O nitric|O oxide|O .|O 
Many|O studies|O have|O revealed|O the|O free|O radical|O nitric|O oxide|O (|O NO|O )|O to|O be|O an|O important|O modulator|O of|O vascular|O and|O neuronal|O physiology|O .|O 
It|O also|O plays|O a|O developmental|O role|O in|O regulating|O synapse|O formation|O and|O patterning|O .|O 
Recent|O studies|O suggest|O that|O NO|O may|O also|O mediate|O the|O switch|O from|O proliferation|O to|O differentiation|O during|O neurogenesis|O .|O 
Many|O mechanisms|O of|O this|O response|O are|O conserved|O between|O neuronal|O precursor|O cells|O and|O the|O cells|O of|O the|O vascular|O system|O ,|O where|O NO|O can|O inhibit|O the|O proliferative|O response|O of|O endothelial|O and|O smooth|O -|O muscle|O cells|O to|O injury|O .|O 
In|O cultured|O neuroblastoma|O cells|O ,|O NO|gene-protein synthase|gene-protein (|O NOS|gene-protein )|O expression|O is|O increased|O in|O the|O presence|O of|O various|O growth|O factors|O and|O mitogens|O .|O 
Subsequent|O production|O of|O NO|O leads|O to|O cessation|O of|O cell|O division|O and|O the|O acquisition|O of|O a|O differentiated|O phenotype|O .|O 
The|O inhibitory|O action|O of|O NO|O on|O neuroblast|O proliferation|O has|O also|O been|O demonstrated|O in|O vivo|O for|O vertebrate|O and|O invertebrate|O nervous|O systems|O ,|O as|O well|O as|O in|O the|O adult|O brain|O .|O 
Potential|O downstream|O effectors|O of|O NO|O include|O the|O second|O messenger|O cyclic|O GMP|O ,|O activation|O of|O the|O tumor|gene-rna -|gene-rna suppressor|gene-rna genes|gene-rna p53|gene-rna and|O Rb|gene-rna ,|O and|O the|O cyclin|gene-protein -|gene-protein dependent|gene-protein kinase|gene-protein inhibitor|gene-protein p21|gene-protein .|O 
These|O studies|O highlight|O a|O new|O role|O for|O NO|O in|O the|O nervous|O system|O ,|O as|O a|O coordinator|O of|O proliferation|O and|O patterning|O during|O neural|O development|O and|O adult|O neurogenesis|O .|O 
Elevated|O expression|O of|O galanin|gene-protein receptors|gene-protein in|O childhood|O neuroblastic|O tumors|O .|O 
The|O neuropeptide|O galanin|gene-protein (|O GAL|gene-protein )|O has|O been|O shown|O to|O be|O present|O in|O certain|O brain|O tumors|O .|O 
In|O order|O to|O learn|O more|O about|O GAL|gene-protein and|O its|O receptors|O in|O human|O tumors|O of|O the|O peripheral|O nervous|O system|O ,|O we|O investigated|O the|O expression|O of|O the|O GAL|gene-protein peptide|O and|O the|O GAL|gene-protein receptors|gene-protein in|O tumor|O tissue|O from|O childhood|O neuroblastic|O tumors|O .|O 
GAL|gene-protein peptide|O concentrations|O up|O to|O 674|O +/-|O 166|O fmol|O /|O mg|O of|O tissue|O were|O detected|O by|O radioimmunoassay|O ,|O but|O no|O significant|O correlation|O with|O standard|O tumor|O markers|O or|O the|O prognosis|O of|O the|O 14|O patients|O investigated|O was|O observed|O .|O 
Ligand|O binding|O experiments|O showed|O different|O levels|O of|O GAL|gene-protein binding|O in|O all|O 28|O primary|O neuroblastomas|O and|O 7|O ganglioneuromas|O investigated|O .|O 
All|O three|O human|O GAL|gene-protein receptor|gene-protein subtypes|O cloned|O to|O date|O could|O be|O detected|O ,|O with|O the|O GALR1|gene-protein receptor|gene-protein subtype|O being|O expressed|O most|O prominently|O .|O 
GAL|gene-protein binding|O did|O not|O significantly|O correlate|O with|O genetic|O markers|O such|O as|O unfavorable|O DNA|O ploidy|O ,|O amplification|O of|O the|O oncogene|O MYCN|gene-rna and|O allelic|O loss|O of|O chromosome|O 1p|O .|O 
However|O ,|O low|O galanin|gene-protein binding|O was|O significantly|O correlated|O with|O survival|O (|O p|O =|O 0.021|O )|O in|O this|O limited|O analysis|O of|O neuroblastic|O tumor|O samples|O .|O 
These|O results|O raise|O the|O possibility|O that|O the|O expression|O of|O GAL|gene-protein binding|O sites|O may|O play|O a|O role|O in|O neuroblastic|O tumor|O biology|O and|O behavior|O .|O 
Rearrangements|O and|O increased|O expression|O of|O cyclin|gene-generic D1|gene-generic (|O CCND1|gene-generic )|O in|O neuroblastoma|O .|O 
Cyclin|gene-protein D1|gene-protein regulates|O G1|O cell|O cycle|O progression|O by|O controlling|O the|O phosphorylation|O of|O the|O retinoblastoma|gene-protein protein|gene-protein .|O 
This|O pathway|O is|O frequently|O deregulated|O in|O many|O malignancies|O .|O 
In|O neuroblastoma|O ,|O however|O ,|O no|O consistent|O G1|O cell|O cycle|O checkpoint|O aberrations|O have|O been|O found|O .|O 
We|O examined|O the|O possible|O deregulation|O of|O cyclin|gene-generic D1|gene-generic (|O CCND1|gene-generic )|O in|O this|O tumor|O .|O 
mRNA|O expression|O profiles|O of|O neuroblastoma|O generated|O by|O SAGE|O (|O Serial|O Analysis|O of|O Gene|O Expression|O )|O revealed|O a|O high|O expression|O of|O CCND1|gene-rna in|O a|O subset|O of|O neuroblastoma|O cell|O lines|O and|O tumors|O .|O 
The|O CCND1|gene-rna expression|O level|O can|O be|O 0.3|O %|O of|O the|O total|O cellular|O mRNA|O .|O 
Northern|O blot|O analysis|O of|O CCND1|gene-rna expression|O showed|O a|O relative|O overexpression|O in|O 16|O of|O 23|O neuroblastoma|O cell|O lines|O and|O 10|O of|O 15|O tumor|O samples|O .|O 
In|O the|O majority|O of|O cases|O ,|O the|O high|O CCND1|gene-rna mRNA|O levels|O also|O led|O to|O high|O CCND1|gene-protein protein|O levels|O .|O 
In|O the|O search|O for|O mechanisms|O causing|O this|O relative|O overexpression|O ,|O we|O screened|O for|O amplifications|O and|O rearrangements|O of|O CCND1|gene-rna .|O 
Five|O amplifications|O were|O found|O in|O 202|O neuroblastoma|O tumors|O and|O cell|O lines|O .|O 
Analysis|O of|O the|O 3'-UTR|O of|O CCND1|gene-rna showed|O a|O rearrangement|O in|O 1|O of|O 96|O tumors|O .|O 
These|O clonal|O aberrations|O of|O CCND1|gene-rna together|O with|O the|O high|O expression|O suggest|O a|O role|O for|O deregulated|O CCND1|gene-generic activity|O in|O neuroblastoma|O tumorigenesis|O .|O 
The|O expression|O of|O multiple|O proto|O -|O oncogenes|O is|O differentially|O regulated|O during|O retinoic|O acid|O induced|O maturation|O of|O human|O neuroblastoma|O cell|O lines|O .|O 
Human|O neuroblastoma|O (|O NB|O )|O is|O a|O highly|O malignant|O tumor|O arising|O in|O cells|O that|O originate|O in|O the|O embryonal|O neural|O crest|O .|O 
Several|O lines|O of|O investigation|O suggest|O that|O both|O NB|O and|O other|O tumors|O of|O developing|O tissues|O are|O blocked|O in|O their|O ability|O to|O differentiate|O and|O achieve|O growth|O arrest|O .|O 
Since|O in|O vivo|O differentiation|O of|O NB|O has|O been|O frequently|O observed|O and|O may|O be|O of|O clinical|O importance|O (|O Fox|O et|O al.|O ,|O 1959|O ;|O Evans|O et|O al.|O ,|O 1976|O )|O ,|O we|O have|O utilized|O the|O in|O vitro|O induction|O of|O NB|O differentiation|O by|O retinoic|O acid|O (|O RA|O )|O to|O study|O the|O molecular|O events|O associated|O with|O NB|O differentiation|O .|O 
We|O have|O focused|O our|O studies|O on|O changes|O that|O occur|O in|O the|O expression|O of|O various|O proto|O -|O oncogenes|O during|O NB|O tumors|O cell|O differentiation|O because|O proto|O -|O oncogenes|O are|O likely|O to|O be|O of|O central|O importance|O in|O mediating|O processes|O critical|O for|O cellular|O growth|O and|O maturation|O .|O 
In|O these|O studies|O ,|O we|O have|O found|O that|O the|O expression|O of|O no|O fewer|O than|O five|O proto|O -|O oncogenes|O including|O c-Ha-ras|gene-rna ,|O c-ets-1|gene-rna ,|O and|O c-fos|gene-rna change|O during|O the|O differentiation|O of|O NB|O cells|O ,|O while|O the|O expression|O of|O c-erb-B|gene-rna changes|O in|O association|O with|O the|O arrest|O of|O growth|O that|O occurs|O during|O NB|O differentiation|O .|O 
In|O some|O cases|O the|O altered|O expression|O of|O a|O proto|O -|O oncogene|O was|O transcriptionally|O regulated|O ,|O while|O in|O others|O post|O -|O transcriptional|O mechanisms|O were|O important|O .|O 
Genesis|gene-protein ,|O a|O winged|O helix|O transcriptional|O repressor|O with|O expression|O restricted|O to|O embryonic|O stem|O cells|O .|O 
A|O novel|O member|O of|O the|O winged|O helix|O (|O formerly|O HNF-3|gene-protein /|O Forkhead|gene-protein )|O transcriptional|O regulatory|O family|O ,|O termed|O Genesis|gene-protein ,|O was|O isolated|O and|O characterized|O .|O 
Putative|O translation|O of|O the|O complete|O cDNA|O revealed|O the|O winged|O helix|O DNA|O binding|O domain|O to|O be|O centrally|O located|O within|O the|O protein|O ,|O with|O regions|O on|O either|O side|O that|O contain|O known|O transcriptional|O regulatory|O motifs|O .|O 
Extensive|O Northern|O analysis|O of|O Genesis|gene-protein found|O that|O the|O message|O was|O exclusively|O expressed|O in|O embryonic|O stem|O cells|O or|O their|O malignant|O equivalent|O ,|O embryonal|O carcinoma|O cells|O .|O 
The|O Genesis|gene-rna transcript|O was|O down|O -|O regulated|O when|O these|O cells|O were|O stimulated|O to|O differentiate|O .|O 
DNA|O sequences|O that|O Genesis|gene-protein protein|O would|O interact|O with|O were|O characterized|O and|O were|O found|O to|O contain|O a|O consensus|O similar|O to|O that|O found|O in|O an|O embryonic|O stem|O cell|O enhancer|O sequence|O .|O 
Co|O -|O transfection|O experiments|O revealed|O that|O Genesis|gene-protein is|O a|O transcriptional|O repressor|O .|O 
Genesis|gene-generic mapped|O to|O mouse|O chromosome|O 4|O in|O a|O region|O syntenic|O with|O human|O chromosome|O 1p31|O ,|O a|O site|O of|O nonrandom|O abnormalities|O in|O germ|O cell|O neoplasia|O ,|O neuroblastoma|O ,|O and|O acute|O lymphoblastic|O leukemia|O .|O 
Genesis|gene-protein is|O a|O candidate|O for|O regulating|O the|O phenotype|O of|O normal|O or|O malignant|O embryonic|O stem|O cells|O .|O 
Genomic|O organization|O and|O neuronal|O cell|O type|O specific|O promoter|O activity|O of|O beta|gene-protein isoform|gene-protein of|gene-protein Ca(2+)|gene-protein /|gene-protein calmodulin|gene-protein dependent|gene-protein protein|gene-protein kinase|gene-protein II|gene-protein of|O rat|O brain|O .|O 
The|O gene|O encoding|O the|O beta|gene-protein isoform|gene-protein of|gene-protein rat|gene-protein Ca(2+)|gene-protein /|gene-protein calmodulin|gene-protein -|gene-protein dependent|gene-protein protein|gene-protein kinase|gene-protein II|gene-protein was|O cloned|O ,|O and|O its|O exon|O -|O intron|O organization|O was|O analyzed|O .|O 
The|O gene|O consisted|O of|O 21|O exons|O spanning|O more|O than|O 80|O kilobase|O pairs|O and|O the|O coding|O sequence|O was|O made|O up|O of|O 20|O exons|O .|O 
Each|O discrete|O functional|O unit|O ,|O such|O as|O the|O ATP|O -|O binding|O site|O ,|O the|O autophosphorylation|O site|O responsible|O for|O Ca(2+)|O -|O independent|O activity|O ,|O the|O calmodulin|gene-protein binding|O site|O ,|O and|O the|O link|O structure|O ,|O was|O encoded|O by|O a|O single|O exon|O .|O 
All|O splice|O junction|O sequences|O flanking|O the|O introns|O conformed|O to|O the|O consensus|O splice|O junction|O sequence|O and|O the|O GT|O -|O AG|O splice|O rule|O .|O 
The|O site|O of|O transcription|O initiation|O was|O -|O 78|O bases|O from|O the|O initiation|O codon|O as|O determined|O by|O 5|O '|O RACE|O analysis|O .|O 
The|O promoter|O activity|O of|O the|O gene|O was|O analyzed|O using|O neuroblastomas|O ,|O as|O well|O as|O non|O -|O neuronal|O cell|O lines|O .|O 
Neuronal|O cell|O type|O -|O specific|O promoter|O activity|O was|O found|O in|O the|O 5|O '|O -|O upstream|O region|O -|O 66|O to|O -|O 35|O bp|O from|O the|O transcription|O initiation|O site|O .|O 
Silence|O elements|O were|O found|O further|O upstream|O at|O -|O 222|O to|O -|O 123|O bp|O and|O -|O 576|O to|O -|O 323|O bp|O .|O 
A|O protein|O bound|O to|O the|O -|O 66|O to|O -|O 35|O region|O was|O found|O in|O the|O nuclear|O extract|O of|O rat|O brain|O ,|O including|O the|O cerebellum|O ,|O forebrain|O ,|O and|O brainstem|O ,|O by|O gel|O mobility|O shift|O assay|O .|O 
Treatment|O of|O postoperative|O chylothorax|O by|O pleurodesis|O with|O the|O streptococcal|O preparation|O OK-432|O .|O 
Of|O the|O 2877|O patients|O who|O underwent|O chest|O surgery|O at|O our|O department|O during|O the|O 20|O -|O year|O period|O between|O 1973|O and|O 1992|O ,|O 9|O (|O 0.3|O %|O )|O developed|O postoperative|O chylothorax|O .|O 
The|O underlying|O disease|O included|O primary|O lung|O cancer|O in|O 5|O patients|O ,|O pulmonary|O metastasis|O in|O 1|O ,|O invasive|O thymoma|O in|O 2|O ,|O and|O neuroblastoma|O of|O the|O posterior|O mediastinum|O in|O 1|O .|O 
For|O the|O treatment|O of|O chylothorax|O ,|O the|O thoracic|O duct|O was|O ligated|O in|O 2|O patients|O with|O a|O high|O volume|O of|O chylous|O leakage|O .|O 
In|O 6|O patients|O treated|O conservatively|O ,|O early|O pleurodesis|O was|O attained|O by|O injecting|O 1|O to|O 5|O doses|O (|O mean|O :|O 2.2|O doses|O )|O of|O the|O streptoccal|O preparation|O OK-432|O intrathoracically|O ;|O favorable|O results|O were|O achieved|O .|O 
In|O 1|O patient|O ,|O the|O diagnosis|O of|O chylothorax|O was|O delayed|O because|O of|O postoperative|O pyothorax|O .|O 
This|O patient|O developed|O nutritional|O deficiency|O ,|O compromised|O immunity|O ,|O and|O disseminated|O intravascular|O coagulation|O (|O DIC|O )|O ,|O which|O led|O to|O death|O before|O the|O chylothorax|O could|O be|O treated|O .|O 
In|O principle|O ,|O postoperative|O chylothorax|O should|O be|O treated|O conservatively|O .|O 
Favorable|O results|O can|O be|O expected|O with|O the|O intrathoracic|O injection|O of|O OK-432|O beginning|O at|O the|O early|O postoperative|O period|O to|O achieve|O pleurodesis|O ,|O combined|O with|O the|O prevention|O of|O nutritional|O deficiency|O ,|O electrolyte|O imbalance|O ,|O and|O infection|O .|O 
Voltage|O -|O dependent|O blockade|O of|O connexin40|gene-protein gap|O junctions|O by|O spermine|O .|O 
The|O effects|O of|O spermine|O and|O spermidine|O ,|O endogenous|O polyamines|O that|O block|O many|O forms|O of|O ion|O channels|O ,|O were|O investigated|O in|O homotypic|O connexin|gene-protein (Cx)-40|gene-protein gap|O junctions|O expressed|O in|O N2A|O cells|O .|O 
Spermine|O blocked|O up|O to|O 95|O %|O of|O I(j)|O through|O homotypic|O Cx40|gene-protein gap|O junctions|O in|O a|O concentration|O -|O and|O transjunctional|O voltage|O (|O V(j)|O )|O -|O dependent|O manner|O .|O 
V(j)|O was|O varied|O from|O 5|O to|O 50|O mV|O in|O 5|O -|O mV|O steps|O and|O the|O dissociation|O constants|O (|O K(m)|O )|O were|O determined|O from|O spermine|O concentrations|O ranging|O from|O 10|O micro|O M|O to|O 2|O mM|O .|O 
The|O K(m)|O values|O ranged|O from|O 4.9|O mM|O to|O 107|O micro|O M|O for|O 8.6|O <|O or|O =|O V(j)|O <|O or|O =|O 37.7|O mV|O ,|O within|O the|O physiological|O range|O of|O intracellular|O spermine|O for|O V(j)|O >|O or|O =|O 20|O mV|O .|O 
The|O K(m)|O values|O for|O spermidine|O were|O >|O or|O =|O 5|O mM|O .|O 
Estimates|O of|O the|O electrical|O distance|O (|O delta|O )|O for|O spermine|O (|O z|O =|O +|O 4|O )|O and|O spermidine|O (|O z|O =|O +|O 3|O )|O were|O 0.96|O and|O 0.76|O respectively|O .|O 
Cx40|gene-protein single|O channel|O conductance|O was|O 129|O pS|O in|O the|O presence|O of|O 2|O -|O mM|O spermine|O and|O channel|O open|O probability|O was|O significantly|O reduced|O in|O a|O V(j)|O -|O dependent|O manner|O .|O 
Similar|O concentrations|O of|O spermine|O did|O not|O block|O I(j)|O through|O homotypic|O Cx43|gene-protein gap|O junctions|O ,|O indicating|O that|O spermine|O selectively|O blocks|O Cx40|gene-protein gap|O junctions|O .|O 
This|O is|O contrary|O to|O our|O previous|O findings|O that|O large|O tetraalkylammonium|O ions|O ,|O also|O known|O to|O block|O several|O forms|O of|O ion|O channels|O ,|O block|O junctional|O currents|O (|O I(j)|O )|O through|O homotypic|O connexin|gene-protein Cx40|gene-protein and|O Cx43|gene-protein gap|O junctions|O .|O 
Tyrosine|O phosphorylation|O of|O the|O beta-amyloid|gene-protein precursor|gene-protein protein|gene-protein cytoplasmic|O tail|O promotes|O interaction|O with|O Shc|gene-protein .|O 
beta-Amyloid|gene-protein precursor|gene-protein protein|gene-protein (|O APP|gene-protein )|O is|O a|O widely|O expressed|O transmembrane|O protein|O of|O unknown|O function|O that|O is|O involved|O in|O the|O pathogenesis|O of|O Alzheimer|O 's|O disease|O .|O 
The|O cytoplasmic|O tail|O of|O APP|gene-protein interacts|O with|O phosphotyrosine|O binding|O (|O PTB|O )|O domain|O containing|O proteins|O (|O Fe65|gene-protein ,|O X11|gene-protein ,|O mDab-1|gene-protein ,|O and|O JIP-1|gene-protein )|O and|O may|O modulate|O gene|O expression|O and|O apoptosis|O .|O 
We|O now|O identify|O Shc|gene-protein A|gene-protein and|O Shc|gene-protein C|gene-protein ,|O PTB|O -|O containing|O adapter|O proteins|O that|O signal|O to|O cellular|O differentiation|O and|O survival|O pathways|O ,|O as|O novel|O APP|gene-protein -|O interacting|O proteins|O .|O 
The|O APP|gene-protein cytoplasmic|O tail|O contains|O a|O PTB|O -|O binding|O motif|O (|O Y|O (|O 682|O )|O ENPTY|O (|O 687|O )|O )|O that|O ,|O when|O phosphorylated|O on|O Tyr|O (|O 682|O )|O ,|O precipitated|O the|O PTB|O domain|O of|O Shc|gene-protein A|gene-protein and|O Shc|gene-protein C|gene-protein ,|O as|O well|O as|O endogenous|O full|O -|O length|O Shc|gene-protein A|gene-protein .|O APP|gene-protein and|O Shc|gene-protein C|gene-protein were|O physically|O associated|O in|O adult|O mouse|O brain|O homogenates|O .|O 
Increase|O in|O phosphorylation|O of|O APP|gene-protein by|O overexpression|O of|O the|O nerve|O growth|O factor|O receptor|O Trk|gene-protein A|gene-protein in|O 293T|O cells|O promoted|O the|O interaction|O of|O transfected|O APP|gene-protein and|O endogenous|O Shc|gene-protein A|gene-protein .|O 
Pervanadate|O treatment|O of|O N2a|O neuroblastoma|O cells|O resulted|O in|O tyrosine|O phosphorylation|O and|O association|O of|O endogenous|O APP|gene-protein and|O Shc|gene-protein A|gene-protein .|O 
Thus|O ,|O APP|gene-protein and|O Shc|gene-protein proteins|O interact|O in|O vitro|O ,|O in|O cells|O ,|O and|O in|O the|O mouse|O brain|O .|O 
Tyrosine|O phosphorylation|O of|O APP|gene-protein may|O promote|O the|O interaction|O with|O Shc|gene-protein proteins|O .|O 
Muscarinic|gene-protein acetylcholine|gene-protein receptor|gene-protein stimulation|O induces|O expression|O of|O the|O activity|gene-rna -|gene-rna regulated|gene-rna cytoskeleton|gene-rna -|gene-rna associated|gene-rna gene|O (|O ARC|gene-rna )|O .|O 
Muscarinic|gene-protein acetylcholine|gene-protein receptors|gene-protein (|O mAChR|gene-protein )|O are|O involved|O in|O learning|O and|O memory|O but|O their|O molecular|O function|O in|O these|O processes|O is|O not|O fully|O understood|O .|O 
In|O this|O study|O ,|O the|O signal|O transduction|O pathway|O coupling|O mAChR|gene-protein activation|O to|O induction|O of|O the|O activity|gene-rna -|gene-rna regulated|gene-rna cytoskeleton|gene-rna -|gene-rna associated|gene-rna gene|O (|O ARC|gene-rna )|O was|O examined|O .|O 
ARC|gene-rna was|O first|O identified|O as|O an|O effector|O immediate|O early|O gene|O induced|O by|O neuronal|O activity|O and|O ARC|gene-protein protein|O is|O thought|O to|O play|O a|O role|O in|O synaptic|O plasticity|O .|O 
In|O rats|O ,|O intraperitoneal|O injection|O of|O pilocarpine|O ,|O a|O potent|O agonist|O of|O mAChR|gene-protein ,|O led|O to|O increased|O ARC|gene-generic expression|O in|O the|O brain|O .|O 
In|O human|O SH-SY5Y|O neuroblastoma|O cells|O mAChR|gene-protein stimulation|O with|O carbachol|O caused|O a|O rapid|O and|O robust|O induction|O of|O ARC|gene-rna expression|O .|O 
This|O effect|O was|O inhibited|O by|O atropine|O ,|O a|O nonselective|O muscarinic|gene-protein receptor|gene-protein antagonist|O as|O well|O as|O by|O M1|O /|O M3|O subtype|O -|O specific|O antagonists|O .|O 
Analysis|O of|O mAChR|gene-protein downstream|O effectors|O revealed|O that|O protein|gene-protein kinase|gene-protein C|gene-protein (|O PKC|gene-protein )|O and|O tyrosine|gene-protein kinases|gene-protein of|O the|O src|gene-protein family|O are|O key|O molecules|O in|O the|O signal|O cascade|O leading|O to|O ARC|gene-generic expression|O .|O 
Our|O data|O suggest|O ,|O for|O the|O first|O time|O ,|O that|O a|O correlation|O exists|O among|O mAChR|gene-protein -|O controlled|O signal|O cascades|O ,|O the|O induction|O of|O the|O effector|O immediate|O early|O gene|O ARC|gene-rna and|O synaptic|O plasticity|O .|O 
Uptake|O and|O cytotoxicity|O of|O ascorbic|O acid|O and|O dehydroascorbic|O acid|O in|O neuroblastoma|O (|O SK-N-SH|O )|O and|O neuroectodermal|O (|O SK-N-LO|O )|O cells|O .|O 
Ascorbic|O acid|O (|O AA|O )|O was|O found|O to|O be|O cytotoxic|O to|O neuroblastoma|O cells|O in|O vitro|O and|O in|O vivo|O .|O 
In|O the|O present|O ,|O study|O we|O investigated|O whether|O the|O reduced|O --|O (|O AA|O )|O or|O oxidized|O form|O (|O dehydroascorbic|O acid|O ,|O DhAA|O )|O and|O its|O rapidly|O formed|O metabolites|O were|O the|O main|O cytotoxic|O agents|O .|O 
In|O neuroblastoma|O SK-N-SH|O cells|O ,|O AA|O was|O found|O to|O be|O more|O cytotoxic|O than|O DhAA|O ,|O although|O considerably|O higher|O amounts|O of|O [14C]DhAA|O than|O of|O [14C]AA|O were|O incorporated|O .|O 
In|O contrast|O ,|O SK-N-LO|O cells|O derived|O from|O neuroectodermal|O tissue|O in|O fact|O showed|O a|O similar|O uptake|O but|O were|O much|O less|O injured|O by|O both|O substances|O .|O 
We|O observed|O that|O uptake|O of|O [14C]AA|O and|O [14C]DhAA|O was|O impaired|O in|O the|O presence|O of|O dithiothreitol|O and|O glutathione|O .|O 
Once|O inside|O the|O cell|O ,|O [14C]DhAA|O was|O partially|O reduced|O to|O [14C]AA|O .|O 
From|O these|O data|O we|O conclude|O first|O that|O at|O least|O part|O of|O AA|O is|O oxidized|O prior|O to|O its|O uptake|O ,|O and|O second|O that|O the|O reduced|O form|O of|O AA|O and|O perhaps|O ascorbyl|O radicals|O but|O not|O DhAA|O or|O its|O metabolites|O are|O the|O most|O important|O forms|O in|O mediating|O cytotoxic|O reactions|O in|O neuroblastoma|O cells|O .|O 
Furthermore|O ,|O the|O results|O strengthen|O the|O previous|O assumption|O that|O AA|O acts|O as|O a|O pro|O -|O oxidant|O in|O neuroblastoma|O cells|O and|O supports|O its|O use|O in|O the|O treatment|O of|O neuroblastoma|O ,|O especially|O in|O combination|O with|O existing|O chemotherapeutics|O .|O 
Allelic|O imbalance|O on|O chromosome|O 18|O in|O neuroblastoma|O .|O 
We|O previously|O demonstrated|O that|O chromosome|O 18|O is|O frequently|O deleted|O in|O neuroblastoma|O .|O 
To|O further|O elucidate|O the|O role|O of|O chromosome|O 18|O deletions|O in|O the|O development|O of|O neuroblastomas|O we|O examined|O 82|O cases|O of|O neuroblastomas|O for|O allelic|O imbalance|O (|O AI|O )|O at|O 17|O loci|O on|O chromosome|O 18|O to|O define|O the|O common|O region|O of|O AI|O in|O neuroblastoma|O .|O 
AI|O at|O one|O or|O more|O loci|O on|O chromosome|O 18|O was|O detected|O in|O 18|O /|O 82|O (|O 22|O %|O )|O cases|O .|O 
AI|O on|O 18q|O was|O detected|O in|O 17|O /|O 82|O (|O 21|O %|O )|O cases|O ,|O whereas|O AI|O on|O 18p|O was|O detected|O in|O 4|O /|O 82|O (|O 5|O %|O )|O cases|O .|O 
There|O was|O a|O distinct|O common|O region|O of|O AI|O at|O 18q21.1|O between|O the|O D18S363|O and|O D18S858|O loci|O .|O 
In|O addition|O ,|O cases|O 16|O and|O 53|O ,|O which|O did|O not|O show|O AI|O at|O 18q21.1|O ,|O showed|O AI|O at|O 18pter-q12.3|O between|O the|O D18S52|O and|O D18S36|O loci|O ,|O indicating|O that|O another|O common|O region|O of|O AI|O may|O exist|O on|O chromosome|O 18|O .|O 
AI|O on|O chromosome|O 18|O did|O not|O significantly|O correlate|O with|O any|O clinicopathological|O findings|O of|O patients|O with|O neuroblastoma|O .|O 
The|O common|O region|O of|O AI|O at|O 18q21.1|O includes|O the|O DCC|gene-rna gene|gene-rna but|O not|O the|O Smad2|gene-rna and|O Smad4|gene-rna genes|O .|O 
However|O ,|O our|O previous|O studies|O together|O with|O the|O present|O study|O indicated|O that|O the|O incidence|O of|O DCC|gene-rna mutation|O is|O much|O less|O than|O that|O of|O AI|O at|O 18q21.1|O in|O neuroblastoma|O .|O 
These|O results|O indicate|O that|O novel|O tumour|O suppressor|O genes|O involved|O in|O the|O development|O of|O neuroblastoma|O are|O present|O at|O 18q21.1|O ,|O and|O possibly|O at|O 18pter-q12.3|O .|O 
Ciliary|gene-protein neurotrophic|gene-protein factor|gene-protein -|O induced|O gene|O expression|O in|O human|O neuroblastoma|O cell|O lines|O .|O 
We|O have|O analyzed|O the|O response|O of|O the|O human|O neuroblastoma|O cell|O lines|O SK-N-SH|O (|O clone|O SY5Y|O )|O and|O SK-N-BE|O to|O the|O ciliary|gene-protein neurotrophic|gene-protein factor|gene-protein CNTF|gene-protein .|O 
In|O both|O cell|O lines|O CNTF|gene-protein induced|O the|O expression|O of|O the|O mRNA|O for|O two|O transcription|O factors|O ,|O c-fos|gene-rna and|O NGF1A|gene-rna .|O 
The|O induction|O was|O rapid|O and|O transient|O reaching|O a|O maximum|O between|O 30|O and|O 60|O min|O after|O exposure|O to|O CNTF|gene-protein and|O subsequently|O declining|O .|O 
The|O level|O of|O induction|O of|O both|O c-fos|gene-rna and|O NGF1A|gene-rna mRNAs|O was|O much|O higher|O in|O SK-N-BE|O neuroblastoma|O cells|O compared|O to|O the|O SY5Y|O .|O 
Both|O cells|O express|O comparable|O levels|O of|O the|O transcript|O for|O the|O CNTF|gene-rna receptor|gene-rna -|gene-rna alpha|gene-rna .|O 
This|O mRNA|O was|O down|O regulated|O after|O 5|O days|O of|O CNTF|gene-protein stimulation|O in|O both|O cell|O lines|O .|O 
CNTF|gene-protein also|O induced|O increased|O levels|O of|O the|O transcript|O for|O the|O growth|O cone|O associated|O protein|O GAP43|gene-protein in|O SK-N-BE|O ,|O but|O not|O in|O SY5Y|O cells|O .|O 
Induction|O followed|O a|O slower|O kinetic|O compared|O to|O that|O observed|O for|O c-fos|gene-rna and|O NGF1A|gene-rna .|O In|O fact|O ,|O the|O GAP43|gene-rna mRNA|O levels|O increased|O during|O 2|O days|O of|O exposure|O to|O CNTF|gene-protein .|O 
Morphological|O analysis|O of|O CNTF|gene-protein treated|O cells|O showed|O that|O SK-N-BE|O undergo|O significant|O differentiation|O in|O response|O to|O CNTF|gene-protein (|O increased|O number|O of|O cells|O with|O neurites|O and|O increased|O neurite|O length|O )|O while|O SY5Y|O did|O not|O show|O appreciable|O morphological|O differentiation|O .|O 
These|O data|O shows|O that|O CNTF|gene-protein may|O elicit|O different|O response|O in|O neuroblastoma|O cell|O lines|O .|O 
Megadoses|O of|O vitamin|O C|O prevent|O the|O development|O of|O tolerance|O and|O physical|O dependence|O on|O morphine|O in|O mice|O .|O 
In|O mice|O ascorbate|O ,|O when|O co|O -|O administered|O with|O morphine|O ,|O suppresses|O the|O development|O of|O tolerance|O and|O physical|O dependence|O on|O the|O drug|O ,|O without|O significantly|O affecting|O its|O analgesic|O properties|O as|O inferred|O from|O unaltered|O ED50|O values|O .|O 
The|O duration|O of|O morphine|O -|O induced|O analgesia|O ,|O however|O ,|O is|O progressively|O reduced|O with|O an|O increase|O in|O the|O amounts|O of|O ascorbate|O .|O 
Ascorbate|O at|O 1|O g|O /|O kg|O body|O weight|O does|O not|O alter|O the|O pH|O of|O blood|O ,|O and|O has|O no|O effect|O on|O the|O levels|O of|O lipid|O -|O peroxides|O in|O blood|O and|O brain|O .|O 
Studies|O presented|O in|O this|O paper|O suggest|O the|O potential|O use|O of|O ascorbate|O in|O the|O prevention|O of|O development|O of|O tolerance|O in|O therapeutic|O applications|O of|O narcotics|O as|O analgesics|O .|O 
Cultured|O Neuroblastoma|O X|O Glioma|O hybrid|O cells|O (|O NG|O 108|O -|O 15|O )|O respond|O to|O opiates|O in|O two|O different|O ways|O .|O 
The|O rapid|O receptor|O mediated|O inhibition|O of|O adenylate|gene-protein cyclase|gene-protein is|O followed|O by|O a|O long|O -|O lived|O compensatory|O increase|O in|O its|O activity|O (|O 1|O -|O 4|O )|O .|O 
In|O a|O recent|O report|O (|O 5|O )|O we|O have|O shown|O that|O ascorbate|O suppresses|O the|O delayed|O etorphine|O -|O induced|O compensatory|O increase|O in|O cAMP|O levels|O in|O NG|O 108|O -|O 15|O cells|O without|O affecting|O the|O short|O -|O term|O inhibitory|O response|O of|O cells|O to|O the|O drug|O .|O 
It|O has|O been|O suggested|O that|O while|O the|O former|O may|O be|O the|O basis|O of|O narcotic|O dependence|O and|O tolerance|O ,|O the|O latter|O is|O responsible|O for|O the|O analgesic|O effect|O .|O 
These|O observations|O ,|O based|O on|O a|O model|O system|O ,|O prompted|O us|O to|O examine|O the|O effect|O of|O ascorbate|O on|O the|O pharmacological|O properties|O of|O morphine|O at|O the|O organismal|O level|O .|O 
DNA|O ploidy|O in|O neuroblastoma|O .|O 
Neuroblastoma|O is|O perhaps|O the|O most|O heterogeneous|O childhood|O cancer|O in|O terms|O of|O clinical|O behavior|O .|O 
Stage|O of|O disease|O ,|O age|O at|O diagnosis|O ,|O levels|O of|O urinary|O catecholamine|O excretion|O ,|O N-myc|gene-rna amplification|O ,|O and|O DNA|O ploidy|O have|O been|O found|O to|O be|O significant|O prognostic|O factors|O .|O 
The|O aims|O of|O this|O combined|O retrospective|O -|O prospective|O study|O are|O to|O verify|O the|O prognostic|O significance|O of|O DNA|O ploidy|O and|O to|O show|O its|O correlation|O with|O other|O prognostic|O signs|O .|O 
Thirty|O six|O fresh|O and|O thirty|O three|O paraffin|O embedded|O samples|O from|O patients|O with|O histologically|O confirmed|O neuroblastoma|O (|O 41|O prior|O to|O receiving|O any|O chemotherapy|O )|O were|O available|O for|O flow|O cytometry|O DNA|O analysis|O .|O 
Our|O results|O showed|O that|O the|O maturation|O induced|O during|O chemotherapy|O could|O give|O rise|O to|O aneuploidy|O therefore|O we|O analyzed|O the|O associations|O between|O the|O DNA|O ploidy|O and|O other|O prognostic|O markers|O only|O in|O patients|O examined|O before|O chemotherapy|O .|O 
There|O were|O no|O significant|O correlations|O between|O DNA|O ploidy|O and|O urinary|O catecholamine|O metabolites|O levels|O or|O tumor|O localization|O .|O 
DNA|O aneuploidy|O was|O significantly|O more|O frequent|O in|O patients|O with|O lower|O clinical|O stage|O ,|O lower|O age|O at|O diagnosis|O ,|O and|O without|O N-myc|gene-rna gene|O amplification|O .|O 
Patients|O with|O DNA|O aneuploid|O neuroblastomas|O died|O less|O frequently|O than|O patients|O with|O DNA|O diploid|O tumors|O .|O 
There|O were|O no|O significant|O associations|O among|O the|O S|O -|O phase|O or|O proliferation|O fraction|O and|O other|O prognostic|O factors|O .|O 
Caspase-1|gene-protein inhibitors|O abolish|O deleterious|O enhancement|O of|O COX-2|gene-protein expression|O induced|O by|O HIV-1|O gp120|O in|O human|O neuroblastoma|O cells|O .|O 
The|O human|O CHP100|O neuroblastoma|O cell|O line|O has|O been|O shown|O to|O provide|O an|O useful|O in|O vitro|O model|O to|O elucidate|O the|O mechanisms|O underlying|O HIV-1|O gp120|O neurotoxicity|O .|O 
Here|O we|O report|O western|O blotting|O evidence|O demonstrating|O that|O exposure|O to|O a|O cytotoxic|O concentration|O of|O the|O viral|O coat|O protein|O up|O -|O regulates|O expression|O of|O the|O inducible|O isoform|O of|O cyclooxygenase|gene-protein (|O COX-2|gene-protein )|O in|O neuroblastoma|O cells|O and|O this|O seems|O to|O be|O due|O to|O the|O previously|O observed|O increase|O in|O secreted|O IL-1beta|gene-protein .|O 
In|O fact|O ,|O here|O we|O show|O that|O acetyl-Tyr-Val-Ala-Asp-chloromethylketone|O (|O Ac-YVAD-CMK|O )|O and|O t-butoxycarbonyl-L-aspartic|O acid|O benzyl|O ester-chloromethylketone|O (|O Boc-Asp-(OBzl)-CMK|O )|O ,|O two|O inhibitors|O of|O Interleukin-1|gene-protein Converting|gene-protein Enzyme|gene-protein (|O ICE|gene-protein ;|O also|O referred|O to|O as|O caspase-1|gene-protein )|O ,|O abolish|O COX-2|gene-protein expression|O enhanced|O by|O gp120|gene-protein and|O consequent|O cell|O death|O .|O 
In|O addition|O ,|O NS-398|O ,|O a|O selective|O inhibitor|O of|O COX-2|gene-protein activity|O ,|O affords|O neuroprotection|O strengthening|O the|O role|O of|O COX-2|gene-protein in|O the|O mechanisms|O of|O death|O .|O 
In|O conclusion|O ,|O the|O present|O data|O support|O the|O notion|O that|O IL-1beta|gene-protein is|O the|O signal|O through|O which|O gp120|gene-protein elevates|O COX-2|gene-protein expression|O and|O the|O latter|O is|O strongly|O implicated|O in|O the|O mechanisms|O underlying|O cytotoxicity|O .|O 
Expression|O and|O down|O -|O regulation|O by|O retinoic|O acid|O of|O IGF|gene-protein binding|gene-protein protein|gene-protein -|gene-protein 2|gene-protein and|O -|gene-protein 4|gene-protein in|O medium|O from|O human|O neuroblastoma|O cells|O .|O 
Insulin|gene-protein -|gene-protein like|gene-protein growth|gene-protein factors|gene-protein (|O IGFs|gene-protein )|O regulate|O the|O autocrine|O /|O paracrine|O growth|O of|O neuroblastomas|O .|O 
The|O IGFs|gene-protein bind|O to|O specific|O binding|O proteins|O (|O IGFBPs|gene-protein )|O which|O modulate|O their|O biological|O activity|O .|O 
We|O investigated|O ,|O by|O Western|O ligand|O blotting|O (|O WLB|O )|O ,|O the|O presence|O of|O IGFBPs|gene-protein and|O their|O possible|O modulation|O by|O retinoic|O acid|O (|O RA|O )|O ,|O IGF-I|gene-protein ,|O IGF-II|gene-protein and|O truncated|O Des(1-3)IGF-I|gene-protein in|O conditioned|O medium|O (|O CM|O )|O of|O the|O human|O neuroblastoma|O SK-N-BE(2)|O cell|O line|O .|O 
We|O demonstrated|O the|O presence|O of|O two|O IGFBPs|gene-protein ,|O with|O MW|O 37|O kDa|O and|O 25|O kDa|O .|O 
Following|O immunoprecipitation|O ,|O they|O turned|O out|O to|O be|O IGFBP|gene-protein -|gene-protein 2|gene-protein and|O -|gene-protein 4|gene-protein ,|O respectively|O .|O 
The|O RA|O -|O induced|O differentiation|O in|O SK-N-BE(2)|O cells|O was|O accompanied|O by|O a|O marked|O reduction|O of|O the|O intensity|O of|O both|O IGFBP|gene-protein bands|O after|O 48|O h|O (|O 32|O %|O and|O 24|O %|O of|O control|O ,|O respectively|O )|O and|O 72|O h|O (|O 2|O %|O and|O 0|O %|O of|O control|O ,|O respectively|O )|O incubation|O .|O 
The|O addition|O of|O exogenous|O IGFs|gene-protein ,|O which|O did|O not|O induce|O cell|O differentiation|O ,|O did|O not|O change|O the|O IGFBP|gene-protein pattern|O significantly|O ,|O except|O for|O the|O truncated|O form|O of|O IGF-I|gene-protein ,|O which|O induced|O a|O marked|O decrease|O in|O both|O the|O 37|O kDa|O and|O 25|O kDa|O bands|O after|O 72|O h|O incubation|O (|O 45|O %|O and|O 18|O %|O of|O control|O ,|O respectively|O )|O .|O 
These|O findings|O suggest|O that|O IGFBPs|gene-protein have|O a|O role|O in|O RA|O -|O induced|O differentiation|O in|O human|O neuroblastoma|O cells|O .|O 
Retinoid|O -|O induced|O differentiation|O of|O neuroblastoma|O :|O comparison|O between|O LG69|O ,|O an|O RXR|gene-protein -|O selective|O analogue|O and|O 9-cis|O retinoic|O acid|O .|O 
The|O aim|O of|O this|O study|O was|O to|O investigate|O in|O vitro|O the|O effects|O of|O all|O -|O trans|O retinoic|O acid|O (|O RA|O )|O ,|O 9-cis|O RA|O and|O the|O RXR|gene-protein -|O selective|O analogue|O ,|O LG69|O ,|O on|O the|O morphological|O differentiation|O ,|O proliferation|O and|O gene|O expression|O of|O neuroblastoma|O cells|O .|O 
Three|O different|O cell|O lines|O were|O cultured|O with|O the|O retinoid|O for|O either|O 9|O continuous|O days|O or|O for|O 5|O days|O followed|O by|O 4|O days|O without|O the|O retinoid|O and|O morphological|O differentiation|O was|O assessed|O both|O qualitatively|O and|O quantitatively|O .|O 
SH|O SY|O 5Y|O cell|O proliferation|O was|O examined|O by|O measuring|O cell|O numbers|O after|O exposure|O to|O the|O retinoids|O and|O RAR-beta|gene-rna gene|O expression|O was|O examined|O by|O Northern|O blot|O analysis|O .|O 
Morphological|O differentiation|O was|O more|O effectively|O induced|O by|O all|O -|O trans|O and|O 9-cis|O RA|O than|O by|O LG69|O .|O SH|O SY|O 5Y|O cells|O ,|O when|O treated|O with|O 9-cis|O RA|O for|O only|O 5|O of|O the|O 9|O days|O of|O culture|O ,|O underwent|O apoptosis|O ,|O but|O this|O was|O not|O seen|O with|O 9|O days|O continuous|O exposure|O nor|O with|O LG69|O .|O 
Inhibition|O of|O SH|O SY|O 5Y|O cell|O proliferation|O by|O all|O -|O trans|O or|O 9-cis|O RA|O was|O dose|O -|O dependent|O ,|O but|O LG69|O had|O little|O effect|O .|O 
Conversely|O ,|O LG69|O induced|O higher|O expression|O of|O RAR-beta|gene-rna than|O all|O -|O trans|O RA|O ,|O but|O less|O than|O that|O produced|O by|O 9-cis|O RA|O .|O 
These|O data|O suggest|O that|O 9-cis|O RA|O as|O a|O single|O agent|O is|O the|O most|O effective|O modulator|O of|O neuroblastoma|O behaviour|O and|O may|O be|O the|O most|O appropriate|O therapeutic|O agent|O .|O 
Transduction|O of|O green|gene-protein fluorescent|gene-protein protein|gene-protein increased|O oxidative|O stress|O and|O enhanced|O sensitivity|O to|O cytotoxic|O drugs|O in|O neuroblastoma|O cell|O lines|O .|O 
Green|gene-protein fluorescent|gene-protein protein|gene-protein (|O GFP|gene-protein )|O is|O employed|O as|O a|O selection|O marker|O for|O gene|O transduction|O and|O to|O track|O tumor|O cells|O .|O 
Transduction|O of|O enhanced|gene-protein GFP|gene-protein (|O eGFP|gene-protein )|O into|O human|O neuroblastoma|O cell|O lines|O via|O a|O lentiviral|O vector|O significantly|O sensitized|O CHLA-20|O (|O wild|O -|O type|O and|O functional|O TP53|gene-rna )|O ,|O and|O to|O a|O lesser|O extent|O CHLA-90|O cells|O (|O multidrug|O -|O resistant|O ,|O mutant|O ,|O and|O nonfunctional|O TP53|gene-rna )|O to|O carboplatin|O ,|O doxorubicin|O ,|O etoposide|O ,|O or|O melphalan|O ,|O relative|O to|O cells|O transduced|O using|O the|O cell|gene-protein surface|gene-protein antigen|gene-protein CD80|gene-protein as|O a|O selection|O marker|O .|O 
Total|O glutathione|O (|O GSH|O )|O was|O significantly|O up|O -|O regulated|O (|O 1.8|O -|O to|O 2.8|O -|O fold|O )|O after|O eGFP|gene-protein (|O but|O not|O CD80|gene-protein )|O transduction|O in|O cell|O lines|O with|O ,|O but|O not|O in|O those|O lacking|O ,|O functional|O p53|gene-protein .|O 
Cytotoxicity|O of|O GSH|O depletion|O by|O buthionine|O sulfoximine|O in|O CHLA-20|O (|O but|O not|O in|O CHLA-20|O -|O eGFP|gene-protein )|O was|O diminished|O by|O hypoxia|O (|O 2|O %|O O(2)|O )|O .|O 
Thus|O ,|O oxidative|O stress|O produced|O by|O GFP|gene-protein selects|O for|O cells|O with|O up|O -|O regulated|O GSH|O in|O a|O p53|gene-generic -|O dependent|O manner|O ,|O and|O also|O enhanced|O the|O cytotoxicity|O of|O anticancer|O drugs|O in|O neuroblastoma|O cell|O lines|O .|O 
Our|O data|O suggest|O caution|O when|O employing|O GFP|gene-protein -|O transduced|O cells|O to|O assess|O drug|O sensitivity|O and|O that|O using|O a|O cell|gene-protein surface|gene-protein antigen|gene-protein as|O a|O selection|O marker|O for|O gene|O transduction|O may|O perturb|O cells|O less|O than|O GFP|gene-protein .|O 
No|O evidence|O for|O the|O presence|O of|O an|O imprinted|O neuroblastoma|O suppressor|gene-rna gene|gene-rna within|O chromosome|O sub|O -|O band|O 1p36.3|O .|O 
Deletion|O of|O the|O distal|O short|O arm|O of|O chromosome|O 1|O occurs|O in|O 35|O %|O of|O primary|O neuroblastomas|O (|O NBs|O )|O .|O 
These|O deletions|O tend|O to|O be|O large|O and|O extend|O to|O the|O telomere|O ,|O but|O a|O common|O region|O within|O sub|O -|O band|O 1p36.3|O is|O consistently|O lost|O .|O 
Despite|O intensive|O investigation|O ,|O no|O candidate|O tumor|O suppressor|O gene|O within|O this|O region|O has|O been|O shown|O to|O undergo|O tumor|O -|O specific|O mutation|O consistent|O with|O biallelic|O inactivation|O .|O 
In|O addition|O ,|O initial|O studies|O demonstrated|O preferential|O loss|O of|O the|O maternally|O inherited|O 1p|O homologue|O in|O NBs|O with|O 1p|O loss|O of|O heterozygosity|O (|O LOH|O )|O without|O MYCN|gene-rna amplification|O .|O 
This|O has|O led|O to|O the|O widely|O accepted|O hypothesis|O that|O a|O genomically|O imprinted|O NB|O suppressor|gene-rna gene|gene-rna is|O the|O target|O of|O 1p|O deletion|O in|O this|O subset|O .|O 
To|O test|O this|O hypothesis|O we|O have|O studied|O 293|O primary|O NBs|O for|O LOH|O within|O 1p36.3|O and|O determined|O the|O parental|O origin|O of|O the|O deleted|O 1p|O homologue|O .|O 
LOH|O within|O 1p36.3|O was|O demonstrated|O in|O 55|O NBs|O (|O 19|O %|O )|O .|O 
Of|O these|O ,|O 29|O occurred|O in|O tumors|O without|O MYCN|gene-rna amplification|O :|O 13|O had|O deletion|O of|O the|O maternally|O inherited|O 1p|O ,|O whereas|O 16|O had|O deletion|O of|O the|O paternally|O inherited|O 1p|O (|O P|O =|O 0.58|O )|O .|O 
These|O data|O strongly|O refute|O a|O parent|O -|O of|O -|O origin|O effect|O for|O 1p|O deletions|O in|O NB|O and|O exclude|O the|O existence|O of|O an|O imprinted|O NB|O suppressor|O locus|O in|O this|O region|O .|O 
The|O promoter|O of|O human|O acetylcholinesterase|gene-protein is|O activated|O by|O a|O cyclic|O adenosine|O 3',5'-monophosphate|O -|O dependent|O pathway|O in|O cultured|O NG108-15|O neuroblastoma|O cells|O .|O 
Different|O transcription|O elements|O have|O been|O proposed|O to|O play|O a|O role|O in|O the|O regulation|O of|O acetylcholinesterase|gene-protein (|O AChE|gene-protein )|O in|O muscle|O and|O neuron|O ,|O and|O cyclic|O adenosine|O 3',5'-monophosphate|O (|O cAMP|O )|O -|O dependent|O pathway|O is|O one|O of|O them|O .|O 
In|O order|O to|O test|O the|O possible|O role|O of|O cAMP|O in|O regulating|O the|O expression|O of|O human|O AChE|gene-protein ,|O an|O approximately|O 2.2|O kb|O DNA|O fragment|O of|O human|O AChE|gene-protein promoter|O was|O linked|O up|O stream|O to|O a|O luciferase|gene-protein reporter|O .|O 
The|O chimeric|O DNA|O was|O transfected|O into|O cultured|O NG108-15|O neuroblastoma|O cells|O .|O 
Application|O of|O Bt(2)|O -|O cAMP|O and|O forskolin|O increased|O the|O promoter|O driven|O luciferase|gene-protein activity|O over|O 2|O -|O fold|O in|O the|O transfected|O NG108-15|O cells|O ;|O the|O increase|O was|O parallel|O to|O the|O activation|O of|O endogenous|O AChE|gene-protein protein|O and|O enzymatic|O activity|O .|O 
The|O intracellular|O cAMP|O level|O was|O increased|O in|O the|O Galpha(sQL)|O (|O constitutively|O active|O mutant|O of|O Galpha(s)|O )|O cDNA|O transfected|O NG108-15|O cells|O .|O 
The|O Galpha(sQL)|O cDNA|O transfected|O cells|O showed|O an|O increase|O of|O over|O 10|O -|O fold|O in|O the|O luciferase|gene-protein activity|O .|O 
In|O addition|O ,|O a|O constitutively|O active|O mutant|O of|O activating|gene-protein transcription|gene-protein factor-1|gene-protein (|O ATF-1|gene-protein )|O was|O able|O to|O turn|O on|O human|O AChE|gene-protein promoter|O by|O approximately|O 4|O -|O fold|O when|O they|O were|O co|O -|O expressed|O in|O the|O neuroblastoma|O cells|O .|O 
These|O results|O support|O the|O involvement|O of|O a|O cAMP|O -|O dependent|O pathway|O in|O regulating|O the|O expression|O of|O human|O AChE|gene-protein .|O 
RIZ1|gene-protein ,|O but|O not|O the|O alternative|O RIZ2|gene-protein product|O of|O the|O same|O gene|O ,|O is|O underexpressed|O in|O breast|O cancer|O ,|O and|O forced|O RIZ1|gene-protein expression|O causes|O G2-M|O cell|O cycle|O arrest|O and/or|O apoptosis|O .|O 
The|O retinoblastoma|gene-rna protein|gene-rna -|gene-rna interacting|gene-rna zinc|gene-rna finger|gene-rna gene|O RIZ|gene-rna maps|O to|O the|O distal|O short|O arm|O of|O human|O chromosome|O 1|O (|O 1p36|O )|O ,|O a|O region|O thought|O to|O harbor|O tumor|O suppressor|O genes|O for|O a|O variety|O of|O human|O cancers|O including|O breast|O cancer|O .|O 
The|O RIZ|gene-rna gene|O normally|O produces|O two|O protein|O products|O of|O different|O length|O ,|O RIZ1|gene-protein and|O RIZ2|gene-protein .|O 
RIZ2|gene-protein is|O generated|O by|O an|O internal|O promoter|O and|O lacks|O an|O NH2|O -|O terminal|O motif|O of|O RIZ1|gene-protein ,|O the|O PR|O domain|O conserved|O in|O a|O subfamily|O of|O zinc|gene-rna finger|gene-rna genes|O that|O function|O as|O negative|O regulators|O of|O tumorigenesis|O .|O 
We|O have|O here|O studied|O whether|O the|O RIZ|gene-rna gene|O may|O play|O a|O role|O in|O human|O neoplasia|O .|O 
We|O found|O that|O expression|O of|O RIZ1|gene-protein is|O commonly|O decreased|O or|O at|O undetectable|O levels|O in|O breast|O cancer|O tissues|O and|O cell|O lines|O .|O 
Decreased|O RIZ1|gene-protein expression|O was|O also|O found|O in|O other|O tumor|O types|O including|O neuroblastoma|O and|O lung|O cancer|O .|O 
Remarkably|O ,|O RIZ2|gene-protein is|O normally|O expressed|O in|O all|O cases|O examined|O ,|O suggesting|O that|O the|O abnormality|O observed|O for|O RIZ1|gene-protein is|O specific|O .|O 
Forced|O RIZ1|gene-protein expression|O in|O breast|O cancer|O cells|O caused|O cell|O cycle|O arrest|O in|O G2-M|O and/or|O programmed|O cell|O death|O .|O 
These|O observations|O suggest|O an|O exclusive|O negative|O selection|O for|O RIZ1|gene-protein but|O not|O RIZ2|gene-protein in|O breast|O cancer|O and|O a|O role|O for|O RIZ1|gene-protein in|O tumor|O suppression|O .|O 
Direct|O transactivation|O of|O the|O anti|O -|O apoptotic|O gene|O apolipoprotein|gene-rna J|gene-rna (|O clusterin|gene-rna )|O by|O B-MYB|gene-protein .|O 
B-MYB|gene-protein is|O a|O ubiquitously|O expressed|O transcription|O factor|O involved|O in|O the|O regulation|O of|O cell|O survival|O ,|O proliferation|O ,|O and|O differentiation|O .|O 
In|O an|O attempt|O to|O isolate|O B-MYB|gene-protein -|O regulated|O genes|O that|O may|O explain|O the|O role|O of|O B-MYB|gene-protein in|O cellular|O processes|O ,|O representational|O difference|O analysis|O was|O performed|O in|O neuroblastoma|O cell|O lines|O with|O different|O levels|O of|O B-MYB|gene-protein expression|O .|O 
One|O of|O the|O genes|O ,|O the|O mRNA|O levels|O of|O which|O were|O enhanced|O in|O B-MYB|gene-protein expressing|O cells|O ,|O was|O ApoJ|gene-rna /|O Clusterin|gene-rna (|O SGP-2|gene-rna /|O TRMP-2|gene-rna )|O (|O ApoJ|gene-rna /|O Clusterin|gene-rna )|O ,|O previously|O implicated|O in|O regulation|O of|O apoptosis|O and|O tumor|O progression|O .|O 
Here|O we|O show|O that|O the|O human|O ApoJ|gene-rna /|O Clusterin|gene-rna gene|O contains|O a|O Myb|gene-protein binding|O site|O in|O its|O 5|O '|O flanking|O region|O ,|O which|O interacts|O with|O bacterially|O synthesized|O B-MYB|gene-protein protein|O and|O mediates|O B-MYB|gene-protein -|O dependent|O transactivation|O of|O the|O ApoJ|gene-rna /|O Clusterin|gene-rna promoter|O in|O transient|O transfection|O assays|O .|O 
Endogenous|O ApoJ|gene-rna /|O Clusterin|gene-rna expression|O is|O induced|O in|O mammalian|O cell|O lines|O following|O transient|O transfection|O of|O a|O B-MYB|gene-rna cDNA|O .|O 
Blockage|O of|O secreted|O clusterin|gene-protein by|O a|O monoclonal|gene-protein antibody|gene-protein results|O in|O increased|O apoptosis|O of|O neuroblastoma|O cells|O exposed|O to|O the|O chemotherapeutic|O drug|O doxorubicin|O .|O 
Thus|O ,|O activation|O of|O ApoJ|gene-rna /|O Clusterin|gene-rna by|O B-MYB|gene-protein may|O be|O an|O important|O step|O in|O the|O regulation|O of|O apoptosis|O in|O normal|O and|O diseased|O cells|O .|O 
The|O biological|O effects|O of|O antisense|O N-myc|gene-rna expression|O in|O human|O neuroblastoma|O .|O 
Department|O of|O Pediatrics|O ,|O University|O of|O Illinois|O ,|O Chicago|O 60612|O .|O 
Although|O N-myc|gene-rna amplification|O and|O overexpression|O are|O believed|O to|O play|O an|O important|O role|O in|O determining|O the|O clinical|O behavior|O of|O neuroblastoma|O (|O NB|O )|O ,|O the|O exact|O function|O of|O N-myc|gene-rna in|O NB|O cell|O growth|O and|O differentiation|O remains|O unknown|O .|O 
To|O better|O understand|O the|O function|O of|O N-myc|gene-rna ,|O an|O established|O human|O NB|O cell|O line|O was|O transfected|O with|O N-myc|gene-rna antisense|O (|O AS|O )|O complementary|O DNA|O in|O an|O effort|O to|O down|O -|O regulate|O N-myc|gene-rna gene|O expression|O .|O 
Five|O clones|O expressing|O AS|O N-myc|gene-rna RNA|O have|O been|O maintained|O in|O culture|O for|O over|O 2|O years|O .|O 
Compared|O to|O control|O cells|O ,|O a|O 30|O -|O 69|O %|O decrease|O in|O the|O quantity|O of|O N-myc|gene-protein protein|O was|O demonstrated|O by|O Western|O blot|O analysis|O in|O 4|O of|O the|O 5|O AS|O clones|O .|O 
All|O 5|O of|O the|O AS|O clones|O exhibited|O a|O 50|O -|O 75|O %|O decrease|O in|O colony|O formation|O in|O soft|O agar|O assays|O compared|O to|O control|O cells|O .|O 
In|O addition|O ,|O all|O 5|O AS|O clones|O expressed|O a|O 3.2|O -|O kilobase|O protein|gene-rna kinase|gene-rna C-alpha|gene-rna transcript|O ,|O whereas|O this|O message|O was|O not|O detected|O by|O Northern|O blot|O analysis|O in|O any|O of|O the|O control|O clones|O .|O 
These|O results|O suggest|O that|O N-myc|gene-rna may|O play|O an|O important|O role|O in|O NB|O cell|O growth|O and|O that|O antisense|O N-myc|gene-rna expression|O is|O associated|O with|O an|O induction|O of|O protein|gene-rna kinase|gene-rna C-alpha|gene-rna RNA|O expression|O .|O 
Further|O characterization|O of|O the|O AS|O clones|O may|O provide|O insight|O into|O the|O function|O of|O N-myc|gene-rna and|O may|O thus|O lead|O to|O a|O better|O understanding|O of|O the|O role|O that|O N-myc|gene-rna plays|O in|O determining|O the|O clinical|O behavior|O of|O this|O childhood|O neoplasm|O .|O 
The|O cannabinoid|gene-protein receptor|gene-protein :|O biochemical|O and|O cellular|O properties|O in|O neuroblastoma|O cells|O .|O 
The|O cannabinoid|gene-protein receptor|gene-protein that|O has|O been|O pharmacologically|O characterized|O for|O hypothermia|O ,|O spontaneous|O activity|O ,|O analgesia|O and|O catalepsy|O in|O rodents|O is|O the|O same|O pharmacological|O receptor|O that|O inhibits|O adenylate|gene-protein cyclase|gene-protein in|O vitro|O .|O 
The|O inhibition|O of|O adenylate|gene-protein cyclase|gene-protein by|O the|O cannabinoid|gene-protein receptor|gene-protein results|O from|O an|O interaction|O with|O Gi|gene-protein ,|O based|O on|O the|O biochemical|O kinetic|O properties|O of|O the|O response|O ,|O the|O sensitivity|O to|O pertussis|gene-protein toxin|gene-protein ADP-ribosylation|O ,|O and|O the|O thermodynamic|O characteristics|O of|O the|O response|O .|O 
From|O precedents|O based|O on|O studies|O of|O the|O well|O -|O characterized|O G|gene-protein protein|gene-protein coupled|gene-protein receptors|gene-protein ,|O rhodopsin|gene-protein and|O the|O beta-adrenergic|gene-protein receptor|gene-protein ,|O we|O can|O predict|O the|O tertiary|O structure|O of|O the|O cannabinoid|gene-protein receptor|gene-protein .|O 
Three|O sites|O of|O potential|O glycosylation|O are|O present|O on|O the|O receptor|O .|O 
However|O ,|O treatment|O of|O N18TG2|O neuroblastoma|O cells|O with|O tunicamycin|O to|O prevent|O glycosylation|O of|O newly|O synthesized|O receptors|O failed|O to|O alter|O cannabinoid|O -|O induced|O inhibition|O of|O cyclic|O AMP|O accumulation|O .|O 
The|O cannabinoid|O response|O was|O rapidly|O desensitized|O (|O within|O 1/2|O h|O )|O .|O 
Treatment|O of|O cells|O with|O tunicamycin|O failed|O to|O alter|O agonist|O -|O induced|O desensitization|O processes|O .|O 
These|O findings|O can|O be|O more|O veraciously|O interpreted|O as|O we|O gain|O a|O better|O understanding|O of|O the|O cellular|O dynamics|O of|O the|O cannabinoid|gene-protein receptor|gene-protein .|O 
Mu-opioids|O activate|O phospholipase|gene-protein C|gene-protein in|O SH-SY5Y|O human|O neuroblastoma|O cells|O via|O calcium|O -|O channel|O opening|O .|O 
We|O have|O recently|O reported|O that|O ,|O in|O SH-SY5Y|O cells|O ,|O mu-opioid|gene-protein receptor|gene-protein occupancy|O activates|O phospholipase|gene-protein C|gene-protein via|O a|O pertussis|gene-protein toxin|gene-protein -|gene-protein sensitive|gene-protein G|gene-protein -|gene-protein protein|gene-protein .|O In|O the|O present|O study|O we|O have|O further|O characterized|O the|O mechanisms|O involved|O in|O this|O process|O .|O 
Fentanyl|O (|O 0.1|O microM|O )|O caused|O a|O monophasic|O increase|O in|O inositol|O 1,4,5-trisphosphate|O mass|O formation|O ,|O with|O a|O peak|O (|O 20.5|O +/-|O 3.6|O pmol|O /|O mg|O of|O protein|O )|O at|O 15|O s|O .|O 
Incubation|O in|O Ca(2+)|O -|O free|O buffer|O abolished|O this|O response|O ,|O while|O Ca2+|O replacement|O 1|O min|O later|O restored|O the|O stimulation|O of|O inositol|O 1,4,5-trisphosphate|O formation|O (|O 20.1|O +/-|O 0.6|O pmol|O /|O mg|O of|O protein|O )|O .|O 
In|O addition|O ,|O nifedipine|O (|O 1|O nM|O -|O 0.1|O mM|O )|O ,|O an|O L|O -|O type|O Ca(2+)|O -|O channel|O antagonist|O ,|O caused|O a|O dose|O -|O dependent|O inhibition|O of|O inositol|O 1,4,5-trisphosphate|O formation|O ,|O with|O an|O IC50|O of|O 60.3|O +/-|O 1.1|O nM|O .|O 
Elevation|O of|O endogenous|O beta|O /|O gamma|O subunits|O by|O selective|O activation|O of|O delta-opioid|gene-protein and|O alpha|gene-protein 2|gene-protein adrenoceptors|gene-protein failed|O to|O stimulate|O phospholipase|gene-protein C|gene-protein .|O 
Fentanyl|O also|O caused|O a|O dose|O -|O dependent|O (|O EC50|O of|O 16.2|O +/-|O 1.0|O nM|O )|O ,|O additive|O enhancement|O of|O carbachol|O -|O induced|O inositol|O 1,4,5-trisphosphate|O formation|O .|O 
In|O summary|O ,|O we|O have|O demonstrated|O that|O in|O SH-SY5Y|O cells|O activation|O of|O the|O mu-opioid|gene-protein receptor|gene-protein allows|O Ca2+|O influx|O to|O activate|O phospholipase|gene-protein C|gene-protein .|O 
However|O ,|O the|O possible|O role|O of|O this|O mechanism|O in|O the|O process|O of|O analgesia|O remains|O to|O be|O elucidated|O .|O 
Human|O neuroblastoma|O cells|O express|O alpha|gene-protein and|O beta|gene-protein platelet|gene-protein -|gene-protein derived|gene-protein growth|gene-protein factor|gene-protein receptors|gene-protein coupling|O with|O neurotrophic|O and|O chemotactic|O signaling|O .|O 
Both|O platelet|gene-protein -|gene-protein derived|gene-protein growth|gene-protein factor|gene-protein (|gene-protein PDGF|gene-protein )|gene-protein A|gene-protein -|O and|O B|gene-protein -|O chains|O are|O expressed|O in|O mammalian|O neurons|O ,|O but|O their|O precise|O roles|O still|O remain|O to|O be|O clarified|O .|O 
In|O the|O present|O studies|O ,|O we|O examined|O the|O expression|O of|O two|O PDGF|gene-rna receptor|gene-rna genes|O in|O human|O tumor|O cell|O lines|O derived|O from|O neural|O crest|O .|O 
The|O expression|O of|O alpha|gene-protein and/or|O beta|gene-protein PDGF|gene-protein receptors|gene-protein was|O detected|O in|O a|O wide|O variety|O of|O neural|O crest|O -|O derived|O human|O tumor|O cell|O lines|O such|O as|O neuroblastoma|O ,|O primitive|O neuroectodermal|O tumor|O ,|O and|O Ewing|O 's|O sarcoma|O by|O RNA|O blot|O analysis|O ,|O and|O confirmed|O by|O immunoblot|O analysis|O .|O 
We|O have|O also|O demonstrated|O that|O PDGF|gene-protein receptors|gene-protein on|O the|O human|O neuroblastoma|O cell|O lines|O were|O biologically|O functional|O .|O 
Accordingly|O ,|O chemotactic|O and|O mitogenic|O activities|O were|O induced|O by|O either|O PDGF-AA|gene-protein or|O PDGF-BB|gene-protein in|O serum|O -|O free|O medium|O .|O 
PDGF|gene-protein isoforms|O as|O well|O as|O nerve|gene-protein growth|gene-protein factor|gene-protein induced|O morphological|O changes|O showing|O neuronal|O cell|O maturation|O .|O 
Moreover|O ,|O PDGF|gene-protein coordinately|O increased|O the|O levels|O of|O the|O transcript|O of|O the|O midsize|gene-rna neurofilament|gene-rna gene|O .|O 
The|O neuroblastoma|O cell|O lines|O also|O expressed|O the|O transcripts|O of|O PDGF|gene-protein A|gene-protein -|O and|O B|gene-protein -|O chains|O .|O 
These|O findings|O suggest|O that|O PDGF|gene-protein isoforms|O are|O involved|O not|O only|O in|O the|O promotion|O of|O the|O neuroblastoma|O cell|O growth|O ,|O but|O also|O in|O neuronal|O cell|O migration|O ,|O growth|O ,|O and|O differentiation|O in|O human|O brain|O development|O .|O 
E2F|gene-protein and|O Sp1|gene-protein /|O Sp3|gene-protein Synergize|O but|O are|O not|O sufficient|O to|O activate|O the|O MYCN|gene-rna gene|O in|O neuroblastomas|O .|O 
Amplification|O of|O the|O MYCN|gene-rna gene|O ,|O resulting|O in|O overexpression|O of|O MYCN|gene-rna ,|O distinguishes|O a|O subset|O of|O neuroblastomas|O with|O poor|O prognosis|O .|O 
We|O recently|O identified|O MYCN|gene-rna as|O a|O target|O gene|O of|O the|O E2F|gene-protein transcription|O factors|O .|O 
Here|O we|O show|O that|O Sp1|gene-protein and|O Sp3|gene-protein cooperate|O with|O E2F-1|gene-protein to|O activate|O the|O MYCN|gene-rna promoter|O .|O 
However|O ,|O in|O a|O neuroblastoma|O cell|O line|O that|O does|O not|O express|O MYCN|gene-rna ,|O overexpression|O of|O E2F-1|gene-protein was|O not|O sufficient|O to|O activate|O the|O MYCN|gene-rna promoter|O even|O in|O the|O presence|O of|O trichostatin|O A|O and|O 5-aza-cytidine|O .|O 
This|O was|O because|O of|O a|O failure|O of|O E2F-1|gene-protein to|O bind|O to|O the|O MYCN|gene-rna promoter|O in|O these|O cells|O ,|O although|O access|O of|O E2F-1|gene-protein to|O the|O inactive|O MYCN|gene-rna promoter|O was|O not|O blocked|O by|O a|O nucleosome|O .|O 
Differences|O in|O nucleosomal|O organization|O of|O the|O MYCN|gene-rna promoter|O in|O different|O cell|O lines|O did|O not|O correlate|O with|O gene|O activation|O per|O se|O but|O with|O the|O switch|O from|O basal|O to|O activated|O transcription|O .|O 
Binding|O of|O E2F|gene-protein and|O Sp1|gene-protein /|O Sp3|gene-protein to|O the|O MYCN|gene-rna promoter|O in|O vivo|O correlated|O with|O acetylation|O of|O histones|gene-protein H3|gene-protein and|O H4|gene-protein and|O recruitment|O of|O RNA|gene-protein polymerase|gene-protein II|gene-protein and|O the|O protein|O acetyltransferase|gene-protein Tip60|gene-protein but|O not|O with|O nucleosome|O remodeling|O .|O 
Our|O results|O define|O distinct|O chromatin|O states|O of|O the|O MYCN|gene-rna promoter|O ,|O indicate|O that|O factors|O in|O addition|O to|O E2F|gene-protein and|O Sp1|gene-protein /|O Sp3|gene-protein are|O required|O to|O activate|O MYCN|gene-rna in|O neuroblastomas|O ,|O and|O provide|O evidence|O for|O a|O novel|O mechanism|O of|O controlling|O access|O of|O E2F|gene-protein to|O selected|O target|O genes|O .|O 
Inducible|O expression|O of|O calcyclin|gene-rna ,|O a|O gene|O with|O strong|O homology|O to|O S-100|gene-protein protein|O ,|O during|O neuroblastoma|O cell|O differentiation|O and|O its|O prevalent|O expression|O in|O Schwann|O -|O like|O cell|O lines|O .|O 
Calcyclin|gene-rna gene|O expression|O was|O evaluated|O in|O different|O neuroblastoma|O cell|O lines|O and|O during|O neuronal|O differentiation|O induced|O by|O retinoic|O acid|O .|O 
Calcyclin|gene-rna gene|O expression|O was|O more|O frequently|O detected|O in|O epithelial|O -|O type|O or|O Schwann|O -|O like|O cells|O rather|O than|O in|O neuroblastic|O cells|O .|O 
This|O result|O indicates|O an|O increase|O of|O G1|O cell|O fraction|O ,|O which|O may|O explain|O the|O limited|O growth|O potential|O usually|O observed|O for|O these|O cells|O .|O 
LAN-5|O cell|O (|O neuronal|O type|O )|O differentiation|O experiments|O showed|O that|O calcyclin|gene-rna gene|O is|O detectable|O after|O 4|O days|O of|O retinoic|O acid|O treatment|O ,|O which|O induces|O G1|O phase|O accumulation|O (|O as|O detected|O by|O cytofluorometric|O analysis|O )|O ,|O and|O cell|O growth|O arrest|O .|O 
Otherwise|O ,|O neither|O block|O of|O cell|O proliferation|O by|O 0.5|O %|O fetal|O calf|O serum|O medium|O nor|O addition|O of|O 15|O %|O fresh|O fetal|O calf|O serum|O after|O cell|O arrest|O induce|O calcyclin|gene-rna expression|O .|O 
The|O increase|O of|O calcyclin|gene-rna mRNA|O levels|O during|O cell|O differentiation|O shows|O that|O calcyclin|gene-rna gene|O expression|O is|O associated|O with|O neuronal|O differentiation|O .|O 
This|O bivalent|O role|O of|O the|O calcyclin|gene-rna gene|O ,|O which|O is|O normally|O expressed|O in|O the|O G1|O phase|O of|O the|O cell|O cycle|O but|O also|O expressed|O during|O retinoic|O acid|O -|O induced|O neuroblastoma|O cell|O differentiation|O ,|O suggests|O that|O (|O at|O least|O in|O neuroblastoma|O cells|O )|O the|O gene|O is|O subject|O to|O a|O complex|O transcriptional|O regulation|O .|O 
Subcellular|O trafficking|O abnormalities|O of|O a|O prion|gene-protein protein|gene-protein with|O a|O disrupted|O disulfide|O loop|O .|O 
The|O single|O disulfide|O loop|O (|O Cys178|O -|O Cys213|O )|O of|O the|O prion|gene-protein protein|gene-protein (|O PrP|gene-protein )|O may|O stabilize|O the|O conformation|O of|O this|O protein|O by|O bridging|O the|O C|O -|O terminal|O alpha-helices|O .|O 
The|O substitution|O mutant|O Cys|O 178|O Ala|O fails|O to|O form|O the|O prion|gene-protein isoform|O PrPSc|gene-protein when|O expressed|O in|O scrapie|O -|O infected|O neuroblastoma|O ScN2a|O cells|O (|O Muramoto|O et|O al.|O ,|O Proc.|O Natl.|O Acad.|O Sci.|O USA|O 93|O ,|O 15457|O -|O 15462|O )|O .|O 
To|O investigate|O the|O reasons|O for|O this|O failure|O ,|O we|O introduced|O the|O C|O 178|O A|O substitution|O in|O the|O full|O length|O mouse|O PrP|gene-rna gene|O as|O well|O as|O in|O its|O N|O -|O terminally|O truncated|O delta|O 23|O -|O 88|O version|O .|O 
The|O resulting|O mutants|O (|O C|O 178|O A|O and|O delta|O C|O 178|O A|O ,|O respectively|O )|O were|O transiently|O expressed|O in|O N2a|O and|O CHO|O cells|O .|O 
Wild|O -|O type|O PrP|gene-rna ,|O wild|O -|O type|O delta|O 23|O -|O 88|O and|O the|O point|O mutant|O E|O 199|O K|O served|O as|O controls|O in|O these|O experiments|O .|O 
Compared|O to|O the|O wild|O -|O type|O controls|O ,|O the|O C|O 178|O A|O mutants|O were|O markedly|O resistant|O to|O proteolysis|O and|O they|O were|O also|O vastly|O insoluble|O in|O sarcosyl|O .|O 
Studying|O the|O metabolic|O fate|O of|O the|O C|O 178|O A|O mutants|O ,|O we|O found|O that|O in|O contrast|O to|O control|O PrP|gene-protein molecules|O ,|O these|O mutants|O (i)|O remained|O sensitive|O to|O the|O diagnostic|O endoglycosidase|gene-protein EndoH|gene-protein ,|O (ii)|O failed|O to|O reach|O the|O cell|O surface|O and|O (iii)|O congregated|O in|O large|O juxtanuclear|O spots|O .|O 
We|O surmise|O that|O these|O severe|O trafficking|O abnormalities|O may|O contribute|O both|O to|O the|O spontaneous|O aggregation|O of|O the|O C|O 178|O A|O mutants|O and|O to|O their|O reported|O inability|O to|O form|O PrP(Sc)|gene-protein .|O 
Resistance|O to|O TRAIL|O -|O induced|O apoptosis|O in|O neuroblastoma|O cells|O correlates|O with|O a|O loss|O of|O caspase-8|gene-rna expression|O .|O 
BACKGROUND|O :|O 
Disruption|O of|O apoptotic|O pathways|O may|O be|O involved|O in|O tumor|O formation|O ,|O regression|O ,|O and|O treatment|O resistance|O of|O neuroblastoma|O (|O NB|O )|O .|O 
TNF|gene-protein -|O related|O apoptosis|O -|O inducing|O ligand|O (|O TRAIL|O )|O is|O a|O potent|O inducer|O of|O apoptosis|O in|O cancer|O cell|O lines|O .|O 
PROCEDURE|O :|O 
In|O this|O study|O we|O analyzed|O the|O expression|O and|O function|O of|O TRAIL|O ,|O its|O agonistic|O and|O antagonistic|O receptors|O ,|O and|O important|O intracellular|O signaling|O elements|O in|O 18|O NB|O cell|O lines|O .|O 
RESULTS|O :|O 
Semiquantitative|O RT|O -|O PCR|O revealed|O that|O TRAIL-R2|gene-protein and|O TRAIL-R3|gene-protein are|O the|O main|O TRAIL|O -|O receptors|O used|O by|O NB|O cells|O .|O 
Sensitivity|O to|O TRAIL|O -|O induced|O apoptosis|O did|O not|O correlate|O with|O mRNA|O expression|O of|O TRAIL|O receptors|O or|O cFLIP|gene-protein .|O 
Surprisingly|O ,|O caspase-8|gene-rna and|O caspase-10|gene-rna mRNA|O was|O detected|O in|O only|O 5|O of|O 18|O NB|O cell|O lines|O .|O 
Interestingly|O ,|O only|O these|O five|O NB|O cell|O lines|O were|O susceptible|O to|O TRAIL|O -|O induced|O apoptosis|O in|O a|O time|O -|O and|O dose|O -|O dependent|O manner|O .|O 
CONCLUSIONS|O :|O 
Treatment|O with|O 5-aza-2'-deoxycytidine|O restored|O mRNA|O expression|O of|O caspase|gene-rna -|gene-rna 8|gene-rna and|O -|gene-rna 10|gene-rna and|O TRAIL|O sensitivity|O of|O resistant|O cell|O lines|O ,|O suggesting|O that|O gene|O methylation|O is|O involved|O in|O caspase|gene-rna inactivation|O .|O 
Since|O many|O cytotoxic|O drugs|O induce|O caspase|gene-protein -|O dependent|O apoptosis|O ,|O failure|O to|O express|O caspase-8|gene-rna and/or|O caspase-10|gene-rna might|O be|O an|O important|O mechanism|O of|O resistance|O to|O chemotherapy|O in|O NB|O .|O 
Developmental|O expression|O in|O the|O mouse|O nervous|O system|O of|O the|O p493F12|gene-protein SAP|gene-protein kinase|gene-protein .|O 
Mitogen|gene-protein -|gene-protein activated|gene-protein protein|gene-protein (|gene-protein MAP|gene-protein )|gene-protein kinases|gene-protein are|O proline|O -|O directed|O ,|O serine|gene-protein /|gene-protein threonine|gene-protein kinases|gene-protein that|O respond|O to|O a|O variety|O of|O extracellular|O signals|O .|O 
A|O subgroup|O of|O these|O kinases|gene-protein ,|O stress|gene-protein -|gene-protein activated|gene-protein protein|gene-protein (|gene-protein SAP|gene-protein )|gene-protein kinases|gene-protein ,|O phosphorylate|O c-jun|gene-protein in|O response|O to|O cellular|O stress|O .|O 
Using|O monoclonal|gene-protein antibody|gene-protein (|gene-protein MAb|gene-protein )|gene-protein 3F12|gene-protein ,|O we|O have|O cloned|O and|O partially|O characterized|O p493F12|gene-protein kinase|gene-protein ,|O a|O mouse|O homologue|O of|O the|O rat|O SAP|gene-protein beta|gene-protein kinase|gene-protein and|O described|O its|O expression|O in|O the|O adult|O and|O developing|O mouse|O .|O 
Unlike|O previously|O reported|O MAP|gene-protein and|O SAP|gene-protein kinases|gene-protein ,|O it|O is|O primarily|O expressed|O as|O a|O 2.7|O kb|O transcript|O in|O neurons|O in|O the|O nervous|O system|O of|O the|O adult|O mouse|O .|O 
A|O 2.4|O kb|O transcript|O is|O also|O expressed|O in|O the|O testis|O .|O 
Immunocytochemically|O ,|O MAb|gene-protein 3F12|gene-protein decorates|O a|O loop|O -|O like|O structure|O encircling|O the|O nucleus|O in|O the|O cytoplasm|O of|O neurons|O in|O the|O adult|O brain|O ,|O and|O distinct|O perinuclear|O dots|O in|O the|O embryos|O .|O 
In|O situ|O hybridization|O first|O reveals|O expression|O in|O post|O -|O mitotic|O neurons|O ,|O on|O embryonic|O day|O 11|O .|O 
The|O mRNA|O is|O also|O expressed|O in|O the|O Neuro-2A|O neuroblastoma|O cell|O line|O and|O is|O not|O upregulated|O in|O response|O to|O differentiating|O agents|O .|O 
The|O neuronal|O specificity|O of|O this|O kinase|gene-protein suggests|O the|O presence|O of|O a|O signal|O transduction|O cascade|O unique|O to|O neurons|O .|O 
As|O the|O amino|O acid|O sequence|O is|O highly|O conserved|O in|O the|O human|O and|O mouse|O ,|O the|O latter|O may|O serve|O as|O a|O model|O for|O regulation|O and|O expression|O of|O this|O kinase|gene-protein .|O 
Role|O of|O CD44H|gene-protein carbohydrate|O structure|O in|O neuroblastoma|O adhesive|O properties|O .|O 
BACKGROUND|O :|O 
CD44|gene-protein represents|O a|O heterogeneous|O group|O of|O surface|O glycoproteins|O involved|O in|O cell|O -|O cell|O and|O cell|O -|O matrix|O interactions|O .|O 
CD44H|gene-protein is|O the|O major|O receptor|O for|O hyaluronate|O ,|O and|O most|O if|O not|O all|O CD44H|gene-protein known|O functions|O are|O attributed|O to|O its|O ability|O to|O recognize|O hyaluronate|O .|O 
We|O have|O previously|O demonstrated|O a|O lack|O of|O CD44|gene-protein expression|O in|O high|O stages|O and|O NMYC|gene-rna -|O amplified|O tumors|O and|O further|O have|O shown|O that|O NMYC|gene-rna -|O amplified|O cell|O lines|O either|O did|O not|O express|O CD44|gene-protein at|O all|O or|O expressed|O a|O nonfunctional|O receptor|O .|O 
On|O the|O other|O hand|O ,|O nonamplified|O cells|O constitutively|O expressed|O an|O active|O receptor|O ,|O suggesting|O that|O absence|O of|O CD44|gene-protein -|O mediated|O hy|O aluronate|O binding|O could|O be|O related|O to|O increased|O malignancy|O in|O human|O neuroblastoma|O .|O 
PROCEDURE|O :|O 
In|O the|O present|O study|O we|O have|O compared|O the|O glycosylated|O structure|O of|O CD44|gene-protein expressed|O by|O NMYC|gene-rna amplified|O vs.|O nonamplified|O cell|O lines|O in|O relation|O to|O their|O adhesive|O properties|O for|O hyaluronate|O .|O 
These|O adhesive|O properties|O were|O measured|O after|O modifications|O of|O the|O carbohydrate|O structure|O with|O enzymes|O and|O inhibitors|O of|O N|O -|O or|O O|O -|O linked|O glycosylation|O .|O 
RESULTS|O AND|O CONCLUSIONS|O :|O 
Our|O results|O indicate|O that|O increased|O sialylation|O ,|O defective|O N|O -|O linked|O glycosylation|O ,|O and|O substitution|O of|O the|O CD44|gene-protein glycoprotein|O with|O keratan|O sulfate|O glycosaminoglycan|O might|O include|O modifications|O observed|O on|O neuroblastoma|O cells|O that|O could|O account|O for|O the|O inability|O of|O the|O receptor|O to|O bind|O hyaluronate|O .|O 
Acute|O effects|O of|O ethanol|O and|O other|O short|O -|O chain|O alcohols|O on|O the|O guanylate|gene-protein cyclase|gene-protein system|O of|O murine|O neuroblastoma|O cells|O (|O clone|O N1E-115|O )|O .|O 
The|O acute|O effects|O of|O ethanol|O were|O studied|O on|O the|O guanylate|gene-protein cyclase|gene-protein system|O of|O cultured|O murine|O neuroblastoma|O clone|O N1E-115|O .|O 
Using|O intact|O cells|O ,|O we|O found|O that|O although|O ethanol|O had|O no|O effect|O on|O basal|O levels|O of|O cyclic|O GMP|O synthesis|O ,|O it|O rapidly|O inhibited|O in|O a|O concentration|O -|O dependent|O manner|O cyclic|O GMP|O synthesis|O mediated|O by|O the|O agonists|O histamine|O (|O histamine|O H1|gene-protein receptor|gene-protein )|O and|O carbachol|O (|O low|O -|O affinity|O muscarinic|gene-protein receptor|gene-protein )|O and|O by|O ionophore|O X537A|O and|O melittin|gene-protein ,|O agents|O which|O bypass|O these|O receptors|O .|O 
At|O 200|O mM|O ethanol|O ,|O inhibition|O was|O about|O 40|O to|O 50|O %|O with|O the|O agonists|O ,|O X537A|O and|O melittin|gene-protein .|O 
Ethanol|O had|O no|O effect|O on|O the|O high|O -|O affinity|O muscarinic|gene-protein receptor|gene-protein ,|O that|O mediates|O inhibition|O of|O cyclic|O AMP|O synthesis|O .|O 
With|O carbachol|O ethanol|O 's|O inhibition|O was|O reversible|O and|O was|O a|O mixed|O competitive|O /|O noncompetitive|O type|O .|O 
For|O a|O series|O of|O alcohols|O ,|O inhibitory|O potency|O with|O carbachol|O correlated|O with|O chain|O length|O directly|O .|O 
In|O addition|O ,|O sucrose|O and|O sodium|O chloride|O ,|O which|O like|O ethanol|O increases|O the|O osmolality|O of|O the|O incubation|O medium|O ,|O mimicked|O the|O effects|O of|O ethanol|O .|O 
In|O a|O crude|O cellular|O homogenate|O ,|O ethanol|O and|O other|O alcohols|O inhibited|O both|O basal|O and|O sodium|O nitroprusside|O -|O stimulated|O guanylate|gene-protein cyclase|gene-protein activity|O .|O 
The|O effect|O of|O ethanol|O on|O basal|O enzyme|O activity|O was|O noncompetitive|O .|O 
Thus|O ,|O the|O inhibition|O by|O ethanol|O and|O other|O alcohols|O of|O receptor|O -|O mediated|O cyclic|O GMP|O synthesis|O appears|O to|O be|O at|O the|O level|O of|O guanylate|gene-protein cyclase|gene-protein .|O 
Gene|O transfer|O :|O a|O review|O of|O methods|O and|O applications|O .|O 
Gene|O transfer|O is|O a|O potentially|O powerful|O tool|O for|O the|O treatment|O of|O a|O wide|O variety|O of|O diseases|O .|O 
The|O transfer|O of|O these|O genes|O is|O achieved|O by|O utilizing|O a|O variety|O of|O vectors|O ,|O including|O retroviral|O ,|O adenoviral|O ,|O adeno|O -|O associated|O virus|O (|O AAV|O )|O and|O a|O number|O of|O non|O -|O viral|O mechanisms|O .|O 
Numerous|O studies|O have|O successfully|O demonstrated|O transduction|O of|O genes|O into|O target|O cells|O with|O a|O variety|O of|O vectors|O ,|O and|O have|O provided|O '|O proof|O -|O in|O -|O principle|O '|O that|O gene|O transfer|O can|O result|O in|O prolonged|O in|O vivo|O expression|O of|O transduced|O genes|O ,|O albeit|O at|O low|O quantities|O .|O 
Furthermore|O ,|O gene|O marking|O studies|O in|O acute|O myeloblastic|O leukemia|O (|O AML|O )|O ,|O chronic|O myeloid|O leukemia|O (|O CML|O )|O and|O neuroblastoma|O have|O elegantly|O demonstrated|O that|O gene|O -|O marked|O tumor|O cells|O contribute|O to|O relapse|O following|O autologous|O transplantation|O .|O 
However|O none|O of|O the|O studies|O examining|O the|O therapeutic|O benefit|O of|O gene|O therapy|O has|O definitively|O demonstrated|O a|O clinically|O meaningful|O benefit|O .|O 
Nonetheless|O ,|O the|O results|O of|O studies|O involving|O gene|O transfer|O for|O severe|O combined|O immunodeficiency|O (|O SCID|O )|O ,|O chronic|O granulomatous|O disease|O (|O CGD|O )|O ,|O melanoma|O and|O lung|O cancer|O highlight|O the|O potential|O benefit|O of|O this|O strategy|O .|O 
This|O review|O will|O discuss|O mechanisms|O of|O achieving|O gene|O transfer|O into|O target|O cells|O .|O 
It|O will|O examine|O some|O of|O the|O pre|O -|O clinical|O and|O clinical|O results|O to|O date|O and|O will|O discuss|O some|O of|O the|O potential|O uses|O of|O gene|O transfer|O for|O therapeutic|O purposes|O .|O 
[|O Peripheral|O blood|O stem|O cell|O transplantation|O in|O adult|O patients|O ]|O 
We|O reported|O the|O experience|O of|O peripheral|O blood|O stem|O cell|O transplantation|O (|O PBSCT|O )|O performed|O in|O adult|O patients|O with|O hematological|O malignancies|O and|O solid|O tumors|O .|O 
After|O myelosuppressive|O chemotherapy|O ,|O peripheral|O blood|O stem|O cells|O were|O collected|O using|O a|O Blood|O Cell|O Separator|O (|O CS-3000|O )|O during|O bone|O marrow|O recovery|O and|O subsequently|O cryopreserved|O in|O 17|O patients|O (|O 9|O :|O malignant|O lymphoma|O ;|O 2|O :|O ALL|O ;|O 2|O :|O AML|O ;|O 2|O :|O multiple|O myeloma|O ;|O 2|O :|O solid|O tumors|O )|O .|O 
In|O 28|O apheresis|O cases|O ,|O the|O collected|O number|O of|O granulocyte|O /|O macrophage|O progenitors|O (|O CFU-GM|O )|O was|O more|O than|O 5|O x|O 10(5)|O /|O kg|O BW|O in|O 17|O apheresis|O cases|O and|O ranged|O between|O 2|O and|O 5|O x|O 10(5)|O /|O kg|O BW|O in|O 4|O of|O such|O cases|O .|O 
Eleven|O patients|O (|O 7|O :|O malignant|O lymphoma|O ;|O 1|O :|O ALL|O ;|O 1|O :|O AML|O ;|O 1|O :|O multiple|O myeloma|O ;|O 1|O :|O neuroblastoma|O )|O underwent|O PBSCT|O following|O myeloablative|O chemotherapy|O .|O 
The|O infused|O number|O of|O CFU-GM|O ranged|O between|O 0.6|O and|O 18.1|O x|O 10(5)|O /|O kg|O BW|O .|O In|O 7|O patients|O ,|O more|O than|O 5|O x|O 10(5)|O CFU-GM|O /|O kg|O BW|O were|O infused|O .|O 
The|O median|O time|O to|O reach|O 500|O neutrophils|O /|O microliter|O or|O 50,000|O platelets|O /|O microliter|O was|O 10|O (|O range|O :|O 8|O -|O 17|O )|O and|O 20|O (|O range|O :|O 8|O -|O 63|O )|O days|O ,|O respectively|O .|O 
One|O patient|O died|O from|O sepsis|O before|O hematologic|O recovery|O occurred|O .|O 
Eight|O patients|O are|O alive|O with|O no|O evidence|O of|O active|O disease|O for|O 7|O -|O 19|O months|O after|O PBSCT|O .|O 
When|O the|O infused|O number|O of|O CFU-GM|O is|O more|O than|O 2|O x|O 10(5)|O /|O kg|O BW|O ,|O PBSCT|O following|O myeloablative|O chemotherapy|O seems|O to|O be|O safe|O and|O useful|O treatment|O .|O 
Selective|O upregulation|O of|O vascular|gene-protein endothelial|gene-protein growth|gene-protein factor|gene-protein receptors|gene-protein neuropilin|gene-protein -|gene-protein 1|gene-protein and|O -|gene-protein 2|gene-protein in|O human|O neuroblastoma|O .|O 
BACKGROUND|O :|O 
Recent|O studies|O show|O that|O vascular|gene-protein endothelial|gene-protein growth|gene-protein factor|gene-protein (|O VEGF|gene-protein )|O and|O its|O receptors|O Flt-1|gene-protein and|O KDR|gene-protein ,|O and|O a|O series|O of|O other|O angiogenic|O molecules|O ,|O are|O upregulated|O in|O advanced|O but|O not|O low|O stage|O human|O neuroblastoma|O .|O 
Neuropilin|gene-protein -|gene-protein 1|gene-protein and|O 2|gene-protein (|O NRP|gene-protein )|O are|O novel|O specific|O receptors|O of|O VEGF|gene-protein (|O 165|O )|O ,|O whose|O role|O is|O unknown|O in|O human|O neuroblastoma|O .|O 
METHODS|O :|O 
Tissue|O biopsies|O of|O 37|O children|O with|O Stage|O I|O -|O IV|O neuroblastoma|O were|O obtained|O ,|O as|O well|O as|O biopsies|O of|O 7|O normal|O adrenals|O as|O controls|O .|O 
The|O mRNA|O expression|O of|O VEGF|gene-rna (|O 165|O )|O and|O its|O receptors|O Flt-1|gene-protein ,|O KDR|gene-protein ,|O NRP1|gene-protein ,|O and|O NRP2|gene-protein was|O evaluated|O by|O real|O -|O time|O reverse|O transcription|O polymerase|gene-protein chain|O reaction|O .|O 
NRP|gene-protein protein|O expression|O was|O detected|O by|O immunocytochemistry|O and|O Western|O blotting|O .|O 
RESULTS|O :|O 
VEGF|gene-rna (|O 165|O )|O mRNA|O was|O upregulated|O in|O Stage|O III|O and|O IV|O and|O Flt-1|gene-rna and|O KDR|gene-rna gene|O expression|O was|O increased|O in|O Stage|O III|O ,|O while|O NRP|gene-rna 1|gene-rna and|O 2|gene-rna mRNA|O and|O protein|O levels|O were|O higher|O in|O Stages|O I|O -|O IV|O vs.|O controls|O (|O P|O <|O 0.05|O )|O .|O 
NRP|gene-protein was|O expressed|O in|O vascular|O endothelial|O but|O not|O tumor|O cells|O .|O 
CONCLUSIONS|O :|O 
These|O results|O show|O for|O the|O first|O time|O that|O human|O neuroblastoma|O expresses|O NRP|gene-protein ,|O and|O that|O NRP|gene-protein co|O -|O regulates|O VEGF|gene-protein angiogenic|O effect|O in|O human|O neuroblastoma|O .|O 
NRP|gene-protein might|O be|O a|O sensitive|O angiogenic|O measure|O of|O VEGF|gene-protein systems|O in|O neuroblastoma|O ,|O particularly|O in|O its|O early|O stages|O .|O 
Cell|O cycle|O -|O dependent|O expression|O of|O HERG1|gene-protein and|O HERG1B|gene-protein isoforms|O in|O tumor|O cells|O .|O 
The|O role|O of|O K(+)|O channel|O activity|O during|O cell|O cycle|O progression|O has|O become|O a|O research|O topic|O of|O considerable|O interest|O .|O 
Blocking|O of|O K(+)|O channels|O inhibits|O the|O proliferation|O of|O many|O cell|O types|O ,|O although|O the|O mechanism|O of|O this|O inhibition|O is|O unclear|O .|O 
There|O is|O speculation|O that|O K(+)|O channels|O differentially|O regulate|O the|O electrical|O potential|O of|O the|O plasma|O membrane|O (|O V(m)|O )|O during|O proliferation|O .|O 
We|O have|O demonstrated|O that|O in|O tumor|O cells|O the|O value|O of|O V(m)|O is|O clamped|O to|O rather|O depolarized|O values|O by|O K(+)|O channels|O belonging|O to|O the|O HERG|gene-protein family|O .|O 
We|O report|O here|O that|O tumor|O cell|O lines|O preferentially|O express|O the|O herg1|gene-rna gene|O and|O a|O truncated|O ,|O N|O -|O deleted|O form|O that|O corresponds|O to|O herg1b|gene-rna .|O 
This|O alternative|O transcript|O is|O also|O expressed|O in|O human|O primary|O acute|O myeloid|O leukemias|O .|O 
Both|O HERG1|gene-protein and|O HERG1B|gene-protein proteins|O are|O expressed|O on|O the|O plasma|O membrane|O of|O tumor|O cells|O and|O can|O form|O heterotetramers|O .|O 
The|O expression|O of|O HERG|gene-protein protein|O isoforms|O is|O strongly|O cell|O cycle|O -|O dependent|O ,|O accounting|O for|O variations|O in|O HERG|gene-protein currents|O along|O the|O mitotic|O cycle|O .|O 
Moreover|O ,|O the|O blocking|O of|O HERG|gene-protein channels|O dramatically|O impairs|O cell|O growth|O of|O HERG|gene-protein -|O bearing|O tumor|O cells|O .|O 
These|O results|O suggest|O that|O modulated|O expression|O of|O different|O K(+)|O channels|O is|O the|O molecular|O basis|O of|O a|O novel|O mechanism|O regulating|O neoplastic|O cell|O proliferation|O .|O 
Myeloablative|O treatment|O supported|O by|O autologous|O stem|O cell|O infusion|O with|O neuroblastoma|O .|O 
Bcr-abl|O antisense|O oligodeoxynucleotides|O (|O AS-ODNs|O )|O have|O provided|O evidence|O of|O an|O antileukemia|O effect|O when|O tested|O in|O vitro|O against|O Philadelphia|O -|O positive|O cells|O .|O 
In|O order|O to|O investigate|O the|O efficacy|O of|O AS-ODNs|O as|O purging|O agents|O in|O chronic|O myeloid|O leukemia|O (|O CML|O )|O patients|O ,|O K562|O cells|O ,|O a|O human|O CML|O cell|O line|O ,|O were|O treated|O in|O vitro|O with|O various|O types|O of|O AS-ODNs|O and|O interferon-alpha|gene-protein .|O 
Cells|O were|O treated|O in|O vitro|O for|O 0|O and|O 36|O hr|O with|O 40|O microgram|O /|O mL|O of|O AS-ODNs|O ,|O respectively|O ,|O and|O incubated|O at|O 37|O degrees|O C|O for|O 36|O hr|O .|O 
Cytotoxic|O effects|O were|O measured|O by|O counting|O the|O number|O of|O viable|O cells|O as|O well|O as|O by|O MTT|O test|O .|O 
Clonogenic|O activities|O were|O evaluated|O by|O methylcellulose|O culture|O for|O 2|O weeks|O .|O 
The|O effects|O of|O purging|O agents|O on|O the|O rearrangement|O of|O bcrabl|gene-rna gene|O were|O evaluated|O by|O RT-PCR|O .|O 
AS-ODNs|O inhibited|O the|O proliferation|O of|O K562|O cells|O with|O time|O in|O cell|O count|O assay|O and|O MTT|O test|O .|O 
AS-ODNs|O were|O superior|O to|O INF-alpha|gene-protein in|O inhibiting|O clonogenic|O activity|O (|O recovery|O rate|O ;|O 26.3|O %|O vs|O 64.0|O %|O )|O .|O 
After|O incubation|O with|O bcr-abl|O AS-ODNs|O primers|O and|O mRNA|O isolated|O from|O K562|O cells|O ,|O positive|O bands|O were|O abolished|O ,|O especially|O of|O b3a2|O type|O and|O phosphorothioate|O type|O .|O 
Our|O results|O suggest|O that|O AS-ODNs|O mediated|O purging|O may|O be|O one|O of|O the|O efficient|O methods|O and|O that|O autograft|O may|O be|O an|O alternative|O treatment|O for|O allograft|O in|O high|O -|O risk|O group|O patients|O of|O CML|O if|O they|O do|O not|O have|O a|O stem|O cell|O donor|O .|O 
Loss|O of|O DCC|gene-rna expression|O in|O neuroblastoma|O is|O associated|O with|O disease|O dissemination|O .|O 
DCC|gene-rna ,|O a|O candidate|O tumor|O suppressor|O gene|O from|O chromosome|O 18q21|O ,|O is|O most|O highly|O expressed|O in|O the|O developing|O nervous|O system|O .|O 
In|O vitro|O studies|O suggest|O a|O role|O for|O DCC|gene-rna in|O neuronal|O differentiation|O ,|O and|O 18q|O allelic|O loss|O occurs|O in|O a|O subset|O of|O neuroblastomas|O .|O 
To|O address|O the|O hypothesis|O that|O loss|O of|O DCC|gene-rna function|O may|O contribute|O to|O tumorigenesis|O in|O cells|O of|O neural|O origin|O ,|O we|O utilized|O a|O combination|O of|O RNase|gene-protein protection|O ,|O immunoblotting|O ,|O and|O immunohistochemical|O approaches|O to|O characterize|O DCC|gene-rna expression|O in|O 62|O primary|O neuroblastomas|O and|O 16|O neuroblastoma|O cell|O lines|O .|O 
The|O DCC|gene-protein protein|O was|O undetectable|O in|O 38|O %|O of|O the|O primary|O tumors|O and|O 56|O %|O of|O the|O cell|O lines|O .|O 
Of|O note|O ,|O primary|O tumors|O lacking|O DCC|gene-rna expression|O were|O more|O likely|O to|O have|O been|O obtained|O from|O patients|O with|O disseminated|O or|O stage|O D|O disease|O (|O P|O =|O 0.01|O )|O .|O 
In|O addition|O ,|O loss|O of|O DCC|gene-rna expression|O was|O observed|O in|O three|O of|O six|O primary|O tumors|O from|O stage|O DS|O patients|O .|O 
No|O consistent|O relationship|O between|O the|O loss|O of|O DCC|gene-rna expression|O and|O N-myc|gene-rna amplification|O was|O observed|O in|O our|O studies|O .|O 
Our|O findings|O suggest|O that|O loss|O of|O DCC|gene-rna expression|O may|O contribute|O to|O the|O dissemination|O of|O neuroblastoma|O cells|O ,|O perhaps|O through|O alterations|O in|O growth|O and|O differentiation|O pathways|O distinct|O from|O those|O regulated|O by|O N-myc|gene-rna .|O 
Epolactaene|O ,|O a|O novel|O neuritogenic|O compound|O in|O human|O neuroblastoma|O cells|O ,|O selectively|O inhibits|O the|O activities|O of|O mammalian|O DNA|gene-protein polymerases|gene-protein and|O human|O DNA|gene-protein topoisomerase|gene-protein II|gene-protein .|O 
We|O chemically|O synthesized|O epolactaene|O ,|O a|O neuritogenic|O compound|O in|O human|O neuroblastoma|O cells|O ,|O and|O investigated|O its|O biochemical|O action|O in|O vitro|O .|O 
Epolactaene|O and|O its|O derivatives|O selectively|O inhibited|O the|O activities|O of|O mammalian|O DNA|gene-protein polymerase|gene-protein alpha|gene-protein and|O beta|gene-protein and|O human|O DNA|gene-protein topoisomerase|gene-protein II|gene-protein ,|O with|O IC(50)|O values|O of|O 25|O ,|O 94|O ,|O and|O 10|O microM|O ,|O respectively|O .|O 
By|O comparison|O with|O its|O structural|O derivatives|O ,|O the|O long|O alkyl|O side|O chain|O in|O epolactaene|O seemed|O to|O have|O an|O important|O role|O in|O this|O inhibitory|O effect|O .|O 
The|O compound|O did|O not|O influence|O the|O activities|O of|O plant|O or|O prokaryotic|O DNA|gene-protein polymerases|gene-protein or|O of|O other|O DNA|O metabolic|O enzymes|O such|O as|O telomerase|gene-protein ,|O RNA|gene-protein polymerase|gene-protein ,|O and|O deoxyribonuclease|gene-protein I|gene-protein .|O 
Epolactaene|O did|O not|O intercalate|O into|O DNA|O .|O 
These|O results|O suggested|O that|O the|O neuritogenic|O compound|O epolactaene|O influences|O both|O DNA|gene-protein polymerases|gene-protein and|O topoisomerase|gene-protein II|gene-protein despite|O the|O dissimilarity|O in|O both|O structure|O and|O properties|O of|O these|O two|O enzymes|O and|O that|O inhibition|O of|O these|O enzymes|O could|O be|O related|O to|O the|O neuritogenic|O effect|O in|O human|O neuroblastoma|O cells|O .|O 
The|O relationship|O between|O the|O neuritogenic|O mechanism|O and|O cell|O cycle|O regulation|O by|O epolactaene|O was|O also|O discussed|O .|O 
Regulation|O of|O striatal|O dopamine|gene-protein receptors|gene-protein by|O estrogen|O .|O 
The|O ability|O of|O estrogen|O to|O modulate|O the|O expression|O of|O ventral|O and|O dorsal|O striatal|O dopamine|gene-protein receptors|gene-protein D(1)|gene-protein ,|O D(2,)|gene-protein and|O D(3)|gene-protein was|O examined|O in|O vivo|O using|O semi|O -|O quantitative|O in|O situ|O hybridization|O and|O ligand|O binding|O autoradiography|O .|O 
Two|O -|O week|O treatment|O with|O subcutaneous|O pellets|O of|O 17beta-estradiol|O (|O 25|O mg|O )|O downregulated|O D(2)|gene-rna dopamine|gene-rna receptor|gene-rna mRNA|O in|O both|O dorsal|O and|O ventral|O striatum|O (|O shell|O and|O core|O regions|O of|O nucleus|O accumbens|O )|O .|O 
No|O significant|O changes|O in|O D(1)|gene-rna or|O D(3)|gene-rna mRNA|O expression|O were|O detected|O .|O 
Ligand|O binding|O autoradiography|O did|O not|O reveal|O changes|O in|O D(1)|gene-protein ,|O D(2,)|gene-protein or|O D(3)|gene-protein receptor|O protein|O expression|O .|O 
We|O also|O assessed|O the|O ability|O of|O 17beta-estradiol|O to|O regulate|O D(2)|gene-rna gene|O promoter|O activity|O in|O NB41A3|O neuroblastoma|O cells|O that|O express|O this|O gene|O endogenously|O using|O co|O -|O transfections|O with|O an|O estrogen|O receptor|O expression|O vector|O .|O 
While|O a|O small|O fragment|O of|O the|O D(2)|gene-rna promoter|O could|O be|O activated|O 2.5|O -|O fold|O by|O estrogen|O ,|O a|O larger|O portion|O of|O the|O D(2)|gene-rna gene|O was|O not|O regulated|O by|O this|O treatment|O .|O 
Estrogens|O do|O not|O appear|O to|O have|O a|O net|O effect|O on|O striatal|O dopamine|gene-protein receptor|gene-protein expression|O .|O 
The|O observed|O downregulation|O of|O D(2)|gene-rna receptor|gene-rna mRNA|O in|O the|O dorsal|O and|O ventral|O striatum|O in|O vivo|O could|O be|O secondary|O to|O the|O increased|O striatal|O dopamine|O release|O induced|O by|O estrogen|O .|O 
Ethanol|O and|O naloxone|O differentially|O upregulate|O delta|gene-rna opioid|gene-rna receptor|gene-rna gene|O expression|O in|O neuroblastoma|O hybrid|O (|O NG108-15|O )|O cells|O .|O 
We|O have|O used|O a|O sensitive|O solution|O hybridization|O assay|O with|O a|O riboprobe|O transcribed|O from|O the|O coding|O sequence|O of|O the|O delta|gene-protein opioid|gene-protein receptor|gene-protein (|O DOR|gene-protein )|O to|O quantitate|O the|O changes|O in|O DOR|gene-rna mRNA|O transcript|O levels|O following|O exposure|O of|O NG108-15|O cells|O to|O ethanol|O and/or|O the|O opioid|O antagonist|O ,|O naloxone|O .|O 
Incubation|O of|O NG108-15|O cells|O with|O 200|O mM|O ethanol|O or|O 1|O microM|O naloxone|O ,|O treatments|O that|O have|O previously|O been|O shown|O to|O upregulate|O DOR|gene-protein binding|O ,|O increased|O DOR|gene-rna mRNA|O transcript|O levels|O 2|O to|O 3|O fold|O .|O 
DOR|gene-rna mRNA|O levels|O peaked|O at|O 24|O to|O 48|O h|O after|O exposure|O to|O either|O ethanol|O or|O naloxone|O .|O 
At|O 168|O h|O ,|O DOR|gene-rna mRNA|O levels|O in|O NG108-15|O cells|O exposed|O to|O naloxone|O had|O returned|O to|O control|O (|O untreated|O )|O levels|O while|O the|O levels|O in|O ethanol|O treated|O cells|O remained|O nearly|O equal|O to|O peak|O values|O .|O 
Exposure|O to|O a|O combination|O of|O ethanol|O plus|O naloxone|O for|O 24|O h|O produced|O an|O additive|O effect|O ,|O so|O that|O DOR|gene-rna mRNA|O transcripts|O were|O increased|O 3|O fold|O .|O 
Northern|O blot|O analysis|O identified|O six|O DOR|gene-rna transcript|O bands|O ranging|O in|O size|O from|O 8.7|O to|O 2.1|O kb|O .|O 
The|O above|O treatments|O increased|O each|O of|O the|O six|O bands|O proportionately|O ,|O so|O that|O no|O difference|O was|O observed|O in|O the|O fraction|O of|O the|O total|O hybridization|O signal|O produced|O by|O each|O band|O of|O the|O Northern|O blot|O .|O 
These|O results|O demonstrate|O that|O each|O of|O the|O DOR|gene-rna transcripts|O in|O NG108-15|O cells|O are|O subject|O to|O homologous|O (|O naloxone|O )|O as|O well|O as|O heterologous|O (|O ethanol|O )|O upregulation|O .|O 
Expression|O of|O the|O periostin|gene-rna mRNA|O level|O in|O neuroblastoma|O .|O 
BACKGROUND|O :|O 
Neuroblastoma|O is|O the|O most|O common|O malignant|O solid|O tumor|O in|O early|O childhood|O .|O 
Whether|O neuroblastoma|O is|O diagnosed|O by|O mass|O screening|O or|O by|O clinical|O symptom|O ,|O it|O has|O been|O reported|O to|O be|O correlated|O with|O prognosis|O of|O the|O disease|O .|O 
The|O periostin|gene-protein protein|O shares|O structural|O and|O sequence|O homology|O with|O fasciclin|gene-protein I|gene-protein ,|O which|O is|O an|O insect|O adhesion|O molecule|O .|O 
METHODS|O :|O 
Expression|O of|O periostin|gene-rna messenger|O RNAs|O were|O evaluated|O by|O real|O -|O time|O reverse|O transcription|O polymerase|gene-protein chain|O reaction|O (|O RT-PCR|O )|O assay|O in|O 24|O tumor|O samples|O from|O neuroblastoma|O using|O LightCycler|O .|O 
The|O data|O were|O analyzed|O in|O reference|O to|O clinicopathologic|O factors|O .|O 
RESULTS|O :|O 
There|O was|O a|O tendency|O for|O higher|O periostin|gene-rna transcripts|O levels|O in|O the|O tumor|O samples|O from|O stage|O IV|O when|O compared|O with|O the|O stage|O I|O (|O P|O =|O .0845|O )|O .|O 
The|O periostin|gene-rna mRNA|O level|O was|O higher|O in|O the|O group|O with|O disease|O diagnosed|O by|O symptom|O than|O in|O the|O group|O with|O disease|O diagnosed|O by|O mass|O screening|O (|O P|O =|O .0266|O )|O .|O 
The|O periostin|gene-rna mRNA|O level|O also|O was|O higher|O in|O the|O group|O with|O disease|O diagnosed|O after|O 1|O year|O of|O age|O than|O in|O the|O group|O with|O disease|O diagnosed|O before|O 1|O year|O of|O age|O (|O P|O =|O .0059|O )|O .|O 
CONCLUSION|O :|O 
Because|O the|O groups|O with|O disease|O diagnosed|O by|O symptom|O or|O after|O 1|O year|O of|O age|O were|O reported|O to|O be|O the|O worse|O prognosis|O ,|O the|O periostin|gene-rna mRNA|O expression|O levels|O were|O correlated|O with|O tumor|O progression|O or|O prognosis|O of|O neuroblastoma|O .|O 
Bak|gene-protein :|O a|O downstream|O mediator|O of|O fenretinide|O -|O induced|O apoptosis|O of|O SH-SY5Y|O neuroblastoma|O cells|O .|O 
Unlike|O 13-cis-retinoic|O acid|O ,|O the|O synthetic|O retinoid|O fenretinide|O [|O N-(4-hydroxyphenyl)retinamide|O ]|O induces|O apoptosis|O of|O neuroblastoma|O cells|O by|O mechanisms|O involving|O retinoic|gene-protein acid|gene-protein receptors|gene-protein and|O oxidative|O stress|O .|O 
After|O screening|O a|O cDNA|O array|O for|O apoptosis|O -|O related|O genes|O ,|O the|O Bcl2|gene-rna -|O related|O protein|O Bak|gene-protein was|O identified|O as|O a|O fenretinide|O -|O inducible|O gene|O in|O SH-SY5Y|O neuroblastoma|O cells|O ,|O and|O this|O was|O confirmed|O by|O Western|O blotting|O and|O flow|O cytometry|O .|O 
Although|O fenretinide|O acts|O synergistically|O in|O vitro|O with|O chemotherapeutic|O drugs|O ,|O these|O drugs|O did|O not|O induce|O Bak|gene-protein expression|O .|O 
Retinoic|gene-protein acid|gene-protein receptor|gene-protein antagonists|O did|O not|O block|O the|O induction|O of|O Bak|gene-protein by|O fenretinide|O .|O 
Conversely|O ,|O Bak|gene-protein induction|O was|O blocked|O by|O the|O antioxidant|O vitamin|O C|O .|O 
Overexpression|O of|O Bak|gene-protein increased|O apoptosis|O in|O both|O the|O presence|O and|O absence|O of|O fenretinide|O ,|O whereas|O expression|O of|O antisense|O Bak|gene-protein inhibited|O fenretinide|O -|O induced|O apoptosis|O .|O 
Bak|gene-protein expression|O was|O also|O induced|O in|O cells|O overexpressing|O the|O stress|O -|O induced|O transcription|O factor|O GADD153|gene-protein ,|O but|O Bak|gene-protein expression|O was|O inhibited|O in|O cells|O expressing|O an|O antisense|O GADD153|gene-protein construct|O .|O 
These|O results|O suggest|O that|O Bak|gene-protein is|O a|O downstream|O mediator|O of|O an|O oxidative|O stress|O pathway|O leading|O to|O apoptosis|O of|O SH-SY5Y|O neuroblastoma|O cells|O in|O response|O to|O fenretinide|O .|O 
MYCN|gene-rna expression|O in|O human|O rhabdomyosarcoma|O cell|O lines|O and|O tumour|O samples|O .|O 
The|O MYCN|gene-rna oncogene|O encodes|O a|O phosphoprotein|O that|O acts|O as|O a|O transcription|O factor|O and|O is|O involved|O in|O the|O regulation|O of|O cell|O proliferation|O and|O differentiation|O in|O normal|O as|O well|O as|O in|O cancer|O cells|O .|O 
MYCN|gene-rna amplification|O and|O expression|O have|O been|O reported|O in|O various|O tumours|O ,|O including|O neuroblastoma|O and|O lung|O cancer|O ,|O but|O little|O is|O known|O about|O its|O expression|O in|O human|O rhabdomyosarcoma|O .|O 
MYCN|gene-rna expression|O and|O amplification|O were|O studied|O in|O five|O alveolar|O and|O five|O embryonal|O rhabdomyosarcoma|O cell|O lines|O and|O in|O 19|O tumour|O biopsies|O .|O 
All|O the|O cell|O lines|O studied|O expressed|O MYCN|gene-rna RNA|O ,|O as|O demonstrated|O by|O northern|O blot|O analysis|O and|O RT-PCR|O ,|O but|O the|O oncogene|O was|O amplified|O in|O only|O one|O .|O 
Similarly|O ,|O MYCN|gene-protein protein|O was|O detected|O in|O all|O cell|O lines|O by|O western|O blot|O analysis|O ,|O with|O higher|O levels|O of|O expression|O in|O alveolar|O than|O in|O embryonal|O rhabdomyosarcoma|O cells|O .|O 
RT-PCR|O analysis|O of|O tumour|O samples|O demonstrated|O 18|O /|O 19|O cases|O positive|O for|O MYCN|gene-rna RNA|O .|O 
Although|O MYCN|gene-generic expression|O was|O higher|O in|O alveolar|O than|O in|O embryonal|O rhabdomyosarcoma|O cell|O lines|O ,|O no|O clear|O relationship|O between|O histology|O and|O level|O of|O MYCN|gene-generic expression|O could|O be|O established|O in|O this|O tumour|O series|O .|O 
These|O data|O suggest|O that|O MYCN|gene-generic expression|O is|O a|O common|O feature|O of|O rhabdomyosarcoma|O ,|O independent|O of|O gene|O amplification|O and|O without|O a|O clear|O relationship|O with|O specific|O histological|O and|O clinical|O features|O .|O 
Functional|O characterization|O of|O the|O promoter|O region|O of|O the|O human|O mu|gene-rna opioid|gene-rna receptor|gene-rna (|O hMOR|gene-rna )|O gene|O :|O identification|O of|O activating|O and|O inhibitory|O regions|O .|O 
The|O mu|gene-protein opioid|gene-protein receptor|gene-protein (|O MOR|gene-protein )|O is|O thought|O to|O mediate|O a|O variety|O of|O morphine|O 's|O effects|O ,|O including|O analgesia|O and|O addiction|O .|O 
The|O expression|O of|O opioid|gene-protein receptors|gene-protein can|O be|O up|O and|O down|O regulated|O ,|O but|O little|O is|O known|O about|O molecular|O processes|O that|O regulate|O expression|O of|O the|O MOR|gene-rna gene|O .|O 
To|O study|O the|O regulatory|O elements|O that|O control|O expression|O of|O the|O human|O MOR|gene-rna (|O hMOR|gene-rna )|O gene|O ,|O 2325|O bp|O of|O the|O 5'|O -|O regulatory|O sequence|O of|O the|O hMOR|gene-rna gene|O were|O cloned|O and|O sequenced|O .|O 
A|O transcription|O initiation|O site|O (|O TIS|O )|O was|O mapped|O 252|O (|O -|O 252|O )|O nucleotides|O upstream|O from|O the|O translation|O start|O site|O (|O +|O 1|O )|O by|O primer|O extension|O experiments|O using|O human|O thalamus|gene-rna poly(A)+|gene-rna mRNA|O .|O 
In|O addition|O ,|O several|O putative|O distal|O TISs|O were|O also|O identified|O ;|O the|O most|O distal|O site|O was|O mapped|O 663|O bp|O upstream|O of|O the|O translation|O start|O site|O .|O 
A|O series|O of|O 5'|O -|O deleted|O hMOR|gene-rna promoter|O -|O luciferase|gene-protein constructs|O were|O made|O and|O transiently|O transfected|O into|O a|O MOR|gene-rna expressing|O neuroblastoma|O cell|O line|O ,|O SK-N-SH|O ,|O and|O a|O non|O -|O expressing|O cell|O line|O ,|O HeLa|O .|O 
These|O transient|O transfection|O studies|O indicated|O that|O the|O region|O from|O -|O 563|O to|O -|O 292|O contained|O a|O strong|O enhancer|O element(s)|O ,|O while|O the|O region|O from|O -|O 776|O to|O -|O 564|O possessed|O a|O repressor|O element(s)|O .|O 
A|O similar|O transfection|O pattern|O was|O observed|O with|O SK-N-SH|O and|O HeLa|O cells|O ,|O suggesting|O that|O there|O is|O not|O a|O tissue|O -|O specific|O element|O in|O the|O region|O from|O -|O 2325|O to|O -|O 252|O .|O 
The|O glial|O transcription|O factor|O Sox10|gene-protein binds|O to|O DNA|O both|O as|O monomer|O and|O dimer|O with|O different|O functional|O consequences|O .|O 
Sox10|gene-protein is|O an|O important|O transcriptional|O regulator|O in|O the|O neural|O crest|O and|O various|O neural|O -|O crest|O derived|O lineages|O ,|O such|O as|O the|O Schwann|O cells|O of|O the|O peripheral|O nervous|O system|O .|O 
Recently|O ,|O we|O identified|O the|O gene|O for|O myelin|gene-protein Protein|gene-protein zero|gene-protein (|O P(0)|gene-protein )|O as|O a|O transcriptional|O target|O of|O Sox10|gene-protein in|O Schwann|O cells|O ,|O allowing|O for|O the|O first|O time|O a|O detailed|O analysis|O of|O Sox10|gene-protein responsive|O elements|O and|O their|O functional|O interaction|O with|O Sox10|gene-protein .|O 
Here|O we|O show|O that|O Sox10|gene-protein functions|O through|O two|O different|O types|O of|O DNA|O response|O elements|O ,|O one|O that|O allows|O binding|O of|O monomers|O ,|O and|O a|O second|O that|O favors|O cooperative|O binding|O of|O two|O molecules|O .|O 
This|O dimeric|O binding|O required|O the|O presence|O of|O two|O heptameric|O Sox|gene-protein binding|O sites|O in|O a|O specific|O orientation|O and|O spacing|O ,|O and|O was|O mediated|O by|O an|O N|O -|O terminal|O region|O of|O Sox10|gene-protein with|O high|O conservation|O in|O the|O related|O Sox9|gene-protein ,|O which|O also|O exhibited|O dimeric|O binding|O .|O 
This|O argues|O that|O the|O conserved|O region|O has|O the|O capacity|O to|O function|O as|O a|O DNA|O -|O dependent|O dimerization|O domain|O .|O 
The|O interaction|O between|O Sox10|gene-protein dimers|O and|O DNA|O differed|O dramatically|O from|O that|O of|O Sox10|gene-protein monomers|O ,|O as|O it|O drastically|O reduced|O the|O protein|O 's|O off|O -|O rate|O and|O increased|O the|O protein|O -|O induced|O angle|O of|O DNA|O bending|O .|O 
These|O results|O indicate|O that|O functionally|O relevant|O interactions|O between|O Sox10|gene-protein and|O DNA|O occur|O through|O completely|O different|O modes|O of|O binding|O .|O 
Muscarinic|gene-protein receptor|gene-protein -|O stimulated|O expression|O of|O c-fos|gene-rna in|O neuroblastoma|O cells|O .|O 
The|O intracellular|O signal|O cascade|O transducing|O muscarinic|gene-protein -|gene-protein receptor|gene-protein -|O stimulation|O to|O gene|O expression|O was|O investigated|O in|O human|O neuroblastoma|O SH-SY5Y|O cells|O .|O 
Naive|O and|O ethanol|O -|O exposed|O SH-SU5Y|O cells|O were|O stimulated|O with|O carbachol|O (|O CCh|O )|O and|O inositol|O 1,4-5-trisphosphate|O (|O IP3|O )|O ,|O 1,2-diacylglycerol|O (|O DAG|O )|O ,|O and|O c-fos|gene-rna mRNA|O levels|O were|O analyzed|O using|O a|O radioreceptor|O assay|O (|O IP3|O )|O thin|O -|O layer|O chromatography|O (|O DAG|O )|O and|O Northern|O blot|O (|O c-fos|gene-rna mRNA|O )|O .|O 
Application|O of|O the|O muscarinic|O agonist|O CCh|O induced|O a|O rapid|O increase|O in|O (|O IP3|O )|O ,|O peaking|O within|O seconds|O after|O the|O CCh|O -|O addition|O .|O 
There|O was|O also|O an|O accumulation|O of|O DAG|O reaching|O maximum|O after|O 5|O min|O of|O receptor|O -|O stimulation|O .|O 
Stimulation|O with|O CCh|O also|O induced|O expression|O of|O the|O immediate|O -|O early|O gene|O c-fos|gene-rna in|O these|O cells|O .|O 
These|O events|O were|O mediated|O via|O muscarinic|gene-protein M1|gene-protein receptors|gene-protein and|O the|O inhibitory|O effects|O of|O H7|gene-protein ,|O staurosporin|O ,|O and|O RO31-7549|O on|O the|O c-fos|gene-rna expression|O indicated|O that|O it|O was|O mediated|O via|O protein|gene-protein kinase|gene-protein C|gene-protein .|O 
Acute|O exposure|O to|O 100|O mM|O ethanol|O inhibited|O the|O formation|O of|O IP3|O and|O the|O expression|O of|O c-fos|gene-rna .|O 
These|O effects|O were|O due|O to|O an|O increase|O in|O the|O EC50|O of|O CCh|O for|O the|O events|O .|O 
Exposure|O to|O 100|O mM|O ethanol|O for|O 4|O days|O caused|O a|O potentiation|O of|O these|O two|O events|O .|O 
The|O EC50|O was|O unaffected|O but|O the|O maximal|O response|O was|O increased|O .|O 
These|O data|O indicate|O that|O this|O signal|O transduction|O system|O is|O inhibited|O by|O acute|O exposure|O to|O 100|O mM|O ethanol|O ,|O an|O effect|O that|O is|O compensated|O for|O after|O exposure|O to|O ethanol|O for|O 4|O days|O .|O 
Cadmium|O -|O mediated|O activation|O of|O the|O metal|O response|O element|O in|O human|O neuroblastoma|O cells|O lacking|O functional|O metal|gene-protein response|gene-protein element|gene-protein -|gene-protein binding|gene-protein transcription|gene-protein factor-1|gene-protein .|O 
Metal|gene-protein response|gene-protein element|gene-protein -|gene-protein binding|gene-protein transcription|gene-protein factor-1|gene-protein (|O MTF-1|gene-protein )|O binds|O specifically|O to|O metal|O response|O elements|O (|O MREs|O )|O and|O transactivates|O metallothionein|gene-rna (|O MT|gene-rna )|O gene|O expression|O in|O response|O to|O zinc|O and|O cadmium|O .|O 
This|O investigation|O contrasts|O the|O mechanism|O of|O mouse|O MT|gene-rna gene|O (|O mMT-I|gene-rna )|O promoter|O activation|O by|O cadmium|O and|O zinc|O in|O IMR-32|O human|O neuroblastoma|O cells|O to|O determine|O whether|O MTF-1|gene-protein binding|O to|O the|O MRE|O is|O necessary|O for|O activation|O by|O these|O metals|O .|O 
Cadmium|O activated|O a|O mMT-1|gene-rna promoter|O (|O -|O 150|O base|O pairs|O )|O luciferase|gene-protein reporter|O 20|O -|O 25|O -|O fold|O through|O a|O MRE|O -|O dependent|O mechanism|O .|O 
In|O contrast|O ,|O zinc|O had|O little|O effect|O on|O the|O mMT-1|gene-rna luciferase|gene-protein reporter|O .|O 
IMR-32|O cells|O lacked|O MRE|O binding|O activity|O ,|O and|O treatment|O with|O zinc|O in|O vitro|O or|O in|O vivo|O did|O not|O generate|O a|O MTF-1|gene-protein .|O 
MRE|O complex|O ,|O suggesting|O that|O IMR-32|O cells|O lack|O functional|O MTF-1|gene-protein .|O 
Overexpression|O of|O mMTF-1|gene-protein regenerated|O a|O zinc|O -|O mediated|O induction|O of|O the|O MRE|O without|O affecting|O cadmium|O activation|O .|O 
Because|O no|O other|O transition|O metals|O tested|O activated|O the|O MRE|O ,|O this|O effect|O appeared|O to|O be|O cadmium|O -|O specific|O .|O 
These|O data|O demonstrate|O that|O in|O IMR-32|O human|O neuroblastoma|O cells|O ,|O zinc|O and|O cadmium|O can|O use|O independent|O mechanisms|O for|O activation|O of|O the|O mMT-I|gene-rna promoter|O and|O cadmium|O -|O mediated|O MRE|O activation|O is|O independent|O of|O MTF-1|gene-protein and|O zinc|O .|O 
alpha-Synuclein|gene-rna maps|O to|O a|O quantitative|O trait|O locus|O for|O alcohol|O preference|O and|O is|O differentially|O expressed|O in|O alcohol|O -|O preferring|O and|O -|O nonpreferring|O rats|O .|O 
Total|O gene|O expression|O analysis|O (|O TOGA|O )|O was|O used|O to|O identify|O genes|O that|O are|O differentially|O expressed|O in|O brain|O regions|O between|O the|O alcohol|O -|O naive|O ,|O inbred|O alcohol|O -|O preferring|O (|O iP|O )|O ,|O and|O -|O nonpreferring|O (|O iNP|O )|O rats|O .|O 
alpha-Synuclein|gene-rna ,|O expressed|O at|O >|O 2|O -|O fold|O higher|O levels|O in|O the|O hippocampus|O of|O the|O iP|O than|O the|O iNP|O rat|O ,|O was|O prioritized|O for|O further|O study|O .|O 
In|O situ|O hybridization|O was|O used|O to|O determine|O specific|O brain|O regions|O and|O cells|O expressing|O alpha-synuclein|gene-rna in|O the|O iP|O and|O iNP|O rats|O .|O 
Similar|O to|O alpha-synuclein|gene-rna mRNA|O levels|O ,|O protein|O levels|O in|O the|O hippocampus|O were|O higher|O in|O iP|O rats|O than|O iNP|O rats|O .|O 
Higher|O protein|O levels|O were|O also|O observed|O in|O the|O caudate|O putamen|O of|O iP|O rats|O compared|O with|O iNP|O rats|O .|O 
Sequence|O analysis|O identified|O two|O single|O nucleotide|O polymorphisms|O in|O the|O 3|O '|O UTR|O of|O the|O cDNA|O .|O 
The|O polymorphism|O was|O used|O to|O map|O the|O gene|O ,|O by|O using|O recombination|O -|O based|O methods|O ,|O to|O chromosome|O 4|O ,|O within|O a|O quantitative|O trait|O locus|O for|O alcohol|O consumption|O that|O was|O identified|O in|O the|O iP|O and|O iNP|O rats|O .|O 
A|O nucleotide|O exchange|O in|O the|O iNP|O 3|O '|O UTR|O reduced|O expression|O of|O the|O luciferase|gene-rna reporter|gene-rna gene|O in|O SK-N-SH|O neuroblastoma|O cells|O .|O 
These|O results|O suggest|O that|O differential|O expression|O of|O the|O alpha-synuclein|gene-rna gene|O may|O contribute|O to|O alcohol|O preference|O in|O the|O iP|O rats|O .|O 
Tethering|O the|O N|O -|O terminus|O of|O the|O prion|gene-protein protein|O compromises|O the|O cellular|O response|O to|O oxidative|O stress|O .|O 
The|O role|O of|O the|O N|O -|O terminal|O half|O of|O the|O prion|gene-protein protein|O (|O PrPC|gene-protein )|O in|O normal|O cellular|O function|O and|O pathology|O remains|O enigmatic|O .|O 
To|O investigate|O the|O biological|O role|O of|O the|O N|O -|O terminus|O of|O PrP|gene-protein ,|O we|O examined|O the|O cellular|O properties|O of|O a|O construct|O of|O murine|O PrP|gene-protein ,|O PrP-DA|gene-protein ,|O in|O which|O the|O N|O -|O terminus|O is|O tethered|O to|O the|O membrane|O by|O an|O uncleaved|O signal|O peptide|O and|O which|O retains|O the|O glycosyl-phosphatidylinositol|O anchor|O .|O 
Human|O neuroblastoma|O SH-SY5Y|O cells|O expressing|O PrP-DA|gene-protein were|O more|O susceptible|O to|O hydrogen|O peroxide|O and|O copper|O induced|O toxicity|O than|O wtPrP|gene-protein expressing|O cells|O .|O 
The|O PrP-DA|gene-protein expressing|O cells|O had|O an|O increased|O level|O of|O intracellular|O free|O radicals|O and|O reduced|O levels|O of|O superoxide|gene-protein dismutase|gene-protein and|O glutathione|gene-protein peroxidase|gene-protein as|O compared|O to|O the|O wtPrP|gene-protein expressing|O cells|O .|O 
The|O membrane|O topology|O ,|O cell|O surface|O location|O ,|O lipid|O raft|O localisation|O ,|O intracellular|O trafficking|O and|O copper|O -|O mediated|O endocytosis|O of|O PrP-DA|gene-protein were|O not|O significantly|O different|O from|O wtPrP|gene-protein .|O 
However|O ,|O cells|O expressing|O PrP-DA|gene-protein accumulated|O an|O N|O -|O terminal|O fragment|O that|O was|O resistant|O to|O proteinase|gene-protein K|gene-protein .|O 
The|O data|O presented|O here|O are|O consistent|O with|O the|O N|O -|O terminal|O region|O of|O PrPC|gene-protein having|O a|O role|O in|O the|O cellular|O response|O to|O oxidative|O stress|O ,|O and|O that|O tethering|O this|O region|O of|O the|O protein|O to|O the|O membrane|O compromises|O this|O function|O through|O the|O accumulation|O of|O a|O protease|gene-protein -|O resistant|O N|O -|O terminal|O fragment|O ,|O similar|O to|O that|O seen|O in|O some|O forms|O of|O human|O prion|gene-protein disease|O .|O 
Retinoic|O acid|O regulation|O of|O the|O VIP|gene-protein and|O PACAP|gene-protein autocrine|O ligand|O and|O receptor|O system|O in|O human|O neuroblastoma|O cell|O lines|O .|O 
Neuroendocrine|O tumors|O ,|O neuroblastoma|O in|O particular|O ,|O commonly|O express|O the|O neuropeptides|O vasoactive|gene-protein intestinal|gene-protein peptide|gene-protein (|O VIP|gene-protein )|O and|O pituitary|gene-protein adenylate|gene-protein cyclase|gene-protein activating|gene-protein peptide|gene-protein (|O PACAP|gene-protein )|O and|O their|O receptors|O .|O 
Retinoic|O acid|O (|O RA|O )|O has|O been|O shown|O to|O induce|O differentiation|O of|O neuroblastoma|O cell|O lines|O ,|O possibly|O by|O augmenting|O or|O interfering|O with|O neuropeptide|O autocrine|O loops|O .|O 
We|O sought|O to|O determine|O which|O receptor|O gene|O subtypes|O are|O expressed|O in|O selected|O human|O neuroblastoma|O cell|O lines|O (|O SH-SY5Y|O ,|O IMR-32|O ,|O and|O LA-N-5|O )|O ,|O and|O the|O effect|O of|O RA|O on|O the|O VIP|gene-protein /|O PACAP|gene-protein ligand|O /|O receptor|O system|O .|O 
Expression|O of|O both|O PACAP1|gene-rna and|O VIP1|gene-rna /|O PACAP2|gene-rna receptor|O genes|O was|O detected|O by|O Northern|O analysis|O ,|O which|O characteristically|O encode|O Type|gene-protein I|gene-protein (|O PACAP|gene-protein -|O preferring|O )|O ,|O and|O Type|gene-protein II|gene-protein (|O bivalent|O VIP|gene-protein /|O PACAP|gene-protein )|O receptors|gene-protein ,|O respectively|O .|O 
Binding|O experiments|O carried|O out|O on|O IMR-32|O cells|O ,|O using|O 125I|O VIP|gene-protein and|O 125I|O PACAP-27|gene-protein as|O tracers|O ,|O corroborated|O that|O both|O receptor|O subtypes|O were|O expressed|O .|O 
In|O contrast|O to|O RA|O upregulation|O of|O VIP|gene-protein binding|O (|O confirmed|O here|O in|O IMR-32|O cells|O )|O ,|O levels|O of|O both|O receptor|O mRNAs|O were|O reduced|O after|O RA|O treatment|O .|O 
VIP|gene-rna mRNA|O in|O each|O cell|O line|O was|O increased|O by|O RA|O ,|O whereas|O PACAP|gene-rna mRNA|O ,|O detected|O in|O IMR-32|O cells|O only|O ,|O was|O reduced|O .|O 
The|O studies|O indicate|O that|O several|O components|O of|O the|O VIP|gene-protein /|O PACAP|gene-protein autocrine|O system|O are|O regulated|O in|O neuroblastoma|O cell|O lines|O during|O RA|O differentiation|O .|O 
Molecular|O cytogenetic|O characterization|O of|O two|O non|O -|O MYCN|gene-rna amplified|O neuroblastoma|O cell|O lines|O with|O complex|O t|O (|O 11|O ;|O 17|O )|O .|O 
The|O pediatric|O tumor|O neuroblastoma|O is|O characterized|O by|O a|O very|O variable|O ,|O and|O at|O times|O unpredictable|O ,|O pattern|O of|O clinical|O behavior|O ,|O ranging|O from|O a|O benign|O localized|O tumor|O to|O an|O aggressive|O malignancy|O with|O poor|O prognosis|O .|O 
Standard|O clinical|O and|O pathological|O assessments|O do|O not|O always|O differentiate|O reliably|O between|O tumor|O subtypes|O and|O ,|O therefore|O ,|O genetic|O markers|O are|O now|O playing|O an|O increasingly|O important|O role|O in|O treatment|O decisions|O .|O 
MYCN|gene-rna oncogene|O amplification|O ,|O for|O example|O ,|O provides|O a|O useful|O marker|O of|O poor|O prognosis|O .|O 
However|O ,|O less|O than|O one|O -|O half|O of|O all|O patients|O who|O present|O with|O ,|O or|O who|O later|O develop|O ,|O metastatic|O disease|O show|O MYCN|gene-rna amplification|O .|O 
Consequently|O ,|O the|O identification|O of|O characteristic|O patterns|O of|O genetic|O alteration|O in|O the|O remaining|O tumors|O is|O of|O importance|O .|O 
In|O this|O report|O ,|O we|O describe|O two|O new|O cell|O lines|O that|O we|O have|O established|O from|O metastatic|O ,|O non|O -|O MYCN|gene-rna amplified|O ,|O advanced|O stage|O neuroblastomas|O .|O 
These|O cell|O lines|O show|O a|O number|O of|O features|O in|O common|O ,|O including|O unbalanced|O translocation|O between|O 11q|O and|O 17q|O ,|O loss|O of|O 3p|O ,|O 4p|O and|O 11q|O and|O gain|O of|O 17q|O .|O 
Therefore|O ,|O they|O provide|O a|O valuable|O resource|O for|O the|O characterization|O of|O genetic|O pathways|O leading|O to|O aggressive|O tumor|O growth|O in|O non|O -|O MYCN|gene-rna amplified|O neuroblastomas|O .|O 
Binding|O of|O Clostridium|O botulinum|O type|O C|O neurotoxin|O to|O different|O neuroblastoma|O cell|O lines|O .|O 
Binding|O of|O type|O C|O neurotoxin|O (|O C1|O toxin|O )|O from|O Clostridium|O botulinum|O (|O strain|O Stockholm|O )|O to|O neuroblastoma|O cell|O lines|O was|O studied|O by|O using|O biotinylated|gene-protein anti|gene-protein -|gene-protein toxin|gene-protein antibody|gene-protein and|O avidin|gene-protein -|gene-protein biotinylated|gene-protein peroxidase|gene-protein complex|gene-protein .|O 
The|O neurotoxin|O bound|O with|O high|O efficiency|O to|O mouse|O neuroblastoma|O (|O NS-20Y|O and|O NIE-115|O )|O cells|O and|O to|O hybridomas|O of|O rat|O glioblastoma|O and|O mouse|O neuroblastoma|O (|O NG108-C15|O )|O cells|O .|O 
The|O toxin|O bound|O little|O to|O human|O neuroblastoma|O ,|O rat|O astrocytoma|O ,|O and|O nonneural|O cell|O lines|O .|O 
Binding|O of|O the|O neurotoxin|O to|O NG108-C15|O cells|O was|O inhibited|O by|O gangliosides|O (|O GT1b|O and|O GM1|O )|O and|O by|O monoclonal|gene-protein antibodies|gene-protein (|O CA-12|gene-protein and|O C-9|gene-protein )|O ,|O although|O inhibition|O was|O not|O complete|O .|O 
Sequential|O preincubation|O of|O C1|O toxin|O with|O GT1b|O and|O CA-12|gene-protein caused|O complete|O inhibition|O .|O 
A|O Scatchard|O plot|O of|O binding|O of|O 125I|O -|O labeled|O C1|O toxin|O to|O NG108-C15|O cells|O showed|O a|O hyperbolic|O curve|O .|O 
Monoclonal|gene-protein antibody|gene-protein CA-12|gene-protein but|O not|O C-9|gene-protein neutralized|O the|O lethal|O activity|O of|O the|O toxin|O toward|O mice|O .|O 
Only|O C-9|gene-protein clearly|O inhibited|O toxin|O binding|O to|O GT1b|O .|O 
These|O results|O suggest|O that|O NG108-C15|O cells|O have|O at|O least|O two|O kinds|O of|O receptors|O for|O C1|O toxin|O .|O 
From|O the|O results|O of|O binding|O tests|O with|O neuraminidase|gene-protein -|O ,|O pronase|gene-protein -|O ,|O and|O trypsin|gene-protein -|O treated|O NG108-C15|O cells|O ,|O the|O chemical|O nature|O of|O the|O high|O -|O affinity|O site|O was|O presumed|O to|O be|O a|O glycoprotein|gene-protein containing|O sialic|O acid|O .|O 
GT1b|O may|O have|O an|O important|O role|O in|O low|O -|O affinity|O sites|O .|O 
The|O clinical|O role|O of|O molecular|O genetics|O in|O soft|O tissue|O tumor|O pathology|O .|O 
Cytogenetic|O and|O molecular|O analysis|O of|O soft|O tissue|O tumors|O has|O yielded|O a|O wealth|O of|O information|O over|O the|O past|O decade|O .|O 
Some|O of|O the|O genetic|O aberrations|O that|O have|O been|O identified|O appear|O to|O be|O fairly|O specific|O for|O individual|O tumor|O types|O .|O 
It|O is|O because|O of|O this|O specificity|O that|O these|O findings|O harbor|O the|O promise|O to|O become|O useful|O as|O diagnostic|O and/or|O prognostic|O markers|O .|O 
Technical|O advances|O that|O allow|O the|O application|O of|O cytogenetic|O and|O molecular|O techniques|O to|O archival|O material|O have|O been|O crucial|O in|O this|O respect|O .|O 
Molecular|O genetics|O has|O already|O become|O an|O integral|O part|O of|O the|O work|O -|O up|O of|O some|O tumors|O ,|O e.g.|O ,|O small|O cell|O sarcomas|O of|O childhood|O ,|O which|O demonstrate|O fairly|O characteristic|O translocations|O ,|O often|O involving|O the|O Ewing|gene-rna 's|gene-rna sarcoma|gene-rna gene|O .|O 
Some|O genetic|O abnormalities|O have|O become|O established|O as|O prognostic|O markers|O ,|O such|O as|O the|O deletion|O of|O the|O short|O arm|O of|O chromosome|O 1|O for|O neuroblastomas|O .|O 
Soft|O tissue|O tumor|O pathology|O has|O also|O benefitted|O from|O major|O advances|O in|O identifying|O genes|O that|O are|O critical|O in|O mesenchymal|O differentiation|O or|O cell|O cycle|O control|O .|O 
MyoD|gene-rna is|O a|O good|O example|O of|O a|O such|O a|O gene|O ,|O that|O has|O become|O useful|O as|O a|O diagnostic|O tool|O in|O rhabdomyosarcomas|O .|O 
Beyond|O potential|O practical|O applications|O of|O cytogenetic|O and|O molecular|O analyses|O in|O the|O diagnosis|O of|O these|O tumors|O ,|O we|O also|O review|O their|O impact|O on|O several|O philosophical|O concepts|O concerning|O soft|O tissue|O neoplasia|O .|O 
Hypoxia|O alters|O gene|O expression|O in|O human|O neuroblastoma|O cells|O toward|O an|O immature|O and|O neural|O crest|O -|O like|O phenotype|O .|O 
Insufficient|O oxygen|O and|O nutrient|O supply|O often|O restrain|O solid|O tumor|O growth|O ,|O and|O the|O hypoxia|gene-protein -|gene-protein inducible|gene-protein factors|gene-protein (|gene-protein HIF|gene-protein )|gene-protein 1|gene-protein alpha|gene-protein and|O HIF-2|gene-protein alpha|gene-protein are|O key|O transcription|O regulators|O of|O phenotypic|O adaptation|O to|O low|O oxygen|O levels|O .|O 
Moreover|O ,|O mouse|O gene|O disruption|O studies|O have|O implicated|O HIF-2|gene-protein alpha|gene-protein in|O embryonic|O regulation|O of|O tyrosine|gene-rna hydroxylase|gene-rna ,|O a|O hallmark|O gene|O of|O the|O sympathetic|O nervous|O system|O .|O 
Neuroblastoma|O tumors|O originate|O from|O immature|O sympathetic|O cells|O ,|O and|O therefore|O we|O investigated|O the|O effect|O of|O hypoxia|O on|O the|O differentiation|O status|O of|O human|O neuroblastoma|O cells|O .|O 
Hypoxia|O stabilized|O HIF-1|gene-protein alpha|gene-protein and|O HIF-2|gene-protein alpha|gene-protein proteins|O and|O activated|O the|O expression|O of|O known|O hypoxia|O -|O induced|O genes|O ,|O such|O as|O vascular|gene-rna endothelial|gene-rna growth|gene-rna factor|gene-rna and|O tyrosine|gene-rna hydroxylase|gene-rna .|O 
These|O changes|O in|O gene|O expression|O also|O occurred|O in|O hypoxic|O regions|O of|O experimental|O neuroblastoma|O xenografts|O grown|O in|O mice|O .|O 
In|O contrast|O ,|O hypoxia|O decreased|O the|O expression|O of|O several|O neuronal|O /|O neuroendocrine|O marker|O genes|O but|O induced|O genes|O expressed|O in|O neural|O crest|O sympathetic|O progenitors|O ,|O for|O instance|O c-kit|gene-rna and|O Notch-1|gene-rna .|O 
Thus|O ,|O hypoxia|O apparently|O causes|O dedifferentiation|O both|O in|O vitro|O and|O in|O vivo|O .|O 
These|O findings|O suggest|O a|O novel|O mechanism|O for|O selection|O of|O highly|O malignant|O tumor|O cells|O with|O stem|O -|O cell|O characteristics|O .|O 
The|O RET|gene-protein and|O TRKA|gene-protein pathways|O collaborate|O to|O regulate|O neuroblastoma|O differentiation|O .|O 
Neuroblastoma|O (|O NB|O )|O is|O a|O childhood|O cancer|O that|O arises|O in|O the|O adrenal|O gland|O and|O often|O shows|O differentiated|O neuronal|O and|O glial|O elements|O .|O 
The|O RET|gene-protein receptor|gene-protein signal|O pathway|O is|O functional|O in|O most|O NB|O ,|O while|O loss|O of|O nerve|gene-rna growth|gene-rna factor|gene-rna (|gene-rna NGF|gene-rna )|gene-rna receptor|gene-rna (|O trkA|gene-rna )|O gene|O expression|O correlates|O with|O an|O aggressive|O phenotype|O .|O 
Thus|O ,|O we|O hypothesized|O that|O the|O RET|gene-protein and|O TRKA|gene-protein signal|O pathways|O collaborate|O to|O instruct|O NB|O differentiation|O ,|O reminiscent|O of|O normal|O neuronal|O maturation|O .|O 
Here|O ,|O we|O demonstrate|O that|O activation|O of|O the|O RET|gene-protein receptor|gene-protein by|O glial|gene-protein cell|gene-protein line|gene-protein -|gene-protein derived|gene-protein neurotrophic|gene-protein factor|gene-protein (|O GDNF|gene-protein )|O increases|O expression|O of|O the|O RET|gene-protein receptor|gene-protein complex|O in|O a|O panel|O of|O malignant|O human|O NB|O cell|O lines|O ,|O indicative|O of|O a|O positive|O feedback|O mechanism|O .|O 
GDNF|gene-protein also|O induces|O growth|O cessation|O concomitant|O with|O an|O arrest|O of|O cells|O in|O the|O G(0)|O /|O G(1)|O phase|O of|O the|O cell|O cycle|O .|O 
Furthermore|O ,|O GDNF|gene-protein synergizes|O with|O ciliary|gene-protein neurotrophic|gene-protein factor|gene-protein (|O CNTF|gene-protein )|O to|O enhance|O TRKA|gene-rna receptor|gene-rna expression|O ,|O thereby|O strengthening|O the|O NGF|gene-protein -|O mediated|O differentiation|O signal|O .|O 
Differentiated|O NB|O cells|O downregulate|O expression|O of|O the|O amplified|O N-myc|gene-rna gene|O ,|O concurrent|O with|O the|O arrest|O of|O cell|O proliferation|O ,|O while|O expressing|O neuron|O -|O specific|O markers|O (|O i.e.|O ,|O SCG10|gene-protein )|O .|O 
Interestingly|O ,|O maintenance|O of|O differentiated|O NB|O cells|O in|O culture|O is|O independent|O of|O the|O trophic|O activity|O of|O GDNF|gene-protein ,|O but|O depends|O on|O TRKA|gene-protein signaling|O ,|O thereby|O re|O -|O enacting|O the|O differentiation|O of|O normal|O sympathoadrenal|O (|O SA|O )|O progenitor|O cells|O .|O 
Ganglioglioma|O :|O a|O correlative|O clinicopathological|O and|O radiological|O study|O of|O ten|O surgically|O treated|O cases|O with|O follow|O -|O up|O .|O 
Gangliogliomas|O are|O rare|O benign|O tumors|O of|O the|O central|O nervous|O system|O containing|O neoplastic|O ganglion|O and|O low|O grade|O glial|O cells|O .|O 
In|O studying|O 10|O surgically|O treated|O cases|O ,|O we|O evaluated|O the|O clinical|O ,|O pathological|O ,|O radiological|O ,|O and|O immunocytochemical|O features|O ,|O with|O follow|O -|O up|O .|O 
Ranging|O from|O 18|O to|O 58|O years|O in|O age|O ,|O 7|O patients|O were|O women|O ,|O and|O 3|O were|O men|O .|O 
The|O most|O common|O presenting|O symptom|O was|O seizure|O .|O 
Computed|O tomographic|O scan|O showed|O a|O low|O density|O enhancing|O mass|O in|O 8|O and|O calcification|O in|O 5|O .|O 
Six|O had|O minimally|O abnormal|O vascularity|O on|O angiography|O .|O 
Seven|O patients|O had|O total|O and|O 3|O had|O subtotal|O resections|O of|O the|O tumor|O .|O 
The|O temporal|O lobe|O was|O the|O location|O of|O the|O tumor|O in|O 6|O cases|O .|O 
All|O of|O the|O cases|O met|O the|O histological|O criteria|O of|O Russell|O and|O Rubinstein|O for|O ganglioglioma|O .|O 
Four|O patients|O received|O postoperative|O radiotherapy|O because|O of|O subtotal|O resection|O or|O aggressive|O histological|O makeup|O .|O 
On|O follow|O -|O up|O ,|O from|O 2.5|O to|O 7|O years|O ,|O 8|O patients|O are|O alive|O and|O tumor|O -|O free|O ,|O and|O 7|O are|O also|O seizure|O -|O free|O .|O 
Two|O died|O after|O operation|O :|O one|O immediately|O and|O the|O other|O of|O a|O glioblastoma|O that|O developed|O 5|O years|O later|O .|O 
Our|O study|O confirms|O that|O ganglioglioma|O is|O a|O distinct|O histological|O entity|O ,|O anatomically|O localized|O ,|O with|O characteristic|O clinical|O and|O radiological|O findings|O and|O long|O term|O survival|O .|O 
Aggressive|O histological|O makeup|O is|O not|O a|O definite|O indication|O of|O malignant|O potential|O .|O 
The|O definitive|O role|O of|O follow|O -|O up|O radiotherapy|O for|O this|O tumor|O needs|O further|O study|O .|O 
Malignant|O evolution|O is|O rare|O ,|O but|O warrants|O follow|O -|O up|O .|O 
Activation|O of|O cyclic|gene-protein AMP|gene-protein -|gene-protein dependent|gene-protein protein|gene-protein kinase|gene-protein and|O stimulation|O of|O protein|O phosphorylation|O in|O response|O to|O adenosine|O in|O C-1300|O murine|O neuroblastoma|O .|O 
DEAE-cellulose|O chromatography|O of|O the|O 20,000|O g|O supernatant|O fraction|O of|O homogenates|O of|O C-1300|O murine|O neuroblastoma|O (|O clone|O N2a|O )|O yields|O one|O major|O and|O two|O minor|O peaks|O of|O cyclic|gene-protein AMP|gene-protein -|gene-protein dependent|gene-protein protein|gene-protein kinase|gene-protein activity|O .|O 
Assessment|O of|O the|O endogenous|O activation|O state|O of|O the|O enzyme(s)|O reveals|O that|O the|O enzyme|O is|O fully|O activated|O by|O the|O treatment|O of|O whole|O cells|O with|O adenosine|O (|O 10|O microM|O )|O in|O the|O presence|O of|O the|O phosphodiesterase|gene-protein inhibitor|O Ro|O 20|O 1724|O (|O 0.7|O mM|O )|O .|O 
This|O treatment|O produces|O a|O large|O elevation|O in|O the|O cyclic|O AMP|O content|O of|O the|O cells|O .|O 
The|O treatment|O of|O whole|O cells|O with|O adenosine|O alone|O (|O 1|O -|O 100|O microM|O )|O or|O Ro|O 20|O 1724|O alone|O (|O 0.1|O -|O 0.7|O mM|O )|O produces|O minimal|O elevations|O in|O cyclic|O AMP|O but|O nevertheless|O causes|O significant|O activations|O of|O cyclic|gene-protein AMP|gene-protein -|gene-protein dependent|gene-protein protein|gene-protein kinase|gene-protein .|O 
The|O autophosphorylation|O of|O whole|O homogenates|O of|O treated|O and|O untreated|O cells|O was|O studied|O using|O [gamma-32P]|O ATP|O ,|O sodium|O dodecyl|O sulfate|O -|O polyacrylamide|O gel|O electrophoresis|O and|O autoradiography|O .|O 
Treatments|O which|O activate|O cyclic|gene-protein AMP|gene-protein -|gene-protein dependent|gene-protein protein|gene-protein kinase|gene-protein selectively|O stimulate|O the|O incorporation|O of|O 32P|O into|O several|O proteins|O .|O 
This|O stimulation|O is|O most|O prominent|O in|O the|O 15,000|O -|O dalton|O protein|O band|O .|O 
The|O addition|O of|O cyclic|O AMP|O to|O phosphorylation|O reactions|O containing|O homogenate|O of|O untreated|O cells|O stimulates|O the|O phosphorylation|O of|O the|O same|O protein|O bands|O .|O 
These|O results|O indicate|O that|O adenosine|O may|O have|O regulatory|O functions|O through|O its|O effect|O on|O the|O cyclic|O AMP|O :|O cyclic|gene-protein AMP|gene-protein -|gene-protein dependent|gene-protein protein|gene-protein kinase|gene-protein system|O .|O 
Receptor|gene-protein for|gene-protein advanced|gene-protein glycation|gene-protein end|gene-protein products|gene-protein (|O RAGE|gene-protein )|O -|O mediated|O neurite|O outgrowth|O and|O activation|O of|O NF-kappaB|gene-protein require|O the|O cytoplasmic|O domain|O of|O the|O receptor|O but|O different|O downstream|O signaling|O pathways|O .|O 
Receptor|gene-protein for|gene-protein advanced|gene-protein glycation|gene-protein end|gene-protein products|gene-protein (|O RAGE|gene-protein )|O mediates|O neurite|O outgrowth|O in|O vitro|O on|O amphoterin|gene-protein -|O coated|O substrates|O .|O 
Ligation|O of|O RAGE|gene-protein by|O two|O other|O ligands|O ,|O advanced|O glycation|O end|O products|O or|O amyloid|gene-protein beta-peptide|gene-protein ,|O is|O suggested|O to|O play|O a|O role|O in|O cell|O injury|O mechanisms|O involving|O cellular|O oxidant|O stress|O and|O activation|O of|O the|O transcription|O factor|O NF-kappaB|gene-protein .|O 
However|O ,|O the|O RAGE|gene-protein signaling|O pathways|O in|O neurite|O outgrowth|O and|O cell|O injury|O are|O largely|O unknown|O .|O 
Here|O we|O show|O that|O transfection|O of|O RAGE|gene-protein to|O neuroblastoma|O cells|O induces|O extension|O of|O filopodia|O and|O neurites|O on|O amphoterin|gene-protein -|O coated|O substrates|O .|O 
Furthermore|O ,|O ligation|O of|O RAGE|gene-protein in|O transfected|O cells|O enhances|O NF-kappaB|gene-protein -|O dependent|O transcription|O .|O 
Both|O the|O RAGE|gene-protein -|O mediated|O neurite|O outgrowth|O and|O activation|O of|O NF-kappaB|gene-protein are|O blocked|O by|O deletion|O of|O the|O cytoplasmic|O domain|O of|O RAGE|gene-protein .|O 
Moreover|O ,|O dominant|O negative|O Rac|gene-protein and|O Cdc42|gene-protein but|O not|O dominant|O negative|O Ras|gene-protein inhibit|O the|O extension|O of|O neurites|O induced|O by|O RAGE|gene-protein -|O amphoterin|gene-protein interaction|O .|O 
In|O contrast|O ,|O the|O activation|O of|O NF-kappaB|gene-protein is|O inhibited|O by|O dominant|O negative|O Ras|gene-protein but|O not|O Rac|gene-protein or|O Cdc42|gene-protein .|O 
These|O data|O suggest|O that|O distinct|O signaling|O pathways|O are|O used|O by|O RAGE|gene-protein to|O induce|O neurite|O outgrowth|O and|O regulate|O gene|O expression|O through|O NF-kappaB|gene-protein .|O 
p73|gene-rna ,|O a|O gene|O related|O to|O p53|gene-rna ,|O is|O not|O mutated|O in|O esophageal|O carcinomas|O .|O 
A|O novel|O gene|O ,|O termed|O p73|gene-rna ,|O encodes|O a|O protein|O with|O a|O significant|O homology|O to|O p53|gene-protein and|O has|O been|O mapped|O at|O chromosome|O 1p36.3|O ,|O which|O is|O a|O locus|O of|O multiple|O suppressor|O genes|O for|O tumors|O including|O neuroblastoma|O and|O other|O cancers|O .|O 
Since|O the|O 1p36|O locus|O is|O reported|O to|O be|O deleted|O and|O p53|gene-rna is|O frequently|O mutated|O in|O esophageal|O carcinomas|O ,|O we|O examined|O loss|O of|O heterozygosity|O (|O LOH|O )|O and|O mutation|O of|O the|O p73|gene-rna gene|O in|O 48|O untreated|O esophageal|O tumors|O ,|O as|O well|O as|O mRNA|O expression|O in|O 8|O tumors|O .|O 
We|O screened|O the|O P1|gene-rna genomic|O library|O to|O obtain|O a|O P1|gene-rna clone|O containing|O the|O p73|gene-rna gene|O and|O found|O a|O polymorphic|O short|O tandem|O CT|O repeat|O site|O at|O intron|O 9|O .|O 
Intragenic|O sequences|O for|O 14|O PCR|O primer|O sets|O and|O a|O primer|O pair|O flanking|O the|O repeat|O were|O also|O determined|O for|O the|O analysis|O of|O PCR|O single|O -|O strand|O conformation|O polymorphism|O (|O SSCP|O )|O and|O LOH|O studies|O ,|O respectively|O .|O 
Expression|O of|O p73|gene-rna mRNA|O was|O detectable|O but|O at|O low|O levels|O in|O all|O 8|O tumor|O tissues|O by|O reverse|gene-protein transcriptase|gene-protein PCR|O .|O 
We|O did|O not|O find|O any|O type|O of|O mutation|O other|O than|O polymorphisms|O in|O the|O 48|O esophageal|O carcinomas|O ,|O though|O aberration|O of|O the|O p53|gene-rna gene|O on|O the|O PCR|O -|O SSCP|O gels|O was|O observed|O in|O 15|O of|O 38|O (|O 39|O %|O )|O tumors|O of|O the|O same|O set|O .|O 
In|O addition|O ,|O LOH|O for|O p73|gene-rna was|O found|O in|O only|O 2|O of|O 25|O (|O 8|O %|O )|O tumors|O .|O 
These|O results|O suggest|O that|O ,|O at|O least|O in|O esophageal|O carcinomas|O ,|O allelic|O loss|O or|O mutation|O of|O p73|gene-rna may|O not|O be|O a|O main|O genetic|O event|O for|O the|O tumorigenesis|O as|O it|O is|O with|O p53|gene-rna .|O 
Motoneuronal|O cell|O death|O is|O not|O correlated|O with|O aggregate|O formation|O of|O androgen|gene-protein receptors|gene-protein containing|O an|O elongated|O polyglutamine|O tract|O .|O 
Spinal|O and|O bulbar|O muscular|O atrophy|O (|O SBMA|O )|O is|O associated|O with|O an|O abnormal|O expansion|O of|O the|O (CAG)(n)repeat|O in|O the|O androgen|gene-rna receptor|gene-rna (|O AR|gene-rna )|O gene|O .|O 
Similar|O mutations|O have|O been|O reported|O in|O other|O proteins|O that|O cause|O neurodegenerative|O disorders|O .|O 
The|O CAG|O -|O coded|O elongated|O polyglutamine|O (|O polyGln|O )|O tracts|O induce|O the|O formation|O of|O neuronal|O intracellular|O aggregates|O .|O 
We|O have|O produced|O a|O model|O to|O study|O the|O effects|O of|O potentially|O '|O neurotoxic|O '|O aggregates|O in|O SBMA|O using|O immortalized|O motoneuronal|O cells|O (|O NSC34|O )|O transfected|O with|O AR|gene-rna containing|O polyGln|O repeats|O of|O different|O sizes|O [|O (|O AR|gene-rna .Q|O (|O n|O =|O 0|O ,|O 23|O or|O 46|O )|O ]|O .|O 
Using|O chimeras|O of|O AR|gene-rna .Q|O (|O n|O )|O and|O the|O green|gene-protein fluorescent|gene-protein protein|gene-protein (|O GFP|gene-protein )|O ,|O we|O have|O shown|O that|O aggregate|O formation|O occurs|O when|O the|O polyGln|O tract|O is|O elongated|O and|O AR|gene-rna is|O activated|O by|O androgens|O .|O 
In|O NSC34|O cells|O co|O -|O expressing|O the|O AR|gene-rna with|O the|O polyGln|O of|O pathological|O length|O (|O AR|gene-rna .Q46|O )|O and|O the|O GFP|gene-protein we|O have|O noted|O the|O presence|O of|O several|O dystrophic|O neurites|O .|O 
Cell|O viability|O analyses|O have|O shown|O a|O reduced|O growth|O /|O survival|O rate|O in|O NSC34|O expressing|O the|O AR|gene-rna .Q46|O ,|O whereas|O testosterone|O treatment|O partially|O counteracted|O both|O cell|O death|O and|O the|O formation|O of|O dystrophic|O neurites|O .|O 
These|O observations|O indicate|O the|O lack|O of|O correlation|O between|O aggregate|O formation|O and|O cell|O survival|O ,|O and|O suggest|O that|O neuronal|O degeneration|O in|O SBMA|O might|O be|O secondary|O to|O axonal|O /|O dendritic|O insults|O .|O 
EWS|gene-rna /|O FLI-1|gene-rna antagonists|O induce|O growth|O inhibition|O of|O Ewing|O tumor|O cells|O in|O vitro|O .|O 
Among|O primitive|O neuroectodermal|O tumors|O ,|O Ewing|O tumors|O are|O characterized|O by|O a|O gene|O rearrangement|O recombining|O the|O 5'-|O EWS|gene-rna gene|O portion|O with|O one|O of|O two|O ETS|gene-rna -|O related|O proto|O -|O oncogenes|O ,|O FLI-1|gene-rna or|O ERG|gene-rna ,|O in|O roughly|O 90|O and|O 10|O %|O of|O cases|O ,|O respectively|O .|O 
We|O attempted|O to|O antagonize|O EWS|gene-rna /|O FLI-1|gene-rna function|O in|O Ewing|O tumor|O cell|O lines|O .|O 
As|O a|O control|O ,|O a|O cell|O line|O derived|O from|O another|O small|O round|O cell|O tumor|O of|O neuroectodermal|O origin|O ,|O neuroblastoma|O ,|O was|O used|O .|O 
This|O cell|O line|O was|O found|O to|O express|O almost|O identical|O patterns|O of|O ETS|gene-protein proteins|O except|O for|O EWS|gene-rna /|O FLI-1|gene-rna and|O a|O novel|O ,|O ELF|gene-protein -|O related|O gene|O product|O .|O 
Stable|O expression|O of|O antisense|O EWS|gene-rna /|O FLI-1|gene-rna cDNA|O resulted|O in|O decreased|O endogenous|O EWS|gene-rna /|O FLI-1|gene-rna RNA|O levels|O and|O growth|O reduction|O of|O ET|O cells|O but|O not|O of|O neuroblastoma|O cells|O .|O 
DNA|O -|O binding|O FLI-1|gene-rna derivatives|O localizing|O to|O the|O nucleus|O in|O which|O the|O 5'-|O EWS|gene-rna regulatory|O domain|O was|O replaced|O by|O bacterial|O beta-galactosidase|gene-protein dominantly|O modulated|O transcriptional|O transactivation|O from|O a|O degenerate|O ETS|gene-protein -|O binding|O motif|O .|O 
Transient|O transfection|O of|O these|O dominant|O -|O negative|O recombinants|O resulted|O in|O a|O significant|O decrease|O in|O the|O relative|O number|O of|O mitoses|O in|O four|O Ewing|O tumor|O cell|O lines|O tested|O but|O not|O in|O the|O neuroblastoma|O cell|O line|O .|O 
The|O presented|O evidence|O for|O modulation|O of|O tumor|O cell|O proliferation|O by|O EWS|gene-rna /|O FLI-1|gene-rna antagonists|O suggests|O a|O causal|O role|O for|O EWS|gene-rna /|O FLI-1|gene-rna -|O mediated|O gene|O activation|O in|O the|O malignant|O transformation|O of|O the|O enigmatic|O Ewing|O tumor|O -|O precursor|O cell|O .|O 
Differential|O regulation|O of|O NF-kappaB|gene-protein ,|O SRE|gene-protein and|O CRE|gene-protein by|O dopamine|O D1|gene-protein and|O D2|gene-protein receptors|gene-protein in|O transfected|O NG108-15|O cells|O .|O 
To|O investigate|O transcriptional|O regulation|O by|O dopamine|gene-protein receptors|gene-protein ,|O we|O established|O NG108-15|O cells|O stably|O expressing|O D1R|gene-protein ,|O D2LR|gene-protein and|O D2SR|gene-protein (|O NGD1R|gene-protein ,|O NGD2LR|gene-protein and|O NGD2SR|gene-protein )|O and|O evaluated|O the|O effects|O of|O these|O receptors|O on|O NF-kappaB|gene-protein ,|O SRE|gene-protein and|O CRE|gene-protein activity|O using|O luciferase|gene-protein reporter|O constructs|O .|O 
Stimulation|O with|O quinpirole|O ,|O a|O selective|O D2R|gene-protein agonist|O ,|O increased|O NF-kappaB|gene-protein and|O SRE|gene-protein activity|O but|O decreased|O CRE|gene-protein activity|O in|O both|O NGD2R|O cell|O lines|O .|O 
By|O contrast|O ,|O stimulation|O with|O SKF|O 38393|O ,|O a|O selective|O D1R|gene-protein agonist|O ,|O decreased|O NF-kappaB|gene-protein and|O SRE|gene-protein activity|O but|O increased|O CRE|gene-protein activity|O in|O NGD1R|O cells|O .|O 
Stimulation|O with|O forskolin|O and|O overexpression|O of|O constitutively|O active|O PKA|gene-protein suppressed|O NF-kappaB|gene-protein activity|O ,|O likely|O due|O to|O D1R|gene-protein stimulation|O .|O 
D2R|gene-protein stimulation|O activated|O ERK|gene-protein ,|O and|O treatment|O with|O U1026|O ,|O a|O selective|O MEK|gene-protein inhibitor|O ,|O eliminated|O D2R|gene-protein -|O induced|O NF-kappaB|gene-protein activation|O .|O 
D2R|gene-protein stimulation|O also|O activated|O the|O neural|O cell|O adhesion|O molecule|O (|O NCAM|O )|O promoter|O ,|O which|O includes|O a|O potential|O NF-kappaB|gene-protein site|O .|O 
Furthermore|O ,|O by|O transfecting|O constitutively|O active|O CaM|gene-protein KII|gene-protein and|O MEKK|gene-protein ,|O and|O dominant|O negative|O p38|gene-protein MAPK|gene-protein ,|O we|O show|O that|O the|O NCAM|gene-rna promoter|O is|O positively|O regulated|O by|O CaM|gene-protein KII|gene-protein but|O negatively|O regulated|O by|O p38|gene-protein MAPK|gene-protein .|O 
These|O results|O indicate|O that|O D2R|gene-protein -|O induced|O NF-kappaB|gene-protein activation|O through|O ERK|gene-protein may|O be|O involved|O in|O activation|O of|O the|O NCAM|gene-rna promoter|O ,|O and|O additionally|O that|O other|O protein|gene-protein kinases|gene-protein such|O as|O CaM|gene-protein KII|gene-protein and|O p38|gene-protein MAPK|gene-protein also|O regulate|O NCAM|gene-rna expression|O .|O 
N-Myc|gene-rna and|O Bcl-2|gene-rna coexpression|O induces|O MMP-2|gene-protein secretion|O and|O activation|O in|O human|O neuroblastoma|O cells|O .|O 
Neuroblastoma|O is|O a|O peripheral|O nervous|O system|O tumor|O that|O accounts|O for|O 8|O -|O 10|O %|O of|O all|O solid|O childhood|O tumors|O .|O 
N-Myc|gene-protein is|O the|O most|O reliable|O prognostic|O indicator|O for|O neuroblastoma|O .|O 
Bcl-2|gene-protein is|O detected|O in|O 40|O -|O 60|O %|O of|O primary|O neuroblastoma|O tumors|O and|O demonstrates|O anti|O -|O apoptotic|O action|O by|O conferring|O resistance|O to|O chemotherapy|O and|O radiation|O treatment|O .|O 
In|O neuroblastoma|O cell|O lines|O ,|O the|O coexpression|O of|O N-Myc|gene-rna and|O Bcl-2|gene-rna leads|O to|O increased|O tumorigenic|O properties|O .|O 
Matrix|gene-protein metalloproteinases|gene-protein (|O MMPs|gene-protein )|O are|O endopeptidases|gene-protein that|O degrade|O a|O wide|O range|O of|O basement|O membrane|O components|O ,|O a|O process|O important|O for|O tumor|O invasion|O .|O 
This|O study|O investigates|O the|O effect|O of|O N-Myc|gene-rna and|O Bcl-2|gene-rna on|O MMP|gene-protein expression|O and|O activation|O .|O 
MMP-2|gene-protein expression|O and|O secretion|O are|O increased|O in|O SHEP|O neuroblastoma|O cells|O expressing|O Bcl-2|gene-protein alone|O (|O SHEP|O /|gene-protein Bcl-2|gene-protein cells|O )|O or|O both|O N-Myc|gene-protein and|O Bcl-2|gene-protein (|O SHEP|O /|O N-Myc|gene-protein /|O Bcl-2|gene-protein cells|O )|O .|O 
MMP-2|gene-protein activity|O is|O increased|O in|O the|O SHEP|O /|O N-Myc|gene-protein /|O Bcl-2|gene-protein cells|O yet|O remains|O unchanged|O in|O SHEP|O /|gene-protein Bcl-2|gene-protein cells|O .|O 
TIMP-2|gene-protein expression|O is|O high|O in|O SHEP|O /|gene-protein Bcl-2|gene-protein cells|O ,|O which|O likely|O inhibits|O MMP-2|gene-protein activity|O ,|O and|O absent|O in|O SHEP|O /|O N-Myc|gene-protein /|O Bcl-2|gene-protein cells|O ,|O allowing|O MMP-2|gene-protein activity|O .|O 
Invasion|O is|O increased|O in|O SHEP|O /|O N-Myc|gene-protein /|O Bcl-2|gene-protein cells|O and|O prevented|O by|O the|O use|O of|O a|O pharmacologic|O MMP-2|gene-protein inhibitor|O .|O 
These|O data|O imply|O that|O N-Myc|gene-rna and|O Bcl-2|gene-rna cooperate|O to|O increase|O the|O expression|O ,|O secretion|O ,|O and|O activation|O of|O MMP-2|gene-protein ,|O which|O likely|O leads|O to|O a|O more|O tumorigenic|O phenotype|O due|O to|O increased|O MMP-2|gene-protein mediated|O invasion|O .|O 
The|O MEIS1|gene-rna oncogene|O is|O highly|O expressed|O in|O neuroblastoma|O and|O amplified|O in|O cell|O line|O IMR32|O .|O 
Neuroblastoma|O is|O an|O embryonal|O tumor|O originating|O from|O neural|O crest|O -|O derived|O cells|O .|O 
Here|O we|O present|O the|O serendipitous|O cloning|O of|O amplified|O sequences|O of|O chromosome|O 2p15|O in|O neuroblastoma|O cell|O line|O IMR32|O .|O 
The|O amplified|O region|O was|O analyzed|O for|O oncogene|O activation|O using|O a|O SAGE|O (|O serial|O analysis|O of|O gene|O expression|O )|O library|O of|O IMR32|O .|O 
SAGE|O permits|O a|O quantitative|O analysis|O of|O all|O transcripts|O of|O a|O tissue|O or|O cell|O line|O .|O 
The|O expression|O of|O genes|O and|O ESTs|O mapping|O within|O a|O 30|O -|O cR|O region|O covering|O the|O amplicon|O was|O compared|O to|O 4|O additional|O SAGE|O libraries|O of|O neuroblastomas|O and|O 12|O SAGE|O libraries|O of|O other|O tissues|O in|O the|O CGAP|O databases|O .|O 
The|O IMR32|O SAGE|O database|O revealed|O increased|O expression|O of|O the|O MEIS1|gene-rna oncogene|O ,|O whereas|O other|O SAGE|O libraries|O showed|O little|O or|O no|O MEIS1|gene-rna expression|O .|O 
MEIS1|gene-rna turned|O out|O to|O be|O highly|O amplified|O and|O overexpressed|O in|O IMR32|O .|O Analysis|O of|O 24|O neuroblastoma|O cell|O lines|O and|O 22|O tumors|O showed|O high|O -|O level|O expression|O in|O about|O 25|O %|O of|O the|O cases|O .|O 
The|O MEIS1|gene-protein homeobox|gene-protein protein|O forms|O a|O complex|O with|O the|O HOXA9|gene-protein and|O PBX|gene-protein proteins|O that|O are|O implicated|O in|O human|O leukemia|O .|O 
MEIS1|gene-rna is|O a|O target|O of|O retroviral|O insertion|O in|O murine|O leukemia|O .|O 
This|O is|O the|O first|O report|O of|O a|O MEIS1|gene-rna amplification|O and|O high|O expression|O levels|O in|O human|O cancer|O and|O the|O first|O time|O that|O identification|O of|O a|O candidate|O target|O of|O amplification|O is|O facilitated|O by|O high|O -|O throughput|O mRNA|O expression|O profiling|O .|O 
Neuroblastomas|O with|O chromosome|O 11q|O loss|O and|O single|O copy|O MYCN|gene-rna comprise|O a|O biologically|O distinct|O group|O of|O tumours|O with|O adverse|O prognosis|O .|O 
Neuroblastoma|O is|O a|O heterogeneous|O tumour|O and|O its|O effective|O clinical|O management|O is|O dependent|O on|O accurate|O prognostic|O evaluation|O .|O 
In|O approximately|O 25|O %|O of|O patients|O amplification|O of|O the|O MYCN|gene-rna oncogene|O is|O known|O to|O be|O associated|O with|O a|O poor|O outcome|O .|O 
In|O order|O to|O identify|O additional|O molecular|O markers|O with|O prognostic|O potential|O in|O non|O -|O MYCN|gene-rna -|O amplified|O neuroblastomas|O ,|O we|O looked|O for|O a|O correlation|O between|O clinical|O outcome|O and|O loss|O of|O heterozygosity|O (|O LOH|O )|O on|O four|O chromosomes|O that|O frequently|O show|O alteration|O in|O neuroblastoma|O (|O chromosomes|O 3|O ,|O 4|O ,|O 11|O and|O 14|O )|O .|O 
Chromosome|O 11q|O loss|O (|O with|O frequent|O parallel|O loss|O of|O chromosomes|O 3p|O ,|O 4p|O and/or|O 14q|O )|O was|O found|O exclusively|O in|O tumours|O without|O MYCN|gene-rna amplification|O and|O was|O significantly|O associated|O with|O poor|O event|O -|O free|O survival|O .|O 
The|O 2|O -|O year|O event|O -|O free|O survival|O rate|O for|O 11q|O LOH|O cases|O was|O 30|O %|O ,|O compared|O to|O 34|O %|O for|O MYCN|gene-rna -|O amplified|O cases|O and|O 100|O %|O for|O cases|O without|O these|O abnormalities|O .|O 
While|O 11q|O LOH|O was|O associated|O predominantly|O with|O advanced|O -|O stage|O disease|O ,|O 2|O cases|O with|O low|O -|O stage|O disease|O and|O 11q|O LOH|O both|O suffered|O relapses|O .|O 
We|O conclude|O that|O chromosome|O 11q|O loss|O defines|O a|O biologically|O distinct|O group|O of|O tumours|O without|O MYCN|gene-rna amplification|O that|O appear|O to|O have|O potential|O for|O aggressive|O metastatic|O growth|O .|O 
Thus|O this|O genetic|O alteration|O may|O be|O an|O important|O new|O prognostic|O marker|O in|O neuroblastoma|O .|O 
Differential|O expression|O of|O two|O types|O of|O the|O neurofibromatosis|gene-rna type|gene-rna 1|gene-rna (|O NF1|gene-rna )|O gene|O transcripts|O related|O to|O neuronal|O differentiation|O .|O 
A|O 360|O residue|O region|O encoded|O by|O the|O neurofibromatosis|gene-rna type|gene-rna 1|gene-rna (|O NF1|gene-rna )|O gene|O shows|O significant|O homology|O to|O the|O catalytic|O domains|O of|O both|O mammalian|O GTPase|gene-protein -|gene-protein activating|gene-protein proteins|gene-protein (|O GAP|gene-protein )|O and|O yeast|O IRA|gene-protein proteins|O .|O 
This|O GAP|O -|O related|O domain|O of|O the|O NF1|gene-rna gene|O (|O NF1-GRD|gene-rna )|O ,|O like|O the|O GAP|gene-protein and|O IRA|gene-protein protein|O ,|O has|O been|O reported|O to|O mediate|O hydrolysis|O of|O Ras|gene-rna -|O bound|O GTP|O to|O GDP|O ,|O resulting|O in|O inactivation|O of|O Ras|gene-protein protein|O .|O 
In|O the|O present|O study|O ,|O we|O identified|O two|O different|O types|O of|O NF1-GRD|gene-rna cDNA|O .|O 
One|O (|O type|O I|O )|O is|O identical|O to|O the|O previously|O reported|O sequence|O ,|O and|O the|O other|O (|O type|O II|O )|O contained|O an|O additional|O 63|O bp|O insertion|O that|O encodes|O for|O a|O region|O of|O 21|O amino|O acids|O in|O the|O center|O of|O the|O NF1-GRD|gene-rna molecule|O .|O 
Alternative|O splicing|O is|O the|O most|O likely|O mechanism|O by|O which|O these|O two|O types|O of|O transcripts|O arise|O .|O 
Our|O observations|O reveal|O that|O the|O type|O I|O transcript|O is|O predominantly|O expressed|O in|O undifferentiated|O cells|O ,|O whereas|O the|O type|O II|O transcript|O predominates|O in|O differentiated|O cells|O .|O 
Furthermore|O ,|O the|O expression|O pattern|O of|O type|O I|O and|O type|O II|O NF1-GRD|gene-rna mRNA|O immediately|O changed|O in|O SH-SY5Y|O neuroblastoma|O cells|O when|O neuronal|O differentiation|O programs|O were|O induced|O by|O retinoic|O acid|O treatment|O .|O 
We|O propose|O that|O the|O differential|O expression|O of|O type|O I|O and|O type|O II|O NF1-GRD|gene-rna transcripts|O might|O be|O an|O '|O on|O /|O off|O '|O switch|O that|O regulates|O the|O catalytic|O activity|O of|O the|O NF1|gene-rna gene|O product|O ,|O which|O plays|O an|O important|O role|O in|O the|O regulation|O of|O neuronal|O differentiation|O .|O 
Cationic|O lipopolyamines|O induce|O degradation|O of|O PrPSc|gene-protein in|O scrapie|O -|O infected|O mouse|O neuroblastoma|O cells|O .|O 
In|O prion|gene-protein diseases|O the|O endogenous|O prion|gene-protein protein|gene-protein (|O PrPC|gene-protein )|O is|O converted|O into|O an|O abnormally|O folded|O isoform|O ,|O denoted|O PrPSc|gene-protein ,|O which|O represents|O the|O major|O component|O of|O infectious|O scrapie|O prions|gene-protein .|O 
The|O mechanism|O of|O the|O conversion|O is|O largely|O unknown|O ,|O but|O the|O conversion|O is|O thought|O to|O occur|O after|O PrPC|gene-protein has|O reached|O the|O plasma|O membrane|O .|O 
Here|O we|O show|O that|O exogenous|O administration|O of|O the|O cationic|O lipopolyamine|O DOSPA|O interfered|O with|O the|O accumulation|O of|O PrPSc|gene-protein in|O scrapie|O -|O infected|O neuroblastoma|O cells|O .|O 
Structural|O analysis|O of|O the|O compounds|O tested|O revealed|O that|O inhibition|O of|O PrPSc|gene-protein was|O specific|O for|O lipids|O with|O a|O headgroup|O composed|O of|O the|O polyamine|O spermine|O and|O a|O quarternary|O ammonium|O ion|O between|O the|O headgroup|O and|O the|O lipophilic|O tail|O .|O 
The|O cationic|O lipopolyamine|O DOSPA|O induced|O the|O cellular|O degradation|O of|O preexisting|O PrPSc|gene-protein aggregates|O within|O 12|O hours|O and|O interfered|O with|O the|O de|O novo|O synthesis|O of|O PrPSc|gene-protein .|O 
Biosynthesis|O of|O PrPC|gene-protein ,|O or|O the|O assembly|O of|O sphingolipid|O -|O cholesterol|O microdomains|O (|O rafts|O )|O on|O the|O plasma|O membrane|O ,|O were|O not|O affected|O by|O this|O inhibitor|O .|O 
After|O removal|O of|O DOSPA|O and|O replating|O into|O normal|O medium|O propagation|O of|O PrPSc|gene-protein commenced|O ,|O although|O initially|O at|O a|O reduced|O rate|O .|O 
Incubation|O of|O ScN2a|O cells|O in|O free|O spermidine|O had|O no|O inhibitory|O effect|O on|O the|O accumulation|O of|O PrPSc|gene-protein .|O 
Our|O results|O indicate|O that|O membrane|O targeting|O of|O a|O small|O polyamine|O molecule|O creates|O a|O potent|O inhibitor|O of|O PrPSc|gene-protein propagation|O and|O offers|O the|O possibility|O to|O degrade|O preexisting|O PrPSc|gene-protein aggregates|O in|O living|O cells|O .|O 
Constitutively|O active|O NFkappa|gene-protein B|gene-protein is|O required|O for|O the|O survival|O of|O S|O -|O type|O neuroblastoma|O .|O 
The|O NFkappaB|gene-protein transcription|O factors|O can|O both|O promote|O cell|O survival|O and|O induce|O apoptosis|O depending|O on|O cell|O type|O and|O context|O .|O 
Neuroblastoma|O (|O NB|O )|O cells|O display|O two|O predominant|O culture|O phenotypes|O identified|O as|O N|O -|O and|O S|O -|O types|O .|O 
Malignant|O S|O -|O type|O cells|O express|O neither|O high|O levels|O of|O MYCN|gene-generic nor|O Bcl-2|gene-generic ,|O suggesting|O that|O other|O survival|O mechanisms|O are|O important|O .|O 
We|O characterized|O NFkappaB|gene-protein activity|O in|O S|O -|O type|O cells|O and|O determined|O its|O role|O in|O their|O survival|O .|O 
S|O -|O type|O lines|O (|O SH-EP1|O and|O SK-N-AS|O )|O were|O treated|O with|O pyrrolidine|O dithiocarbamate|O (|O PDTC|O )|O ,|O a|O NFkappaB|gene-protein inhibitor|O ,|O or|O l-1-tosylamido-2-phenylethyl|O chloromethyl|O ketone|O (|O TPCK|O )|O ,|O a|O serine|O protease|gene-protein inhibitor|O that|O blocks|O IkappaBalpha|gene-protein degradation|O .|O 
Both|O agents|O induced|O cell|O death|O ,|O suggesting|O that|O constitutive|O NFkappaB|gene-protein activity|O is|O required|O for|O survival|O .|O 
The|O transient|O expression|O of|O a|O super|O -|O repressor|O IkappaBalpha|gene-protein mutant|O killed|O S|O -|O type|O cells|O .|O 
The|O inhibition|O of|O NFkappaB|gene-protein produced|O an|O apoptotic|O response|O characterized|O by|O the|O collapse|O of|O the|O mitochondrial|O transmembrane|O electrochemical|O gradient|O ,|O caspase-9|gene-protein activation|O ,|O and|O apoptotic|O DNA|O changes|O .|O 
Constitutive|O NFkappaB|gene-protein DNA|O binding|O activity|O specifically|O involving|O p65|gene-protein and|O p50|gene-protein was|O demonstrated|O in|O S|O -|O but|O not|O N|O -|O type|O cells|O by|O electromobility|O supershift|O and|O gene|O reporter|O assays|O .|O 
This|O study|O demonstrates|O a|O role|O for|O NFkappaB|gene-protein in|O the|O survival|O of|O S|O -|O type|O NB|O tumor|O cells|O and|O suggests|O that|O NFkappaB|gene-protein activity|O and|O function|O differ|O according|O to|O NB|O tumor|O cell|O phenotype|O .|O 
MYCN|gene-rna -|O mediated|O regulation|O of|O the|O MRP1|gene-rna promoter|O in|O human|O neuroblastoma|O .|O 
In|O the|O childhood|O cancer|O neuroblastoma|O (|O NB|O )|O ,|O the|O level|O of|O expression|O of|O the|O multidrug|gene-rna resistance|gene-rna -|gene-rna associated|gene-rna protein|gene-rna (|O MRP1|gene-rna )|O gene|O is|O strongly|O correlated|O with|O expression|O of|O the|O MYCN|gene-rna oncogene|O in|O primary|O NB|O tumors|O ,|O suggesting|O that|O MRP1|gene-rna may|O be|O a|O target|O for|O MYCN|gene-rna -|O mediated|O gene|O regulation|O .|O 
In|O this|O study|O ,|O we|O show|O that|O MYCN|gene-rna induction|O in|O human|O NB|O cells|O results|O in|O increased|O MRP1|gene-rna mRNA|O and|O protein|O levels|O ,|O which|O in|O turn|O is|O accompanied|O by|O increased|O drug|O resistance|O and|O enhanced|O MRP1|gene-rna -|O mediated|O drug|O efflux|O .|O 
Furthermore|O ,|O luciferase|gene-protein activity|O from|O MRP1|gene-rna promoter|O /|O luciferase|gene-rna gene|O reporter|O constructs|O was|O significantly|O increased|O in|O NB|O cells|O with|O exogenous|O overexpression|O of|O MYCN|gene-protein ,|O whereas|O activity|O was|O decreased|O in|O NB|O cells|O stably|O transfected|O with|O MYCN|gene-rna -|O antisense|O vectors|O .|O 
Decreased|O luciferase|gene-protein activity|O was|O observed|O with|O promoter|O constructs|O that|O lacked|O one|O or|O two|O E-box|O sequences|O or|O had|O E-box|O double|O point|O mutations|O ,|O while|O a|O truncated|O MRP1|gene-rna promoter|O lacking|O all|O three|O E-boxes|O exhibited|O only|O basal|O levels|O of|O activity|O .|O 
Specific|O electrophoretic|O mobility|O shifts|O of|O MRP1|gene-rna E-box|O sequences|O were|O detected|O with|O nuclear|O extracts|O from|O NB|O cells|O with|O MYCN|gene-protein overexpression|O ,|O and|O complex|O formation|O was|O inhibited|O with|O the|O addition|O of|O antibodies|O directed|O against|O MYCN|gene-protein or|O MYC|gene-protein .|O 
These|O findings|O indicate|O that|O by|O interacting|O with|O E-box|O elements|O within|O the|O promoter|O ,|O MYCN|gene-generic can|O upregulate|O MRP1|gene-rna expression|O and|O modulate|O drug|O resistance|O in|O NB|O .|O 
Functional|O analysis|O of|O intra|O -|O allelic|O variation|O at|O NACP|gene-rna -|O Rep1|gene-rna in|O the|O alpha-synuclein|gene-rna gene|O .|O 
NACP|gene-rna -|O Rep1|gene-rna ,|O a|O polymorphic|O microsatellite|O upstream|O of|O the|O alpha-synuclein|gene-rna gene|O (|O SNCA|gene-rna )|O ,|O consisting|O of|O the|O nucleotides|O (TC)(x)(T)(2)(TC)(y)(TA)(z)(CA)(w)|O ,|O has|O five|O alleles|O originally|O defined|O by|O 2|O -|O bp|O differences|O in|O (CA)(w)|O .|O 
Different|O NACP|gene-rna -|O Rep1|gene-rna alleles|O have|O been|O associated|O with|O sporadic|O Parkinson|O 's|O disease|O in|O some|O ,|O but|O not|O all|O ,|O studies|O and|O can|O effect|O expression|O driven|O by|O the|O SNCA|gene-rna promoter|O over|O a|O three|O -|O fold|O range|O in|O the|O neuroblastoma|O cell|O line|O ,|O SH-SY5Y|O .|O 
By|O analyzing|O children|O in|O CEPH|O families|O in|O which|O parents|O appeared|O to|O be|O homozygous|O for|O a|O NACP|gene-rna -|O Rep1|gene-rna allele|O ,|O we|O found|O that|O there|O are|O sequence|O differences|O within|O same|O -|O sized|O NACP|gene-rna -|O Rep1|gene-rna alleles|O ,|O contributed|O mainly|O by|O variation|O of|O the|O (TC)(y)(TA)(z)|O portion|O of|O the|O microsatellite|O repeat|O .|O 
To|O test|O whether|O these|O sequence|O differences|O might|O impact|O on|O promoter|O function|O we|O determined|O the|O effect|O of|O two|O sequence|O variant|O alleles|O ,|O both|O of|O size|O "|O 1|O "|O ,|O using|O the|O luciferase|gene-protein reporter|O system|O .|O 
There|O was|O only|O a|O very|O small|O expression|O difference|O between|O these|O two|O variant|O alleles|O .|O 
This|O finding|O implies|O that|O the|O overall|O length|O of|O the|O NACP|gene-rna -|O Rep1|gene-rna allele|O plays|O the|O main|O role|O in|O the|O transcription|O regulation|O by|O the|O NACP|gene-rna -|O Rep1|gene-rna element|O and|O suggests|O that|O functional|O differences|O due|O to|O sequence|O heterogeneity|O within|O NACP|gene-rna -|O Rep1|gene-rna alleles|O of|O the|O same|O length|O are|O probably|O not|O confounding|O factors|O in|O association|O studies|O based|O on|O alleles|O defined|O by|O length|O .|O 
Enhanced|O expression|O of|O N-myc|gene-rna messenger|O RNA|O in|O neuroblastomas|O found|O by|O mass|O screening|O .|O 
A|O substantial|O fraction|O of|O neuroblastomas|O found|O by|O mass|O screening|O have|O been|O suggested|O to|O regress|O spontaneously|O because|O of|O the|O high|O incidence|O of|O infantile|O neuroblastomas|O in|O the|O screening|O population|O .|O 
In|O this|O study|O ,|O 70|O neuroblastomas|O were|O analyzed|O for|O expression|O of|O proto|O -|O oncogenes|O related|O to|O neuronal|O differentiation|O to|O clarify|O the|O biological|O significance|O of|O proto|O -|O oncogene|O expression|O in|O the|O screening|O -|O positive|O and|O -|O negative|O tumors|O .|O 
The|O tumors|O consisted|O of|O 39|O neuroblastomas|O found|O by|O screening|O (|O group|O 1|O )|O ,|O 16|O non|O -|O N-myc|gene-rna -|O amplified|O neuroblastomas|O found|O by|O clinical|O symptom(s)|O (|O group|O 2|O )|O ,|O and|O 15|O N-myc|gene-rna -|O amplified|O neuroblastomas|O found|O by|O clinical|O symptom(s)|O (|O group|O 3|O )|O .|O 
The|O expression|O of|O c-src|gene-rna ,|O trk|gene-rna A|gene-rna ,|O and|O N-myc|gene-rna in|O tumor|O tissues|O was|O analyzed|O by|O quantitative|O RNA|O PCR|O .|O 
Neuronal|O c-srcN2|gene-rna expression|O varied|O significantly|O in|O the|O following|O order|O :|O group|O 1|O >|O group|O 2|O >|O group|O 3|O .|O 
The|O level|O of|O expression|O of|O trk|gene-rna A|gene-rna was|O markedly|O reduced|O in|O group|O 3|O but|O did|O not|O differ|O in|O groups|O 1|O and|O 2|O .|O 
Most|O tumors|O in|O group|O 3|O overexpressed|O N-myc|gene-rna .|O 
However|O ,|O N-myc|gene-rna expression|O in|O group|O 1|O was|O significantly|O higher|O than|O that|O in|O group|O 2|O .|O 
Thus|O ,|O the|O characteristics|O of|O proto|O -|O oncogene|O expression|O in|O screening|O -|O positive|O tumors|O included|O enhanced|O expression|O of|O c-srcN2|gene-rna and|O N-myc|gene-rna mRNA|O ,|O regardless|O of|O nonamplification|O of|O N-myc|gene-rna .|O 
Our|O results|O suggest|O that|O the|O role|O of|O N-myc|gene-rna differs|O in|O neuroblastomas|O detected|O by|O screening|O and|O in|O N-myc|gene-rna -|O amplified|O tumors|O .|O 
The|O mitochondrial|gene-protein proteins|gene-protein of|O the|O neuroblastoma|O cell|O line|O IMR-32|O .|O 
Mitochondrial|gene-protein proteins|gene-protein exert|O important|O functions|O in|O biological|O pathways|O ,|O particularly|O they|O are|O involved|O in|O apoptotic|O processes|O .|O 
We|O applied|O proteomics|O technologies|O to|O analyze|O the|O mitochondrial|gene-protein proteins|gene-protein of|O the|O neuroblastoma|O cell|O line|O IMR-32|O ,|O which|O is|O often|O used|O in|O apoptosis|O studies|O .|O 
The|O proteins|O were|O analyzed|O by|O two|O -|O dimensional|O (|O 2-D|O )|O electrophoresis|O followed|O by|O matrix|O -|O assisted|O laser|O desorption|O /|O ionization|O -|O mass|O spectrometry|O (|O MALDI|O -|O MS|O )|O .|O 
185|O different|O gene|O products|O were|O identified|O ,|O of|O which|O approximately|O 55|O %|O were|O enzymes|O with|O a|O broad|O spectrum|O of|O catalytic|O activities|O .|O 
Sixteen|O proteins|O were|O detected|O only|O in|O this|O preparation|O ,|O the|O others|O have|O been|O detected|O in|O two|O or|O more|O protein|O samples|O analyzed|O by|O MS|O in|O our|O laboratory|O .|O 
The|O 16|O unique|O gene|O products|O were|O represented|O by|O one|O spot|O each|O ,|O whereas|O most|O of|O the|O frequently|O detected|O proteins|O were|O represented|O by|O multiple|O spots|O .|O 
In|O average|O ,|O approximately|O 5|O -|O 10|O spots|O corresponded|O to|O one|O gene|O product|O .|O 
For|O two|O thirds|O of|O the|O proteins|O identified|O ,|O an|O annotation|O exists|O in|O the|O SWISS|O -|O PROT|O database|O about|O their|O subcellular|O location|O .|O 
They|O are|O mainly|O described|O as|O mitochondrial|gene-protein ,|O 8|O as|O endoplasmic|gene-protein reticulum|gene-protein ,|O 3|O as|O peroxisomal|gene-protein and|O only|O 12|O low|O -|O abundance|O proteins|O are|O described|O as|O cytosolic|O proteins|O .|O 
The|O list|O includes|O about|O 30|O unknown|O ,|O hypothetical|O or|O poorly|O described|O gene|O products|O .|O 
Some|O of|O them|O are|O represented|O by|O strong|O spots|O and|O the|O present|O study|O shows|O that|O they|O are|O indeed|O expressed|O and|O are|O localized|O in|O the|O mitochondria|O .|O 
GRP94|gene-protein (|O 94|O kDa|O glucose|O -|O regulated|O protein|O )|O suppresses|O ischemic|O neuronal|O cell|O death|O against|O ischemia|O /|O reperfusion|O injury|O .|O 
The|O 94|O kDa|O glucose|O -|O regulated|O protein|O (|O GRP94|gene-protein )|O ,|O the|O endoplasmic|O reticulum|O (|O ER|O )|O resident|O molecular|O chaperone|O ,|O has|O a|O role|O in|O cell|O death|O due|O to|O endoplasmic|O reticulum|O stress|O (|O ER|O stress|O )|O .|O 
Here|O ,|O we|O report|O that|O expression|O of|O GRP94|gene-protein was|O increased|O in|O human|O neuroblastoma|O cells|O (|O SH-SY5Y|O (|O SY5Y|O )|O cells|O )|O exposed|O to|O hypoxia|O /|O reoxygenation|O (|O H|O /|O R|O )|O .|O 
H|O /|O R|O mediated|O death|O of|O SY5Y|O cells|O was|O associated|O with|O the|O activation|O of|O major|O cysteine|gene-protein proteases|gene-protein ,|O caspase-3|gene-protein and|O calpain|gene-protein ,|O along|O with|O an|O elevated|O intracellular|O calcium|O concentration|O .|O 
Pretreatment|O with|O adenovirus|O -|O mediated|O antisense|O GRP94|gene-protein (|O AdGRP94AS|O )|O led|O to|O reduced|O viability|O of|O SY5Y|O cells|O after|O being|O subjected|O to|O H|O /|O R|O compared|O with|O wild|O -|O type|O cells|O or|O cells|O with|O adenovirus|O -|O mediated|O overexpression|O of|O GRP94|gene-protein (|O AdGRP94S|O )|O .|O 
These|O results|O indicate|O that|O suppression|O of|O GRP94|gene-protein is|O associated|O with|O accelerated|O apoptosis|O and|O that|O expression|O of|O GRP94|gene-protein (|O as|O a|O stress|O protein|O )|O suppresses|O oxidative|O stress|O -|O mediated|O neuronal|O death|O and|O stabilizes|O calcium|O homeostasis|O in|O the|O ER|O .|O 
We|O also|O used|O gerbils|O with|O transient|O forebrain|O ischemia|O to|O study|O the|O role|O of|O GRP94|gene-protein in|O vivo|O .|O 
Neurons|O with|O adenovirus|O -|O mediated|O overexpression|O of|O GRP94|gene-protein were|O resistant|O to|O ischemic|O damage|O .|O 
These|O results|O confirmed|O that|O GRP94|gene-protein could|O suppress|O ischemic|O injury|O to|O neurons|O ,|O suggesting|O that|O gene|O transfer|O of|O GRP94|gene-rna into|O the|O brain|O may|O have|O therapeutic|O potential|O in|O the|O treatment|O of|O cerebrovascular|O disease|O .|O 
Nerve|gene-protein growth|gene-protein factor|gene-protein -|O induced|O differentiation|O of|O human|O neuroblastoma|O and|O neuroepithelioma|O cell|O lines|O .|O 
A|O series|O of|O neuroepithelioma|O and|O neuroblastoma|O cell|O lines|O were|O screened|O for|O nerve|gene-protein growth|gene-protein factor|gene-protein (|O NGF|gene-protein )|O -|O induced|O differentiation|O .|O 
All|O three|O neuroepithelioma|O cell|O lines|O and|O all|O nine|O neuroblastoma|O cell|O lines|O with|O amplified|O N-myc|gene-rna oncogene|O did|O not|O show|O any|O apparent|O NGF|gene-protein -|O induced|O differentiation|O .|O 
However|O ,|O neurite|O extension|O was|O observed|O for|O three|O of|O six|O neuroblastoma|O cell|O lines|O with|O single|O -|O copy|O N-myc|gene-rna oncogene|O .|O 
The|O three|O responsive|O lines|O had|O a|O neuronal|O phenotype|O (|O short|O processes|O )|O which|O was|O enhanced|O by|O the|O addition|O of|O NGF|gene-protein .|O 
The|O three|O nonresponsive|O cell|O lines|O were|O flat|O without|O any|O processes|O .|O 
The|O addition|O of|O NGF|gene-protein to|O the|O responsive|O cell|O lines|O resulted|O in|O an|O up|O -|O regulation|O of|O neurofilament|O mRNA|O expression|O .|O 
Peripherin|gene-protein and|O synapsin|gene-protein ,|O two|O markers|O of|O terminal|O neuronal|O differentiation|O ,|O were|O not|O induced|O .|O 
There|O was|O little|O effect|O of|O NGF|gene-protein on|O the|O rate|O of|O cell|O growth|O or|O colony|O formation|O on|O soft|O agar|O .|O 
Binding|O of|O NGF|gene-protein to|O eight|O of|O the|O cell|O lines|O was|O analyzed|O by|O the|O method|O of|O Scatchard|O .|O 
Two|O responsive|O neuroblastoma|O cell|O lines|O and|O one|O nonresponsive|O neuroepithelioma|O cell|O line|O expressed|O both|O low|O -|O and|O high|O -|O affinity|O binding|O sites|O .|O 
Two|O nonresponsive|O neuroblastoma|O cell|O lines|O expressed|O only|O a|O small|O number|O of|O high|O -|O affinity|O binding|O sites|O ,|O and|O two|O other|O nonresponsive|O neuroblastoma|O cell|O lines|O did|O not|O detectably|O bind|O NGF|gene-protein .|O 
Hence|O ,|O NGF|gene-protein -|O induced|O differentiation|O is|O confined|O to|O a|O particular|O class|O of|O neural|O -|O related|O tumors|O ,|O and|O ,|O even|O for|O these|O cell|O lines|O ,|O differentiation|O is|O incomplete|O .|O 
Distinct|O induction|O of|O c-fos|gene-rna mRNA|O in|O NG108-15|O cells|O transfected|O with|O muscarinic|O m1|gene-protein and|O m3|gene-protein receptors|gene-protein .|O 
The|O differences|O of|O intracellular|O signalling|O mechanisms|O between|O muscarinic|O acetylcholine|O m1|gene-protein and|O m3|gene-protein receptors|gene-protein ,|O which|O are|O coupled|O with|O polyphosphoinositide|O turnover|O ,|O were|O examined|O by|O using|O m1|gene-protein -|O and|O m3|gene-protein -|O transfected|O NG108-15|O cells|O .|O 
The|O c-fos|gene-rna mRNA|O was|O induced|O by|O 1|O mM|O acetylcholine|O peak|O at|O 60|O min|O in|O both|O m1|gene-protein and|O m3|gene-protein cells|O .|O 
The|O c-fos|gene-rna induction|O in|O m1|gene-protein cells|O was|O inhibited|O by|O 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic|O acid|O tetraacetoxymethyl|O ester|O (|O BAPTA-AM|O )|O and|O N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide|O hydrochloride|O (|O W-7|O )|O ,|O but|O was|O not|O inhibited|O by|O prolonged|O treatment|O with|O 12-O-tetradecanoylphorbol|O 13-acetate|O (|O TPA|O )|O ,|O suggesting|O that|O intracellular|O Ca2+|O and|O calmodulin|gene-protein are|O involved|O in|O the|O induction|O .|O 
The|O c-fos|gene-rna induction|O in|O m3|gene-protein cells|O was|O inhibited|O by|O BAPTA-AM|O and|O prolonged|O treatment|O with|O TPA|O ,|O but|O was|O not|O influenced|O by|O W-7|O ,|O suggesting|O that|O protein|gene-protein kinase|gene-protein C|gene-protein is|O mainly|O involved|O in|O m3|gene-protein -|O induced|O c-fos|gene-rna expression|O .|O 
Acetylcholine|O induced|O an|O increase|O in|O inositol|O phosphates|O and|O a|O transient|O increase|O in|O the|O intracellular|O concentration|O of|O Ca2+|O in|O both|O m1|gene-protein and|O m3|gene-protein cells|O .|O 
Sustained|O stimulation|O of|O acetylcholine|O strongly|O increased|O the|O inositol|O monophosphate|O content|O in|O m3|gene-protein cells|O ,|O but|O that|O of|O inositol|O trisphosphate|O and|O inositol|O diphosphate|O in|O m1|gene-protein cells|O .|O 
These|O results|O suggest|O that|O the|O difference|O between|O m1|gene-protein -|O and|O m3|gene-protein -|O induced|O c-fos|gene-rna mRNA|O induction|O mechanisms|O is|O due|O to|O the|O difference|O in|O respective|O properties|O in|O polyphosphoinositide|O turnover|O .|O 
Expression|O of|O matrix|gene-protein metalloproteinases|gene-protein and|O the|O metastasis|gene-rna -|gene-rna associated|gene-rna gene|gene-rna S100A4|gene-rna in|O human|O neuroblastoma|O and|O primitive|O neuroectodermal|O tumor|O cells|O .|O 
BACKGROUND|O :|O 
Matrix|gene-protein metalloproteinases|gene-protein (|O MMPs|gene-protein )|O and|O their|O endogenous|O inhibitors|O (|O tissue|gene-protein inhibitors|gene-protein of|gene-protein MMPs|gene-protein ;|O TIMPs|gene-protein )|O have|O been|O shown|O to|O correlate|O with|O in|O vitro|O invasiveness|O and|O clinical|O outcome|O in|O several|O adult|O malignancies|O .|O 
The|O importance|O of|O MMP|gene-protein and|O TIMP|gene-protein expression|O in|O neuroblastoma|O (|O NB|O )|O and|O primitive|O neuroectodermal|O tumors|O (|O PNET|O )|O is|O incompletely|O understood|O .|O 
The|O aim|O of|O the|O current|O study|O was|O to|O relate|O in|O vitro|O invasion|O of|O NB|O and|O PNET|O cell|O lines|O with|O MMP|gene-protein and|O TIMP|gene-protein expression|O and|O evaluate|O the|O effect|O of|O a|O synthetic|O MMP|gene-protein inhibitor|O .|O 
Furthermore|O ,|O S100A4|gene-generic levels|O were|O determined|O because|O recent|O reports|O have|O suggested|O a|O possible|O association|O between|O MMPs|gene-protein ,|O TIMPs|gene-protein ,|O and|O the|O metastasis|gene-rna -|gene-rna associated|gene-rna gene|gene-rna S100A4|gene-rna .|O 
METHODS|O :|O 
Expression|O of|O MMPs|gene-generic ,|O TIMPs|gene-generic ,|O and|O S100A4|gene-generic was|O evaluated|O at|O both|O mRNA|O and|O protein|O levels|O in|O 2|O human|O NB|O and|O 2|O PNET|O cell|O lines|O .|O 
In|O vitro|O invasion|O and|O effects|O of|O the|O synthetic|O MMP|gene-protein inhibitor|O Marimastat|O were|O assessed|O in|O the|O Transwell|O chamber|O assay|O .|O 
RESULTS|O :|O 
The|O most|O invasive|O cells|O expressed|O the|O highest|O levels|O of|O MMPs|gene-protein and|O S100A4|gene-generic .|O 
Marimastat|O reduced|O invasion|O by|O 30|O %|O .|O 
CONCLUSIONS|O :|O 
In|O vitro|O invasion|O correlated|O with|O MMP|gene-protein and|O S100A4|gene-generic expression|O .|O 
The|O fact|O that|O Marimastat|O reduced|O in|O vitro|O invasion|O is|O encouraging|O for|O further|O studies|O on|O a|O possible|O therapeutic|O application|O for|O proteinase|gene-protein inhibitors|O .|O 
Neuronal|O differentiation|O -|O dependent|O expression|O of|O the|O disialic|O acid|O epitope|O on|O CD166|gene-generic and|O its|O involvement|O in|O neurite|O formation|O in|O Neuro2A|O cells|O .|O 
We|O previously|O demonstrated|O that|O alpha2,8|O -|O linked|O disialic|O acid|O (|O diSia|O )|O residues|O occur|O in|O several|O glycoproteins|gene-protein of|O mammalian|O brains|O (|O Sato|O ,|O C.|O ,|O Fukuoka|O ,|O H.|O ,|O Ohta|O ,|O K.|O ,|O Matsuda|O ,|O T.|O ,|O Koshino|O ,|O R.|O ,|O Kobayashi|O ,|O K.|O ,|O Troy|O ,|O F.|O A.|O ,|O II|O ,|O and|O Kitajima|O ,|O K.|O (|O 2000|O )|O J.|O Biol.|O Chem.|O 275|O ,|O 15422|O -|O 15431|O )|O .|O 
The|O role|O of|O the|O diSia|O epitope|O on|O these|O glycoproteins|gene-protein is|O not|O known|O ,|O whereas|O the|O importance|O of|O the|O diSia|O epitope|O on|O glycolipids|O is|O well|O documented|O in|O neurite|O formation|O .|O 
In|O this|O study|O ,|O we|O demonstrated|O that|O the|O diSia|O epitope|O (|O Neu5Acalpha2|O -->|O 8Neu5Acalpha2|O -->|O 3Gal|O )|O on|O glycoproteins|gene-protein ,|O but|O not|O on|O glycolipids|O ,|O is|O involved|O in|O neurite|O formation|O in|O a|O mouse|O neuroblastoma|O cell|O line|O ,|O Neuro2A|O ,|O based|O on|O the|O following|O lines|O of|O evidence|O .|O 
First|O ,|O the|O amount|O of|O diSia|O epitope|O on|O glycoproteins|gene-protein increased|O during|O retinoic|O acid|O -|O induced|O neurite|O formation|O .|O 
Second|O ,|O retinoic|O acid|O treatment|O primarily|O increased|O the|O diSia|O epitope|O on|O a|O 100|O -|O kDa|O glycoprotein|gene-protein .|O 
We|O identified|O this|O protein|O as|O CD166|gene-protein (|O SC1|gene-protein )|O ,|O an|O immunoglobulin|gene-protein superfamily|O cell|O adhesion|O molecule|O involved|O in|O neurite|O extension|O .|O 
Third|O ,|O a|O monoclonal|gene-protein antibody|gene-protein against|O the|O diSia|O epitope|O specifically|O inhibited|O neurite|O formation|O .|O 
We|O also|O demonstrated|O that|O alpha2,8-sialyltransferase|gene-rna III|gene-rna mRNA|O expression|O increased|O 1.7|O -|O fold|O after|O the|O induction|O of|O neurite|O formation|O ,|O suggesting|O that|O alpha2,8-sialyltransferase|gene-rna III|gene-rna is|O responsible|O for|O formation|O of|O the|O diSia|O epitope|O on|O CD166|gene-protein .|O 
Biology|O of|O tumors|O of|O the|O peripheral|O nervous|O system|O .|O 
Tumors|O of|O the|O peripheral|O nervous|O system|O include|O neuroblastomas|O ,|O pheochromocytomas|O ,|O and|O neuroepitheliomas|O .|O 
Neuroblastomas|O and|O pheochromocytomas|O are|O adrenergic|O in|O origin|O and|O share|O certain|O genetic|O features|O ,|O whereas|O neuroepitheliomas|O are|O thought|O to|O be|O cholinergic|O and|O are|O characterized|O by|O distinct|O genetic|O features|O .|O 
Neuroblastomas|O are|O characterized|O by|O deletion|O of|O the|O short|O arm|O of|O chromosome|O 1|O (|O 1p|O )|O ,|O amplification|O of|O the|O MYCN|gene-rna proto|O -|O oncogene|O ,|O and|O hyperdiploidy|O in|O subsets|O of|O tumors|O .|O 
All|O three|O of|O these|O genetic|O features|O have|O prognostic|O value|O in|O subsets|O of|O patients|O .|O 
Allelic|O loss|O of|O 14q|O also|O occurs|O with|O increased|O frequency|O ,|O but|O the|O prognostic|O importance|O of|O this|O abnormality|O is|O not|O known|O yet|O .|O 
Pheochromocytomas|O have|O not|O been|O studied|O as|O extensively|O ,|O but|O allelic|O loss|O for|O 1p|O appears|O to|O be|O a|O frequent|O change|O ,|O and|O no|O clear|O examples|O of|O oncogene|O activation|O have|O been|O identified|O to|O date|O .|O 
Neuroepitheliomas|O are|O characterized|O by|O translocation|O between|O chromosomes|O 11|O and|O 22|O .|O 
Although|O they|O have|O a|O characteristic|O pattern|O of|O proto|O -|O oncogene|O expression|O ,|O it|O is|O not|O clear|O that|O any|O of|O these|O oncogenes|O are|O activated|O specifically|O ,|O and|O no|O sites|O of|O allelic|O loss|O have|O been|O identified|O to|O date|O .|O 
Thus|O ,|O cytogenetic|O and|O molecular|O analysis|O of|O neuroblastomas|O ,|O pheochromocytomas|O ,|O and|O neuroepitheliomas|O are|O useful|O in|O distinguishing|O them|O from|O each|O other|O and|O from|O other|O tumors|O in|O selected|O cases|O .|O 
Furthermore|O ,|O certain|O genetic|O markers|O are|O useful|O in|O predicting|O clinical|O behavior|O ,|O especially|O for|O neuroblastoma|O .|O 
[|gene-protein Smooth|gene-protein muscle|gene-protein myosin|gene-protein of|gene-protein SM1|gene-protein and|O SM2|gene-protein isoforms|gene-protein expressing|O human|O neuroblastoma|O cell|O line|O of|O MP-N-MS|O ]|O 
Human|O neuroblastoma|O (|O NB|O )|O cell|O lines|O have|O at|O least|O three|O morphological|O appearance|O of|O neuroblastic|O (|O N|O -|O type|O )|O ,|O substrate|O -|O adhessive|O (|O S|O -|O type|O )|O and|O intermediate|O (|O I|O )|O cells|O .|O 
Our|O previous|O study|O revealed|O S|O -|O type|O cells|O expressed|O alpha|gene-protein -|gene-protein smooth|gene-protein muscle|gene-protein actin|gene-protein ,|O desmin|gene-protein and/or|O basic|gene-protein -|gene-protein calponin|gene-protein ,|O indicating|O the|O plausible|O smooth|O muscle|O cell|O characteristics|O of|O S|O -|O type|O cells|O .|O 
In|O this|O study|O ,|O a|O new|O human|O NB|O cell|O line|O ,|O MP-N-MS|O ,|O was|O established|O from|O bone|O marrow|O metastasis|O of|O a|O one|O year|O and|O six|O -|O month|O old|O girl|O with|O advanced|O NB|O ,|O originating|O from|O right|O adrenal|O gland|O .|O 
Morphology|O of|O this|O cell|O line|O is|O composed|O of|O S|O -|O type|O cells|O .|O 
MP-N-MS|O was|O identified|O as|O a|O NB|O cell|O line|O by|O surface|O membrane|O antigen|O analysis|O and|O MYCN|gene-rna gene|O amplification|O .|O 
EWS-FLI1|gene-protein and|O EWS-ERG|gene-protein chimeric|O products|O ,|O observed|O in|O Ewing|O family|O tumors|O ,|O were|O not|O detected|O by|O RT|O -|O PCR|O (|O reverse|gene-protein transcriptase|gene-protein -|O polymerase|gene-protein chain|O reaction|O )|O .|O 
In|O cytoskeletal|O protein|O analysis|O ,|O alpha|gene-protein -|gene-protein smooth|gene-protein muscle|gene-protein actin|gene-protein and|O basic|gene-protein calponin|gene-protein of|O smooth|O muscle|O cell|O markers|O were|O detected|O .|O 
Furthermore|O ,|O smooth|gene-protein myosin|gene-protein of|gene-protein SM1|gene-protein isoform|gene-protein was|O identified|O in|O MP-N-MS|O cell|O line|O by|O immunofluorescence|O ,|O Western|O blot|O and|O RT|O -|O PCR|O ,|O whereas|O smooth|gene-protein myosin|gene-protein of|gene-protein SM2|gene-protein was|O detected|O by|O RT|O -|O PCR|O .|O MP-N-MS|O is|O the|O first|O cell|O line|O ,|O showing|O SM1|gene-protein and|O SM2|gene-protein isoforms|gene-protein .|O 
The|O presence|O of|O smooth|gene-protein muscle|gene-protein myosin|gene-protein of|gene-protein SM1|gene-protein and|O SM2|gene-protein isoforms|gene-protein in|O MP-N-MS|O demonstrated|O the|O mature|O smooth|O muscle|O phenotype|O of|O this|O NB|O cell|O line|O ,|O and|O the|O ability|O of|O NB|O cells|O to|O differentiate|O into|O smooth|O muscle|O cell|O .|O 
Detection|O of|O microscopic|O disease|O :|O comparing|O histology|O ,|O immunocytology|O ,|O and|O RT|O -|O PCR|O of|O tyrosine|gene-protein hydroxylase|gene-protein ,|O GAGE|gene-protein ,|O and|O MAGE|gene-protein .|O 
BACKGROUND|O :|O 
We|O first|O explored|O the|O use|O of|O multiple|O molecular|O markers|O to|O overcome|O tumor|O heterogeneity|O .|O 
Sixty-seven|O neuroblastoma|O (|O NB|O )|O tumors|O were|O tested|O for|O the|O expression|O of|O GAGE|gene-rna ,|O MAGE-2|gene-rna ,|O MAGE-2|gene-rna ,|O MAGE-3|gene-rna ,|O and|O MAGE-4|gene-rna by|O RT|O -|O PCR|O and|O then|O chemiluminescence|O ;|O 82|O %|O of|O tumors|O had|O detectable|O GAGE|gene-rna ,|O and|O 88|O %|O expressed|O at|O least|O one|O of|O the|O four|O MAGE|gene-rna genes|O .|O 
PROCEDURE|O AND|O RESULTS|O :|O 
By|O combining|O GAGE|gene-rna and|O MAGE|gene-rna ,|O 64|O of|O 67|O (|O 95|O %|O )|O of|O tumors|O became|O detectable|O ;|O 17|O of|O 67|O coexpressed|O all|O five|O molecular|O markers|O .|O 
Neither|O GAGE|gene-rna nor|O MAGE|gene-rna expression|O correlated|O with|O stage|O .|O 
GAGE|gene-rna was|O found|O to|O have|O the|O broadest|O (|O 18|O of|O 18|O )|O expression|O among|O stage|O 4|O tumors|O .|O 
Two|O hundred|O fifty-nine|O bone|O marrows|O from|O 99|O patients|O were|O then|O studied|O for|O NB|O positivity|O by|O four|O detection|O methods|O :|O histology|O ,|O immunocytology|O ,|O and|O molecular|O detection|O by|O GAGE|gene-rna and|O tyrosine|gene-rna hydroxylase|gene-rna (|O TH|gene-rna )|O mRNA|O .|O 
Two|O hundred|O seven|O samples|O were|O NB|O -|O positive|O by|O one|O detection|O method|O .|O 
All|O four|O techniques|O were|O comparable|O in|O detecting|O tumor|O cells|O at|O diagnosis|O and|O at|O relapse|O .|O 
GAGE|gene-rna and|O immunocytology|O were|O far|O more|O sensitive|O than|O histology|O and|O TH|gene-rna mRNA|O when|O marrows|O were|O sampled|O during|O chemotherapy|O and|O at|O the|O time|O of|O clinical|O remission|O .|O 
CONCLUSIONS|O :|O 
By|O combining|O multiple|O molecular|O markers|O and|O independent|O screening|O techniques|O ,|O we|O may|O be|O able|O to|O overcome|O tumor|O heterogeneity|O and|O expedite|O the|O detection|O of|O microscopic|O disease|O in|O the|O clinical|O management|O of|O neuroblastoma|O .|O 
Evidence|O for|O interaction|O between|O human|O PRUNE|gene-protein and|O nm23-H1|gene-protein NDPKinase|gene-protein .|O 
We|O have|O isolated|O a|O human|O and|O murine|O homologue|O of|O the|O Drosophila|O prune|gene-rna gene|O through|O dbEST|O searches|O .|O 
The|O gene|O is|O ubiquitously|O expressed|O in|O human|O adult|O tissues|O ,|O while|O in|O mouse|O developing|O embryos|O a|O high|O level|O of|O expression|O is|O confined|O to|O the|O nervous|O system|O particularly|O in|O the|O dorsal|O root|O ganglia|O ,|O cranial|O nerves|O ,|O and|O neural|O retina|O .|O 
The|O gene|O is|O composed|O of|O eight|O exons|O and|O is|O located|O in|O the|O 1q21.3|O chromosomal|O region|O .|O 
A|O pseudogene|O has|O been|O sequenced|O and|O mapped|O to|O chromosomal|O region|O 13q12|O .|O 
PRUNE|gene-protein protein|O retains|O the|O four|O characteristic|O domains|O of|O DHH|gene-protein phosphoesterases|gene-protein .|O 
The|O synergism|O between|O prune|gene-rna and|O awdK-pn|gene-rna in|O Drosophila|O has|O led|O various|O authors|O to|O propose|O an|O interaction|O between|O these|O genes|O .|O 
However|O ,|O such|O an|O interaction|O has|O never|O been|O supported|O by|O biochemical|O data|O .|O 
By|O using|O interaction|O -|O mating|O and|O in|O vitro|O co|O -|O immunoprecipitation|O experiments|O ,|O we|O show|O for|O the|O first|O time|O the|O ability|O of|O human|O PRUNE|gene-protein to|O interact|O with|O the|O human|O homologue|O of|O awd|gene-protein protein|O (|O nm23-H1|gene-protein )|O .|O 
In|O contrast|O ,|O PRUNE|gene-protein is|O impaired|O in|O its|O interaction|O with|O nm-23-H1-S120G|gene-protein mutant|gene-protein ,|O a|O gain|O -|O of|O -|O function|O mutation|O associated|O with|O advanced|O neuroblastoma|O stages|O .|O 
Consistently|O ,|O PRUNE|gene-protein and|O nm23-H1|gene-protein proteins|O partially|O colocalize|O in|O the|O cytoplasm|O .|O 
The|O data|O presented|O are|O consistent|O with|O the|O view|O that|O PRUNE|gene-protein acts|O as|O a|O negative|O regulator|O of|O the|O nm23-H1|gene-protein protein|O .|O 
We|O discuss|O how|O PRUNE|gene-protein regulates|O nm23-H1|gene-protein protein|O and|O postulate|O possible|O implications|O of|O PRUNE|gene-protein in|O neuroblastoma|O progression|O .|O 
NUB-7|O :|O a|O stable|O I|O -|O type|O human|O neuroblastoma|O cell|O line|O inducible|O along|O N|O -|O and|O S|O -|O type|O cell|O lineages|O .|O 
Human|O NB|O cell|O lines|O express|O features|O of|O one|O or|O more|O of|O three|O recognizable|O phenotypes|O that|O include|O N|O -|O type|O (|O neuroblastic|O )|O ,|O S|O -|O type|O (|O Schwannian|O )|O ,|O and|O I|O -|O type|O (|O intermediate|O phenotype|O )|O cells|O .|O 
The|O I|O -|O type|O cell|O ,|O which|O shares|O properties|O of|O both|O N|O -|O and|O S|O -|O type|O cells|O ,|O is|O thought|O to|O represent|O the|O progenitor|O cell|O from|O which|O the|O other|O two|O cell|O types|O are|O derived|O .|O 
The|O MYCN|gene-rna amplified|O NB|O cell|O line|O NUB-7|O ,|O established|O in|O our|O laboratory|O ,|O is|O now|O shown|O to|O be|O composed|O principally|O of|O I|O -|O type|O cells|O .|O 
The|O observed|O phenotype|O was|O stable|O in|O culture|O and|O was|O representative|O of|O the|O original|O surgically|O resected|O tumor|O .|O 
The|O I|O -|O type|O cell|O designation|O was|O established|O based|O on|O morphological|O characteristics|O ,|O the|O coexpression|O of|O various|O N|O -|O type|O (|O neurofilaments|O ,|O peripherin|gene-protein ,|O GAP-43|gene-protein ,|O NCAM|gene-protein ,|O MYCN|gene-protein )|O and|O S|O -|O type|O cell|O (|O vimentin|gene-protein ,|O laminin|gene-protein ,|O fibronectin|gene-protein )|O markers|O ,|O and|O the|O relatively|O high|O level|O of|O expression|O of|O these|O markers|O in|O comparison|O to|O five|O predominantly|O N|O -|O type|O ,|O one|O S|O -|O type|O ,|O and|O one|O N|O /|O S|O mixed|O NB|O cell|O lines|O .|O 
Dibutyryl|O cyclic|O AMP|O and|O retinoic|O acid|O induced|O enhanced|O expression|O of|O N|O -|O and|O S|O -|O type|O phenotypes|O ,|O respectively|O ,|O in|O NUB-7|O as|O supported|O by|O specific|O morphological|O changes|O ,|O reduced|O growth|O ,|O and|O changes|O in|O the|O levels|O of|O expression|O of|O both|O N|O -|O and|O S|O -|O type|O markers|O .|O 
Our|O studies|O with|O the|O NUB-7|O cell|O line|O have|O now|O provided|O convincing|O evidence|O for|O the|O existence|O of|O a|O bipotential|O progenitor|O of|O N|O -|O and|O S|O -|O type|O cells|O in|O NB|O .|O 
As|O well|O ,|O the|O NUB-7|O cell|O line|O may|O also|O represent|O the|O tumor|O counterpart|O of|O a|O sympathetic|O ganglion|O progenitor|O cell|O .|O 
Beta|gene-protein 2-microglobulin|gene-protein expression|O in|O human|O embryonal|O neuroblastoma|O reflects|O its|O developmental|O regulation|O .|O 
Class|gene-protein I|gene-protein major|gene-protein histocompatibility|gene-protein complex|gene-protein (|gene-protein MHC|gene-protein )|gene-protein antigen|gene-protein expression|O in|O neuroblastoma|O may|O play|O a|O role|O in|O the|O oncogenicity|O of|O this|O embryonal|O tumor|O of|O childhood|O .|O 
Since|O N-myc|gene-rna amplification|O in|O neuroblastoma|O tumors|O is|O associated|O with|O rapid|O tumor|O progression|O (|O 33|O )|O and|O N-myc|gene-rna decreases|O Class|gene-protein I|gene-protein MHC|gene-protein antigen|gene-protein expression|O in|O rat|O neuroblastoma|O cells|O (|O 21|O )|O ,|O we|O quantitated|O levels|O of|O N-myc|gene-rna mRNA|O and|O Class|gene-protein I|gene-protein MHC|gene-protein cell|gene-protein surface|gene-protein antigens|gene-protein in|O a|O panel|O of|O 24|O human|O neuroblastoma|O cell|O lines|O .|O 
We|O found|O that|O N-myc|gene-rna expression|O is|O not|O invariably|O associated|O with|O low|O levels|O of|O beta|gene-protein 2-microglobulin|gene-protein (|O B2M|gene-protein )|O and|O Class|gene-protein I|gene-protein MHC|gene-protein antigen|gene-protein expression|O .|O 
As|O we|O considered|O that|O Class|gene-protein I|gene-protein MHC|gene-protein antigens|gene-protein may|O be|O regulated|O in|O association|O with|O the|O differentiation|O stage|O of|O the|O neuroblastoma|O tumor|O ,|O we|O examined|O the|O expression|O of|O B2M|gene-protein during|O development|O of|O the|O human|O adrenal|O medulla|O ,|O the|O tissue|O of|O origin|O of|O most|O neuroblastomas|O .|O 
We|O found|O that|O B2M|gene-protein is|O a|O marker|O of|O differentiated|O adrenal|O medullary|O cells|O ,|O expressed|O late|O during|O the|O third|O trimester|O of|O development|O .|O 
Moreover|O ,|O using|O morphological|O and|O immunological|O criteria|O ,|O we|O found|O that|O B2M|gene-protein is|O expressed|O in|O differentiated|O tumor|O cells|O .|O 
These|O data|O suggest|O that|O the|O expression|O of|O B2M|gene-protein in|O neuroblastoma|O is|O associated|O with|O the|O stage|O of|O differentiation|O of|O the|O tumor|O cell|O and|O not|O N-myc|gene-rna expression|O .|O 
Furthermore|O ,|O these|O findings|O suggest|O that|O neuroblastomas|O may|O correspond|O to|O the|O arrested|O differentiation|O of|O adrenal|O neuroblasts|O at|O different|O stages|O of|O development|O .|O 
Expression|O ,|O cellular|O distribution|O and|O protein|O binding|O of|O the|O glioma|gene-protein amplified|gene-protein sequence|gene-protein (|O GAS41|gene-protein )|O ,|O a|O highly|O conserved|O putative|O transcription|O factor|O .|O 
The|O glioma|gene-protein amplified|gene-protein sequence|gene-protein 41|gene-protein (|O GAS41|gene-protein )|O was|O previously|O isolated|O by|O microdissection|O mediated|O cDNA|O capture|O from|O the|O glioblastoma|O multiforme|O cell|O line|O TX3868|O and|O shown|O to|O be|O frequently|O amplified|O in|O human|O gliomas|O .|O 
We|O determined|O the|O complete|O cDNA|O sequence|O of|O the|O GAS41|gene-rna gene|O ,|O demonstrated|O that|O the|O GAS41|gene-protein protein|O is|O evolutionarily|O conserved|O ,|O specifically|O at|O the|O N-terminus|O ,|O and|O identified|O the|O yeast|O transcription|O factor|O tf2f|O domain|O within|O the|O GAS41|gene-rna sequence|O .|O 
A|O human|O multiple|O -|O tissue|O Northern|O blot|O revealed|O ubiquitous|O expression|O of|O GAS41|gene-rna with|O the|O highest|O expression|O in|O human|O brain|O .|O 
After|O generating|O polyclonal|O antibodies|O we|O found|O GAS41|gene-protein protein|O expression|O in|O the|O nucleus|O of|O the|O TX3868|O cell|O line|O by|O Western|O blot|O analysis|O and|O immunofluorescence|O microscopy|O .|O 
The|O nuclear|O localization|O was|O confirmed|O for|O several|O human|O tumors|O including|O gliomas|O of|O different|O grades|O of|O malignancy|O .|O 
In|O neuroblastoma|O however|O ,|O GAS41|gene-protein was|O found|O in|O the|O nucleoli|O but|O not|O in|O the|O nucleoplasm|O .|O 
Yeast|O two|O -|O hybrid|O screening|O of|O the|O TX3868|O cell|O line|O identified|O the|O nuclear|gene-protein mitotic|gene-protein apparatus|gene-protein protein|O (|O NuMA|gene-protein )|O ,|O the|O KIAA1009|gene-protein protein|O ,|O and|O prefoldin|gene-protein subunit|gene-protein 1|gene-protein (|O PFDN1|gene-protein )|O as|O potential|O interacting|O partners|O of|O GAS41|gene-protein .|O 
We|O generated|O a|O polyclonal|O antibody|O against|O the|O KIAA1009|gene-protein protein|O and|O we|O demonstrated|O that|O the|O KIAA1009|gene-protein protein|O is|O a|O nuclear|O protein|O ,|O which|O appears|O to|O be|O co|O -|O localized|O with|O the|O GAS41|gene-protein protein|O and|O NuMA|gene-protein .|O 
Overexpression|O of|O the|O human|O major|gene-protein vault|gene-protein protein|gene-protein in|O astrocytic|O brain|O tumor|O cells|O .|O 
Evidence|O has|O shown|O that|O the|O major|gene-protein human|gene-protein vault|gene-protein protein|gene-protein (|O MVP|gene-protein )|O ,|O which|O is|O identical|O to|O lung|gene-protein resistance|gene-protein -|gene-protein related|gene-protein protein|gene-protein (|O LRP|gene-protein )|O ,|O may|O be|O causally|O involved|O in|O a|O special|O type|O of|O multidrug|O resistance|O (|O MDR|O )|O .|O 
The|O purpose|O of|O this|O study|O was|O to|O investigate|O the|O expression|O and|O cellular|O localization|O of|O MVP|gene-protein in|O cells|O derived|O from|O brain|O tumors|O and|O other|O tumors|O of|O neuroectodermal|O origin|O .|O 
Using|O both|O established|O cell|O lines|O (|O n|O =|O 22|O )|O and|O primary|O explants|O (|O n|O =|O 30|O )|O ,|O we|O show|O that|O a|O distinct|O overexpression|O of|O the|O MVP|gene-rna gene|O at|O the|O mRNA|O (|O RT|O -|O PCR|O )|O and|O protein|O (|O Western|O blot|O )|O levels|O is|O a|O characteristic|O feature|O of|O cells|O derived|O from|O astrocytic|O brain|O tumors|O .|O 
Primary|O cultures|O obtained|O from|O meningioma|O specimens|O also|O expressed|O high|O MVP|gene-protein levels|O ,|O in|O contrast|O to|O neuroblastoma|O and|O medulloblastoma|O cells|O ,|O which|O rarely|O contained|O detectable|O amounts|O of|O MVP|gene-protein .|O Normal|O human|O astrocytes|O cultured|O in|O vitro|O expressed|O MVP|gene-protein ,|O although|O at|O low|O amounts|O compared|O with|O most|O malignant|O cell|O types|O .|O 
Basal|O MVP|gene-protein expression|O correlated|O with|O resistance|O against|O diverse|O antineoplastic|O drugs|O including|O anthracyclins|O ,|O cisplatin|O and|O etoposide|O .|O 
By|O Western|O blot|O ,|O MVP|gene-protein was|O also|O detected|O in|O all|O tumor|O samples|O taken|O from|O 7|O glioma|O and|O 3|O meningioma|O patients|O .|O 
Taken|O together|O ,|O these|O data|O suggest|O overexpression|O of|O MVP|gene-protein as|O one|O explanation|O for|O the|O low|O efficacy|O of|O chemotherapeutic|O treatment|O of|O astrocytic|O brain|O tumors|O .|O 
High|O intrinsic|O radiosensitivity|O of|O a|O newly|O established|O and|O characterised|O human|O embryonal|O rhabdomyosarcoma|O cell|O line|O .|O 
A|O new|O human|O rhabdomyosarcoma|O cell|O line|O (|O HX170c|O )|O has|O been|O established|O from|O a|O paratesticular|O embryonal|O tumour|O in|O a|O 5|O -|O year|O -|O old|O male|O .|O 
The|O cells|O grew|O as|O an|O adherent|O monolayer|O with|O a|O doubling|O time|O of|O 32|O h|O and|O showed|O pleomorphic|O features|O .|O 
Intermediate|O filament|O analysis|O revealed|O the|O line|O to|O be|O mesenchymal|O in|O origin|O (|O reactivity|O to|O vimentin|gene-protein and|O desmin|gene-protein antibodies|gene-protein )|O .|O 
The|O line|O was|O tumorigenic|O in|O nude|O mice|O ,|O possessed|O elevated|O levels|O of|O creatine|gene-protein phosphokinase|gene-protein (|O mainly|O of|O the|O MM|O isoenzyme|O form|O )|O and|O had|O a|O near|O diploid|O mean|O chromosome|O number|O of|O 50|O .|O 
In|O vitro|O cell|O cloning|O determinations|O gave|O colony|O forming|O efficiencies|O of|O 0.01|O %|O in|O soft|O agar|O and|O 24|O %|O in|O a|O monolayer|O anchorage|O -|O dependent|O assay|O .|O 
Radiosensitivity|O determinations|O using|O a|O monolayer|O clonogenic|O assay|O with|O feeder|O layer|O support|O showed|O the|O cells|O to|O be|O among|O the|O more|O radiosensitive|O human|O tumour|O cell|O types|O (|O surviving|O fraction|O at|O 2|O Gy|O of|O 0.26|O )|O that|O have|O been|O investigated|O .|O 
Furthermore|O ,|O experiments|O utilising|O continuous|O low|O dose|O rate|O radiation|O at|O 3.2|O cGy|O min-1|O ,|O showed|O that|O ,|O under|O these|O experimental|O conditions|O ,|O the|O cells|O possessed|O only|O a|O very|O low|O capacity|O to|O recover|O from|O radiation|O -|O induced|O damage|O (|O dose|O reduction|O factor|O at|O 1|O %|O cell|O survival|O of|O 1.07|O for|O 150|O versus|O 3.2|O cGy|O min-1|O )|O .|O 
As|O other|O human|O tumour|O cells|O of|O an|O embryonal|O cell|O origin|O (|O e.g.|O neuroblastoma|O and|O germ|O cell|O tumours|O of|O the|O testis|O )|O have|O also|O been|O shown|O to|O be|O radiosensitive|O it|O appears|O that|O sensitivity|O to|O radiation|O may|O be|O a|O common|O property|O of|O this|O group|O of|O tumours|O .|O 
Determination|O of|O N-myc|gene-rna gene|O amplification|O in|O neuroblastoma|O by|O differential|O polymerase|gene-protein chain|O reaction|O .|O 
Determination|O of|O N-myc|gene-rna gene|O amplification|O ,|O a|O powerful|O prognostic|O indicator|O in|O the|O childhood|O tumour|O ,|O neuroblastoma|O ,|O has|O routinely|O been|O performed|O by|O Southern|O analysis|O .|O 
We|O have|O developed|O a|O differential|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O assay|O ,|O in|O which|O the|O N-myc|gene-rna target|O gene|O is|O co|O -|O amplified|O with|O a|O control|O gene|O ,|O glyceraldehyde-3-phosphate|gene-rna dehydrogenase|gene-rna (|O GAPDH|gene-rna )|O .|O 
Following|O electrophoresis|O ,|O a|O ratio|O between|O the|O two|O PCR|O products|O within|O a|O given|O DNA|O sample|O is|O then|O determined|O by|O densitometry|O .|O 
This|O assay|O was|O applied|O to|O DNA|O isolated|O from|O 32|O primary|O neuroblastoma|O tumours|O for|O which|O the|O N-myc|gene-rna status|O had|O previously|O been|O determined|O by|O Southern|O analysis|O .|O 
Following|O PCR|O ,|O samples|O containing|O a|O single|O copy|O of|O the|O N-myc|gene-rna oncogene|O were|O clearly|O distinguishable|O from|O samples|O with|O N-myc|gene-rna gene|O amplification|O ,|O based|O on|O an|O N-myc|gene-rna /|O GAPDH|gene-rna ratio|O of|O below|O or|O above|O 1.0|O ,|O respectively|O .|O 
Linear|O regression|O indicated|O a|O highly|O significant|O relationship|O (|O R|O =|O 0.94|O ;|O P|O <|O 0.0001|O )|O between|O N-myc|gene-rna copy|O number|O (|O Southern|O )|O and|O N-myc|gene-rna /|O GAPDH|gene-rna ratio|O (|O PCR|O )|O .|O 
Serial|O dilution|O of|O N-myc|gene-rna amplified|O DNA|O with|O non|O -|O amplified|O control|O DNA|O indicated|O that|O the|O PCR|O assay|O was|O sufficiently|O sensitive|O to|O detect|O two|O -|O fold|O amplification|O .|O 
Moreover|O ,|O such|O serial|O dilution|O allowed|O determination|O of|O N-myc|gene-rna copy|O number|O .|O 
The|O assay|O ,|O which|O requires|O only|O small|O amounts|O of|O tissue|O and|O does|O not|O utilize|O 32P|O -|O radioactivity|O ,|O therefore|O provides|O a|O rapid|O and|O sensitive|O alternative|O to|O Southern|O analysis|O .|O 
Application|O of|O fluorescence|O in|O situ|O hybridization|O to|O detect|O N-myc|gene-rna (|O MYCN|gene-rna )|O gene|O amplification|O on|O paraffin|O -|O embedded|O tissue|O sections|O of|O neuroblastomas|O .|O 
Fluorescence|O in|O situ|O hybridization|O (|O FISH|O )|O was|O applied|O to|O neuroblastoma|O for|O detection|O of|O N-myc|gene-rna (|O MYCN|gene-rna )|O oncogene|O amplification|O ,|O and|O the|O results|O were|O compared|O with|O Southern|O blot|O analysis|O (|O Southern|O )|O .|O 
In|O nine|O neuroblastomas|O (|O formalin|O -|O fixed|O paraffin|O -|O embedded|O tissues|O were|O available|O in|O seven|O cases|O including|O two|O cases|O with|O touch|O preparations|O ,|O and|O two|O cell|O lines|O )|O ,|O all|O five|O cases|O with|O N-myc|gene-rna amplification|O detected|O by|O Southern|O had|O cells|O with|O multiple|O N-myc|gene-rna signals|O by|O FISH|O ,|O and|O three|O cases|O showed|O no|O N-myc|gene-rna amplification|O either|O by|O Southern|O or|O FISH|O procedure|O .|O 
One|O case|O ,|O not|O examined|O by|O Southern|O ,|O showed|O amplified|O signals|O of|O N-myc|gene-rna by|O FISH|O .|O 
These|O data|O indicate|O that|O FISH|O results|O for|O N-myc|gene-rna amplification|O have|O close|O correlation|O with|O Southern|O blot|O analysis|O .|O 
The|O chromosome|O 2|O -|O specific|O repetitive|O DNA|O probe|O was|O also|O applied|O for|O the|O analysis|O of|O ploidy|O by|O FISH|O .|O 
Six|O cases|O with|O N-myc|gene-rna amplification|O by|O Southern|O and/or|O FISH|O had|O diploid|O tumors|O and|O two|O cases|O without|O amplified|O N-myc|gene-rna showed|O aneuploidy|O .|O 
The|O remaining|O one|O case|O consisted|O of|O heterogeneous|O elements|O showing|O diploidy|O in|O undifferentiated|O tissue|O and|O both|O aneuploidy|O (|O ganglionic|O cells|O )|O and|O diploidy|O (|O Schwann|O cells|O )|O in|O differentiated|O area|O .|O 
We|O conclude|O that|O FISH|O is|O a|O practical|O ,|O useful|O and|O reliable|O method|O over|O Southern|O especially|O for|O analysis|O of|O N-myc|gene-rna amplification|O in|O neuroblastoma|O ,|O and|O simultaneous|O cohybridization|O with|O a|O specific|O chromosome|O probe|O is|O of|O great|O value|O in|O predicting|O the|O prognosis|O of|O patients|O .|O 
Utilization|O of|O molecular|O genetics|O in|O the|O differentiation|O between|O adrenal|O cortical|O adenomas|O and|O carcinomas|O .|O 
Distinction|O between|O benign|O adrenal|O cortical|O proliferative|O lesions|O and|O adrenal|O cortical|O carcinoma|O has|O been|O approached|O by|O a|O combination|O of|O histological|O ,|O immunohistochemical|O ,|O and|O macroscopical|O parameters|O .|O 
Modern|O imaging|O studies|O allow|O detection|O of|O small|O adrenal|O cortical|O lesions|O that|O may|O be|O incorrectly|O diagnosed|O .|O 
Differentiation|O between|O benign|O and|O malignant|O tumors|O of|O the|O adrenal|O cortex|O was|O attempted|O by|O microdissection|O of|O nine|O cases|O of|O adrenal|O cortical|O hyperplasia|O ,|O 10|O cortical|O adenomas|O ,|O and|O 18|O adrenal|O cortical|O carcinomas|O with|O subsequent|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O amplification|O for|O loss|O of|O heterozygosity|O (|O LOH|O )|O of|O five|O microsatellites|O of|O putative|gene-rna tumor|gene-rna suppressor|gene-rna gene|gene-rna loci|O :|O p53|gene-rna gene|O (|O 17p|O )|O ,|O the|O neuroblastoma|O candidate|gene-rna gene|gene-rna (|O 1p|O )|O ,|O the|O p16|gene-rna gene|O (|O 9p|O )|O ,|O the|O von|gene-rna Hippel|gene-rna Lindau|gene-rna gene|gene-rna (|O 3p|O )|O ,|O and|O the|O retinoblastoma|O gene|gene-rna (|O 13q|O )|O .|O 
None|O of|O the|O hyperplastic|O lesions|O or|O cortical|O adenomas|O showed|O LOH|O of|O any|O of|O the|O gene|O markers|O used|O .|O 
Conversely|O ,|O genetic|O changes|O were|O observed|O in|O 61|O %|O (|O 11|O of|O 18|O )|O of|O the|O cases|O of|O carcinoma|O .|O 
Forty-four|O percent|O of|O the|O lesions|O showed|O LOH|O for|O p53|gene-rna (|O 7|O of|O 16|O )|O .|O 
LOH|O of|O 1p|O ,|O 3p|O ,|O and|O 9p|O were|O seen|O in|O 22|O %|O ,|O 22|O %|O ,|O and|O 26|O %|O ,|O respectively|O .|O 
LOH|O of|O the|O retinoblastoma|O gene|gene-rna was|O seen|O in|O 80|O %|O or|O four|O of|O five|O of|O the|O informative|O cases|O studied|O .|O 
We|O conclude|O that|O LOH|O studies|O may|O be|O used|O to|O distinguish|O malignant|O from|O nonmalignant|O adrenal|O cortical|O proliferations|O .|O 
Relative|O infrequency|O of|O LOH|O in|O 3p|O may|O furthermore|O help|O to|O differentiate|O adrenal|O lesions|O from|O clear|O cell|O carcinomas|O of|O the|O kidney|O .|O 
VIP|gene-rna gene|O transcription|O is|O regulated|O by|O far|O upstream|O enhancer|O and|O repressor|O elements|O .|O 
SK-N-SH|O human|O neuroblastoma|O subclones|O differ|O widely|O in|O basal|O and|O second|O messenger|O induction|O of|O the|O gene|O encoding|O the|O neuropeptide|O vasoactive|gene-protein intestinal|gene-protein peptide|gene-protein (|O VIP|gene-protein )|O .|O 
These|O differences|O were|O recapitulated|O by|O a|O chimeric|O gene|O which|O consisted|O of|O 5.2|O kb|O of|O the|O human|O VIP|gene-rna gene|O 5|O '|O flanking|O sequence|O fused|O to|O a|O reporter|O .|O 
Subsequent|O gene|O deletion|O experiments|O revealed|O several|O regulatory|O regions|O on|O the|O gene|O ,|O including|O a|O 645|O -|O bp|O sequence|O located|O approximately|O 4.0|O upstream|O from|O the|O transcription|O start|O site|O .|O 
Here|O we|O examined|O this|O upstream|O region|O in|O detail|O .|O 
Inhibitory|O sequences|O were|O found|O to|O be|O present|O on|O each|O end|O of|O the|O 645|O -|O bp|O fragment|O .|O 
When|O removed|O ,|O basal|O transcription|O increased|O more|O than|O 50|O -|O fold|O .|O 
Subsequent|O deletion|O /|O mutation|O analysis|O showed|O that|O the|O 213|O -|O bp|O fragment|O contained|O at|O least|O two|O enhancer|O elements|O .|O 
One|O of|O these|O was|O localized|O to|O an|O AT|O -|O rich|O 42|O -|O bp|O sequence|O shown|O by|O others|O to|O bind|O Oct|gene-protein proteins|O in|O neuroblastoma|O cells|O ,|O while|O the|O other|O corresponded|O to|O a|O composite|O AP-1|O /|O ets|O element|O .|O 
In|O addition|O to|O these|O enhancers|O ,|O a|O 28|O -|O bp|O sequence|O on|O the|O 213|O -|O bp|O fragment|O with|O no|O apparent|O homology|O to|O known|O silencers|O inhibited|O transcription|O .|O 
The|O studies|O provide|O molecular|O details|O of|O a|O complex|O regulatory|O region|O on|O the|O VIP|gene-rna gene|O that|O is|O likely|O to|O be|O used|O to|O finely|O tune|O the|O level|O of|O gene|O transcription|O in|O vivo|O .|O 
The|O transmembrane|O domain|O of|O the|O Alzheimer|gene-protein 's|gene-protein beta-secretase|gene-protein (|O BACE1|gene-protein )|O determines|O its|O late|O Golgi|O localization|O and|O access|O to|O beta|gene-protein -|gene-protein amyloid|gene-protein precursor|gene-protein protein|gene-protein (|O APP|gene-protein )|O substrate|O .|O 
Release|O of|O Abeta|gene-protein peptides|gene-protein from|O beta-amyloid|gene-protein precursor|gene-protein protein|gene-protein (|O APP|gene-protein )|O requires|O sequential|O cleavage|O by|O two|O endopeptidases|gene-protein ,|O beta|gene-protein -|gene-protein and|O gamma|gene-protein -|gene-protein secretases|gene-protein .|O 
beta-Secretase|gene-protein was|O recently|O identified|O as|O a|O novel|O membrane|O -|O bound|O aspartyl|gene-protein protease|gene-protein ,|O named|O BACE1|gene-protein ,|O Asp2|gene-protein ,|O or|O memapsin|gene-protein 2|gene-protein .|O 
Employing|O confocal|O microscopy|O and|O subcellular|O fractionation|O ,|O we|O have|O found|O that|O BACE1|gene-protein is|O largely|O situated|O in|O the|O distal|O Golgi|O membrane|O with|O a|O minor|O presence|O in|O the|O endoplasmic|O reticulum|O ,|O endosomes|O ,|O and|O plasma|O membrane|O in|O human|O neuroblastoma|O SHEP|O cells|O and|O in|O mouse|O Neuro-2a|O cell|O lines|O expressing|O either|O endogenous|O mouse|gene-protein BACE1|gene-protein or|O additional|O exogenous|O human|gene-protein BACE1|gene-protein .|O 
The|O major|O cellular|O beta-secretase|gene-protein activity|O is|O located|O in|O the|O late|O Golgi|O apparatus|O ,|O consistent|O with|O its|O cellular|O localization|O .|O 
Furthermore|O ,|O we|O demonstrate|O that|O the|O single|O transmembrane|O domain|O of|O BACE1|gene-protein alone|O determines|O the|O retention|O of|O BACE1|gene-protein to|O the|O Golgi|O compartments|O ,|O through|O examination|O of|O recombinant|O proteins|O of|O various|O BACE1|gene-protein fragments|O fused|O to|O a|O reporter|O green|gene-protein fluorescence|gene-protein protein|gene-protein .|O 
In|O addition|O ,|O we|O show|O that|O the|O transmembrane|O domain|O of|O BACE1|gene-protein is|O required|O for|O the|O access|O of|O BACE1|gene-protein enzymatic|O activity|O to|O the|O cellular|O APP|gene-protein substrate|O and|O hence|O for|O the|O optimal|O generation|O of|O the|O C|O -|O terminal|O fragment|O of|O APP|gene-protein (|O CTF99|gene-protein )|O .|O 
The|O results|O suggest|O a|O molecular|O and|O cell|O biological|O mechanism|O for|O the|O regulation|O of|O beta-secretase|gene-protein activity|O in|O vivo|O .|O 
[|O Increased|O expression|O of|O the|O MYCN|gene-rna oncogene|O in|O human|O neuroblastoma|O cells|O and|O possible|O ,|O new|O therapeutic|O approaches|O ]|O 
Human|O neuroblastomas|O of|O advanced|O stages|O often|O display|O amplification|O with|O a|O consecutive|O enhanced|O expression|O of|O the|O MYCN|gene-rna oncogene|O .|O 
Enhanced|O MYCN|gene-rna expression|O is|O thought|O to|O contribute|O in|O a|O causative|O manner|O to|O the|O progression|O of|O neuroblastomas|O ,|O but|O the|O mechanisms|O by|O which|O this|O may|O occur|O have|O remained|O unclear|O .|O 
By|O transfecting|O human|O neuroblastoma|O cells|O that|O display|O a|O normal|O MYCN|gene-rna expression|O with|O the|O human|O MYCN|gene-rna oncogene|O ,|O we|O have|O generated|O a|O cell|O line|O with|O enhanced|O MYCN|gene-rna expression|O and|O thereby|O were|O able|O to|O compare|O the|O biological|O and|O biochemical|O properties|O of|O the|O transfected|O and|O non|O -|O transfected|O cells|O .|O 
We|O have|O demonstrated|O autocrine|O growth|O factors|O in|O the|O MYCN|gene-rna -|O transfected|O ,|O but|O not|O the|O non|O -|O transfected|O ,|O neuroblastoma|O cells|O .|O 
Identification|O of|O the|O primary|O structures|O of|O these|O factors|O may|O help|O to|O develop|O specific|O antagonists|O in|O order|O to|O improve|O the|O therapy|O of|O advanced|O neuroblastomas|O .|O 
Currently|O ,|O this|O could|O be|O done|O by|O application|O of|O genistein|O or|O tumor|gene-protein necrosis|gene-protein factor|gene-protein .|O 
As|O we|O could|O demonstrate|O for|O the|O first|O time|O ,|O the|O dietary|O constituent|O genistein|O is|O able|O to|O inhibit|O the|O proliferation|O of|O neuroblastoma|O cells|O with|O enhanced|O and|O normal|O MYCN|gene-rna expression|O ,|O but|O also|O that|O of|O cells|O derived|O from|O other|O solid|O pediatric|O tumors|O .|O 
In|O contrast|O ,|O tumor|gene-protein necrosis|gene-protein factor|gene-protein is|O able|O to|O inhibit|O selectively|O the|O proliferation|O of|O neuroblastoma|O cells|O with|O enhanced|O MYCN|gene-rna expression|O .|O 
We|O suggest|O that|O tumor|gene-protein necrosis|gene-protein factor|gene-protein might|O improve|O the|O therapy|O of|O advanced|O human|O neuroblastomas|O .|O 
Expression|O of|O multiple|gene-rna drug|gene-rna resistance|gene-rna gene|gene-rna ,|O MDR1|gene-rna ,|O and|O N-myc|gene-rna oncogene|O in|O an|O Italian|O population|O of|O human|O neuroblastoma|O patients|O .|O 
Thirty-four|O patients|O of|O an|O Italian|O population|O affected|O by|O neuroblastoma|O (|O NB|O )|O were|O evaluated|O at|O diagnosis|O for|O multidrug|gene-rna resistance|gene-rna gene|gene-rna (|O MDR1|gene-rna )|O and|O N-myc|gene-rna oncogene|O amplification|O .|O 
No|O patients|O showed|O MDR1|gene-rna amplification|O ,|O while|O extra|O copies|O of|O the|O N-myc|gene-rna gene|O were|O found|O in|O 9|O out|O of|O 34|O patients|O (|O 26|O %|O )|O .|O 
N-myc|gene-rna amplification|O was|O correlated|O (|O p|O =|O 0.008|O )|O with|O a|O shorter|O progression|O -|O free|O survival|O .|O 
RNA|O was|O purified|O from|O fresh|O tumor|O biopsies|O and|O analysed|O in|O 29|O NB|O samples|O .|O 
MDR1|gene-rna gene|O expression|O was|O found|O to|O be|O increased|O in|O 5|O out|O of|O 29|O tumor|O samples|O at|O onset|O (|O 17|O %|O )|O and|O in|O 1|O out|O of|O 3|O at|O relapse|O ,|O but|O none|O of|O them|O expressed|O both|O MDR1|gene-rna and|O N-myc|gene-rna genes|O simultaneously|O .|O 
No|O correlation|O was|O found|O between|O MDR1|gene-rna or|O N-myc|gene-rna genes|O expression|O and|O tumor|O progression|O .|O 
MDR1|gene-rna mRNA|O transcription|O may|O occur|O spontaneously|O after|O onset|O ,|O suggesting|O that|O certain|O NB|O tumors|O could|O be|O resistant|O to|O antineoplastic|O drugs|O at|O onset|O .|O 
All|O 5|O patients|O showing|O MDR1|gene-rna mRNA|O transcription|O achieved|O complete|O or|O partial|O clinical|O remission|O after|O polychemotherapy|O .|O 
This|O was|O presumably|O due|O to|O inclusion|O in|O the|O therapeutic|O protocol|O of|O a|O high|O dose|O of|O Cisplatin|O ,|O a|O drug|O not|O susceptible|O to|O the|O effects|O of|O the|O MDR1|gene-protein gene|O product|O .|O 
Our|O findings|O show|O that|O cells|O which|O actively|O transcribe|O for|O the|O MDR1|gene-rna gene|O are|O present|O in|O several|O untreated|O NB|O patients|O .|O 
No|O gene|O amplification|O was|O detected|O and|O probably|O the|O MDR1|gene-rna gene|O expression|O is|O regulated|O at|O the|O transcriptional|O level|O .|O 
Molecular|O cloning|O and|O functional|O characterization|O of|O a|O rat|gene-protein pituitary|gene-protein G|gene-protein protein|gene-protein -|gene-protein coupled|gene-protein adenosine|gene-protein triphosphate|gene-protein (|gene-protein ATP|gene-protein )|gene-protein receptor|gene-protein .|O 
There|O is|O increasing|O evidence|O that|O pituitary|gene-protein ATP|gene-protein receptors|gene-protein may|O play|O a|O novel|O role|O in|O modulating|O pituitary|O function|O .|O 
This|O work|O reports|O the|O isolation|O and|O expression|O of|O a|O pituitary|gene-rna ATP|gene-rna receptor|gene-rna gene|O clone|O from|O a|O rat|O pituitary|O complementary|O DNA|O library|O .|O 
The|O isolated|O clone|O (|O rpP2U|O )|O has|O a|O 1125|O -|O bp|O coding|O sequence|O flanked|O by|O 483|O bp|O of|O 5|O '|O -|O and|O 422|O bp|O of|O 3|O '|O -|O untranslated|O sequences|O .|O 
The|O deduced|O 374|O -|O amino|O acid|O product|O shows|O structural|O features|O common|O to|O other|O G|gene-protein protein|gene-protein -|gene-protein coupled|gene-protein receptors|gene-protein ,|O and|O when|O stably|O transfected|O into|O a|O glioma|O cell|O line|O lacking|O endogenous|O ATP|gene-protein receptors|gene-protein ,|O is|O functionally|O characterized|O as|O a|O P2U|gene-protein purinoceptor|gene-protein .|O 
Specifically|O ,|O the|O ATP|O -|O induced|O intracellular|O Ca2+|O mobilization|O in|O the|O transfected|O cells|O was|O inhibited|O by|O suramin|O ,|O 2-methylthio-ATP|O had|O a|O modest|O stimulatory|O effect|O on|O intracellular|O Ca2+|O mobilization|O ,|O and|O beta|O ,|O gamma-methylene|O ATP|O and|O alpha|O ,|O beta-methylene|O ATP|O had|O no|O effect|O .|O 
The|O cloned|O receptor|O exhibited|O the|O agonist|O potency|O and|O efficacy|O profile|O of|O ATP|O approximately|O equal|O to|O uridine|O triphosphate|O >|O ADP|O approximately|O equal|O to|O uridine|O diphosphate|O >|O GTP|O .|O 
Such|O characteristics|O very|O closely|O mimic|O the|O pharmacologically|O defined|O P2U|gene-protein purinoceptor|gene-protein of|O primary|O rat|O gonadotropes|O and|O mixed|O sheep|O pituitary|O cells|O ,|O and|O Southern|O blot|O analysis|O further|O indicates|O that|O there|O is|O only|O one|O allele|O in|O rat|O genome|O for|O the|O P2U|gene-protein purinoceptor|gene-protein .|O 
These|O findings|O suggest|O that|O the|O P2U|gene-protein purinoceptor|gene-protein is|O the|O predominant|O G|gene-protein protein|gene-protein -|gene-protein linked|gene-protein ATP|gene-protein receptor|gene-protein found|O in|O the|O pituitary|O .|O 
Functional|O availability|O of|O sodium|O channels|O modulated|O by|O cytosolic|O free|O Ca2+|O in|O cultured|O mammalian|O neurons|O (|O N1E-115|O )|O .|O 
1.|O 
Whole|O -|O cell|O sodium|O currents|O (|O INa|O )|O were|O measured|O in|O mouse|O neuroblastoma|O cells|O (|O N1E-115|O )|O at|O different|O [Ca2+]i|O values|O using|O appropriate|O Ca-EGTA|O buffers|O in|O the|O pipettes|O .|O 
2.|O 
INa|O was|O found|O to|O be|O larger|O at|O pCa|O 7|O than|O at|O pCa|O 8|O or|O 9|O with|O a|O ratio|O of|O 1|O :|O 0.65|O or|O 0.55|O ,|O respectively|O .|O 
The|O steady|O -|O state|O inactivation|O (|O h|O infinity|O curve|O )|O was|O independent|O of|O [Ca2+]i|O ,|O thus|O excluding|O surface|O charge|O effects|O as|O a|O cause|O of|O the|O Ca2+|O effect|O .|O 
3.|O 
Recovery|O of|O INa|O from|O slow|O inactivation|O after|O changing|O from|O resting|O (|O -|O 30|O to|O -|O 40|O mV|O )|O to|O holding|O potential|O (|O -|O 70|O mV|O )|O occurred|O in|O a|O similar|O way|O at|O all|O pCa|O values|O .|O 
The|O Ca2+|O effect|O appears|O to|O be|O independent|O of|O slow|O inactivation|O and|O to|O occur|O within|O the|O first|O 2|O min|O of|O pipette|O buffer|O -|O cytoplasm|O equilibration|O .|O 
4.|O 
The|O cell|O membrane|O capacitance|O (|O Cm|O )|O was|O independent|O of|O [Ca2+]i|O ,|O thus|O excluding|O exo|O -|O or|O endo|O cytosis|O of|O sodium|O channel|O -|O containing|O membrane|O as|O a|O cause|O of|O the|O Ca2+|O effect|O .|O 
5.|O 
Non|O -|O stationary|O fluctuation|O analysis|O was|O used|O to|O determine|O simultaneously|O the|O single|O channel|O current|O (|O iNa|O )|O and|O the|O size|O of|O INa|O .|O 
At|O pCa|O values|O of|O 7|O and|O 9|O ,|O iNa|O was|O identical|O ,|O i.e.|O 0.59|O and|O 0.58|O pA|O ,|O while|O INa|O /|O Cm|O differed|O ,|O i.e.|O 41.1|O and|O 22.2|O pA|O pF-1|O ,|O respectively|O .|O 
The|O peak|O open|O probability|O at|O 0|O mV|O was|O about|O 0.5|O for|O both|O pCa|O values|O indicating|O that|O [Ca2+]i|O controls|O the|O fraction|O of|O channels|O available|O for|O activation|O .|O 
6.|O 
Since|O [Ca2+]i|O in|O other|O neurons|O varies|O between|O 30|O and|O 100|O nM|O in|O the|O resting|O and|O active|O state|O ,|O respectively|O ,|O the|O present|O data|O suggest|O a|O modulatory|O role|O for|O [Ca2+]i|O in|O neuronal|O excitability|O .|O 
Pharmacological|O and|O functional|O characterization|O of|O human|O mineralocorticoid|gene-protein and|O glucocorticoid|gene-protein receptor|gene-protein ligands|O .|O 
We|O characterized|O the|O pharmacological|O profiles|O of|O the|O human|O mineralocorticoid|gene-protein and|O glucocorticoid|gene-protein receptor|gene-protein for|O 11|O natural|O and|O synthetic|O steroids|O regarding|O binding|O pharmacology|O ,|O intracellular|O localization|O of|O hormone|O -|O receptor|O complexes|O ,|O and|O agonistic|O or|O antagonistic|O properties|O at|O the|O gene|O expression|O level|O .|O 
The|O sex|O steroid|O progesterone|O bound|O with|O an|O affinity|O (|O ki|O <|O 0.01|O nM|O )|O even|O higher|O than|O that|O of|O aldosterone|O to|O the|O human|O mineralocorticoid|gene-protein receptor|gene-protein and|O effectively|O antagonized|O the|O effect|O of|O aldosterone|O via|O the|O human|O mineralocorticoid|gene-protein receptor|gene-protein in|O functional|O co|O -|O transfection|O assays|O .|O 
This|O indicates|O that|O progesterone|O has|O potent|O antimineralocorticoid|O properties|O ,|O while|O its|O antiglucocorticoid|O effects|O were|O less|O pronounced|O .|O 
The|O partial|O agonistic|O activities|O of|O antihormones|O in|O this|O assay|O suggest|O a|O direct|O interaction|O of|O antihormone|O -|O receptor|O complexes|O with|O the|O response|O elements|O on|O the|O DNA|O .|O 
These|O results|O are|O supported|O by|O immunofluorescence|O studies|O ,|O in|O which|O both|O unliganded|O human|O mineralocorticoid|gene-protein and|O glucocorticoid|gene-protein receptors|gene-protein were|O distributed|O throughout|O the|O cytoplasm|O and|O nucleus|O ,|O whereas|O agonist|O -|O as|O well|O as|O antagonist|O -|O receptor|O complexes|O showed|O an|O exclusively|O nuclear|O localization|O .|O 
These|O results|O contribute|O to|O the|O understanding|O of|O antihormone|O pharmacology|O and|O increase|O our|O understanding|O of|O the|O role|O of|O human|O mineralocorticoid|gene-protein and|O glucocorticoid|gene-protein receptors|gene-protein in|O physiological|O processes|O during|O different|O endocrine|O states|O .|O 
Cytoplasmically|O sequestered|O wild|O -|O type|O p53|gene-protein protein|O in|O neuroblastoma|O is|O relocated|O to|O the|O nucleus|O by|O a|O C|O -|O terminal|O peptide|O .|O 
Cytoplasmic|O sequestration|O of|O wild|O -|O type|O p53|gene-protein protein|O occurs|O in|O a|O subset|O of|O primary|O human|O tumors|O including|O breast|O cancer|O ,|O colon|O cancer|O ,|O and|O neuroblastoma|O (|O NB|O )|O .|O 
The|O sequestered|O p53|gene-protein localizes|O to|O punctate|O cytoplasmic|O structures|O that|O represent|O large|O protein|O aggregates|O .|O 
One|O functional|O consequence|O of|O this|O blocked|O nuclear|O access|O is|O impairment|O of|O the|O p53|gene-protein -|O mediated|O G1|O checkpoint|O after|O DNA|O damage|O .|O 
Here|O we|O show|O that|O cytoplasmic|O p53|gene-protein from|O NB|O cells|O is|O incompetent|O for|O specific|O DNA|O binding|O ,|O probably|O due|O to|O its|O sequestration|O .|O 
Importantly|O ,|O the|O C|O -|O terminal|O domain|O of|O sequestered|O p53|gene-protein is|O masked|O ,|O as|O indicated|O by|O the|O failure|O of|O a|O C|O -|O terminally|O directed|O antibody|O to|O detect|O p53|gene-protein in|O these|O structures|O .|O 
To|O determine|O (i)|O which|O domain|O of|O p53|gene-protein is|O involved|O in|O the|O aggregation|O and|O (ii)|O whether|O this|O phenotype|O is|O potentially|O reversible|O ,|O we|O generated|O stable|O NB|O sublines|O that|O coexpress|O the|O soluble|O C|O -|O terminal|O mouse|O p53|gene-protein peptide|O DD1|gene-protein (|O amino|O acids|O 302|O -|O 390|O )|O .|O 
A|O dramatic|O phenotypic|O reversion|O occurred|O in|O five|O of|O five|O lines|O .|O 
The|O presence|O of|O DD1|gene-protein blocked|O the|O sequestration|O of|O wild|O -|O type|O p53|gene-protein and|O relocated|O it|O to|O the|O nucleus|O ,|O where|O it|O accumulated|O .|O 
The|O nuclear|O translocation|O is|O due|O to|O shuttling|O of|O wild|O -|O type|O p53|gene-protein by|O heteroligomerization|O to|O DD1|gene-protein ,|O as|O shown|O by|O coimmunoprecipitation|O .|O 
As|O expected|O ,|O the|O nuclear|O heterocomplexes|O were|O functionally|O inactive|O ,|O since|O DD1|gene-protein is|O a|O dominant|O negative|O inhibitor|O of|O wild|O -|O type|O p53|gene-protein .|O 
In|O summary|O ,|O we|O show|O that|O nuclear|O access|O of|O p53|gene-protein can|O be|O restored|O in|O NB|O cells|O .|O 
C-kit|gene-protein expression|O in|O pediatric|O solid|O tumors|O :|O a|O comparative|O immunohistochemical|O study|O .|O 
The|O stem|gene-protein cell|gene-protein factor|gene-protein /|O c-kit|gene-protein tyrosine|gene-protein kinase|gene-protein receptor|O pathway|O has|O been|O shown|O to|O be|O important|O for|O tumor|O growth|O and|O progression|O in|O several|O cancers|O ,|O including|O mast|O cell|O diseases|O ,|O gastrointestinal|O stromal|O tumor|O ,|O acute|O myeloid|O leukemia|O ,|O small|O cell|O lung|O carcinoma|O ,|O and|O Ewing|O sarcoma|O .|O 
Studies|O using|O the|O oral|O agent|O STI-571|O (|O Gleevec|O ,|O Novartis|O )|O ,|O an|O inhibitor|O of|O the|O tyrosine|gene-protein kinases|gene-protein bcr-abl|gene-protein ,|O c-kit|gene-protein ,|O and|O PDGFR|gene-protein ,|O have|O shown|O significant|O responses|O in|O patients|O with|O chronic|O myelogenous|O leukemia|O and|O gastrointestinal|O stromal|O tumor|O .|O 
With|O the|O aim|O of|O identifying|O additional|O groups|O of|O tumors|O that|O may|O use|O the|O stem|gene-protein cell|gene-protein factor|gene-protein /|O c-kit|gene-protein pathway|O and|O secondarily|O may|O be|O responsive|O to|O STI-571|O treatment|O ,|O this|O study|O surveyed|O 151|O primary|O tumors|O from|O patients|O treated|O at|O St.|O Jude|O Children|O 's|O Research|O Hospital|O for|O immunohistochemical|O expression|O of|O c-kit|gene-protein .|O 
Formalin|O -|O fixed|O ,|O paraffin|O -|O embedded|O sections|O were|O stained|O with|O rabbit|O polyclonal|O anti|O -|O human|O c-kit|gene-protein (|O CD117|gene-protein ,|O Dako|gene-protein )|O using|O standard|O avidin|O -|O biotin|O -|O peroxidase|gene-protein complex|O technique|O ,|O antigen|O retrieval|O ,|O and|O an|O automated|O stainer|O .|O 
Strong|O ,|O diffuse|O staining|O for|O c-kit|gene-protein was|O seen|O in|O a|O proportion|O of|O synovial|O sarcomas|O ,|O osteosarcomas|O ,|O and|O Ewing|O sarcomas|O .|O 
Strong|O ,|O diffuse|O staining|O was|O less|O common|O in|O neuroblastomas|O ,|O Wilms|O '|O tumors|O ,|O and|O rhabdomyosarcomas|O and|O was|O negative|O in|O alveolar|O soft|O part|O sarcomas|O and|O desmoplastic|O small|O round|O cell|O tumors|O .|O 
Tumors|O with|O strong|O ,|O diffuse|O staining|O for|O c-kit|gene-protein in|O a|O pattern|O similar|O to|O gastrointestinal|O stromal|O tumor|O may|O represent|O suitable|O targets|O for|O new|O therapeutic|O agents|O .|O 
15-Deoxy-Delta(12,14)-prostaglandin|O J(2)|O :|O the|O endogenous|O electrophile|O that|O induces|O neuronal|O apoptosis|O .|O 
Prostaglandin|O D(2)|O (|O PGD(2)|O )|O ,|O a|O major|O cyclooxygenase|gene-protein product|O in|O a|O variety|O of|O tissues|O and|O cells|O ,|O readily|O undergoes|O dehydration|O to|O yield|O the|O bioactive|O cyclopentenone|O -|O type|O PGs|O of|O the|O J(2)|O -|O series|O ,|O such|O as|O 15-deoxy-Delta(12,14)-PGJ(2)|O (|O 15d-PGJ(2)|O )|O .|O 
The|O observation|O that|O the|O level|O of|O 15d-PGJ(2)|O increased|O in|O the|O tissue|O cells|O from|O patients|O with|O sporadic|O amyotrophic|O lateral|O sclerosis|O suggested|O that|O the|O formation|O of|O 15d-PGJ(2)|O may|O be|O closely|O associated|O with|O neuronal|O cell|O death|O during|O chronic|O inflammatory|O processes|O .|O 
In|O vitro|O experiments|O using|O SH-SY5Y|O human|O neuroblastoma|O cells|O revealed|O that|O 15d-PGJ(2)|O induced|O apoptotic|O cell|O death|O .|O 
An|O oligonucleotide|O microarray|O analysis|O demonstrated|O that|O ,|O in|O addition|O to|O the|O heat|O shock|O -|O responsive|O and|O redox|O -|O responsive|O genes|O ,|O the|O p53|gene-generic -|O responsive|O genes|O ,|O such|O as|O gadd45|gene-rna ,|O cyclin|gene-rna G1|gene-rna ,|O and|O cathepsin|gene-rna D|gene-rna ,|O were|O significantly|O up|O -|O regulated|O in|O the|O cells|O treated|O with|O 15d-PGJ(2)|O .|O 
Indeed|O ,|O the|O 15d-PGJ(2)|O induced|O accumulation|O and|O phosphorylation|O of|O p53|gene-generic ,|O which|O was|O accompanied|O by|O a|O preferential|O redistribution|O of|O the|O p53|gene-protein protein|O in|O the|O nuclei|O of|O the|O cells|O and|O by|O a|O time|O -|O dependent|O increase|O in|O p53|gene-rna DNA|O binding|O activity|O ,|O suggesting|O that|O p53|gene-generic accumulated|O in|O response|O to|O the|O treatment|O with|O 15d-PGJ(2)|O was|O functional|O .|O 
The|O 15d-PGJ(2)|O -|O induced|O accumulation|O of|O p53|gene-generic resulted|O in|O the|O activation|O of|O a|O death|O -|O inducing|O caspase|gene-protein cascade|O mediated|O by|O Fas|gene-protein and|O the|O Fas|gene-protein ligand|O .|O 
Sodium|gene-protein channel|gene-protein activation|O does|O not|O alter|O lipid|O metabolism|O in|O cultured|O neuroblastoma|O cells|O .|O 
The|O interaction|O of|O voltage|O -|O sensitive|O Na+|gene-protein -|gene-protein channels|gene-protein and|O membrane|O lipid|O metabolism|O was|O examined|O by|O incubating|O cultured|O neuroblastoma|O cells|O with|O neurotoxins|O which|O alter|O the|O voltage|O -|O dependent|O relationship|O between|O the|O closed|O and|O open|O conformation|O of|O the|O channel|gene-protein protein|gene-protein .|O 
Guanidinium|O flux|O rate|O ,|O a|O measure|O of|O Na+|gene-protein -|gene-protein channel|gene-protein activation|O ,|O was|O increased|O 10|O -|O fold|O by|O the|O combined|O action|O of|O veratridine|O (|O 100|O microM|O )|O and|O scorpion|O venom|O (|O 28|O micrograms|O /|O ml|O )|O .|O 
This|O response|O was|O completely|O blocked|O by|O tetrodotoxin|O (|O 1|O microM|O )|O .|O Under|O the|O same|O experimental|O conditions|O ,|O the|O toxins|O did|O not|O increase|O the|O efflux|O of|O [3H]arachidonic|O acid|O from|O prelabeled|O cell|O membrane|O lipids|O or|O stimulate|O uptake|O of|O exogenous|O [3H]arachidonic|O acid|O .|O 
In|O addition|O ,|O altering|O membrane|O fatty|O acid|O composition|O by|O incubating|O cells|O for|O 24|O hr|O in|O a|O medium|O containing|O 50|O microM|O arachidonic|O or|O oleic|O acid|O did|O not|O alter|O guanidinium|O flux|O rates|O relative|O to|O that|O of|O control|O cultures|O .|O 
When|O cells|O were|O pulsed|O with|O 32Pi|O for|O 60|O min|O and|O stimulated|O by|O veratridine|O plus|O scorpion|O venom|O for|O an|O additional|O 30|O min|O ,|O uptake|O of|O 32Pi|O into|O phosphatidylinositol|O was|O reduced|O ;|O stimulating|O cells|O with|O bradykinin|O ,|O a|O receptor|O agonist|O which|O activates|O the|O inositol|O cycle|O ,|O promoted|O a|O 3.8|O fold|O increase|O .|O 
Polyphosphoinositide|O turnover|O was|O not|O affected|O by|O Na+|gene-protein -|gene-protein channel|gene-protein activation|O ,|O but|O was|O stimulated|O by|O bradykinin|O .|O 
These|O results|O suggest|O that|O voltage|O -|O sensitive|O Na+|gene-protein -|gene-protein channel|gene-protein activation|O in|O cultured|O neuroblastoma|O cells|O can|O function|O independent|O of|O membrane|O phospholipid|O and|O fatty|O acid|O metabolism|O .|O 
Expression|O of|O the|O ALK|gene-rna tyrosine|gene-rna kinase|gene-rna gene|O in|O neuroblastoma|O .|O 
ALK|gene-protein (|O anaplastic|O lymphoma|O kinase|gene-protein )|O is|O a|O tyrosine|gene-protein kinase|gene-protein receptor|gene-protein ,|O expressed|O as|O part|O of|O the|O chimeric|O NPM-ALK|gene-protein protein|O ,|O in|O anaplastic|O large|O cell|O lymphomas|O (|O ALCLs|O )|O exhibiting|O the|O t|O (|O 2|O ;|O 5|O )|O (|O p23|O ;|O q35|O )|O translocation|O .|O 
As|O a|O result|O of|O this|O translocation|O ,|O the|O NPM|gene-rna (|O nucleophosmin|gene-rna )|O gene|O is|O fused|O to|O the|O portion|O of|O the|O ALK|gene-rna gene|O encoding|O its|O intracytoplasmic|O segment|O .|O 
In|O normal|O mouse|O tissues|O ,|O mRNA|O encoding|O the|O Alk|gene-protein receptor|gene-protein has|O been|O found|O only|O in|O neural|O cells|O ,|O suggesting|O involvement|O of|O this|O receptor|O in|O the|O development|O of|O the|O nervous|O system|O .|O 
The|O purpose|O of|O the|O present|O study|O was|O to|O examine|O the|O presence|O of|O ALK|gene-rna transcripts|O and|O protein|O in|O normal|O human|O tissues|O and|O a|O variety|O of|O cell|O lines|O and|O human|O tumors|O .|O 
Emphasis|O was|O placed|O on|O neuroblastomas|O because|O other|O tyrosine|gene-protein kinase|gene-protein receptors|gene-protein are|O expressed|O in|O human|O neuroblastomas|O .|O 
Fifty-six|O cell|O lines|O ,|O including|O 29|O lines|O of|O neural|O origin|O ,|O and|O lymphoid|O and|O nonlymphoid|O tissue|O specimens|O ,|O including|O 24|O neuroblastomas|O ,|O were|O investigated|O for|O ALK|gene-generic expression|O ,|O using|O reverse|O transcriptase|gene-protein -|O polymerase|gene-protein chain|O reaction|O ,|O Western|O blotting|O ,|O and|O immunohistochemistry|O .|O 
The|O results|O confirmed|O that|O mRNA|O encoding|O ALK|gene-protein protein|O was|O not|O detectable|O in|O any|O normal|O or|O neoplastic|O hematopoietic|O tissue|O tested|O ,|O except|O for|O t|O (|O 2|O ;|O 5|O )|O -|O positive|O ALCL|O .|O 
The|O salient|O finding|O was|O that|O 13|O of|O the|O 29|O cell|O lines|O of|O neural|O origin|O and|O 22|O of|O 24|O neuroblastomas|O were|O found|O to|O express|O ALK|gene-rna transcripts|O and|O ALK|gene-protein protein|O .|O 
However|O ,|O no|O correlation|O was|O evident|O between|O any|O known|O prognostic|O factors|O and|O the|O level|O of|O ALK|gene-generic expression|O .|O 
Presenilin-1|gene-rna mutations|O downregulate|O the|O signalling|O pathway|O of|O the|O unfolded|O -|O protein|O response|O .|O 
Missense|O mutations|O in|O the|O human|O presenilin-1|gene-rna (|O PS1|gene-rna )|O gene|O ,|O which|O is|O found|O on|O chromosome|O 14|O ,|O cause|O early|O -|O onset|O familial|O Alzheimer|O 's|O disease|O (|O FAD|O )|O .|O 
FAD|O -|O linked|O PS1|gene-rna variants|O alter|O proteolytic|O processing|O of|O the|O amyloid|gene-protein precursor|gene-protein protein|gene-protein and|O cause|O an|O increase|O in|O vulnerability|O to|O apoptosis|O induced|O by|O various|O cell|O stresses|O .|O 
However|O ,|O the|O mechanisms|O responsible|O for|O these|O phenomena|O are|O not|O clear|O .|O 
Here|O we|O report|O that|O mutations|O in|O PS1|gene-rna affect|O the|O unfolded|O -|O protein|O response|O (|O UPR|O )|O ,|O which|O responds|O to|O the|O increased|O amount|O of|O unfolded|O proteins|O that|O accumulate|O in|O the|O endoplasmic|O reticulum|O (|O ER|O )|O under|O conditions|O that|O cause|O ER|O stress|O .|O 
PS1|gene-rna mutations|O also|O lead|O to|O decreased|O expression|O of|O GRP78|gene-protein /|O Bip|gene-protein ,|O a|O molecular|O chaperone|O ,|O present|O in|O the|O ER|O ,|O that|O can|O enable|O protein|O folding|O .|O 
Interestingly|O ,|O GRP78|gene-protein levels|O are|O reduced|O in|O the|O brains|O of|O Alzheimer|O 's|O disease|O patients|O .|O 
The|O downregulation|O of|O UPR|O signalling|O by|O PS1|gene-rna mutations|O is|O caused|O by|O disturbed|O function|O of|O IRE1|gene-protein ,|O which|O is|O the|O proximal|O sensor|O of|O conditions|O in|O the|O ER|O lumen|O .|O 
Overexpression|O of|O GRP78|gene-protein in|O neuroblastoma|O cells|O bearing|O PS1|gene-rna mutants|O almost|O completely|O restores|O resistance|O to|O ER|O stress|O to|O the|O level|O of|O cells|O expressing|O wild|O -|O type|O PS1|gene-rna .|O 
These|O results|O show|O that|O mutations|O in|O PS1|gene-rna may|O increase|O vulnerability|O to|O ER|O stress|O by|O altering|O the|O UPR|O signalling|O pathway|O .|O 
Proposal|O and|O assessment|O of|O Japanese|O tumor|O node|O metastasis|O postsurgical|O histopathological|O staging|O system|O for|O neuroblastoma|O based|O on|O an|O analysis|O of|O 495|O cases|O .|O 
In|O 1971|O ,|O the|O Japanese|O Society|O of|O Pediatric|O Surgeons|O '|O Committee|O on|O Malignancies|O proposed|O new|O criteria|O for|O neuroblastoma|O staging|O .|O 
It|O was|O fundamentally|O ,|O based|O on|O the|O system|O of|O Evans|O et|O al.|O described|O in|O 1971|O .|O 
The|O main|O difference|O was|O the|O separation|O of|O stage|O IV|O disease|O into|O stages|O IV-A|O ,|O with|O metastases|O to|O bone|O ,|O orbita|O ,|O distant|O lymph|O nodes|O and|O viscera|O other|O than|O liver|O ,|O IV-B|O ,|O the|O primary|O tumor|O extending|O over|O the|O midline|O and|O with|O metastases|O to|O bone|O marrow|O ,|O liver|O and|O skin|O ,|O and|O IV-S|O ,|O which|O was|O the|O same|O as|O that|O of|O Evans|O et|O al.|O 
The|O new|O criteria|O did|O not|O include|O the|O resectability|O of|O the|O primary|O tumor|O ,|O assessment|O of|O regional|O lymph|O node|O involvement|O or|O any|O other|O disease|O assessment|O resulting|O from|O therapeutic|O intervention|O .|O 
For|O the|O purpose|O of|O international|O usage|O ,|O the|O Japanese|O system|O has|O been|O newly|O formulated|O and|O proposed|O as|O the|O Japanese|O Tumor|O Node|O Metastasis|O (|O TNM|O )|O Postsurgical|O Histopathological|O Classification|O for|O Neuroblastoma|O .|O 
In|O the|O present|O report|O ,|O 495|O neuroblastomas|O ,|O registered|O between|O 1970|O and|O 1985|O ,|O were|O analyzed|O retrospectively|O according|O to|O the|O International|O Union|O Against|O Cancer|O (|O UICC|O )|O TNM|O classification|O and|O the|O proposed|O Japanese|O TNM|O system|O .|O 
The|O analyses|O suggested|O that|O the|O Japanese|O system|O reflected|O both|O the|O extent|O of|O tumor|O invasion|O and|O its|O biological|O neuroblastoma|O characteristics|O better|O than|O the|O UICC|O TNM|O classification|O based|O on|O statistical|O analysis|O .|O 
Comparative|O study|O of|O enterovirus|O 71|O infection|O of|O human|O cell|O lines|O .|O 
The|O cell|O tropism|O of|O enterovirus|O 71|O (|O Enteroviridae|O )|O in|O neuronal|O ,|O glial|O and|O laryngeal|O cells|O .|O 
The|O 4643|O strain|O ,|O an|O enterovirus|O 71|O isolate|O from|O a|O patient|O in|O Taiwan|O ,|O was|O used|O to|O infect|O three|O human|O cell|O lines|O representing|O neuronal|O cells|O (|O SK-N-SH|O ,|O neuroblastoma|O )|O ,|O glial|O cells|O (|O U373MG|O ,|O glioblastoma|O )|O ,|O and|O laryngeal|O cells|O (|O HEp-2|O ,|O larynx|O epidermoid|O carcinoma|O )|O .|O 
Immunofluorescent|O staining|O and|O transmission|O electron|O microscopy|O (|O TEM|O )|O were|O used|O to|O detect|O mature|O enterovirus|O 71|O 4643|O virions|O in|O these|O cell|O lines|O .|O 
The|O three|O cell|O lines|O were|O also|O compared|O for|O presence|O of|O virus|O -|O mediated|O cytopathic|O effect|O (|O CPE|O )|O ,|O synthesis|O of|O infected|O cell|O -|O specific|O proteins|O ,|O viral|O (|O -|O )|O RNA|O ,|O and|O virus|O replication|O rate|O .|O 
Virus|O particles|O were|O detected|O by|O TEM|O ,|O and|O viral|O replication|O increased|O over|O time|O ,|O indicating|O the|O existence|O and|O release|O of|O mature|O viruses|O from|O all|O three|O infected|O cell|O lines|O .|O 
The|O most|O severe|O CPE|O and|O the|O highest|O viral|O replication|O rate|O were|O observed|O in|O the|O SK-N-SH|O cells|O .|O 
Further|O screening|O of|O the|O infected|O cell|O lines|O by|O microarray|O analysis|O revealed|O that|O the|O neuron|gene-rna growth|gene-rna factor|gene-rna receptor|gene-rna (|O NGFR|gene-rna )|O gene|O was|O uniquely|O upregulated|O in|O infected|O SK-N-SH|O cells|O ,|O implying|O that|O the|O receptor|O encoded|O by|O this|O gene|O may|O be|O involved|O in|O cell|O tropism|O .|O 
The|O data|O show|O that|O neurons|O are|O vulnerable|O to|O enterovirus|O 71|O 4643|O infection|O and|O are|O consistent|O with|O the|O clinical|O observation|O that|O enterovirus|O 71|O 4643|O targets|O mainly|O neuronal|O cells|O but|O is|O also|O found|O in|O many|O organs|O in|O conjunction|O with|O an|O inflammatory|O reaction|O .|O 
The|O cyclin|gene-protein -|gene-protein dependent|gene-protein kinase|gene-protein inhibitor|gene-protein p27|gene-protein (|O Kip1|gene-protein )|O is|O involved|O in|O thyroid|O hormone|O -|O mediated|O neuronal|O differentiation|O .|O 
The|O thyroid|O hormone|O (|O triiodothyronine|O ,|O T3|O )|O is|O essential|O for|O normal|O brain|O maturation|O .|O 
To|O determine|O the|O mechanisms|O by|O which|O T3|O controls|O neuronal|O proliferation|O and|O differentiation|O ,|O we|O have|O analyzed|O the|O effect|O of|O this|O hormone|O on|O the|O expression|O and|O activity|O of|O cell|O cycle|O -|O regulating|O molecules|O in|O neuroblastoma|O N2a-beta|O cells|O that|O overexpress|O the|O beta1|gene-protein isoform|O of|O the|O T3|gene-protein receptor|gene-protein .|O 
Our|O results|O show|O that|O incubation|O of|O N2a-beta|O cells|O with|O T3|O leads|O to|O a|O rapid|O down|O -|O regulation|O of|O the|O c-myc|gene-rna gene|O and|O to|O a|O decrease|O of|O cyclin|gene-protein D1|gene-protein levels|O .|O 
T3|O also|O causes|O a|O strong|O and|O sustained|O increase|O of|O the|O levels|O of|O the|O cyclin|gene-protein kinase|gene-protein inhibitor|gene-protein p27|gene-protein (|O Kip1|gene-protein )|O .|O 
This|O increase|O is|O secondary|O ,|O to|O the|O augmented|O levels|O of|O p27|gene-rna (|O Kip1|gene-rna )|O transcripts|O as|O well|O as|O to|O stabilization|O of|O the|O p27|gene-protein (|O Kip1|gene-protein )|O protein|O .|O 
The|O increased|O levels|O of|O p27|gene-protein (|O Kip1|gene-protein )|O lead|O to|O a|O significant|O increase|O in|O the|O amount|O of|O p27|gene-protein (|O Kip1|gene-protein )|O associated|O with|O cyclin|gene-protein -|gene-protein dependent|gene-protein kinase|gene-protein 2|gene-protein (|O CDK2|gene-protein )|O ,|O and|O to|O a|O marked|O inhibition|O of|O the|O kinase|gene-protein activity|O of|O the|O cyclin|gene-protein .|O CDK2|gene-protein complexes|O .|O 
As|O a|O consequence|O ,|O the|O retinoblastoma|gene-protein protein|gene-protein (|O pRb|gene-protein )|O and|O the|O retinoblastoma|gene-protein protein|gene-protein -|gene-protein related|gene-protein protein|gene-protein p130|gene-protein are|O hypophosphorylated|O in|O T3|O -|O treated|O N2a-beta|O cells|O .|O 
This|O study|O shows|O for|O the|O first|O time|O that|O T3|O -|O mediated|O growth|O arrest|O and|O neuronal|O differentiation|O are|O associated|O with|O an|O increase|O in|O the|O levels|O of|O a|O cyclin|gene-protein kinase|gene-protein inhibitor|gene-protein ,|O which|O does|O not|O allow|O the|O inactivation|O of|O retinoblastoma|gene-protein proteins|gene-protein required|O for|O progression|O through|O the|O restriction|O point|O in|O the|O cell|O cycle|O .|O 
Human|O neuroblastoma|O cell|O viability|O and|O growth|O are|O affected|O by|O altered|O culture|O conditions|O .|O 
The|O effects|O of|O differing|O culture|O parameters|O are|O seldomly|O investigated|O ,|O even|O though|O they|O influence|O the|O way|O immortalized|O cells|O grow|O and|O die|O .|O 
In|O this|O study|O ,|O the|O changes|O in|O total|O cell|O number|O ,|O confluency|O ,|O membrane|O permeability|O ,|O and|O DNA|O content|O were|O evaluated|O in|O SH-SY5Y|O and|O IMR-32|O human|O neuroblastoma|O cells|O following|O culture|O at|O different|O seeding|O densities|O and|O media|O consistencies|O .|O 
These|O four|O endpoints|O were|O determined|O using|O a|O hemacytometer|O ,|O phase|O -|O contrast|O microscope|O ,|O trypan|O blue|O (|O 0.4|O %|O v|O /|O v|O )|O ,|O and|O propidium|O iodide|O (|O 50|O microg|O /|O mL|O )|O ,|O respectively|O .|O 
Both|O cell|O lines|O (|O SH-SY5Y|O and|O IMR-32|O )|O responded|O in|O a|O similar|O manner|O to|O changing|O culture|O conditions|O ,|O even|O though|O baseline|O values|O for|O all|O four|O endpoints|O were|O different|O .|O 
Higher|O seeding|O densities|O (|O 19,200|O and|O 38,400|O cells|O /|O cm2|O )|O significantly|O increased|O the|O percent|O confluency|O and|O total|O cell|O number|O over|O time|O ,|O but|O decreased|O the|O initial|O percentage|O of|O cells|O with|O fragmented|O (|O subG1|O )|O DNA|O in|O both|O cell|O lines|O when|O compared|O with|O lower|O seeding|O densities|O (|O 4800|O and|O 9600|O cells|O /|O cm2|O ,|O p|O <|O 0.05|O )|O .|O 
Daily|O media|O changes|O significantly|O increased|O the|O percentage|O of|O cells|O in|O S|O and|O G2|O /|O M|O ,|O but|O decreased|O the|O percentage|O of|O cells|O in|O G0|O /|O G1|O phase|O of|O the|O cell|O cycle|O over|O time|O in|O both|O cell|O lines|O when|O compared|O with|O cultures|O without|O media|O changes|O (|O p|O <|O 0.05|O )|O .|O 
Results|O suggest|O that|O environmental|O culture|O conditions|O greatly|O affect|O cellular|O mitosis|O and|O death|O .|O 
This|O information|O may|O be|O of|O particular|O relevance|O in|O the|O investigation|O of|O compounds|O that|O act|O on|O specific|O cell|O -|O cycle|O stages|O ,|O such|O as|O antineoplastic|O agents|O .|O 
Preferential|O expression|O of|O antioxidant|O response|O element|O mediated|O gene|O expression|O in|O astrocytes|O .|O 
Transcriptional|O control|O of|O target|O genes|O by|O antioxidant|O /|O electrophile|O response|O elements|O has|O been|O well|O described|O in|O peripheral|O tissues|O .|O 
Genes|O that|O are|O regulated|O by|O this|O mechanism|O include|O the|O antioxidant|O enzymes|O NAD(P)H|gene-generic :|O quinone|gene-generic oxidoreductase|gene-generic ,|O gamma-glutamyl|gene-generic cystine|gene-generic synthetase|gene-generic and|O glutathione-S-transferase|gene-generic .|O 
Antioxidant|O /|O electrophile|O response|O elements|O within|O a|O gene|O 's|O promoter|O confer|O induction|O by|O low|O -|O molecular|O -|O weight|O electrophilic|O compounds|O such|O as|O tert-butylhydroquinone|O and|O dimethyl|O fumarate|O .|O 
We|O have|O now|O examined|O the|O ability|O of|O antioxidant|O /|O electrophile|O response|O elements|O to|O elicit|O gene|O expression|O in|O neurons|O and|O astrocytes|O in|O both|O brain|O slices|O and|O primary|O cultures|O using|O transient|O transfection|O of|O promoter|O reporter|O constructs|O .|O 
Our|O results|O using|O a|O heat|O -|O stable|O human|O placental|gene-protein alkaline|gene-protein phosphatase|gene-protein reporter|O indicate|O that|O antioxidant|O /|O electrophile|O response|O element|O mediated|O gene|O expression|O is|O largely|O restricted|O to|O astrocyte|O cell|O populations|O .|O 
Placental|gene-protein alkaline|gene-protein phosphatase|gene-protein expression|O was|O significantly|O elevated|O in|O astrocytes|O treated|O with|O the|O antioxidant|O /|O electrophile|O response|O element|O inducer|O dimethyl|O fumarate|O .|O 
Mutant|O constructs|O lacking|O a|O functional|O antioxidant|O /|O electrophile|O response|O element|O abolished|O all|O placental|gene-protein alkaline|gene-protein phosphatase|gene-protein expression|O in|O astrocytes|O .|O 
We|O suggest|O that|O astrocytic|O metabolic|O processes|O that|O normally|O aid|O and/or|O protect|O neurons|O may|O be|O controlled|O via|O this|O inducible|O system|O .|O 
The|O inhibition|O of|O phosphatidylinositol-3-kinase|gene-protein induces|O neurite|O retraction|O and|O activates|O GSK3|gene-rna .|O 
It|O has|O been|O extensively|O described|O that|O neuronal|O differentiation|O involves|O the|O signalling|O through|O neurotrophin|O receptors|O to|O a|O Ras|gene-rna -|O dependent|O mitogen|O -|O activated|O protein|gene-protein kinase|gene-protein (|O MAPK|gene-protein )|O cascade|O .|O 
However|O ,|O signalling|O pathways|O from|O other|O neuritogenic|O factors|O have|O not|O been|O well|O established|O .|O 
It|O has|O been|O reported|O that|O cAMP|O may|O activate|O protein|gene-protein kinase|gene-protein (|O PKA|gene-protein )|O ,|O and|O it|O has|O been|O shown|O that|O PKA|gene-protein -|O mediated|O stimulation|O of|O MAPK|gene-protein pathway|O regulates|O not|O only|O neuritogenesis|O but|O also|O survival|O .|O 
However|O ,|O extracellular|O regulated|gene-protein kinases|gene-protein (|O ERKs|gene-protein )|O mediated|O pathways|O are|O not|O sufficient|O to|O explain|O all|O the|O processes|O which|O occur|O in|O neuronal|O differentiation|O .|O 
Our|O present|O data|O show|O that|O :|O in|O cAMP|O -|O mediated|O neuritogenesis|O ,|O using|O the|O SH-SY5Y|O human|O neuroblastoma|O cell|O line|O ,|O there|O exists|O a|O link|O between|O the|O activation|O of|O PKA|gene-protein and|O stimulation|O of|O phosphatidylinositol|gene-protein 3-kinase|gene-protein (|O PI3K|gene-protein )|O .|O 
Both|O kinase|gene-protein activities|O are|O essential|O to|O the|O initial|O elongation|O steps|O .|O 
Surprisingly|O ,|O this|O neuritogenic|O process|O appears|O to|O be|O independent|O of|O ERKs|gene-protein .|O 
While|O the|O activity|O of|O PI3K|gene-protein is|O essential|O for|O elongation|O and|O maintenance|O of|O neurites|O ,|O its|O inhibition|O causes|O retraction|O .|O 
In|O this|O neurite|O retraction|O process|O ,|O GSK3|gene-rna is|O activated|O .|O 
Using|O both|O a|O pharmacological|O approach|O and|O gene|O transfer|O of|O a|O dominant|O negative|O form|O of|O GSK3|gene-rna ,|O we|O conclude|O that|O this|O induced|O retraction|O is|O a|O GSK3|gene-rna -|O dependent|O process|O which|O in|O turn|O appears|O to|O be|O a|O common|O target|O for|O transduction|O pathways|O involved|O in|O lysophosphatidic|O acid|O -|O mediated|O and|O PI3K|gene-protein -|O mediated|O neurite|O retraction|O .|O 
Stimulation|O of|O Na+-K+-2Cl-|gene-protein cotransporter|gene-protein in|O neuronal|O cells|O by|O excitatory|O neurotransmitter|O glutamate|O .|O 
Na+-K+-2Cl-|gene-protein cotransporters|gene-protein are|O important|O in|O renal|O salt|O reabsorption|O and|O in|O salt|O secretion|O by|O epithelia|O .|O 
They|O are|O also|O essential|O in|O maintenance|O and|O regulation|O of|O ion|O gradients|O and|O cell|O volume|O in|O both|O epithelial|O and|O nonepithelial|O cells|O .|O 
Expression|O of|O Na+-K+-2Cl-|gene-protein cotransporters|gene-protein in|O brain|O tissues|O is|O high|O ;|O however|O ,|O little|O is|O known|O about|O their|O function|O and|O regulation|O in|O neurons|O .|O 
In|O this|O study|O ,|O we|O examined|O regulation|O of|O the|O Na+-K+-2Cl-|gene-protein cotransporter|gene-protein by|O the|O excitatory|O neurotransmitter|O glutamate|O .|O 
The|O cotransporter|gene-protein activity|O in|O human|O neuroblastoma|O SH-SY5Y|O cells|O was|O assessed|O by|O bumetanide|O -|O sensitive|O K+|O influx|O ,|O and|O protein|O expression|O was|O evaluated|O by|O Western|O blot|O analysis|O .|O 
Glutamate|O was|O found|O to|O induce|O a|O dose|O -|O and|O time|O -|O dependent|O stimulation|O of|O Na+-K+-2Cl-|gene-protein cotransporter|gene-protein activity|O in|O SH-SY5Y|O cells|O .|O 
Moreover|O ,|O both|O the|O glutamate|gene-protein ionotropic|gene-protein receptor|gene-protein agonist|O N-methyl-D-aspartic|O acid|O (|O NMDA|O )|O and|O the|O metabotropic|gene-protein receptor|gene-protein agonist|O (+/-)-1-aminocyclopentane-trans-1,3-dicarboxylic|O acid|O (|O trans-ACPD|O )|O significantly|O stimulated|O the|O cotransport|O activity|O in|O these|O cells|O .|O 
NMDA|O -|O mediated|O stimulation|O of|O the|O Na+-K+-2Cl-|gene-protein cotransporter|gene-protein was|O abolished|O by|O the|O selective|O NMDA|gene-protein -|gene-protein receptor|gene-protein antagonist|O (+)-MK-801|O hydrogen|O maleate|O .|O 
trans-ACPD|O -|O mediated|O effect|O on|O the|O cotransporter|gene-protein was|O blocked|O by|O the|O metabotropic|gene-protein receptor|gene-protein antagonist|O (+)-alpha-methyl-(4-carboxyphenyl)glycine|O .|O 
The|O results|O demonstrate|O that|O Na+-K+-2Cl-|gene-protein cotransporters|gene-protein in|O neurons|O are|O regulated|O by|O activation|O of|O both|O ionotropic|gene-protein and|O metabotropic|gene-protein glutamate|gene-protein receptors|gene-protein .|O 
Determination|O of|O transcription|O initiation|O sites|O and|O promoter|O activity|O of|O the|O human|O 5-HT2A|gene-rna receptor|gene-rna gene|O .|O 
The|O regulation|O of|O 5-HT2A|gene-rna receptor|gene-rna (|O 5-HT2AR|gene-rna )|O expression|O has|O been|O implicated|O in|O a|O variety|O of|O pathological|O processes|O .|O 
Previous|O data|O addressing|O the|O regulation|O of|O this|O receptor|O are|O extremely|O complicated|O and|O controversial|O .|O 
In|O order|O to|O understand|O the|O mechanisms|O of|O regulation|O of|O this|O receptor|O ,|O we|O have|O identified|O the|O promoter|O region|O of|O the|O human|O 5-HT2AR|gene-rna gene|O .|O 
Anchored|O PCR|O has|O mapped|O a|O cluster|O of|O transcription|O initiation|O sites|O at|O nucleotides|O -|O 1157|O ,|O -|O 1137|O ,|O -|O 1127|O (|O numbered|O sequentially|O as|O sites|O 1|O ,|O 2|O and|O 3|O )|O .|O 
An|O additional|O initiation|O site|O (|O site|O 4|O )|O was|O detected|O at|O -|O 496|O ,|O 631|O bp|O downstream|O of|O site|O 3|O .|O 
Promoter|O activity|O was|O defined|O by|O transfection|O studies|O .|O 
Several|O 5|O '|O flanking|O fragments|O linked|O to|O the|O human|O growth|gene-rna hormone|gene-rna reporter|gene-rna gene|O were|O transfected|O into|O two|O human|O cell|O lines|O ,|O SHSY-5Y|O (|O neuroblastoma|O )|O and|O HeLa|O (|O cervix|O carcinoma|O )|O which|O express|O 5-HT2AR|gene-rna .|O 
A|O 0.74|O kb|O HaeIII|O /|O PvuII|O fragment|O ,|O which|O encompasses|O the|O initiation|O sites|O 1|O to|O 3|O and|O 5|O '|O of|O the|O downstream|O initiation|O site|O 4|O ,|O exhibited|O significant|O promoter|O activity|O in|O both|O cell|O lines|O .|O 
Inclusion|O of|O additional|O sequences|O upstream|O (|O the|O 1.6|O kb|O PvuII|O /|O PvuII|O fragment|O )|O had|O little|O effect|O on|O the|O promoter|O activity|O ,|O but|O the|O extension|O of|O the|O 0.74|O kb|O fragment|O downstream|O to|O include|O a|O 0.45|O kb|O PvuII|gene-protein /|O SmaI|gene-protein fragment|O drastically|O decreased|O the|O promoter|O activity|O .|O 
These|O results|O suggest|O that|O the|O promoter|O activity|O for|O human|O 5-HT2AR|gene-rna gene|O resides|O in|O the|O 0.74|O kb|O HaeIII|gene-protein /|O PvuII|gene-protein fragment|O and|O the|O 0.45|O kb|O PvuII|gene-protein /|O SmaI|gene-protein fragment|O may|O contain|O a|O silencer|O for|O the|O gene|O expression|O .|O 
3-position|O modification|O of|O myo-inositol|O 1,4,5-trisphosphate|O :|O consequences|O for|O intracellular|O Ca2+|O mobilisation|O and|O enzyme|O recognition|O .|O 
The|O ability|O of|O the|O novel|O D-myo-inositol|O 1,4,5-trisphosphate|O (|O Ins(1,4,5)P3|O )|O analogues|O ,|O L-chiro-inositol|O 2,3,5-trisphosphate|O (|O L-ch-Ins(2,3,5)P3|O )|O and|O D-3-deoxy-3-fluoro-myo-inositol|O 1,4,5-trisphosphate|O (|O 3F-Ins(1,4,5)P3|O )|O ,|O to|O bind|O to|O the|O Ins(1,4,5)P3|gene-protein receptor|gene-protein ,|O mobilise|O intracellular|O Ca2+|O stores|O and|O interact|O with|O metabolic|O enzymes|O has|O been|O investigated|O .|O 
L-ch-Ins(2,3,5)P3|O and|O 3F-Ins(1,4,5)P3|O were|O bound|O by|O the|O Ins(1,4,5)P3|gene-protein receptor|gene-protein from|O bovine|O adrenal|O cortex|O with|O relatively|O high|O affinity|O (|O Ki|O values|O 60.4|O and|O 8.0|O nM|O respectively|O )|O but|O with|O lower|O affinity|O than|O Ins(1,4,5)P3|O (|O KD|O =|O 5.9|O nM|O )|O .|O 
Both|O analogues|O were|O apparent|O full|O agonists|O at|O the|O Ca2+|gene-protein mobilising|gene-protein receptor|gene-protein in|O SH-SY5Y|O cells|O ,|O but|O were|O less|O potent|O than|O Ins(1,4,5)P3|O (|O EC50|O L-ch-Ins(2,3,5)P3|O =|O 1.4|O microM|O ,|O 3F-Ins(1,4,5)P3|O =|O 0.37|O microM|O and|O Ins(1,4,5)P3|O =|O 0.12|O microM|O )|O .|O 
L-ch-Ins(2,3,5)P3|O and|O 3F-Ins(1,4,5)P3|O were|O resistant|O to|O Ins(1,4,5)P3|gene-protein 3-kinase|gene-protein ,|O and|O were|O potent|O inhibitors|O of|O the|O enzyme|O (|O Ki|O values|O 7.1|O and|O 8.6|O microM|O respectively|O )|O .|O 
3F-Ins(1,4,5)P3|O was|O hydrolysed|O by|O Ins(1,4,5)P3|gene-protein 5-phosphatase|gene-protein at|O a|O similar|O rate|O to|O Ins(1,4,5)P3|O ,|O but|O inhibited|O dephosphorylation|O of|O [3H]Ins(1,4,5)P3|O with|O high|O potency|O (|O apparent|O Ki|O =|O 3.9|O microM|O )|O L-ch-Ins(2,3,5)P3|O was|O also|O recognised|O by|O the|O enzyme|O with|O high|O affinity|O (|O Ki|O =|O 7.7|O microM|O )|O but|O was|O resistant|O to|O hydrolysis|O .|O 
These|O results|O suggest|O that|O the|O environment|O around|O C-3|O is|O of|O major|O importance|O for|O recognition|O not|O only|O by|O Ins(1,4,5)P3|gene-protein 3-kinase|gene-protein but|O also|O by|O Ins(1,4,5)P3|gene-protein 5-phosphatase|gene-protein .|O 
[|O Biological|O markers|O for|O the|O prognosis|O of|O neuroblastoma|O :|O proposal|O of|O a|O method|O of|O analysis|O ]|O 
The|O prognosis|O of|O pediatric|O neuroblastoma|O depends|O both|O on|O clinical|O presentation|O and|O on|O certain|O cellular|O and|O molecular|O characteristics|O .|O 
At|O the|O present|O time|O ,|O two|O hypotheses|O can|O be|O drawn|O to|O explain|O both|O clinical|O and|O biological|O heterogeneity|O .|O 
In|O the|O first|O hypothesis|O ,|O neuroblastoma|O progresses|O from|O early|O to|O late|O clinical|O stages|O through|O a|O classical|O multistep|O process|O linked|O to|O an|O accumulation|O of|O molecular|O abnormalities|O .|O 
In|O the|O second|O hypothesis|O ,|O neuroblastoma|O represents|O an|O heterogeneous|O group|O of|O unrelated|O diseases|O ,|O where|O most|O of|O stages|O I|O and|O II|O or|O stage|O IVS|O neuroblastomas|O can|O rather|O be|O considered|O as|O benign|O tumors|O ,|O and|O stage|O IV|O neuroblastoma|O as|O a|O true|O malignant|O proliferation|O .|O 
To|O ascertain|O relevant|O biological|O factors|O for|O the|O prognosis|O of|O the|O disease|O ,|O it|O is|O uppermost|O important|O that|O all|O investigators|O agree|O on|O biological|O criteria|O for|O analysis|O when|O neuroblastoma|O tissue|O is|O available|O in|O screened|O and|O unscreened|O populations|O .|O 
This|O paper|O reviews|O the|O biological|O tools|O available|O for|O prognosis|O in|O neuroblastoma|O ,|O the|O priority|O for|O analysis|O of|O biological|O markers|O according|O to|O reliability|O ,|O feasibility|O ,|O and|O reproducibility|O of|O analysis|O procedure|O ,|O and|O the|O conditions|O of|O tissue|O storage|O for|O further|O analysis|O of|O these|O biological|O markers|O .|O 
The|O standardized|O biological|O evaluation|O of|O neuroblastoma|O will|O allow|O ,|O first|O ,|O to|O collect|O sufficient|O data|O for|O multivariate|O analysis|O of|O prognostic|O factors|O and|O ,|O second|O ,|O to|O better|O define|O the|O putative|O links|O between|O various|O forms|O of|O the|O disease|O .|O 
Differential|O effects|O of|O retinoic|O acid|O isomers|O on|O the|O expression|O of|O nuclear|O receptor|O co|O -|O regulators|O in|O neuroblastoma|O .|O 
Retinoic|O acid|O modulates|O growth|O and|O induces|O differentiation|O and|O apoptosis|O of|O neuroblastoma|O cells|O in|O vitro|O ,|O with|O the|O all|O -|O trans|O and|O 9-cis|O isomers|O having|O different|O biological|O properties|O .|O 
Transcriptional|O activation|O in|O response|O to|O retinoic|O acid|O isomers|O is|O mediated|O by|O retinoic|gene-protein acid|gene-protein receptors|gene-protein and|O retinoid|gene-protein X|gene-protein receptors|gene-protein .|O 
The|O differential|O expression|O of|O co|O -|O activators|O and|O co|O -|O repressors|O which|O preferentially|O interact|O with|O retinoic|gene-protein acid|gene-protein receptors|gene-protein or|O retinoid|gene-protein X|gene-protein receptors|gene-protein may|O be|O a|O mechanism|O leading|O to|O different|O cellular|O responses|O to|O 9-cis|O and|O all|O -|O trans|O retinoic|O acid|O .|O 
To|O test|O this|O hypothesis|O ,|O we|O have|O studied|O the|O expression|O of|O the|O nuclear|O receptor|O co|O -|O regulators|O TIF1alpha|gene-rna ,|O TIF1beta|gene-rna ,|O SUG1|gene-rna and|O SMRT|gene-rna in|O the|O N|O -|O type|O and|O S|O -|O type|O neuroblastoma|O cell|O lines|O SH|O SY|O 5Y|O and|O SH|O S|O EP|O .|O 
Transcripts|O for|O all|O four|O co|O -|O regulators|O were|O expressed|O in|O these|O neuroblastoma|O cells|O .|O 
The|O expression|O of|O TIF1alpha|gene-rna ,|O TIF1beta|gene-rna and|O SUG1|gene-rna did|O not|O change|O in|O response|O to|O retinoic|O acid|O ;|O however|O ,|O SMRT|gene-rna was|O induced|O in|O both|O neuroblastoma|O cell|O lines|O ,|O but|O particularly|O by|O all|O -|O trans|O retinoic|O acid|O in|O SH|O S|O EP|O cells|O .|O 
An|O additional|O co|O -|O activator|O ,|O Trip3|gene-rna ,|O was|O isolated|O by|O differential|O mRNA|O display|O and|O shown|O to|O be|O preferentially|O induced|O by|O 9-cis|O retinoic|O acid|O in|O SH|O SY|O 5Y|O and|O SH|O S|O EP|O cells|O .|O 
These|O data|O suggest|O that|O retinoic|O acid|O isomer|O -|O specific|O induction|O of|O nuclear|O receptor|O co|O -|O regulators|O may|O determine|O ,|O in|O part|O ,|O the|O differential|O biological|O effects|O of|O retinoic|O acid|O isomers|O .|O 
Cyclooxygenase-2|gene-protein expression|O is|O increased|O in|O frontal|O cortex|O of|O Alzheimer|O 's|O disease|O brain|O .|O 
Many|O epidemiological|O studies|O suggest|O that|O use|O of|O nonsteroidal|O anti|O -|O inflammatory|O drugs|O delays|O or|O slows|O the|O clinical|O expression|O of|O Alzheimer|O 's|O disease|O ,|O but|O the|O mechanism|O by|O which|O these|O drugs|O might|O affect|O pathophysiological|O processes|O relevant|O to|O Alzheimer|O 's|O disease|O has|O been|O unclear|O .|O 
Non|O -|O steroidal|O anti|O -|O inflammatory|O drugs|O are|O presumed|O to|O act|O by|O inhibiting|O cyclooxygenase|gene-protein ,|O a|O key|O enzyme|O in|O the|O metabolism|O of|O membrane|O -|O derived|O arachidonic|O acid|O into|O prostaglandins|O .|O 
In|O recent|O years|O ,|O two|O distinct|O isoforms|O of|O cyclooxygenase|gene-protein have|O been|O characterized|O ,|O a|O constitutive|O form|O ,|O cyclooxygenase-1|gene-protein ,|O and|O a|O mitogen|O -|O inducible|O form|O ,|O cyclooxygenase-2|gene-protein .|O 
Cyclooxygenase-2|gene-protein has|O been|O identified|O in|O rodent|O brain|O .|O 
Excitotoxic|O lesions|O cause|O up|O -|O regulation|O of|O cyclooxygenase-2|gene-rna expression|O coincident|O with|O the|O onset|O of|O expression|O of|O markers|O of|O apoptosis|O ;|O cyclooxygenase-2|gene-protein thus|O represents|O a|O possible|O target|O of|O non|O -|O steroidal|O anti|O -|O inflammatory|O drug|O action|O in|O neurodegenerative|O mechanisms|O .|O 
In|O the|O present|O study|O ,|O we|O examined|O cyclooxygenase-2|gene-rna gene|O expression|O in|O Alzheimer|O 's|O disease|O and|O control|O cases|O .|O 
We|O found|O up|O -|O regulation|O of|O cyclooxygenase-2|gene-rna expression|O in|O Alzheimer|O 's|O disease|O frontal|O cortex|O .|O 
Further|O ,|O we|O found|O that|O synthetic|O beta-amyloid|gene-protein peptides|gene-protein induced|O cyclooxygenase-2|gene-rna expression|O in|O SH-SY5Y|O neuroblastoma|O cells|O in|O vitro|O ,|O suggesting|O a|O mechanism|O for|O cyclooxygenase-2|gene-rna up|O -|O regulation|O in|O Alzheimer|O 's|O disease|O .|O 
These|O findings|O support|O the|O investigation|O of|O selective|O cyclooxygenase-2|gene-protein inhibitors|O for|O the|O treatment|O of|O Alzheimer|O 's|O disease|O .|O 
Transcriptional|O effects|O of|O estrogen|O on|O neuronal|gene-rna neurotensin|gene-rna gene|O expression|O involve|O cAMP|O /|O protein|gene-protein kinase|gene-protein A|gene-protein -|O dependent|O signaling|O mechanisms|O .|O 
Steroid|O hormones|O exert|O dramatic|O effects|O on|O neuronal|O expression|O of|O genes|O that|O encode|O neuropeptides|O .|O 
Expression|O of|O the|O neurotensin|gene-rna /|gene-rna neuromedin|gene-rna (|O NT|gene-rna /|gene-rna N|gene-rna )|O gene|O in|O preoptic|O area|O neurons|O is|O dramatically|O enhanced|O by|O estrogen|O in|O vivo|O ,|O even|O though|O its|O promoter|O lacks|O palindromic|O estrogen|O response|O elements|O .|O 
We|O report|O here|O that|O estrogen|O promotes|O transcription|O of|O this|O gene|O by|O interactions|O with|O the|O cAMP|O cascade|O in|O a|O neuronal|O cell|O line|O ,|O SK-N-SH|O ,|O and|O in|O a|O mouse|O model|O .|O 
In|O neuroblastoma|O cells|O ,|O estrogen|O increases|O cAMP|O and|O the|O phosphorylation|O of|O the|O cAMP|gene-protein response|gene-protein element|gene-protein -|gene-protein binding|gene-protein protein|gene-protein in|O a|O time|O frame|O that|O precedes|O induction|O of|O NT|gene-rna /|gene-rna N|gene-rna gene|O transcription|O .|O 
Interference|O with|O the|O cAMP|O /|O protein|gene-protein kinase|gene-protein A|gene-protein signal|O transduction|O cascade|O blocks|O the|O ability|O of|O estrogen|O to|O elicit|O increases|O in|O transcription|O of|O this|O gene|O .|O 
Furthermore|O ,|O in|O studies|O performed|O in|O vivo|O using|O mice|O deficient|O in|O protein|gene-protein kinase|gene-protein A|gene-protein ,|O estrogen|O fails|O to|O induce|O increases|O in|O NT|gene-rna /|gene-rna N|gene-rna mRNA|O but|O retains|O its|O ability|O to|O promote|O estrogen|gene-rna response|gene-rna element|gene-rna -|gene-rna dependent|gene-rna progesterone|gene-rna receptor|gene-rna gene|O transcription|O .|O 
These|O data|O represent|O the|O first|O report|O of|O a|O nonclassical|O effect|O of|O estrogen|O on|O the|O expression|O of|O an|O endogenous|O estrogen|O -|O regulated|O neuropeptide|O gene|O through|O cAMP|O -|O mediated|O mechanisms|O both|O in|O a|O neuroblastoma|O cell|O line|O and|O in|O hypothalamic|O neurons|O .|O 
More|O importantly|O ,|O this|O "|O cross|O -|O talk|O "|O may|O represent|O a|O more|O generalized|O mechanism|O by|O which|O steroid|O hormones|O act|O through|O other|O signal|O transduction|O cascades|O to|O regulate|O the|O expression|O of|O other|O genes|O in|O the|O brain|O .|O 
Pharmacological|O characterization|O of|O AR-M1000390|O at|O human|O delta|gene-protein opioid|gene-protein receptors|gene-protein .|O 
We|O investigated|O the|O pharmacological|O properties|O of|O a|O newly|O synthesised|O delta|O agonist|O AR-M1000390|O ,|O derived|O from|O SNC-80|O (|O (+)-4-[(alphaR)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethyl-benzamide|O )|O ,|O in|O the|O neuroblastoma|O cell|O line|O SK-N-BE|O expressing|O only|O human|O delta-opioid|gene-protein receptors|gene-protein .|O 
Binding|O and|O functional|O experiments|O showed|O a|O weak|O affinity|O (|O K(i)|O =|O 106|O +/-|O 34|O nM|O )|O correlated|O with|O a|O weak|O potency|O (|O EC(50)|O =|O 111|O +/-|O 31|O nM|O )|O to|O inhibit|O the|O forskolin|O -|O stimulated|O cAMP|O accumulation|O .|O 
Sustained|O activation|O of|O opioid|gene-protein receptors|gene-protein in|O the|O presence|O of|O the|O maximal|O inhibitory|O concentration|O of|O AR-M1000390|O produced|O a|O rapid|O and|O strong|O desensitization|O .|O 
In|O order|O to|O examine|O the|O contribution|O of|O internalization|O and|O down|O -|O regulation|O in|O the|O desensitization|O processes|O ,|O binding|O and|O functional|O experiments|O were|O conducted|O in|O the|O presence|O or|O in|O the|O absence|O of|O hypertonic|O sucrose|O solution|O to|O block|O clathrin|gene-protein -|O dependent|O opioid|gene-protein receptor|gene-protein endocytosis|O .|O 
We|O observed|O both|O the|O inability|O of|O AR-M1000390|O to|O down|O -|O regulate|O opioid|gene-protein receptors|gene-protein and|O the|O absence|O of|O any|O effect|O of|O sucrose|O on|O desensitization|O .|O 
The|O lack|O of|O delta-opioid|gene-protein receptor|gene-protein internalization|O by|O AR-M1000390|O was|O further|O corroborated|O by|O confocal|O microscopy|O using|O antibodies|O directed|O either|O against|O the|O endogenous|O delta-opioid|gene-protein receptors|gene-protein or|O the|O FLAG|O -|O tagged|O delta-opioid|gene-protein receptors|gene-protein stably|O expressed|O in|O the|O SK-N-BE|O cells|O .|O 
These|O data|O suggest|O that|O uncoupling|O rather|O than|O internalization|O is|O responsible|O for|O delta-opioid|gene-protein receptors|gene-protein desensitization|O by|O AR-M1000390|O .|O 
Negative|O modulator|O of|O the|O rat|O D2|gene-rna dopamine|gene-rna receptor|gene-rna gene|O .|O 
The|O rat|O D2|gene-rna dopamine|gene-rna receptor|gene-rna gene|O is|O transcribed|O from|O a|O TATA|O -|O less|O promoter|O that|O has|O an|O initiator|O -|O like|O sequence|O and|O several|O putative|O Sp1|gene-protein binding|O sites|O .|O 
The|O main|O activator|O of|O this|O gene|O is|O between|O nucleotides|O -|O 75|O and|O -|O 29|O ,|O and|O a|O strong|O negative|O modulator|O is|O located|O between|O bases|O -|O 217|O and|O -|O 76|O 
In|O the|O present|O investigation|O ,|O a|O small|O deletion|O series|O within|O this|O negative|O modulator|O fused|O with|O the|O reporter|gene-rna gene|gene-rna for|gene-rna chloramphenicol|gene-rna acetyltransferase|gene-rna was|O used|O to|O transfect|O the|O D2|gene-rna -|O expressing|O cells|O ,|O NB41A3|O .|O 
Two|O cis|O -|O acting|O functional|O DNA|O sequences|O were|O identified|O :|O a|O 41|O -|O base|O pair|O segment|O between|O nucleotides|O -|O 116|O and|O -|O 76|O (|O D2Neg-B|gene-rna )|O ,|O which|O decreased|O transcription|O from|O the|O D2|gene-rna promoter|O by|O about|O 45|O %|O ,|O and|O a|O 26|O -|O base|O pair|O segment|O between|O nucleotides|O -|O 160|O and|O -|O 135|O (|O D2Neg-A|gene-rna )|O ,|O which|O ,|O in|O the|O presence|O of|O the|O downstream|O negative|O modulator|O ,|O reduced|O transcription|O down|O to|O the|O level|O of|O a|O promoterless|O vector|O .|O 
DNase|gene-protein I|gene-protein footprinting|O ,|O gel|O mobility|O shift|O ,|O and|O competitive|O cotransfection|O experiments|O suggested|O that|O D2Neg-A|gene-rna functions|O without|O trans|O -|O acting|O factors|O ,|O whereas|O D2Neg-B|gene-rna interacts|O with|O nuclear|O factors|O at|O its|O Sp1|gene-protein binding|O sequences|O .|O 
Gel|O supershift|O with|O anti|gene-protein -|gene-protein Sp1|gene-protein antibody|gene-protein and|O UV|O cross|O -|O linking|O experiments|O revealed|O that|O a|O novel|O 130|O -|O kDa|O factor|O as|O well|O as|O Sp1|gene-protein interact|O with|O D2Neg-B|gene-rna in|O NB41A3|O cells|O .|O 
This|O novel|O protein|O recognizing|O Sp1|gene-protein binding|O sequences|O in|O the|O D2|gene-rna gene|O negative|O modulator|O is|O also|O found|O in|O nuclear|O extract|O from|O the|O rat|O striatum|O .|O 
Molecular|O analysis|O of|O the|O cyclin|gene-rna -|gene-rna dependent|gene-rna kinase|gene-rna inhibitor|gene-rna family|O :|O p16|gene-rna (|O CDKN2|gene-rna /|O MTS1|gene-rna /|O INK4A|gene-rna )|O ,|O p18|gene-rna (|O INK4C|gene-rna )|O and|O p27|gene-rna (|O Kip1|gene-rna )|O genes|O in|O neuroblastomas|O .|O 
BACKGROUND|O .|O 
Chromosomal|O abnormalities|O involving|O band|O 1p32|O ,|O especially|O deletions|O ,|O are|O frequent|O in|O neuroblastomas|O ,|O indicating|O that|O a|O tumor|O suppressor|O gene(s)|O is|O localized|O at|O this|O region|O .|O 
The|O p18|gene-rna gene|O ,|O one|O of|O the|O cyclin|gene-rna -|gene-rna dependent|gene-rna kinase|gene-rna inhibitor|gene-rna (|O CDKI|gene-rna )|O genes|O ,|O maps|O to|O this|O chromosomal|O region|O .|O 
Complexes|O of|O cyclin|gene-protein and|O cyclin|gene-protein -|gene-protein dependent|gene-protein kinase|gene-protein (|O CDK|gene-protein )|O play|O important|O roles|O in|O the|O cell|O cycle|O .|O 
CDKIs|gene-protein inhibit|O the|O kinase|O activities|O of|O these|O complexes|O and|O block|O transitions|O of|O the|O cell|O cycle|O .|O 
Some|O of|O the|O CDKI|gene-rna genes|O may|O be|O tumor|O suppressor|O genes|O .|O 
For|O example|O ,|O the|O CDKI|gene-rna genes|O p16|gene-rna and|O p15|gene-rna are|O frequently|O deleted|O in|O various|O malignancies|O and|O are|O thought|O to|O contribute|O to|O cellular|O transformations|O .|O 
METHODS|O .|O 
To|O elucidate|O the|O importance|O of|O CDKI|gene-rna genes|O ,|O including|O the|O p18|gene-rna as|O well|O as|O the|O p16|gene-rna and|O p27|gene-rna genes|O in|O tumorigenesis|O of|O neuroblastoma|O ,|O 25|O neuroblastomas|O were|O analyzed|O for|O deletions|O by|O Southern|O blot|O analysis|O and|O for|O point|O mutations|O by|O polymerase|gene-protein chain|O reaction|O -|O single|O strand|O conformational|O polymorphism|O .|O 
RESULTS|O .|O 
No|O deletions|O ,|O rearrangements|O ,|O nor|O mutations|O were|O detected|O in|O these|O genes|O ,|O however|O ,|O polymorphisms|O reported|O previously|O were|O detected|O .|O 
CONCLUSIONS|O .|O 
Abnormalities|O ,|O including|O deletions|O and|O point|O mutations|O of|O the|O p16|gene-rna ,|O p18|gene-rna ,|O and|O p27|gene-rna genes|O ,|O were|O not|O observed|O in|O this|O series|O of|O neuroblastomas|O .|O 
Other|O mechanisms|O to|O inactivate|O these|O genes|O ,|O such|O as|O transcriptional|O or|O translational|O defects|O ,|O must|O be|O analyzed|O .|O 
CDKI|gene-rna genes|O rarely|O contributed|O to|O tumorigenesis|O in|O neuroblastomas|O .|O 
A|O lack|O of|O neuroblastoma|O in|O Down|O syndrome|O :|O a|O study|O from|O 11|O European|O countries|O .|O 
An|O epidemiological|O investigation|O in|O 11|O European|O countries|O comprising|O a|O total|O childhood|O population|O of|O 54.1|O million|O children|O and|O using|O 8|O separate|O data|O sources|O was|O conducted|O to|O evaluate|O the|O occurrence|O of|O neuroblastoma|O in|O Down|O syndrome|O (|O DS|O )|O .|O 
No|O cases|O of|O DS|O were|O detected|O among|O 6724|O infants|O and|O children|O with|O neuroblastoma|O ,|O although|O more|O than|O five|O were|O expected|O .|O 
This|O highly|O significant|O result|O (|O P|O =|O 0.0045|O according|O to|O the|O Poisson|O test|O )|O is|O consistent|O with|O data|O in|O the|O literature|O ,|O which|O contains|O only|O two|O poorly|O detailed|O cases|O in|O epidemiological|O studies|O and|O one|O ganglioneuroma|O in|O a|O DS|O mosaic|O patient|O .|O 
Like|O other|O tumors|O ,|O such|O as|O leukemias|O ,|O testicular|O germ|O cell|O tumors|O and|O lymphomas|O are|O in|O excess|O in|O DS|O patients|O ;|O the|O lack|O of|O neuroblastomas|O does|O not|O reflect|O a|O general|O decreased|O incidence|O of|O cancer|O but|O rather|O a|O specific|O underrepresentation|O of|O this|O precise|O tumor|O .|O 
S-100|gene-protein b|gene-protein protein|O ,|O the|O gene|O for|O which|O maps|O to|O the|O long|O arm|O of|O chromosome|O 21|O ,|O (a)|O is|O overproduced|O in|O DS|O patients|O ,|O (b)|O produces|O growth|O inhibition|O and|O differentiation|O of|O neural|O cells|O in|O vitro|O ,|O (c)|O is|O abundant|O in|O good|O -|O prognosis|O neuroblastomas|O ,|O and|O (d)|O has|O been|O shown|O to|O induce|O growth|O inhibition|O and|O differentiation|O and|O cell|O death|O in|O several|O human|O and|O murine|O neuroblastoma|O cell|O lines|O and|O could|O be|O responsible|O for|O this|O variation|O .|O 
Additional|O epidemiological|O and|O experimental|O studies|O are|O warranted|O to|O confirm|O our|O interpretation|O of|O these|O data|O .|O 
The|O human|O synaptotagmin|gene-rna IV|gene-rna gene|O defines|O an|O evolutionary|O break|O point|O between|O syntenic|O mouse|O and|O human|O chromosome|O regions|O but|O retains|O ligand|O inducibility|O and|O tissue|O specificity|O .|O 
Rat|O synaptotagmin|gene-protein IV|gene-protein (|O SYT|gene-protein IV|gene-protein )|O is|O a|O depolarization|O -|O inducible|O synaptic|O vesicle|O protein|O .|O 
SYT|gene-rna IV|gene-rna homozygous|O mutant|O mice|O are|O viable|O and|O have|O deficits|O in|O fine|O motor|O coordination|O and|O some|O forms|O of|O memory|O .|O 
In|O this|O study|O ,|O we|O report|O the|O identification|O of|O a|O human|O SYT|gene-generic IV|gene-generic orthologue|O .|O 
The|O predicted|O amino|O acid|O sequence|O of|O the|O human|O SYT|gene-protein IV|gene-protein clone|O is|O nearly|O 90|O %|O identical|O to|O the|O rat|O and|O mouse|O SYT|gene-protein IV|gene-protein proteins|O .|O 
In|O addition|O ,|O human|O SYT|gene-protein IV|gene-protein has|O a|O characteristic|O serine|O for|O aspartate|O substitution|O within|O the|O first|O C2|O domain|O that|O is|O conserved|O among|O Drosophila|O ,|O Caenorhabditis|O elegans|O ,|O mouse|O ,|O and|O rat|O SYT|gene-protein IV|gene-protein sequences|O .|O 
The|O human|O SYT|gene-rna IV|gene-rna gene|O maps|O to|O chromosome|O band|O 18q12.3|O ,|O a|O region|O that|O defines|O a|O break|O point|O in|O the|O synteny|O with|O mouse|O chromosome|O 18|O and|O has|O been|O implicated|O by|O associated|O markers|O in|O two|O human|O psychiatric|O disorders|O .|O 
In|O the|O human|O neuroblastoma|O cell|O line|O SK-N-SH|O ,|O SYT|gene-rna IV|gene-rna is|O an|O immediate|O -|O early|O gene|O inducible|O by|O elevated|O intracellular|O calcium|O and|O by|O forskolin|O ,|O an|O activator|O of|O adenylyl|gene-protein cyclase|gene-protein .|O 
Expression|O of|O human|O SYT|gene-rna IV|gene-rna mRNA|O is|O restricted|O to|O brain|O and|O is|O not|O detectable|O in|O non|O -|O neuronal|O tissues|O .|O 
Within|O brain|O ,|O human|O SYT|gene-rna IV|gene-rna mRNA|O is|O most|O highly|O expressed|O in|O hippocampus|O ,|O with|O lower|O levels|O present|O in|O amygdala|O and|O thalamus|O .|O 
These|O results|O suggest|O a|O role|O for|O SYT|gene-protein IV|gene-protein in|O human|O brain|O function|O and|O in|O human|O neurological|O disease|O .|O 
Tumor|O -|O targeted|O gene|O therapy|O :|O strategies|O for|O the|O preparation|O of|O ligand|O -|O polyethylene|O glycol-polyethylenimine|O /|O DNA|O complexes|O .|O 
Surface|O -|O shielded|O DNA|O delivery|O systems|O have|O been|O synthesized|O with|O virus|O -|O like|O characteristics|O that|O target|O gene|O expression|O into|O distant|O tumor|O tissues|O .|O 
Polyethylenimine|O (|O PEI|O )|O /|O DNA|O complexes|O (|O '|O polyplexes|O '|O )|O conjugated|O with|O the|O cell|O -|O binding|O ligand|O transferrin|gene-protein (|O Tf|gene-protein )|O or|O epidermal|gene-protein growth|gene-protein factor|gene-protein (|O EGF|gene-protein )|O were|O used|O to|O achieve|O receptor|O -|O mediated|O endocytosis|O .|O 
The|O surface|O charge|O of|O the|O complexes|O was|O masked|O by|O covalently|O linking|O PEI|O to|O polyethylene|O glycol|O (|O PEG|O )|O .|O 
Three|O alternatives|O for|O generating|O these|O surface|O -|O shielded|O formulations|O were|O utilized|O ,|O attaching|O ligand|O and|O PEG|O molecules|O to|O PEI|O either|O before|O or|O after|O DNA|O complex|O formation|O .|O 
The|O stabilized|O formulations|O could|O be|O ultra|O -|O concentrated|O ,|O stored|O frozen|O ,|O and|O applied|O systemically|O after|O thawing|O .|O 
Intravenous|O injection|O of|O Tf|gene-protein -|O PEG|O -|O coated|O polyplexes|O resulted|O in|O gene|O transfer|O to|O subcutaneous|O Neuro2a|O neuroblastoma|O tumors|O of|O syngeneic|O A|O /|O J|O mice|O ;|O EGF|gene-protein -|O PEG|O -|O coated|O polyplexes|O were|O intravenously|O applied|O for|O targeting|O human|O hepatocellular|O carcinoma|O xenografts|O in|O SCID|O mice|O .|O 
In|O these|O models|O ,|O luciferase|gene-rna marker|O gene|O expression|O levels|O in|O tumor|O tissues|O were|O 10|O -|O to|O 100|O -|O fold|O higher|O than|O in|O other|O organ|O tissues|O .|O 
Repeated|O systemic|O application|O of|O Tf|gene-protein -|O PEG|O -|O PEI|O /|O DNA|O complexes|O encoding|O tumor|gene-protein necrosis|gene-protein factor|gene-protein alpha|gene-protein (|O TNF-alpha|gene-protein )|O into|O tumor|O -|O bearing|O mice|O induced|O tumor|O necrosis|O and|O inhibition|O of|O tumor|O growth|O in|O three|O murine|O tumor|O models|O of|O different|O tissue|O origin|O (|O Neuro2a|O ,|O M-3|O or|O B16|O melanoma|O )|O .|O 
Analysis|O of|O the|O c-src|gene-rna gene|O product|O structure|O ,|O abundance|O ,|O and|O protein|O kinase|gene-protein activity|O in|O human|O neuroblastoma|O and|O glioblastoma|O cells|O .|O 
We|O have|O compared|O in|O different|O human|O neuroblastoma|O cell|O lines|O and|O human|O glioblastoma|O cells|O the|O expression|O level|O ,|O structure|O ,|O and|O tyrosine|gene-protein -|gene-protein specific|gene-protein protein|gene-protein kinase|gene-protein activity|O of|O pp60c-src|gene-protein .|O 
Our|O results|O show|O that|O not|O all|O human|O neuroblastoma|O cell|O lines|O express|O pp60c-src|gene-protein molecules|O with|O amino|O -|O terminal|O structural|O alterations|O .|O 
In|O neuroblastoma|O cells|O which|O possess|O pp60c-src|gene-protein with|O altered|O gel|O migration|O ,|O the|O diminished|O polyacrylamide|O gel|O mobility|O of|O pp60c-src|gene-protein was|O found|O not|O to|O be|O dependent|O upon|O amino|O -|O terminal|O phosphorylations|O since|O extensive|O treatment|O of|O these|O molecules|O with|O phosphatase|gene-protein did|O not|O significantly|O change|O their|O gel|O migration|O properties|O .|O 
Similar|O differences|O in|O gel|O migration|O were|O observed|O when|O RNA|O from|O the|O various|O neuroblastoma|O and|O glioblastoma|O cells|O was|O translated|O in|O vitro|O using|O either|O rabbit|O reticulocyte|O or|O wheat|O germ|O lysates|O .|O 
White|O the|O level|O of|O c-src|gene-rna mRNA|O in|O the|O different|O cells|O analyzed|O was|O found|O to|O be|O similar|O ,|O the|O abundance|O of|O pp60c-src|gene-protein in|O these|O same|O cells|O was|O found|O to|O vary|O by|O as|O much|O as|O 12|O -|O fold|O .|O 
This|O suggests|O that|O the|O abundance|O of|O pp60c-src|gene-protein in|O human|O neuroendocrine|O tumors|O is|O regulated|O through|O post|O -|O transcriptional|O and/or|O post|O -|O translational|O events|O which|O may|O be|O related|O to|O the|O stage|O of|O neuronal|O differentiation|O of|O the|O cells|O .|O 
Based|O upon|O determination|O of|O pp60c-src|gene-protein abundance|O by|O immunoblot|O analysis|O ,|O we|O demonstrate|O that|O pp60c-src|gene-protein molecules|O derived|O from|O human|O neuroblastoma|O and|O glioblastoma|O cells|O have|O very|O similar|O in|O vitro|O protein|O kinase|gene-protein activities|O .|O 
Nuclear|O localization|O of|O cystatin|gene-protein B|gene-protein ,|O the|O cathepsin|gene-protein inhibitor|O implicated|O in|O myoclonus|O epilepsy|O (|O EPM1|O )|O .|O 
Cystatin|gene-protein B|gene-protein is|O an|O anti|O -|O protease|gene-protein implicated|O in|O myoclonus|O epilepsy|O ,|O a|O degenerative|O disease|O of|O the|O central|O nervous|O system|O .|O 
In|O vitro|O ,|O cystatin|gene-protein B|gene-protein interacts|O with|O and|O inhibits|O proteases|gene-protein of|O the|O cathepsin|gene-protein family|O .|O 
Confocal|O microscopy|O analysis|O of|O the|O subcellular|O localization|O of|O cystatin|gene-protein B|gene-protein and|O cathepsin|gene-protein B|gene-protein shows|O that|O ,|O in|O vivo|O ,|O the|O two|O proteins|O are|O concentrated|O in|O different|O cell|O compartments|O .|O 
In|O fact|O ,|O cystatin|gene-protein B|gene-protein is|O found|O mainly|O in|O the|O nucleus|O of|O proliferating|O cells|O and|O both|O in|O the|O nucleus|O and|O in|O the|O cytoplasm|O of|O differentiated|O cells|O ,|O while|O cathepsin|gene-protein B|gene-protein ,|O in|O either|O case|O ,|O is|O essentially|O cytoplasmic|O .|O 
However|O ,|O colocalization|O of|O cystatin|gene-protein and|O cathepsin|gene-protein B|gene-protein is|O observed|O in|O the|O isolated|O cell|O matrix|O and|O in|O the|O nuclear|O scaffold|O of|O differentiated|O neuroblastoma|O cells|O but|O not|O of|O proliferating|O cells|O .|O 
This|O suggests|O that|O at|O least|O a|O fraction|O of|O cystatin|gene-protein B|gene-protein is|O bound|O to|O the|O protease|gene-protein in|O differentiated|O cells|O .|O 
The|O electron|O microscopy|O analysis|O of|O the|O cell|O matrix|O confirms|O the|O observation|O made|O with|O confocal|O microscopy|O .|O 
The|O cellular|O activity|O of|O cathepsin|gene-protein B|gene-protein was|O analyzed|O with|O a|O fluorogenic|O cytochemical|O assay|O .|O 
A|O fluorescent|O signal|O is|O observed|O in|O the|O cytoplasm|O of|O proliferating|O cells|O but|O is|O undetectable|O in|O the|O cytoplasm|O of|O differentiated|O cells|O ,|O suggesting|O that|O cathepsin|gene-protein B|gene-protein is|O active|O mainly|O during|O the|O cell|O cycle|O .|O 
This|O result|O is|O consistent|O with|O the|O separate|O compartimentalization|O of|O cystatin|gene-protein B|gene-protein and|O cathepsin|gene-protein B|gene-protein that|O we|O have|O observed|O in|O growing|O cells|O .|O 
Local|O control|O with|O multimodality|O therapy|O for|O stage|O 4|O neuroblastoma|O .|O 
PURPOSE|O :|O 
To|O evaluate|O the|O efficacy|O of|O 21|O Gy|O hyperfractionated|O radiotherapy|O for|O local|O control|O in|O conjunction|O with|O surgery|O and|O intensive|O systemic|O therapy|O for|O patients|O with|O Stage|O 4|O neuroblastoma|O .|O 
METHODS|O AND|O MATERIALS|O :|O 
After|O achieving|O a|O partial|O or|O complete|O remission|O ,|O 47|O children|O ,|O ages|O 1|O -|O 10|O years|O ,|O with|O Stage|O 4|O neuroblastoma|O were|O treated|O on|O four|O consecutive|O institutional|O protocols|O (|O N4|O -|O N7|O )|O with|O dose|O -|O intensive|O multi|O -|O agent|O chemotherapy|O ,|O maximal|O surgical|O debulking|O ,|O and|O hyperfractionated|O radiotherapy|O (|O 1.5|O Gy|O twice|O a|O day|O to|O 21|O Gy|O )|O .|O 
Radiotherapy|O fields|O encompassed|O the|O initial|O tumor|O volume|O and|O regional|O lymph|O nodes|O plus|O a|O 3|O -|O cm|O margin|O .|O 
This|O was|O followed|O by|O consolidation|O with|O either|O autologous|O bone|O marrow|O transplantation|O (|O N4|O and|O N5|O )|O or|O immunotherapy|O (|O N6|O and|O N7|O )|O .|O 
RESULTS|O :|O 
Forty-five|O of|O 47|O patients|O had|O a|O complete|O response|O to|O surgery|O and|O chemotherapy|O prior|O to|O radiotherapy|O .|O 
Five|O -|O year|O actuarial|O rates|O of|O local|O control|O ,|O progression|O -|O free|O survival|O ,|O and|O overall|O survival|O were|O 84|O %|O ,|O 40|O %|O ,|O and|O 45|O %|O ,|O respectively|O .|O 
Among|O 26|O patients|O who|O relapsed|O ,|O 1|O failed|O only|O at|O the|O primary|O site|O ,|O 22|O developed|O distant|O metastases|O exclusively|O ,|O and|O 3|O had|O both|O local|O and|O distant|O failures|O .|O 
There|O were|O no|O acute|O complications|O of|O radiotherapy|O .|O 
CONCLUSION|O :|O 
Hyperfractionated|O radiotherapy|O to|O 21|O Gy|O ,|O in|O conjunction|O with|O dose|O -|O intensive|O systemic|O therapy|O and|O aggressive|O surgical|O resection|O ,|O is|O well|O tolerated|O and|O is|O associated|O with|O durable|O local|O control|O for|O most|O patients|O with|O Stage|O 4|O neuroblastoma|O .|O 
Expression|O of|O protein|gene-protein kinase|gene-protein C|gene-protein isoforms|gene-protein in|O euxanthone|O -|O induced|O differentiation|O of|O neuroblastoma|O cells|O .|O 
Euxanthone|O ,|O a|O potent|O neuritogenic|O compound|O isolated|O from|O the|O roots|O of|O the|O medicinal|O herb|O Polygala|O caudata|O ,|O has|O recently|O been|O shown|O to|O induce|O the|O differentiation|O of|O murine|O neuroblastoma|O Neuro|O 2A|O (|O BU-1|O )|O cells|O .|O 
In|O this|O study|O ,|O the|O role|O of|O protein|gene-protein kinase|gene-protein C|gene-protein (|O PKC|gene-protein )|O and|O the|O expression|O of|O various|O PKC|gene-protein isoforms|gene-protein in|O euxanthone|O -|O treated|O BU-1|O cells|O were|O examined|O .|O 
mRNA|O phenotyping|O using|O the|O reverse|O -|O transcription|O polymerase|gene-protein chain|O reaction|O (|O RT|O -|O PCR|O )|O showed|O that|O BU-1|O cells|O express|O six|O different|O PKC|gene-protein isoforms|O ,|O namely|O PKC|gene-protein -|gene-protein alpha|gene-protein ,|O -|gene-protein beta|gene-protein ,|O -|gene-protein delta|gene-protein ,|O -|gene-protein epsilon|gene-protein ,|O -|gene-protein lambda|gene-protein ,|O and|O -|gene-protein zeta|gene-protein .|O 
Differential|O regulation|O and|O expression|O of|O PKC|gene-protein isoforms|gene-protein was|O observed|O in|O BU-1|O cells|O treated|O with|O 100|O microM|O euxanthone|O .|O 
PKC|gene-protein -|gene-protein apha|gene-protein ,|O -|gene-protein beta|gene-protein ,|O -|gene-protein delta|gene-protein ,|O -|gene-protein lambda|gene-protein and|O -|gene-protein zeta|gene-protein were|O all|O up|O -|O regulated|O ,|O with|O 1.7|O -|O to|O 9.5|O -|O fold|O increase|O ,|O at|O around|O 30|O to|O 60|O minutes|O after|O euxanthone|O treatment|O .|O 
The|O expression|O level|O of|O PKC|gene-protein -|gene-protein epsilon|gene-protein remained|O relatively|O constant|O during|O the|O treatment|O .|O 
PKC|gene-protein -|gene-protein gamma|gene-protein ,|O -|gene-protein eta|gene-protein ,|O and|O -|gene-protein theta|gene-protein were|O not|O detected|O in|O both|O untreated|O and|O euxanthone|O -|O treated|O BU-1|O cells|O .|O 
Staurosporine|O ,|O a|O broad|O spectrum|O PKC|gene-protein inhibitor|O ,|O was|O found|O to|O inhibit|O both|O spontaneous|O and|O euxanthone|O -|O induced|O neuritogenesis|O in|O BU-1|O cells|O .|O 
A|O significant|O reduction|O of|O the|O euxanthone|O -|O induced|O neuritogenic|O effect|O was|O also|O observed|O when|O the|O PKC|gene-protein isoform|gene-protein -|O specific|O inhibitor|O Go6976|O was|O included|O in|O the|O culture|O .|O 
These|O results|O suggest|O that|O the|O euxanthone|O -|O induced|O differentiation|O of|O the|O neuroblastoma|O BU-1|O cells|O may|O be|O mediated|O through|O the|O differential|O expression|O of|O PKC|gene-protein -|gene-protein alpha|gene-protein ,|O -|gene-protein beta|gene-protein ,|O -|gene-protein delta|gene-protein ,|O -|gene-protein lambda|gene-protein and|O -|gene-protein zeta|gene-protein isoforms|O .|O 
Activity|O of|O alpha-secretase|gene-protein as|O the|O common|O final|O effector|O of|O protein|gene-protein kinase|gene-protein C|gene-protein -|O dependent|O and|O -|O independent|O modulation|O of|O amyloid|gene-protein precursor|gene-protein protein|gene-protein metabolism|O .|O 
The|O metabolic|O fate|O of|O the|O amyloid|gene-protein precursor|gene-protein protein|gene-protein (|O APP|gene-protein )|O is|O one|O of|O the|O key|O factors|O in|O the|O pathogenesis|O of|O Alzheimer|O 's|O disease|O (|O AD|O )|O .|O 
A|O complex|O cellular|O mechanism|O regulates|O the|O rate|O at|O which|O the|O precursor|O is|O cleaved|O by|O alpha-secretase|gene-protein and|O released|O as|O soluble|O protein|O in|O the|O extracellular|O space|O .|O 
We|O show|O here|O that|O alpha-secretase|gene-protein constitutes|O the|O common|O final|O effector|O of|O several|O independent|O means|O of|O stimulation|O of|O soluble|gene-protein APP|gene-protein (|O sAPP|gene-protein )|O release|O .|O 
The|O release|O of|O sAPP|gene-protein by|O alpha-secretase|gene-protein resembles|O that|O of|O several|O other|O membrane|O -|O bound|O proteins|O with|O soluble|O counterparts|O ,|O a|O process|O that|O is|O sensitive|O to|O matrix|gene-protein metalloprotease|gene-protein inhibitors|O .|O 
The|O hydroxamic|O acid|O -|O based|O compound|O KD-IX-73-4|O inhibits|O phorbol|O ester|O -|O mediated|O sAPP|gene-protein release|O from|O COS|O cells|O with|O an|O IC50|O of|O 8|O microM|O ,|O consistent|O with|O previous|O data|O for|O the|O same|O compound|O against|O leukocyte|O L-selectin|gene-protein shedding|O .|O 
Beyond|O direct|O protein|gene-protein kinase|gene-protein C|gene-protein (|O PKC|gene-protein )|O activation|O we|O show|O that|O KD-IX-73-4|O inhibits|O also|O receptor|O -|O mediated|O sAPP|gene-protein release|O induced|O by|O carbachol|O in|O SH-SY5Y|O cells|O and|O by|O bradykinin|gene-protein in|O human|O skin|O fibroblasts|O ,|O with|O the|O latter|O being|O a|O PKC|gene-protein -|O independent|O mechanism|O .|O 
Altogether|O these|O data|O suggest|O that|O all|O pharmacological|O means|O of|O stimulating|O sAPP|gene-protein release|O converge|O to|O a|O hydroxamic|O acid|O -|O based|O inhibitor|O -|O sensitive|O proteolytic|O enzyme|O .|O 
Moreover|O ,|O because|O KD-IX-73-4|O was|O effective|O in|O the|O inhibition|O of|O stimulated|O but|O not|O constitutive|O sAPP|gene-protein release|O ,|O these|O data|O suggest|O the|O existence|O of|O different|O enzymes|O regulating|O the|O two|O metabolic|O pathways|O leading|O to|O sAPP|gene-protein secretion|O .|O 
The|O p73|gene-rna gene|O is|O less|O involved|O in|O the|O development|O but|O involved|O in|O the|O progression|O of|O neuroblastoma|O .|O 
We|O performed|O expression|O ,|O mutation|O ,|O loss|O of|O heterozygosity|O (|O LOH|O )|O and|O fluorescence|O in|O situ|O hybridization|O (|O FISH|O )|O analyses|O of|O the|O p73|gene-rna gene|O in|O neuroblastomas|O (|O NBs|O )|O .|O 
Reverse|O transcription|O -|O polymerase|gene-protein chain|O reaction|O (|O RT|O -|O PCR|O )|O using|O primers|O which|O can|O detect|O both|O the|O p73alpha|gene-rna and|O p73beta|gene-rna transcripts|O was|O performed|O on|O 30|O fresh|O NBs|O and|O 22|O NB|O cell|O lines|O .|O 
Aberrant|O expression|O of|O the|O p73|gene-rna gene|O was|O found|O in|O 4|O (|O 25|O %|O )|O of|O 16|O primary|O tumors|O found|O by|O mass|O screening|O and|O in|O 10|O (|O 71.4|O %|O )|O of|O 14|O primary|O tumors|O found|O clinically|O .|O 
The|O rates|O of|O expression|O in|O these|O two|O types|O of|O tumors|O were|O significantly|O different|O (|O p|O =|O 0.026|O ,|O Fisher|O 's|O exact|O test|O )|O .|O 
The|O incidence|O of|O aberrant|O expression|O of|O the|O p73|gene-rna gene|O was|O significantly|O higher|O in|O stage|O IV|O patients|O than|O in|O stages|O I|O ,|O II|O ,|O III|O plus|O IVS|O patients|O (|O p|O =|O 0.0236|O ,|O Fisher|O 's|O exact|O test|O )|O .|O 
No|O homozygous|O deletions|O or|O rearrangements|O of|O the|O p73|gene-rna gene|O were|O found|O in|O any|O samples|O examined|O .|O 
In|O addition|O to|O the|O polymorphism|O in|O exon|O 2|O ,|O a|O silent|O mutation|O (|O codon|O 336|O GCC|O /|O GCT|O )|O was|O found|O in|O one|O primary|O tumor|O .|O 
LOH|O of|O the|O p73|gene-rna gene|O was|O detected|O in|O 5|O (|O 15|O %|O )|O of|O 33|O primary|O NBs|O using|O PCR|O -|O LOH|O analysis|O .|O 
FISH|O analysis|O showed|O that|O all|O 17|O NB|O cell|O lines|O used|O in|O this|O study|O revealed|O allelic|O loss|O of|O the|O p73|gene-rna gene|O ,|O while|O most|O of|O them|O expressed|O the|O p73|gene-rna gene|O .|O 
These|O results|O suggest|O that|O the|O p73|gene-rna gene|O is|O not|O monoallelically|O expressed|O in|O NB|O .|O We|O conclude|O that|O the|O p73|gene-rna gene|O is|O less|O involved|O in|O the|O development|O but|O involved|O in|O the|O progression|O of|O neuroblastoma|O .|O 
Two|O isoforms|O of|O gonadotropin|gene-protein -|gene-protein releasing|gene-protein hormone|gene-protein are|O coexpressed|O in|O neuronal|O cell|O lines|O .|O 
GnRH-I|gene-protein serves|O as|O the|O neuropeptide|O that|O regulates|O mammalian|O reproduction|O .|O 
Recently|O ,|O several|O groups|O have|O identified|O in|O the|O brain|O of|O rodents|O ,|O monkeys|O ,|O and|O humans|O a|O second|O isoform|O of|O GnRH|gene-protein (|O GnRH-II|gene-protein )|O whose|O structure|O is|O 70|O %|O identical|O to|O that|O of|O GnRH-I|gene-protein .|O 
In|O this|O study|O we|O demonstrate|O for|O the|O first|O time|O human|O and|O mouse|O neuronal|O cell|O lines|O that|O express|O both|O GnRH-I|gene-protein and|O GnRH-II|gene-protein .|O 
Following|O the|O screening|O of|O several|O human|O neuronal|O cell|O lines|O by|O RT|O -|O PCR|O and|O Southern|O hybridization|O ,|O we|O demonstrated|O that|O two|O cell|O lines|O ,|O TE-671|O medulloblastoma|O and|O LAN-1|O neuroblastoma|O cells|O ,|O coexpress|O messenger|O RNA|O encoding|O the|O two|O isoforms|O of|O GnRH|gene-protein .|O 
Nucleotide|O sequencing|O indicated|O that|O the|O complementary|O DNA|O fragments|O are|O identical|O to|O those|O of|O the|O known|O human|O GnRH-I|gene-protein and|O GnRH-II|gene-protein sequences|O .|O 
Extracts|O obtained|O from|O the|O TE-671|O and|O LAN-1|O cell|O lines|O as|O well|O as|O from|O the|O immortalized|O mouse|O hypothalamic|O GT1-7|O neuronal|O cell|O line|O were|O found|O to|O contain|O the|O two|O isoforms|O of|O GnRH|gene-protein ,|O which|O exhibited|O identical|O chromatographic|O properties|O as|O synthetic|O GnRH-I|gene-protein and|O GnRH-II|gene-protein ,|O in|O HPLC|O followed|O by|O specific|O RIAs|O .|O 
Furthermore|O ,|O double|O immunofluorescence|O studies|O demonstrated|O the|O two|O GnRH|gene-protein isoforms|O in|O LAN-1|O ,|O TE-671|O ,|O and|O GT1-7|O cells|O .|O 
The|O identification|O of|O neuronal|O cell|O lines|O expressing|O both|O GnRH-I|gene-protein and|O GnRH-II|gene-protein provides|O tools|O for|O studying|O the|O differential|O regulation|O of|O gene|O expression|O and|O secretion|O and|O for|O studying|O the|O interaction|O between|O the|O two|O isoforms|O .|O 
Such|O studies|O may|O contribute|O to|O elucidation|O of|O the|O physiological|O functions|O of|O GnRH-II|gene-protein ,|O which|O are|O still|O unknown|O .|O 
Gene|O expression|O profile|O in|O early|O stage|O of|O retinoic|O acid|O -|O induced|O differentiation|O of|O human|O SH-SY5Y|O neuroblastoma|O cells|O .|O 
PURPOSE|O :|O 
The|O human|O SH-SY5Y|O cell|O line|O is|O an|O established|O model|O for|O retinoic|O acid|O (|O RA|O )|O -|O induced|O neural|O differentiation|O .|O 
We|O employed|O a|O broad|O human|O 15K|O microarray|O (|O 15,000|O genes|O )|O and|O focused|O Neuroarray|O (|O 1152|O genes|O )|O to|O examine|O changes|O in|O gene|O expression|O early|O in|O the|O process|O of|O differentiation|O (|O 6|O hr|O )|O ,|O before|O morphology|O or|O growth|O changes|O are|O observed|O .|O 
METHODS|O :|O 
33|O P|O -|O labeled|O CDNA|O probes|O prepared|O from|O RNA|O extracts|O of|O RA|O -|O treated|O and|O control|O cultures|O were|O hybridized|O to|O array|O membranes|O ,|O and|O levels|O of|O expression|O were|O quantified|O and|O compared|O .|O 
RESULTS|O :|O 
In|O the|O 15K|O array|O ,|O 19|O %|O of|O the|O genes|O were|O decreased|O (|O 0.4|O %|O were|O named|O genes|O and|O the|O remainder|O were|O expressed|O sequence|O tags|O (|O ESTs|O )|O or|O unknowns|O )|O ,|O and|O 9|O %|O were|O increased|O (|O 4.2|O %|O named|O genes|O )|O .|O 
In|O the|O Neuroarray|O ,|O 3|O %|O were|O decreased|O and|O 8|O %|O were|O increased|O .|O 
CONCLUSIONS|O :|O 
Summary|O gene|O profiles|O are|O presented|O ,|O which|O include|O transcription|O factors|O ,|O genes|O associated|O with|O cell|O cycle|O ,|O cell|O shape|O ,|O neurotransmission|O ,|O intermediary|O filaments|O ,|O and|O others|O .|O 
The|O prevalence|O of|O down|O -|O regulated|O genes|O in|O the|O broad|O 15K|O array|O and|O up|O -|O regulated|O genes|O in|O the|O neuro|O -|O focused|O array|O suggests|O a|O pattern|O shift|O in|O gene|O expression|O associated|O with|O differentiation|O .|O 
The|O predominance|O of|O ESTs|O among|O the|O down|O -|O regulated|O genes|O indicates|O a|O great|O number|O of|O as|O -|O yet|O -|O unidentified|O genes|O are|O repressed|O in|O early|O stage|O neural|O differentiation|O .|O 
Propagation|O of|O the|O human|O polyomavirus|O ,|O JCV|O ,|O in|O human|O neuroblastoma|O cell|O lines|O .|O 
Susceptibility|O to|O infection|O by|O the|O human|O polyomavirus|O ,|O JCV|O ,|O is|O determined|O by|O intracellular|O mechanisms|O which|O control|O transcription|O and|O replication|O .|O 
Originally|O thought|O to|O propagate|O well|O only|O in|O human|O cells|O of|O oligodendroglial|O lineage|O ,|O JCV|O has|O recently|O been|O shown|O to|O infect|O astrocytes|O ,|O astrogliomas|O ,|O and|O a|O neuroblastoma|O cell|O line|O .|O 
The|O data|O reported|O here|O describe|O two|O cell|O types|O that|O have|O been|O subcultured|O from|O a|O human|O neuroblastoma|O cell|O line|O ,|O SK-N-SH|O .|O 
The|O SH-SY5Y|O subclone|O displays|O neuronal|O phenotypes|O and|O is|O not|O susceptible|O to|O JCV|O infection|O ,|O while|O the|O SH-EP|O subclone|O displays|O glial|O cell|O phenotypes|O and|O is|O susceptible|O to|O infection|O .|O 
Binding|O of|O nuclear|O proteins|O from|O the|O permissive|O SH-EP|O cells|O to|O the|O nuclear|gene-protein factor-1|gene-protein (|O NF-1|gene-protein )|O site|O in|O the|O JCV|O regulatory|O DNA|O sequences|O results|O in|O a|O gel|O shift|O pattern|O that|O is|O different|O from|O the|O nonpermissive|O SH-SY5Y|O cell|O proteins|O .|O 
Northern|O analysis|O of|O mRNA|O for|O the|O four|O classes|O of|O NF-1|gene-protein proteins|O showed|O a|O predominance|O of|O the|O NF-1|gene-protein /|O X|O class|O in|O SH-EP|O cells|O similar|O to|O the|O highly|O permissive|O human|O fetal|O glial|O cells|O .|O 
Very|O low|O levels|O of|O mRNA|O for|O NF-1|gene-protein /|O X|O were|O seen|O in|O the|O nonpermissive|O SH-SY5Y|O cells|O ,|O similar|O to|O that|O seen|O for|O the|O nonpermissive|O HeLa|O cells|O .|O 
Several|O other|O cell|O lines|O tested|O that|O were|O permissive|O for|O JCV|O infection|O also|O showed|O synthesis|O of|O the|O NF-1|gene-protein /|O X|O class|O of|O proteins|O .|O 
SH-EP|O cells|O represent|O a|O cell|O line|O in|O a|O glial|O cell|O lineage|O which|O is|O susceptible|O to|O JCV|O multiplication|O .|O 
These|O cells|O may|O be|O a|O useful|O cell|O culture|O system|O for|O the|O investigation|O of|O DNA|O binding|O factors|O which|O correlates|O with|O viral|O susceptibility|O .|O 
Induction|O of|O thrombospondin|gene-protein 1|gene-protein by|O retinoic|O acid|O is|O important|O during|O differentiation|O of|O neuroblastoma|O cells|O .|O 
Neuroblastoma|O ,|O a|O malignant|O neoplasm|O that|O arises|O in|O the|O adrenal|O medulla|O or|O sympathetic|O ganglion|O ,|O is|O one|O of|O the|O most|O common|O solid|O tumors|O of|O childhood|O .|O 
Reports|O that|O neuroblastomas|O spontaneously|O mature|O to|O form|O benign|O ganglioneuromas|O have|O prompted|O investigations|O into|O the|O efficacy|O of|O using|O agents|O that|O induce|O neuronal|O differentiation|O in|O the|O treatment|O of|O this|O malignancy|O .|O 
Retinoic|O acid|O is|O one|O agent|O in|O particular|O that|O has|O been|O shown|O to|O induce|O growth|O inhibition|O and|O terminal|O differentiation|O of|O neuroblastoma|O cell|O lines|O in|O vitro|O .|O 
Using|O the|O human|O neuroblastoma|O cell|O line|O SMH-KCNR|O ,|O we|O have|O investigated|O the|O role|O of|O the|O extracellular|O matrix|O protein|O thrombospondin|gene-protein in|O retinoic|O acid|O induced|O neuroblastoma|O differentiation|O .|O 
Treatment|O with|O retinoic|O acid|O results|O in|O a|O rapid|O induction|O (|O within|O 4|O h|O )|O of|O thrombospondin|gene-protein (|O TSP|gene-protein )|O message|O which|O is|O independent|O of|O intervening|O protein|O synthesis|O and|O superinducible|O in|O the|O presence|O of|O cycloheximide|O .|O 
This|O suggests|O that|O TSP|gene-protein functions|O as|O a|O retinoic|O acid|O inducible|O immediate|O early|O response|O gene|O .|O 
A|O concomitant|O increase|O in|O both|O cell|O associated|O and|O soluble|O forms|O of|O TSP|gene-protein protein|O can|O be|O detected|O within|O 24|O h|O of|O retinoic|O acid|O treatment|O .|O 
A|O functional|O role|O for|O TSP|gene-protein in|O SMH-KCNR|O differentiation|O was|O established|O in|O experiments|O which|O showed|O that|O exposure|O to|O anti|gene-protein -|gene-protein TSP|gene-protein monoclonal|gene-protein antibodies|gene-protein delay|O retinoic|O acid|O differentiation|O for|O 48|O h|O .|O 
At|O the|O time|O the|O cells|O overcome|O the|O effects|O of|O TSP|gene-protein inhibition|O ,|O laminin|gene-protein production|O becomes|O maximal|O .|O 
Treatment|O of|O the|O cells|O with|O a|O combination|O of|O anti|gene-protein -|gene-protein TSP|gene-protein and|O antilaminin|gene-protein antibodies|gene-protein results|O in|O complete|O inhibition|O of|O differentiation|O .|O 
Cell|O -|O type|O non|O -|O selective|O transcription|O of|O mouse|O and|O human|O genes|O encoding|O neural|gene-protein -|gene-protein restrictive|gene-protein silencer|gene-protein factor|gene-protein .|O 
Neural|O -|O restrictive|O silencer|O (|O NRS|O )|O has|O been|O identified|O in|O at|O least|O twenty|O neuron|O -|O specific|O genes|O ,|O and|O its|O nuclear|O DNA|O -|O binding|O factor|O ,|O NRSF|gene-protein (|O also|O known|O as|O RE1|gene-protein -|gene-protein silencing|gene-protein transcription|gene-protein factor|gene-protein (|O REST|gene-protein )|O )|O ,|O has|O been|O cloned|O from|O human|O and|O rat|O ,|O and|O was|O shown|O to|O repress|O transcription|O by|O recruiting|O corepressors|O mSin3|O and/or|O CoREST|O via|O its|O N|O -|O and|O C|O -|O terminal|O domains|O ,|O leading|O to|O chromatin|gene-protein reorganization|O by|O mSin3|O -|O associated|O histone|gene-protein deacetylase|gene-protein ,|O HDAC|gene-protein .|O 
However|O ,|O it|O is|O largely|O unknown|O how|O NRSF|gene-rna gene|O expression|O is|O regulated|O .|O 
To|O elucidate|O the|O mechanisms|O for|O gene|O expression|O of|O NRSF|gene-rna ,|O we|O isolated|O the|O transcriptional|O unit|O of|O the|O NRSF|gene-rna gene|O from|O mouse|O and|O human|O ,|O identified|O three|O 5|O '|O -|O non|O -|O coding|O exons|O in|O addition|O to|O three|O coding|O exons|O ,|O determined|O transcription|O start|O sites|O ,|O and|O identified|O two|O basal|O promoter|O activities|O in|O the|O upstream|O of|O the|O first|O two|O non|O -|O coding|O exons|O .|O 
Both|O promoters|O functioned|O equally|O in|O neuronal|O and|O non|O -|O neuronal|O cells|O ,|O suggesting|O that|O levels|O of|O initial|O transcripts|O of|O NRSF|gene-rna gene|O are|O similar|O in|O neuronal|O and|O non|O -|O neuronal|O cells|O .|O 
These|O results|O suggest|O that|O the|O level|O of|O NRSF|gene-rna gene|O expression|O is|O not|O determined|O by|O transcription|O per|O se|O ,|O and|O rather|O is|O modulated|O at|O the|O post|O -|O transcriptional|O level|O ,|O e.g.|O splicing|O ,|O mRNA|O stability|O ,|O and/or|O post|O -|O translational|O modifications|O ,|O in|O a|O cell|O -|O specific|O manner|O .|O 
Consistent|O with|O this|O idea|O ,|O NRSF|gene-protein protein|O was|O apparently|O present|O even|O in|O neuronal|O cells|O and|O tissues|O ,|O but|O was|O unable|O to|O bind|O to|O the|O NRS|O element|O ,|O suggesting|O that|O NRSF|gene-protein is|O regulated|O at|O least|O in|O part|O post|O -|O translationally|O .|O 
The|O mechanism|O for|O the|O rapid|O desensitization|O in|O bradykinin|O -|O stimulated|O inositol|O monophosphate|O production|O in|O NG108-15|O cells|O involves|O interaction|O of|O a|O single|O receptor|O with|O multiple|O signaling|O pathways|O .|O 
We|O have|O previously|O shown|O that|O the|O mechanism|O for|O the|O rapid|O desensitization|O in|O bradykinin|O (|O BDK|O )|O -|O stimulated|O inositol|O monophosphate|O (|O IP|O )|O production|O in|O NG108-15|O cells|O involves|O both|O a|O rapid|O loss|O of|O receptors|O from|O the|O cell|O surface|O and|O an|O uncoupling|O of|O the|O receptor|O :|O G-protein|gene-protein :|O phospholipase|gene-protein C|gene-protein (|O PLC|gene-protein )|O signaling|O process|O ,|O with|O protein|gene-protein kinase|gene-protein C|gene-protein (|O PKC|gene-protein )|O activation|O playing|O a|O role|O only|O at|O a|O postreceptor|O level|O (|O Wolsing|O and|O Rosenbaum|O ,|O 1991|O )|O .|O 
In|O contrast|O to|O BDK|O ,|O a|O 5|O -|O min|O pretreatment|O with|O the|O BDK|gene-protein receptor|gene-protein "|O antagonist|O "|O NPC-567|O is|O sufficient|O to|O cause|O a|O substantial|O decrease|O in|O the|O subsequent|O BDK|O maximal|O response|O (|O Emax|O )|O without|O altering|O either|O the|O BDK|O potency|O (|O EC50|O )|O or|O the|O BDK|gene-protein receptor|gene-protein number|O .|O 
An|O 18|O -|O hr|O pretreatment|O of|O the|O cells|O with|O 200|O ng|O /|O ml|O pertussis|gene-protein toxin|gene-protein (|O PT|gene-protein )|O does|O not|O alter|O the|O BDK|O response|O (|O Fold|O stim|O =|O 2.36|O +/-|O 0.18|O vs.|O 2.00|O +/-|O 0.25|O in|O controls|O ,|O N|O =|O 4|O )|O ,|O reiterating|O previous|O observations|O that|O BDK|O -|O stimulated|O IP|O production|O in|O this|O cell|O line|O is|O mediated|O by|O a|O pertussis|gene-protein toxin|gene-protein (|O PT|gene-protein )|O -|O insensitive|O G-protein|gene-protein .|O 
However|O ,|O PT|gene-protein pretreatment|O significantly|O (|O P|O <|O .05|O )|O attenuates|O the|O receptor|O loss|O that|O accompanies|O the|O desensitization|O process|O .|O 
Taken|O together|O ,|O these|O data|O imply|O that|O the|O BDK|gene-protein receptor|gene-protein in|O NG108-15|O cells|O interacts|O with|O both|O PT|gene-protein -|O sensitive|O and|O PT|gene-protein -|O insensitive|O G-proteins|gene-protein .|O 
Because|O NPC-567|O pretreatment|O results|O in|O a|O desensitization|O that|O is|O not|O accompanied|O by|O receptor|O loss|O ,|O it|O appears|O that|O NPC-567|O is|O able|O to|O facilitate|O an|O agonistic|O interaction|O with|O only|O the|O PT|gene-protein -|O insensitive|O G-proteins|gene-protein that|O are|O available|O to|O the|O receptor|O .|O 
Muscle|gene-protein creatine|gene-protein kinase|gene-protein isoenzyme|gene-protein expression|O in|O adult|O human|O brain|O .|O 
Previous|O studies|O have|O suggested|O that|O MM|gene-protein creatine|gene-protein kinase|gene-protein is|O a|O muscle|O -|O specific|O protein|O and|O is|O not|O present|O in|O adult|O brain|O tissue|O .|O 
We|O have|O isolated|O a|O protein|O from|O human|O brain|O with|O an|O apparent|O molecular|O weight|O of|O 43,000|O as|O determined|O by|O sodium|O dodecyl|O sulfate-polyacrylamide|O gel|O electrophoresis|O which|O is|O identical|O to|O the|O muscle|gene-protein M|gene-protein creatine|gene-protein kinase|gene-protein isoenzyme|gene-protein subunit|O at|O all|O 30|O sequenced|O amino|O acid|O residues|O and|O possesses|O creatine|gene-protein kinase|gene-protein enzymatic|O activity|O following|O nondenaturing|O agarose|O -|O gel|O electrophoresis|O .|O 
Immunohistochemistry|O localizes|O M|gene-protein creatine|gene-protein kinase|gene-protein to|O discrete|O areas|O of|O adult|O human|O brain|O .|O 
Northern|O blot|O analysis|O of|O both|O total|O and|O poly(A)|O -|O selected|O RNA|O isolated|O from|O brain|O did|O not|O detect|O M|gene-rna creatine|gene-rna kinase|gene-rna mRNA|O .|O 
However|O ,|O polymerase|gene-protein chain|O reaction|O amplification|O of|O cDNA|O synthesized|O from|O human|O placenta|O ,|O heart|O ,|O and|O brain|O mRNA|O detected|O M|gene-rna creatine|gene-rna kinase|gene-rna message|O in|O both|O heart|O and|O brain|O but|O not|O placenta|O which|O contains|O no|O detectable|O M|gene-protein creatine|gene-protein kinase|gene-protein protein|O .|O 
N1E115|O and|O NS20Y|O ,|O mouse|O neuroblastoma|O cell|O lines|O which|O have|O been|O used|O as|O models|O of|O neural|O cell|O differentiation|O ,|O were|O found|O also|O to|O express|O MM|gene-protein creatine|gene-protein kinase|gene-protein .|O 
Moreover|O ,|O a|O transiently|O transfected|O reporter|O gene|O with|O 4,800|O base|O pairs|O of|O M|gene-rna creatine|gene-rna kinase|gene-rna upstream|O region|O fused|O to|O chloramphenicol|gene-protein acetyltransferase|gene-protein was|O expressed|O during|O differentiation|O of|O these|O neural|O cell|O lines|O .|O 
In|O summary|O ,|O MM|gene-protein creatine|gene-protein kinase|gene-protein is|O present|O in|O human|O brain|O and|O we|O suggest|O the|O M|gene-rna creatine|gene-rna kinase|gene-rna upstream|O region|O is|O sufficient|O to|O modulate|O M|gene-protein creatine|gene-protein kinase|gene-protein expression|O in|O certain|O neuronal|O cells|O and|O may|O be|O regulated|O independently|O from|O other|O muscle|O genes|O .|O 
Transcriptional|O regulation|O of|O the|O human|O cholecystokinin|gene-rna gene|O :|O composite|O action|O of|O upstream|gene-protein stimulatory|gene-protein factor|gene-protein ,|O Sp1|gene-protein ,|O and|O members|O of|O the|O CREB|gene-protein /|O ATF-AP-1|gene-protein family|O of|O transcription|O factors|O .|O 
We|O have|O examined|O cis|O -|O elements|O and|O trans|O -|O acting|O factors|O that|O regulate|O transcription|O of|O the|O human|O cholecystokinin|gene-rna (|O CCK|gene-rna )|O gene|O .|O 
Transient|O expression|O of|O CCK|gene-rna promoter|O deletion|O constructs|O in|O human|O SK-N-MC|O neuroblastoma|O cells|O depicted|O positive|O cis|O -|O elements|O between|O the|O positions|O -|O 100|O to|O -|O 92|O ,|O -|O 84|O to|O -|O 74|O ,|O and|O -|O 58|O to|O -|O 37|O ,|O 5|O '|O to|O the|O transcription|O initiation|O site|O .|O 
Correspondingly|O ,|O DNase|gene-protein I|gene-protein protection|O analysis|O showed|O that|O transacting|O factors|O bound|O to|O elements|O within|O these|O regions|O .|O 
The|O sequences|O encompass|O a|O putative|O basic|O helix|O -|O loop|O -|O helix|O leucine|O zipper|O (|O bHLH-ZIP|O )|O element|O ,|O an|O Sp1|gene-protein element|O ,|O and|O a|O combined|O cAMP|O -|O and|O TPA|O -|O responsive|O element|O (|O CRE|gene-protein /|O TRE|gene-protein )|O at|O positions|O -|O 97|O to|O -|O 92|O ,|O -|O 39|O to|O -|O 34|O ,|O and|O -|O 80|O to|O -|O 73|O ,|O respectively|O .|O 
Mobility|O and|O supershift|O assays|O demonstrated|O that|O upstream|gene-protein stimulatory|gene-protein factor|gene-protein (|O USF|gene-protein )|O and|O Sp1|gene-protein bind|O to|O the|O former|O elements|O and|O competition|O experiments|O confirmed|O that|O CREB|gene-protein /|O ATF|gene-protein and|O AP-1|gene-protein bind|O to|O the|O CRE|gene-protein /|O TRE|gene-protein element|O .|O 
Mutation|O of|O the|O bHLH-ZIP|O and|O CRE|gene-protein /|O TRE|gene-protein elements|O decreased|O the|O activity|O of|O the|O promoter|O by|O 65|O %|O and|O 42|O %|O ,|O respectively|O .|O 
The|O activity|O of|O the|O promoter|O was|O increased|O six|O -|O and|O two|O -|O fold|O after|O stimulation|O with|O forskolin|O and|O TPA|O ,|O respectively|O .|O 
Stimulation|O was|O eliminated|O after|O mutation|O of|O the|O CRE|gene-protein /|O TRE|gene-protein element|O .|O 
Co|O -|O transfection|O experiments|O with|O pRSV-c-jun|O ,|O pSV-fos|O ,|O and|O pRC-RSV-|O CREB|gene-protein constructs|O showed|O that|O jun|gene-protein ,|O CREB|gene-protein ,|O and|O AP-1|gene-protein stimulate|O transcription|O .|O 
We|O conclude|O that|O USF|gene-protein ,|O Sp1|gene-protein ,|O and|O members|O of|O the|O CREB|gene-protein /|O ATF|gene-protein and|O AP-1|gene-protein family|O of|O transcription|O factors|O are|O the|O major|O determinants|O of|O CCK|gene-rna gene|O transcription|O .|O 
Calcium|O requirement|O for|O cGMP|O production|O during|O muscarinic|O activation|O of|O N1E-115|O neuroblastoma|O cells|O .|O 
Muscarinic|O agonists|O elicit|O large|O increases|O in|O intracellular|O Ca2+|O and|O guanosine|O 3',5'-cyclic|O monophosphate|O (|O cGMP|O )|O in|O N1E-115|O neuroblastoma|O cells|O .|O 
Both|O signals|O are|O blocked|O in|O cells|O loaded|O with|O the|O Ca2+|O buffer|O 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic|O acid|O showing|O that|O the|O increase|O in|O intracellular|O Ca2+|O concentration|O (|O [Ca2+]i|O )|O is|O necessary|O to|O stimulate|O cGMP|O accumulation|O .|O 
Inhibition|O of|O nitric|gene-protein oxide|gene-protein synthase|gene-protein (|O NOS|gene-protein )|O blocks|O the|O cGMP|O response|O without|O affecting|O the|O peak|O amplitude|O of|O the|O intracellular|O Ca2+|O signal|O ,|O and|O it|O is|O concluded|O that|O Ca(2+)|O -|O dependent|O activation|O of|O NOS|gene-protein is|O required|O for|O cGMP|O production|O .|O 
cGMP|O accumulation|O is|O reduced|O by|O 60|O %|O when|O cells|O are|O bathed|O in|O Ca(2+)|O -|O free|O saline|O ,|O but|O the|O peak|O change|O in|O [Ca2+]i|O is|O not|O affected|O .|O 
This|O suggests|O that|O Ca2+|O influx|O is|O strongly|O coupled|O to|O the|O activation|O of|O cGMP|O production|O ,|O even|O though|O it|O makes|O a|O smaller|O contribution|O to|O the|O intracellular|O Ca2+|O signal|O than|O does|O Ca2+|O release|O .|O 
Thapsigargin|O ,|O which|O releases|O Ca2+|O from|O intracellular|O stores|O ,|O activates|O Ca2+|O influx|O and|O increases|O cGMP|O .|O 
The|O cGMP|O increase|O is|O transient|O and|O follows|O approximately|O the|O same|O time|O course|O as|O Ca2+|O store|O depletion|O .|O 
Ca2+|O influx|O remains|O activated|O after|O store|O depletion|O ,|O however|O ,|O which|O indicates|O that|O influx|O alone|O cannot|O sustain|O cGMP|O production|O .|O 
It|O is|O concluded|O that|O summation|O of|O Ca2+|O influx|O and|O Ca2+|O release|O is|O necessary|O to|O reach|O a|O threshold|O Ca2+|O level|O needed|O to|O stimulate|O cGMP|O accumulation|O .|O 
Because|O of|O the|O large|O contribution|O from|O Ca2+|O influx|O ,|O we|O suggest|O that|O NOS|gene-protein or|O a|O cofactor|O necessary|O for|O its|O activation|O may|O be|O located|O close|O to|O Ca2+|O channels|O in|O the|O membrane|O .|O 
Transcriptional|O regulation|O of|O the|O human|O ADP-ribosylation|gene-rna factor|gene-rna 5|gene-rna (|O ARF5|gene-rna )|O gene|O .|O 
Hybridization|O of|O a|O blot|O containing|O 50|O human|O RNAs|O with|O an|O ADP-ribosylation|gene-rna factor|gene-rna 5|gene-rna -|O specific|O (|O ARF5|gene-rna )|O oligonucleotide|O probe|O revealed|O that|O the|O ARF5|gene-rna gene|O is|O expressed|O in|O all|O tissues|O ;|O however|O ,|O the|O level|O of|O expression|O varies|O significantly|O with|O highest|O levels|O in|O pancreas|O ,|O pituitary|O gland|O ,|O and|O placenta|O .|O 
The|O 5|O '|O -|O flanking|O region|O of|O the|O human|O ARF5|gene-rna gene|O lacks|O a|O TATA|O or|O CAAT|O box|O and|O is|O highly|O GC|O -|O rich|O .|O 
Primer|O extension|O analysis|O indicates|O that|O transcription|O initiates|O at|O a|O discrete|O site|O 62|O bp|O 5|O '|O to|O the|O start|O of|O translation|O ;|O however|O ,|O the|O sequence|O surrounding|O the|O transcription|O initiation|O site|O does|O not|O resemble|O the|O initiator|O elements|O described|O for|O other|O TATA|O -|O less|O genes|O .|O 
Transient|O transfection|O of|O ARF5|gene-rna /|O luciferase|gene-rna deletion|O constructs|O into|O human|O IMR-32|O neuroblastoma|O cells|O revealed|O that|O sequences|O within|O 169|O bp|O of|O the|O transcription|O initiation|O site|O were|O necessary|O for|O full|O expression|O .|O 
Two|O GC|O boxes|O within|O this|O region|O were|O modified|O by|O site|O -|O directed|O mutagenesis|O and|O found|O to|O be|O critical|O for|O expression|O of|O the|O reporter|O constructs|O .|O 
Electrophoretic|O mobility|O -|O shift|O assays|O demonstrated|O specific|O DNA|O /|O protein|O complexes|O could|O be|O formed|O with|O oligonucleotides|O containing|O each|O of|O the|O GC|O boxes|O and|O these|O complexes|O could|O be|O effectively|O competed|O by|O oligonucleotides|O containing|O either|O ARF5|gene-rna Sp1|gene-protein site|O or|O by|O an|O oligonucleotide|O containing|O a|O previously|O characterized|O Sp1|gene-protein -|O binding|O sequence|O .|O 
The|O level|O of|O ARF5|gene-rna gene|O expression|O ,|O therefore|O ,|O is|O dependent|O upon|O Sp1|gene-protein or|O an|O Sp1|gene-protein -|O like|O factor|O but|O does|O not|O rely|O upon|O a|O canonical|O initiator|O element|O for|O accurate|O transcription|O initiation|O .|O 
Use|O of|O tumor|O -|O specific|O gene|O expression|O for|O the|O differential|O diagnosis|O of|O neuroblastoma|O from|O other|O pediatric|O small|O round|O -|O cell|O malignancies|O .|O 
The|O differential|O diagnosis|O of|O neuroblastoma|O from|O other|O small|O round|O -|O cell|O tumors|O of|O childhood|O ,|O although|O clinically|O of|O great|O importance|O ,|O is|O sometimes|O difficult|O due|O to|O the|O almost|O indistinguishable|O appearance|O of|O such|O tumors|O by|O conventional|O microscopy|O .|O 
Because|O neuroblastomas|O are|O characterized|O by|O the|O synthesis|O of|O catecholamines|O ,|O we|O investigated|O the|O possibility|O that|O expression|O of|O genes|O involved|O in|O this|O pathway|O could|O serve|O as|O a|O molecular|O marker|O for|O this|O disease|O .|O 
A|O reverse|gene-protein transcriptase|gene-protein polymerase|gene-protein chain|O reaction|O assay|O was|O used|O to|O analyze|O expression|O of|O tyrosine|gene-protein hydroxylase|gene-protein and|O dopa|gene-protein decarboxylase|gene-protein in|O 84|O pediatric|O malignancies|O including|O 55|O neuroblastomas|O ,|O 6|O Ewing|O 's|O sarcomas|O /|O primitive|O neuroectodermal|O tumors|O ,|O 7|O lymphomas|O ,|O 6|O leukemias|O ,|O 2|O rhabdomyosarcomas|O ,|O 6|O osteosarcomas|O ,|O and|O 2|O phaeochromocytomas|O .|O 
Of|O the|O 55|O neuroblastoma|O samples|O analyzed|O ,|O 54|O expressed|O clearly|O detectable|O levels|O of|O both|O genes|O .|O 
The|O one|O sample|O that|O did|O not|O express|O either|O of|O the|O genes|O was|O rediagnosed|O both|O clinically|O and|O by|O molecular|O genetic|O analysis|O as|O a|O Ewing|O 's|O sarcoma|O .|O 
Of|O the|O 29|O non|O -|O neuroblastoma|O tumor|O samples|O examined|O ,|O the|O only|O tumor|O samples|O that|O expressed|O clearly|O detectable|O levels|O of|O both|O tyrosine|gene-protein hydroxylase|gene-protein and|O dopa|gene-protein decarboxylase|gene-protein were|O phaeochromocytomas|O .|O 
Like|O neuroblastomas|O ,|O these|O tumors|O are|O characterized|O by|O high|O levels|O of|O catecholamines|O .|O 
These|O findings|O suggest|O that|O expression|O of|O genes|O involved|O in|O catecholamine|O biosynthesis|O may|O be|O useful|O for|O differentiating|O neuroblastoma|O from|O other|O small|O round|O -|O cell|O tumors|O of|O childhood|O .|O 
Differential|O protein|O expression|O induced|O by|O transient|O transfection|O of|O metallothionein-3|gene-rna gene|O in|O SH-SY5Y|O neuroblastoma|O cell|O line|O .|O 
Metallothionein-3|gene-protein (|O MT-3|gene-protein )|O ,|O also|O known|O as|O growth|gene-protein inhibitory|gene-protein factor|gene-protein (|O GIF|gene-protein )|O ,|O is|O predominantly|O expressed|O in|O central|O nervous|O system|O (|O CNS|O )|O .|O 
It|O belongs|O to|O the|O family|O of|O metallothionein|gene-protein (|O MT|gene-protein )|O but|O has|O several|O unique|O properties|O that|O are|O not|O shared|O by|O other|O family|O members|O such|O as|O MT-1|gene-protein /|O MT-2|gene-protein .|gene-protein 
In|O the|O past|O few|O years|O ,|O MT-3|gene-protein had|O been|O postulated|O to|O be|O a|O multipurpose|O protein|O which|O could|O play|O important|O neuromodulatory|O and|O neuroprotective|O roles|O in|O CNS|O besides|O the|O common|O roles|O of|O MTs|gene-protein .|O 
However|O ,|O the|O primary|O function|O of|O MT-3|gene-protein and|O the|O mechanism|O underlying|O its|O multiple|O functions|O were|O not|O elucidated|O so|O far|O .|O 
In|O present|O study|O ,|O human|O neuroblastoma|O cell|O line|O SH-SY5Y|O was|O employed|O to|O study|O the|O overall|O cellular|O protein|O changes|O induced|O by|O transient|O transfection|O of|O MT-3|gene-rna gene|O ,|O based|O on|O comparative|O proteome|O analysis|O .|O 
Averagely|O about|O 750|O spots|O were|O visualized|O by|O Coomassie|O staining|O in|O one|O 2D|O gel|O ,|O in|O which|O 17|O proteins|O were|O shown|O to|O display|O significant|O and|O reproducible|O changes|O by|O semiquantitative|O analysis|O with|O ImageMaster|O 2D|O Elite|O software|O .|O 
Among|O them|O ,|O 12|O proteins|O were|O up|O -|O regulated|O while|O other|O 5|O proteins|O were|O down|O -|O regulated|O .|O 
Using|O matrix|O -|O assisted|O laser|O desorption|O /|O ionization|O time|O -|O of|O -|O flight|O mass|O spectrometry|O ,|O 10|O proteins|O were|O further|O identified|O to|O be|O zinc|gene-protein finger|gene-protein protein|gene-protein ,|O glutamate|gene-protein transporter|gene-protein ,|O and|O enhancer|gene-protein protein|gene-protein ,|O etc.|O ,|O which|O were|O involved|O in|O several|O important|O pathways|O regulating|O the|O functions|O of|O central|O nervous|O system|O .|O 
The|O results|O showed|O that|O MT-3|gene-protein might|O exert|O its|O unique|O functions|O by|O regulating|O the|O expression|O of|O these|O proteins|O .|O 
Morphologic|O conversion|O of|O a|O neuroblastoma|O -|O derived|O cell|O line|O by|O E6|O -|O mediated|O p53|gene-protein degradation|O .|O 
Neuroblastoma|O -|O derived|O tumor|O cells|O ,|O unlike|O cells|O from|O other|O tumor|O types|O ,|O characteristically|O express|O a|O wildtype|O but|O cytoplasmically|O sequestered|O p53|gene-protein protein|O .|O 
To|O ascertain|O whether|O the|O p53|gene-protein in|O these|O cells|O retained|O any|O physiological|O activity|O ,|O we|O inactivated|O it|O in|O SK-N-SH|O cells|O ,|O a|O neuroblastoma|O -|O derived|O cell|O line|O ,|O by|O introducing|O the|O human|O papilloma|O virus|O type|O 16|O E6|gene-rna expression|gene-rna plasmid|gene-rna .|O 
Parent|O SK-N-SH|O cell|O cultures|O are|O composed|O of|O two|O cell|O types|O exhibiting|O characteristic|O morphologies|O designated|O neuroblastic|O (|O N-type|O )|O or|O substrate|O -|O adherent|O fibroblastic|O (|O S-type|O )|O cells|O ,|O both|O of|O which|O have|O been|O shown|O to|O spontaneously|O transdifferentiate|O or|O interconvert|O .|O 
We|O report|O here|O that|O down|O -|O regulation|O of|O p53|gene-protein resulted|O in|O conversion|O of|O SK-N-SH|O cells|O to|O the|O substrate|O -|O adherent|O fibroblast|O -|O like|O S-type|O cells|O .|O 
The|O morphologic|O conversion|O was|O accompanied|O by|O a|O loss|O of|O neurofilament|O expression|O ,|O a|O marker|O for|O the|O neuronal|O N-type|O cells|O ,|O an|O increase|O in|O the|O expression|O of|O vimentin|gene-protein ,|O and|O a|O lack|O of|O responsiveness|O to|O retinoic|O acid|O -|O induced|O neuronal|O differentiation|O .|O 
Importantly|O ,|O we|O did|O not|O observe|O N-type|O cells|O in|O the|O E6|O -|O transfected|O cell|O population|O ,|O suggesting|O that|O they|O were|O incapable|O of|O transdifferentiating|O to|O the|O N-type|O morphology|O .|O 
We|O also|O tested|O the|O ability|O of|O these|O E6|O -|O transfected|O S-type|O cells|O to|O form|O colonies|O in|O soft|O agar|O and|O observed|O a|O markedly|O reduced|O capacity|O of|O these|O cells|O to|O do|O so|O when|O compared|O with|O the|O parent|O and|O mutant|O E6|O -|O transfected|O cells|O .|O 
These|O results|O suggest|O that|O p53|gene-protein is|O required|O for|O the|O maintenance|O of|O the|O neuroblastic|O tumorigenic|O phenotype|O .|O 
Expression|O of|O MRP|gene-rna and|O cMOAT|gene-rna in|O childhood|O neuroblastomas|O and|O malignant|O liver|O tumors|O and|O its|O relevance|O to|O clinical|O behavior|O .|O 
Advanced|O neuroblastoma|O and|O malignant|O liver|O tumor|O are|O representative|O childhood|O cancers|O for|O which|O combined|O chemotherapy|O including|O cisplatin|O and|O doxorubicin|O is|O routinely|O performed|O .|O 
The|O prognosis|O of|O patients|O with|O tumors|O which|O develop|O multiple|O drug|O resistance|O (|O MDR|O )|O is|O unfavorable|O .|O 
To|O elucidate|O the|O role|O of|O multidrug|gene-protein resistance|gene-protein -|gene-protein associated|gene-protein protein|gene-protein (|O MRP|gene-protein )|O and|O canalicular|gene-protein multispecific|gene-protein organic|gene-protein anion|gene-protein transporter|gene-protein (|O cMOAT|gene-protein )|O in|O the|O clinical|O behavior|O of|O the|O tumors|O ,|O we|O examined|O 42|O neuroblastomas|O and|O 10|O malignant|O liver|O tumors|O for|O the|O expressions|O of|O MRP|gene-rna and|O cMOAT|gene-rna by|O quantitative|O RNA|O -|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O .|O 
The|O amplification|O and|O expression|O of|O N-myc|gene-rna oncogene|O in|O the|O neuroblastomas|O were|O also|O investigated|O .|O 
We|O found|O a|O close|O association|O between|O MRP|gene-rna and|O N-myc|gene-rna expression|O in|O each|O neuroblastoma|O sample|O but|O no|O significant|O relationship|O between|O MRP|gene-rna expression|O and|O the|O patients|O '|O outcome|O .|O 
The|O forced|O expression|O of|O N-myc|gene-rna failed|O to|O enhance|O the|O expression|O of|O MRP|gene-rna in|O N-myc|gene-rna transfected|O neuroblastoma|O cell|O lines|O .|O 
cMOAT|gene-protein was|O rarely|O expressed|O in|O the|O neuroblastomas|O ,|O but|O was|O frequently|O expressed|O in|O the|O malignant|O liver|O tumors|O .|O 
The|O expression|O of|O MRP|gene-rna and|O cMOAT|gene-rna in|O the|O childhood|O liver|O tumors|O was|O more|O common|O and|O higher|O ,|O especially|O in|O advanced|O cases|O with|O a|O poor|O outcome|O ,|O than|O that|O observed|O in|O normal|O liver|O or|O in|O 9|O hepatocellular|O carcinomas|O from|O adult|O patients|O .|O 
The|O enhanced|O expression|O of|O these|O genes|O might|O be|O characteristic|O of|O childhood|O malignant|O liver|O tumors|O and|O related|O to|O their|O clinical|O chemoresistance|O .|O 
Somatostatin|gene-protein receptors|gene-protein in|O Neuro2A|O neuroblastoma|O cells|O :|O ligand|O internalization|O .|O 
1.|O 
Receptor|O -|O dependent|O internalization|O of|O somatostatin|gene-protein (|O SRIF|O )|O agonists|O has|O been|O a|O matter|O of|O controversy|O probably|O because|O [125I]Tyr11-SRIF-14|gene-protein is|O rapidly|O degraded|O .|O 
We|O have|O studied|O the|O internalization|O of|O a|O stable|O somatostatin|gene-protein analogue|O ,|O [125I]-BIM-23027|gene-protein ,|O in|O a|O neuronal|O cell|O line|O ,|O Neuro2A|O ,|O which|O natively|O expresses|O somatostatin|gene-protein sst2|gene-protein receptors|gene-protein .|O 
2.|O 
Incubation|O of|O Neuro2A|O cells|O with|O [125I]-BIM-23027|gene-protein at|O 37|O degrees|O C|O resulted|O in|O a|O time|O -|O dependent|O internalization|O of|O the|O ligand|O ,|O which|O reached|O a|O maximum|O at|O 30|O min|O .|O 
Acid|O -|O washing|O showed|O that|O cell|O -|O surface|O binding|O of|O the|O ligand|O accounted|O for|O only|O 34|O %|O of|O total|O binding|O at|O this|O time|O .|O 
Internalization|O was|O dramatically|O reduced|O at|O 15|O degrees|O C|O .|O 
3.|O 
Internalization|O of|O [125I]-BIM-23027|gene-protein was|O prevented|O by|O inclusion|O of|O unlabelled|O somatostatin|gene-protein receptor|gene-protein agonists|O in|O a|O concentration|O -|O dependent|O manner|O .|O 
The|O IC50|O values|O for|O inhibition|O of|O [125I]-BIM-23027|gene-protein internalization|O were|O approximately|O 100|O fold|O lower|O than|O for|O inhibition|O of|O [125I]-BIM-23027|gene-protein binding|O to|O membrane|O homogenates|O but|O followed|O the|O same|O rank|O order|O of|O potencies|O .|O 
4.|O 
Disruption|O of|O G-protein|gene-protein coupling|O by|O treatment|O with|O pertussis|O toxin|O caused|O a|O 60|O %|O reduction|O in|O internalization|O of|O ligand|O .|O 
A|O combination|O of|O antimycin|O (|O 50|O nM|O )|O and|O deoxyglucose|O (|O 50|O mM|O )|O pretreatment|O ,|O which|O leads|O to|O a|O depletion|O of|O cellular|O ATP|O ,|O decreased|O internalization|O of|O [125I]-BIM-23027|gene-protein by|O 66|O %|O of|O control|O and|O increased|O the|O proportion|O of|O surface|O -|O bound|O ligand|O .|O 
Hypertonic|O sucrose|O ,|O which|O prevents|O clathrin|gene-protein -|O mediated|O endocytosis|O ,|O reversibly|O abolished|O the|O internalization|O of|O ligand|O without|O increasing|O the|O proportion|O bound|O at|O the|O cell|O surface|O .|O 
5.|O 
After|O internalization|O of|O [125I]-BIM-23027|gene-protein ,|O approximately|O half|O of|O the|O ligand|O was|O recycled|O back|O to|O the|O extracellular|O medium|O within|O 20|O min|O at|O 37|O degrees|O C|O .|O 
This|O finding|O suggests|O that|O the|O intracellular|O content|O of|O [125I]-BIM-23027|gene-protein reaches|O a|O steady|O state|O which|O is|O determined|O by|O the|O rates|O of|O both|O internalization|O and|O recycling|O of|O the|O ligand|O .|O 
In|O contrast|O to|O studies|O in|O which|O the|O internalization|O of|O [125I]-Tyr11-SRIF-14|gene-protein was|O examined|O ,|O neither|O internalized|O nor|O recycled|O [125I]-BIM-23027|gene-protein was|O degraded|O to|O its|O component|O amino|O acids|O .|O 
6.|O 
These|O findings|O indicate|O that|O the|O somatostatin|gene-protein agonist|O ,|O [125I]-BIM-23027|gene-protein ,|O is|O internalized|O in|O a|O receptor|O -|O dependent|O manner|O which|O involves|O clathrin|gene-protein -|O coated|O pits|O in|O Neuro2A|O cells|O .|O 
Furthermore|O ,|O much|O of|O the|O internalized|O ligand|O is|O rapidly|O recycled|O back|O to|O the|O extracellular|O medium|O without|O undergoing|O significant|O degradation|O .|O 
Allogeneic|O umbilical|O cord|O blood|O transplantation|O .|O 
Interest|O in|O umbilical|O cord|O blood|O as|O an|O alternate|O source|O of|O hematopoietic|O stem|O cells|O is|O growing|O rapidly|O .|O 
Umbilical|O cord|O blood|O offers|O the|O clinician|O a|O source|O of|O hematopoietic|O stem|O cells|O that|O is|O rarely|O contaminated|O by|O latent|O viruses|O and|O is|O readily|O available|O .|O 
Moreover|O ,|O the|O collection|O of|O umbilical|O cord|O blood|O poses|O no|O risk|O to|O the|O donor|O ;|O there|O is|O no|O need|O for|O general|O anesthesia|O or|O blood|O replacement|O ,|O and|O the|O procedure|O causes|O no|O discomfort|O .|O 
Whether|O cord|O blood|O lymphocytes|O are|O as|O likely|O to|O cause|O GVHD|O as|O lymphocytes|O from|O older|O individuals|O is|O unknown|O .|O 
Current|O clinical|O experience|O would|O suggest|O that|O the|O incidence|O may|O be|O low|O .|O 
Few|O of|O the|O patients|O transplanted|O with|O umbilical|O cord|O blood|O thus|O far|O have|O developed|O clinically|O significant|O GVHD|O ,|O including|O recipients|O of|O HLA|O -|O disparate|O grafts|O .|O 
These|O results|O and|O associated|O laboratory|O findings|O pose|O intriguing|O possibilities|O for|O the|O future|O of|O umbilical|O cord|O blood|O stem|O cells|O in|O the|O setting|O of|O unrelated|O transplantation|O .|O 
With|O the|O marked|O incidence|O of|O grade|O 2|O -|O 4|O acute|O GVHD|O that|O is|O currently|O observed|O after|O unrelated|O bone|O marrow|O transplantation|O ,|O a|O reduction|O in|O incidence|O or|O severity|O would|O be|O a|O major|O advancement|O in|O this|O field|O .|O 
In|O the|O setting|O of|O autologous|O trans|O -|O plantation|O ,|O there|O are|O other|O intriguing|O possibilities|O ;|O for|O example|O ,|O cord|O blood|O may|O be|O an|O optimal|O source|O of|O pluripotential|O stem|O cells|O for|O gene|O therapy|O .|O 
The|O large|O -|O scale|O collection|O and|O storage|O of|O cord|O blood|O stem|O cells|O has|O become|O a|O reality|O .|O 
Pilot|O programs|O for|O the|O banking|O of|O unrelated|O umbilical|O cord|O blood|O have|O already|O begun|O in|O the|O United|O States|O and|O Europe|O .|O 
Not|O only|O is|O there|O the|O potential|O for|O reducing|O the|O time|O from|O search|O initiation|O to|O the|O time|O of|O donor|O stem|O cell|O acquisition|O but|O also|O there|O is|O the|O potential|O for|O reducing|O the|O risks|O associated|O with|O unrelated|O bone|O marrow|O transplantation|O .|O 
There|O is|O also|O the|O hope|O of|O remedying|O the|O shortage|O of|O donors|O from|O ethnic|O and|O racial|O backgrounds|O that|O are|O currently|O underrepresented|O in|O most|O unrelated|O donor|O programs|O .|O 
Even|O with|O the|O creation|O of|O such|O banks|O ,|O it|O should|O not|O be|O forgotten|O that|O the|O collection|O of|O umbilical|O cord|O bloods|O should|O at|O least|O be|O considered|O when|O a|O child|O with|O leukemia|O ,|O lymphoma|O ,|O neuroblastoma|O ,|O marrow|O failure|O syndrome|O ,|O immunodeficiency|O state|O ,|O or|O inborn|O error|O of|O metabolism|O has|O a|O mother|O who|O is|O pregnant|O .|O 
The|O clinical|O results|O to|O date|O in|O small|O recipients|O would|O suggest|O that|O it|O is|O at|O least|O as|O good|O as|O bone|O marrow|O ;|O but|O additional|O patients|O and|O more|O time|O will|O be|O needed|O to|O finalize|O this|O conclusion|O .|O 
p27Kip1|gene-protein accumulation|O is|O associated|O with|O retinoic|O -|O induced|O neuroblastoma|O differentiation|O :|O evidence|O of|O a|O decreased|O proteasome|gene-protein -|O dependent|O degradation|O .|O 
Development|O of|O human|O neuroblastoma|O is|O due|O to|O an|O arrest|O in|O the|O differentiation|O program|O of|O neural|O crest|O sympathoadrenal|O progenitor|O cells|O .|O 
However|O ,|O neuroblastomas|O ,|O as|O well|O as|O their|O derived|O cell|O lines|O ,|O maintain|O the|O potentiality|O of|O terminal|O differentiation|O .|O 
We|O investigated|O the|O molecular|O mechanisms|O by|O which|O retinoic|O acid|O ,|O a|O molecule|O introduced|O in|O clinical|O trials|O for|O chemotherapy|O ,|O induces|O differentiation|O in|O neuroblastoma|O cell|O lines|O .|O 
Our|O findings|O demonstrate|O that|O the|O retinoic|O acid|O -|O dependent|O growth|O arrest|O of|O LAN-5|O neuroblastoma|O cell|O line|O is|O associated|O to|O a|O very|O large|O accumulation|O (|O >|O tenfold|O )|O of|O p27Kip1|gene-protein protein|O ,|O a|O cyclin|gene-protein -|gene-protein dependent|gene-protein kinase|gene-protein inhibitor|gene-protein ;|O the|gene-protein protein|gene-protein binds|O and|O inhibits|O cyclin|gene-protein -|gene-protein dependent|gene-protein kinase|gene-protein 2|gene-protein ,|O 4|gene-protein and|O 6|gene-protein activities|O ,|O thus|O hampering|O pRb|gene-protein and|O p107|gene-protein phosphorylation|O .|O 
p27Kip1|gene-protein build|O -|O up|O was|O observable|O as|O an|O early|O phenomenon|O (|O 12|O -|O 24|O h|O )|O after|O retinoic|O exposure|O and|O resulted|O in|O a|O time|O -|O dependent|O accumulation|O of|O high|O quantities|O of|O a|O free|O p27Kip1|gene-protein form|O .|O 
Furthermore|O ,|O retinoic|O treatment|O causes|O an|O increase|O of|O cyclin|gene-protein -|gene-protein dependent|gene-protein kinase|gene-protein 5|gene-protein level|O and|O activity|O ;|O however|O ,|O immunoprecipitation|O studies|O proved|O the|O absence|O of|O interaction|O with|O p27kip1|gene-protein .|O 
No|O noticeable|O variation|O of|O other|O components|O of|O G1|O phase|O cell|O cycle|O engine|O was|O observed|O .|O 
Pulse|O -|O chase|O experiments|O showed|O a|O remarkable|O elongation|O of|O p27Kip1|gene-protein half|O -|O life|O in|O retinoic|O -|O treated|O LAN-5|O ,|O while|O no|O enhancement|O of|O p27Kip1|gene-rna gene|O expression|O and|O of|O the|O translational|O efficiency|O of|O its|gene-rna messenger|gene-rna RNA|gene-rna were|O demonstrated|O .|O 
In|O vivo|O degradation|O of|O p27Kip1|gene-protein was|O sensitive|O to|O two|O highly|O specific|O proteasome|O inhibitors|O ,|O LLnL|O and|O lactacystin|O ,|O while|O the|O calpain|gene-protein inhibitor|O II|O ALLM|O and|O the|O cysteine|gene-protein protease|gene-protein inhibitor|O E64|O did|O not|O modify|O the|O level|O of|O the|gene-protein protein|gene-protein .|O 
LLnL|O treatment|O caused|O a|O very|O rapid|O (|O 2|O h|O )|O build|O -|O up|O of|O the|O Cdk|gene-protein inhibitor|O content|O and|O the|O accumulation|O of|O higher|O molecular|O weight|O anti|O -|O p27Kip1|gene-protein immunoreactive|O bands|O ,|O which|O probably|O represent|O ubiquitinated|O forms|O of|O the|gene-protein protein|gene-protein .|O 
Finally|O ,|O in|O vitro|O experiments|O demonstrated|O that|O extracts|O prepared|O from|O retinoic|O -|O treated|O LAN-5|O cells|O degraded|O recombinant|O p27Kip1|gene-protein at|O a|O rate|O remarkably|O slower|O than|O the|O untreated|O cells|O .|O 
Our|O results|O indicate|O that|O retinoic|O acid|O strongly|O increases|O p27Kip1|gene-protein levels|O by|O down|O -|O regulating|O the|O ubiquitin|gene-protein -|O proteasome|O p27Kip1|gene-protein degrading|O pathway|O .|O 
Differential|O regulation|O of|O polysialyltransferase|gene-protein expression|O during|O hippocampus|O development|O :|O Implications|O for|O neuronal|O survival|O .|O 
Polysialyltransferases|gene-protein ST8SiaII|gene-protein /|O STX|gene-protein and|O ST8SiaIV|gene-protein /|O PST|gene-protein add|O polysialic|O acid|O (|O PSA|O )|O to|O the|O neural|O cell|O adhesion|O molecule|O (|O NCAM|O )|O .|O 
Surface|O -|O located|O PSA|O is|O involved|O in|O cell|O -|O cell|O interactions|O participating|O in|O structural|O and|O functional|O plasticity|O of|O neuronal|O circuits|O .|O 
This|O study|O was|O undertaken|O to|O investigate|O the|O polysialyltransferase|gene-protein regulation|O pattern|O during|O hippocampal|O development|O .|O 
Polysialyltransferase|gene-protein expression|O levels|O analyzed|O by|O real|O -|O time|O RT|O -|O PCR|O indicated|O that|O ST8SiaII|gene-rna /|O STX|gene-rna mRNA|O is|O markedly|O down|O -|O regulated|O in|O vivo|O ,|O decreasing|O abruptly|O at|O about|O the|O first|O week|O of|O postnatal|O development|O .|O 
ST8SiaII|gene-rna /|O STX|gene-rna mRNA|O is|O also|O down|O -|O regulated|O in|O hippocampal|O cells|O in|O culture|O ,|O accompanying|O the|O morphological|O differentiation|O of|O neuronal|O interconnectivity|O .|O 
In|O contrast|O ,|O ST8SiaIV|gene-generic /|O PST|gene-generic levels|O remain|O comparatively|O low|O during|O hippocampus|O ontogeny|O .|O 
Immunolabeling|O of|O primary|O hippocampal|O culture|O assays|O demonstrated|O that|O PSA|O expression|O parallels|O ST8SiaII|gene-rna /|O STX|gene-rna mRNA|O levels|O .|O 
In|O comparison|O ,|O polysialyltransferase|gene-rna mRNA|O levels|O are|O not|O regulated|O in|O neuroblastoma|O cells|O during|O their|O proliferation|O .|O 
Sequence|O analysis|O of|O the|O 3|O '|O -|O untranslated|O region|O of|O ST8SiaII|gene-rna /|O STX|gene-rna cDNA|O indicated|O putative|O regulatory|O motifs|O .|O 
This|O information|O and|O the|O observed|O changes|O in|O mRNA|O half|O -|O life|O during|O development|O suggest|O that|O ST8SiaII|gene-rna /|O STX|gene-rna might|O be|O also|O regulated|O at|O the|O posttranscriptional|O level|O .|O 
To|O understand|O the|O reasons|O for|O the|O tight|O control|O of|O ST8SiaII|gene-generic /|O STX|gene-generic expression|O during|O development|O ,|O we|O overexpressed|O the|O enzyme|O in|O hippocampal|O primary|O cultures|O by|O transfection|O .|O 
Overexpression|O of|O ST8SiaII|gene-generic /|O STX|gene-generic wild|O type|O as|O well|O as|O of|O a|O mutant|O lacking|O enzymatic|O activity|O affected|O neuronal|O viability|O ,|O leading|O to|O cell|O death|O .|O 
However|O ,|O this|O phenomenon|O was|O abolished|O by|O a|O double|O mutation|O in|O the|O ST8SiaII|gene-rna /|O STX|gene-rna that|O prevents|O formation|O of|O its|O three|O -|O dimentional|O structure|O .|O 
Interestingly|O ,|O the|O overexpressed|O polysialyltransferase|gene-protein accumulates|O not|O only|O in|O the|O perinuclear|O region|O but|O also|O in|O the|O plasma|O membrane|O .|O 
Thus|O ,|O overexpression|O of|O an|O ST8SiaII|gene-generic /|O STX|gene-generic that|O conserves|O its|O structure|O leads|O to|O abnormal|O accumulation|O of|O the|O protein|gene-protein ,|O probably|O on|O the|O neuronal|O surface|O ,|O affecting|O cell|O viability|O .|O 
This|O result|O explains|O the|O importance|O of|O an|O accurate|O regulation|O of|O polysialyltransferase|gene-protein expression|O during|O development|O .|O 
Integrins|gene-protein alpha(v)beta3|gene-protein and|O alpha(v)beta5|gene-protein are|O expressed|O by|O endothelium|O of|O high|O -|O risk|O neuroblastoma|O and|O their|O inhibition|O is|O associated|O with|O increased|O endogenous|O ceramide|O .|O 
Inhibition|O of|O the|O RGD|gene-protein -|gene-protein binding|gene-protein integrins|gene-protein ,|O alpha(v)beta3|gene-protein and|O alpha(v)beta5|gene-protein ,|O prevents|O endothelial|O cell|O anchorage|O and|O induces|O endothelial|O apoptosis|O ,|O which|O results|O in|O disruption|O of|O tumor|O angiogenesis|O and|O inhibition|O of|O tumor|O growth|O in|O animal|O models|O .|O 
In|O this|O study|O ,|O we|O demonstrate|O by|O immunohistochemical|O analysis|O that|O integrin|gene-protein alpha(v)beta3|gene-protein was|O expressed|O by|O 61|O %|O (|O mean|O )|O of|O microvessels|O in|O high|O -|O risk|O neuroblastomas|O (|O stage|O IV|O and|O MYCN|O -|O amplified|O stage|O III|O ;|O n|O =|O 28|O )|O but|O only|O by|O 18|O %|O (|O mean|O )|O of|O microvessels|O in|O low|O -|O risk|O tumors|O (|O stages|O I|O and|O II|O and|O non|O -|O MYCN|O -|O amplified|O stage|O III|O ;|O n|O =|O 12|O )|O .|O 
Integrin|gene-protein alpha(v)beta5|gene-protein was|O found|O on|O 60|O %|O (|O mean|O )|O of|O microvessels|O in|O 21|O Stage|O IV|O tumors|O .|O 
These|O data|O suggest|O that|O neuroblastomas|O may|O be|O targeted|O for|O antiangiogenic|O treatment|O directed|O against|O endothelial|gene-protein integrins|gene-protein alpha(v)beta3|gene-protein and|O alpha(v)beta5|gene-protein .|O 
In|O cell|O culture|O ,|O inhibition|O of|O integrin|gene-protein -|O dependent|O endothelial|O cell|O anchorage|O to|O vitronectin|gene-protein by|O RGDfV|gene-protein ,|O an|O RGD|gene-protein function|gene-protein -|gene-protein blocking|gene-protein cyclic|gene-protein peptide|gene-protein ,|O induced|O apoptosis|O in|O bovine|O brain|O endothelial|O cells|O compared|O with|O the|O control|O peptide|O ,|O RADfV|gene-protein (|O 37.5|O %|O versus|O 8.7|O %|O ,|O respectively|O )|O ,|O as|O detected|O by|O chromatin|O condensation|O and|O nuclear|O fragmentation|O .|O 
Treatment|O with|O RGDfV|gene-protein but|O not|O with|O RADfV|gene-protein ,|O which|O prevented|O attachment|O of|O endothelial|O cells|O to|O vitronectin|gene-protein or|O fibronectin|gene-protein ,|O was|O associated|O with|O up|O to|O a|O 50|O %|O increase|O in|O endogenous|O ceramide|O ,|O a|O lipid|O second|O messenger|O that|O can|O mediate|O cell|O death|O .|O 
Furthermore|O ,|O exogenous|O C2|O -|O ceramide|O was|O cytotoxic|O to|O bovine|O brain|O endothelial|O cells|O and|O induced|O activation|O of|O C-jun|gene-protein N-terminal|gene-protein kinase|gene-protein (|O JNK|gene-protein )|O ,|O a|O MAP|gene-protein kinase|gene-protein that|O can|O be|O activated|O in|O stress|O -|O induced|O apoptosis|O pathways|O .|O 
This|O suggests|O that|O ceramide|O may|O function|O in|O detachment|O -|O induced|O endothelial|O cell|O apoptosis|O ,|O originating|O from|O inhibition|O of|O vitronectin|gene-protein binding|O to|O integrins|gene-protein such|O as|O alpha(v)beta3|gene-protein and|O alpha(v)beta5|gene-protein .|O 
This|O is|O the|O first|O report|O to|O demonstrate|O expression|O of|O integrins|gene-protein alpha(v)beta3|gene-protein and|O alpha(v)beta5|gene-protein by|O microvascular|O endothelium|O of|O a|O childhood|O tumor|O and|O association|O of|O their|O expression|O with|O neuroblastoma|O aggressiveness|O .|O 
Furthermore|O ,|O our|O data|O provide|O the|O first|O suggestion|O that|O inhibition|O of|O endothelial|O cell|O anchorage|O ,|O resulting|O from|O specific|O blockade|O of|O RGD|gene-protein -|gene-protein binding|gene-protein integrins|gene-protein ,|O increases|O endogenous|O ceramide|O ,|O which|O may|O contribute|O to|O endothelial|O cell|O death|O .|O 
Cytoplasmic|O ,|O nuclear|O ,|O and|O golgi|O localization|O of|O RGS|gene-protein proteins|gene-protein .|O 
Evidence|O for|O N-terminal|O and|O RGS|gene-protein domain|O sequences|O as|O intracellular|O targeting|O motifs|O .|O 
RGS|gene-protein proteins|gene-protein comprise|O a|O family|O of|O proteins|O named|O for|O their|O ability|O to|O negatively|O regulate|O heterotrimeric|gene-protein G|gene-protein protein|gene-protein signaling|O .|O 
Biochemical|O studies|O suggest|O that|O members|O of|O this|O protein|O family|O act|O as|O GTPase|gene-protein -|gene-protein activating|gene-protein proteins|gene-protein for|O certain|O Galpha|gene-protein subunits|O ,|O thereby|O accelerating|O the|O turn|O -|O off|O mechanism|O of|O Galpha|gene-protein and|O terminating|O signaling|O by|O both|O Galpha|gene-protein and|O Gbetagamma|gene-protein subunits|O .|O 
In|O the|O present|O study|O ,|O we|O used|O confocal|O microscopy|O to|O examine|O the|O intracellular|O distribution|O of|O several|O RGS|gene-protein proteins|gene-protein in|O COS-7|O cells|O expressing|O RGS|gene-protein -|O green|gene-protein fluorescent|gene-protein protein|gene-protein (|O GFP|gene-protein )|O fusion|O proteins|O and|O in|O cells|O expressing|O RGS|gene-protein proteins|gene-protein endogenously|O .|O 
RGS2|gene-protein and|O RGS10|gene-protein accumulated|O in|O the|O nucleus|O of|O COS-7|O cells|O transfected|O with|O GFP|gene-protein constructs|O of|O these|O proteins|O .|O 
In|O contrast|O ,|O RGS4|gene-protein and|O RGS16|gene-protein accumulated|O in|O the|O cytoplasm|O of|O COS-7|O transfectants|O .|O 
As|O observed|O in|O COS-7|O cells|O ,|O RGS4|gene-protein exhibited|O cytoplasmic|O localization|O in|O mouse|O neuroblastoma|O cells|O ,|O and|O RGS10|gene-protein exhibited|O nuclear|O localization|O in|O human|O glioma|O cells|O .|O 
Deletion|O or|O alanine|O substitution|O of|O an|O N-terminal|O leucine|O repeat|O motif|O present|O in|O both|O RGS4|gene-protein and|O RGS16|gene-protein ,|O a|O domain|O identified|O as|O a|O nuclear|O export|O sequence|O in|O HIV|O Rev|gene-rna and|O other|O proteins|O ,|O promoted|O nuclear|O localization|O of|O these|O proteins|O in|O COS-7|O cells|O .|O 
In|O agreement|O with|O this|O observation|O ,|O treatment|O of|O mouse|O neuroblastoma|O cells|O with|O leptomycin|O B|O to|O inhibit|O nuclear|O protein|O export|O by|O exportin1|gene-protein resulted|O in|O accumulation|O of|O RGS4|gene-protein in|O the|O nucleus|O of|O these|O cells|O .|O 
GFP|gene-protein fusions|O of|O RGS|gene-protein domains|O of|O RGS|gene-protein proteins|O localized|O in|O the|O nucleus|O ,|O suggesting|O that|O nuclear|O localization|O of|O RGS|gene-protein proteins|O results|O from|O nuclear|O targeting|O via|O RGS|gene-protein domain|O sequences|O .|O 
RGSZ|gene-protein ,|O which|O shares|O with|O RGS|gene-protein -|gene-protein GAIP|gene-protein a|O cysteine|O -|O rich|O string|O in|O its|O N-terminal|O region|O ,|O localized|O to|O the|O Golgi|O complex|O in|O COS-7|O cells|O .|O 
Deletion|O of|O the|O N-terminal|O domain|O of|O RGSZ|gene-protein that|O includes|O the|O cysteine|O motif|O promoted|O nuclear|O localization|O of|O RGSZ|gene-protein .|O 
None|O of|O the|O RGS|gene-protein proteins|gene-protein examined|O were|O localized|O at|O the|O plasma|O membrane|O .|O 
These|O results|O demonstrate|O that|O RGS|gene-protein proteins|gene-protein localize|O in|O the|O nucleus|O ,|O the|O cytoplasm|O ,|O or|O shuttle|O between|O the|O nucleus|O and|O cytoplasm|O as|O nucleo|O -|O cytoplasmic|O shuttle|O proteins|O .|O 
RGS|gene-protein proteins|gene-protein localize|O differentially|O within|O cells|O as|O a|O result|O of|O structural|O differences|O among|O these|gene-protein proteins|gene-protein that|O do|O not|O appear|O to|O be|O important|O determinants|O for|O their|O G|gene-protein protein|gene-protein -|O regulating|O activities|O .|O 
These|O findings|O suggest|O involvement|O of|O RGS|gene-protein proteins|gene-protein in|O more|O complex|O cellular|O functions|O than|O currently|O envisioned|O .|O 
Differential|O nm23|gene-rna gene|O expression|O at|O the|O fetal|O -|O maternal|O interface|O .|O 
The|O product|O of|O the|O nm23|gene-rna gene|O has|O been|O proposed|O as|O a|O candidate|O tumour|gene-protein metastasis|gene-protein suppressor|gene-protein protein|gene-protein .|O 
A|O strong|O association|O has|O been|O observed|O between|O reduced|O expression|O of|O the|O nm23|gene-rna gene|O and|O acquisition|O of|O metastatic|O behaviour|O in|O some|O tumour|O cells|O ,|O including|O breast|O cancer|O and|O melanoma|O ,|O but|O not|O in|O others|O ,|O such|O as|O neuroblastoma|O and|O colon|O ,|O cervical|O and|O thyroid|O cancers|O .|O 
During|O the|O early|O gestation|O period|O both|O human|O and|O murine|O trophoblast|O cells|O exhibit|O in|O vitro|O invasive|O properties|O similar|O to|O those|O of|O neoplastic|O cells|O .|O 
Such|O invasive|O properties|O ,|O however|O ,|O disappear|O in|O the|O late|O stage|O of|O gestation|O .|O 
In|O the|O present|O study|O ,|O we|O examined|O the|O abundance|O of|O nm23|gene-rna mRNA|O from|O various|O fetal|O -|O maternal|O interface|O tissues|O (|O uterus|O ,|O decidua|O ,|O placenta|O and|O embryo|O )|O during|O early|O (|O day|O 8|O )|O ,|O mid|O (|O day|O 14|O )|O and|O late|O (|O day|O 18|O )|O stages|O of|O gestation|O in|O CD1|O mice|O ,|O in|O order|O to|O determine|O whether|O nm23|gene-rna plays|O any|O anti|O -|O invasive|O and/or|O biological|O roles|O during|O gestation|O .|O 
nm23|gene-rna was|O found|O to|O be|O expressed|O in|O all|O the|O tissues|O during|O the|O early|O and|O mid|O stages|O of|O gestation|O .|O 
The|O expression|O levels|O were|O ,|O however|O ,|O variable|O among|O different|O tissues|O and|O development|O stages|O .|O 
In|O the|O early|O stage|O ,|O nm23|gene-rna mRNA|O levels|O were|O the|O highest|O and|O similar|O among|O tissues|O from|O the|O uterus|O ,|O decidua|O ,|O placenta|O and|O embryo|O .|O 
In|O the|O mid|O stage|O ,|O the|O mRNA|gene-rna levels|O were|O reduced|O significantly|O in|O the|O uterus|O ,|O decidua|O and|O placenta|O ,|O but|O not|O in|O the|O embryo|O .|O 
In|O the|O late|O stage|O ,|O nm23|gene-rna mRNA|gene-rna was|O further|O reduced|O to|O the|O extent|O that|O it|O could|O not|O be|O seen|O in|O the|O decidua|O ,|O was|O barely|O seen|O in|O the|O uterus|O and|O was|O weakly|O present|O in|O the|O placenta|O .|O 
However|O ,|O the|O mRNA|gene-rna level|O of|O the|O embryo|O in|O the|O late|O stage|O was|O still|O high|O and|O similar|O to|O the|O early|O stage|O .|O 
We|O also|O examined|O nm23|gene-rna expression|O in|O trophoblast|O cells|O from|O normal|O human|O term|O placenta|O and|O a|O highly|O metastatic|O human|O choriocarcinoma|O cell|O line|O ,|O JAR|O .|O 
nm23|gene-rna expression|O was|O significantly|O higher|O in|O JAR|O than|O in|O normal|O placenta|O ,|O indicating|O that|O nm23|gene-rna does|O not|O appear|O to|O have|O an|O anti|O -|O metastatic|O function|O in|O this|O cell|O line|O .|O 
Several|O cytokines|gene-protein --|O interleukin|gene-protein 2|gene-protein (|O IL-2|gene-protein )|O ,|O tumour|gene-protein necrosis|gene-protein factor|gene-protein alpha|gene-protein (|O TNF-alpha|gene-protein )|O and|O interferon|gene-protein gamma|gene-protein (|O IFN-gamma|gene-protein )|O --|O and|O prostaglandin|O E2|O (|O PGE2|O )|O known|O to|O modulate|O tumour|O growth|O and|O metastasis|O were|O examined|O to|O determine|O whether|O they|O regulate|O nm23|gene-rna expression|O in|O JAR|O in|O vitro|O .|O 
The|O B16F10|O melanoma|O cell|O line|O was|O used|O as|O control|O .|O 
No|O effect|O was|O found|O in|O the|O JAR|O cell|O line|O ,|O whereas|O TNF-alpha|gene-protein ,|O IFN-gamma|gene-protein and|O PGE2|O down|O -|O regulated|O nm23|gene-rna expression|O in|O the|O B16F10|O cell|O line|O .|O 
Regulation|O of|O Bcl-2|gene-protein oncoprotein|O levels|O with|O differentiation|O of|O human|O neuroblastoma|O cells|O .|O 
When|O established|O in|O culture|O ,|O human|O neuroblastoma|O cell|O lines|O typically|O are|O comprised|O of|O heterogeneous|O cellular|O subpopulations|O ,|O including|O neuroblastic|O (|O N-type|O )|O ,|O substrate|O -|O adherent|O (|O S-type|O )|O ,|O and|O intermediate|O (|O I-type|O )|O cells|O that|O can|O be|O distinguished|O by|O their|O characteristic|O morphologies|O and|O expression|O of|O differentiation|O -|O associated|O antigens|O .|O 
Here|O we|O examined|O the|O relative|O levels|O of|O the|O Bcl-2|gene-protein oncoprotein|O in|O 15|O clones|O derived|O from|O four|O different|O neuroblastoma|O cell|O lines|O .|O 
Among|O six|O clones|O isolated|O from|O the|O SK-N-SH|O line|O ,|O levels|O of|O p26-Bcl-2|gene-protein correlated|O with|O morphology|O and|O differentiation|O markers|O with|O the|O hierarchy|O of|O bcl-2|gene-protein expression|O being|O :|O N-type|O cells|O >|O N|O /|O I|O -|O type|O >|O I-type|O >|O S-type|O .|O 
Furthermore|O ,|O stimulation|O of|O one|O of|O the|O N-type|O clones|O ,|O SH-SY5Y|O ,|O with|O the|O phorbol|O ester|O ,|O 12-O-tetradecanoylphorbol-13-acetate|O ,|O induced|O differentiation|O toward|O a|O more|O neuronal|O -|O like|O phenotype|O and|O resulted|O in|O a|O 5|O -|O to|O 10|O -|O fold|O elevation|O in|O the|O relative|O levels|O of|O Bcl-2|gene-protein protein|O .|O 
High|O relative|O amounts|O of|O p26-Bcl-2|gene-protein protein|O were|O also|O found|O in|O an|O N-type|O clone|O derived|O from|O the|O SMS-KCN|O line|O .|O 
In|O two|O N-type|O clones|O derived|O from|O the|O LA-N-1|O line|O ,|O however|O ,|O levels|O of|O Bcl-2|gene-protein protein|O were|O only|O moderately|O elevated|O ,|O and|O in|O one|O N-type|O clone|O from|O the|O SK-N-BE(2)|O line|O the|O levels|O of|O Bcl-2|gene-protein protein|O were|O low|O .|O 
Thus|O ,|O high|O relative|O levels|O of|O Bcl-2|gene-protein oncoprotein|O are|O not|O a|O universal|O feature|O of|O N-type|O cells|O (|O three|O of|O six|O clones|O tested|O )|O .|O 
In|O contrast|O ,|O all|O 5|O of|O the|O S-type|O clones|O evaluated|O contained|O relatively|O low|O levels|O of|O Bcl-2|gene-protein protein|O ,|O suggesting|O that|O these|O cells|O (|O which|O may|O represent|O embryonic|O precursors|O of|O Schwann|O ,|O glial|O ,|O and|O melanocytic|O cells|O )|O do|O not|O typically|O express|O the|O bcl-2|gene-rna gene|O at|O high|O levels|O .|O 
Consistent|O with|O this|O inverse|O correlation|O between|O Bcl-2|gene-protein protein|O levels|O and|O S-type|O characteristics|O ,|O stimulation|O of|O an|O I-type|O clone|O derived|O from|O the|O SK-N-BE(2)|O line|O with|O 5-bromodeoxyuridine|O was|O accompanied|O by|O an|O accumulation|O of|O S-type|O cells|O in|O these|O cultures|O ,|O decreased|O Bcl-2|gene-protein protein|O ,|O diminutions|O in|O the|O neuronal|O markers|O neurofilament-M|gene-protein and|O neuron|O -|O specific|O enolase|gene-protein ,|O and|O an|O increase|O in|O the|O relative|O levels|O of|O the|O S-type|O marker|O proteins|O vimentin|gene-protein and|O beta-2-microglobulin|gene-protein .|O 
Conversely|O ,|O stimulation|O of|O this|O I-type|O clone|O with|O retinoic|O acid|O resulted|O in|O an|O accumulation|O of|O N-type|O cells|O (|O which|O are|O thought|O to|O represent|O embryonic|O precursors|O of|O sympathetic|O neurons|O )|O ,|O decreased|O vimentin|gene-protein and|O beta-2-microglobulin|gene-protein ,|O increased|O neurofilament-M|gene-protein ,|O and|O a|O marked|O elevation|O in|O p26-Bcl-2|gene-protein .|O 
Features|O and|O outcome|O of|O neuroblastoma|O detected|O before|O birth|O .|O 
BACKGROUND|O /|O PURPOSE|O :|O 
The|O growing|O use|O of|O routine|O ultrasonography|O during|O pregnancy|O is|O leading|O to|O an|O increasing|O number|O of|O prenatally|O diagnosed|O neuroblastomas|O .|O 
Optimal|O strategy|O has|O not|O yet|O been|O defined|O for|O these|O patients|O ,|O because|O knowledge|O on|O this|O particular|O neuroblastoma|O (|O NB|O )|O population|O is|O still|O limited|O .|O 
However|O ,|O definite|O guidelines|O are|O needed|O to|O avoid|O inadequate|O treatment|O .|O 
The|O authors|O analyzed|O the|O cases|O of|O antenatally|O detected|O NB|O (|O ADNB|O )|O reported|O in|O the|O Italian|O Neuroblastoma|O Registry|O during|O the|O past|O 6|O years|O to|O elucidate|O the|O features|O of|O this|O subset|O of|O NB|O .|O 
METHODS|O :|O 
The|O Italian|O Neuroblastoma|O Registry|O was|O reviewed|O for|O the|O period|O January|O 1993|O to|O December|O 1998|O to|O collect|O clinical|O ,|O radiographic|O ,|O surgical|O ,|O and|O histopathological|O data|O on|O ADNB|O cases|O .|O 
NB|O stage|O was|O evaluated|O according|O to|O INSS|O criteria|O .|O 
All|O patients|O had|O undergone|O imaging|O (|O computed|O tomography|O or|O magnetic|O resonance|O imaging|O )|O of|O the|O primary|O tumor|O and|O bone|O marrow|O biopsy|O before|O surgical|O resection|O .|O 
RESULTS|O :|O 
Seventeen|O patients|O were|O identified|O .|O 
Primary|O tumour|O site|O was|O adrenal|O glands|O in|O 16|O cases|O and|O retroperitoneal|O ganglia|O in|O 1|O .|O 
Stage|O distribution|O was|O stage|O I|O ,|O 13|O cases|O ;|O stage|O II-A|O ,|O 1|O case|O ;|O stage|O II-B|O ,|O 1|O case|O ;|O stage|O IV-S|O ,|O 2|O cases|O .|O 
All|O cases|O underwent|O primary|O tumour|O resection|O .|O 
Mean|O age|O at|O surgery|O was|O 4|O weeks|O .|O 
Resection|O of|O primary|O tumor|O was|O radical|O in|O 16|O cases|O ,|O partial|O in|O 1|O .|O 
All|O tumors|O were|O characterised|O by|O favourable|O histology|O according|O to|O Shimada|O classification|O .|O 
N-myc|gene-rna gene|O amplification|O was|O studied|O in|O 14|O patients|O .|O 
N-myc|gene-rna amplification|O was|O detected|O only|O in|O a|O newborn|O with|O stage|O II-A|O NB|O ,|O who|O died|O of|O massive|O bleeding|O 2|O days|O after|O tumor|O resection|O .|O 
DNA|O index|O and|O 1p|O deletion|O were|O studied|O in|O 11|O and|O 8|O patients|O ,|O respectively|O .|O 
Both|O diploidy|O and|O deletion|O of|O 1p|O were|O observed|O in|O a|O newborn|O who|O subsequently|O died|O of|O disease|O progression|O despite|O surgery|O ,|O chemotherapy|O ,|O and|O radiation|O therapy|O .|O 
Fourteen|O of|O 17|O patients|O currently|O are|O alive|O and|O free|O of|O disease|O ,|O and|O one|O with|O IV-S|O NB|O and|O short|O follow|O -|O up|O is|O alive|O with|O disease|O .|O 
CONCLUSIONS|O :|O 
Our|O data|O give|O evidence|O that|O in|O most|O cases|O infants|O with|O ADNB|O represent|O a|O subset|O of|O patients|O with|O excellent|O outcome|O .|O 
Aggressive|O treatment|O may|O not|O always|O be|O necessary|O .|O 
Infants|O with|O ADNB|O with|O unfavorable|O features|O should|O undergo|O early|O surgical|O excision|O ,|O whereas|O patients|O with|O favourable|O features|O could|O be|O observed|O awaiting|O spontaneous|O regression|O of|O the|O mass|O ,|O reserving|O delayed|O surgery|O for|O tumors|O that|O increase|O in|O size|O or|O do|O not|O regress|O .|O 
Effect|O of|O imatinib|O mesylate|O on|O neuroblastoma|O tumorigenesis|O and|O vascular|gene-protein endothelial|gene-protein growth|gene-protein factor|gene-protein expression|O .|O 
BACKGROUND|O :|O 
Alternative|O treatment|O options|O are|O needed|O for|O advanced|O neuroblastoma|O patients|O because|O their|O prognosis|O remains|O poor|O after|O intensive|O chemotherapy|O .|O 
Neuroblastoma|O cells|O express|O platelet|gene-protein -|gene-protein derived|gene-protein growth|gene-protein factor|gene-protein (|O PDGF|gene-protein )|O ,|O stem|gene-protein cell|gene-protein factor|gene-protein (|O SCF|gene-protein )|O ,|O and|O vascular|gene-protein endothelial|gene-protein growth|gene-protein factor|gene-protein (|O VEGF|gene-protein )|O and|O their|O respective|O receptors|O ,|O PDGFR|gene-protein ,|O c-Kit|gene-protein ,|O and|O Flk-1|gene-protein .|O 
We|O therefore|O evaluated|O the|O effects|O of|O imatinib|O mesylate|O (|O imatinib|O )|O ,|O a|O selective|O inhibitor|O of|O the|O tyrosine|gene-protein kinase|gene-protein activities|O of|O c-Kit|gene-protein and|O PDGFR|gene-protein ,|O on|O the|O growth|O of|O neuroblastoma|O cells|O in|O vivo|O and|O in|O vitro|O .|O 
METHODS|O :|O 
We|O tested|O seven|O human|O neuroblastoma|O cell|O lines|O for|O their|O sensitivity|O to|O imatinib|O .|O 
Cell|O viability|O was|O assessed|O by|O trypan|O blue|O dye|O exclusion|O .|O 
Apoptosis|O was|O evaluated|O by|O nuclear|O staining|O ,|O flow|O cytometry|O ,|O and|O western|O blotting|O .|O 
Protein|O assays|O included|O immunoprecipitation|O ,|O western|O blotting|O ,|O enzyme|O -|O linked|O immunosorbent|O assays|O ,|O and|O immunohistochemistry|O .|O 
mRNA|O expression|O was|O assessed|O by|O northern|O blotting|O .|O 
We|O used|O a|O xenograft|O model|O in|O SCID|O mice|O (|O 10|O mice|O per|O group|O )|O to|O evaluate|O the|O effects|O of|O imatinib|O oral|O therapy|O (|O 50|O or|O 100|O mg|O /|O kg|O every|O 12|O hours|O for|O 14|O days|O )|O on|O neuroblastoma|O tumor|O growth|O .|O 
All|O statistical|O tests|O were|O two|O -|O sided|O .|O 
RESULTS|O :|O 
All|O seven|O neuroblastoma|O cell|O lines|O treated|O with|O imatinib|O displayed|O concentration|O -|O dependent|O decreases|O in|O cell|O viability|O ,|O which|O coincided|O with|O an|O induction|O of|O apoptosis|O ,|O and|O with|O ligand|O -|O stimulated|O phosphorylation|O of|O c-Kit|gene-protein and|O PDGFR|gene-protein .|O 
The|O imatinib|O concentrations|O that|O caused|O 50|O %|O inhibition|O of|O growth|O and|O 50|O %|O inhibition|O of|O ligand|O -|O induced|O phosphorylation|O of|O these|O receptors|gene-protein were|O 9|O -|O 13|O micro|O M|O and|O 0.1|O -|O 0.5|O microM|O ,|O respectively|O .|O 
Expression|O of|O VEGF|gene-protein ,|O but|O not|O phosphorylation|O of|O Flk-1|gene-protein ,|O its|O receptor|O ,|O was|O reduced|O in|O neuroblastoma|O cells|O treated|O with|O imatinib|O at|O 10|O microM|O or|O higher|O .|O 
Mice|O treated|O with|O imatinib|O at|O 50|O mg|O /|O kg|O or|O 100|O mg|O /|O kg|O had|O statistically|O significantly|O smaller|O tumors|O than|O control|O mice|O treated|O with|O vehicle|O (|O mean|O tumor|O volume|O in|O mice|O treated|O with|O imatinib|O at|O 50|O mg|O /|O kg|O =|O 1546|O mm3|O ,|O in|O control|O mice|O =|O 2954|O mm3|O ;|O difference|O =|O 1408|O mm3|O ,|O 95|O %|O confidence|O interval|O [|O CI|O ]|O =|O 657|O to|O 2159|O mm3|O ;|O P|O <|O .001|O ;|O mean|O tumor|O volume|O in|O mice|O treated|O with|O imatinib|O at|O 100|O mg|O /|O kg|O =|O 463|O mm3|O ;|O difference|O =|O 2491|O mm3|O ,|O 95|O %|O CI|O =|O 1740|O to|O 3242|O mm3|O ;|O P|O <|O .001|O )|O .|O 
CONCLUSIONS|O :|O 
Imatinib|O inhibited|O the|O growth|O of|O neuroblastoma|O cells|O in|O vitro|O and|O in|O vivo|O .|O 
This|O inhibition|O was|O associated|O with|O suppression|O of|O PDGFR|gene-protein and|O c-Kit|gene-protein phosphorylation|O and|O inhibition|O of|O VEGF|gene-protein expression|O .|O 
[|O The|O neuroblastoma|O ,|O "|O enfant|O terrible|O "|O among|O pediatric|O tumors|O ]|O 
Neuroblastoma|O belongs|O to|O the|O group|O of|O small|O blue|O round|O cell|O tumors|O and|O originates|O in|O precursor|O cells|O of|O the|O sympathetic|O neural|O tissue|O .|O 
This|O tumor|O occurs|O at|O the|O pediatric|O age|O and|O has|O fascinated|O and|O intrigued|O both|O clinicians|O and|O researchers|O because|O of|O its|O variable|O and|O often|O unpredictable|O clinical|O behaviour|O .|O 
Indeed|O ,|O the|O clinical|O outcome|O of|O neuroblastoma|O patients|O not|O only|O depends|O on|O the|O clinical|O extension|O of|O the|O disease|O ,|O but|O also|O on|O other|O factors|O including|O age|O at|O diagnosis|O ,|O presence|O or|O absence|O in|O the|O tumor|O cells|O of|O molecular|O and|O biological|O characteristics|O with|O prognostic|O value|O (|O e.g.|O amplification|O of|O the|O oncogene|O MYCN|gene-rna ,|O frequently|O associated|O with|O chromosome|O 1p|O -|O deletion|O is|O predictive|O for|O poor|O survival|O chance|O )|O .|O 
In|O 1983|O an|O abdominal|O stage|O 3|O neuroblastoma|O was|O diagnosed|O in|O a|O 9|O -|O months|O old|O boy|O .|O 
He|O died|O of|O the|O disease|O 3|O years|O later|O .|O 
Karyotyping|O studies|O in|O this|O patient|O revealed|O a|O constitutional|O chromosome|O translocation|O t|O (|O 1|O ;|O 17|O )|O with|O a|O breakpoint|O involving|O the|O terminal|O part|O of|O the|O chromosome|O 1p|O arm|O .|O 
We|O hypothesized|O that|O this|O patient|O was|O predisposed|O to|O the|O development|O of|O neuroblastoma|O because|O he|O carried|O in|O all|O his|O somatic|O cells|O a|O chromosomal|O abnormality|O involving|O the|O region|O frequently|O deleted|O in|O neuroblastoma|O tumor|O cells|O .|O 
We|O assumed|O that|O the|O chromosomal|O translocation|O breakpoints|O might|O indicate|O the|O regions|O harbouring|O genes|O involved|O in|O neuroblastoma|O development|O .|O 
A|O somatic|O cell|O fusion|O experiment|O was|O performed|O between|O the|O patient|O 's|O fibroblasts|O (|O the|O only|O remaining|O source|O of|O patient|O material|O )|O and|O a|O fast|O growing|O Chinese|O hamster|O ovary|O cell|O line|O to|O assure|O the|O possibilities|O to|O perform|O further|O research|O .|O 
These|O somatic|O cell|O hybrids|O indeed|O contained|O the|O human|O translocation|O chromosomes|O .|O 
Further|O characterization|O of|O the|O translocation|O breakpoints|O by|O FISH|O (|O fluorescent|O in|O situ|O hybridisation|O )|O resulted|O in|O the|O identification|O of|O NPPA|gene-rna (|O formerly|O PND|gene-rna ,|O the|O gene|O for|O pronatriodilatine|O )|O and|O A12M2|O (|O an|O adenovirus|O integration|O site|O )|O as|O flanking|O markers|O for|O the|O 1p|O breakpoint|O .|O 
The|O 17q|O breakpoint|O was|O located|O between|O the|O NF1|gene-rna (|O neurofibromatosis|gene-rna 1|gene-rna )|O gene|O and|O the|O SCYA7|gene-rna (|O harboring|O the|O gene|O encoding|O the|O monocyte|gene-protein chemotactic|gene-protein protein-3|gene-protein )|O .|O 
Starting|O from|O these|O markers|O chromosome|O walking|O experiments|O furthered|O the|O characterization|O of|O the|O chromosomal|O breakpoint|O regions|O and|O enabled|O to|O identify|O breakpoint|O overlapping|O cosmids|O .|O 
Sequence|O analysis|O of|O these|O markers|O is|O ongoing|O and|O will|O reveal|O if|O the|O breakpoint|O regions|O indeed|O harbour|O a|O gene|O involved|O in|O neuroblastoma|O development|O .|O 
Inositol|O 1,4,5-trisphosphate|O and|O diacylglycerol|O mimic|O bradykinin|gene-protein effects|O on|O mouse|O neuroblastoma|O x|O rat|O glioma|O hybrid|O cells|O .|O 
1.|O The|O role|O of|O inositol|O 1,4,5-trisphosphate|O (|O InsP3|O )|O and|O diacylglycerol|O (|O DAG|O )|O as|O possible|O mediators|O of|O the|O membrane|O current|O responses|O of|O NG108-15|O neuroblastoma|O x|O glioma|O hybrid|O cells|O to|O bradykinin|gene-protein (|O BK|gene-protein ,|O Brown|O &|O Higashida|O ,|O 1988|O b|O )|O has|O been|O tested|O using|O intracellular|O ionophoresis|O of|O InsP3|O and|O external|O application|O of|O phorbol|O dibutyrate|O (|O PDBu|O )|O and|O 1-oleoyl-2-acetylglycerol|O (|O OAG|O )|O .|O 
2.|O Intracellular|O ionophoresis|O of|O InsP3|O into|O cells|O clamped|O at|O -|O 30|O to|O -|O 50|O mV|O produced|O (i)|O a|O transient|O outward|O current|O ,|O (ii)|O a|O transient|O outward|O current|O followed|O by|O an|O inward|O current|O ,|O or|O (iii)|O an|O inward|O current|O .|O 
All|O currents|O were|O accompanied|O by|O an|O increased|O input|O conductance|O .|O 
3.|O The|O transient|O outward|O current|O reversed|O at|O between|O -|O 80|O and|O -|O 90|O mV|O .|O 
The|O reversal|O potential|O was|O shifted|O to|O more|O positive|O potentials|O on|O raising|O extracellular|O [|O K|O +|O ]|O ,|O suggesting|O that|O it|O resulted|O from|O an|O increased|O K|O +|O conductance|O .|O 
4.|O The|O outward|O current|O was|O inhibited|O by|O apamin|O (|O 0.4|O microM|O )|O or|O d-tubocurarine|O (|O 0.2|O -|O 0.5|O mM|O )|O ;|O these|O drugs|O also|O inhibit|O the|O outward|O current|O produced|O by|O BK|gene-protein or|O by|O intracellular|O Ca2|O +|O injections|O (|O Brown|O &|O Higashida|O ,|O 1988|O a|O ,|O b|O )|O .|O 
The|O outward|O current|O was|O also|O slowly|O reduced|O in|O 0|O mM|O [|O Ca2|O +|O ]|O or|O 0.5|O mM|O [|O Cd2|O +|O ]|O plus|O 2|O mM|O [|O Co2|O +|O ]|O solution|O .|O 
5.|O Ionophoretic|O injection|O of|O inositol|O 1,3,4-trisphosphate|O and|O inositol|O 1,3,4,5-tetrakisphosphate|O ,|O guanosine|O trisphosphate|O or|O inorganic|O phosphate|O did|O not|O evoke|O an|O outward|O current|O but|O produced|O only|O an|O inward|O current|O with|O an|O increased|O conductance|O ,|O reversing|O at|O between|O -|O 10|O and|O -|O 20|O mV|O .|O 
6.|O Bath|O application|O of|O PDBu|O (|O 10|O nM-1|O microM|O )|O or|O OAG|O (|O 1|O -|O 10|O microM|O )|O produced|O an|O inward|O current|O with|O a|O fall|O in|O input|O conductance|O .|O 
The|O inward|O current|O was|O voltage|O dependent|O and|O was|O accompanied|O by|O an|O inhibition|O of|O the|O time|O -|O dependent|O current|O relaxations|O associated|O with|O activation|O or|O deactivation|O of|O the|O voltage|O -|O dependent|O K|O +|O current|O ,|O IM|O .|O 
7.|O PDBu|O did|O not|O clearly|O reduce|O the|O Ca2|O +|O current|O or|O the|O Ca2|O +|O -|O dependent|O K|O +|O current|O recorded|O in|O these|O cells|O .|O 
During|O superfusion|O with|O PDBu|O ,|O the|O outward|O current|O produced|O by|O intracellular|O ionophoresis|O of|O InsP3|O was|O greatly|O enhanced|O .|O 
8.|O The|O results|O support|O the|O view|O that|O the|O two|O membrane|O current|O responses|O to|O BK|gene-protein might|O both|O result|O from|O accelerated|O membrane|O phosphatidylinositide|O hydrolysis|O .|O 
One|O product|O ,|O InsP3|O ,|O releases|O Ca2|O +|O and|O activates|O an|O apamin|O -|O curare|O -|O sensitive|O outward|O K|O +|O current|O ;|O this|O effect|O is|O imitated|O by|O intracellular|O InsP3|O ionophoresis|O .|O 
The|O second|O product|O ,|O DAG|O ;|O activates|O protein|gene-protein kinase|gene-protein C|gene-protein to|O inhibit|O the|O voltage|O -|O dependent|O K|O +|O current|O IM|O and|O generate|O an|O inward|O current|O ;|O this|O effect|O is|O imitated|O by|O external|O application|O of|O PDBu|O or|O OAG|O .|O 
S-adenosylmethionine|gene-protein synthetase|gene-protein is|O overexpressed|O in|O murine|O neuroblastoma|O cells|O resistant|O to|O nucleoside|O analogue|O inhibitors|O of|O S-adenosylhomocysteine|gene-protein hydrolase|gene-protein :|O a|O novel|O mechanism|O of|O drug|O resistance|O .|O 
S-Adenosylmethionine|gene-protein (|gene-protein AdoMet|gene-protein )|gene-protein synthetase|gene-protein (|O EC|O 2.5.1.6|O )|O ,|O which|O catalyzes|O the|O synthesis|O of|O AdoMet|gene-protein from|O methionine|O and|O ATP|O ,|O is|O the|O major|O methyl|O donor|O for|O transmethylation|O reactions|O and|O propylamino|O donor|O for|O the|O biosynthesis|O of|O polyamines|O in|O biological|O systems|O .|O 
We|O have|O reported|O previously|O that|O wild|O -|O type|O C-1300|O murine|O neuroblastoma|O (|O wMNB|O )|O cells|O ,|O made|O resistant|O to|O the|O nucleoside|O analogue|O (Z)-5'-fluoro-4',5'-didehydro-5'-deoxyadenosine|O (|O MDL|O 28,842|O )|O ,|O an|O irreversible|O inhibitor|O of|O S-adenosylhomocysteine|gene-protein (|gene-protein AdoHcy|gene-protein )|gene-protein hydrolase|gene-protein (|O EC|O 3.3.1.1|O )|O ,|O express|O increased|O AdoMet|gene-protein synthetase|gene-protein activity|O (|O M.|O R.|O Hamre|O et|O al.|O ,|O Oncol.|O Res.|O ,|O 7|O :|O 487|O -|O 492|O ,|O 1995|O )|O .|O 
In|O the|O present|O study|O ,|O immunoblot|O analyses|O of|O AdoMet|gene-protein Synthetase|gene-protein with|O isoform|O -|O specific|O (|O MATII|gene-protein )|O antibodies|O demonstrated|O an|O elevation|O in|O the|O AdoMet|gene-protein synthetase|gene-protein immunoprotein|O in|O nucleoside|O analogue|O -|O resistant|O MNB|O cells|O (|O rMNB-MDL|O )|O when|O compared|O to|O wild|O -|O type|O ,|O nonresistant|O MNB|O cells|O .|O 
An|O increase|O of|O 2.1|O -|O fold|O was|O observed|O in|O the|O alpha2|O /|O alpha2|O '|O catalytic|O subunit|O ,|O which|O differed|O significantly|O from|O the|O much|O smaller|O increment|O in|O the|O noncatalytic|O beta-subunit|O of|O AdoMet|gene-protein synthetase|gene-protein .|O 
Densitometric|O analyses|O revealed|O that|O an|O increased|O expression|O of|O AdoMet|gene-protein synthetase|gene-protein in|O rMNB-MDL|O cells|O was|O due|O to|O overexpression|O of|O the|O alpha2|O (|O Mr|O 53,000|O ;|O 2.6|O -|O fold|O )|O and|O alpha2|O '|O (|O Mr|O 51,000|O ;|O 1.8|O -|O fold|O )|O subunits|O .|O 
AdoMet|gene-rna synthetase|gene-rna mRNA|O expression|O in|O rMNB-MDL|O cells|O was|O remarkably|O greater|O than|O wMNB|O cells|O ,|O as|O determined|O by|O quantitative|O competitive|O reverse|O transcription|O -|O PCR|O (|O QC|O -|O PCR|O )|O analysis|O .|O 
DNA|O (|O cytosine|O )|O methyl|gene-protein transferase|gene-protein expression|O ,|O measured|O by|O reverse|O transcription|O -|O PCR|O analysis|O ,|O was|O also|O elevated|O significantly|O in|O rMNB-MDL|O cells|O .|O 
In|O contrast|O ,|O Western|O blot|O analyses|O demonstrated|O down|O -|O regulation|O (|O 1.6|O -|O fold|O )|O of|O AdoMet|gene-protein synthetase|gene-protein in|O doxorubicin|O -|O resistant|O human|O leukemia|O cells|O (|O HL-60-R|O )|O expressing|O multidrug|gene-protein resistance|gene-protein protein|gene-protein when|O compared|O with|O wild|O -|O type|O ,|O nonresistant|O HL-60|O cells|O .|O 
The|O resistance|O of|O rMNB-MDL|O cells|O to|O nucleoside|O analogue|O inhibitors|O of|O S-adenosylhomocysteine|gene-protein hydrolase|gene-protein correlates|O directly|O with|O overexpression|O of|O the|O alpha2|O /|O alpha2|O '|O subunits|O of|O AdoMet|gene-protein synthetase|gene-protein .|O 
Cellular|O adaptation|O allows|O sufficient|O AdoMet|gene-protein to|O be|O synthesized|O ,|O so|O that|O viability|O of|O the|O MNB|O cells|O can|O be|O maintained|O even|O in|O the|O presence|O of|O high|O AdoHcy|gene-protein concentrations|O .|O 
This|O novel|O mechanism|O of|O drug|O resistance|O does|O not|O appear|O to|O require|O multidrug|gene-protein resistance|gene-protein protein|gene-protein (|O P-glycoprotein|gene-protein )|O overexpression|O .|O 
Isolation|O of|O a|O novel|O integrin|gene-protein receptor|gene-protein mediating|O Arg|O -|O Gly|O -|O Asp|O -|O directed|O cell|O adhesion|O to|O fibronectin|gene-protein and|O type|gene-protein I|gene-protein collagen|gene-protein from|O human|O neuroblastoma|O cells|O .|O 
Association|O of|O a|O novel|O beta|O 1|O -|O related|O subunit|O with|O alpha|O v|O .|O 
We|O report|O the|O isolation|O from|O two|O human|O neuroblastoma|O cell|O lines|O of|O an|O Arg|O -|O Gly|O -|O Asp|O -|O dependent|O integrin|gene-protein complex|O capable|O of|O binding|O to|O vitronectin|gene-protein ,|O fibronectin|gene-protein ,|O and|O type|gene-protein I|gene-protein collagen|gene-protein .|O 
The|O two|O neuroblastoma|O cell|O lines|O ,|O SK-N-SH|O and|O IMR-32|O ,|O exhibit|O specific|O attachment|O to|O fibronectin|gene-protein and|O type|gene-protein I|gene-protein collagen|gene-protein .|O 
SK-N-SH|O cells|O exhibit|O a|O much|O stronger|O attachment|O to|O vitronectin|gene-protein than|O the|O IMR-32|O cells|O ,|O which|O attach|O poorly|O to|O this|O substrate|gene-protein .|O 
Affinity|O chromatography|O of|O octylglucoside|O extracts|O of|O 125I|O surface|O -|O labeled|O cells|O on|O GRGDSPK|O -|O Sepharose|O columns|O resulted|O in|O the|O specific|O binding|O and|O elution|O with|O GRGDSP|O of|O three|O radiolabeled|O polypeptides|O with|O relative|O molecular|O masses|O of|O 135|O ,|O 115|O ,|O and|O 90|O kD|O when|O analyzed|O by|O SDS-PAGE|O under|O nonreducing|O conditions|O .|O 
In|O the|O SK-N-SH|O cells|O the|O 135|O -|O and|O 90|O -|O kD|O polypeptides|O were|O more|O abundant|O whereas|O in|O the|O IMR-32|O cells|O the|O 135|O -|O and|O 115|O -|O kD|O polypeptides|O were|O more|O highly|O expressed|O .|O 
Liposomes|O prepared|O from|O fractions|O containing|O all|O three|O polypeptides|O bound|O to|O vitronectin|gene-protein ,|O fibronectin|gene-protein ,|O and|O type|gene-protein I|gene-protein collagen|gene-protein ,|O whereas|O liposomes|O prepared|O from|O the|O 135|O -|O and|O 115|O -|O kD|O polypeptides|O bound|O only|O to|O fibronectin|gene-protein and|O type|gene-protein I|gene-protein collagen|gene-protein .|O 
Polyclonal|O antibodies|gene-protein against|O the|O alpha|O /|O beta|O complexes|O of|O both|O the|O vitronectin|gene-protein receptor|gene-protein and|O the|O fibronectin|gene-protein receptor|gene-protein immunoprecipitated|O all|O three|O polypeptides|O .|O 
A|O monoclonal|O antibody|gene-protein against|gene-protein beta|gene-protein 1|gene-protein immunoprecipitated|O only|O the|O 135|O -|O and|O the|O 115|O -|O kD|O polypeptides|O ,|O whereas|O a|O monoclonal|O antibody|gene-protein against|gene-protein beta|gene-protein 3|gene-protein subunit|gene-protein immunoprecipitated|O the|O 135|O -|O and|O 90|O -|O kD|O polypeptides|O .|O 
Although|O ,|O the|O 115|O -|O kD|O polypeptide|O could|O be|O recognized|O by|O an|O anti|gene-protein -|gene-protein beta|gene-protein 1|gene-protein antibody|gene-protein ,|O a|O comparison|O of|O peptide|O maps|O generated|O by|O V8|gene-protein protease|gene-protein digestion|O of|O the|O 115|O -|O kD|O polypeptide|O and|O beta|O 1|O subunit|O immunoprecipitated|O from|O GRGDSPK|O -|O Sepharose|O flow|O -|O through|O material|O indicated|O that|O these|O two|O polypeptides|O are|O distinct|O .|O 
Depletion|O of|O the|O 90|O -|O kD|O polypeptide|O with|O an|O anti|gene-protein -|gene-protein beta|gene-protein 3|gene-protein monoclonal|gene-protein antibody|gene-protein did|O not|O effect|O the|O ability|O of|O the|O 115|O -|O and|O 135|O -|O kD|O polypeptides|O to|O bind|O to|O GRGDSPK|O -|O Sepharose|O .|O 
These|O data|O indicate|O that|O the|O SK-N-SH|O and|O IMR-32|O neuroblastoma|O cells|O express|O a|O novel|O "|O beta|O 1|O -|O like|O "|O integrin|gene-protein subunit|O that|O can|O associate|O with|O alpha|O v|O and|O can|O bind|O to|O RGD|O .|O We|O propose|O to|O name|O this|O beta|O 1|O -|O like|O subunit|O beta|O n|O .|O 
The|O data|O reported|O here|O thus|O demonstrate|O that|O in|O these|O two|O cell|O lines|O alpha|O v|O associates|O with|O two|O beta|O subunits|O ,|O beta|O n|O and|O beta|O 3|O ,|O forming|O two|O heterodimers|O .|O 
The|O alpha|O v|O beta|O n|O complex|O mediates|O binding|O to|O fibronectin|gene-protein and|O type|gene-protein I|gene-protein collagen|gene-protein ,|O whereas|O the|O alpha|O v|O beta|O 3|O complex|O mediates|O binding|O to|O vitronectin|gene-protein .|O 
The|O inhibitor|gene-protein of|gene-protein apoptosis|gene-protein protein|gene-protein survivin|gene-protein is|O associated|O with|O high|O -|O risk|O behavior|O of|O neuroblastoma|O .|O 
BACKGROUND|O /|O PURPOSE|O :|O 
Apoptotic|O factors|O inducing|O or|O preventing|O cell|O death|O may|O intrinsically|O govern|O the|O behavior|O of|O some|O tumors|O .|O 
Survivin|gene-protein is|O a|O recently|O described|O member|O of|O the|O inhibitor|gene-protein of|gene-protein apoptosis|gene-protein protein|O (|O IAP|gene-protein )|O family|O ,|O that|O is|O expressed|O in|O a|O cell|O cycle|O -|O dependent|O manner|O and|O is|O found|O in|O tumors|O of|O unfavorable|O histology|O .|O 
This|O study|O examines|O the|O presence|O of|O several|O apoptotic|O factors|O ,|O including|O survivin|gene-protein ,|O in|O neuroblastoma|O (|O NB|O )|O tumors|O .|O 
Clues|O to|O survivin|gene-protein 's|O function|O in|O NB|O are|O provided|O by|O examining|O its|O association|O with|O behavior|O and|O cell|O dynamics|O in|O tumors|O and|O cell|O lines|O .|O 
METHODS|O :|O 
Expression|O of|O a|O panel|O of|O apoptosis|O factors|O were|O quantified|O in|O 15|O NB|O and|O related|O tumors|O before|O chemotherapy|O and|O in|O 3|O NB|O cell|O lines|O (|O NB7|O ,|O NB10|O ,|O and|O NB16|O )|O .|O 
Survivin|gene-protein and|O other|O apoptotic|O factors|O ,|O as|O well|O N-myc|gene-rna amplification|O in|O primary|O tumors|O was|O correlated|O with|O recurrent|O disease|O and|O outcome|O .|O 
Proliferation|O rate|O ,|O apoptosis|O assays|O ,|O cell|O cycle|O analysis|O ,|O and|O drug|O -|O or|O immune|O -|O mediated|O cell|O death|O were|O assessed|O in|O cell|O lines|O and|O evaluated|O in|O the|O context|O of|O differential|O survivin|gene-rna and|O apoptosis|O gene|O expression|O .|O 
RESULTS|O :|O 
All|O 7|O tumors|O that|O went|O on|O to|O recur|O expressed|O survivin|gene-protein ,|O whereas|O expression|O was|O absent|O in|O all|O 8|O tumors|O that|O went|O into|O remission|O .|O 
N-myc|gene-rna was|O amplified|O in|O 4|O (|O 57.1|O %|O )|O of|O the|O 7|O recurrent|O tumors|O .|O 
Of|O the|O 8|O tumors|O that|O were|O cured|O ,|O Fas|gene-generic was|O expressed|O in|O 3|O (|O 38|O %|O )|O ,|O TRAIL-R1|gene-generic in|O 6|O (|O 75|O %|O )|O and|O tumor|gene-generic necrosis|gene-generic factor|gene-generic (|gene-generic TNF|gene-rna )|gene-generic -|gene-generic R1|gene-generic in|O 8|O (|O 100|O %|O )|O ,|O whereas|O these|O pro|gene-protein -|gene-protein apoptotic|gene-protein receptors|gene-protein were|O present|O in|O only|O 1|O (|O 14|O %|O )|O ,|O 1|O (|O 14|O %|O )|O ,|O and|O 4|O (|O 57|O %|O )|O of|O the|O 7|O tumors|O that|O went|O on|O to|O recur|O ,|O respectively|O .|O 
Of|O the|O 3|O cell|O lines|O ,|O NB10|O expressed|O the|O least|O survivin|gene-protein ,|O displayed|O the|O lowest|O proliferation|O index|O ,|O and|O had|O the|O fewest|O number|O of|O cells|O in|O the|O G2|O /|O M|O (|O mitotic|O )|O phase|O of|O the|O cell|O cycle|O .|O 
Furthermore|O ,|O NB10|O also|O was|O most|O sensitive|O to|O TNF|gene-protein -|gene-protein related|gene-protein apoptosis|gene-protein -|gene-protein inducing|gene-protein ligand|gene-protein (|O TRAIL|gene-protein )|O or|O etoposide|O -|O induced|O cell|O death|O .|O 
CONCLUSIONS|O :|O 
In|O primary|O NB|O tumors|O ,|O survivin|gene-protein expression|O was|O associated|O with|O tumors|O of|O high|O risk|O and|O unfavorable|O prognosis|O ,|O whereas|O pro|gene-protein -|gene-protein apoptotic|gene-protein receptor|gene-protein expression|O was|O more|O abundant|O in|O tumors|O of|O favorable|O prognosis|O .|O 
In|O this|O small|O series|O ,|O survivin|gene-protein expression|O appeared|O to|O be|O more|O predictive|O of|O recurrent|O disease|O than|O N-myc|gene-rna amplification|O .|O 
In|O cell|O lines|O ,|O survivin|gene-protein expression|O was|O cell|O cycle|O dependent|O ,|O and|O its|O expression|O was|O associated|O with|O greater|O proliferation|O rates|O and|O greater|O resistance|O to|O drug|O -|O or|O immune|O -|O mediated|O cell|O death|O .|O 
Survivin|gene-protein expression|O may|O become|O a|O useful|O prognostic|O marker|O in|O NB|O and|O could|O be|O a|O potential|O target|O for|O the|O treatment|O of|O this|O tumor|O .|O 
Analysis|O of|O the|O alpha2C|gene-rna -|gene-rna adrenergic|gene-rna receptor|gene-rna gene|O promoter|O and|O its|O cell|O -|O type|O -|O specific|O activity|O .|O 
As|O an|O initial|O approach|O to|O define|O the|O regulatory|O elements|O and|O transcriptional|O factors|O that|O account|O for|O cell|O -|O restricted|O expression|O of|O the|O alpha2c|gene-rna -|gene-rna adrenergic|gene-rna receptor|gene-rna (|O AR|gene-rna )|O gene|O ,|O we|O isolated|O and|O characterized|O the|gene-rna receptor|gene-rna gene|gene-rna and|O identified|O regions|O of|O the|gene-rna gene|gene-rna conferring|O cell|O -|O specific|O expression|O .|O 
A|O 4300|O -|O nucleotide|O (|O nt|O )|O fragment|O of|O the|O 5|O '|O -|O flanking|O region|O of|O the|O rat|O alpha2c|gene-rna -|gene-rna AR|gene-rna gene|O was|O isolated|O from|O a|O genomic|O library|O .|O 
The|O genomic|O sequence|O contained|O the|O uninterrupted|O sequence|O of|O the|O 5|O '|O -|O untranslated|O region|O of|O a|O previously|O isolated|O alpha2c|gene-rna -|gene-rna AR|gene-rna cDNA|O clone|O indicating|O the|O lack|O of|O introns|O in|O the|O 5|O '|O gene|O segment|O .|O 
RNase|gene-protein protection|O assays|O and/or|O RNA|O blot|O analysis|O indicated|O the|O expression|O of|O alpha2c|gene-rna -|gene-rna AR|gene-rna mRNA|gene-rna in|O rat|O brain|O but|O not|O in|O kidney|O or|O liver|O ,|O which|O is|O consistent|O with|O the|O major|O expression|O of|O this|gene-rna gene|gene-rna in|O neuronal|O tissue|O .|O 
The|O 5|O '|O gene|O segment|O was|O used|O to|O identify|O sites|O of|O transcriptional|O initiation|O and|O promoter|O activity|O by|O RNase|gene-protein protection|O assays|O and|O transient|O transfection|O of|O reporter|gene-rna gene|gene-rna constructs|O .|O 
With|O the|O use|O of|O RNA|O probes|O progressively|O upstream|O of|O the|O translational|O start|O site|O ,|O RNase|gene-protein protection|O assays|O with|O rat|O brain|O total|O RNA|O indicated|O multiple|O sites|O of|O transcriptional|O initiation|O within|O a|O approximately|O 70|O -|O nt|O span|O (|O -|O 660|O to|O -|O 730|O nt|O 5|O '|O to|O the|O translational|O start|O codon|O )|O .|O 
The|O zone|O of|O transcriptional|O initiation|O was|O part|O of|O a|O larger|O GC|O -|O rich|O area|O of|O the|O 5|O '|O gene|O segment|O that|O is|O a|O characteristic|O of|O genes|O initiating|O transcripts|O at|O multiple|O sites|O .|O 
The|O promoter|O activity|O of|O this|O zone|O of|O transcriptional|O initiation|O and|O the|O influence|O of|O gene|O segments|O 5|O '|O to|O this|O area|O were|O addressed|O using|O chloramphenicol|gene-rna acetyl|gene-rna transferase|gene-rna reporter|gene-rna gene|gene-rna constructs|O .|O 
Transient|O transfection|O of|O reporter|gene-rna gene|gene-rna constructs|O indicated|O that|O a|O 96|O -|O nt|O gene|O fragment|O (|O -|O 699|O /|O -|O 603|O relative|O to|O the|O translational|O start|O codon|O )|O was|O sufficient|O to|O direct|O transcription|O in|O the|O neuroblastoma|O X|O glioma|O hybrid|O cell|O line|O NG108-15|O ,|O a|O cell|O line|O expressing|O the|O endogenous|O alpha2c|gene-rna -|gene-rna AR|gene-rna .|O 
Promoter|O activity|O was|O not|O observed|O in|O constructs|O lacking|O the|O zone|O of|O transcriptional|O initiation|O .|O 
The|O promoter|O segment|O was|O inactive|O when|O introduced|O into|O the|O rat|O glioma|O cell|O line|O C6B4|O ,|O the|O rat|O submandibular|O cell|O line|O RSMT-A5|O ,|O and|O the|O rat|O pancreatic|O beta|O cell|O line|O RIN-5AH|O ,|O all|O of|O which|O do|O not|O express|O the|O endogenous|O alpha2c|gene-rna -|gene-rna AR|gene-rna gene|O .|O 
Upon|O incubation|O with|O nuclear|O extracts|O ,|O a|O 129|O -|O nt|O fragment|O encompassing|O the|O promoter|O exhibited|O a|O gel|O mobility|O shift|O pattern|O that|O was|O specific|O for|O cells|O expressing|O the|O receptor|O protein|O and|O involved|O a|O nuclear|O protein|O that|O recognized|O a|O Sp1|O oligonucleotide|O .|O 
These|O data|O indicate|O that|O a|O 96|O -|O nt|O gene|O promoter|O segment|O of|O the|O alpha2c|gene-rna -|gene-rna AR|gene-rna gene|O functions|O in|O a|O cell|O -|O type|O -|O specific|O manner|O .|O 
Modulatory|O effects|O of|O human|O cytomegalovirus|O infection|O on|O malignant|O properties|O of|O cancer|O cells|O .|O 
Although|O there|O is|O no|O definitive|O evidence|O of|O the|O association|O of|O human|O cytomegalovirus|O (|O HCMV|O )|O infection|O with|O human|O cancers|O ,|O the|O oncogenic|O potential|O of|O HCMV|O has|O been|O well|O established|O by|O in|O vitro|O studies|O demonstrating|O the|O ability|O of|O UV|O -|O irradiated|O or|O infectious|O virus|O to|O transform|O a|O variety|O of|O cells|O .|O 
After|O prolonged|O passaging|O the|O transformed|O cell|O type|O was|O maintained|O while|O HCMV|O DNA|O sequences|O were|O no|O more|O detectable|O .|O 
Three|O morphological|O transforming|O regions|O (|O mtr|O )|O of|O HCMV|O have|O been|O identified|O .|O 
The|O effects|O of|O HCMV|O on|O cellular|O functions|O which|O may|O be|O associated|O with|O the|O malignant|O phenotype|O include|O the|O expression|O of|O oncogenes|O and|O transcriptional|O activation|O of|O growth|O factors|O and|O interleukin|gene-protein synthesis|O .|O 
In|O infected|O cells|O ,|O HCMV|O induces|O cytoskeletal|O alterations|O and|O changes|O in|O expression|O of|O cell|O surface|O receptors|O for|O extracellular|O matrix|O proteins|O which|O could|O result|O in|O increased|O motility|O and|O dissemination|O of|O cancer|O cells|O .|O 
Several|O human|O neuroblastoma|O cell|O lines|O undergo|O maturation|O in|O different|O neural|O crest|O derived|O cell|O types|O upon|O treatment|O with|O oncogenic|O potential|O agents|O ,|O i.e.|O retinoic|O acid|O .|O 
The|O persistent|O HCMV|O infection|O of|O neuroblastoma|O cells|O (|O >|O 1|O year|O )|O is|O accompanied|O by|O the|O increased|O expression|O of|O oncoproteins|O (|O i.e.|O N-myc|gene-protein )|O and|O decreased|O expression|O of|O tyrosine|gene-protein hydroxylase|gene-protein and|O dopamine|gene-protein -|gene-protein beta-hydroxylase|gene-protein .|O 
The|O activation|O of|O the|O cellular|O metabolism|O is|O due|O to|O HCMV|O binding|O to|O cellular|O receptors|O (|O prior|O to|O virus|O gene|O expression|O )|O and|O to|O the|O activity|O of|O HCMV|O immediate|O early|O (|O IE|gene-rna )|O gene|O products|O .|O 
IE|gene-protein proteins|O act|O directly|O as|O transcriptional|O activators|O or|O their|O activity|O is|O mediated|O by|O a|O variety|O of|O cellular|O transcription|O factors|O .|O 
HCMV|O infection|O may|O result|O in|O activation|O of|O promoters|O of|O cellular|O genes|O coding|O for|O cytokines|gene-protein ,|O replication|gene-protein enzymes|gene-protein ,|O proto|O -|O oncogenes|O and|O viral|O promoters|O .|O 
Recently|O it|O has|O been|O demonstrated|O that|O HCMV|O IE|gene-protein proteins|O block|O apoptosis|O probably|O by|O suppressing|O the|O ability|O of|O the|O antioncogene|O p53|gene-rna to|O activate|O a|O reporter|gene-rna gene|gene-rna .|O 
The|O interactions|O of|O HCMV|O with|O tumor|O suppressor|O proteins|O such|O as|O p53|gene-protein or|O retinoblastoma|gene-protein (|O pRb|gene-protein )|O susceptibility|O protein|O are|O reminiscent|O of|O those|O mediated|O by|O the|O oncoproteins|O of|O DNA|O tumor|O viruses|O .|O 
The|O acquisition|O of|O a|O fully|O malignant|O phenotype|O by|O normal|O cells|O is|O thought|O to|O require|O several|O mutations|O in|O a|O number|O of|O cellular|O genes|O .|O 
In|O this|O connection|O ,|O HCMV|O may|O play|O the|O role|O of|O a|O nonobligate|O either|O direct|O or|O indirect|O cofactor|O for|O tumor|O genesis|O ,|O e.g.|O by|O blocking|O apoptosis|O ,|O which|O may|O be|O an|O essential|O requirement|O for|O tumor|O progression|O .|O 
Due|O to|O the|O stimulation|O of|O growth|O factors|O and/or|O inhibition|O of|O antioncogenes|O by|O its|O gene|O products|O ,|O HCMV|O may|O modulate|O the|O malignant|O potential|O for|O tumor|O cells|O .|O 
Induction|O of|O chromosomal|O instability|O in|O colonic|O cells|O by|O the|O human|O polyomavirus|O JC|O virus|O .|O 
Most|O colorectal|O cancers|O display|O chromosomal|O instability|O ,|O which|O is|O characterized|O by|O gross|O chromosomal|O rearrangements|O ,|O loss|O of|O heterozygosity|O and|O aneuploidy|O .|O 
We|O have|O previously|O demonstrated|O a|O link|O between|O JC|O virus|O strains|O Mad-1|O and|O Delta98|O and|O colorectal|O cancer|O .|O 
Others|O have|O also|O associated|O the|O virus|O to|O the|O induction|O of|O colon|O cancer|O and|O aneuploid|O brain|O tumors|O by|O producing|O a|O highly|O tumorigenic|O protein|O named|O T|gene-protein antigen|gene-protein (|O TAg|gene-protein )|O ,|O which|O binds|O to|O beta-catenin|gene-protein and|O inactivates|O key|O proteins|O such|O as|O p53|gene-protein .|O 
The|O aim|O is|O to|O demonstrate|O that|O JC|O virus|O is|O capable|O of|O inducing|O chromosomal|O instability|O in|O colonic|O cells|O .|O 
We|O used|O the|O human|O colon|O cancer|O cell|O line|O RKO|O as|O a|O model|O .|O 
The|O cell|O line|O has|O wild-type|O p53|gene-rna ,|O wild-type|O beta-catenin|gene-rna and|O APC|gene-rna and|O is|O diploid|O .|O 
Neuroblastoma|O JCI|O cells|O ,|O which|O are|O infected|O with|O the|O virus|O ,|O VA13|O fibroblasts|O ,|O which|O are|O transformed|O by|O the|O SV40|O TAg|gene-protein ,|O were|O used|O as|O positive|O controls|O .|O 
HCT116|O ,|O which|O has|O mutated|O beta-catenin|gene-rna ,|O and|O SW480|O ,|O which|O is|O a|O model|O of|O CIN|O ,|O were|O also|O used|O as|O controls|O .|O 
The|O genomes|O of|O the|O Mad-1|O and|O Delta98|O strains|O were|O transfected|O into|O cells|O .|O 
As|O negative|O controls|O we|O used|O pUC|O or|O no|O plasmids|O .|O 
Cells|O were|O collected|O at|O 0|O ,|O 7|O ,|O 14|O ,|O and|O 21|O days|O after|O transfection|O .|O 
PCR|O was|O used|O for|O the|O detection|O of|O TAg|gene-protein and|O the|O regulatory|O region|O DNA|O sequences|O at|O different|O time|O frames|O and|O Southern|O blot|O of|O whole|O genomic|O extracts|O for|O viral|O DNA|O integration|O into|O the|O host|O genome|O .|O 
Immunofluorescence|O and|O Western|O blot|O were|O performed|O for|O TAg|gene-protein ,|O viral|O capsid|O proteins|O ,|O and|O nuclear|O beta-catenin|gene-protein expressions|O ,|O whereas|O coimmunoprecipitation|O was|O used|O to|O detect|O protein|O interactions|O .|O 
Karyotype|O analysis|O and|O electron|O microscopy|O were|O performed|O to|O seek|O chromosomal|O instability|O and|O cell|O abnormalities|O ,|O respectively|O .|O 
Retention|O of|O viral|O sequences|O was|O observed|O for|O Mad-1|O -|O and|O Delta98|O -|O transfected|O RKO|O cells|O at|O all|O time|O frames|O with|O PCR|O only|O ,|O whereas|O Southern|O blot|O analysis|O showed|O nonintegrated|O sequences|O at|O T7|O alone|O .|O 
TAg|gene-protein and|O capsid|gene-protein protein|O expressions|O ,|O as|O well|O as|O increased|O p53|gene-protein and|O nuclear|O beta-catenin|gene-protein ,|O were|O observed|O between|O T0|O and|O T7|O for|O Mad-1|O and|O Delta98|O alone|O .|O 
Also|O ,|O interaction|O between|O TAg|gene-protein and|O both|O p53|gene-protein and|O beta-catenin|gene-protein was|O also|O observed|O between|O T0|O and|O T7|O .|O Chromosomal|O instability|O ,|O characterized|O by|O chromosomal|O breakage|O ,|O dicentric|O chromosomes|O ,|O and|O increasing|O ploidy|O ,|O was|O observed|O at|O all|O time|O frames|O for|O Mad-1|O and|O Delta98|O ,|O as|O well|O as|O cell|O abnormalities|O .|O 
In|O conclusion|O ,|O we|O demonstrate|O that|O JC|O virus|O Mad-1|O and|O Delta98|O are|O able|O to|O induce|O chromosomal|O instability|O in|O colonic|O cells|O with|O a|O hit|O and|O run|O mechanism|O that|O involves|O an|O early|O interaction|O with|O beta-catenin|gene-protein and|O p53|gene-protein .|O 
Interaction|O of|O ethanol|O with|O inducers|O of|O glucose|O -|O regulated|O stress|O proteins|O .|O 
Ethanol|O potentiates|O inducers|O of|O grp78|gene-protein transcription|O .|O 
GRP78|gene-protein ,|O a|O molecular|O chaperone|O expressed|O in|O the|O endoplasmic|O reticulum|O ,|O is|O a|O "|O glucose|O -|O regulated|O protein|O "|O induced|O by|O stress|O responses|O that|O deplete|O glucose|O or|O intracisternal|O calcium|O or|O otherwise|O disrupt|O glycoprotein|O trafficking|O .|O 
Previously|O we|O showed|O that|O chronic|O ethanol|O exposure|O increases|O the|O expression|O of|O GRP78|gene-protein .|O 
To|O further|O understand|O the|O mechanism|O underlying|O ethanol|O regulation|O of|O GRP78|gene-protein expression|O ,|O we|O studied|O the|O interaction|O between|O ethanol|O and|O classical|O modulators|O of|O GRP78|gene-protein expression|O in|O NG108-15|O neuroblastoma|O x|O glioma|O cells|O .|O 
We|O found|O that|O ,|O in|O addition|O to|O increasing|O basal|O levels|O of|O GRP78|gene-rna mRNA|O (|O "|O induction|O "|O )|O ,|O ethanol|O produced|O greater|O than|O additive|O increases|O in|O the|O induction|O of|O GRP78|gene-rna mRNA|O by|O the|O "|O classical|O "|O GRP|gene-protein inducers|O A23187|gene-protein ,|O brefeldin|O A|O ,|O and|O thapsigargin|O (|O "|O potentiation|O "|O )|O .|O 
Both|O the|O ethanol|O induction|O and|O potentiation|O responses|O modulated|O grp78|gene-rna gene|O transcription|O as|O determined|O by|O stable|O transfection|O analyses|O with|O the|O rat|O grp78|gene-rna promoter|O .|O 
Ethanol|O potentiated|O the|O action|O of|O all|O classical|O inducers|O of|O grp78|gene-rna transcription|O that|O were|O studied|O .|O 
In|O contrast|O ,|O co|O -|O treatment|O with|O the|O classical|O GRP|gene-protein inducers|O thapsigargin|O and|O tunicamycin|O produced|O only|O simple|O additive|O increases|O in|O grp78|gene-rna promoter|O activity|O .|O 
Transient|O transfection|O studies|O with|O deletion|O mutants|O of|O the|O rat|O grp78|gene-rna promoter|O showed|O that|O cis|O -|O acting|O promoter|O sequences|O required|O for|O ethanol|O induction|O differ|O from|O those|O mediating|O responses|O to|O classical|O GRP|gene-protein inducers|O .|O 
Furthermore|O ,|O linker|O -|O scanning|O mutations|O of|O the|O grp78|gene-rna promoter|O suggested|O that|O the|O ethanol|O potentiation|O response|O required|O a|O cis|O -|O acting|O promoter|O element|O different|O from|O those|O involved|O in|O induction|O by|O ethanol|O or|O classical|O inducing|O agents|O .|O 
While|O the|O ethanol|O induction|O response|O required|O 16|O -|O 24|O h|O to|O be|O detectable|O ,|O ethanol|O potentiation|O of|O thapsigargin|O occurred|O within|O 6|O h|O .|O 
The|O potentiation|O response|O also|O decayed|O rapidly|O after|O ethanol|O removal|O .|O In|O addition|O ,|O the|O protein|gene-protein kinase|gene-protein A|gene-protein inhibitor|O Rp-cAMPS|O and|O protein|gene-protein phosphatase|gene-protein inhibitor|O okadaic|O acid|O both|O increased|O ethanol|O potentiation|O of|O thapsigargin|O while|O Sp-cAMPS|O ,|O an|O activator|O of|O protein|gene-protein kinase|gene-protein A|gene-protein ,|O decreased|O ethanol|O potentiation|O .|O 
Taken|O together|O ,|O our|O findings|O suggest|O two|O mechanisms|O by|O which|O ethanol|O regulates|O grp78|gene-rna transcription|O ,|O both|O differing|O from|O the|O action|O of|O classical|O GRP|gene-protein inducers|O such|O as|O thapsigargin|O .|O 
One|O mechanism|O (|O potentiation|O )|O involves|O a|O protein|O phosphorylation|O cascade|O and|O potentiates|O the|O action|O of|O classical|O GRP|gene-protein inducers|O .|O 
In|O contrast|O ,|O GRP78|gene-rna induction|O by|O ethanol|O involves|O promoter|O sequences|O and|O a|O mechanistic|O pathway|O separate|O from|O that|O of|O the|O ethanol|O potentiation|O response|O or|O classical|O GRP78|gene-rna inducers|O .|O 
These|O studies|O show|O that|O ethanol|O produces|O a|O novel|O and|O complex|O regulation|O of|O grp78|gene-rna transcription|O which|O could|O be|O of|O particular|O importance|O during|O neuronal|O exposure|O to|O GRP|gene-protein -|O inducing|O stressors|O as|O might|O occur|O with|O central|O nervous|O system|O injury|O .|O 
Molecular|O mechanisms|O of|O multidrug|O resistance|O in|O cancer|O chemotherapy|O .|O 
The|O occurrence|O of|O multidrug|O resistance|O (|O MDR|O )|O is|O one|O of|O the|O main|O obstacles|O in|O the|O successful|O chemotherapeutic|O treatment|O of|O cancer|O .|O 
MDR|O cell|O lines|O are|O resistant|O to|O the|O so|O -|O called|O naturally|O occurring|O anti|O -|O cancer|O drugs|O ,|O such|O as|O anthracyclines|O ,|O Vinca|O alkaloids|O and|O epipodophyllotoxins|O ,|O but|O are|O not|O cross|O -|O resistant|O to|O alkylating|O agents|O ,|O antimetabolites|O and|O cisplatin|O .|O 
So|O far|O ,|O three|O separate|O forms|O of|O MDR|O have|O been|O characterized|O in|O more|O detail|O :|O classical|O MDR|O ,|O non|O -|O Pgp|O MDR|O and|O atypical|O MDR|O .|O 
Although|O all|O three|O MDR|O phenotypes|O have|O much|O in|O common|O with|O respect|O to|O cross|O -|O resistance|O patterns|O ,|O the|O underlying|O mechanisms|O certainly|O differ|O .|O 
Atypical|O MDR|O is|O associated|O with|O quantitative|O and|O qualitative|O alterations|O in|O topoisomerase|gene-protein II|gene-protein alpha|gene-protein ,|O a|O nuclear|O enzyme|O that|O actively|O participates|O in|O the|O lethal|O action|O of|O cytotoxic|O drugs|O .|O 
Atypical|O MDR|O cells|O do|O not|O overexpress|O P-glycoprotein|gene-protein ,|O and|O are|O unaltered|O in|O their|O ability|O to|O accumulate|O drugs|O .|O 
In|O this|O review|O we|O will|O focus|O on|O classical|O and|O non|O -|O Pgp|O MDR|O .|O 
The|O molecular|O mechanism|O of|O classical|O and|O non|O -|O Pgp|O MDR|O is|O transcriptional|O activation|O of|O membrane|O -|O bound|O transport|O proteins|O .|O 
These|O transport|O proteins|O belong|O to|O the|O ATP|O -|O binding|O cassette|O (|O ABC|O )|O superfamily|O of|O transport|O systems|O .|O 
The|O classical|O MDR|O phenotype|O is|O characterized|O by|O a|O reduced|O ability|O to|O accumulate|O drugs|O ,|O due|O to|O activity|O of|O an|O energy|O -|O dependent|O uni|O -|O directional|O ,|O membrane|O -|O bound|O ,|O drug|O -|O efflux|O pump|O with|O broad|O substrate|O specificity|O .|O 
The|O classical|O MDR|O drug|O pump|O is|O composed|O of|O a|O transmembrane|O glycoprotein|O (|O P-glyco-protein-Pgp|gene-protein )|O with|O a|O molecular|O weight|O of|O 170|O kD|O ,|O and|O is|O ,|O in|O man|O ,|O encoded|O by|O the|O so|O -|O called|O multidrug|gene-rna resistance|gene-rna (|O MDR1|gene-rna )|O gene|O .|O 
Typically|O ,|O non|O -|O Pgp|O MDR|O has|O no|O P-gly-coprotein|gene-protein expression|O ,|O yet|O has|O about|O the|O same|O cross|O -|O resistance|O pattern|O as|O classical|O MDR|O .|O 
This|O non|O -|O Pgp|O MDR|O phenotype|O is|O caused|O by|O overexpression|O of|O the|O multidrug|gene-rna resistance|gene-rna -|gene-rna associated|gene-rna protein|gene-rna (|O MRP|gene-rna )|O gene|O ,|O which|O encodes|O a|O 190|O kD|O membrane|O -|O bound|O glycoprotein|O (|O MRP|gene-protein )|O .|O 
MRP|gene-protein probably|O works|O by|O direct|O extrusion|O of|O cytotoxic|O drugs|O from|O the|O cell|O and/or|O by|O mediating|O sequestration|O of|O the|O drugs|O into|O intracellular|O compartments|O ,|O both|O leading|O to|O a|O reduction|O in|O effective|O intracellular|O drug|O concentrations|O .|O 
For|O the|O classical|O MDR|O phenotype|O ,|O evidence|O is|O accumulating|O that|O it|O plays|O a|O role|O indeed|O ,|O in|O clinical|O drug|O resistance|O ,|O especially|O in|O some|O hematological|O malignancies|O (|O acute|O myeloid|O leukemia|O ,|O multiple|O myeloma|O and|O non|O -|O Hodgkin|O 's|O lymphoma|O )|O and|O solid|O tumors|O (|O soft|O tissue|O sarcomas|O and|O neuroblastoma|O )|O .|O 
The|O association|O of|O MRP|gene-generic with|O clinical|O drug|O resistance|O has|O not|O been|O elaborated|O ,|O yet|O ,|O and|O studies|O on|O MRP|gene-generic expression|O in|O human|O cancer|O have|O just|O begun|O .|O 
We|O found|O that|O overexpression|O of|O MRP|gene-generic ,|O as|O determined|O by|O RNase|gene-protein protection|O assay|O as|O well|O as|O by|O immunohistochemistry|O ,|O occurs|O in|O several|O human|O cancers|O ,|O among|O which|O are|O cancer|O of|O the|O lung|O ,|O esophagus|O ,|O breast|O and|O ovary|O ,|O and|O leukemias|O .|O 
Further|O studies|O are|O indicated|O to|O establish|O whether|O elevated|O MRP|gene-protein expression|O at|O diagnosis|O is|O an|O unfavorable|O prognostic|O factor|O for|O clinical|O outcome|O of|O chemotherapy|O .|O 
Evaluation|O of|O Epstein|O -|O Barr|O virus|O infection|O in|O sinonasal|O small|O round|O cell|O tumors|O .|O 
Sinonasal|O undifferentiated|O carcinoma|O ,|O olfactory|O neuroblastoma|O and|O malignant|O melanoma|O of|O the|O sinonasal|O regions|O are|O included|O within|O the|O category|O of|O small|O round|O cell|O tumors|O of|O the|O sinonasal|O region|O .|O 
It|O is|O difficult|O to|O diagnose|O these|O tumors|O on|O the|O basis|O of|O light|O -|O microscopic|O features|O alone|O ,|O but|O ,|O in|O some|O instances|O ,|O immunohistochemical|O staining|O evaluating|O cytokeratin|gene-protein and|O S-|gene-protein 100|gene-protein protein|gene-protein ,|O for|O example|O ,|O is|O of|O value|O .|O 
On|O the|O other|O hand|O ,|O the|O sinonasal|O region|O is|O a|O significant|O site|O for|O Epstein|O -|O Barr|O -virus|O (|O EBV|O )|O -|O related|O tumors|O ,|O including|O sinonasal|O undifferentiated|O carcinoma|O or|O malignant|O lymphoma|O .|O 
Twenty-three|O sinonasal|O small|O round|O cell|O tumors|O (|O SSRCT|O )|O comprising|O 5|O sinonasal|O undifferentiated|O carcinomas|O ,|O 9|O olfactory|O neuroblastomas|O and|O 9|O malignant|O melanomas|O were|O evaluated|O for|O the|O presence|O of|O EBV|O infection|O by|O in|O situ|O hybridization|O for|O EBV-encoded|gene-rna RNA|gene-rna ,|O combined|O with|O immunostaining|O for|O EBV|gene-protein -|gene-protein related|gene-protein proteins|gene-protein (|O LMP-1|gene-protein and|O EBNA2|gene-protein )|O .|O 
Furthermore|O ,|O 55|O SSRCT|O comprising|O 37|O sinonasal|O undifferentiated|O carcinomas|O ,|O 9|O olfactory|O neuroblastomas|O ,|O and|O 9|O malignant|O melanomas|O were|O examined|O for|O the|O presence|O of|O cytokeratins|gene-protein (|O AE1|gene-protein /|O AE3|gene-protein and|O CAM5.2|gene-protein )|O ,|O S-|gene-protein 100|gene-protein protein|O and|O p53|gene-protein protein|O using|O immunohistochemical|O staining|O .|O 
According|O to|O in|O situ|O hybridization|O for|O detecting|O EBV-encoded|gene-rna RNA|gene-rna 1|gene-rna (|O EBER1|gene-rna )|O ,|O all|O of|O the|O sinonasal|O undifferentiated|O carcinomas|O showed|O clear|O ,|O intense|O hybridization|O signals|O localized|O over|O the|O nuclei|O of|O the|O tumor|O cells|O and|O ,|O in|O 3|O out|O of|O 9|O (|O 33.3|O %|O )|O malignant|O melanomas|O ,|O hybridization|O signals|O were|O also|O recognized|O .|O 
However|O ,|O none|O of|O the|O olfactory|O neuroblastomas|O revealed|O hybridization|O signals|O .|O 
Immunohistochemically|O ,|O 4|O out|O of|O 5|O (|O 80|O %|O )|O sinonasal|O undifferentiated|O carcinomas|O were|O positive|O for|O LMP|gene-protein -1|gene-protein ,|O whereas|O only|O 2|O out|O 9|O (|O 22.2|O %|O )|O malignant|O melanomas|O and|O no|O olfactory|O neuroblastomas|O were|O positive|O .|O 
With|O regard|O to|O EBNA2|gene-protein ,|O sinonasal|O undifferentiated|O carcinomas|O ,|O malignant|O melanomas|O and|O olfactory|O neuroblastomas|O were|O all|O negative|O .|O 
Out|O of|O 37|O sinonasal|O undifferentiated|O carcinomas|O 35|O (|O 94.6|O %|O )|O showed|O a|O diffuse|O positive|O immunoreaction|O for|O AE1|gene-protein /|O AE3|gene-protein ,|O whereas|O neither|O olfactory|O neuroblastoma|O nor|O malignant|O melanoma|O revealed|O a|O positive|O reaction|O .|O 
All|O 9|O malignant|O melanomas|O and|O 6|O out|O of|O 9|O olfactory|O neuroblastomas|O (|O 75|O %|O )|O were|O positive|O for|O S-|gene-protein 100|gene-protein protein|O ,|O whereas|O only|O 6|O cases|O of|O sinonasal|O undifferentiated|O carcinomas|O (|O 19.4|O %|O )|O were|O positive|O .|O 
As|O for|O p53|gene-protein protein|O ,|O 16|O of|O 37|O sinonasal|O undifferentiated|O carcinomas|O (|O 43.2|O %|O )|O were|O positive|O ,|O whereas|O neither|O olfactory|O neuroblastoma|O nor|O malignant|O melanoma|O revealed|O any|O positive|O reaction|O .|O 
The|O above|O results|O suggest|O that|O EBV|O infection|O is|O closely|O associated|O with|O sinonasal|O undifferentiated|O carcinomas|O ,|O and|O that|O some|O malignant|O melanomas|O may|O also|O have|O a|O relationship|O with|O its|O infection|O .|O 
For|O the|O differential|O diagnosis|O of|O SSRCT|O ,|O it|O is|O important|O to|O evaluate|O EBV|O infection|O along|O with|O immunohistochemical|O staining|O for|O cytokeratins|gene-protein and|O S-|gene-protein 100|gene-protein protein|O .|O 
The|O overexpression|O of|O p53|gene-protein protein|O was|O found|O to|O be|O related|O to|O the|O oncogenesis|O of|O sinonasal|O undifferentiated|O carcinoma|O ;|O however|O ,|O there|O was|O no|O association|O between|O its|O overexpression|O and|O malignant|O melanoma|O or|O olfactory|O neuroblastoma|O .|O 
The|O thyrotropin|gene-rna -|gene-rna releasing|gene-rna hormone|gene-rna gene|O 1998|O :|O cloning|O ,|O characterization|O ,|O and|O transcriptional|O regulation|O in|O the|O central|O nervous|O system|O ,|O heart|O ,|O and|O testis|O .|O 
Mechanisms|O of|O triiodothyronine|O (|O T3|O )|O negative|O regulation|O of|O the|O human|O thyrotropin|gene-rna -|gene-rna releasing|gene-rna hormone|gene-rna (|O TRH|gene-rna )|O gene|O were|O investigated|O with|O a|O chimeric|O construct|O of|O the|O 5|O '|O flanking|O region|O fused|O to|O a|O luciferase|gene-rna reporter|gene-rna gene|O ,|O transfected|O into|O human|O neuroblastoma|O cells|O (|O HTB-11|O )|O .|O 
Maximum|O negative|O regulation|O was|O achieved|O with|O constructs|O containing|O bases|O -|O 242|O to|O +|O 54|O .|O 
Four|O sequences|O in|O this|O region|O exhibited|O homology|O with|O half|O sites|O of|O thyroid|O hormone|O response|O elements|O (|O TRE|O )|O (|O AGGTCA|O )|O .|O 
The|O most|O important|O site|O was|O a|O sequence|O with|O an|O overlapping|O TRE|O /|O CRE|O ,|O involving|O bases|O -|O 53|O to|O -|O 60|O (|O TGACCTCA|O )|O .|O 
Potential|O combinatorial|O interactions|O of|O thyroid|gene-protein hormone|gene-protein receptors|gene-protein and|O CREB|gene-protein at|O this|O site|O were|O explored|O .|O 
Modest|O promoter|O stimulation|O was|O achieved|O with|O dibutyryl|O cyclic|O adenosine|O monophosphate|O (|O cAMP|O )|O (|O 10(-3)|O M|O )|O plus|O IBMX|O (|O 0.5|O mM|O )|O .|O 
Stimulation|O was|O greatly|O enhanced|O (|O +|O 820|O %|O )|O by|O cotransfection|O of|O a|O constitutively|O activated|O protein|gene-protein kinase|gene-protein A|gene-protein (|O pPKA|gene-protein )|O construct|O .|O 
Cotransfection|O with|O pCREB|gene-protein increased|O stimulation|O further|O to|O 1350|O %|O above|O control|O .|O 
Stimulation|O of|O pPKA|gene-protein and|O pCREB|gene-protein interfered|O with|O stimulation|O by|O unliganded|O TRbeta1|gene-protein ,|O and|O co|O -|O transfected|O pPKA|gene-protein and|O pCREB|gene-protein blocked|O T3|O negative|O inhibition|O by|O TRbeta1|gene-protein -|gene-protein T3|gene-protein complexes|O .|O 
When|O this|O site|O was|O mutated|O by|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O mutagenesis|O ,|O the|O mutant|O construct|O failed|O to|O respond|O to|O unliganded|O TRbeta1|gene-protein ,|O and|O stimulation|O by|O pPKA|gene-protein and/or|O pCREB|gene-protein was|O inhibited|O markedly|O ,|O from|O 12.5|O -|O to|O 2.1|O -|O fold|O ,|O p|O <|O 0.001|O .|O 
Moreover|O ,|O TRbeta1|gene-protein -|gene-protein T3|gene-protein complexes|O failed|O to|O show|O any|O inhibition|O of|O the|O mutated|O promoter|O .|O 
These|O results|O suggest|O that|O negative|O regulation|O is|O achieved|O by|O inhibition|O of|O CREB|gene-protein stimulation|O of|O the|O TRH|gene-rna promoter|O at|O this|O overlapping|O TRE|O /|O CRE|O site|O .|O 
The|O two|O cosuppressors|O ,|O NCoR|gene-protein and|O SMRT|gene-protein ,|O were|O able|O to|O augment|O stimulation|O of|O the|O TRH|gene-rna promoter|O by|O unliganded|O TRbeta1|gene-protein and|O enhance|O the|O magnitude|O of|O T3|O inhibition|O .|O 
The|O potential|O role|O of|O the|O TRH|gene-rna gene|O and|O the|O pathophysiology|O of|O thyroid|O hormone|O resistance|O was|O investigated|O with|O three|O mutant|O TRbeta1|gene-protein constructs|O .|O 
Thyroid|O hormone|O resistance|O was|O found|O to|O be|O expressed|O at|O the|O level|O of|O TRH|gene-rna gene|O regulation|O ,|O due|O to|O lowered|O inhibition|O by|O mutant|O TRbeta1|gene-protein -|gene-protein T3|gene-protein complexes|O and|O by|O their|O dominant|O negative|O effects|O on|O wild|O -|O type|O TRbeta1|gene-protein -|gene-protein T3|gene-protein inhibition|O .|O 
TRH|gene-rna gene|O expression|O has|O been|O identified|O in|O the|O heart|O .|O 
Cardiac|O TRH|gene-rna mRNA|O was|O not|O regulated|O by|O T3|O ,|O in|O contrast|O to|O HTB-11|O cells|O ,|O but|O cardiac|O TRH|gene-rna mRNA|O density|O could|O be|O augmented|O by|O glucocorticoids|O and|O by|O testosterone|O .|O 
TRH|gene-protein receptors|gene-protein were|O identified|O using|O Scatchard|O blots|O that|O showed|O a|O kilodalton|O of|O 1.4|O nM|O and|O a|O bmax|O of|O 10|O pmol|O /|O mg|O protein|O .|O 
TRH-R|gene-rna mRNA|O was|O identified|O also|O by|O reverse|O transcription|O polymerase|gene-protein chain|O reaction|O (|O RT-PCR|O )|O .|O 
Enhanced|O ventricular|O contractility|O by|O TRH|gene-rna was|O demonstrated|O in|O both|O an|O open|O -|O chested|O dog|O preparation|O and|O in|O ex|O vivo|O ventricular|O myocytes|O ,|O using|O video|O edge|O cinematography|O .|O 
Under|O controlled|O conditions|O ,|O myocyte|O shortening|O was|O 13.3|O %|O ,|O and|O TRH|gene-rna (|O 10(-6)|O M|O )|O caused|O muscle|O shortening|O to|O increase|O 140|O %|O ,|O (|O p|O <|O 0.005|O )|O .|O 
TRH|gene-rna gene|O expression|O was|O demonstrated|O exclusively|O in|O Leydig|O cells|O of|O the|O testis|O .|O 
High|O affinity|O binding|O sites|O were|O identified|O in|O testicular|O membranes|O with|O a|O kilodalton|O of|O 1.6|O x|O 10(-6)|O M|O .|O TRH|gene-rna was|O able|O to|O inhibit|O LH|O and|O HCG|O -|O activated|O testosterone|O secretion|O significantly|O .|O 
Thus|O ,|O one|O paracrine|O role|O of|O TRH|gene-rna in|O the|O testis|O may|O be|O to|O serve|O as|O inhibitory|O modulator|O of|O gonadotropin|O -|O stimulated|O testosterone|O secretion|O .|O 
N-Myc|gene-rna gene|O amplification|O is|O a|O major|O prognostic|O factor|O in|O localized|O neuroblastoma|O :|O results|O of|O the|O French|O NBL|O 90|O study|O .|O 
PURPOSE|O :|O 
To|O assess|O the|O relevance|O of|O N-Myc|gene-rna gene|O amplification|O (|O NMA|O )|O as|O a|O prognostic|O factor|O in|O localized|O neuroblastoma|O (|O NB|O )|O and|O to|O evaluate|O whether|O less|O intensive|O adjuvant|O treatment|O is|O advisable|O in|O infants|O without|O NMA|O .|O 
PATIENTS|O AND|O METHODS|O :|O 
Assessment|O of|O NBs|O included|O clinical|O and|O imaging|O data|O to|O allow|O tumor|O -|O node|O -|O metastasis|O (|O TNM|O )|O staging|O ,|O biologic|O determinations|O (|O N-Myc|gene-rna gene|O analysis|O )|O ,|O and|O standard|O histology|O and|O work-up|O to|O eliminate|O metastatic|O spread|O (|O metaiodobenzylguanidine|O [|O MIBG|O ]|O scintigraphy|O and|O extensive|O bone|O marrow|O staging|O )|O .|O 
Resectability|O was|O defined|O according|O to|O imaging|O findings|O .|O 
Chemotherapy|O was|O indicated|O in|O children|O older|O than|O 1|O year|O at|O diagnosis|O who|O had|O postoperative|O residual|O disease|O or|O lymph|O node|O (|O LN|O )|O involvement|O ,|O in|O infants|O with|O NMA|O ,|O or|O as|O primary|O treatment|O in|O children|O with|O an|O unresectable|O NB|O ,|O including|O dumbbell|O tumors|O .|O 
Radiotherapy|O was|O recommended|O in|O children|O older|O than|O 1|O who|O presented|O with|O persistent|O gross|O residual|O disease|O at|O the|O end|O of|O therapy|O .|O 
RESULTS|O :|O 
Between|O 1990|O and|O 1994|O ,|O 316|O consecutive|O children|O who|O presented|O with|O a|O localized|O NB|O were|O registered|O in|O the|O NBL|O 90|O study|O .|O 
The|O median|O age|O was|O 12|O months|O ,|O and|O 42|O patients|O had|O dumbbell|O tumors|O (|O 13|O %|O )|O .|O 
NMA|O was|O found|O in|O 22|O of|O 225|O assessable|O children|O (|O 10|O %|O )|O and|O correlated|O with|O adverse|O prognostic|O indicators|O such|O as|O age|O older|O than|O 1|O year|O ,|O an|O abdominal|O primary|O tumor|O ,|O a|O large|O tumor|O (|O T3|O )|O ,|O and|O unresectability|O .|O 
Among|O 186|O children|O who|O had|O primary|O excision|O ,|O five|O died|O of|O surgery|O -|O related|O complications|O .|O 
Primary|O chemotherapy|O was|O given|O to|O 130|O patients|O ,|O which|O allowed|O removal|O of|O the|O tumor|O in|O all|O but|O four|O .|O 
The|O 5|O -|O year|O overall|O survival|O (|O OS|O )|O and|O event|O -|O free|O survival|O (|O EFS|O )|O rates|O were|O ,|O respectively|O ,|O 91|O %|O and|O 84|O %|O with|O a|O median|O follow-up|O time|O of|O 36|O months|O .|O 
The|O outcome|O of|O infants|O and|O older|O children|O was|O similar|O (|O P|O =|O .2|O )|O .|O 
EFS|O of|O patients|O with|O resectable|O tumors|O was|O slightly|O better|O than|O with|O unresectable|O primary|O tumors|O (|O EFS|O ,|O 89|O %|O v|O 78|O %|O ;|O P|O =|O .02|O )|O .|O 
In|O dumbbell|O NBs|O ,|O neurologic|O recovery|O was|O achieved|O in|O 74|O %|O of|O cases|O that|O presented|O with|O symptoms|O ,|O and|O initial|O laminectomy|O was|O avoided|O in|O 75|O %|O of|O children|O .|O 
In|O a|O univariate|O analysis|O ,|O large|O tumors|O ,|O high|O neuron|gene-protein -|gene-protein specific|gene-protein enolase|gene-protein (|O NSE|gene-protein )|O and|O lactate|gene-protein dehydrogenase|gene-protein (|O LDH|gene-protein )|O levels|O ,|O positive|O LNs|O ,|O macroscopic|O residue|O ,|O and|O NMA|O adversely|O influenced|O outcome|O .|O 
In|O the|O multivariate|O analysis|O ,|O NMA|O was|O the|O most|O powerful|O unfavorable|O predictive|O indicator|O :|O OS|O and|O EFS|O rates|O for|O these|O children|O were|O 36|O %|O and|O 32|O %|O ,|O compared|O with|O 98|O %|O and|O 90|O %|O in|O nonamplified|O tumors|O (|O P|O <|O .001|O )|O .|O 
CONCLUSION|O :|O 
Our|O data|O confirm|O the|O overall|O good|O prognosis|O of|O localized|O NBs|O ,|O even|O when|O unresectable|O .|O 
NMA|O is|O the|O most|O relevant|O adverse|O prognostic|O factor|O in|O localized|O NBs|O ,|O and|O more|O intensive|O treatment|O should|O be|O investigated|O in|O these|O patients|O .|O 
Prospective|O studies|O of|O other|O biologic|O factors|O are|O warranted|O to|O tailor|O therapy|O more|O accurately|O .|O 
The|O EFS|O of|O children|O who|O underwent|O primary|O surgery|O was|O excellent|O ,|O and|O further|O justifies|O elimination|O of|O adjuvant|O treatment|O provided|O they|O have|O no|O NMA|O .|O 
Despite|O the|O elimination|O of|O postoperative|O therapy|O ,|O infants|O with|O non|O -|O NMA|O tumors|O have|O an|O excellent|O outcome|O ,|O which|O suggests|O that|O initial|O chemotherapy|O can|O be|O further|O reduced|O in|O case|O of|O unresectable|O NBs|O .|O 
Molecular|O investigation|O of|O TBP|gene-rna allele|O length|O :|O a|O SCA17|O cellular|O model|O and|O population|O study|O .|O 
Recently|O ,|O an|O inherited|O spinocerebellar|O ataxia|O (|O SCA17|O )|O has|O been|O attributed|O to|O polyglutamine|O coding|O expansions|O within|O the|O gene|O coding|O for|O human|O TATA|gene-protein -|gene-protein box|gene-protein binding|gene-protein protein|gene-protein (|O TBP|gene-rna )|O .|O 
The|O normal|O repeat|O range|O is|O 25|O -|O 42|O units|O with|O patients|O having|O as|O few|O as|O 46|O repeats|O .|O 
We|O undertook|O a|O TBP|gene-rna repeat|O length|O population|O study|O showing|O its|O relative|O stability|O ,|O skewed|O distribution|O ,|O and|O substantial|O population|O specific|O differences|O .|O 
To|O investigate|O the|O mechanism|O of|O neurodegeneration|O in|O SCA17|O we|O have|O developed|O a|O cellular|O model|O expressing|O full|O -|O length|O TBP|gene-rna with|O a|O range|O of|O polyQ|O expansions|O .|O 
As|O has|O been|O found|O with|O other|O polyQ|O cellular|O models|O ,|O insoluble|O intracellular|O inclusions|O form|O in|O a|O repeat|O -|O length|O -|O dependent|O manner|O .|O 
In|O addition|O ,|O we|O have|O shown|O that|O the|O expanded|O TBP|gene-protein polyQ|O tract|O is|O able|O to|O interact|O with|O other|O overexpressed|O polyQ|O -|O containing|O proteins|O .|O 
Importantly|O ,|O overexpression|O of|O expanded|O TBP|gene-rna results|O in|O increased|O Cre|gene-rna -|O dependent|O transcriptional|O activity|O .|O 
As|O TBP|gene-rna is|O required|O for|O transcription|O by|O all|O RNA|gene-protein polymerases|gene-protein ,|O this|O may|O indicate|O a|O mechanism|O for|O aberrant|O polyQ|O gain|O of|O function|O .|O 
Evidence|O for|O hypoxia|O -|O induced|O neuronal|O -|O to|O -|O chromaffin|O metaplasia|O in|O neuroblastoma|O .|O 
We|O present|O evidence|O that|O in|O neuroblastoma|O ,|O a|O pediatric|O malignancy|O of|O embryonal|O sympathetic|O origin|O ,|O hypoxia|O ,|O underlies|O a|O phenotypic|O switch|O from|O a|O primitive|O neuronal|O to|O a|O chromaffin|O cell|O type|O .|O 
This|O conclusion|O is|O based|O on|O morphological|O and|O molecular|O data|O on|O 116|O clinical|O tumors|O and|O is|O supported|O by|O data|O on|O the|O phenotypic|O effects|O of|O hypoxia|O on|O neuroblastoma|O cell|O lines|O when|O studied|O in|O monolayer|O culture|O and|O as|O tumor|O xenografts|O .|O 
In|O the|O clinical|O material|O ,|O extensive|O chromaffin|O features|O were|O seen|O in|O regions|O of|O chronic|O tumor|O hypoxia|O .|O 
This|O was|O the|O exclusive|O form|O of|O intra|O -|O tumoral|O maturation|O of|O stroma|O -|O poor|O tumors|O and|O was|O also|O seen|O in|O stroma|O -|O rich|O tumors|O ,|O either|O exclusively|O or|O in|O combination|O with|O ganglion|O -|O like|O cells|O .|O 
In|O neuroblastoma|O cell|O lines|O ,|O hypoxia|O induced|O changes|O in|O gene|O expression|O associated|O with|O the|O chromaffin|O features|O observed|O in|O vivo|O .|O 
We|O therefore|O propose|O tumor|O hypoxia|O as|O a|O major|O cue|O determining|O phenotype|O in|O sympathetic|O tumors|O of|O neuroblastic|O origin|O .|O 
Because|O it|O appears|O to|O be|O reversible|O upon|O reoxygenation|O in|O monolayer|O culture|O ,|O we|O suggest|O the|O term|O metaplasia|O for|O the|O phenomenon|O .|O 
Neurotoxicity|O of|O pneumolysin|gene-protein ,|O a|O major|O pneumococcal|O virulence|O factor|O ,|O involves|O calcium|O influx|O and|O depends|O on|O activation|O of|O p38|gene-protein mitogen|gene-protein -|gene-protein activated|gene-protein protein|gene-protein kinase|gene-protein .|O 
Neuronal|O injury|O in|O bacterial|O meningitis|O is|O caused|O by|O the|O interplay|O of|O host|O inflammatory|O responses|O and|O direct|O bacterial|O toxicity|O .|O 
We|O investigated|O the|O mechanisms|O by|O which|O pneumolysin|gene-protein ,|O a|O cytosolic|O pneumococcal|O protein|O ,|O induces|O damage|O to|O neurons|O .|O 
The|O toxicity|O after|O exposure|O of|O human|O SH-SY5Y|O neuroblastoma|O cells|O and|O hippocampal|O organotypic|O cultures|O to|O pneumolysin|gene-protein was|O time|O -|O and|O dose|O -|O dependent|O .|O 
Pneumolysin|gene-protein led|O to|O a|O strong|O calcium|O influx|O apparently|O mediated|O by|O pores|O on|O the|O cell|O membrane|O formed|O by|O the|O toxin|O itself|O and|O not|O by|O voltage|O -|O gated|O calcium|O channels|O .|O 
Buffering|O of|O intracellular|O calcium|O with|O BAPTA-AM|O [|O 1,2-bis(o-aminophenoxy)ethaneN,N,N',N'-tetraacetic|O acid|O tetra(acetomethoxyl)|O ester|O ]|O improved|O survival|O of|O neuronal|O cells|O following|O challenge|O with|O pneumolysin|gene-protein .|O 
Western|O blotting|O revealed|O increased|O phosphorylation|O of|O p38|gene-protein mitogen|gene-protein -|gene-protein activated|gene-protein protein|gene-protein kinase|gene-protein (|O p38|gene-protein MAPK|gene-protein )|O as|O early|O as|O 30|O min|O after|O challenge|O with|O pneumolysin|gene-protein .|O 
SB|O 203580|O ,|O a|O potent|O and|O selective|O inhibitor|O of|O p38|gene-protein MAPK|gene-protein ,|O rescued|O human|O neuronal|O cells|O from|O pneumolysin|gene-protein -|O induced|O death|O .|O 
Inhibition|O of|O the|O mitochondrial|O permeability|O transition|O pore|O using|O bongkrekate|O and|O caspase|gene-protein inhibition|O also|O improved|O survival|O following|O challenge|O with|O the|O toxin|O .|O 
Modulation|O of|O cell|O death|O pathways|O activated|O by|O pneumolysin|gene-protein may|O influence|O the|O outcome|O of|O pneumococcal|O meningitis|O .|O 
Doxorubicin|O -|O loaded|O Fab'|gene-protein fragments|O of|O anti|O -|O disialoganglioside|O immunoliposomes|O selectively|O inhibit|O the|O growth|O and|O dissemination|O of|O human|O neuroblastoma|O in|O nude|O mice|O .|O 
Neuroblastoma|O (|O NB|O )|O is|O the|O most|O common|O extracranial|O solid|O tumor|O in|O children|O .|O 
Intensive|O therapeutic|O intervention|O does|O not|O prolong|O the|O overall|O disease|O -|O free|O survival|O rate|O for|O this|O tumor|O .|O 
NB|O tumor|O ,|O but|O not|O normal|O tissues|O ,|O overexpress|O the|O disialoganglioside|O (|O GD(2)|O )|O at|O the|O cell|O surface|O .|O 
Anti|gene-protein -|gene-protein GD(2)|gene-protein whole|gene-protein antibodies|gene-protein (|O aGD(2)|gene-protein )|O or|O their|O corresponding|O Fab'|gene-protein fragments|O were|O covalently|O coupled|O to|O Stealth|O immunoliposomes|O (|O aGD(2)-SIL|gene-protein or|O Fab'-SIL|gene-protein )|O ,|O and|O their|O binding|O to|O GD(2)|O -|O positive|O NB|O cells|O was|O measured|O .|O 
Cytotoxic|O effects|O of|O immunoliposomes|O loaded|O with|O doxorubicin|O (|O DXR|O )|O were|O determined|O .|O 
Radiolabelled|O immunoliposomes|O were|O used|O to|O evaluate|O pharmacokinetics|O (|O PK|O )|O .|O 
The|O effectiveness|O of|O different|O liposomal|O formulations|O of|O DXR|O was|O tested|O against|O a|O metastatic|O model|O of|O human|O NB|O in|O nude|O mice|O .|O 
aGD(2)-SIL|gene-protein and|O Fab'-SIL|gene-protein showed|O concentration|O -|O dependent|O specific|O binding|O and|O uptake|O by|O GD(2)|O -|O positive|O NB|O cells|O .|O 
DXR|O entrapped|O in|O aGD(2)-SIL|gene-protein or|O Fab'-SIL|gene-protein (|O aGD(2)-SIL|gene-protein [|O DXR|O ]|O ,|O Fab'-SIL|gene-protein [|O DXR|O ]|O )|O showed|O higher|O cytotoxicities|O than|O nontargeted|O liposomes|O (|O SL|O [|O DXR|O ]|O )|O .|O 
DXR|O -|O loaded|O Fab'-SIL|gene-protein (|O Fab'-SIL|gene-protein [|O DXR|O ]|O )|O also|O showed|O specific|O binding|O ,|O uptake|O ,|O and|O cytotoxic|O effects|O on|O several|O GD(2)|O -|O positive|O NB|O cells|O in|O vitro|O .|O 
PK|O studies|O showed|O that|O Fab'-SIL|gene-protein had|O long|O -|O circulating|O profiles|O in|O blood|O compared|O with|O aGD(2)-SIL|gene-protein ,|O with|O the|O PK|O profile|O for|O Fab'-SIL|gene-protein being|O almost|O identical|O to|O that|O obtained|O with|O nontargeted|O Stealth|O liposomes|O .|O 
In|O vivo|O ,|O long|O -|O term|O survivors|O were|O obtained|O in|O mice|O treated|O with|O Fab'-SIL|gene-protein [|gene-protein DXR|gene-protein ]|gene-protein but|O not|O in|O untreated|O animals|O ,|O or|O those|O treated|O with|O free|O aGD(2)|gene-protein Fab'|gene-protein ,|O Fab'-SIL|gene-protein (|O no|O drug|O )|O ,|O free|O -|O DXR|O ,|O or|O nontargeted|O Stealth|O liposomes|O [|O DXR|O ]|O (|O no|O antibody|O ;|O P|O <|O 0.0001|O )|O .|O 
Immunoliposomes|O containing|O DXR|O prevented|O the|O establishment|O and|O growth|O of|O the|O tumor|O in|O all|O of|O the|O organs|O examined|O .|O 
In|O conclusion|O ,|O Fab'-SIL|gene-protein [|O DXR|O ]|O formulations|O led|O to|O the|O total|O inhibition|O of|O metastatic|O growth|O of|O human|O NB|O in|O a|O nude|O mouse|O metastatic|O model|O .|O 
This|O formulation|O should|O receive|O clinical|O evaluation|O as|O adjuvant|O therapy|O of|O NB|O .|O 
Genes|O modulated|O by|O expression|O of|O GD3|gene-rna synthase|gene-rna in|O Chinese|O hamster|O ovary|O cells|O .|O 
Evidence|O that|O the|O Tis21|gene-rna gene|O is|O involved|O in|O the|O induction|O of|O GD3|gene-protein 9-O-acetylation|O .|O 
9-O-Acetylation|O is|O a|O common|O sialic|O acid|O modification|O ,|O expressed|O in|O a|O developmentally|O regulated|O and|O tissue|O /|O cell|O type|O -|O specific|O manner|O .|O 
The|O relevant|O 9-O-acetyltransferase(s)|gene-protein have|O not|O been|O isolated|O or|O cloned|O ;|O nor|O have|O mechanisms|O for|O their|O regulation|O been|O elucidated|O .|O 
We|O previously|O showed|O that|O transfection|O of|O the|O GD3|gene-rna synthase|gene-rna (|O ST8Sia-I|gene-rna )|O gene|O into|O Chinese|O hamster|O ovary|O (|O CHO|O )|O -|O K1|O cells|O gave|O expression|O of|O not|O only|O the|O disialoganglioside|O GD3|gene-protein but|O also|O 9-O-acetyl-GD3|gene-protein .|O 
We|O now|O use|O differential|O display|O PCR|O between|O wild|O type|O CHO-K1|O cells|O and|O clones|O stably|O expressing|O GD3|gene-rna synthase|gene-rna (|O CHO-GD3|O cells|O )|O to|O detect|O any|O increased|O expression|O of|O other|O genes|O and|O explore|O the|O possible|O induction|O of|O a|O 9-O-acetyltransferase|gene-protein .|O 
The|O four|O CHO|gene-rna mRNAs|O showing|O major|O up|O -|O regulation|O were|O homologous|O to|O VCAM-1|gene-rna ,|O Tis21|gene-rna ,|O the|O KC|gene-rna -|gene-rna protein|gene-rna -|gene-rna like|gene-rna protein|gene-rna ,|O and|O a|O functionally|O unknown|gene-rna type|gene-rna II|gene-rna transmembrane|gene-rna protein|gene-rna .|O 
A|O moderate|O increase|O in|O expression|O of|O the|O FxC1|gene-rna and|O SPR-1|gene-rna genes|O was|O also|O seen|O .|O 
Interestingly|O ,|O these|O are|O different|O from|O genes|O observed|O by|O others|O to|O be|O up|O -|O regulated|O after|O transfection|O of|O GD3|gene-rna synthase|gene-rna into|O a|O neuroblastoma|O cell|O line|O .|O 
We|O also|O isolated|O a|O CHO-GD3|O mutant|O lacking|O 9-O-acetyl-GD3|gene-protein following|O chemical|O mutagenesis|O (|O CHO-GD3-OAc(-)|O )|O .|O 
Analysis|O of|O the|O above|O differential|O display|O PCR|O -|O derived|O genes|O in|O these|O cells|O showed|O that|O expression|O of|O Tis21|gene-rna was|O selectively|O reduced|O .|O 
Transfection|O of|O a|O mouse|O Tis21|gene-rna cDNA|O into|O the|O CHO-GD3-OAc(-)|O mutant|O cells|O restored|O 9-O-acetyl-GD3|gene-protein expression|O .|O 
Since|O the|O only|O major|O gangliosides|O expressed|O by|O CHO-GD3|O cells|O are|O GD3|gene-protein and|O 9-O-acetyl-GD3|gene-protein (|O in|O addition|O to|O GM3|O ,|O the|O predominant|O ganglioside|O type|O in|O wild|O -|O type|O CHO-K1|O cells|O )|O ,|O we|O conclude|O that|O GD3|O enhances|O its|O own|O 9-O-acetylation|O via|O induction|O of|O Tis21|gene-rna .|O 
This|O is|O the|O first|O known|O nuclear|O inducible|O factor|O for|O 9-O-acetylation|O and|O also|O the|O first|O proof|O that|O 9-O-acetylation|O can|O be|O directly|O regulated|O by|O GD3|gene-protein synthase|gene-protein .|O 
Finally|O ,|O transfection|O of|O CHO-GD3-OAc(-)|O mutant|O cells|O with|O ST6Gal-I|O induced|O 9-O-acetylation|O specifically|O on|O sialylated|O N-glycans|O ,|O in|O a|O manner|O similar|O to|O wild|O -|O type|O cells|O .|O 
This|O indicates|O separate|O machineries|O for|O 9-O-acetylation|O on|O alpha|O 2|O -|O 8|O -|O linked|O sialic|O acids|O of|O gangliosides|O and|O on|O alpha|O 2|O -|O 6|O -|O linked|O sialic|O acids|O on|O N-glycans|O .|O 
Intensified|O chemotherapy|O increases|O the|O survival|O rates|O in|O patients|O with|O stage|O 4|O neuroblastoma|O with|O MYCN|gene-rna amplification|O .|O 
PURPOSE|O :|O 
Patients|O with|O high|O -|O risk|O neuroblastoma|O who|O have|O multiple|O copies|O of|O MYCN|gene-rna fare|O much|O worse|O than|O do|O those|O without|O MYCN|gene-rna amplification|O ;|O however|O ,|O it|O has|O not|O been|O clarified|O whether|O intensified|O chemotherapy|O with|O or|O without|O blood|O stem|O cell|O transplantation|O can|O alter|O the|O extremely|O poor|O prognosis|O of|O patients|O with|O amplified|O MYCN|gene-rna .|O 
METHODS|O AND|O RESULTS|O :|O 
Between|O 1985|O and|O 1999|O ,|O 301|O patients|O older|O than|O age|O 12|O months|O with|O stage|O 4|O neuroblastoma|O were|O treated|O .|O 
From|O January|O 1985|O to|O February|O 1991|O ,|O 80|O patients|O with|O stage|O 4|O neuroblastoma|O with|O and|O without|O MYCN|gene-rna amplification|O uniformly|O received|O induction|O chemotherapy|O with|O regimen|O A(1)|O (|O cyclophosphamide|O 1,200|O mg|O /|O m(2)|O and|O vincristine|O 1.5|O mg|O /|O m(2)|O on|O day|O 1|O ,|O tetra-hydropyranyl|O [|O THP|O ]|O -|O Adriamycin|O 40|O mg|O /|O m(2)|O on|O day|O 3|O ,|O and|O cisplatin|O 90|O mg|O /|O m(2)|O on|O day|O 5|O )|O .|O 
Among|O 22|O patients|O with|O MYCN|gene-rna amplification|O ,|O nine|O (|O 40.9|O %|O )|O achieved|O a|O complete|O remission|O and|O seven|O (|O 31.8|O %|O )|O underwent|O stem|O cell|O transplantation|O .|O 
Of|O 58|O patients|O without|O MYCN|gene-rna amplification|O ,|O 43|O (|O 74.1|O %|O )|O achieved|O a|O complete|O remission|O and|O 14|O (|O 24.1|O %|O )|O underwent|O stem|O cell|O transplantation|O .|O 
The|O 5|O -|O year|O relapse|O -|O free|O survival|O rates|O were|O 23.2|O %|O for|O stage|O 4|O patients|O with|O MYCN|gene-rna amplification|O and|O 33.3|O %|O for|O those|O without|O MYCN|gene-rna amplification|O (|O P|O =|O 0.029|O )|O ;|O the|O 5|O -|O year|O overall|O survival|O rates|O were|O 32.8|O %|O for|O stage|O 4|O patients|O with|O MYCN|gene-rna amplification|O and|O 42.8|O %|O for|O those|O without|O MYCN|gene-rna amplification|O (|O P|O >|O 0.05|O )|O .|O 
From|O March|O 1991|O to|O June|O 1998|O ,|O patients|O with|O stage|O 4|O neuroblastoma|O who|O had|O 10|O or|O more|O copies|O of|O MYCN|gene-rna were|O treated|O with|O regimen|O A(3)|O (|O cyclophosphamide|O 1,200|O mg|O /|O m(2)|O per|O day|O on|O days|O 1|O and|O 2|O ,|O THP-Adriamycin|O 40|O mg|O /|O m(2)|O on|O day|O 3|O ,|O etoposide|O 100|O mg|O /|O m(2)|O per|O day|O on|O days|O 1|O to|O 5|O ,|O and|O cisplatin|gene-protein 25|O mg|O /|O m(2)|O per|O day|O on|O days|O 1|O to|O 5|O )|O ;|O those|O with|O fewer|O than|O 10|O copies|O of|O MYCN|gene-rna received|O regimen|O new|O A|O (|O cyclophosphamide|O 1,200|O mg|O /|O m|O on|O day|O 1|O ,|O THP-Adriamycin|O 40|O mg|O /|O m|O on|O day|O 3|O ,|O etoposide|O 100|O mg|O /|O m|O per|O day|O on|O days|O 1|O to|O 5|O ,|O and|O cisplatin|gene-protein 90|O mg|O /|O m|O on|O day|O 5|O )|O ,|O which|O is|O similar|O in|O intensity|O to|O regimen|O A|O .|O 
Among|O 88|O patients|O with|O MYCN|gene-rna amplification|O ,|O 63|O (|O 71.6|O %|O )|O achieved|O a|O complete|O remission|O and|O 63|O (|O 71.68|O %|O )|O underwent|O stem|O cell|O transplantation|O .|O 
Of|O 133|O patients|O without|O MYCN|gene-rna amplification|O ,|O 93|O (|O 69.9|O %|O )|O achieved|O a|O complete|O remission|O and|O 71|O (|O 53.4|O %|O )|O underwent|O stem|O cell|O transplantation|O .|O 
The|O 5|O -|O year|O relapse|O -|O free|O survival|O rates|O were|O 36.0|O %|O for|O stage|O 4|O patients|O with|O MYCN|gene-rna amplification|O and|O 32.2|O %|O for|O those|O without|O MYCN|gene-rna amplification|O (|O P|O >|O 0.05|O )|O ,|O the|O 5|O -|O year|O overall|O survival|O rates|O were|O 34.0|O %|O for|O stage|O 4|O patients|O with|O MYCN|gene-rna amplification|O and|O 38.9|O %|O for|O those|O without|O MYCN|gene-rna amplification|O (|O P|O >|O 0.05|O )|O .|O 
The|O difference|O in|O relapse|O -|O free|O survival|O rates|O was|O significantly|O different|O (|O P|O =|O 0.003|O )|O between|O patients|O with|O MYCN|gene-rna -|O amplified|O tumor|O treated|O before|O (|O regimen|O A(1)|O )|O versus|O after|O 1991|O (|O regimen|O A(3)|O )|O .|O 
CONCLUSIONS|O :|O 
With|O the|O use|O of|O the|O more|O intensive|O induction|O regimen|O A|O plus|O blood|O stem|O cell|O transplantation|O for|O MYCN|gene-rna -|O amplified|O patients|O ,|O survival|O curves|O for|O those|O with|O or|O without|O MYCN|gene-rna amplification|O now|O appear|O similar|O .|O 
Higher|O doses|O of|O chemotherapy|O may|O ameliorate|O the|O effect|O of|O MYCN|gene-rna amplification|O in|O patients|O with|O high|O -|O risk|O neuroblastoma|O .|O 
Defective|O neurite|O outgrowth|O in|O aphidicolin|O /|O cAMP|O -|O induced|O motor|O neurons|O expressing|O mutant|O Cu|gene-rna /|gene-rna Zn|gene-rna superoxide|gene-rna dismutase|gene-rna .|O 
Amyotrophic|O lateral|O sclerosis|O (|O ALS|O )|O is|O a|O progressive|O neurodegenerative|O disorder|O characterized|O by|O motor|O neuron|O involvement|O .|O 
Mutations|O in|O the|O human|O Cu|gene-rna /|gene-rna Zn|gene-rna superoxide|gene-rna dismutase|gene-rna (|O SOD1|gene-rna )|O gene|O are|O found|O in|O some|O cases|O of|O familial|O ALS|O .|O 
Many|O studies|O have|O reported|O SOD1|gene-rna mutation|O -|O related|O neurodegeneration|O .|O 
However|O ,|O whether|O or|O not|O a|O mutant|O SOD1|gene-rna affects|O neural|O development|O has|O not|O been|O demonstrated|O .|O 
We|O developed|O motor|O neuron|O -|O neuroblastoma|O hybrid|O cells|O that|O expressed|O a|O mutant|O (|O G|O 93|O A|O )|O or|O the|O wild|O type|O (|O WT|O )|O SOD1|gene-rna .|O 
Cells|O were|O differentiated|O by|O dibutyryl|O cAMP|O and|O aphidicolin|O .|O 
The|O mutant|O showed|O a|O defect|O in|O neurite|O outgrowth|O and|O had|O decreased|O viability|O .|O 
Cytochrome|gene-protein c|gene-protein released|O and|O nuclear|O fragmentation|O were|O observed|O .|O 
Western|O blot|O analysis|O showed|O that|O the|O amount|O of|O neurofilament|O and|O microtubule|gene-protein associated|gene-protein proteins|gene-protein -|gene-protein 2|gene-protein (|O MAP-2|gene-protein )|gene-protein decreased|O during|O differentiation|O .|O 
These|O results|O suggest|O that|O the|O defect|O in|O neurite|O outgrowth|O of|O mutant|O SOD1|gene-rna cells|O is|O a|O cytoskeletal|O defect|O and|O is|O associated|O with|O neuronal|O death|O .|O 
Clinical|O significance|O of|O intensive|O surgery|O with|O intraoperative|O radiation|O for|O advanced|O neuroblastoma|O :|O does|O it|O really|O make|O sense|O ?|O 
PURPOSE|O :|O 
The|O aim|O of|O this|O study|O was|O to|O evaluate|O the|O significance|O of|O intensive|O surgery|O combined|O with|O intraoperative|O radiation|O therapy|O (|O IORT|O )|O in|O advanced|O neuroblastoma|O .|O 
METHODS|O :|O 
Clinical|O features|O and|O outcome|O were|O reviewed|O in|O 33|O advanced|O neuroblastoma|O patients|O (|O 24|O with|O INSS|O stage|O 4|O ,|O 9|O with|O stage|O 3|O )|O ,|O who|O had|O surgery|O (|O total|O excision|O 29|O ,|O subtotal|O excision|O 4|O )|O with|O IORT|O (|O 10|O to|O 15|O Gy|O )|O against|O the|O primary|O tumor|O site|O .|O 
RESULTS|O :|O 
Three|O patients|O (|O 8.8|O %|O )|O had|O relapse|O at|O the|O primary|O site|O ,|O all|O of|O which|O arose|O from|O the|O unirradiated|O area|O after|O stem|O cell|O transplantation|O .|O 
Among|O 29|O patients|O with|O total|O excision|O ,|O disease|O -|O free|O survival|O was|O obtained|O in|O 15|O (|O 51.7|O %|O )|O for|O an|O average|O of|O 6.9|O years|O ,|O which|O included|O 5|O survivors|O of|O 9|O patients|O (|O 55.9|O %|O )|O with|O amplified|O N-myc|gene-rna .|O 
In|O contrast|O ,|O none|O of|O 4|O patients|O with|O macroscopic|O residual|O survived|O .|O 
The|O Kaplan|O -|O Meier|O analysis|O showed|O significantly|O longer|O survival|O rates|O in|O the|O patients|O with|O total|O resection|O compared|O with|O those|O with|O macroscopic|O remnants|O .|O 
CONCLUSIONS|O :|O 
The|O intensive|O surgery|O with|O IORT|O dramatically|O increased|O the|O local|O eradication|O and|O improved|O the|O outcome|O even|O in|O advanced|O neuroblastoma|O with|O N-myc|gene-rna amplification|O .|O 
However|O ,|O long|O -|O term|O survival|O was|O not|O obtained|O in|O patients|O with|O unresectable|O residual|O disease|O .|O 
These|O results|O may|O indicate|O the|O key|O role|O of|O surgical|O eradication|O in|O advanced|O neuroblastoma|O .|O 
Expression|O of|O prolactin|gene-protein -|gene-protein releasing|gene-protein peptide|gene-protein and|O its|O receptor|gene-protein in|O the|O human|O adrenal|O glands|O and|O tumor|O tissues|O of|O adrenocortical|O tumors|O ,|O pheochromocytomas|O and|O neuroblastomas|O .|O 
Adrenal|O tumors|O ,|O such|O as|O pheochromocytomas|O ,|O are|O known|O to|O express|O various|O peptides|O and|O their|O receptors|O .|O 
Prolactin|gene-protein -|gene-protein releasing|gene-protein peptide|gene-protein (|O PrRP|gene-protein )|O is|O a|O novel|O neuropeptide|O isolated|O from|O bovine|O hypothalamic|O tissues|O .|O 
In|O the|O present|O study|O ,|O expression|O of|O PrRP|gene-protein receptor|gene-protein was|O studied|O in|O the|O human|O brain|O ,|O pituitaries|O ,|O adrenal|O glands|O and|O tumor|O tissues|O of|O adrenocortical|O tumors|O ,|O pheochromocytomas|O ,|O a|O ganglioneuroblastoma|O and|O neuroblastomas|O by|O reverse|gene-protein transcriptase|gene-protein polymerase|gene-protein chain|O reaction|O (|O RT|O -|O PCR|O )|O and|O Northern|O blot|O analysis|O .|O 
The|O presence|O of|O immunoreactive|O -|O PrRP|gene-protein in|O the|O adrenal|O glands|O and|O in|O these|O tumor|O tissues|O was|O studied|O by|O radioimmunoassay|O .|O 
Human|O brain|O tissues|O and|O pituitaries|O were|O obtained|O at|O autopsy|O .|O 
Normal|O portions|O of|O adrenal|O glands|O and|O tumor|O tissues|O were|O obtained|O at|O surgery|O .|O 
RT|O -|O PCR|O analysis|O showed|O expression|O of|O PrRP|gene-protein receptor|gene-protein in|O the|O human|O brain|O ,|O pituitaries|O ,|O normal|O portions|O of|O adrenal|O glands|O and|O various|O tumor|O tissues|O .|O 
Northern|O blot|O analysis|O showed|O high|O expression|O of|O PrRP|gene-protein receptor|gene-protein only|O in|O tumor|O tissues|O of|O pheochromocytomas|O ,|O indicating|O that|O PrRP|gene-protein receptor|gene-protein expression|O is|O high|O in|O pheochromocytomas|O .|O 
Immunoreactive|O -|O PrRP|gene-protein was|O detected|O in|O normal|O portions|O of|O adrenal|O glands|O (|O 0.162|O +/-|O 0.024|O pmol|O /|O g|O wet|O weight|O ,|O n|O =|O 4|O ,|O mean|O +/-|O S.E.M.|O )|O ,|O four|O out|O of|O six|O cases|O of|O pheochromocytomas|O (|O 0.050|O -|O 7.9|O pmol|O /|O g|O wet|O weight|O )|O ,|O one|O neuroblastoma|O and|O some|O adrenocortical|O tumors|O .|O 
The|O present|O study|O has|O shown|O that|O PrRP|gene-rna receptor|gene-rna mRNA|O was|O widely|O expressed|O in|O the|O brain|O tissues|O ,|O pituitaries|O ,|O adrenal|O glands|O and|O various|O tumors|O .|O 
The|O high|O expression|O of|O PrRP|gene-protein receptor|gene-protein in|O pheochromocytomas|O suggests|O potential|O pathophysiological|O roles|O of|O PrRP|gene-protein in|O these|O tumors|O .|O 
Primary|O neuroblastoma|O of|O the|O maxillary|O sinus|O .|O 
Although|O neuroblastoma|O is|O the|O most|O common|O of|O extracranial|O solid|O tumors|O of|O childhood|O and|O infancy|O ,|O we|O report|O the|O first|O case|O of|O an|O isolated|O neuroblastoma|O of|O a|O paranasal|O sinus|O .|O 
A|O 15|O -|O year|O -|O old|O girl|O with|O a|O right|O maxillary|O sinus|O mass|O was|O asymptomatic|O except|O for|O persistent|O epiphora|O .|O 
Computed|O tomography|O and|O magnetic|O resonance|O imaging|O scans|O showed|O that|O the|O mass|O extended|O into|O the|O nasal|O cavity|O ,|O encroached|O on|O the|O lamina|O papyracea|O ,|O and|O obstructed|O the|O nasofrontal|O duct|O .|O 
An|O extensive|O workup|O revealed|O no|O evidence|O of|O systemic|O disease|O .|O 
The|O patient|O underwent|O right|O craniofacial|O resection|O .|O 
Immunohistochemistry|O and|O electronmicroscopic|O findings|O were|O consistent|O with|O conventional|O neuroblastoma|O .|O 
Fluorescence|O in|O situ|O hybridization|O analysis|O was|O performed|O with|O probes|O selected|O to|O demonstrate|O genetic|O alterations|O associated|O with|O neuroblastoma|O .|O 
Studies|O revealed|O deletion|O of|O chromosome|O arm|O 1p|O ,|O gain|O of|O chromosome|O 17|O ,|O and|O normal|O N-myc|gene-rna gene|O copy|O number|O .|O 
In|O summary|O ,|O the|O tumor|O exhibited|O morphologic|O features|O and|O genetic|O alterations|O more|O consistent|O with|O those|O of|O neuroblastoma|O than|O with|O those|O of|O esthesioneuroblastoma|O .|O 
Selective|O dopaminergic|O neurotoxicity|O of|O isoquinoline|O derivatives|O related|O to|O Parkinson|O 's|O disease|O :|O studies|O using|O heterologous|O expression|O systems|O of|O the|O dopamine|gene-protein transporter|gene-protein .|O 
Endogenous|O isoquinoline|O (|O IQ|O )|O derivatives|O structurally|O related|O to|O the|O selective|O dopaminergic|O neurotoxin|O 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine|O (|O MPTP|O )|O and|O its|O active|O metabolite|O 1-methyl-4-phenylpyridine|O (|O MPP(+)|O )|O may|O contribute|O to|O dopaminergic|O neurodegeneration|O in|O Parkinson|O 's|O disease|O .|O 
We|O addressed|O the|O importance|O of|O the|O DAT|gene-protein molecule|O for|O selective|O dopaminergic|O toxicity|O by|O testing|O the|O differential|O cytotoxicity|O of|O 22|O neutral|O and|O quaternary|O compounds|O from|O three|O classes|O of|O isoquinoline|O derivatives|O (|O 3|O ,|O IQs|O ;|O 4,3,4-dihydroisoquinolines|O and|O 15|O ,|O 1,2,3,4-tetrahydroisoquinolines|O )|O as|O well|O as|O MPP(+)|O in|O non|O -|O neuronal|O and|O neuronal|O heterologous|O expression|O systems|O of|O the|O DAT|gene-rna gene|O (|O human|O embryonic|O kidney|O HEK-293|O and|O mouse|O neuroblastoma|O Neuro-2A|O cells|O ,|O respectively|O )|O .|O 
Cell|O death|O was|O estimated|O using|O the|O MTT|O assay|O and|O the|O Trypan|O blue|O exclusion|O method|O .|O 
Nine|O isoquinolines|O and|O MPP(+)|O showed|O general|O cytotoxicity|O in|O both|O parental|O cell|O lines|O after|O 72|O hr|O with|O half|O -|O maximal|O toxic|O concentrations|O (|O TC(50)|O values|O )|O in|O the|O micromolar|O range|O .|O 
The|O rank|O order|O of|O toxic|O potency|O was|O :|O papaverine|O >|O salsolinol|O =|O tetrahydropapaveroline|O =|O 1-benzyl-TIQ|O =|O norsalsolinol|O >|O tetrahyd|O ropapaverine|O >|O 2[N]-methyl-salsolinol|O >|O 2[N]-methyl-norsalsolinol|O >|O 2[N]-Me-IQ(+)|O =|O MPP(+)|O .|O 
Besides|O MPP(+)|O ,|O only|O the|O 2[N]-methylated|O compounds|O 2[N]-methyl-IQ(+)|O ,|O 2[N]-methyl-norsalsolinol|O and|O 2[N]-methyl-salsolinol|O showed|O enhanced|O cytotoxicity|O in|O both|O DAT|gene-rna expressing|O cell|O lines|O with|O 2|O -|O to|O 14|O -|O fold|O reduction|O of|O TC(50)|O values|O compared|O to|O parental|O cell|O lines|O .|O 
The|O rank|O order|O of|O selectivity|O in|O both|O cell|O systems|O was|O :|O MPP(+)|O >>|O 2[N]-Me-IQ(+)|O >|O 2[N]-methyl-norsalsolinol|O =|O 2[N]-methyl-salsolinol|O .|O 
Our|O results|O suggest|O that|O 2[N]-methylated|O isoquinoline|O derivatives|O structurally|O related|O to|O MPTP|O /|O MPP(+)|O are|O selectively|O toxic|O to|O dopaminergic|O cells|O via|O uptake|O by|O the|O DAT|gene-protein ,|O and|O therefore|O may|O play|O a|O role|O in|O the|O pathogenesis|O of|O Parkinson|O 's|O disease|O .|O 
Cerebral|O localization|O and|O regulation|O of|O the|O cell|O volume|O -|O sensitive|O serum|gene-protein -|gene-protein and|gene-protein glucocorticoid|gene-protein -|gene-protein dependent|gene-protein kinase|gene-protein SGK1|gene-protein .|O 
The|O serum|gene-protein -|gene-protein and|gene-protein glucocorticoid|gene-protein -|gene-protein dependent|gene-protein kinase|gene-protein SGK1|gene-protein is|O regulated|O by|O alterations|O of|O cell|O volume|O ,|O whereby|O cell|O shrinkage|O increases|O and|O cell|O swelling|O decreases|O the|O transcription|O ,|O expression|O and|O activity|O of|O SGK1|gene-rna .|O 
The|O kinase|gene-protein is|O expressed|O in|O all|O human|O tissues|O studied|O including|O the|O brain|O .|O 
The|O present|O study|O was|O performed|O to|O localize|O the|O sites|O of|O SGK1|gene-rna transcription|O in|O the|O brain|O ,|O to|O elucidate|O the|O influence|O of|O the|O hydration|O status|O on|O SGK1|gene-rna transcription|O and|O to|O explore|O the|O functional|O significance|O of|O altered|O SGK1|gene-rna expression|O .|O 
Northern|O blot|O analysis|O of|O human|O brain|O showed|O SGK1|gene-rna to|O be|O expressed|O in|O all|O cerebral|O structures|O examined|O :|O amygdala|O ,|O caudate|O nucleus|O ,|O corpus|O callosum|O ,|O hippocampus|O ,|O substantia|O nigra|O ,|O subthalamic|O nucleus|O and|O thalamus|O .|O 
In|O situ|O hybridization|O and|O immunohistochemistry|O in|O the|O rat|O revealed|O increased|O expression|O of|O SGK1|gene-protein in|O neurons|O of|O the|O hippocampal|O area|O CA3|O after|O dehydration|O ,|O compared|O with|O similar|O slices|O from|O brains|O of|O euvolaemic|O rats|O .|O 
Additionally|O ,|O several|O oligodendrocytes|O ,|O a|O few|O microglial|O cells|O ,|O but|O no|O astrocytes|O ,|O were|O positive|O for|O SGK1|gene-protein .|O 
The|O abundance|O of|O SGK1|gene-rna mRNA|O in|O the|O temporal|O lobe|O ,|O including|O hippocampus|O ,|O was|O increased|O by|O dehydration|O and|O SGK1|gene-rna transcription|O in|O neuroblastoma|O cells|O was|O stimulated|O by|O an|O increase|O of|O extracellular|O osmolarity|O .|O 
Co|O -|O expression|O studies|O in|O Xenopus|O laevis|O oocytes|O revealed|O that|O SGK1|gene-protein markedly|O increased|O the|O activity|O of|O the|O neuronal|O K+|O channel|O Kv1.3|O .|O 
As|O activation|O of|O K+|O channels|O modifies|O excitation|O of|O neuronal|O cells|O ,|O SGK1|gene-protein may|O participate|O in|O the|O regulation|O of|O neuronal|O excitability|O .|O 
Factors|O secreted|O by|O human|O neuroblastoma|O mediated|O doxorubicin|O resistance|O by|O activating|O STAT3|gene-rna and|O inhibiting|O apoptosis|O .|O 
BACKGROUND|O :|O 
The|O transcription|O factor|O Stat3|gene-protein has|O been|O reported|O to|O play|O a|O key|O role|O in|O protecting|O cells|O against|O apoptosis|O by|O up|O -|O regulating|O expression|O of|O the|O anti|O -|O apoptotic|O gene|O BCl-xL|gene-rna .|O 
This|O investigation|O analyzes|O the|O relationship|O between|O the|O development|O of|O resistance|O to|O doxorubicin|O -|O mediated|O apoptosis|O in|O neuroblastoma|O cells|O (|O SKN-SH|O )|O and|O activation|O of|O the|O Stat3|gene-rna signaling|O pathway|O .|O 
MATERIALS|O AND|O METHODS|O :|O 
A|O drug|O -|O resistant|O cell|O line|O (|O SKN-SH|O /|O Dox6|O )|O was|O generated|O by|O continuous|O exposure|O to|O incremental|O concentrations|O of|O doxorubicin|O .|O 
Specific|O antibodies|O were|O utilized|O for|O Western|O blots|O and|O confocal|O microscopy|O to|O determine|O the|O nuclear|O localization|O of|O activated|O Stat3|gene-protein .|O 
RESULTS|O :|O 
Doxorubicin|O -|O mediated|O DNA|O fragmentation|O was|O inhibited|O and|O caspase-3|gene-protein activity|O decreased|O in|O SKN-SH|O /|O Dox6|O cells|O .|O 
Up|O -|O regulation|O of|O Stat3|gene-protein phosphorylation|O and|O Bcl-xL|gene-generic expression|O ,|O increased|O nuclear|O translocation|O of|O phospho-Stat3|gene-generic ,|O and|O binding|O to|O DNA|O occurred|O only|O in|O resistant|O SKN-SH|O /|O Dox6|O cells|O .|O 
The|O expression|O of|O Bcl-xL|gene-rna was|O inhibited|O by|O AG490|O ,|O an|O inhibitor|O of|O the|O JAK|gene-protein /|O Stat3|gene-protein signaling|O pathway|O ,|O suggesting|O that|O the|O regulation|O of|O Bcl-xL|gene-rna and|O Stat3|gene-rna involved|O a|O common|O mechanism|O .|O 
Activation|O of|O Stat3|gene-rna in|O SKN-SH|O /|O Dox6|O cells|O was|O contingent|O upon|O stimulation|O evoked|O by|O ligands|O secreted|O by|O the|O drug|O -|O resistant|O cells|O .|O 
Evidence|O to|O support|O this|O hypothesis|O was|O provided|O by|O experiments|O in|O which|O doxorubicin|O -|O sensitive|O SKN-SH|O cells|O were|O preincubated|O with|O conditioned|O media|O obtained|O from|O doxorubicin|O -|O resistant|O SKN-SH|O /|O Dox6|O cells|O .|O 
This|O treatment|O increased|O Stat3|gene-rna activation|O .|O 
It|O also|O rendered|O SKN-SH|O cells|O resistant|O to|O doxorubicin|O as|O demonstrated|O by|O a|O sharp|O decrease|O in|O doxorubicin|O -|O induced|O DNA|O degradation|O and|O cytotoxic|O potency|O .|O 
CONCLUSIONS|O :|O 
These|O findings|O suggest|O that|O the|O resistance|O of|O SKN-SH|O /|O Dox6|O cells|O to|O doxorubicin|O may|O be|O mediated|O by|O anti|O -|O apoptotic|O factor(s)|O that|O are|O synthesized|O and|O secreted|O by|O tumor|O cells|O in|O response|O to|O cytotoxic|O agents|O .|O 
Expression|O of|O KIF3C|gene-rna kinesin|gene-protein during|O neural|O development|O and|O in|O vitro|O neuronal|O differentiation|O .|O 
KIF3A|gene-protein ,|O KIF3B|gene-protein and|O KIF3C|gene-protein are|O kinesin|gene-protein -|O related|O motor|O subunits|O of|O the|O KIF3|gene-protein family|O that|O associate|O to|O form|O the|O kinesin-II|gene-protein motor|O complex|O in|O which|O KIF3C|gene-protein and|O KIF3B|gene-protein are|O alternative|O partners|O of|O KIF3A|gene-protein .|O 
We|O have|O analysed|O the|O expression|O of|O Kif3|gene-rna mRNAs|O during|O prenatal|O murine|O development|O .|O 
Kif3c|gene-rna transcripts|O are|O detectable|O from|O embryonic|O day|O 12.5|O and|O persist|O throughout|O development|O both|O in|O the|O CNS|O and|O in|O some|O peripheral|O ganglia|O .|O 
Comparison|O of|O the|O expression|O patterns|O of|O the|O Kif3|gene-rna genes|O revealed|O that|O Kif3c|gene-rna and|O Kif3a|gene-rna mRNAs|O colocalize|O in|O the|O CNS|O ,|O while|O only|O Kif3a|gene-rna is|O also|O present|O outside|O the|O CNS|O .|O 
In|O contrast|O ,|O Kif3b|gene-rna is|O detectable|O in|O several|O non|O -|O neural|O tissues|O .|O 
We|O have|O also|O performed|O immunocytochemical|O analyses|O of|O the|O developing|O rat|O brain|O and|O have|O found|O the|O presence|O of|O the|O KIF3C|gene-protein protein|O in|O selected|O brain|O regions|O and|O in|O several|O fibre|O systems|O .|O 
Using|O neuroblastoma|O cells|O as|O an|O in|O vitro|O model|O for|O neuronal|O differentiation|O ,|O we|O found|O that|O retinoic|O acid|O stimulated|O the|O expression|O of|O the|O three|O Kif3|gene-rna and|O the|O kinesin|gene-rna -|gene-rna associated|gene-rna protein|gene-rna genes|O ,|O although|O with|O different|O time|O courses|O .|O 
The|O selective|O expression|O of|O Kif3c|gene-rna in|O the|O nervous|O system|O during|O embryonic|O development|O and|O its|O up|O -|O regulation|O during|O neuroblastoma|O differentiation|O suggest|O a|O role|O for|O this|O motor|O during|O maturation|O of|O neuronal|O cells|O .|O 
Transforming|O growth|gene-protein factor|gene-protein -|gene-protein beta|gene-protein and|O ciliary|gene-protein neurotrophic|gene-protein factor|gene-protein synergistically|O induce|O vasoactive|gene-rna intestinal|gene-rna peptide|gene-rna gene|O expression|O through|O the|O cooperation|O of|O Smad|gene-protein ,|O STAT|gene-protein ,|O and|O AP-1|gene-protein sites|O .|O 
The|O cytokine|gene-protein ciliary|gene-protein neurotrophic|gene-protein factor|gene-protein (|O CNTF|gene-protein )|O and|O transforming|gene-protein growth|gene-protein factor|gene-protein -|gene-protein beta|gene-protein (|O TGF-beta|gene-protein )|O both|O induce|O transcription|O of|O the|O vasoactive|gene-rna intestinal|gene-rna peptide|gene-rna (|O VIP|gene-rna )|O gene|O through|O a|O 180|O -|O base|O pair|O cytokine|gene-rna response|gene-rna element|gene-rna (|O CyRE|gene-rna )|O in|O the|O VIP|gene-rna promoter|O .|O 
While|O CNTF|gene-protein induces|O STAT|gene-protein and|O AP-1|gene-protein proteins|O to|O bind|O to|O cognate|O sites|O in|O the|O VIP|gene-rna CyRE|gene-rna ,|O the|O mechanism|O through|O which|O TGF-beta|gene-protein acts|O to|O induce|O VIP|gene-rna gene|O transcription|O is|O not|O known|O .|O 
Here|O we|O show|O that|O Smad3|gene-protein and|O Smad4|gene-protein proteins|O can|O bind|O to|O two|O distinct|O sites|O within|O the|O VIP|gene-rna CyRE|gene-rna .|O 
These|O sites|O are|O absolutely|O required|O for|O the|O induction|O of|O VIP|gene-rna CyRE|gene-rna transcription|O by|O TGF-beta|gene-protein .|O 
TGF-beta|gene-protein induces|O endogenous|O Smad|gene-protein -|O containing|O complexes|O to|O bind|O to|O these|O sites|O in|O human|O neuroblastoma|O cells|O .|O 
CNTF|gene-protein and|O TGF-beta|gene-protein synergize|O to|O induce|O VIP|gene-rna mRNA|O expression|O and|O transcription|O through|O the|O VIP|gene-rna CyRE|gene-rna .|O 
This|O synergy|O is|O dependent|O on|O the|O Smad|gene-protein ,|O STAT|gene-protein ,|O and|O AP-1|gene-protein sites|O ,|O suggesting|O that|O these|O two|O independent|O cytokine|gene-protein pathways|O synergize|O through|O the|O cooperation|O of|O pathway|O -|O specific|O transcription|O factors|O binding|O to|O distinct|O sites|O within|O the|O VIP|gene-rna CyRE|gene-rna .|O 
Correlation|O of|O MYCN|gene-rna amplification|O ,|O Trk-A|gene-rna and|O CD44|gene-rna expression|O with|O clinical|O stage|O in|O 250|O patients|O with|O neuroblastoma|O .|O 
In|O contrast|O to|O MYCN|gene-rna amplification|O ,|O expression|O of|O either|O trk-A|gene-rna or|O CD44|gene-rna in|O neuroblastoma|O is|O a|O favourable|O prognostic|O factor|O and|O were|O therefore|O investigated|O in|O tumours|O from|O 250|O patients|O .|O 
One|O hundred|O and|O eleven|O localised|O /|O 4s|O (|O Group|O 1|O )|O and|O 139|O stage|O 4|O (|O Group|O 2|O )|O tumours|O were|O analysed|O .|O 
MYCN|gene-rna copy|O number|O was|O obtained|O by|O Southern|O blotting|O or|O PCR|O amplification|O and|O was|O detected|O in|O 28|O stage|O 4|O tumours|O .|O 
Trk-A|gene-rna and|O CD44|gene-rna expression|O was|O detected|O by|O immunoperoxidase|gene-protein staining|O using|O murine|O monoclonal|O antibodies|O 5C3|gene-protein and|O L178|gene-protein ,|O respectively|O .|O 
Expression|O was|O scored|O as|O positive|O (|O homogeneous|O )|O ,|O mixed|O (|O heterogeneous|O )|O or|O non|O -|O reactive|O (|O negative|O )|O .|O 
Trk-A|gene-rna expression|O was|O found|O in|O 95|O %|O of|O Group|O 1|O tumours|O and|O 49|O %|O of|O Group|O 2|O tumours|O .|O 
CD44|gene-rna expression|O was|O found|O in|O 100|O %|O of|O Group|O 1|O tumours|O ,|O the|O majority|O of|O which|O had|O a|O strong|O homogeneous|O expression|O .|O 
Lack|O of|O CD44|gene-rna expression|O occurred|O in|O 25|O %|O of|O tumours|O ,|O all|O stage|O 4|O neuroblastoma|O .|O 
Of|O the|O 28|O MYCN|gene-rna amplified|O tumours|O ,|O 27|O /|O 28|O (|O 96|O %|O )|O were|O trk-A|gene-rna negative|O ,|O and|O 13|O /|O 28|O (|O 46|O %|O )|O CD44|gene-rna negative|O .|O 
We|O conclude|O that|O (1)|O a|O significant|O percentage|O of|O stage|O 4|O neuroblastoma|O express|O either|O or|O both|O trk-A|gene-rna and|O CD44|gene-rna ,|O (2)|O the|O absence|O of|O CD44|gene-rna expression|O is|O highly|O restricted|O to|O stage|O 4|O neuroblastoma|O and|O is|O associated|O with|O the|O lack|O of|O trk-A|gene-rna expression|O ,|O (3)|O trk-A|gene-rna negativity|O among|O CD44|gene-rna -|O positive|O tumours|O is|O associated|O with|O stage|O 4|O neuroblastoma|O and|O (4)|O the|O absence|O of|O trk-A|gene-rna expression|O is|O highly|O correlated|O with|O MYCN|gene-rna amplification|O .|O 
Regulation|O of|O the|O human|gene-rna TRH|gene-rna (|O hTRH|gene-rna )|O gene|O by|O human|O thyroid|gene-rna hormone|gene-rna receptor|gene-rna beta|gene-rna 1|gene-rna (|O hTR|gene-rna beta|gene-rna 1|gene-rna )|O mutants|O .|O 
TRH|gene-rna is|O negatively|O regulated|O by|O T3|gene-protein both|O in|O the|O hypothalamic|O paraventricular|O nucleus|O and|O transient|O transfection|O models|O .|O 
Mutations|O in|O hTR|gene-rna beta|gene-rna 1|gene-rna genes|O are|O associated|O with|O the|O syndrome|O of|O generalized|O resistance|O to|O thyroid|gene-protein hormone|gene-protein .|O 
To|O investigate|O potential|O effects|O of|O mutant|O TRs|gene-protein on|O T3|gene-protein regulation|O of|O the|O hTRH|gene-rna gene|O ,|O transient|O gene|O expression|O assays|O were|O performed|O in|O human|O neuroblastoma|O (|O HTB-11|O )|O cells|O with|O an|O hTRH|gene-rna promoter|O -|O luciferase|gene-protein construct|O ,|O wild|O type|O (|O WT|O )|O hTR|gene-rna beta|gene-rna 1|gene-rna ,|O and|O three|O qualitatively|O distinct|O hTR|gene-rna beta|gene-rna 1|gene-rna mutant|O forms|O (|O ED|gene-rna ,|O OK|gene-rna and|O PV|gene-rna )|O .|O 
In|O the|O presence|O of|O T3|gene-protein (|O 10(-9)|O M|O )|O ,|O liganded|O WT|O -|O hTR|gene-rna beta|gene-rna 1|gene-rna inhibited|O hTRH|gene-rna promoter|O activity|O significantly|O (|O 40|O %|O )|O .|O 
Cotransfection|O of|O each|O of|O the|O two|O mutants|O (|O ED|gene-rna and|O OK|gene-rna )|O achieved|O similar|O levels|O of|O inhibition|O only|O at|O 10|O to|O 100|O fold|O increased|O T3|gene-protein concentrations|O .|O 
Of|O interest|O ,|O a|O 10x|O excess|O of|O mutant|O ED|gene-rna or|O OK|gene-rna could|O also|O exert|O dominant|O negative|O effects|O upon|O WT|O hTR|gene-rna beta|gene-rna 1|gene-rna -|O T3|gene-protein mediated|O inhibitory|O actions|O on|O the|O hTRH|gene-rna promoter|O .|O 
In|O contrast|O ,|O mutant|O TR|gene-protein -|O PV|gene-rna exerted|O neither|O inhibitory|O nor|O dominant|O negative|O effects|O at|O even|O higher|O concentrations|O of|O T3|gene-protein .|O 
Moreover|O ,|O all|O three|O unliganded|O mutant|O forms|O stimulated|O TRH|gene-rna promoter|O activity|O significantly|O in|O the|O absence|O of|O T3|gene-protein ,|O despite|O their|O different|O mutations|O in|O the|O ligand|O -|O binding|O domain|O (|O LBD|O )|O .|O 
These|O data|O demonstrate|O that|O thyroid|gene-protein hormone|gene-protein resistance|O at|O the|O level|O of|O TRH|gene-rna gene|O regulation|O ,|O due|O to|O reduced|O inhibitory|O actions|O of|O mutant|O TR|gene-protein -|O T3|gene-protein complexes|O ,|O as|O well|O as|O dominant|O negative|O effects|O upon|O WT|O hTR|gene-rna beta|gene-rna 1|gene-rna mediated|O inhibition|O ,|O likely|O contribute|O to|O elevated|O TSH|gene-protein values|O observed|O in|O the|O syndrome|O of|O thyroid|gene-protein hormone|gene-protein resistance|O .|O 
Transcription|O of|O the|O mouse|O mu|gene-rna -|gene-rna opioid|gene-rna receptor|gene-rna gene|O is|O regulated|O by|O two|O promoters|O .|O 
Two|O transcription|O initiation|O sites|O have|O been|O identified|O in|O the|O mouse|O mu|gene-rna -|gene-rna opioid|gene-rna receptor|gene-rna (|O MOR|gene-rna )|O gene|O at|O approximately|O -|O 793|O and|O -|O 268|O upstream|O of|O the|O translation|O start|O site|O .|O 
To|O test|O if|O the|O MOR|gene-rna gene|O contains|O two|O functional|O promoters|O ,|O chimeric|O constructs|O of|O mouse|O MOR|gene-rna deletion|O fragments|O ,|O fused|O to|O a|O luciferase|gene-rna reporter|gene-rna gene|O ,|O were|O transiently|O transfected|O into|O the|O neuroblastoma|O cell|O line|O SK-N-SH|O ,|O a|O MOR|gene-rna -|O expressing|O cell|O line|O ,|O and|O two|O MOR|gene-rna -|O non|O -|O expressing|O cell|O lines|O .|O 
Results|O from|O transient|O transfection|O assays|O confirmed|O the|O existence|O of|O two|O functional|O independent|O promoters|O in|O the|O mouse|O MOR|gene-rna gene|O ,|O and|O also|O revealed|O that|O the|O region|O from|O -|O 1337|O to|O -|O 93|O does|O not|O contain|O all|O the|O elements|O necessary|O to|O confer|O tissue|O -|O specific|O expression|O of|O the|O MOR|gene-rna gene|O .|O 
Long|O -|O term|O regulation|O of|O opioid|gene-protein receptors|gene-protein in|O neuroblastoma|O and|O lymphoma|O cell|O lines|O .|O 
Long|O -|O term|O regulation|O of|O opioid|O binding|O was|O studied|O in|O the|O human|O neuroblastoma|O NMB|O and|O in|O the|O murine|O lymphoma|O R1.1|O and|O R1.EGO|O cell|O lines|O .|O 
Binding|O was|O down|O -|O regulated|O following|O prolonged|O exposure|O to|O opioid|O agonists|O and|O up|O -|O regulated|O following|O exposure|O to|O antagonist|O .|O 
Down|O -|O regulation|O was|O inhibited|O by|O the|O metabolic|O blocker|O sodium-azide|O and|O by|O the|O protein|gene-protein kinase|gene-protein H-7|gene-protein .|O 
Up|O -|O regulation|O was|O blocked|O by|O the|O protein|O and|O mRNA|O synthesis|O blockers|O cycloheximide|O ,|O alpha-amanitin|gene-protein and|O actinomycin|O D|O .|O 
A|O significant|O difference|O was|O found|O between|O the|O response|O of|O neuronal|O and|O immune|O cells|O to|O ethanol|O exposure|O :|O while|O opioid|O binding|O in|O neuroblastoma|O culture|O underwent|O a|O pronounced|O (|O 75|O %|O )|O up|O -|O regulation|O ,|O no|O effect|O of|O ethanol|O on|O opioid|gene-protein receptors|gene-protein in|O lymphoma|O cultures|O was|O detected|O .|O 
The|O described|O cell|O lines|O present|O an|O excellent|O experimental|O model|O to|O study|O long|O -|O term|O regulation|O of|O opioid|gene-protein receptors|gene-protein in|O the|O nervous|O and|O immune|O systems|O and|O to|O elucidate|O the|O biological|O effects|O of|O chronic|O use|O of|O opiates|O and|O alcohol|O .|O 
Expression|O of|O MDR1|gene-rna /|O p-glycoprotein|gene-rna and|O multidrug|gene-rna resistance|gene-rna -|gene-rna associated|gene-rna protein|gene-rna in|O childhood|O solid|O tumours|O .|O 
We|O evaluated|O the|O expression|O of|O MDR1|gene-rna /|O p-glycoprotein|gene-rna in|O paediatric|O tumours|O using|O reverse|gene-protein transcriptase|gene-protein polymerase|gene-protein chain|O reaction|O (|O RT|O -|O PCR|O )|O ,|O RNA|O dot|O blot|O analysis|O ,|O and|O immunohistochemistry|O on|O formalin|O fixed|O paraffin|O -|O embedded|O material|O with|O JSB-1|gene-protein and|O C-219|gene-protein monoclonal|O antibodies|O ,|O and|O compared|O these|O three|O techniques|O .|O 
The|O expression|O of|O multidrug|gene-rna resistance|gene-rna -|gene-rna associated|gene-rna protein|gene-rna (|O MRP|gene-rna )|O gene|O was|O examined|O by|O RT|O -|O PCR|O assay|O .|O 
We|O studied|O MDR1|gene-rna /|O p-glycoprotein|gene-rna and|O MRP|gene-rna expression|O in|O 13|O samples|O from|O 10|O neuroblastoma|O patients|O ,|O 11|O samples|O from|O 10|O nephroblastoma|O patients|O ,|O 2|O rhabdomyosarcomas|O ,|O 1|O adrenocortical|O carcinoma|O and|O 10|O benign|O tumours|O or|O tumour|O -|O like|O lesions|O .|O 
Eleven|O of|O 13|O neuroblastomas|O ,|O 7|O of|O 11|O nephroblastomas|O ,|O 2|O rhabdomyosarcomas|O ,|O 1|O adrenocortical|O carcinoma|O ,|O and|O 7|O of|O 10|O benign|O tumours|O or|O tumour|O -|O like|O lesions|O showed|O MDR1|gene-rna PCR|O products|O .|O 
By|O RNA|O dot|O blot|O analysis|O ,|O MDR1|gene-rna transcripts|O were|O detectable|O in|O 11|O of|O 34|O specimens|O .|O 
Immunohistochemically|O ,|O we|O detected|O positive|O reaction|O products|O for|O JSB-1|gene-protein in|O 26|O of|O 36|O samples|O .|O 
There|O was|O a|O significant|O correlation|O between|O the|O immunoreactivity|O for|O JSB-1|gene-protein and|O the|O expression|O of|O MDR1|gene-rna mRNA|O expression|O by|O RT|O -|O PCR|O (|O P|O =|O 0.0001|O )|O .|O 
However|O ,|O the|O presence|O of|O p-glycoprotein|gene-protein immunostaining|O does|O not|O correlate|O with|O the|O MDR1|gene-rna expression|O shown|O by|O RT|O -|O PCR|O in|O every|O case|O .|O 
As|O for|O MRP|gene-rna mRNA|O expression|O ,|O 9|O of|O 13|O neuroblastomas|O and|O 10|O of|O 11|O nephroblastomas|O revealed|O PCR|O products|O .|O 
Phase|O I|O trial|O and|O pharmacokinetic|O (|O PK|O )|O and|O pharmacodynamics|O (|O PD|O )|O study|O of|O topotecan|O using|O a|O five|O -|O day|O course|O in|O children|O with|O refractory|O solid|O tumors|O :|O a|O pediatric|O oncology|O group|O study|O .|O 
PURPOSE|O :|O 
A|O phase|O I|O trial|O was|O conducted|O in|O children|O with|O refractory|O solid|O tumors|O to|O determine|O the|O maximum|O tolerated|O dose|O (|O MTD|O )|O ,|O dose|O -|O limiting|O toxicity|O (|O DLT|O )|O ,|O pharmacokinetics|O ,|O and|O pharmacodynamics|O for|O topotecan|O administered|O by|O a|O 30|O -|O min|O infusion|O for|O 5|O consecutive|O days|O .|O 
PATIENTS|O AND|O METHODS|O :|O 
Forty|O children|O with|O a|O variety|O of|O recurrent|O solid|O tumors|O ,|O including|O nine|O patients|O with|O neuroblastoma|O and|O 10|O with|O brain|O tumors|O ,|O were|O given|O topotecan|O as|O a|O 30|O -|O min|O infusion|O for|O 5|O consecutive|O days|O ,|O beginning|O with|O a|O dose|O of|O 1.4|O mg|O /|O m2|O /|O day|O .|O 
The|O dose|O was|O escalated|O in|O 20|O %|O increments|O after|O establishing|O that|O DLT|O was|O not|O present|O at|O the|O prior|O dose|O .|O 
Drug|O toxicity|O was|O graded|O using|O standard|O criteria|O .|O 
Dose|O -|O limiting|O toxicity|O was|O defined|O as|O grade|O 3|O or|O 4|O nonhematopoietic|O toxicity|O or|O grade|O 4|O hematopoietic|O toxicity|O lasting|O >|O 7|O days|O .|O 
Pharmacokinetic|O studies|O were|O performed|O during|O the|O first|O infusion|O course|O .|O 
RESULTS|O :|O 
The|O DLT|O was|O hematopoietic|O and|O involved|O both|O platelets|O and|O neutrophils|O .|O 
Grade|O 4|O hematopoietic|O toxicity|O of|O brief|O duration|O was|O seen|O at|O all|O dose|O levels|O .|O 
Over|O half|O of|O the|O patients|O received|O red|O blood|O cell|O transfusion|O support|O ,|O and|O 19|O /|O 40|O received|O platelet|O transfusions|O .|O 
Hospital|O admissions|O for|O fever|O and|O neutropenia|O or|O for|O documented|O infections|O occurred|O in|O 32|O of|O 169|O courses|O of|O therapy|O .|O 
Gastrointestinal|O symptoms|O with|O nausea|O and|O vomiting|O or|O diarrhea|O were|O mild|O to|O moderate|O in|O 12|O of|O the|O 40|O patients|O .|O 
Antitumor|O responses|O were|O seen|O in|O three|O patients|O with|O neuroblastoma|O .|O 
An|O additional|O four|O patients|O (|O one|O with|O neuroblastoma|O ,|O two|O with|O anaplastic|O astrocytomas|O ,|O one|O with|O Ewing|O )|O had|O stable|O disease|O with|O continued|O therapy|O for|O >|O 6|O months|O .|O 
Using|O a|O limited|O sampling|O model|O ,|O pharmacokinetic|O studies|O were|O performed|O in|O 36|O of|O the|O 40|O patients|O .|O 
Topotecan|O lactone|O and|O total|O clearance|O were|O similar|O to|O those|O reported|O in|O other|O pediatric|O populations|O receiving|O topotecan|O by|O continuous|O infusion|O .|O 
A|O pharmacodynamic|O relation|O between|O systemic|O exposure|O to|O topotecan|O lactone|O and|O myclosuppression|O was|O observed|O .|O 
CONCLUSIONS|O :|O 
In|O heavily|O pretreated|O children|O ,|O the|O MTD|O for|O topotecan|O given|O by|O intermittent|O 30|O -|O min|O infusion|O for|O 5|O days|O is|O 1.4|O mg|O /|O m2|O without|O GCSF|gene-protein and|O 2.0|O mg|O /|O m2|O /|O day|O with|O GCSF|gene-protein .|O 
The|O dose|O -|O limiting|O toxicity|O is|O hematopoietic|O .|O 
Data|O from|O this|O study|O provide|O the|O basis|O for|O further|O studies|O of|O topotecan|O in|O children|O with|O cancer|O .|O 
Diagnosis|O and|O management|O of|O adrenal|O tumors|O .|O 
Tumors|O of|O the|O adrenal|O gland|O are|O not|O uncommon|O .|O 
Patients|O with|O these|O tumors|O usually|O demonstrate|O symptoms|O associated|O with|O the|O biochemical|O substance|O or|O hormone|O produced|O by|O the|O tumor|O .|O 
Tumors|O of|O the|O adrenal|O cortex|O ,|O whether|O benign|O or|O malignant|O ,|O are|O often|O associated|O with|O excess|O production|O of|O steroids|O ,|O whereas|O tumors|O of|O the|O medulla|O are|O generally|O associated|O with|O overproduction|O of|O catecholamines|O .|O 
With|O the|O ubiquitous|O use|O of|O computed|O tomographic|O imaging|O ,|O many|O asymptomatic|O adrenal|O lesions|O are|O discovered|O ,|O presenting|O a|O management|O problem|O for|O the|O clinician|O .|O 
The|O algorithm|O for|O investigating|O so|O -|O called|O adrenal|O "|O incidentalomas|O "|O in|O the|O current|O era|O of|O cost|O containment|O continues|O to|O evolve|O .|O 
This|O review|O addresses|O current|O trends|O in|O the|O clinical|O evaluation|O ,|O biochemical|O testing|O ,|O and|O nuclear|O and|O radiologic|O imaging|O in|O the|O diagnostic|O work|O -|O up|O of|O these|O neoplasms|O .|O 
The|O mainstay|O of|O treatment|O is|O still|O surgical|O extirpation|O ,|O the|O only|O curative|O modality|O .|O 
However|O ,|O advances|O have|O occurred|O in|O adjuvant|O therapies|O ,|O perhaps|O best|O typified|O by|O the|O neoadjuvant|O use|O of|O 131I-methyl|O iodobenzylguanidine|O in|O the|O treatment|O of|O neuroblastoma|O .|O 
Consolidation|O chemoradiotherapy|O and|O autologous|O bone|O marrow|O transplantation|O versus|O continued|O chemotherapy|O for|O metastatic|O neuroblastoma|O :|O a|O report|O of|O two|O concurrent|O Children|O 's|O Cancer|O Group|O studies|O .|O 
PURPOSE|O :|O 
To|O compare|O event|O -|O free|O survival|O (|O EFS|O )|O for|O patients|O with|O stage|O IV|O neuroblastoma|O who|O were|O treated|O with|O induction|O chemotherapy|O followed|O by|O additional|O courses|O of|O the|O same|O chemotherapy|O or|O by|O intensive|O chemoradiotherapy|O and|O autologous|O bone|O marrow|O transplantation|O (|O ABMT|O )|O .|O 
METHODS|O :|O 
Two|O hundred|O seven|O children|O who|O were|O diagnosed|O with|O stage|O IV|O neuroblastoma|O after|O 1|O year|O of|O age|O were|O given|O five|O to|O seven|O courses|O of|O induction|O chemotherapy|O consisting|O of|O cisplatin|O ,|O etoposide|O ,|O doxorubicin|O ,|O and|O cyclophosphamide|O (|O CCC-321-P2|O )|O .|O 
This|O chemotherapy|O was|O continued|O for|O 13|O total|O courses|O for|O some|O patients|O ,|O whereas|O intensive|O chemoradiotherapy|O with|O ABMT|O was|O given|O to|O others|O (|O CCG-321-P3|O )|O .|O 
The|O decision|O to|O continue|O chemotherapy|O versus|O to|O consolidate|O with|O chemoradiotherapy|O was|O not|O randomized|O but|O was|O made|O by|O parents|O and|O physicians|O .|O 
Marrow|O used|O for|O ABMT|O was|O purged|O ex|O vivo|O and|O was|O free|O of|O immunocytologically|O detectable|O neuroblastoma|O cells|O .|O 
RESULTS|O :|O 
One|O hundred|O fifty-nine|O of|O 207|O patients|O (|O 77|O %|O )|O remained|O event|O -|O free|O during|O induction|O therapy|O .|O 
Of|O these|O ,|O 67|O received|O chemoradiotherapy|O /|O ABMT|O (|O CCG-321-P3|O )|O and|O 74|O continued|O chemotherapy|O (|O CCG-321-P2|O )|O .|O 
Using|O Cox|O regression|O analysis|O ,|O the|O relative|O risk|O (|O RR|O )|O of|O an|O event|O after|O chemoradiotherapy|O /|O ABMT|O was|O estimated|O to|O be|O 58|O %|O of|O that|O for|O patients|O who|O continued|O chemotherapy|O (|O P|O =|O .01|O )|O .|O 
Similarly|O ,|O Kaplan|O -|O Meier|O analysis|O estimated|O EFS|O at|O four|O years|O for|O the|O chemoradiotherapy|O /|O ABMT|O and|O chemotherapy|O groups|O to|O be|O 40|O %|O and|O 19|O %|O respectively|O (|O P|O =|O .019|O )|O .|O 
Subgroups|O appearing|O to|O benefit|O from|O chemoradiotherapy|O /|O ABMT|O were|O those|O with|O only|O a|O partial|O tumor|O response|O to|O induction|O chemotherapy|O (|O RR|O =|O 0.43|O ;|O P|O =|O .008|O ;|O EFS|O ,|O 29|O %|O v|O 6|O %|O )|O and|O those|O whose|O tumors|O had|O amplification|O of|O the|O N-myc|gene-rna gene|O (|O RR|O =|O 0.26|O ;|O P|O =|O .112|O ;|O EFS|O ,|O 67|O %|O v|O 0|O %|O )|O .|O 
CONCLUSION|O :|O 
Consolidation|O with|O intensive|O ,|O myeloablative|O chemoradiotherapy|O followed|O by|O purged|O ABMT|O may|O be|O more|O effective|O than|O continuing|O chemotherapy|O for|O patients|O with|O stage|O IV|O neuroblastoma|O .|O 
Expression|O of|O mRNAs|O of|O multiple|O growth|O factors|O and|O receptors|O by|O neuronal|O cell|O lines|O :|O detection|O with|O RT|O -|O PCR|O .|O 
Neurons|O and|O glia|O are|O capable|O of|O both|O secreting|O and|O responding|O to|O a|O large|O variety|O of|O growth|O factors|O .|O 
However|O ,|O information|O on|O multiple|O expression|O of|O growth|O factors|O and|O their|O receptors|O was|O usually|O obtained|O from|O uncorrelated|O observations|O ,|O using|O cells|O from|O various|O animals|O of|O origin|O ,|O developmental|O stages|O ,|O growth|O phases|O ,|O culture|O ages|O and|O culture|O conditions|O .|O 
Because|O of|O its|O specificity|O and|O extreme|O sensitivity|O ,|O reverse|O transcription|O -|O polymerase|gene-protein chain|O reaction|O (|O RT|O -|O PCR|O )|O is|O uniquely|O suitable|O to|O study|O a|O large|O panel|O of|O growth|O factors|O and|O their|O receptors|O from|O a|O limited|O cell|O sample|O ,|O free|O of|O these|O intervening|O variables|O .|O 
In|O this|O paper|O we|O evaluate|O the|O expression|O of|O mRNA|O of|O a|O total|O of|O 35|O growth|O factor|O -|O related|O proteins|O by|O conducting|O RT|O -|O PCR|O on|O three|O neuronal|O cell|O lines|O :|O the|O PC12|O rat|O pheochromocytoma|O line|O ,|O the|O MAH|O rat|O sympathoadrenal|O progenitor|O line|O ,|O and|O the|O N18|O mouse|O neuroblastoma|O line|O .|O 
Three|O types|O of|O results|O are|O presented|O .|O 
The|O first|O confirms|O the|O existing|O knowledge|O such|O as|O the|O presence|O of|O Trk-A|gene-protein (|O NFG|gene-protein receptor|gene-protein )|O in|O PC12|O .|O 
The|O second|O consists|O of|O new|O information|O that|O expands|O and|O extends|O earlier|O observations|O ,|O such|O as|O the|O presence|O of|O CNTF|gene-protein receptor|gene-protein complex|gene-protein in|O PC12|O ,|O which|O explains|O our|O previous|O report|O that|O CNTF|gene-protein enhances|O the|O biological|O effects|O of|O NGF|gene-protein on|O these|O cells|O .|O 
The|O third|O consists|O of|O novel|O information|O that|O leads|O the|O way|O to|O further|O experimentation|O by|O the|O more|O conventional|O methods|O .|O 
These|O include|O the|O strong|O expression|O of|O Trk-B|gene-rna by|O MAH|O ,|O predicting|O the|O biological|O responsiveness|O of|O MAH|O to|O BDNF|gene-protein and|O NT-4|gene-protein ,|O and|O the|O expression|O of|O CNTF|gene-protein receptor|gene-protein in|O N18|O .|O 
Our|O results|O also|O suggest|O that|O CNTF|gene-protein is|O an|O autocrine|O factor|O for|O PC12|O and|O MAH|O ,|O since|O both|O lines|O express|O the|O growth|O factor|O as|O well|O as|O the|O receptor|O .|O 
Thus|O ,|O RT|O -|O PCR|O is|O a|O valuable|O tool|O in|O growth|O factor|O research|O that|O can|O be|O used|O in|O complement|O to|O ,|O and|O interactively|O with|O ,|O other|O approaches|O such|O as|O bioassay|O ,|O receptor|O binding|O ,|O and|O immunochemical|O determination|O .|O 
It|O will|O be|O particularly|O useful|O for|O screening|O a|O large|O number|O of|O growth|O factors|O in|O minute|O areas|O of|O the|O brain|O in|O patients|O suffering|O from|O neurodegenerative|O diseases|O such|O as|O Parkinson|O 's|O and|O Alzheimer|O 's|O .|O 
Alcohol|O inhibits|O neurite|O extension|O and|O increases|O N-myc|gene-protein and|O c-myc|gene-protein proteins|O .|O 
Alcohol|O teratogenesis|O may|O be|O due|O ,|O in|O part|O ,|O to|O inhibition|O of|O neuronal|O differentiation|O by|O alcohol|O .|O 
Because|O decreases|O in|O the|O N-myc|gene-protein and|O c-myc|gene-protein proteins|O are|O believed|O to|O be|O linked|O causally|O to|O neuronal|O differentiation|O ,|O we|O hypothesized|O that|O alcohol|O would|O increase|O N-myc|gene-protein and|O c-myc|gene-protein proteins|O in|O undifferentiated|O neuronal|O cells|O and|O would|O oppose|O the|O decreases|O in|O these|O two|O proteins|O that|O normally|O precede|O differentiation|O .|O 
In|O undifferentiated|O LA-N-5|O cultured|O human|O neuroblastoma|O cells|O ,|O alcohol|O increased|O N-myc|gene-protein protein|O levels|O (|O 178|O %|O vs.|O control|O cells|O )|O and|O c-myc|gene-protein levels|O (|O 222|O %|O of|O control|O )|O .|O 
Retinoic|O acid|O decreased|O N-myc|gene-protein and|O c-myc|gene-protein and|O induced|O neurite|O outgrowth|O (|O a|O differentiation|O marker|O )|O .|O 
Alcohol|O prevented|O retinoic|O acid|O -|O elicited|O decreases|O in|O both|O myc|gene-protein isoforms|O and|O prevented|O neurite|O outgrowth|O .|O 
A|O significant|O 100|O %|O increase|O in|O c-myc|gene-protein and|O an|O upward|O trend|O (|O 48|O %|O )|O in|O N-myc|gene-protein were|O observed|O in|O CA1|O pyramidal|O neurons|O of|O the|O dorsal|O hippocampus|O in|O mouse|O fetuses|O exposed|O prenatally|O to|O alcohol|O .|O 
These|O data|O suggest|O that|O increases|O in|O N-myc|gene-protein and|O c-myc|gene-protein protein|O levels|O are|O associated|O with|O inhibition|O of|O neurite|O extension|O by|O alcohol|O .|O 
Change|O in|O glycosylation|O of|O membrane|gene-protein glycoproteins|gene-protein after|O transfection|O of|O NIH|O 3T3|O with|O human|O tumor|O DNA|O .|O 
Altered|O glycosylation|O of|O membrane|gene-protein glycoproteins|gene-protein was|O demonstrated|O in|O NIH|O 3T3|O cells|O transformed|O by|O transfection|O with|O DNA|O from|O human|O neuroblastoma|O and|O bladder|O carcinoma|O cell|O lines|O .|O 
The|O oncogenes|O of|O these|O two|O cell|O lines|O have|O been|O identified|O as|O N-ras|gene-rna and|O c-H-ras-1|gene-rna ,|O respectively|O .|O 
The|O fucose|O -|O labeled|O membrane|gene-protein glycopeptides|gene-protein of|O transfection|O -|O induced|O transformants|O had|O decreased|O binding|O to|O concanavalin|gene-protein A-Sepharose|gene-protein when|O compared|O in|O dual|O -|O isotope|O experiments|O to|O those|O from|O NIH|O 3T3|O cells|O ,|O whereas|O binding|O to|O lentil|O lectin|gene-protein -|gene-protein Sepharose|gene-protein and|O leukoagglutinating|O phytohemagglutinin|gene-protein -|O agarose|O was|O increased|O .|O 
Binding|O affinities|O to|O these|O immobilized|O lectins|gene-protein lead|O to|O the|O interpretation|O of|O the|O results|O as|O a|O decrease|O in|O biantennary|gene-protein glycopeptides|gene-protein with|O a|O simultaneous|O increase|O in|O tri|gene-protein -|gene-protein or|O tetra|gene-protein antennary|gene-protein glycopeptides|gene-protein .|O 
Sephadex|O G-50|O profiles|O also|O indicated|O a|O size|O increase|O of|O the|O glycopeptides|gene-protein of|O the|O transformants|O .|O 
None|O of|O these|O changes|O was|O growth|O related|O .|O 
This|O altered|O glycosylation|O ,|O representing|O a|O heretofore|O unreported|O effect|O of|O the|O onc|gene-rna genes|O ,|O may|O be|O necessary|O for|O the|O transformed|O phenotype|O .|O 
The|O HL-60|O transforming|O sequence|O :|O a|O ras|gene-rna oncogene|O coexisting|O with|O altered|O myc|gene-rna genes|O in|O hematopoietic|O tumors|O .|O 
The|O oncogene|O of|O the|O HL-60|O human|O promyelocytic|O leukemia|O cell|O line|O has|O been|O passed|O serially|O through|O NIH|O /|O 3T3|O mouse|O fibroblasts|O .|O 
Oncogene|O -|O specific|O probes|O prepared|O from|O the|O resulting|O tertiary|O transfectants|O by|O molecular|O cloning|O have|O been|O used|O to|O show|O that|O loss|O of|O the|O transfected|O oncogene|O from|O NIH|O /|O 3T3|O cells|O correlates|O with|O reversion|O to|O nontransformed|O morphology|O .|O 
Analysis|O of|O cells|O transfected|O by|O the|O oncogenes|O of|O other|O tumors|O and|O tumor|O cell|O lines|O indicates|O that|O the|O transforming|O gene|O of|O the|O HL-60|O leukemia|O cell|O line|O is|O closely|O related|O to|O oncogenes|O of|O a|O Burkitt|O 's|O lymphoma|O ,|O an|O acute|O myelogenous|O leukemia|O ,|O an|O adenocarcinoma|O of|O the|O colon|O ,|O a|O neuroblastoma|O ,|O and|O two|O sarcomas|O .|O 
This|O oncogene|O is|O distantly|O related|O to|O the|O viral|O oncogenes|O of|O Kirsten|O and|O Harvey|O sarcoma|O viruses|O .|O 
It|O has|O been|O termed|O N-ras|gene-rna .|O 
The|O active|O N-ras|gene-rna oncogene|O coexists|O with|O altered|O versions|O of|O the|O myc|gene-rna oncogene|O in|O the|O HL-60|O and|O AW|O Ramos|O human|O tumors|O .|O 
This|O suggests|O a|O multistep|O mechanism|O involving|O both|O ras|gene-rna and|O myc|gene-rna genes|O in|O the|O creation|O of|O these|O tumors|O .|O 
Neuroblastoma|O with|O intraspinal|O (|O dumbbell|O )|O extension|O .|O 
Twenty-three|O patients|O with|O neurogenic|O tumors|O having|O extradural|O extension|O (|O dumbbell|O tumors|O )|O were|O treated|O over|O a|O 30|O -|O year|O period|O .|O 
Three|O had|O ganglioneuroma|O ,|O 6|O had|O ganglioneuroblastoma|O ,|O and|O 14|O had|O neuroblastoma|O .|O 
Nineteen|O patients|O with|O malignant|O tumors|O had|O symptoms|O of|O spinal|O -|O cord|O compression|O ;|O three|O patients|O with|O ganglioneuroma|O and|O one|O with|O a|O malignant|O tumor|O had|O no|O neurologic|O symptoms|O .|O 
Delays|O in|O diagnosis|O were|O frequent|O ranging|O from|O 6|O weeks|O to|O 3|O years|O in|O 10|O patients|O .|O 
Sixteen|O patients|O had|O abnormal|O x-rays|O of|O the|O spine|O .|O 
All|O patients|O with|O malignant|O tumors|O had|O positive|O myelograms|O .|O 
Three|O patients|O with|O ganglioneuroma|O and|O 13|O with|O malignant|O tumors|O are|O alive|O and|O free|O of|O disease|O .|O 
Seven|O patients|O with|O malignant|O tumors|O died|O :|O five|O with|O stage|O IV|O and|O 1|O with|O stage|O III|O tumors|O from|O disease|O ,|O and|O 1|O with|O stage|O II|O tumor|O during|O laminectomy|O .|O 
Age|O and|O stage|O were|O important|O prognostic|O factors|O ;|O location|O was|O not|O .|O 
Treatment|O consisted|O of|O excision|O and|O radiation|O or|O radiation|O only|O .|O 
Patients|O receiving|O lower|O -|O dose|O (|O less|O than|O 2000|O rad|O )|O radiation|O did|O as|O well|O as|O those|O receiving|O much|O larger|O doses|O .|O 
Morbidity|O in|O patients|O with|O malignant|O tumors|O was|O high|O ;|O 4|O have|O spinal|O deformity|O (|O 3|O severe|O )|O and|O 8|O of|O 13|O surviving|O patients|O have|O residual|O neurologic|O deficits|O .|O 
Earlier|O diagnosis|O ,|O a|O surgical|O approach|O which|O does|O not|O introduce|O morbidity|O ,|O and|O low|O -|O dose|O radiation|O in|O younger|O patients|O are|O important|O factors|O in|O reducing|O morbidity|O .|O 
Expression|O of|O the|O amplified|O domain|O in|O human|O neuroblastoma|O cells|O .|O 
Screening|O of|O a|O partial|O cDNA|O library|O prepared|O from|O the|O human|O neuroblastoma|O cell|O line|O BE(2)-C|O with|O genomic|O DNA|O probes|O containing|O sequences|O representative|O of|O the|O amplified|O domain|O of|O that|O cell|O line|O allowed|O us|O to|O identify|O cloned|O transcripts|O from|O an|O active|O gene|O within|O the|O domain|O .|O 
The|O gene|O BE(2)-C-59|gene-rna is|O amplified|O ca.|O 150|O -|O fold|O and|O encodes|O a|O 3.0|O -|O and|O a|O 1.5|O -|O kilobase|O RNA|O transcript|O ,|O both|O of|O which|O are|O overproduced|O in|O BE(2)-C|O cells|O .|O 
A|O survey|O of|O a|O large|O variety|O of|O human|O tumor|O cell|O types|O indicated|O that|O this|O gene|O is|O amplified|O to|O varying|O degrees|O in|O all|O neuroblastoma|O cell|O lines|O and|O a|O retinoblastoma|O cell|O line|O that|O exhibit|O obvious|O cytological|O manifestations|O of|O DNA|O sequence|O amplification|O ,|O i.e.|O ,|O homogeneously|O staining|O regions|O and|O double|O -|O minute|O chromosomes|O .|O 
The|O BE(2)-C-59|gene-rna gene|O is|O not|O amplified|O ,|O however|O ,|O in|O other|O nonrelated|O tumor|O types|O ,|O even|O those|O containing|O amplified|O DNA|O .|O 
Although|O the|O functional|O significance|O of|O this|O specific|O gene|O amplification|O in|O neuroblastoma|O cells|O remains|O unknown|O ,|O an|O indication|O that|O it|O may|O relate|O to|O the|O malignant|O phenotype|O of|O these|O cells|O follows|O from|O the|O remainder|O of|O our|O data|O which|O show|O that|O the|O amplified|O BE(2)-C-59|gene-rna gene|O shares|O partial|O homology|O with|O both|O the|O second|O and|O third|O exons|O ,|O but|O not|O the|O first|O exon|O ,|O of|O the|O human|O c-myc|gene-rna oncogene|O .|O 
Presence|O of|O circulating|O anti|gene-protein -|gene-protein c-myb|gene-protein oncogene|gene-protein product|gene-protein antibodies|gene-protein in|O human|O sera|O .|O 
Bacterially|O expressed|O mouse|O c-myb|gene-protein protein|O was|O purified|O from|O E.|O coli|O extracts|O and|O used|O as|O antigen|O to|O screen|O human|O sera|O for|O circulating|O anti|gene-protein -|gene-protein c-myb|gene-protein oncogene|gene-protein product|gene-protein antibodies|gene-protein .|O 
Using|O Western|O blotting|O ,|O we|O have|O found|O that|O human|O sera|O contain|O IgG|gene-protein antibodies|gene-protein to|O the|O c-myb|gene-rna gene|O product|O .|O 
The|O percentage|O of|O positive|O sera|O in|O cancer|O patients|O appears|O to|O be|O dependent|O upon|O cancer|O type|O and|O is|O significantly|O higher|O in|O breast|O -|O cancer|O patients|O than|O in|O normal|O donors|O :|O 43|O %|O of|O sera|O from|O breast|O -|O cancer|O patients|O are|O positive|O ,|O whereas|O in|O neuroblastoma|O cancer|O patients|O the|O production|O of|O IgG|gene-protein anti|gene-protein -|gene-protein c-myb|gene-protein appears|O to|O be|O rare|O .|O 
No|O significant|O correlation|O was|O observed|O between|O the|O presence|O of|O circulating|O anti|gene-protein -|gene-protein c-myb|gene-protein antibodies|gene-protein and|O the|O expression|O of|O the|O c-myb|gene-rna gene|O in|O breast|O tumors|O .|O 
Molecular|O evaluation|O of|O abnormalities|O of|O the|O short|O arm|O of|O chromosome|O 1|O in|O neuroblastoma|O .|O 
Cytogenetic|O analyses|O have|O documented|O the|O consistent|O deletion|O of|O part|O of|O the|O short|O arm|O of|O chromosome|O 1|O in|O neuroblastoma|O cells|O suggesting|O the|O presence|O of|O a|O suppressor|O gene|O in|O this|O chromosomal|O region|O .|O 
To|O determine|O ,|O the|O smallest|O region|O of|O deletion|O overlap|O at|O the|O molecular|O level|O on|O independently|O derived|O tumors|O and|O to|O define|O the|O location|O of|O the|O breakpoints|O more|O precisely|O ,|O Southern|O analyses|O were|O performed|O on|O a|O somatic|O cell|O hybrid|O panel|O containing|O the|O normal|O and|O altered|O chromosomes|O 1|O from|O seven|O neuroblastoma|O lines|O .|O 
By|O this|O method|O we|O were|O able|O to|O analyze|O a|O panel|O of|O 20|O cloned|O sequences|O and|O two|O isozymes|O to|O determine|O the|O location|O of|O the|O breakpoints|O .|O 
Our|O findings|O indicate|O that|O the|O proximal|O breakpoints|O of|O chromosome|O 1|O deletions|O ranged|O over|O a|O distance|O of|O more|O than|O 50|O cM|O with|O the|O most|O distal|O deletion|O breakpoint|O occurring|O between|O MYCL1|gene-rna and|O D1S57|gene-rna .|O 
In|O addition|O ,|O using|O restriction|O fragment|O length|O polymorphisms|O ,|O it|O was|O determined|O that|O in|O at|O least|O three|O of|O the|O five|O cell|O lines|O in|O which|O MYCL1|gene-rna was|O deleted|O from|O a|O chromosome|O 1|O ,|O the|O gene|O was|O translocated|O to|O another|O chromosome|O thus|O retaining|O the|O diploid|O complement|O .|O 
We|O propose|O that|O the|O neuroblastoma|O susceptibility|O gene|O is|O located|O distal|O to|O MYCL1|O and|O that|O there|O is|O another|O gene|O which|O is|O linked|O to|O MYCL1|gene-rna that|O may|O be|O involved|O in|O this|O neoplasm|O .|O 
[|O Is|O there|O a|O correlation|O in|O the|O frequent|O association|O of|O neuroblastoma|O -|O fetal|O malformations|O ?|O ]|O 
We|O discuss|O the|O pathogenicity|O of|O the|O association|O between|O neuroblastoma|O and|O fetal|O malformations|O .|O 
It|O appears|O to|O us|O that|O the|O role|O of|O certain|O oncogenes|O could|O possibly|O go|O further|O than|O only|O activate|O tumors|O and|O play|O a|O role|O in|O the|O initiation|O of|O the|O process|O of|O fetal|O malformations|O .|O 
Chromosomal|O localization|O of|O amplified|O N-myc|gene-rna in|O neuroblastoma|O cells|O using|O a|O biotinylated|O probe|O .|O 
G|O -|O banded|O chromosome|O analysis|O of|O neuroblastoma|O cells|O from|O two|O children|O revealed|O homogeneously|O staining|O regions|O (|O hsr|O )|O in|O one|O patient|O and|O double|O minutes|O (|O dmin|O )|O in|O the|O other|O .|O 
Subsequently|O ,|O both|O abnormalities|O were|O confirmed|O as|O areas|O of|O N-myc|gene-rna amplification|O using|O chromosomal|O in|O situ|O hybridization|O with|O a|O biotinylated|O N-myc|gene-rna probe|O .|O 
In|O addition|O ,|O the|O first|O patient|O 's|O karyotype|O contained|O a|O possible|O derivative|O chromosome|O 17|O ,|O which|O was|O also|O demonstrated|O to|O contain|O amplified|O N-myc|gene-rna ,|O indicating|O the|O presence|O of|O an|O hsr|O unidentified|O by|O G|O -|O banding|O .|O 
Intercellular|O heterogeneity|O in|O the|O degree|O of|O amplification|O was|O also|O identified|O in|O the|O nuclei|O of|O interphase|O cells|O .|O 
This|O technique|O provides|O a|O quick|O method|O for|O detecting|O gene|O amplification|O ,|O the|O identification|O of|O which|O may|O have|O useful|O clinical|O implications|O .|O 
[|O Immunohistochemical|O differential|O diagnosis|O of|O 60|O cases|O of|O rhabdomyosarcoma|O ]|O 
Using|O the|O avidin|gene-protein -|O biotin|gene-protein complex|O immunoperoxidase|gene-protein technique|O and|O antibodies|gene-protein to|O myoglobin|gene-protein ,|O desmin|gene-protein ,|O CLA|gene-protein ,|O NSE|gene-protein ,|O GFAP|gene-protein ,|O keratin|gene-protein ,|O fibronectin|gene-protein ,|O alpha|gene-protein 1AT|gene-protein ,|O lysozyme|gene-protein ,|O S-100|gene-protein protein|O ,|O vimentin|gene-protein ,|O cytokeratin|gene-protein ,|O actin|gene-protein ,|O the|O authors|O studied|O 60|O cases|O of|O rhabdomyosarcoma|O (|O RMS|O )|O histopathologically|O diagnosed|O previously|O .|O 
Thirty-six|O cases|O showed|O both|O myoglobin|gene-protein and|O desmin|gene-protein positive|O stain|O ,|O an|O objective|O evidence|O of|O the|O origin|O from|O skeletal|O muscles|O .|O 
The|O other|O 24|O cases|O were|O identified|O as|O of|O non|O -|O skeletal|O muscle|O origin|O ,|O including|O MFH|O ,|O lymphoma|O ,|O melanoma|O ,|O neuroblastoma|O ,|O malignant|O neurilemmoma|O ,|O leiomyosarcoma|O etc|O .|O 
This|O study|O strongly|O suggests|O that|O histologic|O examination|O of|O RMS|O may|O lead|O to|O incorrect|O diagnosis|O .|O 
Our|O findings|O indicate|O that|O myoglobin|gene-protein is|O a|O highly|O sensitive|O and|O specific|O tumor|O marker|O for|O RMS|O .|O 
Induction|O of|O neuronal|O differentiation|O by|O p73|gene-rna in|O a|O neuroblastoma|O cell|O line|O .|O 
The|O p53|gene-rna -|O related|O p73|gene-rna and|O p63|gene-rna genes|O encode|O proteins|O that|O share|O considerable|O structural|O and|O functional|O homology|O with|O p53|gene-rna .|O 
Despite|O similarities|O ,|O their|O deletion|O in|O mice|O has|O different|O outcomes|O ,|O implying|O that|O the|O three|O genes|O may|O play|O distinct|O roles|O in|O vivo|O .|O 
Here|O we|O show|O that|O endogenous|O p73|gene-protein levels|O increase|O in|O neuroblastoma|O cells|O induced|O to|O differentiate|O by|O retinoic|O acid|O and|O that|O exogenously|O expressed|O p73|gene-protein ,|O but|O not|O p53|gene-protein ,|O is|O sufficient|O to|O induce|O both|O morphological|O (|O neurite|O outgrowth|O )|O and|O biochemical|O (|O expression|O of|O neurofilaments|gene-protein and|O neural|gene-protein cell|gene-protein adhesion|gene-protein molecule|gene-protein (|O N-CAM|gene-protein )|O ;|O down|O -|O regulation|O of|O N-MYC|gene-rna and|O up|O -|O regulation|O of|O pRB|gene-rna )|O markers|O of|O neuronal|O differentiation|O .|O 
This|O activity|O is|O shared|O ,|O to|O different|O extents|O ,|O by|O all|O p73|gene-protein isoforms|gene-protein ,|O whereas|O the|O transcriptionally|O inactive|O mutants|O of|O p73|gene-protein isoforms|gene-protein are|O ineffective|O .|O 
Conversely|O ,|O blockage|O of|O endogenous|O p73|gene-protein isoforms|gene-protein with|O a|O dominant|O negative|O p73|gene-protein results|O in|O the|O abrogation|O of|O retinoid|O -|O induced|O N-CAM|gene-protein promoter|O -|O driven|O transcription|O .|O 
Our|O results|O indicate|O that|O the|O p73|gene-protein isoforms|gene-protein activate|O a|O pathway|O that|O is|O not|O shared|O by|O p53|gene-protein and|O that|O is|O required|O for|O neuroblastoma|O cell|O differentiation|O in|O vitro|O .|O 
High|O -|O voltage|O -|O activated|O calcium|gene-rna channel|gene-rna messenger|O RNA|O expression|O in|O the|O 140|O -|O 3|O neuroblastoma|O -|O glioma|O cell|O line|O .|O 
Expression|O of|O calcium|gene-protein channel|gene-protein alpha1|gene-protein subunits|gene-protein in|O oocytes|O or|O cell|O lines|O has|O proven|O to|O be|O a|O powerful|O method|O in|O the|O analysis|O of|O structure|O -|O function|O relations|O ,|O but|O these|O experimental|O systems|O are|O of|O limited|O value|O in|O the|O examination|O of|O neuron|O -|O specific|O functions|O such|O as|O transmitter|O release|O .|O 
Cell|O lines|O derived|O from|O neurons|O are|O often|O capable|O of|O these|O functions|O ,|O but|O their|O intrinsic|O calcium|gene-protein channel|gene-protein alpha1|gene-protein subunits|gene-protein are|O complicating|O factors|O in|O experimental|O design|O .|O 
We|O have|O examined|O the|O biophysical|O and|O molecular|O properties|O of|O calcium|O channels|O in|O a|O little|O studied|O neuroblastoma|O -|O glioma|O hybrid|O cell|O line|O ,|O 140|O -|O 3|O ,|O a|O close|O relative|O of|O the|O NG|O 108|O -|O 15|O cell|O line|O ,|O to|O test|O whether|O this|O cell|O line|O might|O serve|O a|O role|O as|O an|O expression|O system|O for|O neural|O mechanisms|O .|O 
This|O cell|O was|O selected|O as|O it|O contains|O an|O intact|O transmitter|O release|O mechanism|O yet|O secretes|O little|O in|O response|O to|O depolarization|O .|O 
Patch|O -|O clamp|O recording|O revealed|O only|O a|O prominent|O low|O -|O threshold|O ,|O rapidly|O inactivating|O calcium|O current|O with|O a|O single|O -|O channel|O conductance|O of|O approximately|O 7|O pS|O that|O was|O identified|O as|O T|O type|O .|O 
A|O search|O for|O calcium|gene-rna channel|gene-rna alpha1|gene-rna subunit|gene-rna messenger|O RNA|O in|O the|O 140|O -|O 3|O cells|O with|O three|O different|O tests|O only|O revealed|O alpha1C|gene-protein ,|O whereas|O alpha1A|gene-protein -|gene-protein alpha1C|gene-protein were|O present|O in|O the|O parent|O NG|O 108|O -|O 15|O line|O .|O 
We|O made|O a|O particular|O effort|O to|O search|O for|O alpha1E|gene-protein ,|O since|O this|O subunit|O has|O been|O associated|O with|O a|O low|O -|O voltage|O -|O activated|O current|O .|O 
Our|O findings|O suggest|O that|O ,|O since|O the|O principal|O nerve|O terminal|O -|O associated|O calcium|O channels|O (|O alpha1A|gene-protein ,|O alpha1B|gene-protein ,|O alpha1E|gene-protein )|O are|O absent|O in|O the|O 140|O -|O 3|O cell|O ,|O this|O cell|O line|O may|O prove|O a|O particularly|O useful|O model|O for|O the|O analysis|O of|O the|O role|O of|O high|O -|O voltage|O -|O activated|O calcium|O channels|O in|O complex|O functions|O of|O neuronal|O cells|O .|O 
GC|O -|O and|O E|O -|O box|O motifs|O as|O regulatory|O elements|O in|O the|O proximal|O promoter|O region|O of|O the|O neuronal|gene-rna nicotinic|gene-rna receptor|gene-rna alpha7|gene-rna subunit|gene-rna gene|O .|O 
The|O alpha7|gene-protein subunit|gene-protein is|O a|O component|O of|O alpha-bungarotoxin|O -|O sensitive|O nicotinic|gene-protein acetylcholine|gene-protein receptors|gene-protein expressed|O in|O bovine|O adrenomedullary|O chromaffin|O cells|O .|O 
The|O proximal|O promoter|O of|O the|O gene|O coding|O for|O this|O subunit|O contains|O several|O GC|O -|O boxes|O and|O one|O E|O -|O box|O .|O 
Deletion|O analysis|O and|O transient|O transfections|O showed|O that|O a|O 120|O -|O base|O pair|O region|O (|O -|O 77|O to|O +|O 43|O )|O including|O all|O of|O these|O elements|O gave|O rise|O to|O approximately|O 70|O and|O 95|O %|O of|O the|O maximal|O transcriptional|O activity|O observed|O in|O chromaffin|O and|O SHSY-5Y|O neuroblastoma|O cells|O ,|O respectively|O .|O 
Site|O -|O directed|O mutagenesis|O of|O the|O different|O elements|O indicated|O that|O both|O GC|O and|O E|O motifs|O contribute|O to|O the|O activity|O of|O the|O alpha7|gene-rna gene|O in|O a|O very|O prominent|O way|O .|O 
Using|O electrophoretic|O mobility|O shift|O assays|O ,|O the|O upstream|gene-protein stimulatory|gene-protein factor|gene-protein (|O USF|gene-protein )|O was|O shown|O to|O be|O a|O component|O of|O the|O complexes|O that|O interacted|O with|O the|O E|O -|O box|O when|O nuclear|O extracts|O from|O chromaffin|O and|O SHSY-5Y|O cells|O were|O used|O .|O 
Binding|O of|O the|O early|gene-protein growth|gene-protein response|gene-protein gene|gene-protein transcription|gene-protein factor|gene-protein (|O Egr-1|gene-protein )|O to|O three|O different|O GC|O -|O boxes|O was|O also|O demonstrated|O by|O shift|O assays|O and|O DNase|gene-protein I|gene-protein footprint|O analysis|O .|O 
Likewise|O ,|O alpha7|gene-rna promoter|O activity|O increased|O by|O up|O to|O 5|O -|O fold|O when|O alpha7|gene-rna constructs|O and|O an|O Egr-1|gene-protein expression|O vector|O were|O cotransfected|O into|O chromaffin|O cell|O cultures|O .|O 
Mutagenesis|O of|O individual|O GC|O -|O boxes|O had|O little|O effect|O on|O Egr-1|gene-protein activation|O .|O 
By|O contrast|O ,|O pairwise|O suppression|O of|O GC|O -|O boxes|O abolished|O activation|O ,|O especially|O when|O the|O most|O promoter|O -|O proximal|O of|O the|O Egr-1|gene-protein sites|O was|O removed|O .|O 
Taken|O together|O ,|O these|O studies|O indicate|O that|O the|O alpha7|gene-rna gene|O is|O likely|O to|O be|O a|O target|O for|O multiple|O signaling|O pathways|O ,|O in|O which|O various|O regulatory|O elements|O are|O involved|O .|O 
Beta-catenin|gene-protein and|O cyclin|gene-protein D1|gene-protein expression|O in|O human|O hepatocellular|O carcinoma|O .|O 
To|O understand|O the|O nature|O and|O roles|O of|O mutated|O beta-catenin|gene-rna in|O human|O hepatocellular|O carcinomas|O (|O HCCs|O )|O ,|O 57|O cases|O of|O surgically|O resected|O HCCs|O were|O studied|O .|O 
DNAs|O extracted|O from|O each|O tumor|O were|O examined|O for|O somatic|O mutations|O of|O exon|O 3|O ,|O and|O the|O protein|O expressions|O of|O beta-catenin|gene-protein ,|O cyclin|gene-protein D1|gene-protein ,|O and|O Ki-67|gene-protein were|O observed|O by|O immunohistochemical|O staining|O .|O 
beta-catenin|gene-rna mutations|O in|O exon|O 3|O were|O detected|O in|O 10|O (|O 17.5|O %|O )|O out|O of|O 57|O HCCs|O ,|O including|O nine|O missense|O mutations|O and|O one|O deletion|O mutation|O .|O 
All|O of|O the|O cases|O with|O gene|O alterations|O had|O the|O anti|gene-protein -|gene-protein HCV|gene-protein antibody|gene-protein ,|O and|O tested|O negative|O for|O the|O HBs|gene-protein antigen|gene-protein in|O the|O sera|O .|O 
All|O of|O the|O mutations|O occurred|O at|O the|O serine|O /|O threonine|O phosphorylation|O sites|O of|O glycogen|gene-protein synthase|gene-protein kinase-3beta|gene-protein (|O GSK-3beta|gene-protein )|O or|O their|O neighboring|O residues|O .|O 
Significant|O correlation|O with|O intracellular|O expression|O (|O p|O =|O 0.00055|O )|O was|O shown|O in|O the|O HCCs|O harboring|O beta-catenin|gene-rna mutations|O .|O 
The|O intracellular|O accumulation|O of|O beta-catenin|gene-protein showed|O significant|O correlation|O with|O the|O cyclin|gene-protein D1|gene-protein expression|O (|O p|O =|O 0.00858|O )|O ,|O and|O with|O a|O higher|O proliferation|O index|O (|O p|O =|O 0.00072|O )|O .|O 
In|O addition|O ,|O the|O beta-catenin|gene-rna mutations|O showed|O significant|O association|O with|O the|O cyclin|gene-protein D1|gene-protein expression|O (|O p|O =|O 0.0424|O )|O .|O 
These|O results|O suggest|O that|O accumulated|O beta-catenin|gene-protein proteins|O may|O bind|O to|O the|O lymphocyte|gene-protein enhancer|gene-protein binding|gene-protein factor-1|gene-protein (|O LEF-1|gene-protein )|O ,|O form|O the|O beta-catenin|gene-protein /|O LEF-1|gene-protein complex|O ,|O and|O stimulate|O such|O promoters|O regulating|O the|O cell|O cycle|O as|O the|O cyclin|gene-rna D1|gene-rna gene|O .|O 
This|O is|O the|O first|O report|O to|O demonstrate|O a|O significant|O correlation|O between|O beta-catenin|gene-protein and|O the|O cyclin|gene-protein D1|gene-protein expression|O in|O human|O HCCs|O .|O 
Cancer|O 1992|O May|O 1;6|O 9|O (|O 9|O )|O :|O 238|O 5-92|O Primitive|O neuroectodermal|O tumors|O after|O prophylactic|O central|O nervous|O system|O irradiation|O in|O children|O .|O 
Association|O with|O an|O activated|O K-ras|gene-rna gene|O .|O 
Laboratory|O of|O Neuropathology|O ,|O Institute|O of|O Pathology|O ,|O University|O of|O Zurich|O ,|O Switzerland|O .|O 
Three|O patients|O had|O supratentorial|O malignant|O brain|O tumors|O 7|O to|O 9|O years|O after|O prophylactic|O central|O nervous|O system|O (|O CNS|O )|O treatment|O for|O acute|O lymphocytic|O leukemia|O or|O malignant|O T-cell|O lymphoma|O .|O 
Therapy|O was|O administered|O at|O the|O age|O of|O 3|O to|O 8|O years|O and|O included|O cranial|O irradiation|O (|O total|O dose|O ,|O 1800|O to|O 2400|O cGy|O )|O and|O intrathecal|O methotrexate|O .|O 
The|O brain|O tumors|O had|O histologic|O and|O immunohistochemical|O features|O of|O primitive|O neuroectodermal|O tumors|O (|O PNET|O )|O ,|O including|O neuroblastic|O rosettes|O ,|O rhythmic|O arrangement|O of|O tumor|O cells|O ,|O and|O immunohistochemical|O expression|O of|O glial|gene-protein ,|O and|O in|O one|O patient|O neuronal|gene-protein ,|O marker|gene-protein proteins|gene-protein .|O 
Using|O polymerase|O chain|O reaction|O -|O mediated|O DNA|O amplification|O from|O paraffin|O -|O embedded|O tissues|O and|O subsequent|O DNA|O sequence|O analysis|O ,|O an|O activating|O point|O mutation|O was|O detected|O in|O the|O K-ras|gene-rna protooncogene|O in|O one|O tumor|O .|O 
This|O mutation|O was|O a|O G|O to|O A|O transition|O in|O position|O 2|O of|O codon|O 12|O ,|O substituting|O aspartate|O (|O GAT|O )|O for|O glycine|O (|O GGT|O )|O .|O 
This|O type|O of|O mutation|O has|O not|O been|O observed|O before|O in|O human|O brain|O tumors|O ,|O but|O it|O is|O frequent|O in|O radiation|O -|O induced|O murine|O lymphomas|O .|O 
These|O observations|O suggest|O that|O PNET|O can|O be|O induced|O after|O completion|O of|O the|O embryonal|O and|O fetal|O development|O of|O the|O human|O CNS|O .|O 
Oncogene|O -|O activating|O point|O mutations|O may|O represent|O a|O pathogenetic|O mechanism|O involved|O in|O the|O genesis|O of|O radiation|O -|O induced|O brain|O tumors|O .|O 
J|O Hepatol|O 1992|O Mar;1|O 4|O (|O 2-3|O )|O :|O 34|O 2-6|O Infrequent|O point|O mutations|O in|O codons|O 12|O and|O 61|O of|O ras|gene-rna oncogenes|O in|O human|O hepatocellular|O carcinomas|O .|O 
DNA|O from|O human|O hepatocellular|O carcinomas|O (|O HCC|O )|O were|O analysed|O for|O the|O presence|O of|O mutations|O in|O codons|O 12|O and|O 61|O of|O the|O K-ras|gene-rna ,|O H-ras|gene-rna and|O N-ras|gene-rna genes|O .|O 
The|O relevant|O ras|gene-rna sequences|O were|O amplified|O in|O vitro|O using|O the|O polymerase|gene-protein chain|O reaction|O and|O point|O mutations|O detected|O by|O selective|O hybridisation|O using|O mutation|O -|O specific|O synthetic|O oligonucleotides|O .|O 
In|O one|O of|O the|O 19|O HCCs|O a|O mutation|O in|O codon|O 61|O of|O the|O K-ras|gene-rna gene|O was|O detected|O ,|O whilst|O in|O 3|O /|O 19|O HCCs|O a|O mutation|O was|O found|O in|O codon|O 61|O of|O the|O N-ras|gene-rna gene|O .|O 
The|O mutations|O were|O all|O heterozygous|O A|O -|O T|O transversions|O and|O were|O found|O in|O HCCs|O arising|O in|O patients|O with|O underlying|O cirrhosis|O .|O 
In|O two|O of|O these|O patients|O where|O the|O corresponding|O normal|O tissue|O was|O available|O only|O the|O wild|O -|O type|O ras|gene-rna gene|O was|O detected|O ,|O indicating|O that|O oncogenic|O activation|O of|O the|O ras|gene-rna gene|O was|O a|O consequence|O of|O somatic|O mutation|O .|O 
In|O another|O patient|O the|O same|O mutation|O in|O codon|O 61|O of|O the|O N-ras|gene-rna gene|O was|O found|O in|O cirrhotic|O liver|O tissue|O and|O in|O all|O four|O patients|O the|O same|O mutation|O was|O also|O detected|O in|O formalin|O -|O fixed|O ,|O paraffin|O -|O embedded|O liver|O biopsy|O HCC|O tissue|O obtained|O at|O diagnosis|O .|O 
These|O results|O indicate|O that|O mutational|O activation|O of|O the|O ras|gene-rna genes|O at|O codon|O 61|O is|O an|O infrequent|O but|O possibly|O early|O event|O in|O the|O development|O of|O HCC|O in|O Britain|O .|O 
Surg|O Oncol|O 1992|O Dec;|O 1|O (|O 6|O )|O :|O 40|O 5-11|O Analysis|O of|O ras|gene-rna oncogene|O mutations|O in|O human|O squamous|O cell|O carcinoma|O of|O the|O head|O and|O neck|O .|O 
Department|O of|O Otolaryngology|O ,|O Hospital|O Central|O de|O Asturias|O ,|O Oviedo|O ,|O Spain|O .|O 
The|O presence|O of|O proto|O -|O oncogene|O mutations|O at|O codons|O 12|O ,|O 13|O and|O 61|O of|O the|O Ha|gene-rna -|gene-rna ,|O Ki|gene-rna -|gene-rna ,|O and|O N|gene-rna -|gene-rna ras|gene-rna in|O primary|O head|O and|O neck|O squamous|O cell|O carcinoma|O are|O analysed|O in|O this|O study|O .|O 
Oncogene|O ras|gene-rna -|O specific|O sequences|O were|O amplified|O by|O the|O polymerase|O chain|O reaction|O and|O probed|O with|O mutation|O specific|O oligonucleotide|O probes|O .|O 
Mutations|O were|O detected|O in|O 8|O of|O 22|O samples|O (|O 36.3|O %|O )|O .|O 
No|O mutations|O were|O detected|O on|O patients|O '|O peripheral|O blood|O DNA|O .|O 
We|O found|O that|O histologically|O and|O clinically|O ,|O squamous|O cell|O carcinomas|O with|O or|O without|O a|O ras|gene-rna mutation|O do|O not|O differ|O significantly|O from|O each|O other|O .|O 
Cancer|O Res|O 1992|O Nov|O 1;5|O 2|O (|O 21|O )|O :|O 599|O 1-6|O Presence|O of|O ras|gene-rna oncogene|O mutations|O and|O human|O papillomavirus|O DNA|O in|O human|O prostate|O carcinomas|O .|O 
Department|O of|O Pathology|O ,|O Fukui|O Medical|O School|O ,|O Matsuoka|O ,|O Japan|O .|O 
The|O frequency|O of|O H-ras|gene-rna ,|O K-ras|gene-rna ,|O and|O N-ras|gene-rna mutations|O and|O the|O presence|O of|O high|O -|O risk|O human|O papillomavirus|O (|O HPV|O 16|O ,|O 18|O ,|O and|O 33|O )|O DNA|O were|O studied|O in|O 75|O paraffin|O -|O embedded|O specimens|O obtained|O from|O 68|O Japanese|O patients|O with|O a|O variety|O of|O prostate|O carcinomas|O by|O using|O polymerase|O chain|O reaction|O and|O DNA|O hybridization|O with|O sequence|O -|O specific|O oligonucleotides|O .|O 
Ten|O specimens|O each|O of|O normal|O and|O benign|O hyperplastic|O prostatic|O tissues|O from|O the|O same|O number|O of|O patients|O were|O also|O examined|O for|O this|O analysis|O .|O 
Of|O 68|O carcinoma|O cases|O ,|O ras|gene-rna gene|O mutations|O were|O present|O in|O 16|O cases|O (|O 24|O %|O )|O and|O HPV|O DNAs|O in|O 28|O cases|O (|O 41|O %|O )|O .|O 
Eleven|O mutations|O were|O detected|O in|O codon|O 61|O of|O H-ras|gene-rna ,|O 4|O in|O codon|O 12|O of|O N-ras|gene-rna ,|O and|O 2|O in|O codon|O 61|O of|O K-ras|gene-rna .|O 
HPV|O 16|O ,|O 18|O ,|O and|O 33|O DNAs|O were|O found|O in|O 11|O ,|O 17|O ,|O and|O 5|O cases|O ,|O respectively|O .|O 
Eight|O of|O the|O 16|O cases|O with|O ras|gene-rna mutation|O also|O harbored|O HPV|O DNAs|O .|O 
The|O frequency|O of|O ras|gene-rna mutations|O and|O the|O HPV|O infection|O increased|O in|O patients|O with|O advanced|O stages|O of|O the|O tumor|O and|O with|O the|O higher|O Gleason|O score|O .|O 
There|O was|O the|O predominant|O presence|O of|O H-ras|gene-rna codon|O 61.2|O (|O CAG|O -->|O CTG|O )|O mutation|O and|O HPV|O 18|O DNA|O in|O prostatic|O carcinomas|O metastasizing|O to|O the|O bone|O .|O 
None|O of|O the|O normal|O or|O benign|O hyperplastic|O prostatic|O specimens|O contained|O either|O ras|gene-rna mutation|O or|O HPV|O DNA|O .|O 
Our|O results|O suggest|O that|O ras|gene-rna gene|O mutations|O and|O HPV|O infections|O are|O relatively|O frequent|O ,|O at|O least|O in|O prostate|O carcinoma|O of|O Japanese|O patients|O .|O 
These|O two|O factors|O appear|O to|O be|O related|O to|O the|O progression|O of|O the|O tumor|O .|O 
Moreover|O ,|O H-ras|gene-rna codon|O 61.2|O mutation|O and|O HPV|O 18|O infection|O may|O have|O some|O predictive|O roles|O for|O bone|O metastasis|O in|O prostate|O carcinoma|O .|O 
Jpn|O J|O Cancer|O Res|O 1992|O Oct;8|O 3|O (|O 10|O )|O :|O 105|O 7-62|O ras|gene-rna mutations|O in|O endocrine|O tumors|O :|O mutation|O detection|O by|O polymerase|O chain|O reaction|O -|O single|O strand|O conformation|O polymorphism|O .|O 
Otsuka|O Department|O of|O Clinical|O and|O Molecular|O Nutrition|O ,|O School|O of|O Medicine|O ,|O University|O of|O Tokushima|O .|O 
To|O elucidate|O the|O molecular|O basis|O for|O endocrine|O tumorigenesis|O ,|O ras|gene-rna mutations|O in|O human|O endocrine|O tumors|O were|O analyzed|O using|O polymerase|O chain|O reaction|O -|O single|O strand|O conformation|O polymorphism|O (|O PCR-SSCP|O )|O analysis|O .|O 
Mutations|O of|O the|O H|gene-rna -|gene-rna ,|O K|gene-rna -|gene-rna ,|O N|gene-rna -|gene-rna ras|gene-rna genes|O were|O examined|O in|O genomic|O DNAs|O from|O 169|O successfully|O amplified|O primary|O endocrine|O tumors|O out|O of|O 189|O samples|O .|O 
Four|O out|O of|O 24|O thyroid|O follicular|O adenomas|O analyzed|O contained|O mutated|O N-ras|gene-rna codon|O 61|O ,|O and|O one|O contained|O the|O mutated|O H-ras|gene-rna codon|O 61|O .|O 
One|O of|O the|O 19|O pheochromocytomas|O revealed|O mutation|O of|O the|O H-ras|gene-rna codon|O 13|O .|O 
No|O mutations|O of|O the|O ras|O gene|O were|O detected|O in|O pituitary|O adenomas|O ,|O parathyroid|O tumors|O ,|O thyroid|O cancers|O ,|O endocrine|O pancreatic|O tumors|O ,|O and|O adrenocortical|O tumors|O .|O 
Based|O on|O these|O findings|O we|O conclude|O that|O activation|O of|O the|O ras|gene-rna gene|O may|O play|O a|O role|O in|O the|O tumorigenesis|O of|O a|O limited|O number|O of|O thyroid|O follicular|O adenomas|O and|O pheochromocytomas|O ,|O and|O that|O mutation|O of|O the|O ras|gene-rna gene|O is|O not|O frequent|O in|O other|O human|O endocrine|O tumors|O .|O 
Cancer|O Res|O 1992|O May|O 15|O ;5|O 2|O (|O 10|O )|O :|O 290|O 3-6|O ras|gene-rna gene|O mutations|O as|O a|O prognostic|O marker|O in|O adenocarcinoma|O of|O the|O human|O lung|O without|O lymph|O node|O metastasis|O .|O 
Department|O of|O Surgery|O II|O ,|O Faculty|O of|O Medicine|O ,|O Kyushu|O University|O ,|O Fukuoka|O ,|O Japan|O .|O 
Adenocarcinoma|O of|O the|O lung|O obtained|O at|O surgical|O resection|O was|O examined|O for|O mutation|O at|O codons|O 12|O ,|O 13|O ,|O and|O 61|O of|O the|O oncogenes|O K-ras|gene-rna ,|O H-ras|gene-rna ,|O and|O N-ras|gene-rna ,|O using|O polymerase|O chain|O reaction|O and|O oligonucleotide|O hybridization|O techniques|O .|O 
The|O mutation|O was|O detected|O in|O 18|O of|O the|O 115|O cases|O (|O 15.7|O %|O )|O ,|O and|O 15|O of|O 18|O were|O at|O codon|O 12|O ,|O 2|O were|O at|O codon|O 13|O of|O K-ras|gene-rna ,|O and|O 1|O was|O at|O codon|O 61|O of|O N-ras|gene-rna .|O 
G|O to|O T|O transversions|O were|O most|O common|O .|O 
The|O ras|gene-rna gene|O mutations|O were|O more|O frequent|O in|O the|O male|O patients|O (|O P|O =|O 0.0048|O )|O .|O 
No|O significant|O differences|O were|O found|O to|O be|O related|O to|O stage|O of|O the|O disease|O or|O tumor|O -|O nodes|O -|O metastases|O classification|O between|O positive|O and|O negative|O groups|O of|O the|O ras|gene-rna gene|O mutations|O .|O 
A|O history|O of|O tobacco|O use|O was|O not|O always|O a|O factor|O contributing|O to|O mutation|O .|O 
Of|O the|O completely|O resected|O group|O without|O lymph|O node|O metastasis|O ,|O the|O 5|O -|O year|O survival|O rate|O in|O the|O ras|gene-rna -|O positive|O group|O was|O 53.3|O %|O ,|O which|O was|O significantly|O poorer|O than|O the|O 83.6|O %|O survival|O rate|O in|O the|O ras|gene-rna -|O negative|O group|O (|O P|O less|O than|O 0.05|O )|O .|O 
Our|O findings|O suggest|O that|O ras|gene-rna gene|O mutations|O may|O be|O prognostic|O ,|O especially|O in|O the|O early|O stage|O adenocarcinoma|O of|O the|O lung|O .|O 
Eur|O J|O Cancer|O 1992|O ;2|O 8|O (|O 2-3|O )|O :|O 33|O 3-6|O 
Mutations|O in|O the|O ras|gene-rna protooncogenes|O are|O rare|O events|O in|O renal|O cell|O cancer|O .|O 
Mutations|O in|O codon|O 12|O ,|O 13|O or|O 61|O of|O one|O of|O the|O three|O ras|gene-rna genes|O ,|O Ha-ras|gene-rna ,|O Ki-ras|gene-rna ,|O and|O N-ras|gene-rna ,|O convert|O these|O genes|O into|O active|O oncogenes|O .|O 
To|O determine|O the|O role|O mutated|O ras|gene-rna genes|O play|O in|O the|O carcinogenesis|O of|O renal|O cell|O carcinoma|O ,|O we|O analysed|O tumour|O DNA|O and|O unaffected|O renal|O tissue|O derived|O from|O 55|O patients|O .|O 
The|O polymerase|gene-protein chain|O reaction|O technique|O was|O used|O to|O amplify|O DNA|O fragments|O containing|O Ki|gene-rna -|gene-rna ,|O Ha|gene-rna -|gene-rna ,|O and|O N|gene-rna -|gene-rna ras|gene-rna codons|O 12|O ,|O 13|O ,|O and|O 61|O .|O 
The|O amplified|O fragments|O were|O then|O probed|O on|O slot|O -|O blots|O with|O labeled|O mutation|O -|O specific|O oligomers|O .|O 
A|O single|O Ki-ras|gene-rna mutation|O (|O codon|O 12|O ,|O gly|O ->|O val|O )|O was|O detected|O in|O a|O patient|O with|O a|O pT2N2M1|O tumour|O .|O 
We|O concluded|O that|O ras|gene-rna oncogene|O mutations|O do|O not|O play|O an|O important|O role|O in|O the|O initiation|O of|O renal|O cell|O carcinoma|O .|O 
Analysis|O of|O ras|gene-rna gene|O mutations|O in|O acute|O myeloid|O leukemia|O by|O the|O polymerase|gene-protein chain|O reaction|O and|O oligonucleotide|O probes|O .|O 
In|O vitro|O deoxyribonucleic|O acid|O (|O DNA|O )|O amplification|O by|O the|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O followed|O by|O hybridization|O with|O oligonucleotide|O probes|O were|O used|O to|O study|O ras|gene-rna gene|O mutations|O in|O acute|O myeloid|O leukemia|O (|O AML|O )|O .|O 
The|O DNA|O of|O 30|O AML|O patients|O at|O presentation|O of|O the|O disease|O at|O the|O University|O of|O Malaya|O Hospital|O ,|O Kuala|O Lumpur|O were|O screened|O for|O ras|gene-rna gene|O mutations|O in|O codons|O 12|O ,|O 13|O and|O 61|O of|O the|O N-ras|gene-rna ,|O K-ras|gene-rna and|O H-ras|gene-rna genes|O .|O 
Four|O patients|O (|O 13.3|O %|O )|O had|O ras|gene-rna gene|O mutations|O .|O 
They|O were|O all|O below|O their|O early|O thirties|O in|O age|O .|O 
Of|O the|O four|O patients|O with|O ras|gene-rna gene|O mutations|O ,|O three|O were|O M3|O and|O one|O was|O M4|O according|O to|O the|O French|O American|O British|O (|O FAB|O )|O classification|O of|O AML|O .|O 
Oncogene|O 1991|O Aug|O ;|O 6|O (|O 8|O )|O :|O 1353|O -|O 62|O 
Mutations|O of|O ras|gene-rna genes|O distinguish|O a|O subset|O of|O non|O -|O small|O -|O cell|O lung|O cancer|O cell|O lines|O from|O small|O -|O cell|O lung|O cancer|O cell|O lines|O .|O 
NCI|O -|O Navy|O Medical|O Oncology|O Branch|O ,|O National|O Cancer|O Institute|O ,|O Bethesda|O ,|O Maryland|O 20889|O -|O 5105|O .|O 
We|O screened|O a|O panel|O of|O 103|O human|O lung|O cancer|O cell|O lines|O for|O the|O presence|O of|O point|O mutations|O at|O codons|O 12|O ,|O 13|O or|O 61|O of|O the|O human|O K|gene-rna -|gene-rna ,|O H|gene-rna -|gene-rna and|O N|gene-rna -|gene-rna ras|gene-rna genes|O ,|O using|O restriction|O fragment|O length|O polymorphisms|O (|O RFLP|O )|O ,|O created|O through|O mismatched|O primers|O during|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O of|O genomic|O DNA|O .|O 
We|O found|O ras|gene-rna mutations|O in|O 22|O /|O 61|O (|O 36|O %|O )|O non|O -|O small|O -|O cell|O lung|O cancer|O (|O NSCLC|O )|O cell|O lines|O ,|O predominantly|O in|O K-ras|gene-rna codon|O 12|O .|O Identical|O mutations|O were|O present|O in|O uncultured|O tumor|O materials|O corresponding|O to|O 11|O cell|O lines|O containing|O mutated|O ras|gene-rna genes|O .|O 
ras|gene-rna mutations|O were|O found|O not|O only|O in|O adenocarcinoma|O cell|O lines|O (|O 9|O /|O 32|O ,|O 28|O %|O )|O ,|O but|O also|O in|O cell|O lines|O derived|O from|O other|O types|O of|O NSCLC|O (|O 13|O /|O 29|O ,|O 45|O %|O )|O .|O 
In|O contrast|O ,|O none|O of|O 37|O small|O -|O cell|O lung|O cancer|O (|O SCLC|O )|O cell|O lines|O and|O five|O extra|O -|O pulmonary|O small|O -|O cell|O cancer|O cell|O lines|O had|O ras|gene-rna mutations|O .|O 
ras|gene-rna mutations|O were|O not|O correlated|O with|O sex|O of|O the|O patients|O ,|O tumor|O extent|O ,|O prior|O therapy|O status|O or|O in|O vitro|O culture|O time|O .|O 
G|O to|O T|O or|O A|O to|O T|O transversions|O were|O the|O most|O common|O base|O substitutions|O ,|O occurring|O in|O codons|O 12|O and|O 61|O respectively|O .|O 
We|O conclude|O that|O ras|gene-rna mutations|O play|O a|O role|O in|O the|O pathogenesis|O of|O a|O subset|O of|O NSCLC|O but|O are|O not|O involved|O in|O SCLC|O .|O 
Division|O of|O Hematology|O and|O Oncology|O ,|O University|O of|O North|O Carolina|O ,|O Chapel|O Hill|O 27599-7295|O .|O 
ras|gene-rna gene|O mutations|O are|O the|O most|O frequent|O molecular|O changes|O found|O in|O the|O preleukemic|O syndromes|O of|O adults|O and|O may|O play|O a|O role|O in|O initiating|O these|O diseases|O and|O in|O their|O progression|O to|O acute|O leukemia|O .|O 
However|O ,|O little|O is|O known|O about|O the|O incidence|O or|O importance|O of|O these|O genetic|O mutations|O in|O childhood|O myeloproliferative|O states|O (|O MPS|O )|O .|O 
The|O bone|O marrow|O (|O BM|O )|O monosomy|O 7|O syndrome|O accounts|O for|O a|O large|O percentage|O of|O childhood|O MPS|O .|O 
Although|O the|O duration|O of|O the|O MPS|O is|O quite|O variable|O ,|O children|O with|O monosomy|O 7|O eventually|O develop|O acute|O myeloid|O leukemia|O (|O AML|O )|O .|O 
We|O investigated|O 20|O children|O (|O 13|O with|O MPS|O ,|O 7|O with|O AML|O )|O with|O BM|O monosomy|O 7|O or|O 7q-|O for|O the|O presence|O of|O ras|gene-rna gene|O mutations|O using|O the|O polymerase|gene-protein chain|O reaction|O and|O hybridization|O with|O mutation|O -|O specific|O oligonucleotides|O .|O 
Mutations|O of|O N-ras|gene-rna and|O K-ras|gene-rna were|O detected|O in|O three|O children|O .|O 
Two|O patients|O carrying|O a|O ras|gene-rna mutation|O were|O in|O the|O myeloproliferative|O phase|O ,|O and|O one|O had|O acute|O leukemia|O .|O 
All|O three|O patients|O with|O ras|gene-rna mutations|O either|O died|O of|O their|O disease|O or|O relapsed|O after|O BM|O transplantation|O as|O compared|O with|O 8|O of|O 17|O without|O ras|gene-rna mutations|O .|O 
However|O ,|O this|O difference|O is|O not|O statistically|O significant|O (|O P|O =|O .14|O ,|O not|O significant|O )|O .|O 
We|O conclude|O that|O ras|gene-rna mutations|O are|O observed|O in|O childhood|O monosomy|O 7|O ,|O though|O less|O frequently|O than|O in|O adult|O MDS|O ,|O and|O may|O play|O a|O limited|O role|O in|O the|O progression|O of|O this|O disease|O to|O acute|O leukemia|O .|O 
More|O patients|O are|O needed|O to|O address|O the|O prognostic|O role|O of|O ras|gene-rna mutations|O in|O this|O rare|O disease|O .|O 
Activated|O protooncogenes|gene-rna in|O human|O lung|O tumors|O from|O smokers|O .|O 
Fourteen|O primary|O human|O lung|O tumor|O DNAs|O from|O smokers|O were|O analyzed|O for|O transforming|O activity|O by|O two|O DNA|O transfection|O assays|O .|O 
Activated|O protooncogenes|gene-rna were|O detected|O in|O 3|O of|O 11|O tumor|O DNAs|O by|O the|O NIH|O 3T3|O focus|O assay|O ,|O whereas|O activated|O protooncogenes|gene-rna were|O detected|O in|O 11|O of|O 13|O tumor|O DNAs|O by|O the|O NIH|O 3T3|O cotransfection|O -|O nude|O mouse|O tumorigenicity|O assay|O .|O 
K|gene-rna -|gene-rna or|O N|gene-rna RAS|gene-rna genes|O activated|O by|O point|O mutation|O at|O codons|O 12|O or|O 61|O were|O detected|O in|O a|O large|O cell|O carcinoma|O ,|O a|O squamous|O cell|O carcinoma|O ,|O and|O 5|O adenocarcinomas|O .|O 
An|O HRAS|gene-rna oncogene|O activated|O by|O a|O different|O mechanism|O was|O detected|O in|O an|O epidermoid|O carcinoma|O .|O 
One|O adenocarcinoma|O was|O found|O to|O contain|O an|O activated|O RAF|gene-rna gene|O .|O 
Two|O unidentified|O transforming|O genes|O were|O detected|O in|O a|O squamous|O cell|O carcinoma|O DNA|O and|O two|O adenocarcinoma|O DNAs|O .|O 
Eight|O of|O 10|O lung|O adenocarcinomas|O that|O had|O formed|O metastases|O at|O the|O time|O of|O surgery|O were|O found|O to|O contain|O RAS|gene-rna oncogenes|O .|O 
No|O significant|O increase|O in|O metastasis|O was|O observed|O in|O the|O lung|O adenocarcinomas|O that|O contained|O one|O or|O more|O 6|O -|O kilobase|O EcoRI|O alleles|O of|O the|O LMYC|gene-rna gene|O .|O 
Overall|O ,|O 12|O of|O 14|O (|O 86|O %|O )|O of|O the|O lung|O tumor|O DNAs|O from|O smokers|O were|O found|O to|O contain|O activated|O protooncogenes|gene-rna .|O 
A|O T-cell|O neoplasia|O showing|O clinicopathologic|O features|O of|O malignant|O histiocytosis|O with|O novel|O chromosomal|O abnormalities|O and|O N-ras|gene-rna mutation|O .|O 
Malignant|O histiocytosis|O (|O MH|O )|O is|O a|O distinct|O disease|O entity|O defined|O clinically|O and|O morphologically|O .|O 
However|O ,|O the|O neoplastic|O origin|O of|O MH|O is|O not|O well|O established|O .|O 
The|O authors|O report|O a|O 26-year-old|O woman|O who|O showed|O the|O typical|O clinicopathologic|O features|O of|O so-called|O MH|O .|O 
Cytogenetic|O and|O molecular|O genetic|O examinations|O were|O performed|O in|O addition|O to|O the|O morphologic|O and|O immunologic|O approach|O .|O 
The|O expression|O of|O CD2|gene-rna and|O T-cell|gene-rna receptor|gene-rna gene|O rearrangements|O indicated|O the|O T-cell|O origin|O of|O this|O case|O .|O 
CD30|gene-protein ,|O which|O is|O positive|O for|O anaplastic|O large|O cell|O lymphoma|O (|O Ki-1|O lymphoma|O )|O ,|O was|O not|O expressed|O .|O 
The|O cytogenetic|O study|O revealed|O a|O clonal|O chromosome|O abnormality|O involving|O 3q25|O ,|O 6p21|O ,|O 11p15|O ,|O and|O 11q21|O .|O 
An|O N-ras|gene-rna point|O mutation|O within|O codon|O 12|O (|O GGT|O ----|O GCT|O )|O was|O also|O detected|O .|O 
These|O finding|O indicate|O that|O MH|O defined|O clinically|O and|O morphologically|O is|O not|O a|O tumor|O of|O true|O histiocytic|O origin|O and|O that|O it|O should|O be|O reclassified|O on|O the|O basis|O of|O immunologic|O ,|O cytogenetic|O ,|O and|O molecular|O genetic|O data|O .|O 
Point|O mutations|O in|O codons|O 12|O ,|O 13|O or|O 61|O of|O the|O oncogenes|O Ha-ras|gene-rna ,|O Ki-ras|gene-rna or|O N-ras|gene-rna have|O been|O identified|O in|O human|O malignancies|O of|O many|O types|O .|O 
Using|O the|O PCR|O (|O polymerase|gene-protein chain|O reaction|O )|O technique|O for|O DNA|O amplification|O in|O vitro|O and|O stringent|O probing|O of|O the|O amplified|O DNA|O on|O dot|O blots|O with|O a|O library|O of|O specific|O oligonucleotides|O ,|O we|O have|O screened|O for|O the|O presence|O of|O ras|gene-rna mutations|O in|O oral|O and|O para|O -|O oral|O malignancies|O and|O some|O associated|O lesions|O .|O 
The|O material|O ,|O from|O UK|O patients|O ,|O consisted|O of|O 22|O oral|O squamous|O -|O cell|O carcinomas|O including|O 5|O neck|O metastases|O ,|O 1|O oral|O mucosal|O dysplasia|O ,|O 1|O proliferative|O verrucous|O leukoplakia|O ,|O 1|O antral|O and|O 1|O tonsillar|O carcinoma|O ,|O 1|O basal|O -|O cell|O carcinoma|O ,|O 1|O salivary|O adenocarcinoma|O ,|O 1|O salivary|O adenoid|O cystic|O carcinoma|O and|O 1|O lung|O adenocarcinoma|O metastatic|O to|O the|O gingiva|O .|O 
Genomic|O DNA|O was|O extracted|O from|O tissues|O which|O were|O fresh|O or|O preserved|O in|O liquid|O nitrogen|O .|O 
Two|O DNA|O samples|O contained|O point|O mutations|O in|O codon|O 61|O of|O Ki-ras|gene-rna .|O 
One|O of|O these|O mutations|O was|O in|O the|O lymphocytes|O infiltrating|O a|O retromolar|O SCC|O .|O 
The|O other|O mutation|O (|O CAA|O to|O CAU|O ;|O substitution|O of|O glutamine|O by|O histidine|O )|O was|O in|O the|O lung|O adenocarcinoma|O metastasis|O .|O 
The|O absence|O of|O ras|gene-rna mutations|O in|O the|O epithelium|O of|O primary|O oral|O squamous|O -|O cell|O carcinomas|O is|O of|O considerable|O interest|O as|O other|O work|O in|O our|O Department|O on|O Indian|O cases|O of|O oral|O carcinomas|O associated|O with|O chewing|O tobacco|O (|O quid|O )|O revealed|O that|O 35|O %|O of|O these|O had|O a|O codon|O 12|O ,|O 13|O or|O 61|O mutation|O in|O Ha-ras|gene-rna .|O 
While|O ras|gene-rna activations|O arising|O from|O point|O mutations|O may|O occur|O in|O a|O high|O proportion|O of|O oral|O malignancies|O associated|O with|O chewing|O tobacco|O (|O quid|O )|O ,|O this|O was|O not|O the|O case|O in|O UK|O oral|O malignancies|O ,|O even|O where|O tobacco|O was|O smoked|O .|O 
ras|gene-rna gene|O mutations|O in|O human|O prostate|O cancer|O .|O 
Point|O mutations|O at|O codons|O 12|O ,|O 13|O ,|O or|O 61|O of|O the|O Ha|gene-rna -|gene-rna ,|O Ki|gene-rna -|gene-rna ,|O and|O N|gene-rna -|gene-rna ras|gene-rna genes|O are|O able|O to|O convert|O these|O normal|O cellular|O genes|O into|O activated|O oncogenes|O .|O 
Previous|O studies|O have|O shown|O that|O ras|gene-rna gene|O mutations|O occur|O in|O a|O variety|O of|O human|O solid|O tumors|O and|O may|O be|O important|O in|O the|O pathogenesis|O of|O some|O of|O these|O tumors|O .|O 
In|O order|O to|O test|O the|O hypothesis|O that|O ras|gene-rna gene|O mutations|O may|O be|O associated|O with|O prostate|O cancer|O ,|O we|O have|O used|O an|O oligodeoxynucleotide|O hybridization|O assay|O to|O detect|O wild-type|O and|O mutant|O alleles|O in|O genomic|O DNA|O from|O prostate|O tumors|O and|O prostate|O tumor|O cell|O lines|O amplified|O using|O the|O polymerase|gene-protein chain|O reaction|O .|O 
Twenty-four|O primary|O prostate|O tumors|O (|O 23|O acinar|O tumors|O and|O one|O ductal|O tumor|O )|O and|O five|O prostate|O tumor|O cell|O lines|O were|O examined|O for|O mutations|O at|O codons|O 12|O ,|O 13|O ,|O and|O 61|O of|O the|O Ki-ras|gene-rna ,|O Ha-ras|gene-rna ,|O and|O N-ras|gene-rna genes|O .|O 
Two|O mutations|O were|O detected|O :|O an|O A|O ----|O G|O transition|O causing|O a|O glutamine|O to|O arginine|O amino|O acid|O substitution|O at|O codon|O 61|O of|O the|O Ha-ras|gene-rna gene|O in|O a|O primary|O prostatic|O duct|O adenocarcinoma|O and|O a|O G|O ----|O T|O transversion|O causing|O a|O glycine|O to|O valine|O amino|O acid|O substitution|O at|O codon|O 12|O of|O the|O Ha-ras|gene-rna gene|O in|O a|O prostate|O tumor|O cell|O line|O (|O TSU-PR1|O )|O derived|O from|O a|O lymph|O node|O metastasis|O .|O 
While|O the|O overall|O frequency|O of|O ras|gene-rna gene|O mutations|O in|O prostate|O tumors|O is|O low|O ,|O when|O these|O mutations|O do|O occur|O they|O may|O have|O a|O role|O in|O the|O progression|O of|O disease|O or|O the|O development|O of|O the|O unusual|O ductal|O variant|O of|O prostatic|O adenocarcinoma|O .|O 
N-ras|gene-rna 61|O oncogene|O mutations|O in|O Hurthle|O cell|O tumors|O .|O 
Department|O of|O Surgery|O ,|O University|O of|O Chicago|O ,|O Pritzker|O School|O of|O Medicine|O ,|O IL|O 60637|O .|O 
Mutations|O of|O ras|gene-rna oncogenes|O are|O believed|O to|O play|O an|O important|O role|O in|O the|O initiation|O or|O progression|O of|O human|O tumors|O .|O 
In|O thyroid|O tumors|O the|O incidence|O of|O ras|gene-rna activation|O by|O specific|O point|O mutations|O has|O been|O reported|O to|O range|O from|O 33|O %|O in|O follicular|O adenomas|O up|O to|O 60|O %|O in|O anaplastic|O carcinomas|O .|O 
Because|O of|O our|O long|O -|O standing|O interest|O in|O Hurthle|O cell|O tumors|O ,|O we|O began|O a|O study|O of|O 70|O such|O cases|O to|O determine|O the|O incidence|O of|O ras|gene-rna mutations|O and|O their|O clinical|O correlates|O .|O 
Analysis|O of|O N-ras|gene-rna sequences|O at|O codon|O position|O 61|O ,|O with|O the|O polymerase|O chain|O reaction|O method|O and|O oligonucleotide|O probe|O hybridization|O ,|O showed|O point|O mutations|O of|O the|O normal|O codon|O CAA|O *|O in|O eight|O tumor|O samples|O .|O 
One|O was|O a|O mutation|O from|O CAA|O to|O AAA|O ,|O one|O from|O CAA|O to|O CTA|O ,|O *|O and|O six|O from|O CAA|O to|O CGA|O .|O 
These|O mutations|O would|O result|O in|O amino|O acid|O substitutions|O of|O lysine|O ,|O leucine|O ,|O or|O arginine|O for|O the|O normal|O glutamine|O at|O position|O 61|O in|O the|O N-ras|gene-protein protein|O .|O 
Identical|O ras|gene-rna mutations|O in|O two|O tumors|O and|O some|O of|O their|O surrounding|O thyroid|O tissue|O may|O indicate|O that|O activating|O ras|gene-rna point|O mutations|O are|O an|O early|O event|O in|O carcinogenesis|O .|O 
The|O incidence|O of|O mutations|O was|O 1|O of|O 24|O (|O 4|O %|O )|O of|O the|O histologically|O benign|O tumors|O ,|O 5|O of|O 34|O (|O 15|O %|O )|O of|O the|O intermediate|O tumors|O (|O with|O vascular|O or|O capsular|O permeation|O )|O ,|O and|O 2|O of|O 12|O (|O 17|O %|O )|O in|O the|O malignant|O group|O .|O 
Four|O of|O these|O eight|O patients|O died|O of|O metastatic|O thyroid|O disease|O and|O four|O are|O alive|O without|O evidence|O of|O recurrence|O .|O 
Identifying|O the|O nature|O of|O the|O genetic|O mutations|O in|O thyroid|O neoplasms|O and|O their|O prevalence|O in|O the|O various|O tumor|O phenotypes|O is|O critical|O to|O understanding|O their|O pathogenesis|O .|O 
Mutational|O activation|O of|O ras|gene-rna oncogenes|O in|O human|O tumors|O occurs|O predominantly|O through|O point|O mutations|O in|O two|O functional|O regions|O of|O the|O molecules|O ,|O codons|O 12|O ,|O 13|O (|O GTP|O -|O binding|O domain|O )|O or|O codon|O 61|O (|O GTPase|O domain|O )|O .|O 
We|O examined|O the|O prevalence|O of|O point|O mutations|O in|O codons|O 12|O ,|O 13|O ,|O and|O 61|O of|O the|O oncogenes|O K-ras|gene-rna ,|O N-ras|gene-rna ,|O and|O H-ras|gene-rna in|O benign|O and|O malignant|O human|O thyroid|O tumors|O by|O hybridization|O of|O PCR|O -|O amplified|O tumor|O DNA|O with|O synthetic|O oligodeoxynucleotide|O probes|O .|O 
None|O of|O the|O eight|O normal|O thyroid|O tissues|O harbored|O point|O mutations|O .|O 
Four|O of|O nineteen|O nodules|O from|O multinodular|O goiters|O (|O 21|O %|O )|O ,|O 6|O /|O 24|O microfollicular|O adenomas|O (|O 25|O %|O )|O ,|O 3|O /|O 14|O papillary|O carcinomas|O (|O 21|O %|O )|O ,|O and|O 0|O /|O 3|O follicular|O carcinomas|O contained|O ras|gene-rna point|O mutations|O .|O 
The|O predominant|O mutation|O was|O a|O valine|O for|O glycine|O substitution|O in|O codon|O 12|O of|O H-ras|gene-rna .|O 
None|O of|O the|O multinodular|O goiter|O tumors|O known|O to|O be|O polyclonal|O (|O and|O thus|O due|O to|O hyperplasia|O )|O had|O point|O mutations|O ,|O whereas|O one|O of|O the|O two|O monoclonal|O adenomas|O arising|O in|O nodular|O glands|O contained|O in|O H-ras|gene-rna codon|O 12|O valine|O substitution|O ,|O which|O was|O confirmed|O by|O sequencing|O the|O tumor|O DNA|O .|O 
These|O data|O show|O that|O ras|gene-rna activation|O is|O about|O equally|O prevalent|O in|O benign|O and|O malignant|O thyroid|O neoplasms|O ,|O and|O thus|O may|O be|O an|O early|O event|O in|O the|O tumorigenic|O process|O .|O 
Infrequent|O ras|gene-rna oncogene|O point|O mutations|O in|O renal|O cell|O carcinoma|O .|O 
The|O role|O of|O ras|gene-rna oncogenes|O in|O the|O pathogenesis|O of|O renal|O cell|O carcinoma|O is|O unclear|O .|O 
We|O have|O previously|O shown|O that|O insertion|O of|O a|O mutated|O ras|gene-rna oncogene|O into|O cultured|O human|O proximal|O tubular|O cells|O ,|O the|O normal|O counterpart|O of|O renal|O cell|O carcinomas|O ,|O initiates|O a|O series|O of|O transformation|O events|O which|O results|O in|O cells|O possessing|O a|O renal|O cancer|O phenotype|O .|O 
These|O data|O suggested|O a|O role|O for|O mutated|O ras|gene-rna genes|O in|O the|O initiation|O and|O maintenance|O of|O this|O disease|O .|O 
Therefore|O ,|O to|O assess|O the|O involvement|O of|O ras|gene-rna genes|O in|O renal|O carcinogenesis|O ,|O 51|O primary|O and|O metastatic|O renal|O carcinomas|O ,|O including|O three|O oncocytomas|O ,|O were|O analyzed|O for|O point|O mutations|O in|O codons|O 12|O ,|O 13|O and|O 61|O of|O the|O Ha-ras|gene-rna ,|O Ki-ras|gene-rna and|O N-ras|gene-rna proto|O -|O oncogenes|O using|O polymerase|gene-protein -|O catalyzed|O chain|O reaction|O methodology|O .|O 
A|O mutated|O Ha-ras|gene-rna gene|O was|O found|O in|O one|O renal|O cancer|O metastatic|O to|O lung|O for|O an|O overall|O incidence|O of|O 2|O %|O .|O 
These|O data|O indicate|O that|O ras|gene-rna oncogenes|O ,|O activated|O by|O point|O mutations|O ,|O do|O not|O play|O a|O major|O role|O in|O the|O initiation|O ,|O maintenance|O or|O metastases|O of|O renal|O carcinomas|O .|O 
Analysis|O of|O N-RAS|gene-rna exon-1|O mutations|O in|O myelodysplastic|O syndromes|O by|O polymerase|gene-protein chain|O reaction|O and|O direct|O sequencing|O .|O 
Mutations|O in|O codons|O 12|O or|O 13|O of|O the|O first|O exon|O of|O the|O N-RAS|gene-rna gene|O have|O been|O reported|O in|O myelodysplastic|O syndromes|O (|O MDS|O )|O in|O frequencies|O that|O vary|O between|O 9|O %|O and|O 40|O %|O depending|O on|O the|O techniques|O used|O in|O analysis|O .|O 
Gene|O amplification|O and|O direct|O sequencing|O provides|O the|O only|O unambiguous|O method|O of|O detecting|O those|O mutations|O that|O induce|O amino|O acid|O alterations|O .|O 
Using|O this|O technique|O ,|O we|O analyzed|O 21|O MDS|O patients|O for|O mutations|O in|O exon-1|O of|O N-RAS|gene-rna .|O 
Codon|O 12|O mutations|O substituting|O aspartic|O acid|O (|O GAT|O )|O for|O glycine|O (|O GGT|O )|O were|O found|O in|O four|O cases|O ,|O and|O a|O codon|O 13|O mutation|O substituting|O alanine|O (|O GCT|O )|O for|O glycine|O (|O GGT|O )|O was|O detected|O in|O one|O patient|O .|O 
We|O conclude|O that|O N-RAS|gene-rna exon-1|O mutations|O in|O one|O patient|O .|O 
We|O conclude|O that|O N-RAS|gene-rna exon-1|O mutations|O producing|O amino|O acid|O changes|O occur|O in|O about|O 20|O %|O to|O 25|O %|O of|O MDS|O cases|O .|O 
A|O novel|O mutation|O of|O the|O N-RAS|gene-rna gene|O of|O T-ALL|O blast|O cells|O was|O detected|O by|O a|O direct|O sequencing|O of|O in|O vitro|O amplified|O exon-1|O of|O the|O N-RAS|gene-rna gene|O .|O 
Threonine|O (|O ACA|O )|O was|O substituted|O for|O alanine|O (|O GCA|O )|O at|O codon|O 11|O .|O 
This|O mutation|O would|O have|O been|O overlooked|O by|O conventional|O probe|O hybridization|O techniques|O .|O 
A|O search|O for|O other|O mutations|O in|O N-RAS|gene-rna exon-1|O in|O T-ALL|O revealed|O a|O codon|O 13|O mutation|O substituting|O aspartic|O acid|O (|O GAT|O )|O for|O glycine|O (|O GGT|O )|O in|O one|O of|O 18|O patients|O .|O 
No|O mutations|O at|O codon|O 12|O were|O detected|O .|O 
The|O presence|O of|O mutations|O activating|O the|O N-ras|gene-rna gene|O was|O investigated|O by|O the|O polymerase|O chain|O reaction|O technique|O in|O twenty|O patients|O with|O acute|O myeloblastic|O leukemia|O (|O AML|O )|O at|O onset|O and|O in|O four|O patients|O with|O Ph1|O positive|O chronic|O myelogeneous|O leukemia|O (|O CML|O )|O either|O in|O chronic|O phase|O or|O in|O blast|O crisis|O .|O 
Four|O remission|O samples|O and|O four|O relapses|O from|O the|O AML|O cases|O were|O also|O studied|O .|O 
Mutations|O were|O found|O in|O five|O out|O of|O twenty|O (|O 25|O %|O )|O untreated|O AML|O cases|O at|O onset|O .|O 
No|O mutations|O were|O detected|O in|O the|O complete|O remission|O samples|O ,|O two|O of|O them|O with|O N-ras|gene-rna mutations|O during|O the|O leukemic|O phase|O .|O 
Two|O out|O of|O the|O four|O leukemia|O relapses|O were|O positive|O for|O the|O same|O N-ras|gene-rna mutation|O shown|O at|O presentation|O ,|O whereas|O no|O new|O mutations|O were|O found|O in|O the|O other|O two|O initially|O negative|O cases|O .|O 
An|O N-ras|gene-rna mutation|O appeared|O during|O the|O blast|O crisis|O of|O one|O of|O the|O four|O CML|O ,|O which|O were|O all|O negative|O during|O the|O chronic|O phase|O .|O 
In|O conclusion|O ,|O whereas|O some|O data|O appear|O to|O be|O consistent|O with|O a|O role|O of|O the|O N-ras|gene-rna mutations|O as|O initiating|O events|O in|O myeloid|O leukemias|O ,|O in|O other|O cases|O N-ras|gene-rna activation|O seems|O to|O represent|O a|O factor|O involved|O in|O progression|O .|O 
These|O data|O suggest|O that|O a|O partial|O overlapping|O between|O initiation|O and|O progression|O factors|O could|O exist|O in|O naturally|O occurring|O tumors|O .|O 
We|O have|O used|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O ,|O an|O amplification|O procedure|O ,|O and|O oligonucleotide|O hybridization|O to|O detect|O ras|gene-rna gene|O point|O mutations|O in|O DNA|O from|O melanoma|O tumor|O samples|O .|O 
Genomic|O DNA|O was|O examined|O from|O 40|O specimens|O of|O melanotic|O lesions|O ,|O including|O benign|O nevi|O ,|O primary|O melanomas|O ,|O lymph|O node|O metastases|O ,|O and|O systemic|O metastases|O .|O 
Adjacent|O normal|O skin|O or|O peripheral|O blood|O was|O analyzed|O as|O control|O material|O in|O 28|O cases|O .|O 
ras|gene-rna mutations|O were|O detected|O overall|O in|O 25|O %|O of|O malignant|O tumors|O .|O 
In|O addition|O ,|O mutations|O of|O all|O three|O ras|gene-rna genes|O were|O detected|O .|O 
We|O observed|O ras|gene-rna mutations|O in|O 2|O of|O 4|O benign|O atypical|O nevi|O (|O 2|O X|O K|gene-rna 12|O )|O ,|O 4|O of|O 22|O primary|O melanomas|O (|O 3|O X|O K|gene-rna 12|O ,|O 1|O X|O H|gene-rna 12|O ,|O 1|O X|O N|gene-rna 61|O )|O ,|O and|O 4|O of|O 14|O secondary|O (|O 5|O X|O K|gene-rna 12|gene-rna ,|O 1|O X|O N|gene-rna 61|O )|O tumors|O .|O 
One|O with|O a|O primary|O melanoma|O had|O concurrent|O K|gene-rna 12|O and|O H|gene-rna 12|O ,|O and|O two|O patients|O with|O secondary|O tumors|O had|O concurrent|O K|gene-rna 12|O /|O N|gene-rna 61|O and|O K|gene-rna 12|O Asp|O /|O K|gene-rna 12|O Val|O mutations|O ,|O respectively|O ,|O making|O a|O total|O of|O 10|O of|O 40|O (|O 25|O %|O )|O patients|O with|O ras|gene-rna mutations|O .|O 
This|O is|O the|O first|O demonstration|O of|O K-ras|gene-rna mutations|O in|O human|O melanoma|O .|O 
The|O presence|O of|O K-ras|gene-rna mutations|O in|O nevi|O ,|O putative|O melanoma|O precursors|O ,|O suggests|O that|O ras|gene-rna activation|O may|O be|O an|O early|O event|O in|O melanoma|O development|O .|O 
No|O correlation|O between|O tumor|O thickness|O and|O the|O presence|O of|O a|O ras|gene-rna mutation|O was|O observed|O .|O 
The|O frequency|O of|O RAS|gene-rna activation|O was|O studied|O in|O 48|O patients|O with|O acute|O myeloid|O leukaemia|O (|O AML|O )|O or|O with|O myelodysplastic|O syndromes|O (|O MDS|O )|O ,|O in|O order|O to|O address|O the|O question|O of|O whether|O patients|O possessing|O monosomy|O 7|O or|O other|O alterations|O of|O chromosome|O 7|O have|O a|O higher|O incidence|O of|O RAS|gene-rna activation|O than|O those|O lacking|O chromosome|O 7|O abnormalities|O .|O 
Samples|O were|O screened|O for|O oncogenic|O point|O mutation|O by|O DNA|O amplification|O followed|O by|O oligonucleotide|O hybridization|O analysis|O at|O codons|O 12|O ,|O 13|O and|O 61|O of|O N-RAS|gene-rna and|O codons|O 12|O and|O 13|O of|O K-RAS|gene-rna .|O 
Two|O additional|O samples|O were|O considered|O to|O have|O activated|O RAS|gene-rna due|O to|O additional|O karyotypic|O abnormalities|O t|O (|O 5|O ;|O 12|O )|O or|O loss|O of|O both|O copies|O of|O chromosome|O 17|O and|O hence|O ,|O the|O neurofibromatosis|O (|O NF1|O )|O loci|O .|O 
The|O group|O of|O chronic|O myelomonocytic|O leukaemia|O (|O CMML|O )|O patients|O had|O activated|O RAS|gene-rna in|O 4|O /|O 11|O cases|O and|O inclusion|O of|O two|O CMMLt|O patients|O (|O with|O monosomy|O 7|O )|O brings|O this|O incidence|O to|O 5|O /|O 13|O .|O 
No|O change|O in|O frequency|O of|O RAS|gene-rna activation|O was|O seen|O between|O groups|O containing|O de|O novo|O AML|O samples|O with|O or|O without|O chromosome|O 7|O abnormalities|O (|O 1|O /|O 5|O and|O 2|O /|O 12|O ,|O respectively|O )|O .|O 
However|O ,|O assessment|O of|O MDS|O samples|O in|O the|O process|O of|O ,|O or|O subsequent|O to|O ,|O leukaemic|O progression|O showed|O a|O difference|O between|O the|O two|O groups|O .|O 
The|O frequency|O of|O RAS|gene-rna activation|O in|O samples|O with|O monosomy|O 7|O was|O 4|O /|O 9|O samples|O while|O none|O of|O the|O seven|O samples|O without|O chromosome|O 7|O changes|O showed|O RAS|gene-rna activation|O .|O 
Acute|O leukemic|O transformation|O of|O myelodysplastic|O syndrome|O --|O immunophenotypic|O ,|O genotypic|O ,|O and|O cytogenetic|O studies|O .|O 
The|O clinical|O and|O biological|O characteristics|O of|O myelodysplastic|O syndrome|O (|O MDS|O )|O in|O acute|O leukemic|O transformation|O were|O studied|O in|O 23|O patients|O .|O 
All|O had|O myeloid|O transformation|O according|O to|O FAB|O criteria|O ,|O but|O coexpression|O of|O lymphoid|O -|O associated|O antigens|O was|O detected|O in|O five|O of|O the|O 20|O patients|O who|O underwent|O an|O immunophenotypic|O study|O .|O 
Rearrangement|O of|O the|O immunoglobulin|gene-rna heavy|gene-rna chain|gene-rna gene|O was|O also|O observed|O in|O one|O of|O the|O five|O patients|O who|O coexpressed|O lymphoid|O markers|O and|O that|O of|O the|O T-cell|gene-rna receptor|gene-rna beta|gene-rna chain|gene-rna gene|O in|O another|O one|O .|O None|O had|O pure|O lymphoid|O transformation|O .|O 
Clonal|O chromosomal|O abnormalities|O were|O noted|O in|O 12|O (|O 63|O %|O )|O of|O the|O 19|O patients|O who|O underwent|O cytogenetic|O study|O ,|O most|O commonly|O -|O 7|O (|O six|O patients|O or|O 32|O %|O )|O .|O 
In|O the|O 18|O patients|O who|O underwent|O serial|O analyses|O both|O at|O MDS|O diagnosis|O and|O at|O acute|O transformation|O ,|O seven|O (|O 39|O %|O )|O underwent|O karyotypic|O evolution|O .|O 
The|O most|O common|O new|O or|O additional|O aberrations|O were|O +|O 8|O and|O +|O 21|O .|O 
N-ras|gene-rna gene|O mutation|O was|O detected|O in|O two|O of|O the|O nine|O patients|O at|O acute|O leukemic|O transformation|O .|O 
The|O median|O interval|O from|O diagnosis|O of|O MDS|O to|O onset|O of|O acute|O transformation|O was|O 10|O months|O (|O 1|O -|O 36|O months|O )|O .|O 
Patients|O with|O a|O normal|O karyotype|O at|O diagnosis|O had|O a|O significantly|O longer|O chronic|O phase|O duration|O than|O those|O with|O chromosomal|O abnormalities|O (|O median|O of|O 20|O months|O vs.|O 5|O months|O )|O .|O 
However|O ,|O all|O had|O a|O short|O survival|O time|O after|O diagnosis|O of|O acute|O leukemia|O ,|O whether|O chromosomal|O anomalies|O were|O present|O or|O not|O .|O 
Analysis|O of|O N-ras|O mutations|O in|O human|O cutaneous|O melanoma|O :|O tumor|O heterogeneity|O detected|O by|O polymerase|O chain|O reaction|O /|O single|O -|O stranded|O conformation|O polymorphism|O analysis|O .|O 
Determination|O of|O the|O activation|O state|O of|O oncogenes|gene-rna as|O well|O as|O tumor|gene-rna suppressor|gene-rna genes|O is|O a|O main|O subject|O of|O interest|O in|O the|O analysis|O of|O the|O mechanism|O of|O tumor|O initiation|O .|O 
In|O human|O melanoma|O ,|O the|O c-myc|gene-rna and|O N-ras|gene-rna oncogenes|O have|O been|O found|O to|O be|O activated|O in|O approximately|O 50|O %|O and|O 15|O %|O of|O the|O analyzed|O material|O ,|O respectively|O .|O 
These|O studies|O have|O mostly|O been|O done|O on|O fresh|O tumor|O material|O or|O cell|O lines|O .|O 
Only|O in|O a|O few|O cases|O has|O an|O attempt|O been|O made|O to|O look|O at|O tumor|O heterogeneity|O or|O clonality|O with|O respect|O to|O the|O activation|O of|O oncogenes|gene-rna .|O 
We|O have|O adjusted|O the|O polymerase|O chain|O reaction|O (|O PCR|O )|O /|O single|O -|O stranded|O conformation|O polymorphism|O analysis|O (|O SSCP|O )|O technique|O to|O screen|O paraffin|O -|O embedded|O melanoma|O material|O for|O the|O presence|O of|O N-ras|gene-rna mutations|O and|O found|O genetic|O defects|O at|O particular|O progression|O stages|O .|O 
In|O one|O melanoma|O of|O the|O skin|O ,|O we|O were|O able|O to|O sublocalize|O an|O N-ras|gene-rna mutation|O in|O the|O intraepidermal|O tumor|O part|O ,|O that|O was|O absent|O in|O the|O part|O deeply|O invading|O the|O dermal|O layer|O .|O 
We|O conclude|O that|O a|O thorough|O investigation|O of|O N-ras|gene-rna activation|O in|O human|O melanoma|O should|O include|O analysis|O of|O histologically|O different|O parts|O of|O the|O tumor|O .|O 
Genetic|O alterations|O in|O thyroid|O hyperfunctioning|O adenomas|O .|O 
Thirty-seven|O thyroid|O autonomously|O hyperfunctioning|O adenomas|O were|O screened|O for|O mutations|O in|O the|O TSH|gene-rna receptor|gene-rna (|O TSHR|gene-rna )|O ,|O G|gene-rna alpha|gene-rna s|gene-rna (|O gsp|gene-rna )|O ,|O and|O ras|gene-rna genes|O .|O 
Polymerase|gene-protein chain|O reaction|O -|O amplified|O fragments|O of|O the|O TSHR|gene-rna C|O -|O terminal|O part|O (|O exon|O 10|O )|O ,|O the|O G|gene-rna alpha|gene-rna s|gene-rna (|O exons|O 8|O and|O 9|O )|O ,|O and|O the|O three|O ras|gene-rna genes|O were|O obtained|O from|O the|O genomic|O DNA|O extracted|O from|O 37|O tumors|O and|O their|O adjacent|O normal|O tissues|O and|O were|O studied|O by|O direct|O nucleotide|O sequencing|O and|O hybridization|O with|O synthetic|O probes|O .|O 
A|O point|O mutation|O in|O the|O third|O intracellular|O loop|O (|O codon|O 623|O )|O of|O the|O TSHR|gene-rna was|O found|O in|O 3|O of|O 37|O adenomas|O studied|O .|O 
This|O mutation|O codes|O for|O a|O change|O (|O Ala|O to|O Ser|O )|O in|O the|O TSHR|gene-generic structure|O and|O is|O somatic|O and|O heterozygotic|O .|O 
Constitutive|O activation|O of|O the|O TSHR|gene-rna was|O demonstrated|O by|O an|O increase|O in|O basal|O cAMP|O levels|O after|O transfection|O of|O Chinese|O hamster|O ovary|O cells|O with|O a|O mutated|O Ser|O 623|O -|O TSHR|gene-rna complementary|O DNA|O .|O 
Nine|O gsp|gene-rna [00ae]MDRV[00af]|O -|O and|O one|O ras|gene-rna -|O activating|O mutations|O were|O also|O detected|O .|O 
No|O simultaneous|O alteration|O of|O the|O studied|O genes|O was|O present|O .|O 
Thus|O ,|O in|O hyperfunctioning|O thyroid|O adenomas|O ,|O our|O data|O suggest|O that|O a|O mutational|O activation|O of|O the|O TSHR|gene-rna and|O gsp|gene-rna genes|O may|O play|O a|O tumorigenic|O role|O through|O constitutive|O activation|O of|O the|O cAMP|O pathway|O .|O 
Point|O mutations|O of|O ras|gene-rna genes|O in|O human|O adrenal|O cortical|O tumors|O :|O absence|O in|O adrenocortical|O hyperplasia|O .|O 
Point|O mutations|O of|O ras|gene-rna genes|O (|O K-|gene-rna ,|O H-|gene-rna ,|O and|O N|gene-rna -|gene-rna ras|gene-rna )|O at|O codons|O 12|O ,|O 13|O ,|O and|O 61|O and|O of|O the|O Gi2|gene-rna alpha|gene-rna gene|O at|O codons|O 179|O and|O 205|O ,|O were|O studied|O in|O 56|O primary|O adrenal|O cortical|O tumors|O and|O 6|O adrenal|O cortical|O hyperplasias|O .|O 
Of|O 56|O tumors|O ,|O 24|O were|O carcinomas|O and|O 32|O were|O benign|O .|O 
The|O 24|O carcinomas|O and|O 20|O of|O the|O benign|O tumors|O were|O from|O American|O patients|O ;|O the|O 12|O remaining|O adenomas|O were|O from|O Japanese|O patients|O .|O 
Of|O the|O benign|O tumors|O 12|O were|O cortisol|O -|O producing|O adenomas|O ,|O 15|O were|O aldosterone|O -|O producing|O adenomas|O ,|O 3|O were|O nonfunctioning|O adenomas|O ,|O and|O 2|O were|O adenomas|O that|O produced|O a|O virilizing|O syndrome|O .|O 
Tumor|O DNA|O obtained|O from|O archival|O formalin|O -|O fixed|O ,|O paraffin|O -|O embedded|O tissue|O or|O fresh|O frozen|O tissue|O was|O amplified|O by|O polymerase|O chain|O reaction|O ;|O and|O point|O mutations|O were|O detected|O by|O sequence|O -|O specific|O oligonucleotide|O hybridization|O .|O 
Activating|O ras|gene-rna mutations|O were|O found|O in|O 7|O of|O 56|O (|O 12.5|O %|O )|O of|O all|O tumors|O :|O 3|O of|O 24|O (|O 12.5|O %|O )|O carcinomas|O and|O 4|O of|O 32|O (|O 12.5|O %|O )|O adenomas|O .|O 
Of|O adenomas|O from|O an|O American|O population|O ,|O 4|O of|O 20|O (|O 20|O %|O )|O exhibited|O positive|O ras|gene-rna mutations|O ,|O whereas|O none|O was|O present|O in|O the|O Japanese|O tumors|O .|O 
All|O mutations|O detected|O were|O adenine|O to|O guanine|O transitions|O at|O the|O second|O position|O of|O N-ras|gene-rna codon|O 61|O ,|O resulting|O in|O a|O conversion|O from|O glutamine|O to|O arginine|O .|O 
No|O mutations|O were|O found|O in|O K-ras|gene-rna or|O H-ras|gene-rna genes|O .|O 
Furthermore|O ,|O no|O mutations|O of|O the|O Gi2|gene-rna alpha|gene-rna gene|O were|O identified|O .|O 
These|O findings|O demonstrate|O that|O N-ras|gene-rna mutations|O at|O codon|O 61|O may|O contribute|O to|O the|O genesis|O of|O both|O benign|O and|O malignant|O human|O adrenal|O cortical|O tumors|O .|O 
Finally|O ,|O no|O mutations|O of|O the|O ras|gene-rna or|O Gi2|gene-rna alpha|gene-rna genes|O were|O identified|O in|O hyperplastic|O adrenocortical|O tissues|O .|O 
Karyotypic|O and|O ras|gene-rna gene|O mutational|O analysis|O in|O idiopathic|O myelofibrosis|O .|O 
Karyotypic|O analysis|O was|O performed|O in|O a|O total|O of|O 69|O patients|O with|O well|O -|O characterized|O idiopathic|O myelofibrosis|O .|O 
Karyotypic|O abnormalities|O were|O detected|O in|O 46|O %|O of|O cases|O examined|O during|O the|O chronic|O phase|O (|O 29|O /|O 63|O )|O ;|O with|O three|O abnormalities|O ,|O del|O (|O 13q|O )|O ,|O del|O (|O 20q|O )|O and|O partial|O trisomy|O 1q|O ,|O accounting|O for|O 75|O %|O of|O all|O abnormalities|O at|O diagnosis|O .|O 
The|O absence|O of|O del|O (|O 5q|O )|O ,|O trisomy|O 8|O and|O 21|O ,|O as|O well|O as|O the|O rarity|O of|O monosomy|O 7|O ,|O contrasts|O with|O pooled|O published|O data|O and|O may|O reflect|O our|O exclusion|O of|O closely|O related|O disorders|O ,|O in|O particular|O MDS|O with|O fibrosis|O .|O 
Chromosomal|O aberrations|O increased|O to|O approximately|O 90|O %|O (|O 8|O /|O 9|O )|O in|O patients|O analysed|O during|O acute|O transformation|O .|O 
Mutational|O activation|O of|O codons|O 12|O ,|O 13|O and|O 61|O of|O N|gene-rna -|gene-rna ,|O Ha|gene-rna -|gene-rna and|O Ki|gene-rna -|gene-rna ras|gene-rna genes|O were|O assessed|O by|O polymerase|O chain|O reaction|O and|O hybridization|O with|O synthetic|O non|O -|O radioactive|O digoxigenin|O -|O labelled|O probes|O .|O 
Three|O mutations|O were|O detected|O in|O samples|O of|O peripheral|O blood|O DNA|O taken|O from|O 50|O patients|O during|O the|O chronic|O phase|O of|O their|O disease|O :|O one|O N|gene-rna 12|O Asp|O (|O GGT|O -->|O GAT|O )|O and|O two|O N|gene-rna 12|O Ser|O (|O GGT|O -->|O AGT|O )|O mutations|O .|O 
The|O results|O from|O this|O study|O indicate|O that|O karyotypic|O abnormalities|O are|O present|O in|O at|O least|O 29|O %|O of|O cases|O at|O diagnosis|O and|O that|O del|O (|O 13q|O )|O ,|O del|O (|O 20q|O )|O and|O partial|O trisomy|O 1q|O are|O the|O most|O frequent|O findings|O .|O 
Ras|gene-rna mutations|O were|O relatively|O infrequent|O (|O 6|O %|O )|O and|O appeared|O restricted|O to|O the|O N-ras|gene-rna gene|O .|O 
High|O incidence|O of|O conservative|O RAS|gene-rna mutations|O in|O acute|O myeloid|O leukemia|O .|O 
RAS|gene-rna mutations|O are|O found|O in|O about|O 25|O %|O of|O acute|O myeloid|O leukemia|O (|O AML|O )|O cases|O .|O 
The|O importance|O of|O these|O changes|O is|O unknown|O .|O 
If|O RAS|gene-rna mutations|O confer|O growth|O advantage|O to|O leukemia|O subclones|O in|O which|O they|O emerge|O ,|O substantially|O more|O nonconservative|O than|O conservative|O mutations|O should|O be|O found|O .|O 
The|O incidence|O of|O conservative|O mutations|O was|O not|O reported|O previously|O .|O 
We|O sequenced|O N-RAS|gene-rna and|O K-RAS|gene-rna codons|O 12|O and|O 13|O and|O N-RAS|gene-rna codon|O 61|O in|O 20|O subjects|O with|O newly|O diagnosed|O AML|O .|O 
Four|O nonconservative|O N-RAS|gene-rna mutations|O and|O 4|O conservative|O K-RAS|gene-rna mutations|O were|O found|O .|O 
There|O were|O no|O differences|O between|O subjects|O with|O AML|O and|O nonconservative|O RAS|gene-rna mutations|O and|O those|O with|O conservative|O or|O without|O RAS|gene-rna mutations|O .|O 
Additional|O studies|O are|O needed|O to|O examine|O the|O incidence|O of|O conservative|O RAS|gene-rna mutations|O in|O subjects|O with|O AML|O .|O 
RAS|gene-rna and|O FMS|gene-rna mutations|O following|O cytotoxic|O therapy|O for|O childhood|O acute|O lymphoblastic|O leukaemia|O .|O 
Patients|O who|O have|O received|O cytotoxic|O therapy|O for|O primary|O neoplastic|O disease|O are|O at|O an|O increased|O risk|O of|O developing|O secondary|O (|O therapy|O -|O related|O )|O acute|O myeloid|O leukaemia|O (|O AML|O )|O or|O myelodysplasia|O (|O MDS|O )|O .|O 
RAS|gene-rna and|O FMS|gene-rna mutations|O have|O been|O observed|O in|O patients|O with|O AML|O and|O MDS|O .|O 
It|O has|O been|O suggested|O that|O the|O mutational|O status|O within|O these|gene-rna genes|gene-rna may|O be|O predictive|O of|O early|O secondary|O leukaemic|O disease|O .|O 
In|O this|O study|O we|O have|O screened|O 50|O haematologically|O normal|O patients|O in|O complete|O remission|O from|O childhood|O acute|O lymphoblastic|O leukaemia|O (|O ALL|O )|O for|O activating|O point|O mutations|O in|O the|O RAS|gene-rna and|O FMS|gene-rna proto|O -|O oncogenes|O .|O 
Such|O patients|O may|O be|O considered|O at|O risk|O of|O therapy|O -|O related|O disease|O .|O 
Codons|O 12|O ,|O 13|O and|O 61|O were|O screened|O in|O RAS|gene-rna and|O codon|O 969|O in|O FMS|gene-rna using|O the|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O followed|O by|O oligonucleotide|O hybridization|O (|O ONH|O )|O .|O 
Three|O of|O the|O 50|O patients|O (|O 6|O %|O )|O were|O found|O to|O harbour|O N12|O RAS|gene-rna mutations|O .|O 
One|O of|O these|O three|O patients|O (|O 2|O %|O )|O had|O both|O a|O N12|O RAS|gene-rna and|O FMS|gene-rna 969|O mutation|O .|O 
Upon|O sequencing|O the|O RAS|gene-rna mutations|O ,|O substitutions|O of|O serine|O ,|O cysteine|O and|O aspartic|O acid|O for|O glycine|O were|O identified|O .|O 
The|O FMS|gene-rna 969|O mutation|O was|O also|O confirmed|O ,|O by|O sequencing|O ,|O as|O a|O histidine|O substitution|O .|O 
RAS|gene-rna mutations|O were|O not|O detected|O in|O presentation|O samples|O indicating|O that|O these|O lesions|O have|O been|O somatically|O acquired|O presumably|O subsequent|O to|O cytotoxic|O therapy|O for|O the|O primary|O disease|O .|O 
Continued|O follow-up|O of|O these|O patients|O may|O indicate|O a|O role|O for|O these|O mutations|O in|O the|O development|O of|O secondary|O malignancies|O .|O 
Detection|O of|O high|O incidence|O of|O H-RAS|gene-rna oncogene|O point|O mutations|O in|O acute|O myelogenous|O leukemia|O .|O 
We|O have|O been|O analyzing|O RAS|gene-protein p21|gene-protein proteins|O and|O the|O DNA|O sequence|O of|O leukemic|O cells|O .|O 
We|O report|O here|O that|O these|O cells|O have|O high|O expression|O of|O H-RAS|gene-protein p21|gene-protein ,|O which|O originates|O from|O point|O mutations|O of|O RAS|gene-rna oncogenes|O .|O 
The|O leukemic|O cells|O from|O six|O patients|O with|O acute|O myelogenous|O leukemia|O were|O separated|O from|O heparinized|O whole|O blood|O and|O bone|O marrow|O by|O a|O density|O gradient|O technique|O .|O 
The|O expression|O of|O RAS|gene-rna oncogenes|O was|O analyzed|O by|O a|O fluorescence|O -|O activated|O cell|O sorting|O with|O a|O panel|O of|O monoclonal|gene-protein antibodies|gene-protein .|O 
The|O high|O expression|O of|O DWP|gene-protein ,|O which|O was|O reported|O to|O recognized|O activated|O RAS|gene-rna oncogene|O ,|O was|O found|O in|O two|O patients|O and|O was|O associated|O with|O high|O levels|O of|O H-RAS|gene-protein expression|O .|O 
These|O facts|O prompted|O us|O to|O analyze|O the|O DNA|O sequence|O of|O RAS|gene-rna genes|O with|O an|O automated|O DNA|O sequencer|O .|O 
Unexpectedly|O ,|O various|O kinds|O of|O H-RAS|gene-rna point|O mutations|O were|O found|O in|O all|O six|O cases|O ,|O including|O two|O cases|O of|O hot|O -|O spot|O point|O mutation|O at|O codon|O 12|O ,|O whereas|O K-RAS|gene-rna point|O mutation|O (|O no|O hot|O -|O spot|O point|O mutations|O )|O was|O found|O in|O six|O cases|O .|O 
The|O same|O H-RAS|gene-rna point|O mutations|O ,|O at|O codons|O 10|O ,|O 11|O ,|O and|O 15|O ,|O were|O found|O in|O all|O six|O cases|O .|O 
To|O our|O knowledge|O ,|O there|O is|O no|O report|O on|O H-RAS|gene-rna point|O mutation|O in|O human|O leukemias|O .|O 
Minute|O alterations|O of|O the|O p53|gene-rna tumor|gene-rna suppressor|gene-rna gene|O and|O N-ras|gene-rna oncogene|O were|O investigated|O in|O 106|O samples|O for|O the|O p53|gene-rna gene|O and|O 23|O samples|O for|O the|O N-ras|gene-rna gene|O obtained|O from|O patients|O with|O various|O types|O of|O hematologic|O malignancies|O using|O polymerase|O chain|O reaction|O -|O single|O strand|O conformation|O polymorphism|O (|O PCR-SSCP|O )|O and|O direct|O nucleotide|O sequencing|O .|O 
Mobility|O shifts|O suggesting|O sequence|O alteration|O were|O observed|O in|O 9|O cases|O (|O 8.5|O %|O )|O in|O exons|O 5|O through|O 8|O containing|O evolutionarily|O highly|O conserved|O regions|O of|O the|O p53|gene-rna gene|O by|O PCR-SSCP|O ;|O missense|O point|O mutations|O in|O 3|O cases|O (|O 1|O acute|O myelogenous|O leukemia|O (|O AML|O )|O ,|O 1|O chronic|O myelogenous|O leukemia|O (|O CML|O )|O in|O the|O accelerated|O phase|O ,|O and|O 1|O CML|O in|O the|O blast|O crisis|O )|O ,|O silent|O point|O mutation|O in|O 1|O case|O (|O malignant|O lymphoma|O )|O ,|O and|O frame|O shift|O mutations|O due|O to|O insertions|O and|O deletions|O causing|O stop|O codons|O in|O 3|O cases|O (|O 1|O AML|O ,|O 1|O CML|O in|O the|O chronic|O phase|O and|O 1|O acute|O lymphoblastic|O leukemia|O (|O ALL|O )|O )|O .|O 
p53|gene-rna gene|O alterations|O did|O not|O always|O cluster|O within|O evolutionarily|O highly|O conserved|O regions|O ,|O and|O there|O were|O various|O base|O change|O forms|O in|O cases|O with|O p53|gene-rna point|O mutations|O .|O 
p53|gene-rna mutations|O were|O detected|O in|O 2|O cases|O out|O of|O 4|O cases|O with|O 17|O monosomy|O .|O 
There|O was|O no|O case|O with|O p53|gene-rna gene|O alteration|O in|O myelodysplastic|O syndrome|O (|O MDS|O )|O cases|O .|O 
Mobility|O shifts|O suggesting|O sequence|O alteration|O were|O observed|O in|O 5|O cases|O (|O 22|O %|O )|O in|O exon|O 1|O and|O 2|O of|O the|O N-ras|gene-rna gene|O by|O PCR-SSCP|O .|O 
3|O cases|O (|O 1|O MDS|O ,|O 1|O MDS|O overt|O AML|O and|O 1|O ALL|O )|O were|O detected|O to|O contain|O missense|O point|O mutations|O .|O 
However|O ,|O simultaneous|O mutations|O in|O both|gene-rna the|gene-rna genes|gene-rna were|O detected|O in|O only|O 2|O cases|O out|O of|O 23|O ,|O thereby|O indicating|O infrequent|O occurrence|O of|O concomitant|O mutation|O of|O both|gene-rna the|gene-rna genes|gene-rna in|O hematologic|O malignancies|O .|O 
Analysis|O of|O multiple|O molecular|O changes|O in|O human|O endocrine|O tumours|O .|O 
To|O define|O the|O molecular|O changes|O occurring|O in|O endocrine|O tumours|O ,|O we|O have|O analysed|O three|O human|O endocrine|O tumours|O established|O in|O our|O laboratory|O :|O BON|O ,|O a|O functioning|O carcinoid|O tumour|O from|O the|O pancreas|O ;|O SIM|O ,|O a|O nonfunctioning|O carcinoid|O of|O the|O ileum|O ;|O and|O STAN|O ,|O a|O pheochromocytoma|O .|O 
A|O homozygous|O point|O mutation|O of|O the|O N-ras|gene-rna gene|O was|O identified|O at|O codon|O 61|O in|O BON|O cells|O in|O conjunction|O with|O overexpression|O of|O N-ras|gene-rna mRNA|O and|O protein|gene-protein .|O 
BON|O cells|O also|O exhibited|O increased|O expression|O of|O c-myc|gene-rna and|O cdc2|gene-rna kinase|gene-rna mRNA|O and|O protein|gene-protein ;|O TGF-beta|gene-rna 1|gene-rna ,|O p53|gene-rna and|O retinoblastoma|gene-rna (|O RB|gene-rna )|O mRNA|O and|O protein|gene-protein levels|O were|O decreased|O .|O 
In|O addition|O ,|O increased|O expression|O of|O the|O mdm2|gene-rna oncogene|O and|O both|O the|O truncated|O and|O the|O wild-type|O RB|gene-protein protein|O were|O noted|O in|O BON|O .|O 
SIM|O cells|O exhibited|O moderately|O increased|O N-ras|gene-rna and|O c-myc|gene-rna mRNA|O levels|O along|O with|O decreased|O levels|O of|O RB|gene-rna mRNA|O and|O protein|gene-protein .|O 
Similar|O to|O BON|O and|O SIM|O ,|O analysis|O of|O STAN|O showed|O increased|O N-ras|gene-generic and|O c-myc|gene-generic levels|O .|O 
Our|O data|O show|O multiple|O molecular|O changes|O in|O the|O three|O human|O endocrine|O tumours|O with|O the|O BON|O cell|O line|O exhibiting|O the|O most|O dramatic|O changes|O .|O 
Furthermore|O ,|O our|O data|O suggest|O the|O existence|O of|O different|O molecular|O pathways|O in|O the|O pathogenesis|O of|O endocrine|O tumours|O .|O 
These|O cell|O lines|O will|O provide|O unique|O in|O vitro|O models|O to|O further|O analyse|O the|O significance|O of|O these|O molecular|O alterations|O .|O 
N-RAS|gene-rna mutations|O and|O susceptibility|O to|O lymphokine|O -|O activated|O killer|O (|O LAK|O )|O cells|O in|O human|O melanoma|O .|O 
RAS|gene-rna oncogene|O expression|O has|O been|O reported|O to|O affect|O several|O biological|O features|O of|O rodent|O tumours|O cells|O ,|O including|O lysability|O by|O activated|O natural|O killer|O cells|O .|O 
In|O order|O to|O examine|O whether|O expression|O of|O mutated|O RAS|gene-rna genes|O in|O human|O melanoma|O cells|O alters|O their|O susceptibility|O to|O lysis|O by|O LAK|O cells|O ,|O seven|O melanoma|O lines|O were|O assessed|O for|O the|O presence|O of|O Ki|gene-rna -|gene-rna and|O N|gene-rna -|gene-rna RAS|gene-rna genes|O bearing|O all|O possible|O mutations|O at|O codons|O 12|O ,|O 13|O and|O 61|O .|O 
A|O panel|O of|O 21|O clones|O deriving|O from|O the|O metastatic|O lesion|O Me665|O /|O 2|O ,|O which|O had|O a|O Gln|O -->|O Arg|O substitution|O at|O codon|O 61|O of|O N-RAS|gene-rna (|O N-RAS|gene-rna /|O 61|O +|O )|O ,|O were|O also|O examined|O .|O 
Melanoma|O cells|O and|O clones|O were|O used|O as|O targets|O of|O allogeneic|O LAK|O in|O a|O 4|O -|O h|O 51Cr|O -|O release|O assay|O .|O 
LAK|O showed|O a|O higher|O lysis|O on|O melanoma|O lines|O and|O clones|O harbouring|O a|O mutated|O RAS|gene-rna compared|O with|O counterparts|O bearing|O no|O RAS|gene-rna mutations|O .|O 
In|O addition|O ,|O LAK|O -|O mediated|O lysis|O drastically|O decreased|O on|O Me665|O /|O 2|O sublines|O progressively|O selected|O by|O exposure|O to|O LAK|O .|O 
This|O loss|O was|O paralleled|O by|O a|O reduction|O or|O even|O disappearance|O of|O N-RAS|gene-rna /|O 61|O +|O mRNA|O signal|O in|O Me665|O /|O 2|O sublines|O .|O 
To|O evaluate|O whether|O N-RAS|gene-rna could|O directly|O modulate|O LAK|O susceptibility|O to|O lysis|O ,|O N-RAS|gene-rna /|O 61|O +|O gene|O was|O transfected|O in|O two|O N-RAS|gene-rna wild|O type|O (|O N-RAS|gene-rna /|O 61|O -|O )|O 665|O /|O 2|O melanoma|O clones|O by|O a|O cosmid|O vector|O .|O 
In|O contrast|O to|O the|O high|O lysability|O of|O melanoma|O cells|O constitutively|O expressing|O the|O mutationally|O active|O N-RAS|gene-rna oncogene|O ,|O N-RAS|gene-rna /|O 61|O +|O transfectants|O did|O not|O show|O a|O consistent|O high|O lysability|O by|O LAK|O ,|O compared|O with|O some|O control|O pSV2neo|O transfectants|O .|O 
(|O ABSTRACT|O TRUNCATED|O AT|O 250|O WORDS|O )|O 
A|O series|O of|O 152|O human|O bladder|O tumors|O ,|O 14|O bladder|O tumor|O cell|O lines|O ,|O and|O 1|O immortal|O urothelial|O cell|O line|O were|O examined|O by|O single|O -|O strand|O conformation|O polymorphism|O (|O SSCP|O )|O and|O designed|O restriction|O fragment|O .|O length|O polymorphism|O analyses|O for|O mutations|O in|O exons|O 1|O and|O 2|O of|O the|O H-ras|gene-rna gene|O .|O 
Nine|O tumors|O (|O 6|O %|O )|O contained|O mutations|O .|O 
There|O was|O complete|O concordance|O between|O SSCP|O and|O restriction|O fragment|O length|O polymorphism|O analyses|O .|O 
Six|O mutations|O in|O exon|O 1|O and|O three|O in|O exon|O 2|O were|O identified|O by|O SSCP|O analysis|O .|O 
Subsequent|O restriction|O fragment|O length|O polymorphism|O analysis|O showed|O that|O of|O the|O exon|O 1|O mutations|O ,|O four|O were|O in|O codon|O 12|O and|O two|O in|O codon|O 13|O ,|O and|O all|O three|O exon|O 2|O mutations|O were|O in|O codon|O 61|O .|O 
Eight|O mutations|O were|O confirmed|O by|O direct|O sequencing|O .|O 
One|O codon|O 13|O mutation|O could|O not|O be|O identified|O by|O direct|O sequencing|O .|O 
Distinct|O strand|O mobility|O shifts|O detected|O by|O SSCP|O analysis|O identified|O specific|O point|O mutations|O ,|O and|O in|O all|O cases|O ,|O strands|O containing|O different|O mutations|O migrated|O differently|O .|O 
The|O base|O substitutions|O identified|O in|O these|O bladder|O tumors|O were|O diverse|O and|O included|O four|O transversions|O (|O three|O G|O -->|O T|O and|O one|O A|O -->|O T|O )|O and|O four|O transitions|O (|O two|O G|O -->|O A|O and|O two|O A|O -->|O G|O )|O .|O 
This|O pattern|O of|O base|O substitutions|O is|O compatible|O with|O interactions|O of|O the|O urothelium|O with|O more|O than|O one|O class|O of|O environmental|O agent|O during|O bladder|O tumor|O development|O .|O 
No|O correlation|O was|O found|O between|O tumor|O grade|O and/or|O stage|O and|O the|O presence|O of|O H-ras|gene-rna mutation|O .|O 
We|O conclude|O that|O H-ras|gene-rna mutation|O does|O not|O play|O a|O role|O in|O the|O development|O of|O the|O majority|O of|O transitional|O cell|O tumors|O of|O the|O bladder|O .|O 
Frequency|O of|O RAS|gene-rna and|O p53|gene-rna mutations|O in|O acute|O promyelocytic|O leukemias|O .|O 
The|O frequency|O of|O RAS|gene-rna and|O p53|gene-rna mutations|O was|O investigated|O in|O 30|O acute|O promyelocytic|O leukemias|O by|O single|O strand|O conformation|O polymorphism|O analysis|O and|O direct|O sequencing|O of|O genomic|O DNA|O .|O 
Only|O two|O cases|O bore|O N-RAS|gene-rna codon|O 12|O mutations|O and|O none|O had|O p53|gene-rna mutations|O responsible|O for|O aminoacid|O substitutions|O .|O 
It|O would|O ,|O therefore|O ,|O seem|O that|O neither|O RAS|gene-rna nor|O p53|gene-rna are|O involved|O in|O acute|O promyelocytic|O leukemogenesis|O .|O 
Ras|gene-rna gene|O point|O mutation|O is|O a|O rare|O event|O in|O premalignant|O tissues|O and|O malignant|O cells|O and|O tissues|O from|O oral|O mucosal|O lesions|O .|O 
Three|O series|O of|O biopsy|O specimens|O of|O premalignant|O and|O malignant|O oral|O lesions|O ,|O together|O with|O seven|O human|O keratinocyte|O cultures|O ,|O previously|O established|O from|O oral|O squamous|O cell|O carcinomas|O ,|O were|O analysed|O for|O point|O mutation|O in|O exons|O 1|O and|O 2|O of|O the|O c-Ha-ras|gene-rna ,|O c-Ki-ras|gene-rna and|O N-ras|gene-rna genes|O by|O direct|O nucleotide|O sequencing|O of|O DNAs|O amplified|O in|O the|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O .|O 
Only|O one|O out|O of|O 12|O biopsy|O samples|O (|O 8.3|O %|O )|O ,|O a|O well|O -|O differentiated|O carcinoma|O which|O was|O the|O latest|O in|O a|O series|O of|O floor|O of|O mouth|O lesions|O from|O 1|O of|O the|O 3|O patients|O studied|O ,|O harboured|O a|O mutant|O c-Ha-ras|gene-rna gene|O ,|O being|O heterozygous|O at|O codon|O 12|O for|O a|O GGA|O -|O GTA|O change|O .|O 
One|O cell|O line|O (|O H357|O )|O showed|O heterozygosity|O in|O both|O exons|O 1|O and|O 2|O of|O c-Ha-ras|gene-rna ,|O harbouring|O a|O GGT|O to|O AGT|O mutation|O over|O codon|O 13|O and|O a|O CAG|O to|O CAA|O mutation|O over|O codon|O 61|O .|O 
The|O remaining|O six|O oral|O carcinoma|O cell|O lines|O (|O 85.7|O %|O )|O were|O homozygous|O normal|O at|O both|O exons|O 1|O and|O 2|O of|O c-Ha-ras|gene-rna .|O 
All|O cell|O lines|O showed|O normal|O c-Ki-ras|gene-rna and|O N-ras|gene-rna loci|O .|O 
We|O conclude|O that|O ras|gene-rna gene|O mutation|O is|O an|O infrequent|O occurrence|O in|O the|O malignant|O progression|O of|O oral|O epithelial|O cells|O ,|O despite|O the|O probable|O importance|O of|O chemical|O carcinogens|O in|O the|O aetiology|O of|O the|O disease|O .|O 
We|O emphasise|O the|O need|O to|O search|O for|O other|O cellular|O sequences|O which|O may|O be|O targets|O for|O chemical|O or|O viral|O carcinogens|O .|O 
Persistence|O of|O an|O activating|O N-RAS|gene-rna oncogene|O mutation|O in|O clonogenic|O progenitor|O cells|O from|O an|O acute|O myeloid|O leukaemia|O patient|O in|O remission|O .|O 
A|O patient|O with|O acute|O myeloid|O leukaemia|O (|O AML|O )|O with|O an|O activating|O N-RAS|gene-rna oncogene|O mutation|O was|O studied|O in|O a|O haemopoietic|O clonogenic|O progenitor|O cell|O assay|O .|O 
Individual|O colonies|O and|O clusters|O were|O analysed|O by|O polymerase|gene-protein chain|O reaction|O and|O oligonucleotide|O hybridization|O for|O the|O original|O mutation|O .|O 
The|O mutation|O was|O detected|O in|O a|O majority|O of|O leukaemic|O clusters|O ,|O but|O also|O in|O almost|O half|O of|O the|O differentiated|O colonies|O .|O 
However|O ,|O the|O mutation|O could|O still|O be|O detected|O in|O the|O bone|O marrow|O .|O 
Only|O differentiated|O colonies|O and|O no|O leukaemic|O clusters|O were|O grown|O from|O the|O remission|O bone|O marrow|O ,|O but|O the|O original|O mutation|O was|O still|O detectable|O in|O almost|O half|O of|O the|O colonies|O .|O 
Low|O incidence|O of|O c-Ha-ras|gene-rna gene|O mutations|O in|O benign|O and|O malignant|O cutaneous|O lesions|O from|O transplant|O recipients|O .|O 
Transplant|O recipients|O successively|O develop|O benign|O ,|O premalignant|O and|O malignant|O skin|O lesions|O on|O sun|O -|O exposed|O areas|O .|O 
It|O has|O been|O suggested|O that|O UV|O radiations|O might|O induce|O mutations|O in|O ras|gene-rna oncogenes|O and|O p53|gene-rna tumour|O -|O suppressor|O gene|O ,|O responsible|O for|O skin|O cancers|O .|O 
With|O PCR|O and|O oligoprobe|O hybridization|O ,|O we|O investigated|O c-Ha-ras|gene-rna gene|O mutations|O at|O codons|O 12|O and|O 61|O in|O 120|O cutaneous|O lesions|O from|O grafted|O patients|O ,|O since|O they|O could|O represent|O a|O marker|O of|O the|O evolution|O of|O benign|O skin|O lesions|O towards|O malignancy|O in|O this|O population|O ;|O 29|O similar|O skin|O biopsies|O from|O non|O -|O immunosuppressed|O patients|O were|O also|O analyzed|O .|O 
In|O transplant|O recipients|O ,|O we|O detected|O mutations|O at|O codon|O 12|O only|O in|O 1|O /|O 42|O non|O -|O melanoma|O skin|O cancers|O and|O 2|O /|O 29|O pre|O -|O cancerous|O keratoses|O .|O 
No|O mutation|O was|O detected|O in|O 11|O cases|O of|O cutaneous|O Bowen|O 's|O disease|O from|O grafted|O patients|O and|O in|O pre|O -|O malignant|O and|O malignant|O skin|O samples|O from|O control|O patients|O .|O 
Benign|O warts|O exhibited|O an|O overall|O incidence|O of|O 18|O %|O and|O 15|O %|O of|O mutations|O at|O codon|O 12|O of|O c-Ha-ras|gene-rna gene|O in|O grafted|O and|O control|O patients|O respectively|O .|O 
We|O detected|O only|O one|O mutation|O at|O codon|O 61|O in|O a|O plantar|O wart|O .|O 
Human|O papillomaviruses|O (|O HPV|O )|O are|O thought|O to|O be|O involved|O in|O the|O malignant|O evolution|O of|O cutaneous|O disorders|O in|O transplant|O recipients|O and|O cooperate|O with|O a|O ras|gene-rna oncogene|O to|O induce|O malignancy|O in|O vitro|O .|O 
The|O presence|O of|O HPV|O DNA|O in|O our|O series|O of|O skin|O samples|O from|O grafted|O patients|O showed|O no|O correlation|O with|O the|O occurrence|O of|O c-Ha-ras|gene-rna mutations|O .|O 
Our|O findings|O indicate|O that|O c-Ha-ras|gene-rna -|O gene|O activation|O by|O mutations|O is|O rare|O in|O cutaneous|O lesions|O from|O transplant|O recipients|O ,|O and|O is|O unlikely|O to|O play|O a|O crucial|O role|O in|O transformation|O towards|O malignancy|O in|O skin|O carcinogenesis|O among|O grafted|O patients|O .|O 
Gene|O analysis|O of|O K|gene-rna -|gene-rna ,|O H|gene-rna -|gene-rna ras|gene-rna ,|O p53|gene-rna ,|O and|O retinoblastoma|gene-rna susceptibility|O genes|O in|O human|O lung|O cancer|O cell|O lines|O by|O the|O polymerase|gene-protein chain|O reaction|O /|O single|O -|O strand|O conformation|O polymorphism|O method|O .|O 
In|O order|O to|O know|O the|O involvement|O of|O multiple|O gene|O alterations|O in|O the|O pathogenesis|O of|O human|O lung|O cancer|O ,|O we|O examined|O the|O genes|O of|O K|gene-rna -|gene-rna ,|O H|gene-rna -|gene-rna ras|gene-rna (|O codons|O 12|O ,|O 13|O ,|O 61|O )|O ,|O p53|gene-rna (|O exons|O 5|O -|O 9|O )|O and|O the|O retinoblastoma|gene-rna susceptibility|O gene|O (|O RB|gene-rna )|O (|O exons|O 20|O -|O 22|O )|O using|O the|O polymerase|gene-protein chain|O reaction|O /|O single|O -|O strand|O conformation|O polymorphism|O method|O in|O 32|O human|O lung|O cancer|O cell|O lines|O (|O 5|O squamous|O -|O cell|O carcinomas|O ,|O 10|O adenocarcinomas|O ,|O 3|O large|O -|O cell|O carcinomas|O ,|O 14|O small|O -|O cell|O carcinomas|O )|O .|O 
In|O 18|O non|O -|O small|O -|O cell|O lung|O cancer|O lines|O ,|O gene|O alterations|O were|O found|O in|O 4|O for|O K-ras|gene-rna (|O 22|O %|O )|O ,|O none|O for|O H-ras|gene-rna (|O 0|O %|O )|O ,|O 4|O for|O p53|gene-rna (|O 22|O %|O )|O and|O none|O for|O the|O RB|gene-rna (|O 0|O %|O )|O gene|O .|O 
In|O 14|O small|O -|O cell|O lung|O cancer|O (|O SCLC|O )|O lines|O ,|O no|O gene|O alterations|O were|O found|O in|O K-ras|gene-rna (|O 0|O %|O )|O ,|O or|O H-ras|gene-rna (|O 0|O %|O )|O ,|O but|O 6|O were|O found|O for|O p53|gene-rna (|O 43|O %|O )|O and|O 3|O for|O the|O RB|gene-rna (|O 21|O %|O )|O gene|O .|O 
Coincident|O abnormalities|O of|O K-ras|gene-rna and|O p53|gene-rna ,|O or|O K-ras|gene-rna and|O RB|gene-rna genes|O were|O not|O found|O in|O any|O cell|O lines|O ,|O and|O those|O of|O the|O p53|gene-rna and|O RB|gene-rna genes|O were|O found|O in|O only|O 2|O SCLC|O lines|O .|O No|O association|O was|O observed|O between|O these|O three|O gene|O alterations|O and|O N-myc|gene-rna amplification|O .|O 
Although|O the|O above|O three|O genes|gene-rna may|O be|O involved|O to|O some|O extent|O in|O the|O pathogenesis|O of|O lung|O cancer|O ,|O more|O factors|O are|O required|O for|O its|O development|O .|O 
Mutations|O of|O the|O p53|gene-rna tumor|O suppressor|O gene|O and|O the|O ras|gene-rna gene|O family|O in|O intrahepatic|O cholangiocellular|O carcinomas|O in|O Japan|O and|O Thailand|O .|O 
The|O incidence|O and|O pattern|O of|O mutations|O of|O the|O ras|gene-rna oncogenes|O and|O the|O p53|gene-rna tumor|O suppressor|O gene|O have|O been|O shown|O to|O differ|O among|O different|O cancer|O types|O and|O even|O among|O the|O same|O cancer|O types|O with|O different|O etiological|O backgrounds|O .|O 
For|O example|O ,|O in|O a|O previous|O study|O we|O showed|O that|O not|O only|O the|O etiology|O but|O also|O the|O incidence|O of|O point|O mutation|O of|O the|O c-Ki-ras|gene-rna oncogene|O in|O cholangiocellular|O carcinomas|O (|O CCCs|O )|O differ|O between|O Japanese|O and|O Thai|O patients|O .|O 
In|O the|O study|O presented|O here|O ,|O we|O examined|O the|O incidence|O of|O mutations|O in|O the|O ras|gene-rna gene|O family|O and|O the|O p53|gene-rna gene|O in|O CCCs|O of|O both|O Japanese|O and|O Thai|O patients|O by|O single|O -|O strand|O conformation|O polymorphism|O and|O direct|O sequencing|O analyses|O and|O compared|O the|O pattern|O of|O p53|gene-rna mutation|O between|O these|O two|O CCC|O groups|O .|O 
Although|O the|O incidence|O of|O ras|gene-rna mutation|O differed|O markedly|O between|O Japanese|O (|O seven|O of|O 12|O ,|O 58|O %|O )|O and|O Thai|O (|O two|O of|O 26|O ,|O 8|O %|O )|O cases|O ,|O the|O incidence|O of|O p53|gene-rna mutation|O was|O similar|O :|O four|O of|O 12|O (|O 33|O %|O )|O and|O nine|O of|O 26|O (|O 35|O %|O )|O ,|O respectively|O .|O 
Except|O for|O one|O case|O in|O which|O deletion|O -|O insertion|O was|O detected|O in|O the|O second|O exon|O of|O the|O N-ras|gene-rna gene|O ,|O all|O ras|gene-rna mutations|O occurred|O at|O codon|O 12|O or|O 13|O of|O the|O c-Ki-ras|gene-rna gene|O .|O 
All|O p53|gene-rna mutations|O but|O one|O were|O detected|O in|O a|O highly|O conserved|O region|O ,|O and|O the|O predominant|O form|O of|O the|O mutations|O was|O G|O :|O C|O -->|O A|O :|O T|O transition|O at|O CpG|O sites|O in|O both|O Japanese|O and|O Thai|O cases|O ,|O similar|O to|O that|O reported|O for|O colorectal|O cancers|O .|O 
Therefore|O ,|O in|O contrast|O to|O the|O ras|gene-rna oncogenes|O ,|O mutation|O of|O the|O p53|gene-rna gene|O was|O frequently|O involved|O in|O the|O development|O of|O CCCs|O in|O both|O Japanese|O and|O Thai|O patients|O ,|O irrespective|O of|O any|O difference|O in|O etiology|O .|O 
Mutations|O in|O the|O P53|gene-rna and|O RAS|gene-rna family|O genes|O are|O associated|O with|O tumor|O progression|O of|O BCR|gene-rna /|O ABL|gene-rna negative|O chronic|O myeloproliferative|O disorders|O .|O 
We|O have|O investigated|O the|O involvement|O of|O the|O p53|gene-rna tumor|O suppressor|O gene|O and|O RAS|gene-rna family|O proto|O -|O oncogenes|O in|O BCR|gene-rna /|O ABL|gene-rna -|O negative|O chronic|O myeloproliferative|O disorders|O (|O CMPD|O )|O ,|O including|O nine|O cases|O of|O myelosclerosis|O with|O myeloid|O metaplasia|O ,|O four|O polycythemia|O vera|O ,|O 10|O essential|O thrombocythemia|O ,|O one|O juvenile|O chronic|O myeloid|O leukemia|O ,|O and|O eight|O BCR|gene-rna /|O ABL|gene-rna -|O negative|O chronic|O myeloid|O leukemia|O .|O 
Twenty-five|O samples|O were|O studied|O in|O the|O chronic|O phase|O ,|O while|O seven|O samples|O were|O analyzed|O in|O the|O acute|O accelerated|O or|O blastic|O phase|O .|O 
The|O presence|O of|O mutations|O in|O p53|gene-rna exons|O 5|O -|O 9|O ,|O as|O well|O as|O in|O N|gene-rna -|gene-rna ,|O K|gene-rna -|gene-rna ,|O H|gene-rna -|gene-rna Ras|gene-rna exons|O 1|O and|O 2|O (|O containing|O codons|O 12|O ,|O 13|O ,|O and|O 61|O )|O was|O tested|O by|O the|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O single|O strand|O conformation|O polymorphism|O technique|O and|O by|O PCR|O direct|O sequencing|O .|O 
In|O addition|O ,|O restriction|O analysis|O was|O performed|O to|O screen|O for|O gross|O rearrangements|O within|O the|O p53|gene-rna locus|O .|O 
Alterations|O of|O the|O p53|gene-rna tumor|O suppressor|O gene|O and|O Ras|gene-rna family|O proto|O -|O oncogenes|O were|O detected|O in|O 2|O /|O 7|O and|O 3|O /|O 7|O cases|O of|O acute|O phase|O BCR|gene-rna /|O ABL|gene-rna -|O negative|O CMPD|O ,|O respectively|O ,|O while|O consistently|O negative|O in|O all|O the|O chronic|O phase|O samples|O analyzed|O .|O 
These|O results|O suggest|O that|O p53|gene-rna inactivation|O and/or|O Ras|gene-rna activation|O might|O play|O a|O role|O in|O acute|O transformation|O of|O BCR|gene-rna /|O ABL|gene-rna -|O negative|O CMPD|O .|O 
ras|gene-rna gene|O mutations|O and|O HPV|O infection|O are|O common|O in|O human|O laryngeal|O carcinoma|O .|O 
To|O evaluate|O the|O role|O of|O ras|gene-rna activation|O and|O human|O papillomavirus|O (|O HPV|O )|O infection|O in|O laryngeal|O carcinoma|O ,|O we|O analyzed|O tumor|O DNA|O from|O 43|O cases|O ,|O including|O 25|O primary|O laryngeal|O tumors|O ,|O 12|O lymph|O -|O node|O and|O one|O skin|O metastases|O ,|O and|O 5|O recurrent|O laryngeal|O carcinomas|O .|O 
Thirteen|O normal|O laryngeal|O tissues|O and|O 7|O benign|O laryngeal|O nodule|O biopsy|O specimens|O along|O with|O normal|O tissue|O surrounding|O laryngeal|O carcinoma|O in|O 2|O cases|O were|O also|O included|O .|O 
The|O polymerase|gene-protein -|O chain|O -|O reaction|O technique|O was|O used|O to|O amplify|O DNA|O fragments|O containing|O codon|O 12|O and|O 61|O of|O H|gene-rna -|gene-rna ,|O K|gene-rna -|gene-rna and|O N|gene-rna -|gene-rna ras|gene-rna ,|O also|O HPV|O 16|O ,|O 18|O and|O 33|O DNA|O ,|O subsequently|O hybridized|O with|O sequence|O -|O specific|O oligonucleotides|O .|O 
DNA|O samples|O from|O 22|O patients|O with|O laryngeal|O carcinoma|O revealed|O ras|gene-rna mutations|O (|O 18|O in|O N-ras|gene-rna codon|O 12|O ,|O 6|O in|O H-ras|gene-rna codon|O 61|O ,|O and|O 3|O in|O K-ras|gene-rna codon|O 61|O )|O .|O 
Likewise|O ,|O HPV|O DNA|O was|O found|O in|O 16|O cases|O (|O HPV|O 16|O ,|O 18|O and|O 33|O in|O 3|O cases|O ,|O 14|O cases|O and|O 1|O case|O respectively|O )|O .|O 
ras|gene-rna mutations|O were|O significantly|O higher|O in|O metastatic|O tumors|O (|O 10|O of|O 13|O cases|O )|O than|O in|O primary|O (|O 11|O of|O 25|O cases|O )|O and|O recurrent|O laryngeal|O carcinomas|O (|O 1|O of|O 5|O cases|O )|O .|O 
HPV|O DNA|O was|O detected|O in|O 60|O %|O of|O recurrent|O ,|O 44|O %|O of|O primary|O and|O 15|O %|O of|O metastatic|O tumors|O .|O 
Only|O 2|O of|O the|O 13|O normal|O laryngeal|O tissues|O and|O 1|O out|O of|O 7|O laryngeal|O nodule|O specimens|O were|O found|O to|O contain|O HPV|O DNA|O .|O 
These|O results|O suggest|O that|O ras|gene-rna activation|O ,|O especially|O in|O N-ras|gene-rna codon|O 12.1|O (|O GGT|O -->|O AGT|O )|O and|O HPV|O infection|O are|O 2|O important|O factors|O in|O (|O multistage|O )|O laryngeal|O carcinogenesis|O .|O 
The|O ras|gene-rna mutation|O may|O be|O associated|O with|O metastatic|O ability|O of|O the|O tumor|O .|O 
Multiple|O genetic|O lesions|O in|O acquired|O immunodeficiency|O syndrome|O -|O related|O non|O -|O Hodgkin|O 's|O lymphoma|O .|O 
Non|O -|O Hodgkin|O 's|O lymphoma|O (|O NHL|O )|O develops|O in|O about|O 5|O %|O to|O 10|O %|O of|O acquired|O immunodeficiency|O syndrome|O (|O AIDS|O )|O patients|O .|O 
The|O vast|O majority|O of|O AIDS|O -|O NHL|O are|O clinically|O aggressive|O B-cell|O NHL|O that|O are|O histologically|O classified|O as|O small|O noncleaved|O cell|O lymphoma|O (|O SNCCL|O )|O ,|O large|O cell|O immunoblastic|O plasmacytoid|O lymphoma|O (|O LC-IBPL|O )|O ,|O and|O large|O noncleaved|O cell|O lymphoma|O (|O LNCCL|O )|O .|O 
In|O an|O attempt|O to|O understand|O the|O molecular|O pathogenesis|O of|O these|O tumors|O ,|O we|O have|O investigated|O the|O involvement|O of|O dominantly|O acting|O oncogenes|O (|O c-myc|gene-rna ,|O N|gene-rna -|gene-rna ,|O K|gene-rna -|gene-rna ,|O H|gene-rna -|gene-rna Ras|gene-rna )|O ,|O tumor|O suppressor|O genes|O (|O p53|gene-rna ,|O RB1|gene-rna )|O ,|O and|O Epstein|O -|O Barr|O virus|O (|O EBV|O )|O infection|O in|O 27|O AIDS|O -|O NHL|O samples|O (|O 16|O SNCCL|O ,|O 5|O LC-IBP|O ,|O and|O 6|O LNCCL|O )|O .|O 
The|O following|O lesions|O were|O detected|O in|O AIDS|O -|O NHL|O :|O EBV|O infection|O (|O 10|O /|O 24|O ;|O 41.6|O %|O )|O ,|O c-myc|gene-rna rearrangement|O (|O 19|O /|O 24|O ;|O 79.1|O %|O )|O ,|O Ras|gene-rna mutation|O (|O 4|O /|O 27|O ;|O 14.8|O %|O )|O ,|O and|O p53|O loss|O /|O mutation|O (|O 10|O /|O 27|O ;|O 37.0|O %|O )|O .|O 
These|O lesions|O are|O not|O uniformly|O distributed|O ,|O but|O ,|O rather|O ,|O cluster|O with|O specific|O types|O of|O AIDS|O -|O NHL|O :|O EBV|O infection|O is|O preferentially|O associated|O with|O LC-IBPL|O (|O 4|O /|O 4|O ;|O 100|O %|O )|O ,|O while|O it|O is|O present|O in|O only|O a|O fraction|O of|O SNCCL|O (|O 5|O /|O 16|O ;|O 31.2|O %|O )|O and|O LNCCL|O (|O 1|O /|O 4|O ;|O 25|O %|O )|O ;|O c-myc|gene-rna oncogene|O activation|O clusters|O with|O SNCCL|O (|O 16|O /|O 16|O ;|O 100|O %|O )|O ,|O whereas|O it|O is|O less|O frequent|O in|O LC-IBPL|O (|O 1|O /|O 4|O ;|O 25|O %|O )|O and|O LNCCL|O (|O 2|O /|O 4|O ;|O 50|O %|O )|O ;|O p53|gene-rna inactivation|O is|O restricted|O to|O SNCCL|O (|O 10|O /|O 16|O ;|O 62.5|O %|O )|O and|O consistently|O associated|O with|O c-myc|gene-rna activation|O .|O 
These|O data|O show|O that|O AIDS|O -|O NHL|O are|O associated|O with|O multiple|O genetic|O lesions|O that|O involve|O both|O proto|gene-rna -|gene-rna oncogenes|gene-rna and|O tumor|gene-rna suppressor|gene-rna genes|gene-rna and|O may|O accumulate|O in|O the|O relatively|O short|O period|O of|O time|O (|O 4|O to|O 6|O years|O )|O between|O human|O immunodeficiency|O virus|O infection|O and|O AIDS|O -|O NHL|O development|O .|O 
These|O genetic|O lesions|O differ|O in|O the|O various|O AIDS|O -|O NHL|O subtypes|O ,|O suggesting|O the|O involvement|O of|O distinct|O molecular|O pathway|O .|O 
Analysis|O of|O karyotype|O ,|O SCE|O ,|O and|O point|O mutation|O of|O RAS|gene-rna oncogene|O in|O Indian|O MDS|O patients|O .|O 
Thirty|O Indian|O patients|O diagnosed|O as|O having|O primary|O myelodysplastic|O syndrome|O as|O per|O the|O French|O -|O American|O -|O British|O classification|O were|O investigated|O ,|O on|O admission|O ,|O for|O the|O frequencies|O of|O nonrandom|O karyotype|O abnormalities|O ,|O sister|O chromatid|O exchange|O ,|O and|O point|O mutations|O of|O the|O RAS|gene-rna oncogene|O .|O 
Successful|O karyotype|O analysis|O was|O possible|O in|O 24|O patients|O ,|O of|O whom|O 9|O (|O 37.5|O %|O )|O showed|O nonrandom|O karyotypic|O changes|O .|O 
Anomalies|O of|O chromosomes|O 5|O ,|O 7|O ,|O and|O 8|O were|O detected|O in|O their|O bone|O marrow|O (|O BM|O )|O .|O 
In|O addition|O ,|O two|O new|O anomalies|O ,|O del|O (|O 8|O )|O (|O q22|O )|O and|O +|O 19|O ,|O were|O observed|O for|O the|O first|O time|O in|O our|O series|O .|O 
Six|O MDS|O patients|O were|O studied|O for|O SCE|O in|O either|O BM|O or|O peripheral|O blood|O .|O 
These|O data|O revealed|O a|O normal|O SCE|O incidence|O .|O 
Of|O the|O 10|O MDS|O patients|O studied|O for|O point|O mutations|O of|O NRAS|gene-rna 12|O and|O 61|O and|O KRAS|gene-rna 12|O and|O 61|O ,|O one|O patient|O exhibited|O a|O base|O substitution|O at|O position|O 1|O of|O the|O 12th|O codon|O of|O the|O KRAS|gene-rna gene|O .|O 
These|O data|O ,|O gathered|O for|O the|O first|O time|O on|O the|O Indian|O patients|O ,|O throw|O some|O light|O on|O the|O nature|O of|O genetic|O changes|O in|O MDS|O of|O our|O country|O .|O 
Infrequent|O ras|gene-rna mutation|O in|O human|O stomach|O cancers|O .|O 
Mutations|O of|O ras|gene-rna oncogenes|O in|O 37|O human|O stomach|O cancers|O and|O 13|O adenomas|O were|O investigated|O with|O regard|O to|O the|O histological|O phenotypes|O using|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O ,|O allele|O -|O specific|O oligonucleotide|O hybridization|O and/or|O direct|O sequencing|O of|O the|O PCR|O products|O .|O 
The|O ras|gene-rna mutation|O was|O found|O only|O in|O one|O case|O (|O 2.7|O %|O )|O ,|O the|O histology|O of|O which|O was|O poorly|O differentiated|O adenocarcinoma|O .|O 
We|O found|O no|O mutation|O in|O stomach|O adenomas|O .|O 
The|O mutation|O consisted|O of|O a|O guanine|O -|O to|O -|O adenine|O transition|O in|O the|O first|O base|O of|O codon|O 13|O of|O c-Ki-ras|gene-rna which|O replaced|O wild-type|O glycine|O with|O serine|O ,|O indicating|O that|O a|O putative|O glycine|O -|O to|O -|O aspartic|O acid|O change|O is|O not|O necessarily|O the|O critical|O event|O for|O c-Ki-ras|gene-rna gene|O activation|O in|O codon|O 13|O .|O 
These|O results|O further|O confirm|O the|O infrequency|O of|O ras|gene-rna mutation|O in|O stomach|O tumors|O and|O also|O suggest|O that|O ras|gene-rna mutations|O are|O not|O specific|O to|O the|O differentiated|O type|O of|O stomach|O cancer|O .|O 
Analysis|O of|O mutations|O of|O neurofibromatosis|gene-rna type|gene-rna 1|gene-rna gene|O and|O N-ras|gene-rna gene|O in|O acute|O myelogenous|O leukemia|O .|O 
Neurofibromatosis|gene-rna type|gene-rna 1|gene-rna (|O NF1|gene-rna )|O gene|O is|O a|O tumor|gene-rna suppressor|gene-rna gene|gene-rna ,|O and|O the|O NF1|gene-rna gene|O product|O ,|O neurofibromin|gene-protein ,|O can|O downregulate|O the|O N-ras|gene-rna gene|O .|O 
Because|O the|O N-ras|gene-rna gene|O is|O often|O mutated|O in|O acute|O myelogenous|O leukemia|O (|O AML|O )|O ,|O we|O wondered|O if|O the|O NF1|gene-rna gene|O might|O be|O mutated|O in|O those|O AML|O samples|O not|O having|O N-ras|gene-rna mutations|O .|O 
We|O investigated|O the|O mutational|O status|O of|O the|O N-ras|gene-rna gene|O and|O the|O FLR|O exon|O of|O codons|O 1371|O -|O 1423|O of|O the|O open|O reading|O frame|O of|O the|O full-length|O NF1|gene-rna cDNA|O ,|O which|O has|O a|O strong|O homology|O with|O the|O mammalian|O ras|gene-protein GTPase|gene-protein -|gene-protein activating|gene-protein protein|gene-protein (|O GAP|gene-protein )|O ,|O especially|O for|O a|O stretch|O of|O three|O consecutive|O amino|O acids|O (|O F|O ,|O L|O ,|O R|O )|O ,|O by|O single-strand|O conformation|O polymorphism|O analysis|O and|O direct|O sequencing|O in|O samples|O from|O patients|O with|O AML|O .|O 
Of|O 48|O AML|O patients|O ,|O 10|O (|O 21|O %|O )|O had|O point|O (|O missense|O )|O mutations|O of|O the|O N-ras|gene-rna gene|O involving|O codons|O 12|O ,|O 13|O and|O 61|O .|O 
However|O ,|O mutations|O in|O the|O FLR|O exon|O of|O the|O NF1|gene-rna gene|O were|O not|O detected|O in|O any|O of|O the|O AML|O samples|O .|O 
We|O also|O examined|O the|O difference|O of|O clinical|O response|O to|O induction|O therapy|O between|O AML|O patients|O with|O and|O without|O N-ras|gene-rna mutation|O .|O 
A|O significantly|O lower|O rate|O of|O complete|O remission|O was|O noted|O in|O individuals|O with|O N-ras|gene-rna gene|O mutations|O .|O 
These|O results|O suggest|O that|O mutation|O of|O the|O NF1|gene-rna gene|O ,|O at|O least|O in|O the|O FLR|O exon|O ,|O is|O very|O rare|O in|O AML|O and|O the|O NF1|gene-rna gene|O probably|O is|O not|O a|O functional|O complement|O of|O the|O N-ras|gene-rna gene|O mutation|O .|O 
The|O presence|O of|O N-ras|gene-rna gene|O mutation|O may|O be|O associated|O with|O a|O lower|O clinical|O response|O to|O antileukemic|O therapy|O .|O 
Detection|O of|O K-ras|gene-rna point|O mutations|O at|O codon|O 12|O in|O pancreatic|O juice|O for|O the|O diagnosis|O of|O pancreatic|O cancer|O by|O hybridization|O protection|O assay|O :|O a|O simple|O method|O for|O the|O determination|O of|O the|O types|O of|O point|O mutation|O .|O 
The|O present|O study|O was|O undertaken|O to|O detect|O K-ras|gene-rna oncogene|O point|O mutations|O at|O codon|O 12|O in|O pure|O pancreatic|O juice|O (|O PPJ|O )|O by|O the|O hybridization|O protection|O assay|O (|O HPA|O )|O method|O for|O the|O diagnosis|O of|O pancreatic|O cancer|O (|O PC|O )|O .|O 
This|O assay|O can|O be|O carried|O out|O within|O 30|O min|O and|O can|O determine|O not|O only|O the|O presence|O of|O a|O mutation|O ,|O but|O also|O the|O mutational|O type|O of|O K-ras|gene-rna at|O codon|O 12|O .|O 
The|O minimal|O ratio|O of|O mutant|O DNA|O detectable|O by|O the|O HPA|O was|O 5|O -|O 10|O %|O of|O the|O total|O DNA|O .|O 
PPJ|O was|O collected|O through|O a|O cannula|O under|O duodenal|O fiberscope|O control|O from|O 20|O patients|O with|O PC|O and|O 20|O patients|O with|O chronic|O pancreatitis|O (|O CP|O )|O .|O 
Analysis|O of|O PPJ|O by|O the|O HPA|O revealed|O that|O the|O incidence|O of|O K-ras|gene-rna point|O mutations|O at|O codon|O 12|O was|O 55|O %|O (|O 11|O /|O 20|O )|O in|O patients|O with|O PC|O and|O 0|O %|O (|O 0|O /|O 20|O )|O in|O those|O with|O CP|O .|O 
Mutational|O types|O of|O K-ras|gene-rna at|O codon|O 12|O in|O PC|O were|O aspartic|O acid|O (|O Asp|O )|O in|O nine|O cases|O ,|O both|O Asp|O and|O cysteine|O in|O one|O case|O ,|O and|O arginine|O in|O one|O case|O .|O 
Analysis|O of|O K-ras|gene-rna point|O mutations|O at|O codon|O 12|O in|O PPJ|O using|O the|O HPA|O method|O seems|O promising|O as|O a|O new|O genetic|O test|O for|O the|O diagnosis|O of|O PC|O ,|O because|O the|O HPA|O method|O is|O simple|O ,|O and|O can|O easily|O determine|O the|O mutational|O type|O .|O 
C-Ha-ras|gene-rna oncogene|O in|O oral|O leukoplakia|O tissues|O .|O 
The|O amplification|O and|O the|O G|O -|O T|O mutation|O at|O codon|O 12|O of|O the|O C-Ha-ras|gene-rna oncogene|O in|O oral|O leukoplakia|O tissues|O were|O analyzed|O by|O using|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O and|O molecular|O biologic|O technique|O .|O 
The|O results|O showed|O that|O these|O tissues|O had|O no|O amplification|O of|O Ha-ras|gene-rna oncogene|O .|O 
Only|O one|O case|O harbored|O G|O -|O T|O mutation|O in|O 11|O oral|O leukoplakias|O ,|O but|O this|O mutation|O was|O absent|O in|O 10|O normal|O oral|O mucosal|O tissues|O .|O 
The|O possible|O role|O and|O significance|O of|O C-Ha-ras|gene-rna oncogene|O in|O oral|O precancerous|O lesions|O were|O also|O discussed|O .|O 
Single|O somatic|O ras|gene-rna gene|O point|O mutation|O in|O soft|O tissue|O malignant|O fibrous|O histiocytomas|O .|O 
The|O frequency|O of|O ras|gene-rna gene|O mutations|O in|O human|O soft|O tissue|O malignant|O fibrous|O histiocytomas|O within|O and|O around|O the|O hot|O spot|O codons|O (|O 12|O ,|O 13|O ,|O and|O 61|O )|O of|O all|O ras|gene-rna genes|O ,|O (|O H-ras-1|gene-rna ,|O K-ras-2|gene-rna ,|O and|O N-ras|gene-rna )|O was|O studied|O by|O nested|O polymerase|gene-protein chain|O reaction|O and|O direct|O DNA|O sequencing|O from|O archival|O formalin|O -|O fixed|O ,|O paraffin|O -|O embedded|O tissue|O .|O 
Light|O microscopy|O and|O immunohistochemistry|O served|O to|O define|O malignant|O fibrous|O histiocytoma|O .|O 
All|O of|O the|O four|O differentiation|O subtypes|O (|O storiform|O -|O pleomorphic|O ,|O inflammatory|O ,|O myxoid|O ,|O and|O giant|O cell|O )|O were|O investigated|O .|O 
Nine|O of|O thirty-two|O malignant|O fibrous|O histiocytomas|O (|O 28|O %|O )|O contained|O ras|gene-rna gene|O point|O mutations|O .|O 
The|O highest|O incidence|O was|O found|O in|O the|O myxoid|O subtype|O (|O four|O of|O nine|O )|O .|O 
H-ras-1|gene-rna gene|O codon|O 12.2|O was|O the|O only|O codon|O affected|O and|O contained|O in|O all|O mutated|O cases|O a|O GGC|O -->|O GTC|O exchange|O .|O 
Seven|O of|O the|O nine|O mutations|O were|O homozygous|O and|O probably|O affected|O more|O than|O 80|O %|O of|O the|O tumor|O DNA|O .|O 
The|O flanking|O regions|O of|O all|O hotspot|O codons|O did|O not|O contain|O any|O point|O mutation|O .|O 
The|O presence|O of|O a|O single|O and|O often|O homozygous|O point|O mutation|O of|O the|O H-ras-1|gene-rna gene|O ,|O especially|O in|O myxoid|O malignant|O fibrous|O histiocytoma|O could|O serve|O as|O a|O basis|O for|O further|O genomic|O discrimination|O of|O myxoid|O sarcomas|O .|O 
Concomitant|O point|O mutation|O of|O tumor|O suppressor|O gene|O p53|gene-rna and|O oncogene|O c-N-ras|gene-rna in|O malignant|O neuroendocrine|O pancreatic|O tumor|O .|O 
Activation|O by|O point|O mutation|O of|O ras|gene-rna family|O genes|O as|O well|O as|O point|O mutations|O of|O the|O p53|gene-rna tumor|O suppressor|O gene|O are|O found|O in|O many|O tumors|O .|O 
Here|O we|O describe|O a|O rare|O case|O of|O malignant|O neuroendocrine|O pancreatic|O tumor|O with|O multiple|O metastases|O in|O different|O organs|O showing|O strong|O positivity|O for|O synaptophysin|gene-protein ,|O glucagon|gene-protein -|gene-protein like|gene-protein peptide|gene-protein 1|gene-protein ,|O pan-cytokeratin|gene-protein ,|O moderate|O positivity|O for|O chromogranin|gene-protein ,|O Phe-5|gene-protein and|O calcitonin|gene-protein and|O weak|O positivity|O for|O vasointestinal|gene-protein peptide|gene-protein .|O 
We|O found|O a|O point|O mutation|O at|O codon|O 61|O of|O the|O c-N-ras|gene-rna oncogene|O ,|O and|O point|O mutations|O in|O the|O p53|gene-rna tumor|O suppressor|O gene|O in|O the|O primary|O tumor|O as|O well|O as|O in|O its|O metastases|O in|O liver|O .|O 
The|O mutation|O in|O the|O c-N-ras|gene-rna gene|O was|O a|O cytosine|O to|O adenine|O transversion|O ,|O resulting|O in|O the|O amino|O -|O acid|O lysine|O .|O 
Allele|O specific|O hybridization|O showed|O that|O the|O mutation|O involved|O one|O of|O two|O c-N-ras|gene-rna alleles|O as|O the|O oligonucleotide|O for|O the|O normal|O codon|O also|O hybridized|O to|O amplified|O tumor|O DNA|O .|O 
Concomitant|O mutation|O of|O the|O p53|gene-rna tumor|O suppressor|O gene|O at|O codons|O 248|O and|O 249|O was|O found|O .|O 
The|O mutation|O in|O codon|O 248|O was|O a|O cytosine|O to|O guanine|O transversion|O resulting|O in|O the|O amino|O -|O acid|O glycine|O .|O 
The|O mutation|O in|O codon|O 249|O was|O a|O third|O base|O ,|O G|O -|O >|O T|O ,|O transversion|O leading|O to|O a|O change|O from|O arginine|O to|O serine|O .|O 
This|O is|O the|O first|O time|O that|O concomitant|O point|O mutations|O in|O c-N-ras|gene-rna and|O p53|gene-rna have|O been|O found|O in|O a|O neuroendocrine|O pancreatic|O tumor|O .|O 
Based|O upon|O these|O and|O our|O previous|O results|O ,|O we|O concluded|O that|O these|O genetic|O changes|O may|O play|O a|O role|O in|O the|O development|O of|O this|O particular|O pancreatic|O tumor|O .|O 
Activation|O of|O beta-catenin|gene-generic -|O Tcf|gene-generic signaling|O in|O colon|O cancer|O by|O mutations|O in|O beta-catenin|gene-rna or|O APC|gene-rna .|O 
Inactivation|O of|O the|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|O APC|gene-rna )|O tumor|O suppressor|O gene|O initiates|O colorectal|O neoplasia|O .|O 
One|O of|O the|O biochemical|O activities|O associated|O with|O the|O APC|gene-protein protein|O is|O down|O -|O regulation|O of|O transcriptional|O activation|O mediated|O by|O beta-catenin|gene-generic and|O T|O cell|gene-generic transcription|gene-generic factor|gene-generic 4|gene-generic (|O Tcf-4|gene-generic )|O .|O 
The|O protein|gene-protein products|gene-protein of|O mutant|O APC|gene-rna genes|O present|O in|O colorectal|O tumors|O were|O found|O to|O be|O defective|O in|O this|O activity|O .|O 
Furthermore|O ,|O colorectal|O tumors|O with|O intact|O APC|gene-rna genes|O were|O found|O to|O contain|O activating|O mutations|O of|O beta-catenin|gene-rna that|O altered|O functionally|O significant|O phosphorylation|O sites|O .|O 
These|O results|O indicate|O that|O regulation|O of|O beta-catenin|gene-generic is|O critical|O to|O APC|gene-rna 's|O tumor|O suppressive|O effect|O and|O that|O this|O regulation|O can|O be|O circumvented|O by|O mutations|O in|O either|O APC|gene-rna or|O beta-catenin|gene-rna .|O 
K-ras|gene-rna mutations|O are|O found|O in|O DNA|O extracted|O from|O the|O plasma|O of|O patients|O with|O colorectal|O cancer|O .|O 
BACKGROUND|O &|O AIMS|O :|O Circulating|O DNA|O can|O be|O isolated|O from|O the|O plasma|O of|O healthy|O subjects|O and|O from|O patients|O with|O cancer|O .|O 
The|O aim|O of|O this|O study|O was|O to|O detect|O K-ras|gene-rna mutations|O in|O DNA|O extracted|O from|O the|O plasma|O of|O patients|O with|O colorectal|O cancer|O .|O 
METHODS|O :|O Tumor|O and|O plasma|O DNA|O were|O extracted|O from|O 14|O patients|O with|O colorectal|O cancer|O (|O stages|O A|O -|O D|O )|O ,|O and|O K-ras|gene-rna alterations|O were|O detected|O using|O a|O polymerase|O chain|O reaction|O assay|O that|O uses|O sequence|O -|O specific|O primers|O to|O amplify|O mutant|O DNA|O .|O 
These|O results|O were|O confirmed|O with|O another|O polymerase|O chain|O reaction|O assay|O that|O creates|O an|O enzyme|O restriction|O site|O in|O the|O absence|O of|O a|O K-ras|gene-rna mutation|O followed|O by|O direct|O sequencing|O and|O additional|O cloning|O techniques|O .|O 
RESULTS|O :|O Seven|O patients|O (|O 50|O %|O )|O had|O a|O codon|O 12|O K-ras|gene-rna mutation|O within|O their|O primary|O tumor|O ,|O and|O identical|O mutations|O were|O found|O in|O the|O plasma|O DNA|O of|O 6|O patients|O (|O 86|O %|O )|O .|O 
Mutant|O DNA|O was|O not|O detected|O in|O the|O plasma|O specimens|O of|O 7|O patients|O whose|O tumors|O tested|O negative|O for|O K-ras|gene-rna alterations|O or|O in|O healthy|O control|O subjects|O .|O 
Similar|O results|O were|O obtained|O using|O all|O three|O molecular|O biological|O techniques|O .|O 
CONCLUSIONS|O :|O K-ras|gene-rna abnormalities|O can|O be|O detected|O in|O circulating|O DNA|O extracted|O from|O the|O plasma|O specimens|O of|O patients|O with|O colorectal|O cancer|O .|O 
[|O Carcinogenic|O mechanisms|O of|O multiple|O genes|O in|O cervical|O carcinoma|O ]|O 
The|O alterations|O of|O multiple|O genes|O and|O their|O carcinogenic|O mechanism|O in|O cervical|O carcinoma|O were|O studies|O by|O molecular|O hybridisation|O ,|O PCR|O and|O PCR|O -|O ASO|O techniques|O .|O 
The|O G|O -|O T|O point|O mutation|O in|O the|O 12th|O coden|O of|O Ha-ras|gene-rna was|O detected|O in|O cervical|O carcinomas|O with|O mutation|O frequency|O of|O 18.2|O %|O (|O 8|O /|O 44|O )|O ,|O and|O the|O amplification|O rate|O of|O Ha-ras|gene-rna gene|O was|O 45|O %|O (|O 9|O /|O 20|O )|O .|O 
The|O c-erb|gene-rna B2|gene-rna was|O amplified|O 3|O -|O 30|O fold|O with|O an|O amplification|O rate|O of|O 73.3|O %|O (|O 11|O /|O 15|O )|O in|O cervical|O carcinomas|O and|O 5|O cancerous|O samples|O showed|O gene|O rearrangement|O .|O 
The|O elevated|O copies|O of|O c-myc|gene-rna gene|O with|O amplification|O rate|O of|O 91.7|O %|O (|O 11|O /|O 12|O )|O were|O observed|O in|O cervical|O carcinomas|O .|O 
The|O study|O of|O HPV16|gene-rna viral|O gene|O showed|O that|O the|O existence|O of|O HPV16|gene-rna DNA|O sequence|O was|O positively|O associated|O with|O c-myc|gene-rna gene|O amplification|O in|O cervical|O cancerous|O samples|O .|O 
The|O p53|gene-rna and|O Rb|gene-rna tumor|gene-rna suppressor|gene-rna genes|O absence|O of|O deletion|O were|O observed|O in|O the|O 12|O specimens|O of|O cervical|O carcinoma|O investigated|O .|O 
As|O mentioned|O above|O ,|O the|O study|O on|O alteration|O and|O carcinogenic|O mechanism|O of|O multiple|O genes|O indicated|O that|O 3|O oncogenes|gene-rna and|O HPV16|gene-rna viral|O gene|O were|O activated|O or|O integrated|O throygh|O different|O mechanisms|O and|O they|O played|O roles|O in|O co|O -|O carcinogenesis|O .|O 
The|O integration|O of|O HPV16|gene-rna gene|O might|O promote|O the|O c-myc|gene-rna gene|O at|O the|O early|O stage|O in|O carcinogenesis|O of|O cervical|O carcinoma|O ,|O while|O the|O alteration|O of|O Ha-ras|gene-rna and|O c-erb|gene-rna B2|gene-rna gene|O might|O be|O middle|O -|O late|O event|O .|O 
As|O for|O the|O roles|O of|O the|O p53|gene-rna and|O Rb|gene-rna tumor|gene-rna suppresor|gene-rna gene|O in|O cervical|O carcinogenesis|O need|O further|O researches|O .|O 
Beta-catenin|gene-rna mutations|O in|O cell|O lines|O established|O from|O human|O colorectal|O cancers|O .|O 
beta-catenin|gene-rna has|O functions|O as|O both|O an|O adhesion|O and|O a|O signaling|O molecule|O .|O 
Disruption|O of|O these|O functions|O through|O mutations|O of|O the|O beta-catenin|gene-rna gene|O (|O CTNNB1|gene-rna )|O may|O be|O important|O in|O the|O development|O of|O colorectal|O tumors|O .|O 
We|O examined|O the|O entire|O coding|O sequence|O of|O beta-catenin|gene-rna by|O reverse|gene-protein transcriptase|gene-protein -|O PCR|O (|O RT|O -|O PCR|O )|O and|O direct|O sequencing|O of|O 23|O human|O colorectal|O cancer|O cell|O lines|O from|O 21|O patients|O .|O 
In|O two|O cell|O lines|O ,|O there|O was|O apparent|O instability|O of|O the|O beta-catenin|gene-rna mRNA|O .|O 
Five|O different|O mutations|O (|O 26|O %|O )|O were|O found|O in|O the|O remaining|O 21|O cell|O lines|O (|O from|O 19|O patients|O )|O .|O 
A|O three|O -|O base|O deletion|O (|O codon|O 45|O )|O was|O identified|O in|O the|O cell|O line|O HCT|O 116|O ,|O whereas|O cell|O lines|O SW|O 48|O ,|O HCA|O 46|O ,|O CACO|O 2|O ,|O and|O Colo|O 201|O each|O contained|O single|O -|O base|O missense|O mutations|O (|O codons|O 33|O ,|O 183|O ,|O 245|O ,|O and|O 287|O ,|O respectively|O )|O .|O 
All|O 23|O cell|O lines|O had|O full-length|O beta-catenin|gene-protein protein|O that|O was|O detectable|O by|O Western|O blotting|O and|O that|O coprecipitated|O with|O E-cadherin|gene-protein .|O 
In|O three|O of|O the|O cell|O lines|O with|O CTNNB1|gene-rna mutations|O ,|O complexes|O of|O beta-catenin|gene-protein with|O alpha-catenin|gene-protein and|O APC|gene-protein were|O detectable|O .|O 
In|O SW48|O and|O HCA|O 46|O ,|O however|O ,|O we|O did|O not|O detect|O complexes|O of|O beta-catenin|gene-protein protein|O with|O alpha-catenin|gene-protein and|O APC|gene-protein ,|O respectively|O .|O 
These|O results|O show|O that|O selection|O of|O CTNNB1|gene-rna mutations|O occurs|O in|O up|O to|O 26|O %|O of|O colorectal|O cancers|O from|O which|O cell|O lines|O are|O derived|O .|O 
In|O these|O cases|O ,|O mutation|O selection|O is|O probably|O for|O altered|O beta-catenin|gene-generic function|O ,|O which|O may|O significantly|O alter|O intracellular|O signaling|O and|O intercellular|O adhesion|O and|O may|O serve|O as|O a|O complement|O to|O APC|gene-rna mutations|O in|O the|O early|O stages|O of|O tumorigenesis|O .|O 
Prognostic|O value|O of|O specific|O KRAS|gene-rna mutations|O in|O lung|O adenocarcinomas|O .|O 
Adenocarcinomas|O of|O the|O lung|O remain|O a|O significant|O public|O health|O problem|O .|O 
Locally|O defined|O (|O stage|O I|O )|O tumors|O are|O considered|O amenable|O to|O resection|O with|O curative|O intent|O .|O 
However|O ,|O only|O about|O 45|O %|O of|O these|O patients|O survive|O for|O 5|O years|O .|O 
The|O median|O survival|O for|O more|O advanced|O tumors|O is|O drastically|O lower|O .|O 
Much|O research|O has|O been|O focused|O on|O identifying|O a|O valid|O genetic|O biomarker|O of|O prognosis|O .|O 
Mutations|O of|O the|O proto|O -|O oncogene|O KRAS|gene-rna have|O been|O identified|O by|O some|O groups|O as|O being|O a|O valid|O prognostic|O indicator|O for|O adenocarcinoma|O of|O the|O lung|O .|O 
To|O evaluate|O the|O effect|O of|O KRAS|gene-rna gene|O mutation|O on|O the|O survival|O of|O patients|O with|O lung|O adenocarcinoma|O ,|O 181|O archival|O tumors|O were|O examined|O by|O PCR|O and|O denaturing|O gradient|O gel|O electrophoresis|O .|O 
Mutations|O in|O either|O codon|O 12|O or|O 13|O were|O found|O in|O 31.5|O %|O of|O the|O samples|O .|O 
The|O most|O common|O mutation|O was|O a|O G|O -->|O T|O transversion|O in|O codon|O 12|O ,|O representing|O 66.7|O %|O of|O the|O mutations|O .|O 
No|O difference|O was|O observed|O in|O the|O survival|O of|O patients|O with|O a|O KRAS|gene-rna mutation|O versus|O those|O whose|O tumors|O contained|O wild-type|O KRAS|gene-rna .|O 
This|O lack|O of|O difference|O was|O also|O observed|O when|O the|O analysis|O was|O restricted|O to|O those|O with|O stage|O I|O tumors|O or|O when|O patients|O with|O stage|O I|O or|O II|O disease|O were|O grouped|O together|O .|O 
However|O ,|O certain|O amino|O acid|O substitutions|O ,|O including|O cysteine|O ,|O arginine|O ,|O and|O aspartate|O ,|O indicated|O a|O significantly|O poorer|O prognosis|O ,|O whereas|O hydrophobic|O amino|O acid|O substitutions|O showed|O a|O significantly|O better|O prognosis|O than|O wild-type|O (|O P|O =|O 0.04|O )|O .|O 
Sample|O sizes|O were|O small|O for|O this|O analysis|O due|O to|O the|O number|O of|O possible|O mutations|O .|O 
As|O expected|O ,|O the|O stage|O of|O tumor|O at|O resection|O was|O the|O most|O significant|O predictor|O of|O outcome|O .|O 
Beta-catenin|gene-rna has|O been|O identified|O as|O an|O oncogene|O in|O colon|O cancer|O and|O melanoma|O .|O 
Phosphorylation|O of|O sites|O in|O exon|O 3|O of|O beta-catenin|gene-rna leads|O to|O degradation|O of|O this|O protein|gene-protein .|O 
These|O sites|O are|O primary|O targets|O for|O activating|O mutations|O .|O 
The|O frequency|O with|O which|O oncogenic|O mutations|O at|O these|O sites|O are|O found|O in|O colorectal|O cancer|O is|O unknown|O ,|O as|O is|O the|O frequency|O of|O their|O occurrence|O in|O other|O malignancies|O .|O 
We|O analyzed|O 92|O colorectal|O cancers|O (|O CRCs|O )|O and|O 57|O cancer|O cell|O lines|O (|O representing|O a|O diversity|O of|O tumor|O types|O )|O to|O determine|O the|O frequency|O of|O activating|O mutations|O in|O this|gene-rna gene|gene-rna .|O 
Mutations|O in|O exon|O 3|O of|O beta-catenin|gene-rna were|O found|O in|O 2|O of|O 92|O CRCs|O and|O in|O the|O colorectal|O cancer|O cell|O line|O HCT|O 116|O .|O 
Both|O tumors|O with|O beta-catenin|gene-rna mutations|O exhibited|O widespread|O microsatellite|O instability|O ,|O which|O is|O indicative|O of|O a|O replication|O error|O phenotype|O ,|O a|O phenotype|O known|O to|O be|O present|O in|O HCT|O 116|O .|O 
This|O suggests|O that|O mutations|O in|O beta-catenin|gene-rna are|O infrequent|O in|O CRC|O and|O miscellaneous|O cancer|O cell|O lines|O and|O may|O occur|O in|O association|O with|O a|O replication|O error|O phenotype|O .|O 
Peutz|O -|O Jeghers|O polyps|O ,|O dysplasia|O ,|O and|O K-ras|gene-rna codon|O 12|O mutations|O .|O 
BACKGROUND|O :|O Peutz|O -|O Jeghers|O syndrome|O (|O PJS|O )|O is|O a|O rare|O ,|O autosomal|O dominant|O ,|O polyposis|O syndrome|O ,|O associated|O with|O an|O increased|O risk|O of|O gastrointestinal|O and|O extragastrointestinal|O malignancy|O .|O 
Occasionally|O dysplasia|O occurs|O in|O PJS|O polyps|O .|O 
AIMS|O :|O In|O colorectal|O carcinomas|O ,|O mutations|O in|O codon|O 12|O of|O the|O K-ras|gene-rna oncogene|O are|O common|O and|O are|O found|O at|O similar|O frequency|O in|O precursor|O adenomas|O .|O 
Therefore|O ,|O K-ras|gene-rna codon|O 12|O point|O mutations|O in|O PJS|O polyps|O ,|O were|O evaluated|O .|O 
MATERIALS|O AND|O METHODS|O :|O Fifty|O two|O PJS|O polyps|O ,|O including|O four|O with|O dysplasia|O ,|O collected|O from|O 19|O patients|O with|O PJS|O ,|O were|O analysed|O for|O mutations|O in|O the|O K-ras|gene-rna codon|O 12|O by|O a|O mutant|O enriched|O polymerase|gene-protein chain|O reaction|O procedure|O ,|O followed|O by|O allele|O specific|O oligodeoxynucleotide|O hybridisation|O .|O 
RESULTS|O :|O A|O K-ras|gene-rna codon|O 12|O mutation|O was|O identified|O ,|O in|O one|O colonic|O polyp|O with|O dysplasia|O .|O 
The|O mutation|O was|O found|O in|O the|O non|O -|O neoplasmic|O epithelial|O cells|O and|O not|O in|O the|O dysplastic|O component|O of|O the|O polyp|O .|O 
CONCLUSIONS|O :|O K-ras|gene-rna codon|O 12|O point|O mutations|O are|O very|O rare|O in|O PJS|O polyps|O ,|O by|O contrast|O with|O colorectal|O adenomas|O .|O 
Detection|O of|O Ki-ras|gene-rna mutations|O by|O PCR|O and|O differential|O hybridization|O and|O of|O p53|gene-rna mutations|O by|O SSCP|O analysis|O in|O endoscopically|O obtained|O lavage|O solution|O from|O patients|O with|O long|O -|O standing|O ulcerative|O colitis|O .|O 
OBJECTIVES|O :|O 
The|O goal|O of|O this|O study|O was|O the|O early|O detection|O of|O malignant|O transformation|O in|O patients|O with|O long|O -|O standing|O ulcerative|O colitis|O ;|O therefore|O ,|O mutations|O of|O the|O Ki-ras|gene-rna and|O p53|gene-rna gene|O were|O analyzed|O in|O lavage|O solution|O and|O biopsies|O obtained|O at|O surveillance|O colonoscopy|O .|O 
METHODS|O :|O 
DNA|O was|O isolated|O from|O 14|O patients|O (|O nine|O female|O ,|O five|O male|O )|O with|O a|O history|O of|O pancolitis|O for|O more|O than|O 10|O yr|O .|O 
Exon|O 1|O of|O the|O Ki-ras|gene-rna gene|O and|O exons|O 5|O -|O 8|O of|O the|O p53|gene-rna gene|O were|O amplified|O via|O polymerase|gene-protein chain|O reaction|O .|O 
Mutations|O of|O the|O p53|gene-rna gene|O were|O detected|O via|O single-strand|O conformation|O polymorphism|O analysis|O ;|O point|O mutations|O of|O the|O Ki-ras|gene-rna gene|O were|O hybridized|O on|O dot|O blots|O with|O oligonucleotides|O marked|O with|O digoxigenin|O .|O 
RESULTS|O :|O 
Wild-type|O Ki-ras|gene-rna and|O wild-type|O p53|gene-rna were|O detected|O in|O all|O cases|O of|O ulcerative|O colitis|O and|O in|O four|O of|O seven|O control|O patients|O .|O 
In|O two|O ulcerative|O colitis|O patients|O ,|O a|O mutation|O was|O found|O in|O the|O Ki-ras|gene-rna gene|O (|O Gly|O -->|O Asp|O 12|O and|O Gly|O -->|O Val|O 12|O )|O ,|O and|O in|O one|O patient|O ,|O a|O mutation|O in|O exon|O 5|O of|O the|O p53|gene-rna gene|O .|O 
Mutations|O were|O found|O only|O in|O the|O lavage|O fluid|O ,|O whereas|O random|O biopsies|O were|O negative|O .|O 
CONCLUSIONS|O :|O 
From|O colonic|O lavage|O fluid|O ,|O it|O is|O possible|O to|O extract|O DNA|O of|O sufficient|O quantity|O and|O quality|O for|O polymerase|gene-protein chain|O reaction|O -|O based|O amplification|O and|O subsequent|O analysis|O via|O single-strand|O conformation|O polymorphism|O or|O hybridization|O .|O 
Mutations|O were|O found|O in|O three|O of|O 14|O patients|O with|O long|O -|O standing|O ulcerative|O colitis|O but|O were|O not|O found|O in|O controls|O .|O 
The|O method|O may|O be|O useful|O for|O the|O screening|O of|O such|O patients|O .|O 
Gain|O -|O of|O -|O function|O mutations|O of|O c-kit|gene-rna in|O human|O gastrointestinal|O stromal|O tumors|O .|O 
Gastrointestinal|O stromal|O tumors|O (|O GISTs|O )|O are|O the|O most|O common|O mesenchymal|O tumors|O in|O the|O human|O digestive|O tract|O ,|O but|O their|O molecular|O etiology|O and|O cellular|O origin|O are|O unknown|O .|O 
Sequencing|O of|O c-kit|gene-rna complementary|O DNA|O ,|O which|O encodes|O a|O proto|O -|O oncogenic|O receptor|O tyrosine|gene-protein kinase|gene-protein (|O KIT|gene-protein )|O ,|O from|O five|O GISTs|O revealed|O mutations|O in|O the|O region|O between|O the|O transmembrane|O and|O tyrosine|gene-protein kinase|gene-protein domains|O .|O 
All|O of|O the|O corresponding|O mutant|O KIT|gene-rna proteins|gene-protein were|O constitutively|O activated|O without|O the|O KIT|gene-rna ligand|O ,|O stem|gene-protein cell|gene-protein factor|gene-protein (|O SCF|gene-protein )|O .|O 
Stable|O transfection|O of|O the|O mutant|O c-kit|gene-rna complementary|O DNAs|O induced|O malignant|O transformation|O of|O Ba|O /|O F3|O murine|O lymphoid|O cells|O ,|O suggesting|O that|O the|O mutations|O contribute|O to|O tumor|O development|O .|O 
GISTs|O may|O originate|O from|O the|O interstitial|O cells|O of|O Cajal|O (|O ICCs|O )|O because|O the|O development|O of|O ICCs|O is|O dependent|O on|O the|O SCF|gene-protein -|gene-rna KIT|gene-rna interaction|O and|O because|O ,|O like|O GISTs|O ,|O these|O cells|O express|O both|O KIT|gene-rna and|O CD34|gene-rna .|O 
Sporadic|O medulloblastomas|O contain|O oncogenic|O beta-catenin|gene-rna mutations|O .|O 
The|O beta-catenin|gene-rna ,|O glycogen|gene-rna synthase|gene-rna kinase|gene-rna 3beta|gene-rna (|O GSK-3beta|gene-rna )|O ,|O and|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|O APC|gene-rna )|O gene|gene-generic products|gene-generic interact|O to|O form|O a|O network|O that|O influences|O the|O rate|O of|O cell|O proliferation|O .|O 
Medulloblastoma|O occurs|O as|O part|O of|O Turcot|O 's|O syndrome|O ,|O and|O patients|O with|O Turcot|O 's|O who|O develop|O medulloblastomas|O have|O been|O shown|O to|O harbor|O germ|O -|O line|O APC|gene-rna mutations|O .|O 
Although|O APC|gene-rna mutations|O have|O been|O investigated|O and|O not|O identified|O in|O sporadic|O medulloblastomas|O ,|O the|O status|O of|O the|O beta-catenin|gene-rna and|O GSK-3beta|gene-rna genes|O has|O not|O been|O evaluated|O in|O this|O tumor|O .|O 
Here|O we|O show|O that|O 3|O of|O 67|O medulloblastomas|O harbor|O beta-catenin|gene-rna mutations|O ,|O each|O of|O which|O converts|O a|O GSK-3beta|gene-rna phosphorylation|O site|O from|O serine|O to|O cysteine|O .|O 
The|O beta-catenin|gene-rna mutation|O seen|O in|O the|O tumors|O was|O not|O present|O in|O matched|O constitutional|O DNA|O in|O the|O two|O cases|O where|O matched|O DNA|O was|O available|O .|O 
A|O loss|O of|O heterozygosity|O analysis|O of|O 32|O medulloblastomas|O with|O paired|O normal|O DNA|O samples|O was|O performed|O with|O four|O microsatellite|O markers|O flanking|O the|O GSK-3beta|gene-rna locus|O ;|O loss|O of|O heterozygosity|O with|O at|O least|O one|O marker|O was|O identified|O in|O 7|O tumors|O .|O 
Sequencing|O of|O the|O remaining|O GSK-3beta|O allele|O in|O these|O cases|O failed|O to|O identify|O any|O mutations|O .|O 
Taken|O together|O ,|O these|O data|O suggest|O that|O activating|O mutations|O in|O the|O beta-catenin|gene-rna gene|O may|O be|O involved|O in|O the|O development|O of|O a|O subset|O of|O medulloblastomas|O .|O 
The|O GSK-3beta|gene-rna gene|O does|O not|O appear|O to|O be|O a|O target|O for|O inactivation|O in|O this|O tumor|O .|O 
Immunoperoxidase|gene-protein staining|O for|O cytokeratins|gene-protein 8|gene-protein and|O 18|gene-protein is|O very|O sensitive|O for|O detection|O of|O occult|O node|O metastasis|O of|O colorectal|O cancer|O :|O a|O comparison|O with|O genetic|O analysis|O of|O K-ras|gene-rna .|O 
AIMS|O :|O 
Recent|O reports|O suggest|O that|O genetic|O examination|O of|O K-ras|gene-rna or|O p53|gene-rna mutation|O is|O more|O sensitive|O for|O the|O detection|O of|O occult|O lymph|O node|O metastasis|O in|O colorectal|O carcinomas|O than|O conventional|O examination|O by|O haematoxylin|O and|O eosin|O (|O H|O &|O E|O )|O staining|O or|O immunohistochemistry|O for|O gene|gene-generic products|gene-generic .|O 
The|O aim|O of|O this|O study|O was|O ,|O first|O ,|O to|O define|O the|O microscopic|O characteristics|O of|O metastatic|O cancer|O cells|O in|O lymph|O nodes|O stained|O by|O the|O anti|O -|O cytokeratin|gene-protein antibody|gene-protein CAM5.2|gene-protein for|O cytokeratins|gene-protein 8|gene-protein and|O 18|gene-protein ,|O and|O ,|O second|O ,|O to|O compare|O the|O detection|O rate|O of|O occult|O lymph|O node|O metastasis|O for|O immunohistochemical|O vs|O genetic|O methods|O .|O 
METHODS|O AND|O RESULTS|O :|O 
K-ras|gene-rna mutations|O were|O first|O examined|O in|O primary|O tumours|O of|O seven|O cases|O which|O showed|O distant|O metastasis|O or|O local|O recurrence|O within|O 5|O years|O of|O the|O initial|O surgery|O in|O spite|O of|O the|O original|O reporting|O of|O no|O lymph|O node|O metastasis|O by|O routine|O H|O &|O E|O staining|O .|O 
K-ras|gene-rna mutations|O were|O positive|O in|O three|O cases|O in|O primary|O tumours|O and|O lymph|O nodes|O ,|O and|O the|O remaining|O four|O primary|O tumours|O were|O negative|O for|O p53|gene-rna mutation|O as|O well|O as|O K-ras|gene-rna mutation|O .|O 
Therefore|O ,|O genetic|O analysis|O of|O occult|O lymph|O node|O metastasis|O was|O uninformative|O ,|O but|O occult|O metastasis|O was|O detected|O by|O cytokeratin|gene-protein staining|O in|O two|O of|O these|O four|O cases|O .|O 
Comparative|O study|O of|O cytokeratin|gene-protein -|O positive|O cells|O was|O performed|O on|O each|O of|O the|O 43|O lymph|O nodes|O from|O three|O cases|O with|O K-ras|gene-rna mutations|O .|O 
Cancer|O cells|O were|O detected|O in|O 28|O of|O the|O 43|O lymph|O nodes|O (|O 65.1|O %|O )|O by|O cytokeratin|gene-protein staining|O and|O in|O 10|O of|O the|O 43|O corresponding|O lymph|O nodes|O (|O 23.3|O %|O )|O by|O genetic|O analysis|O .|O 
Artefactual|O contamination|O by|O cancer|O cells|O was|O present|O in|O eight|O of|O the|O 28|O cytokeratin|gene-protein positive|O lymph|O nodes|O ,|O and|O three|O of|O the|O eight|O nodes|O were|O genetically|O positive|O .|O 
CONCLUSIONS|O :|O 
This|O study|O suggests|O that|O cytokeratin|gene-protein immunohistochemistry|O is|O more|O sensitive|O and|O specific|O for|O the|O detection|O of|O occult|O lymph|O node|O metastasis|O than|O genetic|O diagnosis|O by|O K-ras|gene-rna mutation|O in|O cases|O with|O genetic|O alterations|O as|O well|O as|O in|O cases|O without|O them|O .|O 
A|O beta-catenin|gene-rna mutation|O in|O a|O sporadic|O colorectal|O tumor|O of|O the|O RER|O phenotype|O and|O absence|O of|O beta-catenin|gene-rna germline|O mutations|O in|O FAP|O patients|O .|O 
As|O a|O signaling|O protein|O in|O the|O Wnt|O pathway|O beta-catenin|gene-protein plays|O a|O crucial|O role|O in|O the|O regulation|O of|O cellular|O proliferation|O .|O 
Recently|O ,|O oncogenic|O beta-catenin|gene-rna mutations|O were|O described|O in|O human|O colorectal|O cancer|O and|O melanoma|O cell|O lines|O .|O 
Since|O activating|O mutations|O in|O the|O beta-catenin|gene-rna gene|O have|O similar|O effects|O on|O the|O biochemical|O level|O as|O inactivating|O mutations|O in|O the|O tumor|gene-rna suppressor|gene-rna gene|gene-rna APC|gene-rna ,|O it|O is|O speculated|O that|O beta-catenin|gene-rna mutations|O may|O substitute|O APC|gene-rna gene|O inactivation|O in|O carcinogenesis|O .|O 
To|O address|O this|O question|O we|O analyzed|O twenty-three|O sporadic|O colorectal|O tumors|O of|O different|O progression|O states|O for|O mutations|O in|O the|O beta-catenin|gene-rna gene|O .|O 
Eighteen|O of|O these|O tumors|O showed|O the|O wildtype|O APC|gene-rna gene|O sequence|O .|O 
In|O only|O one|O of|O the|O tumors|O with|O wildtype|O APC|O a|O beta-catenin|gene-rna gene|O mutation|O was|O found|O .|O 
This|O tumor|O was|O of|O the|O RER|O (|O replication|O error|O )|O phenotype|O which|O may|O explain|O the|O finding|O that|O the|O mutation|O occurred|O in|O a|O sequential|O repeat|O motif|O of|O the|O beta-catenin|gene-rna gene|O .|O 
The|O second|O aim|O of|O this|O study|O was|O to|O investigate|O whether|O differences|O in|O the|O phenotypic|O variability|O in|O FAP|O (|O familial|O adenomatous|O polyposis|O coli|O )|O might|O be|O due|O to|O inherited|O alterations|O in|O the|O beta-catenin|gene-rna gene|O .|O 
For|O this|O we|O analyzed|O DNA|O from|O fourteen|O FAP|O patients|O from|O eight|O different|O families|O for|O germline|O mutations|O in|O the|O beta-catenin|gene-rna gene|O .|O 
We|O did|O not|O find|O any|O beta-catenin|gene-rna gene|O alteration|O in|O these|O samples|O .|O 
Our|O results|O indicate|O that|O somatic|O beta-catenin|gene-rna activating|O mutations|O contribute|O only|O to|O a|O minor|O part|O of|O human|O colorectal|O tumors|O and|O that|O germline|O beta-catenin|gene-rna mutations|O do|O not|O play|O a|O role|O in|O the|O variability|O of|O symptoms|O in|O FAP|O .|O 
Exposure|O to|O aromatic|O amines|O is|O considered|O a|O major|O risk|O factor|O for|O the|O development|O of|O bladder|O cancer|O .|O 
In|O this|O study|O ,|O we|O have|O analysed|O the|O pattern|O of|O point|O mutations|O in|O several|O tumour|O genes|O in|O 21|O cases|O of|O bladder|O cancer|O arising|O among|O western|O European|O workers|O exposed|O to|O aromatic|O amines|O in|O an|O attempt|O to|O determine|O whether|O this|O exposure|O may|O be|O associated|O with|O a|O unique|O spectrum|O of|O mutations|O .|O 
Of|O the|O four|O genes|O analysed|O (|O p53|gene-rna ,|O p16MTS1|gene-rna ,|O p21WAF1|gene-rna and|O H-ras|gene-rna )|O ,|O only|O p53|O showed|O a|O high|O frequency|O of|O mutations|O (|O in|O 8|O out|O of|O 21|O cases|O ,|O 38|O %|O )|O .|O 
Two|O mutations|O were|O found|O in|O p16|gene-rna ,|O one|O in|O H-ras|O and|O none|O in|O p21|gene-rna exon|O 3|O .|O All|O mutations|O were|O at|O G|O :|O C|O base|O pairs|O ,|O mostly|O at|O non|O -|O CpG|O residues|O .|O 
This|O spectrum|O of|O mutations|O ,|O which|O is|O highly|O suggestive|O of|O an|O involvement|O of|O exogenous|O carcinogens|O ,|O is|O however|O identical|O to|O the|O spectrum|O of|O p53|gene-rna mutations|O detected|O in|O bladder|O cancers|O of|O the|O general|O population|O .|O 
In|O exposed|O workers|O ,|O p53|O mutations|O were|O associated|O with|O tumour|O grade|O and|O with|O high|O occupational|O and|O tobacco|O exposure|O .|O 
Taken|O together|O ,|O our|O data|O suggest|O that|O the|O same|O carcinogens|O may|O be|O responsible|O for|O the|O development|O of|O bladder|O cancers|O in|O workers|O exposed|O to|O aromatic|O amines|O and|O in|O the|O general|O population|O .|O 
Clear|O cell|O carcinoma|O of|O the|O pancreas|O :|O an|O adenocarcinoma|O with|O ductal|O phenotype|O .|O 
AIMS|O :|O 
Primary|O clear|O cell|O carcinoma|O of|O the|O pancreas|O resembling|O metastatic|O renal|O carcinoma|O has|O only|O rarely|O been|O described|O .|O 
To|O date|O it|O has|O been|O poorly|O characterized|O as|O a|O distinct|O tumour|O entity|O .|O 
METHODS|O AND|O RESULTS|O :|O 
We|O report|O a|O case|O of|O clear|O cell|O carcinoma|O in|O a|O 53|O -|O year|O -|O old|O man|O involving|O the|O head|O of|O the|O pancreas|O and|O which|O had|O a|O small|O intraductal|O papillary|O component|O .|O 
The|O clear|O cell|O portion|O comprised|O about|O 90|O %|O of|O the|O tumour|O mass|O .|O 
It|O showed|O predominantly|O a|O solid|O growth|O pattern|O with|O a|O few|O scattered|O tubular|O structures|O .|O 
Immunocytochemically|O the|O tumour|O cells|O stained|O positively|O for|O cytokeratins|gene-protein 7|gene-protein ,|gene-protein 8|gene-protein ,|O 18|gene-protein and|O 19|gene-protein ,|O whereas|O the|O reaction|O for|O vimentin|gene-protein and|O neuroendocrine|gene-protein markers|gene-protein was|O negative|O .|O 
K-ras|gene-rna analysis|O revealed|O a|O point|O mutation|O at|O codon|O 12|O with|O mutation|O of|O GGT|O to|O GAT|O .|O 
CONCLUSION|O :|O 
The|O intraductal|O tumour|O component|O of|O this|O clear|O cell|O carcinoma|O as|O well|O as|O the|O cytokeratin|gene-protein pattern|O and|O the|O K-ras|gene-rna mutation|O suggest|O that|O this|O rare|O type|O of|O pancreatic|O cancer|O has|O a|O ductal|O phenotype|O .|O 
Primary|O cancer|O of|O the|O small|O intestine|O and|O mutational|O analysis|O of|O the|O K-ras|gene-rna and|O p53|gene-rna genes|O .|O 
A|O 69|O -|O year|O -|O old|O woman|O was|O admitted|O to|O Hokuso|O Shiroi|O Hospital|O because|O of|O recurrent|O pain|O in|O the|O lower|O right|O side|O of|O the|O abdomen|O .|O 
Small|O -|O intestinal|O cancer|O was|O strongly|O suspected|O after|O fluoroscopy|O of|O the|O small|O intestine|O .|O 
Laparotomy|O showed|O advanced|O cancer|O of|O the|O ileum|O ,|O of|O complete|O annular|O constrictive|O type|O ,|O 9.5|O x|O 5|O cm|O in|O size|O .|O 
Histologically|O it|O was|O moderately|O differentiated|O tubular|O adenocarcinoma|O .|O 
Neither|O visceral|O nor|O nodal|O metastases|O were|O found|O ,|O and|O the|O patient|O has|O been|O well|O for|O the|O 20|O months|O since|O surgery|O .|O 
The|O strong|O resemblance|O between|O the|O epidemiological|O characteristics|O of|O small|O -|O intestinal|O cancers|O and|O colorectal|O cancers|O prompted|O us|O to|O investigate|O the|O carcinogenetic|O mechanisms|O at|O the|O molecular|O level|O .|O 
A|O point|O mutation|O at|O codon|O 12|O of|O the|O K-ras|gene-rna gene|O was|O found|O ,|O while|O no|O alterations|O were|O noted|O in|O the|O p53|gene-rna gene|O ,|O whose|O mutations|O are|O frequent|O in|O colon|O cancers|O .|O 
The|O carcinogenetic|O mechanisms|O of|O the|O small|O -|O intestinal|O cancer|O we|O experienced|O may|O thus|O differ|O from|O those|O of|O colon|O cancers|O .|O 
Somatic|O mutations|O of|O the|O beta-catenin|gene-rna gene|O are|O frequent|O in|O mouse|O and|O human|O hepatocellular|O carcinomas|O .|O 
Hepatocellular|O carcinoma|O (|O HCC|O )|O is|O the|O major|O primary|O malignant|O tumor|O in|O the|O human|O liver|O ,|O but|O the|O molecular|O changes|O leading|O to|O liver|O cell|O transformation|O remain|O largely|O unknown|O .|O 
The|O Wnt|gene-generic -|O beta-catenin|gene-generic pathway|O is|O activated|O in|O colon|O cancers|O and|O some|O melanoma|O cell|O lines|O ,|O but|O has|O not|O yet|O been|O investigated|O in|O HCC|O .|O 
We|O have|O examined|O the|O status|O of|O the|O beta-catenin|gene-rna gene|O in|O different|O transgenic|O mouse|O lines|O of|O HCC|O obtained|O with|O the|O oncogenes|O c-myc|gene-rna or|O H-ras|gene-rna .|O 
Fifty|O percent|O of|O the|O hepatic|O tumors|O in|O these|O transgenic|O mice|O had|O activating|O somatic|O mutations|O within|O the|O beta-catenin|gene-rna gene|O similar|O to|O those|O found|O in|O colon|O cancers|O and|O melanomas|O .|O 
These|O alterations|O in|O the|O beta-catenin|gene-rna gene|O (|O point|O mutations|O or|O deletions|O )|O lead|O to|O a|O disregulation|O of|O the|O signaling|O function|O of|O beta-catenin|gene-generic and|O thus|O to|O carcinogenesis|O .|O 
We|O then|O analyzed|O human|O HCCs|O and|O found|O similar|O mutations|O in|O eight|O of|O 31|O (|O 26|O %|O )|O human|O liver|O tumors|O tested|O and|O in|O HepG2|O and|O HuH6|O hepatoma|O cells|O .|O 
The|O mutations|O led|O to|O the|O accumulation|O of|O beta-catenin|gene-protein in|O the|O nucleus|O .|O 
Thus|O alterations|O in|O the|O beta-catenin|gene-rna gene|O frequently|O are|O selected|O for|O during|O liver|O tumorigenesis|O and|O suggest|O that|O disregulation|O of|O the|O Wnt|gene-generic -|O beta-catenin|gene-generic pathway|O is|O a|O major|O event|O in|O the|O development|O of|O HCC|O in|O humans|O and|O mice|O .|O 
Significance|O of|O chromosomal|O alterations|O and|O mutations|O of|O the|O N-RAS|gene-rna and|O TP53|gene-rna genes|O in|O relation|O to|O leukemogenesis|O of|O acute|O myeloid|O leukemia|O .|O 
We|O examined|O chromosomes|O and|O mutations|O of|O the|O N-RAS|gene-rna and|O TP53|gene-rna genes|O in|O 73|O patients|O with|O acute|O myeloid|O leukemia|O (|O AML|O )|O .|O 
Twenty-six|O patients|O showed|O a|O reciprocal|O chromosomal|O translocation|O or|O an|O inversion|O ,|O and|O 34|O patients|O showed|O only|O unbalanced|O aberrations|O .|O 
Balanced|O aberrations|O were|O predominantly|O detected|O in|O the|O AML|O patients|O who|O did|O not|O have|O myelodysplasia|O ,|O preceding|O myelodysplastic|O syndrome|O ,|O and|O a|O history|O of|O chemotherapy|O or|O radiation|O therapy|O .|O 
In|O contrast|O ,|O unbalanced|O aberrations|O were|O more|O frequently|O seen|O in|O the|O patients|O with|O AML|O with|O trilineage|O myelodysplasia|O ,|O AML|O transformed|O from|O MDS|O ,|O and|O therapy|O -|O related|O AML|O .|O 
Twenty-two|O mutations|O of|O the|O N-RAS|gene-rna and|O TP53|gene-rna genes|O were|O detected|O ,|O and|O these|O mutations|O were|O frequently|O associated|O with|O unbalanced|O chromosomal|O aberrations|O .|O 
Furthermore|O ,|O the|O spectrum|O of|O mutations|O was|O suggestive|O of|O an|O exposure|O to|O alkylating|O chemicals|O .|O 
Low-frequency|O mutation|O of|O Ha-ras|gene-rna and|O Ki-ras|gene-rna oncogenes|O in|O transitional|O cell|O carcinoma|O of|O the|O bladder|O .|O 
BACKGROUND|O ,|O PATIENTS|O AND|O METHODS|O :|O 
The|O objective|O was|O to|O study|O the|O frequency|O of|O mutations|O of|O Ha-ras|gene-rna and|O Ki-ras|gene-rna oncogenes|O in|O bladder|O tumours|O .|O 
Transitional|O cell|O tumours|O of|O the|O bladder|O from|O 55|O patients|O were|O subjected|O to|O analyses|O of|O Ha-ras|gene-rna and|O Ki-ras|gene-rna oncogenes|O using|O a|O variety|O of|O techniques|O including|O sequencing|O to|O detect|O mutations|O .|O 
RESULTS|O :|O 
Two|O tumours|O (|O 4|O %|O )|O exhibited|O mutation|O of|O the|O Ki-ras|gene-rna oncogene|O ,|O both|O tumours|O were|O fast|O growing|O and|O invasive|O .|O 
We|O did|O not|O detect|O Ha-ras|gene-rna mutation|O in|O any|O of|O the|O samples|O .|O 
Nineteen|O tumours|O (|O 35|O %|O )|O with|O established|O invasion|O of|O the|O detrusor|O muscle|O ,|O did|O not|O reveal|O any|O mutation|O .|O 
CONCLUSION|O :|O 
Analyses|O of|O ras|gene-rna oncogenes|O seem|O to|O be|O of|O limited|O value|O for|O the|O biological|O assessment|O of|O transitional|O cell|O carcinomas|O .|O 
Frequent|O beta-catenin|gene-rna abnormalities|O in|O bone|O and|O soft-tissue|O tumors|O .|O 
We|O have|O screened|O mutations|O of|O the|O beta-catenin|gene-rna gene|O by|O using|O the|O polymerase|gene-protein chain|O reaction|O -|O single|O strand|O conformation|O polymorphism|O (|O PCR|O -|O SSCP|O )|O method|O in|O 62|O malignant|O bone|O and|O soft-tissue|O tumors|O ,|O including|O malignant|O fibrous|O histiocytomas|O (|O MFHs|O )|O ,|O osteosarcomas|O ,|O synovial|O sarcomas|O ,|O liposarcomas|O ,|O malignant|O schwannomas|O ,|O and|O other|O types|O of|O tumors|O ,|O as|O well|O as|O 11|O benign|O tumors|O .|O 
beta-Catenin|gene-rna -|O activating|O missense|O mutations|O were|O found|O in|O two|O malignant|O tumors|O .|O 
One|O found|O in|O MFH|O occurred|O at|O codon|O 45|O and|O caused|O an|O amino|O acid|O substitution|O from|O serine|O (|O one|O of|O the|O GSK3|gene-protein beta|gene-protein -|O targeted|O phosphorylation|O sites|O )|O to|O phenylalanine|O .|O 
The|O other|O ,|O detected|O in|O synovial|O sarcoma|O at|O codon|O 32|O ,|O resulted|O in|O an|O amino|O acid|O change|O from|O aspartic|O acid|O (|O located|O adjacent|O to|O the|O phosphorylation|O target|O ,|O serine|O ,|O encoded|O by|O codon|O 33|O )|O to|O tyrosine|O .|O 
Furthermore|O ,|O we|O found|O accumulation|O of|O beta-catenin|gene-protein by|O western|O -|O blotting|O analysis|O in|O 12|O of|O 19|O malignant|O tumors|O in|O which|O we|O found|O no|O mutation|O involving|O exon|O 3|O .|O 
Our|O results|O suggested|O the|O possible|O involvement|O of|O beta-catenin|gene-rna activation|O ,|O by|O beta-catenin|gene-rna gene|O mutation|O or|O alteration|O of|O other|O factor(s)|O ,|O in|O the|O formation|O and/or|O progression|O of|O various|O types|O of|O bone|O and|O soft-tissue|O tumors|O .|O 
K-ras|gene-rna point|O mutations|O in|O the|O supernatants|O of|O pancreatic|O juice|O and|O bile|O are|O reliable|O for|O diagnosis|O of|O pancreas|O and|O biliary|O tract|O carcinomas|O complementary|O to|O cytologic|O examination|O .|O 
In|O order|O to|O clarify|O whether|O DNA|O analysis|O for|O K-ras|gene-rna mutation|O can|O be|O used|O to|O diagnose|O cancers|O in|O supernatants|O of|O pancreatic|O juice|O and|O bile|O ,|O samples|O from|O 29|O cases|O of|O pancreatic|O ,|O biliary|O tract|O ,|O gastric|O ,|O and|O neuroendocrine|O carcinomas|O ,|O 1|O malignant|O lymphoma|O case|O ,|O 2|O cases|O of|O pancreatic|O adenoma|O ,|O 9|O cases|O of|O chronic|O pancreatitis|O and|O 21|O other|O non|O -|O cancer|O cases|O were|O examined|O .|O 
Polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O products|O for|O K-ras|gene-rna gene|O codons|O 2|O to|O 97|O of|O exons|O 1|O and|O 2|O were|O generated|O with|O 33|O /|O 33|O (|O 100|O %|O )|O pancreatic|O juice|O and|O 41|O /|O 41|O (|O 100|O %|O )|O bile|O samples|O .|O 
By|O the|O single|O strand|O conformation|O polymorphism|O (|O SSCP|O )|O method|O ,|O point|O mutations|O were|O detected|O in|O the|O pancreatic|O juice|O or|O bile|O supernatants|O of|O 13|O /|O 13|O (|O 100|O %|O )|O pancreas|O cancer|O cases|O ,|O 5|O /|O 14|O (|O 35.7|O %|O )|O biliary|O tract|O cancer|O cases|O ,|O 1|O /|O 2|O (|O 50.0|O %|O )|O pancreatic|O adenoma|O cases|O and|O 3|O /|O 9|O (|O 33.3|O %|O )|O chronic|O pancreatitis|O cases|O .|O 
Direct|O sequencing|O confirmed|O identical|O point|O mutations|O in|O the|O supernatants|O ,|O malignant|O cells|O of|O cytologic|O smears|O of|O pancreatic|O juice|O or|O bile|O and|O cancer|O tissues|O .|O 
The|O DNA|O analysis|O demonstrated|O the|O presence|O of|O K-ras|gene-rna point|O mutations|O in|O 3|O cases|O of|O pancreatic|O carcinomas|O with|O false-negative|O cytologic|O diagnoses|O .|O 
This|O novel|O method|O allows|O simultaneous|O testing|O for|O genetic|O abnormalities|O in|O supernatants|O of|O pancreatic|O juice|O and|O bile|O ,|O after|O removing|O cells|O for|O cytologic|O diagnosis|O and|O screening|O for|O pancreatic|O and|O biliary|O tract|O tumors|O .|O 
Lung|O cancer|O incidence|O is|O increasing|O in|O women|O with|O little|O or|O no|O tobacco|O exposure|O ,|O and|O the|O cause|O of|O this|O trend|O is|O not|O known|O .|O 
One|O possibility|O is|O increased|O sensitivity|O to|O environmental|O tobacco|O smoke|O in|O women|O nonsmokers|O diagnosed|O with|O lung|O cancer|O .|O 
To|O determine|O whether|O mutations|O associated|O with|O tobacco|O exposure|O are|O found|O in|O the|O lung|O tumors|O of|O women|O who|O are|O lifetime|O nonsmokers|O or|O occasional|O smokers|O ,|O we|O compared|O the|O p53|gene-rna and|O K-ras|gene-rna mutational|O spectra|O in|O lung|O carcinomas|O from|O 23|O female|O nonsmokers|O ,|O 2|O female|O occasional|O smokers|O (|O <|O 10|O pack|O -|O years|O )|O ,|O and|O 30|O female|O long-term|O smokers|O (|O 20|O -|O 100|O pack|O -|O years|O )|O .|O 
We|O also|O looked|O for|O p53|gene-rna and|O K-ras|gene-rna mutations|O in|O three|O carcinoid|O lung|O tumors|O ,|O two|O from|O female|O nonsmokers|O and|O one|O from|O a|O female|O occasional|O smoker|O .|O 
For|O the|O p53|gene-rna gene|O ,|O exons|O 4|O -|O 8|O were|O examined|O for|O mutations|O ;|O for|O the|O K-ras|gene-rna gene|O ,|O exon|O 1|O was|O examined|O .|O 
No|O mutations|O were|O found|O in|O the|O carcinoid|O tumors|O .|O 
In|O lung|O carcinomas|O ,|O p53|gene-rna mutations|O were|O identified|O in|O six|O (|O 26.1|O %|O )|O of|O the|O cases|O from|O lifetime|O nonsmokers|O and|O consisted|O of|O five|O transitions|O (|O including|O three|O C|O to|O T|O ,|O one|O G|O to|O A|O ,|O and|O one|O T|O to|O C|O )|O and|O one|O T|O to|O A|O transversion|O .|O 
In|O comparison|O ,|O p53|gene-rna mutations|O were|O identified|O in|O 10|O (|O 31.3|O %|O )|O of|O the|O 32|O lung|O carcinomas|O from|O short-term|O and|O long-term|O smokers|O and|O consisted|O of|O six|O transversions|O (|O four|O G|O to|O T|O ,|O one|O A|O to|O T|O ,|O and|O one|O G|O to|O C|O )|O ,|O one|O A|O to|O G|O transition|O ,|O one|O C|O to|O T|O transition|O ,|O and|O two|O deletions|O of|O one|O to|O four|O bp|O .|O 
Mutations|O in|O the|O p53|gene-rna gene|O found|O in|O nonsmokers|O also|O occurred|O in|O either|O different|O codons|O or|O different|O positions|O within|O a|O codon|O compared|O with|O those|O seen|O in|O long-term|O smokers|O .|O 
K-ras|gene-rna mutations|O in|O codon|O 12|O were|O identified|O in|O two|O lung|O carcinomas|O (|O 8.7|O %|O )|O from|O lifetime|O nonsmokers|O .|O 
The|O K-ras|gene-rna mutations|O found|O were|O a|O G|O to|O T|O transversion|O and|O a|O G|O to|O A|O transition|O .|O 
Eight|O (|O 25|O %|O )|O of|O the|O 32|O lung|O carcinomas|O from|O smokers|O contained|O K-ras|gene-rna mutations|O in|O codons|O 12|O and|O 13|O (|O four|O G|O to|O T|O transversions|O and|O four|O G|O to|O A|O transitions|O )|O .|O 
In|O addition|O ,|O six|O silent|O mutations|O that|O are|O most|O likely|O polymorphisms|O were|O found|O in|O both|O smokers|O and|O nonsmokers|O .|O 
These|O results|O confirm|O that|O K-ras|gene-rna mutations|O are|O more|O frequent|O in|O smokers|O than|O in|O nonsmokers|O ,|O but|O that|O the|O same|O type|O of|O mutation|O in|O the|O K-ras|gene-rna gene|O is|O found|O in|O both|O groups|O .|O 
In|O contrast|O ,|O although|O the|O frequency|O of|O mutation|O in|O the|O p53|gene-rna gene|O was|O similar|O in|O lifetime|O nonsmokers|O compared|O with|O long-term|O smokers|O ,|O the|O types|O and|O spectra|O of|O mutation|O are|O significantly|O different|O .|O 
Two|O of|O the|O C|O to|O T|O transitions|O found|O in|O nonsmokers|O ,|O but|O none|O of|O those|O found|O in|O smokers|O ,|O occur|O at|O the|O C|O of|O a|O CpG|O site|O .|O 
These|O results|O suggest|O the|O mutagen(s)|O and/or|O mechanisms|O of|O p53|gene-rna mutations|O in|O women|O nonsmokers|O are|O different|O from|O those|O responsible|O for|O p53|gene-rna mutations|O in|O women|O smokers|O ,|O which|O are|O probably|O largely|O induced|O by|O tobacco|O mutagens|O .|O 
Molecular|O screening|O of|O patients|O with|O long|O standing|O extensive|O ulcerative|O colitis|O :|O detection|O of|O p53|gene-rna and|O Ki-ras|gene-rna mutations|O by|O single|O strand|O conformation|O polymorphism|O analysis|O and|O differential|O hybridisation|O in|O colonic|O lavage|O fluid|O .|O 
BACKGROUND|O :|O 
In|O patients|O with|O long|O standing|O ulcerative|O colitis|O at|O risk|O of|O developing|O malignancy|O ,|O mutations|O of|O the|O p53|gene-rna and|O Ki-ras|gene-rna gene|O were|O investigated|O in|O lavage|O solution|O obtained|O at|O surveillance|O colonoscopy|O .|O 
METHODS|O :|O 
DNA|O was|O isolated|O from|O 31|O consecutive|O patients|O with|O total|O or|O subtotal|O ulcerative|O colitis|O and|O a|O disease|O duration|O of|O between|O seven|O and|O 26|O years|O .|O 
Twenty|O seven|O control|O patients|O showed|O no|O macroscopic|O or|O microscopic|O inflammation|O on|O colonoscopy|O .|O 
Exons|O 5|O -|O 8|O of|O the|O p53|gene-rna gene|O and|O exon|O 1|O of|O the|O Ki-ras|gene-rna gene|O were|O amplified|O by|O polymerase|gene-protein chain|O reaction|O .|O 
Mutations|O of|O the|O p53|gene-rna gene|O were|O detected|O by|O single|O strand|O conformation|O polymorphism|O analysis|O .|O 
Point|O mutations|O of|O the|O Ki-ras|gene-rna gene|O were|O hybridised|O on|O dot|O blots|O with|O oligonucleotides|O marked|O with|O digoxigenin|O .|O 
RESULTS|O :|O 
In|O all|O cases|O of|O ulcerative|O colitis|O and|O in|O all|O of|O the|O 27|O control|O patients|O ,|O wild|O type|O p53|gene-rna and|O wild|O type|O Ki-ras|gene-rna could|O be|O detected|O .|O 
In|O four|O patients|O with|O ulcerative|O colitis|O ,|O a|O mutation|O in|O exon|O 5|O to|O 7|O of|O the|O p53|gene-rna gene|O was|O found|O ,|O and|O two|O patients|O had|O a|O mutation|O of|O the|O Ki-ras|gene-rna gene|O (|O Gly|O to|O Asp|O -|O 12|O ,|O Gly|O to|O Val|O -|O 12|O )|O .|O 
None|O of|O these|O patients|O had|O dysplasia|O in|O serial|O biopsy|O specimens|O ,|O and|O all|O but|O one|O had|O had|O the|O disease|O for|O more|O than|O 10|O years|O .|O 
One|O control|O patient|O had|O a|O mutation|O .|O 
CONCLUSIONS|O :|O 
Mutations|O were|O more|O frequent|O in|O patients|O with|O long|O standing|O ulcerative|O colitis|O (|O 19|O %|O )|O than|O in|O control|O patients|O (|O 3|O %|O ,|O p|O =|O 0.07|O )|O .|O 
The|O technique|O may|O be|O useful|O for|O screening|O for|O early|O malignancy|O in|O ulcerative|O colitis|O .|O 
Genetic|O epidemiology|O of|O mutated|O K-ras|gene-rna proto|O -|O oncogene|O ,|O altered|O suppressor|gene-rna genes|gene-rna ,|O and|O microsatellite|O instability|O in|O colorectal|O adenomas|O .|O 
BACKGROUND|O :|O 
The|O genetic|O epidemiology|O of|O colorectal|O adenomas|O has|O not|O been|O studied|O prospectively|O in|O colonoscopy|O patients|O without|O cancer|O .|O 
AIMS|O :|O 
To|O study|O genetic|O alterations|O in|O colorectal|O adenomas|O and|O correlate|O these|O with|O patient|O demographics|O and|O adenoma|O characteristics|O .|O 
METHODS|O :|O 
Mutations|O and|O allelic|O deletions|O in|O 201|O adenomas|O from|O 60|O patients|O were|O compared|O with|O demographic|O features|O ,|O adenoma|O characteristics|O ,|O and|O family|O history|O .|O 
RESULTS|O :|O 
The|O most|O common|O alteration|O was|O K-ras|gene-rna proto|O -|O oncogene|O mutation|O ,|O present|O in|O 35|O %|O of|O adenomas|O and|O 65|O %|O of|O patients|O .|O 
Patients|O 65|O years|O of|O age|O and|O older|O had|O a|O decreased|O probability|O of|O K-ras|gene-rna mutations|O (|O 26|O %|O versus|O 45|O %|O )|O .|O 
Overexpression|O of|O p53|gene-rna gene|O product|O was|O present|O in|O only|O 6|O %|O of|O adenomas|O but|O was|O more|O frequent|O in|O villous|O or|O tubulovillous|O adenomas|O (|O 19|O %|O versus|O 3|O %|O )|O .|O 
Allelic|O loss|O of|O chromosome|O 18q|O was|O present|O in|O only|O 2|O %|O of|O adenomas|O and|O was|O significantly|O less|O frequent|O than|O p53|gene-rna overexpression|O .|O 
DNA|O replication|O errors|O (|O RER|O )|O were|O present|O in|O 7|O %|O of|O adenomas|O and|O 15|O %|O of|O patients|O ,|O including|O multiple|O adenomas|O in|O four|O patients|O (|O two|O with|O hereditary|O non|O -|O polyposis|O colorectal|O cancer|O syndrome|O )|O .|O 
Only|O 36|O %|O of|O RER|O positive|O adenomas|O had|O alteration|O of|O BAT-26|O alleles|O ,|O none|O had|O alteration|O of|O BAT-25|gene-rna ,|O and|O only|O one|O (|O 8|O %|O )|O had|O mutation|O in|O the|O transforming|gene-rna growth|gene-rna factor|gene-rna beta|gene-rna type|gene-rna II|gene-rna receptor|gene-rna gene|O .|O 
RER|O positive|O adenomas|O were|O more|O likely|O to|O have|O a|O K-ras|gene-rna mutation|O .|O 
In|O patients|O with|O multiple|O adenomas|O ,|O there|O was|O concordance|O of|O p53|gene-rna overexpression|O and|O RER|O but|O not|O of|O K-ras|gene-rna mutations|O .|O 
CONCLUSIONS|O :|O 
Genetic|O progression|O in|O colorectal|O adenomas|O is|O heterogeneous|O ,|O involving|O factors|O related|O to|O patient|O age|O and|O the|O presence|O of|O RER|O for|O the|O occurrence|O of|O ras|gene-rna mutations|O ,|O but|O different|O intraindividual|O characteristics|O for|O the|O occurrence|O of|O p53|gene-rna alterations|O and|O RER|O .|O 
Frequent|O mutations|O in|O the|O beta-catenin|gene-rna gene|O in|O desmoid|O tumors|O from|O patients|O without|O familial|O adenomatous|O polyposis|O .|O 
Mutations|O in|O the|O APC|gene-rna gene|O contribute|O to|O development|O of|O sporadic|O desmoid|O tumors|O as|O well|O as|O to|O the|O hereditary|O tumors|O that|O usually|O accompany|O familial|O adenomatous|O polyposis|O (|O FAP|O )|O .|O 
Adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|O APC|gene-rna )|O mutations|O cause|O an|O intracellular|O accumulation|O of|O beta-catenin|gene-protein that|O results|O in|O abnormal|O signaling|O in|O the|O wnt|gene-generic /|O wingless|gene-generic pathway|O .|O 
Mutations|O of|O the|O beta-catenin|gene-rna gene|O itself|O have|O also|O been|O noted|O in|O several|O types|O of|O tumors|O .|O 
In|O this|O study|O we|O screened|O the|O beta-catenin|gene-rna gene|O in|O 13|O sporadic|O desmoid|O tumors|O for|O alterations|O in|O exon|O 3|O ,|O which|O encodes|O several|O serine|O /|O threonine|O residues|O that|O are|O targets|O for|O phosphorylation|O by|O GSK-3beta|gene-protein .|O 
Somatic|O substitutions|O at|O codons|O 41|O (|O threonine|O )|O and|O 45|O (|O serine|O )|O were|O identified|O in|O seven|O independent|O tumors|O ,|O respectively|O .|O 
Although|O no|O APC|gene-rna mutations|O were|O detected|O among|O the|O remaining|O six|O tumors|O ,|O we|O found|O accumulation|O of|O beta-catenin|gene-protein by|O Western|O blotting|O analysis|O in|O one|O such|O tumor|O for|O which|O frozen|O tissues|O were|O available|O .|O 
Our|O results|O have|O suggested|O that|O possible|O involvement|O of|O beta-catenin|gene-rna activation|O by|O beta-catenin|gene-rna gene|O mutation|O or|O alteration|O of|O other|O factor(s)|O can|O contribute|O to|O desmoid|O tumorigenesis|O .|O 
H-ras|gene-rna and|O K-ras|gene-rna mutations|O in|O soft|O tissue|O sarcoma|O :|O comparative|O studies|O of|O sarcomas|O from|O Korean|O and|O American|O patients|O .|O 
BACKGROUND|O :|O 
The|O authors|O '|O recent|O investigation|O of|O Korean|O patients|O with|O sarcoma|O has|O suggested|O that|O ras|gene-rna gene|O activation|O may|O play|O a|O role|O in|O oncogenesis|O .|O 
The|O authors|O attempted|O to|O extend|O the|O mutation|O analysis|O to|O sarcomas|O in|O American|O patients|O to|O determine|O whether|O there|O were|O racial|O or|O geographic|O factors|O relevant|O to|O the|O initiation|O or|O progression|O of|O sarcoma|O .|O 
METHODS|O :|O 
H-ras|gene-rna and|O K-ras|gene-rna genes|O were|O examined|O in|O sarcomas|O obtained|O from|O patients|O in|O the|O midwestern|O U.|O S.|O using|O the|O polymerase|gene-protein chain|O reaction|O technique|O and|O direct|O automated|O sequencing|O analysis|O .|O 
Tumors|O studied|O included|O 29|O malignant|O fibrous|O histiocytomas|O ,|O 7|O liposarcomas|O ,|O 5|O rhabdomyosarcomas|O ,|O and|O 9|O leiomyosarcomas|O .|O 
RESULTS|O :|O 
Of|O the|O 50|O sarcomas|O evaluated|O ,|O only|O 1|O (|O 2|O %|O )|O definable|O mutation|O was|O found|O ;|O a|O GGC|O to|O AGC|O transition|O at|O codon|O 12|O of|O H-ras|gene-rna was|O found|O in|O a|O rhabdomyosarcoma|O .|O 
None|O of|O the|O patients|O had|O a|O K-ras|gene-rna mutation|O .|O 
The|O rates|O of|O incidence|O of|O ras|gene-rna point|O mutations|O in|O these|O samples|O were|O much|O lower|O (|O H-ras|gene-rna :|O 2|O %|O ;|O 95|O %|O confidence|O interval|O [|O 95|O %|O CI|O ]|O ,|O 0|O -|O 11.5|O %|O and|O K-ras|gene-rna :|O 0|O %|O )|O than|O described|O for|O both|gene-rna genes|gene-rna in|O Korean|O studies|O (|O H-ras|gene-rna :|O 16|O %|O ;|O 95|O %|O CI|O ,|O 5.2|O -|O 26.8|O %|O and|O K-ras|gene-rna :|O 44|O %|O ;|O 95|O %|O CI|O ,|O 29.5|O -|O 58.5|O %|O )|O .|O 
CONCLUSIONS|O :|O 
Although|O the|O reason|O for|O this|O discrepancy|O is|O not|O clear|O ,|O there|O were|O no|O major|O differences|O found|O in|O histology|O or|O clinical|O stages|O .|O 
Based|O on|O this|O study|O of|O 50|O sarcoma|O samples|O from|O American|O patients|O and|O the|O authors|O '|O previous|O study|O of|O 45|O Korean|O tumor|O samples|O ,|O the|O authors|O conclude|O that|O differing|O genetic|O and/or|O environmental|O mechanisms|O can|O affect|O sarcoma|O development|O or|O progression|O .|O 
Mutation|O of|O the|O H-ras|gene-rna and|O K-ras|gene-rna genes|O appears|O to|O be|O uncommon|O in|O sarcomas|O occurring|O in|O American|O patients|O ,|O suggesting|O that|O the|O activation|O by|O point|O mutations|O of|O the|O H-ras|gene-rna and|O K-ras|gene-rna genes|O does|O not|O play|O a|O significant|O role|O in|O the|O pathogenesis|O or|O progression|O of|O sarcoma|O in|O these|O patients|O .|O 
Beta-catenin|gene-protein accumulation|O and|O mutation|O of|O the|O CTNNB1|gene-rna gene|O in|O hepatoblastoma|O .|O 
Hepatoblastoma|O is|O a|O rare|O malignant|O tumor|O of|O the|O liver|O that|O occurs|O in|O children|O at|O an|O average|O age|O of|O 2|O to|O 3|O years|O .|O 
Epidemiologic|O studies|O have|O shown|O an|O increased|O frequency|O of|O this|O tumor|O type|O in|O families|O affected|O by|O adenomatous|O polyposis|O coli|O .|O 
In|O addition|O to|O the|O epidemiologic|O data|O ,|O molecular|O genetic|O studies|O suggest|O that|O inactivation|O of|O the|O APC|gene-rna tumor|gene-rna suppressor|gene-rna may|O be|O involved|O in|O hepatoblastoma|O tumorigenesis|O .|O 
A|O major|O function|O of|O APC|gene-rna is|O the|O downregulation|O of|O beta-catenin|gene-protein ,|O a|O transcription|O -|O activating|O protein|O with|O oncogenic|O potential|O .|O 
In|O an|O ongoing|O immunohistochemical|O study|O of|O beta-catenin|gene-rna expression|O in|O sporadic|O cases|O of|O tumor|O types|O that|O are|O associated|O with|O adenomatous|O polyposis|O coli|O ,|O we|O observed|O increased|O beta-catenin|gene-protein levels|O in|O the|O cytoplasm|O and|O in|O the|O nuclei|O of|O three|O investigated|O hepatoblastomas|O .|O 
Sequencing|O of|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O (|O CTNNB1|gene-rna )|O revealed|O an|O activating|O mutation|O in|O one|O of|O the|O tumor|O samples|O .|O 
Our|O data|O indicate|O for|O the|O first|O time|O that|O beta-catenin|gene-protein accumulation|O may|O play|O a|O role|O in|O the|O development|O of|O hepatoblastoma|O and|O that|O activating|O mutations|O of|O the|O beta-catenin|gene-rna gene|O may|O substitute|O biallelic|O APC|gene-rna inactivation|O in|O this|O tumor|O type|O .|O 
Beta-catenin|gene-rna mutations|O are|O specific|O for|O colorectal|O carcinomas|O with|O microsatellite|O instability|O but|O occur|O in|O endometrial|O carcinomas|O irrespective|O of|O mutator|O pathway|O .|O 
Some|O colorectal|O tumors|O with|O wild-type|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna gene|O have|O activating|O mutations|O in|O beta-catenin|gene-rna (|O encoded|O by|O CTNNB1|gene-rna )|O that|O result|O in|O decreased|O phosphorylation|O by|O GSK-3beta|gene-protein and|O increased|O signaling|O through|O the|O Tcf|gene-protein /|O Lef|gene-protein transcription|O factors|O .|O 
To|O investigate|O the|O relationship|O between|O CTNNB1|gene-rna mutations|O and|O underlying|O pathways|O of|O genomic|O instability|O ,|O we|O examined|O 80|O colorectal|O cancers|O stratified|O by|O the|O presence|O or|O absence|O of|O microsatellite|O instability|O (|O MSI|O )|O .|O 
CTNNB1|gene-rna mutations|O were|O identified|O in|O 13|O (|O 25|O %|O )|O of|O 53|O cancers|O with|O high|O frequency|O MSI|O (|O MSI-H|O )|O ,|O including|O 12|O point|O mutations|O at|O exon|O 3|O phosphorylation|O sites|O (|O codons|O 41|O and|O 45|O )|O and|O one|O deletion|O of|O the|O entire|O exon|O 3|O degradation|O box|O .|O 
No|O CTNNB1|gene-rna mutations|O were|O identified|O in|O 27|O microsatellite|O stable|O or|O low|O frequency|O MSI|O (|O MSI-L|O )|O colorectal|O cancers|O (|O P|O <|O 0.01|O )|O .|O 
In|O contrast|O ,|O CTNNB1|gene-rna mutations|O were|O identified|O in|O 3|O of|O 9|O (|O 33|O %|O )|O MSI-H|O and|O 10|O of|O 20|O (|O 50|O %|O )|O MSS|O /|O MSI-L|O endometrial|O carcinomas|O ,|O suggesting|O a|O more|O generalized|O involvement|O in|O these|O tumors|O .|O 
Only|O six|O (|O 46|O %|O )|O of|O the|O endometrial|O carcinoma|O CTNNB1|gene-rna mutations|O occurred|O at|O residues|O directly|O phosphorylated|O by|O GSK-3beta|gene-protein ,|O and|O only|O one|O of|O these|O was|O at|O either|O codon|O 41|O or|O 45|O .|O 
All|O point|O mutations|O in|O MSI-H|O cancers|O were|O transitions|O ,|O whereas|O 64|O %|O of|O those|O in|O MSS|O /|O MSI-L|O cancers|O were|O transversions|O (|O P|O <|O 0.01|O )|O .|O 
The|O molecular|O mechanisms|O involved|O in|O the|O generation|O of|O epithelial|O ovarian|O cancers|O are|O poorly|O understood|O ,|O but|O evidence|O suggests|O that|O the|O different|O histological|O subtypes|O may|O arise|O from|O independent|O tumorigenic|O events|O .|O 
beta-Catenin|gene-rna is|O emerging|O as|O an|O important|O oncogene|O in|O the|O transformation|O of|O a|O number|O of|O epithelial|O cancers|O ,|O and|O mutations|O have|O been|O reported|O in|O a|O small|O study|O of|O endometrioid|O ovarian|O adenocarcinomas|O .|O 
Mutations|O in|O the|O NH(2)|O -|O regulatory|O domain|O of|O beta-catenin|gene-rna stabilise|O the|O cytoplasmic|O levels|O of|O this|gene-protein protein|gene-protein ,|O which|O promotes|O up|O -|O regulation|O of|O the|O beta-catenin|gene-rna -|O T-cell|gene-protein factor|gene-protein -|O lymphoid|gene-protein enhancer|gene-protein factor|gene-protein transcriptional|O complex|O .|O 
We|O report|O here|O beta-catenin|gene-rna (|O CTNNB1|gene-rna )|O exon|O 3|O mutation|O analysis|O in|O 149|O epithelial|O ovarian|O carcinomas|O .|O 
This|O revealed|O 10|O /|O 63|O (|O 16|O %|O )|O endometrioid|O ovarian|O tumours|O with|O activating|O mutations|O of|O the|O beta-catenin|gene-rna gene|O .|O 
All|O mutations|O were|O missense|O changes|O within|O the|O GSK3beta|gene-protein consensus|O site|O ,|O affecting|O serine|O residues|O at|O codons|O 33|O and|O 37|O and|O glycine|O at|O codon|O 34|O .|O Immuno|O -|O histochemical|O analysis|O identified|O cytoplasmic|O stabilisation|O and|O nuclear|O translocation|O in|O those|O endometrioid|O tumours|O with|O mutations|O .|O 
This|O phenotypic|O change|O was|O also|O identified|O in|O 3|O other|O endometrioid|O tumours|O that|O did|O not|O have|O somatic|O mutations|O within|O exon|O 3|O of|O CTNNB1|gene-rna .|O Stabilisation|O of|O the|O free|O ,|O monomeric|O pool|O of|O beta-catenin|gene-protein and|O the|O probable|O resulting|O constitutive|O activation|O of|O its|O Tcf|gene-protein -|O associated|O transcriptional|O complex|O appears|O to|O be|O a|O specific|O oncogenic|O event|O in|O endometrioid|O ovarian|O adenocarcinoma|O .|O 
BACKGROUND|O /|O AIMS|O 
:|O Partial|O gastrectomy|O is|O a|O well|O -|O established|O pre|O -|O malignant|O condition|O .|O 
It|O is|O postulated|O that|O in|O the|O gastric|O stump|O an|O accelerated|O neoplastic|O process|O takes|O place|O ,|O similar|O to|O that|O of|O (|O intestinal|O type|O )|O adenocarcinoma|O from|O the|O non|O -|O operated|O stomach|O .|O 
K-ras|gene-rna codon|O 12|O mutation|O is|O one|O of|O the|O most|O frequent|O oncogenic|O alterations|O in|O human|O solid|O neoplasms|O .|O 
It|O is|O rare|O in|O conventional|O gastric|O carcinoma|O and|O has|O not|O been|O studied|O in|O gastric|O stump|O carcinoma|O .|O 
The|O aim|O of|O this|O study|O was|O to|O compare|O the|O prevalence|O of|O K-ras|gene-rna codon|O 12|O point|O mutations|O in|O gastric|O stump|O carcinomas|O with|O those|O in|O conventional|O carcinomas|O from|O the|O non|O -|O operated|O stomach|O .|O 
METHODOLOGY|O :|O Twenty-four|O gastric|O stump|O carcinomas|O were|O compared|O with|O 26|O conventional|O gastric|O carcinomas|O .|O 
Stage|O ,|O histology|O ,|O and|O demographics|O were|O comparable|O in|O both|O groups|O .|O 
Mutations|O in|O codon|O 12|O of|O the|O K-ras|gene-rna gene|O were|O examined|O with|O a|O polymerase|O chain|O reaction|O (|O PCR|O )|O -|O based|O method|O and|O subsequent|O dot|O blot|O hybridization|O with|O mutation|O -|O specific|O probes|O .|O 
The|O results|O of|O Helicobacter|O pylori|O infection|O ,|O Epstein|O -|O Barr|O virus|O infection|O and|O p53|gene-protein immunohistochemistry|O were|O partially|O known|O from|O a|O previous|O study|O .|O 
RESULTS|O :|O In|O one|O of|O the|O gastric|O stump|O carcinomas|O as|O well|O as|O in|O one|O of|O the|O conventional|O gastric|O carcinomas|O a|O K-ras|gene-rna codon|O 12|O point|O mutation|O was|O found|O .|O 
p53|gene-protein immunohistochemistry|O results|O were|O comparable|O in|O both|O groups|O .|O 
Interestingly|O ,|O Helicobacter|O pylori|O infection|O rate|O and|O Epstein|O -|O Barr|O virus|O in|O situ|O hybridization|O for|O EBER1|O ,|O as|O previously|O studied|O ,|O appeared|O were|O significantly|O different|O in|O the|O two|O groups|O .|O 
CONCLUSIONS|O :|O K-ras|gene-rna codon|O 12|O point|O mutations|O are|O rare|O in|O both|O gastric|O stump|O carcinomas|O and|O conventional|O gastric|O carcinomas|O .|O 
This|O supports|O the|O postulated|O hypothesis|O that|O the|O pathways|O of|O carcinogenesis|O in|O both|O gastric|O stump|O carcinoma|O and|O conventional|O gastric|O carcinoma|O share|O common|O features|O .|O 
However|O ,|O these|O groups|O differ|O in|O infection|O rate|O of|O Helicobacter|O pylori|O and|O of|O Epstein|O -|O Barr|O virus|O ,|O which|O suggests|O that|O some|O neoplastic|O stimuli|O differ|O as|O well|O .|O 
Activation|O of|O beta-catenin|gene-rna -|O mediated|O transcription|O is|O the|O nuclear|O end|O point|O of|O organ|O -|O specific|O Wnt|gene-protein signaling|O .|O In|O the|O developing|O kidney|O ,|O Wnt-4|gene-protein ,|O a|O secreted|O glycoprotein|O ,|O acts|O as|O an|O autoinducer|O of|O the|O mesenchymal|O to|O epithelial|O transition|O that|O underlies|O normal|O nephron|O development|O .|O 
Dysregulation|O of|O this|O epithelial|O transformation|O process|O may|O lead|O to|O Wilms|O '|O tumors|O (|O WTs|O )|O .|O 
In|O this|O study|O ,|O we|O investigated|O the|O potential|O role|O of|O the|O beta-catenin|gene-rna proto|O -|O oncogene|O ,|O a|O candidate|O downstream|O target|O molecule|O of|O Wnt-4|gene-protein signaling|O ,|O in|O the|O development|O of|O WTs|O .|O 
In|O 6|O of|O 40|O tumors|O (|O 15|O %|O )|O ,|O mutation|O analysis|O revealed|O heterozygous|O missense|O mutations|O or|O small|O deletions|O that|O result|O in|O the|O loss|O of|O important|O regulatory|O phosphorylation|O sites|O within|O the|O beta-catenin|gene-protein protein|O .|O 
These|O findings|O indicate|O that|O activating|O beta-catenin|gene-rna mutations|O may|O play|O a|O significant|O role|O in|O the|O development|O of|O WTs|O and|O establish|O a|O direct|O link|O between|O Wilms|O '|O tumorigenesis|O and|O the|O Wnt|gene-protein signal|O transduction|O pathway|O governing|O normal|O kidney|O development|O .|O 
OBJECTIVE|O :|O 
Mutations|O at|O codons|O 12|O ,|O 13|O or|O 61|O of|O ras|gene-rna which|O result|O in|O constitutive|O activation|O occur|O frequently|O in|O human|O malignancies|O .|O 
There|O have|O been|O varied|O reports|O on|O their|O prevalence|O and|O hence|O their|O likely|O significance|O in|O the|O pathogenesis|O of|O primary|O thyroid|O neoplasia|O .|O 
To|O address|O this|O ,|O we|O have|O examined|O a|O large|O series|O of|O benign|O and|O malignant|O thyroid|O tumours|O for|O ras|gene-rna mutations|O .|O 
DESIGN|O :|O 
Genomic|O DNA|O was|O analysed|O for|O the|O presence|O of|O mutations|O at|O codons|O 12|O ,|O 13|O and|O 61|O of|O H-ras|gene-rna ,|O K-ras|gene-rna and|O N-ras|gene-rna by|O allele|O -|O specific|O oligonucleotide|O hybridization|O .|O 
Direct|O DNA|O sequencing|O was|O used|O to|O confirm|O the|O mutations|O .|O 
PATIENTS|O :|O A|O total|O of|O 90|O samples|O with|O benign|O (|O 66|O )|O and|O malignant|O (|O 24|O )|O thyroid|O disease|O were|O investigated|O .|O 
RESULTS|O :|O A|O total|O of|O 14|O /|O 90|O (|O 15.5|O %|O )|O samples|O had|O a|O ras|gene-rna mutation|O .|O 
All|O mutations|O were|O at|O codon|O 61|O of|O either|O N-ras|gene-rna or|O K-ras|gene-rna .|O 
The|O positive|O cases|O were|O 1|O /|O 25|O (|O 4|O %|O )|O nodular|O goitre|O ,|O 7|O /|O 38|O (|O 18|O %|O )|O follicular|O adenoma|O ,|O 4|O /|O 9|O (|O 44|O %|O )|O follicular|O carcinoma|O ,|O 1|O /|O 1|O anaplastic|O carcinoma|O ,|O 1|O /|O 1|O follicular|O variant|O of|O papillary|O carcinoma|O ,|O and|O 1|O metastatic|O follicular|O carcinoma|O in|O which|O the|O primary|O tumour|O had|O the|O same|O mutation|O .|O 
CONCLUSIONS|O :|O 
Our|O data|O demonstrate|O a|O relatively|O low|O overall|O prevalence|O of|O ras|gene-rna mutations|O in|O thyroid|O neoplasia|O ,|O with|O a|O predominance|O in|O follicular|O neoplasms|O .|O 
Their|O presence|O in|O follicular|O adenomas|O suggests|O that|O they|O may|O have|O an|O early|O aetiological|O role|O in|O the|O development|O of|O thyroid|O neoplasia|O .|O 
Analysis|O of|O K-ras|gene-rna ,|O N-ras|gene-rna ,|O H-ras|gene-rna ,|O and|O p53|gene-rna in|O lung|O neuroendocrine|O neoplasms|O .|O 
This|O study|O screened|O 11|O samples|O of|O typical|O carcinoid|O (|O TC|O )|O ,|O 4|O samples|O of|O atypical|O carcinoid|O (|O AC|O )|O ,|O 1|O sample|O of|O large|O cell|O neuroendocrine|O carcinoma|O (|O LCNEC|O )|O ,|O and|O four|O metastases|O for|O point|O mutations|O in|O exons|O 5|O to|O 8|O of|O the|O p53|gene-rna gene|O ,|O and|O exons|O 1|O and|O 2|O of|O the|O K-ras|gene-rna .|O 
H-ras|gene-rna ,|O and|O N-ras|gene-rna genes|O using|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O -|O single-strand|O conformation|O polymorphism|O (|O SSCP|O )|O and|O direct|O sequencing|O and|O by|O immunohistochemistry|O for|O p53|gene-rna .|O 
Exon|O 1|O of|O K-ras|gene-rna was|O mutated|O in|O two|O samples|O of|O low-grade|O AC|O and|O a|O metastasis|O from|O one|O of|O these|O tumors|O (|O GAT12|O and|O AGT12|O ,|O respectively|O )|O .|O 
No|O mutations|O in|O N-ras|gene-rna or|O H-ras|gene-rna were|O found|O .|O 
Mutations|O in|O exons|O 5|O and|O 8|O of|O the|O p53|gene-rna gene|O were|O identified|O in|O a|O high-grade|O AC|O and|O a|O LCNEC|O .|O 
Positive|O immunostaining|O for|O p53|gene-rna was|O present|O in|O three|O samples|O ,|O with|O only|O one|O genotypic|O mutation|O shown|O (|O LCNEC|O )|O .|O 
In|O conclusion|O ,|O point|O mutations|O of|O the|O p53|O gene|O were|O infrequent|O in|O these|O pulmonary|O neuroendocrine|O tumors|O ,|O did|O not|O correlate|O in|O all|O samples|O with|O immunostaining|O ,|O and|O were|O associated|O with|O the|O higher-grade|O tumors|O .|O 
Second|O ,|O the|O presence|O of|O K-ras|gene-rna mutations|O seems|O to|O be|O associated|O with|O the|O higher-grade|O carcinomas|O .|O 
Third|O ,|O N-ras|gene-rna and|O H-ras|gene-rna mutations|O were|O not|O found|O with|O these|O pulmonary|O neuroendocrine|O tumors|O .|O 
Nuclear|O accumulation|O of|O mutated|O beta-catenin|gene-generic in|O hepatocellular|O carcinoma|O is|O associated|O with|O increased|O cell|O proliferation|O .|O 
Inappropriate|O activation|O of|O the|O Wnt|gene-generic pathway|O resulting|O from|O beta-catenin|gene-rna gene|O alterations|O has|O recently|O been|O implicated|O in|O the|O development|O of|O hepatocellular|O carcinoma|O (|O HCC|O )|O .|O 
To|O explore|O the|O in|O vivo|O effects|O of|O mutated|O beta-catenin|gene-rna ,|O HCC|O specimens|O from|O 32|O patients|O carrying|O one|O or|O several|O tumors|O were|O screened|O for|O somatic|O mutations|O in|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O ,|O and|O the|O expression|O and|O subcellular|O localization|O of|O beta-catenin|gene-protein was|O studied|O by|O immunohistochemistry|O .|O 
Missense|O mutations|O or|O interstitial|O deletions|O in|O beta-catenin|gene-rna exon|O 3|O were|O detected|O in|O 12|O of|O 35|O (|O 34|O %|O )|O HCC|O samples|O .|O 
After|O immunostaining|O ,|O most|O tumors|O exhibited|O increased|O membranous|O and/or|O cytoplasmic|O expression|O of|O beta-catenin|gene-protein compared|O with|O adjacent|O nontumoral|O liver|O .|O 
Strong|O nuclear|O accumulation|O of|O beta-catenin|gene-protein was|O observed|O either|O focally|O or|O uniformly|O in|O 15|O of|O 35|O (|O 43|O %|O )|O tumor|O specimens|O ,|O but|O not|O in|O cirrhotic|O nodules|O or|O dysplastic|O liver|O cells|O in|O adjacent|O liver|O .|O 
Aberrant|O nuclear|O expression|O of|O beta-catenin|gene-protein was|O significantly|O associated|O with|O the|O presence|O of|O mutations|O in|O the|O beta-catenin|gene-rna gene|O (|O P|O <|O 0.005|O )|O .|O 
Moreover|O ,|O nuclear|O beta-catenin|gene-protein staining|O correlated|O significantly|O with|O increased|O Ki-67|O proliferative|O index|O in|O tumor|O (|O P|O <|O 0.001|O )|O and|O seemed|O to|O be|O associated|O with|O poor|O outcome|O in|O patients|O with|O HCC|O .|O 
In|O conclusion|O ,|O our|O data|O indicate|O that|O activation|O of|O the|O Wnt|gene-generic /|O beta-catenin|gene-generic pathway|O in|O HCC|O results|O mainly|O from|O somatic|O mutations|O in|O the|O beta-catenin|gene-rna gene|O and|O may|O promote|O tumor|O progression|O by|O stimulating|O tumor|O cell|O proliferation|O .|O 
Molecular|O detection|O of|O neoplastic|O cells|O in|O lymph|O nodes|O of|O metastatic|O colorectal|O cancer|O patients|O predicts|O recurrence|O .|O 
Disseminated|O disease|O ,|O especially|O to|O the|O liver|O ,|O constitutes|O the|O major|O risk|O of|O recurrence|O for|O colorectal|O cancer|O patients|O .|O 
However|O ,|O successful|O resection|O can|O still|O be|O achieved|O in|O 25|O -|O 35|O %|O of|O colorectal|O cancer|O patients|O with|O isolated|O metastases|O .|O 
To|O evaluate|O the|O clinical|O value|O of|O occult|O micrometastatic|O disease|O detection|O in|O lymph|O nodes|O ,|O we|O tested|O genetic|O (|O K-ras|gene-rna and|O p53|gene-rna gene|O mutations|O )|O and|O epigenetic|O (|O p16|gene-rna promoter|O hypermethylation|O )|O molecular|O markers|O in|O the|O perihepatic|O lymph|O nodes|O from|O colorectal|O cancer|O patients|O with|O isolated|O liver|O metastases|O .|O 
DNA|O was|O extracted|O from|O 21|O paraffin|O -|O embedded|O liver|O metastases|O and|O 80|O lymph|O nodes|O from|O 21|O colorectal|O cancer|O patients|O .|O 
K-ras|gene-rna and|O p53|gene-rna gene|O mutations|O were|O identified|O in|O DNA|O from|O liver|O metastases|O by|O PCR|O amplification|O followed|O by|O cycle|O sequencing|O .|O 
A|O sensitive|O oligonucleotide|O -|O mediated|O mismatch|O ligation|O assay|O was|O used|O to|O search|O for|O the|O presence|O of|O K-ras|gene-rna and|O p53|gene-rna mutations|O to|O detect|O occult|O disease|O in|O 68|O lymph|O nodes|O from|O tumors|O positive|O for|O these|O gene|O mutations|O .|O 
Promoter|O hypermethylation|O at|O the|O p16|gene-rna tumor|O suppressor|O gene|O was|O examined|O in|O both|O liver|O lesions|O and|O lymph|O nodes|O by|O methylation|O -|O specific|O PCR|O .|O 
Sixteen|O of|O the|O 21|O (|O 76|O %|O )|O liver|O metastases|O harbored|O either|O gene|O point|O mutations|O or|O p16|gene-rna promoter|O hypermethylation|O .|O 
Twelve|O of|O the|O 68|O lymph|O nodes|O were|O positive|O for|O tumor|O cells|O by|O molecular|O evaluation|O and|O negative|O for|O tumor|O cells|O by|O histopathology|O and|O cytokeratin|gene-protein immunohistochemistry|O ,|O whereas|O none|O were|O positive|O for|O tumor|O cells|O by|O histopathology|O or|O negative|O for|O tumor|O cells|O by|O molecular|O analysis|O (|O P|O =|O 0.0005|O ,|O McNemar|O 's|O test|O )|O .|O 
Moreover|O ,|O in|O three|O patients|O with|O lymph|O nodes|O that|O were|O histologically|O negative|O at|O all|O sites|O ,|O molecular|O screening|O detected|O tumor|O DNA|O at|O one|O or|O more|O lymph|O nodes|O .|O 
Survival|O analysis|O showed|O a|O median|O survival|O of|O 1056|O days|O for|O patients|O without|O evidence|O of|O lymph|O node|O involvement|O by|O molecular|O analysis|O and|O 165|O days|O for|O patients|O with|O positive|O lymph|O nodes|O by|O this|O approach|O (|O P|O =|O 0.0005|O )|O .|O 
These|O results|O indicate|O that|O lymph|O node|O metastasis|O screening|O in|O colorectal|O cancer|O patients|O by|O molecular|O -|O based|O techniques|O increases|O the|O sensitivity|O of|O tumor|O cell|O detection|O and|O can|O be|O a|O good|O predictor|O of|O recurrence|O in|O colorectal|O cancer|O patients|O with|O resectable|O liver|O metastases|O .|O 
c-kit|gene-rna proto|O -|O oncogene|O exon|O 8|O in|O -|O frame|O deletion|O plus|O insertion|O mutations|O in|O acute|O myeloid|O leukaemia|O .|O 
Genomic|O DNA|O from|O 60|O cases|O of|O acute|O myeloid|O leukaemia|O (|O AML|O )|O was|O screened|O for|O mutations|O in|O the|O c-kit|gene-rna gene|O .|O 
DNA|O from|O all|O 21|O exons|O was|O subjected|O to|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O amplification|O and|O analysis|O by|O conformation|O sensitive|O gel|O electrophoresis|O (|O CSGE|O )|O ;|O exons|O showing|O altered|O CSGE|O patterns|O were|O then|O sequenced|O .|O 
Mutations|O were|O identified|O only|O in|O those|O patients|O with|O inv|O (|O 16|O )|O (|O 3|O /|O 7|O cases|O )|O or|O t|O (|O 8|O ;|O 21|O )|O (|O 1|O /|O 2|O cases|O )|O and|O comprised|O three|O in|O -|O frame|O deletion|O plus|O insertion|O mutations|O (|O exon|O 8|O )|O and|O one|O point|O mutation|O (|O exon|O 10|O ,|O GTA|O -->|O ATA|O ,|O Val|O 530|O Ile|O )|O .|O 
Exons|O 8|O and|O 10|O were|O then|O analysed|O in|O 31|O further|O cases|O of|O inv|O (|O 16|O )|O (|O n|O =|O 14|O )|O and|O t|O (|O 8|O ;|O 21|O )|O (|O n|O =|O 17|O )|O ,|O revealing|O four|O additional|O exon|O 8|O in|O -|O frame|O deletion|O plus|O insertion|O mutations|O ,|O all|O of|O which|O were|O in|O cases|O of|O inv|O (|O 16|O )|O .|O 
All|O exon|O 8|O in|O -|O frame|O deletion|O plus|O insertion|O mutations|O (|O n|O =|O 7|O )|O involved|O the|O loss|O or|O replacement|O of|O the|O codon|O for|O Asp|O 419|O which|O is|O highly|O conserved|O cross|O species|O and|O is|O located|O in|O the|O receptor|O 's|O extracellular|O domain|O .|O 
The|O high|O frequency|O of|O the|O c-kit|gene-rna proto|O -|O oncogene|O exon|O 8|O deletion|O plus|O insertion|O mutations|O in|O AML|O suggests|O an|O essential|O role|O for|O this|O region|O of|O the|O receptor|O 's|O extracellular|O domain|O .|O 
The|O association|O with|O inv|O (|O 16|O )|O invites|O speculation|O as|O to|O the|O link|O between|O these|O two|O changes|O in|O the|O pathogenesis|O of|O AML|O .|O 
Comparative|O immunohistochemical|O and|O molecular|O analysis|O of|O uterine|O and|O extrauterine|O leiomyosarcomas|O .|O 
Histologic|O criteria|O defining|O malignancy|O in|O smooth|O muscle|O tumors|O are|O currently|O site|O specific|O .|O 
This|O study|O was|O undertaken|O to|O determine|O whether|O ,|O in|O leiomyosarcomas|O (|O LMS|O )|O occurring|O in|O different|O anatomic|O locations|O ,|O there|O were|O differences|O in|O patterns|O of|O expression|O of|O molecules|O that|O have|O been|O demonstrated|O to|O be|O associated|O with|O biologically|O aggressive|O behavior|O in|O malignant|O neoplasms|O ,|O and|O also|O to|O determine|O their|O diagnostic|O utility|O .|O 
Formalin|O -|O fixed|O paraffin|O -|O embedded|O tissue|O blocks|O were|O selected|O from|O 16|O extrauterine|O leiomyosarcomas|O (|O EULMS|O )|O ,|O 14|O cases|O of|O uterine|O leiomyosarcomas|O (|O ULMS|O )|O and|O from|O five|O cases|O each|O of|O uterine|O and|O extrauterine|O leiomyomas|O (|O LM|O )|O .|O 
Utilizing|O immunohistochemical|O (|O ABC|O )|O techniques|O with|O antigen|O retrieval|O ,|O we|O assessed|O serial|O sections|O of|O each|O tumor|O for|O immunoreactivity|O with|O Glut1|gene-protein ,|O CD44s|gene-protein ,|O bcl2|gene-protein ,|O cyclin|gene-protein D1|gene-protein ,|O and|O estrogen|gene-protein receptor|gene-protein .|O 
Molecular|O genotyping|O for|O detecting|O k-ras-2|gene-rna point|O mutation|O ,|O p53|gene-rna gene|O loss|O ,|O and|O mdm2|gene-rna gene|O amplification|O was|O performed|O on|O microdissected|O tumor|O samples|O from|O the|O same|O histologic|O sections|O .|O 
All|O of|O the|O uterine|O and|O extrauterine|O LM|O were|O diffusely|O positive|O for|O CD44s|gene-protein ,|O bcl2|gene-protein ,|O and|O cyclin|gene-protein D1|gene-protein ,|O and|O uniformly|O negative|O for|O Glut1|gene-protein .|O 
In|O contrast|O ,|O 50|O %|O of|O the|O ULMS|O and|O 25|O %|O of|O EULMS|O were|O Glutl|gene-protein positive|O .|O 
Moreover|O ,|O Glut1|gene-protein positivity|O closely|O correlated|O with|O aggressive|O biologic|O behavior|O reflected|O by|O distant|O metastatic|O spread|O .|O 
Eighty|O -|O percent|O of|O LM|O and|O 70|O %|O of|O the|O ULMS|O were|O estrogen|gene-protein receptor|gene-protein positive|O ,|O whereas|O only|O one|O retroperitoneal|O tumor|O had|O focal|O weak|O positivity|O .|O 
Over|O 80|O %|O of|O the|O extrauterine|O and|O 50|O %|O of|O the|O uterine|O sarcomas|O showed|O absence|O of|O CD44s|gene-protein immunoreactivity|O .|O 
Percentage|O of|O cyclin|gene-protein D1|gene-protein immunoreactivity|O was|O independent|O of|O tumor|O grade|O and|O inversely|O proportional|O to|O the|O percent|O of|O bcl2|gene-protein positivity|O .|O 
An|O LMS|O of|O the|O male|O breast|O contained|O k-ras-2|gene-rna exon|O 1|O point|O mutation|O (|O codon|O 12|O aspartate|O substitution|O of|O glycine|O )|O .|O 
P53|gene-rna allelic|O imbalance|O was|O present|O in|O 29|O %|O of|O ULMS|O and|O 57|O %|O EULMS|O .|O 
Mdm2|gene-rna amplification|O was|O present|O in|O three|O of|O six|O EULMS|O but|O not|O in|O ULMS|O .|O 
In|O addition|O to|O clinical|O staging|O ,|O Glut1|gene-protein positivity|O together|O with|O patterns|O of|O immunoreactivity|O of|O CD44|gene-protein and|O bcl2|gene-protein may|O be|O helpful|O in|O identifying|O aggressive|O smooth|O muscle|O tumors|O of|O the|O uterus|O and|O some|O EULMS|O .|O 
The|O presence|O of|O estrogen|gene-protein receptor|gene-protein staining|O may|O be|O helpful|O in|O identifying|O uterine|O versus|O nonuterine|O LMS|O .|O 
Although|O sample|O numbers|O are|O too|O small|O for|O definite|O conclusions|O ,|O this|O study|O suggests|O that|O there|O are|O differences|O in|O glucose|O transport|O ,|O expression|O of|O adhesion|O molecules|O ,|O and|O estrogen|gene-protein receptors|gene-protein in|O ULMS|O and|O EULMS|O ,|O which|O in|O part|O may|O be|O due|O to|O the|O estrogen|O dependency|O of|O the|O ULMS|O .|O 
P53|gene-rna mutations|O and|O mdm2|gene-rna amplifications|O appear|O to|O be|O more|O frequent|O in|O EULMS|O .|O 
[|O Detection|O of|O K-ras|gene-rna mutations|O in|O colon|O cancer|O by|O PHA|O -|O PHFA|O (|O preferential|O homoduplex|O formation|O assay|O )|O ]|O 
The|O mutations|O of|O K-ras|gene-rna gene|O have|O been|O demonstrated|O at|O frequencies|O of|O about|O 40|O %|O in|O human|O colorectal|O cancer|O .|O 
We|O applied|O a|O developed|O PCR|O -|O preferential|O homoduplex|O formation|O assay|O (|O PCR|O -|O PHFA|O )|O to|O detect|O a|O point|O mutation|O of|O K-ras|gene-rna gene|O in|O the|O surgical|O specimens|O from|O thirty|O patients|O with|O colorectal|O cancer|O .|O 
This|O method|O is|O based|O on|O the|O strand|O competition|O during|O hybridization|O between|O a|O double|O labeled|O amplicon|O ,|O prepared|O from|O biotin|O and|O DNP|O labeled|O primers|O ,|O and|O an|O unlabeled|O amplicon|O .|O 
The|O procedure|O of|O this|O method|O is|O simple|O and|O speedy|O ,|O and|O suitable|O to|O detect|O mutations|O in|O a|O small|O number|O of|O samples|O .|O 
By|O using|O this|O method|O ,|O the|O mutations|O were|O found|O in|O 37|O %|O (|O 11|O /|O 30|O )|O and|O confirmed|O by|O sequencing|O analysis|O .|O 
The|O results|O suggest|O that|O the|O PCR|O -|O PHFA|O system|O may|O be|O useful|O for|O detecting|O low|O frequent|O mutation|O of|O K-ras|gene-rna gene|O even|O in|O the|O case|O of|O an|O early|O cancer|O .|O 
Beta-catenin|gene-rna mutations|O are|O frequent|O in|O human|O hepatocellular|O carcinomas|O associated|O with|O hepatitis|O C|O virus|O infection|O .|O 
Hepatocellular|O carcinoma|O (|O HCC|O )|O is|O one|O of|O the|O most|O common|O fatal|O cancers|O worldwide|O .|O 
Hepatitis|O B|O virus|O and|O hepatitis|O C|O virus|O infections|O ,|O exposure|O to|O aflatoxin|O ,|O and|O excessive|O intake|O of|O alcohol|O have|O been|O identified|O as|O major|O risk|O factors|O .|O 
However|O ,|O the|O molecular|O mechanisms|O underlying|O their|O development|O are|O still|O poorly|O understood|O .|O 
Recently|O ,|O beta-catenin|gene-generic ,|O one|O of|O the|O key|O components|O of|O the|O Wnt|gene-generic signaling|O pathway|O ,|O has|O been|O found|O to|O be|O mutated|O in|O about|O 20|O %|O of|O HCCs|O ,|O suggesting|O a|O role|O of|O the|O Wnt|gene-generic pathway|O in|O their|O development|O .|O 
In|O this|O study|O ,|O we|O examined|O beta-catenin|gene-rna and|O APC|gene-rna mutations|O in|O 22|O HCCs|O associated|O with|O HCV|O infection|O ,|O using|O single|O -|O strand|O conformation|O polymorphism|O (|O SSCP|O )|O followed|O by|O direct|O DNA|O sequencing|O .|O 
beta-Catenin|gene-rna mutations|O were|O found|O in|O nine|O (|O 41|O %|O )|O cases|O ,|O but|O no|O APC|gene-rna mutations|O were|O found|O .|O 
beta-Catenin|gene-protein immunohistochemistry|O revealed|O nuclear|O accumulation|O of|O beta-catenin|gene-protein protein|O in|O all|O nine|O tumors|O with|O a|O beta-catenin|gene-rna mutation|O and|O two|O additional|O tumors|O without|O a|O mutation|O .|O 
These|O results|O suggest|O that|O activation|O of|O the|O Wnt|gene-generic signaling|O pathway|O by|O beta-catenin|gene-rna mutation|O contributes|O significantly|O to|O the|O hepatocellular|O carcinogenesis|O associated|O with|O HCV|O infection|O .|O 
Close|O correlation|O between|O beta-catenin|gene-rna gene|O alterations|O and|O nuclear|O accumulation|O of|O the|O protein|gene-protein in|O human|O hepatocellular|O carcinomas|O .|O 
Several|O lines|O of|O evidence|O indicate|O that|O beta-catenin|gene-protein acquires|O oncogenic|O activity|O when|O its|O intracellular|O concentration|O increases|O as|O a|O result|O of|O either|O mutation|O in|O the|O beta-catenin|gene-rna gene|O itself|O or|O inactivation|O of|O the|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|O APC|gene-rna )|O gene|O .|O 
In|O an|O attempt|O to|O elucidate|O the|O molecular|O mechanisms|O underlying|O hepatocellular|O carcinogenesis|O ,|O we|O have|O studied|O the|O frequency|O of|O beta-catenin|gene-rna gene|O alterations|O in|O exon|O 3|O ,|O a|O region|O known|O to|O represent|O a|O mutation|O hot|O spot|O ,|O and|O its|O inappropriate|O protein|gene-protein expression|O by|O immunohistochemistry|O in|O 73|O hepatocellular|O carcinomas|O (|O HCCs|O )|O .|O 
The|O results|O were|O correlated|O with|O different|O clinical|O and|O pathological|O data|O ,|O particularly|O with|O the|O presence|O or|O not|O of|O an|O associated|O cirrhosis|O .|O 
Fourteen|O (|O 19|O %|O )|O HCCs|O showed|O beta-catenin|gene-rna gene|O alterations|O with|O missense|O mutations|O in|O nine|O cases|O and|O interstitial|O deletions|O in|O five|O cases|O .|O 
These|O genetic|O alterations|O were|O present|O in|O both|O cirrhotic|O and|O non|O -|O cirrhotic|O groups|O .|O 
By|O contrast|O ,|O we|O did|O not|O find|O any|O beta-catenin|gene-rna gene|O alterations|O in|O the|O nine|O fibromellar|O carcinomas|O we|O examined|O .|O 
Nuclear|O accumulation|O of|O the|O protein|gene-protein was|O observed|O in|O 18|O of|O them|O (|O 25|O %|O )|O .|O 
Remarkably|O ,|O these|O included|O ten|O of|O the|O 14|O tumors|O harboring|O somatic|O mutations|O in|O the|O beta-catenin|gene-rna gene|O (|O P|O <|O 0.001|O )|O .|O 
Our|O results|O indicate|O that|O accumulation|O of|O beta-catenin|gene-protein resulting|O from|O genetic|O mutations|O is|O a|O frequent|O event|O in|O non|O -|O fibrolamellar|O type|O hepatocellular|O carcinoma|O .|O 
The|O close|O association|O between|O increased|O beta-catenin|gene-protein protein|O stability|O and|O mutation|O indicates|O that|O immunohistochemistry|O may|O be|O a|O powerful|O method|O for|O the|O detection|O of|O the|O mutated|O protein|gene-protein in|O future|O clinical|O practice|O .|O 
A|O novel|O case|O of|O a|O sporadic|O desmoid|O tumour|O with|O mutation|O of|O the|O beta|gene-rna catenin|gene-rna gene|O .|O 
A|O 42|O year|O old|O man|O without|O familial|O adenomatous|O polyposis|O had|O recurrent|O desmoid|O tumours|O in|O the|O left|O subclavicular|O site|O .|O 
Histological|O examination|O showed|O a|O typical|O desmoid|O tumour|O .|O 
Molecular|O analysis|O was|O performed|O in|O genomic|O DNA|O from|O this|O tumour|O ,|O using|O polymerase|gene-protein chain|O reaction|O -|O single|O strand|O conformation|O polymorphism|O (|O PCR|O -|O SSCP|O )|O and|O direct|O sequencing|O methods|O .|O 
No|O mutation|O could|O be|O detected|O in|O the|O entire|O coding|O sequence|O of|O the|O APC|gene-rna gene|O ,|O nor|O in|O H-ras|gene-rna ,|O K-ras|gene-rna ,|O N-ras|gene-rna ,|O or|O p53|gene-rna genes|O .|O 
On|O seeking|O a|O mutation|O of|O the|O beta|gene-rna catenin|gene-rna gene|O (|O CTNNB1|gene-rna )|O ,|O an|O activating|O mutation|O from|O ACC|O (|O Thr|O )|O to|O GCC|O (|O Ala|O )|O at|O codon|O 41|O was|O found|O .|O 
Immunohistochemical|O staining|O showed|O that|O accumulated|O beta|gene-protein catenin|gene-protein protein|O was|O predominantly|O localised|O in|O the|O nuclei|O of|O desmoid|O cells|O .|O 
This|O is|O the|O first|O example|O of|O a|O sporadic|O desmoid|O tumour|O in|O which|O a|O mutation|O of|O the|O beta|gene-protein catenin|gene-protein gene|O was|O revealed|O .|O 
Esophageal|O stromal|O tumors|O :|O a|O clinicopathologic|O ,|O immunohistochemical|O ,|O and|O molecular|O genetic|O study|O of|O 17|O cases|O and|O comparison|O with|O esophageal|O leiomyomas|O and|O leiomyosarcomas|O .|O 
Although|O rare|O elsewhere|O in|O the|O gastrointestinal|O tract|O ,|O leiomyomas|O (|O LMs|O )|O are|O the|O most|O common|O esophageal|O mesenchymal|O neoplasms|O .|O 
In|O contrast|O ,|O gastrointestinal|O stromal|O tumors|O (|O GISTs|O )|O predominate|O in|O the|O stomach|O and|O intestines|O but|O have|O not|O been|O documented|O in|O the|O esophagus|O .|O 
This|O study|O was|O undertaken|O to|O determine|O the|O clinicopathologic|O features|O and|O frequency|O of|O esophageal|O GISTs|O compared|O with|O LMs|O and|O leiomyosarcomas|O (|O LMSs|O )|O of|O the|O esophagus|O .|O 
A|O total|O of|O 68|O stromal|O /|O smooth|O muscle|O tumors|O from|O the|O Armed|O Forces|O Institute|O of|O Pathology|O and|O the|O Haartman|O Institute|O of|O University|O of|O Helsinki|O were|O reclassified|O by|O current|O histologic|O and|O immunohistochemical|O criteria|O .|O 
There|O were|O 17|O GISTs|O ,|O 48|O LMs|O ,|O and|O three|O LMSs|O .|O 
The|O esophageal|O GISTs|O occurred|O in|O 12|O men|O and|O five|O women|O with|O a|O median|O age|O of|O 63|O years|O (|O range|O ,|O 49|O -|O 75|O years|O )|O .|O 
All|O tumors|O were|O from|O the|O lowest|O third|O of|O the|O esophagus|O ,|O and|O the|O most|O common|O complaint|O was|O dysphagia|O ,|O whereas|O two|O tumors|O were|O detected|O incidentally|O .|O 
Histologically|O the|O tumors|O had|O an|O overall|O basophilic|O appearance|O and|O showed|O combinations|O of|O solid|O ,|O myxoid|O ,|O and|O perivascular|O collarlike|O patterns|O with|O a|O spindle|O cell|O histology|O in|O 13|O patients|O and|O epithelioid|O histology|O in|O four|O patients|O .|O 
All|O tumors|O were|O positive|O for|O CD117|gene-protein and|O for|O CD34|gene-protein ,|O whereas|O two|O patients|O were|O also|O positive|O for|O alpha|gene-protein -|gene-protein smooth|gene-protein muscle|gene-protein actin|gene-protein (|O SMA|gene-protein )|O and|O three|O patients|O were|O positive|O for|O desmin|gene-protein .|O 
One|O patient|O showed|O a|O unique|O immunophenotype|O with|O coexpression|O of|O CD117|gene-protein ,|O CD34|gene-protein ,|O SMA|gene-protein ,|O and|O desmin|gene-protein .|O 
Nine|O patients|O died|O of|O disease|O ,|O including|O all|O who|O had|O a|O tumor|O larger|O than|O 10|O cm|O ,|O and|O also|O one|O patient|O whose|O tumor|O showed|O five|O mitoses|O per|O 50|O high|O -|O power|O fields|O .|O 
In|O comparison|O ,|O esophageal|O LMs|O (|O n|O =|O 48|O )|O occurred|O in|O a|O younger|O population|O (|O median|O age|O ,|O 35|O years|O )|O but|O ,|O similar|O to|O the|O GIST|O group|O ,|O men|O predominated|O (|O 67|O %|O )|O .|O 
All|O LMs|O were|O clinically|O indolent|O tumors|O with|O no|O tumor|O -|O related|O mortality|O .|O 
The|O LMs|O showed|O eosinophilic|O cytoplasm|O ,|O and|O were|O positive|O for|O desmin|gene-protein and|O SMA|gene-protein ,|O and|O negative|O for|O CD117|gene-protein and|O CD34|gene-protein .|O 
All|O three|O LMSs|O were|O large|O high|O -|O grade|O tumors|O that|O showed|O muscle|O cell|O markers|O but|O no|O CD117|gene-protein .|O 
All|O patients|O died|O of|O disease|O .|O 
Esophageal|O GISTs|O showed|O mutations|O in|O exon|O 11|O of|O c-kit|gene-rna as|O described|O previously|O in|O gastric|O and|O intestinal|O GISTs|O .|O 
The|O separation|O of|O GISTs|O from|O esophageal|O LMs|O is|O important|O diagnostically|O because|O the|O former|O group|O has|O a|O high|O risk|O of|O malignant|O behavior|O .|O 
APC|gene-rna mutations|O are|O sufficient|O for|O the|O growth|O of|O early|O colorectal|O adenomas|O .|O 
It|O is|O not|O clear|O whether|O APC|gene-rna mutations|O are|O sufficient|O for|O early|O colorectal|O adenomas|O to|O grow|O or|O whether|O additional|O mutations|O at|O other|O loci|O are|O required|O .|O 
We|O previously|O have|O screened|O 210|O early|O colorectal|O adenomas|O from|O familial|O adenomatous|O polyposis|O patients|O for|O mutations|O and|O allelic|O loss|O at|O APC|gene-rna .|O 
Here|O ,|O we|O determined|O whether|O allelic|O loss|O at|O APC|gene-rna had|O any|O effect|O on|O the|O nearby|O alpha-catenin|gene-rna gene|O .|O 
However|O ,|O loss|O on|O 5q|O in|O familial|O adenomatous|O polyposis|O adenomas|O rarely|O extended|O as|O far|O as|O alpha-catenin|gene-rna ,|O and|O no|O differences|O in|O alpha-catenin|gene-protein protein|O expression|O were|O found|O in|O tumors|O that|O showed|O loss|O encompassing|O both|O APC|gene-rna and|O alpha-catenin|gene-rna .|O 
We|O then|O screened|O all|O 210|O tumors|O for|O mutations|O at|O candidate|O loci|O other|O than|O APC|gene-rna (|O K-ras|gene-rna ,|O beta-catenin|gene-rna ,|O and|O allelic|O loss|O at|O 1p33|O -|O p35|O and|O 1p36|O )|O and|O for|O microsatellite|O instability|O (|O MSI|O )|O .|O 
Each|O of|O these|O loci|O has|O been|O implicated|O previously|O in|O early|O colorectal|O tumorigenesis|O .|O 
One|O tumor|O harbored|O a|O beta-catenin|gene-rna mutation|O and|O another|O MSI|O ,|O but|O none|O showed|O K-ras|gene-rna mutation|O or|O allelic|O loss|O at|O 1p33|O -|O p35|O or|O 1p36|O .|O 
These|O data|O support|O the|O following|O hypotheses|O derived|O from|O sporadic|O colorectal|O tumors|O :|O beta-catenin|gene-rna mutations|O are|O generally|O an|O alternative|O to|O mutations|O at|O APC|gene-rna ,|O MSI|O is|O not|O usually|O an|O early|O phenomenon|O in|O colorectal|O tumorigenesis|O ,|O and|O K-ras|gene-rna mutations|O are|O more|O typical|O of|O large|O -|O and|O moderate|O -|O sized|O adenomas|O .|O 
Contrary|O to|O some|O previous|O reports|O ,|O chromosome|O 1p|O allelic|O loss|O is|O infrequent|O in|O very|O early|O adenomas|O .|O 
APC|gene-rna mutations|O are|O generally|O sufficient|O for|O colorectal|O tumors|O to|O grow|O to|O about|O 1|O -|O cm|O diameter|O ,|O although|O chance|O mutations|O at|O other|O loci|O can|O provide|O these|O early|O colorectal|O adenomas|O with|O a|O selective|O advantage|O ,|O and|O some|O colorectal|O tumors|O may|O develop|O along|O a|O pathway|O not|O involving|O APC|gene-rna .|O 
Aberrations|O of|O the|O K-ras|gene-rna ,|O p53|gene-rna ,|O and|O APC|gene-rna genes|O in|O extrahepatic|O bile|O duct|O cancer|O .|O 
BACKGROUND|O AND|O OBJECTIVES|O :|O 
The|O genetic|O alterations|O involved|O in|O extrahepatic|O bile|O duct|O (|O EHBD|O )|O cancer|O are|O poorly|O understood|O .|O 
Our|O aim|O was|O to|O identify|O aberrations|O of|O the|O K-ras|gene-rna ,|O p53|gene-rna ,|O and|O APC|gene-rna genes|O in|O EHBD|O cancer|O .|O 
METHODS|O :|O 
We|O investigated|O aberrations|O of|O these|O genes|O in|O 52|O EHBD|O cancers|O using|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O single|O -|O strand|O conformation|O polymorphism|O analysis|O ,|O followed|O by|O direct|O sequence|O determination|O and|O a|O PCR|O restriction|O fragment|O length|O polymorphism|O assay|O .|O 
RESULTS|O :|O 
The|O K-ras|gene-rna ,|O p53|gene-rna ,|O and|O APC|gene-rna genes|O were|O mutated|O in|O 9.6|O %|O ,|O 32.7|O %|O ,|O and|O 0|O %|O of|O EHBD|O cancers|O ,|O respectively|O .|O 
Loss|O of|O heterozygosity|O at|O the|O p53|gene-rna and|O APC|gene-rna gene|O loci|O was|O identified|O in|O 15.6|O %|O and|O 38.5|O %|O of|O EHBD|O cancers|O ,|O respectively|O .|O 
CONCLUSIONS|O :|O 
Our|O results|O suggest|O that|O an|O unknown|gene-rna suppressor|gene-rna gene|gene-rna on|O 5q|O other|O than|O the|O APC|gene-rna gene|O may|O be|O responsible|O for|O EHBD|O cancer|O .|O 
Nuclear|O localization|O and|O mutation|O of|O beta-catenin|gene-generic in|O medulloblastomas|O .|O 
The|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|O APC|gene-rna )|O gene|O ,|O a|O member|O of|O the|O Wingless|gene-generic /|O Wnt|gene-generic signal|O transduction|O pathway|O ,|O has|O been|O implicated|O in|O the|O development|O of|O medulloblastomas|O in|O Turcot|O 's|O syndrome|O .|O 
beta-catenin|gene-generic also|O functions|O in|O this|O highly|O conserved|O signaling|O pathway|O and|O is|O instrumental|O in|O growth|O and|O development|O .|O 
Mutations|O in|O either|O APC|gene-rna or|O beta-catenin|gene-rna can|O stabilize|O beta-catenin|gene-protein protein|O .|O 
Stabilized|O beta-catenin|gene-protein complexes|O with|O Tcf|gene-protein /|O Lef|gene-protein transcription|O factors|O and|O moves|O from|O the|O cytoplasm|O into|O the|O nucleus|O where|O it|O regulates|O the|O transcription|O of|O c-Myc|gene-rna and|O other|O genes|O .|O 
Nuclear|O localization|O of|O beta-catenin|gene-protein therefore|O implies|O activation|O of|O the|O signaling|O pathway|O .|O 
We|O have|O analyzed|O the|O subcellular|O localization|O of|O beta-catenin|gene-protein in|O 51|O sporadic|O medulloblastomas|O and|O in|O 1|O medulloblastoma|O arising|O in|O a|O patient|O with|O Turcot|O 's|O syndrome|O .|O 
Nuclear|O beta-catenin|gene-protein staining|O was|O present|O in|O 9|O of|O the|O sporadic|O tumors|O (|O 18|O %|O )|O and|O in|O the|O 1|O medulloblastoma|O from|O a|O Turcot|O 's|O patient|O .|O 
The|O remaining|O 41|O cases|O did|O not|O show|O nuclear|O staining|O .|O 
This|O confirms|O earlier|O observations|O that|O Wingless|gene-generic /|O Wnt|gene-generic signaling|O is|O involved|O in|O a|O subset|O of|O sporadic|O medulloblastomas|O .|O 
We|O also|O examined|O 48|O glial|O and|O meningeal|O CNS|O tumors|O ,|O all|O of|O which|O were|O negative|O for|O nuclear|O beta-catenin|gene-protein .|O 
Exon|O 3|O of|O beta-catenin|gene-rna was|O sequenced|O in|O 6|O of|O the|O 9|O sporadic|O medulloblastomas|O with|O nuclear|O beta-catenin|gene-protein staining|O .|O 
Five|O of|O the|O 6|O tumors|O sequenced|O had|O mutations|O affecting|O highly|O conserved|O beta-catenin|gene-generic phosphorylation|O sites|O involved|O in|O protein|gene-protein stability|O .|O 
These|O data|O suggest|O a|O simple|O immunohistochemical|O method|O to|O screen|O for|O beta-catenin|gene-rna mutations|O in|O medulloblastomas|O .|O 
Screening|O of|O human|O bladder|O carcinomas|O for|O the|O presence|O of|O Ha-ras|gene-rna codon|O 12|O mutation|O .|O 
Contradictory|O results|O were|O obtained|O from|O previous|O studies|O aiming|O at|O defining|O the|O frequency|O of|O Ha-ras|gene-rna codon|O 12|O mutations|O in|O bladder|O tumors|O .|O 
Differences|O in|O the|O sensitivities|O of|O the|O methods|O used|O could|O account|O for|O this|O discrepancy|O .|O 
In|O this|O study|O ,|O we|O reevaluated|O the|O frequency|O of|O Ha-ras|gene-rna codon|O 12|O mutations|O in|O a|O series|O of|O 87|O human|O bladder|O tumors|O using|O a|O combination|O of|O two|O different|O methods|O .|O 
The|O first|O was|O derived|O from|O the|O protocol|O of|O Ooi|O et|O al|O and|O consisted|O in|O a|O one|O -|O step|O allele|O -|O specific|O polymerase|O chain|O reaction|O using|O mismatched|O primers|O in|O two|O separate|O PCR|O .|O 
This|O method|O is|O very|O rapid|O and|O highly|O sensitive|O ,|O detecting|O the|O presence|O of|O minor|O populations|O (|O less|O than|O 10|O %|O )|O of|O mutant|O alleles|O .|O 
The|O second|O strategy|O consisted|O in|O screening|O all|O tumors|O using|O natural|O restriction|O fragment|O length|O polymorphism|O (|O RFLP|O )|O analysis|O .|O 
The|O two|O methods|O were|O in|O complete|O concordance|O and|O enabled|O us|O to|O show|O that|O only|O one|O out|O of|O 87|O primary|O bladder|O carcinomas|O (|O 1|O %|O )|O exhibited|O the|O mutation|O ,|O in|O accordance|O with|O previous|O studies|O .|O 
Genetic|O ,|O immunohistochemical|O ,|O and|O clinical|O features|O of|O medullary|O carcinoma|O of|O the|O pancreas|O :|O A|O newly|O described|O and|O characterized|O entity|O .|O 
Medullary|O carcinomas|O of|O the|O pancreas|O are|O a|O recently|O described|O ,|O histologically|O distinct|O subset|O of|O poorly|O differentiated|O adenocarcinomas|O that|O may|O have|O a|O unique|O pathogenesis|O and|O clinical|O course|O .|O 
To|O further|O evaluate|O these|O neoplasms|O ,|O we|O studied|O genetic|O ,|O pathological|O ,|O and|O clinical|O features|O of|O 13|O newly|O identified|O medullary|O carcinomas|O of|O the|O pancreas|O .|O 
Nine|O (|O 69|O %|O )|O of|O these|O had|O wild-type|O K-ras|gene-rna genes|O ,|O and|O one|O had|O microsatellite|O instability|O (|O MSI|O )|O .|O 
This|O MSI|O medullary|O carcinoma|O ,|O along|O with|O three|O previously|O reported|O MSI|O medullary|O carcinomas|O ,|O were|O examined|O immunohistochemically|O for|O Mlh1|gene-rna and|O Msh2|gene-rna expression|O ,|O and|O all|O four|O expressed|O Msh2|gene-rna but|O did|O not|O express|O Mlh1|gene-rna .|O 
In|O contrast|O ,|O all|O of|O the|O medullary|O carcinomas|O without|O MSI|O expressed|O both|O Msh2|gene-rna and|O Mlh1|gene-rna .|O 
Remarkably|O ,|O the|O MSI|O medullary|O carcinoma|O of|O the|O pancreas|O in|O the|O present|O series|O arose|O in|O a|O patient|O with|O a|O synchronous|O but|O histologically|O distinct|O cecal|O carcinoma|O that|O also|O had|O MSI|O and|O did|O not|O express|O Mlh1|gene-rna .|O 
The|O synchronous|O occurrence|O of|O two|O MSI|O carcinomas|O suggests|O an|O inherited|O basis|O for|O the|O development|O of|O these|O carcinomas|O .|O 
Indeed|O ,|O the|O medullary|O phenotype|O ,|O irrespective|O of|O MSI|O ,|O was|O highly|O associated|O with|O a|O family|O history|O of|O cancer|O in|O first-degree|O relatives|O (|O P|O <|O 0.001|O )|O .|O 
Finally|O ,|O one|O medullary|O carcinoma|O with|O lymphoepithelioma|O -|O like|O features|O contained|O Epstein|O -|O Barr|O virus|O -|O encoded|O RNA-1|O by|O in|O situ|O hybridization|O .|O 
Therefore|O ,|O because|O of|O medullary|O carcinoma|O 's|O special|O genetic|O ,|O immunohistochemical|O ,|O and|O clinical|O features|O ,|O recognition|O of|O the|O medullary|O variant|O of|O pancreatic|O adenocarcinoma|O is|O important|O .|O 
Only|O by|O classifying|O medullary|O carcinoma|O as|O special|O subset|O of|O adenocarcinoma|O can|O we|O hope|O to|O further|O elucidate|O its|O unique|O pathogenesis|O .|O 
Spindle|O cell|O tumor|O of|O urinary|O bladder|O serosa|O with|O phenotypic|O and|O genotypic|O features|O of|O gastrointestinal|O stromal|O tumor|O .|O 
Most|O mesenchymal|O tumors|O of|O the|O gastrointestinal|O tract|O are|O now|O referred|O to|O as|O gastrointestinal|O stromal|O tumors|O (|O GISTs|O )|O .|O 
The|O tumors|O differ|O from|O ordinary|O leiomyomas|O and|O schwannomas|O in|O several|O respects|O :|O the|O GISTs|O typically|O express|O c-kit|gene-rna protein|O (|O CD117|gene-protein )|O and|O CD34|gene-protein ,|O 30|O %|O to|O 50|O %|O of|O them|O are|O (|O often|O focally|O )|O positive|O for|O alpha|gene-protein -|gene-protein smooth|gene-protein muscle|gene-protein actin|gene-protein ,|O and|O all|O are|O negative|O for|O desmin|gene-protein and|O S100|gene-protein protein|O .|O 
Recently|O ,|O mutations|O in|O the|O exon|O 11|O of|O the|O c-kit|gene-rna gene|O have|O been|O identified|O and|O confirmed|O as|O a|O molecular|O genetic|O marker|O for|O the|O subset|O of|O GISTs|O .|O 
In|O this|O report|O ,|O we|O describe|O a|O mesenchymal|O tumor|O removed|O from|O the|O pelvic|O cavity|O of|O a|O 52|O -|O year|O -|O old|O woman|O ,|O who|O is|O alive|O without|O disease|O 36|O months|O after|O the|O surgery|O .|O 
The|O 5|O -|O cm|O tumor|O was|O densely|O attached|O to|O the|O external|O aspect|O of|O the|O urinary|O bladder|O but|O was|O attached|O to|O small|O intestine|O by|O only|O filmy|O adhesions|O .|O 
The|O tumor|O grossly|O resembled|O a|O leiomyoma|O and|O was|O histologically|O composed|O of|O sheets|O of|O spindle|O cells|O with|O a|O dense|O collagenous|O background|O .|O 
The|O mitotic|O activity|O was|O low|O ,|O less|O then|O 1|O per|O 50|O high|O -|O power|O fields|O .|O 
Immunohistochemically|O ,|O the|O tumor|O cells|O were|O negative|O for|O alpha|gene-protein -|gene-protein smooth|gene-protein muscle|gene-protein actin|gene-protein and|O desmin|gene-protein and|O positive|O for|O CD117|gene-protein and|O CD34|gene-protein .|O 
Molecular|O genetic|O analysis|O of|O the|O exon|O 11|O of|O the|O c-kit|gene-rna gene|O revealed|O a|O point|O mutation|O in|O the|O region|O commonly|O mutated|O in|O GISTs|O .|O 
This|O mutation|O substituted|O T|O for|O A|O in|O the|O codon|O 557|O ,|O leading|O to|O the|O change|O of|O amino|O acid|O sequence|O (|O tryptophan|O for|O arginine|O )|O of|O the|O KIT|gene-protein protein|O .|O 
This|O case|O illustrates|O that|O tumors|O phenotypically|O and|O genotypically|O similar|O to|O GISTs|O may|O present|O in|O sites|O other|O than|O the|O tubular|O gastrointestinal|O tract|O .|O 
p53|gene-rna and|O K-ras|gene-rna gene|O mutations|O in|O carcinoma|O of|O the|O rectum|O among|O Finnish|O women|O .|O 
AIMS|O /|O BACKGROUND|O :|O 
The|O aim|O of|O this|O study|O was|O to|O identify|O p53|gene-rna and|O K-ras|gene-rna gene|O mutations|O in|O carcinoma|O of|O the|O rectum|O among|O Finnish|O women|O .|O 
Mutation|O patterns|O might|O give|O clues|O to|O aetiological|O factors|O when|O comparisons|O are|O made|O with|O other|O human|O tumours|O .|O 
METHODS|O :|O 
Of|O 134|O women|O with|O carcinoma|O of|O the|O rectum|O ,|O paraffin|O wax|O embedded|O specimens|O of|O the|O tumour|O tissue|O were|O obtained|O from|O 118|O patients|O .|O 
Genomic|O DNA|O was|O extracted|O ,|O and|O exons|O 4|O -|O 8|O of|O the|O p53|gene-rna gene|O and|O codons|O 12|O /|O 13|O and|O 61|O of|O the|O K-ras|gene-rna gene|O were|O amplified|O ,|O and|O analysed|O for|O mutations|O by|O single|O strand|O conformation|O polymorphism|O and|O direct|O sequencing|O .|O 
The|O production|O of|O p53|gene-protein and|O K-ras|gene-protein proteins|O was|O studied|O by|O immunohistochemistry|O .|O 
RESULTS|O :|O 
The|O overall|O crude|O frequency|O for|O mutations|O in|O the|O p53|gene-rna gene|O was|O 35|O %|O but|O the|O true|O frequency|O appears|O to|O be|O higher|O (|O up|O to|O 56|O %|O )|O .|O 
In|O the|O K-ras|gene-rna gene|O ,|O the|O mutation|O frequency|O (|O 15|O %|O )|O was|O significantly|O lower|O than|O that|O reported|O for|O colon|O cancer|O .|O 
In|O the|O p53|gene-rna gene|O ,|O the|O mutation|O frequency|O increased|O significantly|O with|O patient|O age|O .|O 
In|O a|O high|O proportion|O of|O patients|O (|O 14|O %|O )|O the|O rectal|O tumours|O contained|O small|O subclones|O of|O tumour|O cells|O that|O displayed|O extremely|O rare|O mutations|O at|O codons|O 110|O and|O 232|O of|O the|O p53|gene-rna gene|O .|O 
Hot|O spot|O codon|O 175|O mutations|O were|O significantly|O less|O common|O in|O rectal|O cancer|O than|O in|O cancer|O of|O the|O colon|O .|O 
CONCLUSIONS|O :|O 
Rectal|O cancer|O among|O Finnish|O women|O has|O characteristics|O in|O the|O mutations|O of|O the|O p53|gene-rna and|O K-ras|gene-rna genes|O that|O are|O uncommon|O in|O other|O human|O tumours|O ,|O including|O cancer|O of|O the|O colon|O .|O 
Multiple|O molecular|O marker|O testing|O (|O p53|gene-rna ,|O C-Ki-ras|gene-rna ,|O c-erbB-2|gene-rna )|O improves|O estimation|O of|O prognosis|O in|O potentially|O curative|O resected|O non|O -|O small|O cell|O lung|O cancer|O .|O 
A|O prospective|O study|O was|O performed|O in|O patients|O with|O non|O -|O small|O cell|O lung|O cancer|O (|O NSCLC|O )|O to|O evaluate|O the|O prognostic|O importance|O of|O multiple|O molecular|O marker|O (|O p53|gene-rna ,|O c-Ki-ras|gene-rna ,|O c-erbB-2|gene-rna )|O testing|O .|O 
103|O patients|O with|O potentially|O curative|O resections|O (|O RO|O resection|O )|O for|O NSCLC|O in|O histopathological|O stages|O I|O -|O IIIA|O were|O included|O .|O 
SSCP|O analysis|O and|O DNA|O sequencing|O for|O p53|gene-rna and|O c-Ki-ras|gene-rna genes|O were|O performed|O on|O paired|O tumour|O and|O normal|O lung|O tissue|O samples|O and|O immunohistochemistry|O (|O c-erbB-2|gene-protein )|O was|O done|O on|O frozen|O tissue|O sections|O with|O a|O specific|O anti|gene-protein -|gene-protein c-erbB-2|gene-rna monoclonal|gene-protein antibody|gene-protein .|O 
46|O /|O 103|O (|O 44.6|O %|O )|O NSCLC|O showed|O p53|gene-rna mutations|O and|O 17|O /|O 103|O (|O 16.5|O %|O )|O c-Ki-ras|gene-rna mutations|O including|O 12|O /|O 37|O (|O 32.4|O %|O )|O adenocarcinomas|O .|O 
Overexpression|O of|O c-erbB-2|gene-rna (|O p185|gene-rna )|O was|O detected|O in|O 56|O /|O 103|O (|O 54.4|O %|O )|O tumours|O .|O 
24|O /|O 103|O (|O 23.3|O %|O )|O NSCLC|O were|O negative|O for|O alterations|O in|O all|O 3|O parameters|O (|O c-Ki-ras|gene-rna ,|O p53|gene-rna and|O p185|gene-rna )|O whereas|O 79|O /|O 103|O (|O 76.7|O %|O )|O were|O positive|O for|O at|O least|O one|O of|O the|O 3|O parameters|O .|O 
In|O a|O regression|O model|O including|O a|O multiple|O molecular|O marker|O parameter|O (|O negative|O for|O all|O 3|O markers|O versus|O positive|O for|O at|O least|O one|O marker|O )|O ,|O histopathological|O stage|O (|O P|O <|O 0.00001|O )|O ,|O respectively|O the|O pT|O (|O P|O <|O 0.01|O )|O and|O pN|O (|O P|O <|O 0.00001|O )|O categories|O and|O the|O multiple|O molecular|O marker|O parameter|O (|O P|O <|O 0.01|O )|O were|O of|O significant|O prognostic|O importance|O .|O 
This|O study|O demonstrates|O that|O testing|O 3|O molecular|O markers|O (|O c-Ki-ras|gene-rna ,|O p53|gene-rna and|O c-erbB-2|gene-rna )|O improves|O estimation|O of|O prognosis|O compared|O to|O single|O marker|O testing|O and|O appears|O to|O define|O low|O (|O 82.6|O %|O +/-|O 7.9|O %|O 5|O -|O year|O survival|O )|O and|O high|O risk|O (|O 40.2|O %|O +/-|O 5.5|O %|O 5|O -|O year|O survival|O )|O groups|O for|O treatment|O failure|O in|O potentially|O curative|O (|O RO|O )|O resected|O NSCLC|O .|O 
Missense|O mutation|O of|O the|O MET|gene-rna gene|O detected|O in|O human|O glioma|O .|O 
Multiple|O mechanisms|O ,|O such|O as|O gene|O mutations|O ,|O amplifications|O ,|O and|O rearrangements|O ,|O as|O well|O as|O perturbed|O mitogen|O and|O receptor|O function|O ,|O are|O likely|O to|O contribute|O to|O glioma|O formation|O .|O 
The|O MET|gene-rna (|O also|O known|O as|O c-met|gene-rna proto|O -|O oncogene|O located|O at|O 7q31|O -|O 34|O has|O been|O shown|O to|O be|O amplified|O in|O human|O gliomas|O ,|O and|O activating|O mutations|O within|O the|O tyrosine|gene-protein kinase|gene-protein domain|O of|O MET|gene-rna have|O been|O causally|O related|O to|O tumorigenesis|O in|O hereditary|O papillary|O renal|O cell|O carcinoma|O .|O 
To|O elucidate|O the|O role|O of|O MET|gene-rna gene|O in|O glioma|O formation|O ,|O sporadic|O gliomas|O from|O 11|O patients|O were|O examined|O for|O MET|gene-rna gene|O mutations|O and|O allelic|O duplications|O or|O deletions|O by|O polymerase|gene-protein chain|O reaction|O -|O single|O strand|O conformational|O polymorphism|O analysis|O and|O fluorescence|O in|O situ|O hybridization|O .|O 
Three|O of|O 11|O sporadic|O gliomas|O showed|O a|O deletion|O of|O one|O copy|O of|O the|O MET|gene-rna gene|O ,|O and|O a|O specific|O MET|gene-rna gene|O missense|O mutation|O in|O the|O remaining|O gene|O copy|O was|O detected|O in|O one|O of|O those|O tumors|O .|O 
The|O corresponding|O sequence|O in|O non|O -|O tumor|O DNA|O was|O normal|O in|O all|O cases|O .|O 
Three|O of|O 11|O sporadic|O gliomas|O showed|O duplication|O of|O one|O copy|O of|O the|O MET|gene-rna gene|O ,|O but|O none|O of|O them|O contained|O mutations|O .|O 
One|O tumor|O showed|O MET|gene-rna amplification|O without|O mutation|O .|O 
Three|O showed|O neither|O allelic|O change|O nor|O mutation|O .|O 
These|O data|O suggest|O that|O somatic|O MET|gene-rna gene|O mutation|O may|O play|O a|O role|O in|O the|O development|O of|O a|O subgroup|O of|O sporadic|O gliomas|O .|O 
However|O ,|O MET|gene-rna mutations|O appear|O to|O be|O absent|O in|O the|O majority|O of|O sporadic|O gliomas|O .|O 
beta-catenin|gene-rna expression|O and|O mutational|O analysis|O in|O renal|O cell|O carcinomas|O .|O 
beta-Catenin|gene-rna acts|O as|O a|O downstream|O transcriptional|O activator|O of|O the|O Wingless|gene-rna -|O Wnt|gene-rna signaling|O pathway|O .|O 
The|O beta-catenin|gene-rna -|O Tcf|gene-rna complex|O transactivates|O the|O downstream|O genes|O that|O regulate|O cell|O proliferation|O or|O inhibit|O apoptosis|O .|O 
The|O activation|O of|O this|O pathway|O through|O stabilization|O of|O beta-catenin|gene-generic is|O caused|O either|O by|O inactivating|O mutations|O of|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|O APC|gene-rna )|O tumor|O suppressor|O gene|O or|O by|O activating|O mutations|O in|O beta-catenin|gene-rna exon|O 3|O .|O 
To|O determine|O whether|O the|O abnormal|O expression|O and|O activating|O mutations|O in|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O are|O implicated|O in|O renal|O cell|O carcinogenesis|O ,|O 52|O renal|O cell|O carcinomas|O (|O RCC|O )|O were|O analyzed|O by|O immunohistochemistry|O ,|O polymerase|gene-protein chain|O reaction|O -|O single|O -|O strand|O conformational|O polymorphism|O analysis|O (|O PCR|O -|O SSCP|O )|O ,|O and|O direct|O DNA|O sequencing|O .|O 
Immunohistochemically|O ,|O all|O cases|O ,|O as|O well|O as|O normal|O kidneys|O ,|O showed|O membranous|O and|O /|O or|O cytoplasmic|O staining|O patterns|O without|O nuclear|O localization|O .|O 
However|O ,|O the|O cytoplasmic|O accumulations|O of|O beta-catenin|gene-protein were|O observed|O in|O five|O (|O 22.7|O %|O )|O of|O 22|O cases|O of|O conventional|O (|O clear|O cell|O )|O renal|O carcinoma|O ,|O but|O not|O in|O papillary|O or|O chromophobe|O renal|O carcinomas|O .|O 
The|O beta|gene-rna -|gene-rna catenin|gene-rna mutation|O was|O identified|O in|O only|O one|O case|O of|O conventional|O renal|O carcinoma|O and|O was|O a|O single|O -|O base|O missense|O mutation|O on|O codon|O 61|O ,|O leading|O to|O substitution|O of|O glutamine|O by|O arginine|O .|O 
In|O conclusion|O ,|O this|O study|O demonstrates|O that|O beta-catenin|gene-rna mutations|O are|O a|O relatively|O rare|O event|O in|O RCC|O and|O that|O cytoplasmic|O accumulations|O of|O beta-catenin|gene-protein protein|O are|O found|O only|O in|O conventional|O (|O clear|O cell|O )|O renal|O carcinomas|O .|O 
These|O data|O suggest|O that|O the|O activation|O of|O the|O beta-catenin|gene-generic signaling|O pathway|O may|O partly|O play|O a|O role|O in|O the|O development|O of|O conventional|O RCC|O .|O 
NAD(P)H:quinone|gene-protein oxidoreductase|gene-protein -|O dependent|O risk|O for|O colorectal|O cancer|O and|O its|O association|O with|O the|O presence|O of|O K-ras|gene-rna mutations|O in|O tumors|O .|O 
NAD(P)H:quinone|gene-protein oxidoreductase|gene-protein (|O NQO1|gene-protein )|O is|O a|O polymorphic|O enzyme|O involved|O in|O the|O detoxification|O of|O potentially|O mutagenic|O and|O carcinogenic|O quinones|O .|O 
The|O homozygous|O C609T|O NQO1|gene-protein genotype|O resulting|O in|O loss|O of|O reductase|gene-protein activity|O is|O found|O in|O 2|O -|O 20|O %|O of|O individuals|O .|O 
In|O the|O present|O study|O ,|O the|O NQO1|gene-protein -|O dependent|O risk|O for|O sporadic|O colorectal|O cancer|O (|O CRC|O )|O was|O studied|O in|O 247|O incident|O CRC|O cases|O and|O 296|O hospital|O -|O based|O controls|O recruited|O during|O 1996|O -|O 1997|O .|O 
Four|O subgroups|O of|O cases|O were|O studied|O :|O (i)|O all|O CRCs|O ;|O (ii)|O a|O molecular|O CRC|O subgroup|O (|O n|O =|O 117|O ,|O cases|O with|O molecular|O tumor|O analyses|O )|O ;|O (iii)|O within|O the|O molecular|O subgroup|O those|O tumors|O with|O K-ras|gene-rna mutations|O in|O codon|O 12|O (|O CRC|O K|gene-rna 12|O )|O ;|O (iv)|O within|O the|O molecular|O subgroup|O those|O tumors|O with|O K-ras|gene-rna mutations|O in|O codon|O 13|O (|O CRC|O K|gene-rna 13|O )|O .|O 
The|O C609T|O NQO1|gene-protein genotype|O was|O found|O to|O be|O twice|O as|O prevalent|O in|O all|O CRC|O patients|O (|O 6.8|O %|O )|O compared|O with|O controls|O (|O 3|O %|O )|O and|O six|O times|O more|O common|O in|O the|O subset|O CRC|O K|gene-rna 12|O (|O 20|O %|O )|O .|O 
Multivariant|O analyses|O in|O the|O overall|O population|O of|O 247|O cases|O and|O 296|O controls|O showed|O a|O significant|O age|O and|O gender|O adjusted|O risk|O for|O CRC|O associated|O with|O the|O C609T|O NQO1|gene-protein genotype|O (|O OR|O 2.9|O ,|O 95|O %|O CI|O 1.19|O -|O 6.97|O ;|O P|O =|O 0.01|O )|O or|O with|O any|O variant|O genotype|O (|O the|O low|O activity|O allele|O frequency|O ,|O i.e.|O heterozygotes|O plus|O homozygotes|O )|O (|O OR|O 1.41|O ,|O 95|O %|O CI|O 1.02|O -|O 1.92|O ;|O P|O =|O 0.03|O )|O .|O 
Within|O cases|O of|O the|O molecular|O subgroup|O (|O n|O =|O 117|O )|O the|O C609T|O NQO1|gene-protein genotype|O was|O associated|O with|O the|O presence|O of|O K-ras|gene-rna codon|O 12|O mutation|O (|O OR|O 6.5|O 95|O %|O ,|O CI|O 1.39|O -|O 34.9|O ;|O P|O =|O 0.003|O )|O .|O 
Logistic|O regression|O showed|O an|O age|O and|O gender|O adjusted|O risk|O for|O K-ras|gene-rna codon|O 12|O mutant|O CRC|O associated|O with|O the|O C609T|O NQO1|gene-protein genotype|O (|O OR|O 10.5|O ,|O 95|O %|O CI|O 2.99|O -|O 36.7|O ;|O P|O :|O =|O 0.0002|O )|O or|O with|O any|O variant|O NQO1|gene-protein genotype|O (|O OR|O 2.23|O ,|O 95|O %|O CI|O 1.23|O -|O 4.00|O ;|O P|O =|O 0.007|O )|O compared|O with|O the|O control|O group|O .|O 
Genetically|O determined|O variations|O in|O NQO1|gene-protein may|O modify|O the|O risk|O for|O CRC|O and|O these|O risks|O may|O be|O greatest|O for|O tumors|O containing|O K-ras|gene-rna codon|O 12|O mutations|O .|O 
CRC|O with|O K-ras|gene-rna codon|O 12|O mutations|O may|O represent|O a|O distinct|O and|O etiologically|O more|O homogeneous|O subtype|O of|O the|O disease|O ,|O which|O may|O be|O associated|O with|O toxicants|O that|O are|O metabolized|O via|O a|O NQO1|gene-protein -|O dependent|O pathway|O .|O 
Comparison|O of|O K-ras|gene-rna point|O mutations|O at|O codon|O 12|O and|O p21|gene-protein expression|O in|O pancreatic|O cancer|O between|O Japanese|O and|O Chinese|O patients|O .|O 
BACKGROUND|O ANF|O OBJECTIVES|O :|O 
K-ras|gene-rna (|O Kirsten-ras|gene-rna )|O point|O mutation|O (|O PM|O )|O in|O codon|O 12|O are|O suggested|O to|O be|O significantly|O associated|O with|O the|O tumorigenesis|O of|O pancreatic|O cancer|O .|O 
The|O incidences|O of|O K-ras|gene-rna PMs|O in|O human|O pancreatic|O cancer|O are|O reported|O to|O be|O different|O between|O Europeans|O and|O Japanese|O .|O 
The|O present|O study|O was|O designed|O to|O compare|O the|O incidences|O and|O profile|O of|O K-ras|gene-rna PMs|O and|O ras|gene-protein -|gene-protein p21|gene-protein expression|O in|O primary|O invasive|O ductal|O carcinoma|O (|O IDC|O )|O of|O the|O pancreas|O between|O Japanese|O and|O Chinese|O .|O 
METHODS|O :|O 
The|O specimens|O included|O 51|O Japanese|O and|O 34|O Chinese|O patients|O with|O the|O primary|O IDC|O of|O the|O pancreas|O .|O 
K-ras|gene-rna PMs|O were|O tested|O by|O allele|O specific|O oligonucleotide|O dot|O blot|O hybridization|O methods|O and|O ras|gene-protein -|gene-protein p21|gene-protein expression|O was|O stained|O by|O the|O immunohistochemical|O method|O .|O 
RESULTS|O :|O 
K-ras|gene-rna PMs|O were|O detected|O in|O 48|O Japanese|O IDCs|O (|O 94|O %|O )|O and|O in|O 24|O Chinese|O ones|O (|O 71|O %|O )|O .|O 
There|O was|O a|O significant|O difference|O between|O the|O two|O groups|O .|O 
The|O GAT|O mutation|O was|O more|O frequent|O both|O in|O Japanese|O (|O 61|O %|O ,|O 33|O /|O 54|O )|O and|O in|O Chinese|O (|O 60|O %|O ,|O 18|O /|O 30|O )|O IDCs|O .|O 
The|O transitions|O /|O transversions|O ratio|O in|O the|O Japanese|O group|O was|O 2.4|O in|O this|O study|O .|O 
By|O contrast|O ,|O that|O in|O the|O Chinese|O group|O was|O 1.5|O .|O 
The|O expression|O of|O p21|gene-protein was|O detected|O in|O 24|O Japanese|O IDCs|O (|O 47|O %|O )|O and|O in|O 24|O Chinese|O IDCs|O (|O 71|O %|O )|O .|O 
There|O was|O a|O significant|O difference|O between|O the|O two|O groups|O .|O 
The|O expression|O of|O p21|gene-protein and|O the|O patterns|O of|O K-ras|gene-rna PMs|O did|O not|O show|O any|O significant|O influence|O on|O the|O survival|O of|O the|O patients|O both|O in|O Japanese|O and|O Chinese|O .|O 
In|O the|O present|O study|O ,|O Chinese|O IDC|O had|O a|O lower|O frequency|O of|O K-ras|gene-rna PMs|O in|O codon|O 12|O than|O Japanese|O IDC|O .|O 
The|O pattern|O of|O K-ras|gene-rna PMs|O in|O Chinese|O IDC|O was|O different|O from|O that|O in|O Japanese|O and|O European|O IDC|O ,|O respectively|O .|O 
CONCLUSIONS|O :|O 
Ki-ras|gene-rna PM|O and|O p21|gene-protein expression|O were|O frequently|O seen|O both|O in|O Japanese|O and|O Chinese|O patients|O with|O pancreatic|O cancer|O .|O 
Factors|O such|O as|O lifestyle|O and|O environment|O may|O have|O influences|O on|O pancreatic|O carcinogenesis|O in|O various|O populations|O .|O 
Aberrant|O expression|O of|O beta-catenin|gene-protein and|O mutation|O of|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O in|O renal|O and|O urothelial|O carcinomas|O .|O 
The|O present|O study|O attempted|O to|O clarify|O the|O significance|O of|O aberrant|O expression|O of|O beta-catenin|gene-protein protein|O and|O mutation|O of|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O in|O renal|O and|O urothelial|O carcinogenesis|O .|O 
beta-Catenin|gene-protein expression|O was|O examined|O immunohistochemically|O and|O mutation|O of|O the|O beta-catenin|gene-rna gene|O was|O analyzed|O by|O polymerase|gene-protein chain|O reaction|O -|O single|O strand|O conformation|O polymorphism|O (|O SSCP|O )|O and|O direct|O sequencing|O .|O 
beta-Catenin|gene-protein immunoreactivity|O was|O observed|O at|O the|O cell|O membrane|O in|O all|O 30|O renal|O cell|O carcinomas|O (|O RCC|O )|O examined|O ,|O and|O no|O RCC|O showed|O a|O mobility|O -|O shifted|O SSCP|O band|O .|O 
Of|O 46|O transitional|O cell|O carcinomas|O (|O TCC|O )|O examined|O ,|O there|O was|O reduced|O expression|O of|O beta-catenin|gene-protein ,|O as|O compared|O with|O its|O expression|O in|O non|O -|O cancerous|O transitional|O epithelium|O ,|O in|O 22|O cases|O (|O 48|O %|O )|O and|O beta-catenin|gene-protein accumulation|O in|O the|O nucleus|O in|O five|O cases|O (|O 11|O %|O )|O .|O 
Of|O four|O renal|O pelvis|O TCC|O examined|O ,|O point|O mutation|O of|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O at|O codon|O 45|O resulting|O in|O amino|O acid|O substitution|O (|O Ser|O to|O Phe|O )|O was|O detected|O in|O one|O (|O 25|O %|O )|O .|O 
The|O incidence|O of|O reduced|O expression|O of|O beta-catenin|gene-protein correlated|O significantly|O with|O the|O growth|O pattern|O (|O superficial|O type|O vs|O invasive|O type|O )|O of|O TCC|O (|O P|O <|O 0.05|O )|O .|O 
These|O data|O indicate|O that|O :|O (1)|O aberrant|O beta-catenin|gene-protein expression|O may|O be|O at|O least|O partly|O involved|O in|O urothelial|O carcinogenesis|O ,|O but|O less|O significantly|O so|O in|O renal|O carcinogenesis|O ,|O and|O (2)|O it|O may|O be|O associated|O with|O the|O progression|O of|O TCC|O showing|O invasive|O growth|O .|O 
Mutational|O analysis|O of|O the|O beta-catenin|gene-rna gene|O in|O gastric|O carcinomas|O .|O 
Previous|O studies|O reported|O that|O mutation|O of|O the|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|O APC|gene-rna )|O gene|O was|O not|O observed|O in|O the|O majority|O of|O gastric|O cancers|O .|O 
To|O evaluate|O the|O role|O of|O the|O APC|gene-rna /|O beta-catenin|gene-rna /|O Tcf|gene-rna pathway|O ,|O we|O analyzed|O mutations|O in|O the|O beta-catenin|gene-rna gene|O and|O the|O accumulation|O of|O beta-catenin|gene-protein protein|O in|O gastric|O carcinomas|O .|O 
An|O interstitial|O deletion|O spanning|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O was|O observed|O in|O 1|O of|O 13|O gastric|O cancer|O cell|O lines|O .|O 
No|O missense|O mutation|O was|O found|O in|O these|O 13|O cell|O lines|O .|O 
Nuclear|O and/or|O cytoplasmic|O localization|O of|O beta-catenin|gene-generic was|O observed|O in|O 16|O of|O 70|O primary|O gastric|O carcinomas|O by|O immunohistochemistry|O ,|O while|O we|O found|O no|O mutations|O in|O exon|O 3|O in|O 35|O carcinoma|O tissues|O available|O for|O PCR|O amplification|O .|O 
Our|O findings|O suggest|O that|O somatic|O mutations|O of|O the|O beta-catenin|gene-rna gene|O are|O rare|O in|O human|O gastric|O carcinomas|O and|O that|O accumulation|O of|O normal|O beta-catenin|gene-protein protein|O in|O a|O subset|O of|O gastric|O cancers|O may|O be|O due|O to|O other|O mechanisms|O of|O its|O activation|O .|O 
beta|gene-rna -|gene-rna Catenin|gene-rna mutations|O and|O aberrant|O nuclear|O expression|O during|O endometrial|O tumorigenesis|O .|O 
To|O clarify|O the|O possible|O role|O of|O aberrant|O beta-catenin|gene-rna expression|O during|O endometrial|O tumorigenesis|O ,|O a|O total|O of|O 199|O cases|O of|O endometrial|O carcinomas|O (|O endometrioid|O type|O )|O ,|O as|O well|O as|O 37|O cases|O of|O simple|O /|O complex|O and|O 32|O of|O atypical|O hyperplasias|O ,|O was|O consecutively|O investigated|O for|O immunohistochemistry|O ,|O along|O with|O 141|O normal|O endometrial|O samples|O distant|O from|O carcinomas|O .|O 
Of|O 199|O carcinoma|O cases|O ,|O 73|O tumours|O as|O well|O as|O 44|O normal|O samples|O were|O also|O analysed|O using|O a|O combination|O of|O RT-PCR|O and|O Southern|O blot|O hybridization|O ,|O Western|O blot|O ,|O and|O mutation|O gene|O assays|O .|O 
Cell|O membrane|O beta-catenin|gene-generic immunoreactivity|O showed|O a|O stepwise|O decrease|O from|O normal|O ,|O through|O atypical|O hyperplasia|O ,|O to|O grade|O 3|O carcinomas|O .|O 
In|O contrast|O ,|O the|O nuclear|O accumulation|O in|O atypical|O hyperplasias|O and|O grade|O 1|O or|O 2|O tumours|O was|O higher|O than|O in|O simple|O /|O complex|O hyperplasias|O .|O 
Mutations|O in|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O involving|O codons|O 33|O ,|O 34|O ,|O 37|O ,|O 41|O ,|O and|O 45|O were|O observed|O in|O 16|O (|O 22.9|O %|O )|O of|O 70|O endometrial|O carcinomas|O ,|O as|O well|O as|O 3|O (|O 12.5|O %|O )|O of|O 24|O atypical|O hyperplasias|O ,|O the|O results|O being|O significantly|O related|O to|O low|O membrane|O and|O high|O nuclear|O immunoreactivity|O but|O not|O relative|O mRNA|O expression|O levels|O ,|O suggesting|O that|O the|gene-rna gene|gene-rna mutations|O may|O be|O closely|O associated|O with|O changes|O in|O subcellular|O distribution|O .|O 
In|O addition|O to|O significant|O association|O between|O beta-catenin|gene-rna mutation|O and|O low|O grade|O histological|O malignancy|O (|O P|O =|O 0.048|O )|O ,|O the|O mutations|O were|O detected|O in|O none|O of|O 15|O and|O 13|O (|O 26|O %|O )|O of|O 50|O tumours|O with|O or|O without|O lymph|O node|O metastasis|O ,|O the|O difference|O being|O significant|O (|O P|O =|O 0.027|O )|O .|O 
These|O findings|O suggest|O that|O beta-catenin|gene-rna abnormalities|O may|O play|O an|O important|O role|O in|O a|O relatively|O early|O event|O during|O the|O endometrial|O hyperplasia|O -|O carcinoma|O sequence|O .|O 
K-ras|gene-rna exon|O 2|O point|O mutations|O in|O human|O endometrial|O cancer|O .|O 
In|O the|O present|O study|O ,|O we|O screened|O for|O the|O K-ras|gene-rna exon|O 2|O point|O mutations|O in|O a|O group|O of|O 87|O gynecological|O neoplasms|O (|O 82|O endometrial|O carcinomas|O ,|O four|O carcinomas|O of|O the|O uterine|O cervix|O and|O one|O uterine|O carcinosarcoma|O )|O using|O the|O non|O -|O isotopic|O PCR-SSCP|O -|O direct|O sequencing|O techniques|O .|O 
Direct|O sequencing|O analysis|O revealed|O CAA|O -->|O CAC|O (|O Gln|O -->|O His|O )|O K-ras|gene-rna codon|O 61|O point|O mutations|O in|O two|O (|O 2.4|O %|O )|O of|O the|O 82|O endometrial|O carcinomas|O mentioned|O above|O .|O 
These|O two|O cases|O were|O endometrial|O endometrioid|O carcinomas|O at|O an|O early|O clinical|O stage|O of|O disease|O (|O stage|O IB|O and|O IC|O due|O to|O FIGO|O )|O .|O 
Those|O endometrial|O carcinomas|O that|O showed|O K-ras|gene-rna exon|O 2|O point|O mutations|O revealed|O a|O strong|O positivity|O for|O heterogeneous|O nuclear|O retinoblastoma|O protein|O staining|O ;|O none|O of|O these|O ,|O however|O ,|O have|O had|O the|O K-ras|gene-rna codon|O 12|O point|O mutation|O .|O 
In|O addition|O ,|O there|O were|O no|O K-ras|gene-rna gene|O point|O mutations|O in|O three|O endometrial|O carcinomas|O lacking|O the|O Rb|O protein|O immunohistochemically|O .|O 
None|O of|O the|O cervical|O carcinomas|O tested|O had|O K-ras|gene-rna gene|O point|O mutations|O ,|O whereas|O one|O carcinosarcoma|O harbored|O K-ras|gene-rna codon|O 61|O point|O mutation|O (|O CAA|O -->|O CAC|O )|O .|O 
In|O conclusion|O ,|O our|O data|O support|O the|O view|O that|O K-ras|gene-rna exon|O 2|O point|O mutations|O are|O rare|O events|O in|O human|O endometrial|O cancer|O .|O 
Rb|gene-rna and|O K-ras|gene-rna gene|O abnormalities|O may|O occur|O independently|O of|O each|O other|O during|O endometrial|O carcinogenesis|O in|O humans|O .|O 
H-ras|gene-rna oncogene|O mutation|O in|O dedifferentiated|O liposarcoma|O .|O 
Polymerase|gene-protein chain|O reaction|O -|O restriction|O fragment|O length|O polymorphism|O analysis|O .|O 
Point|O mutations|O of|O the|O ras|gene-rna gene|O family|O (|O K-ras|gene-rna ,|O H-ras|gene-rna ,|O and|O N-ras|gene-rna )|O are|O thought|O to|O be|O involved|O in|O the|O development|O of|O a|O variety|O of|O human|O tumors|O .|O 
Dedifferentiated|O liposarcoma|O is|O characterized|O by|O the|O coexistence|O of|O well|O -|O differentiated|O (|O WD|O )|O and|O high-grade|O anaplastic|O (|O HG|O )|O components|O .|O 
The|O presence|O of|O point|O mutations|O at|O codons|O 12|O and|O 13|O of|O the|O H-ras|gene-rna gene|O was|O studied|O in|O 34|O liposarcomas|O ,|O comprising|O 15|O well|O -|O differentiated|O liposarcomas|O and|O 19|O dedifferentiated|O liposarcomas|O ,|O and|O in|O 8|O storiform|O -|O pleomorphic|O type|O malignant|O fibrous|O histiocytomas|O (|O MFHs|O )|O using|O polymerase|gene-protein chain|O reaction|O -|O restriction|O fragment|O length|O polymorphism|O and|O direct|O sequencing|O analysis|O .|O 
The|O 2|O components|O of|O dedifferentiated|O liposarcoma|O were|O analyzed|O independently|O .|O 
H-ras|gene-rna mutations|O were|O seen|O only|O in|O dedifferentiated|O liposarcomas|O (|O 4|O /|O 19|O [|O 21|O %|O ]|O )|O ,|O 1|O in|O WD|O components|O and|O 3|O in|O HG|O components|O .|O 
The|O mutation|O was|O not|O seen|O in|O any|O of|O 15|O cases|O of|O well|O -|O differentiated|O liposarcoma|O .|O MFHs|O showed|O an|O H-ras|gene-rna mutation|O in|O 1|O (|O 12|O %|O )|O of|O 8|O cases|O .|O 
Relevance|O of|O Ki-67|O antigen|O expression|O and|O K-ras|gene-rna mutation|O in|O colorectal|O liver|O metastases|O .|O 
AIMS|O :|O 
The|O liver|O is|O a|O frequent|O site|O of|O metastases|O from|O colorectal|O cancer|O .|O 
While|O these|O lesions|O are|O potentially|O amenable|O to|O surgical|O resection|O ,|O they|O are|O usually|O very|O aggressive|O ,|O and|O recurrence|O is|O frequent|O .|O 
Mutations|O of|O the|O proto|O -|O oncogene|O K|gene-rna -|gene-rna ras|gene-rna are|O thought|O to|O impart|O a|O strong|O growth|O signal|O to|O tumour|O cells|O and|O are|O closely|O associated|O with|O the|O development|O of|O malignancies|O of|O the|O colon|O and|O rectum|O .|O 
Hepatic|O metastases|O from|O colorectal|O cancer|O have|O notably|O elevated|O proliferative|O rates|O .|O 
The|O present|O study|O was|O performed|O to|O investigate|O the|O relationship|O between|O proliferation|O or|O K|gene-rna -|gene-rna ras|gene-rna mutation|O and|O prognosis|O following|O curative|O resection|O of|O colorectal|O liver|O metastases|O .|O 
METHODS|O :|O Colorectal|O liver|O metastases|O from|O 41|O patients|O undergoing|O curative|O hepatic|O resection|O were|O examined|O for|O proliferation|O status|O and|O presence|O of|O K|gene-rna -|gene-rna ras|gene-rna mutations|O .|O 
The|O proliferative|O activity|O was|O assessed|O by|O Ki-67|O immunohistochemistry|O .|O 
DNA|O from|O the|O same|O tissue|O samples|O was|O screened|O for|O point|O mutations|O in|O codon|O 12|O of|O the|O K|gene-rna -|gene-rna ras|gene-rna gene|O using|O a|O novel|O microplate|O -|O based|O allelic|O -|O specific|O hybridization|O assay|O .|O 
Ki-67|O scores|O and|O K|gene-rna -|gene-rna ras|gene-rna status|O were|O then|O related|O with|O patient|O survival|O as|O determined|O through|O retrospective|O analysis|O .|O 
RESULTS|O :|O 
Median|O survival|O was|O 40|O months|O .|O 
Patients|O with|O high|O Ki-67|O scores|O (|O >|O or|O =|O 50|O %|O )|O had|O significantly|O shorter|O median|O survival|O compared|O with|O those|O with|O low|O scores|O (|O 30|O vs|O 44|O months|O ,|O log|O -|O rank|O P|O =|O 0.02|O )|O .|O 
A|O high|O Ki-67|O score|O was|O an|O independent|O negative|O prognostic|O factor|O by|O multivariate|O regression|O analysis|O (|O relative|O risk|O =|O 3.04|O ,|O P|O =|O 0.036|O )|O .|O 
K|gene-rna -|gene-rna ras|gene-rna point|O mutations|O were|O detected|O in|O 6|O /|O 41|O patients|O (|O 15|O %|O )|O ,|O but|O mutational|O status|O did|O not|O correlate|O with|O Ki-67|O score|O or|O survival|O .|O 
CONCLUSIONS|O :|O These|O findings|O suggest|O that|O the|O tumour|O proliferative|O index|O is|O a|O useful|O predictor|O of|O aggressive|O tumour|O behaviour|O and|O an|O indicator|O of|O patient|O survival|O .|O 
The|O presence|O of|O K|gene-rna -|gene-rna ras|gene-rna mutations|O does|O not|O appear|O to|O correlate|O with|O tumour|O proliferation|O status|O or|O patient|O survival|O .|O 
Sporadic|O fundic|O gland|O polyps|O :|O common|O gastric|O polyps|O arising|O through|O activating|O mutations|O in|O the|O beta-catenin|gene-rna gene|O .|O 
Fundic|O gland|O polyps|O (|O FGPs|O )|O are|O the|O most|O common|O gastric|O polyps|O .|O 
FGPs|O traditionally|O have|O been|O regarded|O as|O nondysplastic|O hamartomatous|O or|O hyperplastic|O lesions|O ,|O but|O their|O pathogenesis|O remains|O unclear|O .|O 
We|O have|O recently|O shown|O that|O somatic|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|O APC|gene-rna )|O gene|O alterations|O are|O frequently|O present|O in|O FGPs|O associated|O with|O familial|O adenomatous|O polyposis|O (|O FAP|O )|O ,|O raising|O the|O possibility|O that|O mutations|O of|O the|O beta-catenin|gene-rna gene|O affecting|O the|O APC|gene-rna /|O beta-catenin|gene-rna pathway|O might|O be|O involved|O in|O the|O pathogenesis|O of|O sporadic|O FGPs|O .|O 
We|O analyzed|O somatic|O beta-catenin|gene-rna gene|O mutations|O in|O 57|O sporadic|O FGPs|O from|O 40|O patients|O without|O FAP|O and|O in|O 19|O FGPs|O from|O 13|O FAP|O patients|O .|O 
Direct|O DNA|O sequencing|O of|O exon|O 3|O encompassing|O the|O glycogen|O synthase|O kinase-3beta|O phosphorylation|O region|O for|O beta-catenin|gene-rna was|O used|O with|O confirmation|O by|O HIN:fI|gene-protein restriction|gene-protein endonuclease|gene-protein digestion|O .|O 
The|O foveolar|O epithelium|O and|O dilated|O fundic|O glands|O of|O the|O polyps|O were|O separately|O microdissected|O and|O analyzed|O in|O 22|O of|O 57|O sporadic|O FGPs|O .|O 
Activating|O beta-catenin|gene-rna gene|O mutations|O were|O present|O in|O 91|O %|O (|O 52|O of|O 57|O )|O of|O sporadic|O FGPs|O .|O 
Both|O the|O foveolar|O epithelium|O and|O the|O dilated|O fundic|O gland|O epithelium|O comprising|O the|O polyps|O were|O shown|O to|O have|O the|O same|O somatic|O beta-catenin|gene-rna mutation|O in|O 21|O of|O 22|O (|O 95|O %|O )|O sporadic|O FGPs|O .|O 
In|O contrast|O ,|O beta-catenin|gene-rna gene|O mutations|O were|O not|O present|O in|O any|O of|O the|O 19|O FAP|O -|O associated|O FGPs|O (|O P|O :|O <|O 0.000001|O )|O .|O 
The|O high|O frequency|O of|O beta-catenin|gene-rna mutations|O in|O sporadic|O FGPs|O indicates|O that|O these|O lesions|O arise|O through|O activating|O mutations|O of|O the|O beta-catenin|gene-rna gene|O .|O 
Beta-catenin|gene-rna mutations|O in|O gastrointestinal|O tract|O polyps|O have|O previously|O only|O been|O demonstrated|O in|O a|O subset|O of|O adenomatous|O (|O dysplastic|O )|O or|O neoplastic|O polyps|O .|O 
Sporadic|O FGPs|O are|O therefore|O the|O only|O lesions|O of|O the|O gastrointestinal|O tract|O to|O demonstrate|O beta-catenin|gene-rna mutations|O while|O lacking|O dysplastic|O morphology|O .|O 
Frequent|O k|gene-rna -|gene-rna ras|gene-rna -|gene-rna 2|gene-rna mutations|O and|O p16|gene-rna (|O INK4A|gene-rna )|O methylation|O in|O hepatocellular|O carcinomas|O in|O workers|O exposed|O to|O vinyl|O chloride|O .|O 
Vinyl|O chloride|O (|O VC|O )|O is|O a|O know|O animal|O and|O human|O carcinogen|O associated|O with|O liver|O angiosarcomas|O (|O LAS|O )|O and|O hepatocellular|O carcinomas|O (|O HCC|O )|O .|O 
In|O VC|O -|O associated|O LAS|O mutations|O of|O the|O K|gene-rna -|gene-rna ras|gene-rna -|gene-rna 2|gene-rna gene|O have|O been|O reported|O ;|O however|O ,|O no|O data|O about|O the|O prevalence|O of|O such|O mutations|O in|O VC|O associated|O HCCs|O are|O available|O .|O 
Recent|O data|O indicate|O K|gene-rna -|gene-rna ras|gene-rna -|gene-rna 2|gene-rna mutations|O induce|O P16|gene-rna methylation|O accompanied|O by|O inactivation|O of|O the|O p16|gene-rna gene|O .|O 
The|O presence|O of|O K|gene-rna -|gene-rna ras|gene-rna -|gene-rna 2|gene-rna mutations|O was|O analysed|O in|O tissue|O from|O 18|O patients|O with|O VC|O associated|O HCCs|O .|O 
As|O a|O control|O group|O ,|O 20|O patients|O with|O hepatocellular|O carcinoma|O due|O to|O hepatitis|O B|O (|O n|O =|O 7|O )|O ,|O hepatitis|O C|O (|O n|O =|O 5|O )|O and|O alcoholic|O liver|O cirrhosis|O (|O n|O =|O 8|O )|O was|O used|O .|O 
The|O specific|O mutations|O were|O determined|O by|O direct|O sequencing|O of|O codon|O 12|O and|O 13|O of|O the|O K|gene-rna -|gene-rna ras|gene-rna -|gene-rna 2|gene-rna gene|O in|O carcinomatous|O and|O adjacent|O non|O -|O neoplastic|O liver|O tissue|O after|O microdissection|O .|O 
The|O status|O of|O p16|gene-rna was|O evaluated|O by|O methylation|O -|O specific|O PCR|O (|O MSP|O )|O ,|O microsatellite|O analysis|O ,|O DNA|O sequencing|O and|O immunohistochemical|O staining|O .|O 
All|O patients|O had|O a|O documented|O chronic|O quantitated|O exposure|O to|O VC|O (|O average|O 8883|O ppmy|O ,|O average|O duration|O :|O 245|O months|O )|O .|O 
K|gene-rna -|gene-rna ras|gene-rna -|gene-rna 2|gene-rna mutations|O were|O found|O in|O 6|O of|O 18|O (|O 33|O %|O )|O examined|O VC|O -|O associated|O HCCs|O and|O in|O 3|O cases|O of|O adjacent|O non|O -|O neoplastic|O liver|O tissue|O .|O 
There|O were|O 3|O G|O -->|O A|O point|O mutations|O in|O the|O tumour|O tissue|O .|O 
All|O 3|O mutations|O found|O in|O non|O -|O neoplastic|O liver|O from|O VC|O -|O exposed|O patients|O were|O also|O G|O -->|O A|O point|O mutations|O (|O codon|O 12|O -|O and|O codon|O 13|O -|O aspartate|O mutations|O )|O .|O 
Hypermethylation|O of|O the|O 5|O '|O CpG|O island|O of|O the|O p16|gene-rna gene|O was|O found|O in|O 13|O of|O 18|O examined|O carcinomas|O (|O 72|O %|O )|O .|O 
Of|O 6|O cancers|O with|O K|gene-rna -|gene-rna ras|gene-rna -|gene-rna 2|gene-rna mutations|O ,|O 5|O specimens|O also|O showed|O methylated|O p16|gene-rna .|O 
Within|O the|O control|O group|O ,|O K|gene-rna -|gene-rna ras|gene-rna -|gene-rna 2|gene-rna mutation|O were|O found|O in|O 3|O of|O 20|O (|O 15|O %|O )|O examined|O HCC|O .|O p16|gene-rna methylation|O occurred|O in|O 11|O out|O of|O 20|O (|O 55|O %|O )|O patients|O .|O 
K|gene-rna -|gene-rna ras|gene-rna -|gene-rna 2|gene-rna mutations|O and|O p16|gene-rna methylation|O are|O frequent|O events|O in|O VC|O associated|O HCCs|O .|O 
We|O observed|O a|O K|gene-rna -|gene-rna ras|gene-rna -|gene-rna 2|gene-rna mutation|O pattern|O characteristic|O of|O chloroethylene|O oxide|O ,|O a|O carcinogenic|O metabolite|O of|O VC|O .|O 
Our|O results|O strongly|O suggest|O that|O K|gene-rna -|gene-rna ras|gene-rna -|gene-rna 2|gene-rna mutations|O play|O an|O important|O role|O in|O the|O pathogenesis|O of|O VC|O -|O associated|O HCC|O .|O 
Beta-catenin|gene-rna mutations|O in|O biliary|O tract|O cancers|O :|O a|O population|O -|O based|O study|O in|O China|O .|O 
beta-Catenin|gene-protein is|O an|O ubiquitously|O expressed|O cytoplasmic|O protein|O that|O has|O a|O crucial|O role|O in|O both|O cadherin|gene-protein -|O mediated|O cell|O -|O cell|O adhesion|O and|O as|O a|O downstream|O signaling|O molecule|O in|O the|O wingless|gene-protein /|O Wnt|gene-protein pathway|O .|O Activating|O mutations|O in|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O ,|O at|O the|O phosphorylation|O sites|O for|O ubiquitination|O and|O degradation|O of|O beta-catenin|gene-protein ,|O are|O present|O in|O a|O variety|O of|O cancers|O .|O 
Because|O alterations|O of|O the|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|O APC|gene-rna )|O gene|O are|O present|O in|O biliary|O tract|O cancers|O and|O the|O APC|gene-protein protein|O modulates|O levels|O of|O beta-catenin|gene-protein ,|O we|O evaluated|O the|O role|O of|O beta-catenin|gene-protein in|O biliary|O tract|O cancer|O by|O sequencing|O the|O third|O exon|O of|O the|O beta-catenin|gene-rna gene|O among|O 107|O biliary|O tract|O cancers|O and|O 7|O gallbladder|O adenomas|O from|O a|O population|O -|O based|O study|O in|O CHINA|O :|O Point|O mutations|O of|O serine|O or|O threonine|O phosphorylation|O sites|O in|O exon|O 3|O of|O beta-catenin|gene-rna were|O present|O in|O 8|O of|O 107|O (|O 7.5|O %|O )|O biliary|O tract|O cancers|O and|O 4|O of|O 7|O (|O 57.1|O %|O )|O gallbladder|O adenomas|O .|O 
Mutations|O of|O beta-catenin|gene-rna were|O more|O frequent|O in|O ampullary|O and|O gallbladder|O carcinomas|O than|O in|O bile|O duct|O carcinomas|O (|O P|O =|O 0.04|O )|O and|O in|O papillary|O adenocarcinomas|O than|O other|O histological|O types|O of|O carcinomas|O (|O P|O =|O 0.02|O )|O .|O 
These|O results|O suggest|O that|O the|O molecular|O pathways|O of|O biliary|O tract|O neoplasms|O vary|O by|O anatomical|O subsite|O and|O histological|O subtype|O .|O 
Intratumor|O heterogeneity|O of|O k-ras|gene-rna and|O p53|gene-rna mutations|O among|O human|O colorectal|O adenomas|O containing|O early|O cancer|O .|O 
The|O molecular|O pathways|O and|O the|O timing|O of|O genetic|O events|O during|O human|O colorectal|O carcinogenesis|O are|O still|O not|O fully|O understood|O .|O 
We|O have|O addressed|O the|O intratumor|O heterogeneity|O of|O the|O mutational|O status|O of|O the|O k-ras|gene-rna oncogene|O and|O of|O the|O p53|gene-rna oncosuppressor|O gene|O during|O the|O adenoma|O -|O carcinoma|O sequence|O by|O investigating|O 26|O human|O colorectal|O adenomas|O containing|O early|O cancer|O .|O 
An|O intratumor|O comparative|O analysis|O was|O obtained|O among|O the|O adenomatous|O and|O carcinomatous|O component|O pairs|O .|O 
Additionally|O ,|O we|O have|O analyzed|O 17|O adenomas|O having|O cancer|O in|O the|O near|O vicinity|O .|O 
The|O adenomatous|O components|O of|O the|O adenomas|O containing|O early|O cancer|O and|O the|O adenomas|O having|O cancer|O in|O the|O near|O vicinity|O had|O comparable|O frequencies|O for|O k-ras|gene-rna mutations|O (|O 28|O and|O 47|O %|O )|O but|O different|O for|O p53|gene-rna mutations|O (|O 52|O and|O 7|O %|O ,|O p|O -|O value|O =|O 0.01|O )|O .|O 
Interestingly|O ,|O the|O adenomatous|O and|O carcinomatous|O components|O of|O the|O adenomas|O containing|O early|O cancer|O were|O rarely|O heterogeneous|O for|O the|O k-ras|gene-rna mutational|O status|O (|O only|O in|O 13|O %|O of|O the|O cases|O )|O but|O were|O characterized|O by|O heterogeneity|O of|O the|O p53|gene-rna status|O in|O 59|O %|O of|O the|O cases|O (|O p|O -|O value|O <|O 0.01|O )|O .|O 
In|O addition|O ,|O the|O mutations|O of|O p53|gene-rna for|O the|O adenomatous|O components|O of|O the|O adenomas|O containing|O early|O cancer|O were|O statistically|O significantly|O associated|O with|O severe|O dysplasia|O (|O p|O -|O value|O =|O 0.01|O )|O .|O 
Intratumor|O homogeneity|O of|O k-ras|gene-rna status|O during|O the|O human|O colorectal|O adenoma|O -|O carcinoma|O sequence|O suggests|O that|O the|O role|O of|O k-ras|gene-rna is|O more|O related|O to|O tumor|O initiation|O than|O to|O tumor|O progression|O .|O 
On|O the|O contrary|O ,|O intratumor|O heterogeneity|O of|O p53|gene-rna mutations|O indicates|O that|O the|O type|O of|O the|O p53|gene-rna mutations|O may|O also|O be|O relevant|O for|O selection|O and|O expansion|O of|O new|O subclones|O leading|O to|O tumor|O progression|O .|O 
Loss|O of|O heterozygosity|O at|O 4p16.3|O and|O mutation|O of|O FGFR3|gene-rna in|O transitional|O cell|O carcinoma|O .|O 
4p16.3|O has|O previously|O been|O identified|O as|O a|O region|O of|O non|O -|O random|O LOH|O in|O transitional|O cell|O carcinoma|O ,|O suggesting|O the|O presence|O of|O a|O tumour|gene-rna suppressor|gene-rna gene|gene-rna .|O 
One|O candidate|O within|O this|O region|O is|O fibroblast|gene-rna growth|gene-rna factor|gene-rna receptor|gene-rna 3|gene-rna (|O FGFR3|gene-rna )|O .|O 
Germline|O mutations|O in|O FGFR3|gene-rna are|O known|O to|O cause|O several|O autosomal|O dominant|O skeletal|O dysplasias|O ,|O the|O severity|O of|O which|O depends|O on|O the|O position|O and|O nature|O of|O the|O mutation|O in|O the|gene-protein protein|gene-protein .|O 
We|O investigated|O the|O frequency|O and|O nature|O of|O FGFR3|gene-rna mutations|O in|O a|O panel|O of|O transitional|O cell|O carcinomas|O and|O cell|O lines|O and|O studied|O the|O possible|O link|O between|O mutation|O and|O loss|O of|O heterozygosity|O (|O LOH|O )|O on|O 4p16.3|O .|O 
FGFR3|gene-rna coding|O sequence|O from|O 63|O transitional|O cell|O carcinomas|O (|O TCC|O )|O of|O various|O stages|O and|O grades|O ,|O and|O 18|O cell|O lines|O was|O analysed|O by|O fluorescent|O SSCP|O .|O 
Samples|O with|O abnormal|O migration|O patterns|O were|O sequenced|O to|O identify|O the|O mutation|O or|O polymorphism|O .|O 
Thirty-one|O of|O the|O 63|O tumours|O had|O previously|O been|O assessed|O to|O have|O LOH|O at|O 4p16.3|O .|O 
Twenty-six|O of|O the|O 63|O tumours|O (|O 41|O %|O )|O and|O 4|O /|O 18|O (|O 22|O %|O )|O of|O the|O cell|O lines|O had|O missense|O mutations|O in|O FGFR3|gene-rna .|O 
All|O mutations|O detected|O in|O our|O panel|O have|O been|O reported|O in|O the|O germline|O where|O all|O apart|O from|O one|O cause|O lethal|O conditions|O .|O 
One|O tumour|O contained|O K|O 652|O Q|O which|O has|O recently|O been|O identified|O in|O less|O severe|O cases|O of|O skeletal|O dysplasia|O .|O 
Tumours|O with|O and|O without|O LOH|O at|O 4p16.3|O had|O mutations|O in|O FGFR3|gene-rna suggesting|O that|O these|O two|O events|O are|O not|O causally|O linked|O .|O 
The|O frequency|O of|O FGFR3|gene-rna mutation|O indicates|O that|O this|gene-protein protein|gene-protein plays|O an|O important|O role|O in|O TCC|O .|O 
Autosomal|O dominant|O disorders|O of|O skeletal|O and|O cranial|O development|O have|O been|O linked|O to|O fibroblast|gene-rna growth|gene-rna factor|gene-rna receptor|gene-rna (|gene-rna FGFR|gene-rna )|gene-rna 2|gene-rna and|O FGFR3|gene-rna .|O 
Here|O we|O report|O two|O identical|O mutations|O in|O FGFR2|gene-rna that|O cause|O craniosynostosis|O syndromes|O ,|O Crouzon|O ,|O Apert|O ,|O and|O Pfeiffer|O in|O gastric|O carcinoma|O .|O 
A|O missense|O mutation|O (|O Ser|O 267|O Pro|O )|O in|O exon|O IIIa|O and|O a|O splice|O site|O mutation|O (|O 940|O -|O 2|O A|O -->|O G|O )|O in|O exon|O IIIc|O were|O detected|O in|O gastric|O cancer|O patients|O .|O 
Interestingly|O ,|O these|O heterozygous|O somatic|O mutations|O are|O identical|O to|O the|O germinal|O activating|O mutations|O in|O FGFR2|gene-rna reported|O previously|O in|O craniosynostosis|O syndromes|O .|O 
In|O addition|O ,|O the|O two|O novel|O mutations|O of|O FGFR3|gene-rna in|O colorectal|O carcinomas|O were|O identified|O .|O 
All|O identified|O mutations|O occurred|O at|O highly|O conserved|O sequences|O ,|O not|O only|O in|O the|O FGFR|gene-rna family|O of|O molecules|O ,|O but|O also|O throughout|O evolution|O and|O clustered|O in|O the|O immunoglobulin|O -|O like|O loop|O -|O III|O domain|O ,|O highlighting|O the|O functional|O importance|O of|O this|O domain|O .|O 
Our|O results|O indicate|O that|O FGFR2|gene-rna and|O FGFR3|gene-rna ,|O in|O addition|O to|O their|O potential|O role|O in|O skeletal|O dysplasias|O ,|O play|O an|O important|O role|O in|O tumorigenesis|O .|O 
Frequent|O nuclear|O beta-catenin|gene-protein accumulation|O and|O associated|O mutations|O in|O endometrioid|O -|O type|O endometrial|O and|O ovarian|O carcinomas|O with|O squamous|O differentiation|O .|O 
Focal|O squamous|O differentiation|O is|O a|O common|O feature|O of|O endometrioid|O endometrial|O and|O ovarian|O carcinomas|O (|O E-Em|O and|O E-Ova|O Cas|O )|O .|O 
A|O close|O association|O between|O mutated|O beta-catenin|gene-protein accumulation|O and|O alteration|O in|O cellular|O morphology|O has|O recently|O been|O demonstrated|O in|O murine|O L|O cell|O lines|O .|O 
To|O clarify|O the|O possible|O role|O of|O beta-catenin|gene-generic abnormalities|O and|O changes|O in|O tumour|O morphology|O ,|O 60|O grade|O (|O G|O )|O 1|O or|O G2|O E-Em|O Cas|O with|O areas|O of|O squamous|O differentiation|O (|O SqD|O )|O ,|O including|O morules|O and|O squamous|O metaplastic|O (|O SqM|O )|O foci|O ,|O as|O well|O as|O 32|O G1|O or|O G2|O tumours|O without|O such|O lesions|O ,|O were|O investigated|O and|O the|O results|O compared|O with|O findings|O for|O c-jun|gene-protein and|O wnt-1|gene-protein expression|O .|O 
Twenty-three|O E-Ova|O Cas|O ,|O with|O and|O without|O SqD|O lesions|O ,|O were|O also|O examined|O .|O 
In|O E-Em|O Cas|O ,|O frequent|O nuclear|O beta-catenin|gene-protein accumulation|O was|O observed|O in|O 22|O (|O 84.6|O %|O )|O of|O 26|O tumours|O with|O morules|O and|O 15|O (|O 45.5|O %|O )|O of|O 33|O with|O SqM|O foci|O ,|O in|O contrast|O to|O 4|O (|O 12.5|O %|O )|O of|O 32|O without|O such|O lesions|O .|O 
Similar|O findings|O were|O also|O noted|O for|O mutations|O in|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O ,|O involving|O codons|O 32|O ,|O 33|O ,|O 34|O ,|O 37|O ,|O 41|O ,|O and|O 45|O ,|O the|O single|O nucleotide|O substitutions|O being|O identical|O between|O SqD|O and|O the|O surrounding|O carcinoma|O tissue|O in|O most|O informative|O cases|O .|O 
The|O mutations|O were|O positively|O related|O to|O nuclear|O immunopositivity|O ,|O but|O inversely|O to|O membrane|O expression|O ,|O while|O there|O was|O no|O association|O with|O the|O status|O of|O c-jun|gene-protein or|O wnt-1|gene-protein .|O 
These|O E-Ova|O Cas|O ,|O nuclear|O beta-catenin|gene-protein accumulation|O and|O mutations|O were|O limited|O to|O tumours|O with|O SqD|O features|O ,|O independent|O of|O c-jun|gene-protein and|O wnt-1|gene-protein status|O .|O 
These|O data|O indicate|O that|O beta-catenin|gene-generic abnormalities|O are|O relatively|O common|O in|O E-Em|O and|O E-Ova|O Cas|O with|O SqD|O features|O ,|O implying|O a|O role|O in|O the|O squamous|O differentiation|O of|O tumour|O cells|O ,|O not|O necessarily|O related|O to|O c-jun|gene-protein and/or|O wnt-1|gene-protein status|O .|O 
Adenosquamous|O carcinoma|O of|O the|O pancreas|O :|O a|O clinicopathologic|O series|O of|O 25|O cases|O .|O 
BACKGROUND|O :|O 
Adenosquamous|O carcinoma|O is|O a|O rare|O aggressive|O subtype|O of|O pancreatic|O adenocarcinoma|O .|O 
We|O describe|O the|O clinical|O ,|O pathologic|O ,|O and|O molecular|O characteristics|O of|O 25|O of|O these|O lesions|O ,|O the|O largest|O series|O to|O date|O .|O 
METHODS|O :|O 
Twenty-five|O cases|O of|O adenosquamous|O carcinoma|O of|O the|O pancreas|O diagnosed|O between|O 1961|O and|O 1994|O were|O retrieved|O from|O the|O files|O of|O the|O Endocrine|O Registry|O of|O the|O Armed|O Forces|O Institute|O of|O Pathology|O .|O 
Histologic|O features|O were|O reviewed|O ,|O histochemical|O ,|O immunohistochemical|O ,|O and|O molecular|O (|O k-ras|gene-rna )|O studies|O were|O performed|O ,|O and|O patient|O follow-up|O was|O obtained|O .|O 
RESULTS|O :|O 
The|O patients|O included|O 17|O men|O and|O eight|O women|O ,|O aged|O 28|O to|O 82|O years|O (|O mean|O ,|O 65.4|O y|O )|O .|O 
The|O patients|O usually|O experienced|O weight|O loss|O (|O n|O =|O 17|O )|O or|O painless|O jaundice|O (|O n|O =|O 11|O )|O ,|O while|O also|O presenting|O with|O other|O abdominal|O symptoms|O .|O 
The|O tumors|O affected|O the|O head|O most|O frequently|O (|O n|O =|O 17|O )|O ,|O followed|O by|O the|O tail|O (|O n|O =|O 9|O )|O or|O body|O (|O n|O =|O 4|O )|O .|O 
Five|O cases|O involved|O more|O than|O one|O anatomic|O region|O of|O the|O pancreas|O .|O 
Microscopically|O ,|O all|O tumors|O demonstrated|O dual|O differentiation|O toward|O adenocarcinoma|O and|O squamous|O cell|O carcinoma|O .|O 
All|O cases|O tested|O were|O immunoreactive|O with|O keratin|gene-protein (|O AE1|gene-protein :|O AE3|gene-protein and|O CK1|gene-protein )|O ,|O whereas|O other|O keratin|gene-protein markers|O were|O variably|O expressed|O :|O CK|gene-protein 5|gene-protein /|O 6|gene-protein (|O 88|O %|O )|O ,|O CK7|gene-protein (|O 68|O %|O )|O ,|O Cam5.2|gene-protein (|O 41|O %|O )|O ,|O and|O CK20|gene-protein (|O 26|O %|O )|O .|O 
CA-19-9|gene-protein (|O 84|O %|O )|O and|O CEA|gene-protein (|O 74|O %|O )|O were|O positive|O in|O the|O majority|O of|O the|O cases|O .|O 
K-ras|O oncogene|O mutations|O were|O identified|O in|O seven|O of|O 13|O cases|O .|O 
All|O patients|O died|O from|O their|O disease|O an|O average|O of|O 5.8|O months|O after|O diagnosis|O (|O range|O ,|O 1|O to|O 33|O months|O )|O .|O 
CONCLUSIONS|O :|O 
Adenosquamous|O carcinoma|O of|O the|O pancreas|O represents|O a|O distinct|O clinical|O and|O pathologic|O entity|O ,|O demonstrating|O the|O expected|O immunoprofile|O and|O k-ras|O oncogene|O mutation|O of|O a|O ductal|O origin|O ,|O with|O a|O worse|O prognosis|O than|O ductal|O adenocarcinoma|O .|O 
Genetic|O alterations|O associated|O with|O hepatocellular|O carcinomas|O define|O distinct|O pathways|O of|O hepatocarcinogenesis|O .|O 
BACKGROUND|O &|O AIMS|O :|O 
To|O evaluate|O how|O characterization|O of|O genetic|O alterations|O can|O help|O in|O the|O elucidation|O of|O liver|O carcinogenesis|O pathways|O ,|O 137|O tumors|O were|O analyzed|O .|O 
METHODS|O :|O 
High-density|O allelotype|O ,|O p53|gene-rna ,|O Axin1|gene-rna ,|O and|O beta-catenin|gene-rna gene|O mutations|O were|O determined|O .|O 
Alterations|O were|O analyzed|O according|O to|O clinical|O parameters|O .|O 
RESULTS|O :|O 
Tumors|O could|O be|O divided|O into|O 2|O groups|O according|O to|O chromosome|O stability|O status|O .|O 
In|O the|O first|O group|O ,|O demonstrating|O a|O chromosome|O stability|O ,|O beta-catenin|gene-rna mutation|O associated|O with|O chromosome|O 8p|O losses|O were|O frequently|O found|O as|O the|O single|O genetic|O alterations|O .|O 
beta-catenin|gene-rna mutations|O were|O associated|O with|O large|O tumor|O size|O and|O with|O negative|O hepatitis|O B|O virus|O status|O .|O 
In|O the|O second|O group|O ,|O demonstrating|O a|O chromosome|O instability|O ,|O the|O most|O frequent|O allelic|O losses|O were|O on|O chromosome|O 1p|O ,|O 4q|O ,|O 6q|O ,|O 9p|O ,|O 13q|O ,|O 16p|O ,|O 16q|O ,|O and|O 17p|O ;|O Axin1|gene-rna and|O p53|gene-rna were|O frequently|O mutated|O .|O 
All|O of|O these|O alterations|O ,|O except|O losses|O on|O 6q|O and|O 9p|O ,|O were|O associated|O with|O hepatitis|O B|O virus|O infection|O .|O 
P53|gene-rna mutations|O ,|O 17p|O ,|O 13q|O losses|O ,|O and|O a|O high|O value|O of|O the|O fractional|O allelic|O loss|O index|O were|O associated|O with|O poor|O differentiated|O tumors|O ,|O independently|O of|O risk|O factors|O .|O 
Finally|O ,|O in|O the|O whole|O series|O ,|O chromosome|O 9p|O and|O 6q|O losses|O were|O associated|O with|O poor|O prognosis|O .|O 
CONCLUSIONS|O :|O Two|O main|O pathways|O defined|O by|O genetic|O alterations|O show|O different|O risk|O factors|O and|O clinical|O characteristics|O .|O 
Furthermore|O ,|O loss|O of|O chromosome|O 9p|O or|O 6q|O is|O an|O independent|O prognostic|O indicator|O .|O 
Discordance|O between|O K-ras|gene-rna mutations|O in|O bone|O marrow|O micrometastases|O and|O the|O primary|O tumor|O in|O colorectal|O cancer|O .|O 
PURPOSE|O :|O To|O study|O bone|O marrow|O micrometastases|O from|O colorectal|O cancer|O patients|O for|O the|O presence|O of|O K-ras|O mutations|O and|O to|O compare|O their|O genotype|O with|O that|O of|O the|O corresponding|O primary|O tumor|O .|O 
PATIENTS|O AND|O METHODS|O :|O Bilateral|O iliac|O crest|O aspiration|O was|O performed|O in|O 51|O patients|O undergoing|O surgery|O for|O colorectal|O cancer|O ,|O and|O bone|O marrow|O micrometastases|O were|O detected|O by|O immunohistochemistry|O .|O 
The|O presence|O of|O K-ras|O mutations|O was|O determined|O by|O single-strand|O conformation|O polymorphism|O analysis|O on|O both|O primary|O tumors|O and|O paired|O bone|O marrow|O samples|O and|O was|O confirmed|O by|O sequencing|O .|O 
RESULTS|O :|O In|O six|O patients|O with|O primary|O tumor|O mutations|O ,|O it|O was|O possible|O to|O amplify|O a|O mutated|O K-ras|gene-rna gene|O also|O from|O the|O bone|O marrow|O sample|O .|O 
In|O three|O of|O those|O patients|O the|O pattern|O of|O K-ras|O mutations|O differed|O between|O both|O samples|O ,|O in|O two|O patients|O the|O mutation|O was|O identical|O between|O the|O bone|O marrow|O and|O its|O primary|O tumor|O ,|O and|O in|O one|O patient|O the|O same|O mutation|O plus|O a|O different|O one|O were|O found|O .|O 
Fifteen|O of|O 17|O K-ras|gene-rna mutations|O found|O in|O primary|O tumors|O were|O located|O in|O codon|O 12|O ,|O whereas|O in|O bone|O marrow|O ,|O five|O of|O seven|O mutations|O were|O found|O in|O codon|O 13|O (|O P|O =|O .003|O )|O .|O 
CONCLUSION|O :|O Our|O results|O demonstrate|O that|O ,|O at|O least|O for|O K-ras|gene-rna mutations|O ,|O disseminated|O epithelial|O cells|O are|O not|O always|O clonal|O with|O the|O primary|O tumor|O and|O they|O question|O the|O malignant|O genotype|O of|O bone|O marrow|O micrometastases|O .|O 
They|O also|O indicate|O that|O different|O tumoral|O clones|O may|O be|O circulating|O simultaneously|O or|O sequentially|O in|O the|O same|O patient|O .|O 
Detecting|O colorectal|O cancer|O in|O stool|O with|O the|O use|O of|O multiple|O genetic|O targets|O .|O 
BACKGROUND|O :|O Colorectal|O cancer|O cells|O are|O shed|O into|O the|O stool|O ,|O providing|O a|O potential|O means|O for|O the|O early|O detection|O of|O the|O disease|O using|O noninvasive|O approaches|O .|O 
Our|O goal|O was|O to|O develop|O reliable|O ,|O specific|O molecular|O genetic|O tests|O for|O the|O detection|O of|O colorectal|O cancer|O in|O stool|O samples|O .|O 
METHODS|O :|O Stool|O DNA|O was|O isolated|O from|O paired|O stools|O and|O primary|O tumor|O samples|O from|O 51|O colorectal|O cancer|O patients|O .|O 
Three|O genetic|O targets|O -|O TP53|gene-rna ,|O BAT26|gene-rna ,|O and|O K-RAS|gene-rna -|O were|O used|O to|O detect|O tumor|O -|O associated|O mutations|O in|O the|O stool|O prior|O to|O or|O without|O regard|O to|O the|O molecular|O analyses|O of|O the|O paired|O tumors|O .|O 
TP53|O gene|O mutations|O were|O detected|O with|O a|O mismatch|O -|O ligation|O assay|O that|O detects|O nine|O common|O p53|O gene|O mutations|O .|O 
Deletions|O within|O the|O BAT26|gene-rna locus|O were|O detected|O by|O a|O modified|O solid-phase|O minisequencing|O method|O .|O 
Mutations|O in|O codons|O 12|O and|O 13|O of|O K-RAS|gene-rna were|O detected|O with|O a|O digital|O polymerase|gene-protein chain|O reaction|O -|O based|O method|O .|O 
RESULTS|O :|O TP53|O gene|O mutations|O were|O detected|O in|O the|O tumor|O DNA|O of|O 30|O patients|O ,|O all|O of|O whom|O had|O the|O identical|O TP53|gene-rna mutation|O in|O their|O stools|O .|O 
Tumors|O from|O three|O patients|O contained|O a|O noninherited|O deletion|O at|O the|O BAT26|gene-rna locus|O ,|O and|O the|O same|O alterations|O were|O identified|O in|O these|O patients|O '|O stool|O specimens|O .|O 
Nineteen|O of|O 50|O tumors|O tested|O had|O a|O K-RAS|gene-rna mutation|O ;|O identical|O mutations|O were|O detected|O in|O the|O paired|O stool|O DNA|O samples|O from|O eight|O patients|O .|O 
In|O no|O case|O was|O a|O mutation|O found|O in|O stool|O that|O was|O not|O also|O present|O in|O the|O primary|O tumor|O .|O 
Thus|O ,|O the|O three|O genetic|O markers|O together|O detected|O 36|O (|O 71|O %|O )|O of|O 51|O patients|O (|O 95|O %|O confidence|O interval|O [|O CI|O ]|O =|O 56|O %|O to|O 83|O %|O )|O with|O colorectal|O cancer|O and|O 36|O (|O 92|O %|O )|O of|O 39|O patients|O (|O 95|O %|O CI|O =|O 79|O %|O to|O 98|O %|O )|O whose|O tumors|O had|O an|O alteration|O .|O 
CONCLUSION|O :|O We|O were|O able|O to|O detect|O the|O majority|O of|O colorectal|O cancers|O by|O analyzing|O stool|O DNA|O for|O just|O three|O genetic|O markers|O .|O 
Additional|O work|O is|O needed|O to|O determine|O the|O specificity|O of|O these|O genetic|O tests|O for|O detecting|O colorectal|O neoplasia|O in|O asymptomatic|O patients|O and|O to|O more|O precisely|O estimate|O the|O prevalence|O of|O the|O mutations|O and|O sensitivity|O of|O the|O assay|O .|O 
beta-Catenin|gene-protein plays|O a|O key|O role|O in|O the|O Wnt|gene-rna signaling|O pathway|O ,|O and|O mutations|O of|O CTNNB1|gene-rna ,|O the|O gene|O that|O encodes|O beta-catenin|gene-protein ,|O have|O been|O identified|O in|O about|O one-fourth|O of|O human|O hepatocellular|O carcinomas|O from|O regions|O of|O low|O aflatoxin|O B1|O exposure|O .|O 
In|O this|O study|O 62|O hepatocellular|O carcinomas|O (|O HCCs|O )|O from|O people|O highly|O exposed|O to|O aflatoxin|O B1|O in|O Guangxi|O ,|O People|O 's|O Republic|O of|O China|O ,|O were|O laser|O -|O capture|O microdissected|O and|O examined|O for|O CTNNB1|gene-rna mutations|O .|O 
In|O addition|O ,|O 41|O of|O the|O HCCs|O were|O evaluated|O for|O the|O presence|O of|O the|O beta-catenin|gene-protein protein|O by|O immunohistochemical|O methods|O .|O 
Twenty|O of|O the|O HCCs|O showed|O positive|O results|O for|O beta-catenin|gene-protein ,|O with|O strong|O membrane|O staining|O ,|O while|O adjacent|O non|O -|O neoplastic|O liver|O tissue|O lacked|O or|O showed|O only|O weak|O membrane|O staining|O .|O 
One|O HCC|O ,|O in|O which|O a|O CTNNB1|gene-rna mutation|O was|O not|O detected|O ,|O showed|O nuclear|O staining|O for|O the|O beta-catenin|gene-protein protein|O .|O 
Mutations|O of|O CTNNB1|gene-rna were|O identified|O in|O five|O HCCs|O .|O 
These|O consisted|O of|O four|O point|O mutations|O in|O the|O glycogen|gene-protein serine|gene-protein kinase-3beta|gene-protein phosphorylation|O region|O of|O codons|O 32|O -|O 45|O and|O one|O deletion|O of|O codons|O 32|O -|O 38|O .|O 
These|O mutations|O were|O similar|O to|O those|O previously|O reported|O for|O human|O HCC|O ,|O although|O at|O a|O lower|O frequency|O .|O 
A|O signature|O mutation|O profile|O associated|O with|O aflatoxin|O B1|O exposure|O could|O not|O be|O identified|O .|O 
The|O immunohistochemical|O findings|O indicate|O a|O role|O for|O accumulation|O of|O beta-catenin|gene-protein and|O possibly|O increased|O Wnt|gene-rna signaling|O in|O aflatoxin|O B1|O -|O associated|O HCC|O .|O 
The|O low|O frequency|O of|O CTNNB1|gene-rna mutations|O ,|O however|O ,|O suggests|O that|O mutation|O of|O another|O Wnt|gene-rna signaling|O component|O ,|O such|O as|O the|O Wnt|gene-rna scaffolding|O protein|O axin|gene-protein or|O the|O adenomatous|gene-protein polyposis|gene-protein coli|gene-protein protein|gene-protein ,|O both|O of|O which|O modulate|O beta-catenin|gene-protein stability|O ,|O also|O may|O be|O involved|O in|O aflatoxin|O -|O associated|O HCC|O .|O 
Primitive|O neuroectodermal|O tumors|O (|O PNETs|O )|O represent|O the|O most|O frequent|O malignant|O brain|O tumors|O in|O childhood|O .|O 
The|O majority|O of|O these|O neoplasms|O occur|O in|O the|O cerebellum|O and|O are|O classified|O as|O medulloblastomas|O (|O MB|O )|O .|O 
Most|O PNETs|O develop|O sporadically|O ;|O however|O ,|O their|O incidence|O is|O highly|O elevated|O in|O patients|O carrying|O germline|O APC|gene-rna gene|O mutations|O .|O 
The|O APC|gene-rna gene|O encodes|O a|O central|O component|O of|O the|O WNT|gene-generic /|O wingless|gene-generic developmental|O signaling|O pathway|O .|O 
It|O regulates|O the|O levels|O of|O cytoplasmic|O beta-catenin|gene-protein protein|O that|O plays|O a|O central|O role|O in|O neural|O development|O and|O cell|O proliferation|O .|O 
We|O analyzed|O 87|O sporadic|O PNETs|O and|O 10|O PNET|O cell|O lines|O for|O mutations|O of|O the|O APC|gene-rna gene|O and|O beta-catenin|gene-rna (|O CTNNB1|gene-rna )|O gene|O using|O single|O strand|O conformational|O polymorphism|O (|O SSCP|O )|O and|O sequencing|O analysis|O .|O 
We|O examined|O the|O mutation|O cluster|O region|O of|O APC|gene-rna (|O codons|O 1255|O --|O 1641|O )|O for|O germline|O variants|O and|O somatic|O mutations|O .|O 
The|O medulloblastoma|O cell|O line|O MHH-MED-2|O carried|O a|O Glu|O 1317|O Gln|O missense|O germline|O variant|O and|O a|O sporadic|O MB|O sample|O showed|O a|O somatic|O Pro|O 1319|O Leu|O substitution|O .|O 
Mutational|O analysis|O of|O exon|O 3|O of|O CTNNB1|gene-rna uncovered|O 4|O PNETs|O (|O 4.8|O %|O )|O with|O somatic|O missense|O mutations|O .|O 
These|O mutations|O caused|O amino|O acid|O substitutions|O in|O 3|O of|O 80|O medulloblastomas|O (|O Ser|O 33|O Phe|O ,|O Ser|O 33|O Cys|O and|O Ser|O 37|O Cys|O )|O and|O 1|O of|O 4|O supratentorial|O PNETs|O (|O Gly|O 34|O Val|O )|O .|O 
All|O mutations|O affected|O GSK-3|gene-rna beta|gene-rna phosphorylation|O sites|O of|O the|O degradation|O targeting|O box|O of|O beta-catenin|gene-rna and|O resulted|O in|O nuclear|O beta-catenin|gene-protein protein|O accumulation|O .|O 
Deletions|O of|O CTNNB1|gene-rna were|O not|O detected|O by|O PCR|O amplification|O with|O primers|O spanning|O exons|O 1|O --|O 5|O .|O 
Our|O data|O indicate|O that|O inappropriate|O activation|O of|O the|O WNT|gene-generic /|O wingless|gene-generic signaling|O pathway|O by|O mutations|O of|O its|O components|O may|O contribute|O to|O the|O pathogenesis|O of|O a|O subset|O of|O PNETs|O .|O 
Anaplastic|O pancreatic|O carcinomas|O are|O rare|O tumors|O ,|O frequently|O displaying|O a|O variety|O of|O growth|O patterns|O .|O 
The|O literature|O lacks|O a|O comprehensive|O study|O of|O this|O tumor|O .|O 
Thirty-five|O cases|O of|O anaplastic|O carcinoma|O of|O the|O pancreas|O diagnosed|O between|O 1955|O and|O 1997|O were|O retrieved|O from|O the|O Endocrine|O Registry|O at|O the|O Armed|O Forces|O Institute|O of|O Pathology|O .|O 
Histology|O ,|O immunophenotype|O ,|O molecular|O analysis|O ,|O and|O patient|O follow-up|O were|O analyzed|O .|O 
The|O tumors|O of|O 10|O women|O and|O 25|O men|O ,|O aged|O 34|O to|O 85|O years|O (|O mean|O age|O at|O presentation|O ,|O 62.5|O years|O )|O ,|O were|O studied|O .|O 
Patients|O had|O vague|O symptoms|O (|O weight|O loss|O ,|O pain|O ,|O and|O fatigue|O ,|O nausea|O ,|O or|O vomiting|O )|O ,|O lasting|O an|O average|O of|O 13.2|O weeks|O .|O 
The|O tumors|O ,|O of|O an|O average|O size|O of|O 9.2|O cm|O ,|O were|O usually|O in|O the|O head|O or|O tail|O of|O the|O pancreas|O .|O 
The|O tumors|O were|O widely|O infiltrative|O ,|O histomorphologically|O separated|O into|O predominantly|O large|O ,|O pleomorphic|O cell|O ,|O or|O spindle|O cell|O groups|O .|O 
Tumor|O phagocytosis|O and|O necrosis|O were|O noted|O .|O 
Immunohistochemical|O studies|O confirmed|O an|O epithelial|O origin|O with|O at|O least|O one|O epithelial|O marker|O in|O 78|O %|O of|O the|O tumors|O .|O 
K-ras|gene-rna mutations|O by|O sequence|O analysis|O were|O found|O in|O eight|O of|O 12|O cases|O tested|O .|O 
Surgical|O biopsy|O /|O excision|O was|O used|O in|O all|O patients|O .|O 
Twenty-nine|O of|O 35|O patients|O died|O of|O disease|O (|O average|O ,|O 5.2|O months|O )|O ,|O three|O died|O with|O no|O evidence|O of|O disease|O (|O average|O ,|O 56.9|O months|O )|O ,|O and|O three|O patients|O were|O alive|O at|O last|O follow-up|O (|O average|O ,|O 94.0|O months|O )|O ,|O one|O with|O residual|O disease|O .|O 
There|O was|O no|O statistically|O significant|O difference|O in|O survival|O between|O patients|O with|O and|O without|O a|O K-ras|gene-rna mutation|O .|O 
Anaplastic|O carcinoma|O of|O the|O pancreas|O usually|O occurs|O in|O the|O head|O of|O the|O pancreas|O in|O older|O men|O .|O 
The|O epithelial|O nature|O of|O the|O pleomorphic|O cells|O (|O giant|O or|O spindled|O )|O can|O usually|O be|O documented|O .|O 
Patients|O with|O K-ras|gene-rna mutations|O have|O a|O shorter|O survival|O time|O ,|O even|O though|O the|O overall|O prognosis|O for|O all|O anaplastic|O carcinomas|O is|O fatal|O (|O 93|O %|O fatality|O ;|O average|O survival|O ,|O 448|O days|O )|O .|O 
This|O is|O a|O US|O government|O work|O .|O 
There|O are|O no|O restriction|O on|O its|O use|O .|O 
Genetic|O alteration|O of|O the|O beta-catenin|gene-rna gene|O (|O CTNNB1|gene-rna )|O in|O human|O lung|O cancer|O and|O malignant|O mesothelioma|O and|O identification|O of|O a|O new|O 3p21.3|O homozygous|O deletion|O .|O 
The|O beta-catenin|gene-rna gene|O (|O CTNNB1|gene-rna )|O has|O been|O shown|O to|O be|O genetically|O mutated|O in|O various|O human|O malignancies|O .|O 
To|O determine|O whether|O the|O beta-catenin|gene-rna gene|O is|O responsible|O for|O oncogenesis|O in|O thoracic|O malignancies|O ,|O we|O searched|O for|O the|O mutation|O in|O 166|O lung|O cancers|O (|O 90|O primary|O tumors|O and|O 76|O cell|O lines|O )|O ,|O one|O blastoma|O and|O 10|O malignant|O mesotheliomas|O (|O two|O primary|O tumors|O and|O eight|O cell|O lines|O )|O .|O 
Among|O the|O lung|O cancers|O ,|O including|O 43|O small|O cell|O lung|O cancers|O (|O SCLCs|O )|O and|O 123|O non|O -|O small|O cell|O lung|O cancers|O (|O NSCLCs|O )|O ,|O we|O identified|O four|O alterations|O in|O exon|O 3|O ,|O which|O is|O the|O target|O region|O of|O mutation|O for|O stabilizing|O beta-catenin|gene-rna .|O 
One|O primary|O adenocarcinoma|O had|O a|O somatic|O mutation|O from|O C|O to|O G|O ,|O leading|O to|O an|O amino|O acid|O substitution|O from|O Ser|O to|O Cys|O at|O codon|O 37|O .|O 
Among|O the|O cell|O lines|O ,|O SCLC|O NCI-H1092|O had|O a|O mutation|O from|O A|O to|O G|O ,|O leading|O to|O an|O Asp|O to|O Gly|O substitution|O at|O codon|O 6|O ,|O NSCLC|O HCC15|O had|O a|O mutation|O from|O C|O to|O T|O ,|O leading|O to|O a|O Ser|O to|O Phe|O substitution|O at|O codon|O 45|O ,|O and|O NSCLC|O NCI-H358|O had|O a|O mutation|O from|O A|O to|O G|O ,|O leading|O to|O a|O Thr|O to|O Ala|O substitution|O at|O codon|O 75|O .|O 
One|O blastoma|O also|O had|O a|O somatic|O mutation|O from|O C|O to|O G|O ,|O leading|O to|O a|O Ser|O to|O Cys|O substitution|O at|O codon|O 37|O .|O 
Among|O the|O 10|O malignant|O mesotheliomas|O ,|O we|O identified|O a|O homozygous|O deletion|O in|O the|O NCI-H28|O cell|O line|O .|O 
Cloning|O of|O the|O rearranged|O fragment|O from|O NCI-H28|O indicated|O that|O all|O the|O exons|O except|O exon|O 1|O of|O the|O beta-catenin|gene-rna gene|O are|O deleted|O and|O that|O the|O deletion|O junction|O is|O 13|O kb|O downstream|O from|O exon|O 1|O .|O 
Furthermore|O ,|O Northern|O blot|O analysis|O of|O 26|O lung|O cancer|O and|O eight|O mesothelioma|O cell|O line|O RNAs|gene-rna detected|O ubiquitous|O expression|O of|O the|O beta-catenin|gene-generic messages|O except|O NCI-H28|O ,|O although|O Western|O blot|O analysis|O showed|O that|O relatively|O less|O amounts|O of|O protein|O products|O were|O expressed|O in|O some|O of|O lung|O cancer|O cell|O lines|O .|O 
Our|O findings|O suggest|O that|O the|O beta-catenin|gene-rna gene|O is|O infrequently|O mutated|O in|O lung|O cancer|O and|O that|O the|O NCI-H28|O homozygous|O deletion|O of|O the|O beta-catenin|gene-rna gene|O might|O indicate|O the|O possibility|O of|O a|O new|O tumor|gene-rna suppressor|gene-rna gene|gene-rna residing|O in|O this|O region|O at|O 3p21.3|O ,|O where|O various|O types|O of|O human|O cancers|O show|O frequent|O allelic|O loss|O .|O 
Adenocarcinoma|O arising|O in|O gastric|O heterotopic|O pancreas|O :|O clinicopathological|O and|O immunohistochemical|O study|O with|O genetic|O analysis|O of|O a|O case|O .|O 
Heterotopic|O pancreas|O in|O the|O stomach|O is|O a|O relatively|O common|O congenital|O condition|O ,|O but|O the|O risk|O of|O malignant|O transformation|O is|O extremely|O low|O .|O 
In|O this|O study|O ,|O we|O describe|O a|O case|O of|O adenocarcinoma|O arising|O from|O a|O gastric|O heterotopic|O pancreas|O and|O we|O consider|O its|O morphological|O and|O immunohistochemical|O features|O and|O genetic|O analysis|O ,|O in|O order|O to|O examine|O its|O histogenesis|O .|O 
This|O unusual|O sequela|O was|O seen|O in|O a|O 57|O -|O year|O -|O old|O woman|O .|O 
Image|O studies|O showed|O a|O protruding|O lesion|O with|O a|O central|O ulcer|O located|O in|O the|O lesser|O curvature|O from|O the|O angle|O to|O the|O body|O of|O the|O stomach|O .|O 
A|O biopsy|O specimen|O confirmed|O this|O lesion|O as|O adenocarcinoma|O before|O total|O gastrectomy|O .|O 
The|O tumor|O showed|O mixed|O patterns|O of|O solid|O neoplastic|O -|O cell|O proliferation|O and|O moderately|O differentiated|O glandular|O structures|O ,|O and|O also|O showed|O transitional|O lesions|O to|O obvious|O malignancy|O ,|O that|O is|O ,|O dysplasia|O ,|O or|O adenocarcinoma|O in|O situ|O .|O 
Neoplastic|O cells|O had|O positive|O immunoreactivity|O for|O carbohydrate|gene-protein antigen|gene-protein (|O CA|gene-protein )|O 19|gene-protein -|gene-protein 9|gene-protein ,|O mucin|gene-protein (|O MUC|gene-protein )|O 1|O ,|O and|O insulin|gene-protein ,|O and|O the|O mutant|O allele|O -|O specific|O amplification|O method|O revealed|O a|O point|O mutation|O at|O K-ras|gene-rna codon|O 12|O (|O GGT|O [|O Gly|O ]|O -->|O GAT|O [|O Asp|O ]|O )|O ,|O which|O is|O the|O most|O common|O mutational|O change|O observed|O in|O patients|O with|O pancreatic|O carcinoma|O .|O 
Gastrointestinal|O autonomic|O nerve|O tumor|O (|O GANT|O )|O is|O a|O gastrointestinal|O neoplasm|O that|O ultrastructurally|O recapitulates|O the|O enteric|O neural|O plexus|O .|O 
This|O study|O identifies|O and|O defines|O the|O features|O of|O 10|O cases|O of|O this|O rare|O mesenchymal|O tumor|O and|O compares|O its|O clinicopathologic|O and|O molecular|O genetic|O features|O with|O the|O data|O on|O gastrointestinal|O stromal|O tumor|O (|O GIST|O )|O .|O 
The|O majority|O of|O patients|O in|O this|O series|O presented|O at|O an|O older|O age|O (|O mean|O 64|O years|O )|O .|O 
Tumors|O arose|O from|O the|O stomach|O (|O 6|O )|O ,|O small|O intestine|O (|O 2|O )|O ,|O and|O retroperitoneum|O (|O 2|O )|O .|O 
Mean|O tumor|O size|O was|O 14|O cm|O ;|O however|O ,|O four|O neoplasms|O were|O <|O 6|O cm|O .|O 
Histologically|O ,|O tumors|O were|O spindled|O or|O epithelioid|O ;|O one|O epithelioid|O tumor|O demonstrated|O a|O previously|O undescribed|O rhabdoid|O histologic|O phenotype|O .|O 
All|O tumors|O were|O positive|O for|O CD117|gene-protein (|O KIT|gene-protein )|O ,|O while|O eight|O of|O 10|O were|O positive|O for|O CD34|gene-protein .|O 
In|O contrast|O ,|O only|O two|O were|O positive|O for|O S-100|gene-protein ,|O and|O all|O were|O negative|O for|O actin|gene-protein and|O desmin|gene-protein .|O 
Five|O GANTs|O demonstrated|O GIST|O -|O specific|O gain|O -|O of|O -|O function|O mutations|O in|O the|O juxtamembrane|O domain|O of|O the|O c-kit|gene-rna gene|O (|O 50|O %|O )|O .|O 
Three|O of|O 10|O patients|O died|O of|O disease|O in|O 22|O -|O 30|O months|O ,|O one|O patient|O died|O in|O the|O postoperative|O period|O ,|O and|O one|O patient|O died|O of|O complications|O of|O CML|O .|O 
Pseudomyxoma|O peritonei|O (|O PMP|O )|O is|O a|O clinical|O syndrome|O characterized|O by|O mucinous|O ascites|O and|O peritoneal|O lesions|O composed|O of|O histologically|O bland|O to|O low-grade|O adenomatous|O mucinous|O epithelium|O within|O pools|O of|O extracellular|O mucin|O ,|O often|O with|O an|O associated|O mucinous|O adenoma|O of|O the|O appendix|O .|O 
There|O is|O evidence|O that|O the|O peritoneal|O lesions|O in|O PMP|O are|O clonally|O derived|O from|O the|O associated|O appendiceal|O adenoma|O .|O 
Little|O is|O known|O about|O the|O molecular|O genetic|O alterations|O or|O hereditary|O factors|O involved|O in|O the|O development|O of|O appendiceal|O mucinous|O tumors|O and|O PMP|O .|O 
We|O report|O the|O only|O known|O example|O of|O appendiceal|O mucinous|O adenomas|O in|O identical|O twin|O brothers|O ,|O one|O of|O whom|O developed|O PMP|O .|O 
We|O analyzed|O the|O status|O of|O the|O K-RAS|gene-rna and|O APC|gene-rna genes|O in|O these|O tumors|O using|O digital|O polymerase|O chain|O reaction|O and|O digital|O single|O nucleotide|O polymorphism|O (|O SNP|O )|O assay|O .|O 
Identical|O K-RAS|gene-rna mutations|O were|O detected|O in|O the|O appendiceal|O adenoma|O and|O peritoneal|O tumor|O from|O the|O twin|O with|O PMP|O ,|O whereas|O the|O adenoma|O from|O the|O other|O twin|O harbored|O a|O different|O mutation|O .|O 
Digital|O SNP|O analysis|O demonstrated|O loss|O of|O heterozygosity|O of|O APC|gene-rna only|O in|O the|O adenoma|O from|O the|O twin|O without|O PMP|O but|O not|O from|O the|O appendiceal|O or|O peritoneal|O tumors|O of|O the|O twin|O with|O PMP|O .|O 
The|O adjacent|O normal|O tissue|O in|O each|O case|O retained|O both|O APC|gene-rna alleles|O .|O 
The|O K-RAS|gene-rna mutational|O analysis|O supports|O the|O view|O that|O PMP|gene-rna is|O clonally|O derived|O from|O the|O associated|O appendiceal|O mucinous|O adenoma|O .|O 
The|O lack|O of|O loss|O of|O heterozygosity|O of|O APC|gene-rna in|O the|O adenoma|O and|O peritoneal|O tumor|O from|O the|O twin|O with|O PMP|O suggests|O that|O loss|O of|O heterozygosity|O of|O APC|gene-rna is|O not|O necessarily|O involved|O in|O the|O development|O of|O all|O appendiceal|O adenomas|O or|O PMP|O .|O 
The|O different|O types|O of|O mutations|O in|O K-RAS|gene-rna and|O the|O different|O allelic|O status|O of|O the|O APC|gene-rna locus|O in|O the|O tumors|O from|O both|O twins|O suggest|O that|O mutation|O in|O K-RAS|gene-rna and|O loss|O of|O heterozygosity|O of|O APC|gene-rna occurs|O somatically|O in|O adenomas|O and|O is|O independent|O of|O the|O identical|O genetic|O background|O of|O the|O twins|O .|O 
Most|O hepatocellular|O carcinomas|O (|O HCCs|O )|O first|O occur|O as|O well-differentiated|O HCCs|O ,|O from|O which|O poorly|O differentiated|O HCC|O cells|O develop|O because|O of|O dedifferentiation|O .|O 
In|O this|O study|O ,|O we|O try|O to|O clarify|O the|O changes|O of|O dedifferentiation|O and|O cell|O proliferative|O activity|O and|O their|O relationship|O in|O small|O HCCs|O (|O less|O than|O 3.0|O cm|O in|O diameter|O )|O and|O try|O to|O learn|O the|O mechanism|O of|O these|O changes|O by|O analysing|O the|O expressions|O and|O genetic|O changes|O of|O proliferation|O -|O related|O genes|O p53|gene-rna and|O beta-catenin|gene-rna .|O 
Of|O 41|O surgically|O resected|O small|O HCCs|O ,|O 11|O were|O identified|O to|O have|O tumor|O heterogeneity|O .|O 
DNA|O from|O the|O 11|O small|O HCCs|O ,|O consisting|O of|O 29|O intratumoral|O lesions|O and|O 11|O noncancerous|O liver|O tissues|O adjacent|O to|O HCCs|O ,|O was|O extracted|O from|O paraffin|O embedded|O tissue|O sections|O .|O 
Exons|O 5|O -|O 8|O of|O p53|gene-rna gene|O and|O exon|O 3|O of|O beta-catenin|gene-rna gene|O were|O amplified|O by|O polymerase|O chain|O reaction|O and|O analyzed|O by|O direct|O sequence|O .|O 
The|O serial|O sections|O were|O also|O immunostained|O by|O anti|gene-protein -|gene-protein Ki-67|gene-protein ,|O p53|gene-protein and|O beta-catenin|gene-protein antibody|gene-protein .|O 
Immunohistochemistry|O showed|O that|O the|O p53|gene-protein overexpression|O was|O significantly|O related|O to|O the|O proliferative|O activities|O as|O evaluated|O by|O Ki-67|gene-protein immunostaining|O and|O to|O the|O histological|O differentiation|O .|O 
The|O expression|O of|O beta-catenin|gene-protein was|O found|O to|O be|O heterogeneously|O distributed|O not|O only|O in|O various|O histological|O grades|O of|O the|O same|O tumor|O but|O also|O in|O areas|O of|O the|O same|O histological|O grade|O .|O p53|gene-rna and|O beta-catenin|gene-rna gene|O mutations|O were|O detected|O in|O 1|O tumor|O respectively|O ,|O both|O of|O which|O were|O second|O primary|O HCCs|O and|O also|O recurred|O later|O .|O 
The|O p53|gene-rna mutation|O showed|O the|O same|O mutation|O pattern|O in|O heterogeneous|O subpopulations|O .|O 
beta-catenin|gene-rna mutation|O was|O detected|O only|O in|O the|O less|O differentiated|O lesion|O but|O not|O in|O the|O well-differentiated|O lesion|O of|O tumor|O .|O 
In|O conclusion|O ,|O our|O findings|O suggest|O that|O there|O was|O histological|O heterogeneity|O in|O small|O but|O established|O HCC|O ,|O which|O was|O accompanied|O by|O increased|O proliferative|O activity|O and|O p53|gene-protein overexpression|O .|O 
The|O overexpression|O of|O beta-catenin|gene-protein may|O be|O related|O to|O the|O proliferative|O activity|O and|O dedifferentiation|O of|O HCC|O .|O 
The|O association|O of|O K-ras|gene-rna gene|O mutation|O and|O vascular|gene-rna endothelial|gene-rna growth|gene-rna factor|gene-rna gene|O expression|O in|O pancreatic|O carcinoma|O .|O 
BACKGROUND|O :|O Previously|O ,|O the|O authors|O reported|O the|O role|O of|O the|O vascular|gene-protein endothelial|gene-protein growth|gene-protein factor|gene-protein (|O VEGF|gene-protein )|O as|O an|O angiogenic|O factor|O in|O 40|O patients|O with|O pancreatic|O carcinoma|O .|O 
In|O this|O study|O ,|O they|O investigated|O the|O mechanism|O underlying|O the|O regulation|O of|O VEGF|gene-rna gene|O expression|O and|O evaluated|O VEGF|gene-rna expression|O and|O K-ras|gene-rna gene|O status|O in|O 48|O patients|O with|O pancreatic|O carcinoma|O .|O 
METHODS|O :|O The|O authors|O used|O quantitative|O reverse|gene-protein transcriptase|gene-protein -|O polymerase|gene-protein chain|O reaction|O analysis|O and|O direct|O sequencing|O techniques|O for|O a|O retrospective|O study|O of|O VEGF|gene-rna gene|O expression|O and|O K-ras|gene-rna gene|O status|O in|O tumor|O tissue|O samples|O from|O 48|O patients|O with|O pancreatic|O carcinoma|O .|O 
Immunohistochemistry|O also|O was|O used|O to|O investigate|O VEGF|gene-protein protein|O expression|O .|O 
RESULTS|O :|O Thirty-one|O tumors|O (|O 64.6|O %|O )|O were|O evaluated|O with|O high|O VEGF|gene-generic expression|O ,|O and|O 17|O tumors|O (|O 35.4|O %|O )|O were|O evaluated|O with|O low|O VEGF|gene-generic expression|O .|O 
Of|O the|O 48|O primary|O pancreatic|O tumors|O studied|O ,|O 33|O tumors|O (|O 68.8|O %|O )|O contained|O mutations|O of|O the|O K-ras|gene-rna gene|O .|O 
There|O was|O a|O significant|O correlation|O between|O VEGF|gene-generic expression|O and|O K-ras|gene-rna status|O .|O 
Twenty-five|O of|O 33|O tumors|O (|O 75.8|O %|O )|O with|O mutant|O K-ras|gene-rna genes|O showed|O high|O VEGF|gene-generic expression|O ,|O whereas|O only|O 6|O of|O 15|O tumors|O with|O the|O wild|O type|O K-ras|gene-rna (|O 40.0|O %|O )|O showed|O high|O VEGF|gene-generic expression|O (|O P|O =|O 0.038|O )|O .|O 
The|O mean|O (|O +/-|O standard|O error|O )|O VEGF|gene-generic conservation|O rate|O for|O the|O 33|O tumors|O with|O mutant|O K-ras|gene-rna was|O 1.839|O +/-|O 1.241|O ,|O and|O that|O for|O the|O 15|O tumors|O with|O wild|O type|O K-ras|gene-rna was|O 1.057|O +/-|O 0.983|O (|O P|O =|O 0.037|O )|O .|O 
Furthermore|O ,|O the|O median|O survival|O for|O patients|O with|O mutant|O K-ras|gene-rna was|O shorter|O than|O for|O those|O with|O wild|O type|O K-ras|gene-rna (|O 10.6|O months|O vs.|O 27.6|O months|O ,|O respectively|O ;|O P|O =|O 0.026|O )|O ,|O whereas|O the|O median|O survival|O for|O patients|O with|O high|O VEGF|gene-generic expression|O was|O shorter|O compared|O with|O that|O for|O patients|O with|O low|O VEGF|gene-generic expression|O (|O 9.5|O months|O vs.|O 26.4|O months|O ,|O respectively|O ;|O P|O =|O 0.002|O )|O .|O 
Cox|O regression|O model|O analysis|O indicated|O that|O only|O the|O VEGF|gene-generic status|O was|O a|O significant|O factor|O for|O prognosis|O (|O P|O =|O 0.024|O )|O .|O 
Other|O variables|O ,|O i.e.|O ,|O K-ras|gene-rna status|O ,|O histopathologic|O tumor|O grade|O ,|O tumor|O status|O ,|O lymph|O node|O status|O ,|O metastatic|O status|O ,|O gender|O ,|O and|O age|O at|O surgery|O ,|O were|O not|O significant|O .|O 
CONCLUSIONS|O :|O The|O results|O of|O this|O study|O suggest|O that|O K-ras|gene-rna oncogene|O mutation|O may|O be|O associated|O with|O VEGF|gene-generic expression|O and|O that|O patients|O with|O pancreatic|O carcinoma|O who|O have|O high|O VEGF|gene-generic expression|O are|O associated|O with|O a|O poor|O prognosis|O .|O 
The|O molecular|O basis|O of|O carcinogenesis|O in|O gastrointestinal|O carcinoid|O tumors|O is|O not|O well|O understood|O .|O 
To|O clarify|O the|O contribution|O of|O the|O Wnt|gene-generic /|O beta-catenin|gene-generic signaling|O to|O this|O type|O of|O carcinogenesis|O ,|O we|O investigated|O 72|O cases|O of|O gastrointestinal|O carcinoid|O tumor|O both|O immunohistochemically|O and|O by|O direct|O sequencing|O of|O beta-catenin|gene-rna .|O 
Accumulation|O of|O beta-catenin|gene-protein in|O the|O cytoplasm|O and/or|O nucleus|O was|O observed|O in|O 57|O cases|O (|O 79.2|O %|O )|O .|O 
We|O also|O detected|O mutations|O in|O exon|O 3|O of|O beta-catenin|gene-rna in|O 27|O cases|O (|O 37.5|O %|O )|O and|O one|O mutation|O in|O APC|gene-rna (|O 1.4|O %|O )|O .|O 
OBJECTIVES|O :|O Vinyl|O chloride|O (|O VC|O )|O and|O its|O metabolites|O are|O human|O carcinogens|O associated|O with|O liver|O angiosarcomas|O (|O LAS|O )|O and|O also|O with|O hepatocellular|O carcinomas|O (|O HCCs|O )|O .|O 
In|O VC|O associated|O LAS|O mutations|O of|O the|O K-ras-2|gene-rna gene|O have|O been|O reported|O ,|O however|O ,|O no|O data|O about|O the|O prevalence|O of|O such|O mutations|O in|O VC|O -|O associated|O HCCs|O are|O available|O .|O 
The|O aim|O of|O the|O study|O was|O to|O evaluate|O possible|O specific|O K-ras-2|gene-rna oncogene|O mutations|O in|O the|O case|O of|O HCCs|O due|O to|O VC|O .|O 
METHODS|O :|O The|O presence|O of|O K-ras-2|gene-rna mutations|O was|O analysed|O in|O tissue|O from|O 12|O patients|O with|O VC|O -|O associated|O HCCs|O .|O 
All|O patients|O had|O known|O long-term|O exposure|O to|O VC|O (|O average|O exposure|O amount|O :|O 9,942|O ppm|O -|O years|O )|O .|O 
Twenty|O patients|O with|O hepatocellular|O carcinoma|O due|O to|O hepatitis|O B|O (|O n|O =|O 7|O )|O ,|O hepatitis|O C|O (|O n|O =|O 5|O )|O and|O alcoholic|O liver|O cirrhosis|O (|O n|O =|O 8|O )|O served|O as|O a|O control|O group|O .|O 
The|O specific|O mutations|O were|O determined|O by|O direct|O sequencing|O of|O codons|O 12|O and|O 13|O of|O the|O K-ras-2|gene-rna gene|O in|O carcinomatous|O and|O adjacent|O non|O -|O neoplastic|O liver|O tissue|O after|O microdissection|O .|O 
Immunohistochemical|O analysis|O was|O performed|O to|O detect|O p21ras|gene-protein protein|O .|O 
RESULTS|O :|O K-ras-2|gene-rna mutations|O were|O found|O in|O five|O of|O 12|O (|O 42|O %|O )|O examined|O HCCs|O and|O in|O three|O cases|O of|O adjacent|O non|O -|O neoplastic|O liver|O tissue|O (|O 25|O %|O )|O .|O 
There|O were|O three|O guanine|O to|O adenine|O (|O G|O -->|O A|O )|O point|O mutations|O in|O the|O tumour|O tissue|O .|O 
All|O three|O mutations|O found|O in|O non|O -|O neoplastic|O liver|O from|O VC|O -|O exposed|O patients|O were|O also|O G|O -->|O A|O point|O mutations|O (|O codon|O 12|O -|O and|O codon|O 13|O -|O aspartate|O mutations|O )|O .|O 
Within|O the|O control|O group|O ,|O K-ras-2|gene-rna mutations|O were|O found|O in|O three|O of|O 20|O (|O 15|O %|O )|O examined|O HCCs|O .|O 
CONCLUSIONS|O :|O Mutations|O of|O the|O K-ras-2|gene-rna gene|O in|O hepatocellular|O carcinomas|O associated|O with|O VC|O exposure|O are|O frequent|O events|O .|O 
We|O observed|O a|O K-ras-2|gene-rna mutation|O pattern|O characteristic|O of|O chloroethylene|O oxide|O ,|O one|O of|O the|O carcinogenic|O metabolites|O of|O VC|O analysed|O in|O animal|O models|O .|O 
Our|O results|O suggest|O that|O VC|O had|O direct|O toxic|O effects|O not|O only|O on|O endothelial|O cells|O but|O also|O on|O hepatocytes|O ,|O as|O it|O was|O previously|O only|O described|O in|O animal|O models|O .|O 
BACKGROUND|O :|O The|O point|O mutations|O of|O fibroblast|gene-rna growth|gene-rna factor|gene-rna receptor|gene-rna 3|gene-rna (|O FGFR3|gene-rna )|O are|O associated|O with|O autosomal|O dominant|O human|O skeletal|O disorders|O such|O as|O thanatophoric|O dysplasia|O (|O TD|O )|O .|O 
However|O ,|O point|O mutations|O were|O reported|O in|O a|O small|O series|O of|O bladder|O carcinomas|O ,|O suggesting|O their|O oncogenic|O role|O .|O 
In|O view|O of|O these|O findings|O ,|O the|O authors|O investigated|O the|O incidence|O of|O TD|O mutations|O in|O the|O FGFR3|gene-rna gene|O in|O a|O large|O series|O of|O bladder|O carcinomas|O to|O clarify|O their|O role|O in|O the|O progression|O of|O bladder|O carcinoma|O .|O 
METHODS|O :|O Specimens|O of|O transitional|O cell|O carcinoma|O of|O the|O urinary|O bladder|O from|O 81|O patients|O were|O screened|O for|O the|O FGFR3|gene-rna mutations|O (|O codons|O 248|O ,|O 249|O ,|O 372|O ,|O 373|O ,|O 375|O ,|O 652|O ,|O 809|O )|O that|O have|O been|O reported|O in|O TD|O ,|O using|O polymerase|O chain|O reaction|O -|O restriction|O fragment|O length|O polymorphism|O ,|O single-strand|O conformation|O polymorphism|O ,|O and|O DNA|O sequencing|O .|O 
RESULTS|O :|O Point|O mutations|O were|O detected|O in|O 25|O of|O 81|O carcinomas|O (|O 2|O at|O codon|O 248|O ,|O 11|O at|O codon|O 249|O ,|O 1|O at|O codon|O 372|O ,|O 9|O at|O codon|O 375|O ,|O 2|O at|O codon|O 652|O )|O .|O 
Although|O no|O significant|O relation|O was|O found|O between|O the|O occurrence|O of|O TD|O mutations|O and|O patient|O age|O and|O clinical|O status|O ,|O the|O incidence|O of|O TD|O mutations|O was|O significantly|O higher|O in|O low-grade|O or|O superficial|O tumors|O than|O high-grade|O or|O muscle|O invasive|O tumors|O .|O 
CONCLUSIONS|O :|O These|O findings|O indicate|O that|O TD|O mutations|O in|O the|O FGFR3|gene-rna gene|O do|O not|O cause|O disease|O progression|O of|O bladder|O carcinoma|O .|O 
Gastrointestinal|O stromal|O tumors|O (|O GISTs|O )|O ,|O the|O most|O common|O mesenchymal|O tumors|O of|O the|O digestive|O tract|O ,|O are|O believed|O to|O arise|O from|O the|O interstitial|O cells|O of|O Cajal|O .|O 
GISTs|O are|O characterized|O by|O mutations|O in|O the|O proto|O -|O oncogene|O KIT|gene-rna that|O lead|O to|O constitutive|O activation|O of|O its|O tyrosine|gene-protein kinase|gene-protein activity|O .|O 
The|O tyrosine|gene-protein kinase|gene-protein inhibitor|gene-protein STI571|gene-protein ,|O active|O against|O the|O BCR|gene-protein -|gene-protein ABL|gene-protein fusion|gene-protein protein|gene-protein in|O chronic|O myeloid|O leukemia|O ,|O was|O recently|O shown|O to|O be|O highly|O effective|O in|O GISTs|O .|O 
We|O used|O 13,826|O -|O element|O cDNA|O microarrays|O to|O define|O the|O expression|O patterns|O of|O 13|O KIT|gene-rna mutation|O -|O positive|O GISTs|O and|O compared|O them|O with|O the|O expression|O profiles|O of|O a|O group|O of|O spindle|O cell|O tumors|O from|O locations|O outside|O the|O gastrointestinal|O tract|O .|O 
Our|O results|O showed|O a|O remarkably|O distinct|O and|O uniform|O expression|O profile|O for|O all|O of|O the|O GISTs|O .|O 
In|O particular|O ,|O hierarchical|O clustering|O of|O a|O subset|O of|O 113|O cDNAs|O placed|O all|O of|O the|O GIST|O samples|O into|O one|O branch|O ,|O with|O a|O Pearson|O correlation|O >|O 0.91|O .|O 
This|O homogeneity|O suggests|O that|O the|O molecular|O pathogenesis|O of|O a|O GIST|O results|O from|O expansion|O of|O a|O clone|O that|O has|O acquired|O an|O activating|O mutation|O in|O KIT|gene-rna without|O the|O extreme|O genetic|O instability|O found|O in|O the|O common|O epithelial|O cancers|O .|O 
The|O complexity|O of|O KIT|gene-rna gene|O mutations|O and|O chromosome|O rearrangements|O and|O their|O clinical|O correlation|O in|O gastrointestinal|O stromal|O (|O pacemaker|O cell|O )|O tumors|O .|O 
Gastrointestinal|O stromal|O (|O pacemaker|O cell|O )|O tumors|O (|O GIST|O /|O GIPACTs|O )|O are|O frequently|O associated|O with|O activating|O KIT|gene-rna mutations|O ,|O primarily|O of|O exon|O 11|O and|O rarely|O of|O exons|O 9|O and|O 13|O ,|O as|O well|O as|O certain|O chromosome|O rearrangements|O .|O 
Reports|O regarding|O the|O frequency|O and|O prognostic|O significance|O of|O KIT|gene-rna mutations|O are|O conflicting|O and|O few|O cases|O have|O been|O completely|O sequenced|O .|O 
Furthermore|O ,|O there|O are|O few|O detailed|O analyses|O of|O chromosome|O alterations|O in|O GIST|O /|O GIPACTs|O .|O 
In|O a|O detailed|O analysis|O of|O 14|O GIST|O /|O GIPACTs|O from|O 12|O patients|O ,|O we|O found|O a|O wider|O spectrum|O of|O KIT|gene-rna mutations|O than|O previously|O reported|O ,|O including|O 11|O different|O in-frame|O mutations|O involving|O exons|O 11|O ,|O 14|O ,|O and|O 15|O .|O 
No|O mutations|O were|O detected|O in|O four|O malignant|O tumors|O .|O 
The|O shorter|O (|O GNNK|gene-protein -|gene-protein )|O KIT|gene-protein isoform|O was|O preferentially|O expressed|O .|O 
Cytogenetic|O and|O spectral|O karyotype|O analyses|O of|O 10|O tumors|O revealed|O clonal|O abnormalities|O in|O eight|O tumors|O ;|O the|O most|O common|O were|O terminal|O 1p|O deletions|O and|O losses|O of|O chromosomes|O 14|O and/or|O 22|O .|O 
Neither|O KIT|gene-rna mutation|O status|O nor|O chromosome|O aberrations|O correlated|O with|O tumor|O phenotype|O or|O clinical|O behavior|O in|O our|O series|O .|O 
We|O screened|O for|O genetic|O alterations|O of|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|O APC|gene-rna )|O and|O beta-catenin|gene-rna genes|O in|O 17|O frozen|O specimens|O from|O 12|O cases|O of|O sporadic|O desmoid|O tumors|O and|O then|O subdivided|O these|O cases|O into|O two|O groups|O according|O to|O the|O results|O of|O mutational|O analysis|O .|O 
We|O further|O examined|O mRNA|O expression|O of|O beta-catenin|gene-protein and|O cyclin|gene-protein D1|gene-protein by|O TaqMan|gene-protein PCR|O and|O compared|O the|O mRNA|O expression|O within|O both|O groups|O .|O 
Single-strand|O conformation|O polymorphism|O analysis|O followed|O by|O DNA|O direct|O sequencing|O revealed|O beta-catenin|gene-rna mutation|O in|O 3|O of|O 12|O cases|O (|O 6|O of|O 17|O specimens|O )|O ,|O whereas|O no|O APC|gene-rna missense|O mutations|O in|O the|O mutation|O cluster|O region|O were|O found|O .|O 
TaqMan|gene-protein PCR|O revealed|O extremely|O higher|O mRNA|O expression|O of|O beta-catenin|gene-protein and|O cyclin|gene-protein D1|gene-protein in|O desmoid|O tumors|O ,|O compared|O with|O those|O of|O normal|O skeletal|O muscles|O .|O 
In|O the|O beta-catenin|gene-rna mutated|O group|O ,|O cyclin|gene-protein D1|gene-protein mRNA|O expression|O was|O significantly|O higher|O than|O that|O of|O the|O beta-catenin|gene-rna wild-type|O group|O (|O p|O =|O 0.0120|O ,|O Mann|O -|O Whitney|O U|O test|O )|O .|O 
In|O addition|O ,|O in|O the|O beta-catenin|gene-rna mutated|O group|O ,|O beta-catenin|gene-protein mRNA|O expression|O was|O also|O significantly|O higher|O than|O that|O of|O the|O beta-catenin|gene-rna wild-type|O group|O (|O p|O =|O 0.0036|O ,|O Mann|O -|O Whitney|O U|O test|O )|O .|O 
All|O cases|O of|O desmoid|O tumors|O showed|O detectable|O beta-catenin|gene-protein nuclear|O expression|O immunohistochemically|O .|O 
These|O results|O suggest|O that|O a|O continuously|O elevated|O beta-catenin|gene-protein protein|O level|O caused|O by|O the|O beta-catenin|gene-rna mutation|O itself|O may|O have|O a|O stronger|O power|O that|O can|O transactivate|O transcription|O in|O vivo|O .|O 
Furthermore|O ,|O the|O results|O provide|O a|O possible|O association|O between|O higher|O beta-catenin|gene-protein mRNA|O expression|O and|O mutated|O beta-catenin|gene-rna in|O sporadic|O desmoid|O tumors|O .|O 
This|O may|O suggest|O that|O the|O beta-catenin|gene-rna gene|O may|O be|O up|O -|O regulated|O by|O mutated|O or|O continuously|O elevated|O beta-catenin|gene-protein protein|O ,|O that|O is|O ,|O the|O beta-catenin|gene-rna gene|O may|O also|O be|O one|O of|O the|O targeted|O genes|O in|O the|O APC|gene-rna -|O beta-catenin|gene-rna -|O Tcf|gene-protein pathway|O .|O 
K-ras|gene-rna mutation|O in|O helicobacter|O pylori|O -|O associated|O chronic|O gastritis|O in|O patients|O with|O and|O without|O gastric|O cancer|O .|O 
Mutations|O of|O an|O oncogene|O ,|O K-ras|gene-rna ,|O are|O associated|O with|O the|O development|O and|O progression|O of|O many|O types|O of|O human|O cancer|O .|O 
To|O elucidate|O the|O significance|O of|O K-ras|gene-rna mutations|O in|O gastric|O carcinogenesis|O ,|O we|O examined|O K-ras|gene-rna mutations|O in|O gastric|O cancers|O and|O in|O Helicobacter|O pylori|O -|O associated|O chronic|O gastritis|O (|O H.|O pylori|O -|O CG|O )|O ,|O which|O is|O associated|O with|O an|O increased|O risk|O for|O the|O gastric|O cancer|O development|O .|O 
Specimens|O of|O gastric|O cancer|O and|O H.|O pylori|O -|O CG|O were|O obtained|O from|O 64|O gastric|O cancer|O patients|O with|O H.|O pylori|O -|O CG|O ,|O 99|O cancer|O -|O free|O H.|O pylori|O -|O CG|O patients|O and|O 30|O H.|O pylori|O -|O negative|O healthy|O subjects|O .|O 
K-ras|gene-rna mutations|O were|O examined|O by|O polymerase|gene-protein chain|O reaction|O -|O single|O strand|O conformation|O polymorphism|O (|O PCR-SSCP|O )|O ,|O followed|O by|O DNA|O sequencing|O analysis|O .|O 
K-ras|gene-rna mutations|O were|O detected|O in|O 4|O of|O 48|O (|O 8.3|O %|O )|O gastric|O cancers|O ,|O in|O 10|O of|O 163|O (|O 6.1|O %|O )|O H.|O pylori|O -|O CG|O and|O none|O of|O the|O 30|O H.|O pylori|O -|O negative|O healthy|O subjects|O .|O 
In|O the|O gastric|O cancer|O patients|O ,|O mutated|O K-ras|gene-rna was|O detected|O in|O differentiated|O type|O cancers|O but|O not|O in|O any|O of|O the|O undifferentiated|O type|O cancers|O .|O 
K-ras|gene-rna mutations|O in|O H.|O pylori|O -|O CG|O were|O significantly|O more|O frequent|O in|O gastric|O cancer|O patients|O than|O in|O cancer|O -|O free|O patients|O (|O 10.9|O %|O vs.|O 3.0|O %|O ,|O p|O =|O 0.044|O )|O .|O 
In|O addition|O ,|O K-ras|gene-rna mutations|O in|O H.|O pylori|O -|O CG|O were|O significantly|O more|O frequent|O in|O patients|O with|O K-ras|gene-rna mutated|O gastric|O cancer|O than|O in|O patients|O with|O K-ras|gene-rna unmutated|O gastric|O cancer|O (|O 50.0|O %|O vs.|O 3.7|O %|O ,|O p|O =|O 0.037|O )|O .|O 
These|O data|O suggest|O that|O the|O genetic|O mechanism(s)|O of|O carcinogenesis|O differs|O between|O the|O differentiated|O type|O and|O the|O undifferentiated|O type|O of|O gastric|O cancer|O and|O that|O K-ras|gene-rna mutations|O may|O be|O involved|O in|O the|O early|O stages|O of|O gastric|O carcinogenesis|O of|O the|O differentiated|O type|O .|O 
c-kit|gene-rna mutations|O in|O gastrointestinal|O stromal|O tumors|O occur|O preferentially|O in|O the|O spindle|O rather|O than|O in|O the|O epithelioid|O cell|O variant|O .|O 
Gastrointestinal|O stromal|O tumors|O (|O GISTs|O )|O coexpress|O CD34|gene-protein and|O the|O Kit|gene-protein tyrosine|gene-protein -|gene-protein kinase|gene-protein receptor|gene-protein (|O CD117|gene-protein )|O .|O 
A|O subset|O of|O GISTs|O carry|O gain|O -|O of|O -|O function|O mutations|O of|O the|O c-kit|gene-rna proto|O -|O oncogene|O in|O its|O juxtamembrane|O domain|O .|O 
The|O relationship|O between|O the|O mutational|O status|O and|O histological|O as|O well|O as|O immunohistochemical|O features|O has|O not|O been|O assessed|O in|O detail|O .|O 
36|O GISTs|O and|O 14|O other|O gastrointestinal|O mesenchymal|O tumors|O were|O investigated|O for|O their|O morphology|O and|O immunophenotype|O as|O well|O as|O for|O the|O presence|O of|O c-kit|gene-rna mutations|O .|O 
DNA|O was|O extracted|O from|O formalin|O -|O fixed|O ,|O paraffin|O -|O embedded|O tissue|O .|O 
Exons|O 9|O ,|O 11|O ,|O 13|O ,|O and|O 17|O of|O c-kit|gene-rna were|O analyzed|O by|O SSCP|O .|O 
Bands|O with|O altered|O mobility|O were|O excised|O ,|O reamplified|O ,|O and|O sequenced|O .|O 
C-kit|gene-rna mutations|O in|O Exon|O 11|O encoding|O the|O juxtamembrane|O domain|O were|O identified|O in|O 19|O cases|O (|O 52.8|O %|O )|O ,|O with|O deletions|O in|O 12|O cases|O ,|O insertions|O in|O 3|O cases|O (|O 2|O of|O these|O as|O duplications|O )|O ,|O and|O point|O mutations|O in|O 4|O cases|O .|O 
The|O mutations|O clustered|O between|O Codons|O 553|O and|O 561|O ,|O pinpointing|O the|O critical|O region|O for|O deregulated|O Kit|gene-protein receptor|gene-protein activation|O .|O In|O both|O Exons|O 9|O and|O 13|O ,|O single|O mutations|O could|O be|O identified|O ,|O whereas|O no|O mutations|O were|O found|O in|O Exon|O 17|O .|O 
There|O were|O c-kit|gene-rna mutations|O in|O 66.6|O %|O of|O benign|O GISTs|O (|O 14|O /|O 21|O )|O ,|O 83.3|O %|O of|O the|O malignant|O (|O 5|O /|O 6|O )|O ,|O and|O 40|O %|O of|O the|O cases|O of|O intermediate|O malignancy|O (|O 2|O /|O 5|O )|O .|O 
A|O low|O frequency|O of|O mutations|O in|O benign|O GISTs|O ,|O as|O reported|O previously|O by|O other|O researchers|O ,|O could|O not|O be|O observed|O in|O our|O panel|O .|O 
Interestingly|O ,|O all|O GISTs|O with|O c-kit|gene-rna mutations|O displayed|O a|O spindle|O cell|O phenotype|O ,|O whereas|O mutations|O were|O absent|O in|O all|O 7|O tumors|O with|O an|O epithelioid|O component|O (|O P|O =|O .03|O )|O .|O 
Diagnostic|O biochip|O array|O for|O fast|O and|O sensitive|O detection|O of|O K-ras|gene-rna mutations|O in|O stool|O .|O 
BACKGROUND|O :|O Tumor|O cells|O that|O shed|O into|O stool|O are|O attractive|O targets|O for|O molecular|O screening|O and|O early|O detection|O of|O colon|O or|O pancreatic|O malignancies|O .|O 
We|O developed|O a|O diagnostic|O test|O to|O screen|O for|O 10|O of|O the|O most|O common|O mutations|O of|O codons|O 12|O and|O 13|O of|O the|O K-ras|gene-rna gene|O by|O hybridization|O to|O a|O new|O biochip|O array|O .|O 
METHODS|O :|O DNA|O was|O isolated|O from|O 26|O stool|O samples|O by|O column|O -|O based|O extraction|O from|O 9|O cell|O lines|O .|O 
Peptide|O nucleic|O acid|O (|O PNA|O )|O -|O mediated|O PCR|O clamping|O was|O used|O for|O mutant|O -|O specific|O amplification|O .|O 
We|O used|O a|O biochip|O ,|O consisting|O of|O a|O small|O plastic|O support|O with|O covalently|O immobilized|O 13mer|O oligonucleotides|O .|O 
The|O read|O out|O of|O the|O biochip|O was|O done|O by|O confocal|O time|O -|O resolved|O laser|O scanning|O .|O 
Hybridization|O ,|O scanning|O ,|O and|O data|O evaluation|O could|O be|O performed|O in|O <|O 2|O h|O .|O 
RESULTS|O :|O Approximately|O 80|O ng|O of|O DNA|O was|O obtained|O from|O 200|O -|O mg|O stool|O samples|O .|O 
No|O inhibition|O of|O the|O PCR|O by|O remaining|O impurities|O from|O stool|O was|O observed|O .|O 
Mutation|O detection|O was|O possible|O in|O 1000|O -|O fold|O excess|O of|O wild-type|O sequence|O .|O 
Discrimination|O ratios|O between|O the|O mutations|O were|O >|O 19|O as|O demonstrated|O by|O hybridization|O with|O tumor|O cell|O line|O DNA|O .|O 
Stool|O samples|O (|O n|O =|O 26|O )|O were|O analyzed|O in|O parallel|O with|O PNA-PCR|O ,|O restriction|O assay|O for|O K-ras|gene-rna codon|O 12|O mutations|O ,|O sequencing|O ,|O and|O hybridization|O to|O the|O biochip|O .|O 
Nine|O mutations|O were|O found|O by|O hybridization|O ,|O all|O confirmed|O by|O sequencing|O .|O 
PNA-PCR|O alone|O leads|O to|O an|O overestimation|O of|O mutations|O because|O suppression|O of|O the|O wild|O type|O is|O not|O effective|O enough|O with|O high|O concentrations|O of|O wild-type|O DNA|O .|O 
The|O restriction|O assay|O found|O only|O four|O mutations|O .|O 
CONCLUSIONS|O :|O The|O K-ras|gene-rna biochip|O is|O well|O suited|O for|O fast|O mutation|O detection|O from|O stool|O in|O colorectal|O cancer|O screening|O .|O 
Mutations|O in|O the|O ras|gene-rna genes|O are|O key|O events|O in|O the|O process|O of|O carcinogenesis|O ;|O in|O particular|O ,|O point|O mutations|O in|O codon|O 61|O of|O exon|O 2|O of|O the|O N-ras|gene-rna gene|O occur|O frequently|O in|O cutaneous|O melanoma|O .|O 
To|O investigate|O whether|O these|O mutations|O occur|O in|O early|O or|O late|O tumor|O progression|O phases|O ,|O we|O searched|O for|O point|O mutations|O in|O the|O N|gene-rna -|gene-rna and|O K|gene-rna -|gene-rna ras|gene-rna genes|O in|O 69|O primary|O cutaneous|O melanoma|O ,|O 35|O metastases|O ,|O and|O seven|O nevocellular|O nevi|O in|O association|O with|O cutaneous|O melanoma|O .|O 
Lesions|O were|O microdissected|O in|O order|O to|O procure|O pure|O tumor|O samples|O from|O the|O distinctive|O growth|O phases|O of|O the|O cutaneous|O melanoma|O ;|O the|O very|O sensitive|O denaturing|O gradient|O gel|O electrophoresis|O technique|O was|O used|O to|O visualize|O the|O mutations|O ,|O and|O was|O followed|O by|O sequencing|O .|O 
Point|O mutations|O in|O the|O N-ras|gene-rna gene|O but|O not|O in|O the|O K-ras|gene-rna gene|O were|O detected|O on|O denaturing|O gradient|O gel|O electrophoresis|O .|O 
Twenty-three|O primary|O (|O 33|O %|O )|O and|O nine|O metastatic|O (|O 26|O %|O )|O melanomas|O showed|O bandshifts|O for|O N-ras|gene-rna .|O In|O the|O majority|O of|O cases|O ,|O mutations|O occurring|O in|O early|O growth|O phases|O (|O i.e.|O ,|O the|O "|O intraepidermal|O "|O radial|O growth|O phase|O )|O ,|O were|O preserved|O in|O later|O growth|O phases|O (|O i.e.|O ,|O the|O invasive|O radial|O growth|O phase|O ,|O vertical|O growth|O phase|O ,|O and|O metastatic|O phase|O )|O ,|O which|O proves|O the|O clonal|O relationship|O between|O the|O successive|O growth|O phases|O .|O 
In|O three|O cases|O ,|O however|O ,|O the|O mutations|O differed|O between|O the|O distinctive|O growth|O phases|O within|O the|O same|O cutaneous|O melanoma|O ,|O due|O to|O the|O occurrence|O of|O an|O additional|O mutation|O (|O especially|O in|O codon|O 61|O )|O in|O a|O later|O tumor|O progression|O phase|O .|O 
Our|O approach|O also|O permitted|O us|O to|O analyze|O the|O mutational|O status|O of|O nevi|O ,|O associated|O with|O cutaneous|O melanoma|O .|O 
Six|O out|O of|O seven|O associated|O nevi|O carried|O the|O same|O sequence|O (|O mutated|O or|O wild-type|O )|O as|O the|O primary|O cutaneous|O melanoma|O ,|O whereas|O in|O one|O case|O the|O sequence|O for|O N-ras|gene-rna differed|O between|O the|O primary|O melanoma|O and|O the|O associated|O nevus|O .|O 
Pancreatic|O cancer|O after|O remote|O peptic|O ulcer|O surgery|O .|O 
BACKGROUND|O :|O Peptic|O ulcer|O surgery|O may|O carry|O an|O increased|O risk|O for|O pancreatic|O cancer|O development|O .|O 
Molecular|O analysis|O of|O K-ras|gene-rna codon|O 12|O ,|O frequently|O mutated|O in|O conventional|O pancreatic|O cancers|O ,|O might|O provide|O insight|O into|O the|O aetiological|O mechanisms|O .|O 
METHODS|O :|O The|O relative|O risk|O of|O pancreatic|O cancer|O was|O computed|O by|O multivariate|O and|O person|O -|O year|O analysis|O in|O a|O cohort|O of|O 2633|O patients|O who|O had|O undergone|O gastrectomy|O .|O 
Lung|O cancer|O risk|O was|O analysed|O as|O an|O indirect|O means|O of|O assessing|O smoking|O behaviour|O .|O 
K-ras|gene-rna codon|O 12|O mutational|O analysis|O was|O performed|O on|O 15|O postgastrectomy|O pancreatic|O cancers|O .|O 
RESULTS|O :|O There|O was|O an|O overall|O increased|O risk|O of|O pancreatic|O carcinoma|O of|O 1.8|O (|O 95|O %|O confidence|O interval|O ,|O 1.3|O to|O 2.6|O )|O five|O to|O 59|O years|O postoperatively|O ,|O which|O gradually|O increased|O to|O 3.6|O at|O 35|O years|O or|O more|O after|O surgery|O (|O chi(2)|O test|O for|O trend|O ,|O p|O <|O 0.05|O )|O .|O 
Multivariate|O analysis|O indicated|O that|O parameters|O other|O than|O postoperative|O interval|O did|O not|O influence|O the|O risk|O .|O 
Lung|O cancer|O risk|O was|O significantly|O increased|O after|O surgery|O ,|O but|O no|O time|O trend|O was|O observed|O .|O 
The|O spectrum|O and|O prevalence|O of|O K-ras|gene-rna codon|O 12|O mutations|O were|O comparable|O to|O conventional|O pancreatic|O cancer|O .|O 
CONCLUSIONS|O :|O Remote|O partial|O gastrectomy|O is|O associated|O with|O an|O increased|O risk|O of|O pancreatic|O cancer|O .|O 
Postgastrectomy|O and|O non|O -|O postgastrectomy|O pancreatic|O cancers|O may|O share|O similar|O aetiological|O factors|O ,|O such|O as|O smoking|O .|O 
However|O ,|O the|O neoplastic|O process|O in|O patients|O who|O have|O undergone|O gastrectomy|O appears|O to|O be|O accelerated|O by|O factors|O related|O to|O the|O surgery|O itself|O .|O 
Gallbladder|O carcinoma|O has|O two|O main|O morphologic|O developmental|O pathways|O :|O a|O dysplasia|O -|O carcinoma|O sequence|O and|O an|O adenoma|O -|O carcinoma|O sequence|O .|O 
beta-Catenin|gene-rna is|O a|O key|O regulator|O of|O the|O cadherin|gene-protein -|O mediated|O cell|O adhesion|O system|O ,|O and|O altered|O expression|O and|O mutation|O of|O beta-catenin|gene-rna have|O been|O identified|O in|O many|O human|O malignancies|O .|O 
To|O clarify|O its|O role|O in|O gallbladder|O carcinogenesis|O ,|O we|O investigated|O mutation|O and|O immunohistochemical|O expression|O of|O beta-catenin|gene-protein in|O adenomas|O ,|O dysplasias|O ,|O and|O carcinomas|O .|O 
We|O classified|O adenomas|O according|O to|O the|O expression|O of|O apomucins|gene-protein and|O cytokeratin|gene-protein and|O compared|O the|O mutational|O and|O expression|O pattern|O among|O each|O type|O .|O 
beta-Catenin|gene-rna mutations|O were|O identified|O in|O 58|O %|O (|O 14|O of|O 24|O )|O of|O the|O adenomas|O ,|O and|O they|O were|O absent|O from|O all|O carcinomas|O (|O 37|O cases|O )|O and|O dysplasias|O (|O 13|O cases|O )|O .|O 
Altered|O expression|O of|O beta-catenin|gene-protein ,|O such|O as|O nuclear|O or|O cytoplasmic|O expression|O and|O loss|O of|O membranous|O expression|O ,|O was|O also|O significantly|O higher|O in|O adenomas|O than|O in|O dysplasias|O or|O carcinomas|O (|O p|O <|O 0.001|O )|O .|O 
Of|O the|O adenomas|O ,|O papillary|O adenomas|O and|O tubular|O adenomas|O of|O intestinal|O type|O showed|O infrequent|O beta-catenin|gene-rna abnormality|O ,|O which|O was|O similar|O to|O the|O carcinomas|O .|O 
The|O cytoplasmic|O and|O nuclear|O expression|O of|O beta-catenin|gene-protein in|O carcinomas|O was|O correlated|O with|O less|O aggressive|O tumor|O behavior|O ;|O in|O particular|O ,|O cytoplasmic|O expression|O was|O associated|O with|O improved|O patient|O outcome|O (|O p|O =|O 0.028|O )|O .|O 
Mucinous|O and|O nonmucinous|O appendiceal|O adenocarcinomas|O :|O different|O clinicopathological|O features|O but|O similar|O genetic|O alterations|O .|O 
The|O genetic|O alterations|O of|O appendiceal|O carcinomas|O have|O not|O been|O reported|O in|O detail|O .|O 
We|O studied|O the|O clinicopathological|O factors|O and|O genetic|O alterations|O including|O microsatellite|O instability|O ,|O p53|gene-protein overexpression|O ,|O and|O mutations|O of|O the|O K-ras|gene-rna proto|O -|O oncogene|O of|O 30|O appendiceal|O adenocarcinomas|O ,|O consisting|O of|O 23|O mucinous|O and|O 7|O nonmucinous|O carcinomas|O .|O 
Sixteen|O (|O 70|O %|O )|O mucinous|O carcinomas|O presented|O with|O pseudomyxoma|O peritonei|O ,|O but|O 6|O of|O 7|O (|O 86|O %|O )|O nonmucinous|O carcinomas|O presented|O with|O appendicitis|O (|O P|O =|O .002|O )|O .|O 
All|O carcinomas|O were|O microsatellite|O stable|O ,|O and|O p53|gene-protein overexpression|O was|O present|O in|O only|O 1|O of|O 30|O (|O 3|O %|O )|O carcinomas|O .|O 
K-ras|gene-rna mutation|O was|O present|O in|O 11|O of|O 20|O (|O 55|O %|O )|O carcinomas|O ,|O including|O 8|O of|O 16|O (|O 50|O %|O )|O mucinous|O and|O 3|O of|O 4|O (|O 75|O %|O )|O nonmucinous|O carcinomas|O .|O 
The|O mean|O survival|O of|O patients|O with|O mucinous|O carcinomas|O was|O 26|O +/-|O 19|O months|O compared|O with|O 13|O +/-|O 9|O months|O for|O patients|O with|O nonmucinous|O carcinomas|O (|O P|O =|O .0002|O )|O .|O 
Two|O case|O reports|O of|O childhood|O liver|O cell|O adenomas|O harboring|O beta-catenin|gene-rna abnormalities|O .|O 
The|O benign|O epithelial|O neoplasm|O liver|O cell|O adenoma|O is|O rare|O ,|O especially|O in|O childhood|O .|O 
We|O report|O 2|O such|O cases|O ,|O 1|O of|O which|O was|O associated|O with|O Prader|O -|O Willi|O syndrome|O .|O 
Differential|O diagnosis|O of|O the|O liver|O cell|O adenomas|O on|O the|O basis|O of|O histopathologic|O findings|O proved|O difficult|O and|O was|O based|O on|O the|O absence|O of|O cellular|O and|O nuclear|O atypia|O ,|O mitotic|O activity|O ,|O and|O invasive|O growth|O .|O 
In|O both|O cases|O ,|O immunohistochemical|O staining|O demonstrated|O the|O nuclear|O accumulation|O of|O beta-catenin|gene-protein ,|O and|O in|O 1|O case|O ,|O the|O tumor|O cells|O carried|O a|O mutation|O of|O the|O beta-catenin|gene-rna gene|O .|O 
Recently|O ,|O disregulation|O of|O the|O Wnt|gene-protein /|O beta-catenin|gene-protein pathway|O ,|O attributable|O to|O abnormalities|O of|O the|O beta-catenin|gene-rna gene|O ,|O has|O been|O reported|O to|O be|O a|O major|O event|O in|O the|O development|O of|O hepatocellular|O carcinomas|O and|O hepatoblastomas|O .|O 
Our|O report|O may|O be|O the|O first|O to|O describe|O the|O beta-catenin|gene-rna abnormalities|O in|O childhood|O liver|O cell|O adenoma|O .|O 
These|O findings|O imply|O that|O abnormalities|O of|O beta-catenin|gene-rna can|O be|O an|O early|O initiating|O event|O in|O human|O liver|O tumorigenesis|O .|O 
Copyright|O 2002|O ,|O Elsevier|O Science|O (|O USA|O )|O .|O 
Screening|O of|O H-ras|gene-rna gene|O point|O mutations|O in|O 50|O cases|O of|O bladder|O carcinoma|O .|O 
BACKGROUND|O :|O 
Mutation|O converts|O the|O H-ras|gene-rna gene|O into|O an|O activated|O oncogene|O in|O about|O 10|O %|O of|O human|O bladder|O cancers|O .|O 
Codons|O 12|O and|O 61|O are|O the|O major|O "|O hot|O spots|O "|O for|O activation|O .|O 
A|O simple|O and|O accurate|O method|O to|O detect|O point|O mutations|O in|O these|O codons|O may|O be|O clinically|O useful|O for|O early|O diagnosis|O of|O bladder|O cancer|O .|O 
METHODS|O :|O 
Bladder|O cancer|O samples|O from|O 50|O patients|O ,|O plus|O 10|O samples|O of|O normal|O bladder|O mucosa|O ,|O were|O analyzed|O for|O possible|O point|O mutation|O of|O the|O H-ras|gene-rna gene|O at|O either|O codon|O 12|O or|O codon|O 61|O .|O 
The|O H-ras|gene-rna gene|O DNA|O segments|O that|O include|O these|O 2|O codons|O were|O amplified|O by|O PCR|O methods|O ,|O then|O the|O possible|O presence|O of|O a|O point|O mutation|O was|O evaluated|O at|O each|O codon|O by|O susceptibility|O of|O the|O respective|O DNA|O segments|O to|O digestion|O with|O the|O restriction|gene-protein enzyme|gene-protein and|O by|O dot|O blot|O hybridization|O assay|O .|O 
A|O bladder|O cancer|O patient|O who|O had|O an|O H-ras|gene-rna gene|O mutation|O was|O examined|O to|O see|O whether|O the|O mutation|O was|O also|O detectable|O in|O the|O cells|O released|O in|O the|O urine|O .|O 
RESULTS|O :|O 
Definite|O or|O possible|O point|O mutations|O were|O found|O in|O 6|O (|O 12|O %|O )|O out|O of|O 50|O bladder|O cancer|O patients|O ,|O while|O no|O mutation|O was|O detected|O in|O normal|O mucosa|O .|O 
A|O point|O mutation|O could|O also|O be|O detected|O in|O cells|O isolated|O from|O the|O patient|O 's|O urine|O sample|O .|O 
CONCLUSION|O :|O 
The|O prevalence|O of|O point|O mutations|O at|O codon|O 12|O or|O codon|O 61|O of|O the|O H-ras|gene-rna gene|O found|O in|O this|O study|O was|O similar|O to|O that|O previously|O estimated|O for|O human|O bladder|O cancer|O by|O DNA|O transfection|O assay|O .|O 
The|O method|O we|O have|O used|O for|O detecting|O point|O mutations|O of|O the|O H-ras|gene-rna gene|O provides|O a|O simple|O and|O highly|O accurate|O way|O to|O detect|O mutated|O cancer|O cells|O even|O in|O the|O urine|O .|O 
It|O may|O be|O clinically|O usable|O for|O early|O diagnosis|O of|O bladder|O cancer|O .|O 
Gastrointestinal|O stromal|O tumors|O (|O GISTs|O )|O ,|O the|O specific|O KIT|gene-protein -|O positive|O mesenchymal|O tumors|O of|O the|O gastrointestinal|O tract|O ,|O have|O been|O sporadically|O reported|O in|O the|O rectum|O ,|O but|O there|O are|O few|O clinicopathologic|O series|O .|O 
In|O this|O study|O we|O analyzed|O the|O clinicopathologic|O features|O of|O 133|O anorectal|O GISTs|O ,|O 3|O intramural|O leiomyomas|O (|O LMs|O )|O ,|O and|O 8|O leiomyosarcomas|O (|O LMSs|O )|O from|O the|O files|O of|O the|O Armed|O Forces|O Institute|O of|O Pathology|O and|O the|O Haartman|O Institute|O of|O the|O University|O of|O Helsinki|O .|O 
Ninety-six|O GISTs|O were|O documented|O as|O KIT|gene-protein -|O positive|O and|O three|O additional|O ones|O as|O CD34|gene-protein -|O positive|O .|O 
Thirty-four|O tumors|O were|O included|O by|O their|O histologic|O similarity|O to|O KIT|gene-protein -|O or|O CD34|gene-protein -|O positive|O cases|O .|O 
GIST|O -|O specific|O c-kit|gene-rna gene|O mutations|O ,|O mostly|O in|O exon|O 11|O ,|O were|O documented|O in|O 18|O of|O 29|O cases|O (|O 62|O %|O )|O .|O 
The|O GISTs|O occurred|O in|O adults|O with|O the|O age|O range|O of|O 17|O -|O 90|O years|O (|O median|O 60|O years|O )|O with|O a|O significant|O male|O predominance|O (|O 71|O %|O )|O .|O 
The|O tumors|O ranged|O from|O small|O asymptomatic|O intramural|O nodules|O to|O large|O masses|O that|O bulged|O into|O pelvis|O causing|O pain|O ,|O rectal|O bleeding|O ,|O or|O obstruction|O .|O 
They|O were|O mostly|O highly|O cellular|O spindle|O cell|O tumors|O ;|O four|O tumors|O had|O an|O epithelioid|O morphology|O .|O 
The|O tumors|O coexpressed|O CD34|gene-protein and|O KIT|gene-protein and|O were|O rarely|O positive|O for|O smooth|gene-protein muscle|gene-protein actin|gene-protein or|O desmin|gene-protein and|O never|O for|O S-100|gene-protein protein|O .|O 
Seventy|O percent|O of|O patients|O with|O tumors|O >|O 5|O cm|O with|O more|O than|O 5|O mitoses|O /|O 50|O high|O power|O fields|O (|O HPF|O )|O (|O n|O =|O 31|O )|O died|O of|O disease|O ,|O whereas|O only|O one|O tumor|O <|O 2|O cm|O with|O <|O 5|O mitoses|O /|O 50|O HPF|O (|O n|O =|O 21|O )|O recurred|O and|O none|O caused|O death|O .|O 
Long|O latency|O was|O common|O between|O primary|O operation|O and|O recurrences|O and|O metastases|O ;|O either|O one|O occurred|O in|O 60|O of|O 111|O patients|O with|O follow|O -|O up|O (|O 54|O %|O )|O .|O 
Distant|O metastases|O were|O in|O the|O liver|O ,|O bones|O ,|O and|O lungs|O .|O 
Three|O benign|O actin|gene-protein -|O and|O desmin|gene-protein -|O positive|O and|O KIT|gene-protein -|O negative|O intramural|O LMs|O ,|O similar|O to|O those|O seen|O in|O the|O esophagus|O ,|O were|O identified|O .|O 
There|O were|O eight|O LMSs|O ,|O six|O of|O which|O formed|O a|O polypoid|O intraluminal|O mass|O and|O were|O actin|gene-protein -|O positive|O and|O KIT|gene-protein -|O negative|O .|O 
Despite|O high|O mitotic|O counts|O ,|O only|O one|O LMS|O patient|O died|O of|O disease|O .|O 
A|O great|O majority|O of|O rectal|O smooth|O muscle|O and|O stromal|O tumors|O are|O GISTs|O ,|O which|O have|O a|O spectrum|O from|O minimal|O indolent|O tumors|O to|O overt|O sarcomas|O .|O 
Intramural|O LMs|O are|O exceptional|O ,|O and|O true|O LMSs|O are|O rare|O ,|O and|O similar|O to|O colonic|O ones|O ,|O often|O present|O as|O intraluminal|O polypoid|O masses|O that|O appear|O to|O have|O a|O better|O prognosis|O than|O GISTs|O with|O similar|O mitotic|O rates|O .|O 
A|O number|O of|O genetic|O alterations|O have|O been|O described|O in|O colorectal|O cancers|O .|O 
They|O include|O allelic|O losses|O on|O specific|O chromosomal|O arms|O ,|O mutations|O of|O oncogenes|gene-rna ,|O tumor|gene-rna suppressor|gene-rna genes|O and|O mismatch|gene-rna repair|gene-rna genes|O ,|O microsatellite|O instability|O in|O coding|O repeat|O sequences|O of|O target|O genes|O and|O methylation|O defects|O in|O gene|O promoters|O .|O 
Since|O these|O alterations|O have|O been|O reported|O by|O different|O groups|O on|O different|O tumors|O and|O cell|O lines|O ,|O the|O complete|O repertoire|O of|O genetic|O alterations|O for|O any|O given|O tumor|O sample|O remains|O unknown|O .|O 
In|O the|O present|O study|O ,|O we|O analysed|O a|O series|O of|O 22|O colorectal|O cancer|O cell|O lines|O for|O 31|O different|O genetic|O alterations|O .|O 
We|O found|O significant|O correlations|O between|O mutational|O profiles|O in|O these|O colorectal|O cell|O lines|O associated|O with|O differences|O in|O mismatch|O repair|O status|O .|O This|O panel|O of|O colon|O cancer|O cell|O lines|O is|O representative|O of|O the|O genetic|O heterogeneity|O occurring|O in|O sporadic|O colorectal|O carcinoma|O .|O 
Our|O results|O may|O prove|O to|O be|O very|O useful|O for|O understanding|O the|O different|O biological|O pathways|O involved|O in|O the|O development|O of|O colon|O cancer|O ,|O and|O for|O groups|O studying|O cellular|O biology|O and|O pharmacology|O on|O the|O same|O cell|O lines|O .|O 
Topographic|O analysis|O of|O K|gene-rna -|gene-rna ras|gene-rna mutations|O in|O histologically|O normal|O lung|O tissues|O and|O tumours|O of|O lung|O cancer|O patients|O .|O 
Mutations|O in|O the|O K|gene-rna -|gene-rna ras|gene-rna gene|O are|O very|O common|O in|O lung|O tumours|O and|O are|O implicated|O in|O the|O development|O of|O lung|O cancer|O ,|O but|O the|O timing|O of|O their|O occurrence|O remains|O poorly|O understood|O .|O 
We|O investigated|O K|gene-rna -|gene-rna ras|gene-rna mutations|O in|O cell|O samples|O microdissected|O by|O laser|O capture|O microscopy|O at|O multiple|O sites|O from|O lung|O tissue|O sections|O representing|O tumour|O tissue|O and|O matched|O histologically|O normal|O tissue|O obtained|O from|O 48|O lung|O cancer|O patients|O .|O 
K|gene-rna -|gene-rna ras|gene-rna mutations|O were|O detected|O in|O cell|O samples|O from|O 10|O of|O 38|O (|O 26.3|O %|O )|O lung|O adenocarcinomas|O and|O in|O none|O of|O the|O histologically|O normal|O or|O tumour|O cell|O samples|O taken|O from|O 10|O lung|O squamous|O cell|O carcinomas|O .|O 
Of|O the|O K|gene-rna -|gene-rna ras|gene-rna mutation|O -|O positive|O adenocarcinomas|O ,|O in|O 4|O cases|O a|O mutation|O was|O found|O in|O only|O the|O tumour|O tissue|O ,|O in|O 1|O case|O a|O mutation|O was|O found|O only|O in|O the|O histologically|O normal|O tissue|O ,|O and|O in|O 5|O cases|O mutations|O were|O found|O in|O both|O the|O tumour|O tissue|O and|O histologically|O normal|O tissue|O .|O 
Among|O these|O 5|O cases|O ,|O 2|O had|O identical|O mutations|O in|O both|O the|O tumour|O tissue|O and|O histologically|O normal|O tissue|O ,|O 2|O had|O 1|O mutation|O in|O the|O tumour|O tissue|O and|O 2|O mutations|O in|O the|O histologically|O normal|O tissue|O ,|O 1|O of|O which|O was|O identical|O to|O the|O mutation|O found|O in|O the|O tumour|O ,|O and|O 1|O case|O had|O 2|O codon|O 12|O mutations|O in|O tumour|O tissue|O and|O 2|O mutations|O ,|O in|O codons|O 9|O and|O 11|O ,|O in|O histologically|O normal|O tissue|O .|O 
Altered|O expression|O and|O mutation|O of|O beta-catenin|gene-rna gene|O in|O gastric|O carcinomas|O and|O cell|O lines|O .|O 
beta-catenin|gene-protein serves|O not|O only|O as|O a|O structural|O component|O of|O the|O E-cadherin|gene-protein -|O mediated|O cell|O -|O cell|O adhesion|O system|O ,|O but|O also|O as|O a|O signaling|O molecule|O of|O the|O Wnt|gene-generic /|O wingless|gene-generic pathway|O .|O 
Deregulated|O expression|O of|O beta-catenin|gene-protein and|O mutations|O of|O the|O gene|gene-rna have|O been|O identified|O in|O a|O number|O of|O human|O malignancies|O .|O 
To|O determine|O the|O role|O of|O beta-catenin|gene-generic defects|O in|O stomach|O cancer|O ,|O we|O investigated|O beta-catenin|gene-rna exon|O 3|O mutations|O and|O altered|O protein|gene-protein expression|O in|O 77|O primary|O gastric|O carcinomas|O and|O 11|O cell|O lines|O .|O 
In|O addition|O ,|O the|O immunohistochemical|O expression|O pattern|O of|O beta-catenin|gene-protein in|O 303|O consecutive|O gastric|O cancers|O was|O determined|O and|O their|O relationships|O with|O clinicopathologic|O features|O and|O patient|O outcome|O were|O investigated|O .|O 
This|O study|O revealed|O 5|O %|O (|O 4|O of|O 77|O )|O tumors|O and|O 27|O %|O (|O 3|O of|O 11|O )|O cell|O lines|O with|O beta-catenin|gene-rna gene|O alteration|O ,|O 6|O missense|O mutations|O ,|O and|O 1|O interstitial|O deletion|O .|O 
These|O genetic|O changes|O were|O shown|O to|O correlate|O closely|O with|O nuclear|O localization|O of|O the|O protein|gene-protein (|O p|O =|O 0.001|O )|O .|O 
In|O an|O immunohistochemical|O analysis|O ,|O abnormal|O expressions|O of|O beta-catenin|gene-protein ,|O such|O as|O nuclear|O accumulation|O and|O loss|O of|O membranous|O distribution|O ,|O were|O detected|O in|O 27|O %|O (|O 81|O of|O 303|O )|O of|O tumors|O overall|O .|O 
These|O altered|O beta-catenin|gene-protein expressions|O were|O more|O commonly|O observed|O in|O 37|O %|O (|O 58|O of|O 158|O )|O diffuse|O type|O gastric|O carcinomas|O (|O p|O <|O 0.001|O )|O .|O 
Loss|O of|O membranous|O beta-catenin|gene-protein staining|O was|O associated|O with|O poor|O survival|O (|O p|O =|O 0.045|O )|O .|O 
In|O conclusion|O ,|O our|O results|O demonstrate|O that|O beta-catenin|gene-rna mutations|O are|O common|O in|O gastric|O cancer|O cell|O lines|O but|O occur|O infrequently|O in|O gastric|O carcinoma|O tissues|O .|O 
These|O mutations|O are|O one|O of|O the|O causes|O of|O the|O nuclear|O accumulation|O of|O beta-catenin|gene-protein .|O 
Frequent|O abnormalities|O of|O beta-catenin|gene-protein expression|O in|O gastric|O carcinoma|O support|O the|O idea|O that|O both|O structural|O and|O signaling|O functions|O of|O the|O protein|gene-protein play|O a|O critical|O role|O in|O gastric|O carcinogenesis|O .|O 
K-ras|gene-rna mutations|O in|O endometrial|O carcinomas|O with|O microsatellite|O instability|O .|O 
K-ras|gene-rna mutations|O are|O known|O to|O occur|O in|O hyperplasias|O and|O carcinomas|O of|O the|O endometrium|O .|O 
No|O clear|O correlation|O has|O been|O found|O yet|O between|O K-ras|gene-rna mutations|O and|O microsatellite|O instability|O (|O MI|O )|O in|O these|O lesions|O .|O 
Fifty-eight|O endometrial|O carcinomas|O (|O ECs|O )|O and|O 22|O endometrial|O hyperplasias|O (|O EHs|O )|O were|O analysed|O for|O K-ras|gene-rna mutation|O by|O single|O -|O strand|O conformational|O polymorphism|O analysis|O (|O SSCP|O )|O ,|O restriction|O analysis|O ,|O and|O DNA|O sequencing|O .|O 
MI|O status|O had|O been|O established|O previously|O at|O five|O dinucleotide|O loci|O and|O was|O reconfirmed|O with|O markers|O BAT-25|O and|O BAT-26|O by|O SSCP|O .|O 
K-ras|gene-rna mutations|O were|O detected|O in|O 11|O ECs|O (|O 18.9|O %|O )|O .|O 
All|O 11|O tumours|O were|O endometrioid|O carcinomas|O .|O 
K-ras|gene-rna mutations|O were|O more|O frequent|O in|O MI|O -|O positive|O (|O 6|O /|O 14|O ,|O 42.8|O %|O )|O than|O in|O MI|O -|O negative|O tumours|O (|O 5|O /|O 44|O ,|O 11.3|O %|O )|O (|O p|O =|O 0.017|O )|O .|O 
Methylation|O -|O related|O transitions|O were|O detected|O in|O five|O of|O the|O six|O MI|O -|O positive|O tumours|O but|O in|O only|O one|O of|O the|O five|O MI|O -|O negative|O carcinomas|O .|O 
K-ras|gene-rna mutation|O was|O identified|O in|O only|O one|O atypical|O EH|O (|O 1|O /|O 22|O ,|O 4.5|O %|O )|O ;|O in|O this|O case|O ,|O the|O EH|O co|O -|O existed|O with|O EC|O and|O both|O lesions|O exhibited|O MI|O .|O 
The|O results|O support|O a|O close|O relationship|O between|O K-ras|gene-rna mutations|O and|O the|O phenomenon|O of|O MI|O in|O endometrial|O carcinomas|O .|O 
The|O frequent|O occurrence|O of|O methylation|O -|O related|O transitions|O in|O these|O tumours|O may|O indicate|O a|O cause|O -|O effect|O relationship|O with|O the|O altered|O methylation|O status|O which|O has|O been|O described|O in|O association|O with|O MI|O .|O 
Genetic|O changes|O in|O contralateral|O bronchioloalveolar|O carcinomas|O of|O the|O lung|O .|O 
OBJECTIVE|O :|O 
The|O pattern|O of|O metastases|O and|O recurrence|O of|O bronchioloalveolar|O carcinoma|O (|O BAC|O )|O differs|O from|O adenocarcinoma|O of|O the|O lung|O ,|O occurring|O more|O frequently|O within|O the|O lung|O without|O extrapulmonary|O involvement|O .|O 
Analyses|O of|O genetic|O differences|O of|O contralateral|O BACs|O may|O help|O to|O explain|O these|O clinical|O differences|O .|O 
METHODS|O :|O 
We|O compared|O paired|O tumors|O from|O 5|O patients|O with|O contralateral|O metachronous|O BACs|O for|O loss|O of|O heterozygosity|O (|O LOH|O )|O on|O 6|O chromosomal|O arms|O (|O 2q|O ,|O 3p|O ,|O 5q|O ,|O 9p|O ,|O 13q|O and|O 17p|O )|O and|O mutational|O analysis|O of|O p53|gene-rna and|O K-ras|gene-rna .|O 
RESULTS|O :|O 
Two|O patients|O ,|O patients|O 1|O and|O 2|O ,|O had|O discordant|O patterns|O of|O LOH|O on|O 2|O and|O 3|O of|O the|O chromosome|O arms|O ,|O respectively|O .|O 
In|O addition|O ,|O patient|O 2|O had|O a|O detectable|O K-ras|gene-rna mutation|O in|O his|O initial|O tumor|O but|O not|O in|O his|O second|O .|O 
These|O results|O suggest|O that|O in|O patients|O 1|O and|O 2|O ,|O the|O contralateral|O tumors|O were|O clonally|O unrelated|O .|O 
Patient|O 3|O had|O no|O mutations|O in|O the|O K-ras|gene-rna or|O p53|gene-rna gene|O and|O no|O LOH|O on|O any|O of|O the|O 5|O informative|O chromosome|O arms|O .|O 
Patient|O 4|O had|O LOH|O of|O 9p|O and|O mutated|O K-ras|gene-rna in|O both|O the|O first|O and|O the|O second|O tumor|O ,|O with|O a|O mutation|O in|O the|O p53|gene-rna gene|O in|O the|O first|O but|O not|O in|O the|O second|O tumor|O .|O 
Patient|O 5|O had|O LOH|O of|O 17p|O and|O the|O same|O p53|gene-rna mutations|O in|O both|O the|O first|O and|O the|O second|O tumor|O ,|O with|O a|O mutation|O of|O K-ras|gene-rna in|O the|O first|O tumor|O but|O not|O in|O the|O second|O .|O 
CONCLUSIONS|O :|O 
The|O preponderance|O of|O evidence|O suggests|O that|O in|O patients|O 3|O ,|O 4|O and|O 5|O ,|O the|O paired|O tumors|O were|O clonally|O related|O .|O 
The|O different|O patterns|O of|O LOH|O and|O mutations|O in|O clinically|O similar|O contralateral|O metachronous|O BACs|O provide|O evidence|O of|O genetic|O heterogeneity|O in|O the|O tumors|O of|O this|O patient|O group|O .|O 
Carcinoid|O tumors|O of|O the|O extrahepatic|O bile|O ducts|O :|O a|O study|O of|O seven|O cases|O .|O 
The|O authors|O report|O seven|O patients|O with|O carcinoid|O tumors|O of|O the|O extrahepatic|O bile|O ducts|O (|O EHBDs|O )|O .|O 
All|O patients|O were|O women|O ,|O with|O an|O average|O age|O at|O diagnosis|O of|O 49.8|O years|O (|O range|O ,|O 37|O -|O 67|O yrs|O )|O .|O 
The|O most|O common|O presenting|O symptom|O was|O painless|O jaundice|O with|O or|O without|O pruritus|O .|O 
Although|O one|O patient|O had|O peptic|O ulcer|O disease|O before|O the|O onset|O of|O obstructive|O jaundice|O ,|O none|O had|O systemic|O endocrine|O manifestations|O .|O 
These|O neoplasms|O were|O most|O often|O located|O in|O the|O common|O bile|O duct|O .|O 
Grossly|O ,|O the|O carcinoid|O tumors|O were|O usually|O nodular|O and|O poorly|O demarcated|O ,|O and|O ranged|O from|O 1.1|O to|O 2.7|O cm|O in|O size|O .|O 
Only|O one|O of|O the|O neoplasms|O was|O polypoid|O .|O 
Microscopically|O ,|O the|O tumors|O had|O a|O trabecular|O or|O nesting|O pattern|O with|O occasional|O tubule|O formation|O ,|O and|O were|O composed|O of|O relatively|O small|O cells|O with|O granular|O chromatin|O .|O 
All|O of|O the|O neoplasms|O expressed|O chromogranin|gene-protein and|O two|O expressed|O synaptophysin|gene-protein .|O 
Three|O expressed|O serotonin|O and|O two|O of|O the|O three|O were|O also|O immunoreactive|O for|O pancreatic|gene-protein polypeptide|gene-protein or|O somatostatin|gene-protein .|O 
Two|O tumors|O were|O focally|O positive|O for|O gastrin|gene-protein and|O one|O of|O these|O two|O tumors|O was|O also|O positive|O for|O serotonin|O and|O pancreatic|gene-protein polypeptide|gene-protein .|O 
All|O seven|O carcinoid|O tumors|O showed|O no|O immunoreactivity|O for|O p53|gene-protein ,|O and|O assays|O for|O p53|gene-rna loss|O of|O heterozygosity|O analysis|O were|O negative|O in|O two|O ,|O suggesting|O that|O p53|gene-rna mutations|O do|O not|O play|O a|O role|O in|O the|O pathogenesis|O of|O EHBD|O carcinoids|O .|O 
A|O mutation|O in|O codon|O 12|O of|O K-ras|gene-rna was|O found|O in|O one|O carcinoid|O tumor|O whereas|O two|O of|O two|O showed|O immunoreactivity|O for|O Dpc4|gene-protein protein|O .|O 
In|O view|O of|O the|O small|O number|O of|O carcinoids|O studied|O ,|O the|O importance|O of|O these|O findings|O in|O the|O pathogenesis|O of|O these|O tumors|O is|O unclear|O .|O 
Ultrastructural|O examination|O of|O three|O of|O the|O tumors|O revealed|O numerous|O membrane|O -|O bound|O ,|O round|O neurosecretory|O granules|O .|O 
Clinically|O ,|O these|O lesions|O had|O an|O indolent|O course|O .|O 
Even|O in|O the|O presence|O of|O lymph|O node|O metastases|O (|O noted|O in|O two|O patients|O )|O ,|O all|O of|O the|O patients|O remained|O disease|O free|O 2|O to|O 11|O years|O (|O average|O follow|O up|O ,|O 6.6|O yrs|O )|O after|O segmental|O resection|O or|O pancreaticoduodenectomy|O (|O Whipple|O 's|O procedure|O )|O .|O 
Because|O carcinoid|O tumors|O of|O the|O EHBD|O are|O of|O low|O malignant|O potential|O ,|O they|O should|O be|O separated|O from|O the|O more|O common|O adenocarcinomas|O in|O this|O location|O .|O 
Microsatellite|O instability|O and|O k-ras|gene-rna ,|O p53|gene-rna mutations|O in|O thyroid|O lymphoma|O .|O 
Patho|O -|O epidemiological|O studies|O showed|O that|O thyroid|O lymphoma|O (|O TL|O )|O arises|O in|O inflammatory|O lesions|O of|O chronic|O lymphocytic|O thyroiditis|O (|O CLTH|O )|O .|O 
Replication|O error|O (|O RER|O )|O is|O found|O in|O inflammatory|O lesions|O and|O associated|O cancer|O ,|O suggesting|O that|O chronic|O inflammation|O could|O be|O a|O risk|O factor|O for|O neoplastic|O development|O through|O causing|O RER|O .|O 
To|O clarify|O whether|O RER|O is|O involved|O in|O the|O pathogenesis|O of|O TL|O ,|O we|O examined|O the|O microsatellite|O instability|O (|O MSI|O )|O in|O 9|O cases|O with|O CLTH|O and|O 19|O with|O TL|O ,|O including|O 10|O diffuse|O large|O B-cell|O lymphoma|O (|O DLBL|O )|O ,|O 4|O follicle|O center|O cell|O lymphoma|O ,|O 3|O marginal|O zone|O B-cell|O lymphoma|O of|O extranodal|O (|O MALT|O )|O type|O ,|O and|O 2|O lymphoplasmacytic|O type|O .|O 
Sixteen|O distinct|O microsatellite|O repeats|O were|O analyzed|O .|O 
Mutations|O of|O p53|gene-rna and|O k-ras|gene-rna genes|O were|O also|O examined|O .|O 
When|O alterations|O at|O 2|O or|O more|O microsatellite|O loci|O were|O judged|O as|O positive|O ,|O only|O 5|O DLBL|O cases|O exhibited|O MSI|O .|O 
The|O frequency|O of|O MSI|O in|O DLBL|O was|O significantly|O higher|O than|O that|O in|O other|O types|O of|O TL|O and|O CLTH|O (|O P|O <|O 0.05|O )|O .|O 
Four|O of|O 19|O cases|O (|O 21.1|O %|O )|O showed|O point|O mutation|O of|O the|O k-ras|gene-rna gene|O .|O 
The|O k-ras|gene-rna mutations|O occurred|O in|O the|O cases|O with|O DLBL|O with|O RER|O ,|O and|O four|O of|O five|O cases|O with|O RER|O had|O a|O k-ras|gene-rna mutation|O ,|O indicating|O a|O close|O association|O between|O RER|O and|O k-ras|gene-rna mutation|O .|O 
p53|gene-rna mutations|O were|O not|O found|O in|O the|O CLTH|O .|O 
Two|O of|O 19|O TL|O cases|O showed|O mutations|O of|O p53|gene-rna gene|O .|O 
There|O was|O no|O significant|O association|O between|O RER|O and|O p53|gene-rna mutation|O .|O 
These|O findings|O indicate|O that|O genomic|O instability|O contributes|O to|O the|O progression|O of|O TL|O from|O low|O grade|O to|O high|O grade|O ,|O but|O not|O to|O the|O development|O of|O low|O grade|O lymphoma|O in|O CLTH|O lesions|O .|O 
N-RAS|gene-rna gene|O mutation|O in|O patients|O with|O aplastic|O anemia|O and|O aplastic|O anemia|O /|O paroxysmal|O nocturnal|O hemoglobinuria|O during|O evolution|O to|O clonal|O disease|O .|O 
Long|O -|O term|O survivors|O of|O aplastic|O anemia|O (|O AA|O )|O have|O a|O high|O incidence|O of|O clonal|O disorders|O ,|O in|O particular|O paroxysmal|O nocturnal|O hemoglobinuria|O (|O PNH|O )|O ,|O myelodysplastic|O syndromes|O (|O MDS|O )|O ,|O and|O acute|O nonlymphocytic|O leukemia|O .|O 
To|O investigate|O the|O potential|O involvement|O of|O N-RAS|gene-rna gene|O mutations|O in|O the|O predisposition|O to|O leukemic|O evolution|O ,|O a|O subset|O of|O patients|O at|O potentially|O increased|O risk|O for|O clonal|O disease|O was|O selected|O based|O on|O evidence|O of|O existing|O clonal|O evolution|O .|O 
Nine|O patients|O showed|O a|O monoclonal|O pattern|O of|O X-chromosome|O inactivation|O ,|O 18|O demonstrated|O a|O PNH|O clone|O ,|O and|O in|O 3|O MDS|O developed|O during|O the|O course|O of|O this|O study|O .|O 
No|O mutations|O were|O detected|O during|O the|O aplastic|O phase|O of|O disease|O ;|O 2|O of|O 3|O patients|O with|O MDS|O after|O AA|O also|O showed|O no|O mutations|O .|O 
However|O ,|O in|O 1|O patient|O in|O whom|O the|O disease|O transformed|O from|O AA|O /|O PNH|O to|O MDS|O ,|O a|O mutation|O of|O GGT|O -->|O GAT|O at|O N-RAS|gene-rna codon|O 13|O became|O detectable|O ,|O whereas|O the|O PNH|O mutation|O disappeared|O .|O 
The|O authors|O conclude|O that|O N-RAS|gene-rna mutations|O are|O not|O an|O early|O event|O preceding|O transformation|O of|O AA|O or|O AA|O /|O PNH|O to|O leukemia|O .|O 
In|O a|O subset|O of|O patients|O ,|O RAS|gene-rna mutations|O may|O occur|O at|O the|O time|O of|O evolution|O to|O MDS|O ,|O but|O preexisting|O RAS|gene-rna mutations|O do|O not|O explain|O the|O propensity|O of|O AA|O to|O leukemogenesis|O .|O 
Although|O PNH|O is|O also|O associated|O with|O leukemia|O ,|O this|O may|O arise|O in|O the|O non|O -|O PNH|O cells|O ,|O indicating|O that|O PIG-A|gene-rna gene|O mutation|O is|O not|O per|O se|O oncogenic|O .|O 
Somatic|O mutations|O of|O the|O APC|gene-rna ,|O KRAS|gene-rna ,|O and|O TP53|gene-rna genes|O in|O nonpolypoid|O colorectal|O adenomas|O .|O 
Colorectal|O adenomas|O are|O macroscopically|O visible|O morphological|O changes|O of|O the|O mucosa|O that|O can|O develop|O focal|O carcinoma|O in|O the|O absence|O of|O surgical|O intervention|O .|O 
The|O successive|O molecular|O changes|O proposed|O to|O occur|O at|O different|O stages|O in|O the|O adenoma|O -|O carcinoma|O sequence|O were|O primarily|O based|O on|O DNA|O studies|O of|O exophytic|O ,|O polypoid|O -|O type|O adenomas|O .|O 
Not|O all|O colorectal|O lesions|O ,|O however|O ,|O display|O an|O exophytic|O phenotype|O and|O a|O presumed|O distinct|O colorectal|O neoplasm|O ,|O the|O nonpolypoid|O adenoma|O ,|O was|O subsequently|O described|O as|O a|O precursor|O of|O colorectal|O cancer|O .|O 
The|O low|O incidence|O of|O KRAS|gene-rna mutations|O in|O nonpolypoid|O colorectal|O adenomas|O reported|O previously|O suggested|O a|O different|O genetic|O basis|O for|O the|O transformation|O process|O in|O these|O lesions|O .|O 
We|O have|O pursued|O the|O identification|O of|O genetic|O changes|O in|O benign|O sporadic|O nonpolypoid|O colorectal|O adenomas|O in|O a|O selected|O Swedish|O patient|O group|O with|O no|O family|O history|O of|O colorectal|O cancer|O .|O 
Mutation|O screening|O of|O the|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|O APC|gene-rna )|O ,|O KRAS|gene-rna ,|O and|O TP53|gene-rna genes|O was|O conducted|O using|O the|O protein|O truncation|O test|O ,|O heteroduplex|O -|O single|O -|O strand|O conformation|O polymorphism|O analysis|O ,|O and|O denaturing|O gradient|O gel|O electrophoresis|O on|O PCR|O -|O amplified|O fragments|O .|O 
Fourteen|O mutations|O in|O the|O APC|gene-rna gene|O were|O characterized|O in|O 10|O /|O 20|O samples|O .|O 
Mutations|O in|O the|O KRAS|gene-rna and|O TP53|gene-rna genes|O were|O identified|O in|O 3|O /|O 57|O and|O 4|O /|O 51|O adenomas|O ,|O respectively|O .|O 
The|O mutation|O frequencies|O and|O distribution|O of|O mutations|O in|O APC|gene-rna correlate|O with|O published|O data|O on|O exophytic|O adenomas|O .|O 
The|O low|O mutation|O frequency|O of|O the|O TP53|gene-rna gene|O is|O consistent|O with|O the|O benign|O nature|O of|O the|O research|O material|O .|O 
KRAS|gene-rna activation|O (|O an|O early|O event|O in|O polypoid|O colorectal|O adenomas|O )|O apparently|O does|O not|O play|O a|O significant|O role|O in|O nonpolypoid|O adenoma|O development|O but|O may|O result|O in|O the|O development|O of|O a|O polypoid|O configuration|O .|O 
Beta|gene-protein -|gene-protein and|O gamma|gene-protein -|gene-protein catenin|gene-protein mutations|O ,|O but|O not|O E-cadherin|gene-protein inactivation|O ,|O underlie|O T-cell|gene-protein factor|gene-protein /|O lymphoid|gene-protein enhancer|gene-protein factor|gene-protein transcriptional|O deregulation|O in|O gastric|O and|O pancreatic|O cancer|O .|O 
Adenomatous|gene-protein polyposis|gene-protein coli|gene-protein (|O APC|gene-protein )|O mutations|O are|O present|O in|O >|O 70|O %|O of|O colon|O cancers|O .|O 
The|O APC|gene-protein protein|O binds|O to|O beta-catenin|gene-protein (|O beta-cat|gene-protein )|O ,|O a|O protein|O first|O identified|O because|O of|O its|O role|O in|O E-cadherin|gene-protein (|O E-cad|gene-protein )|O cell|O adhesion|O .|O 
In|O some|O colon|O cancers|O lacking|O APC|gene-protein defects|O ,|O mutations|O in|O presumptive|O glycogen|gene-protein synthase|gene-protein kinase|gene-protein 3beta|gene-protein phosphorylation|O sites|O near|O the|O beta-cat|gene-protein NH2|O terminus|O appear|O to|O render|O beta-cat|gene-protein resistant|O to|O regulation|O by|O APC|gene-protein and|O glycogen|gene-protein synthase|gene-protein kinase|gene-protein 3beta|gene-protein .|O 
In|O cells|O with|O APC|gene-protein or|O beta-cat|gene-protein defects|O ,|O beta-cat|gene-protein is|O stabilized|O and|O ,|O in|O turn|O ,|O binds|O to|O and|O activates|O T-cell|gene-protein factor|gene-protein (|O Tcf|gene-protein )|O /|O lymphoid|gene-protein enhancer|gene-protein factor|gene-protein (|O Lef|gene-protein )|O transcription|O factors|O .|O 
To|O further|O explore|O the|O role|O of|O APC|gene-protein ,|O beta-cat|gene-protein ,|O Tcf|gene-protein ,|O and|O E-cad|gene-protein defects|O in|O gastrointestinal|O cancers|O ,|O we|O assessed|O gastric|O and|O pancreatic|O cancers|O for|O constitutive|O Tcf|gene-protein transcriptional|O activity|O (|O CTTA|O )|O .|O 
Two|O of|O four|O gastric|O and|O two|O of|O eight|O pancreatic|O cancer|O lines|O showed|O CTTA|O .|O 
One|O gastric|O and|O one|O pancreatic|O cancer|O had|O mutations|O in|O the|O NH2|O -|O terminal|O phosphorylation|O sites|O of|O beta-cat|gene-protein .|O 
The|O other|O gastric|O cancer|O with|O CTTA|O had|O a|O missense|O mutation|O at|O serine|O 28|O of|O gamma-cat|gene-protein ,|O a|O potential|O phosphorylation|O site|O in|O this|O beta-cat|gene-protein -|O related|O protein|O .|O 
Although|O E-cad|gene-protein is|O an|O important|O binding|O partner|O for|O beta-cat|gene-protein and|O gamma-cat|gene-protein ,|O E-cad|gene-protein inactivation|O did|O not|O result|O in|O CTTA|O .|O 
The|O beta-cat|gene-protein and|O gamma-cat|gene-protein mutant|O proteins|O identified|O in|O our|O studies|O strongly|O activated|O Tcf|gene-protein transcription|O in|O vitro|O ,|O whereas|O beta-cat|gene-protein mutant|O proteins|O with|O large|O NH2|O -|O terminal|O deletions|O had|O only|O modest|O effects|O on|O Tcf|gene-protein .|O 
Our|O results|O suggest|O a|O role|O for|O Tcf|gene-protein deregulation|O in|O gastric|O and|O pancreatic|O cancer|O ,|O resulting|O from|O beta-cat|gene-protein and|O gamma-cat|gene-protein mutations|O in|O some|O cases|O and|O ,|O in|O others|O ,|O from|O yet|O to|O be|O defined|O defects|O .|O 
Furthermore|O ,|O these|O data|O imply|O that|O the|O consequences|O of|O APC|gene-protein and|O beta-cat|gene-protein mutations|O are|O distinct|O from|O the|O effects|O of|O E-cad|gene-protein inactivation|O .|O 
Mutations|O of|O c-kit|gene-rna JM|O domain|O are|O found|O in|O a|O minority|O of|O human|O gastrointestinal|O stromal|O tumors|O .|O 
The|O c-kit|gene-rna gene|O encodes|O a|O transmembrane|gene-protein receptor|gene-protein kinase|gene-protein (|O KIT|gene-protein )|O which|O is|O expressed|O in|O the|O majority|O of|O human|O gastrointestinal|O stromal|O tumors|O (|O GISTs|O )|O ,|O a|O subtype|O of|O gastrointestinal|O mesenchymal|O neoplasms|O .|O 
A|O previous|O study|O identified|O mutations|O in|O the|O juxtamembrane|O (|O JM|O )|O domain|O of|O c-kit|gene-rna in|O five|O of|O six|O GISTs|O (|O Science|O 279|O :|O 577|O ,|O 1998|O )|O .|O 
To|O better|O define|O the|O frequency|O and|O spectrum|O of|O c-kit|gene-rna gene|O mutations|O in|O mesenchymal|O neoplasms|O of|O the|O GI|O tract|O that|O had|O been|O characterized|O for|O KIT|gene-protein protein|O expression|O ,|O we|O examined|O archived|O tissue|O samples|O for|O mutations|O in|O the|O JM|O domain|O by|O PCR|O amplification|O and|O DNA|O sequencing|O .|O 
c-kit|gene-rna JM|O domain|O mutations|O were|O found|O in|O nine|O of|O 56|O mesenchymal|O tumors|O (|O 46|O GISTs|O ,|O eight|O leiomyomas|O ,|O two|O leiomyosarcomas|O )|O and|O occurred|O exclusively|O in|O GISTs|O (|O 21|O %|O )|O .|O 
Seven|O of|O the|O nine|O mutations|O consisted|O of|O intragenic|O deletions|O of|O one|O to|O 19|O codons|O .|O 
There|O was|O one|O insertion|O mutation|O that|O added|O 12|O codons|O and|O one|O missense|O mutation|O (|O Val|O 560|O Asp|O )|O .|O 
None|O of|O the|O mutations|O disrupted|O the|O downstream|O reading|O frame|O of|O the|O gene|gene-rna .|O 
The|O single|O missense|O mutation|O (|O Val|O 560|O Asp|O )|O is|O very|O similar|O to|O the|O only|O other|O missense|O mutation|O reported|O in|O GISTs|O (|O Val|O 599|O Asp|O )|O .|O 
Of|O the|O 46|O GISTs|O ,|O 43|O were|O strongly|O positive|O for|O KIT|gene-protein protein|O expression|O and|O negative|O for|O diffuse|O expression|O of|O desmin|gene-protein .|O 
Neither|O KIT|gene-protein expression|O nor|O gene|O mutations|O were|O found|O in|O gastrointestinal|O leiomyomas|O or|O leiomyosarcomas|O .|O 
We|O conclude|O that|O mutation|O of|O the|O c-kit|gene-rna JM|O domain|O does|O not|O occur|O in|O gastrointestinal|O mesenchymal|O neoplasms|O with|O well|O developed|O -|O smooth|O muscle|O differentiation|O ,|O and|O is|O restricted|O to|O GISTs|O .|O 
However|O ,|O since|O these|O mutations|O are|O only|O found|O in|O a|O minority|O of|O GISTs|O ,|O further|O investigation|O into|O the|O mechanisms|O of|O c-kit|gene-rna gene|O activation|O in|O this|O group|O of|O neoplasms|O is|O warranted|O .|O 
Genetic|O alterations|O of|O mixed|O hyperplastic|O adenomatous|O polyps|O in|O the|O colon|O and|O rectum|O .|O 
Some|O mixed|O hyperplastic|O adenomatous|O polyps|O (|O MHAPs|O )|O contain|O dysplastic|O lesions|O or|O even|O carcinomas|O .|O 
These|O polyps|O are|O considered|O to|O be|O different|O from|O ordinary|O hyperplastic|O polyps|O and|O may|O have|O a|O preneoplastic|O potential|O .|O 
We|O investigated|O APC|gene-rna and|O K-ras|gene-rna mutations|O in|O MHAPs|O of|O the|O colon|O and|O rectum|O ,|O and|O also|O in|O colorectal|O adenomas|O and|O hyperplastic|O polyps|O to|O identify|O molecular|O differences|O between|O MHAPs|O ,|O adenomas|O and|O hyperplastic|O polyps|O ,|O using|O direct|O sequencing|O of|O mutation|O cluster|O regions|O (|O MCR|O )|O in|O APC|gene-rna and|O K-ras|gene-rna .|O 
No|O APC|gene-rna mutations|O were|O identified|O in|O 12|O MHAPs|O and|O 8|O hyperplastic|O polyps|O ,|O whereas|O 10|O of|O 27|O (|O 37.0|O %|O )|O adenomas|O showed|O somatic|O mutations|O .|O 
K-ras|gene-rna mutations|O were|O identified|O in|O one|O of|O 12|O (|O 8.3|O %|O )|O MHAPs|O ,|O one|O of|O 8|O (|O 12.5|O %|O )|O hyperplastic|O polyps|O ,|O and|O 10|O of|O 27|O (|O 37.0|O %|O )|O adenomas|O .|O 
p53|gene-rna mutation|O was|O found|O in|O a|O carcinoma|O arising|O in|O an|O MHAP|O .|O 
Mutations|O other|O than|O APC|gene-rna mutations|O may|O play|O a|O role|O in|O the|O development|O of|O MHAPs|O .|O 
Inverse|O relationship|O between|O APC|gene-rna gene|O mutation|O in|O gastric|O adenomas|O and|O development|O of|O adenocarcinoma|O .|O 
Gastric|O cancer|O is|O common|O among|O the|O world|O ,|O but|O genetic|O mechanisms|O of|O gastric|O carcinogenesis|O are|O not|O well|O understood|O .|O 
Gastric|O polypoid|O adenomas|O and|O flat|O dysplasias|O are|O regarded|O as|O precursor|O lesions|O .|O 
However|O ,|O a|O detailed|O molecular|O study|O of|O these|O lesions|O has|O not|O been|O done|O to|O determine|O their|O role|O as|O precancerous|O lesions|O .|O 
We|O investigated|O mutations|O of|O the|O APC|gene-rna ,|O beta-catenin|gene-rna ,|O and|O K-ras|gene-rna genes|O ,|O and|O microsatellite|O instability|O (|O MSI|O )|O status|O in|O 35|O adenomas|O and|O 47|O flat|O dysplasias|O without|O adenocarcinoma|O ,|O 35|O adenomas|O /|O dysplasias|O associated|O with|O adenocarcinomas|O ,|O and|O 39|O adenocarcinomas|O (|O 20|O diffuse|O type|O and|O 19|O intestinal|O type|O )|O .|O 
Somatic|O APC|gene-rna gene|O mutations|O were|O identified|O in|O 76|O %|O (|O 59|O of|O 78|O )|O of|O adenomas|O or|O flat|O dysplasias|O without|O associated|O adenocarcinoma|O ,|O but|O in|O only|O 3|O %|O (|O 1|O of|O 30|O )|O of|O adenomas|O /|O dysplasias|O associated|O with|O adenocarcinoma|O ,|O and|O in|O only|O 4|O %|O (|O 3|O of|O 69|O )|O of|O adenocarcinomas|O (|O P|O <|O 0.000001|O )|O .|O 
No|O mutations|O of|O beta-catenin|gene-rna were|O found|O in|O adenocarcinomas|O ,|O or|O adenomas|O /|O dysplasia|O without|O APC|gene-rna mutation|O .|O 
K-ras|gene-rna mutations|O were|O detected|O in|O 5|O %|O (|O 4|O of|O 82|O )|O of|O gastric|O adenomas|O /|O dysplasia|O without|O carcinoma|O ,|O 3|O %|O (|O 1|O of|O 39|O )|O of|O adenocarcinomas|O without|O associated|O adenoma|O /|O dysplasia|O ,|O and|O not|O in|O 32|O adenocarcinomas|O with|O associated|O adenoma|O /|O dysplasia|O .|O 
High|O level|O of|O MSI|O (|O MSI-H|O )|O was|O more|O frequent|O in|O gastric|O adenoma|O /|O dysplasia|O associated|O with|O carcinoma|O (|O 17|O %|O ,|O 6|O of|O 35|O )|O than|O in|O adenomas|O /|O dysplasia|O without|O carcinoma|O (|O 3|O %|O ,|O 2|O of|O 75|O ;|O P|O =|O 0.01|O )|O .|O 
MSI-H|O was|O also|O more|O frequent|O in|O intestinal|O type|O adenocarcinoma|O (|O 20|O %|O ,|O 11|O of|O 54|O )|O than|O in|O diffuse|O type|O (|O 0|O %|O ,|O 0|O of|O 20|O ;|O P|O =|O 0.03|O )|O .|O 
APC|gene-rna gene|O mutations|O were|O present|O in|O six|O of|O nine|O (|O 67|O %|O )|O of|O gastric|O adenomas|O /|O dysplasias|O with|O low|O level|O of|O MSI|O ,|O but|O in|O none|O of|O the|O eight|O adenomas|O /|O dysplasia|O with|O MSI-H|O phenotype|O (|O P|O =|O 0.009|O )|O .|O 
Our|O results|O indicate|O that|O somatic|O mutation|O of|O the|O APC|gene-rna gene|O plays|O an|O important|O role|O in|O the|O pathogenesis|O of|O gastric|O adenoma|O and|O dysplasia|O but|O has|O a|O limited|O role|O in|O neoplastic|O progression|O to|O adenocarcinoma|O .|O 
Gastric|O adenomas|O or|O dysplasias|O without|O APC|gene-rna mutations|O but|O with|O or|O without|O MSI|O may|O have|O a|O different|O biological|O behavior|O ,|O and|O are|O precursors|O of|O intestinal|O -|O type|O of|O gastric|O adenocarcinomas|O .|O 
Comparison|O of|O ras|gene-rna activation|O in|O prostate|O carcinoma|O in|O Japanese|O and|O American|O men|O .|O 
BACKGROUND|O :|O 
Comparative|O studies|O of|O point|O mutations|O in|O K|gene-rna -|gene-rna ,|O N|gene-rna -|gene-rna ,|O and|O H|gene-rna -|gene-rna ras|gene-rna oncogenes|O were|O performed|O on|O prostate|O carcinoma|O from|O Japanese|O and|O American|O patients|O to|O clarify|O the|O racial|O difference|O .|O 
METHODS|O :|O 
We|O probed|O for|O mutations|O in|O 70|O Japanese|O and|O 31|O American|O specimens|O using|O polymerase|gene-protein chain|O reaction|O -|O single|O -|O strand|O conformation|O polymorphism|O (|O PCR|O -|O SSCP|O )|O analysis|O and|O immunohistochemistry|O for|O ras|gene-protein p21|gene-protein .|O 
RESULTS|O :|O 
Within|O the|O 70|O Japanese|O specimens|O ,|O eight|O mutations|O in|O codon|O 12|O of|O K-ras|gene-rna (|O five|O GGT|O -->|O GTT|O transversions|O and|O three|O CGT|O -->|O GAT|O transitions|O )|O and|O one|O mutation|O in|O codon|O 12|O of|O the|O N-ras|gene-rna gene|O (|O a|O GGT|O -->|O GTT|O transversion|O )|O were|O confirmed|O ,|O whereas|O the|O American|O samples|O yielded|O only|O one|O definable|O mutation|O ,|O a|O GGT|O -->|O GAT|O transition|O ,|O in|O codon|O 12|O of|O K-ras|gene-rna .|O 
CONCLUSIONS|O :|O 
The|O frequency|O of|O ras|gene-rna gene|O mutations|O in|O clinical|O carcinoma|O in|O Japanese|O men|O was|O higher|O than|O that|O in|O American|O men|O .|O 
It|O is|O suggested|O that|O there|O may|O be|O fundamental|O differences|O in|O the|O etiology|O of|O prostate|O carcinoma|O in|O Japan|O and|O the|O United|O States|O ,|O perhaps|O based|O on|O genetics|O and/or|O environmental|O factors|O .|O 
Mutational|O activation|O of|O the|O K-ras|gene-rna oncogene|O and|O the|O effect|O of|O chemotherapy|O in|O advanced|O adenocarcinoma|O of|O the|O lung|O :|O a|O prospective|O study|O .|O 
PURPOSE|O :|O 
To|O determine|O whether|O the|O clinical|O course|O and|O the|O response|O to|O chemotherapy|O of|O patients|O with|O advanced|O adenocarcinoma|O of|O the|O lung|O depends|O on|O the|O presence|O or|O absence|O of|O a|O ras|gene-rna mutation|O in|O the|O tumor|O .|O 
Mutational|O activation|O of|O K-ras|gene-rna is|O a|O strong|O adverse|O prognostic|O factor|O in|O stage|O I|O or|O II|O lung|O cancer|O and|O laboratory|O studies|O have|O suggested|O that|O ras|gene-rna mutations|O lead|O to|O resistance|O against|O ionizing|O radiation|O and|O chemotherapy|O .|O 
PATIENTS|O AND|O METHODS|O :|O 
Patients|O with|O advanced|O adenocarcinoma|O of|O the|O lung|O with|O measurable|O or|O assessable|O disease|O received|O chemotherapy|O with|O mesna|O ,|O ifosfamide|O ,|O carboplatin|O ,|O and|O etoposide|O (|O MICE|O )|O .|O 
Archival|O biopsies|O ,|O fresh|O biopsies|O ,|O or|O fine|O -|O needle|O aspirations|O were|O tested|O for|O the|O presence|O of|O ras|gene-rna gene|O mutations|O .|O 
Associations|O of|O ras|gene-rna mutations|O with|O clinical|O characteristics|O ,|O response|O to|O chemotherapy|O ,|O and|O survival|O were|O studied|O .|O 
RESULTS|O :|O 
The|O presence|O or|O absence|O of|O ras|gene-rna gene|O mutations|O could|O be|O established|O in|O 69|O of|O 83|O patients|O (|O 83|O %|O )|O .|O 
A|O total|O of|O 261|O courses|O of|O MICE|O were|O administered|O to|O 62|O informative|O patients|O ,|O 16|O of|O whom|O were|O shown|O to|O have|O a|O K-ras|gene-rna mutation|O -|O positive|O tumor|O .|O 
The|O frequency|O of|O mutations|O (|O 26|O %|O )|O and|O the|O type|O of|O mutations|O closely|O matched|O the|O pattern|O we|O have|O previously|O reported|O in|O operable|O disease|O .|O 
Patients|O with|O a|O ras|gene-rna mutation|O in|O their|O tumor|O were|O more|O likely|O to|O have|O a|O close|O relative|O with|O lung|O cancer|O ,|O but|O other|O clinical|O characteristics|O ,|O such|O as|O pattern|O of|O metastases|O ,|O response|O ,|O and|O survival|O ,|O were|O similar|O between|O the|O ras|gene-rna mutation|O -|O positive|O and|O ras|gene-rna mutation|O -|O negative|O groups|O .|O 
CONCLUSION|O :|O 
Patients|O with|O advanced|O lung|O adenocarcinoma|O who|O harbor|O a|O ras|gene-rna mutation|O may|O have|O major|O responses|O to|O chemotherapy|O and|O have|O similar|O progression|O -|O free|O and|O overall|O survival|O as|O patients|O with|O ras|gene-rna mutation|O -|O negative|O tumors|O .|O 
K-ras|gene-rna mutations|O may|O represent|O one|O of|O several|O ways|O in|O which|O early|O tumors|O are|O enabled|O to|O metastasize|O to|O distant|O sites|O .|O 
Biochemical|O characterization|O of|O a|O novel|O KRAS|gene-rna insertion|O mutation|O from|O a|O human|O leukemia|O .|O 
A|O novel|O alteration|O in|O exon|O 1|O of|O KRAS|gene-rna was|O detected|O by|O single|O strand|O conformational|O polymorphism|O analysis|O of|O DNA|O amplified|O from|O the|O bone|O marrow|O of|O a|O 4|O -|O year|O -|O old|O child|O with|O myeloid|O leukemia|O .|O 
Sequencing|O of|O this|O mutant|O allele|O revealed|O an|O insertion|O of|O three|O nucleotides|O between|O codons|O 10|O and|O 11|O resulting|O in|O an|O in|O -|O frame|O insertion|O of|O glycine|O .|O 
Expression|O of|O the|O mutant|gene-protein protein|gene-protein in|O NIH|O 3T3|O cells|O caused|O cellular|O transformation|O ,|O and|O expression|O in|O COS|O cells|O activated|O the|O Ras|gene-rna -|O mitogen|gene-protein -|gene-protein activated|gene-protein protein|gene-protein kinase|gene-protein signaling|O pathway|O .|O 
Surprisingly|O ,|O Ras|gene-protein .|O GTP|O levels|O measured|O in|O COS|O cells|O established|O that|O this|O novel|O mutant|gene-protein accumulates|O to|O 90|O %|O in|O the|O GTP|O state|O ,|O considerably|O higher|O than|O a|O residue|O 12|O mutant|gene-protein .|O 
Biochemical|O analysis|O confirmed|O that|O the|O higher|O Ras|gene-protein .|O GTP|O levels|O correspond|O to|O a|O dramatic|O decrease|O in|O intrinsic|O GTP|O hydrolysis|O as|O well|O as|O resistance|O to|O GTPase|gene-protein -|gene-protein activating|gene-protein proteins|gene-protein .|O 
This|O mutation|O is|O the|O first|O dominant|O Ras|gene-rna mutation|O found|O in|O human|O cancer|O that|O does|O not|O involve|O residues|O 12|O ,|O 13|O ,|O or|O 61|O ,|O and|O its|O biochemical|O properties|O should|O help|O elucidate|O the|O mechanism|O of|O oncogenic|O activation|O .|O 
Alterations|O of|O p16|gene-rna /|O CDKN2|gene-rna ,|O p53|gene-rna and|O ras|gene-rna genes|O in|O oral|O squamous|O cell|O carcinomas|O and|O premalignant|O lesions|O .|O 
Exons|O 1|O -|O 3|O of|O the|O p16|gene-rna /|O CDKN2|gene-rna gene|O ,|O exons|O 4|O -|O 9|O of|O the|O p53|gene-rna gene|O and|O exons|O 1|O and|O 2|O of|O H|gene-rna -|gene-rna ,|O K|gene-rna -|gene-rna and|O N|gene-rna -|gene-rna ras|gene-rna genes|O were|O screened|O for|O mutations|O by|O a|O combination|O of|O immunohistochemistry|O and|O single|O -|O strand|O conformational|O polymorphism|O (|O SSCP|O )|O analyses|O of|O polymerase|gene-protein chain|O reaction|O products|O from|O human|O surgical|O samples|O of|O both|O frank|O oral|O squamous|O cell|O carcinomas|O and|O premalignant|O lesions|O .|O 
The|O samples|O included|O 20|O squamous|O cell|O carcinomas|O ,|O 10|O epithelial|O dysplasias|O and|O 10|O epithelial|O hyperplasias|O .|O 
No|O identifiable|O gene|O mutations|O were|O detected|O in|O any|O of|O the|O dysplasias|O or|O hyperplasias|O ,|O while|O 2|O (|O 10|O %|O )|O deletions|O and|O 2|O (|O 10|O %|O )|O mutations|O of|O p16|gene-rna /|O CDKN2|gene-rna ,|O along|O with|O 5|O (|O 25|O %|O )|O p53|gene-rna mutations|O were|O found|O in|O the|O advanced|O carcinomas|O ,|O yielding|O characteristic|O p16|gene-rna /|O CDKN2|gene-rna and|O p53|gene-rna changes|O .|O 
A|O mutation|O in|O the|O K-ras|gene-rna gene|O was|O found|O in|O single|O carcinoma|O and|O dysplastic|O samples|O .|O 
From|O the|O data|O ,|O it|O can|O be|O argued|O that|O p16|gene-rna /|O CDKN2|gene-rna and|O p53|gene-rna mutations|O are|O relatively|O late|O occurrences|O in|O human|O oral|O tumorigenesis|O and|O that|O genetic|O alterations|O of|O the|O ras|gene-rna genes|O may|O not|O play|O a|O significant|O role|O in|O squamous|O neoplasia|O .|O 
Expression|O and|O mutation|O of|O H-ras|gene-rna in|O uterine|O cervical|O cancer|O .|O 
In|O cervical|O cancer|O ,|O abnormalities|O of|O ras|gene-rna genes|O have|O not|O been|O fully|O investigated|O .|O 
We|O studied|O the|O expression|O and|O mutation|O of|O H-ras|gene-rna oncogene|O in|O cervical|O cancer|O to|O investigate|O their|O relationship|O and|O usefulness|O as|O an|O independent|O prognostic|O indicator|O .|O 
Twenty-seven|O paraffin|O -|O embedded|O resection|O specimens|O of|O cervical|O cancer|O (|O 21|O squamous|O ,|O 3|O adeno|O ,|O 2|O adenosquamous|O ,|O and|O 1|O small|O cell|O )|O were|O examined|O by|O immunohistochemistry|O using|O a|O mAb|gene-protein H-ras|gene-protein p21|gene-protein and|O by|O PCR|O and|O allele|O -|O specific|O oligonucleotide|O hybridization|O using|O H-ras|gene-rna codon|O 12|O and|O 61|O amplimers|O and|O oligonucleotide|O probes|O .|O 
A|O strong|O immunoreaction|O was|O noted|O in|O 10|O cases|O (|O 37|O %|O )|O and|O weak|O immunoreaction|O in|O an|O additional|O 6|O cases|O (|O 22|O %|O )|O .|O 
H-ras|gene-rna codon|O 12|O mutations|O were|O detected|O in|O 6|O of|O 27|O cases|O (|O 22|O %|O )|O and|O all|O of|O the|O mutations|O were|O guanine|O to|O adenine|O transitions|O .|O 
There|O was|O no|O mutation|O in|O codon|O 61|O .|O 
Cases|O with|O codon|O 12|O mutations|O included|O all|O 3|O squamous|O ,|O 2|O adeno|O ,|O and|O I|O adenosquamous|O carcinoma|O .|O 
Only|O 3|O of|O 16|O (|O 19|O %|O )|O cases|O with|O positive|O staining|O and|O 3|O of|O 11|O (|O 27|O %|O )|O cases|O with|O negative|O staining|O showed|O mutations|O .|O 
No|O correlation|O was|O found|O between|O ras|gene-rna gene|O alterations|O and|O patient|O survival|O time|O .|O 
Our|O findings|O indicate|O that|O expression|O and|O mutation|O of|O H-ras|gene-rna oncogene|O occur|O in|O cervical|O cancer|O but|O their|O determination|O adds|O no|O useful|O prognostic|O information|O .|O 
Low|O frequency|O of|O p53|gene-rna mutations|O in|O human|O thyroid|O tumours|O ;|O p53|gene-rna and|O Ras|gene-rna mutation|O in|O two|O out|O of|O fifty-six|O thyroid|O tumours|O .|O 
OBJECTIVE|O :|O 
p53|gene-protein is|O a|O well|O -|O known|O nuclear|gene-protein phosphoprotein|gene-protein encoded|O by|O a|O suppressor|O gene|O know|O to|O be|O mutated|O in|O various|O kinds|O of|O human|O tumours|O .|O 
A|O relationship|O between|O p53|gene-rna gene|O mutation|O and|O tumour|O progression|O seems|O to|O be|O a|O common|O feature|O of|O several|O neoplasias|O .|O 
DESIGN|O :|O 
In|O order|O to|O investigate|O the|O role|O of|O p53|gene-rna mutations|O in|O human|O thyroid|O tumours|O ,|O DNA|O samples|O derived|O from|O fifty-six|O neoplastic|O tissues|O ,|O ranging|O from|O benign|O adenomas|O to|O undifferentiated|O carcinomas|O ,|O were|O examined|O for|O the|O presence|O of|O p53|gene-rna gene|O mutations|O .|O 
METHODS|O :|O 
The|O analysis|O has|O been|O conducted|O using|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O amplification|O of|O the|O exons|O 5|O -|O 9|O of|O the|O p53|gene-rna gene|O followed|O by|O single|O strand|O conformation|O polymorphism|O (|O SSCP|O )|O and|O sequence|O analyses|O .|O 
RESULTS|O :|O 
One|O anaplastic|O carcinoma|O and|O one|O papillary|O carcinoma|O showed|O p53|gene-rna gene|O mutations|O in|O exons|O 5|O and|O 8|O ,|O respectively|O .|O 
A|O cell|O line|O established|O from|O the|O papillary|O carcinoma|O showed|O the|O same|O mutation|O present|O in|O the|O original|O tumour|O .|O 
Both|O p53|gene-rna mutations|O were|O heterozygous|O .|O 
The|O p53|gene-rna positive|O samples|O were|O analysed|O for|O other|O genetic|O alterations|O frequently|O detected|O in|O human|O thyroid|O carcinomas|O (|O mutations|O of|O the|O RET|gene-rna ,|O TRK|gene-rna ,|O and|O ras|gene-rna oncogenes|O )|O :|O both|O p53|gene-rna -|O mutated|O samples|O proved|O to|O be|O mutated|O at|O level|O of|O codon|O 13|O of|O the|O c-Ki-ras|gene-rna gene|O .|O 
CONCLUSIONS|O :|O 
Our|O data|O confirm|O that|O p53|gene-rna gene|O alterations|O are|O rare|O in|O well|O -|O differentiated|O thyroid|O tumours|O ,|O that|O they|O are|O an|O important|O requirement|O for|O the|O establishment|O in|O culture|O of|O human|O thyroid|O carcinoma|O cell|O lines|O ,|O and|O that|O they|O can|O be|O associated|O with|O other|O genetic|O alterations|O ,|O namely|O ras|gene-rna mutations|O ,|O in|O the|O malignant|O progression|O of|O thyroid|O tumours|O .|O 
Molecular|O mechanisms|O of|O tumor|O progression|O in|O chronic|O myeloproliferative|O disorders|O .|O 
We|O have|O investigated|O the|O involvement|O of|O tumor|O suppressor|O genes|O (|O p53|gene-rna and|O RB1|gene-rna )|O and|O dominantly|O acting|O oncogenes|O (|O Ras|gene-rna family|O genes|O )|O in|O BCR|gene-rna /|O ABL|gene-rna positive|O and|O negative|O chronic|O myeloproliferative|O disorders|O (|O CMPD|O )|O at|O different|O stages|O of|O the|O disease|O ,|O including|O 26|O cases|O of|O BCR|gene-rna /|O ABL|gene-rna +|O chronic|O myeloid|O leukemia|O (|O CML|O )|O blast|O crisis|O ,|O 9|O myelosclerosis|O with|O myeloid|O metaplasia|O ,|O 4|O polycythemia|O vera|O ,|O 10|O essential|O thrombocythemia|O ,|O 1|O juvenile|O CML|O ,|O and|O 8|O BCR|gene-rna /|O ABL|gene-rna -|O CML|O .|O 
The|O presence|O of|O mutations|O in|O p53|gene-rna exons|O 5|O through|O 9|O ,|O as|O well|O as|O in|O RB1|gene-rna exons|O 10|O -|O 27|O and|O in|O N|gene-rna -|gene-rna ,|O K|gene-rna -|gene-rna ,|O H|gene-rna -|gene-rna Ras|gene-rna exons|O 1|O and|O 2|O was|O tested|O by|O the|O PCR|O -|O Single|O Strand|O Conformation|O Polymorphism|O technique|O and|O by|O PCR|O -|O Direct|O Sequencing|O .|O 
In|O addition|O ,|O Southern|O blot|O analysis|O was|O used|O to|O investigate|O the|O occurrence|O of|O gross|O rearrangements|O in|O the|O p53|gene-rna gene|O as|O well|O as|O loss|O of|O heterozygosity|O at|O 17p13|O ,|O the|O site|O of|O p53|gene-rna .|O 
Acute|O phase|O BCR|gene-rna /|O ABL|gene-rna -|O CMPD|O cases|O displayed|O a|O high|O frequency|O of|O p53|gene-rna (|O 2|O /|O 7|O )|O and|O Ras|gene-rna (|O 3|O /|O 7|O )|O lesions|O ,|O whereas|O BCR|gene-rna /|O ABL|gene-rna -|O CMPD|O in|O chronic|O phase|O displayed|O only|O germline|O p53|gene-rna and|O Ras|gene-rna sequences|O .|O 
Conversely|O ,|O p53|gene-rna inactivation|O was|O restricted|O to|O only|O 1|O /|O 26|O cases|O of|O BCR|gene-rna /|O ABL|gene-rna +|O CML|O blast|O crisis|O .|O 
No|O alterations|O in|O the|O RB1|gene-rna gene|O were|O detected|O in|O any|O of|O the|O cases|O analyzed|O .|O 
These|O data|O indicate|O that|O p53|gene-rna inactivation|O and/or|O Ras|gene-rna activation|O might|O play|O a|O role|O in|O acute|O transformation|O of|O BCR|gene-rna /|O ABL|gene-rna -|O CMPD|O and|O that|O the|O molecular|O mechanisms|O of|O tumor|O progression|O may|O be|O different|O in|O BCR|gene-rna /|O ABL|gene-rna +|O versus|O BCR|gene-rna /|O ABL|gene-rna -|O CMPD|O .|O 
Screening|O of|O human|O bladder|O tumors|O and|O urine|O sediments|O for|O the|O presence|O of|O H-ras|gene-rna mutations|O .|O 
A|O series|O of|O 111|O human|O bladder|O tumors|O were|O screened|O using|O oligonucleotide|O mutant|O specific|O probes|O ,|O restriction|O enzyme|O analysis|O and|O single|O -|O stranded|O confirmation|O polymorphism|O (|O SSCP|O )|O for|O the|O presence|O of|O H-ras|gene-rna activation|O events|O .|O 
Thirty-three|O tumors|O were|O found|O to|O harbor|O H-ras|gene-rna mutations|O where|O a|O glycine|O to|O valine|O (|O G|O -->|O T|O )|O change|O in|O codon|O 12|O was|O the|O most|O common|O point|O mutation|O recorded|O (|O 26|O tumors|O )|O .|O 
Additional|O mutations|O involved|O glycine|O to|O cysteine|O at|O codon|O 13|O (|O 2|O tumors|O )|O and|O glutamine|O to|O arginine|O /|O lysine|O /|O leucine|O at|O codon|O 61|O (|O 3|O /|O 1|O /|O 1|O tumors|O ,|O respectively|O )|O .|O 
Ambiguous|O signals|O recorded|O with|O oligonucleotide|O probes|O were|O further|O analyzed|O using|O SSCP|O analysis|O revealing|O the|O presence|O of|O H-ras|gene-rna mutations|O in|O restricted|O regions|O of|O some|O tumors|O .|O 
The|O apparent|O sensitivity|O of|O SSCP|O enabled|O us|O to|O extend|O this|O study|O to|O DNA|O isolated|O from|O urine|O sediments|O where|O 4|O of|O the|O 9|O patients|O studied|O showed|O representation|O of|O mutant|O H-ras|gene-rna .|O 
Our|O study|O demonstrates|O a|O sensitive|O ,|O non|O -|O invasive|O assay|O for|O the|O screening|O of|O urine|O -|O borne|O cells|O ,|O with|O no|O requirement|O for|O prior|O knowledge|O of|O the|O mutational|O change|O at|O the|O H-ras|gene-rna locus|O .|O 
Identification|O of|O a|O point|O mutation|O in|O the|O catalytic|O domain|O of|O the|O protooncogene|O c-kit|gene-rna in|O peripheral|O blood|O mononuclear|O cells|O of|O patients|O who|O have|O mastocytosis|O with|O an|O associated|O hematologic|O disorder|O .|O 
Both|O stem|O cells|O and|O mast|O cells|O express|O c-kit|gene-rna and|O proliferate|O after|O exposure|O to|O c-kit|gene-generic ligand|O .|O 
Mutations|O in|O c-kit|gene-rna may|O enhance|O or|O interfere|O with|O the|O ability|O of|O c-kit|gene-protein receptor|O to|O initiate|O the|O intracellular|O pathways|O resulting|O in|O cell|O proliferation|O .|O 
These|O observations|O suggested|O to|O us|O that|O mastocytosis|O might|O in|O some|O patients|O result|O from|O mutations|O in|O c-kit|gene-rna .|O 
cDNA|O synthesized|O from|O peripheral|O blood|O mononuclear|O cells|O of|O patients|O with|O indolent|O mastocytosis|O ,|O mastocytosis|O with|O an|O associated|O hematologic|O disorder|O ,|O aggressive|O mastocytosis|O ,|O solitary|O mastocytoma|O ,|O and|O chronic|O myelomonocytic|O leukemia|O unassociated|O with|O mastocytosis|O was|O thus|O screened|O for|O a|O mutation|O of|O c-kit|gene-rna .|O 
This|O analysis|O revealed|O that|O four|O of|O four|O mastocytosis|O patients|O with|O an|O associated|O hematologic|O disorder|O with|O predominantly|O myelodysplastic|O features|O had|O an|O A|O -->|O T|O substitution|O at|O nt|O 2468|O of|O c-kit|gene-rna mRNA|O that|O causes|O an|O Asp|O -|O 816|O -->|O Val|O substitution|O .|O 
One|O of|O one|O patient|O examined|O who|O had|O mastocytosis|O with|O an|O associated|O hematologic|O disorder|O had|O the|O corresponding|O mutation|O in|O genomic|O DNA|O .|O 
Identical|O or|O similar|O amino|O acid|O substitutions|O in|O mast|O cell|O lines|O result|O in|O ligand|O -|O independent|O autophosphorylation|O of|O the|O c-kit|gene-protein receptor|O .|O 
This|O mutation|O was|O not|O identified|O in|O the|O patients|O within|O the|O other|O disease|O categories|O or|O in|O 67|O of|O 67|O controls|O .|O 
The|O identification|O of|O the|O point|O mutation|O Asp|O 816|O Val|O in|O c-kit|gene-rna in|O patients|O with|O mastocytosis|O with|O an|O associated|O hematologic|O disorder|O provides|O insight|O not|O only|O into|O the|O pathogenesis|O of|O this|O form|O of|O mastocytosis|O but|O also|O into|O how|O hematopoiesis|O may|O become|O dysregulated|O and|O may|O serve|O to|O provide|O a|O means|O of|O confirming|O the|O diagnosis|O ,|O assessing|O prognosis|O ,|O and|O developing|O intervention|O strategies|O .|O 
Detection|O of|O point|O mutations|O in|O N-ras|gene-rna and|O K-ras|gene-rna genes|O of|O human|O embryonal|O rhabdomyosarcomas|O using|O oligonucleotide|O probes|O and|O the|O polymerase|gene-protein chain|O reaction|O .|O 
Previous|O studies|O have|O demonstrated|O that|O genes|O of|O the|O ras|gene-rna family|O (|O H|gene-rna ,|O K|gene-rna ,|O and|O N|gene-rna )|O can|O be|O activated|O by|O point|O mutations|O at|O codons|O 12|O ,|O 13|O ,|O and|O 61|O .|O 
In|O the|O present|O study|O we|O have|O used|O oligonucleotide|O probes|O corresponding|O to|O these|O regions|O to|O assess|O the|O role|O of|O ras|gene-rna gene|O mutations|O in|O the|O genesis|O of|O human|O rhabdomyosarcoma|O .|O 
To|O increase|O the|O sensitivity|O of|O this|O method|O the|O appropriate|O regions|O of|O the|O three|O ras|gene-rna genes|O were|O first|O amplified|O using|O the|O polymerase|gene-protein chain|O reaction|O .|O 
The|O results|O show|O that|O 35|O %|O (|O 5|O /|O 14|O )|O embryonal|O rhabdomyosarcomas|O investigated|O contain|O mutations|O in|O the|O N-ras|gene-rna or|O K-ras|gene-rna genes|O .|O 
Thus|O ras|gene-rna gene|O mutation|O is|O implicated|O in|O the|O development|O of|O mesenchymal|O and|O embryonal|O tumors|O in|O addition|O to|O its|O previously|O documented|O role|O in|O epithelial|O and|O hematological|O neoplasia|O .|O 
Ras|gene-rna oncogene|O mutations|O in|O benign|O and|O malignant|O thyroid|O neoplasms|O .|O 
Department|O of|O Pathology|O ,|O Massachusetts|O General|O Hospital|O ,|O Harvard|O Medical|O School|O ,|O Boston|O 02114|O .|O 
Current|O models|O for|O tumorigenesis|O propose|O that|O a|O series|O of|O genetic|O alterations|O occur|O during|O the|O progression|O from|O the|O normal|O cell|O to|O the|O malignant|O phenotype|O .|O 
Mutations|O in|O each|O of|O the|O three|O ras|gene-rna genes|O (|O K-ras|gene-rna ,|O H-ras|gene-rna ,|O and|O N-ras|gene-rna )|O have|O been|O identified|O in|O many|O human|O neoplasms|O ,|O including|O thyroid|O cancer|O .|O 
In|O this|O study|O we|O examined|O genomic|O DNA|O from|O benign|O and|O malignant|O thyroid|O neoplasms|O for|O mutations|O that|O are|O known|O to|O activate|O the|O ras|gene-rna oncogenes|O (|O codons|O 12|O ,|O 13|O ,|O and|O 61|O )|O .|O 
DNA|O from|O frozen|O surgically|O excised|O tissue|O (|O n|O =|O 8|O )|O and|O from|O formalin|O -|O fixed|O paraffin|O -|O embedded|O tissue|O (|O n|O =|O 30|O )|O was|O amplified|O by|O the|O polymerase|gene-protein chain|O reaction|O and|O screened|O for|O mutations|O using|O oligonucleotide|O -|O specific|O hybridization|O .|O 
No|O mutations|O were|O identified|O in|O follicular|O adenomas|O (|O n|O =|O 9|O )|O .|O 
In|O follicular|O carcinomas|O ,|O 2|O of|O 14|O tumors|O contained|O mutations|O (|O N-ras|gene-rna 61|O ,|O Gln|O to|O Arg|O )|O ,|O and|O both|O of|O these|O patients|O had|O bone|O metastases|O .|O 
One|O of|O 15|O papillary|O carcinomas|O had|O a|O ras|gene-rna mutation|O (|O H-ras|gene-rna 12|O ,|O Gly|O to|O Ser|O )|O .|O 
In|O contrast|O to|O other|O studies|O ,|O we|O found|O that|O ras|gene-rna mutations|O are|O relatively|O uncommon|O in|O both|O benign|O and|O malignant|O thyroid|O neoplasms|O .|O 
Studies|O of|O larger|O numbers|O of|O tumors|O and|O comparisons|O of|O different|O patient|O populations|O will|O be|O required|O to|O assess|O a|O possible|O association|O of|O mutations|O in|O N-ras|gene-rna 61|O with|O clinically|O aggressive|O follicular|O cancer|O .|O 
Point|O mutations|O in|O the|O Ha-ras|gene-rna oncogene|O are|O detectable|O in|O formalin|O -|O fixed|O tissues|O of|O oral|O squamous|O cell|O carcinomas|O ,|O but|O are|O infrequent|O in|O British|O cases|O .|O 
Oncogene|O expression|O in|O human|O neoplasia|O has|O been|O examined|O extensively|O in|O the|O past|O decade|O .|O 
More|O recently|O the|O advent|O of|O the|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O has|O facilitated|O studies|O of|O oncogenes|O and|O other|O DNA|O structures|O .|O 
Those|O few|O studies|O which|O have|O so|O far|O searched|O for|O oncogene|O changes|O in|O oral|O cancer|O have|O utilized|O frozen|O specimens|O .|O 
We|O report|O here|O an|O adaptation|O of|O the|O PCR|O technique|O applicable|O to|O DNA|O extracted|O from|O archival|O specimens|O .|O 
Our|O data|O complement|O recent|O findings|O that|O Ha-ras|gene-rna mutations|O are|O infrequent|O in|O oral|O squamous|O cell|O carcinomas|O among|O white|O caucasoid|O populations|O .|O 
Mutation|O analysis|O of|O K-ras-2|gene-rna in|O liver|O angiosarcoma|O and|O adjacent|O nonneoplastic|O liver|O tissue|O from|O patients|O occupationally|O exposed|O to|O vinyl|O chloride|O .|O 
Vinyl|O chloride|O (|O VC|O )|O is|O a|O potent|O liver|O carcinogen|O that|O induces|O angiosarcomas|O in|O humans|O and|O animals|O .|O 
Recent|O evidence|O shows|O that|O liver|O tumors|O from|O patients|O with|O VC|O exposure|O may|O have|O a|O specific|O K-ras|gene-rna mutation|O pattern|O .|O 
This|O study|O was|O performed|O to|O determine|O the|O status|O of|O K-ras-2|gene-rna in|O liver|O angiosarcomas|O (|O LAS|O )|O from|O workers|O occupationally|O exposed|O to|O VC|O .|O 
We|O examined|O the|O presence|O of|O K-ras-2|gene-rna mutations|O in|O 15|O LAS|O from|O patients|O with|O known|O exposure|O to|O VC|O (|O median|O exposure|O :|O 8,260|O ppm|O [|O range|O 3,900|O -|O 21,000|O ppm|O ]|O ]|O .|O 
In|O all|O cases|O ,|O other|O risk|O factors|O for|O the|O development|O of|O LAS|O were|O excluded|O .|O 
Direct|O DNA|O sequencing|O after|O microdissection|O of|O the|O tumor|O cells|O was|O used|O for|O the|O analysis|O .|O 
Heterozygous|O mutations|O of|O K-ras-2|gene-rna were|O detected|O in|O 8|O /|O 15|O LAS|O (|O 53|O %|O )|O .|O 
Five|O patients|O (|O 33|O %|O )|O had|O a|O mutation|O of|O codon|O 12|O and|O three|O of|O codon|O 13|O (|O 20|O %|O )|O .|O 
The|O most|O common|O changes|O were|O G|O -->|O A|O transitions|O in|O five|O LAS|O which|O lead|O to|O the|O substitution|O of|O aspartic|O acid|O for|O glycine|O in|O the|O resulting|O p21|gene-protein protein|O .|O 
In|O two|O patients|O (|O 13|O %|O )|O ,|O mutations|O of|O the|O K-ras-2|gene-rna gene|O were|O identified|O in|O the|O adjacent|O nonneoplastic|O liver|O tissue|O .|O 
These|O data|O indicate|O that|O VC|O induces|O a|O high|O frequency|O of|O G|O -->|O A|O transitions|O in|O human|O LAS|O .|O 
This|O mutation|O pattern|O is|O likely|O a|O consequence|O of|O VC|O -|O DNA|O -|O adduct|O formation|O .|O 
ras|gene-rna Gene|O mutations|O and|O expression|O of|O Ras|gene-rna signal|O transduction|O mediators|O in|O gastric|O adenocarcinomas|O .|O 
OBJECTIVE|O :|O 
To|O investigate|O ras|gene-rna gene|O alteration|O in|O human|O gastric|O adenocarcinomas|O and|O its|O potential|O relationship|O to|O ras|gene-rna signal|O transduction|O mediators|O .|O 
DESIGN|O :|O 
Genomic|O DNA|O from|O 104|O gastric|O tumors|O were|O analyzed|O by|O sequencing|O of|O polymerase|gene-protein chain|O reaction|O -|O amplified|O products|O for|O the|O presence|O of|O ras|gene-rna mutations|O .|O 
All|O the|O samples|O were|O further|O investigated|O with|O the|O use|O of|O immunohistochemical|O analysis|O for|O ERK1|gene-rna and|O ERK2|gene-rna .|O 
SETTING|O :|O 
Tertiary|O care|O teaching|O hospital|O .|O 
PATIENTS|O :|O 
Seventy|O patients|O from|O a|O Korean|O population|O and|O 34|O from|O a|O Midwestern|O US|O population|O composed|O of|O white|O Americans|O and|O African|O Americans|O .|O 
RESULTS|O :|O 
Fifteen|O tumors|O (|O 14|O %|O )|O were|O positive|O for|O either|O H-ras|gene-rna or|O K-ras|gene-rna mutation|O :|O 9|O (|O 13|O %|O )|O of|O 70|O Korean|O patients|O and|O 6|O (|O 18|O %|O )|O of|O 34|O US|O patients|O .|O 
Seven|O (|O 78|O %|O )|O of|O the|O 9|O mutated|O tumors|O from|O Korean|O patients|O and|O all|O 6|O (|O 100|O %|O )|O from|O the|O US|O patients|O were|O intestinal|O -|O type|O lesions|O .|O 
Either|O ERK1|gene-rna and/or|O ERK2|gene-rna was|O overexpressed|O in|O 68|O samples|O (|O 65|O %|O )|O .|O 
No|O association|O was|O established|O between|O ras|gene-rna mutations|O and|O overexpression|O of|O ERK|gene-rna 1|gene-rna /|O 2|gene-rna .|O 
However|O ,|O the|O correlation|O between|O ERK|gene-rna 1|gene-rna /|O 2|gene-rna and|O progression|O (|O early|O vs|O late|O )|O was|O statistically|O significant|O (|O P|O =|O .007|O )|O .|O 
CONCLUSIONS|O :|O 
These|O data|O suggest|O that|O ras|gene-rna mutations|O are|O uncommon|O in|O gastric|O adenocarcinomas|O and|O that|O differing|O racial|O and/or|O geographic|O mechanisms|O may|O not|O underlie|O ras|gene-rna gene|O alteration|O .|O 
Most|O ras|gene-rna mutations|O were|O ,|O however|O ,|O observed|O in|O the|O group|O of|O intestinal|O -|O type|O samples|O ,|O supporting|O the|O different|O genetic|O mechanisms|O of|O carcinogenesis|O between|O the|O intestinal|O -|O and|O diffuse|O -|O type|O tumors|O .|O 
It|O is|O noteworthy|O that|O enhanced|O ERK|gene-rna 1|gene-rna /|O 2|gene-rna activity|O could|O be|O one|O of|O the|O characteristics|O of|O tumor|O invasiveness|O in|O gastric|O cancers|O .|O 
Molecular|O genetic|O analysis|O of|O malignant|O melanomas|O for|O aberrations|O of|O the|O WNT|gene-generic signaling|O pathway|O genes|O CTNNB1|gene-rna ,|O APC|gene-rna ,|O ICAT|gene-rna and|O BTRC|gene-rna .|O 
Aberrant|O activation|O of|O the|O Wnt|gene-generic signaling|O pathway|O has|O been|O reported|O in|O different|O human|O tumor|O types|O ,|O including|O malignant|O melanomas|O .|O 
We|O investigated|O 37|O malignant|O melanomas|O (|O 15|O primary|O tumors|O and|O 22|O metastases|O )|O for|O alterations|O of|O 4|O genes|gene-rna encoding|O members|O of|O this|O pathway|O ,|O i.e.|O ,|O CTNNB1|gene-rna (|O beta-catenin|gene-rna gene|O ,|O 3p22.1|O )|O ,|O APC|gene-rna (|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna gene|O ,|O 5q22.2|O )|O ,|O BTRC|gene-rna (|O beta-transducin|gene-rna repeat|gene-rna -|gene-rna containing|gene-rna protein|gene-rna gene|O ,|O 10q24.3|O )|O and|O ICAT|gene-rna (|O inhibitor|gene-rna of|gene-rna beta-catenin|gene-rna and|gene-rna Tcf-4|gene-rna ,|O 1p36.2|O )|O .|O 
Mutational|O analysis|O of|O CTNNB1|gene-rna identified|O somatic|O mutations|O in|O 1|O primary|O melanoma|O and|O 1|O melanoma|O metastasis|O from|O 2|O different|O patients|O (|O 5|O %|O )|O .|O 
Both|O mutations|O affected|O the|O N|O -|O terminal|O degradation|O box|O of|O beta-catenin|gene-rna ,|O which|O is|O important|O for|O the|O regulation|O of|O beta-catenin|gene-rna homeostasis|O .|O 
Another|O primary|O melanoma|O carried|O a|O somatic|O APC|gene-rna missense|O mutation|O within|O the|O known|O mutation|O cluster|O region|O in|O exon|O 15|O .|O 
Fourteen|O tumors|O (|O 40|O %|O )|O showed|O LOH|O at|O microsatellite|O markers|O on|O 1p36|O .|O 
None|O of|O the|O tumors|O had|O lost|O both|O copies|O of|O the|O ICAT|gene-rna gene|O ,|O but|O 1|O melanoma|O metastasis|O carried|O a|O somatic|O point|O mutation|O altering|O the|O translation|O start|O codon|O of|O ICAT|gene-rna .|O 
Real|O -|O time|O RT|O -|O PCR|O showed|O markedly|O reduced|O ICAT|gene-rna transcript|O levels|O (|O <|O or|O =|O 20|O %|O relative|O to|O normal|O skin|O and|O benign|O melanocytic|O nevi|O )|O in|O 28|O /|O 36|O malignant|O melanomas|O (|O 78|O %|O )|O ,|O including|O 13|O /|O 14|O tumors|O with|O LOH|O on|O 1p36|O .|O 
Allelic|O loss|O on|O 10q|O was|O detected|O in|O 15|O tumors|O (|O 44|O %|O )|O .|O 
We|O found|O neither|O mutations|O nor|O complete|O loss|O of|O expression|O of|O the|O BTRC|gene-rna gene|O in|O our|O melanoma|O series|O .|O 
Taken|O together|O ,|O our|O results|O indicate|O that|O the|O Wnt|gene-generic pathway|O may|O be|O altered|O in|O malignant|O melanomas|O by|O different|O mechanisms|O ,|O including|O rare|O somatic|O mutations|O in|O CTNNB1|gene-rna ,|O APC|gene-rna or|O ICAT|gene-rna ,|O as|O well|O as|O low|O or|O absent|O expression|O of|O ICAT|gene-rna transcripts|O .|O 
Molecular|O characteristics|O of|O serrated|O adenomas|O of|O the|O colorectum|O .|O 
BACKGROUND|O :|O 
Serrated|O adenomas|O (|O SAs|O )|O of|O the|O colorectum|O combine|O architectural|O features|O of|O hyperplastic|O polyps|O and|O cytological|O features|O of|O classical|O adenomas|O .|O 
Molecular|O studies|O comparing|O SAs|O and|O classical|O adenomas|O suggest|O that|O each|O may|O be|O a|O distinct|O entity|O ;|O in|O particular|O ,|O it|O has|O been|O proposed|O that|O microsatellite|O instability|O (|O MSI|O )|O distinguishes|O SAs|O from|O classical|O adenomas|O and|O that|O SAs|O and|O the|O colorectal|O cancers|O arising|O from|O them|O develop|O along|O a|O pathway|O driven|O by|O low|O level|O microsatellite|O instability|O (|O MSI-L|O )|O .|O 
AIMS|O :|O 
To|O define|O the|O molecular|O characteristics|O of|O SAs|O of|O the|O colorectum|O .|O 
MATERIALS|O AND|O METHODS|O :|O 
We|O analysed|O 39|O SAs|O from|O 27|O patients|O ,|O including|O eight|O SAs|O from|O patients|O with|O familial|O adenomatous|O polyposis|O (|O FAP|O )|O .|O 
We|O screened|O these|O polyps|O for|O selected|O molecular|O changes|O ,|O including|O loss|O of|O heterozygosity|O (|O LOH|O )|O close|O to|O APC|gene-rna (|O 5q21|O )|O and|O CRAC1|gene-rna (|O 15q13|O -|O q22|O )|O ,|O MSI|O ,|O and|O mutations|O of|O K-ras|gene-rna ,|O APC|gene-rna ,|O p53|gene-rna ,|O and|O beta-catenin|gene-rna .|O 
Expression|O patterns|O of|O beta-catenin|gene-protein ,|O p53|gene-protein ,|O MLH1|gene-protein ,|O MSH2|gene-protein ,|O E-cadherin|gene-protein ,|O and|O O(6)-methylguanine|gene-protein DNA|gene-protein methyltransferase|gene-protein (|O MGMT|gene-protein )|O were|O assessed|O by|O immunohistochemistry|O .|O 
Comparative|O genomic|O hybridisation|O was|O performed|O on|O several|O polyps|O .|O 
RESULTS|O :|O 
MSI|O was|O rare|O (|O <|O 5|O %|O cases|O )|O and|O there|O was|O no|O loss|O of|O expression|O of|O mismatch|gene-protein repair|gene-protein proteins|gene-protein .|O 
Wnt|gene-protein pathway|O abnormalities|O (|O APC|gene-rna mutation|O /|O LOH|O ,|O beta-catenin|gene-generic mutation|O /|O nuclear|O expression|O )|O occurred|O in|O 11|O SAs|O ,|O including|O 6|O /|O 31|O (|O 19|O %|O )|O non|O -|O FAP|O tumours|O .|O 
CRAC1|gene-rna LOH|O occurred|O in|O 23|O %|O of|O tumours|O .|O 
K-ras|gene-rna mutations|O and|O p53|gene-generic mutations|O /|O overexpression|O were|O found|O in|O 15|O %|O and|O 8|O %|O of|O SAs|O ,|O respectively|O .|O 
Loss|O of|O MGMT|gene-protein expression|O occurred|O in|O 18|O %|O of|O polyps|O and|O showed|O a|O borderline|O association|O with|O K-ras|gene-rna mutations|O .|O 
Aberrant|O E-cadherin|gene-protein expression|O was|O found|O in|O seven|O polyps|O .|O 
Comparative|O genomic|O hybridisation|O detected|O no|O gains|O or|O deletions|O of|O chromosomal|O material|O .|O 
CONCLUSIONS|O :|O 
The|O serrated|O pathway|O of|O colorectal|O tumorigenesis|O appears|O to|O be|O heterogeneous|O .|O 
In|O common|O with|O classical|O adenomas|O ,|O some|O SAs|O develop|O along|O pathways|O involving|O changes|O in|O APC|gene-rna /|O beta-catenin|gene-rna .|O 
SAs|O rarely|O show|O MSI|O or|O any|O evidence|O of|O chromosomal|O -|O scale|O genetic|O instability|O .|O 
K-ras|gene-rna mutations|O may|O however|O be|O less|O common|O in|O SAs|O than|O in|O classical|O adenomas|O .|O 
Some|O SAs|O may|O harbour|O changes|O in|O the|O CRAC1|gene-rna gene|O .|O 
Changes|O in|O known|O genes|O do|O not|O account|O for|O the|O growth|O of|O the|O majority|O of|O SAs|O .|O 
Invasive|O ductal|O adenocarcinoma|O of|O the|O remnant|O pancreatic|O body|O 9|O years|O after|O resection|O of|O an|O intraductal|O papillary|O -|O mucinous|O carcinoma|O of|O the|O pancreatic|O head|O :|O a|O case|O report|O and|O comparison|O of|O DNA|O sequence|O in|O K-ras|gene-rna gene|O mutation|O .|O 
Recently|O ,|O there|O have|O been|O a|O few|O case|O reports|O of|O invasive|O ductal|O adenocarcinoma|O (|O IDC|O )|O developed|O in|O the|O remnant|O pancreas|O after|O partial|O pancreatectomy|O for|O intraductal|O papillary|O -|O mucinous|O neoplasm|O (|O IPMN|O )|O .|O 
It|O is|O necessary|O to|O clarify|O their|O histogenetic|O relationships|O among|O two|O sporadic|O tumors|O and|O their|O surrounding|O duct|O epithelium|O and|O it|O would|O be|O more|O reliable|O if|O genetic|O analysis|O is|O added|O to|O the|O conventional|O histology|O .|O 
We|O report|O a|O 76|O -|O year|O -|O old|O woman|O who|O received|O pancreaticoduodenectomy|O for|O IPMN|O with|O a|O focal|O in|O situ|O carcinoma|O (|O IPMC|O )|O ,|O which|O was|O transitional|O to|O the|O surrounding|O duct|O epithelium|O with|O papillary|O proliferation|O and|O a|O wide|O variety|O of|O dysplasia|O .|O 
Nine|O years|O after|O the|O operation|O ,|O she|O died|O of|O IDC|O in|O the|O remnant|O pancreatic|O body|O and|O its|O surrounding|O duct|O epithelium|O consisted|O of|O hyperplastic|O mucous|O cells|O with|O slight|O -|O mild|O dysplasia|O .|O 
Analysis|O of|O K-ras|gene-rna mutation|O at|O codon|O 12|O (|O wild|O -|O GGT|O )|O by|O direct|O sequencing|O after|O polymerase|gene-protein chain|O reaction|O indicated|O that|O their|O transitioning|O patterns|O differed|O from|O each|O other|O :|O CGT|O in|O IPMC|O ;|O no|O mutation|O in|O the|O mildly|O dysplastic|O duct|O epithelium|O around|O IPMC|O ;|O GAT|O in|O IDC|O of|O the|O remnant|O pancreas|O ;|O and|O AGT|O in|O mucous|O cell|O hyperplasia|O with|O mild|O dysplasia|O close|O to|O the|O IDC|O .|O 
This|O is|O the|O first|O report|O in|O which|O the|O DNA|O sequence|O of|O K-ras|gene-rna mutation|O was|O determined|O for|O the|O two|O sporadic|O pancreatic|O cancers|O and|O surrounding|O duct|O changes|O .|O 
The|O following|O two|O suggestions|O are|O made|O :|O (1)|O the|O cell|O -|O origin|O might|O have|O differed|O between|O the|O two|O types|O of|O cancer|O (|O IDC|O and|O IPMC|O )|O ;|O and|O (2)|O no|O precursor|O lesion|O toward|O IDC|O or|O IPMC|O was|O identified|O in|O their|O surrounding|O duct|O epithelium|O .|O 
p16|gene-rna and|O p53|gene-rna gene|O alterations|O and|O accumulations|O in|O the|O malignant|O evolution|O of|O intraductal|O papillary|O -|O mucinous|O tumors|O of|O the|O pancreas|O .|O 
BACKGROUND|O /|O PURPOSE|O :|O 
In|O general|O ,|O intraductal|O papillary|O -|O mucinous|O tumors|O of|O the|O pancreas|O have|O a|O favorable|O prognosis|O .|O 
However|O ,|O some|O invasive|O carcinomas|O show|O a|O rapid|O progression|O and|O a|O poor|O prognosis|O ,|O such|O as|O invasive|O ductal|O carcinomas|O of|O the|O pancreas|O .|O 
The|O aim|O of|O this|O study|O was|O to|O clarify|O the|O genetic|O backgrounds|O underlying|O the|O evolution|O necessary|O for|O these|O tumors|O to|O become|O invasive|O carcinomas|O .|O 
METHODS|O :|O 
Twenty-three|O patients|O with|O intraductal|O papillary|O -|O mucinous|O tumors|O ,|O including|O 9|O adenomas|O ,|O 5|O borderline|O tumors|O ,|O 3|O noninvasive|O carcinomas|O ,|O and|O 6|O invasive|O carcinomas|O ,|O along|O with|O 24|O patients|O with|O invasive|O ductal|O carcinomas|O were|O studied|O .|O 
After|O microdissection|O ,|O K|gene-rna -|gene-rna ras|gene-rna mutation|O and|O loss|O of|O heterozygosity|O (|O LOH|O )|O of|O the|O p16|gene-rna and|O p53|gene-rna genes|O were|O investigated|O .|O 
RESULTS|O :|O 
In|O the|O intraductal|O papillary|O -|O mucinous|O tumors|O ,|O K|gene-rna -|gene-rna ras|gene-rna mutations|O were|O frequently|O seen|O ,|O without|O a|O relationship|O to|O histological|O grade|O .|O 
LOH|O of|O the|O p16|gene-rna gene|O was|O observed|O increasingly|O with|O increasing|O degrees|O of|O histological|O atypia|O .|O 
LOH|O of|O the|O p53|gene-rna gene|O was|O seen|O only|O in|O invasive|O carcinomas|O .|O 
The|O frequency|O of|O each|O genetic|O alteration|O in|O invasive|O carcinomas|O was|O the|O same|O as|O that|O in|O invasive|O ductal|O carcinomas|O .|O 
The|O accumulation|O of|O genetic|O alterations|O was|O as|O common|O in|O invasive|O carcinomas|O ,|O as|O they|O were|O in|O invasive|O ductal|O carcinomas|O .|O 
CONCLUSIONS|O :|O 
The|O p16|gene-rna and|O p53|gene-rna gene|O alterations|O and|O accumulations|O observed|O are|O crucial|O events|O during|O the|O carcinogenesis|O and|O malignant|O progression|O of|O intraductal|O papillary|O -|O mucinous|O tumors|O of|O the|O pancreas|O .|O 
A|O case|O of|O smouldering|O mastocytosis|O with|O peripheral|O blood|O eosinophilia|O and|O lymphadenopathy|O .|O 
Systemic|O mastocytosis|O (|O SM|O )|O is|O a|O clonal|O hematologic|O disease|O showing|O abnormal|O growth|O and|O accumulation|O of|O mast|O cells|O (|O MC|O )|O in|O visceral|O organs|O with|O or|O without|O skin|O involvement|O .|O 
The|O clinical|O course|O in|O SM|O is|O variable|O .|O 
In|O fact|O ,|O indolent|O and|O aggressive|O variants|O have|O been|O described|O .|O 
In|O addition|O ,|O SM|O patients|O may|O acquire|O an|O associated|O hematologic|O clonal|O non|O -|O MC|O lineage|O disease|O (|O AHNMD|O )|O .|O 
In|O some|O cases|O ,|O hematologic|O parameters|O are|O indicative|O of|O slowly|O progressing|O SM|O although|O the|O clinical|O course|O remains|O indolent|O over|O years|O .|O 
These|O cases|O have|O been|O referred|O to|O as|O smouldering|O SM|O .|O 
We|O report|O on|O a|O smouldering|O patient|O presenting|O with|O typical|O skin|O lesions|O ,|O hypercellular|O marrow|O with|O focal|O MC|O aggregates|O ,|O persistent|O leukocytosis|O (|O 20,000|O -|O 30,000|O /|O microl|O )|O with|O eosinophilia|O (|O 5|O -|O 10|O %|O )|O ,|O marked|O lymphadenopathy|O ,|O and|O splenomegaly|O .|O 
The|O C-KIT|gene-rna mutation|O Asp|O -|O 816|O -|O Val|O confirmed|O the|O diagnosis|O of|O SM|O .|O 
The|O clinical|O picture|O remained|O stable|O during|O an|O observation|O period|O of|O 10|O years|O without|O signs|O of|O progression|O to|O an|O AHNMD|O or|O a|O high|O grade|O MC|O disease|O .|O 
These|O data|O show|O that|O some|O patients|O with|O SM|O can|O remain|O in|O a|O clinically|O indolent|O smouldering|O state|O over|O years|O even|O when|O presenting|O with|O marked|O eosinophilia|O and|O lymphadenopathy|O .|O 
Fibromatosis|O of|O the|O breast|O and|O mutations|O involving|O the|O APC|gene-rna /|O beta-catenin|gene-rna pathway|O .|O 
Fibromatoses|O of|O the|O breast|O are|O nonmetastasizing|O tumors|O ,|O but|O can|O be|O infiltrative|O and|O locally|O recurrent|O .|O 
Breast|O fibromatoses|O are|O rare|O ,|O and|O their|O specific|O genetic|O alterations|O have|O not|O been|O elucidated|O .|O 
However|O ,|O their|O occasional|O occurrence|O in|O patients|O with|O familial|O adenomatous|O polyposis|O (|O FAP|O )|O and|O their|O morphologic|O identification|O with|O other|O deep|O fibromatoses|O (|O desmoid|O tumors|O )|O suggest|O that|O alterations|O of|O the|O APC|gene-rna /|O beta-catenin|gene-rna pathway|O might|O be|O involved|O in|O the|O pathogenesis|O of|O sporadic|O and|O FAP|O -|O associated|O breast|O fibromatoses|O .|O 
We|O analyzed|O somatic|O beta-catenin|gene-rna and|O APC|gene-rna gene|O mutations|O in|O 33|O breast|O fibromatoses|O (|O 32|O sporadic|O and|O 1|O FAP|O -|O associated|O )|O using|O immunohistochemistry|O for|O beta-catenin|gene-protein ,|O 5q|O allelic|O loss|O assays|O ,|O and|O direct|O DNA|O sequencing|O for|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O and|O the|O mutation|O cluster|O region|O of|O the|O APC|gene-rna gene|O .|O 
Nuclear|O accumulation|O of|O beta-catenin|gene-protein was|O present|O in|O the|O stromal|O tumor|O cells|O in|O most|O (|O 82|O %|O )|O cases|O but|O not|O in|O normal|O stroma|O or|O mammary|O epithelial|O cells|O .|O 
Somatic|O alterations|O of|O the|O APC|gene-rna /|O beta-catenin|gene-rna pathway|O were|O detected|O in|O 79|O %|O of|O breast|O fibromatoses|O ,|O including|O activating|O beta-catenin|gene-rna gene|O mutations|O in|O 15|O cases|O and|O somatic|O APC|gene-rna alterations|O (|O mutation|O or|O 5q|O allelic|O loss|O or|O both|O )|O in|O 11|O .|O 
These|O findings|O indicate|O that|O alterations|O of|O the|O APC|gene-rna /|O beta-catenin|gene-rna pathway|O with|O resultant|O nuclear|O translocation|O of|O beta-catenin|gene-protein are|O important|O in|O the|O pathogenesis|O of|O both|O sporadic|O and|O FAP|O -|O associated|O breast|O fibromatosis|O .|O 
The|O spectrum|O of|O beta-catenin|gene-rna and|O APC|gene-rna alterations|O is|O similar|O to|O that|O described|O for|O desmoid|O tumors|O of|O the|O abdomen|O ,|O paraspinal|O region|O ,|O and|O extremities|O .|O 
APC|gene-rna and|O K-ras|gene-rna gene|O mutation|O in|O aberrant|O crypt|O foci|O of|O human|O colon|O .|O 
AIM|O :|O 
To|O study|O the|O genetic|O alteration|O in|O ACF|O and|O to|O define|O the|O possibility|O that|O ACF|O may|O be|O a|O very|O early|O morphological|O lesion|O with|O molecular|O changes|O ,|O and|O to|O explore|O the|O relationship|O between|O ACF|O and|O colorectal|O adenoma|O even|O carcinoma|O .|O 
METHODS|O :|O 
DNA|O from|O 35|O CRC|O ,|O 15|O adenomas|O ,|O 34|O ACF|O and|O 10|O normal|O mucus|O was|O isolated|O by|O means|O of|O microdissection|O .|O 
Direct|O gene|O sequencing|O of|O K-ras|gene-rna gene|O including|O codon|O 12|O ,|O 13|O and|O 61|O as|O well|O as|O the|O mutation|O cluster|O region|O (|O MCR|O )|O of|O APC|gene-rna gene|O was|O performed|O .|O 
RESULTS|O :|O 
K-ras|gene-rna gene|O mutation|O frequency|O in|O ACF|O ,|O adenoma|O and|O carcinoma|O was|O 17.6|O %|O (|O 6|O /|O 34|O )|O ,|O 13.3|O %|O (|O 2|O /|O 15|O )|O ,|O and|O 14.3|O %|O (|O 5|O /|O 35|O )|O respectively|O ,|O showing|O no|O difference|O (|O P|O >|O 0.05|O )|O in|O K-ras|gene-rna gene|O mutation|O among|O three|O pathologic|O procedures|O .|O 
The|O K-ras|gene-rna gene|O mutation|O in|O adenoma|O ,|O carcinoma|O and|O 4|O ACF|O restricted|O in|O codon|O 12|O (|O GGT|O GAT|O )|O ,|O but|O the|O other|O 2|O mutations|O from|O ACF|O located|O in|O codon|O 13|O (|O GGC|O GAC|O )|O .|O 
K-ras|gene-rna gene|O mutation|O was|O found|O more|O frequently|O in|O older|O patients|O and|O patients|O with|O polypoid|O cancer|O .|O 
No|O mutation|O in|O codon|O 61|O was|O found|O in|O the|O three|O tissue|O types|O .|O 
Mutation|O rate|O of|O APC|gene-rna gene|O in|O adenoma|O and|O carcinoma|O was|O 22.9|O %|O (|O 8|O /|O 35|O )|O and|O 26.7|O %|O (|O 4|O /|O 15|O )|O ,|O which|O was|O higher|O than|O ACF|O (|O 2.9|O %|O )|O (|O P|O <|O 0.05|O )|O .|O 
APC|gene-rna gene|O mutation|O in|O carcinoma|O was|O not|O correlated|O with|O age|O of|O patients|O ,|O location|O ,|O size|O and|O differentiation|O of|O tumor|O .|O 
CONCLUSION|O :|O 
ACF|O might|O be|O a|O very|O early|O morphological|O lesion|O in|O the|O tumorogenesis|O of|O colorectal|O tumor|O .|O 
The|O morphological|O feature|O and|O gene|O mutation|O status|O was|O different|O in|O ACF|O and|O adenoma|O .|O 
ACF|O is|O possibly|O putative|O microadenoma|O that|O might|O be|O the|O precursor|O of|O adenoma|O .|O 
In|O addition|O ,|O the|O development|O of|O a|O subgroup|O of|O colorectal|O carcinomas|O might|O undergo|O a|O way|O of|O normal|O epithelium|O ACF|O carcinomas|O .|O 
Prognostic|O impact|O of|O molecular|O genetic|O alterations|O in|O hepatoblastoma|O .|O 
BACKGROUND|O :|O 
During|O recent|O years|O ,|O we|O identified|O characteristic|O genetic|O alterations|O in|O sporadic|O hepatoblastoma|O (|O HB|O )|O .|O 
These|O include|O loss|O of|O heterozygosity|O (|O LOH|O )|O at|O the|O chromosomal|O region|O 11p15.5|O ,|O LOH|O on|O chromosome|O arms|O 1p|O and|O 1q|O ,|O activating|O mutations|O in|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O ,|O as|O well|O as|O overexpression|O of|O the|O c-met|gene-rna oncogene|O ,|O which|O encodes|O the|O hepatocyte|gene-protein growth|gene-protein factor|gene-protein receptor|gene-protein .|O 
We|O now|O wanted|O to|O evaluate|O the|O prognostic|O relevance|O of|O these|O abnormalities|O concerning|O the|O outcome|O in|O a|O large|O group|O of|O patients|O .|O 
PROCEDURE|O :|O 
All|O but|O 7|O of|O 56|O patients|O with|O HB|O were|O treated|O either|O with|O primary|O resection|O for|O small|O tumors|O ,|O or|O neo|O -|O adjuvant|O chemotherapy|O with|O ifosfamide|O ,|O cisplatin|O and|O doxorubicin|O (|O IPA|O )|O before|O delayed|O surgery|O in|O case|O of|O extended|O disease|O and|O additional|O adjuvant|O IPA|O therapy|O in|O all|O cases|O .|O 
Seven|O tumors|O were|O primarily|O resected|O and|O adjuvantly|O treated|O with|O different|O cytotoxic|O drugs|O .|O 
LOH|O 11p15.5|O ,|O LOH|O 1p|O ,|O and|O LOH|O 1q|O were|O detected|O in|O tumor|O tissue|O in|O comparison|O to|O normal|O liver|O and/or|O peripheral|O blood|O leukocytes|O by|O PCR|O based|O microsatellite|O analysis|O .|O 
Beta-catenin|gene-rna mutations|O were|O analysed|O with|O SSCP|O ,|O deletion|O screening|O and|O direct|O sequencing|O .|O 
RT|O -|O PCR|O was|O used|O for|O identification|O of|O c-met|gene-rna mRNA|O overexpression|O .|O 
The|O results|O were|O correlated|O with|O the|O tumors|O '|O stage|O ,|O histological|O type|O and|O epithelial|O differentiation|O ,|O as|O well|O as|O with|O the|O patients|O '|O outcome|O .|O 
RESULTS|O :|O 
Overall|O disease|O -|O free|O survival|O after|O median|O follow|O -|O up|O of|O 5|O years|O was|O 43|O /|O 56|O patients|O (|O 77|O %|O )|O .|O 
LOH|O 11p15.5|O was|O found|O in|O 15|O /|O 56|O ,|O LOH|O 1p|O in|O 11|O /|O 53|O ,|O LOH|O 1q|O in|O 7|O /|O 53|O and|O beta-catenin|gene-rna mutations|O in|O 25|O /|O 55|O HB|O .|O 
13|O /|O 23|O HB|O had|O a|O c-met|gene-rna overexpression|O .|O 
LOH|O 11p15.5|O and|O LOH|O 1p|O were|O significantly|O more|O often|O found|O in|O embryonal|O HB|O ,|O while|O there|O was|O no|O correlation|O of|O other|O genetic|O alterations|O with|O histological|O type|O or|O differentiation|O .|O 
Furthermore|O ,|O statistical|O analysis|O revealed|O no|O correlation|O of|O any|O of|O these|O disorders|O with|O initial|O tumor|O stage|O ,|O nor|O with|O the|O patients|O '|O outcome|O .|O 
CONCLUSION|O :|O 
None|O of|O the|O investigated|O molecular|O genetic|O alterations|O are|O suited|O to|O serve|O as|O a|O prognostic|O indicator|O in|O HB|O .|O 
Further|O investigations|O ,|O especially|O genetic|O screening|O of|O tumor|O tissue|O may|O reveal|O prognostic|O markers|O for|O this|O neoplasm|O .|O 
KIT|gene-rna activation|O is|O a|O ubiquitous|O feature|O of|O gastrointestinal|O stromal|O tumors|O .|O 
Gastrointestinal|O stromal|O tumors|O (|O GISTs|O )|O are|O the|O most|O common|O mesenchymal|O tumors|O of|O the|O gastrointestinal|O tract|O ,|O and|O they|O are|O generally|O resistant|O to|O chemotherapy|O and|O radiation|O therapy|O .|O 
Most|O GISTs|O express|O the|O KIT|gene-protein receptor|gene-protein tyrosine|gene-protein kinase|gene-protein protein|O ,|O and|O a|O subset|O of|O GISTs|O contain|O activating|O mutations|O within|O the|O KIT|gene-rna juxtamembrane|O region|O .|O 
We|O evaluated|O 48|O GISTs|O ,|O including|O 10|O benign|O ,|O 10|O borderline|O ,|O and|O 28|O malignant|O cases|O ,|O to|O determine|O whether|O KIT|gene-generic expression|O and|O activation|O are|O general|O properties|O of|O these|O tumors|O .|O 
Immunohistochemical|O KIT|gene-protein expression|O was|O demonstrated|O in|O each|O case|O .|O 
Somatic|O KIT|gene-rna mutations|O were|O found|O in|O 44|O tumors|O (|O 92|O %|O )|O ,|O of|O which|O 34|O (|O 71|O %|O )|O had|O juxtamembrane|O region|O mutations|O .|O 
Other|O GISTs|O had|O KIT|gene-rna mutations|O in|O the|O extracellular|O region|O (|O n|O =|O 6|O )|O and|O in|O two|O different|O regions|O in|O the|O tyrosine|gene-protein kinase|gene-protein domain|O (|O n|O =|O 4|O )|O .|O 
Contrary|O to|O previous|O reports|O ,|O KIT|gene-rna mutations|O were|O not|O identified|O preferentially|O in|O higher|O -|O grade|O tumors|O :|O indeed|O ,|O they|O were|O found|O in|O each|O of|O 10|O histologically|O benign|O GISTs|O .|O 
Notably|O ,|O mutations|O in|O all|O KIT|gene-rna domains|O were|O associated|O with|O high|O -|O level|O KIT|gene-generic activation|O /|O phosphorylation|O ,|O and|O KIT|gene-rna activation|O was|O also|O demonstrated|O in|O the|O four|O GISTs|O that|O lacked|O detectable|O KIT|gene-rna genomic|O and|O cDNA|O mutations|O .|O 
These|O studies|O underscore|O the|O role|O of|O KIT|gene-rna activation|O in|O GIST|O pathogenesis|O ,|O and|O they|O suggest|O that|O activated|O KIT|gene-rna might|O represent|O a|O universal|O therapeutic|O target|O in|O GISTs|O .|O 
beta-catenin|gene-protein nuclear|O expression|O correlates|O with|O cyclin|gene-protein D1|gene-protein overexpression|O in|O sporadic|O desmoid|O tumours|O .|O 
The|O immunohistochemical|O expression|O of|O beta-catenin|gene-protein ,|O cyclin|gene-protein D1|gene-protein ,|O Ki-67|gene-protein and|O PCNA|gene-protein was|O Examined|O in|O 38|O cases|O of|O sporadic|O extra|O -|O abdominal|O or|O abdominal|O -|O wall|O desmoid|O tumours|O without|O familial|O adenomatous|O polyposis|O (|O FAP|O )|O ,|O to|O evaluate|O the|O hypothesis|O that|O the|O accumulated|O beta-catenin|gene-protein within|O the|O nuclei|O could|O affect|O the|O regulation|O of|O the|O cyclin|gene-rna D1|gene-rna gene|O .|O 
There|O was|O a|O statistically|O significant|O correlation|O between|O beta-catenin|gene-protein accumulation|O and|O cyclin|gene-protein D1|gene-protein overexpression|O (|O p|O =|O 0.029|O )|O .|O 
Each|O group|O with|O beta-catenin|gene-protein accumulation|O or|O cyclin|gene-protein D1|gene-protein overexpression|O showed|O a|O higher|O PCNA|gene-protein -|O LI|O than|O those|O without|O ,|O the|O difference|O being|O statistically|O significant|O (|O p|O =|O 0.007|O ,|O p|O =|O 0.004|O ,|O respectively|O )|O .|O 
Differential|O PCR|O was|O also|O performed|O to|O detect|O amplification|O of|O the|O cyclin|gene-rna D1|gene-rna gene|O and|O mutational|O analysis|O was|O undertaken|O for|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O .|O 
Amplification|O of|O the|O cyclin|gene-rna D1|gene-rna gene|O was|O observed|O in|O 13|O out|O of|O 22|O cases|O (|O 59.1|O %|O )|O .|O 
There|O were|O nine|O -|O point|O mutations|O in|O 7|O out|O of|O 18|O cases|O (|O 38.9|O %|O )|O .|O 
The|O distribution|O of|O beta-catenin|gene-rna mutation|O fell|O within|O a|O wide|O range|O ,|O from|O codon|O 21|O to|O codon|O 67|O .|O 
In|O conclusion|O ,|O beta-catenin|gene-protein nuclear|O expression|O correlated|O with|O cyclin|gene-protein D1|gene-protein overexpression|O in|O sporadic|O desmoid|O tumours|O ,|O which|O could|O be|O an|O in|O vivo|O model|O system|O for|O the|O APC|gene-protein -|O beta-catenin|gene-protein -|O Tcf|gene-protein pathway|O .|O 
In|O addition|O ,|O beta-catenin|gene-rna mutations|O in|O desmoid|O tumours|O occurred|O at|O an|O unusually|O wide|O range|O of|O sites|O within|O the|O gene|gene-rna .|O 
Ras|gene-rna mutations|O are|O rare|O in|O solitary|O cold|O and|O toxic|O thyroid|O nodules|O .|O 
OBJECTIVE|O :|O 
Activation|O of|O ras|gene-rna proto|O -|O oncogenes|O as|O a|O result|O of|O point|O mutations|O is|O detectable|O in|O a|O significant|O percentage|O of|O most|O types|O of|O tumour|O .|O 
Similar|O to|O neoplasms|O of|O other|O organs|O ,|O mutations|O of|O all|O three|O ras|gene-rna genes|O can|O be|O found|O in|O thyroid|O tumours|O .|O 
H|gene-rna -|gene-rna ,|O K|gene-rna -|gene-rna and|O N|gene-rna -|gene-rna ras|gene-rna mutations|O have|O been|O detected|O in|O up|O to|O 20|O %|O of|O follicular|O adenomas|O and|O adenomatous|O nodules|O which|O were|O not|O functionally|O characterized|O .|O 
This|O raises|O the|O question|O as|O to|O whether|O ras|gene-rna mutations|O are|O specific|O for|O hypofunctional|O nodules|O and|O TSH|gene-protein receptor|gene-protein mutations|O for|O hyperfunctioning|O nodules|O .|O 
DESIGN|O :|O 
To|O investigate|O ras|gene-rna and|O TSH|gene-protein receptor|gene-protein mutations|O with|O respect|O to|O functional|O differentiation|O we|O studied|O 41|O scintigraphically|O cold|O nodules|O and|O 47|O toxic|O thyroid|O nodules|O .|O 
To|O address|O the|O likelihood|O of|O a|O somatic|O mutation|O we|O also|O studied|O the|O clonal|O origin|O of|O these|O tumours|O .|O 
MEASUREMENTS|O :|O 
Genomic|O DNA|O was|O extracted|O from|O nodular|O and|O surrounding|O tissue|O .|O 
Mutational|O hot|O spots|O in|O exons|O 1|O and|O 2|O of|O the|O H|gene-rna -|gene-rna and|O K|gene-rna -|gene-rna ras|gene-rna gene|O were|O PCR|O amplified|O and|O sequenced|O using|O big|O dye|O terminator|O chemistry|O .|O 
Denaturing|O gradient|O gel|O electrophoresis|O (|O DGGE|O )|O was|O used|O to|O verify|O sequencing|O results|O for|O the|O H-ras|gene-rna gene|O and|O to|O analyse|O the|O N-ras|gene-rna gene|O because|O its|O greater|O sensitivity|O in|O detecting|O somatic|O mutations|O .|O 
Clonality|O of|O nodular|O thyroid|O tissue|O was|O evaluated|O using|O X|O -|O Chromosome|O inactivation|O based|O on|O PCR|O amplification|O of|O the|O human|gene-protein androgen|gene-protein receptor|gene-protein locus|O .|O 
RESULTS|O :|O 
Monoclonal|O origin|O was|O detectable|O in|O 14|O of|O 23|O informative|O samples|O from|O cold|O thyroid|O nodules|O .|O 
In|O toxic|O thyroid|O nodules|O the|O frequency|O of|O clonal|O tissue|O was|O 20|O in|O 30|O informative|O cases|O .|O 
Only|O one|O point|O mutation|O could|O be|O found|O in|O the|O N-ras|gene-rna gene|O codon|O 61|O (|O Gly|O to|O Arg|O )|O in|O a|O cold|O adenomatous|O nodule|O which|O was|O monoclonal|O .|O 
In|O toxic|O thyroid|O nodules|O no|O ras|gene-rna mutation|O was|O detectable|O .|O 
CONCLUSION|O :|O 
Our|O study|O suggests|O that|O ras|gene-rna mutations|O are|O rare|O in|O solitary|O cold|O and|O toxic|O thyroid|O nodules|O and|O that|O the|O frequent|O monoclonal|O origin|O of|O these|O tumours|O implies|O somatic|O mutations|O in|O genes|O other|O than|O H|gene-rna -|gene-rna ,|O K|gene-rna -|gene-rna and|O N|gene-rna -|gene-rna ras|gene-rna .|O 
Cytoplasmic|O /|O nuclear|O expression|O without|O mutation|O of|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O is|O frequent|O in|O the|O development|O of|O the|O neoplasm|O of|O the|O uterine|O cervix|O .|O 
OBJECTIVE|O :|O 
The|O dual|O function|O of|O beta-catenin|gene-protein (|O e.g.|O ,|O as|O an|O intermediate|O protein|O between|O adherence|O junctions|O and|O the|O microfilaments|O ,|O and|O as|O a|O mediator|O of|O the|O Wnt|gene-protein signaling|O pathway|O )|O is|O currently|O known|O .|O 
Stabilization|O of|O beta-catenin|gene-protein and|O subsequent|O activation|O of|O the|O Wnt|gene-protein signaling|O pathway|O are|O involved|O in|O the|O development|O of|O some|O malignancies|O .|O 
We|O analyzed|O the|O immunohistochemical|O localization|O of|O beta-catenin|gene-protein and|O the|O somatic|O mutation|O of|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O in|O the|O malignant|O phenotype|O of|O the|O uterine|O cervix|O .|O 
METHODS|O :|O 
Immunohistochemical|O localization|O of|O beta-catenin|gene-protein and|O mutation|O of|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O were|O analyzed|O in|O 38|O precancerous|O lesions|O and|O 43|O cancerous|O lesions|O .|O 
RESULTS|O :|O 
In|O normal|O cervix|O ,|O beta-catenin|gene-protein was|O observed|O around|O the|O plasma|O membrane|O of|O the|O cells|O in|O the|O basal|O and|O parabasal|O layers|O of|O the|O epithelium|O .|O 
The|O frequency|O of|O cytoplasmic|O /|O nuclear|O beta-catenin|gene-protein expression|O correlated|O with|O a|O high|O histological|O grade|O of|O cervical|O intraepithelial|O neoplasia|O .|O 
Among|O invasive|O carcinomas|O ,|O 11|O (|O 73|O %|O )|O of|O 15|O samples|O showed|O cytoplasmic|O /|O nuclear|O localization|O to|O variable|O extents|O .|O 
A|O mutational|O analysis|O showed|O that|O mutation|O occurred|O in|O 7|O of|O 68|O specimens|O .|O 
Six|O cases|O with|O mutations|O revealed|O cytoplasmic|O /|O nuclear|O beta-catenin|gene-protein expression|O ,|O though|O 32|O (|O 84|O %|O )|O of|O the|O 38|O samples|O showing|O cytoplasmic|O /|O nuclear|O beta-catenin|gene-protein expression|O were|O not|O associated|O with|O the|O mutation|O .|O 
CONCLUSION|O :|O 
These|O results|O indicate|O that|O cytoplasmic|O /|O nuclear|O expression|O of|O beta-catenin|gene-protein is|O associated|O with|O the|O malignant|O phenotype|O of|O the|O cervix|O ,|O but|O the|O contribution|O of|O mutation|O of|O the|O beta-catenin|gene-rna gene|O is|O limited|O .|O 
K-ras|gene-rna and|O p53|gene-rna mutations|O in|O colonic|O lavage|O fluid|O of|O patients|O with|O colorectal|O neoplasias|O .|O 
BACKGROUND|O :|O 
The|O adenoma|O -|O carcinoma|O sequence|O has|O its|O molecular|O basis|O in|O several|O gene|O mutations|O of|O which|O K-ras|gene-rna and|O p53|gene-rna are|O of|O paramount|O importance|O .|O 
The|O aims|O of|O this|O study|O were|O to|O evaluate|O whether|O these|O genetic|O alterations|O can|O be|O detected|O in|O colonic|O lavage|O fluid|O from|O patients|O with|O colorectal|O adenomas|O and|O carcinomas|O .|O 
METHODS|O :|O 
In|O 45|O patients|O with|O adenomas|O ,|O 20|O patients|O with|O colorectal|O carcinomas|O and|O 38|O patients|O with|O non|O -|O neoplastic|O and|O noninflammatory|O diseases|O of|O the|O colon|O p53|gene-rna and|O K-ras|gene-rna mutations|O were|O evaluated|O in|O colonic|O lavage|O fluid|O employing|O single|O -|O strand|O confirmation|O polymorphism|O analysis|O and|O dot|O -|O blot|O hybridization|O ,|O respectively|O .|O 
RESULTS|O :|O 
Mutations|O of|O the|O K-ras|gene-rna and|O the|O p53|gene-rna gene|O were|O found|O in|O 15.6|O %|O (|O p|O =|O 0.065|O )|O of|O patients|O with|O adenomas|O ,|O in|O 25.0|O %|O (|O p|O =|O 0.016|O )|O of|O patients|O with|O carcinomas|O and|O in|O 2.6|O %|O in|O the|O control|O group|O .|O 
CONCLUSION|O :|O 
Genetic|O alterations|O in|O the|O colonic|O lavage|O fluid|O could|O be|O an|O additional|O diagnostic|O tool|O for|O the|O surveillance|O of|O patients|O with|O colorectal|O neoplasias|O .|O 
K-ras|gene-rna mutation|O at|O codon|O 12|O in|O stage|O I|O pancreatic|O adenocarcinoma|O :|O analysis|O by|O laser|O capture|O microdissection|O and|O direct|O sequencing|O .|O 
Pancreatic|O ductal|O adenocarcinoma|O has|O been|O reported|O to|O carry|O a|O rate|O mutation|O high|O in|O codon|O 12|O of|O the|O K-ras|gene-rna oncogene|O .|O 
To|O avoid|O the|O pitfalls|O of|O conventional|O methods|O of|O tissue|O dissection|O that|O might|O affect|O the|O sensitivity|O and|O specificity|O of|O detecting|O K-ras|gene-rna mutation|O ,|O laser|O capture|O microdissection|O (|O LCM|O )|O technique|O was|O used|O .|O 
Pancreatic|O adenocarcinoma|O tissues|O were|O obtained|O from|O 15|O patients|O who|O underwent|O Whipple|O 's|O procedure|O .|O 
Selected|O tissues|O procured|O by|O LCM|O were|O analyzed|O by|O direct|O sequencing|O after|O polymerase|gene-protein chain|O reaction|O amplification|O of|O K-ras|gene-rna sequences|O at|O codon|O 12|O .|O 
K-ras|gene-rna mutation|O was|O noted|O in|O nine|O patients|O .|O 
All|O mutations|O showed|O G|O to|O A|O substitution|O at|O codon|O 12|O .|O 
The|O mutational|O pattern|O (|O GGT|O to|O GAT|O )|O is|O similar|O in|O both|O western|O and|O eastern|O reports|O .|O 
LCM|O is|O a|O feasible|O method|O to|O effectively|O obtain|O pure|O tumor|O cells|O from|O a|O surgical|O specimen|O .|O 
It|O remains|O to|O be|O determined|O whether|O this|O low|O mutation|O rate|O is|O a|O result|O of|O relatively|O early|O stage|O of|O disease|O or|O different|O carcinogenesis|O in|O different|O geographic|O regions|O .|O 
K-ras|gene-rna gene|O mutations|O in|O non|O -|O small|O cell|O lung|O cancer|O in|O Japanese|O .|O 
To|O evaluate|O the|O association|O of|O mutations|O in|O the|O K-ras|gene-rna gene|O with|O the|O incidence|O of|O non|O -|O small|O cell|O lung|O cancer|O (|O NSCLC|O )|O in|O Japanese|O patients|O ,|O 410|O patients|O treated|O surgically|O were|O studied|O .|O 
DNA|O was|O extracted|O from|O frozen|O specimens|O ,|O and|O polymerase|gene-protein chain|O reaction|O -|O sequence|O specific|O oligonucleotide|O probe|O (|O PCR|O -|O SSOP|O )|O hybridization|O assay|O was|O used|O to|O examine|O K-ras|gene-rna mutations|O in|O codons|O 12|O ,|O 13|O and|O 61|O .|O 
K-ras|gene-rna mutations|O were|O found|O in|O 33|O patients|O (|O 8.0|O %|O )|O ,|O and|O all|O were|O smokers|O or|O ex|O -|O smokers|O .|O 
There|O were|O no|O significant|O differences|O in|O clinical|O or|O pathological|O stage|O between|O wild|O -|O type|O cases|O and|O mutant|O cases|O .|O 
The|O most|O frequently|O identified|O mutation|O was|O a|O G|O -->|O T|O transversion|O (|O 25|O /|O 33|O ,|O 75.8|O %|O )|O that|O resulted|O in|O the|O substitution|O of|O a|O glycine|O for|O a|O cysteine|O or|O a|O valine|O .|O 
Previous|O studies|O have|O shown|O that|O the|O majority|O of|O K-ras|gene-rna mutations|O among|O smokers|O are|O G|O -->|O T|O transversion|O .|O 
In|O our|O study|O ,|O K-ras|gene-rna mutations|O were|O found|O only|O in|O smokers|O ,|O and|O there|O was|O a|O high|O frequency|O of|O G|O -->|O T|O transversions|O .|O 
A|O clear|O correlation|O exists|O between|O smoking|O and|O K-ras|gene-rna gene|O mutations|O .|O 
p53|gene-rna and|O K-ras|gene-rna mutations|O in|O lung|O cancers|O from|O former|O and|O never|O -|O smoking|O women|O .|O 
Somatic|O p53|gene-rna mutations|O are|O common|O in|O lung|O cancer|O .|O 
Active|O cigarette|O smoking|O is|O positively|O correlated|O with|O the|O total|O frequency|O of|O p53|gene-rna mutations|O and|O G|O :|O C|O to|O T|O :|O A|O transversions|O on|O the|O nontranscribed|O (|O DNA|O coding|O )|O strand|O .|O 
Mutational|O hotspots|O within|O the|O p53|gene-rna gene|O ,|O e.g.|O ,|O codon|O 157|O ,|O have|O been|O identified|O for|O tobacco|O -|O related|O lung|O cancer|O ,|O whereas|O these|O same|O mutations|O are|O found|O rarely|O in|O other|O cancers|O .|O 
Such|O data|O implicate|O specific|O p53|gene-rna mutations|O as|O molecular|O markers|O of|O smoking|O .|O 
Because|O limited|O data|O exist|O concerning|O the|O p53|gene-rna mutation|O frequency|O and|O spectra|O in|O ex|O -|O smokers|O and|O nonsmokers|O ,|O we|O have|O analyzed|O p53|gene-rna and|O K-ras|gene-rna mutations|O in|O 126|O lung|O cancers|O from|O a|O population|O -|O based|O case|O -|O control|O study|O of|O nonsmoking|O (|O n|O =|O 117|O )|O or|O ex|O -|O smoking|O (|O n|O =|O 9|O )|O women|O from|O Missouri|O with|O quantitative|O assessments|O of|O exposure|O to|O environmental|O tobacco|O smoke|O .|O 
Mutations|O in|O the|O p53|gene-rna gene|O were|O found|O in|O lung|O cancers|O from|O lifetime|O nonsmokers|O (|O 19|O %|O )|O and|O ex|O -|O smokers|O (|O 67|O %|O ;|O odds|O ratio|O ,|O 9.08|O ;|O 95|O %|O confidence|O interval|O ,|O 2.06|O -|O 39.98|O )|O .|O 
All|O deletions|O were|O found|O in|O tumors|O from|O patients|O who|O were|O either|O ex|O -|O smokers|O or|O nonsmokers|O exposed|O to|O passive|O smoking|O .|O 
The|O G|O :|O C|O to|O A|O :|O T|O transitions|O (|O 11|O of|O 28|O ;|O 39|O %|O )|O were|O the|O most|O frequent|O p53|gene-rna mutations|O found|O and|O clustered|O in|O tumors|O from|O lifetime|O nonsmokers|O without|O passive|O smoke|O exposure|O .|O 
The|O incidence|O of|O K-ras|gene-rna codon|O 12|O or|O 13|O mutations|O was|O 11|O %|O (|O 14|O of|O 115|O analyzed|O )|O with|O no|O difference|O between|O long|O -|O term|O ex|O -|O smokers|O and|O nonsmokers|O .|O 
These|O and|O other|O results|O indicate|O that|O p53|gene-rna mutations|O occur|O more|O commonly|O in|O smokers|O and|O ex|O -|O smokers|O than|O in|O never|O -|O smokers|O .|O 
Such|O comparisons|O provide|O additional|O evidence|O of|O genetic|O damage|O caused|O by|O tobacco|O smoke|O during|O lung|O carcinogenesis|O .|O 
A|O case|O of|O '|O smouldering|O '|O mastocytosis|O with|O high|O mast|O cell|O burden|O ,|O monoclonal|O myeloid|O cells|O ,|O and|O C-KIT|gene-rna mutation|O Asp|O -|O 816|O -|O Val|O .|O 
Mastocytosis|O is|O a|O term|O used|O for|O a|O group|O of|O disorders|O characterized|O by|O abnormal|O growth|O and|O accumulation|O of|O tissue|O mast|O cells|O (|O MC|O )|O in|O one|O or|O more|O organ|O systems|O .|O 
In|O patients|O with|O systemic|O mastocytosis|O (|O SM|O )|O the|O clinical|O course|O may|O be|O indolent|O or|O aggressive|O or|O even|O complicated|O by|O leukemic|O progression|O or|O an|O associated|O clonal|O hematologic|O non|O mast|O cell|O lineage|O disease|O (|O AHNMD|O )|O .|O 
However|O ,|O at|O first|O presentation|O (|O diagnosis|O )|O it|O may|O be|O difficult|O to|O define|O the|O category|O of|O disease|O and|O the|O prognosis|O .|O 
We|O report|O on|O a|O 48|O -|O year|O -|O old|O female|O patient|O with|O SM|O with|O urticaria|O pigmentosa|O -|O like|O skin|O lesions|O and|O mediator|O -|O related|O symptoms|O .|O 
She|O was|O found|O to|O have|O splenomegaly|O ,|O a|O high|O infiltration|O grade|O (|O MC|O )|O in|O bone|O marrow|O biopsies|O (|O >|O 30|O %|O )|O ,|O mild|O anemia|O ,|O and|O a|O high|O serum|O tryptase|gene-protein level|O (|O >|O 500|O ng|O /|O ml|O )|O .|O 
In|O addition|O ,|O she|O exhibited|O discrete|O histologic|O signs|O of|O myeloproliferation|O in|O the|O '|O non|O -|O affected|O '|O marrow|O and|O monoclonal|O blood|O cells|O established|O by|O C-KIT|gene-rna 2468|O A|O -->|O T|O mutation|O (|O Asp|O -|O 816|O -|O Val|O )|O -|O analysis|O and|O HUMARA|O assay|O .|O 
Despite|O these|O findings|O ,|O however|O ,|O the|O clinical|O course|O was|O stable|O over|O years|O and|O no|O AHNMD|O or|O organ|O impairment|O developed|O .|O 
Because|O of|O the|O '|O intermediate|O '|O clinical|O signs|O and|O absence|O of|O progression|O to|O aggressive|O disease|O ,|O we|O proposed|O the|O term|O '|O smouldering|O mastocytosis|O '|O .|O 
Mutations|O in|O c-kit|gene-rna gene|O exons|O 9|O and|O 13|O in|O gastrointestinal|O stromal|O tumors|O among|O Japanese|O .|O 
Gain|O -|O of|O -|O function|O mutation|O in|O c-kit|gene-rna proto|O -|O oncogene|O exon|O 11|O has|O been|O described|O in|O about|O 20|O --|O 50|O %|O of|O gastrointestinal|O stroma|O tumor|O (|O GIST|O )|O .|O 
Recently|O ,|O additional|O mutational|O hot|O -|O spots|O in|O exon|O 9|O and|O exon|O 13|O of|O the|O c-kit|gene-rna gene|O have|O been|O reported|O in|O GISTs|O without|O mutations|O of|O exon|O 11|O ,|O but|O a|O subsequent|O report|O in|O a|O Western|O population|O indicated|O that|O only|O a|O small|O portion|O of|O GISTs|O (|O eight|O of|O 200|O GISTs|O ,|O 4|O %|O )|O showed|O mutations|O in|O these|O regions|O .|O 
In|O this|O study|O ,|O we|O evaluated|O mutations|O in|O exon|O 9|O and|O exon|O 13|O of|O the|O c-kit|gene-rna gene|O by|O both|O polymerase|gene-protein chain|O reaction|O -|O single|O strand|O conformation|O polymorphism|O analysis|O and|O direct|O sequencing|O in|O 48|O GISTs|O in|O a|O Japanese|O population|O ,|O for|O which|O the|O clinicopathological|O and|O immunohistochemical|O features|O and|O mutations|O in|O exon|O 11|O had|O previously|O been|O reported|O .|O 
C-kit|gene-rna gene|O mutation|O in|O exon|O 9|O ,|O representing|O insertion|O of|O GCC|O TAT|O ,|O was|O identified|O in|O only|O 4|O of|O 48|O GISTs|O (|O 8|O %|O )|O ,|O and|O none|O of|O the|O GISTs|O had|O mutations|O in|O exon|O 13|O .|O 
All|O four|O GISTs|O with|O mutation|O in|O exon|O 9|O were|O high|O -|O risk|O ,|O and|O the|O patients|O died|O of|O multiple|O tumor|O metastasis|O .|O 
Mutations|O in|O exon|O 9|O and|O exon|O 13|O of|O the|O c-kit|gene-rna gene|O were|O also|O rare|O events|O in|O Japanese|O GISTs|O and|O were|O related|O to|O a|O poor|O prognosis|O .|O 
These|O results|O in|O Japanese|O are|O consistent|O with|O those|O in|O Western|O populations|O ,|O although|O a|O preferential|O occurrence|O of|O GISTs|O with|O exon|O 9|O mutation|O in|O the|O small|O intestine|O ,|O which|O was|O suggested|O in|O a|O previous|O report|O ,|O was|O not|O observed|O .|O 
[|O Abnormalities|O of|O the|O p53|gene-rna ,|O N-ras|gene-rna ,|O DCC|gene-rna and|O FLT-3|gene-rna genes|O in|O myelodysplastic|O syndromes|O ]|O 
The|O molecular|O mechanism|O of|O carcinogenesis|O is|O a|O multistep|O process|O that|O is|O characterized|O by|O both|O activation|O of|O oncogenes|O and|O inactivation|O of|O tumor|O suppressor|O genes|O .|O 
In|O the|O present|O study|O ,|O mutations|O of|O N-ras|gene-rna ,|O p53|gene-rna and|O FMS|gene-rna -|gene-rna like|gene-rna tyrosine|gene-protein kinase|gene-protein 3|gene-rna (|O FLT-3|gene-rna )|O genes|O and|O loss|O of|O expression|O of|O the|O deleted|gene-rna in|gene-rna colorectal|gene-rna carcinoma|gene-rna (|O DCC|gene-rna )|O gene|O were|O analyzed|O in|O 59|O patients|O with|O myelodysplastic|O syndromes|O (|O MDS|O )|O .|O 
Mutations|O of|O N-ras|gene-rna ,|O p53|gene-rna ,|O and|O FLT-3|gene-rna genes|O were|O detected|O in|O 7|O ,|O 7|O ,|O 1|O of|O the|O 59|O patients|O with|O MDS|O ,|O respectively|O .|O 
Loss|O of|O DCC|gene-rna expression|O was|O detected|O in|O 16|O patients|O .|O 
Type|O of|O MDS|O patients|O with|O N-ras|gene-rna mutation|O were|O all|O refractory|O anemia|O with|O excess|O of|O blasts|O in|O transformation|O (|O RAEB-T|O )|O .|O 
Abnormalities|O of|O p53|gene-rna and|O DCC|gene-rna genes|O were|O significantly|O associated|O with|O survival|O time|O (|O p|O <|O 0.02|O ,|O p|O <|O 0.004|O ,|O respectively|O )|O .|O 
H-ras|gene-rna oncogene|O mutation|O in|O dedifferentiated|O chondrosarcoma|O :|O polymerase|gene-protein chain|O reaction|O -|O restriction|O fragment|O length|O polymorphism|O analysis|O .|O 
Dedifferentiated|O chondrosarcomas|O ,|O which|O are|O known|O for|O their|O poor|O prognosis|O ,|O are|O characterized|O by|O conventional|O chondrosarcoma|O with|O high|O -|O grade|O anaplastic|O components|O .|O 
Activating|O mutations|O in|O ras|gene-rna genes|O are|O a|O common|O genetic|O abnormality|O in|O human|O malignancies|O .|O 
The|O presence|O of|O point|O mutations|O at|O codons|O 12|O and|O 13|O of|O the|O H-ras|gene-rna gene|O was|O studied|O in|O 20|O formalin|O -|O fixed|O paraffin|O -|O embedded|O chondrosarcomas|O ,|O comprising|O 11|O cases|O of|O conventional|O chondrosarcoma|O (|O six|O Grade|O 1|O cases|O and|O five|O Grade|O 2|O cases|O )|O and|O nine|O cases|O of|O dedifferentiated|O chondrosarcoma|O ,|O using|O polymerase|gene-protein chain|O reaction|O -|O restriction|O fragment|O length|O polymorphism|O and|O direct|O sequencing|O analysis|O .|O 
H-ras|gene-rna mutations|O were|O only|O seen|O in|O two|O out|O of|O the|O nine|O cases|O of|O dedifferentiated|O chondrosarcoma|O (|O 2|O /|O 9|O ,|O 22|O %|O )|O and|O they|O were|O not|O seen|O in|O any|O of|O the|O cases|O of|O conventional|O chondrosarcoma|O (|O 0|O /|O 11|O ,|O 0|O %|O )|O .|O 
Dedifferentiated|O chondrosarcomas|O had|O a|O worse|O prognosis|O than|O conventional|O chondrosarcomas|O (|O P|O <|O .01|O )|O ;|O among|O the|O patients|O with|O dedifferentiated|O chondrosarcomas|O ,|O those|O with|O H-ras|gene-rna mutation|O (|O n|O =|O 2|O )|O tended|O to|O have|O a|O worse|O prognosis|O than|O those|O without|O (|O n|O =|O 7|O )|O ,|O although|O the|O difference|O was|O not|O statistically|O significant|O (|O P|O =|O 0.068|O )|O .|O 
Our|O results|O would|O seem|O to|O suggest|O that|O H-ras|gene-rna mutation|O may|O occur|O during|O the|O course|O of|O dedifferentiation|O and|O may|O also|O have|O some|O effect|O on|O malignant|O potential|O .|O 
Prognostic|O significance|O of|O K-ras|gene-rna and|O TP53|gene-rna mutations|O in|O the|O role|O of|O adjuvant|O chemotherapy|O on|O survival|O in|O patients|O with|O Dukes|O C|O colon|O cancer|O .|O 
PURPOSE|O :|O 
Mutations|O in|O K-ras|gene-rna and|O TP53|gene-rna genes|O are|O common|O in|O colorectal|O cancer|O .|O 
They|O affect|O biologic|O behavior|O and|O might|O influence|O chemotherapy|O susceptibility|O in|O these|O tumors|O .|O 
We|O investigated|O whether|O the|O survival|O of|O patients|O with|O Dukes|O C|O colon|O cancer|O treated|O with|O adjuvant|O chemotherapy|O is|O influenced|O by|O K-ras|gene-rna and|O TP53|gene-rna mutations|O .|O 
METHODS|O :|O 
Mutation|O screening|O of|O the|O hot|O spots|O of|O the|O K-ras|gene-rna gene|O and|O of|O the|O evolutionarily|O conserved|O regions|O of|O the|O TP53|gene-rna gene|O was|O performed|O by|O denaturing|O gradient|O gel|O electrophoresis|O technique|O in|O formalin|O -|O fixed|O paraffin|O -|O embedded|O specimens|O of|O 55|O consecutive|O patients|O with|O Dukes|O C|O colon|O cancer|O treated|O with|O adjuvant|O 5-fluorouracil|O -|O based|O chemotherapy|O .|O 
The|O median|O follow|O -|O up|O was|O 47|O (|O range|O ,|O 32|O -|O 66|O )|O months|O .|O 
RESULTS|O :|O 
Alterations|O in|O the|O mutation|O hot|O spots|O of|O K-ras|gene-rna were|O found|O at|O codon|O 12|O (|O n|O =|O 11|O )|O and|O 13|O (|O n|O =|O 4|O )|O in|O 15|O of|O the|O 55|O carcinomas|O (|O 27|O percent|O )|O .|O 
No|O mutation|O was|O found|O at|O codon|O 61|O .|O Mutations|O of|O a|O probably|O causative|O nature|O in|O the|O evolutionarily|O conserved|O regions|O (|O exons|O 5|O -|O 8|O )|O of|O the|O TP53|gene-rna gene|O were|O found|O in|O 24|O tumors|O (|O 44|O percent|O )|O .|O 
K-ras|gene-rna and|O TP53|gene-rna mutations|O were|O found|O equally|O in|O the|O group|O with|O recurrent|O disease|O (|O 7|O /|O 26|O (|O 26|O percent|O )|O and|O 12|O /|O 27|O (|O 44|O percent|O )|O ,|O respectively|O )|O and|O in|O the|O group|O without|O recurrences|O (|O 8|O /|O 28|O (|O 24|O percent|O )|O and|O 12|O /|O 28|O (|O 43|O percent|O )|O ,|O respectively|O )|O .|O 
Cancer|O -|O specific|O survival|O did|O not|O differ|O significantly|O between|O patients|O with|O K-ras|gene-rna or|O TP53|gene-rna or|O both|O mutated|O and|O nonmutated|O tumors|O ,|O respectively|O (|O log|O -|O rank|O test|O :|O K-ras|O ,|O P|O =|O 0.72|O and|O TP53|gene-rna ,|O P|O =|O 0.77|O ;|O K-ras|gene-rna and|O TP53|gene-rna ,|O P|O =|O 0.8|O )|O .|O 
Also|O ,|O potentially|O aggressive|O K-ras|gene-rna codon|O 12|O and|O 13|O mutations|O had|O the|O same|O survival|O as|O tumors|O without|O these|O mutations|O (|O log|O -|O rank|O test|O ;|O P|O =|O 0.73|O )|O .|O 
CONCLUSIONS|O :|O 
Patients|O with|O K-ras|gene-rna or|O TP53|gene-rna or|O both|O mutated|O Dukes|O C|O colon|O tumors|O have|O the|O same|O survival|O as|O nonmutated|O tumors|O when|O treated|O with|O adjuvant|O chemotherapy|O .|O 
Frequent|O beta-catenin|gene-rna mutations|O in|O juvenile|O nasopharyngeal|O angiofibromas|O .|O 
Juvenile|O nasopharyngeal|O angiofibromas|O (|O JNAs|O )|O are|O locally|O aggressive|O vascular|O tumors|O occurring|O predominantly|O in|O adolescent|O males|O .|O 
The|O pathogenesis|O of|O JNAs|O is|O unknown|O .|O 
Recently|O ,|O JNAs|O have|O been|O reported|O to|O occur|O at|O increased|O frequency|O among|O patients|O with|O familial|O adenomatous|O polyposis|O ,|O suggesting|O that|O alterations|O of|O the|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|O APC|gene-rna )|O /|O beta-catenin|gene-rna pathway|O might|O also|O be|O involved|O in|O the|O pathogenesis|O of|O sporadic|O JNAs|O .|O 
We|O analyzed|O somatic|O beta-catenin|gene-rna and|O APC|gene-rna gene|O mutations|O in|O 16|O sporadic|O JNAs|O from|O nonfamilial|O adenomatous|O polyposis|O patients|O using|O immunohistochemistry|O for|O beta-catenin|gene-protein ,|O and|O direct|O DNA|O sequencing|O for|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O and|O the|O mutation|O cluster|O region|O of|O the|O APC|gene-rna gene|O .|O 
Nuclear|O accumulation|O of|O beta-catenin|gene-protein was|O diffusely|O present|O in|O the|O stromal|O cells|O but|O not|O in|O the|O endothelial|O cells|O of|O all|O 16|O JNAs|O .|O 
Activating|O beta-catenin|gene-rna gene|O mutations|O were|O present|O in|O 75|O %|O (|O 12|O of|O 16|O )|O of|O JNAs|O .|O 
Six|O JNA|O patients|O also|O had|O recurrent|O tumors|O after|O surgery|O ,|O and|O in|O all|O cases|O the|O beta-catenin|gene-rna gene|O status|O of|O the|O recurrent|O JNA|O was|O identical|O to|O the|O initial|O tumor|O .|O 
No|O mutations|O in|O the|O mutation|O cluster|O region|O of|O the|O APC|gene-rna gene|O were|O detected|O in|O the|O four|O JNAs|O without|O beta-catenin|gene-rna mutations|O .|O 
The|O high|O frequency|O of|O beta-catenin|gene-rna mutations|O in|O sporadic|O JNAs|O and|O the|O presence|O of|O identical|O beta-catenin|gene-rna gene|O mutations|O in|O recurrent|O tumors|O indicates|O that|O activating|O beta-catenin|gene-rna gene|O mutations|O are|O important|O in|O the|O pathogenesis|O of|O JNAs|O .|O 
The|O immunohistochemical|O localization|O of|O beta-catenin|gene-protein only|O to|O the|O nuclei|O of|O stromal|O cells|O further|O suggests|O that|O the|O stromal|O cells|O ,|O rather|O than|O endothelial|O cells|O ,|O are|O the|O neoplastic|O cells|O of|O JNAs|O .|O 
K-ras|gene-rna and|O p16|gene-rna aberrations|O confer|O poor|O prognosis|O in|O human|O colorectal|O cancer|O .|O 
PURPOSE|O :|O 
Mutations|O in|O the|O K-ras|gene-rna gene|O are|O frequent|O in|O human|O cancer|O .|O 
ras|gene-rna activation|O in|O primary|O cells|O results|O in|O a|O cellular|O senescence|O phenotype|O that|O is|O precluded|O by|O inactivation|O of|O p16|gene-rna .|O 
At|O the|O clinical|O level|O ,|O this|O may|O imply|O a|O differential|O behavior|O for|O tumors|O with|O alternative|O or|O cooperative|O activation|O of|O K-ras|gene-rna function|O and|O impairment|O of|O p16|gene-rna pathways|O .|O 
PATIENTS|O AND|O METHODS|O :|O 
We|O have|O determined|O the|O presence|O of|O mutations|O in|O the|O K-ras|gene-rna gene|O and|O the|O methylation|O status|O of|O p16|gene-rna promoter|O in|O a|O series|O of|O 119|O prospectively|O collected|O colorectal|O carcinomas|O .|O 
p53|gene-rna mutations|O and|O p14|gene-rna alternative|O reading|O frame|O methylation|O status|O were|O also|O assessed|O .|O 
Associations|O with|O survival|O were|O investigated|O .|O 
RESULTS|O :|O 
K-ras|gene-rna mutations|O were|O present|O in|O 44|O (|O 38|O %|O )|O of|O 115|O cases|O ,|O and|O p16|gene-rna methylation|O was|O present|O in|O 42|O (|O 37|O %|O )|O of|O 113|O cases|O .|O 
p53|gene-rna mutations|O were|O detected|O in|O 50|O %|O (|O 56|O of|O 115|O )|O and|O p14|gene-rna methylation|O in|O 29|O %|O (|O 32|O of|O 112|O )|O of|O cases|O .|O 
K-ras|gene-rna and|O p16|gene-rna alterations|O were|O independent|O genetic|O events|O .|O 
Presence|O of|O K-ras|gene-rna or|O p16|gene-rna genetic|O alterations|O (|O analyzed|O independently|O )|O was|O associated|O with|O shorter|O survival|O ,|O although|O differences|O were|O not|O statistically|O significant|O .|O 
Cox|O analysis|O of|O the|O two|O variables|O combined|O showed|O a|O diminished|O survival|O as|O the|O results|O of|O an|O interaction|O between|O p16|gene-rna and|O K-ras|gene-rna .|O 
Alternative|O alteration|O of|O K-ras|gene-rna and|O p16|gene-rna genes|O was|O an|O independent|O prognostic|O factor|O in|O human|O colorectal|O cancer|O in|O univariate|O and|O multivariate|O analysis|O .|O 
Differences|O were|O maintained|O when|O cases|O undergoing|O radical|O surgery|O and|O without|O distant|O metastases|O were|O considered|O .|O 
CONCLUSION|O :|O 
These|O results|O suggest|O that|O the|O combined|O K-ras|gene-rna and|O p16|gene-rna analyses|O may|O be|O of|O prognostic|O use|O in|O human|O colorectal|O cancer|O .|O 
Expression|O of|O E-cadherin|gene-protein and|O beta-catenin|gene-protein in|O primary|O and|O peritoneal|O metastatic|O ovarian|O carcinoma|O .|O 
Protein|O expression|O levels|O of|O E-cadherin|gene-protein and|O beta-catenin|gene-protein were|O examined|O in|O 39|O primary|O and|O 10|O metastatic|O ovarian|O carcinoma|O to|O elucidate|O the|O role|O of|O these|O molecules|O in|O the|O extension|O of|O ovarian|O carcinoma|O by|O immunohistochemistry|O .|O 
Twenty-two|O of|O 39|O (|O 56|O %|O )|O ovarian|O carcinomas|O were|O preserved|O type|O and|O 17|O of|O 39|O (|O 44|O %|O )|O were|O reduced|O type|O of|O E-cadherin|gene-protein .|O 
In|O contrast|O ,|O 36|O of|O 39|O (|O 92|O %|O )|O ovarian|O carcinomas|O were|O preserved|O type|O and|O 3|O of|O 39|O (|O 8|O %|O )|O were|O reduced|O type|O of|O beta-catenin|gene-protein .|O 
E-cadherin|gene-protein expression|O in|O well|O -|O differentiated|O carcinoma|O was|O higher|O than|O that|O in|O moderately|O /|O poorly|O -|O differentiated|O carcinoma|O (|O p|O <|O 0.05|O )|O .|O 
Interestingly|O ,|O 6|O of|O 10|O (|O 60|O %|O )|O peritoneal|O metastatic|O lesions|O resulted|O in|O the|O reduced|O expression|O of|O E-cadherin|gene-protein compared|O with|O primary|O lesions|O .|O 
In|O contrast|O ,|O only|O 2|O of|O 10|O (|O 20|O %|O )|O metastatic|O lesions|O showed|O reduced|O expression|O of|O beta-catenin|gene-protein compared|O with|O primary|O lesions|O .|O 
Mutation|O of|O exon|O 3|O of|O beta-catenin|gene-rna gene|O was|O rare|O (|O 3|O %|O ,|O 1|O /|O 39|O )|O in|O carcinoma|O .|O 
These|O results|O suggested|O that|O the|O cell|O adhesion|O molecule|O E-cadherin|gene-protein might|O play|O an|O important|O role|O in|O the|O formation|O of|O peritoneal|O metastasis|O .|O 
In|O contrast|O ,|O beta-catenin|gene-protein is|O not|O a|O good|O indicator|O of|O metastasis|O in|O human|O ovarian|O carcinoma|O .|O 
K-ras|gene-rna mutations|O in|O the|O bile|O of|O patients|O with|O primary|O sclerosing|O cholangitis|O .|O 
BACKGROUND|O AND|O AIMS|O :|O 
The|O development|O of|O cholangiocarcinoma|O (|O CCC|O )|O is|O a|O complication|O of|O primary|O sclerosing|O cholangitis|O (|O PSC|O )|O .|O 
To|O date|O ,|O no|O reliable|O factors|O have|O been|O described|O which|O can|O define|O those|O PSC|O patients|O at|O high|O risk|O for|O the|O development|O of|O CCC|O and|O the|O clinical|O diagnosis|O of|O CCC|O in|O PSC|O patients|O is|O difficult|O .|O 
Therefore|O ,|O molecular|O markers|O of|O cholangiocarcinogenesis|O ,|O such|O as|O K-ras|gene-rna mutations|O ,|O may|O improve|O the|O early|O diagnosis|O of|O CCC|O or|O the|O timing|O of|O liver|O transplantation|O .|O 
METHODS|O :|O 
K-ras|gene-rna mutations|O were|O analysed|O by|O enriched|O polymerase|gene-protein chain|O reaction|O /|O restriction|O fragment|O length|O polymorphism|O in|O the|O bile|O fluid|O of|O 56|O PSC|O patients|O and|O 20|O patients|O with|O other|O cholestatic|O diseases|O .|O 
To|O assess|O the|O value|O of|O K-ras|gene-rna mutations|O as|O a|O risk|O factor|O for|O cholangiocarcinogenesis|O ,|O patients|O were|O prospectively|O investigated|O over|O a|O mean|O period|O of|O 31.5|O months|O .|O 
RESULTS|O :|O 
In|O contrast|O with|O the|O control|O group|O ,|O 17|O (|O 30|O %|O )|O patients|O with|O PSC|O revealed|O K-ras|gene-rna mutations|O in|O bile|O fluid|O .|O 
The|O mean|O Mayo|O score|O was|O not|O significantly|O different|O between|O PSC|O patients|O with|O (|O mean|O score|O 0.70|O )|O and|O without|O (|O mean|O score|O 0.13|O ;|O p|O =|O 0.2|O )|O K-ras|gene-rna mutations|O .|O 
In|O contrast|O with|O the|O group|O of|O PSC|O patients|O without|O K-ras|gene-rna mutations|O ,|O four|O CCCs|O and|O two|O dysplasia|O were|O diagnosed|O in|O the|O group|O of|O patients|O with|O K-ras|gene-rna mutations|O during|O the|O follow|O up|O investigation|O (|O p|O <|O 0.001|O )|O .|O 
CONCLUSIONS|O :|O 
Our|O results|O indicate|O that|O K-ras|gene-rna mutations|O in|O bile|O fluid|O of|O PSC|O patients|O represent|O frequent|O early|O events|O during|O cholangiocarcinogenesis|O .|O 
However|O ,|O most|O of|O the|O PSC|O patients|O with|O K-ras|gene-rna mutations|O remained|O tumour|O free|O after|O a|O long|O follow|O up|O investigation|O which|O is|O in|O agreement|O with|O the|O fact|O that|O these|O mutations|O are|O not|O specific|O for|O malignancy|O but|O may|O also|O occur|O in|O normal|O bile|O duct|O mucosa|O or|O in|O dysplasias|O .|O 
Therefore|O ,|O analysis|O of|O K-ras|gene-rna mutations|O in|O bile|O should|O not|O be|O used|O for|O diagnosis|O of|O CCC|O in|O PSC|O patients|O .|O 
However|O ,|O the|O results|O of|O our|O prospective|O follow|O up|O investigation|O indicate|O that|O K-ras|gene-rna mutations|O in|O bile|O fluid|O of|O PSC|O patients|O have|O to|O be|O considered|O as|O risk|O factors|O for|O the|O development|O of|O CCC|O which|O may|O have|O implications|O for|O the|O timing|O of|O liver|O transplantation|O .|O 
We|O screened|O 90|O cases|O of|O gastric|O carcinoma|O (|O GCA|O )|O samples|O for|O beta-catenin|gene-rna exon|O 3|O mutation|O and|O assessed|O its|O possible|O relationship|O with|O microsatellite|O instability|O (|O MSI|O )|O .|O 
Three|O mutations|O were|O detected|O in|O two|O samples|O ,|O including|O a|O single|O mutation|O in|O an|O intestinal|O type|O and|O double|O mutations|O in|O a|O diffuse|O type|O GCA|O .|O 
One|O of|O the|O mutations|O found|O in|O the|O diffuse|O type|O GCA|O sample|O was|O a|O non|O -|O sense|O mutation|O at|O codon|O 68|O (|O CAG|O -->|O TAG|O )|O .|O 
This|O novel|O mutation|O was|O predicted|O to|O disrupt|O the|O binding|O of|O beta-catenin|gene-protein to|O alpha-catenin|gene-protein and|O may|O be|O related|O to|O the|O diffuse|O type|O morphology|O .|O 
The|O other|O two|O mutations|O were|O missense|O mutations|O involved|O or|O related|O to|O the|O GSK-3beta|gene-rna phosphorylation|O site|O ,|O which|O have|O been|O reported|O previously|O .|O 
No|O MSI|O can|O be|O demonstrated|O in|O the|O two|O cases|O with|O beta-catenin|gene-rna mutation|O .|O 
Pancreatic|O tumours|O :|O molecular|O pathways|O implicated|O in|O ductal|O cancer|O are|O involved|O in|O ampullary|O but|O not|O in|O exocrine|O nonductal|O or|O endocrine|O tumorigenesis|O .|O 
Alterations|O of|O K|gene-rna -|gene-rna ras|gene-rna ,|O p53|gene-rna ,|O p16|gene-rna and|O DPC4|gene-rna /|O Smad4|gene-rna characterize|O pancreatic|O ductal|O cancer|O (|O PDC|O )|O .|O 
Reports|O of|O inactivation|O of|O these|O latter|O two|O genes|gene-rna in|O pancreatic|O endocrine|O tumours|O (|O PET|O )|O suggest|O that|O common|O molecular|O pathways|O are|O involved|O in|O the|O tumorigenesis|O of|O pancreatic|O exocrine|O and|O endocrine|O epithelia|O .|O 
We|O characterized|O 112|O primary|O pancreatic|O tumours|O for|O alterations|O in|O p16|gene-rna and|O DPC4|gene-rna and|O immunohistochemical|O expression|O of|O DPC4|gene-rna .|O 
The|O cases|O included|O 34|O PDC|O ,|O 10|O intraductal|O papillary|O -|O mucinous|O tumours|O (|O IPMT|O )|O ,|O 6|O acinar|O carcinomas|O (|O PAC|O )|O ,|O 5|O solid|O -|O pseudopapillary|O tumours|O (|O SPT|O )|O ,|O 16|O ampulla|O of|O Vater|O cancers|O (|O AVC|O )|O and|O 41|O PET|O .|O 
All|O tumours|O were|O also|O presently|O or|O previously|O analysed|O for|O K|gene-rna -|gene-rna ras|gene-rna and|O p53|gene-rna mutations|O and|O allelic|O loss|O at|O 9p|O ,|O 17p|O and|O 18q|O .|O 
Alterations|O in|O K|gene-rna -|gene-rna ras|gene-rna ,|O p53|gene-rna ,|O p16|gene-rna and|O DPC4|gene-rna were|O found|O in|O 82|O %|O ,|O 53|O %|O ,|O 38|O %|O and|O 9|O %|O of|O PDC|O ,|O respectively|O and|O in|O 47|O %|O ,|O 60|O %|O ,|O 25|O %|O and|O 6|O %|O of|O AVC|O .|O 
Alterations|O in|O these|O genes|gene-rna were|O virtually|O absent|O in|O PET|O ,|O PAC|O or|O SPT|O ,|O while|O in|O IPMT|O only|O K|gene-rna -|gene-rna ras|gene-rna mutations|O were|O present|O (|O 30|O %|O )|O .|O 
Positive|O immunostaining|O confirmed|O the|O absence|O of|O DPC4|gene-rna alterations|O in|O all|O IPMT|O ,|O SPT|O ,|O PAC|O and|O PET|O ,|O while|O 47|O %|O of|O PDC|O and|O 38|O %|O of|O AVC|O were|O immunonegative|O .|O 
These|O data|O suggest|O that|O pancreatic|O exocrine|O and|O endocrine|O tumourigenesis|O involves|O different|O genetic|O targets|O and|O that|O among|O exocrine|O pancreatic|O neoplasms|O ,|O only|O ductal|O and|O ampullary|O cancers|O share|O common|O molecular|O events|O .|O 
Activated|O fibroblast|gene-protein growth|gene-protein factor|gene-protein receptor|gene-rna 3|gene-rna is|O an|O oncogene|O that|O contributes|O to|O tumor|O progression|O in|O multiple|O myeloma|O .|O 
The|O t|O (|O 4|O ;|O 14|O )|O translocation|O occurs|O frequently|O in|O multiple|O myeloma|O (|O MM|O )|O and|O results|O in|O the|O simultaneous|O dysregulated|O expression|O of|O 2|O potential|O oncogenes|O ,|O FGFR3|gene-rna (|O fibroblast|gene-rna growth|gene-rna factor|gene-rna receptor|gene-rna 3|gene-rna )|O from|O der|O (|O 14|O )|O and|O multiple|O myeloma|O SET|gene-protein domain|gene-protein protein|gene-protein /|O Wolf|gene-rna -|gene-rna Hirschhorn|gene-rna syndrome|gene-rna candidate|gene-rna gene|gene-rna 1|gene-rna from|O der|O (|O 4|O )|O .|O 
It|O is|O now|O shown|O that|O myeloma|O cells|O carrying|O a|O t|O (|O 4|O ;|O 14|O )|O translocation|O express|O a|O functional|O FGFR3|gene-rna that|O in|O some|O cases|O is|O constitutively|O activated|O by|O the|O same|O mutations|O that|O cause|O thanatophoric|O dysplasia|O .|O 
As|O with|O activating|O mutations|O of|O K-ras|gene-rna and|O N-ras|gene-rna ,|O which|O are|O reported|O in|O approximately|O 40|O %|O of|O patients|O with|O MM|O ,|O activating|O mutations|O of|O FGFR3|gene-rna occur|O during|O tumor|O progression|O .|O 
However|O ,|O the|O constitutive|O activation|O of|O ras|gene-rna and|O FGFR3|gene-rna does|O not|O occur|O in|O the|O same|O myeloma|O cells|O .|O 
Thus|O the|O activated|O forms|O of|O these|gene-protein proteins|gene-protein appear|O to|O share|O an|O overlapping|O role|O in|O tumor|O progression|O ,|O suggesting|O that|O they|O also|O share|O the|O signaling|O cascade|O .|O 
Consistent|O with|O this|O prediction|O ,|O it|O is|O shown|O that|O activated|O FGFR3|gene-rna -|O when|O expressed|O at|O levels|O similar|O to|O those|O seen|O in|O t|O (|O 4|O ;|O 14|O )|O myeloma|O -|O is|O an|O oncogene|O that|O acts|O through|O the|O MAP|gene-protein kinase|gene-protein pathway|O to|O transform|O NIH|O 3T3|O cells|O ,|O which|O can|O then|O generate|O tumors|O in|O nude|O mice|O .|O 
Thus|O ,|O FGFR3|gene-rna ,|O when|O overexpressed|O in|O MM|O ,|O may|O be|O not|O only|O oncogenic|O when|O stimulated|O by|O FGF|gene-protein ligands|O in|O the|O bone|O marrow|O microenvironment|O ,|O but|O is|O also|O a|O target|O for|O activating|O mutations|O that|O enable|O FGFR3|gene-rna to|O play|O a|O ras|gene-rna -|O like|O role|O in|O tumor|O progression|O .|O 
K-ras|gene-rna oncogene|O mutation|O in|O cancer|O and|O precancerous|O lesions|O of|O the|O gallbladder|O .|O 
BACKGROUND|O AND|O OBJECTIVES|O :|O 
To|O determine|O whether|O K-ras|gene-rna mutation|O plays|O any|O role|O in|O the|O development|O and|O progression|O of|O gallbladder|O cancer|O ,|O or|O has|O any|O clinical|O or|O pathological|O significance|O in|O gallbladder|O cancer|O patients|O ,|O we|O investigated|O the|O presence|O and|O incidence|O of|O this|O mutation|O in|O the|O normal|O mucosa|O ,|O and|O precancerous|O and|O cancerous|O lesions|O of|O the|O gallbladder|O .|O 
METHODS|O :|O 
DNA|O was|O obtained|O from|O normal|O mucosa|O ,|O dysplastic|O mucosa|O ,|O primary|O cancer|O tissues|O ,|O and|O metastatic|O lymph|O nodes|O that|O were|O identified|O and|O microdissected|O from|O the|O paraffin|O blocks|O of|O 20|O gallbladder|O cancer|O cases|O .|O 
K-ras|gene-rna codon|O 12|O mutations|O were|O investigated|O using|O a|O modified|O two|O -|O step|O polymerase|gene-protein chain|O reaction|O and|O the|O restriction|O fragment|O length|O polymorphism|O method|O ,|O and|O by|O direct|O sequencing|O with|O an|O automated|O sequencer|O .|O 
RESULTS|O :|O 
K-ras|gene-rna mutations|O were|O detected|O in|O the|O tissues|O of|O 10|O out|O of|O the|O 20|O patients|O .|O 
A|O mutation|O was|O present|O in|O the|O dysplastic|O epithelium|O associated|O with|O the|O primary|O carcinoma|O in|O 3|O out|O of|O 12|O specimens|O ,|O in|O metastatic|O carcinoma|O in|O 1|O out|O of|O 5|O patients|O ,|O and|O in|O primary|O carcinoma|O in|O 8|O out|O of|O 20|O patients|O .|O 
Mutation|O was|O found|O only|O once|O in|O the|O dysplastic|O ,|O noncancerous|O epithelium|O ,|O and|O only|O once|O in|O a|O metastatic|O tumor|O although|O not|O detectable|O in|O the|O primary|O cancer|O .|O 
Direct|O sequencing|O showed|O that|O the|O mutations|O were|O G|O to|O C|O substitutions|O (|O GGT|O -->|O CGT|O )|O at|O the|O first|O site|O of|O codon|O 12|O ,|O except|O in|O two|O cases|O (|O GGT|O -->|O TGT|O )|O .|O 
There|O were|O no|O correlations|O between|O K-ras|gene-rna mutations|O and|O clinicopathological|O factors|O .|O 
CONCLUSIONS|O :|O 
K-ras|gene-rna mutations|O were|O detected|O in|O half|O of|O the|O gallbladder|O cancer|O cases|O .|O 
We|O suggest|O that|O K-ras|gene-rna mutation|O may|O play|O a|O role|O in|O the|O development|O of|O premalignant|O lesions|O or|O early|O carcinogenesis|O in|O some|O gallbladder|O cancers|O .|O 
We|O were|O unable|O to|O find|O any|O evidence|O that|O K-ras|gene-rna mutation|O plays|O any|O role|O in|O tumor|O progression|O or|O metastasis|O ,|O or|O that|O it|O has|O any|O clinicopathological|O significance|O .|O 
Detection|O and|O analysis|O of|O beta-catenin|gene-rna mutations|O in|O prostate|O cancer|O .|O 
BACKGROUND|O :|O 
E-cadherin|gene-protein and|O alpha-catenin|gene-protein are|O components|O of|O adherens|O junctions|O which|O mediate|O calcium|O -|O dependent|O ,|O cell|O -|O cell|O adhesion|O in|O a|O homotypic|O manner|O .|O 
Both|O these|O molecules|O have|O been|O defined|O as|O useful|O tumor|O markers|O as|O their|O altered|O expression|O correlates|O with|O increased|O tumor|O aggressiveness|O and|O dedifferentiation|O .|O 
More|O recently|O ,|O alterations|O of|O a|O third|O component|O of|O adherens|O junctions|O ,|O beta-catenin|gene-protein ,|O have|O been|O observed|O to|O play|O a|O role|O in|O several|O human|O cancers|O .|O 
Dysregulation|O of|O beta-catenin|gene-protein ,|O either|O by|O direct|O mutation|O or|O by|O defects|O in|O interacting|O pathways|O /|O regulators|O ,|O can|O result|O in|O its|O cytoplasmic|O accumulation|O and|O nuclear|O translocation|O .|O 
In|O the|O nucleus|O ,|O beta-catenin|gene-protein forms|O a|O transcriptional|O complex|O capable|O of|O upregulating|O target|O genes|O ,|O many|O of|O which|O encode|O proliferative|O factors|O .|O 
Given|O its|O oncogenic|O activity|O and|O connection|O to|O human|O cancer|O ,|O we|O examined|O the|O beta-catenin|gene-rna gene|O and|O its|O expression|O in|O prostate|O cancer|O .|O 
METHODS|O :|O 
By|O single|O -|O stranded|O conformational|O polymorphism|O (|O SSCP|O )|O and|O DNA|O sequencing|O analyses|O ,|O we|O screened|O exon|O 3|O of|O beta-catenin|gene-rna from|O a|O panel|O of|O 81|O primary|O tumors|O obtained|O at|O radical|O prostatectomy|O ,|O 22|O lymph|O node|O metastases|O from|O untreated|O patients|O ,|O and|O a|O unique|O set|O of|O 61|O metastatic|O tissues|O from|O 19|O patients|O who|O died|O of|O hormone|O -|O refractory|O disease|O .|O 
RESULTS|O :|O 
We|O found|O putative|O activating|O mutations|O (|O missense|O and|O deletion|O )|O at|O a|O rate|O of|O 5|O %|O (|O 7|O /|O 138|O )|O .|O 
One|O patient|O had|O the|O same|O 72|O base|O pair|O deletion|O in|O each|O of|O nine|O separate|O metastases|O examined|O ,|O indicating|O that|O this|O change|O was|O associated|O with|O a|O clonal|O population|O of|O metastatic|O cells|O .|O 
CONCLUSIONS|O :|O 
Immunohistological|O staining|O of|O mutation|O -|O positive|O tumors|O demonstrated|O beta-catenin|gene-protein accumulation|O and|O nuclear|O localization|O in|O a|O heterogeneous|O fashion|O .|O 
Consistent|O with|O this|O in|O vivo|O finding|O ,|O our|O in|O vitro|O analyses|O demonstrate|O that|O certain|O mutations|O can|O result|O in|O increased|O beta-catenin|gene-protein nuclear|O activity|O in|O prostate|O cancer|O cell|O lines|O .|O 
These|O data|O implicate|O the|O beta-catenin|gene-protein signaling|O pathway|O in|O the|O development|O of|O a|O subset|O of|O prostate|O cancers|O .|O 
K-ras|gene-rna and|O p53|gene-rna in|O pancreatic|O cancer|O :|O association|O with|O medical|O history|O ,|O histopathology|O ,|O and|O environmental|O exposures|O in|O a|O population|O -|O based|O study|O .|O 
Pancreatic|O cancer|O is|O a|O highly|O fatal|O cancer|O with|O few|O identified|O risk|O factors|O .|O 
Increased|O risk|O of|O pancreatic|O cancer|O in|O tobacco|O smokers|O and|O among|O diabetic|O patients|O is|O well|O established|O ,|O and|O some|O reports|O have|O suggested|O associations|O with|O coffee|O consumption|O and|O occupational|O exposure|O to|O organochlorines|O .|O 
At|O present|O ,|O there|O is|O little|O information|O regarding|O the|O possible|O association|O of|O these|O risk|O factors|O with|O the|O known|O genetic|O alterations|O found|O in|O pancreatic|O cancers|O ,|O such|O as|O activation|O of|O the|O K-ras|gene-rna oncogene|O and|O inactivation|O of|O the|O p53|gene-rna tumor|O suppressor|O gene|O .|O 
Knowledge|O of|O such|O relationships|O may|O help|O to|O understand|O the|O molecular|O pathways|O of|O pancreatic|O tumorigenesis|O .|O 
We|O investigated|O the|O association|O between|O these|O molecular|O defects|O and|O risk|O factors|O for|O pancreatic|O cancer|O in|O 61|O newly|O diagnosed|O patients|O identified|O through|O an|O ongoing|O study|O of|O pancreatic|O cancer|O in|O the|O San|O Francisco|O Bay|O Area|O .|O 
Interview|O information|O was|O obtained|O regarding|O environmental|O exposures|O ,|O medical|O history|O ,|O and|O demographic|O factors|O .|O 
Serum|O levels|O of|O dichlorodiphenyltrichloroethylene|O (|O DDE|O )|O and|O polychlorinated|O biphenyls|O were|O available|O on|O a|O subset|O of|O 24|O patients|O .|O 
Tumor|O blocks|O were|O located|O from|O local|O hospitals|O and|O used|O for|O K-ras|gene-rna mutational|O analysis|O at|O codon|O 12|O and|O for|O p53|gene-protein protein|O immunohistochemistry|O .|O 
The|O molecular|O analyses|O were|O facilitated|O through|O the|O use|O of|O laser|O capture|O microdissection|O ,|O which|O provides|O a|O reliable|O method|O to|O obtain|O almost|O pure|O populations|O of|O tumor|O cells|O .|O 
Mutations|O in|O K-ras|gene-rna codon|O 12|O were|O found|O in|O 46|O (|O 75|O %|O )|O of|O 61|O pancreatic|O cancers|O .|O 
A|O prior|O diagnosis|O of|O diabetes|O was|O significantly|O associated|O with|O K-ras|gene-rna negative|O tumors|O (|O P|O =|O 0.002|O ,|O Fisher|O 's|O exact|O test|O )|O .|O 
The|O absence|O of|O this|O mutation|O was|O also|O associated|O with|O increased|O serum|O levels|O of|O DDE|O ,|O although|O this|O association|O was|O not|O statistically|O significant|O (|O P|O =|O 0.16|O ,|O Wilcoxon|O 's|O test|O )|O .|O 
There|O was|O no|O difference|O in|O polychlorinated|O biphenyl|O levels|O between|O the|O K-ras|gene-rna wild|O -|O type|O and|O mutant|O groups|O .|O 
Immunohistochemical|O staining|O for|O p53|gene-protein protein|O did|O not|O differ|O by|O patient|O characteristics|O or|O clinical|O history|O ,|O but|O significant|O associations|O were|O found|O with|O poor|O glandular|O differentiation|O (|O P|O =|O 0.002|O ,|O chi2|O trend|O test|O )|O ,|O severe|O nuclear|O atypia|O (|O P|O =|O 0.0007|O ,|O chi2|O trend|O test|O )|O ,|O and|O high|O tumor|O grade|O (|O P|O =|O 0.004|O ,|O chi2|O trend|O test|O )|O .|O 
Our|O results|O are|O suggestive|O of|O the|O presence|O of|O K-ras|gene-rna codon|O 12|O mutation|O -|O independent|O tumorigenesis|O pathways|O in|O patients|O with|O prior|O diabetes|O and|O possibly|O in|O patients|O with|O higher|O serum|O levels|O of|O DDE|O .|O 
Our|O results|O also|O support|O a|O role|O for|O the|O p53|gene-protein tumor|O suppressor|O protein|O in|O the|O maintenance|O of|O genomic|O integrity|O .|O 
Prognostic|O value|O of|O the|O preserved|O expression|O of|O the|O E-cadherin|gene-protein and|O catenin|gene-protein families|O of|O adhesion|O molecules|O and|O of|O beta-catenin|gene-rna mutations|O in|O synovial|O sarcoma|O .|O 
This|O study|O addresses|O the|O immunohistochemical|O expression|O of|O the|O E-cadherin|gene-protein and|O catenin|gene-protein families|O and|O mutations|O of|O the|O beta-catenin|gene-rna gene|O detected|O by|O PCR|O -|O SSCP|O in|O synovial|O sarcoma|O .|O 
Immunohistochemical|O analysis|O was|O performed|O for|O 72|O cases|O ,|O with|O follow|O -|O up|O data|O available|O on|O 62|O .|O 
The|O prognostic|O value|O of|O the|O expression|O of|O these|O proteins|gene-protein was|O evaluated|O .|O 
Reduced|O immunoreactivity|O for|O E-cadherin|gene-protein and|O alpha-catenin|gene-protein was|O significantly|O correlated|O with|O a|O poor|O survival|O rate|O (|O p|O =|O 0.0040|O and|O 0.0053|O ,|O respectively|O )|O .|O 
According|O to|O multivariate|O analysis|O ,|O low|O AJC|O stage|O (|O stages|O I|O and|O II|O :|O p|O <|O 0.0001|O )|O ,|O the|O preservation|O of|O alpha-catenin|gene-protein expression|O (|O p|O =|O 0.0001|O )|O ,|O and|O a|O low|O necrotic|O rate|O (|O <|O 50|O %|O :|O p|O =|O 0.0139|O )|O were|O independent|O favourable|O prognostic|O factors|O .|O 
Widespread|O aberrant|O staining|O of|O beta-catenin|gene-protein protein|O within|O cytoplasm|O and/or|O nuclei|O was|O observed|O in|O 28|O cases|O (|O 38.9|O %|O )|O and|O was|O significantly|O correlated|O with|O poor|O survival|O (|O p|O =|O 0.0122|O )|O .|O 
In|O addition|O ,|O there|O was|O a|O trend|O towards|O a|O correlation|O between|O widespread|O aberrant|O staining|O of|O beta-catenin|gene-protein and|O the|O MIB-1|O labelling|O index|O (|O p|O =|O 0.0535|O )|O .|O 
Mutational|O analysis|O of|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O was|O performed|O for|O 49|O cases|O .|O 
Nucleotide|O sequencing|O analysis|O revealed|O that|O four|O (|O 8.2|O %|O )|O contained|O point|O mutations|O (|O three|O in|O codon|O 32|O ,|O GAC|O to|O TAC|O ;|O one|O in|O codon|O 37|O ,|O TCT|O to|O TTT|O )|O .|O 
Survival|O data|O were|O available|O for|O three|O out|O of|O four|O cases|O with|O beta-catenin|gene-rna mutations|O ;|O two|O of|O these|O patients|O died|O within|O 1|O year|O (|O died|O of|O disease|O at|O 6|O and|O 11|O months|O ,|O respectively|O )|O .|O 
These|O results|O suggest|O that|O E-cadherin|gene-protein and|O alpha-catenin|gene-protein undertake|O important|O roles|O as|O intercellular|O adhesion|O molecules|O ;|O their|O preserved|O expression|O is|O associated|O with|O a|O better|O overall|O survival|O rate|O in|O synovial|O sarcoma|O and|O may|O have|O prognostic|O value|O .|O 
Abnormal|O levels|O of|O beta-catenin|gene-protein ,|O with|O or|O without|O mutation|O ,|O could|O contribute|O to|O the|O development|O and|O progression|O of|O synovial|O sarcoma|O ,|O through|O increasing|O the|O proliferative|O activity|O of|O the|O tumour|O cells|O .|O 
Beta-catenin|gene-protein in|O soft|O tissue|O sarcomas|O :|O expression|O is|O related|O to|O proliferative|O activity|O in|O high|O -|O grade|O sarcomas|O .|O 
Besides|O its|O role|O in|O cell|O adhesion|O ,|O beta-catenin|gene-protein exerts|O a|O function|O as|O an|O oncoprotein|gene-protein .|O 
The|O aim|O of|O this|O study|O was|O the|O characterization|O of|O its|O expression|O ,|O possible|O mutation|O ,|O and|O the|O assessment|O of|O beta-catenin|gene-protein as|O a|O prognostic|O indicator|O for|O soft|O tissue|O sarcomas|O .|O 
A|O total|O of|O 115|O soft|O tissue|O sarcomas|O were|O analyzed|O using|O immunohistochemistry|O ,|O immunogold|O -|O electron|O microscopy|O ,|O and|O DNA|O analysis|O .|O 
Information|O from|O 56|O patients|O was|O available|O for|O follow|O -|O up|O .|O 
A|O statistically|O significant|O correlation|O was|O found|O between|O intracellular|O distribution|O of|O beta-catenin|gene-protein and|O the|O proliferative|O activity|O (|O MIB-1|gene-rna expression|O )|O in|O high|O -|O grade|O sarcomas|O (|O P|O =|O .0008|O )|O .|O 
Beta-catenin|gene-protein was|O identified|O with|O intracytoplasmic|O and|O nuclear|O accumulation|O ,|O showing|O additional|O membranous|O staining|O in|O sarcomas|O with|O epithelioid|O pattern|O .|O 
Ultrastructurally|O ,|O a|O colocalization|O between|O beta-catenin|gene-protein and|O nuclear|O heterochromatin|O was|O demonstrated|O .|O 
In|O 22|O analyzed|O tumors|O ,|O only|O one|O (|O yet|O undescribed|O )|O mutation|O of|O the|O beta-catenin|gene-rna gene|O (|O C|O -|O A|O transversion|O )|O could|O be|O detected|O .|O 
Prognostic|O validity|O of|O the|O cellular|O expression|O of|O beta-catenin|gene-protein ,|O however|O ,|O was|O not|O proven|O .|O 
Apart|O from|O its|O membranous|O function|O as|O an|O effective|O molecule|O for|O cell|O -|O adhesion|O in|O sarcomas|O with|O epithelioid|O pattern|O ,|O beta-catenin|gene-protein may|O act|O as|O an|O oncoprotein|gene-protein in|O sarcomas|O with|O intracytoplasmic|O and|O nuclear|O localization|O with|O binding|O to|O nuclear|O DNA|O .|O 
A|O previously|O discussed|O stimulation|O of|O cell|O proliferation|O caused|O by|O an|O increased|O beta-catenin|gene-protein level|O can|O also|O be|O postulated|O for|O high|O -|O grade|O soft|O tissue|O sarcomas|O in|O correlation|O with|O the|O rate|O of|O proliferation|O .|O 
Mutations|O of|O the|O beta-catenin|gene-rna gene|O are|O probably|O of|O lesser|O importance|O for|O the|O accumulation|O of|O beta-catenin|gene-protein in|O soft|O tissue|O sarcomas|O .|O 
Gastrointestinal|O stromal|O tumor|O of|O the|O rectum|O with|O activating|O mutation|O of|O c-kit|gene-rna :|O report|O of|O a|O case|O .|O 
Nonepithelial|O malignancies|O of|O the|O large|O bowel|O are|O rare|O .|O 
A|O new|O disease|O entity|O ,|O gastrointestinal|O stromal|O tumors|O ,|O has|O attracted|O attention|O among|O primary|O mesenchymal|O tumors|O of|O the|O gastrointestinal|O tract|O .|O 
Here|O we|O present|O a|O case|O of|O spindle|O -|O cell|O sarcoma|O of|O the|O rectum|O ,|O lacking|O either|O smooth|O muscle|O cells|O or|O neural|O elements|O .|O 
Immunohistochemical|O findings|O and|O sequencing|O of|O the|O c-kit|gene-rna proto|O -|O oncogene|O diagnosed|O this|O tumor|O as|O a|O malignant|O gastrointestinal|O stromal|O tumor|O of|O the|O rectum|O .|O 
Significance|O of|O K-ras|gene-rna mutation|O and|O CEA|gene-protein level|O in|O pancreatic|O juice|O in|O the|O diagnosis|O of|O pancreatic|O cancer|O .|O 
The|O early|O diagnosis|O of|O pancreatic|O carcinoma|O is|O essential|O for|O increasing|O patient|O survival|O rates|O .|O 
In|O this|O study|O ,|O 52|O patients|O with|O suspected|O pancreatic|O diseases|O were|O examined|O to|O investigate|O the|O value|O of|O K-ras|gene-rna codon|O 12|O point|O mutation|O ,|O levels|O of|O carcinoembryonic|gene-protein antigen|gene-protein (|O CEA|gene-protein )|O and|O carbohydrate|gene-protein antigen|gene-protein (|O CA19-9|gene-protein )|O ,|O and|O cytology|O of|O pancreatic|O juice|O in|O the|O diagnosis|O of|O pancreatic|O carcinoma|O .|O 
Pancreatic|O juice|O was|O taken|O without|O secretin|gene-protein stimulation|O .|O 
K-ras|gene-rna mutation|O was|O detected|O by|O enriched|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O restriction|O fragment|O length|O polymorphism|O (|O RFLP|O )|O .|O 
K-ras|gene-rna mutation|O in|O pancreatic|O juice|O was|O more|O frequent|O in|O carcinoma|O than|O in|O benign|O diseases|O (|O P|O =|O 0.0448|O )|O .|O 
The|O positive|O predictive|O value|O of|O K-ras|gene-rna mutation|O for|O the|O diagnosis|O of|O neoplastic|O disease|O was|O 83|O %|O .|O 
The|O CEA|gene-protein level|O in|O pancreatic|O juice|O in|O carcinoma|O was|O significantly|O greater|O than|O that|O in|O benign|O disease|O (|O P|O <|O 0.0001|O )|O .|O 
When|O the|O cutoff|O level|O of|O CEA|gene-protein was|O set|O at|O 50|O ng|O /|O ml|O ,|O its|O accuracy|O for|O the|O diagnosis|O of|O carcinoma|O was|O 85|O %|O .|O 
A|O multivariate|O analysis|O showed|O that|O K-ras|gene-rna mutation|O and|O CEA|gene-protein level|O in|O pancreatic|O juice|O ,|O as|O well|O as|O serum|O CA19-9|gene-protein level|O and|O age|O of|O the|O patient|O were|O independent|O variables|O for|O the|O diagnosis|O of|O carcinoma|O ,|O and|O the|O accuracy|O of|O diagnosis|O by|O this|O analysis|O was|O increased|O to|O 90|O %|O .|O 
In|O conclusion|O ,|O both|O K-ras|gene-rna mutation|O and|O CEA|gene-protein level|O in|O pancreatic|O juice|O may|O be|O valuable|O for|O the|O diagnosis|O of|O carcinoma|O .|O 
Better|O discrimination|O was|O possible|O with|O a|O multivariate|O analysis|O .|O 
Mutations|O and|O copy|O number|O increase|O of|O HRAS|gene-rna in|O Spitz|O nevi|O with|O distinctive|O histopathological|O features|O .|O 
Spitz|O nevus|O is|O a|O benign|O melanocytic|O neoplasm|O that|O can|O be|O difficult|O or|O impossible|O to|O histologically|O distinguish|O from|O melanoma|O .|O 
We|O have|O recently|O described|O copy|O number|O increases|O of|O chromosome|O 11p|O in|O a|O subset|O of|O Spitz|O nevi|O .|O 
To|O study|O the|O molecular|O and|O histological|O features|O of|O this|O group|O ,|O we|O studied|O 102|O Spitz|O nevi|O for|O 11p|O copy|O number|O increases|O using|O fluorescence|O in|O situ|O hybridization|O (|O FISH|O )|O on|O tissue|O arrays|O .|O 
Copy|O number|O increases|O of|O at|O least|O threefold|O were|O found|O in|O 12|O cases|O (|O 11.8|O %|O )|O and|O involved|O the|O HRAS|gene-rna gene|O on|O chromosome|O 11p|O .|O 
Sequence|O analysis|O of|O HRAS|gene-rna showed|O frequent|O oncogenic|O mutations|O in|O cases|O with|O copy|O number|O increase|O (|O 8|O /|O 12|O or|O 67|O %|O )|O ,|O contrasting|O with|O rare|O HRAS|gene-rna mutations|O in|O cases|O with|O normal|O HRAS|gene-rna copy|O numbers|O (|O 1|O /|O 21|O or|O 5|O %|O ,|O P|O :|O <|O 0.0001|O )|O .|O 
Tumors|O with|O 11p|O copy|O number|O increases|O were|O larger|O ,|O predominantly|O intradermal|O ,|O had|O marked|O desmoplasia|O ,|O characteristic|O cytological|O features|O ,|O and|O had|O an|O infiltrating|O growth|O pattern|O .|O 
Proliferation|O rates|O in|O the|O majority|O of|O these|O cases|O were|O low|O to|O absent|O .|O 
HRAS|gene-rna activation|O by|O either|O mutation|O or|O copy|O number|O increase|O alone|O could|O explain|O several|O of|O the|O histological|O features|O that|O overlap|O with|O those|O of|O melanoma|O .|O 
We|O speculate|O that|O HRAS|gene-rna activation|O in|O the|O absence|O of|O co|O -|O operating|O additional|O genetic|O alterations|O drives|O the|O partially|O transformed|O melanocytes|O of|O these|O Spitz|O nevi|O into|O senescence|O or|O a|O stable|O growth|O arrest|O .|O 
Although|O there|O is|O no|O data|O suggesting|O that|O Spitz|O nevi|O with|O HRAS|gene-rna activation|O are|O at|O risk|O for|O progression|O to|O melanoma|O ,|O future|O studies|O are|O warranted|O to|O assess|O their|O biological|O behavior|O more|O accurately|O .|O 
Reassessment|O of|O K-ras|gene-rna mutations|O at|O codon|O 12|O by|O direct|O PCR|O and|O sequencing|O from|O tissue|O microdissection|O in|O human|O pancreatic|O adenocarcinomas|O .|O 
K-ras|gene-rna mutations|O at|O codon|O 12|O have|O been|O detected|O in|O almost|O all|O pancreatic|O adenocarcinomas|O by|O highly|O sensitive|O assays|O .|O 
We|O reassessed|O the|O K-ras|gene-rna mutation|O status|O by|O direct|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O and|O sequencing|O from|O tissue|O microdissection|O without|O DNA|O extraction|O in|O 10|O pancreatic|O adenocarcinomas|O ,|O and|O also|O assessed|O the|O K-ras|gene-rna and|O DPC4|gene-rna genes|O in|O nine|O pancreatic|O cancer|O cell|O lines|O .|O 
Eight|O pancreatic|O adenocarcinomas|O were|O found|O to|O harbor|O K-ras|gene-rna mutations|O at|O codon|O 12|O of|O either|O GTT|O or|O GAT|O ,|O five|O of|O which|O were|O inferred|O to|O harbor|O amplified|O mutant|O alleles|O .|O 
Mutations|O at|O the|O sites|O other|O than|O codon|O 12|O were|O found|O in|O seven|O of|O 70|O clones|O (|O seven|O of|O 9,380|O bases|O )|O by|O the|O TA|O cloning|O analysis|O ,|O suggesting|O that|O artifactual|O mutations|O at|O the|O first|O or|O second|O base|O of|O codon|O 12|O before|O and|O during|O PCR|O could|O occur|O at|O a|O frequency|O of|O approximately|O 10(-3)|O ,|O enough|O for|O highly|O sensitive|O assays|O to|O detect|O .|O 
Two|O cell|O lines|O without|O K-ras|gene-rna mutations|O at|O codon|O 12|O were|O found|O to|O have|O homozygous|O deletions|O at|O the|O DPC4|gene-rna gene|O .|O 
Thus|O the|O K-ras|gene-rna mutation|O status|O was|O demonstrated|O to|O be|O correctly|O determined|O by|O just|O direct|O sequencing|O from|O tissue|O microdissection|O .|O 
All|O possible|O mutations|O or|O multiple|O mutations|O at|O K-ras|gene-rna codon|O 12|O that|O have|O been|O reported|O in|O pancreatic|O adenocarcinomas|O might|O include|O artifacts|O or|O mutations|O without|O a|O selective|O advantage|O .|O 
In|O addition|O ,|O we|O must|O be|O very|O cautious|O about|O contamination|O .|O 
Detection|O of|O K-ras|gene-rna and|O p53|gene-rna mutations|O in|O bronchoscopically|O obtained|O malignant|O and|O non|O -|O malignant|O tissue|O from|O patients|O with|O non|O -|O small|O cell|O lung|O cancer|O .|O 
Molecular|O screening|O may|O increase|O the|O likelihood|O to|O identify|O early|O malignant|O lesions|O in|O non|O -|O small|O cell|O lung|O cancer|O .|O 
However|O the|O presence|O of|O gene|O mutations|O in|O non|O -|O malignant|O bronchial|O tissue|O has|O remained|O controversial|O .|O 
The|O present|O study|O was|O carried|O out|O to|O investigate|O systematically|O the|O presence|O of|O mutations|O of|O the|O K-ras|gene-rna and|O p53|gene-rna gene|O in|O bronchial|O biopsies|O taken|O during|O routine|O bronchoscopy|O of|O normal|O as|O well|O as|O tumour|O tissues|O from|O a|O series|O of|O 40|O patients|O with|O histologically|O verified|O non|O -|O small|O cell|O lung|O cancer|O (|O NSCLC|O )|O .|O 
K-ras|gene-rna mutations|O were|O analysed|O with|O specific|O detection|O oligonucleotides|O ,|O p53|gene-rna mutations|O were|O examined|O by|O SSCP|O analysis|O .|O 
In|O all|O biopsies|O the|O wildtype|O of|O both|O K-ras|gene-rna and|O p53|gene-rna could|O be|O detected|O .|O 
The|O overall|O frequency|O of|O mutations|O was|O 14|O (|O 35|O %|O )|O with|O 2|O K-ras|gene-rna mutations|O (|O 5|O %|O )|O and|O 12|O mutations|O of|O the|O p53|gene-rna gene|O (|O 30|O %|O )|O .|O 
In|O 3|O cases|O (|O 1|O ras|gene-rna mutation|O ,|O 2|O p53|gene-rna mutations|O )|O the|O same|O mutation|O could|O be|O shown|O in|O the|O tumour|O biopsy|O and|O in|O the|O distant|O normal|O control|O .|O 
In|O another|O case|O only|O the|O normal|O appearing|O tissue|O had|O a|O mutation|O of|O the|O p53|gene-rna gene|O .|O 
All|O other|O mutations|O could|O be|O detected|O in|O the|O tumour|O tissue|O only|O .|O 
Our|O data|O confirm|O that|O K-ras|gene-rna mutations|O and|O p53|gene-rna can|O be|O detected|O not|O only|O in|O malignant|O but|O also|O in|O non|O -|O malignant|O bioptic|O samples|O from|O patients|O with|O NSCLC|O .|O 
The|O use|O of|O molecular|O screening|O for|O the|O early|O detection|O of|O lung|O cancer|O may|O be|O a|O promising|O new|O approach|O .|O 
Molecular|O and|O biological|O analysis|O of|O carcinoma|O of|O the|O small|O intestine|O :|O beta-catenin|gene-rna gene|O mutation|O by|O interstitial|O deletion|O involving|O exon|O 3|O and|O replication|O error|O phenotype|O .|O 
The|O genetic|O mechanisms|O of|O carcinomas|O of|O the|O small|O intestine|O are|O not|O well|O understood|O .|O 
We|O report|O the|O results|O of|O analysis|O of|O genetic|O alterations|O in|O a|O case|O of|O small|O intestinal|O carcinoma|O .|O 
A|O tumor|O in|O the|O terminal|O ileum|O was|O resected|O in|O a|O 59|O -|O yr|O -|O old|O woman|O .|O 
Histologically|O ,|O the|O tumor|O was|O classified|O as|O well|O -|O differentiated|O adenocarcinoma|O .|O 
We|O screened|O for|O genetic|O alterations|O in|O adenomatous|gene-rna polyposis|gene-rna coli|gene-rna (|O APC|gene-rna )|O ,|O beta-catenin|gene-rna ,|O K-ras|gene-rna ,|O and|O p53|gene-rna genes|O ,|O as|O well|O as|O microsatellite|O instability|O ,|O which|O are|O known|O to|O be|O involved|O in|O colorectal|O tumorigenesis|O .|O 
The|O tumor|O exhibited|O somatic|O interstitial|O deletion|O of|O 425-bp|O ,|O which|O included|O the|O entire|O exon|O 3|O in|O beta-catenin|gene-rna gene|O .|O 
Immunohistochemical|O staining|O confirmed|O accumulation|O of|O aberrant|O beta-catenin|gene-protein protein|O in|O the|O cytoplasm|O and|O nuclei|O of|O the|O malignant|O tissue|O .|O 
Furthermore|O ,|O a|O frameshift|O mutation|O in|O the|O transforming|O growth|gene-rna factor|gene-rna beta|gene-rna receptor|gene-rna type|gene-rna II|gene-rna gene|O with|O replication|O error|O phenotype|O was|O detected|O in|O the|O tumor|O DNA|O .|O 
In|O contrast|O ,|O no|O genetic|O alterations|O were|O found|O in|O the|O APC|gene-rna ,|O K-ras|gene-rna ,|O and|O p53|gene-rna genes|O .|O 
Our|O results|O suggested|O that|O both|O beta-catenin|gene-rna gene|O mutation|O and|O replication|O error|O phenotype|O might|O contribute|O to|O carcinogenesis|O of|O the|O small|O intestinal|O tumor|O in|O our|O case|O .|O 
This|O is|O the|O first|O report|O that|O activation|O of|O beta-catenin|gene-rna gene|O by|O somatic|O gene|O mutation|O is|O involved|O in|O the|O development|O of|O carcinoma|O of|O the|O small|O intestine|O .|O 
Mutation|O of|O the|O SRC|gene-rna gene|O in|O endometrial|O carcinoma|O .|O 
Recently|O ,|O an|O activating|O mutation|O of|O the|O SRC|gene-rna gene|O has|O been|O implicated|O in|O about|O one-tenth|O of|O advanced|O colon|O cancers|O .|O 
The|O SRC|gene-rna 531|O mutation|O results|O in|O truncation|O of|O SRC|gene-rna directly|O C|O -|O terminal|O to|O the|O regulatory|O Tyr|O 530|O and|O appears|O to|O activate|O the|O Tyr|O 530|O .|O 
To|O investigate|O whether|O mutation|O of|O SRC|gene-rna plays|O an|O important|O role|O in|O the|O development|O and|O progression|O of|O gynecological|O tumors|O ,|O we|O performed|O mutational|O analysis|O of|O the|O entire|O coding|O region|O of|O SRC|gene-rna in|O 70|O ovarian|O carcinomas|O ,|O 68|O endometrial|O carcinomas|O and|O 3|O endometrial|O stromal|O sarcomas|O by|O means|O of|O polymerase|gene-protein chain|O reaction|O -|O single|O strand|O conformation|O polymorphism|O (|O PCR|O -|O SSCP|O )|O followed|O by|O nucleotide|O sequencing|O and|O restriction|O fragment|O length|O polymorphism|O (|O RFLP|O )|O analysis|O .|O 
We|O found|O one|O truncated|O mutation|O at|O codon|O 531|O (|O Gln|O to|O Stop|O )|O in|O an|O endometrial|O carcinoma|O .|O 
However|O ,|O we|O found|O no|O mutation|O of|O this|O gene|gene-rna in|O ovarian|O carcinoma|O or|O endometrial|O stromal|O sarcoma|O .|O 
Our|O results|O suggest|O that|O mutation|O of|O SRC|gene-rna may|O be|O implicated|O in|O a|O small|O proportion|O of|O endometrial|O carcinomas|O .|O 
Mastocytosis|O cells|O bearing|O a|O c-kit|gene-rna activating|O point|O mutation|O are|O characterized|O by|O hypersensitivity|O to|O stem|gene-protein cell|gene-protein factor|gene-protein and|O increased|O apoptosis|O .|O 
Mastocytosis|O is|O characterized|O by|O abnormal|O infiltration|O of|O mast|O cells|O into|O various|O organs|O .|O 
An|O activating|O mutation|O in|O c-kit|gene-rna ,|O involving|O an|O A|O -->|O T|O substitution|O at|O nucleotide|O 2648|O has|O recently|O been|O described|O in|O some|O patients|O with|O mastocytosis|O .|O 
We|O describe|O a|O 12|O -|O year|O -|O old|O girl|O with|O this|O mutation|O in|O her|O bone|O marrow|O cells|O at|O diagnosis|O with|O a|O myelodysplastic|O syndrome|O (|O MDS|O )|O without|O evidence|O of|O mastocytosis|O ,|O and|O then|O in|O peripheral|O blood|O mononuclear|O cells|O 1|O year|O later|O after|O the|O emergence|O of|O mastocytosis|O .|O 
The|O role|O of|O the|O c-Kit|gene-protein receptor|gene-protein and|O its|O ligand|O stem|gene-protein cell|gene-protein factor|gene-protein (|O SCF|gene-protein )|O in|O the|O pathogenesis|O of|O the|O disease|O was|O analysed|O in|O marrow|O cell|O clonogenic|O assays|O .|O 
We|O show|O that|O the|O genetic|O abnormalities|O in|O the|O patient|O resulted|O in|O factor|O -|O independent|O growth|O and|O hypersensitivity|O of|O primitive|O progenitors|O to|O SCF|gene-protein ,|O with|O increased|O production|O of|O mast|O cells|O .|O 
Increased|O apoptosis|O and|O cluster|O formation|O ,|O consistent|O with|O the|O myelodysplastic|O nature|O of|O the|O disorder|O ,|O accompanied|O accumulation|O of|O abnormal|O cells|O with|O increasing|O concentrations|O of|O SCF|gene-protein .|O 
Nonfunctioning|O islet|O cell|O carcinoma|O of|O the|O pancreas|O with|O high|O serum|gene-protein CEA|gene-protein &|O CA19-9|gene-protein ,|O K-ras|gene-rna codon|O 12|O mutation|O ,|O and|O microsatellite|O instability|O .|O 
A|O 55|O -|O year|O -|O old|O man|O with|O nonfunctioning|O islet|O cell|O carcinoma|O showing|O elevation|O of|O serum|gene-protein carcinoembryonic|gene-protein antigen|gene-protein (|O CEA|gene-protein )|O and|O carbohydrate|gene-protein antigen|gene-protein 19-9|gene-protein (|O CA19-9|gene-protein )|O levels|O is|O described|O with|O genetic|O analyses|O .|O 
Pathological|O examination|O of|O the|O resected|O specimen|O revealed|O two|O independent|O islet|O cell|O carcinomas|O ,|O one|O in|O the|O body|O and|O the|O other|O in|O the|O tail|O of|O the|O pancreas|O .|O 
It|O was|O proved|O immunohistochemically|O that|O the|O tumor|O cells|O ,|O particularly|O those|O in|O the|O tail|O ,|O were|O immunoreactive|O to|O CEA|gene-protein and|O CA|gene-protein 19-9|gene-protein and|O had|O the|O property|O of|O duct|O cells|O ,|O as|O well|O as|O endocrine|O cells|O .|O 
Gastrin|gene-protein was|O demonstrated|O immunohistochemically|O in|O these|O tumor|O cells|O ,|O although|O its|O level|O in|O serum|O was|O not|O elevated|O .|O 
Genetic|O analyses|O of|O the|O fresh|O specimens|O from|O the|O tumor|O in|O the|O body|O revealed|O K-ras|gene-rna codon|O 12|O mutation|O and|O microsatellite|O instability|O .|O 
These|O findings|O are|O consistent|O with|O its|O progressive|O clinical|O course|O and|O strongly|O suggest|O that|O these|O tumors|O originate|O ,|O not|O from|O the|O islet|O cells|O of|O Langerhans|O ,|O but|O from|O protodifferentiated|O cells|O ,|O capable|O of|O giving|O rise|O to|O all|O the|O pancreatic|O cell|O types|O .|O 
Prognostic|O role|O of|O K-ras|gene-rna in|O patients|O with|O progressive|O colon|O cancer|O who|O received|O treatment|O with|O Marimastat|O (|O BB2516|O )|O .|O 
We|O determined|O the|O prognostic|O role|O of|O K-ras|gene-rna mutation|O in|O tumor|O tissue|O of|O patients|O with|O refractory|O colon|O cancer|O who|O received|O Marimastat|O (|O BB2516|O )|O .|O 
DNA|O was|O extracted|O from|O paraffin|O -|O stored|O tumor|O tissue|O of|O 27|O patients|O who|O previously|O failed|O 5-fluorouracil|O and|O were|O treated|O with|O BB2516|O .|O 
The|O presence|O of|O K-ras|gene-rna mutation|O was|O characterized|O by|O Polymerase|gene-protein Chain|O Reaction|O using|O ras|gene-rna -|O and|O p53|gene-rna -|O specific|O primers|O .|O 
ras|gene-protein and|O p53|gene-protein oncoprotein|O expression|O was|O analyzed|O by|O an|O automated|O biotin|O -|O avidin|gene-protein immunoproxidase|O technique|O .|O 
Seventeen|O patients|O had|O a|O normal|O K-ras|gene-rna sequence|O and|O 10|O patients|O had|O a|O K-ras|gene-rna mutation|O .|O 
Median|O survival|O of|O patients|O with|O a|O normal|O ras|gene-rna sequence|O was|O 330|O days|O from|O the|O time|O of|O BB2516|O treatment|O compared|O with|O 160|O days|O for|O patients|O with|O a|O K-ras|gene-rna mutation|O (|O p|O =|O 0.0442|O ,|O Wilcoxon|O ;|O 0.0130|O Log|O -|O Rank|O )|O .|O 
No|O differences|O in|O age|O ,|O sex|O ,|O cancer|O stage|O ,|O surgical|O treatment|O ,|O or|O chemotherapy|O treatment|O were|O observed|O .|O 
Abnormalities|O involving|O ras|gene-rna expression|O did|O not|O affect|O survival|O .|O 
By|O comparison|O ,|O median|O survival|O for|O patients|O with|O p53|gene-rna mutation|O or|O p53|gene-rna overexpression|O was|O both|O 158|O days|O after|O BB2516|O treatment|O .|O 
Patients|O having|O both|O K-ras|gene-rna and|O p53|gene-rna mutations|O had|O the|O poorest|O median|O survival|O of|O 113|O days|O (|O p|O =|O 0.035|O )|O .|O 
There|O is|O a|O suggestion|O by|O univariate|O analysis|O that|O the|O presence|O of|O a|O K-ras|gene-rna mutation|O may|O predict|O survival|O in|O patients|O with|O progressive|O colon|O cancer|O .|O 
Further|O assessment|O with|O larger|O patient|O numbers|O and|O multivariate|O analysis|O is|O indicated|O .|O 
Somatic|O mutations|O of|O the|O MET|gene-rna oncogene|O are|O selected|O during|O metastatic|O spread|O of|O human|O HNSC|O carcinomas|O .|O 
A|O metastatic|O cancer|O develops|O by|O accumulation|O of|O mutations|O in|O genes|O that|O control|O growth|O ,|O survival|O and|O spreading|O .|O 
The|O latter|O genes|O have|O not|O yet|O been|O identified|O .|O 
In|O lymph|O node|O metastases|O of|O head|O and|O neck|O squamous|O cell|O carcinomas|O (|O HNSCC|O )|O ,|O we|O found|O mutations|O in|O the|O MET|gene-rna oncogene|O ,|O which|O encodes|O the|O tyrosine|gene-protein kinase|gene-protein receptor|gene-protein for|O Scatter|gene-protein Factor|gene-protein ,|O a|O cytokine|O that|O stimulates|O epithelial|O cell|O motility|O and|O invasiveness|O during|O embryogenesis|O and|O tissue|O remodeling|O .|O 
We|O identified|O two|O somatic|O mutations|O :|O the|O Y|O 1230|O C|O ,|O known|O as|O a|O MET|gene-rna germline|O mutation|O which|O predisposes|O to|O hereditary|O renal|O cell|O carcinoma|O ,|O and|O the|O Y|O 1235|O D|O that|O is|O novel|O and|O changes|O a|O critical|O tyrosine|O ,|O known|O to|O regulate|O MET|gene-rna kinase|gene-protein activity|O .|O 
The|O mutated|O MET|gene-protein receptors|gene-protein are|O constitutively|O active|O and|O confer|O an|O invasive|O phenotype|O to|O transfected|O cells|O .|O 
Interestingly|O ,|O cells|O carrying|O the|O MET|gene-rna mutations|O are|O selected|O during|O metastatic|O spread|O :|O transcripts|O of|O the|O mutant|O alleles|O are|O highly|O represented|O in|O metastases|O ,|O but|O barely|O detectable|O in|O primary|O tumors|O .|O 
These|O data|O indicate|O that|O cells|O expressing|O mutant|O MET|gene-rna undergo|O clonal|O expansion|O during|O HNSCC|O progression|O and|O suggest|O that|O MET|gene-rna might|O be|O one|O of|O the|O long|O sought|O oncogenes|O controlling|O progression|O of|O primary|O cancers|O to|O metastasis|O .|O 
Mutational|O analysis|O of|O the|O CTNNB1|gene-rna (|O beta-catenin|gene-rna )|O gene|O in|O human|O endometrial|O cancer|O :|O frequent|O mutations|O at|O codon|O 34|O that|O cause|O nuclear|O accumulation|O .|O 
Recently|O ,|O CTNNB1|gene-protein (|O beta-catenin|gene-protein )|O has|O been|O found|O to|O function|O as|O an|O oncoprotein|O that|O works|O in|O the|O Wnt|gene-generic signaling|O pathway|O ,|O and|O mutation|O of|O this|O gene|gene-rna has|O been|O reported|O in|O various|O human|O cancers|O .|O 
In|O this|O study|O ,|O we|O analyzed|O 44|O endometrial|O cancers|O and|O found|O somatic|O missense|O mutations|O in|O five|O (|O 11|O %|O )|O tumors|O .|O 
Interestingly|O ,|O four|O (|O 80|O %|O )|O of|O the|O five|O tumors|O with|O mutations|O would|O cause|O amino|O acid|O alterations|O at|O residues|O next|O to|O Ser|O 33|O ,|O one|O of|O the|O targets|O for|O phosphorylation|O of|O glycogen|gene-protein synthase|gene-protein kinase|gene-protein (|gene-protein GSK|gene-protein )|gene-protein -|gene-protein 3beta|gene-protein .|O 
The|O tumors|O with|O mutations|O showed|O accumulation|O of|O the|O CTNNB1|gene-protein protein|O in|O cytoplasm|O and|O nucleus|O .|O 
This|O is|O the|O first|O report|O of|O frequent|O somatic|O mutation|O of|O the|O CTNNB1|gene-rna gene|O at|O codons|O adjacent|O to|O those|O encoding|O to|O Ser|O /|O Thr|O residues|O in|O endometrial|O cancer|O .|O 
H-ras|gene-rna gene|O mutations|O in|O salivary|O gland|O mucoepidermoid|O carcinomas|O .|O 
BACKGROUND|O :|O 
The|O authors|O '|O recent|O investigation|O of|O salivary|O gland|O tumors|O in|O ras|gene-rna gene|O alteration|O has|O suggested|O that|O K-ras|gene-rna activation|O may|O not|O play|O a|O role|O in|O their|O oncogenesis|O but|O H-ras|gene-rna may|O ,|O especially|O in|O mucoepidermoid|O carcinomas|O .|O 
A|O study|O was|O undertaken|O to|O assess|O the|O overall|O incidence|O of|O mutated|O H-ras|gene-rna genes|O in|O mucoepidermoid|O carcinomas|O and|O to|O discover|O its|O potential|O correlation|O with|O clinicopathologic|O parameters|O .|O 
METHODS|O :|O 
Fifty|O samples|O from|O patients|O with|O salivary|O gland|O mucoepidermoid|O carcinoma|O were|O analyzed|O for|O point|O mutations|O at|O codons|O 12|O ,|O 13|O ,|O and|O 61|O of|O the|O H-ras|gene-rna gene|O using|O the|O polymerase|gene-protein chain|O reaction|O followed|O by|O automated|O direct|O sequencing|O methodology|O .|O 
RESULTS|O :|O 
Mutated|O H-ras|gene-rna genes|O were|O detected|O in|O 9|O patients|O ,|O for|O an|O overall|O incidence|O of|O 18|O %|O (|O 9|O of|O 50|O patients|O )|O .|O 
All|O but|O 1|O of|O the|O mutations|O occurred|O at|O codon|O 12|O :|O a|O GGC|O -|O to|O -|O GTC|O transversion|O in|O 8|O patients|O and|O a|O GGC|O -|O to|O -|O GAC|O transition|O in|O 1|O patient|O ,|O resulting|O in|O the|O amino|O acid|O substitution|O of|O valine|O and|O aspartic|O acid|O ,|O respectively|O ,|O for|O glycine|O .|O 
One|O of|O the|O samples|O showed|O concurrent|O mutations|O at|O codons|O 12|O (|O GGC|O -|O to|O -|O GTC|O )|O and|O 13|O (|O GGT|O -|O to|O -|O GGA|O )|O .|O 
None|O of|O the|O samples|O demonstrated|O mutations|O involving|O codon|O 61|O .|O 
The|O H-ras|gene-rna mutations|O were|O observed|O in|O 5|O %|O (|O 1|O of|O 21|O )|O ,|O 17|O %|O (|O 2|O of|O 12|O )|O ,|O and|O 35|O %|O (|O 6|O of|O 17|O )|O of|O low|O ,|O intermediate|O ,|O and|O high|O grade|O lesions|O ,|O respectively|O .|O 
CONCLUSIONS|O :|O 
These|O data|O suggest|O involvement|O of|O H-ras|gene-rna activation|O in|O conjunction|O with|O other|O yet|O -|O unknown|O events|O in|O the|O development|O and/or|O progression|O of|O mucoepidermoid|O carcinomas|O .|O 
It|O is|O noteworthy|O that|O a|O stepwise|O increase|O in|O the|O frequency|O of|O H-ras|gene-rna mutations|O strongly|O correlates|O with|O tumor|O grade|O (|O P|O =|O 0.017|O )|O .|O 
Molecular|O analysis|O of|O this|O gene|O alteration|O may|O provide|O assistance|O in|O the|O determination|O of|O tumor|O grade|O and|O differentiation|O .|O 
Predominance|O of|O beta-catenin|gene-rna mutations|O and|O beta-catenin|gene-rna dysregulation|O in|O sporadic|O aggressive|O fibromatosis|O (|O desmoid|O tumor|O )|O .|O 
Aggressive|O fibromatosis|O (|O also|O called|O desmoid|O tumor|O )|O occurs|O as|O a|O sporadic|O lesion|O or|O as|O part|O of|O Familial|O Adenomatous|O Polyposis|O ,|O which|O is|O caused|O by|O germ|O line|O mutations|O in|O the|O Adenomatous|gene-rna polyposis|gene-rna Coli|gene-rna (|O APC|gene-rna )|O gene|O .|O 
APC|gene-rna is|O involved|O in|O the|O regulation|O of|O the|O cellular|O level|O of|O beta-catenin|gene-generic ,|O which|O is|O a|O mediator|O in|O Wnt|O signaling|O .|O 
Mutational|O analysis|O of|O the|O beta-catenin|gene-rna and|O APC|gene-rna genes|O was|O performed|O in|O 42|O sporadic|O aggressive|O fibromatoses|O .|O 
Nine|O tumors|O had|O mutations|O in|O APC|gene-rna ,|O and|O 22|O had|O a|O point|O mutation|O in|O beta-catenin|gene-rna at|O either|O codon|O 45|O or|O codon|O 41|O (|O producing|O a|O stabilized|O beta-catenin|gene-protein protein|O product|O )|O .|O 
Immunohistochemistry|O showed|O an|O elevated|O beta-catenin|gene-protein protein|O level|O in|O all|O tumors|O ,|O regardless|O of|O mutational|O status|O .|O 
Beta-catenin|gene-protein localized|O to|O the|O nucleus|O ,|O and|O was|O not|O tyrosine|O phosphorylated|O in|O the|O six|O tumors|O in|O which|O this|O was|O tested|O .|O 
The|O demonstration|O of|O mutations|O in|O two|O mediators|O in|O the|O Wnt|O -|O APC|O -|O beta-catenin|gene-protein pathway|O implicates|O beta-catenin|gene-protein stabilization|O as|O the|O key|O factor|O in|O the|O pathogenesis|O of|O aggressive|O fibromatosis|O .|O 
This|O is|O the|O first|O demonstration|O of|O somatic|O beta-catenin|gene-rna mutations|O in|O a|O locally|O invasive|O ,|O but|O non|O metastatic|O lesion|O composed|O of|O spindle|O cells|O ,|O illustrating|O the|O importance|O of|O beta-catenin|gene-generic stabilization|O in|O a|O variety|O of|O cell|O types|O and|O neoplastic|O processes|O .|O 
Moreover|O ,|O this|O tumor|O has|O one|O of|O the|O highest|O reported|O frequencies|O of|O beta-catenin|gene-rna mutations|O of|O any|O tumor|O type|O .|O 
Frequent|O mutation|O of|O beta-catenin|gene-rna and|O APC|gene-rna genes|O in|O primary|O colorectal|O tumors|O from|O patients|O with|O hereditary|O nonpolyposis|O colorectal|O cancer|O .|O 
Hereditary|O nonpolyposis|O colorectal|O cancer|O (|O HNPCC|O )|O is|O characterized|O by|O defective|O DNA|O mismatch|O repair|O ,|O which|O results|O in|O genetic|O instability|O of|O tumors|O ;|O however|O ,|O only|O a|O few|O target|O genes|O have|O been|O recognized|O .|O 
Our|O previous|O study|O detected|O a|O low|O frequency|O of|O APC|gene-rna gene|O mutation|O (|O 21|O %|O )|O in|O colorectal|O tumors|O from|O HNPCC|O patients|O ,|O in|O contrast|O to|O a|O high|O frequency|O of|O APC|gene-rna gene|O alteration|O (|O >|O 70|O %|O )|O in|O non|O -|O HNPCC|O tumors|O .|O 
Because|O both|O beta-catenin|gene-rna and|O ACP|gene-rna gene|O mutations|O have|O recently|O been|O shown|O to|O activate|O the|O same|O signaling|O pathway|O ,|O we|O analyzed|O beta-catenin|gene-rna mutation|O in|O HNPCC|O tumors|O .|O 
A|O notable|O frequency|O of|O beta-catenin|gene-rna gene|O mutation|O (|O 43|O %|O ,|O 12|O of|O 28|O )|O was|O found|O to|O occur|O in|O HNPCC|O colorectal|O tumors|O .|O 
Beta-catenin|gene-rna mutations|O were|O not|O detected|O in|O tumors|O with|O APC|gene-rna mutations|O .|O 
All|O beta-catenin|gene-rna mutations|O detected|O in|O HNPCC|O tumors|O existed|O within|O the|O regulatory|O domain|O of|O beta-catenin|gene-rna .|O 
Immunohistochemical|O staining|O of|O tumors|O with|O this|O mutation|O showed|O accumulation|O of|O beta-catenin|gene-protein protein|O in|O nuclei|O .|O 
These|O and|O previous|O data|O from|O our|O laboratory|O suggest|O that|O activation|O of|O the|O beta-catenin|gene-rna -|O Tcf|O signaling|O pathway|O ,|O through|O either|O beta-catenin|gene-protein or|O APC|gene-rna mutation|O ,|O contributes|O to|O HNPCC|O colorectal|O carcinogenesis|O in|O approximately|O 65|O %|O of|O cases|O .|O 
Diagnosis|O of|O pancreatic|O cancer|O by|O detecting|O telomerase|gene-protein activity|O in|O pancreatic|O juice|O :|O comparison|O with|O K-ras|gene-rna mutations|O .|O 
OBJECTIVE|O :|O 
Telomerase|gene-protein activity|O is|O reported|O to|O be|O specific|O and|O very|O frequent|O in|O human|O malignancy|O .|O 
K-ras|gene-rna mutations|O are|O also|O very|O frequently|O detected|O in|O pancreatic|O cancer|O ,|O but|O their|O specificity|O for|O pancreatic|O cancer|O is|O controversial|O .|O 
We|O examined|O the|O telomerase|gene-protein activity|O and|O K-ras|gene-rna mutations|O in|O pancreatic|O juice|O from|O patients|O with|O pancreatic|O disease|O .|O 
METHODS|O :|O 
Pancreatic|O juice|O was|O obtained|O endoscopically|O at|O endoscopic|O retrograde|O pancreatography|O from|O 10|O patients|O with|O pancreatic|O cancer|O ,|O three|O with|O chronic|O pancreatitis|O ,|O and|O three|O with|O a|O normal|O pancreas|O .|O 
The|O telomerase|gene-protein activity|O in|O pancreatic|O juice|O was|O assayed|O by|O telomeric|O repeat|O amplification|O protocol|O .|O 
K-ras|gene-rna mutations|O in|O exon|O 1|O codon|O 12|O were|O examined|O by|O the|O two-step|O polymerase|gene-protein chain|O reaction|O combined|O with|O restriction|gene-protein enzyme|gene-protein digestion|O ,|O followed|O by|O single-strand|O conformation|O polymorphism|O analysis|O and|O direct|O sequencing|O .|O 
RESULTS|O :|O 
Telomerase|gene-protein activity|O of|O >|O 5.0|O was|O detected|O in|O eight|O of|O 10|O (|O 80|O %|O )|O subjects|O with|O pancreatic|O cancer|O ,|O but|O in|O none|O with|O chronic|O pancreatitis|O or|O normal|O pancreas|O .|O 
K-ras|gene-rna mutations|O were|O detected|O not|O only|O in|O eight|O of|O 10|O (|O 80|O %|O )|O subjects|O with|O pancreatic|O cancer|O but|O also|O in|O two|O of|O three|O with|O chronic|O pancreatitis|O and|O in|O one|O of|O three|O with|O a|O normal|O pancreas|O .|O 
CONCLUSIONS|O :|O 
It|O was|O shown|O that|O the|O detection|O of|O telomerase|gene-protein activity|O in|O pancreatic|O juice|O is|O a|O more|O useful|O diagnostic|O tool|O for|O pancreatic|O cancer|O than|O that|O of|O K-ras|gene-rna mutations|O .|O 
Protein|O expression|O and|O genetic|O alterations|O of|O p53|gene-rna and|O ras|gene-rna in|O intrahepatic|O cholangiocarcinoma|O .|O 
AIMS|O :|O 
The|O significance|O of|O molecular|O and|O genetic|O alterations|O of|O p53|gene-rna and|O ras|gene-rna in|O the|O development|O and|O progression|O as|O well|O as|O the|O histological|O differentiation|O of|O intrahepatic|O cholangiocarcinoma|O (|O ICC|O )|O was|O evaluated|O .|O 
METHODS|O AND|O RESULTS|O :|O 
We|O examined|O immunohistochemically|O ras|gene-protein p21|gene-protein protein|O and|O p53|gene-rna -|O related|O products|O (|O p53|gene-protein protein|gene-protein ,|O WAF-1|gene-protein and|O mdm-2|gene-protein )|O in|O 43|O cases|O of|O ICC|O .|O 
In|O addition|O ,|O point|O mutations|O of|O ras|gene-rna and|O p53|gene-rna were|O examined|O genetically|O in|O selected|O ICC|O cases|O by|O polymerase|gene-protein chain|O reaction|O -|O restriction|O fragment|O length|O polymorphism|O (|O PCR|O -|O RFLP|O )|O and|O direct|O sequence|O analysis|O .|O 
Point|O mutation|O of|O K-ras|gene-rna gene|O codon|O 12|O was|O detected|O in|O three|O of|O 14|O cases|O and|O one|O of|O 15|O cases|O by|O PCR|O -|O RFLP|O and|O direct|O sequence|O analysis|O ,|O respectively|O .|O 
Immunoreactivity|O of|O ras|gene-protein p21|gene-protein protein|O was|O not|O detected|O .|O 
Point|O mutation|O of|O p53|gene-rna was|O detected|O in|O three|O of|O 15|O cases|O .|O 
p53|gene-protein protein|O was|O immunohistochemically|O detectable|O in|O 33|O of|O 43|O cases|O .|O 
Immunoreactivity|O of|O p53|gene-protein was|O more|O frequent|O in|O well|O -|O differentiated|O and|O less|O frequent|O in|O poorly|O differentiated|O cases|O .|O 
Immunoreactivity|O of|O WAF-1|gene-protein and|O mdm-2|gene-protein was|O seen|O in|O 16|O and|O eight|O of|O 43|O cases|O ,|O respectively|O .|O 
Both|O proteins|gene-protein were|O frequently|O detected|O in|O the|O cases|O positive|O for|O p53|gene-protein protein|O .|O 
CONCLUSION|O :|O 
These|O results|O suggest|O that|O dysregulation|O of|O ras|gene-generic is|O involved|O in|O at|O least|O 20|O %|O of|O ICC|O and|O expression|O of|O p53|gene-protein protein|O is|O more|O significantly|O involved|O in|O ICC|O ,|O particularly|O in|O the|O well|O and|O moderately|O differentiated|O cases|O .|O 
While|O some|O cases|O of|O p53|gene-protein expression|O may|O be|O explainable|O by|O point|O mutation|O of|O p53|gene-rna ,|O there|O may|O be|O some|O epigenetic|O phenomena|O that|O stabilize|O p53|gene-protein protein|O in|O ICC|O .|O 
That|O is|O ,|O wild|O type|O p53|gene-rna may|O be|O stabilized|O and|O then|O detectable|O by|O forming|O complexes|O with|O other|O molecules|O of|O p53|gene-protein downstream|O effector|O genes|O ,|O such|O as|O WAF-1|gene-rna and|O mdm-2|gene-rna .|O 
beta-catenin|gene-protein expression|O pattern|O in|O stage|O I|O and|O II|O ovarian|O carcinomas|O :|O relationship|O with|O beta-catenin|gene-rna gene|O mutations|O ,|O clinicopathological|O features|O ,|O and|O clinical|O outcome|O .|O 
The|O immunohistochemical|O expression|O pattern|O of|O beta-catenin|gene-protein has|O been|O correlated|O with|O beta-catenin|gene-rna gene|O mutations|O ,|O clinicopathological|O features|O ,|O and|O disease|O outcome|O in|O 69|O stage|O I|O and|O II|O ovarian|O carcinomas|O .|O 
beta-Catenin|gene-protein expression|O was|O localized|O in|O the|O nuclei|O ,|O in|O addition|O to|O the|O cytoplasm|O and|O membrane|O ,|O in|O 11|O tumors|O (|O 16|O %|O )|O :|O nine|O endometrioid|O carcinomas|O with|O widespread|O nuclear|O expression|O and|O two|O serous|O carcinomas|O with|O focal|O nuclear|O expression|O .|O 
The|O remaining|O 58|O carcinomas|O (|O 84|O %|O )|O only|O had|O membranous|O beta-catenin|gene-protein expression|O .|O 
All|O but|O one|O of|O the|O endometrioid|O carcinomas|O with|O nuclear|O beta-catenin|gene-protein expression|O had|O considerable|O squamous|O metaplasia|O ,|O and|O five|O of|O these|O cases|O had|O large|O areas|O of|O endometrioid|O tumor|O of|O low|O malignant|O potential|O .|O 
In|O addition|O ,|O beta-catenin|gene-protein nuclear|O expression|O was|O observed|O in|O atypical|O epithelial|O cells|O in|O endometriotic|O glands|O adjacent|O to|O an|O endometrioid|O carcinoma|O .|O 
Sequencing|O was|O performed|O on|O 25|O tumors|O and|O corresponding|O normal|O tissue|O :|O all|O 13|O endometrioid|O tumors|O as|O well|O as|O 12|O carcinomas|O of|O other|O histological|O types|O (|O four|O serous|O ,|O two|O clear|O cell|O ,|O two|O mucinous|O ,|O and|O two|O mixed|O )|O .|O 
There|O were|O oncogenic|O mutations|O in|O the|O phosphorylation|O sequence|O for|O GSK-3beta|gene-rna in|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O in|O seven|O endometrioid|O carcinomas|O with|O beta-catenin|gene-protein nuclear|O expression|O .|O 
Three|O mutations|O affected|O codon|O 32|O (|O D|O 32|O G|O ,|O D|O 32|O Y|O ,|O and|O D|O 32|O Y|O )|O ,|O one|O affected|O codon|O 33|O (|O S|O 33|O C|O )|O ,|O two|O affected|O codon|O 37|O (|O S|O 37|O C|O and|O S|O 37|O F|O )|O ,|O and|O one|O affected|O codon|O 41|O (|O T|O 41|O A|O )|O .|O 
No|O mutations|O were|O observed|O in|O the|O other|O 18|O carcinomas|O analyzed|O ,|O comprising|O two|O endometrioid|O and|O two|O serous|O carcinomas|O with|O beta-catenin|gene-protein nuclear|O expression|O ,|O and|O 14|O carcinomas|O of|O different|O histological|O types|O with|O only|O membranous|O expression|O .|O 
In|O the|O univariate|O and|O multivariate|O survival|O analyses|O ,|O beta-catenin|gene-protein nuclear|O expression|O was|O selected|O as|O an|O indicator|O of|O good|O prognosis|O ,|O because|O no|O patient|O whose|O tumor|O expressed|O beta-catenin|gene-protein in|O the|O nuclei|O showed|O relapses|O or|O died|O ,|O in|O contrast|O to|O the|O 19|O relapses|O and|O deaths|O among|O patients|O with|O tumors|O that|O only|O had|O beta-catenin|gene-protein membranous|O expression|O ,|O including|O three|O of|O the|O four|O patients|O with|O endometrioid|O carcinomas|O .|O 
Oncogenic|O beta-catenin|gene-rna mutation|O is|O characteristic|O of|O a|O group|O of|O endometrioid|O carcinomas|O with|O a|O good|O prognosis|O ,|O most|O of|O which|O originate|O from|O previous|O benign|O or|O borderline|O lesions|O .|O 
Endometrioid|O carcinomas|O with|O exclusively|O membranous|O expression|O of|O beta-catenin|gene-protein seem|O to|O represent|O a|O different|O subgroup|O of|O carcinomas|O that|O probably|O have|O a|O worse|O prognosis|O .|O 
In|O early-stage|O ovarian|O cancer|O ,|O determination|O of|O the|O beta-catenin|gene-protein expression|O pattern|O could|O prove|O to|O be|O a|O useful|O marker|O for|O selecting|O low-risk|O patients|O .|O 
ras|gene-rna gene|O mutations|O in|O ethmoid|O sinus|O adenocarcinoma|O :|O prognostic|O implications|O .|O 
BACKGROUND|O :|O 
The|O presence|O of|O mutations|O of|O the|O 3|O ras|gene-rna proto|O -|O oncogenes|O in|O 31|O cases|O of|O ethmoid|O sinus|O adenocarcinoma|O ,|O an|O uncommon|O tumor|O type|O epidemiologically|O related|O to|O professional|O exposure|O to|O wood|O dust|O ,|O was|O studied|O .|O 
METHODS|O :|O 
The|O authors|O studied|O 31|O patients|O with|O ethmoid|O sinus|O adenocarcinoma|O .|O 
The|O polymerase|gene-protein chain|O reaction|O was|O used|O to|O amplify|O ras|gene-rna specific|O sequences|O of|O DNA|O isolated|O from|O paraffin|O embedded|O tumor|O samples|O .|O 
ras|gene-rna point|O mutations|O were|O subsequently|O detected|O with|O mutation|O specific|O oligonucleotide|O probes|O .|O 
RESULTS|O :|O 
H-ras|gene-rna was|O found|O to|O be|O mutated|O in|O 5|O cases|O (|O 16|O %|O )|O .|O 
It|O is|O noteworthy|O that|O all|O of|O these|O mutations|O were|O identical|O and|O consisted|O of|O a|O G|O -|O for|O -|O T|O transversion|O at|O the|O second|O base|O of|O codon|O 12|O .|O 
H-ras|gene-rna mutations|O were|O related|O to|O a|O worse|O prognosis|O ,|O with|O shorter|O tumor|O free|O survival|O (|O P|O =|O 0.04|O )|O and|O overall|O survival|O (|O P|O =|O 0.008|O )|O .|O 
T|O classification|O was|O a|O significant|O clinical|O factor|O related|O to|O survival|O (|O P|O =|O 0.01|O for|O disease|O free|O survival|O and|O P|O =|O 0.006|O for|O overall|O survival|O )|O .|O 
The|O prognostic|O value|O of|O H-ras|gene-rna mutation|O was|O consistent|O after|O adjustment|O for|O T|O classification|O .|O 
H-ras|gene-rna mutations|O showed|O no|O association|O with|O patients|O '|O previous|O exposure|O to|O wood|O dust|O .|O 
K-ras|gene-rna was|O found|O to|O be|O transformed|O in|O a|O single|O case|O ;|O this|O was|O the|O only|O patient|O in|O the|O series|O to|O develop|O lymph|O node|O metastases|O .|O 
In|O this|O case|O ,|O both|O the|O nasal|O tumor|O and|O the|O lymph|O nodes|O showed|O the|O GAT|O -|O for|O -|O GGT|O mutation|O at|O codon|O 12|O of|O K-ras|gene-rna .|O 
No|O activation|O of|O the|O N-ras|gene-rna gene|O was|O detected|O .|O 
CONCLUSIONS|O :|O 
The|O presence|O of|O H-ras|gene-rna point|O mutations|O defines|O a|O subgroup|O of|O patients|O with|O ethmoid|O sinus|O adenocarcinomas|O for|O whom|O the|O prognosis|O is|O very|O poor|O .|O 
The|O finding|O that|O all|O of|O these|O mutations|O are|O identical|O emphasizes|O the|O peculiarity|O of|O this|O type|O of|O tumor|O .|O 
Additional|O value|O of|O K-ras|gene-rna point|O mutations|O in|O bronchial|O wash|O fluids|O for|O diagnosis|O of|O peripheral|O lung|O tumours|O .|O 
The|O purpose|O of|O this|O study|O was|O to|O examine|O the|O additional|O diagnostic|O value|O of|O K-ras|gene-rna point|O mutations|O in|O the|O clinical|O diagnosis|O of|O peripheral|O lung|O tumours|O .|O 
To|O this|O end|O ,|O bronchial|O wash|O fluids|O obtained|O during|O bronchoscopy|O from|O patients|O suspected|O of|O having|O lung|O cancer|O were|O studied|O .|O 
Only|O those|O patients|O were|O investigated|O for|O whom|O the|O cytological|O diagnosis|O was|O not|O conclusive|O for|O malignancy|O .|O 
As|O a|O control|O group|O ,|O patients|O without|O lung|O cancer|O were|O investigated|O .|O 
The|O method|O of|O "|O point|O mutation|O detection|O using|O the|O exonuclease|gene-protein amplification|O coupled|O capture|O technique|O "|O (|O Point|O -|O EXACCT|O )|O for|O analysis|O of|O K-ras|gene-rna codon|O 12|O was|O performed|O in|O bronchial|O wash|O fluids|O and|O the|O corresponding|O tumour|O tissue|O ,|O if|O available|O .|O 
K-ras|gene-rna point|O mutations|O were|O identified|O in|O 4|O out|O of|O 19|O (|O 21|O %|O )|O bronchial|O wash|O fluids|O from|O patients|O without|O a|O decisive|O diagnosis|O of|O malignancy|O .|O 
The|O diagnosis|O of|O malignancy|O was|O further|O based|O on|O cytological|O examination|O of|O bronchial|O brush|O specimens|O ,|O perthoracic|O needle|O aspiration|O ,|O histological|O investigation|O of|O biopsy|O and|O resection|O specimens|O ,|O needle|O aspiration|O of|O a|O lymph|O node|O in|O the|O neck|O and|O pleural|O fluid|O examination|O .|O 
Four|O of|O the|O patients|O who|O were|O K-ras|gene-rna -|O positive|O yielded|O positive|O malignant|O tissue|O via|O bronchoscopy|O even|O though|O the|O bronchial|O wash|O was|O negative|O for|O malignancy|O .|O 
The|O bronchial|O wash|O was|O positive|O for|O K-ras|gene-rna in|O two|O of|O the|O four|O patients|O whose|O tumour|O tissue|O demonstrated|O the|O K-ras|gene-rna mutations|O .|O 
Analysis|O of|O bronchial|O wash|O fluids|O from|O 11|O patients|O without|O lung|O cancer|O revealed|O no|O K-ras|gene-rna codon|O 12|O mutations|O .|O 
In|O conclusion|O ,|O K-ras|gene-rna point|O mutations|O can|O be|O identified|O in|O bronchial|O wash|O fluids|O obtained|O during|O bronchoscopic|O procedures|O .|O 
K-ras|gene-rna can|O be|O used|O as|O a|O biomarker|O in|O the|O clinical|O diagnosis|O of|O lung|O cancer|O and|O may|O serve|O as|O an|O adjunct|O to|O cytology|O in|O lung|O cancer|O diagnosis|O .|O 
Establishment|O and|O characterization|O of|O 12|O human|O colorectal|O -|O carcinoma|O cell|O lines|O .|O 
In|O this|O article|O ,|O we|O describe|O the|O characteristics|O of|O 12|O human|O colorectal|O -|O carcinoma|O cell|O lines|O established|O from|O 6|O primary|O tumors|O and|O 6|O metastatic|O sites|O of|O 11|O Korean|O colorectal|O -|O carcinoma|O patients|O ,|O including|O the|O morphology|O in|O vivo|O and|O in|O vitro|O and|O mutations|O of|O K-ras2|gene-rna ,|O p15|gene-rna ,|O p16|gene-rna ,|O p53|gene-rna ,|O APC|gene-rna ,|O beta-catenin|gene-rna ,|O hMLH1|gene-rna and|O hMSH2|gene-rna genes|O in|O vitro|O .|O 
No|O lines|O were|O contaminated|O with|O Mycoplasma|O or|O bacteria|O .|O 
All|O lines|O were|O proven|O to|O be|O unique|O by|O DNA|O -|O fingerprinting|O analysis|O .|O 
All|O lines|O expressed|O the|O surface|O carcino|O -|O embryonic|O antigen|O and|O secreted|O it|O into|O the|O supernatant|O fluid|O .|O 
The|O morphological|O correlation|O between|O the|O original|O tumors|O and|O cultured|O cells|O suggested|O that|O the|O original|O tumors|O showing|O mucinous|O adenocarcinoma|O correlated|O with|O floating|O aggregates|O in|O culture|O ,|O and|O degree|O of|O desmoplasia|O in|O the|O original|O tumor|O correlated|O with|O attached|O growth|O in|O culture|O .|O 
Five|O of|O the|O cell|O lines|O showed|O mutations|O in|O the|O K-ras2|gene-rna gene|O ,|O and|O 6|O of|O the|O cell|O lines|O showed|O mutations|O in|O the|O p53|gene-rna gene|O .|O 
The|O p15|gene-rna gene|O was|O deleted|O in|O 2|O cell|O lines|O ,|O and|O the|O p16|gene-rna gene|O was|O hypermethylated|O in|O 3|O cell|O lines|O .|O 
The|O mutation|O of|O mismatch|O -|O repair|O genes|O (|O hMLH1|gene-rna and|O hMSH2|gene-rna )|O was|O found|O in|O 4|O lines|O ,|O the|O APC|gene-rna gene|O and|O beta-catenin|gene-rna gene|O were|O mutated|O in|O 9|O and|O 2|O lines|O respectively|O .|O 
These|O well|O -|O characterized|O colorectal|O -|O cancer|O cell|O lines|O should|O serve|O as|O useful|O tools|O for|O investigating|O the|O biological|O characteristics|O of|O colorectal|O cancer|O .|O 
Novel|O mutations|O of|O the|O MET|gene-rna proto|O -|O oncogene|O in|O papillary|O renal|O carcinomas|O .|O 
Hereditary|O papillary|O renal|O carcinoma|O (|O HPRC|O )|O is|O characterized|O by|O multiple|O ,|O bilateral|O papillary|O renal|O carcinomas|O .|O 
Previously|O ,|O we|O demonstrated|O missense|O mutations|O in|O the|O tyrosine|O kinase|O domain|O of|O the|O MET|gene-rna proto|O -|O oncogene|O in|O HPRC|O and|O a|O subset|O of|O sporadic|O papillary|O renal|O carcinomas|O .|O 
In|O this|O study|O ,|O we|O screened|O a|O large|O panel|O of|O sporadic|O papillary|O renal|O carcinomas|O and|O various|O solid|O tumors|O for|O mutations|O in|O the|O MET|gene-rna proto|O -|O oncogene|O .|O 
Summarizing|O these|O and|O previous|O results|O ,|O mutations|O of|O the|O MET|gene-rna proto|O -|O oncogene|O were|O detected|O in|O 17|O /|O 129|O sporadic|O papillary|O renal|O carcinomas|O but|O not|O in|O other|O solid|O tumors|O .|O 
We|O detected|O five|O novel|O missense|O mutations|O ;|O three|O of|O five|O mutations|O were|O located|O in|O the|O ATP|O -|O binding|O region|O of|O the|O tyrosine|O kinase|O domain|O of|O MET|gene-rna .|O 
One|O novel|O mutation|O in|O MET|gene-rna ,|O V|O 1110|O I|O ,|O was|O located|O at|O a|O codon|O homologous|O to|O an|O activating|O mutation|O in|O the|O c-erbB|gene-rna proto|O -|O oncogene|O .|O 
These|O mutations|O caused|O constitutive|O phosphorylation|O of|O MET|gene-rna when|O transfected|O into|O NIH3T3|O cells|O .|O 
Molecular|O modeling|O studies|O suggest|O that|O these|O activating|O mutations|O interfere|O with|O the|O intrasteric|O mechanism|O of|O tyrosine|gene-protein kinase|gene-protein autoinhibition|O and|O facilitate|O transition|O to|O the|O active|O form|O of|O the|O MET|gene-protein kinase|gene-protein .|O 
The|O low|O frequency|O of|O MET|gene-rna mutations|O in|O noninherited|O papillary|O renal|O carcinomas|O (|O PRC|O )|O suggests|O that|O noninherited|O PRC|O may|O develop|O by|O a|O different|O mechanism|O than|O hereditary|O papillary|O renal|O carcinoma|O .|O 
Lack|O of|O constitutive|O activation|O of|O MAP|gene-protein kinase|gene-protein pathway|O in|O human|O acute|O myeloid|O leukemia|O cells|O with|O N-Ras|gene-rna mutation|O .|O 
Mitogen|gene-protein -|gene-protein activated|gene-protein protein|gene-protein (|O MAP|gene-protein )|O kinases|gene-protein act|O as|O transducers|O of|O extracellular|O signaling|O via|O tyrosine|gene-protein kinase|gene-protein -|gene-protein growth|gene-protein factor|gene-protein receptors|gene-protein and|O G-protein|gene-protein -|gene-protein linked|gene-protein receptors|gene-protein to|O transcription|gene-protein factors|gene-protein .|O 
Constitutive|O activation|O of|O MAP|gene-protein kinase|gene-protein has|O been|O observed|O in|O a|O variety|O of|O solid|O tumors|O including|O renal|O cancer|O and|O breast|O cancer|O .|O 
Recently|O ,|O we|O have|O reported|O that|O constitutively|O activated|O MAP|gene-protein kinase|gene-protein was|O observed|O in|O 50|O %|O of|O human|O primary|O acute|O myeloid|O leukemia|O (|O AML|O )|O cells|O .|O 
Ras|gene-rna is|O one|O of|O the|O components|O of|O G-proteins|gene-protein and|O transduces|O the|O signal|O from|O cytokine|gene-protein receptors|gene-protein to|O raf-1|gene-protein theoretically|O resulting|O in|O the|O activation|O of|O MAP|gene-protein kinase|gene-protein pathway|O .|O 
In|O the|O present|O study|O ,|O we|O have|O examined|O the|O correlation|O of|O Ras|gene-rna mutations|O and|O the|O activation|O of|O MAP|gene-protein kinase|gene-protein pathway|O in|O patients|O with|O AML|O .|O 
Twenty|O out|O of|O 22|O AML|O cases|O with|O activating|O N-Ras|gene-rna mutations|O showed|O no|O phosphorylated|O forms|O of|O ERK2|gene-protein .|O 
ERK2|gene-protein phosphorylation|O was|O tightly|O correlated|O with|O ERK1|gene-protein phosphorylation|O and|O MAP|gene-protein kinase|gene-protein activity|O detected|O by|O in|O vitro|O kinase|gene-protein assay|O .|O 
Three|O samples|O with|O N-Ras|gene-rna mutations|O were|O stimulated|O with|O IL-3|gene-protein ,|O GM-CSF|gene-protein and|O G-CSF|gene-protein separately|O but|O ERK2|gene-rna activation|O was|O induced|O in|O none|O of|O these|O samples|O stimulated|O with|O these|O cytokines|gene-protein .|O 
In|O contrast|O ,|O ERK2|gene-rna was|O constitutively|O activated|O in|O all|O of|O four|O pancreatic|O carcinoma|O cases|O with|O K-Ras|gene-rna mutation|O at|O codon|O 12|O .|O 
These|O results|O suggest|O that|O function|O of|O the|O Ras|gene-rna mutations|O may|O be|O different|O between|O solid|O tumors|O ,|O such|O as|O pancreatic|O carcinoma|O and|O colorectal|O carcinoma|O ,|O and|O AML|O .|O 
Mutated|O Ras|gene-rna does|O not|O always|O stimulate|O MAP|gene-protein kinase|gene-protein pathway|O constitutively|O and|O may|O rather|O inhibit|O classical|O MAP|gene-protein kinase|gene-protein cascade|O in|O AML|O blasts|O from|O leukemia|O patients|O .|O 
Detection|O of|O K-ras|gene-rna and|O p53|gene-rna gene|O mutations|O in|O pancreatic|O juice|O for|O the|O diagnosis|O of|O intraductal|O papillary|O mucinous|O tumors|O .|O 
The|O aim|O of|O this|O study|O was|O to|O investigate|O mutations|O of|O the|O K-ras|gene-rna oncogene|O and|O the|O p53|gene-rna tumor|O suppressor|O gene|O in|O pancreatic|O juice|O and|O to|O evaluate|O our|O method|O for|O the|O diagnosis|O of|O intraductal|O papillary|O mucinous|O tumors|O (|O IPMT|O )|O .|O 
Pancreatic|O juice|O was|O collected|O endoscopically|O from|O 12|O patients|O with|O IPMT|O who|O underwent|O surgical|O resection|O (|O eight|O carcinomas|O and|O four|O adenomas|O )|O and|O eight|O cases|O without|O evident|O pancreatic|O diseases|O .|O 
DNA|O was|O extracted|O and|O both|gene-rna genes|gene-rna were|O examined|O by|O polymerase|gene-protein chain|O reaction|O single|O -|O strand|O conformation|O polymorphism|O (|O PCR|O -|O SSCP|O )|O analysis|O and|O direct|O sequencing|O .|O 
In|O addition|O ,|O surgically|O resected|O specimens|O were|O analyzed|O for|O both|gene-rna genes|gene-rna by|O the|O same|O methods|O ,|O and|O p53|gene-generic overexpression|O was|O investigated|O immunohistochemically|O .|O 
K-ras|gene-rna point|O mutations|O were|O detected|O in|O pancreatic|O juice|O from|O all|O 12|O patients|O (|O 100|O %|O )|O and|O p53|gene-rna mutations|O were|O detected|O in|O five|O of|O 12|O (|O 42|O %|O )|O .|O 
They|O were|O detected|O not|O only|O in|O carcinoma|O but|O also|O in|O adenoma|O and|O there|O was|O no|O difference|O between|O the|O mutations|O detected|O in|O pancreatic|O juice|O and|O surgical|O specimens|O .|O 
No|O mutations|O were|O found|O in|O any|O cases|O without|O pancreatic|O diseases|O .|O 
These|O findings|O suggest|O that|O alterations|O of|O K-ras|gene-rna and|O p53|gene-rna gene|O are|O common|O events|O in|O the|O development|O of|O IPMT|O and|O that|O genetic|O analysis|O of|O them|O in|O pancreatic|O juice|O can|O be|O a|O useful|O tool|O for|O the|O clinical|O diagnosis|O of|O IPMT|O before|O surgery|O .|O 
Analysis|O of|O K-ras|gene-rna codon|O 12|O point|O mutations|O using|O duodenal|O lavage|O fluid|O for|O diagnosis|O of|O pancreatic|O carcinoma|O .|O 
We|O evaluated|O the|O diagnostic|O significance|O of|O the|O K-ras|gene-rna point|O mutations|O at|O codon|O 12|O in|O duodenal|O lavage|O fluid|O (|O DLF|O )|O compared|O with|O pure|O pancreatic|O juice|O (|O PPJ|O )|O .|O 
The|O DLF|O was|O easily|O and|O safely|O collected|O by|O injecting|O distilled|O water|O into|O the|O duodenum|O and|O then|O aspirating|O through|O the|O working|O channel|O of|O the|O endoscope|O during|O endoscopic|O retrograde|O cholangiopancreatography|O .|O 
Two|O types|O of|O DLF|O are|O collected|O this|O way|O :|O DLF|O 1|O is|O collected|O just|O after|O insertion|O of|O the|O endoscope|O into|O the|O duodenum|O and|O DLF|O 2|O is|O collected|O after|O cholangiopancreatography|O and/or|O collection|O of|O the|O PPJ|O using|O secretin|gene-protein .|O 
Analysis|O of|O K-ras|gene-rna mutations|O was|O performed|O using|O enriched|O polymerase|gene-protein chain|O reaction|O .|O In|O patients|O with|O pancreatic|O carcinoma|O (|O PC|O )|O ,|O K-ras|gene-rna mutations|O were|O detected|O in|O 14|O of|O 23|O (|O 60.9|O %|O )|O in|O DLF|O 1|O ,|O 16|O of|O 21|O (|O 76.2|O %|O )|O in|O DLF|O 2|O ,|O 14|O of|O 20|O (|O 70.0|O %|O )|O in|O PPJ|O ,|O and|O 19|O of|O 21|O (|O 90.5|O %|O )|O in|O either|O DLF|O 1|O or|O DLF|O 2|O .|O 
In|O patients|O with|O noncancerous|O pancreatic|O diseases|O consisting|O of|O pancreatic|O cystic|O diseases|O and|O chronic|O pancreatitis|O ,|O the|O incidence|O of|O K-ras|gene-rna mutations|O was|O 2|O of|O 21|O (|O 9.5|O %|O )|O in|O DLF|O 1|O and|O 7|O of|O 19|O (|O 36.8|O %|O )|O in|O DLF|O 2|O .|O 
These|O values|O were|O lower|O than|O that|O in|O PPJ|O ,|O and|O there|O was|O significant|O difference|O between|O the|O incidence|O in|O DLF|O 1|O and|O PPJ|O .|O 
These|O results|O suggested|O that|O DLF|O may|O provide|O a|O new|O and|O useful|O material|O for|O analysis|O of|O K-ras|gene-rna codon|O 12|O point|O mutations|O in|O the|O diagnosis|O of|O PC|O .|O 
Mutations|O of|O the|O beta-catenin|gene-rna gene|O in|O endometrial|O carcinomas|O .|O 
To|O investigate|O the|O contribution|O of|O beta-catenin|gene-rna to|O the|O development|O of|O endometrial|O carcinoma|O ,|O we|O searched|O for|O genetic|O alterations|O of|O the|O beta-catenin|gene-rna gene|O in|O primary|O endometrial|O carcinomas|O .|O 
Mutational|O analysis|O of|O exon|O 3|O of|O the|O beta-catenin|gene-rna gene|O ,|O encoding|O the|O serine|O /|O threonine|O residues|O for|O GSK-3|gene-protein beta|gene-protein phosphorylation|O ,|O was|O performed|O for|O 35|O tumors|O .|O 
Nucleotide|O sequencing|O analysis|O revealed|O that|O 5|O tumors|O (|O 5|O /|O 35|O ,|O 14|O %|O )|O contained|O mutations|O (|O S|O 33|O C|O ,|O S|O 37|O C|O ,|O S|O 37|O F|O ,|O T|O 41|O A|O )|O that|O altered|O potential|O GSK-3|gene-protein beta|gene-protein phosphorylation|O sites|O .|O 
Each|O of|O the|O mutations|O resulted|O in|O the|O substitution|O of|O serine|O /|O threonine|O residues|O that|O have|O been|O implicated|O in|O the|O down-regulation|O of|O beta-catenin|gene-protein through|O phosphorylation|O by|O GSK-3|gene-protein beta|gene-protein kinase|gene-protein .|O 
Furthermore|O ,|O the|O incidence|O of|O beta-catenin|gene-rna mutations|O was|O significantly|O higher|O in|O early-onset|O (|O 3|O of|O 5|O )|O than|O that|O in|O late-onset|O tumors|O (|O 2|O of|O 30|O )|O (|O P|O =|O 0.014|O ,|O Fisher|O 's|O exact|O test|O )|O .|O 
Replication|O error|O (|O RER|O )|O -|O positive|O phenotype|O was|O not|O detected|O in|O tumors|O with|O the|O beta-catenin|gene-rna gene|O mutation|O ,|O although|O 10|O of|O 35|O tumors|O revealed|O RER|O .|O 
We|O performed|O immunohistochemistry|O of|O beta-catenin|gene-protein in|O 17|O cases|O for|O which|O tissue|O samples|O were|O available|O .|O 
We|O confirmed|O accumulation|O of|O beta-catenin|gene-protein protein|O in|O both|O the|O nucleus|O and|O cytoplasm|O in|O 3|O tumors|O ,|O including|O two|O in|O which|O amino|O acid|O alterations|O had|O occurred|O at|O codon|O 33|O and|O 37|O .|O 
The|O other|O case|O had|O no|O mutation|O in|O exon|O 3|O .|O 
Our|O results|O suggested|O that|O mutations|O at|O serine|O /|O threonine|O residues|O involved|O in|O phosphorylation|O by|O GSK-3|gene-protein beta|gene-protein affected|O the|O stability|O of|O beta-catenin|gene-protein .|O 
Accumulation|O of|O mutant|O beta-catenin|gene-protein could|O contribute|O to|O the|O development|O of|O a|O subset|O of|O endometrial|O carcinomas|O ,|O particularly|O those|O of|O the|O early-onset|O type|O .|O 
In|O serous|O ovarian|O neoplasms|O the|O frequency|O of|O Ki-ras|gene-rna mutations|O correlates|O with|O their|O malignant|O potential|O .|O 
We|O analysed|O 44|O tissue|O samples|O from|O serous|O ovarian|O neoplasms|O of|O different|O malignant|O potential|O for|O Ki-ras|gene-rna mutations|O by|O denaturing|O gradient|O gel|O electrophoresis|O (|O DGGE|O )|O and|O direct|O sequencing|O after|O microdissection|O .|O 
Point|O mutations|O at|O codon|O 12|O were|O found|O in|O 7|O of|O 20|O tumours|O of|O low|O malignant|O potential|O (|O LMP|O )|O (|O 35|O %|O )|O and|O in|O 2|O of|O 6|O well|O -|O differentiated|O carcinomas|O (|O 33|O %|O )|O .|O 
In|O contrast|O ,|O no|O mutations|O were|O detected|O in|O the|O 11|O poorly|O differentiated|O ovarian|O carcinoma|O samples|O or|O in|O the|O 7|O serous|O cystadenomas|O .|O 
The|O frequency|O of|O Ki-ras|gene-rna mutations|O in|O serous|O ovarian|O tumours|O seems|O to|O correlate|O with|O the|O malignant|O potential|O of|O the|O neoplasms|O .|O 
The|O data|O favour|O the|O hypothesis|O of|O a|O de|O novo|O development|O of|O poorly|O differentiated|O ovarian|O carcinomas|O and|O do|O not|O support|O an|O evolution|O from|O LMP|O tumours|O or|O well|O -|O differentiated|O carcinomas|O .|O 
K-ras|gene-rna mutations|O in|O colorectal|O adenocarcinomas|O and|O neighbouring|O transitional|O mucosa|O .|O 
The|O K-ras|gene-rna gene|O in|O codons|O 12|O and|O 13|O was|O investigated|O using|O allele|O -|O specific|O polymerase|gene-protein chain|O reaction|O in|O matched|O normal|O mucosa|O (|O n|O =|O 106|O )|O ,|O transitional|O mucosa|O (|O n|O =|O 69|O )|O and|O tumours|O (|O n|O =|O 149|O )|O from|O 149|O patients|O with|O colorectal|O adenocarcinomas|O .|O 
K-ras|gene-rna mutations|O in|O codon|O 12|O were|O detected|O in|O 41|O /|O 149|O (|O 28|O %|O )|O of|O tumours|O and|O 4|O /|O 69|O (|O 6|O %|O )|O of|O transitional|O mucosa|O samples|O ,|O but|O not|O in|O the|O normal|O mucosa|O .|O 
Further|O ,|O mutation|O rates|O were|O increased|O in|O younger|O patients|O (|O P|O =|O 0.001|O )|O and|O in|O mucinous|O carcinomas|O (|O 50|O %|O )|O compared|O with|O well|O differentiated|O (|O 17|O %|O )|O ,|O moderately|O differentiated|O (|O 26|O %|O )|O or|O poorly|O differentiated|O (|O 24|O %|O )|O tumours|O .|O 
Our|O findings|O indicate|O that|O mucinous|O carcinoma|O may|O represent|O a|O distinct|O genetic|O entity|O .|O 
Mutations|O of|O ras|gene-rna genes|O are|O relatively|O frequent|O in|O Japanese|O prostate|O cancers|O :|O pointing|O to|O genetic|O differences|O between|O populations|O .|O 
Point|O mutations|O of|O the|O ras|gene-rna gene|O family|O are|O thought|O to|O be|O involved|O in|O the|O development|O of|O a|O variety|O of|O human|O tumors|O .|O 
However|O ,|O it|O remains|O unknown|O whether|O the|O ras|gene-rna gene|O might|O play|O a|O key|O role|O in|O prostate|O carcinogenesis|O .|O 
We|O therefore|O analysed|O Ki|gene-rna -|gene-rna ,|O N|gene-rna -|gene-rna and|O H|gene-rna -|gene-rna ras|gene-rna gene|O mutations|O in|O a|O series|O of|O 81|O Japanese|O prostate|O cancers|O using|O PCR|O -|O SSCP|O analysis|O and|O Mutant|O -|O Allele|O -|O Specific|O Amplification|O (|O MASA|O )|O method|O .|O 
Mutated|O as|gene-rna genes|O were|O detected|O in|O 20|O of|O the|O 81|O samples|O (|O 24|O %|O )|O ;|O three|O of|O 22|O latent|O ,|O one|O of|O five|O stage|O B|O ,|O four|O of|O 14|O stage|O C|O and|O 12|O of|O 40|O stage|O D|O cancers|O .|O 
Of|O the|O twenty|O as|O gene|O mutations|O ,|O 13|O were|O in|O Ki-ras|gene-rna (|O codon|O 12|O )|O ,|O five|O in|O H-ras|gene-rna codon|O 61|O and|O two|O H-ras|gene-rna codon|O 13|O .|O 
The|O observed|O frequency|O of|O ras|gene-rna gene|O mutations|O was|O higher|O than|O that|O reported|O in|O the|O literature|O for|O some|O non|O -|O Japanese|O prostate|O cancers|O ,|O suggesting|O the|O possibility|O of|O genetic|O differences|O between|O populations|O .|O 
Activation|O of|O the|O beta-catenin|gene-rna gene|O in|O primary|O hepatocellular|O carcinomas|O by|O somatic|O alterations|O involving|O exon|O 3|O .|O 
We|O screened|O 75|O primary|O hepatocellular|O carcinomas|O for|O somatic|O mutations|O in|O the|O entire|O coding|O region|O of|O the|O beta-catenin|gene-rna gene|O .|O 
We|O detected|O somatic|O mutations|O in|O 14|O tumors|O ;|O 12|O were|O considered|O to|O cause|O amino|O acid|O substitutions|O and|O 2|O were|O interstitial|O deletions|O of|O 51|O or|O 195|O nucleotides|O of|O genomic|O DNA|O ,|O corresponding|O to|O exon|O 3|O .|O 
Among|O the|O 12|O point|O mutations|O ,|O 6|O occurred|O at|O potential|O serine|O /|O threonine|O phosphorylation|O residues|O of|O codons|O 33|O ,|O 41|O ,|O or|O 45|O .|O 
The|O remaining|O six|O tumors|O contained|O a|O mutation|O at|O codon|O 32|O (|O aspartic|O acid|O )|O or|O 34|O (|O glycine|O )|O ,|O flanking|O to|O the|O serine|O residue|O at|O codon|O 33|O .|O 
By|O Western|O blot|O analysis|O ,|O we|O confirmed|O accumulation|O of|O beta-catenin|gene-protein in|O five|O tumors|O for|O which|O frozen|O tissues|O were|O available|O ;|O the|O five|O included|O tumors|O in|O which|O amino|O acid|O alterations|O had|O occurred|O at|O codons|O 32|O ,|O 34|O ,|O or|O 45|O ,|O and|O one|O with|O a|O 17|O -|O amino|O acid|O deletion|O .|O 
Our|O results|O suggested|O that|O accumulation|O of|O beta-catenin|gene-protein due|O to|O amino|O acid|O substitutions|O at|O potential|O serine|O /|O threonine|O phosphorylation|O residues|O or|O at|O their|O neighboring|O codons|O or|O interstitial|O deletions|O involving|O exon|O 3|O could|O contribute|O to|O hepatocellular|O carcinogenesis|O .|O 
Mutations|O in|O the|O beta-catenin|gene-rna gene|O (|O CTNNB1|gene-rna )|O in|O endometrioid|O ovarian|O carcinomas|O .|O 
Mutations|O of|O the|O beta-catenin|gene-rna gene|O (|O CTNNB1|gene-rna )|O have|O recently|O been|O implicated|O in|O the|O initiation|O of|O some|O colon|O carcinomas|O and|O melanomas|O .|O 
In|O these|O tumors|O ,|O beta-catenin|gene-protein abnormally|O accumulates|O in|O the|O cell|O nuclei|O .|O 
In|O an|O ongoing|O immunohistochemical|O study|O of|O the|O cadherin|gene-protein -|O catenin|gene-protein complex|O protein|O expression|O in|O ovarian|O carcinomas|O ,|O we|O observed|O beta-catenin|gene-protein in|O tumor|O cell|O nuclei|O in|O some|O cases|O ;|O this|O prompted|O us|O to|O study|O whether|O or|O not|O this|O abnormal|O immunostaining|O pattern|O was|O due|O to|O mutation|O in|O the|O beta-catenin|gene-rna gene|O itself|O .|O 
This|O study|O examines|O beta-catenin|gene-protein immunohistochemical|O expression|O in|O 40|O stage|O I|O and|O II|O ovarian|O borderline|O tumors|O and|O carcinomas|O of|O the|O most|O common|O histological|O types|O .|O 
Membrane|O expression|O was|O heterogeneous|O in|O all|O 40|O cases|O .|O 
However|O ,|O the|O cytoplasm|O and|O nucleus|O of|O five|O (|O one|O borderline|O tumor|O and|O four|O carcinomas|O )|O of|O the|O six|O endometrioid|O lesions|O contained|O beta-catenin|gene-protein expression|O .|O 
PCR|O and|O sequencing|O analyses|O of|O a|O 200|O -|O bp|O fragment|O of|O exon|O 3|O of|O the|O CTNNB1|gene-rna gene|O ,|O encompassing|O the|O sequence|O for|O glycogen|gene-protein synthetase|gene-protein kinase|gene-protein -|gene-protein 3beta|gene-protein phosphorylation|O ,|O were|O performed|O in|O 11|O tumors|O .|O 
Heterozygous|O substitution|O mutations|O at|O codon|O 37|O in|O two|O cases|O (|O S|O 37|O F|O and|O S|O 37|O C|O )|O and|O at|O codon|O 41|O in|O one|O case|O (|O T|O 41|O A|O )|O were|O found|O in|O three|O endometrioid|O lesions|O (|O one|O borderline|O tumor|O and|O two|O carcinomas|O )|O with|O abnormal|O beta-catenin|gene-protein expression|O .|O 
Three|O endometrioid|O carcinomas|O and|O five|O tumors|O of|O other|O histological|O types|O analyzed|O showed|O normal|O DNA|O sequences|O .|O 
These|O results|O implicate|O beta-catenin|gene-rna gene|O mutations|O in|O ovarian|O malignant|O transformation|O with|O a|O characteristic|O phenotype|O :|O endometrioid|O ovarian|O carcinoma|O .|O 
Translocations|O of|O the|O MLL|gene-rna gene|O at|O chromosome|O band|O 11q23|O are|O the|O most|O common|O cytogenetic|O alterations|O in|O de|O novo|O leukemia|O in|O infants|O and|O in|O leukemia|O related|O to|O chemotherapy|O with|O DNA|gene-protein topoisomerase|gene-protein II|gene-protein inhibitors|O .|O 
Experiments|O on|O knock-in|O mice|O suggest|O that|O additional|O mutational|O events|O may|O by|O required|O for|O full|O leukemogenesis|O .|O 
Therefore|O ,|O we|O used|O single-strand|O conformation|O polymorphism|O analysis|O and|O an|O allele|O -|O specific|O restriction|gene-protein enzyme|gene-protein assay|O to|O investigate|O the|O frequency|O of|O KRAS|gene-rna and|O NRAS|gene-rna mutations|O in|O 32|O pediatric|O leukemias|O with|O translocation|O of|O the|O MLL|gene-rna gene|O .|O 
Of|O 25|O de|O novo|O cases|O ,|O 13|O were|O acute|O lymphoblastic|O leukemia|O (|O ALL|O )|O ,|O 10|O were|O acute|O myeloid|O leukemia|O (|O AML|O )|O ,|O and|O 2|O were|O biphenotypic|O .|O 
Three|O secondary|O leukemias|O were|O AML|O ,|O 1|O was|O biphenotypic|O ,|O 1|O was|O ALL|O ,|O and|O 2|O were|O diagnosed|O as|O myelodysplasia|O .|O 
The|O frequency|O of|O RAS|gene-rna mutations|O was|O 2|O of|O 10|O in|O de|O novo|O AML|O .|O Both|O mutations|O occurred|O in|O infant|O monoblastic|O variants|O .|O 
RAS|gene-rna mutations|O were|O otherwise|O absent|O in|O this|O series|O .|O 
This|O is|O the|O first|O report|O of|O congenital|O leukemias|O where|O translocation|O of|O the|O MLL|gene-rna gene|O and|O RAS|gene-rna mutation|O coexist|O .|O 
The|O frequency|O of|O RAS|gene-rna mutations|O in|O de|O novo|O AMLs|O with|O MLL|O gene|O translocations|O is|O similar|O to|O that|O in|O other|O forms|O of|O AML|O ,|O but|O RAS|gene-rna mutations|O play|O a|O limited|O role|O in|O lymphoid|O and|O treatment|O -|O related|O leukemias|O with|O similar|O translocations|O .|O 
A|O novel|O chromosomal|O translocation|O t|O (|O 4|O ;|O 14|O )|O (|O p16.3|O ;|O q32|O )|O in|O multiple|O myeloma|O involves|O the|O fibroblast|gene-rna growth|gene-rna -|gene-rna factor|gene-rna receptor|gene-rna 3|gene-rna gene|O .|O 
Chromosomal|O translocations|O involving|O the|O immunoglobulin|O heavy|O chain|O (|O IGH|O )|O locus|O at|O chromosome|O 14q32|O represent|O a|O common|O mechanism|O of|O oncogene|O activation|O in|O lymphoid|O malignancies|O .|O 
In|O multiple|O myeloma|O (|O MM|O )|O ,|O the|O most|O consistent|O chromosomal|O abnormality|O is|O the|O 14q|O +|O marker|O ,|O which|O originates|O in|O one|O third|O of|O cases|O through|O a|O t|O (|O 11|O ;|O 14|O )|O (|O q13|O ;|O q32|O )|O chromosomal|O translocation|O ;|O in|O the|O remaining|O cases|O ,|O the|O identity|O of|O the|O partner|O chromosomes|O has|O not|O been|O well|O established|O .|O 
We|O used|O a|O Southern|O blot|O approach|O based|O on|O the|O linkage|O analysis|O of|O the|O joining|O (|O J|O )|O and|O the|O constant|O (|O C|O )|O mu|O ,|O alpha|O ,|O and|O gamma|O regions|O to|O detect|O cases|O bearing|O IGH|O switch|O -|O mediated|O chromosomal|O translocations|O .|O 
We|O evaluated|O DNA|O of|O 88|O nonkaryotyped|O patients|O with|O MM|O (|O 78|O cases|O )|O or|O plasma|O cell|O leukemia|O (|O PCL|O )|O (|O 10|O cases|O )|O and|O found|O the|O presence|O of|O "|O illegitimate|O "|O rearranged|O IGH|O fragments|O (|O no|O comigration|O between|O the|O J|O and|O C|O regions|O )|O in|O 21|O cases|O .|O 
To|O confirm|O this|O analysis|O ,|O we|O cloned|O the|O illegitimate|O rearranged|O fragments|O from|O three|O samples|O ,|O and|O the|O molecular|O and|O fluorescent|O in|O situ|O hybridization|O (|O FISH|O )|O analyses|O indicated|O the|O presence|O of|O chromosomal|O translocations|O juxtaposing|O a|O switch|O IGH|O region|O to|O sequences|O from|O chromosomes|O 11q13|O (|O one|O PCL|O case|O )|O or|O 4p16.3|O (|O two|O MM|O cases|O )|O .|O 
Interestingly|O ,|O the|O breakpoints|O on|O 4p16.3|O occurred|O about|O 14|O kb|O apart|O in|O a|O genomic|O region|O located|O approximately|O 50|O kb|O centromeric|O to|O the|O fibroblast|gene-protein growth|gene-protein -|gene-protein factor|gene-protein receptor|gene-rna 3|gene-rna (|O FGFR3|gene-rna )|O gene|O .|O 
Moreover|O ,|O Southern|O blot|O analysis|O using|O 4p16.3|O genomic|O probes|O detected|O a|O rearrangement|O in|O an|O additional|O MM|O tumor|O .|O 
FISH|O analysis|O of|O the|O MM|O -|O derived|O KMS-11|O cell|O line|O ,|O reported|O to|O be|O associated|O with|O a|O t|O (|O 4|O ;|O 14|O )|O (|O p16.3|O ;|O q32|O )|O ,|O showed|O that|O the|O FGFR3|gene-rna gene|O was|O translocated|O on|O 14q32|O .|O 
High|O levels|O of|O FGFR3|gene-rna mRNA|O expression|O were|O observed|O in|O the|O cloned|O MM|O tumors|O and|O KMS-11|O cell|O line|O ,|O but|O not|O in|O the|O cases|O that|O were|O apparently|O negative|O for|O this|O lesion|O .|O 
Furthermore|O ,|O a|O point|O mutation|O at|O codon|O 373|O in|O the|O transmembrane|O domain|O of|O the|O FGFR3|gene-rna gene|O resulting|O in|O an|O amino|O acid|O substitution|O (|O Tyr|O -->|O Cys|O )|O was|O detected|O in|O the|O KMS-11|O cell|O line|O .|O 
These|O findings|O indicate|O that|O the|O t|O (|O 4|O ;|O 14|O )|O (|O p16.3|O ;|O q32|O )|O represents|O a|O novel|O ,|O recurrent|O chromosomal|O translocation|O in|O MM|O ,|O and|O suggest|O that|O the|O FGFR3|gene-rna gene|O may|O be|O the|O target|O of|O this|O abnormality|O and|O thus|O contribute|O to|O tumorigenesis|O in|O MM|O .|O 
Response|O to|O radiotherapy|O of|O human|O uterine|O cervix|O carcinoma|O is|O not|O correlated|O with|O rearrangements|O of|O the|O Ha-ras-1|gene-rna and/or|O c-myc|gene-rna genes|O .|O 
An|O association|O between|O the|O presence|O of|O the|O activated|O form|O of|O Ha-ras-1|gene-rna and|O c-myc|gene-rna genes|O and|O increased|O cellular|O radioresistance|O has|O been|O shown|O in|O several|O cell|O lines|O .|O 
The|O aim|O of|O this|O study|O was|O to|O determine|O whether|O such|O an|O association|O could|O be|O observed|O in|O clinical|O tumour|O biopsies|O .|O 
We|O examined|O 70|O tumour|O specimens|O and|O 51|O samples|O of|O peripheral|O blood|O obtained|O from|O untreated|O patients|O with|O carcinoma|O of|O the|O uterine|O cervix|O mainly|O stage|O II|O and|O III|O .|O 
In|O addition|O to|O initial|O clinical|O tumour|O response|O to|O radiotherapy|O ,|O radiosensitivity|O was|O also|O analysed|O by|O the|O subrenal|O capsule|O assay|O (|O SRCA|O )|O .|O 
Mutations|O in|O exons|O 1|O and|O 2|O of|O the|O Ha-ras-1|gene-rna gene|O were|O examined|O using|O PCR|O single-strand|O conformation|O polymorphism|O (|O PCR|O -|O SSCP|O )|O and|O direct|O sequencing|O ;|O and|O restriction|O fragment|O length|O polymorphism|O of|O the|O Ha-ras-1|gene-rna gene|O was|O analysed|O using|O Southern|O hybridisation|O .|O 
Eight|O (|O 11|O %|O )|O out|O of|O 70|O tumours|O contained|O mutations|O in|O exons|O 1|O and|O 2|O of|O the|O Ha-ras-1|gene-rna gene|O .|O 
Eleven|O (|O 22|O %|O )|O out|O of|O the|O 51|O tumours|O displayed|O rearrangements|O of|O the|O Ha-ras-1|gene-rna gene|O (|O six|O tumours|O (|O 12|O %|O )|O showed|O alterations|O of|O allele|O length|O ,|O one|O amplification|O and|O four|O (|O 8|O %|O )|O loss|O of|O one|O Ha-ras-1|gene-rna allele|O )|O .|O 
In|O addition|O ,|O 12|O (|O 17|O %|O )|O out|O of|O 70|O patients|O demonstrated|O the|O presence|O of|O rare|O alleles|O .|O 
Only|O one|O of|O the|O 70|O tumours|O contained|O an|O amplified|O c-myc|gene-rna gene|O .|O 
Long-term|O follow-up|O of|O patients|O with|O chronic|O pancreatitis|O and|O K-ras|gene-rna gene|O mutation|O detected|O in|O pancreatic|O juice|O .|O 
BACKGROUND|O &|O AIMS|O :|O 
Conflicting|O reports|O have|O raised|O the|O question|O whether|O K-ras|gene-rna gene|O mutations|O in|O chronic|O pancreatitis|O are|O related|O to|O the|O development|O of|O pancreatic|O neoplasm|O .|O 
The|O aim|O of|O the|O present|O study|O was|O to|O clarify|O this|O issue|O by|O surveying|O patients|O with|O chronic|O pancreatitis|O and|O K-ras|gene-rna gene|O mutation|O over|O 4|O years|O .|O 
METHODS|O :|O 
K-ras|gene-rna point|O mutations|O at|O codon|O 12|O in|O duodenal|O juices|O obtained|O during|O exocrine|O function|O tests|O were|O examined|O by|O enriched|O polymerase|gene-protein chain|O reaction|O -|O restriction|O fragment|O length|O polymorphism|O and|O direct|O DNA|O sequence|O analysis|O ,|O and|O long-term|O follow-up|O of|O these|O patients|O was|O performed|O .|O 
RESULTS|O :|O 
K-ras|gene-rna gene|O mutation|O was|O found|O in|O 20|O of|O 54|O patients|O (|O 37|O %|O )|O with|O chronic|O pancreatitis|O .|O 
The|O types|O of|O mutation|O were|O GAT|O in|O 7|O ,|O GTT|O in|O 11|O ,|O and|O TGT|O in|O 2|O patients|O .|O 
Pancreatic|O neoplasm|O occurred|O in|O none|O of|O the|O mutation|O -|O positive|O patients|O over|O a|O mean|O follow-up|O period|O of|O 78|O months|O .|O 
CONCLUSIONS|O :|O 
K-ras|gene-rna gene|O mutation|O in|O patients|O with|O chronic|O pencreatitis|O did|O not|O seem|O to|O be|O related|O to|O the|O development|O of|O pancreatic|O neoplasm|O during|O the|O follow-up|O period|O ,|O and|O analysis|O of|O K-ras|gene-rna gene|O mutation|O seems|O of|O little|O use|O for|O diagnosing|O pancreatic|O neoplasm|O in|O patients|O with|O chronic|O pancreatitis|O .|O 
Rapid|O and|O large-scale|O method|O to|O detect|O K-ras|gene-rna gene|O mutations|O in|O tumor|O samples|O .|O 
We|O have|O developed|O a|O rapid|O and|O large-scale|O method|O for|O the|O detection|O of|O K-ras|gene-rna gene|O mutations|O in|O tumors|O .|O 
First|O ,|O DNA|O is|O amplified|O by|O an|O asymmetric|O PCR|O ;|O second|O ,|O the|O single-strand|O dinitrophenyl|O (|O DNP|O )|O -|O labeled|O amplified|O DNA|O is|O hybridized|O specifically|O to|O oligonucleotide|O probes|O affixed|O on|O a|O tube|O .|O 
Finally|O ,|O perfectly|O matched|O duplexes|O are|O easily|O detected|O by|O a|O monoclonal|O anti|gene-protein -|gene-protein DNP|gene-protein antibody|gene-protein bearing|O 125I|O .|O 
The|O usefulness|O of|O this|O technique|O is|O illustrated|O by|O analyzing|O K-ras|gene-rna codon|O 12|O mutations|O in|O human|O colorectal|O samples|O .|O 
This|O reliable|O assay|O procedure|O can|O be|O applied|O to|O the|O rapid|O screening|O of|O virtually|O any|O genetic|O disease|O caused|O by|O previously|O described|O point|O mutations|O .|O 
Identification|O of|O H|gene-rna ,|O K|gene-rna ,|O and|O N|gene-rna -|gene-rna ras|gene-rna point|O mutations|O in|O stage|O IB|O cervical|O carcinoma|O .|O 
OBJECTIVE|O :|O 
The|O ras|gene-rna oncogenes|O ,|O Harvey|gene-rna (|O H|gene-rna )|O ,|O Kirsten|gene-rna (|O K|gene-rna )|O ,|O and|O neuroblastoma|gene-rna (|O N|gene-rna )|O ,|O are|O a|O family|O of|O genes|O coding|O for|O a|O membrane|O -|O associated|O protein|O (|O p21|gene-protein )|O which|O possesses|O inherent|O guanine|gene-protein triphosphatase|gene-protein (|O GTPase|gene-protein )|O activity|O .|O 
Point|O mutagenesis|O at|O codons|O 12|O ,|O 13|O ,|O and|O 61|O has|O been|O implicated|O in|O ras|gene-rna activation|O and|O subsequent|O cellular|O transformation|O .|O 
Given|O the|O epidemiologic|O relationship|O of|O HPV|O infection|O with|O cervical|O carcinoma|O and|O the|O tumorigenic|O interaction|O of|O HPV|O and|O mutated|O ras|gene-rna oncogenes|O ,|O this|O study|O was|O undertaken|O to|O identify|O if|O mutated|O ras|gene-rna oncogenes|O were|O present|O in|O early|O invasive|O cervical|O carcinomas|O .|O 
METHODS|O :|O 
A|O combination|O of|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O and|O dot|O -|O blot|O hybridization|O was|O used|O to|O determine|O the|O frequency|O and|O types|O of|O ras|gene-rna point|O mutants|O occurring|O in|O cervical|O carcinoma|O .|O 
Thirty-three|O patients|O with|O early|O -|O stage|O cervical|O carcinoma|O were|O identified|O .|O 
DNA|O was|O extracted|O from|O archival|O tumor|O samples|O .|O 
ras|gene-rna genes|O were|O PCR|O amplified|O using|O flanking|O primers|O and|O hybridized|O with|O a|O series|O of|O labeled|O allele|O -|O specific|O oligonucleotides|O corresponding|O to|O wild|O -|O type|O forms|O of|O K|gene-rna 12|O ,|O 61|O ,|O N|gene-rna 12|O ,|O 13|O ,|O 61|O ,|O and|O H|gene-rna 12|O ,|O 61|O ,|O as|O well|O as|O to|O all|O combinations|O of|O substitution|O mutations|O (|O 7|O wild|O -|O type|O ,|O 45|O mutants|O )|O .|O 
RESULTS|O :|O 
ras|gene-rna mutations|O were|O identified|O in|O 24.2|O %|O of|O specimens|O .|O 
The|O detected|O mutations|O in|O H|gene-rna ,|O K|gene-rna ,|O and|O N|gene-rna -|gene-rna ras|gene-rna all|O occurred|O at|O codon|O 61|O .|O 
This|O was|O not|O the|O result|O of|O PCR|O or|O hybridization|O artifact|O in|O that|O mutations|O were|O detected|O in|O position|O 12|O and|O 13|O in|O appropriate|O control|O samples|O .|O 
CONCLUSIONS|O :|O 
Mutant|O ras|gene-rna has|O been|O shown|O to|O convert|O HPV|O immortalized|O keratinocytes|O to|O the|O tumorigenic|O state|O .|O 
Our|O results|O indicate|O that|O a|O significant|O percentage|O (|O 24.2|O %|O )|O of|O these|O early|O -|O stage|O cervical|O cancers|O contain|O activated|O ras|gene-rna .|O 
Additional|O studies|O will|O be|O needed|O to|O evaluate|O whether|O codon|O 61|O represents|O a|O characteristic|O "|O hot|O -|O spot|O "|O of|O ras|gene-rna mutation|O in|O a|O subset|O of|O cervical|O carcinoma|O .|O 
A|O one|O -|O step|O DGGE|O scanning|O method|O for|O detection|O of|O mutations|O in|O the|O K|gene-rna -|gene-rna ,|O N|gene-rna -|gene-rna ,|O and|O H|gene-rna -|gene-rna ras|gene-rna oncogenes|O :|O mutations|O at|O codons|O 12|O ,|O 13|O and|O 61|O are|O rare|O in|O B|O -|O cell|O non|O -|O Hodgkin|O 's|O lymphoma|O .|O 
Mutations|O in|O the|O N|gene-rna -|gene-rna ,|O K|gene-rna -|gene-rna ,|O and|O H|gene-rna -|gene-rna ras|gene-rna genes|O are|O key|O events|O in|O the|O process|O of|O carcinogenesis|O of|O many|O human|O cancers|O and|O may|O serve|O as|O important|O targets|O for|O therapeutic|O intervention|O .|O 
We|O developed|O a|O simple|O diagnostic|O method|O that|O in|O one|O step|O and|O within|O 5|O hr|O determines|O the|O mutational|O status|O of|O any|O of|O the|O 3|O ras|gene-rna genes|O in|O a|O given|O tumor|O sample|O .|O 
The|O method|O combines|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O with|O denaturing|O gradient|O gel|O electrophoresis|O (|O DGGE|O )|O and|O allows|O simultaneous|O mutation|O scanning|O of|O 6|O regions|O covering|O "|O hot|O -|O spot|O "|O codons|O 12|O ,|O 13|O and|O 61|O of|O the|O 3|O ras|gene-rna genes|O .|O 
The|O sensitivity|O of|O the|O assay|O was|O demonstrated|O by|O the|O analysis|O of|O control|O mutations|O ,|O either|O naturally|O occurring|O or|O created|O by|O site|O -|O directed|O mutagenesis|O .|O 
We|O further|O demonstrate|O that|O unambiguous|O identification|O of|O ras|gene-rna mutations|O can|O be|O achieved|O by|O heteroduplex|O analysis|O in|O denaturing|O gradient|O gels|O ,|O circumventing|O sequence|O analysis|O .|O 
We|O applied|O the|O method|O to|O establish|O the|O mutational|O status|O of|O all|O 3|O ras|gene-rna genes|O in|O 123|O samples|O of|O B|O -|O cell|O non|O -|O Hodgkin|O 's|O lymphoma|O .|O 
Altogether|O ,|O one|O diffuse|O large|O B|O -|O cell|O lymphoma|O and|O one|O B|O -|O cell|O chronic|O lymphocytic|O leukemia|O (|O B-CLL|O )|O harbored|O a|O mutation|O (|O G|O 12|O S|O and|O G|O 12|O A|O ,|O respectively|O )|O in|O the|O K-ras|gene-rna gene|O ,|O and|O one|O B-CLL|O harbored|O a|O mutation|O (|O Q|O 61|O R|O )|O in|O the|O N-ras|gene-rna gene|O .|O 
We|O therefore|O conclude|O that|O ras|gene-rna mutations|O only|O contribute|O rarely|O ,|O if|O at|O all|O ,|O to|O carcinogenesis|O in|O B|O -|O cell|O non|O -|O Hodgkin|O 's|O lymphoma|O .|O 
Mutation|O of|O ras|gene-rna oncogene|O in|O gastric|O adenocarcinoma|O :|O association|O with|O histological|O phenotype|O .|O 
In|O order|O to|O explore|O the|O role|O of|O ras|gene-rna oncogene|O in|O gastric|O carcinomas|O from|O Korean|O patients|O ,|O we|O examined|O the|O frequency|O of|O point|O mutations|O all|O three|O ras|gene-rna oncogenes|O (|O Ki|gene-rna -|gene-rna ,|O Ha|gene-rna -|gene-rna ,|O and|O N|gene-rna -|gene-rna ras|gene-rna )|O .|O 
A|O total|O of|O 57|O DNA|O samples|O were|O prepared|O from|O 3|O gastric|O carcinoma|O cell|O lines|O ,|O 10|O malignant|O ascites|O ,|O and|O 44|O frozen|O gastric|O tumor|O tissues|O .|O 
Exons|O 1|O and|O 2|O of|O each|O ras|gene-rna oncogene|O were|O amplified|O by|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O ,|O and|O analyzed|O by|O single|O strand|O conformation|O polymorphism|O (|O SSCP|O )|O and|O direct|O sequencing|O .|O 
Mutated|O ras|gene-rna genes|O were|O detected|O in|O 6|O out|O of|O 57|O samples|O (|O 10|O %|O )|O .|O 
One|O cell|O line|O and|O 2|O tumors|O showed|O a|O mutation|O at|O exon|O 1|O of|O Ki-ras|gene-rna .|O N-ras|gene-rna mutations|O were|O also|O detected|O at|O exon|O 1|O of|O 3|O tumors|O .|O 
Histologically|O ,|O all|O the|O ras|gene-rna mutation|O cases|O exhibited|O a|O diffuse|O phenotype|O .|O 
In|O summary|O ,|O we|O performed|O a|O comprehensive|O analysis|O to|O investigate|O the|O mutation|O of|O all|O three|O ras|gene-rna oncogenes|O in|O gastric|O carcinoma|O .|O 
The|O results|O demonstrate|O infrequent|O mutations|O of|O Ki|gene-rna -|gene-rna and|O N|gene-rna -|gene-rna ras|gene-rna which|O may|O favor|O the|O development|O of|O diffuse|O type|O gastric|O carcinomas|O ,|O implicating|O a|O different|O genetic|O pathway|O in|O diffuse|O and|O intestinal|O type|O gastric|O carcinomas|O .|O 
Sclerosing|O pancreatitis|O showing|O rapidly|O progressive|O changes|O with|O recurrent|O mass|O formation|O .|O 
CONCLUSION|O :|O 
Sclerosing|O pancreatitis|O might|O develop|O repeatedly|O or|O might|O rapidly|O extend|O to|O the|O whole|O pancreas|O with|O recurrent|O mass|O formation|O .|O 
BACKGROUND|O :|O 
Nothing|O is|O known|O concerning|O course|O or|O development|O of|O sclerosing|O pancreatitis|O .|O 
METHODS|O :|O 
A|O 63|O -|O yr|O -|O old|O male|O was|O followed|O up|O for|O 2.5|O yr|O .|O 
RESULTS|O :|O 
The|O patient|O was|O admitted|O because|O of|O a|O tumor|O in|O the|O body|O and|O tail|O of|O the|O pancreas|O .|O 
Serum|gene-protein pancreatic|gene-protein enzymes|gene-protein were|O transiently|O elevated|O ,|O but|O tumor|O markers|O were|O all|O negative|O .|O 
Imaging|O studies|O showed|O a|O tumor|O 7|O cm|O in|O size|O .|O 
The|O main|O pancreatic|O duct|O was|O normal|O in|O the|O head|O and|O obstructed|O at|O the|O body|O on|O endoscopic|O retrograde|O pancreatography|O (|O ERCP|O )|O .|O 
The|O K-ras|gene-rna oncogene|O mutation|O was|O positive|O in|O pure|O pancreatic|O juice|O .|O 
Distal|O pancreatectomy|O was|O performed|O because|O pancreatic|O cancer|O was|O highly|O suspected|O .|O 
Pathological|O findings|O showed|O that|O the|O tumor|O was|O a|O densely|O fibrotic|O mass|O without|O malignant|O cells|O .|O 
Inflammatory|O cell|O infiltration|O was|O observed|O in|O the|O stroma|O .|O 
One|O year|O later|O ,|O another|O mass|O 3|O cm|O in|O size|O was|O noted|O in|O the|O remnant|O pancreatic|O head|O .|O 
ERCP|O revealed|O diffuse|O irregular|O narrowing|O of|O the|O main|O pancreatic|O duct|O ,|O its|O branches|O ,|O and|O the|O common|O bile|O duct|O .|O 
Liver|O dysfunction|O improved|O and|O an|O elevation|O of|O serum|gene-protein pancreatic|gene-protein enzymes|gene-protein subsided|O without|O any|O specific|O treatment|O ,|O and|O the|O mass|O diminished|O in|O size|O .|O 
The|O patterns|O of|O various|O imaging|O studies|O on|O the|O second|O tumor|O were|O the|O same|O as|O those|O of|O the|O previous|O resected|O mass|O .|O 
Corticosteroid|O was|O not|O administered|O .|O 
A|O new|O c-kit|gene-rna mutation|O in|O a|O case|O of|O aggressive|O mast|O cell|O disease|O .|O 
Systemic|O mast|O cell|O disease|O (|O SMCD|O )|O is|O a|O disorder|O characterized|O by|O a|O mast|O cell|O proliferation|O in|O various|O tissues|O .|O 
Mast|O cells|O express|O the|O c-kit|gene-rna proto|O -|O oncogene|O .|O 
A|O few|O cases|O of|O c-kit|gene-rna mutations|O have|O been|O described|O in|O SMCD|O .|O 
We|O report|O an|O aggressive|O SMCD|O in|O a|O patient|O who|O presented|O with|O a|O bone|O marrow|O infiltration|O by|O abnormal|O mast|O cells|O .|O 
Molecular|O studies|O of|O mast|O cell|O DNA|O and|O RNA|O revealed|O a|O new|O c-kit|gene-rna heterozygous|O mutation|O (|O Asp|O 820|O Gly|O )|O .|O 
This|O mutation|O leads|O to|O a|O drastic|O amino|O -|O acid|O change|O and|O is|O located|O close|O to|O the|O highly|O oncogenic|O Asp|O 816|O Val|O .|O 
These|O findings|O suggest|O that|O the|O Asp|O 820|O Gly|O has|O a|O potential|O role|O in|O c-kit|gene-rna activation|O .|O 
K-ras|gene-rna mutations|O and|O prognosis|O in|O large|O -|O bowel|O carcinomas|O .|O 
BACKGROUND|O :|O 
Colorectal|O carcinogenesis|O is|O regarded|O as|O a|O multistep|O process|O involving|O several|O genetic|O alterations|O ,|O with|O mutation|O in|O the|O K-ras|gene-rna gene|O in|O about|O half|O of|O the|O tumours|O .|O 
We|O aimed|O at|O clarifying|O the|O role|O of|O this|O genetic|O alteration|O related|O to|O survival|O and|O clinicopathologic|O variables|O .|O 
METHODS|O :|O 
One|O hundred|O large|O -|O bowel|O carcinomas|O operated|O on|O between|O 1978|O and|O 1982|O were|O studied|O for|O the|O presence|O of|O point|O mutations|O in|O codons|O 12|O and|O 13|O of|O the|O K-ras|gene-rna gene|O ,|O using|O enriched|O polymerase|gene-protein chain|O reaction|O amplification|O ,|O restriction|O fragment|O length|O polymorphism|O analysis|O ,|O and|O direct|O sequencing|O .|O 
RESULTS|O :|O 
Forty|O mutations|O were|O found|O (|O 40|O %|O )|O :|O 31|O in|O codon|O 12|O and|O 9|O in|O codon|O 13|O ,|O 7|O different|O types|O .|O 
There|O was|O no|O relationship|O between|O tumours|O with|O and|O without|O K-ras|gene-rna mutations|O with|O regard|O to|O Dukes|O '|O stages|O ,|O age|O or|O sex|O of|O the|O patient|O ,|O tumour|O localization|O ,|O histologic|O grade|O ,|O DNA|O ploidy|O pattern|O ,|O HLA-DR|O staining|O pattern|O ,|O or|O survival|O .|O 
Samples|O from|O 5|O different|O localizations|O in|O 7|O carcinomas|O showed|O identical|O K-ras|gene-rna mutation|O pattern|O ,|O as|O did|O 19|O recurrences|O /|O metastases|O originating|O from|O 11|O carcinomas|O .|O 
CONCLUSIONS|O :|O 
When|O present|O ,|O the|O primary|O tumour|O shows|O homogeneous|O distribution|O of|O K-ras|gene-rna mutation|O ,|O and|O the|O mutation|O follows|O the|O carcinoma|O in|O the|O secondary|O deposit|O ,|O regardless|O of|O lymphogenous|O or|O hematogenous|O spread|O .|O 
The|O presence|O of|O K-ras|gene-rna mutation|O does|O not|O seem|O to|O have|O prognostic|O significance|O for|O the|O patient|O ,|O and|O the|O precise|O nucleotide|O change|O is|O furthermore|O not|O predictive|O of|O tumour|O behaviour|O .|O 
Analysis|O of|O K-ras|gene-rna oncogene|O mutations|O in|O chronic|O pancreatitis|O with|O ductal|O hyperplasia|O .|O 
BACKGROUND|O :|O 
K-ras|gene-rna oncogene|O mutations|O have|O been|O identified|O in|O up|O to|O 95|O %|O of|O pancreatic|O cancers|O ,|O implying|O their|O critical|O role|O in|O their|O molecular|O pathogenesis|O .|O 
However|O ,|O the|O earliest|O stage|O in|O which|O K-ras|gene-rna mutations|O can|O be|O detected|O in|O potential|O precursor|O lesions|O of|O pancreatic|O cancer|O remains|O unclear|O .|O 
This|O study|O evaluates|O pancreatic|O ductal|O hyperplasia|O in|O the|O setting|O of|O chronic|O pancreatitis|O ,|O which|O predisposes|O to|O pancreatic|O cancer|O development|O ,|O for|O K-ras|gene-rna codon|O 12|O and|O 13|O mutations|O .|O 
METHODS|O :|O 
Paraffin|O -|O embedded|O surgical|O specimens|O from|O 42|O patients|O with|O chronic|O pancreatitis|O were|O examined|O microscopically|O for|O the|O presence|O of|O ductal|O hyperplasia|O .|O 
Both|O hyperplastic|O and|O nonhyperplastic|O ducts|O were|O microdissected|O from|O the|O specimens|O that|O contained|O hyperplasia|O (|O 11|O of|O 42|O )|O .|O 
Four|O of|O the|O remaining|O specimens|O without|O hyperplasia|O served|O as|O controls|O .|O 
Genomic|O DNA|O was|O extracted|O ,|O and|O polymerase|gene-protein chain|O reaction|O and|O amplification|O of|O the|O K-ras|gene-rna oncogene|O was|O performed|O .|O 
Polymerase|gene-protein chain|O reaction|O products|O were|O evaluated|O by|O means|O of|O hybridization|O to|O mutant|O specific|O oligonucleotide|O probes|O and|O by|O means|O of|O automated|O DNA|O sequencing|O .|O 
RESULTS|O :|O 
K-ras|gene-rna codon|O 12|O mutations|O representing|O glycine|O to|O valine|O substitutions|O were|O present|O in|O 2|O of|O (|O 18|O %|O )|O 11|O patients|O with|O ductal|O hyperplasia|O .|O 
No|O mutations|O were|O found|O in|O the|O controls|O without|O ductal|O hyperplasia|O .|O 
CONCLUSIONS|O :|O 
Our|O study|O supports|O the|O premise|O that|O K-ras|gene-rna mutations|O develop|O in|O a|O subset|O of|O chronic|O pancreatitis|O associated|O hyperplasia|O and|O provides|O a|O genetic|O basis|O for|O the|O potential|O progression|O of|O chronic|O pancreatitis|O to|O pancreatic|O cancer|O .|O 
Detection|O of|O k-ras|gene-rna point|O mutations|O in|O codons|O 12|O and|O 13|O in|O non|O -|O small|O cell|O lung|O cancers|O .|O 
Point|O mutations|O of|O the|O K-ras|gene-rna gene|O have|O been|O reported|O in|O a|O wide|O variety|O of|O human|O tumors|O .|O 
By|O using|O polymerase|gene-protein chain|O reaction|O followed|O by|O direct|O DNA|O sequencing|O ,|O we|O screened|O for|O point|O mutations|O at|O codons|O 12|O and|O 13|O of|O the|O K-ras|gene-rna gene|O in|O specimens|O obtained|O from|O fresh|O frozen|O tumors|O in|O 38|O patients|O with|O non|O -|O small|O cell|O lung|O cancers|O .|O 
Point|O mutations|O were|O detected|O in|O two|O of|O 38|O (|O 5.3|O %|O )|O resected|O non|O -|O small|O cell|O lung|O cancers|O .|O 
Both|O of|O them|O were|O G|O to|O T|O transversions|O .|O 
One|O patient|O was|O found|O to|O have|O a|O K-ras|gene-rna codon|O 13|O point|O mutation|O (|O GGC|O to|O TGC|O ,|O gly|O to|O cys|O )|O ,|O while|O the|O other|O had|O a|O codon|O 12|O point|O mutation|O (|O GGT|O to|O GTT|O ,|O gly|O to|O val|O )|O .|O 
Based|O on|O the|O limited|O numbers|O in|O this|O study|O ,|O we|O found|O that|O the|O frequency|O of|O K-ras|gene-rna point|O mutations|O in|O codons|O 12|O and|O 13|O among|O Asian|O patients|O with|O lung|O adenocarcinomas|O was|O lower|O than|O that|O detected|O among|O Caucasian|O patients|O .|O 
Prevalence|O of|O mutations|O of|O ras|gene-rna and|O p53|gene-rna in|O benign|O and|O malignant|O thyroid|O tumors|O from|O children|O exposed|O to|O radiation|O after|O the|O Chernobyl|O nuclear|O accident|O .|O 
Starting|O 4|O years|O after|O the|O Chernobyl|O accident|O ,|O a|O dramatic|O increase|O in|O incidence|O of|O thyroid|O carcinoma|O was|O noticed|O in|O children|O from|O contaminated|O areas|O .|O 
The|O incidence|O of|O benign|O thyroid|O lesions|O in|O the|O exposed|O population|O was|O also|O increased|O .|O 
To|O study|O the|O possible|O role|O of|O ras|gene-rna and|O p53|gene-rna genes|O in|O radiation|O -|O induced|O thyroid|O tumorigenesis|O ,|O 33|O papillary|O carcinomas|O ,|O one|O follicular|O carcinoma|O and|O 22|O benign|O lesions|O removed|O from|O children|O aged|O 5|O -|O 19|O were|O screened|O for|O point|O mutations|O of|O H|gene-rna -|gene-rna ,|O K|gene-rna -|gene-rna ,|O and|O N|gene-rna -|gene-rna ras|gene-rna ,|O as|O well|O as|O of|O p53|gene-rna (|O exons|O 5|O -|O 8|O )|O using|O single|O strand|O conformation|O polymorphism|O (|O SSCP|O )|O analysis|O .|O 
Ras|gene-rna point|O mutations|O were|O detected|O in|O 1|O /|O 1|O case|O of|O follicular|O carcinoma|O (|O N-ras|gene-rna codon|O 61|O CAA|O gln|O -->|O AAA|O lys|O )|O ,|O and|O in|O 3|O /|O 7|O follicular|O adenomas|O (|O N-ras|gene-rna codon|O 61|O CAA|O gln|O -->|O CGA|O arg|O x|O 2|O ,|O CAA|O gln|O -->|O AAA|O lys|O )|O .|O 
None|O of|O the|O cases|O of|O papillary|O thyroid|O carcinoma|O was|O positive|O for|O ras|gene-rna oncogene|O abnormalities|O .|O 
The|O lack|O of|O K-ras|gene-rna mutations|O was|O confirmed|O by|O allele|O -|O specific|O oligonucleotide|O hybridization|O (|O ASOH|O )|O ,|O and|O by|O sequencing|O in|O five|O cases|O .|O 
Somatic|O point|O mutations|O in|O p53|gene-rna were|O found|O by|O SSCP|O in|O 2|O /|O 33|O papillary|O thyroid|O carcinomas|O ,|O with|O one|O missense|O mutation|O (|O exon|O 5|O ,|O codon|O 160|O ATG|O met|O -->|O GTG|O val|O )|O and|O another|O silent|O mutation|O (|O codon|O 182|O ,|O TGC|O cys|O -->|O TGT|O cys|O )|O .|O 
Immunohisto-chemically|O ,|O focally|O positive|O p53|gene-rna staining|O was|O found|O in|O four|O papillary|O carcinomas|O being|O primarily|O confined|O to|O solid|O and|O poorly|O -|O differentiated|O areas|O in|O tumors|O .|O 
These|O data|O demonstrate|O that|O as|O opposed|O to|O the|O few|O reports|O on|O tumors|O arising|O after|O therapeutic|O external|O irradiation|O ,|O ras|gene-rna mutations|O are|O not|O primary|O events|O in|O the|O development|O of|O post|O -|O Chernobyl|O thyroid|O papillary|O carcinomas|O .|O 
p53|gene-rna mutations|O do|O not|O appear|O to|O be|O important|O in|O the|O development|O of|O these|O tumors|O ,|O but|O may|O in|O some|O cases|O have|O a|O role|O in|O progression|O to|O a|O more|O aggressive|O phenotype|O that|O has|O not|O yet|O fully|O manifested|O in|O these|O pediatric|O neoplasms|O .|O 
Mutation|O of|O the|O ras|gene-rna genes|O is|O a|O rare|O genetic|O event|O in|O the|O histologic|O transformation|O of|O follicular|O lymphoma|O .|O 
The|O role|O of|O ras|gene-rna gene|O mutations|O in|O the|O progression|O of|O follicular|O lymphoma|O has|O been|O ascertained|O by|O SSCP|O -|O PCR|O and|O sequencing|O .|O 
A|O total|O of|O 40|O transformed|O lymphomas|O were|O studied|O ,|O 16|O of|O which|O had|O a|O matched|O preceding|O low|O -|O grade|O biopsy|O .|O 
Only|O one|O transformed|O lymphoma|O was|O found|O to|O have|O a|O missense|O mutation|O at|O codon|O 12|O of|O N-ras|gene-rna ,|O resulting|O in|O an|O amino|O acid|O change|O of|O glycine|O to|O serine|O .|O 
We|O conclude|O that|O mutation|O within|O the|O ras|gene-rna gene|O family|O is|O a|O rare|O event|O in|O the|O transformation|O of|O follicular|O lymphoma|O .|O 
Double|O mutations|O of|O the|O N-ras|gene-rna gene|O in|O a|O patient|O with|O acute|O myelomonocytic|O leukemia|O .|O 
We|O report|O a|O patient|O with|O acute|O myelomonocytic|O leukemia|O (|O AMMoL|O )|O who|O showed|O two|O independent|O point|O mutations|O of|O the|O N-ras|gene-rna gene|O at|O codons|O 12|O and|O 13|O .|O 
Longitudinal|O analysis|O revealed|O that|O one|O mutation|O at|O codon|O 13|O was|O detectable|O throughout|O his|O disease|O course|O and|O the|O other|O at|O codon|O 12|O emerged|O as|O a|O second|O mutation|O 14|O months|O after|O the|O diagnosis|O was|O made|O ,|O at|O the|O refractory|O stage|O .|O 
Cloning|O to|O vector|O and|O subsequent|O sequencing|O confirmed|O that|O these|O mutations|O occurred|O in|O different|O alleles|O .|O 
Chromosome|O findings|O showed|O a|O simple|O abnormal|O karyotype|O at|O presentation|O and|O further|O karyotypic|O aberrations|O during|O his|O disease|O course|O ,|O concomitantly|O with|O the|O second|O mutation|O of|O the|O N-ras|gene-rna gene|O .|O 
These|O findings|O revealed|O a|O close|O relationship|O among|O the|O disease|O progression|O ,|O karyotypic|O evolution|O and|O a|O newly|O -|O appearing|O N-ras|gene-rna mutation|O .|O 
Monosomy|O 7|O and|O activating|O RAS|gene-rna mutations|O accompany|O malignant|O transformation|O in|O patients|O with|O congenital|O neutropenia|O .|O 
Individuals|O with|O severe|O forms|O of|O congenital|O neutropenia|O suffer|O from|O recurrent|O infections|O .|O 
The|O therapeutic|O use|O of|O recombinant|gene-protein human|gene-protein granulocyte|gene-protein colony|gene-protein -|gene-protein stimulating|gene-protein factor|gene-protein (|O rhG-CSF|gene-protein )|O to|O increase|O the|O neutrophil|O count|O is|O associated|O with|O fewer|O infections|O and|O an|O improved|O quality|O of|O life|O .|O 
However|O ,|O the|O long-term|O effects|O of|O this|O new|O therapy|O are|O largely|O unknown|O .|O 
In|O particular|O ,|O it|O is|O unclear|O if|O myeloid|O leukemia|O ,|O a|O known|O complication|O of|O some|O forms|O of|O congenital|O neutropenia|O ,|O will|O occur|O with|O increased|O frequency|O among|O patients|O who|O receive|O long-term|O treatment|O with|O hematopoietic|gene-protein growth|gene-protein factors|gene-protein .|O 
We|O report|O 13|O patients|O with|O congenital|O disorders|O of|O myelopoiesis|O who|O developed|O leukemic|O transformation|O with|O either|O myelodysplastic|O syndrome|O (|O MDS|O )|O or|O acute|O myelogenous|O leukemia|O (|O AML|O )|O and|O 1|O who|O acquired|O a|O clonal|O cytogenetic|O abnormality|O without|O evidence|O of|O MDS|O or|O AML|O while|O receiving|O rhG-CSF|gene-protein .|O 
The|O bone|O marrows|O of|O 10|O patients|O showed|O monosomy|O 7|O and|O 5|O had|O activating|O RAS|gene-rna mutations|O .|O 
These|O abnormalities|O were|O not|O detected|O in|O pretreatment|O bone|O marrows|O and|O cessation|O of|O rhG-CSF|gene-protein was|O not|O associated|O with|O either|O clinical|O improvement|O or|O cytogenetic|O remission|O .|O 
We|O conclude|O that|O patients|O with|O severe|O forms|O of|O congenital|O neutropenia|O are|O at|O relatively|O high|O risk|O of|O developing|O MDS|O and|O AML|O .|O 
The|O occurrence|O of|O monosomy|O 7|O and|O RAS|gene-rna mutations|O in|O these|O cases|O suggests|O that|O the|O myeloid|O progenitors|O of|O some|O patients|O are|O genetically|O predisposed|O to|O malignant|O transformation|O .|O 
The|O relationship|O between|O therapeutic|O rhG-CSF|gene-protein and|O leukemogenesis|O in|O patients|O with|O severe|O chronic|O neutropenia|O is|O unclear|O .|O 
Infrequent|O involvement|O of|O mutations|O on|O neurofibromatosis|gene-rna type|gene-rna 1|gene-rna ,|O H-ras|gene-rna ,|O K-ras|gene-rna and|O N-ras|gene-rna in|O urothelial|O tumors|O .|O 
The|O neurofibromatosis|gene-rna type|gene-rna 1|gene-rna (|O NF1|gene-rna )|O gene|O is|O considered|O a|O tumor|O -|O suppressor|O gene|O whose|O product|O acts|O upstream|O of|O ras|gene-rna .|O 
The|O ras|gene-rna gene|O is|O an|O oncogene|O very|O commonly|O detected|O in|O human|O cancers|O and|O consists|O of|O three|O families|O ,|O H-ras|gene-rna ,|O K-ras|gene-rna and|O N-ras|gene-rna .|O 
These|O genes|gene-rna are|O converted|O to|O active|O oncogenes|O by|O point|O mutations|O in|O codon|O 12|O ,|O 13|O ,|O or|O 61|O .|O 
Examination|O was|O made|O of|O the|O mutations|O of|O these|O genes|gene-rna in|O 39|O urothelial|O malignant|O tumors|O (|O 31|O bladder|O cancer|O ,|O 6|O renal|O pelvic|O tumor|O ,|O and|O 2|O ureter|O tumors|O )|O using|O polymerase|gene-protein chain|O reaction|O single-stranded|O conformation|O polymorphism|O and|O direct|O sequencing|O methods|O .|O 
Three|O of|O 39|O (|O 7.7|O %|O )|O cases|O showed|O mobility|O shifts|O in|O the|O ras|gene-rna family|O gene|O but|O no|O point|O mutations|O in|O NF1|gene-rna and|O N-ras|gene-rna genes|O could|O be|O detected|O .|O 
Mutations|O were|O found|O in|O 1|O case|O in|O H-ras|gene-rna at|O codon|O 13|O (|O GGT|O -|O GTT|O /|O GGT|O )|O and|O K-ras|gene-rna at|O codon|O 12|O in|O 2|O cases|O (|O GGT|O -|O GCT|O /|O GGT|O ,|O GGT|O -|O GTT|O /|O GGT|O )|O .|O 
All|O 3|O cases|O had|O progressed|O far|O beyond|O grade|O 2|O and|O stage|O pT2|O .|O 
It|O follows|O from|O the|O above|O that|O NF1|gene-rna and|O ras|gene-rna gene|O mutations|O are|O infrequent|O in|O the|O pathogenesis|O of|O urothelial|O tumors|O .|O 
Mutational|O activation|O of|O N|gene-rna -|gene-rna and|O K|gene-rna -|gene-rna ras|gene-rna oncogenes|O in|O plasma|O cell|O dyscrasias|O .|O 
The|O frequency|O of|O N|gene-rna -|gene-rna and|O K|gene-rna -|gene-rna ras|gene-rna oncogene|O mutations|O was|O investigated|O in|O plasma|O cell|O dyscrasias|O .|O 
Genomic|O DNAs|O from|O 128|O patients|O were|O selected|O for|O this|O study|O :|O 30|O monoclonal|O gammopathies|O of|O undetermined|O significance|O ,|O 8|O solitary|O plasmacytomas|O ,|O 77|O multiple|O myelomas|O (|O MM|O )|O ,|O and|O 13|O plasma|O cell|O leukemias|O (|O PCL|O )|O .|O 
A|O two|O -|O step|O experimental|O approach|O was|O devised|O .|O 
All|O samples|O were|O screened|O for|O mutations|O by|O single-strand|O conformation|O polymorphism|O analysis|O .|O 
DNA|O fragments|O displaying|O an|O altered|O electrophoretic|O mobility|O were|O further|O studied|O by|O direct|O sequencing|O to|O confirm|O and|O characterize|O the|O nature|O of|O the|O mutations|O .|O 
Ras|gene-rna mutations|O are|O not|O randomly|O distributed|O because|O they|O are|O detectable|O only|O in|O MM|O (|O 9|O %|O )|O and|O PCL|O (|O 30.7|O %|O )|O .|O 
N-ras|gene-rna codons|O 12|O ,|O 13|O ,|O and|O 61|O and|O K-ras|gene-rna codon|O 12|O were|O found|O to|O be|O mutated|O ,|O but|O N-ras|gene-rna codon|O 61|O mutation|O was|O the|O most|O frequent|O finding|O (|O 63.6|O %|O )|O .|O 
In|O conclusion|O ,|O ras|gene-rna mutations|O were|O found|O in|O PCL|O ,|O and|O in|O a|O subset|O of|O MM|O characterized|O by|O advanced-stage|O disease|O and|O adverse|O prognostic|O parameters|O .|O 
Furthermore|O ,|O based|O on|O our|O findings|O ,|O it|O is|O possible|O to|O speculate|O that|O ras|gene-rna mutations|O represent|O a|O late|O molecular|O lesion|O in|O the|O process|O of|O multistep|O carcinogenesis|O .|O 
H-ras-1|gene-rna gene|O mutations|O in|O basal|O cell|O carcinoma|O :|O automated|O direct|O sequencing|O of|O clinical|O specimens|O .|O 
Ras|gene-rna oncogenes|O are|O activated|O by|O point|O mutations|O occurring|O in|O codons|O 12|O ,|O 13|O or|O 61|O and|O almost|O any|O base|O pair|O mutation|O occurring|O within|O the|O first|O two|O positions|O of|O any|O of|O these|O codons|O results|O in|O activation|O of|O the|O gene|O .|O 
Although|O ras|gene-rna point|O mutations|O have|O been|O reported|O to|O occur|O in|O several|O skin|O neoplasms|O including|O squamous|O carcinoma|O ,|O keratoacanthoma|O and|O melanoma|O ,|O their|O frequency|O of|O occurrence|O in|O basal|O cell|O carcinoma|O is|O not|O known|O .|O 
We|O examined|O basal|O cell|O carcinomas|O from|O 13|O patients|O for|O activating|O mutations|O in|O the|O H-ras-1|gene-rna gene|O by|O automated|O direct|O sequencing|O of|O polymerase|gene-protein chain|O reaction|O assay|O amplified|O targets|O .|O 
We|O amplified|O sequences|O in|O exon|O 1|O that|O flanked|O codons|O 12|O and|O 13|O and|O amplified|O sequences|O in|O exon|O 2|O that|O flanked|O codon|O 61|O .|O 
The|O PCR|O products|O were|O centrifuged|O and|O directly|O sequenced|O using|O antisense|O primers|O in|O an|O automated|O sequencer|O using|O fluorescent|O dideoxyterminators|O .|O 
One|O tumor|O was|O found|O to|O show|O an|O activating|O G|O to|O A|O transversion|O in|O codon|O 13|O which|O code|O for|O aspartic|O acid|O instead|O of|O glycine|O .|O 
Although|O H-ras|gene-rna mutations|O may|O be|O found|O in|O some|O skin|O tumors|O ,|O they|O are|O not|O frequent|O in|O basal|O cell|O carcinomas|O .|O 
From|O this|O study|O we|O believe|O that|O direct|O sequencing|O of|O clinical|O material|O is|O of|O value|O and|O has|O advantages|O over|O other|O techniques|O .|O 
Additional|O studies|O need|O to|O be|O undertaken|O to|O understand|O the|O true|O clinical|O significance|O of|O ras|gene-rna mutations|O in|O basal|O cell|O carcinomas|O when|O they|O occur|O .|O 
Possible|O role|O of|O activated|O ras|gene-rna genes|O in|O human|O esophageal|O carcinogenesis|O .|O 
Activation|O by|O point|O mutation|O of|O the|O H|gene-rna -|gene-rna ,|O K|gene-rna -|gene-rna and|O N|gene-rna -|gene-rna ras|gene-rna genes|O is|O found|O in|O many|O tumors|O .|O 
However|O ,|O no|O such|O mutation|O has|O yet|O been|O found|O in|O human|O esophageal|O carcinomas|O from|O various|O parts|O of|O the|O world|O .|O 
We|O have|O confirmed|O the|O absence|O of|O mutation|O at|O codons|O 12|O ,|O 13|O and|O 61|O of|O K|gene-rna -|gene-rna and|O N|gene-rna -|gene-rna ras|gene-rna and|O at|O codons|O 12|O and|O 61|O of|O H-ras|gene-rna in|O 25|O primary|O tumors|O obtained|O in|O France|O .|O 
In|O contrast|O ,|O among|O 7|O human|O esophageal|O carcinoma|O cell|O lines|O (|O TE1|O ,|O TE2|O ,|O TE3|O ,|O TE8|O ,|O TE9|O ,|O TE10|O ,|O TE13|O )|O with|O different|O degrees|O of|O tumorigenicity|O in|O nude|O mice|O ,|O 3|O highly|O tumorigenic|O lines|O (|O TE1|O ,|O TE2|O and|O TE8|O )|O exhibited|O activation|O of|O ras|gene-rna oncogenes|O ;|O 2|O showed|O a|O G|O 35|O to|O A|O 35|O transition|O of|O K-ras|gene-rna gene|O and|O one|O a|O H-ras|gene-rna G|O 35|O to|O T|O 35|O transversion|O .|O 
Since|O these|O cell|O lines|O had|O been|O established|O from|O tumors|O of|O Japanese|O patients|O from|O Sendai|O ,|O we|O examined|O 3|O primary|O esophageal|O tumors|O from|O Tokyo|O and|O 19|O from|O Sendai|O ,|O including|O the|O primary|O tumors|O from|O which|O the|O TE|O cell|O lines|O had|O been|O derived|O .|O 
No|O ras|gene-rna mutation|O was|O detected|O ,|O which|O suggests|O that|O the|O ras|gene-rna gene|O mutations|O in|O the|O TE|O cell|O lines|O are|O either|O due|O to|O their|O long-term|O culture|O or|O that|O only|O a|O small|O portion|O of|O the|O original|O tumors|O contained|O such|O mutations|O .|O 
In|O order|O to|O directly|O examine|O the|O effect|O of|O ras|gene-rna gene|O mutation|O ,|O one|O of|O the|O non|O -|O tumorigenic|O cell|O lines|O ,|O TE13|O ,|O was|O transfected|O with|O a|O plasmid|O coding|O for|O a|O mutated|O H-ras|gene-rna gene|O (|O G|O 35|O to|O T|O 35|O )|O .|O 
Transfected|O clones|O expressing|O high|O levels|O of|O mutated|O ras|gene-rna gene|O were|O able|O to|O induce|O tumors|O in|O nude|O mice|O .|O 
Thus|O ,|O although|O no|O primary|O human|O esophageal|O tumor|O contained|O mutated|O ras|gene-rna genes|O ,|O our|O studies|O do|O not|O exclude|O a|O significant|O role|O of|O mutated|O ras|gene-rna genes|O in|O cell|O proliferation|O and|O malignant|O transformation|O of|O human|O esophageal|O cells|O .|O 
H-ras|gene-rna mutations|O in|O human|O pituitary|O carcinoma|O metastases|O .|O 
Molecular|O mechanisms|O of|O pituitary|O tumorigenesis|O were|O studied|O using|O Polymerase|gene-protein chain|O reaction|O -|O single|O stranded|O conformational|O polymorphism|O with|O DNA|O sequencing|O to|O identify|O potential|O mutations|O in|O the|O ras|gene-rna protooncogenes|O and|O the|O tumor|gene-rna suppressor|gene-rna gene|gene-rna p53|gene-rna in|O invasive|O pituitary|O adenomas|O and|O carcinomas|O .|O 
Sequencing|O of|O exons|O 5|O through|O 8|O of|O the|O p53|gene-rna gene|O revealed|O no|O mutations|O ,|O nor|O were|O mutations|O detected|O in|O the|O N|gene-rna -|gene-rna or|O K|gene-rna -|gene-rna ras|gene-rna protooncogenes|O in|O four|O of|O the|O carcinomas|O and|O their|O respective|O metastatic|O deposits|O .|O 
Point|O mutations|O of|O H-ras|gene-rna however|O ,|O were|O identified|O in|O three|O distant|O metastatic|O pituitary|O tumor|O secondaries|O ,|O but|O not|O in|O their|O respective|O primary|O pituitary|O carcinomas|O ,|O or|O in|O six|O invasive|O adenomas|O .|O 
Two|O of|O the|O mutations|O included|O a|O G|O to|O C|O substitution|O at|O codon|O 12|O ,|O and|O a|O G|O to|O A|O substitution|O at|O codon|O 18|O ,|O resulting|O in|O a|O glycine|O to|O arginine|O ,|O and|O an|O alanine|O to|O threonine|O change|O at|O these|O amino|O acids|O ,|O respectively|O .|O 
A|O third|O mutation|O involved|O a|O single|O base|O pair|O (|O adenine|O )|O deletion|O in|O codon|O 3|O of|O H-ras|gene-rna which|O causes|O a|O frame|O shift|O ,|O resulting|O in|O a|O termination|O signal|O at|O codon|O 19|O .|O 
These|O results|O suggest|O that|O point|O mutations|O in|O p53|gene-rna and|O ras|gene-rna are|O not|O associated|O with|O pituitary|O tumorigenesis|O ,|O however|O ,|O point|O mutations|O of|O the|O H-ras|gene-rna gene|O may|O be|O important|O in|O the|O formation|O and|O or|O growth|O of|O pituitary|O metastases|O .|O 
This|O observed|O genomic|O instability|O will|O be|O of|O value|O in|O predicting|O the|O potential|O metastatic|O behavior|O of|O these|O aggressive|O pituitary|O tumors|O .|O 
Non|O -|O involvement|O of|O ras|gene-rna mutations|O in|O flat|O colorectal|O adenomas|O and|O carcinomas|O .|O 
Ras|gene-rna gene|O mutations|O occur|O relatively|O early|O during|O colorectal|O tumor|O development|O and|O have|O been|O observed|O in|O 40|O -|O 50|O %|O of|O malignant|O colorectal|O tumors|O .|O 
Advances|O in|O endoscopic|O techniques|O have|O made|O it|O possible|O to|O detect|O small|O ,|O flat|O colorectal|O tumors|O that|O could|O not|O be|O detected|O by|O standard|O examinations|O .|O 
To|O determine|O whether|O ras|gene-rna gene|O mutations|O are|O also|O involved|O in|O the|O genesis|O of|O small|O ,|O flat|O colorectal|O tumors|O ,|O we|O examined|O ras|gene-rna point|O mutations|O in|O 34|O cases|O of|O small|O polypoid|O or|O flat|O elevated|O colorectal|O tumors|O (|O 32|O adenomas|O ,|O 2|O carcinomas|O )|O and|O in|O 26|O cases|O of|O small|O ,|O flat|O colorectal|O tumors|O (|O 13|O adenomas|O ,|O 13|O carcinomas|O )|O by|O means|O of|O the|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O and|O dot|O -|O blot|O hybridization|O .|O 
Ras|gene-rna gene|O point|O mutations|O were|O observed|O in|O 16|O of|O the|O 34|O tumors|O of|O the|O former|O type|O (|O 47|O %|O )|O ,|O but|O in|O none|O of|O the|O 26|O tumors|O of|O the|O latter|O type|O ,|O even|O though|O the|O grade|O of|O dysplasia|O was|O severe|O in|O the|O flat|O tumors|O .|O 
Our|O results|O suggest|O that|O different|O genetic|O pathways|O for|O tumor|O progression|O may|O exist|O for|O polypoid|O and|O for|O flat|O colorectal|O carcinomas|O .|O 
Prognostic|O importance|O of|O mutations|O in|O the|O ras|gene-rna proto|O -|O oncogenes|O in|O de|O novo|O acute|O myeloid|O leukemia|O .|O 
Mutations|O of|O the|O N|gene-rna -|gene-rna and|O K|gene-rna -|gene-rna ras|gene-rna genes|O are|O the|O most|O frequent|O genetic|O aberrations|O in|O acute|O myeloid|O leukemia|O (|O AML|O )|O and|O their|O detection|O in|O preleukemic|O conditions|O such|O as|O the|O myelodysplastic|O syndrome|O (|O MDS|O )|O suggests|O a|O role|O in|O the|O earliest|O phases|O of|O leukemogenesis|O .|O 
Despite|O these|O observations|O ,|O little|O is|O known|O about|O the|O clinical|O importance|O of|O ras|gene-rna mutations|O in|O AML|O .|O 
We|O studied|O the|O clinical|O impact|O of|O ras|gene-rna mutations|O in|O 99|O patients|O with|O de|O novo|O AML|O .|O 
All|O patients|O were|O treated|O in|O two|O prospective|O multicenter|O trials|O .|O 
The|O polymerase|gene-protein chain|O reaction|O was|O used|O to|O amplify|O areas|O surrounding|O the|O codons|O 12|O ,|O 13|O ,|O and|O 61|O of|O the|O three|O ras|gene-rna genes|O N|gene-rna -|gene-rna ,|O K|gene-rna -|gene-rna ,|O and|O H|gene-rna -|gene-rna ras|gene-rna from|O DNA|O from|O bone|O marrow|O cells|O ,|O ras|gene-rna mutations|O were|O detected|O by|O an|O algorithm|O based|O on|O allele|O -|O specific|O oligonucleotide|O hybridization|O .|O 
Eighteen|O of|O 99|O (|O 18|O %|O )|O patients|O harbored|O mutations|O in|O either|O N|gene-rna -|gene-rna or|O K|gene-rna -|gene-rna ras|gene-rna .|O 
All|O of|O the|O observed|O mutations|O occurred|O in|O N-ras|gene-rna (|O N|O =|O 10|O )|O and|O K-ras|gene-rna (|O N|O =|O 5|O )|O or|O concurrently|O in|O both|O N|gene-rna -|gene-rna and|O K|gene-rna -|gene-rna ras|gene-rna (|O N|O =|O 3|O )|O .|O 
There|O were|O no|O significant|O differences|O between|O ras|gene-rna -|O negative|O and|O ras|gene-rna -|O positive|O patients|O according|O to|O age|O ,|O sex|O ,|O blood|O counts|O ,|O cytogenetic|O abnormalities|O ,|O or|O French|O -|O American|O -|O British|O classification|O .|O 
However|O ,|O univariate|O analysis|O suggested|O a|O longer|O survival|O in|O ras|gene-rna -|O positive|O patients|O (|O P|O =|O .11|O )|O .|O 
When|O adjusted|O for|O age|O ,|O which|O was|O the|O most|O important|O factor|O affecting|O outcome|O ,|O the|O presence|O of|O a|O ras|gene-rna mutation|O emerged|O as|O a|O significant|O predictor|O for|O improved|O survival|O (|O P|O =|O .03|O )|O and|O along|O with|O lower|O bone|O marrow|O blast|O counts|O (|O P|O =|O .02|O )|O and|O better|O cytogenetic|O category|O (|O P|O =|O .01|O )|O .|O 
However|O ,|O the|O presence|O of|O an|O aberrant|O ras|gene-rna allele|O was|O strongly|O correlated|O with|O lower|O bone|O marrow|O blast|O counts|O (|O P|O =|O .007|O )|O .|O 
Thus|O ,|O whether|O a|O mutation|O in|O the|O N-ras|gene-rna or|O K-ras|gene-rna proto|O -|O oncogenes|O directly|O affects|O treatment|O outcome|O or|O indirectly|O through|O an|O association|O with|O lower|O leukemic|O burden|O remains|O to|O be|O determined|O .|O 
Nevertheless|O ,|O these|O findings|O counter|O the|O prevailing|O bias|O that|O oncogene|O mutations|O lead|O to|O more|O aggressive|O behavior|O in|O human|O malignancies|O .|O 
Ras|gene-rna mutations|O in|O human|O melanoma|O :|O a|O marker|O of|O malignant|O progression|O .|O 
In|O this|O study|O we|O address|O whether|O there|O is|O an|O association|O between|O ras|gene-rna mutations|O and|O disease|O progression|O in|O malignant|O melanoma|O .|O 
DNA|O was|O extracted|O from|O 100|O paraffin|O -|O embedded|O melanomas|O and|O sequences|O around|O the|O 12th|O ,|O 13th|O and|O 61st|O codons|O of|O N|gene-rna -|gene-rna ,|O H|gene-rna -|gene-rna ,|O and|O K|gene-rna -|gene-rna ras|gene-rna were|O amplified|O using|O the|O polymerase|gene-protein chain|O reaction|O and|O probed|O for|O single|O base|O pair|O mutations|O using|O synthetic|O oligonucleotide|O probes|O .|O 
Thirty-six|O melanomas|O contained|O mutations|O ,|O which|O in|O 25|O cases|O (|O 69|O %|O )|O occurred|O at|O the|O 61st|O codon|O of|O N-ras|gene-rna .|O 
The|O results|O from|O dot|O blot|O hybridizations|O were|O confirmed|O by|O subcloning|O and|O sequencing|O the|O polymerase|gene-protein chain|O reaction|O products|O from|O two|O tumors|O .|O 
No|O ras|gene-rna mutations|O were|O found|O in|O Clark|O 's|O level|O I|O melanomas|O ,|O whereas|O 19|O %|O of|O level|O II|O and|O 45|O %|O of|O the|O more|O advanced|O primary|O tumors|O contained|O ras|gene-rna mutations|O (|O Chi|O squared|O test|O :|O p|O <|O 0.05|O )|O .|O 
The|O median|O Breslow|O thickness|O of|O primary|O melanomas|O with|O ras|gene-rna mutations|O was|O 0.72|O mm|O ,|O significantly|O thicker|O than|O the|O 0.42|O mm|O of|O melanomas|O without|O mutations|O (|O Mann|O -|O Whitney|O U|O test|O ,|O p|O =|O 0.042|O )|O .|O 
Ras|gene-rna mutations|O were|O found|O more|O frequently|O in|O primary|O tumors|O from|O continuously|O exposed|O skin|O (|O 56|O %|O )|O than|O tumors|O from|O intermittently|O or|O non|O -|O sun|O exposed|O sites|O (|O 21|O %|O )|O .|O 
Fifty|O percent|O of|O locally|O recurrent|O and|O 47|O %|O of|O metastatic|O melanomas|O had|O ras|gene-rna mutations|O .|O 
We|O conclude|O that|O ras|gene-rna mutations|O occur|O in|O a|O subset|O of|O melanomas|O from|O sun|O -|O exposed|O skin|O as|O a|O feature|O of|O tumor|O progression|O .|O 
H-ras|gene-rna gene|O mutations|O in|O salivary|O gland|O pleomorphic|O adenomas|O .|O 
The|O DNA|O from|O 17|O specimens|O of|O pleomorphic|O adenoma|O of|O the|O salivary|O glands|O was|O screened|O for|O the|O presence|O of|O ras|gene-rna gene|O mutations|O ,|O which|O are|O known|O to|O be|O involved|O in|O the|O pathogenesis|O of|O various|O human|O neoplasias|O .|O 
By|O a|O sensitive|O method|O of|O hybridization|O with|O synthetic|O oligonucleotide|O probes|O on|O in|O vitro|O amplified|O tumor|O DNA|O ,|O point|O mutations|O ,|O mainly|O in|O codon|O 12|O of|O the|O H-ras|gene-rna gene|O ,|O were|O detected|O in|O six|O tumor|O specimens|O (|O 35|O %|O )|O .|O 
This|O high|O incidence|O of|O mutated|O ras|gene-rna genes|O suggests|O that|O their|O alteration|O may|O play|O a|O role|O in|O the|O pathogenesis|O of|O pleomorphic|O adenomas|O .|O 
PCR|O amplification|O and|O analysis|O of|O ras|gene-rna oncogenes|O from|O thyroid|O cytologic|O smears|O .|O 
Fine|O needle|O aspiration|O (|O FNA|O )|O cytology|O represents|O a|O reliable|O diagnostic|O procedure|O for|O preoperative|O identification|O of|O thyroid|O carcinoma|O .|O 
For|O improving|O its|O diagnostic|O accuracy|O ,|O a|O technique|O that|O allows|O the|O analysis|O of|O cancer|O -|O related|O gene|O abnormalities|O on|O thyroid|O FNA|O smears|O has|O been|O developed|O .|O 
Cells|O were|O collected|O by|O scraping|O from|O thyroid|O smears|O ,|O DNA|O -|O extracted|O and|O ras|gene-rna proto|O -|O oncogene|O sequences|O amplified|O by|O the|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O .|O 
Preliminary|O destaining|O of|O cytologic|O smears|O was|O essential|O for|O efficient|O PCR|O amplification|O .|O 
Twelve|O thyroid|O FNA|O cytologic|O smears|O ,|O characterized|O by|O the|O indeterminate|O pattern|O of|O follicular|O neoplasia|O ,|O were|O analysed|O for|O the|O presence|O of|O ras|gene-rna mutations|O known|O to|O confer|O an|O oncogenic|O potential|O .|O 
The|O same|O nucleotide|O substitution|O at|O codon|O 12|O of|O the|O H-ras|gene-rna proto|O -|O oncogene|O was|O detected|O in|O two|O different|O thyroid|O nodules|O among|O six|O cases|O that|O ,|O at|O final|O histology|O ,|O were|O identified|O as|O follicular|O carcinomas|O .|O 
No|O ras|gene-rna mutations|O were|O observed|O in|O the|O remaining|O six|O cases|O that|O were|O diagnosed|O as|O follicular|O adenoma|O at|O histologic|O examination|O .|O 
Molecular|O analysis|O of|O FNA|O smears|O may|O provide|O additional|O information|O on|O the|O nature|O of|O the|O lesion|O underlying|O thyroid|O neoplasia|O ,|O thus|O improving|O diagnostic|O accuracy|O of|O conventional|O FNA|O cytology|O .|O 
A|O truncated|O beta-catenin|gene-protein disrupts|O the|O interaction|O between|O E-cadherin|gene-protein and|O alpha-catenin|gene-protein :|O a|O cause|O of|O loss|O of|O intercellular|O adhesiveness|O in|O human|O cancer|O cell|O lines|O .|O 
Cadherin|gene-protein cell|O adhesion|O molecules|O play|O an|O essential|O role|O in|O creating|O tight|O intercellular|O association|O and|O are|O considered|O to|O work|O as|O an|O invasion|O suppressor|O system|O of|O cancer|O cells|O .|O 
They|O form|O a|O molecular|O complex|O with|O catenins|gene-protein ,|O a|O group|O of|O cytoplasmic|O proteins|O including|O alpha|gene-protein -|gene-protein and|O beta|gene-protein -|gene-protein catenins|gene-protein .|O 
While|O alpha-catenin|gene-protein has|O been|O demonstrated|O to|O be|O crucial|O for|O cadherin|gene-protein function|O ,|O the|O role|O of|O beta-catenin|gene-protein is|O not|O yet|O fully|O understood|O .|O 
In|O this|O study|O ,|O we|O analyzed|O the|O cadherin|gene-protein -|O catenin|gene-protein system|O in|O two|O human|O cell|O lines|O ,|O HSC-39|O and|O its|O putative|O subline|O HSC-40A|O ,|O derived|O from|O a|O signet|O ring|O cell|O carcinoma|O of|O stomach|O .|O 
These|O cells|O grow|O as|O loose|O aggregates|O or|O single|O cells|O ,|O suggesting|O that|O their|O cadherin|gene-protein system|O is|O not|O functional|O .|O 
In|O these|O cell|O lines|O ,|O an|O identical|O 321|O -|O base|O pair|O in-frame|O mRNA|O deletion|O of|O beta-catenin|gene-rna was|O identified|O ;|O this|O led|O to|O a|O 107|O -|O amino|O -|O acid|O deletion|O in|O the|O NH2|O -|O terminal|O region|O of|O the|O protein|gene-protein .|O 
Southern|O blot|O analysis|O disclosed|O a|O homozygous|O deletion|O in|O part|O of|O the|O beta-catenin|gene-rna gene|O .|O 
On|O the|O other|O hand|O ,|O these|O cells|O expressed|O E-cadherin|gene-protein ,|O alpha-catenin|gene-protein ,|O and|O plakoglobin|gene-protein of|O normal|O size|O .|O 
Immunoprecipitation|O analyses|O showed|O that|O E-cadherin|gene-protein was|O coprecipitated|O with|O the|O mutated|O beta-catenin|gene-protein but|O not|O with|O alpha-catenin|gene-protein ,|O and|O antibodies|gene-protein against|O beta-catenin|gene-protein did|O not|O copurify|O alpha-catenin|gene-protein .|O 
However|O ,|O the|O recombinant|O fusion|O protein|O containing|O wild-type|O beta-catenin|gene-protein precipitated|O alpha-catenin|gene-protein from|O these|O cells|O .|O 
These|O results|O suggest|O that|O the|O dysfunction|O of|O E-cadherin|gene-protein in|O these|O cell|O lines|O is|O due|O primarily|O to|O its|O failure|O to|O interact|O with|O alpha-catenin|gene-protein ,|O and|O that|O this|O defect|O results|O from|O the|O mutation|O in|O beta-catenin|gene-protein .|O 
Thus|O ,|O it|O is|O most|O likely|O that|O the|O association|O between|O E-cadherin|gene-protein and|O alpha-catenin|gene-protein is|O mediated|O by|O beta-catenin|gene-protein ,|O and|O that|O this|O process|O is|O blocked|O by|O NH2|O -|O terminal|O deletion|O in|O beta-catenin|gene-rna .|O 
These|O findings|O indicate|O that|O genetic|O abnormality|O of|O beta-catenin|gene-generic is|O one|O of|O the|O mechanisms|O responsible|O for|O loosening|O of|O cell|O -|O cell|O contact|O ,|O and|O may|O be|O involved|O in|O enhancement|O of|O tumor|O invasion|O in|O human|O cancers|O .|O 
Specific|O PCR|O amplification|O for|O N-ras|gene-rna mutations|O in|O neoplastic|O thyroid|O diseases|O .|O 
We|O analyzed|O point|O mutations|O of|O N-ras|gene-rna protooncogene|O codon|O 61|O in|O thyroid|O neoplasms|O by|O means|O of|O a|O mutation|O -|O specific|O PCR|O method|O .|O 
In|O this|O method|O ,|O one|O of|O the|O paired|O primers|O has|O a|O base|O at|O the|O 3'|O terminal|O that|O is|O complementary|O to|O a|O mutated|O base|O of|O the|O DNA|O sequence|O to|O be|O analyzed|O .|O 
With|O this|O primer|O ,|O only|O alleles|O which|O have|O the|O same|O mutation|O can|O be|O amplified|O .|O 
Among|O 24|O thyroid|O tissues|O ,|O we|O detected|O 2|O point|O mutations|O out|O of|O 7|O follicular|O carcinomas|O (|O 29|O %|O )|O .|O 
One|O tumor|O had|O a|O cytosine|O to|O adenine|O substitution|O mutation|O at|O the|O first|O base|O of|O codon|O 61|O ,|O and|O the|O other|O had|O an|O adenine|O to|O guanine|O substitution|O mutation|O in|O the|O second|O base|O of|O the|O same|O codon|O .|O 
The|O same|O mutations|O were|O not|O detected|O in|O 7|O follicular|O adenomas|O or|O 1|O papillary|O carcinoma|O .|O 
These|O results|O were|O confirmed|O by|O both|O dot|O blot|O hybridization|O and|O direct|O sequencing|O method|O .|O 
Mutation|O of|O N-ras|gene-rna codon|O 61|O may|O be|O significant|O in|O malignant|O transformation|O of|O follicular|O thyroid|O tumors|O .|O 
Because|O of|O its|O easy|O availability|O ,|O the|O mutation|O -|O specific|O PCR|O method|O is|O a|O useful|O screening|O test|O for|O N-ras|gene-rna mutations|O .|O 
ras|gene-rna -|O family|O gene|O mutations|O in|O neoplasia|O of|O the|O ampulla|O of|O Vater|O .|O 
Mutations|O in|O the|O first|O and|O second|O exons|O of|O Ha|gene-rna -|gene-rna ,|O Ki|gene-rna -|gene-rna and|O N|gene-rna -|gene-rna ras|gene-rna oncogenes|O were|O investigated|O in|O 17|O epithelial|O tumors|O of|O the|O ampulla|O of|O Vater|O by|O single|O -|O strand|O conformation|O polymorphism|O analysis|O and|O direct|O sequencing|O of|O DNA|O fragments|O amplified|O by|O polymerase|gene-protein chain|O reaction|O .|O 
The|O panel|O included|O 12|O intestinal|O -|O type|O adenocarcinomas|O ,|O 3|O villous|O adenomas|O ,|O 1|O papillary|O carcinoma|O and|O 1|O neuroendocrine|O carcinoma|O .|O 
Six|O cases|O (|O 35|O %|O )|O contained|O ras|gene-rna mutations|O ,|O affecting|O codon|O 12|O of|O Ki-ras|gene-rna in|O 2|O adenomas|O and|O 3|O carcinomas|O ,|O and|O of|O N-ras|gene-rna in|O 1|O adenoma|O .|O 
All|O mutations|O were|O found|O in|O adenomas|O and|O among|O cancers|O with|O adenomatous|O areas|O ,|O whereas|O none|O of|O the|O cases|O lacking|O adenomatous|O areas|O contained|O mutations|O .|O 
This|O suggested|O that|O ampullary|O cancers|O represent|O heterogeneous|O diseases|O with|O respect|O to|O the|O presence|O or|O absence|O of|O adenomatous|O areas|O and|O ,|O among|O those|O with|O adenomatous|O areas|O ,|O with|O respect|O to|O the|O presence|O of|O activated|O ras|gene-rna genes|O .|O 
Ki-ras|gene-rna mutated|O cases|O included|O 3|O of|O 4|O tumors|O which|O mainly|O involved|O the|O intraduodenal|O bile|O duct|O ,|O thus|O suggesting|O that|O a|O proportion|O of|O Ki-ras|gene-rna -|O mutated|O ampullary|O cancers|O might|O correspond|O to|O those|O originating|O from|O the|O epithelium|O of|O the|O bile|O duct|O component|O of|O the|O ampulla|O .|O 
Point|O mutations|O of|O the|O N-ras|gene-rna gene|O in|O the|O blood|O plasma|O DNA|O of|O patients|O with|O myelodysplastic|O syndrome|O or|O acute|O myelogenous|O leukaemia|O .|O 
Oncogene|O mutations|O are|O frequently|O found|O in|O several|O tumour|O types|O and|O ,|O among|O these|O ,|O point|O mutations|O of|O the|O ras|gene-rna gene|O are|O particularly|O significant|O .|O 
A|O predominance|O of|O N-ras|gene-rna mutations|O has|O been|O found|O in|O the|O bone|O marrow|O DNA|O of|O patients|O with|O myelodysplastic|O syndrome|O (|O MDS|O )|O or|O acute|O myelogenous|O leukaemia|O (|O AML|O )|O .|O 
On|O the|O other|O hand|O ,|O increased|O levels|O of|O plasma|O DNA|O have|O previously|O been|O observed|O in|O patients|O suffering|O from|O various|O malignant|O diseases|O .|O 
In|O the|O present|O work|O we|O have|O investigated|O ,|O by|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O ,|O point|O mutations|O of|O the|O N-ras|gene-rna gene|O in|O the|O DNA|O of|O plasma|O ,|O blood|O cells|O and|O bone|O marrow|O of|O 10|O patients|O suffering|O from|O AML|O or|O MDS|O .|O 
The|O different|O ras|gene-rna mutations|O detected|O in|O five|O cases|O were|O always|O present|O in|O the|O plasma|O DNA|O while|O sometimes|O absent|O in|O the|O DNA|O of|O peripheral|O blood|O cells|O or|O bone|O marrow|O .|O 
This|O indicates|O that|O a|O bone|O marrow|O biopsy|O or|O aspiration|O does|O not|O necessarily|O contain|O all|O the|O malignant|O clones|O involved|O in|O the|O disease|O .|O 
Plasma|O could|O thus|O prove|O to|O be|O an|O easily|O accessible|O and|O useful|O material|O for|O detection|O and|O monitoring|O of|O myeloid|O disorders|O .|O 
Loss|O of|O E-cadherin|gene-protein -|O dependent|O cell|O -|O cell|O adhesion|O due|O to|O mutation|O of|O the|O beta|gene-rna -|gene-rna catenin|gene-rna gene|O in|O a|O human|O cancer|O cell|O line|O ,|O HSC-39|O .|O 
Detachment|O of|O cell|O -|O cell|O adhesion|O is|O indispensable|O for|O the|O first|O step|O of|O invasion|O and|O metastasis|O of|O cancer|O .|O 
This|O mechanism|O is|O frequently|O associated|O with|O the|O impairment|O of|O either|O E-cadherin|gene-protein expression|O or|O function|O .|O 
However|O ,|O mechanisms|O of|O such|O abnormalities|O have|O not|O been|O fully|O elucidated|O .|O 
In|O this|O study|O ,|O we|O demonstrated|O that|O the|O function|O of|O E-cadherin|gene-protein was|O completely|O abolished|O in|O the|O human|O gastric|O cancer|O cell|O line|O HSC-39|O ,|O despite|O the|O high|O expression|O of|O E-cadherin|gene-protein ,|O because|O of|O mutations|O in|O one|O of|O the|O E-cadherin|gene-protein -|O associated|O cytoplasmic|O proteins|O ,|O beta-catenin|gene-protein .|O 
Although|O immunofluorescence|O staining|O of|O HSC-39|O cells|O by|O using|O an|O anti|gene-protein -|gene-protein E-cadherin|gene-protein antibody|gene-protein (|O HECD-1|gene-protein )|O revealed|O the|O strong|O and|O uniform|O expression|O of|O E-cadherin|gene-protein on|O the|O cell|O surface|O ,|O cell|O compaction|O and|O cell|O aggregation|O were|O not|O observed|O in|O this|O cell|O .|O 
Western|O blotting|O (|O immunoblotting|O )|O using|O HECD-1|gene-protein exhibited|O a|O 120|O -|O kDa|O band|O which|O is|O equivalent|O to|O normal|O E-cadherin|gene-protein .|O Northern|O (|O RNA|O )|O blotting|O demonstrated|O a|O 4.7|O -|O kb|O band|O ,|O the|O same|O as|O mature|O E-cadherin|gene-rna mRNA|O .|O 
Immunoprecipitation|O of|O metabolically|O labeled|O proteins|O with|O HECD-1|gene-protein revealed|O three|O bands|O corresponding|O to|O E-cadherin|gene-protein ,|O alpha-catenin|gene-protein ,|O and|O gamma-catenin|gene-protein and|O a|O 79|O -|O kDa|O band|O which|O was|O apparently|O smaller|O than|O that|O of|O normal|O beta-catenin|gene-protein ,|O indicating|O truncated|O beta-catenin|gene-protein .|O 
The|O 79|O -|O kDa|O band|O was|O immunologically|O identified|O as|O beta-catenin|gene-protein by|O using|O immunoblotting|O with|O anti|gene-protein -|gene-protein beta-catenin|gene-protein antibodies|gene-protein .|O 
Examination|O of|O beta-catenin|gene-rna mRNA|O by|O the|O reverse|gene-protein transcriptase|gene-protein -|O PCR|O method|O revealed|O a|O transcript|O which|O was|O shorter|O than|O that|O of|O normal|O beta-catenin|gene-protein .|O 
The|O sequencing|O of|O PCR|O product|O for|O beta-catenin|gene-protein confirmed|O deletion|O in|O 321|O bases|O from|O nucleotides|O +82|O to|O +402|O .|O 
Sequential|O acquisition|O of|O trisomy|O 8|O and|O N-ras|gene-rna mutation|O in|O acute|O myeloid|O leukaemia|O demonstrated|O by|O analysis|O of|O isolated|O leukaemic|O colonies|O .|O 
Specific|O chromosomal|O aberrations|O and|O point|O mutations|O of|O the|O N-ras|gene-rna proto|O -|O oncogene|O are|O characteristic|O genetic|O alterations|O in|O acute|O leukaemias|O .|O 
However|O ,|O the|O relationships|O between|O these|O two|O different|O genetic|O changes|O are|O unclear|O .|O 
Here|O we|O have|O determined|O the|O order|O of|O genetic|O events|O in|O a|O patient|O with|O acute|O myeloid|O leukaemia|O characterized|O by|O trisomy|O 8|O and|O a|O point|O mutation|O of|O N-ras|gene-rna at|O codon|O 12|O (|O N12|O -|O cys|O )|O and|O codon|O 61|O (|O N61|O -|O his|O )|O .|O 
30|O colonies|O obtained|O by|O in|O vitro|O clonogenic|O assay|O of|O leukaemic|O cells|O from|O a|O patient|O with|O AML|O were|O individually|O analysed|O for|O the|O presence|O of|O trisomy|O 8|O and|O each|O of|O two|O different|O N-ras|gene-rna mutations|O by|O fluorescence|O in|O situ|O hybridization|O (|O FISH|O )|O and|O the|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O .|O 
Trisomy|O 8|O was|O detected|O in|O 25|O /|O 26|O evaluable|O colonies|O .|O 
19|O /|O 26|O colonies|O contained|O the|O N12|O -|O cys|O mutation|O .|O 
The|O N61|O -|O his|O mutation|O was|O not|O detected|O in|O any|O of|O the|O colonies|O obtained|O .|O 
All|O the|O colonies|O with|O the|O N12|O cys|O mutation|O were|O also|O trisomic|O from|O chromosome|O 8|O ,|O whereas|O 6|O /|O 25|O colonies|O with|O trisomy|O 8|O had|O no|O N-ras|gene-rna mutation|O .|O 
These|O data|O suggest|O that|O trisomy|O 8|O was|O acquired|O before|O N12|O cys|O mutation|O in|O the|O pathogenesis|O of|O this|O leukaemia|O and|O that|O two|O genetic|O events|O can|O co-operate|O within|O a|O single|O subclone|O .|O 
N-ras|gene-rna mutation|O of|O thyroid|O tumor|O with|O special|O reference|O to|O the|O follicular|O type|O .|O 
Using|O the|O method|O of|O polymerase|gene-protein chain|O reaction|O -|O single|O strand|O conformation|O polymorphism|O ,|O the|O point|O mutations|O of|O the|O ras|gene-rna oncogenes|O in|O a|O total|O of|O 33|O thyroid|O tissues|O ,|O including|O 12|O follicular|O adenomas|O ,|O 6|O follicular|O carcinomas|O ,|O 11|O papillary|O carcinomas|O ,|O and|O 4|O undifferentiated|O carcinomas|O ,|O were|O examined|O .|O 
The|O frequency|O of|O the|O mutation|O was|O 3|O %|O (|O 1|O /|O 33|O )|O in|O codon|O 12|O ,|O 13|O of|O Ki-ras|gene-rna and|O 18|O %|O (|O 6|O /|O 33|O )|O in|O codon|O 61|O of|O N-ras|gene-rna ,|O including|O 17|O %|O (|O 2|O /|O 12|O )|O in|O follicular|O adenoma|O ,|O 50|O %|O (|O 3|O /|O 6|O )|O in|O follicular|O carcinoma|O ,|O 0|O %|O (|O 0|O /|O 11|O )|O in|O papillary|O carcinoma|O and|O 25|O %|O (|O 1|O /|O 4|O )|O in|O undifferentiated|O carcinoma|O .|O 
In|O follicular|O adenoma|O ,|O positivity|O was|O observed|O in|O microfollicular|O or|O trabecular|O subtypes|O .|O 
Furthermore|O ,|O the|O mutation|O of|O ras|gene-rna ,|O was|O examined|O in|O histologically|O different|O parts|O ,|O coexisting|O in|O the|O same|O tumor|O in|O a|O total|O of|O four|O cases|O .|O 
Both|O the|O undifferentiated|O carcinoma|O and|O coexisting|O follicular|O adenoma|O ,|O and|O both|O the|O microfollicular|O adenoma|O and|O trabecular|O nodule|O growing|O in|O the|O tumor|O ,|O had|O the|O same|O N-ras|gene-rna (|O 61|O )|O mutation|O .|O 
Direct|O sequencing|O analysis|O showed|O that|O all|O mutations|O were|O CAA|O (|O Gln|O )|O to|O CGA|O (|O Arg|O )|O transition|O of|O codon|O 61|O ,|O except|O for|O CAA|O to|O AAA|O transversion|O in|O one|O case|O of|O follicular|O carcinoma|O .|O 
A|O similar|O genetic|O abnormality|O of|O N-ras|gene-rna genes|O at|O codon|O 61|O between|O follicular|O adenoma|O and|O follicular|O carcinoma|O suggests|O that|O the|O mutation|O of|O N-ras|gene-rna at|O codon|O 61|O might|O play|O a|O part|O in|O oncogenesis|O in|O follicular|O tumors|O .|O 
p53|gene-rna and|O N-ras|gene-rna mutations|O in|O two|O new|O leukemia|O cell|O lines|O established|O from|O a|O patient|O with|O multilineage|O CD7|gene-protein -|O positive|O acute|O leukemia|O .|O 
Two|O new|O myeloid|O cell|O lines|O (|O K051|O and|O K052|O )|O were|O established|O from|O a|O patient|O with|O multilineage|O CD7|gene-protein -|O positive|O acute|O leukemia|O .|O 
The|O K051|O and|O K052|O were|O established|O from|O the|O patient|O 's|O bone|O marrow|O cells|O at|O diagnosis|O and|O at|O relapse|O ,|O respectively|O .|O 
The|O K051|O cell|O expressed|O myeloid|gene-protein -|gene-protein associated|gene-protein antigens|gene-protein (|O CD13|gene-protein and|O CD33|gene-protein )|O ,|O a|O platelet|gene-protein -|gene-protein associated|gene-protein antigen|gene-protein (|O CD41|gene-protein )|O ,|O and|O an|O erythroid|gene-protein antigen|gene-protein (|O glycophorin|gene-protein A|gene-protein )|O .|O 
The|O K052|O cell|O expressed|O myeloid|gene-protein -|gene-protein associated|gene-protein antigens|gene-protein (|O CD13|gene-protein ,|O CD14|gene-protein ,|O and|O CD33|gene-protein )|O ,|O lymphoid|gene-protein markers|gene-protein (|O CD2|gene-protein ,|O CD5|gene-protein ,|O and|O CD7|gene-protein )|O ,|O and|O HLA-DR|gene-protein .|O 
Chromosome|O analysis|O of|O both|O cell|O lines|O showed|O a|O 17p|O -|O chromosome|O .|O 
Both|O cell|O lines|O were|O investigated|O for|O aberrations|O of|O the|O p53|gene-rna gene|O and|O the|O N-ras|gene-rna gene|O .|O 
A|O p53|gene-rna mutation|O detected|O in|O both|O cell|O lines|O consisted|O of|O a|O C|O -->|O T|O substitution|O in|O codon|O 248|O .|O 
An|O N-ras|gene-rna mutation|O detected|O only|O in|O the|O K052|O cell|O consisted|O of|O a|O G|O -->|O C|O substitution|O in|O codon|O 13|O .|O 
Expression|O of|O the|O multidrug|gene-rna resistance|gene-rna gene|gene-rna (|O MDR1|gene-rna )|O was|O also|O investigated|O by|O the|O semiquantitative|O reverse|gene-protein transcriptase|gene-protein -|O polymerase|gene-protein chain|O reaction|O (|O RT|O -|O PCR|O )|O .|O 
MDR1|gene-rna -|O mRNA|O was|O more|O highly|O expressed|O by|O the|O K052|O cell|O than|O the|O K051|O cell|O ,|O being|O equivalent|O to|O that|O in|O HEL|O cells|O .|O 
The|O functional|O MDR1|gene-protein -|O protein|O against|O vincristine|O was|O also|O observed|O ,|O and|O its|O function|O was|O inhibited|O by|O verapamile|O and|O Cyclosporin|O A|O .|O 
The|O K052|O cells|O were|O capable|O of|O phenotypic|O or|O morphologic|O differentiation|O after|O being|O incubated|O with|O granulocyte|gene-protein colony|gene-protein -|gene-protein stimulating|gene-protein factor|gene-protein ,|O interleukin-2|gene-protein ,|O phorbol|O 12-myristate|O 13-acetate|O ,|O or|O 1,25-dihydroxy-vitamin|O D3|O .|O 
In|O contrast|O ,|O the|O K051|O cells|O responded|O phenotypically|O to|O retinoic|O acid|O .|O 
Thus|O ,|O the|O K051|O and|O K052|O cell|O lines|O will|O be|O useful|O for|O investigating|O the|O cellular|O and|O molecular|O events|O in|O leukemogenesis|O and|O differentiation|O ,|O and|O the|O mechanism|O of|O expression|O of|O the|O MDR1|gene-rna gene|O .|O 
Mutations|O in|O the|O ras|gene-rna proto|O -|O oncogenes|O in|O patients|O with|O myelodysplastic|O syndromes|O .|O 
Activation|O of|O the|O N|gene-rna -|gene-rna and|O K|gene-rna -|gene-rna ras|gene-rna proto|O -|O oncogenes|O is|O the|O most|O common|O molecular|O abnormality|O in|O myelodysplastic|O syndromes|O (|O MDS|O )|O and|O acute|O myeloid|O leukemia|O (|O AML|O )|O .|O 
In|O retrospective|O studies|O ,|O approximately|O 3|O -|O 36|O %|O of|O MDS|O patients|O were|O reported|O to|O harbor|O a|O mutated|O ras|gene-rna proto|O -|O oncogene|O ,|O with|O some|O series|O suggesting|O the|O presence|O of|O ras|gene-rna -|O mutations|O are|O associated|O with|O progressive|O disease|O and|O a|O poor|O prognosis|O .|O 
Since|O hematopoietic|gene-protein growth|gene-protein factors|gene-protein such|O as|O granulocyte|gene-protein colony|gene-protein -|gene-protein stimulating|gene-protein factor|gene-protein (|O G-CSF|gene-protein )|O are|O currently|O used|O for|O therapy|O in|O MDS|O but|O may|O stimulate|O the|O proliferation|O of|O leukemic|O cells|O ,|O we|O assessed|O the|O frequency|O and|O significance|O of|O ras|gene-rna mutations|O in|O 27|O MDS|O patients|O ,|O 15|O of|O whom|O underwent|O G-CSF|gene-protein therapy|O .|O 
Patients|O were|O analyzed|O for|O the|O presence|O of|O mutations|O in|O codons|O 12|O ,|O 13|O ,|O and|O 61|O of|O the|O N|gene-rna -|gene-rna and|O K|gene-rna -|gene-rna ras|gene-rna proto|O -|O oncogenes|O .|O 
Only|O three|O patients|O (|O 11|O %|O ,|O two|O refractory|O anemia|O with|O excess|O of|O blasts|O (|O RAEB|O )|O ,|O one|O RAEB|O in|O transformation|O (|O RAEB-T|O )|O )|O harbored|O activated|O ras|gene-rna oncogenes|O with|O the|O mutations|O localized|O in|O N-ras|gene-rna codons|O 12|O and|O 61|O .|O 
Patients|O were|O followed|O for|O periods|O of|O up|O to|O 4|O years|O or|O until|O death|O supervened|O .|O 
Patients|O exhibiting|O ras|gene-rna mutations|O were|O no|O more|O likely|O to|O develop|O AML|O compared|O to|O ras|gene-rna -|O negative|O patients|O (|O 1|O /|O 3|O vs.|O 10|O /|O 24|O )|O or|O to|O have|O decreased|O survival|O (|O p|O =|O 0.64|O )|O .|O 
These|O data|O indicate|O that|O ,|O in|O this|O group|O of|O MDS|O patients|O ,|O ras|gene-rna mutations|O do|O not|O appear|O to|O correlate|O with|O a|O poor|O prognosis|O ,|O and|O do|O not|O adversely|O interact|O with|O exogenously|O administered|O G-CSF|gene-protein .|O 
A|O point|O mutation|O at|O codon|O 13|O of|O the|O N-ras|gene-rna oncogene|O in|O myelodysplastic|O syndrome|O .|O 
Patients|O with|O a|O myelodysplastic|O syndrome|O (|O MDS|O )|O which|O has|O a|O risk|O of|O leukaemic|O change|O exhibit|O a|O variable|O clinical|O course|O .|O 
It|O has|O been|O suggested|O that|O the|O development|O of|O leukaemia|O in|O patients|O with|O MDS|O may|O be|O related|O to|O chromosomal|O abnormalities|O or|O genetic|O alterations|O :|O somatic|O mutation|O of|O the|O N-ras|gene-rna gene|O is|O now|O considered|O to|O be|O a|O critical|O step|O in|O the|O genetic|O basis|O of|O human|O leukaemogenesis|O .|O 
Here|O we|O report|O that|O DNAs|O of|O bone|O -|O marrow|O cells|O from|O three|O out|O of|O eight|O patients|O with|O MDS|O contained|O an|O activated|O N-ras|gene-rna oncogene|O ,|O as|O detected|O by|O an|O in|O vivo|O selection|O assay|O in|O nude|O mice|O with|O transfected|O NIH|O 3T3|O cells|O .|O 
Molecular|O analysis|O revealed|O the|O same|O single|O nucleotide|O substitution|O at|O codon|O 13|O in|O all|O three|O transforming|O N-ras|gene-rna genes|O .|O 
Each|O of|O the|O three|O patients|O showed|O a|O progression|O of|O the|O disease|O and|O a|O resulting|O leukaemic|O change|O within|O the|O following|O year|O .|O 
Our|O observation|O of|O the|O mutation|O at|O codon|O 13|O in|O leukaemic|O cell|O DNAs|O from|O all|O three|O cases|O suggests|O that|O activation|O of|O the|O N-ras|gene-rna gene|O is|O important|O in|O the|O development|O of|O leukaemia|O in|O some|O MDS|O cases|O .|O 
Preferential|O and|O novel|O activation|O of|O H-ras|gene-rna in|O human|O bladder|O carcinomas|O .|O 
In|O a|O survey|O of|O primary|O human|O bladder|O carcinomas|O from|O 24|O patients|O ,|O using|O the|O NIH|O /|O 3T3|O transfection|O nude|O mouse|O tumor|O assay|O ,|O we|O have|O detected|O an|O activated|O c-H-ras-1|gene-rna gene|O in|O four|O cases|O .|O 
Two|O of|O these|O scored|O negative|O in|O primary|O transfections|O using|O a|O NIH|O /|O 3T3|O focus|O assay|O .|O 
Oligonucleotide|O analysis|O of|O genomic|O and|O enzymatically|O amplified|O DNA|O revealed|O substitution|O of|O valine|O at|O codon|O 12|O in|O DNA|O from|O three|O transfectants|O and|O their|O parental|O carcinomas|O ,|O which|O was|O absent|O from|O the|O DNA|O of|O normal|O tissue|O of|O each|O of|O these|O patients|O .|O 
The|O fourth|O activation|O was|O identified|O as|O a|O cysteine|O substitution|O at|O codon|O 13|O ,|O a|O novel|O activation|O of|O c-H-ras-1|gene-rna in|O a|O solid|O tumor|O sample|O .|O 
Thus|O ,|O all|O seven|O activated|O ras|gene-rna genes|O reported|O in|O human|O urothelial|O tumors|O (|O Fujita|O et|O al.|O ,|O Proc.|O Natl.|O Acad.|O Sci.|O USA|O 82|O ,|O 3849|O -|O 3853|O ,|O 1985|O )|O have|O been|O c-H-ras-1|gene-rna genes|O ,|O strongly|O suggesting|O that|O this|O member|O of|O the|O ras|gene-rna gene|O family|O is|O preferentially|O activated|O in|O cells|O of|O transitional|O origin|O .|O 
Ras|gene-rna oncogene|O mutation|O in|O multiple|O myeloma|O .|O 
The|O frequency|O of|O ras|gene-rna (|O H|gene-rna -|gene-rna ,|O K|gene-rna -|gene-rna ,|O and|O N|gene-rna -|gene-rna ras|gene-rna )|O and|O c-myc|gene-rna oncogenes|O was|O investigated|O in|O multiple|O myeloma|O (|O MM|O )|O .|O 
By|O means|O of|O the|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O /|O oligonucleotide|O hybridization|O method|O ,|O DNA|O from|O 56|O tumor|O biopsies|O was|O analyzed|O for|O the|O presence|O of|O activating|O mutations|O involving|O codons|O 12|O and|O 61|O of|O the|O H|gene-rna -|gene-rna ,|O K|gene-rna -|gene-rna ,|O and|O N|gene-rna -|gene-rna ras|gene-rna genes|O and|O codon|O 13|O of|O the|O N-ras|gene-rna gene|O .|O 
Mutations|O ,|O involving|O the|O N|gene-rna -|gene-rna or|O K|gene-rna -|gene-rna ras|gene-rna genes|O ,|O were|O detected|O in|O 18|O of|O 56|O (|O 32|O %|O )|O cases|O of|O which|O 12|O /|O 43|O (|O 27|O %|O )|O were|O at|O diagnosis|O and|O 6|O /|O 13|O (|O 46|O %|O )|O were|O after|O treatment|O .|O 
In|O some|O cases|O ,|O multiple|O mutations|O affecting|O different|O ras|gene-rna alleles|O were|O detected|O .|O 
Direct|O nucleotide|O sequence|O analysis|O of|O PCR|O products|O indicated|O that|O a|O more|O heterogeneous|O nature|O of|O the|O base|O pair|O changes|O than|O previously|O shown|O for|O other|O tumors|O along|O with|O a|O preferential|O involvement|O of|O N-ras|gene-rna codon|O 61|O .|O 
The|O heterogeneity|O of|O MM|O cases|O with|O respect|O to|O the|O presence|O of|O ras|gene-rna oncogenes|O prompted|O an|O analysis|O of|O possible|O correlations|O with|O different|O clinico|O -|O pathologic|O characteristics|O of|O MM|O from|O which|O a|O correlation|O between|O the|O presence|O of|O ras|gene-rna oncogenes|O and|O a|O partial|O or|O complete|O lack|O of|O response|O to|O therapy|O emerged|O .|O 
The|O frequency|O of|O activating|O rearrangements|O or|O mutations|O of|O the|O c-myc|gene-rna gene|O were|O studied|O by|O Southern|O blot|O analysis|O and|O PCR|O sequencing|O ,|O respectively|O .|O 
However|O ,|O contrary|O to|O previous|O reports|O involving|O mostly|O MM|O cell|O lines|O ,|O no|O structural|O alterations|O of|O the|O c-myc|gene-rna gene|O were|O found|O .|O 
These|O results|O indicate|O that|O ras|gene-rna ,|O but|O not|O c-myc|gene-rna ,|O oncogenes|O are|O activated|O in|O vivo|O in|O MM|O cells|O ,|O representing|O the|O first|O oncogene|O alteration|O that|O has|O been|O associated|O at|O appreciable|O frequency|O with|O this|O type|O of|O malignancy|O .|O 
While|O the|O mechanism|O of|O occurrence|O and|O biological|O role|O of|O ras|gene-rna activation|O in|O MM|O remains|O to|O be|O elucidated|O ,|O the|O preliminary|O correlations|O observed|O in|O this|O study|O between|O the|O presence|O of|O ras|gene-rna oncogenes|O and|O poor|O therapeutic|O response|O suggest|O that|O further|O investigations|O of|O the|O possible|O prognostic|O significance|O of|O these|O alterations|O are|O necessary|O .|O 
Activated|O N-ras|gene-rna oncogenes|O in|O human|O neuroblastoma|O .|O 
Fifteen|O primary|O neuroblastomas|O and|O four|O bone|O marrow|O samples|O from|O neuroblastoma|O patients|O ,|O representing|O clinical|O Stages|O I|O to|O IV|O ,|O have|O been|O screened|O for|O mutations|O in|O codons|O 12|O ,|O 13|O ,|O and|O 61|O of|O N-ras|gene-rna .|O 
Neuroblastoma|O DNAs|O were|O subjected|O to|O the|O polymerase|gene-protein chain|O reaction|O to|O amplify|O the|O relevant|O sequences|O and|O were|O then|O hybridized|O with|O specific|O oligonucleotides|O to|O locate|O and|O identify|O point|O mutations|O .|O 
The|O results|O show|O that|O one|O Stage|O I|O tumor|O contained|O an|O N-ras|gene-rna gene|O that|O was|O activated|O by|O a|O GC|O -|O CG|O transversion|O of|O the|O first|O base|O of|O codon|O 61|O ,|O while|O in|O one|O Stage|O II|O tumor|O ,|O activation|O of|O N-ras|gene-rna involved|O a|O GC|O -|O CG|O transversion|O of|O the|O first|O position|O of|O codon|O 13|O .|O 
N-ras|gene-rna activations|O were|O not|O detected|O in|O the|O six|O Stage|O III|O tumors|O and|O eight|O Stage|O IV|O tumors|O that|O were|O examined|O .|O 
N-ras|gene-rna mutations|O in|O human|O cutaneous|O melanoma|O from|O sun|O -|O exposed|O body|O sites|O .|O 
In|O 7|O of|O 37|O patients|O with|O cutaneous|O melanoma|O ,|O mutations|O in|O the|O N-ras|gene-rna gene|O were|O found|O .|O 
The|O primary|O tumors|O of|O these|O seven|O patients|O were|O exclusively|O localized|O on|O body|O sites|O continuously|O exposed|O to|O sunlight|O .|O 
Moreover|O ,|O the|O ras|gene-rna mutations|O were|O all|O at|O or|O near|O dipyrimidine|O sites|O known|O to|O be|O targets|O of|O UV|O damage|O .|O 
Two|O primary|O tumors|O were|O biclonal|O with|O respect|O to|O ras|gene-rna mutation|O .|O 
An|O active|O role|O for|O UV|O irradiation|O in|O induction|O of|O the|O mutations|O is|O suggested|O .|O 
Acute|O myeloid|O leukemia|O :|O analysis|O of|O ras|gene-rna gene|O mutations|O and|O clonality|O defined|O by|O polymorphic|O X|O -|O linked|O loci|O .|O 
In|O vitro|O DNA|O amplification|O and|O synthetic|O oligonucleotide|O hybridization|O was|O used|O to|O analyze|O 57|O acute|O myelocytic|O leukemias|O (|O AML|O )|O for|O the|O presence|O of|O ras|gene-rna gene|O mutations|O .|O 
We|O demonstrated|O mutated|O alleles|O in|O 19|O %|O of|O primary|O AMLs|O (|O 10|O /|O 51|O )|O as|O well|O as|O in|O five|O of|O six|O secondary|O leukemias|O .|O 
Mutations|O occurred|O predominantly|O at|O N-ras|gene-rna codons|O 12|O ,|O 13|O ,|O or|O 61|O (|O 13|O cases|O )|O and|O twice|O at|O Ki-ras|gene-rna codons|O 12|O and|O 13|O .|O 
Ras|gene-rna gene|O mutations|O were|O preferentially|O associated|O with|O an|O M4|O morphology|O according|O to|O the|O FAB|O (|O French|O -|O American|O -|O British|O )|O classification|O ,|O but|O no|O particular|O correlation|O was|O observed|O with|O respect|O to|O clinical|O parameter|O (|O sex|O ,|O age|O ,|O course|O of|O disease|O )|O or|O immunophenotype|O and|O karyotype|O .|O 
Mutated|O ras|gene-rna alleles|O were|O absent|O in|O nine|O mutation|O -|O positive|O cases|O analyzed|O during|O remission|O .|O 
However|O ,|O a|O more|O complex|O pattern|O emerged|O from|O the|O five|O patients|O analyzed|O in|O relapse|O exhibiting|O identical|O ras|gene-rna mutations|O in|O three|O cases|O ,|O absence|O of|O a|O mutated|O allele|O in|O one|O patient|O ,|O and|O acquisition|O of|O a|O N-ras|gene-rna mutation|O in|O yet|O another|O case|O ,|O in|O which|O no|O mutation|O had|O been|O detected|O initially|O .|O 
Moreover|O ,|O restriction|O fragment|O length|O polymorphisms|O (|O RFLP|O )|O of|O the|O X|O -|O chromosome|O genes|O hypoxanthine|gene-protein phosphoribosyl|gene-protein transferase|gene-protein (|O HPRT|gene-protein )|O and|O phosphoglycerate|gene-protein kinase|gene-protein (|O PGK|gene-protein )|O were|O studied|O in|O 19|O of|O the|O AML|O patients|O .|O 
Nine|O cases|O (|O 47|O %|O )|O were|O heterozygous|O for|O BglI|gene-protein or|O BamHI|gene-protein RFLPs|O at|O the|O PGK|gene-generic or|O HPRT|gene-generic loci|O ,|O respectively|O ,|O and|O therefore|O suitable|O for|O clonal|O analysis|O investigating|O X|O -|O chromosome|O inactivation|O .|O 
All|O of|O the|O patients|O exhibited|O a|O monoclonal|O leukemic|O cell|O population|O at|O presentation|O .|O 
In|O addition|O ,|O five|O of|O seven|O cases|O studied|O in|O remission|O showed|O reemergence|O of|O a|O polyclonal|O pattern|O .|O 
However|O ,|O two|O children|O exhibited|O persistence|O of|O monoclonal|O hematopoiesis|O despite|O complete|O clinical|O /|O hematological|O remission|O and|O a|O corresponding|O loss|O of|O a|O mutated|O ras|gene-rna allele|O in|O one|O of|O the|O patients|O .|O 
These|O data|O indicate|O the|O value|O of|O molecular|O genetic|O approaches|O for|O evaluation|O of|O the|O heterogeneous|O nature|O of|O remission|O and|O relapse|O in|O AML|O .|O 
Activated|O N-ras|gene-rna gene|O was|O found|O in|O human|O hepatoma|O tissue|O but|O only|O in|O a|O small|O fraction|O of|O the|O tumor|O cells|O .|O 
Activated|O N-ras|gene-rna gene|O was|O isolated|O from|O human|O hepatoma|O tissue|O by|O DNA|O transfection|O assay|O coupled|O with|O the|O neomycin|O selection|O method|O and|O molecular|O cloning|O and|O a|O point|O mutation|O in|O the|O codon|O 61|O (|O CAA|O ----|O AAA|O )|O was|O noted|O .|O 
However|O ,|O examination|O of|O the|O proportion|O of|O the|O mutated|O N-ras|gene-rna gene|O in|O the|O tumor|O part|O by|O molecular|O cloning|O and|O by|O hybridization|O using|O synthetic|O oligonucleotide|O probes|O indicated|O that|O the|O mutated|O gene|gene-rna occurred|O with|O very|O low|O frequency|O .|O 
The|O activated|O N-ras|gene-rna gene|O appears|O located|O only|O in|O a|O small|O fraction|O of|O the|O tumor|O cells|O .|O 
The|O experimental|O data|O indicate|O activation|O of|O this|O gene|gene-rna as|O possibly|O not|O the|O major|O cause|O of|O carcinoma|O ,|O but|O rather|O a|O manifestation|O of|O tumor|O heterogeneity|O .|O 
Detection|O of|O ras|gene-rna gene|O mutations|O in|O human|O lung|O cancers|O by|O single-strand|O conformation|O polymorphism|O analysis|O of|O polymerase|gene-protein chain|O reaction|O products|O .|O 
A|O simple|O ,|O sensitive|O method|O of|O DNA|O analysis|O of|O nucleotide|O substitutions|O ,|O namely|O ,|O single-strand|O conformation|O polymorphism|O analysis|O of|O polymerase|gene-protein chain|O reaction|O products|O (|O PCR|O -|O SSCP|O analysis|O )|O ,|O was|O used|O for|O detection|O of|O mutated|O ras|gene-rna genes|O in|O surgical|O specimens|O of|O human|O lung|O cancer|O .|O 
Of|O a|O total|O of|O 129|O tumors|O analysed|O ,|O 22|O contained|O a|O mutated|O ras|gene-rna gene|O .|O 
Of|O the|O 66|O adenocarcinomas|O analysed|O ,|O 14|O contained|O an|O activated|O c-Ki-ras2|gene-rna gene|O (|O the|O mutations|O in|O codon|O 12|O in|O 6|O ,|O in|O codon|O 13|O in|O 4|O ,|O in|O codon|O 18|O in|O one|O ,|O and|O in|O codon|O 61|O in|O 3|O )|O ,|O one|O contained|O a|O c-Ha-ras1|gene-rna gene|O with|O a|O mutation|O in|O codon|O 61|O and|O 3|O contained|O N-ras|gene-rna genes|O with|O mutations|O (|O in|O codon|O 12|O in|O one|O and|O in|O codon|O 61|O in|O 2|O )|O .|O 
Mutated|O rats|gene-rna genes|O were|O also|O found|O in|O 2|O of|O 36|O squamous|O cell|O carcinomas|O (|O c-Ha-ras1|gene-rna genes|O with|O mutations|O in|O codon|O 61|O )|O and|O 2|O of|O 14|O large|O cell|O carcinomas|O (|O c-Ki-ras2|gene-rna genes|O with|O mutations|O in|O codon|O 12|O )|O .|O 
No|O mutation|O of|O the|O ras|gene-rna gene|O was|O detected|O in|O 8|O small|O cell|O carcinomas|O and|O 5|O adenosquamous|O cell|O carcinomas|O .|O 
These|O results|O indicate|O that|O activation|O of|O the|O ras|gene-rna gene|O was|O not|O frequent|O (|O 17|O %|O )|O in|O human|O lung|O cancers|O ,|O that|O among|O these|O lung|O cancers|O mutation|O of|O the|O ras|gene-rna gene|O was|O most|O frequent|O in|O adenocarcinomas|O (|O 27|O %|O )|O and|O 73|O %|O of|O the|O point|O mutations|O were|O in|O the|O c-Ki-ras2|gene-rna gene|O in|O codon|O 12|O ,|O 13|O ,|O 18|O or|O 61|O .|O 
Analysis|O of|O ras|gene-rna gene|O mutations|O in|O human|O hepatic|O malignant|O tumors|O by|O polymerase|gene-protein chain|O reaction|O and|O direct|O sequencing|O .|O 
The|O ras|gene-rna gene|O is|O one|O of|O the|O oncogenes|O most|O commonly|O detected|O in|O human|O cancers|O ,|O and|O it|O consists|O of|O three|O families|O (|O H-ras|gene-rna ,|O K-ras|gene-rna ,|O N-ras|gene-rna )|O .|O 
These|O genes|gene-rna are|O converted|O to|O active|O oncogenes|O by|O point|O mutations|O occurring|O in|O either|O codon|O 12|O ,|O 13|O ,|O or|O 61|O .|O 
We|O analyzed|O mutations|O of|O these|O codons|O in|O 23|O primary|O hepatic|O malignant|O tumors|O (|O 12|O hepatocellular|O carcinomas|O ,|O nine|O cholangiocarcinomas|O ,|O and|O two|O hepatoblastomas|O )|O by|O a|O method|O to|O directly|O sequence|O nucleotides|O ,|O using|O polymerase|gene-protein chain|O reaction|O and|O a|O direct|O sequencing|O method|O .|O 
Of|O 23|O hepatic|O malignant|O tumors|O ,|O point|O mutations|O at|O K-ras|gene-rna codon|O 12|O or|O K-ras|gene-rna codon|O 61|O were|O found|O in|O six|O of|O nine|O cholangiocarcinomas|O .|O 
In|O contrast|O ,|O there|O were|O no|O point|O mutations|O in|O any|O of|O 12|O hepatocellular|O carcinomas|O or|O two|O hepatoblastomas|O around|O codon|O 12|O ,|O 13|O ,|O or|O 61|O of|O the|O ras|gene-rna genes|O .|O 
These|O observations|O suggest|O that|O ras|gene-rna gene|O mutations|O are|O not|O related|O to|O pathogenesis|O of|O hepatocellular|O carcinoma|O ,|O but|O play|O an|O important|O role|O in|O pathogenesis|O of|O cholangiocarcinoma|O .|O 
Point|O mutations|O of|O c-ras|gene-rna genes|O in|O human|O bladder|O cancer|O and|O kidney|O cancer|O .|O 
Point|O mutations|O of|O c-ras|gene-rna genes|O at|O codons|O 12|O ,|O 13|O and|O 61|O were|O analyzed|O in|O 26|O cases|O of|O bladder|O cancer|O and|O 16|O cases|O of|O kidney|O cancer|O .|O 
DNA|O prepared|O from|O either|O frozen|O tissues|O or|O 10|O %|O formalin|O -|O fixed|O ,|O paraffin|O -|O embedded|O tissues|O were|O amplified|O by|O means|O of|O polymerase|gene-protein chain|O reaction|O methods|O ,|O and|O mutations|O were|O analyzed|O by|O dot|O blot|O hybridization|O assays|O with|O oligonucleotide|O probes|O .|O 
In|O three|O cases|O of|O bladder|O cancer|O c-ras|gene-rna mutations|O were|O found|O ,|O at|O codons|O 13|O and|O 61|O of|O c-Ha-ras|gene-rna and|O at|O codon|O 61|O of|O c-Ki-ras|gene-rna ,|O while|O no|O mutation|O was|O found|O in|O kidney|O cancer|O .|O 
No|O mutation|O was|O found|O in|O normal|O bladder|O epithelial|O tissues|O from|O the|O same|O patients|O .|O 
Our|O findings|O ,|O taken|O together|O ,|O may|O indicate|O relative|O scarcity|O of|O c-ras|gene-rna mutations|O in|O these|O types|O of|O human|O cancer|O .|O 
The|O results|O of|O dot|O blot|O hybridization|O assays|O and|O DNA|O sequencing|O showed|O a|O G|O -|O to|O -|O C|O transition|O of|O the|O first|O nucleotide|O at|O codon|O 13|O c-Ha-ras|gene-rna .|O 
This|O is|O the|O first|O time|O that|O such|O a|O point|O mutation|O has|O been|O detected|O in|O human|O cancer|O tissues|O .|O 
Ras|gene-rna gene|O mutation|O and|O amplification|O in|O human|O nonmelanoma|O skin|O cancers|O .|O 
Our|O previous|O studies|O have|O shown|O that|O human|O skin|O cancers|O occurring|O on|O sun|O -|O exposed|O body|O sites|O frequently|O contain|O activated|O Ha-ras|gene-rna oncogenes|O capable|O of|O inducing|O morphologic|O and|O tumorigenic|O transformation|O of|O NIH|O 3T3|O cells|O .|O 
In|O this|O study|O ,|O we|O analyzed|O human|O primary|O squamous|O cell|O carcinomas|O (|O SCCs|O )|O and|O basal|O cell|O carcinomas|O (|O BCCs|O )|O occurring|O on|O sun|O -|O exposed|O body|O sites|O for|O mutations|O in|O codons|O 12|O ,|O 13|O ,|O and|O 61|O of|O Ha-ras|gene-rna ,|O Ki-ras|gene-rna ,|O and|O N-ras|gene-rna oncogenes|O by|O amplification|O of|O genomic|O tumor|O DNAs|O by|O the|O polymerase|gene-protein chain|O reaction|O ,|O followed|O by|O dot|O -|O blot|O hybridization|O to|O synthetic|O oligonucleotide|O probes|O designed|O to|O detect|O single|O base|O -|O pair|O mutations|O .|O 
In|O addition|O to|O the|O primary|O human|O skin|O cancers|O ,|O we|O also|O analyzed|O Ha-ras|gene-rna -|O positive|O NIH|O 3T3|O transformants|O for|O mutations|O in|O the|O Ha-ras|gene-rna oncogene|O .|O 
The|O results|O indicated|O that|O all|O three|O NIH|O 3T3|O transformants|O ,|O 11|O of|O 24|O (|O 46|O %|O )|O SCCs|O ,|O and|O 5|O of|O 16|O (|O 31|O %|O )|O BCCs|O contained|O mutations|O at|O the|O second|O position|O of|O Ha-ras|gene-rna codon|O 12|O (|O GGC|O ----|O GTC|O )|O ,|O predicting|O a|O glycine|O -|O to|O -|O valine|O amino|O acid|O substitution|O ,|O whereas|O only|O 1|O of|O 40|O skin|O cancers|O (|O an|O SCC|O )|O displayed|O a|O mutation|O in|O the|O first|O position|O of|O Ki-ras|gene-rna codon|O 12|O (|O GGT|O ----|O AGT|O )|O ,|O predicting|O a|O glycine|O -|O to|O -|O serine|O amino|O acid|O change|O .|O 
In|O addition|O ,|O three|O of|O the|O SCCs|O contained|O highly|O amplified|O copies|O of|O the|O N-ras|gene-rna oncogene|O in|O their|O genomic|O DNA|O .|O 
Interestingly|O ,|O two|O of|O the|O SCCs|O containing|O amplified|O N-ras|gene-rna sequences|O also|O had|O G|O ----|O T|O mutations|O in|O codon|O 12|O of|O the|O Ha-ras|gene-rna oncogene|O .|O 
These|O studies|O demonstrate|O that|O mutations|O in|O codon|O 12|O of|O the|O Ha-ras|gene-rna oncogene|O occurred|O at|O a|O high|O frequency|O in|O human|O skin|O cancers|O originating|O on|O sun|O -|O exposed|O body|O sites|O ,|O whereas|O mutation|O in|O codon|O 12|O of|O Ki-ras|gene-rna or|O amplification|O of|O N-ras|gene-rna occurred|O at|O a|O low|O frequency|O .|O 
Since|O the|O mutations|O in|O the|O Ha-ras|gene-rna and|O Ki-ras|gene-rna oncogenes|O were|O located|O opposite|O potential|O pyrimidine|O dimer|O sites|O (|O C|O -|O C|O )|O ,|O it|O is|O likely|O that|O these|O mutations|O were|O induced|O by|O ultraviolet|O radiation|O present|O in|O sunlight|O .|O 
Analysis|O of|O oncogene|gene-rna alterations|O in|O human|O endometrial|O carcinoma|O :|O prevalence|O of|O ras|gene-rna mutations|O .|O 
The|O molecular|O genetics|O of|O human|O endometrial|O carcinoma|O have|O yet|O to|O be|O defined|O to|O any|O significant|O extent|O .|O 
Cell|O lines|O from|O 11|O endometrial|O carcinomas|O were|O examined|O for|O alterations|O in|O proto|gene-rna -|gene-rna oncogenes|gene-rna that|O might|O predictably|O be|O present|O ,|O based|O on|O existing|O data|O from|O the|O better|O -|O characterized|O human|O carcinomas|O of|O the|O uterine|O cervix|O ,|O ovary|O ,|O and|O breast|O .|O 
Codons|O 12|O ,|O 13|O ,|O and|O 61|O of|O the|O Ha-ras|gene-rna ,|O Ki-ras|gene-rna ,|O and|O N-ras|gene-rna genes|O were|O examined|O for|O possible|O point|O mutations|O ,|O and|O the|O c-erbB2|gene-rna /|O neu|gene-rna ,|O c-myc|gene-rna ,|O and|O epidermal|gene-rna growth|gene-rna factor|gene-rna receptor|gene-rna (|O EGFR|gene-rna )|O genes|O were|O examined|O for|O amplification|O or|O overexpression|O .|O 
Ras|gene-rna mutations|O were|O found|O in|O seven|O of|O 11|O (|O 64|O %|O )|O tumors|O ,|O including|O three|O in|O codon|O 61|O of|O Ha-ras|gene-rna (|O CAG|O ----|O CAT|O )|O and|O four|O in|O codon|O 12|O of|O Ki-ras|gene-rna (|O GGT|O ----|O GAT|O in|O two|O and|O GGT|O ----|O GTT|O in|O two|O )|O .|O 
No|O evidence|O was|O found|O for|O amplification|O or|O overexpression|O of|O the|O c-erbB2|gene-rna or|O EGFR|gene-rna genes|O in|O any|O tumor|O .|O 
One|O tumor|O contained|O amplified|O c-myc|gene-rna sequences|O and|O exhibited|O relative|O overexpression|O of|O c-myc|gene-rna .|O 
These|O data|O suggest|O that|O the|O amplification|O or|O overexpression|O of|O several|O proto|gene-rna -|gene-rna oncogenes|gene-rna frequently|O observed|O in|O other|O human|O gynecologic|O and|O breast|O tumors|O are|O not|O prevalent|O in|O endometrial|O carcinoma|O and|O that|O ras|gene-rna gene|O mutations|O are|O relatively|O common|O in|O this|O tumor|O type|O .|O 
Analysis|O of|O N-ras|gene-rna gene|O mutations|O in|O medulloblastomas|O by|O polymerase|gene-protein chain|O reaction|O and|O oligonucleotide|O probes|O in|O formalin|O -|O fixed|O ,|O paraffin|O -|O embedded|O tissues|O .|O 
Precise|O data|O on|O the|O incidence|O of|O transforming|O ras|gene-rna oncogenes|O in|O pediatric|O tumors|O and|O the|O correlations|O with|O the|O histopathological|O properties|O of|O the|O tumors|O are|O very|O limited|O .|O 
Additionally|O the|O presence|O of|O ras|gene-rna activation|O in|O medulloblastomas|O has|O not|O been|O investigated|O so|O far|O .|O 
Using|O a|O combination|O of|O techniques|O including|O in|O vitro|O gene|O amplification|O by|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O and|O detection|O of|O single|O base|O mutations|O by|O sequence|O -|O specific|O oligonucleotides|O we|O studied|O N-ras|gene-rna activation|O (|O mutations|O at|O codon|O 12|O ,|O 13|O ,|O and|O 61|O )|O in|O 32|O medulloblastomas|O .|O 
DNA|O was|O isolated|O from|O 20|O microns|O sections|O of|O formalin|O -|O fixed|O paraffin|O -|O embedded|O tissue|O .|O 
Mutations|O were|O found|O in|O 3|O out|O of|O 32|O examined|O medulloblastomas|O .|O 
In|O all|O cases|O only|O mutations|O of|O codon|O 61|O were|O found|O :|O two|O of|O three|O mutations|O were|O C|O to|O A|O mutations|O at|O position|O 1|O of|O the|O codon|O 61|O (|O leading|O to|O a|O substitution|O of|O a|O glutamine|O residue|O for|O a|O lysine|O )|O and|O one|O was|O A|O to|O T|O mutation|O at|O position|O 3|O in|O the|O same|O codon|O (|O glutamine|O -|O histidine|O )|O .|O 
Our|O results|O indicate|O 10|O %|O incidence|O N-ras|gene-rna mutation|O in|O medulloblastoma|O ,|O higher|O than|O in|O other|O CNS|O tumors|O studied|O so|O far|O .|O 
The|O main|O advantages|O of|O the|O procedure|O described|O are|O its|O greatly|O improved|O sensitivity|O ,|O the|O increased|O speed|O with|O which|O tumor|O samples|O can|O be|O analyzed|O ,|O and|O the|O possibility|O of|O using|O paraffin|O -|O embedded|O sections|O to|O analyze|O various|O rare|O tumors|O in|O retrospect|O .|O 
RAS|gene-rna gene|O mutations|O in|O multiple|O myeloma|O and|O related|O monoclonal|O gammopathies|O .|O 
The|O presence|O of|O RAS|gene-rna gene|O mutations|O in|O precancerous|O lesions|O suggests|O that|O they|O participate|O in|O the|O early|O stages|O of|O neoplastic|O development|O .|O 
Furthermore|O ,|O neoplastic|O progression|O from|O monoclonal|O gammopathy|O of|O undetermined|O significance|O (|O MGUS|O )|O to|O overt|O multiple|O myeloma|O (|O MM|O )|O have|O been|O frequently|O observed|O .|O 
These|O observations|O prompted|O us|O to|O study|O the|O pathogenetic|O role|O of|O RAS|gene-rna genes|O in|O MM|O and|O related|O monoclonal|O gammopathies|O .|O 
DNA|O from|O 18|O patients|O with|O monoclonal|O gamma-globulinemia|O including|O 12|O MM|O were|O investigated|O for|O the|O presence|O of|O N|gene-rna -|gene-rna and|O K|gene-rna -|gene-rna RAS|gene-rna gene|O mutations|O by|O polymerase|gene-protein chain|O reaction|O (|O PCR|O )|O /|O oligonucleotide|O hybridization|O .|O 
Mutations|O involving|O codons|O 12|O ,|O 13|O or|O 61|O of|O N-RAS|gene-rna gene|O were|O identified|O in|O 3|O of|O the|O 12|O MM|O patients|O ,|O 1|O of|O the|O solitary|O plasmacytoma|O patients|O and|O none|O of|O the|O 3|O of|O the|O MGUS|O patients|O .|O 
In|O the|O case|O of|O plasmacytoma|O ,|O RAS|gene-rna mutations|O were|O detected|O in|O his|O bone|O marrow|O specimens|O .|O 
K-ras|gene-rna activation|O in|O premalignant|O and|O malignant|O epithelial|O lesions|O of|O the|O human|O uterus|O .|O 
We|O previously|O reported|O (|O Cancer|O Res.|O ,|O 50|O :|O 6139|O -|O 6145|O ,|O 1990|O )|O a|O significant|O frequency|O of|O activating|O point|O mutations|O in|O codon|O 12|O of|O the|O K-ras|gene-rna oncogene|O in|O endometrial|O adenocarcinomas|O of|O the|O uterine|O corpus|O (|O series|O 1|O )|O .|O 
To|O further|O define|O the|O role|O of|O ras|gene-rna activation|O in|O the|O development|O of|O endometrial|O adenocarcinoma|O ,|O we|O surveyed|O cystic|O ,|O adenomatous|O ,|O and|O atypical|O hyperplasias|O of|O uterine|O endometrium|O and|O additional|O cases|O of|O endometrial|O and|O cervical|O carcinoma|O (|O series|O 2|O )|O for|O the|O presence|O of|O activating|O mutations|O in|O cellular|O protooncogenes|O of|O the|O ras|gene-rna family|O .|O 
Polymerase|gene-protein chain|O reaction|O was|O performed|O from|O deparaffinized|O sections|O of|O formalin|O -|O fixed|O paraffin|O -|O embedded|O tissue|O .|O 
We|O screened|O for|O point|O mutations|O in|O codons|O 12|O ,|O 13|O ,|O and|O 61|O of|O the|O K|gene-rna -|gene-rna ,|O H|gene-rna -|gene-rna ,|O and|O N|gene-rna -|gene-rna ras|gene-rna genes|O by|O dot|O blot|O hybridization|O analysis|O with|O mutation|O -|O specific|O oligomers|O .|O 
Mutations|O in|O K-ras|gene-rna were|O also|O confirmed|O by|O direct|O genomic|O DNA|O sequencing|O .|O 
Of|O 19|O endometrial|O adenocarcinomas|O in|O series|O 2|O ,|O point|O mutations|O in|O ras|gene-rna genes|O were|O found|O in|O 7|O tumors|O .|O 
Six|O contained|O single-base|O substitutions|O ,|O five|O in|O codon|O 12|O of|O K-ras|gene-rna and|O one|O in|O codon|O 12|O of|O N-ras|gene-rna .|O 
The|O seventh|O tumor|O contained|O two|O different|O point|O mutations|O in|O codon|O 12|O of|O K-ras|gene-rna .|O 
In|O one|O endometrial|O adenocarcinoma|O ,|O tumor|O cells|O with|O point|O mutations|O in|O K-ras|gene-rna were|O predominantly|O localized|O to|O a|O portion|O that|O had|O a|O more|O aggressive|O histological|O pattern|O .|O 
In|O endometrial|O hyperplasia|O ,|O K-ras|gene-rna mutations|O ,|O one|O in|O codon|O 12|O and|O one|O in|O codon|O 13|O ,|O were|O found|O in|O 2|O of|O 16|O hyperplasias|O histologically|O classified|O as|O atypical|O and|O clinically|O considered|O premalignant|O .|O 
None|O of|O 6|O adenomatous|O hyperplasias|O and|O none|O of|O 12|O cystic|O hyperplasias|O ,|O the|O latter|O of|O which|O is|O considered|O clinically|O benign|O ,|O contained|O any|O detectable|O ras|gene-rna mutations|O .|O 
No|O mutations|O in|O H-ras|gene-rna were|O detected|O in|O either|O carcinomas|O or|O hyperplastic|O tissue|O .|O 
Mutation|O analysis|O of|O the|O ras|gene-rna gene|O in|O myelocytic|O leukemia|O by|O polymerase|gene-protein chain|O reaction|O and|O oligonucleotide|O probes|O .|O 
Twenty-nine|O patients|O with|O acute|O myelocytic|O leukemia|O (|O AML|O )|O and|O 14|O patients|O with|O Philadelphia|O chromosome|O -|O positive|O chronic|O myelocytic|O leukemia|O (|O CML|O )|O were|O analyzed|O to|O detect|O the|O presence|O of|O mutations|O in|O their|O ras|gene-rna genes|O by|O the|O polymerase|gene-protein chain|O reaction|O and|O oligonucleotide|O hybridization|O methods|O .|O 
Deoxyribonucleic|O acid|O (|O DNA|O )|O isolated|O from|O blood|O or|O bone|O marrow|O samples|O was|O screened|O for|O mutations|O in|O codons|O 12|O ,|O 13|O and|O 61|O of|O N-ras|gene-rna and|O in|O codons|O 12|O and|O 61|O of|O K-ras|gene-rna and|O H-ras|gene-rna .|O 
We|O detected|O mutations|O of|O the|O ras|gene-rna gene|O in|O 7|O patients|O with|O AML|O (|O 7|O /|O 29|O )|O ,|O all|O in|O N-ras|gene-rna .|O 
The|O mutations|O were|O 3|O GGT|O ->|O GAT|O transitions|O in|O codon|O 12|O ,|O 1|O GGT|O ->|O TGT|O transition|O in|O codon|O 13|O ,|O and|O 3|O CAA|O ->|O AAA|O transitions|O in|O codon|O 61|O .|O 
No|O correlation|O has|O been|O observed|O between|O French|O -|O American|O -|O British|O subtypes|O and|O the|O incidence|O of|O N-ras|gene-rna mutation|O ,|O nor|O between|O cytogenetic|O changes|O and|O the|O incidence|O of|O N-ras|gene-rna mutation|O .|O 
All|O ras|gene-rna gene|O mutations|O detected|O by|O the|O oligonucleotide|O hybridization|O method|O were|O further|O confirmed|O by|O direct|O sequencing|O .|O 
No|O mutations|O were|O detected|O in|O ras|O genes|O in|O samples|O from|O the|O 14|O Philadelphia|O chromosome|O -|O positive|O CML|O patients|O (|O 12|O in|O chronic|O phase|O ,|O 2|O in|O blastic|O phase|O )|O .|O 
These|O findings|O are|O in|O line|O with|O previous|O results|O indicating|O that|O ras|gene-rna gene|O mutations|O in|O the|O codons|O tested|O play|O only|O a|O small|O role|O in|O the|O tumorigenesis|O of|O CML|O .|O 
N-ras|gene-rna gene|O mutations|O in|O acute|O myeloid|O leukemia|O :|O accurate|O detection|O by|O solid-phase|O minisequencing|O .|O 
Mutations|O in|O the|O N-ras|gene-rna gene|O are|O found|O in|O one-third|O of|O patients|O with|O acute|O myeloid|O leukemia|O .|O 
The|O N-ras|gene-rna mutations|O could|O serve|O as|O markers|O for|O residual|O cells|O ,|O if|O a|O highly|O sensitive|O method|O for|O detecting|O the|O mutations|O was|O available|O .|O 
We|O applied|O a|O new|O method|O ,|O solid-phase|O minisequencing|O ,|O to|O analyze|O bone|O -|O marrow|O cells|O from|O 16|O patients|O with|O acute|O myeloid|O leukemia|O for|O mutations|O in|O codon|O 12|O ,|O 13|O and|O 61|O of|O the|O N-ras|gene-rna gene|O .|O 
In|O the|O solid-phase|O minisequencing|O technique|O the|O mutations|O are|O identified|O by|O a|O primer|O extension|O reaction|O ,|O in|O which|O a|O single|O labelled|O nucleoside|O triphosphate|O is|O incorporated|O into|O an|O immobilized|O DNA|O fragment|O previously|O amplified|O by|O the|O polymerase|gene-protein chain|O reaction|O .|O 
We|O identified|O N-ras|gene-rna mutations|O in|O 5|O of|O the|O patients|O (|O 30|O %|O )|O .|O 
In|O one|O patient|O ,|O we|O observed|O 2|O mutations|O that|O were|O shown|O to|O be|O located|O in|O different|O alleles|O .|O 
With|O the|O solid-phase|O minisequencing|O method|O ,|O we|O were|O able|O to|O determine|O the|O proportion|O of|O mutated|O cells|O in|O the|O samples|O .|O 
We|O found|O that|O in|O 4|O of|O the|O samples|O only|O a|O fraction|O (|O 7|O -|O 64|O %|O )|O of|O the|O blasts|O carried|O an|O N-ras|gene-rna mutation|O ,|O and|O in|O one|O sample|O practically|O all|O blast|O cells|O were|O mutated|O .|O 
The|O method|O was|O highly|O sensitive|O ,|O allowing|O us|O to|O identify|O N-ras|gene-rna mutations|O even|O when|O the|O sample|O consisted|O of|O 99.7|O %|O normal|O cells|O and|O only|O 0.3|O %|O mutated|O blasts|O .|O 
Longitudinal|O analysis|O of|O point|O mutations|O of|O the|O N-ras|gene-rna proto|O -|O oncogene|O in|O patients|O with|O myelodysplasia|O using|O archived|O blood|O smears|O .|O 
We|O performed|O a|O longitudinal|O analysis|O of|O point|O mutations|O of|O the|O N-ras|gene-rna proto|O -|O oncogene|O in|O patients|O with|O myelodysplasia|O and|O a|O follow-up|O of|O at|O least|O 2.5|O years|O after|O diagnosis|O .|O 
Point|O mutations|O at|O codons|O 12|O ,|O 13|O ,|O and|O 61|O of|O the|O N-ras|gene-rna oncogene|O were|O analyzed|O after|O in|O vitro|O amplification|O of|O N-ras|gene-rna specific|O sequences|O followed|O by|O dot|O -|O blot|O hybridization|O .|O 
Lysed|O cells|O scraped|O from|O archived|O blood|O and|O bone|O marrow|O smears|O were|O used|O as|O template|O for|O a|O polymerase|gene-protein chain|O reaction|O .|O 
In|O 3|O of|O 90|O patients|O tested|O (|O 3.3|O %|O )|O ,|O a|O mutation|O in|O codon|O 12|O could|O be|O detected|O in|O the|O most|O recent|O blood|O smears|O .|O 
All|O available|O blood|O and|O bone|O marrow|O samples|O of|O these|O patients|O were|O subsequently|O analyzed|O for|O the|O occurrence|O of|O that|O particular|O mutation|O .|O 
In|O all|O three|O cases|O the|O mutation|O was|O not|O detectable|O at|O diagnosis|O ,|O but|O was|O acquired|O later|O during|O the|O course|O of|O the|O disease|O .|O 
In|O two|O of|O these|O patients|O this|O event|O was|O associated|O with|O rapid|O deterioration|O and|O transformation|O to|O acute|O leukemia|O .|O 
However|O ,|O the|O third|O patient|O showed|O a|O protracted|O course|O during|O a|O period|O of|O 5|O years|O after|O acquisition|O of|O the|O mutation|O .|O 
